<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34870676</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>08</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6114</ISSN><JournalIssue CitedMedium="Internet"><Volume>182</Volume><Issue>2</Issue><PubDate><Year>2022</Year><Month>Feb</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA internal medicine</Title><ISOAbbreviation>JAMA Intern Med</ISOAbbreviation></Journal><ArticleTitle>Association Between Cataract Extraction and Development of Dementia.</ArticleTitle><Pagination><StartPage>134</StartPage><EndPage>141</EndPage><MedlinePgn>134-141</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamainternmed.2021.6990</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Visual function is important for older adults. Interventions to preserve vision, such as cataract extraction, may modify dementia risk.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine whether cataract extraction is associated with reduced risk of dementia among older adults.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">This prospective, longitudinal cohort study analyzed data from the Adult Changes in Thought study, an ongoing, population-based cohort of randomly selected, cognitively normal members of Kaiser Permanente Washington. Study participants were 65 years of age or older and dementia free at enrollment and were followed up biennially until incident dementia (all-cause, Alzheimer disease, or Alzheimer disease and related dementia). Only participants who had a diagnosis of cataract or glaucoma before enrollment or during follow-up were included in the analyses (ie, a total of 3038 participants). Data used in the analyses were collected from 1994 through September 30, 2018, and all data were analyzed from April 6, 2019, to September 15, 2021.</AbstractText><AbstractText Label="EXPOSURES" NlmCategory="METHODS">The primary exposure of interest was cataract extraction. Data on diagnosis of cataract or glaucoma and exposure to surgery were extracted from electronic medical records. Extensive lists of dementia-related risk factors and health-related variables were obtained from study visit data and electronic medical records.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="METHODS">The primary outcome was dementia as defined by Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition) criteria. Multivariate Cox proportional hazards regression analyses were conducted with the primary outcome. To address potential healthy patient bias, weighted marginal structural models incorporating the probability of surgery were used and the association of dementia with glaucoma surgery, which does not restore vision, was evaluated.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In total, 3038 participants were included (mean [SD] age at first cataract diagnosis, 74.4 (6.2) years; 1800 women (59%) and 1238 men (41%); and 2752 (91%) self-reported White race). Based on 23&#x202f;554 person-years of follow-up, cataract extraction was associated with significantly reduced risk (hazard ratio, 0.71; 95% CI, 0.62-0.83; P&#x2009;&lt;&#x2009;.001) of dementia compared with participants without surgery after controlling for years of education, self-reported White race, and smoking history and stratifying by apolipoprotein E genotype, sex, and age group at cataract diagnosis. Similar results were obtained in marginal structural models after adjusting for an extensive list of potential confounders. Glaucoma surgery did not have a significant association with dementia risk (hazard ratio, 1.08; 95% CI, 0.75-1.56; P&#x2009;=&#x2009;.68). Similar results were found with the development of Alzheimer disease dementia.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">This cohort study found that cataract extraction was significantly associated with lower risk of dementia development. If validated in future studies, cataract surgery may have clinical relevance in older adults at risk of developing dementia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Cecilia S</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, University of Washington, Seattle.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Roger and Angie Karalis Johnson Retina Center, Seattle, Washington.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gibbons</LastName><ForeName>Laura E</ForeName><Initials>LE</Initials><AffiliationInfo><Affiliation>Department of General Internal Medicine, University of Washington, Seattle.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Aaron Y</ForeName><Initials>AY</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, University of Washington, Seattle.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Roger and Angie Karalis Johnson Retina Center, Seattle, Washington.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yanagihara</LastName><ForeName>Ryan T</ForeName><Initials>RT</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, University of Washington, Seattle.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blazes</LastName><ForeName>Marian S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, University of Washington, Seattle.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Michael L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Department of General Internal Medicine, University of Washington, Seattle.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCurry</LastName><ForeName>Susan M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>School of Nursing, University of Washington, Seattle.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bowen</LastName><ForeName>James D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Neurology, Swedish Medical Center, Seattle, Washington.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCormick</LastName><ForeName>Wayne C</ForeName><Initials>WC</Initials><AffiliationInfo><Affiliation>Department of General Internal Medicine, University of Washington, Seattle.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crane</LastName><ForeName>Paul K</ForeName><Initials>PK</Initials><AffiliationInfo><Affiliation>Department of General Internal Medicine, University of Washington, Seattle.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Larson</LastName><ForeName>Eric B</ForeName><Initials>EB</Initials><AffiliationInfo><Affiliation>Kaiser Permanente Washington Health Research Institute, Seattle, Washington.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG060942</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG006781</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005136</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 EY029246</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG066567</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Intern Med</MedlineTA><NlmUniqueID>101589534</NlmUniqueID><ISSNLinking>2168-6106</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>doi: 10.1001/jama.2021.24119</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002386" MajorTopicYN="Y">Cataract</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002387" MajorTopicYN="Y">Cataract Extraction</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005901" MajorTopicYN="Y">Glaucoma</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr A. Y. Lee reported receiving grants from Carl Zeiss Meditec, Novartis, Regeneron, and Santen; receiving personal fees from Genentech/Roche, Johnson &amp; Johnson, Topcon, the US Food and Drug Administration, and Verana Health; and receiving nonfinancial support from Microsoft and NVIDIA outside the submitted work. Dr McCurry reported receiving grants from the National Institute on Aging during the conduct of the study. Dr Larson reported receiving royalties from UpToDate outside of the submitted work. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>6</Day><Hour>12</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>12</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34870676</ArticleId><ArticleId IdType="pmc">PMC8649913</ArticleId><ArticleId IdType="doi">10.1001/jamainternmed.2021.6990</ArticleId><ArticleId IdType="pii">2786583</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Livingston G, Huntley J, Sommerlad A, et al. . Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020;396(10248):413-446. doi:10.1016/S0140-6736(20)30367-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30367-6</ArticleId><ArticleId IdType="pmc">PMC7392084</ArticleId><ArticleId IdType="pubmed">32738937</ArticleId></ArticleIdList></Reference><Reference><Citation>Correia C, Lopez KJ, Wroblewski KE, et al. . Global Sensory Impairment in Older Adults in the United States. J Am Geriatr Soc. 2016;64(2):306-313. doi:10.1111/jgs.13955</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jgs.13955</ArticleId><ArticleId IdType="pmc">PMC4808743</ArticleId><ArticleId IdType="pubmed">26889840</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawes P, Wolski L, Himmelsbach I, Regan J, Leroi I. Interventions for hearing and vision impairment to improve outcomes for people with dementia: a scoping review. Int Psychogeriatr. 2019;31(2):203-221. doi:10.1017/S1041610218000728</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S1041610218000728</ArticleId><ArticleId IdType="pubmed">30244688</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenowitz WD, Kaup AR, Lin FR, Yaffe K. Multiple sensory impairment is associated with increased risk of dementia among Black and White older adults. J Gerontol A Biol Sci Med Sci. 2019;74(6):890-896. doi:10.1093/gerona/gly264</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/gerona/gly264</ArticleId><ArticleId IdType="pmc">PMC6521912</ArticleId><ArticleId IdType="pubmed">30452551</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen SP, Bhattacharya J, Pershing S. Association of vision loss with cognition in older adults. JAMA Ophthalmol. 2017;135(9):963-970. doi:10.1001/jamaophthalmol.2017.2838</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaophthalmol.2017.2838</ArticleId><ArticleId IdType="pmc">PMC5710542</ArticleId><ArticleId IdType="pubmed">28817745</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng DD, Swenor BK, Christ SL, West SK, Lam BL, Lee DJ. Longitudinal associations between visual impairment and cognitive functioning: the Salisbury Eye Evaluation study. JAMA Ophthalmol. 2018;136(9):989-995. doi:10.1001/jamaophthalmol.2018.2493</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaophthalmol.2018.2493</ArticleId><ArticleId IdType="pmc">PMC6142982</ArticleId><ArticleId IdType="pubmed">29955805</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee CM, Afshari NA. The global state of cataract blindness. Curr Opin Ophthalmol. 2017;28(1):98-103. doi:10.1097/ICU.0000000000000340</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ICU.0000000000000340</ArticleId><ArticleId IdType="pubmed">27820750</ArticleId></ArticleIdList></Reference><Reference><Citation>Grodstein F, Chen J, Hankinson SE. Cataract extraction and cognitive function in older women. Epidemiology. 2003;14(4):493-497. doi:10.1097/01.ede.0000083503.34133.8c</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.ede.0000083503.34133.8c</ArticleId><ArticleId IdType="pubmed">12843777</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamura H, Tsukamoto H, Mukai S, et al. . Improvement in cognitive impairment after cataract surgery in elderly patients. J Cataract Refract Surg. 2004;30(3):598-602. doi:10.1016/j.jcrs.2003.10.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcrs.2003.10.019</ArticleId><ArticleId IdType="pubmed">15050255</ArticleId></ArticleIdList></Reference><Reference><Citation>Gray CS, Karimova G, Hildreth AJ, Crabtree L, Allen D, O&#x2019;connell JE. Recovery of visual and functional disability following cataract surgery in older people: Sunderland Cataract Study. J Cataract Refract Surg. 2006;32(1):60-66. doi:10.1016/j.jcrs.2005.07.040</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcrs.2005.07.040</ArticleId><ArticleId IdType="pubmed">16516780</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyata K, Yoshikawa T, Morikawa M, et al. . Effect of cataract surgery on cognitive function in elderly: results of Fujiwara-kyo Eye Study. PLoS One. 2018;13(2):e0192677. doi:10.1371/journal.pone.0192677</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0192677</ArticleId><ArticleId IdType="pmc">PMC5819799</ArticleId><ArticleId IdType="pubmed">29462175</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu WK, Chen YT, Wang SJ, Kuo SC, Shia BC, Liu CJL. Cataract surgery is associated with a reduced risk of dementia: a nationwide population-based cohort study. Eur J Neurol. 2015;22(10):1370-1377, e79-e80. doi:10.1111/ene.12561</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.12561</ArticleId><ArticleId IdType="pubmed">25196252</ArticleId></ArticleIdList></Reference><Reference><Citation>Kukull WA, Higdon R, Bowen JD, et al. . Dementia and Alzheimer disease incidence: a prospective cohort study. Arch Neurol. 2002;59(11):1737-1746. doi:10.1001/archneur.59.11.1737</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.59.11.1737</ArticleId><ArticleId IdType="pubmed">12433261</ArticleId></ArticleIdList></Reference><Reference><Citation>Larson EB, Wang L, Bowen JD, et al. . Exercise is associated with reduced risk for incident dementia among persons 65 years of age and older. Ann Intern Med. 2006;144(2):73-81. doi:10.7326/0003-4819-144-2-200601170-00004</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-144-2-200601170-00004</ArticleId><ArticleId IdType="pubmed">16418406</ArticleId></ArticleIdList></Reference><Reference><Citation>Crane PK, Gibbons LE, McCurry SM, et al. . Importance of home study visit capacity in dementia studies. Alzheimers Dement. 2016;12(4):419-426. doi:10.1016/j.jalz.2015.10.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2015.10.007</ArticleId><ArticleId IdType="pmc">PMC4841701</ArticleId><ArticleId IdType="pubmed">26602628</ArticleId></ArticleIdList></Reference><Reference><Citation>Shintani AK, Girard TD, Eden SK, Arbogast PG, Moons KGM, Ely EW. Immortal time bias in critical care research: application of time-varying Cox regression for observational cohort studies. Crit Care Med. 2009;37(11):2939-2945. doi:10.1097/CCM.0b013e3181b7fbbb</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0b013e3181b7fbbb</ArticleId><ArticleId IdType="pmc">PMC3365557</ArticleId><ArticleId IdType="pubmed">19770737</ArticleId></ArticleIdList></Reference><Reference><Citation>Sylvestre M-P, Huszti E, Hanley JA. Do OSCAR winners live longer than less successful peers? a reanalysis of the evidence. Ann Intern Med. 2006;145(5):361-363. doi:10.7326/0003-4819-145-5-200609050-00009</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-145-5-200609050-00009</ArticleId><ArticleId IdType="pubmed">16954361</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xe9;vesque LE, Hanley JA, Kezouh A, Suissa S. Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ. 2010;340:b5087. doi:10.1136/bmj.b5087</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.b5087</ArticleId><ArticleId IdType="pubmed">20228141</ArticleId></ArticleIdList></Reference><Reference><Citation>Kollman C. Survival analysis and the immortal time bias. JAMA Ophthalmol. 2018;136(11):1314-1315. doi:10.1001/jamaophthalmol.2018.3499</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaophthalmol.2018.3499</ArticleId><ArticleId IdType="pubmed">30352116</ArticleId></ArticleIdList></Reference><Reference><Citation>Yadav K, Lewis RJ. Immortal time bias in observational studies. JAMA. 2021;325(7):686-687. doi:10.1001/jama.2020.9151</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.9151</ArticleId><ArticleId IdType="pubmed">33591334</ArticleId></ArticleIdList></Reference><Reference><Citation>Teng EL, Hasegawa K, Homma A, et al. . The Cognitive Abilities Screening Instrument (CASI): a practical test for cross-cultural epidemiological studies of dementia. Int Psychogeriatr. 1994;6(1):45-58. doi:10.1017/S1041610294001602</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S1041610294001602</ArticleId><ArticleId IdType="pubmed">8054493</ArticleId></ArticleIdList></Reference><Reference><Citation>Crane PK, Trittschuh E, Mukherjee S, et al. ; Executive Prominent Alzheimer&#x2019;s Disease: Genetics and Risk Factors (EPAD:GRF) Investigators . Incidence of cognitively defined late-onset Alzheimer&#x2019;s dementia subgroups from a prospective cohort study. Alzheimers Dement. 2017;13(12):1307-1316. doi:10.1016/j.jalz.2017.04.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2017.04.011</ArticleId><ArticleId IdType="pmc">PMC5723557</ArticleId><ArticleId IdType="pubmed">28623677</ArticleId></ArticleIdList></Reference><Reference><Citation>American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders, 4th ed. American Psychiatric Association; 1994.</Citation></Reference><Reference><Citation>McKhann GM, Knopman DS, Chertkow H, et al. . The diagnosis of dementia due to Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7(3):263-269. doi:10.1016/j.jalz.2011.03.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2011.03.005</ArticleId><ArticleId IdType="pmc">PMC3312024</ArticleId><ArticleId IdType="pubmed">21514250</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer&#x2019;s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#x2019;s Disease. Neurology. 1984;34(7):939-944. doi:10.1212/WNL.34.7.939</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.34.7.939</ArticleId><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383. doi:10.1016/0021-9681(87)90171-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0021-9681(87)90171-8</ArticleId><ArticleId IdType="pubmed">3558716</ArticleId></ArticleIdList></Reference><Reference><Citation>Radloff LS. The CES-D Scale: a self-report depression scale for research in the general population. Appl Psychol Meas. 1977;1(3):385-401. doi:10.1177/014662167700100306</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/014662167700100306</ArticleId></ArticleIdList></Reference><Reference><Citation>Robins JM, Hern&#xe1;n MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology. 2000;11(5):550-560. doi:10.1097/00001648-200009000-00011</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00001648-200009000-00011</ArticleId><ArticleId IdType="pubmed">10955408</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim ZW, Chee ML, Soh ZD, et al. . Association between visual impairment and decline in cognitive function in a multiethnic Asian population. JAMA Netw Open. 2020;3(4):e203560. doi:10.1001/jamanetworkopen.2020.3560</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2020.3560</ArticleId><ArticleId IdType="pmc">PMC7180417</ArticleId><ArticleId IdType="pubmed">32324240</ArticleId></ArticleIdList></Reference><Reference><Citation>Loughrey DG, Kelly ME, Kelley GA, Brennan S, Lawlor BA. Association of age-related hearing loss with cognitive function, cognitive impairment, and dementia: a systematic review and meta-analysis. JAMA Otolaryngol Head Neck Surg. 2018;144(2):115-126. doi:10.1001/jamaoto.2017.2513</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoto.2017.2513</ArticleId><ArticleId IdType="pmc">PMC5824986</ArticleId><ArticleId IdType="pubmed">29222544</ArticleId></ArticleIdList></Reference><Reference><Citation>Uhlmann RF, Larson EB, Rees TS, Koepsell TD, Duckert LG. Relationship of hearing impairment to dementia and cognitive dysfunction in older adults. JAMA. 1989;261(13):1916-1919. doi:10.1001/jama.1989.03420130084028</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.1989.03420130084028</ArticleId><ArticleId IdType="pubmed">2926927</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitson HE, Cronin-Golomb A, Cruickshanks KJ, et al. . American Geriatrics Society and National Institute on Aging Bench-to-Bedside conference: sensory impairment and cognitive decline in older adults. J Am Geriatr Soc. 2018;66(11):2052-2058. doi:10.1111/jgs.15506</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jgs.15506</ArticleId><ArticleId IdType="pmc">PMC6410371</ArticleId><ArticleId IdType="pubmed">30248173</ArticleId></ArticleIdList></Reference><Reference><Citation>Mamo SK, Reed NS, Price C, et al. . Hearing loss treatment in older adults with cognitive impairment: a systematic review. J Speech Lang Hear Res. 2018;61(10):2589-2603. doi:10.1044/2018_JSLHR-H-18-0077</Citation><ArticleIdList><ArticleId IdType="doi">10.1044/2018_JSLHR-H-18-0077</ArticleId><ArticleId IdType="pmc">PMC6428235</ArticleId><ArticleId IdType="pubmed">30304320</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers MAM, Langa KM. Untreated poor vision: a contributing factor to late-life dementia. Am J Epidemiol. 2010;171(6):728-735. doi:10.1093/aje/kwp453</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwp453</ArticleId><ArticleId IdType="pmc">PMC2842219</ArticleId><ArticleId IdType="pubmed">20150357</ArticleId></ArticleIdList></Reference><Reference><Citation>Killen A, Firbank MJ, Collerton D, et al. . The assessment of cognition in visually impaired older adults. Age Ageing. 2013;42(1):98-102. doi:10.1093/ageing/afs157</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ageing/afs157</ArticleId><ArticleId IdType="pmc">PMC4153986</ArticleId><ArticleId IdType="pubmed">23108164</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenner MH, Curbow B, Javitt JC, Legro MW, Sommer A. Vision change and quality of life in the elderly: response to cataract surgery and treatment of other chronic ocular conditions. Arch Ophthalmol. 1993;111(5):680-685. doi:10.1001/archopht.1993.01090050114040</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archopht.1993.01090050114040</ArticleId><ArticleId IdType="pubmed">8489453</ArticleId></ArticleIdList></Reference><Reference><Citation>Boucard CC, Hernowo AT, Maguire RP, et al. . Changes in cortical grey matter density associated with long-standing retinal visual field defects. Brain. 2009;132(pt 7):1898-1906. doi:10.1093/brain/awp119</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awp119</ArticleId><ArticleId IdType="pmc">PMC2702836</ArticleId><ArticleId IdType="pubmed">19467992</ArticleId></ArticleIdList></Reference><Reference><Citation>von dem Hagen EAH, Houston GC, Hoffmann MB, Jeffery G, Morland AB. Retinal abnormalities in human albinism translate into a reduction of grey matter in the occipital cortex. Eur J Neurosci. 2005;22(10):2475-2480. doi:10.1111/j.1460-9568.2005.04433.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1460-9568.2005.04433.x</ArticleId><ArticleId IdType="pubmed">16307590</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanson RLW, Gale RP, Gouws AD, et al. . Following the status of visual cortex over time in patients with macular degeneration reveals atrophy of visually deprived brain regions. Invest Ophthalmol Vis Sci. 2019;60(15):5045-5051. doi:10.1167/iovs.18-25823</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.18-25823</ArticleId><ArticleId IdType="pubmed">31800962</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin H, Zhang L, Lin D, et al. . Visual restoration after cataract surgery promotes functional and structural brain recovery. EBioMedicine. 2018;30:52-61. doi:10.1016/j.ebiom.2018.03.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2018.03.002</ArticleId><ArticleId IdType="pmc">PMC5952227</ArticleId><ArticleId IdType="pubmed">29548900</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts KL, Allen HA. Perception and cognition in the ageing brain: a brief review of the short- and long-term links between perceptual and cognitive decline. Front Aging Neurosci. 2016;8:39. doi:10.3389/fnagi.2016.00039</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2016.00039</ArticleId><ArticleId IdType="pmc">PMC4772631</ArticleId><ArticleId IdType="pubmed">26973514</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmoll C, Tendo C, Aspinall P, Dhillon B. Reaction time as a measure of enhanced blue-light mediated cognitive function following cataract surgery. Br J Ophthalmol. 2011;95(12):1656-1659. doi:10.1136/bjophthalmol-2011-300677</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bjophthalmol-2011-300677</ArticleId><ArticleId IdType="pubmed">21951571</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandewalle G, Maquet P, Dijk DJ. Light as a modulator of cognitive brain function. Trends Cogn Sci. 2009;13(10):429-438. doi:10.1016/j.tics.2009.07.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tics.2009.07.004</ArticleId><ArticleId IdType="pubmed">19748817</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee CS, Larson EB, Gibbons LE, et al. . Associations between recent and established ophthalmic conditions and risk of Alzheimer&#x2019;s disease. Alzheimers Dement. 2019;15(1):34-41. doi:10.1016/j.jalz.2018.06.2856</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.06.2856</ArticleId><ArticleId IdType="pmc">PMC6333518</ArticleId><ArticleId IdType="pubmed">30098888</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34880498</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>22</Day></DateCompleted><DateRevised><Year>2025</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>600</Volume><Issue>7889</Issue><PubDate><Year>2021</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Exercise plasma boosts memory and dampens brain inflammation via clusterin.</ArticleTitle><Pagination><StartPage>494</StartPage><EndPage>499</EndPage><MedlinePgn>494-499</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41586-021-04183-x</ELocationID><Abstract><AbstractText>Physical exercise is generally beneficial to all aspects of human and animal health, slowing cognitive ageing and neurodegeneration<sup>1</sup>. The cognitive benefits of physical exercise are tied to an increased plasticity and reduced inflammation within the hippocampus<sup>2-4</sup>, yet little is known about the factors and mechanisms that mediate these effects. Here we show that 'runner plasma', collected from voluntarily running mice and infused into sedentary mice, reduces baseline neuroinflammatory gene expression and experimentally induced brain inflammation. Plasma proteomic analysis revealed a concerted increase in complement cascade inhibitors including clusterin (CLU). Intravenously injected CLU binds to brain endothelial cells and reduces neuroinflammatory gene expression in a mouse model of acute brain inflammation and a mouse model of Alzheimer's disease. Patients with cognitive impairment who participated in structured exercise for 6 months had higher plasma levels of CLU. These findings demonstrate the existence of anti-inflammatory exercise factors that are transferrable, target the cerebrovasculature and benefit the brain, and are present in humans who engage in exercise.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s), under exclusive licence to Springer Nature Limited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>De Miguel</LastName><ForeName>Zurine</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Glenn Center for the Biology of Aging, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wu Tsai Neurosciences Institute, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Psychology Department, California State University, Monterey Bay, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Khoury</LastName><ForeName>Nathalie</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Glenn Center for the Biology of Aging, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wu Tsai Neurosciences Institute, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Betley</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurosciences Graduate Training Program, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lehallier</LastName><ForeName>Benoit</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0001-7452-3785</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Glenn Center for the Biology of Aging, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wu Tsai Neurosciences Institute, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Alkahest Inc, San Carlos, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Willoughby</LastName><ForeName>Drew</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Glenn Center for the Biology of Aging, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wu Tsai Neurosciences Institute, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olsson</LastName><ForeName>Niclas</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-9746-0542</Identifier><AffiliationInfo><Affiliation>Department of Chemical and Systems Biology, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Calico Life Sciences, South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Andrew C</ForeName><Initials>AC</Initials><Identifier Source="ORCID">0000-0002-6756-4746</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Glenn Center for the Biology of Aging, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wu Tsai Neurosciences Institute, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hahn</LastName><ForeName>Oliver</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Glenn Center for the Biology of Aging, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wu Tsai Neurosciences Institute, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Nannan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Glenn Center for the Biology of Aging, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wu Tsai Neurosciences Institute, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vest</LastName><ForeName>Ryan T</ForeName><Initials>RT</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Glenn Center for the Biology of Aging, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wu Tsai Neurosciences Institute, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonanno</LastName><ForeName>Liana N</ForeName><Initials>LN</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Glenn Center for the Biology of Aging, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wu Tsai Neurosciences Institute, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yerra</LastName><ForeName>Lakshmi</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>The Veterans Affairs Palo Alto HealthCare System, Palo Alto, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Lichao</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-1811-7568</Identifier><AffiliationInfo><Affiliation>Chan Zuckerberg Biohub, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saw</LastName><ForeName>Nay Lui</ForeName><Initials>NL</Initials><AffiliationInfo><Affiliation>Behavioral and Functional Neuroscience Laboratory, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fairchild</LastName><ForeName>J Kaci</ForeName><Initials>JK</Initials><AffiliationInfo><Affiliation>The Veterans Affairs Palo Alto HealthCare System, Palo Alto, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Davis</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Glenn Center for the Biology of Aging, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wu Tsai Neurosciences Institute, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Hui</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-6787-7403</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Glenn Center for the Biology of Aging, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wu Tsai Neurosciences Institute, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McAlpine</LastName><ForeName>Patrick L</ForeName><Initials>PL</Initials><Identifier Source="ORCID">0000-0002-9950-7156</Identifier><AffiliationInfo><Affiliation>Otolaryngology Head and Neck Surgery Research Division, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Contrepois</LastName><ForeName>K&#xe9;vin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Genetics, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shamloo</LastName><ForeName>Mehrdad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Behavioral and Functional Neuroscience Laboratory, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elias</LastName><ForeName>Joshua E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Department of Chemical and Systems Biology, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Chan Zuckerberg Biohub, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rando</LastName><ForeName>Thomas A</ForeName><Initials>TA</Initials><Identifier Source="ORCID">0000-0001-5843-8564</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Glenn Center for the Biology of Aging, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Veterans Affairs Palo Alto HealthCare System, Palo Alto, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wyss-Coray</LastName><ForeName>Tony</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-5893-0831</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA. twc@stanford.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Glenn Center for the Biology of Aging, Stanford University School of Medicine, Stanford, CA, USA. twc@stanford.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wu Tsai Neurosciences Institute, Stanford University, Stanford, CA, USA. twc@stanford.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG066515</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG047820</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG036695</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>I01 BX001319</GrantID><Acronym>BX</Acronym><Agency>BLRD VA</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG071783</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32 AG067652</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>12</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051152">Clusterin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Endocrinol. 2022 Feb;18(2):68. doi: 10.1038/s41574-021-00624-9.</RefSource><PMID Version="1">34931019</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Cell Res. 2022 Mar;32(3):223-224. doi: 10.1038/s41422-022-00621-1.</RefSource><PMID Version="1">35075253</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051152" MajorTopicYN="N">Clusterin</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004660" MajorTopicYN="Y">Encephalitis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042783" MajorTopicYN="N">Endothelial Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D040901" MajorTopicYN="N">Proteomics</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing interests</b> N.O. is affiliated with Calico Life Sciences and has no financial interests to declare. The other authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>7</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>10</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>9</Day><Hour>6</Hour><Minute>55</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>12</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34880498</ArticleId><ArticleId IdType="mid">NIHMS1841142</ArticleId><ArticleId IdType="pmc">PMC9721468</ArticleId><ArticleId IdType="doi">10.1038/s41586-021-04183-x</ArticleId><ArticleId IdType="pii">10.1038/s41586-021-04183-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Prakash RS, Voss MW, Erickson KI &amp; Kramer AF Physical activity and cognitive vitality. Annu. Rev. Psychol 66, 769&#x2013;797 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25251492</ArticleId></ArticleIdList></Reference><Reference><Citation>Gleeson M et al. The anti-inflammatory effects of exercise: mechanisms and implications for the prevention and treatment of disease. Nat. Rev. Immunol 11, 607&#x2013;615 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21818123</ArticleId></ArticleIdList></Reference><Reference><Citation>He XF et al. Voluntary exercise promotes glymphatic clearance of amyloid beta and reduces the activation of astrocytes and microglia in aged mice. Front. Mol. Neurosci 10, 144 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5437122</ArticleId><ArticleId IdType="pubmed">28579942</ArticleId></ArticleIdList></Reference><Reference><Citation>van Praag H, Christie BR, Sejnowski TJ &amp; Gage FH Running enhances neurogenesis, learning, and long-term potentiation in mice. Proc. Natl Acad. Sci. USA 96, 13427&#x2013;13431 (1999).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC23964</ArticleId><ArticleId IdType="pubmed">10557337</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawley JA, Hargreaves M, Joyner MJ &amp; Zierath JR Integrative biology of exercise. Cell 159, 738&#x2013;749 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25417152</ArticleId></ArticleIdList></Reference><Reference><Citation>Chin LM, Keyser RE, Dsurney J &amp; Chan L Improved cognitive performance following aerobic exercise training in people with traumatic brain injury. Arch. Phys. Med. Rehabil 96, 754&#x2013;759 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4380661</ArticleId><ArticleId IdType="pubmed">25433219</ArticleId></ArticleIdList></Reference><Reference><Citation>Horder H et al. Midlife cardiovascular fitness and dementia: a 44-year longitudinal population study in women. Neurology 90, e1298&#x2013;e1305 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5894933</ArticleId><ArticleId IdType="pubmed">29540588</ArticleId></ArticleIdList></Reference><Reference><Citation>da Costa Daniele TM et al. Exercise effects on brain and behavior in healthy mice, Alzheimer&#x2019;s disease and Parkinson&#x2019;s disease model&#x2014;a systematic review and meta-analysis. Behav. Brain Res 383, 112488 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31991178</ArticleId></ArticleIdList></Reference><Reference><Citation>Trejo JL, Carro E &amp; Torres-Aleman I Circulating insulin-like growth factor I mediates exercise-induced increases in the number of new neurons in the adult hippocampus. J. Neurosci 21, 1628&#x2013;1634 (2001).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762955</ArticleId><ArticleId IdType="pubmed">11222653</ArticleId></ArticleIdList></Reference><Reference><Citation>Fabel K et al. VEGF is necessary for exercise-induced adult hippocampal neurogenesis. Eur. J. Neurosci 18, 2803&#x2013;2812 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">14656329</ArticleId></ArticleIdList></Reference><Reference><Citation>Leiter O et al. Exercise-induced activated platelets increase adult hippocampal precursor proliferation and promote neuronal differentiation. Stem Cell Rep 12, 667&#x2013;679 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6450435</ArticleId><ArticleId IdType="pubmed">30905740</ArticleId></ArticleIdList></Reference><Reference><Citation>Horowitz AM et al. Blood factors transfer beneficial effects of exercise on neurogenesis and cognition to the aged brain. Science 369, 167&#x2013;173 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7879650</ArticleId><ArticleId IdType="pubmed">32646997</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen MB et al. Brain endothelial cells are exquisite sensors of age-related circulatory cues. Cell Rep 30, 4418&#x2013;4432 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7292569</ArticleId><ArticleId IdType="pubmed">32234477</ArticleId></ArticleIdList></Reference><Reference><Citation>Batista CRA, Gomes GF, Candelario-Jalil E, Fiebich BL &amp; de Oliveira ACP Lipopolysaccharide-induced neuroinflammation as a bridge to understand neurodegeneration. Int. J. Mol. Sci 20, 2293 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6539529</ArticleId><ArticleId IdType="pubmed">31075861</ArticleId></ArticleIdList></Reference><Reference><Citation>Conway EM Complement-coagulation connections. Blood Coagul. Fibrinolysis 29, 243&#x2013;251 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29517503</ArticleId></ArticleIdList></Reference><Reference><Citation>Markiewski MM, Nilsson B, Ekdahl KN, Mollnes TE &amp; Lambris JD Complement and coagulation: strangers or partners in crime? Trends Immunol 28, 184&#x2013;192 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17336159</ArticleId></ArticleIdList></Reference><Reference><Citation>Hicks AL, Kent-Braun J &amp; Ditor DS Sex differences in human skeletal muscle fatigue. Exerc. Sport Sci. Rev 29, 109&#x2013;112 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11474957</ArticleId></ArticleIdList></Reference><Reference><Citation>Yip KS, Suvorov A, Connerney J, Lodato NJ &amp; Waxman DJ Changes in mouse uterine transcriptome in estrus and proestrus. Biol. Reprod 89, 13 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4076348</ArticleId><ArticleId IdType="pubmed">23740946</ArticleId></ArticleIdList></Reference><Reference><Citation>Harold D et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer&#x2019;s disease. Nat. Genet 41, 1088&#x2013;1093 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2845877</ArticleId><ArticleId IdType="pubmed">19734902</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer&#x2019;s disease. Nat. Genet 41, 1094&#x2013;1099 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19734903</ArticleId></ArticleIdList></Reference><Reference><Citation>Pereira RM et al. Protective molecular mechanisms of clusterin against apoptosis in cardiomyocytes. Heart Fail. Rev 23, 123&#x2013;129 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">28948410</ArticleId></ArticleIdList></Reference><Reference><Citation>Thangaraj SS et al. Contact activation-induced complex formation between complement factor H and coagulation factor XIIa. J. Thromb. Haemost 18, 876&#x2013;884 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31984663</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunt LC, Upadhyay A, Jazayeri JA, Tudor EM &amp; White JD An anti-inflammatory role for leukemia inhibitory factor receptor signaling in regenerating skeletal muscle. Histochem. Cell Biol 139, 13&#x2013;34 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">22926285</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamagishi S et al. Pigment epithelium-derived factor inhibits TNF-alpha-induced interleukin-6 expression in endothelial cells by suppressing NADPH oxidase-mediated reactive oxygen species generation. J. Mol. Cell. Cardiol 37, 497&#x2013;506 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15276019</ArticleId></ArticleIdList></Reference><Reference><Citation>Pohlkamp T, Wasser CR &amp; Herz J Functional roles of the interaction of APP and lipoprotein receptors. Front. Mol. Neurosci 10, 54 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5331069</ArticleId><ArticleId IdType="pubmed">28298885</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang AC et al. Physiological blood-brain transport is impaired with age by a shift in transcytosis. Nature 583, 425&#x2013;430 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8331074</ArticleId><ArticleId IdType="pubmed">32612231</ArticleId></ArticleIdList></Reference><Reference><Citation>Middeldorp J et al. Preclinical assessment of young blood plasma for Alzheimer disease. JAMA Neurol 73, 1325&#x2013;1333 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5172595</ArticleId><ArticleId IdType="pubmed">27598869</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Z, Xu MJ &amp; Gao B Hepatocytes: a key cell type for innate immunity. Cell. Mol. Immunol 13, 301&#x2013;315 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4856808</ArticleId><ArticleId IdType="pubmed">26685902</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin C et al. ApoE attenuates unresolvable inflammation by complex formation with activated C1q. Nat. Med 25, 496&#x2013;506 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6420126</ArticleId><ArticleId IdType="pubmed">30692699</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong S et al. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science 352, 712&#x2013;716 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5094372</ArticleId><ArticleId IdType="pubmed">27033548</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirszbaum L, Bozas SE &amp; Walker ID SP-40,40, a protein involved in the control of the complement pathway, possesses a unique array of disulphide bridges. FEBS Lett 297, 70&#x2013;76 (1992).</Citation><ArticleIdList><ArticleId IdType="pubmed">1551440</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu JL et al. Plasma biomarkers are associated with agitation and regional brain atrophy in Alzheimer&#x2019;s disease. Sci. Rep 7, 5035 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5506051</ArticleId><ArticleId IdType="pubmed">28698646</ArticleId></ArticleIdList></Reference><Reference><Citation>Yousef H et al. Aged blood impairs hippocampal neural precursor activity and activates microglia via brain endothelial cell VCAM1. Nat. Med 25, 988&#x2013;1000 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6642642</ArticleId><ArticleId IdType="pubmed">31086348</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JW et al. Neuro-inflammation induced by lipopolysaccharide causes cognitive impairment through enhancement of beta-amyloid generation. J. Neuroinflammation 5, 37 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2556656</ArticleId><ArticleId IdType="pubmed">18759972</ArticleId></ArticleIdList></Reference><Reference><Citation>Monje ML, Toda H &amp; Palmer TD Inflammatory blockade restores adult hippocampal neurogenesis. Science 302, 1760&#x2013;1765 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">14615545</ArticleId></ArticleIdList></Reference><Reference><Citation>Rockenstein E, Mallory M, Mante M, Sisk A &amp; Masliaha E Early formation of mature amyloid-&#x3b2; protein deposits in a mutant APP transgenic model depends on levels of A&#x3b2;1&#x2013;42. J. Neurosci. Res 66, 573&#x2013;582 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11746377</ArticleId></ArticleIdList></Reference><Reference><Citation>Villeda SA et al. The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature 477, 90&#x2013;94 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3170097</ArticleId><ArticleId IdType="pubmed">21886162</ArticleId></ArticleIdList></Reference><Reference><Citation>Liddelow SA et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature 541, 481&#x2013;487 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5404890</ArticleId><ArticleId IdType="pubmed">28099414</ArticleId></ArticleIdList></Reference><Reference><Citation>Love MI, Huber W &amp; Anders S Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15, 550 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4302049</ArticleId><ArticleId IdType="pubmed">25516281</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabula Muris C et al. Single-cell transcriptomics of 20 mouse organs creates a Tabula Muris. Nature 562, 367&#x2013;372 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6642641</ArticleId><ArticleId IdType="pubmed">30283141</ArticleId></ArticleIdList></Reference><Reference><Citation>Hahn O et al. A nutritional memory effect counteracts benefits of dietary restriction in old mice. Nat. Metab 1, 1059&#x2013;1073 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6861129</ArticleId><ArticleId IdType="pubmed">31742247</ArticleId></ArticleIdList></Reference><Reference><Citation>Brake MA et al. Assessing blood clotting and coagulation factors in mice. Curr. Protoc. Mouse Biol 9, e61 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6771260</ArticleId><ArticleId IdType="pubmed">30875463</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng Z et al. An ATF6-tPA pathway in hepatocytes contributes to systemic fibrinolysis and is repressed by DACH1. Blood 133, 743&#x2013;753 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6376283</ArticleId><ArticleId IdType="pubmed">30504459</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith AA, Jacobson LJ, Miller BI, Hathaway WE &amp; Manco-Johnson MJ A new euglobulin clot lysis assay for global fibrinolysis. Thromb. Res 112, 329&#x2013;337 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">15041279</ArticleId></ArticleIdList></Reference><Reference><Citation>Yousef H, Czupalla CJ, Lee D, Butcher EC &amp; Wyss-Coray T Papain-based single cell isolation of primary murine brain endothelial cells using flow cytometry. Bio Protoc 8, e3091 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6482965</ArticleId><ArticleId IdType="pubmed">31032379</ArticleId></ArticleIdList></Reference><Reference><Citation>Han Y, Li M, Qiu F, Zhang M &amp; Zhang YH Cell-permeable organic fluorescent probes for live-cell long-term super-resolution imaging reveal lysosome-mitochondrion interactions. Nat. Commun 8, 1307 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5670236</ArticleId><ArticleId IdType="pubmed">29101340</ArticleId></ArticleIdList></Reference><Reference><Citation>Dempsey GT, Vaughan JC, Chen KH, Bates M &amp; Zhuang X Evaluation of fluorophores for optimal performance in localization-based super-resolution imaging. Nat. Methods 8, 1027&#x2013;1036 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3272503</ArticleId><ArticleId IdType="pubmed">22056676</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes CS et al. Ultrasensitive proteome analysis using paramagnetic bead technology. Mol. Syst. Biol 10, 757 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4299378</ArticleId><ArticleId IdType="pubmed">25358341</ArticleId></ArticleIdList></Reference><Reference><Citation>Rappsilber J, Ishihama Y &amp; Mann M Stop and go extraction tips for matrix-assisted laser desorption/ionization, nanoelectrospray, and LC/MS sample pretreatment in proteomics. Anal. Chem 75, 663&#x2013;670 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12585499</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahnenfuhrer A, A. topGO: enrichment analysis for Gene Ontology. R package version 2.18.0 10.18129/B9.bioc.topGO (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.18129/B9.bioc.topGO</ArticleId></ArticleIdList></Reference><Reference><Citation>Supek F, Bosnjak M, Skunca N &amp; Smuc T REVIGO summarizes and visualizes long lists of Gene Ontology terms. PLoS ONE 6, e21800 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3138752</ArticleId><ArticleId IdType="pubmed">21789182</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert MS et al. The diagnosis of mild cognitive impairment due to Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement 7, 270&#x2013;279 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312027</ArticleId><ArticleId IdType="pubmed">21514249</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold L et al. Aptamer-based multiplexed proteomic technology for biomarker discovery. PLoS ONE 5, e15004 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3000457</ArticleId><ArticleId IdType="pubmed">21165148</ArticleId></ArticleIdList></Reference><Reference><Citation>SOMAscan Technical White Paper (Somalogic, 2015); http://www.somalogic.com/wp-content/uploads/2016/08/SSM-002-Rev-3-SOMAscan-Technical-White-Paper.pdf</Citation></Reference><Reference><Citation>Perez-Riverol Y et al. The PRIDE database and related tools and resources in 2019: improving support for quantification data. Nucleic Acids Res 47, D442&#x2013;D450 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6323896</ArticleId><ArticleId IdType="pubmed">30395289</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaum N, et al. Ageing hallmarks exhibit organ-specific temporal signatures. Nature 583, 596&#x2013;602 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7757734</ArticleId><ArticleId IdType="pubmed">32669715</ArticleId></ArticleIdList></Reference><Reference><Citation>Bostrom P et al. A PGC1-&#x3b1;-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 481, 463&#x2013;468 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3522098</ArticleId><ArticleId IdType="pubmed">22237023</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho HC et al. The concentrations of serum, plasma and platelet BDNF are all increased by treadmill VO2max performance in healthy college men. Neurosci. Lett 519, 78&#x2013;83 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22617010</ArticleId></ArticleIdList></Reference><Reference><Citation>Colt EW, Wardlaw SL &amp; Frantz AG The effect of running on plasma &#x3b2;-endorphin. Life Sci 28, 1637&#x2013;1640 (1981).</Citation><ArticleIdList><ArticleId IdType="pubmed">7242250</ArticleId></ArticleIdList></Reference><Reference><Citation>El Hayek L et al. Lactate mediates the effects of exercise on learning and memory through sirt1-dependent activation of hippocampal brain-derived neurotrophic factor (BDNF). J. Neurosci 39, 2369&#x2013;2382 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6435829</ArticleId><ArticleId IdType="pubmed">30692222</ArticleId></ArticleIdList></Reference><Reference><Citation>Eliakim A et al. Physical fitness, endurance training, and the growth hormone-insulin-like growth factor I system in adolescent females. J. Clin. Endocrinol. Metab 81, 3986&#x2013;3992 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8923848</ArticleId></ArticleIdList></Reference><Reference><Citation>Eliakim A, Brasel JA, Mohan S, Wong WL &amp; Cooper DM Increased physical activity and the growth hormone-IGF-I axis in adolescent males. Am. J. Physiol 275, R308&#x2013;R314 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9688993</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira JC et al. Maximal lactate steady state in running mice: effect of exercise training. Clin. Exp. Pharmacol. Physiol 34, 760&#x2013;765 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17600553</ArticleId></ArticleIdList></Reference><Reference><Citation>Koehl M et al. Exercise-induced promotion of hippocampal cell proliferation requires &#x3b2;-endorphin. FASEB J 22, 2253&#x2013;2262 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18263701</ArticleId></ArticleIdList></Reference><Reference><Citation>Koziris LP et al. Serum levels of total and free IGF-I and IGFBP-3 are increased and maintained in long-term training. J. Appl. Physiol 86, 1436&#x2013;1442 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10194233</ArticleId></ArticleIdList></Reference><Reference><Citation>Moon HY et al. Running-induced systemic cathepsin B secretion is associated with memory function. Cell Metab 24, 332&#x2013;340 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6029441</ArticleId><ArticleId IdType="pubmed">27345423</ArticleId></ArticleIdList></Reference><Reference><Citation>Schabitz WR et al. Intravenous brain-derived neurotrophic factor reduces infarct size and counterregulates Bax and Bcl-2 expression after temporary focal cerebral ischemia. Stroke 31, 2212&#x2013;2217 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10978054</ArticleId></ArticleIdList></Reference><Reference><Citation>Wrann CD et al. Exercise induces hippocampal BDNF through a PGC-1&#x3b1;/FNDC5 pathway. Cell Metab 18, 649&#x2013;659 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3980968</ArticleId><ArticleId IdType="pubmed">24120943</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">35025654</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>28</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>375</Volume><Issue>6577</Issue><PubDate><Year>2022</Year><Month>Jan</Month><Day>14</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>Cryo-EM structures of amyloid-&#x3b2; 42 filaments from human brains.</ArticleTitle><Pagination><StartPage>167</StartPage><EndPage>172</EndPage><MedlinePgn>167-172</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/science.abm7285</ELocationID><Abstract><AbstractText>Filament assembly of amyloid-&#x3b2; peptides ending at residue 42 (A&#x3b2;42) is a central event in Alzheimer&#x2019;s disease. Here, we report the cryo&#x2013;electron microscopy (cryo-EM) structures of A&#x3b2;42 filaments from human brains. Two structurally related S-shaped protofilament folds give rise to two types of filaments. Type I filaments were found mostly in the brains of individuals with sporadic Alzheimer&#x2019;s disease, and type II filaments were found in individuals with familial Alzheimer&#x2019;s disease and other conditions. The structures of A&#x3b2;42 filaments from the brain differ from those of filaments assembled in vitro. By contrast, in <i>App</i><sup>NL-F</sup> knock-in mice, A&#x3b2;42 deposits were made of type II filaments. Knowledge of A&#x3b2;42 filament structures from human brains may lead to the development of inhibitors of assembly and improved imaging agents.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Yang</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0003-2238-6437</Identifier><AffiliationInfo><Affiliation>Medical Research Council Laboratory of Molecular Biology, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Arseni</LastName><ForeName>Diana</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-7585-288X</Identifier><AffiliationInfo><Affiliation>Medical Research Council Laboratory of Molecular Biology, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Zhang</LastName><ForeName>Wenjuan</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0002-3011-9956</Identifier><AffiliationInfo><Affiliation>Medical Research Council Laboratory of Molecular Biology, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Melissa</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-0698-6996</Identifier><AffiliationInfo><Affiliation>Medical Research Council Laboratory of Molecular Biology, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xf6;vestam</LastName><ForeName>Sofia</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-2152-1476</Identifier><AffiliationInfo><Affiliation>Medical Research Council Laboratory of Molecular Biology, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schweighauser</LastName><ForeName>Manuel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Medical Research Council Laboratory of Molecular Biology, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kotecha</LastName><ForeName>Abhay</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-4480-5439</Identifier><AffiliationInfo><Affiliation>Thermo Fisher Scientific, Eindhoven, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murzin</LastName><ForeName>Alexey G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>Medical Research Council Laboratory of Molecular Biology, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peak-Chew</LastName><ForeName>Sew Y</ForeName><Initials>SY</Initials><AffiliationInfo><Affiliation>Medical Research Council Laboratory of Molecular Biology, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Macdonald</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-8401-8897</Identifier><AffiliationInfo><Affiliation>Medical Research Council Laboratory of Molecular Biology, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lavenir</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0001-8616-891X</Identifier><AffiliationInfo><Affiliation>Medical Research Council Laboratory of Molecular Biology, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garringer</LastName><ForeName>Holly J</ForeName><Initials>HJ</Initials><Identifier Source="ORCID">0000-0002-1899-7676</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Indiana University, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gelpi</LastName><ForeName>Ellen</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-2948-4187</Identifier><AffiliationInfo><Affiliation>Institute of Neurology, Medical University, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Newell</LastName><ForeName>Kathy L</ForeName><Initials>KL</Initials><Identifier Source="ORCID">0000-0002-1648-7357</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Indiana University, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kovacs</LastName><ForeName>Gabor G</ForeName><Initials>GG</Initials><Identifier Source="ORCID">0000-0003-3841-5511</Identifier><AffiliationInfo><Affiliation>Institute of Neurology, Medical University, Vienna, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tanz Centre and Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vidal</LastName><ForeName>Ruben</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-5803-3871</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Indiana University, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghetti</LastName><ForeName>Bernardino</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-1842-8019</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Indiana University, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryskeldi-Falcon</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-8176-2618</Identifier><AffiliationInfo><Affiliation>Medical Research Council Laboratory of Molecular Biology, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scheres</LastName><ForeName>Sjors H W</ForeName><Initials>SHW</Initials><Identifier Source="ORCID">0000-0002-0462-6540</Identifier><AffiliationInfo><Affiliation>Medical Research Council Laboratory of Molecular Biology, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goedert</LastName><ForeName>Michel</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-5214-7886</Identifier><AffiliationInfo><Affiliation>Medical Research Council Laboratory of Molecular Biology, Cambridge, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MC_U105192716</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_UP_1201/25</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_U105184291</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P30 AG010133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG071177</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MC_U105184326</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>U01 NS110437</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MC_UP_A025_1013</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Science. 2022 Jan 14;375(6577):147-148. doi: 10.1126/science.abn5428.</RefSource><PMID Version="1">35025652</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000648" MajorTopicYN="Y">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001923" MajorTopicYN="Y">Brain Chemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020285" MajorTopicYN="N">Cryoelectron Microscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055879" MajorTopicYN="N">Gene Knock-In Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D023421" MajorTopicYN="N">Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000648" MajorTopicYN="Y">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011487" MajorTopicYN="N">Protein Conformation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072757" MajorTopicYN="N">Protein Conformation, beta-Strand</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072417" MajorTopicYN="N">Protein Domains</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017510" MajorTopicYN="N">Protein Folding</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>
<b>Competing interests:</b> The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>1</Month><Day>13</Day><Hour>17</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>7</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35025654</ArticleId><ArticleId IdType="mid">EMS140501</ArticleId><ArticleId IdType="pmc">PMC7612234</ArticleId><ArticleId IdType="doi">10.1126/science.abm7285</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Long JM, Holtzman DM. Alzheimer&#x2019;s disease: An update on pathobiology and treatment strategies. Cell. 2019;179:312&#x2013;339.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6778042</ArticleId><ArticleId IdType="pubmed">31564456</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy JA, Higgins GA. Alzheimer&#x2019;s disease: The amyloid cascade hypothesis. Science. 1992;256:184&#x2013;185.</Citation><ArticleIdList><ArticleId IdType="pubmed">1566067</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Kaether C, Thinakran G, Sisodia S. Trafficking and proteolytic processing ofAPP . Cold Spring Harb Perspect Med. 2012;2:a006270.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3331683</ArticleId><ArticleId IdType="pubmed">22553493</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki N, Cheung TT, Cai XD, Odaka A, Otvos L, Eckman C, Golde TE, Younkin SG. An increased percentage of long amyloid beta secreted by familial amyloid beta protein precursor (beta APP 717) mutants. Science. 1994;264:1336&#x2013;1340.</Citation><ArticleIdList><ArticleId IdType="pubmed">8191290</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, Bird TD, Hardy J, Hutton M, Kukull W, Larson E, et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer&#x2019;s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer&#x2019;s disease. Nature Med. 1996;2:864&#x2013;870.</Citation><ArticleIdList><ArticleId IdType="pubmed">8705854</ArticleId></ArticleIdList></Reference><Reference><Citation>Citron M, Vigo-Pelfrey C, Teplow DB, Miller C, Schenk D, Johnston J, Winblad B, Venizelos N, Lannfelt L, Selkoe DJ. Excessive production of amyloid-beta protein by peripheral cells of symptomatic and presymptomatic patients carrying the Swedish familial Alzheimer disease mutation. Proc Natl Acad Sci USA. 1994;91:11993&#x2013;11997.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC45362</ArticleId><ArticleId IdType="pubmed">7991571</ArticleId></ArticleIdList></Reference><Reference><Citation>de la Vega M Pagnon, Giedraitis V, Michno W, Kilander L, G&#xfc;ner G, Zielinski M, L&#xf6;wenmark M, Brundin R, Danfors T, S&#xf6;derberg L, Alazuloff I, et al. The Uppsala APP deletion causes early onset autosomal dominant Alzheimer&#x2019;s disease by altering APP processing and increasing amyloid &#x3b2; fibril formation. Sci Transl Med. 2021;13:eabc6184.</Citation><ArticleIdList><ArticleId IdType="pubmed">34380771</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y. Visualization of Abeta42(43) and Abeta40 in senile plaques with end-specific Abeta monoclonals: Evidence that an initially deposited species is Abeta42(43) Neuron. 1994;13:45&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">8043280</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xfc;ntert A, D&#xf6;beli H, Bohrmann B. High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain. Neuroscience. 2006;143:461&#x2013;475.</Citation><ArticleIdList><ArticleId IdType="pubmed">17008022</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR, Walter J, Saido TC, F&#xe4;ndrich M. Neuropathology and biochemistry of A&#x3b2; and its aggregates in Alzheimer&#x2019;s disease. Acta Neuropathol. 2015;129:167&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pubmed">25534025</ArticleId></ArticleIdList></Reference><Reference><Citation>Attems J, Jellinger KA, Lintner F. Alzheimer&#x2019;s disease pathology influences severity and topographical distribution of cerebral amyloid angiopathy. Acta Neuropathol. 2005;110:222&#x2013;231.</Citation><ArticleIdList><ArticleId IdType="pubmed">16133541</ArticleId></ArticleIdList></Reference><Reference><Citation>Kollmer M, Close W, Funk L, Rasmussen J, Bsoul A, Schierhorn A, Schmidt M, Sigurdson CJ, Jucker M, F&#xe4;ndrich M. Cryo-EM structure and polymorphism of A&#x3b2; amyloid fibrils purified from Alzheimer&#x2019;s brain tissue. Nature Commun. 2019;10:4760.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6820800</ArticleId><ArticleId IdType="pubmed">31664019</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarrett JT, Berger EP, Lansbury PT. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: Implications for the pathogenesis of Alzheimer&#x2019;s disease. Biochemistry. 1993;32:4693&#x2013;4697.</Citation><ArticleIdList><ArticleId IdType="pubmed">8490014</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR, R&#xfc;b U, Orantes M, Braak H. Phases of Abeta deposition in the human brain and its relevance for the development of Alzheimer&#x2019;s disease. Neurology. 2002;58:1791&#x2013;1800.</Citation><ArticleIdList><ArticleId IdType="pubmed">12084879</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Luehmann M, Coomaraswamy J, Bolmont T, Kaeser S, Schaefer C, Kilger E, Neuenschwander A, Abramowski D, Frey P, Jaton AL, Vigouret JM, et al. Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science. 2006;313:1781&#x2013;1784.</Citation><ArticleIdList><ArticleId IdType="pubmed">16990547</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau HHC, Ingelsson M, Watts JC. The existence of A&#x3b2; strains and their potential for driving phenotypic heterogeneity in Alzheimer&#x2019;s disease. Acta Neuropathol. 2021;142:17&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">32743745</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaunmuktane Z, Mead S, Ellis M, Wadsworth JDF, Nicoll AJ, Kenny J, Launchbury F, Linehan J, Richard-Loendt A, Walker AS, Rudge P, et al. Evidence for human transmission of amyloid-&#x3b2; pathology and cerebral amyloid angiopathy. Nature. 2015;525:247&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="pubmed">26354483</ArticleId></ArticleIdList></Reference><Reference><Citation>Frontzek K, Lutz MI, Aguzzi A, Kovacs GG, Budka H. Amyloid-&#x3b2; pathology and cerebral amyloid angiopathy are frequent in iatrogenic Creutzfeldt-Jakob disease after dural grafting. Swiss Med Weekly. 2016;146:w14287</Citation><ArticleIdList><ArticleId IdType="pubmed">26812492</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaunmuktane Z, Quaegebeur A, Taipa R, Viana-Baptista M, Barbosa R, Koriath C, Sciot R, Mead S, Brandner S. Evidence of amyloid-&#x3b2; cerebral angiopathy transmission through neurosurgery. Acta Neuropathol. 2018;135:671&#x2013;679.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5904220</ArticleId><ArticleId IdType="pubmed">29450646</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarutani A, Arai T, Murayama S, Hisanaga SI, Hasegawa M. Potent prion-like behaviors of pathogenic a-synuclein and evaluation of inacrtivation methods. Acta Neuropathol Commun. 2018;18:29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5907316</ArticleId><ArticleId IdType="pubmed">29669601</ArticleId></ArticleIdList></Reference><Reference><Citation>Schweighauser M, Shi Y, Tarutani A, Kametani F, Murzin AG, Ghetti B, Matsubara T, Tomita T, Ando T, Hasegawa K, Murayama S, et al. Structures of &#x3b1;-synuclein filaments from multiple system atrophy. Nature. 2020;585:464&#x2013;469.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7116528</ArticleId><ArticleId IdType="pubmed">32461689</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzpatrick AWP, Falcon B, He S, Murzin AG, Murshudov G, Garringer HJ, Crowther RA, Ghetti B, Goedert M, Scheres SHW. Cryo-EM structures of tau filaments from Alzheimer&#x2019;s disease. Nature. 2017;547:185&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5552202</ArticleId><ArticleId IdType="pubmed">28678775</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcon B, Zhang W, Schweighauser M, Murzin AG, Vidal R, Garringer HJ, Ghetti B, Scheres SHW, Goedert M. Tau filaments from multiple cases of sporadic and inherited Alzheimer&#x2019;s disease adopt a common fold. Acta Neuropathol. 2018;146:699&#x2013;708.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6208733</ArticleId><ArticleId IdType="pubmed">30276465</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenberg SG, Davies P. A preparation of Alzheimer paired helical filaments that displays distinct tau proteins by polyacrylamide gel electrophoresis. Proc Natl Acad Sci USA. 1990;87:5827&#x2013;5831.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC54421</ArticleId><ArticleId IdType="pubmed">2116006</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawaya MR, Hughes MP, Rodriguez JA, Riek R, Eisenberg DS. The expanding amyloid family: Structure, stability, function, and pathogenesis. Cell. 2021;184:4857&#x2013;4873.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8772536</ArticleId><ArticleId IdType="pubmed">34534463</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh U, Thurber KR, Yau W-Y, Tycko R. Molecular structure of a prevalent amyloid-&#x3b2; fibril polymorph from Alzheimer&#x2019;s disease brain tissue. Proc Natl Acad Sci USA. 2021;118:e2023089118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7848700</ArticleId><ArticleId IdType="pubmed">33431654</ArticleId></ArticleIdList></Reference><Reference><Citation>Gremer L, Sch&#xf6;lzel D, Schenk C, Reinartz E, Labahn J, Ravelli RBG, Tusche M, Lopez-Iglesias C, Hoyer W, Heise H, Willbold D, et al. Fibril structure of amyloid-&#x3b2;(1-42) by cryo-electron microscopy. Science. 2017;358:116&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6080689</ArticleId><ArticleId IdType="pubmed">28882996</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao Y, Ma B, McElheny D, Parthasarathy S, Long F, Hoshi M, Nussinov R, Ishii Y. A&#x3b2;(1-42) fibril structure illuminates self-recognition and replication of amyloid in Alzheimer&#x2019;s disease. Nature Struct Mol Biol. 2015;22:499&#x2013;505.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4476499</ArticleId><ArticleId IdType="pubmed">25938662</ArticleId></ArticleIdList></Reference><Reference><Citation>Colvin MT, Silvers Rl, Ni QZ, Can TV, Sergeyev I, Rosay M, Donovan KJ, Michael B, Wall J, Linse S, Griffin RC. Atomic resolution structure of monomorphic A&#x3b2;42 amyloid fibrils. J Am Chem Soc. 2016;138:9663&#x2013;9674.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5389415</ArticleId><ArticleId IdType="pubmed">27355699</ArticleId></ArticleIdList></Reference><Reference><Citation>W&#xe4;lti MA, Ravotti F, Arai H, Glabe CG, Wall JS, B&#xf6;ckmann A, G&#xfc;ntert P, Meier BH, Riek R. Atomic resolution structure of a disease-relevant A&#x3b2;(1-42) amyloid fibril. Proc Natl Acad Sci USA. 2016;113:E4976&#x2013;E4984.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5003276</ArticleId><ArticleId IdType="pubmed">27469165</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xfc;tz AK, Vagt T, Huber M, Ovchinnikova OY, Cadalbert R, Wall J, G&#xfc;ntert P, B&#xf6;ckmann A, Glockshuber R, Meier BH. Atomic-resolution three-dimensional structure of amyloid &#x3b2; fibrils bearing the Osaka mutation. Angew Chem Int Ed. 2015;54:331&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4502972</ArticleId><ArticleId IdType="pubmed">25395337</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar R, Kuhn PH, Haass C, Kennedy ME, Rajendran L, Wong PC, Lichtenthaler SF. Function, therapeutic potential and cell biology of BACE proteases: Current status and future prospects. J Neurochem. 2014;130:4&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4086641</ArticleId><ArticleId IdType="pubmed">24646365</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W, Falcon B, Murzin AG, Fan J, Crowther RA, Goedert M, Scheres SHW. Heparin-induced tau filaments are polymorphic and differ from those of Alzheimer&#x2019;s and Pick&#x2019;s diseases. eLife. 2019;8:e43584.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6375701</ArticleId><ArticleId IdType="pubmed">30720432</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf6;vestam S, Schweighauser M, Matsubara T, Murayama S, Tomita T, Ando T, Hasegawa K, Yoshida M, Tarutani A, Hasegawa M, Goedert M, et al. Seeded assembly in vitro does not replicate the structures of &#x3b1;-synuclein filaments from multiple system atrophy. FEBS Open Bio. 2021;11:999&#x2013;1013.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8016116</ArticleId><ArticleId IdType="pubmed">33548114</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito T, Matsuba Y, Mihira N, Takano J, Nilsson P, Itohara S, Iwata N, Saido TC. Single APP knock-in mouse models of Alzheimer&#x2019;s disease. Nature Neurosci. 2014;17:661&#x2013;663.</Citation><ArticleIdList><ArticleId IdType="pubmed">24728269</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, Zhang W, Yang Y, Murzin AG, Falcon B, Kotecha A, van Beers M, Tarutani A, Kametani F, Garringer HJ, Vidal R, et al. Structure-based classification of tauopathies. Nature. 2021;598:359&#x2013;363.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7611841</ArticleId><ArticleId IdType="pubmed">34588692</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen CD, Joseph-Mathurin N, Sinha N, Zhou A, Li Y, Friedrichsen K, McCullough A, Franklin EE, Hornbeck R, Gordon B, Sharma V, et al. Comparing amyloid-&#x3b2; plaque burden with antemortem PiB PET in autosomal dominant and late-onset Alzheimer&#x2019;s disease. Acta Neuropathol. 2021;142:689&#x2013;708.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8815340</ArticleId><ArticleId IdType="pubmed">34319442</ArticleId></ArticleIdList></Reference><Reference><Citation>Lichtenthaler SF, Beher D, Grimm HS, Wang R, Shearman MS, Masters CL, Beyreuther K. The intramembrane cleavage site of the amyloid precursor protein depends on the length of its transmembrane domain. Proc Natl Acad Sci USA. 2002;99:1365&#x2013;1370.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC122196</ArticleId><ArticleId IdType="pubmed">11805291</ArticleId></ArticleIdList></Reference><Reference><Citation>Guardia-Laguarta C, Pera M, Clarim&#xf3;n J, Molinuevo JL, S&#xe1;nchez-Valle R, Llad&#xf3; A, Coma M, G&#xf3;mez-Isla T, Blesa R, Ferrer I, Lle&#xf3; A. Clinical, neuropathologic, and biochemical profile of the amyloid precursor protein I716F mutation. J Neuropathol Exp Neurol. 2010;69:553&#x2013;59. doi: 10.1097/NEN.0b013e3181c6b84.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e3181c6b84</ArticleId><ArticleId IdType="pubmed">20010303</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasmussen J, Mahler J, Beschorner N, Kaeser SA, H&#xe4;sler LM, Baumann F, Nystr&#xf6;m S, Portelius E, Blennow K, Lashley T, Fox NC, et al. Amyloid polymorphisms constitute distinct clouds of conformational variants in different etiological subtypes of Alzheimer&#x2019;s disease. Proc Natl Acad Sci USA. 2017;114:13018&#x2013;13023.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5724274</ArticleId><ArticleId IdType="pubmed">29158413</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu JX, Qiang W, Yau WM, Schwieters CD, Meredith SC, Tycko R. Molecular structure of &#x3b2;-amyloid fibrils in Alzheimer&#x2019;s disease brain tissue. Cell. 2013;154:1257&#x2013;1268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3814033</ArticleId><ArticleId IdType="pubmed">24034249</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray ME, Dickson DW. Is pathological aging a successful resistance against amyloid-beta or preclinical Alzheimer&#x2019;s disease? Alzheimer&#x2019;s Res Ther. 2014;6:24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4055017</ArticleId><ArticleId IdType="pubmed">25031637</ArticleId></ArticleIdList></Reference><Reference><Citation>Murrell JR, Farlow M, Ghetti B, Benson MD. A mutation in the amyloid precursor protein associated with hereditary Alzheimer&#x2019;s disease. Science. 1991;254:97&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">1925564</ArticleId></ArticleIdList></Reference><Reference><Citation>Maarouf CL, Daugs ID, Spina S, Vidal R, Kokjohn TA, Patton RL, Kalback WM, Luehrs DC, Walker DG, Casta&#xf1;o EM, Beach TG, et al. Histopathological and molecular heterogeneity among individuals with dementia associated with presenilin mutations. Mol Neurodeg. 2008;3:20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2600784</ArticleId><ArticleId IdType="pubmed">19021905</ArticleId></ArticleIdList></Reference><Reference><Citation>Klotz S, Fischer P, Hinterberger M, Ricken G, H&#xf6;nigschnabl S, Gelpi E, Kovacs GG. Multiple system aging-related tau astrogliopathy with complex proteinopathy in an oligosymptomatic octogenarian. Neuropathology. 2021;41:72&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7984345</ArticleId><ArticleId IdType="pubmed">33263220</ArticleId></ArticleIdList></Reference><Reference><Citation>Spina S, Farlow MR, Unverzagt FW, Kareken DA, Murrell JR, Fraser G, Epperson F, Crowther RA, Spillantini MG, Goedert M, Ghetti B. The tauopathy associated with mutation +3 in intron 10 of Tau: Characterization of the MSTD family. Brain. 2008;131:72&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2702832</ArticleId><ArticleId IdType="pubmed">18065436</ArticleId></ArticleIdList></Reference><Reference><Citation>N&#xe4;slund J, Schierhorn A, Hellman U, L Lannfelt, Roses AD, Tjernberg LO, Silberring J, Gandy SE, Winblad B, Greengard P, Norstedt C, et al. Relative abundance of Alzheimer A&#x3b2; amyloid peptide variants in Alzheimer disease and normal aging. Proc Natl Acad Sci USA. 1994;91:8378&#x2013;8382.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC44609</ArticleId><ArticleId IdType="pubmed">8078890</ArticleId></ArticleIdList></Reference><Reference><Citation>Kakuda N, Miyasaka T, Iwasaki N, Nirasawa T, Wada-Kakuda S, Takahashi-Fujigasaki J, Murayama S, Ihara Y, Ikegawa M. Distinct deposition of amyloid-&#x3b2; species in brains with Alzheimer&#x2019;s disease pathology visualized with MALDI imaging mass spectrometry. Acta Neuropathol Commun. 2017;5:73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5641992</ArticleId><ArticleId IdType="pubmed">29037261</ArticleId></ArticleIdList></Reference><Reference><Citation>Farlow JL, Robak LA, Hetrick K, Bowling K, Boerwinkle E, Coban-Akdemir ZH, Gambin T, Gibbs RA, Gu S, Jain P, Jankovic J, et al. Whole-exome sequencing in familial Parkinson disease. JAMA Neurol. 2016;73:68&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4946647</ArticleId><ArticleId IdType="pubmed">26595808</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Spillantini MG, Cairns NJ, Crowther RA. Tau proteins of Alzheimer paired helical filaments: Abnormal phosphorylation of all six brain isoforms. Neuron. 1992;8:159&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pubmed">1530909</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng SQ, Palovcak E, Armache JP, Verba KA, Cheng Y, Agard DA. MotionCor2: Anisotropic correction of beam-induced motion for improved cryoelectron microscopy. Nature Meth. 2017;14:331&#x2013;332.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5494038</ArticleId><ArticleId IdType="pubmed">28250466</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K. Gctf: Real-time CTF determination and correction. J Struct Biol. 2016;193:1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4711343</ArticleId><ArticleId IdType="pubmed">26592709</ArticleId></ArticleIdList></Reference><Reference><Citation>He S, Scheres SHW. Helical reconstruction in RELION. J Struct Biol. 2017;198:163&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5479445</ArticleId><ArticleId IdType="pubmed">28193500</ArticleId></ArticleIdList></Reference><Reference><Citation>Zivanov J, Nakane T, Forsberg BO, Kimanius D, Hagen WJ, Lindahl E, Scheres SHW. New tools for automated high-resolution cryo-EM structure determination in RELION-3. eLife. 2018;7:e42166.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6250425</ArticleId><ArticleId IdType="pubmed">30412051</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheres SHW. Amyloid structure determination in RELION-3.1. Acta Crystallogr D Struct Biol. 2020;76:94&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7008511</ArticleId><ArticleId IdType="pubmed">32038040</ArticleId></ArticleIdList></Reference><Reference><Citation>Zivanov J, Nakane T, Scheres SHW. A Bayesian approach to beam-induced motion correction in cryo-EM single-particle analysis. IUCrJ. 2019;6:5&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6327179</ArticleId><ArticleId IdType="pubmed">30713699</ArticleId></ArticleIdList></Reference><Reference><Citation>Zivanov J, Nakane T, Scheres SHW. Estimation of high-order aberrations and anisotropic magnification from cryo-EM data sets in RELION-3.1. IUCrJ. 2020;7:253&#x2013;267.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7055373</ArticleId><ArticleId IdType="pubmed">32148853</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S, McMullan G, Faruqi AR, Murshudov GN, Short JM, Scheres SHW, Henderson R. High-resolution noise substitution to measure overfitting and validate resolution in 3D structure determination by single particle electron cryomicroscopy. Ultramicroscopy. 2013;135:24&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3834153</ArticleId><ArticleId IdType="pubmed">23872039</ArticleId></ArticleIdList></Reference><Reference><Citation>Warmack RA, Boyer DR, Zee C-T, Richards LS, Sawaya MR, Cascio D, Gonen T, Eisenberg DS, Clarke SG. Structure of amyloid-&#x3b2; (20-34) with Alzheimer&#x2019;s-associated isomerization at Asp23 reveals a distinct protofilament interface. Nature Commun. 2019;10:2257.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6659688</ArticleId><ArticleId IdType="pubmed">31350392</ArticleId></ArticleIdList></Reference><Reference><Citation>Casa&#xf1;al A, Lohkamp B, Emsley P. Current developments in Coot for macromolecular model building of electron cryo-microscopy and crystallographic data. Protein Sci. 2020;29:1069&#x2013;1078.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7096722</ArticleId><ArticleId IdType="pubmed">31730249</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams CJ, Headd JJ, Moriarty NW, Prisant MG, Videau LL, Deis LN, Verma V, Keedy DA, Hintze BJ, Chen VB, Jain S, et al. MolProbity: More and better reference data for improved all-atom structure validation. Protein Sci. 2018;27:293&#x2013;315.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5734394</ArticleId><ArticleId IdType="pubmed">29067766</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown A, Long F, Nicholls RA, Toots J, Emsley P, Murshudov G. Tools for macromolecular model building and refinement into electron cryo-microscopy reconstructions. Acta Crystallogr D Biol Crystallogr. 2015;71:136&#x2013;153.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4304694</ArticleId><ArticleId IdType="pubmed">25615868</ArticleId></ArticleIdList></Reference><Reference><Citation>Afonine PV, Poon BK, Read RJ, Sobolev OV, Terwilliger TC, Urzhumtsev A, Adams PD. Real-space refinement in PHENIX for cryo-EM and crystallography. Acta Crystallogr D Struct Biol. 2018;74:531&#x2013;544.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6096492</ArticleId><ArticleId IdType="pubmed">29872004</ArticleId></ArticleIdList></Reference><Reference><Citation>Pettersen EF, Goddard TD, Huang CC, Meng EC, Couch GS, Croll TI, Morris JH, Ferrin TE. UCSF ChimeraX: Structure visualization for researchers, educators, and developers. Protein Sci. 2021;30:70&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7737788</ArticleId><ArticleId IdType="pubmed">32881101</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34878820</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>31</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>623</Issue><PubDate><Year>2021</Year><Month>Dec</Month><Day>08</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>Slow-wave sleep affects synucleinopathy and regulates proteostatic processes in mouse models of Parkinson's disease.</ArticleTitle><Pagination><StartPage>eabe7099</StartPage><MedlinePgn>eabe7099</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.abe7099</ELocationID><Abstract><AbstractText>Slow-wave sleep (SWS) modulation in rodent models of Alzheimer&#x2019;s disease alters extracellular amyloid burden. In Parkinson&#x2019;s disease (PD), SWS appears to be closely linked with disease symptoms and progression. PD is characterized by damaging intracellular &#x3b1;-synuclein (&#x3b1;Syn) deposition that propagates extracellularly, contributing to disease spread. Intracellular &#x3b1;Syn is sensitive to degradation, whereas extracellular &#x3b1;Syn may be eliminated by glymphatic clearance, a process increased during SWS. Here, we explored whether long-term slow-wave modulation in murine models of PD presenting &#x3b1;Syn aggregation alters pathological protein burden and, thus, might constitute a valuable therapeutic target. Sleep-modulating treatments showed that enhancing slow waves in both VMAT2-deficient and A53T mouse models of PD reduced pathological &#x3b1;Syn accumulation compared to control animals. Nonpharmacological sleep deprivation had the opposite effect in VMAT2-deficient mice, severely increasing the pathological burden. We also found that SWS enhancement was associated with increased recruitment of aquaporin-4 to perivascular sites, suggesting a possible increase of glymphatic function. Furthermore, mass spectrometry data revealed differential and specific up-regulation of functional protein clusters linked to proteostasis upon slow wave&#x2013;enhancing interventions. Overall, the beneficial effect of SWS enhancement on neuropathological outcome in murine synucleinopathy models mirrors findings in models of Alzheimer. Modulating SWS might constitute an effective strategy for modulating PD pathology in patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Morawska</LastName><ForeName>Marta M</ForeName><Initials>MM</Initials><Identifier Source="ORCID">0000-0003-1612-6786</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University Hospital Zurich (USZ), Frauenklinikstrasse 26, Zurich 8091, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Zurich (UZH), Neuroscience Center Zurich (ZNZ), Winterthurerstrasse 190, Zurich 8057, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moreira</LastName><ForeName>Carlos G</ForeName><Initials>CG</Initials><Identifier Source="ORCID">0000-0003-3197-3668</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University Hospital Zurich (USZ), Frauenklinikstrasse 26, Zurich 8091, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>ETH Zurich, Neuroscience Center Zurich (ZNZ), Winterthurerstrasse 190, Zurich 8057, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ginde</LastName><ForeName>Varun R</ForeName><Initials>VR</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Hospital Zurich (USZ), Frauenklinikstrasse 26, Zurich 8091, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valko</LastName><ForeName>Philipp O</ForeName><Initials>PO</Initials><Identifier Source="ORCID">0000-0002-8435-1697</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University Hospital Zurich (USZ), Frauenklinikstrasse 26, Zurich 8091, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weiss</LastName><ForeName>Tobias</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-5533-9429</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University Hospital Zurich (USZ), Frauenklinikstrasse 26, Zurich 8091, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>B&#xfc;chele</LastName><ForeName>Fabian</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Hospital Zurich (USZ), Frauenklinikstrasse 26, Zurich 8091, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Imbach</LastName><ForeName>Lukas L</ForeName><Initials>LL</Initials><Identifier Source="ORCID">0000-0002-6135-8642</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University Hospital Zurich (USZ), Frauenklinikstrasse 26, Zurich 8091, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masneuf</LastName><ForeName>Sophie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Hospital Zurich (USZ), Frauenklinikstrasse 26, Zurich 8091, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kollarik</LastName><ForeName>Sedef</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-4502-1126</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University Hospital Zurich (USZ), Frauenklinikstrasse 26, Zurich 8091, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Zurich (UZH), Neuroscience Center Zurich (ZNZ), Winterthurerstrasse 190, Zurich 8057, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prymaczok</LastName><ForeName>Natalia</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>ETH Zurich, Laboratory of Physical Chemistry, Department of Chemistry and Applied Biosciences, Vladimir-Prelog-Weg 2, Zurich 8093, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gerez</LastName><ForeName>Juan A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>ETH Zurich, Laboratory of Physical Chemistry, Department of Chemistry and Applied Biosciences, Vladimir-Prelog-Weg 2, Zurich 8093, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Riek</LastName><ForeName>Roland</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>ETH Zurich, Laboratory of Physical Chemistry, Department of Chemistry and Applied Biosciences, Vladimir-Prelog-Weg 2, Zurich 8093, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baumann</LastName><ForeName>Christian R</ForeName><Initials>CR</Initials><Identifier Source="ORCID">0000-0003-3417-1978</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University Hospital Zurich (USZ), Frauenklinikstrasse 26, Zurich 8091, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Zurich (UZH), Neuroscience Center Zurich (ZNZ), Winterthurerstrasse 190, Zurich 8057, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Competence Sleep and Health Zurich, University of Zurich, Frauenklinikstrasse 26, Zurich 8091, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Noain</LastName><ForeName>Daniela</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-5482-7933</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University Hospital Zurich (USZ), Frauenklinikstrasse 26, Zurich 8091, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Zurich (UZH), Neuroscience Center Zurich (ZNZ), Winterthurerstrasse 190, Zurich 8057, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Competence Sleep and Health Zurich, University of Zurich, Frauenklinikstrasse 26, Zurich 8091, Switzerland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>12</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="Y">Parkinson Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077310" MajorTopicYN="Y">Sleep, Slow-Wave</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000080874" MajorTopicYN="Y">Synucleinopathies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>8</Day><Hour>17</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34878820</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.abe7099</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34887588</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>06</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>AAV capsid variants with brain-wide transgene expression and decreased liver targeting after intravenous delivery in mouse and marmoset.</ArticleTitle><Pagination><StartPage>106</StartPage><EndPage>115</EndPage><MedlinePgn>106-115</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41593-021-00969-4</ELocationID><Abstract><AbstractText>Genetic intervention is increasingly being explored as a therapeutic option for debilitating disorders of the central nervous system. The safety and efficacy of gene therapies rely upon expressing a transgene in affected cells while minimizing off-target expression. Here we show organ-specific targeting of adeno-associated virus (AAV) capsids after intravenous delivery, which we achieved by employing a Cre-transgenic-based screening platform and sequential engineering of AAV-PHP.eB between the surface-exposed AA452 and AA460 of VP3. From this selection, we identified capsid variants that were enriched in the brain and targeted away from the liver in C57BL/6J mice. This tropism extends to marmoset (Callithrix jacchus), enabling robust, non-invasive gene delivery to the marmoset brain after intravenous administration. Notably, the capsids identified result in distinct transgene expression profiles within the brain, with one exhibiting high specificity to neurons. The ability to cross the blood-brain barrier with neuronal specificity in rodents and non-human primates enables new avenues for basic research and therapeutic possibilities unattainable with naturally occurring serotypes.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s), under exclusive licence to Springer Nature America, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Goertsen</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Flytzanis</LastName><ForeName>Nicholas C</ForeName><Initials>NC</Initials><AffiliationInfo><Affiliation>Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Goeden</LastName><ForeName>Nick</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chuapoco</LastName><ForeName>Miguel R</ForeName><Initials>MR</Initials><Identifier Source="ORCID">0000-0001-5397-996X</Identifier><AffiliationInfo><Affiliation>Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cummins</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yijing</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Chinese Academy of Sciences Key Laboratory of Brain Connectome and Manipulation, Shenzhen Key Laboratory of Translational Research for Brain Diseases, The Brain Cognition and Brain Disease Institute, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences; Shenzhen-Hong Kong Institute of Brain Science-Shenzhen Fundamental Research Institutions, Shenzhen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>Yingying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Chinese Academy of Sciences Key Laboratory of Brain Connectome and Manipulation, Shenzhen Key Laboratory of Translational Research for Brain Diseases, The Brain Cognition and Brain Disease Institute, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences; Shenzhen-Hong Kong Institute of Brain Science-Shenzhen Fundamental Research Institutions, Shenzhen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Qiangge</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>McGovern Institute for Brain Research, Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>Jitendra</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>McGovern Institute for Brain Research, Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Picower Institute of Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tan &amp; Yang Center for Autism Research, McGovern Institute of Brain Research, Massachusetts Institute of Technology, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duan</LastName><ForeName>Yangyang</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-0823-6574</Identifier><AffiliationInfo><Affiliation>Division of Life Science, State Key Laboratory of Molecular Neuroscience and Molecular Neuroscience Center, Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Liping</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0001-6893-3809</Identifier><AffiliationInfo><Affiliation>Chinese Academy of Sciences Key Laboratory of Brain Connectome and Manipulation, Shenzhen Key Laboratory of Translational Research for Brain Diseases, The Brain Cognition and Brain Disease Institute, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences; Shenzhen-Hong Kong Institute of Brain Science-Shenzhen Fundamental Research Institutions, Shenzhen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feng</LastName><ForeName>Guoping</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-8021-277X</Identifier><AffiliationInfo><Affiliation>McGovern Institute for Brain Research, Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Chinese Academy of Sciences Key Laboratory of Brain Connectome and Manipulation, Shenzhen Key Laboratory of Translational Research for Brain Diseases, The Brain Cognition and Brain Disease Institute, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences; Shenzhen-Hong Kong Institute of Brain Science-Shenzhen Fundamental Research Institutions, Shenzhen, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Brain Science, Disease and Drug Development, Shenzhen-Hong Kong Institute of Brain Science, HKUST Shenzhen Research Institute, Shenzhen, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ip</LastName><ForeName>Nancy Y</ForeName><Initials>NY</Initials><Identifier Source="ORCID">0000-0002-2763-8907</Identifier><AffiliationInfo><Affiliation>Division of Life Science, State Key Laboratory of Molecular Neuroscience and Molecular Neuroscience Center, Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hong Kong Center for Neurodegenerative Diseases, Hong Kong Science Park, Hong Kong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Brain Science, Disease and Drug Development, Shenzhen-Hong Kong Institute of Brain Science, HKUST Shenzhen Research Institute, Shenzhen, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pickel</LastName><ForeName>James</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-3617-3072</Identifier><AffiliationInfo><Affiliation>National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gradinaru</LastName><ForeName>Viviana</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0001-5868-348X</Identifier><AffiliationInfo><Affiliation>Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA. viviana@caltech.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>DP2 NS087949</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 MH117069</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 OD026638</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>12</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Mov Disord. 2022 May;37(5):892. doi: 10.1002/mds.29017.</RefSource><PMID Version="1">35362633</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D061605" MajorTopicYN="N">Administration, Intravenous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002144" MajorTopicYN="N">Callithrix</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002213" MajorTopicYN="Y">Capsid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000229" MajorTopicYN="Y">Dependovirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005822" MajorTopicYN="N">Genetic Vectors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008099" MajorTopicYN="N">Liver</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014161" MajorTopicYN="N">Transduction, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019076" MajorTopicYN="N">Transgenes</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>6</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>10</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>10</Day><Hour>6</Hour><Minute>36</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34887588</ArticleId><ArticleId IdType="doi">10.1038/s41593-021-00969-4</ArticleId><ArticleId IdType="pii">10.1038/s41593-021-00969-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Naso, M. F., Tomkowicz, B., Perry, W. L. &amp; Strohl, W. R. Adeno-associated virus (AAV) as a vector for gene therapy. BioDrugs 31, 317&#x2013;334 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28669112</ArticleId><ArticleId IdType="pmc">5548848</ArticleId><ArticleId IdType="doi">10.1007/s40259-017-0234-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaudet, D., M&#xe9;thot, J. &amp; Kastelein, J. Gene therapy for lipoprotein lipase deficiency. Curr. Opin. Lipidol. 23, 310&#x2013;320 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22691709</ArticleId><ArticleId IdType="doi">10.1097/MOL.0b013e3283555a7e</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Zaidy, S. A. &amp; Mendell, J. R. From clinical trials to clinical practice: practical considerations for gene replacement therapy in SMA type 1. Pediatr. Neurol. 100, 3&#x2013;11 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31371124</ArticleId><ArticleId IdType="doi">10.1016/j.pediatrneurol.2019.06.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Ameri, H. Prospect of retinal gene therapy following commercialization of voretigene neparvovec-rzyl for retinal dystrophy mediated by RPE65 mutation. J. Curr. Ophthalmol. 30, 1&#x2013;2 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29564403</ArticleId><ArticleId IdType="pmc">5859497</ArticleId><ArticleId IdType="doi">10.1016/j.joco.2018.01.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Evens, H., Chuah, M. K. &amp; VandenDriessche, T. Haemophilia gene therapy: from trailblazer to gamechanger. Haemophilia 24, 50&#x2013;59 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29878653</ArticleId><ArticleId IdType="doi">10.1111/hae.13494</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginn, S. L., Amaya, A. K., Alexander, I. E., Edelstein, M. &amp; Abedi, M. R. Gene therapy clinical trials worldwide to 2017: an update. J. Gene Med. 20, e3015 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29575374</ArticleId><ArticleId IdType="doi">10.1002/jgm.3015</ArticleId></ArticleIdList></Reference><Reference><Citation>Srivastava, A. In vivo tissue-tropism of adeno-associated viral vectors. Curr. Opin. Virol. 21, 75&#x2013;80 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27596608</ArticleId><ArticleId IdType="pmc">5138125</ArticleId><ArticleId IdType="doi">10.1016/j.coviro.2016.08.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Zincarelli, C., Soltys, S., Rengo, G. &amp; Rabinowitz, J. E. Analysis of AAV serotypes 1&#x2013;9 mediated gene expression and tropism in mice after systemic injection. Mol. Ther. 16, 1073&#x2013;1080 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18414476</ArticleId><ArticleId IdType="doi">10.1038/mt.2008.76</ArticleId></ArticleIdList></Reference><Reference><Citation>Gray, S. J., Woodard, K. T. &amp; Samulski, R. J. Viral vectors and delivery strategies for CNS gene therapy. Ther. Deliv. 1, 517&#x2013;534 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">22833965</ArticleId><ArticleId IdType="doi">10.4155/tde.10.50</ArticleId></ArticleIdList></Reference><Reference><Citation>Golebiowski, D. et al. Direct intracranial injection of AAVrh8 encoding monkey &#x3b2;-N-acetylhexosaminidase causes neurotoxicity in the primate brain. Hum. Gene Ther. 28, 510&#x2013;522 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28132521</ArticleId><ArticleId IdType="pmc">5488349</ArticleId><ArticleId IdType="doi">10.1089/hum.2016.109</ArticleId></ArticleIdList></Reference><Reference><Citation>Hocquemiller, M., Giersch, L., Audrain, M., Parker, S. &amp; Cartier, N. Adeno-associated virus-based gene therapy for CNS diseases. Hum. Gene Ther. 27, 478&#x2013;496 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27267688</ArticleId><ArticleId IdType="pmc">4960479</ArticleId><ArticleId IdType="doi">10.1089/hum.2016.087</ArticleId></ArticleIdList></Reference><Reference><Citation>Kubes, P. &amp; Jenne, C. Immune responses in the liver. Annu. Rev. Immunol. 36, 247&#x2013;277 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29328785</ArticleId><ArticleId IdType="doi">10.1146/annurev-immunol-051116-052415</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao, B. Basic liver immunology. Cell. Mol. Immunol. 13, 265&#x2013;266 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27041634</ArticleId><ArticleId IdType="pmc">4856812</ArticleId><ArticleId IdType="doi">10.1038/cmi.2016.09</ArticleId></ArticleIdList></Reference><Reference><Citation>Ronzitti, G., Gross, D.-A. &amp; Mingozzi, F. Human immune responses to adeno-associated virus (AAV) vectors. Front. Immunol. 11, 670 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32362898</ArticleId><ArticleId IdType="pmc">7181373</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2020.00670</ArticleId></ArticleIdList></Reference><Reference><Citation>Verdera, H. C., Kuranda, K. &amp; Mingozzi, F. AAV vector immunogenicity in humans: a long journey to successful gene transfer. Mol. Ther. 28, 723&#x2013;746 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31972133</ArticleId><ArticleId IdType="pmc">7054726</ArticleId><ArticleId IdType="doi">10.1016/j.ymthe.2019.12.010</ArticleId></ArticleIdList></Reference><Reference><Citation>Gray, S. J. et al. Optimizing promoters for recombinant adeno-associated virus-mediated gene expression in the peripheral and central nervous system using self-complementary vectors. Hum. Gene Ther. 22, 1143&#x2013;1153 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21476867</ArticleId><ArticleId IdType="pmc">3177952</ArticleId><ArticleId IdType="doi">10.1089/hum.2010.245</ArticleId></ArticleIdList></Reference><Reference><Citation>de Leeuw, C. N. et al. Targeted CNS delivery using human MiniPromoters and demonstrated compatibility with adeno-associated viral vectors. Mol. Ther. Methods Clin. Dev. 1, 5 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24761428</ArticleId><ArticleId IdType="pmc">3992516</ArticleId><ArticleId IdType="doi">10.1038/mtm.2013.5</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen, W. E. et al. Global representations of goal-directed behavior in distinct cell types of mouse neocortex. Neuron 94, 891&#x2013;907 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28521139</ArticleId><ArticleId IdType="pmc">5723385</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2017.04.017</ArticleId></ArticleIdList></Reference><Reference><Citation>Shima, Y. et al. A mammalian enhancer trap resource for discovering and manipulating neuronal cell types. eLife 5, e13503 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26999799</ArticleId><ArticleId IdType="pmc">4846381</ArticleId><ArticleId IdType="doi">10.7554/eLife.13503</ArticleId></ArticleIdList></Reference><Reference><Citation>Graybuck, L. T. et al. Enhancer viruses for combinatorial cell-subclass-specific labeling. Neuron 109, 1449&#x2013;1464 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33789083</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2021.03.011</ArticleId></ArticleIdList></Reference><Reference><Citation>Mich, J. K. et al. Functional enhancer elements drive subclass-selective expression from mouse to primate neocortex. Cell Rep. 34, 108754 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33789096</ArticleId><ArticleId IdType="pmc">8163032</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2021.108754</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan, K. Y. et al. Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems. Nat. Neurosci. 20, 1172&#x2013;1179 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28671695</ArticleId><ArticleId IdType="pmc">5529245</ArticleId><ArticleId IdType="doi">10.1038/nn.4593</ArticleId></ArticleIdList></Reference><Reference><Citation>Vormstein-Schneider, D. et al. Viral manipulation of functionally distinct interneurons in mice, non-human primates and humans. Nat. Neurosci. 23, 1629&#x2013;1636 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32807948</ArticleId><ArticleId IdType="pmc">8015416</ArticleId><ArticleId IdType="doi">10.1038/s41593-020-0692-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Keaveney, M. K. et al. A microRNA-based gene-targeting tool for virally labeling interneurons in the rodent cortex. Cell Rep. 24, 294&#x2013;303 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29996091</ArticleId><ArticleId IdType="pmc">6095194</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2018.06.049</ArticleId></ArticleIdList></Reference><Reference><Citation>Hordeaux, J. et al. MicroRNA-mediated inhibition of transgene expression reduces dorsal root ganglion toxicity by AAV vectors in primates. Sci. Transl. Med. 12, eaba9188 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33177182</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.aba9188</ArticleId></ArticleIdList></Reference><Reference><Citation>Deverman, B. E. et al. Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204&#x2013;209 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26829320</ArticleId><ArticleId IdType="pmc">5088052</ArticleId><ArticleId IdType="doi">10.1038/nbt.3440</ArticleId></ArticleIdList></Reference><Reference><Citation>Zelikowsky, M. et al. The neuropeptide Tac2 controls a distributed brain state induced by chronic social isolation stress. Cell 173, 1265&#x2013;1279 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29775595</ArticleId><ArticleId IdType="pmc">5967263</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2018.03.037</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng, J. et al. TRIM9-mediated resolution of neuroinflammation confers neuroprotection upon ischemic stroke in mice. Cell Rep. 27, 549&#x2013;560 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30970257</ArticleId><ArticleId IdType="pmc">6485958</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2018.12.055</ArticleId></ArticleIdList></Reference><Reference><Citation>Graybuck, L. T. et al. Enhancer viruses for combinatorial cell-subclass-specific labeling. Neuron 109, 1449&#x2013;1464.e13 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33789083</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2021.03.011</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao, G. et al. Adeno-associated virus-mediated gene transfer to nonhuman primate liver can elicit destructive transgene-specific T cell responses. Hum. Gene Ther. 20, 930&#x2013;942 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19441963</ArticleId><ArticleId IdType="pmc">2829282</ArticleId><ArticleId IdType="doi">10.1089/hum.2009.060</ArticleId></ArticleIdList></Reference><Reference><Citation>Mingozzi, F. &amp; High, K. A. Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood 122, 23&#x2013;36 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23596044</ArticleId><ArticleId IdType="pmc">3701904</ArticleId><ArticleId IdType="doi">10.1182/blood-2013-01-306647</ArticleId></ArticleIdList></Reference><Reference><Citation>Calcedo, R., Chichester, J. A. &amp; Wilson, J. M. Assessment of humoral, innate, and T-cell immune responses to adeno-associated virus vectors. Hum. Gene Ther. Methods 29, 86&#x2013;95 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29668327</ArticleId><ArticleId IdType="doi">10.1089/hgtb.2018.038</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar, S. et al. Multiplexed Cre-dependent selection yields systemic AAVs for targeting distinct brain cell types. Nat. Methods 17, 541&#x2013;550 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">7219404</ArticleId><ArticleId IdType="doi">10.1038/s41592-020-0799-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuzaki, Y. et al. Intravenous administration of the adeno-associated virus-PHP.B capsid fails to upregulate transduction efficiency in the marmoset brain. Neurosci. Lett. 665, 182&#x2013;188 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29175632</ArticleId><ArticleId IdType="doi">10.1016/j.neulet.2017.11.049</ArticleId></ArticleIdList></Reference><Reference><Citation>Hordeaux, J. et al. The neurotropic properties of AAV-PHP.B are limited to C57BL/6J mice. Mol. Ther. 26, 664&#x2013;668 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29428298</ArticleId><ArticleId IdType="pmc">5911151</ArticleId><ArticleId IdType="doi">10.1016/j.ymthe.2018.01.018</ArticleId></ArticleIdList></Reference><Reference><Citation>Kern, A. et al. Identification of a heparin-binding motif on adeno-associated virus type 2 capsids. J. Virol. 77, 11072&#x2013;11081 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">14512555</ArticleId><ArticleId IdType="pmc">224995</ArticleId><ArticleId IdType="doi">10.1128/JVI.77.20.11072-11081.2003</ArticleId></ArticleIdList></Reference><Reference><Citation>Girod, A. et al. Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2. Nat. Med. 5, 1052&#x2013;1056 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10470084</ArticleId><ArticleId IdType="doi">10.1038/12491</ArticleId></ArticleIdList></Reference><Reference><Citation>Michelfelder, S. et al. Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21850255</ArticleId><ArticleId IdType="pmc">3151269</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0023101</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen, S., Bryant, K. D., Brown, S. M., Randell, S. H. &amp; Asokan, A. Terminal N-linked galactose is the primary receptor for adeno-associated virus 9. J. Biol. Chem. 286, 13532&#x2013;13540 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21330365</ArticleId><ArticleId IdType="pmc">3075699</ArticleId><ArticleId IdType="doi">10.1074/jbc.M110.210922</ArticleId></ArticleIdList></Reference><Reference><Citation>Summerford, C., Johnson, J. S. &amp; Samulski, R. J. AAVR: a multi-serotype receptor for AAV. Mol. Ther. 24, 663&#x2013;666 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27081719</ArticleId><ArticleId IdType="pmc">4886949</ArticleId><ArticleId IdType="doi">10.1038/mt.2016.49</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, R. et al. Adeno-associated virus 2 bound to its cellular receptor AAVR. Nat. Microbiol. 4, 675&#x2013;682 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30742069</ArticleId><ArticleId IdType="doi">10.1038/s41564-018-0356-7</ArticleId></ArticleIdList></Reference><Reference><Citation>DiMattia, M. A. et al. Structural insight into the unique properties of adeno-associated virus serotype 9. J. Virol. 86, 6947&#x2013;6958 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22496238</ArticleId><ArticleId IdType="pmc">3393551</ArticleId><ArticleId IdType="doi">10.1128/JVI.07232-11</ArticleId></ArticleIdList></Reference><Reference><Citation>Foust, K. D. et al. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat. Biotechnol. 27, 59&#x2013;65 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19098898</ArticleId><ArticleId IdType="doi">10.1038/nbt.1515</ArticleId></ArticleIdList></Reference><Reference><Citation>Samaranch, L. et al. Adeno-associated virus serotype 9 transduction in the central nervous system of nonhuman primates. Hum. Gene Ther. 23, 382&#x2013;389 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22201473</ArticleId><ArticleId IdType="doi">10.1089/hum.2011.200</ArticleId></ArticleIdList></Reference><Reference><Citation>Flotte, T. R. &amp; B&#xfc;ning, H. Severe toxicity in nonhuman primates and piglets with systemic high-dose administration of adeno-associated virus serotype 9-like vectors: putting patients first. Hum. Gene Ther. 29, 283&#x2013;284 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29378415</ArticleId><ArticleId IdType="doi">10.1089/hum.2018.021</ArticleId></ArticleIdList></Reference><Reference><Citation>Unzu, C. et al. Transient and intensive pharmacological immunosuppression fails to improve AAV-based liver gene transfer in non-human primates. J. Transl. Med. 10, 122 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22704060</ArticleId><ArticleId IdType="pmc">3412719</ArticleId><ArticleId IdType="doi">10.1186/1479-5876-10-122</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannelli, S. G. et al. Cas9/sgRNA selective targeting of the P23H Rhodopsin mutant allele for treating retinitis pigmentosa by intravitreal AAV9.PHP.B-based delivery. Hum. Mol. Genet. 27, 761&#x2013;779 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29281027</ArticleId><ArticleId IdType="doi">10.1093/hmg/ddx438</ArticleId></ArticleIdList></Reference><Reference><Citation>Schubert, R. et al. Virus stamping for targeted single-cell infection in vitro and in vivo. Nat. Biotechnol. 36, 81&#x2013;88 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29251729</ArticleId><ArticleId IdType="doi">10.1038/nbt.4034</ArticleId></ArticleIdList></Reference><Reference><Citation>Morabito, G. et al. AAV-PHP.B-mediated global-scale expression in the mouse nervous system enables GBA1 gene therapy for wide protection from synucleinopathy. Mol. Ther. 25, 2727&#x2013;2742 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28882452</ArticleId><ArticleId IdType="pmc">5768559</ArticleId><ArticleId IdType="doi">10.1016/j.ymthe.2017.08.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Hillier, D. et al. Causal evidence for retina-dependent and -independent visual motion computations in mouse cortex. Nat. Neurosci. 20, 960&#x2013;968 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28530661</ArticleId><ArticleId IdType="pmc">5490790</ArticleId><ArticleId IdType="doi">10.1038/nn.4566</ArticleId></ArticleIdList></Reference><Reference><Citation>Dayton, R. D., Grames, M. S. &amp; Klein, R. L. More expansive gene transfer to the rat CNS: AAV PHP.EB vector dose&#x2013;response and comparison to AAV PHP.B. Gene Ther. 25, 392&#x2013;400 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30013186</ArticleId><ArticleId IdType="doi">10.1038/s41434-018-0028-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Rincon, M. Y. et al. Widespread transduction of astrocytes and neurons in the mouse central nervous system after systemic delivery of a self-complementary AAV-PHP.B vector. Gene Ther. 25, 83&#x2013;92 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29523880</ArticleId><ArticleId IdType="doi">10.1038/s41434-018-0005-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuste, R. et al. A community-based transcriptomics classification and nomenclature of neocortical cell types. Nat. Neurosci. 23, 1456&#x2013;1468 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32839617</ArticleId><ArticleId IdType="pmc">7683348</ArticleId><ArticleId IdType="doi">10.1038/s41593-020-0685-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Krienen, F. M. et al. Innovations present in the primate interneuron repertoire. Nature 586, 262&#x2013;269 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32999462</ArticleId><ArticleId IdType="pmc">7957574</ArticleId><ArticleId IdType="doi">10.1038/s41586-020-2781-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Hinderer, C. et al. Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration of an adeno-associated virus vector expressing human SMN. Hum. Gene Ther. 29, 285&#x2013;298 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29378426</ArticleId><ArticleId IdType="pmc">5865262</ArticleId><ArticleId IdType="doi">10.1089/hum.2018.015</ArticleId></ArticleIdList></Reference><Reference><Citation>Coune, P. G., Schneider, B. L. &amp; Aebischer, P. Parkinson&#x2019;s disease: gene therapies. Cold Spring Harb. Perspect. Med. 2, a009431 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22474617</ArticleId><ArticleId IdType="pmc">3312404</ArticleId><ArticleId IdType="doi">10.1101/cshperspect.a009431</ArticleId></ArticleIdList></Reference><Reference><Citation>Piguet, F. et al. Rapid and complete reversal of sensory ataxia by gene therapy in a novel model of Friedreich ataxia. Mol. Ther. 26, 1940&#x2013;1952 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29853274</ArticleId><ArticleId IdType="pmc">6094869</ArticleId><ArticleId IdType="doi">10.1016/j.ymthe.2018.05.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Combs, B., Kneynsberg, A. &amp; Kanaan, N. M. Gene therapy models of alzheimer&#x2019;s disease and other dementias. Methods Mol. Biol. 1382, 339&#x2013;366 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26611599</ArticleId><ArticleId IdType="pmc">4734109</ArticleId><ArticleId IdType="doi">10.1007/978-1-4939-3271-9_25</ArticleId></ArticleIdList></Reference><Reference><Citation>Challis, R. C. et al. Systemic AAV vectors for widespread and targeted gene delivery in rodents. Nat. Protoc. 14, 379&#x2013;414 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30626963</ArticleId><ArticleId IdType="doi">10.1038/s41596-018-0097-3</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34880495</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>29</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>601</Volume><Issue>7891</Issue><PubDate><Year>2022</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Structure of pathological TDP-43 filaments from ALS with FTLD.</ArticleTitle><Pagination><StartPage>139</StartPage><EndPage>143</EndPage><MedlinePgn>139-143</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41586-021-04199-3</ELocationID><Abstract><AbstractText>The abnormal aggregation of TAR DNA-binding protein 43&#x2009;kDa (TDP-43) in neurons and glia is the defining pathological hallmark of the&#xa0;neurodegenerative disease amyotrophic lateral sclerosis (ALS) and multiple forms of frontotemporal lobar degeneration (FTLD)<sup>1,2</sup>. It is also common in other diseases, including Alzheimer's and Parkinson's. No disease-modifying therapies exist for these conditions and early diagnosis is not possible. The structures of pathological TDP-43 aggregates are unknown. Here we used cryo-electron microscopy to determine the structures of aggregated TDP-43 in the frontal and motor cortices of an individual who had ALS with FTLD and from the frontal cortex of a second individual with the same diagnosis. An identical amyloid-like filament structure comprising a single protofilament was found in both brain regions and individuals. The ordered filament core spans residues 282-360 in the TDP-43 low-complexity domain and adopts a previously undescribed double-spiral-shaped fold, which shows no similarity to those of TDP-43 filaments formed in vitro<sup>3,4</sup>. An abundance of glycine and neutral polar residues facilitates numerous turns and restricts &#x3b2;-strand length, which results in an absence of &#x3b2;-sheet stacking that is associated with cross-&#x3b2; amyloid structure. An uneven distribution of residues gives rise to structurally and chemically distinct surfaces that face external densities and suggest possible ligand-binding sites. This work enhances our understanding of the molecular pathogenesis of ALS and FTLD and informs the development of diagnostic and therapeutic agents that target aggregated TDP-43.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s), under exclusive licence to Springer Nature Limited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Arseni</LastName><ForeName>Diana</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-7585-288X</Identifier><AffiliationInfo><Affiliation>MRC Laboratory of Molecular Biology, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hasegawa</LastName><ForeName>Masato</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-7415-8159</Identifier><AffiliationInfo><Affiliation>Department of Brain and Neurosciences, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murzin</LastName><ForeName>Alexey G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>MRC Laboratory of Molecular Biology, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kametani</LastName><ForeName>Fuyuki</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0001-9125-7001</Identifier><AffiliationInfo><Affiliation>Department of Brain and Neurosciences, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arai</LastName><ForeName>Makoto</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-3400-9815</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioural Sciences, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoshida</LastName><ForeName>Mari</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Medical Science of Aging, Aichi Medical University, Aichi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryskeldi-Falcon</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-8176-2618</Identifier><AffiliationInfo><Affiliation>MRC Laboratory of Molecular Biology, Cambridge, UK. bfalcon@mrc-lmb.cam.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MC_U105192716</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_UP_1201/25</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>12</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598624">TARDBP protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2022 Jan;601(7891):29-30. doi: 10.1038/d41586-021-03605-0.</RefSource><PMID Version="1">34880481</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020285" MajorTopicYN="Y">Cryoelectron Microscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="Y">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005625" MajorTopicYN="N">Frontal Lobe</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057174" MajorTopicYN="N">Frontotemporal Lobar Degeneration</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009044" MajorTopicYN="N">Motor Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>
<b>Competing interests</b>
. The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>8</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>11</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>9</Day><Hour>6</Hour><Minute>55</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>7</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34880495</ArticleId><ArticleId IdType="mid">EMS140820</ArticleId><ArticleId IdType="pmc">PMC7612255</ArticleId><ArticleId IdType="doi">10.1038/s41586-021-04199-3</ArticleId><ArticleId IdType="pii">10.1038/s41586-021-04199-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Neumann M, et al. Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis. Science. 2006;314:130&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun. 2006;351:602&#x2013;611.</Citation><ArticleIdList><ArticleId IdType="pubmed">17084815</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Q, Boyer DR, Sawaya MR, Ge P, Eisenberg DS. Cryo-EM structures of four polymorphic TDP-43 amyloid cores. Nature Struct Mol Biol. 2019;26:619&#x2013;627.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7047951</ArticleId><ArticleId IdType="pubmed">31235914</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q, Babinchak WM, Surewicz WK. Cryo-EM structure of amyloid fibrils formed by the entire low complexity domain of TDP-43. Nature Commun. 2021;12:1620.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7955110</ArticleId><ArticleId IdType="pubmed">33712624</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, et al. Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol. 2013;74:20&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3785076</ArticleId><ArticleId IdType="pubmed">23686809</ArticleId></ArticleIdList></Reference><Reference><Citation>Nonaka T, et al. Prion-like Properties of Pathological TDP-43 Aggregates from Diseased Brains. Cell Rep. 2013;4:124&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pubmed">23831027</ArticleId></ArticleIdList></Reference><Reference><Citation>Phukan J, Pender NP, Hardiman O. Cognitive impairment in amyotrophic lateral sclerosis. Lancet Neurol. 2007;6:994&#x2013;1003.</Citation><ArticleIdList><ArticleId IdType="pubmed">17945153</ArticleId></ArticleIdList></Reference><Reference><Citation>Sreedharan J, et al. TDP-43 Mutations in familial and sporadic amyotrophic lateral sclerosis. Science. 2008;319:1668&#x2013;1672.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7116650</ArticleId><ArticleId IdType="pubmed">18309045</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabashi E, et al. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nature Genet. 2008;40:572&#x2013;574.</Citation><ArticleIdList><ArticleId IdType="pubmed">18372902</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Deerlin VM, et al. TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis. Lancet Neurol. 2008;7:409&#x2013;416.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3546119</ArticleId><ArticleId IdType="pubmed">18396105</ArticleId></ArticleIdList></Reference><Reference><Citation>Hergesheimer RC, et al. The debated toxic role of aggregated TDP-43 in amyotrophic lateral sclerosis: a resolution in sight? Brain. 2019;142:1176&#x2013;1194.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6487324</ArticleId><ArticleId IdType="pubmed">30938443</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayala YM, et al. Structural determinants of the cellular localization and shuttling of TDP-43. J Cell Sci. 2008;121:3778&#x2013;3785.</Citation><ArticleIdList><ArticleId IdType="pubmed">18957508</ArticleId></ArticleIdList></Reference><Reference><Citation>Afroz T, et al. Functional and dynamic polymerization of the ALS-linked protein TDP-43 antagonizes its pathologic aggregation. Nature Commun. 2017;8:45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5491494</ArticleId><ArticleId IdType="pubmed">28663553</ArticleId></ArticleIdList></Reference><Reference><Citation>Colombrita C, et al. TDP-43 is recruited to stress granules in conditions of oxidative insult. J Neurochem. 2009;111:1051&#x2013;1061.</Citation><ArticleIdList><ArticleId IdType="pubmed">19765185</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa M, et al. Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Ann Neurol. 2008;64:60&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2674108</ArticleId><ArticleId IdType="pubmed">18546284</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin W-L, Dickson DW. Ultrastructural localization of TDP-43 in filamentous neuronal inclusions in various neurodegenerative diseases. Acta Neuropathol. 2008;116:205&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2706695</ArticleId><ArticleId IdType="pubmed">18607609</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori F, et al. Maturation process of TDP-43-positive neuronal cytoplasmic inclusions in amyotrophic lateral sclerosis with and without dementia. Acta Neuropathol. 2008;116:193&#x2013;203.</Citation><ArticleIdList><ArticleId IdType="pubmed">18560845</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuji H, et al. Molecular analysis and biochemical classification of TDP-43 proteinopathy. Brain. 2012;135:3380&#x2013;3391.</Citation><ArticleIdList><ArticleId IdType="pubmed">23035040</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IRA, et al. A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol. 2011;122:111&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3285143</ArticleId><ArticleId IdType="pubmed">21644037</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang L-L, et al. Structural transformation of the amyloidogenic core region of TDP-43 protein initiates its aggregation and cytoplasmic inclusion. J Biol Chem. 2013;288:19614&#x2013;19624.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3707662</ArticleId><ArticleId IdType="pubmed">23689371</ArticleId></ArticleIdList></Reference><Reference><Citation>Kametani F, et al. Mass spectrometric analysis of accumulated TDP-43 in amyotrophic lateral sclerosis brains. Sci Rep. 2016;6:23281.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4793195</ArticleId><ArticleId IdType="pubmed">26980269</ArticleId></ArticleIdList></Reference><Reference><Citation>Sunde M, et al. Common core structure of amyloid fibrils by synchrotron X-ray diffraction. J Mol Biol. 1997;273:729&#x2013;739.</Citation><ArticleIdList><ArticleId IdType="pubmed">9356260</ArticleId></ArticleIdList></Reference><Reference><Citation>Binda C, et al. Cross-talk and ammonia channeling between active centers in the unexpected domain arrangement of glutamate synthase. Structure. 2000;8:1299&#x2013;1308.</Citation><ArticleIdList><ArticleId IdType="pubmed">11188694</ArticleId></ArticleIdList></Reference><Reference><Citation>Parkinson GN, Cuenca F, Neidle S. Topology conservation and loop flexibility in quadruplex&#x2212;drug recognition: crystal structures of inter- and intramolecular telomeric DNA quadruplex&#x2212;drug complexes. J Mol Biol. 2008;381:1145&#x2013;1156.</Citation><ArticleIdList><ArticleId IdType="pubmed">18619463</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, et al. Structure-based classification of tauopathies. Nature. 2021 doi: 10.1038/s41586-021-03911-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03911-7</ArticleId><ArticleId IdType="pmc">PMC7611841</ArticleId><ArticleId IdType="pubmed">34588692</ArticleId></ArticleIdList></Reference><Reference><Citation>Schweighauser M, et al. Structures of &#x3b1;-synuclein filaments from multiple system atrophy. Nature. 2020;585:464&#x2013;469.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7116528</ArticleId><ArticleId IdType="pubmed">32461689</ArticleId></ArticleIdList></Reference><Reference><Citation>Kollmer M, et al. Cryo-EM structure and polymorphism of A&#x3b2; amyloid fibrils purified from Alzheimer&#x2019;s brain tissue. Nature Commun. 2019;10:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6820800</ArticleId><ArticleId IdType="pubmed">31664019</ArticleId></ArticleIdList></Reference><Reference><Citation>Krebs MRH, et al. The binding of thioflavin-T to amyloid fibrils: localisation and implications. J Struct Biol. 2005;149:30&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">15629655</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, et al. Cryo-EM structures of tau filaments from Alzheimer&#x2019;s disease with PET ligand APN-1607. Acta Neuropathol. 2021;141:697&#x2013;708.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8043864</ArticleId><ArticleId IdType="pubmed">33723967</ArticleId></ArticleIdList></Reference><Reference><Citation>Bigio EH, et al. Inclusions in frontotemporal lobar degeneration with TDP-43 proteinopathy (FTLD-TDP) and amyotrophic lateral sclerosis (ALS), but not FTLD with FUS proteinopathy (FTLD-FUS), have properties of amyloid. Acta Neuropathol. 2013;125:463&#x2013;465.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3593646</ArticleId><ArticleId IdType="pubmed">23378033</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson JL, et al. TDP-43 skeins show properties of amyloid in a subset of ALS cases. Acta Neuropathol. 2013;125:121&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3536927</ArticleId><ArticleId IdType="pubmed">23124365</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y, et al. Physiologically important electrolytes as regulators of TDP-43 aggregation and droplet-phase behavior. Biochemistry. 2019;58:590&#x2013;607.</Citation><ArticleIdList><ArticleId IdType="pubmed">30489059</ArticleId></ArticleIdList></Reference><Reference><Citation>Marqui&#xe9; M, et al. Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol. 2015;78:787&#x2013;800.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4900162</ArticleId><ArticleId IdType="pubmed">26344059</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowe VJ, et al. An autoradiographic evaluation of AV-1451 tau PET in dementia. Acta Neuropathol Commun. 2016;4:58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4906968</ArticleId><ArticleId IdType="pubmed">27296779</ArticleId></ArticleIdList></Reference><Reference><Citation>Sander K, et al. Characterization of tau positron emission tomography tracer [18F]AV-1451 binding to postmortem tissue in Alzheimer&#x2019;s disease, primary tauopathies, and other dementias. Alzheimers Dement. 2016;12:1116&#x2013;1124.</Citation><ArticleIdList><ArticleId IdType="pubmed">26892233</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W, et al. Heparin-induced tau filaments are polymorphic and differ from those in Alzheimer&#x2019;s and Pick&#x2019;s diseases. eLife. 2019;8:e43584.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6375701</ArticleId><ArticleId IdType="pubmed">30720432</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray DT, et al. Structure of FUS protein fibrils and its relevance to self-assembly and phase separation of low-complexity domains. Cell. 2017;171:615&#x2013;627.:e16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5650524</ArticleId><ArticleId IdType="pubmed">28942918</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu J, et al. CryoEM structure of the low-complexity domain of hnRNPA2 and its conversion to pathogenic amyloid. Nature Commun. 2020;11:4090.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7427792</ArticleId><ArticleId IdType="pubmed">32796831</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y, et al. The nuclear localization sequence mediates hnRNPA1 amyloid fibril formation revealed by cryoEM structure. Nature Commun. 2020;11:6349.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7733464</ArticleId><ArticleId IdType="pubmed">33311513</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee M, Ghosh U, Thurber KR, Kato M, Tycko R. Molecular structure and interactions within amyloid-like fibrils formed by a low-complexity protein sequence from FUS. Nature Commun. 2020;11:5735.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7665218</ArticleId><ArticleId IdType="pubmed">33184287</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen AK-H, et al. Induction of amyloid fibrils by the C-terminal fragments of TDP-43 in amyotrophic lateral sclerosis. J Am Chem Soc. 2010;132:1186&#x2013;1187.</Citation><ArticleIdList><ArticleId IdType="pubmed">20055380</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo W, et al. An ALS-associated mutation affecting TDP-43 enhances protein aggregation, fibril formation and neurotoxicity. Nature Struct Mol Biol. 2011;18:822&#x2013;830.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3357956</ArticleId><ArticleId IdType="pubmed">21666678</ArticleId></ArticleIdList></Reference><Reference><Citation>Laferri&#xe8;re F, et al. TDP-43 extracted from frontotemporal lobar degeneration subject brains displays distinct aggregate assemblies and neurotoxic effects reflecting diseaseprogression rates. Nature Neurosci. 2019;22:65.</Citation><ArticleIdList><ArticleId IdType="pubmed">30559480</ArticleId></ArticleIdList></Reference><Reference><Citation>Porta S, et al. Patient-derived frontotemporal lobar degeneration brain extracts induce formation and spreading of TDP-43 pathology in vivo. Nature Commun. 2018;9:4220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6181940</ArticleId><ArticleId IdType="pubmed">30310141</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida M. Amyotrophic lateral sclerosis with dementia: The clinicopathological spectrum. Neuropathology. 2004;24:87&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">15068178</ArticleId></ArticleIdList></Reference><Reference><Citation>Taniguchi-Watanabe S, et al. Biochemical classification of tauopathies by immunoblot, protein sequence and mass spectrometric analyses of sarkosyl-insoluble and trypsin-resistant tau. Acta Neuropathol. 2016;131:267&#x2013;280.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4713716</ArticleId><ArticleId IdType="pubmed">26538150</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa M, et al. Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Ann Neurol. 2008;64:60&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2674108</ArticleId><ArticleId IdType="pubmed">18546284</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuji H, et al. Epitope mapping of antibodies against TDP-43 and detection of protease-resistant fragments of pathological TDP-43 in amyotrophic lateral sclerosis and frontotemporal lobar degeneration. Biochem Biophys Res Commun. 2012;417:116&#x2013;121.</Citation><ArticleIdList><ArticleId IdType="pubmed">22133678</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarutani A, Hasegawa M. In: Experimental Models of Parkinson&#x2019;s Disease. Imai Y, editor. Springer; US: 2021. Electron microscopic analysis of &#x3b1;-synuclein fibrils; pp. 17&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">34043188</ArticleId></ArticleIdList></Reference><Reference><Citation>Kametani F, et al. Comparison of common and disease-specific post-translational modifications of pathological tau associated with a wide range of tauopathies. Front Neurosci. 2020;14:581936.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7672045</ArticleId><ArticleId IdType="pubmed">33250706</ArticleId></ArticleIdList></Reference><Reference><Citation>Zivanov J, Nakane T, Scheres SHW. A Bayesian approach to beam-induced motion correction in cryo-EM single-particle analysis. IUCrJ. 2019;6:5&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6327179</ArticleId><ArticleId IdType="pubmed">30713699</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohou A, Grigorieff N. CTFFIND4: Fast and accurate defocus estimation from electron micrographs. J Struct Biol. 2015;192:216&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6760662</ArticleId><ArticleId IdType="pubmed">26278980</ArticleId></ArticleIdList></Reference><Reference><Citation>He S, Scheres SHW. Helical reconstruction in RELION. J Struct Biol. 2017;198:163&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5479445</ArticleId><ArticleId IdType="pubmed">28193500</ArticleId></ArticleIdList></Reference><Reference><Citation>Zivanov J, et al. New tools for automated high-resolution cryo-EM structure determination in RELION-3. eLife. 2018;7:e42166.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6250425</ArticleId><ArticleId IdType="pubmed">30412051</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheres SHW. Amyloid structure determination in RELION-3.1. Acta Crystallogr Sect Struct Biol. 2020;76:94&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7008511</ArticleId><ArticleId IdType="pubmed">32038040</ArticleId></ArticleIdList></Reference><Reference><Citation>Zivanov J, Nakane T, Scheres SHW. Estimation of high-order aberrations and anisotropic magnification from cryo-EM data sets in RELION-3.1. IUCrJ. 2020;7:253&#x2013;267.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7055373</ArticleId><ArticleId IdType="pubmed">32148853</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S, et al. High-resolution noise substitution to measure overfitting and validate resolution in 3D structure determination by single particle electron cryo-microscopy. Ultramicroscopy. 2013;135:24&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3834153</ArticleId><ArticleId IdType="pubmed">23872039</ArticleId></ArticleIdList></Reference><Reference><Citation>Casa&#xf1;al A, Lohkamp B, Emsley P. Current developments in Coot for macromolecular model building of electron cryo-microscopy and erystallographic data. Protein Sci. 2020;29:1055&#x2013;1064.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7096722</ArticleId><ArticleId IdType="pubmed">31730249</ArticleId></ArticleIdList></Reference><Reference><Citation>Croll TI. ISOLDE: a physically realistic environment for model building into low-resolution electron-density maps. Acta Crystallogr Sect Struct Biol. 2018;74:519&#x2013;530.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6096486</ArticleId><ArticleId IdType="pubmed">29872003</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown A, et al. Tools for macromolecular model building and refinement into electron cryo-microscopy reconstructions. Acta Crystallogr D Biol Crystallogr. 2015;71:136&#x2013;153.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4304694</ArticleId><ArticleId IdType="pubmed">25615868</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamashita K, Palmer CM, Burnley T, Murshudov GN. Cryo-EM single particle structure refinement and map calculation using Servalcat. bioRxiv. 2021:2021.05.04.442493. doi: 10.1101/2021.05.04.442493.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.05.04.442493</ArticleId><ArticleId IdType="pmc">PMC8489229</ArticleId><ArticleId IdType="pubmed">34605431</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams CJ, et al. MolProbity: More and better reference data for improved all-atom structure validation. Protein Sci. 2018;27:293&#x2013;315.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5734394</ArticleId><ArticleId IdType="pubmed">29067766</ArticleId></ArticleIdList></Reference><Reference><Citation>Pettersen EF, et al. UCSF ChimeraX: Structure visualization for researchers, educators, and developers. Protein Sci. 2021;30:70&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7737788</ArticleId><ArticleId IdType="pubmed">32881101</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">34910503</PMID><DateRevised><Year>2023</Year><Month>04</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2375-2548</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>51</Issue><PubDate><Year>2021</Year><Month>Dec</Month><Day>17</Day></PubDate></JournalIssue><Title>Science advances</Title><ISOAbbreviation>Sci Adv</ISOAbbreviation></Journal><ArticleTitle>Single-synapse analyses of Alzheimer's disease implicate pathologic tau, DJ1, CD47, and ApoE.</ArticleTitle><Pagination><StartPage>eabk0473</StartPage><MedlinePgn>eabk0473</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">eabk0473</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1126/sciadv.abk0473</ELocationID><Abstract><AbstractText>Synaptic molecular characterization is limited for Alzheimer&#x2019;s disease (AD). Our newly invented mass cytometry&#x2013;based method, synaptometry by time of flight (SynTOF), was used to measure 38 antibody probes in approximately 17 million single-synapse events from human brains without pathologic change or with pure AD or Lewy body disease (LBD), nonhuman primates (NHPs), and PS/APP mice. Synaptic molecular integrity in humans and NHP was similar. Although not detected in human synapses, A&#x3b2; was in PS/APP mice single-synapse events. Clustering and pattern identification of human synapses showed expected disease-specific differences, like increased hippocampal pathologic tau in AD and reduced caudate dopamine transporter in LBD, and revealed previously unidentified findings including increased hippocampal CD47 and lowered DJ1 in AD and higher ApoE in AD with dementia. Our results were independently supported by multiplex ion beam imaging of intact tissue. This highlights the higher depth and breadth of insight on neurodegenerative diseases obtainable through SynTOF.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Phongpreecha</LastName><ForeName>Thanaphong</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-9245-6686</Identifier><AffiliationInfo><Affiliation>Department of Pathology, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anesthesiology, Perioperative, and Pain Medicine, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Data Science, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gajera</LastName><ForeName>Chandresh R</ForeName><Initials>CR</Initials><Identifier Source="ORCID">0000-0002-4638-2097</Identifier><AffiliationInfo><Affiliation>Department of Pathology, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Candace C</ForeName><Initials>CC</Initials><Identifier Source="ORCID">0000-0002-2446-2264</Identifier><AffiliationInfo><Affiliation>Department of Pathology, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vijayaragavan</LastName><ForeName>Kausalia</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-9830-5704</Identifier><AffiliationInfo><Affiliation>Department of Pathology, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Alan L</ForeName><Initials>AL</Initials><Identifier Source="ORCID">0000-0003-1716-0134</Identifier><AffiliationInfo><Affiliation>Department of Anesthesiology, Perioperative, and Pain Medicine, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Data Science, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Becker</LastName><ForeName>Martin</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-4296-3481</Identifier><AffiliationInfo><Affiliation>Department of Anesthesiology, Perioperative, and Pain Medicine, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Data Science, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fallahzadeh</LastName><ForeName>Ramin</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-9966-850X</Identifier><AffiliationInfo><Affiliation>Department of Anesthesiology, Perioperative, and Pain Medicine, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Data Science, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fernandez</LastName><ForeName>Rosemary</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-3378-0109</Identifier><AffiliationInfo><Affiliation>Department of Pathology, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Postupna</LastName><ForeName>Nadia</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-4939-4915</Identifier><AffiliationInfo><Affiliation>Department of Pathology, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sherfield</LastName><ForeName>Emily</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tebaykin</LastName><ForeName>Dmitry</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-0913-8834</Identifier><AffiliationInfo><Affiliation>Department of Pathology, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Latimer</LastName><ForeName>Caitlin</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-3727-4278</Identifier><AffiliationInfo><Affiliation>Department of Pathology, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shively</LastName><ForeName>Carol A</ForeName><Initials>CA</Initials><Identifier Source="ORCID">0000-0002-1536-2288</Identifier><AffiliationInfo><Affiliation>Department of Pathology/Comparative Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Register</LastName><ForeName>Thomas C</ForeName><Initials>TC</Initials><Identifier Source="ORCID">0000-0002-4078-0166</Identifier><AffiliationInfo><Affiliation>Department of Pathology/Comparative Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Craft</LastName><ForeName>Suzanne</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine-Geriatrics, Wake Forest School of Medicine, Winston-Salem, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montine</LastName><ForeName>Kathleen S</ForeName><Initials>KS</Initials><AffiliationInfo><Affiliation>Department of Pathology, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fox</LastName><ForeName>Edward J</ForeName><Initials>EJ</Initials><AffiliationInfo><Affiliation>Department of Pathology, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poston</LastName><ForeName>Kathleen L</ForeName><Initials>KL</Initials><Identifier Source="ORCID">0000-0003-3424-7143</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosurgery, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keene</LastName><ForeName>C Dirk</ForeName><Initials>CD</Initials><Identifier Source="ORCID">0000-0002-5291-1469</Identifier><AffiliationInfo><Affiliation>Department of Pathology, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Angelo</LastName><ForeName>Michael</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-1531-5067</Identifier><AffiliationInfo><Affiliation>Department of Pathology, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bendall</LastName><ForeName>Sean C</ForeName><Initials>SC</Initials><Identifier Source="ORCID">0000-0003-1341-2453</Identifier><AffiliationInfo><Affiliation>Department of Pathology, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aghaeepour</LastName><ForeName>Nima</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-6117-8764</Identifier><AffiliationInfo><Affiliation>Department of Anesthesiology, Perioperative, and Pain Medicine, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Data Science, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montine</LastName><ForeName>Thomas J</ForeName><Initials>TJ</Initials><Identifier Source="ORCID">0000-0002-1346-2728</Identifier><AffiliationInfo><Affiliation>Department of Pathology, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>L30 AG074138</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066515</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UF1 AG057707</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R35 GM138353</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R24 AG073199</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG072947</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL087103</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG056287</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG057915</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL122393</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG068279</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG058829</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG049638</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 NS062684</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066509</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>12</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Adv</MedlineTA><NlmUniqueID>101653440</NlmUniqueID><ISSNLinking>2375-2548</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>15</Day><Hour>17</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>12</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34910503</ArticleId><ArticleId IdType="pmc">PMC8673771</ArticleId><ArticleId IdType="doi">10.1126/sciadv.abk0473</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Scheff S. W., Price D. A., Synaptic pathology in Alzheimer&#x2019;s disease: A review of ultrastructural studies. Neurobiol. Aging 24, 1029&#x2013;1046 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">14643375</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry R. D., Masliah E., Salmon D. P., Butters N., DeTeresa R., Hill R., Hansen L. A., Katzman R., Physical basis of cognitive alterations in Alzheimer&#x2019;s disease: Synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 30, 572&#x2013;580 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">1789684</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E., Terry R. D., Alford M., DeTeresa R., Hansen L. A., Cortical and subcortical patterns of synaptophysinlike immunoreactivity in Alzheimer&#x2019;s disease. Am. J. Pathol. 138, 235&#x2013;246 (1991).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1886043</ArticleId><ArticleId IdType="pubmed">1899001</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman B. T., Van Hoesen G. W., Kromer L. J., Damasio A. R., Perforant pathway changes and the memory impairment of Alzheimer&#x2019;s disease. Ann. Neurol. 20, 472&#x2013;481 (1986).</Citation><ArticleIdList><ArticleId IdType="pubmed">3789663</ArticleId></ArticleIdList></Reference><Reference><Citation>DeKosky S. T., Scheff S. W., Synapse loss in frontal cortex biopsies in Alzheimer&#x2019;s disease: Correlation with cognitive severity. Ann. Neurol. 27, 457&#x2013;464 (1990).</Citation><ArticleIdList><ArticleId IdType="pubmed">2360787</ArticleId></ArticleIdList></Reference><Reference><Citation>Gylys K. H., Bilousova T., Flow cytometry analysis and quantitative characterization of tau in synaptosomes from Alzheimer&#x2019;s disease brains. Methods Mol. Biol. 1523, 273&#x2013;284 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5755961</ArticleId><ArticleId IdType="pubmed">27975256</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoo B. C., Cairns N., Fountoulakis M., Lubec G., Synaptosomal proteins, beta-soluble N-ethylmaleimide-sensitive factor attachment protein (beta-SNAP), gamma-SNAP and synaptotagmin I in brain of patients with Down syndrome and Alzheimer&#x2019;s disease. Dement. Geriatr. Cogn. Disord. 12, 219&#x2013;225 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11244216</ArticleId></ArticleIdList></Reference><Reference><Citation>Wijasa T. S., Sylvester M., Brocke-Ahmadinejad N., Schwartz S., Santarelli F., Gieselmann V., Klockgether T., Brosseron F., Heneka M. T., Quantitative proteomics of synaptosome S-nitrosylation in Alzheimer&#x2019;s disease. J. Neurochem. 152, 710&#x2013;726 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31520481</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez-Nievas B. G., Stein T. D., Tai H. C., Dols-Icardo O., Scotton T. C., Barroeta-Espar I., Fernandez-Carballo L., de Munain E. L., Perez J., Marquie M., Serrano-Pozo A., Frosch M. P., Lowe V., Parisi J. E., Petersen R. C., Ikonomovic M. D., L&#xf3;pez O. L., Klunk W., Hyman B. T., G&#xf3;mez-Isla T., Dissecting phenotypic traits linked to human resilience to Alzheimer&#x2019;s pathology. Brain 136, 2510&#x2013;2526 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3722351</ArticleId><ArticleId IdType="pubmed">23824488</ArticleId></ArticleIdList></Reference><Reference><Citation>Koopmans F., van Nierop P., Andres-Alonso M., Byrnes A., Cijsouw T., Coba M. P., Cornelisse L. N., Farrell R. J., Goldschmidt H. L., Howrigan D. P., Hussain N. K., Imig C., de Jong A. P. H., Jung H., Kohansalnodehi M., Kramarz B., Lipstein N., Lovering R. C., Gillavry H. M., Mariano V., Mi H., Ninov M., Osumi-Sutherland D., Pielot R., Smalla K.-H., Tang H., Tashman K., Toonen R. F. G., Verpelli C., Reig-Viader R., Watanabe K., van Weering J., Achsel T., Ashrafi G., Asi N., Brown T. C., De Camilli P., Feuermann M., Foulger R. E., Gaudet P., Joglekar A., Kanellopoulos A., Malenka R., Nicoll R. A., Pulido C., de Juan-Sanz J., Sheng M., S&#xfc;dhof T. C., Tilgner H. U., Bagni C., Bay&#xe9;s &#xc0;., Biederer T., Brose N., Chua J. J. E., Dieterich D. C., Gundelfinger E. D., Hoogenraad C., Huganir R. L., Jahn R., Kaeser P. S., Kim E., Kreutz M. R., McPherson P. S., Neale B. M., O&#x2019;Conner V., Posthuma D., Ryan T. A., Sala C., Feng G., Hyman S. E., Thomas P. D., Smit A. B., Verhage M., SynGO: An evidence-based, expert-curated knowledge base for the synapse. Neuron 103, 217&#x2013;234.e4 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6764089</ArticleId><ArticleId IdType="pubmed">31171447</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson E. C. B., Dammer E. B., Duong D. M., Ping L., Zhou M., Yin L., Higginbotham L. A., Guajardo A., White B., Troncoso J. C., Thambisetty M., Montine T. J., Lee E. B., Trojanowski J. Q., Beach T. G., Reiman E. M., Haroutunian V., Wang M., Schadt E., Zhang B., Dickson D. W., Ertekin-Taner N., Golde T. E., Petyuk V. A., de Jager P. L., Bennett D. A., Wingo T. S., Rangaraju S., Hajjar I., Shulman J. M., Lah J. J., Levey A. I., Seyfried N. T., Large-scale proteomic analysis of Alzheimer&#x2019;s disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation. Nat. Med. 26, 769&#x2013;780 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7405761</ArticleId><ArticleId IdType="pubmed">32284590</ArticleId></ArticleIdList></Reference><Reference><Citation>Wingo A. P., Dammer E. B., Breen M. S., Logsdon B. A., Duong D. M., Troncosco J. C., Thambisetty M., Beach T. G., Serrano G. E., Reiman E. M., Caselli R. J., Lah J. J., Seyfried N. T., Levey A. I., Wingo T. S., Large-scale proteomic analysis of human brain identifies proteins associated with cognitive trajectory in advanced age. Nat. Commun. 10, 1619 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6453881</ArticleId><ArticleId IdType="pubmed">30962425</ArticleId></ArticleIdList></Reference><Reference><Citation>Henstridge C. M., Jackson R. J., Kim J. S. M., Herrmann A. G., Wright A. K., Harris S. E., Bastin M. E., Starr J. M., Wardlaw J., Gillingwater T. H., Smith C., McKenzie C. A., Cox S. R., Deary I. J., Spires-Jones T. L., Post-mortem brain analyses of the Lothian Birth Cohort 1936: Extending lifetime cognitive and brain phenotyping to the level of the synapse. Acta Neuropathol. Commun. 3, 53 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4559320</ArticleId><ArticleId IdType="pubmed">26335101</ArticleId></ArticleIdList></Reference><Reference><Citation>Colom-Cadena M., Pegueroles J., Herrmann A. G., Henstridge C. M., Mu&#xf1;oz L., Querol-Vilaseca M., Mart&#xed;n-Paniello C. S., Luque-Cabecerans J., Clarimon J., Belbin O., N&#xfa;&#xf1;ez-Llaves R., Blesa R., Smith C., McKenzie C. A., Frosch M. P., Roe A., Fortea J., Andilla J., Loza-Alvarez P., Gelpi E., Hyman B. T., Spires-Jones T. L., Lle&#xf3; A., Synaptic phosphorylated &#x3b1;-synuclein in dementia with Lewy bodies. Brain 140, 3204&#x2013;3214 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5841145</ArticleId><ArticleId IdType="pubmed">29177427</ArticleId></ArticleIdList></Reference><Reference><Citation>Tai H. C., Wang B. Y., Serrano&#xbf;Pozo A., Frosch M. P., Spires-Jones T. L., Hyman B. T., Frequent and symmetric deposition of misfolded tau oligomers within presynaptic and postsynaptic terminals in Alzheimer&#xbf;s disease. Acta Neuropathol. Commun. 2, 146 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4209049</ArticleId><ArticleId IdType="pubmed">25330988</ArticleId></ArticleIdList></Reference><Reference><Citation>Gajera C. R., Fernandez R., Postupna N., Montine K. S., Fox E. J., Tebaykin D., Angelo M., Bendall S. C., Keene C. D., Montine T. J., Mass synaptometry: High-dimensional multi parametric assay for single synapses. J. Neurosci. Methods 312, 73&#x2013;83 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6363340</ArticleId><ArticleId IdType="pubmed">30465796</ArticleId></ArticleIdList></Reference><Reference><Citation>Gajera C. R., Fernandez R., Montine K. S., Fox E. J., Mrdjen D., Postupna N. O., Keene C. D., Bendall S. C., Montine T. J., Mass-tag barcoding for multiplexed analysis of human synaptosomes and other anuclear events. Cytometry A 99, 939&#x2013;945 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8590852</ArticleId><ArticleId IdType="pubmed">33818911</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman B. T., Phelps C. H., Beach T. G., Bigio E. H., Cairns N. J., Carrillo M. C., Dickson D. W., Duyckaerts C., Frosch M. P., Masliah E., Mirra S. S., Nelson P. T., Schneider J. A., Thal D. R., Thies B., Trojanowski J. Q., Vinters H. V., Montine T. J., National Institute on Aging-Alzheimer&#x2019;s Association guidelines for the neuropathologic assessment of Alzheimer&#x2019;s disease. Alzheimers Dement. 8, 1&#x2013;13 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3266529</ArticleId><ArticleId IdType="pubmed">22265587</ArticleId></ArticleIdList></Reference><Reference><Citation>Montine T. J., Phelps C. H., Beach T. G., Bigio E. H., Cairns N. J., Dickson D. W., Duyckaerts C., Frosch M. P., Masliah E., Mirra S. S., Nelson P. T., Schneider J. A., Thal D. R., Trojanowski J. Q., Vinters H. V., Hyman B. T.; National Institute on Aging; Alzheimer&#x2019;s Association , National Institute on Aging-Alzheimer&#x2019;s Association guidelines for the neuropathologic assessment of Alzheimer&#x2019;s disease: A practical approach. Acta Neuropathol. 123, 1&#x2013;11 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3268003</ArticleId><ArticleId IdType="pubmed">22101365</ArticleId></ArticleIdList></Reference><Reference><Citation>Montine T. J., Bukhari S. A., White L. R., Cognitive impairment in older adults and therapeutic strategies. Pharmacol. Rev. 73, 152&#x2013;162 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7736830</ArticleId><ArticleId IdType="pubmed">33298513</ArticleId></ArticleIdList></Reference><Reference><Citation>Somogyi P., Tam&#xe1;s G., Lujan R., Buhl E. H., Salient features of synaptic organisation in the cerebral cortex. Brain Res. Brain Res. Rev. 26, 113&#x2013;135 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9651498</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolam J. P., Pissadaki E. K., Living on the edge with too many mouths to feed: Why dopamine neurons die. Mov. Disord. 27, 1478&#x2013;1483 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3504389</ArticleId><ArticleId IdType="pubmed">23008164</ArticleId></ArticleIdList></Reference><Reference><Citation>Smiley J. F., Goldman-Rakic P. S., Heterogeneous targets of dopamine synapses in monkey prefrontal cortex demonstrated by serial section electron microscopy: A laminar analysis using the silver-enhanced diaminobenzidine sulfide (SEDS) immunolabeling technique. Cereb. Cortex 3, 223&#x2013;238 (1993).</Citation><ArticleIdList><ArticleId IdType="pubmed">7686795</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacey C. J., Boyes J., Gerlach O., Chen L., Magill P. J., Bolam J. P., GABA(B) receptors at glutamatergic synapses in the rat striatum. Neuroscience 136, 1083&#x2013;1095 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16226840</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts V. J., Barth S. L., Meunier H., Vale W., Hybridization histochemical and immunohistochemical localization of inhibin/activin subunits and messenger ribonucleic acids in the rat brain. J. Comp. Neurol. 364, 473&#x2013;493 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8820878</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller G. W., Erickson J. D., Perez J. T., Penland S. N., Mash D. C., Rye D. B., Levey A. I., Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson&#x2019;s disease. Exp. Neurol. 156, 138&#x2013;148 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10192785</ArticleId></ArticleIdList></Reference><Reference><Citation>Booij J., Tissingh G., Boer G. J., Speelman J. D., Stoof J. C., Janssen A. G., Wolters E. C., van Royen E. A., [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson&#x2019;s disease. J. Neurol. Neurosurg. Psychiatry 62, 133&#x2013;140 (1997).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC486723</ArticleId><ArticleId IdType="pubmed">9048712</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaguri H., Nilsson P., Hashimoto S., Nagata K., Saito T., de Strooper B., Hardy J., Vassar R., Winblad B., Saido T. C., APP mouse models for Alzheimer&#x2019;s disease preclinical studies. EMBO J. 36, 2473&#x2013;2487 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5579350</ArticleId><ArticleId IdType="pubmed">28768718</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L., Selkoe D. J., Neurotoxicity of amyloid &#x3b2;-protein: Synaptic and network dysfunction. Cold Spring Harb. Perspect. Med. 2, a006338 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3385944</ArticleId><ArticleId IdType="pubmed">22762015</ArticleId></ArticleIdList></Reference><Reference><Citation>Aghaeepour N., Simonds E. F., Knapp D. J. H. F., Bruggner R. V., Sachs K., Culos A., Gherardini P. F., Samusik N., Fragiadakis G. K., Bendall S. C., Gaudilliere B., Angst M. S., Eaves C. J., Weiss W. A., Fantl W. J., Nolan G. P., GateFinder: Projection-based gating strategy optimization for flow and mass cytometry. Bioinformatics 34, 4131&#x2013;4133 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6247943</ArticleId><ArticleId IdType="pubmed">29850785</ArticleId></ArticleIdList></Reference><Reference><Citation>McKeith I. G., Boeve B. F., Dickson D. W., Halliday G., Taylor J. P., Weintraub D., Aarsland D., Galvin J., Attems J., Ballard C. G., Bayston A., Beach T. G., Blanc F., Bohnen N., Bonanni L., Bras J., Brundin P., Burn D., Chen-Plotkin A., Duda J. E., el-Agnaf O., Feldman H., Ferman T. J., ffytche D., Fujishiro H., Galasko D., Goldman J. G., Gomperts S. N., Graff-Radford N. R., Honig L. S., Iranzo A., Kantarci K., Kaufer D., Kukull W., Lee V. M. Y., Leverenz J. B., Lewis S., Lippa C., Lunde A., Masellis M., Masliah E., McLean P., Mollenhauer B., Montine T. J., Moreno E., Mori E., Murray M., O&#x2019;Brien J. T., Orimo S., Postuma R. B., Ramaswamy S., Ross O. A., Salmon D. P., Singleton A., Taylor A., Thomas A., Tiraboschi P., Toledo J. B., Trojanowski J. Q., Tsuang D., Walker Z., Yamada M., Kosaka K., Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology 89, 88&#x2013;100 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5496518</ArticleId><ArticleId IdType="pubmed">28592453</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballmaier M., O&#x2019;Brien J. T., Burton E. J., Thompson P. M., Rex D. E., Narr K. L., McKeith I. G., DeLuca H., Toga A. W., Comparing gray matter loss profiles between dementia with Lewy bodies and Alzheimer&#x2019;s disease using cortical pattern matching: Diagnosis and gender effects. NeuroImage 23, 325&#x2013;335 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15325380</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren L., Bosse M., Thompson S., Risom T., Vijayaragavan K., Caffrey E. M., Marquez D., Angoshtari R., Greenwald N. F., Fienberg H., Wang J., Kambham N., Kirkwood D., Nolan G., Montine T. J., Galli S. J., West R., Bendall S. C., Angelo M., MIBI-TOF: A multiplexed imaging platform relates cellular phenotypes and tissue structure. Sci. Adv. 5, eaax5851 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6785247</ArticleId><ArticleId IdType="pubmed">31633026</ArticleId></ArticleIdList></Reference><Reference><Citation>Rangaraju V., Calloway N., Ryan T. A., Activity-driven local ATP synthesis is required for synaptic function. Cell 156, 825&#x2013;835 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3955179</ArticleId><ArticleId IdType="pubmed">24529383</ArticleId></ArticleIdList></Reference><Reference><Citation>Postupna N., Latimer C. S., Larson E. B., Sherfield E., Paladin J., Shively C. A., Jorgensen M. J., Andrews R. N., Kaplan J. R., Crane P. K., Montine K. S., Craft S., Keene C. D., Montine T. J., Human striatal dopaminergic and regional serotonergic synaptic degeneration with lewy body disease and inheritance of APOE &#x3b5;4. Am. J. Pathol. 187, 884&#x2013;895 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5397713</ArticleId><ArticleId IdType="pubmed">28212814</ArticleId></ArticleIdList></Reference><Reference><Citation>Gratuze M., Holtzman D. M., Targeting pre-synaptic tau accumulation: A new strategy to counteract tau-mediated synaptic loss and memory deficits. Neuron 109, 741&#x2013;743 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33662267</ArticleId></ArticleIdList></Reference><Reference><Citation>Bay&#xe9;s &#xc0;., Collins M. O., Reig-Viader R., Gou G., Goulding D., Izquierdo A., Choudhary J. S., Emes R. D., Grant S. G. N., Evolution of complexity in the zebrafish synapse proteome. Nat. Commun. 8, 14613 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5337974</ArticleId><ArticleId IdType="pubmed">28252024</ArticleId></ArticleIdList></Reference><Reference><Citation>B. C. Carlyle et al., Multiplexed fractionated proteomics reveals synaptic factors associated with cognitive resilience in Alzheimer&#x2019;s disease. bioRxiv 2020.07.31.230680 [Preprint]. 1 August 2020. 10.1101/2020.07.31.230680.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.07.31.230680</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi J., Sullards M. C., Olzmann J. A., Rees H. D., Weintraub S. T., Bostwick D. E., Gearing M., Levey A. I., Chin L. S., Li L., Oxidative damage of DJ-1 is linked to sporadic Parkinson and Alzheimer diseases. J. Biol. Chem. 281, 10816&#x2013;10824 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850953</ArticleId><ArticleId IdType="pubmed">16517609</ArticleId></ArticleIdList></Reference><Reference><Citation>Solti K., Kuan W. L., F&#xf3;rizs B., Kustos G., Mih&#xe1;ly J., Varga Z., Herberth B., Moravcsik &#xc9;., Kiss R., K&#xe1;rp&#xe1;ti M., Mikes A., Zhao Y., Imre T., Rochet J. C., Aigbirhio F., Williams-Gray C. H., Barker R. A., T&#xf3;th G., DJ-1 can form &#x3b2;-sheet structured aggregates that co-localize with pathological amyloid deposits. Neurobiol. Dis. 134, 104629 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31669752</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore D. J., Zhang L., Troncoso J., Lee M. K., Hattori N., Mizuno Y., Dawson T. M., Dawson V. L., Association of DJ-1 and parkin mediated by pathogenic DJ-1 mutations and oxidative stress. Hum. Mol. Genet. 14, 71&#x2013;84 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15525661</ArticleId></ArticleIdList></Reference><Reference><Citation>Heutink P., PINK-1 and DJ-1&#x2014;New genes for autosomal recessive Parkinson&#x2019;s disease. J. Neural Transm. Suppl. 2006, 215&#x2013;219 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17017532</ArticleId></ArticleIdList></Reference><Reference><Citation>Montine T. J., Montine K. S., McMahan W., Markesbery W. R., Quinn J. F., Morrow J. D., F2-isoprostanes in Alzheimer and other neurodegenerative diseases. Antioxid. Redox Signal. 7, 269&#x2013;275 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15650414</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohnishi H., Kaneko Y., Okazawa H., Miyashita M., Sato R., Hayashi A., Tada K., Nagata S., Takahashi M., Matozaki T., Differential localization of Src homology 2 domain-containing protein tyrosine phosphatase substrate-1 and CD47 and its molecular mechanisms in cultured hippocampal neurons. J. Neurosci. 25, 2702&#x2013;2711 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725182</ArticleId><ArticleId IdType="pubmed">15758180</ArticleId></ArticleIdList></Reference><Reference><Citation>Toth A. B., Terauchi A., Zhang L. Y., Johnson-Venkatesh E. M., Larsen D. J., Sutton M. A., Umemori H., Synapse maturation by activity-dependent ectodomain shedding of SIRP&#x3b1;. Nat. Neurosci. 16, 1417&#x2013;1425 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3820962</ArticleId><ArticleId IdType="pubmed">24036914</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T. W., Isenberg J. S., Shih H. B., Wang Y., Roberts D. D., Amyloid-&#x3b2; inhibits No-cGMP signaling in a CD36- and CD47-dependent manner. PLOS ONE 5, e15686 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3008726</ArticleId><ArticleId IdType="pubmed">21203512</ArticleId></ArticleIdList></Reference><Reference><Citation>Han M. H., Lundgren D. H., Jaiswal S., Chao M., Graham K. L., Garris C. S., Axtell R. C., Ho P. P., Lock C. B., Woodard J. I., Brownell S. E., Zoudilova M., Hunt J. F. V., Baranzini S. E., Butcher E. C., Raine C. S., Sobel R. A., Han D. K., Weissman I., Steinman L., Janus-like opposing roles of CD47 in autoimmune brain inflammation in humans and mice. J. Exp. Med. 209, 1325&#x2013;1334 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3405500</ArticleId><ArticleId IdType="pubmed">22734047</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehrman E. K., Wilton D. K., Litvina E. Y., Welsh C. A., Chang S. T., Frouin A., Walker A. J., Heller M. D., Umemori H., Chen C., Stevens B., CD47 protects synapses from excess microglia-mediated pruning during development. Neuron 100, 120&#x2013;134.e6 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6314207</ArticleId><ArticleId IdType="pubmed">30308165</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartels T., De Schepper S., Hong S., Microglia modulate neurodegeneration in Alzheimer&#x2019;s and Parkinson&#x2019;s diseases. Science 370, 66&#x2013;69 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33004513</ArticleId></ArticleIdList></Reference><Reference><Citation>Chao M. P., Takimoto C. H., Feng D. D., Kenna K. M., Gip P., Liu J., Volkmer J.-P., Weissman I. L., Majeti R., Therapeutic targeting of the macrophage immune checkpoint CD47 in myeloid malignancies. Front. Oncol. 9, 1380 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6990910</ArticleId><ArticleId IdType="pubmed">32038992</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulrich J. D., Ulland T. K., Mahan T. E., Nystr&#xf6;m S., Nilsson K. P., Song W. M., Zhou Y., Reinartz M., Choi S., Jiang H., Stewart F. R., Anderson E., Wang Y., Colonna M., Holtzman D. M., ApoE facilitates the microglial response to amyloid plaque pathology. J. Exp. Med. 215, 1047&#x2013;1058 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5881464</ArticleId><ArticleId IdType="pubmed">29483128</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y., Yamada K., Liddelow S. A., Smith S. T., Zhao L., Luo W., Tsai R. M., Spina S., Grinberg L. T., Rojas J. C., Gallardo G., Wang K., Roh J., Robinson G., Finn M. B., Jiang H., Sullivan P. M., Baufeld C., Wood M. W., Sutphen C., Cue L. M., Xiong C., Del-Aguila J. L., Morris J. C., Cruchaga C.; Alzheimer&#x2019;s Disease Neuroimaging Initiative, Fagan A. M., Miller B. L., Boxer A. L., Seeley W. W., Butovsky O., Barres B. A., Paul S. M., Holtzman D. M., ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature 549, 523&#x2013;527 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5641217</ArticleId><ArticleId IdType="pubmed">28959956</ArticleId></ArticleIdList></Reference><Reference><Citation>Huynh T.-P. V., Liao F., Francis C. M., Robinson G. O., Serrano J. R., Jiang H., Roh J., Finn M. B., Sullivan P. M., Esparza T. J., Stewart F. R., Mahan T. E., Ulrich J. D., Cole T., Holtzman D. M., Age-dependent effects of apoE reduction using antisense oligonucleotides in a model of &#x3b2;-amyloidosis. Neuron 96, 1013&#x2013;1023.e4 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5728673</ArticleId><ArticleId IdType="pubmed">29216448</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G. M., Knopman D. S., Chertkow H., Hyman B. T., Jack C. R. Jr., Kawas C. H., Klunk W. E., Koroshetz W. J., Manly J. J., Mayeux R., Mohs R. C., Morris J. C., Rossor M. N., Scheltens P., Carrillo M. C., Thies B., Weintraub S., Phelps C. H., The diagnosis of dementia due to Alzheimer&#x2019;s disease: Recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 7, 263&#x2013;269 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312024</ArticleId><ArticleId IdType="pubmed">21514250</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandura D. R., Baranov V. I., Ornatsky O. I., Antonov A., Kinach R., Lou X., Pavlov S., Vorobiev S., Dick J. E., Tanner S. D., Mass cytometry: Technique for real time single cell multitarget immunoassay based on inductively coupled plasma time-of-flight mass spectrometry. Anal. Chem. 81, 6813&#x2013;6822 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19601617</ArticleId></ArticleIdList></Reference><Reference><Citation>Uhlen M., Bandrowski A., Carr S., Edwards A., Ellenberg J., Lundberg E., Rimm D. L., Rodriguez H., Hiltke T., Snyder M., Yamamoto T., A proposal for validation of antibodies. Nat. Methods 13, 823&#x2013;827 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10335836</ArticleId><ArticleId IdType="pubmed">27595404</ArticleId></ArticleIdList></Reference><Reference><Citation>Holcomb L., Gordon M. N., McGowan E., Yu X., Benkovic S., Jantzen P., Wright K., Saad I., Mueller R., Morgan D., Sanders S., Zehr C., O&#x2019;Campo K., Hardy J., Prada C. M., Eckman C., Younkin S., Hsiao K., Duff K., Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat. Med. 4, 97&#x2013;100 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9427614</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanley N., Stelzer I. A., Tsai A. S., Fallahzadeh R., Ganio E., Becker M., Phongpreecha T., Nassar H., Ghaemi S., Maric I., Culos A., Chang A. L., Xenochristou M., Han X., Espinosa C., Rumer K., Peterson L., Verdonk F., Gaudilliere D., Tsai E., Feyaerts D., Einhaus J., Ando K., Wong R. J., Obermoser G., Shaw G. M., Stevenson D. K., Angst M. S., Gaudilliere B., Aghaeepour N., VoPo leverages cellular heterogeneity for predictive modeling of single-cell data. Nat. Commun. 11, 3738 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7385162</ArticleId><ArticleId IdType="pubmed">32719375</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Gassen S., Callebaut B., Van Helden M. J., Lambrecht B. N., Demeester P., Dhaene T., Saeys Y., FlowSOM: Using self-organizing maps for visualization and interpretation of cytometry data. Cytometry A 87, 636&#x2013;645 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25573116</ArticleId></ArticleIdList></Reference><Reference><Citation>Weber L. M., Robinson M. D., Comparison of clustering methods for high-dimensional single-cell flow and mass cytometry data. Cytometry A 89, 1084&#x2013;1096 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27992111</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X., Song W., Wong B. Y., Zhang T., Yu S., Lin G. N., Ding X., A comparison framework and guideline of clustering methods for mass cytometry data. Genome Biol. 20, 297 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6929440</ArticleId><ArticleId IdType="pubmed">31870419</ArticleId></ArticleIdList></Reference><Reference><Citation>X. Guo, L. Gao, X. Liu, J. Yin, Improved deep embedded clustering with local structure preservation, in Proceedings of the Twenty-Sixth International Joint Conference on Artificial Intelligence (IJCAI, 2017), pp. 1753&#x2013;1759.</Citation></Reference><Reference><Citation>Hornik K., A CLUE for CLUster ensembles. J. Stat. Softw. 14, 1&#x2013;25 (2005).</Citation></Reference><Reference><Citation>Gylys K. H., Fein J. A., Cole G. M., Quantitative characterization of crude synaptosomal fraction (P-2) components by flow cytometry. J. Neurosci. Res. 61, 186&#x2013;192 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10878591</ArticleId></ArticleIdList></Reference><Reference><Citation>Gylys K. H., Fein J. A., Yang F., Wiley D. J., Miller C. A., Cole G. M., Synaptic changes in Alzheimer&#x2019;s disease: Increased amyloid-beta and gliosis in surviving terminals is accompanied by decreased PSD-95 fluorescence. Am. J. Pathol. 165, 1809&#x2013;1817 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1618663</ArticleId><ArticleId IdType="pubmed">15509549</ArticleId></ArticleIdList></Reference><Reference><Citation>Culos A., Tsai A. S., Stanley N., Becker M., Ghaemi M. S., McIlwain D. R., Fallahzadeh R., Tanada A., Nassar H., Espinosa C., Xenochristou M., Ganio E., Peterson L., Han X., Stelzer I. A., Ando K., Gaudilliere D., Phongpreecha T., Mari&#x107; I., Chang A. L., Shaw G. M., Stevenson D. K., Bendall S., Davis K. L., Fantl W., Nolan G. P., Hastie T., Tibshirani R., Angst M. S., Gaudilliere B., Aghaeepour N., Integration of mechanistic immunological knowledge into a machine learning pipeline improves predictions. Nat. Mach. Intell. 2, 619&#x2013;628 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7720904</ArticleId><ArticleId IdType="pubmed">33294774</ArticleId></ArticleIdList></Reference><Reference><Citation>Phongpreecha T., Fernandez R., Mrdjen D., Culos A., Gajera C. R., Wawro A. M., Stanley N., Gaudilliere B., Poston K. L., Aghaeepour N., Montine T. J., Single-cell peripheral immunoprofiling of Alzheimer&#x2019;s and Parkinson&#x2019;s diseases. Sci. Adv. 6, eabd5575 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7688332</ArticleId><ArticleId IdType="pubmed">33239300</ArticleId></ArticleIdList></Reference><Reference><Citation>M. M. B. Bosse, S. C. Bendall, M. R. Angelo, MIBI staining: Human BioMolecular Atlas Program (HuBMAP) Method Development Community. protocols.io. 2021 (10.17504/protocols.io.bt9tnr6n).</Citation><ArticleIdList><ArticleId IdType="doi">10.17504/protocols.io.bt9tnr6n</ArticleId></ArticleIdList></Reference><Reference><Citation>M. M. B. Bosse, S. C. Camacho, S. C. Bendall, M. R. Angelo, MIBI and IHC solutions: Human BioMolecular Atlas Program (HuBMAP) Method Development Community. protocols.io. 2021 (10.17504/protocols.io.bhmej43e).</Citation><ArticleIdList><ArticleId IdType="doi">10.17504/protocols.io.bhmej43e</ArticleId></ArticleIdList></Reference><Reference><Citation>Traka M., Podojil J. R., McCarthy D. P., Miller S. D., Popko B., Oligodendrocyte death results in immune-mediated CNS demyelination. Nat. Neurosci. 19, 65&#x2013;74 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4837900</ArticleId><ArticleId IdType="pubmed">26656646</ArticleId></ArticleIdList></Reference><Reference><Citation>Barron T., Saifetiarova J., Bhat M. A., Kim J. H., Myelination of Purkinje axons is critical for resilient synaptic transmission in the deep cerebellar nucleus. Sci. Rep. 8, 1022 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5773691</ArticleId><ArticleId IdType="pubmed">29348594</ArticleId></ArticleIdList></Reference><Reference><Citation>Boggs J. M., Homchaudhuri L., Ranagaraj G., Liu Y., Smith G. S. T., Harauz G., Interaction of myelin basic protein with cytoskeletal and signaling proteins in cultured primary oligodendrocytes and N19 oligodendroglial cells. BMC Res. Notes 7, 387 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4078013</ArticleId><ArticleId IdType="pubmed">24956930</ArticleId></ArticleIdList></Reference><Reference><Citation>Voskuhl R. R., Pribyl T. M., Kampf K., Handley V., Liu H. B., Feng J. M., Campagnoni C. W., Soldan S. S., Messing A., Campagnoni A. T., Experimental autoimmune encephalomyelitis relapses are reduced in heterozygous golli MBP knockout mice. J. Neuroimmunol. 139, 44&#x2013;50 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12799019</ArticleId></ArticleIdList></Reference><Reference><Citation>Treutlein E. M., Kern K., Weigert A., Tarighi N., Schuh C. D., N&#xfc;sing R. M., Schreiber Y., Ferreir&#xf3;s N., Br&#xfc;ne B., Geisslinger G., Pierre S., Scholich K., The prostaglandin E2 receptor EP3 controls CC-chemokine ligand 2-mediated neuropathic pain induced by mechanical nerve damage. J. Biol. Chem. 293, 9685&#x2013;9695 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6016472</ArticleId><ArticleId IdType="pubmed">29752406</ArticleId></ArticleIdList></Reference><Reference><Citation>Tafoya L. C., Mameli M., Miyashita T., Guzowski J. F., Valenzuela C. F., Wilson M. C., Expression and function of SNAP-25 as a universal SNARE component in GABAergic neurons. J. Neurosci. 26, 7826&#x2013;7838 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674219</ArticleId><ArticleId IdType="pubmed">16870728</ArticleId></ArticleIdList></Reference><Reference><Citation>Postupna N. O., Keene C. D., Latimer C., Sherfield E. E., van Gelder R. D., Ojemann J. G., Montine T. J., Darvas M., Flow cytometry analysis of synaptosomes from post-mortem human brain reveals changes specific to Lewy body and Alzheimer&#x2019;s disease. Lab. Investig. 94, 1161&#x2013;1172 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4184945</ArticleId><ArticleId IdType="pubmed">25068655</ArticleId></ArticleIdList></Reference><Reference><Citation>Won S., Incontro S., Nicoll R. A., Roche K. W., PSD-95 stabilizes NMDA receptors by inducing the degradation of STEP61. Proc. Natl. Acad. Sci. U.S.A. 113, E4736&#x2013;E4744 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4987792</ArticleId><ArticleId IdType="pubmed">27457929</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon S. R., Maute R. L., Dulken B. W., Hutter G., George B. M., McCracken M. N., Gupta R., Tsai J. M., Sinha R., Corey D., Ring A. M., Connolly A. J., Weissman I. L., PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature 545, 495&#x2013;499 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5931375</ArticleId><ArticleId IdType="pubmed">28514441</ArticleId></ArticleIdList></Reference><Reference><Citation>Kojima Y., Volkmer J. P., McKenna K., Civelek M., Lusis A. J., Miller C. L., Direnzo D., Nanda V., Ye J., Connolly A. J., Schadt E. E., Quertermous T., Betancur P., Maegdefessel L., Matic L. P., Hedin U., Weissman I. L., Leeper N. J., CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis. Nature 536, 86&#x2013;90 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4980260</ArticleId><ArticleId IdType="pubmed">27437576</ArticleId></ArticleIdList></Reference><Reference><Citation>Willingham S. B., Volkmer J. P., Gentles A. J., Sahoo D., Dalerba P., Mitra S. S., Wang J., Contreras-Trujillo H., Martin R., Cohen J. D., Lovelace P., Scheeren F. A., Chao M. P., Weiskopf K., Tang C., Volkmer A. K., Naik T. J., Storm T. A., Mosley A. R., Edris B., Schmid S. M., Sun C. K., Chua M. S., Murillo O., Rajendran P., Cha A. C., Chin R. K., Kim D., Adorno M., Raveh T., Tseng D., Jaiswal S., Enger P. O., Steinberg G. K., Li G., So S. K., Majeti R., Harsh G. R., van de Rijn M., Teng N. N. H., Sunwoo J. B., Alizadeh A. A., Clarke M. F., Weissman I. L., The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc. Natl. Acad. Sci. U.S.A. 109, 6662&#x2013;6667 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3340046</ArticleId><ArticleId IdType="pubmed">22451913</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashok A., Karmakar S., Chandel R., Ravikumar R., Dalal S., Kong Q., Singh N., Prion protein modulates iron transport in the anterior segment: Implications for ocular iron homeostasis and prion transmission. Exp. Eye Res. 175, 1&#x2013;13 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6167182</ArticleId><ArticleId IdType="pubmed">29859760</ArticleId></ArticleIdList></Reference><Reference><Citation>Lund C., Olsen C. M., Tveit H., Tranulis M. A., Characterization of the prion protein 3F4 epitope and its use as a molecular tag. J. Neurosci. Methods 165, 183&#x2013;190 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17644183</ArticleId></ArticleIdList></Reference><Reference><Citation>Kascsak R. J., Rubenstein R., Merz P. A., Tonna-DeMasi M., Fersko R., Carp R. I., Wisniewski H. M., Diringer H., Mouse polyclonal and monoclonal antibody to scrapie-associated fibril proteins. J. Virol. 61, 3688&#x2013;3693 (1987).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC255980</ArticleId><ArticleId IdType="pubmed">2446004</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilch S., Nunziante M., Ertmer A., Wopfner F., Laszlo L., Sch&#xe4;tzl H. M., Recognition of lumenal prion protein aggregates by post-ER quality control mechanisms is mediated by the preoctarepeat region of PrP. Traffic 5, 300&#x2013;313 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15030571</ArticleId></ArticleIdList></Reference><Reference><Citation>Yelamanchili S. V., Pendyala G., Brunk I., Darna M., Albrecht U., Ahnert-Hilger G., Differential sorting of the vesicular glutamate transporter 1 into a defined vesicular pool is regulated by light signaling involving the clock gene Period2. J. Biol. Chem. 281, 15671&#x2013;15679 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16595674</ArticleId></ArticleIdList></Reference><Reference><Citation>Dimant H., Zhu L., Kibuuka L. N., Fan Z., Hyman B. T., McLean P. J., Direct visualization of CHIP-mediated degradation of alpha-synuclein in vivo: Implications for PD therapeutics. PLOS ONE 9, e92098 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3963877</ArticleId><ArticleId IdType="pubmed">24664141</ArticleId></ArticleIdList></Reference><Reference><Citation>Larson M. E., Sherman M. A., Greimel S., Kuskowski M., Schneider J. A., Bennett D. A., Lesne S. E., Soluble &#x3b1;-synuclein is a novel modulator of Alzheimer&#x2019;s disease pathophysiology. J. Neurosci. 32, 10253&#x2013;10266 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3425439</ArticleId><ArticleId IdType="pubmed">22836259</ArticleId></ArticleIdList></Reference><Reference><Citation>Jakes R., Crowther R. A., Lee V. M. Y., Trojanowski J. Q., Iwatsubo T., Goedert M., Epitope mapping of LB509, a monoclonal antibody directed against human alpha-synuclein. Neurosci. Lett. 269, 13&#x2013;16 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10821633</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-Nogales M., Santos-Galindo M., Merch&#xe1;n-Rubira J., Hoozemans J. J. M., R&#xe1;bano A., Ferrer I., Avila J., Hern&#xe1;ndez F., Lucas J. J., Tau-positive nuclear indentations in P301S tauopathy mice. Brain Pathol. 27, 314&#x2013;322 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8029483</ArticleId><ArticleId IdType="pubmed">27338164</ArticleId></ArticleIdList></Reference><Reference><Citation>Demars M., Hu Y. S., Gadadhar A., Lazarov O., Impaired neurogenesis is an early event in the etiology of familial Alzheimer&#x2019;s disease in transgenic mice. J. Neurosci. Res. 88, 2103&#x2013;2117 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3696038</ArticleId><ArticleId IdType="pubmed">20209626</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcock D. M., Lewis M. R., van Nostrand W. E., Davis J., Previti M. L., Gharkholonarehe N., Vitek M. P., Colton C. A., Progression of amyloid pathology to Alzheimer&#x2019;s disease pathology in an amyloid precursor protein transgenic mouse model by removal of nitric oxide synthase 2. J. Neurosci. 28, 1537&#x2013;1545 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2621082</ArticleId><ArticleId IdType="pubmed">18272675</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin S. A., Sens M. A., Combs C. K., Amyloid precursor protein mediates a tyrosine kinase-dependent activation response in endothelial cells. J. Neurosci. 29, 14451&#x2013;14462 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2820274</ArticleId><ArticleId IdType="pubmed">19923279</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramaker J. M., Swanson T. L., Copenhaver P. F., Amyloid precursor proteins interact with the heterotrimeric G protein Go in the control of neuronal migration. J. Neurosci. 33, 10165&#x2013;10181 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3682380</ArticleId><ArticleId IdType="pubmed">23761911</ArticleId></ArticleIdList></Reference><Reference><Citation>Hilbich C., M&#xf6;nning U., Grund C., Masters C. L., Beyreuther K., Amyloid-like properties of peptides flanking the epitope of amyloid precursor protein-specific monoclonal antibody 22C11. J. Biol. Chem. 268, 26571&#x2013;26577 (1993).</Citation><ArticleIdList><ArticleId IdType="pubmed">7504673</ArticleId></ArticleIdList></Reference><Reference><Citation>Kash S. F., Johnson R. S., Tecott L. H., Noebels J. L., Mayfield R. D., Hanahan D., Baekkeskov S., Epilepsy in mice deficient in the 65-kDa isoform of glutamic acid decarboxylase. Proc. Natl. Acad. Sci. U.S.A. 94, 14060&#x2013;14065 (1997).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC28432</ArticleId><ArticleId IdType="pubmed">9391152</ArticleId></ArticleIdList></Reference><Reference><Citation>Erlander M. G., Tillakaratne N. J., Feldblum S., Patel N., Tobin A. J., Two genes encode distinct glutamate decarboxylases. Neuron 7, 91&#x2013;100 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">2069816</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldblum S., Erlander M. G., Tobin A. J., Different distributions of GAD65 and GAD67 mRNAs suggest that the two glutamate decarboxylases play distinctive functional roles. J. Neurosci. Res. 34, 689&#x2013;706 (1993).</Citation><ArticleIdList><ArticleId IdType="pubmed">8315667</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang Y. C., Gottlieb D. I., Characterization of the proteins purified with monoclonal antibodies to glutamic acid decarboxylase. J. Neurosci. 8, 2123&#x2013;2130 (1988).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6569335</ArticleId><ArticleId IdType="pubmed">3385490</ArticleId></ArticleIdList></Reference><Reference><Citation>Blasio S. D., Wortel I. M. N., van Bladel D. A. G., de Vries L. E., Boer T. D.-d., Worah K., de Haas N., Buschow S. I., de Vries I. J. M., Figdor C. G., Hato S. V., Human CD1c(+) DCs are critical cellular mediators of immune responses induced by immunogenic cell death. Oncoimmunology 5, e1192739 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5007971</ArticleId><ArticleId IdType="pubmed">27622063</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng M., Marjon K. D., Zhu F., Weissman-Tsukamoto R., Levett A., Sullivan K., Kao K. S., Markovic M., Bump P. A., Jackson H. M., Choi T. S., Chen J., Banuelos A. M., Liu J., Gip P., Cheng L., Wang D., Weissman I. L., Programmed cell removal by calreticulin in tissue homeostasis and cancer. Nat. Commun. 9, 3194 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6086865</ArticleId><ArticleId IdType="pubmed">30097573</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang C. W., Chiang C. W., Gaffaney J. D., Chapman E. R., Jackson M. B., Lipid-anchored synaptobrevin provides little or no support for exocytosis or liposome fusion. J. Biol. Chem. 291, 2848&#x2013;2857 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4742749</ArticleId><ArticleId IdType="pubmed">26663078</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoch S., De&#xe1;k F., K&#xf6;nigstorfer A., Mozhayeva M., Sara Y., S&#xfc;dhof T. C., Kavalali E. T., SNARE function analyzed in synaptobrevin/VAMP knockout mice. Science 294, 1117&#x2013;1122 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11691998</ArticleId></ArticleIdList></Reference><Reference><Citation>Nyarko J. N. K., Quartey M. O., Heistad R. M., Pennington P. R., Poon L. J., Knudsen K. J., Allonby O., el Zawily A. M., Freywald A., Rauw G., Baker G. B., Mousseau D. D., Glycosylation states of pre- and post-synaptic markers of 5-HT neurons differ with sex and 5-HTTLPR genotype in cortical autopsy samples. Front. Neurosci. 12, 545 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6096231</ArticleId><ArticleId IdType="pubmed">30147642</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Q., Yen A., Rymarczyk G., Asai H., Trengrove C., Aziz N., Kirber M. T., Mostoslavsky G., Ikezu T., Wolozin B., Bolotina V. M., Impairment of PARK14-dependent Ca(2+) signalling is a novel determinant of Parkinson&#x2019;s disease. Nat. Commun. 7, 10332 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4729940</ArticleId><ArticleId IdType="pubmed">26755131</ArticleId></ArticleIdList></Reference><Reference><Citation>Maeder C. I., Kim J.-I., Liang X., Kaganovsky K., Shen A., Li Q., Li Z., Wang S., Xu X. Z. S., Li J. B., Xiang Y. K., Ding J. B., Shen K., The THO complex coordinates transcripts for synapse development and dopamine neuron survival. Cell 174, 1436&#x2013;1449.e20 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6542560</ArticleId><ArticleId IdType="pubmed">30146163</ArticleId></ArticleIdList></Reference><Reference><Citation>Watts J. C., Condello C., Stohr J., Oehler A., Lee J., DeArmond S. J., Lannfelt L., Ingelsson M., Giles K., Prusiner S. B., Serial propagation of distinct strains of A&#x3b2; prions from Alzheimer&#x2019;s disease patients. Proc. Natl. Acad. Sci. U.S.A. 111, 10323&#x2013;10328 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4104857</ArticleId><ArticleId IdType="pubmed">24982139</ArticleId></ArticleIdList></Reference><Reference><Citation>Miners J. S., Palmer J. C., Love S., Pathophysiology of hypoperfusion of the precuneus in early Alzheimer&#x2019;s disease. Brain Pathol. 26, 533&#x2013;541 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4982069</ArticleId><ArticleId IdType="pubmed">26452729</ArticleId></ArticleIdList></Reference><Reference><Citation>Clippinger A. K., D&#x2019;Alton S., Lin W. L., Gendron T. F., Howard J., Borchelt D. R., Cannon A., Carlomagno Y., Chakrabarty P., Cook C., Golde T. E., Levites Y., Ranum L., Schultheis P. J., Xu G., Petrucelli L., Sahara N., Dickson D. W., Giasson B., Lewis J., Robust cytoplasmic accumulation of phosphorylated TDP-43 in transgenic models of tauopathy. Acta Neuropathol. 126, 39&#x2013;50 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3690181</ArticleId><ArticleId IdType="pubmed">23666556</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo W., Dou F., Rodina A., Chip S., Kim J., Zhao Q., Moulick K., Aguirre J., Wu N., Greengard P., Chiosis G., Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies. Proc. Natl. Acad. Sci. U.S.A. 104, 9511&#x2013;9516 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1890525</ArticleId><ArticleId IdType="pubmed">17517623</ArticleId></ArticleIdList></Reference><Reference><Citation>Colton C. A., Vitek M. P., Wink D. A., Xu Q., Cantillana V., Previti M. L., van Nostrand W. E., Weinberg J. B., Dawson H., NO synthase 2 (NOS2) deletion promotes multiple pathologies in a mouse model of Alzheimer&#x2019;s disease. Proc. Natl. Acad. Sci. U.S.A. 103, 12867&#x2013;12872 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1550768</ArticleId><ArticleId IdType="pubmed">16908860</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan A., Kumar A., Peterhoff C., Duff K., Nixon R. A., Axonal transport rates in vivo are unaffected by tau deletion or overexpression in mice. J. Neurosci. 28, 1682&#x2013;1687 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2814454</ArticleId><ArticleId IdType="pubmed">18272688</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandhi N. S., Landrieu I., Byrne C., Kukic P., Amniai L., Cantrelle F. X., Wieruszeski J. M., Mancera R. L., Jacquot Y., Lippens G., A phosphorylation-induced turn defines the Alzheimer&#x2019;s disease AT8 antibody epitope on the tau protein. Angew. Chem. Int. Ed. Engl. 54, 6819&#x2013;6823 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25881502</ArticleId></ArticleIdList></Reference><Reference><Citation>Ando K., Maruko-Otake A., Ohtake Y., Hayashishita M., Sekiya M., Iijima K. M., Stabilization of microtubule-unbound tau via tau phosphorylation at Ser262/356 by Par-1/MARK contributes to augmentation of AD-related phosphorylation and A&#x3b2;42-induced tau toxicity. PLOS Genet. 12, e1005917 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4811436</ArticleId><ArticleId IdType="pubmed">27023670</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilousova T., Melnik M., Miyoshi E., Gonzalez B. L., Poon W. W., Vinters H. V., Miller C. A., Corrada M. M., Kawas C., Hatami A., Albay R. III, Glabe C., Gylys K. H., Apolipoprotein E/Amyloid-&#x3b2; complex accumulates in alzheimer disease cortical synapses via apolipoprotein E receptors and is enhanced by APOE4. Am. J. Pathol. 189, 1621&#x2013;1636 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6680253</ArticleId><ArticleId IdType="pubmed">31108099</ArticleId></ArticleIdList></Reference><Reference><Citation>McQuade A., Kang Y. J., Hasselmann J., Jairaman A., Sotelo A., Coburn M., Shabestari S. K., Chadarevian J. P., Fote G., Tu C. H., Danhash E., Silva J., Martinez E., Cotman C., Prieto G. A., Thompson L. M., Steffan J. S., Smith I., Davtyan H., Cahalan M., Cho H., Blurton-Jones M., Gene expression and functional deficits underlie TREM2-knockout microglia responses in human models of Alzheimer&#x2019;s disease. Nat. Commun. 11, 5370 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7584603</ArticleId><ArticleId IdType="pubmed">33097708</ArticleId></ArticleIdList></Reference><Reference><Citation>Siedlak S. L., Jiang Y., Huntley M. L., Wang L., Gao J., Xie F., Liu J., Su B., Perry G., Wang X., TMEM230 accumulation in granulovacuolar degeneration bodies and dystrophic neurites of Alzheimer&#x2019;s disease. J. Alzheimers Dis. 58, 1027&#x2013;1033 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28527219</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies P., Hinkle K. M., Sukar N. N., Sepulveda B., Mesias R., Serrano G., Alessi D. R., Beach T. G., Benson D. L., White C. L. III, Cowell R. M., Das S. S., West A. B., Melrose H. L., Comprehensive characterization and optimization of anti-LRRK2 (leucine-rich repeat kinase 2) monoclonal antibodies. Biochem. J. 453, 101&#x2013;113 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3682752</ArticleId><ArticleId IdType="pubmed">23560750</ArticleId></ArticleIdList></Reference><Reference><Citation>Bae E. J., Yang N. Y., Song M., Lee C. S., Lee J. S., Jung B. C., Lee H. J., Kim S., Masliah E., Sardi S. P., Lee S. J., Glucocerebrosidase depletion enhances cell-to-cell transmission of &#x3b1;-synuclein. Nat. Commun. 5, 4755 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4452288</ArticleId><ArticleId IdType="pubmed">25156829</ArticleId></ArticleIdList></Reference><Reference><Citation>Tay S. P., Yeo C. W. S., Chai C., Chua P. J., Tan H. M., Ang A. X. Y., Yip D. L. H., Sung J. X., Tan P. H., Bay B. H., Wong S. H., Tang C., Tan J. M. M., Lim K. L., Parkin enhances the expression of cyclin-dependent kinase 6 and negatively regulates the proliferation of breast cancer cells. J. Biol. Chem. 285, 29231&#x2013;29238 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2937954</ArticleId><ArticleId IdType="pubmed">20630868</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin J. W., Fan X., del Cid-Pellitero E., Liu X. X., Zhou L., Dai C., Gibbs E., He W., Li H., Wu X., Hill A., Leavitt B. R., Cashman N., Liu L., Lu J., Durcan T. M., Dong Z., Fon E. A., Wang Y. T., Development of an &#x3b1;-synuclein knockdown peptide and evaluation of its efficacy in Parkinson&#x2019;s disease models. Commun. Biol. 4, 232 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7895943</ArticleId><ArticleId IdType="pubmed">33608634</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruan Y., Hu K., Chen H., Autophagy inhibition enhances isorhamnetin-induced mitochondria-dependent apoptosis in non-small cell lung cancer cells. Mol. Med. Rep. 12, 5796&#x2013;5806 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4581743</ArticleId><ArticleId IdType="pubmed">26238746</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaut J. P., Byun J., Tran H. D., Lauber W. M., Carroll J. A., Hotchkiss R. S., Belaaouaj A., Heinecke J. W., Myeloperoxidase produces nitrating oxidants in vivo. J. Clin. Invest. 109, 1311&#x2013;1319 (2002).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC150982</ArticleId><ArticleId IdType="pubmed">12021246</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhiman M., Nakayasu E. S., Madaiah Y. H., Reynolds B. K., Wen J. J., Almeida I. C., Garg N. J., Enhanced nitrosative stress during Trypanosoma cruzi infection causes nitrotyrosine modification of host proteins: Implications in Chagas&#x2019; disease. Am. J. Pathol. 173, 728&#x2013;740 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2527084</ArticleId><ArticleId IdType="pubmed">18688021</ArticleId></ArticleIdList></Reference><Reference><Citation>Venkatesan A., Uzasci L., Chen Z., Rajbhandari L., Anderson C., Lee M. H., Bianchet M. A., Cotter R., Song H., Nath A., Impairment of adult hippocampal neural progenitor proliferation by methamphetamine: Role for nitrotyrosination. Mol. Brain 4, 28 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3142219</ArticleId><ArticleId IdType="pubmed">21708025</ArticleId></ArticleIdList></Reference><Reference><Citation>Newton K., Matsumoto M. L., Wertz I. E., Kirkpatrick D. S., Lill J. R., Tan J., Dugger D., Gordon N., Sidhu S. S., Fellouse F. A., Komuves L., French D. M., Ferrando R. E., Lam C., Compaan D., Yu C., Bosanac I., Hymowitz S. G., Kelley R. F., Dixit V. M., Ubiquitin chain editing revealed by polyubiquitin linkage-specific antibodies. Cell 134, 668&#x2013;678 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18724939</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira J. V., Soares A. R., Ramalho J. S., Pereira P., Girao H., K63 linked ubiquitin chain formation is a signal for HIF1A degradation by chaperone-mediated autophagy. Sci. Rep. 5, 10210 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4426689</ArticleId><ArticleId IdType="pubmed">25958982</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen M. H., Hagemann T. L., Quinlan R. A., Messing A., Perng M. D., Caspase cleavage of GFAP produces an assembly-compromised proteolytic fragment that promotes filament aggregation. ASN Neuro 5, e00125 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3833455</ArticleId><ArticleId IdType="pubmed">24102621</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y. S., Lim S. C., Chen M. H., Quinlan R. A., Perng M. D., Alexander disease causing mutations in the C-terminal domain of GFAP are deleterious both to assembly and network formation with the potential to both activate caspase 3 and decrease cell viability. Exp. Cell Res. 317, 2252&#x2013;2266 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4308095</ArticleId><ArticleId IdType="pubmed">21756903</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker S. A., Gajera C. R., Wawro A. M., Corces M. R., Montine T. J., GATM and GAMT synthesize creatine locally throughout the mammalian body and within oligodendrocytes of the brain. Brain Res. 1770, 147627 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34418357</ArticleId></ArticleIdList></Reference><Reference><Citation>Wawro A. M., Gajera C. R., Baker S. A., Nirschl J. J., Vogel H., Montine T. J., Creatine transport and pathological changes in creatine transporter deficient mice. J. Inherit. Metab. Dis. 44, 939&#x2013;948 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33389772</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">34910517</PMID><DateRevised><Year>2024</Year><Month>05</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2375-2548</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>51</Issue><PubDate><Year>2021</Year><Month>Dec</Month><Day>17</Day></PubDate></JournalIssue><Title>Science advances</Title><ISOAbbreviation>Sci Adv</ISOAbbreviation></Journal><ArticleTitle>Misexpression of genes lacking CpG islands drives degenerative changes during aging.</ArticleTitle><Pagination><StartPage>eabj9111</StartPage><MedlinePgn>eabj9111</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">eabj9111</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1126/sciadv.abj9111</ELocationID><Abstract><AbstractText>Cellular aging is characterized by disruption of the nuclear lamina and its associated heterochromatin. How these structural changes within the nucleus contribute to age-related degeneration of the organism is unclear. Genes lacking CpG islands (CGI<sup>&#x2212;</sup> genes) generally associate with heterochromatin when they are inactive. Here, we show that the expression of these genes is globally activated in aged cells and tissues. This CGI<sup>&#x2212;</sup> gene misexpression is a common feature of normal and pathological aging in mice and humans. We report evidence that CGI<sup>&#x2212;</sup> gene up-regulation is directly responsible for age-related physiological deterioration, notably for increased secretion of inflammatory mediators.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Jun-Yeong</ForeName><Initials>JY</Initials><Identifier Source="ORCID">0000-0002-4342-1863</Identifier><AffiliationInfo><Affiliation>Davis Center for Regenerative Biology and Medicine, MDI Biological Laboratory, Bar Harbor, ME 04609, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>Ian</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Davis Center for Regenerative Biology and Medicine, MDI Biological Laboratory, Bar Harbor, ME 04609, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Youth</LastName><ForeName>Elliot H H</ForeName><Initials>EHH</Initials><Identifier Source="ORCID">0000-0002-9866-3747</Identifier><AffiliationInfo><Affiliation>Davis Center for Regenerative Biology and Medicine, MDI Biological Laboratory, Bar Harbor, ME 04609, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Brown University, Providence, RI 02912, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jonghwan</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-9919-9843</Identifier><AffiliationInfo><Affiliation>Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Churchill</LastName><ForeName>Gary</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-9190-9284</Identifier><AffiliationInfo><Affiliation>The Jackson Laboratory, Bar Harbor, ME 04609, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Godwin</LastName><ForeName>James</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-9234-7807</Identifier><AffiliationInfo><Affiliation>Davis Center for Regenerative Biology and Medicine, MDI Biological Laboratory, Bar Harbor, ME 04609, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Jackson Laboratory, Bar Harbor, ME 04609, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Korstanje</LastName><ForeName>Ron</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-2808-1610</Identifier><AffiliationInfo><Affiliation>The Jackson Laboratory, Bar Harbor, ME 04609, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beck</LastName><ForeName>Samuel</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-0184-8367</Identifier><AffiliationInfo><Affiliation>Davis Center for Regenerative Biology and Medicine, MDI Biological Laboratory, Bar Harbor, ME 04609, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG068179</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG038070</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P20 GM104318</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P20 GM103423</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM112722</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>12</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Adv</MedlineTA><NlmUniqueID>101653440</NlmUniqueID><ISSNLinking>2375-2548</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>15</Day><Hour>17</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>12</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34910517</ArticleId><ArticleId IdType="pmc">PMC8673774</ArticleId><ArticleId IdType="doi">10.1126/sciadv.abj9111</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Margueron R., Justin N., Ohno K., Sharpe M. L., Son J., Drury W. J., Voigt P., Martin S. R., Taylor W. R., De Marco V., Pirrotta V., Reinberg D., Gamblin S. J., Role of the polycomb protein EED in the propagation of repressive histone marks. Nature 461, 762&#x2013;767 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3772642</ArticleId><ArticleId IdType="pubmed">19767730</ArticleId></ArticleIdList></Reference><Reference><Citation>Dixon J. R., Jung I., Selvaraj S., Shen Y., Antosiewicz-Bourget J. E., Lee A. Y., Ye Z., Kim A., Rajagopal N., Xie W., Diao Y., Liang J., Zhao H., Lobanenkov V. V., Ecker J. R., Thomson J. A., Ren B., Chromatin architecture reorganization during stem cell differentiation. Nature 518, 331&#x2013;336 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4515363</ArticleId><ArticleId IdType="pubmed">25693564</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah P. P., Donahue G., Otte G. L., Capell B. C., Nelson D. M., Cao K., Aggarwala V., Cruickshanks H. A., Rai T. S., McBryan T., Gregory B. D., Adams P. D., Berger S. L., Lamin B1 depletion in senescent cells triggers large-scale changes in gene expression and the chromatin landscape. Genes Dev. 27, 1787&#x2013;1799 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3759695</ArticleId><ArticleId IdType="pubmed">23934658</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W., Li J., Suzuki K., Qu J., Wang P., Zhou J., Liu X., Ren R., Xu X., Ocampo A., Yuan T., Yang J., Li Y., Shi L., Guan D., Pan H., Duan S., Ding Z., Li M., Yi F., Bai R., Wang Y., Chen C., Yang F., Li X., Wang Z., Aizawa E., Goebl A., Soligalla R. D., Reddy P., Esteban C. R., Tang F., Liu G. H., Belmonte J. C. I., A Werner syndrome stem cell model unveils heterochromatin alterations as a driver of human aging. Science 348, 1160&#x2013;1163 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4494668</ArticleId><ArticleId IdType="pubmed">25931448</ArticleId></ArticleIdList></Reference><Reference><Citation>Beyret E., Liao H. K., Yamamoto M., Hernandez-Benitez R., Fu Y., Erikson G., Reddy P., Izpisua Belmonte J. C., Single-dose CRISPR&#x2013;Cas9 therapy extends lifespan of mice with Hutchinson&#x2013;Gilford progeria syndrome. Nat. Med. 25, 419&#x2013;422 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6541418</ArticleId><ArticleId IdType="pubmed">30778240</ArticleId></ArticleIdList></Reference><Reference><Citation>Scaffidi P., Misteli T., Lamin A-dependent nuclear defects in human aging. Science 312, 1059&#x2013;1063 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1855250</ArticleId><ArticleId IdType="pubmed">16645051</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandra T., Ewels P. A., Schoenfelder S., Furlan-Magaril M., Wingett S. W., Kirschner K., Thuret J. Y., Andrews S., Fraser P., Reik W., Global reorganization of the nuclear landscape in senescent cells. Cell Rep. 10, 471&#x2013;483 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4542308</ArticleId><ArticleId IdType="pubmed">25640177</ArticleId></ArticleIdList></Reference><Reference><Citation>Beck S., Lee B. K., Rhee C., Song J., Woo A. J., Kim J., CpG island-mediated global gene regulatory modes in mouse embryonic stem cells. Nat. Commun. 5, 5490 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4236720</ArticleId><ArticleId IdType="pubmed">25405324</ArticleId></ArticleIdList></Reference><Reference><Citation>Beck S., Rhee C., Song J., Lee B.-K., LeBlanc L., Cannon L., Kim J., Implications of CpG islands on chromosomal architectures and modes of global gene regulation. Nucleic Acids Res. 46, 4382&#x2013;4391 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5961348</ArticleId><ArticleId IdType="pubmed">29529258</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J.-Y., Song J., Leblanc L., Davis I., Kim J., Beck S., Conserved dual-mode gene regulation programs in higher eukaryotes. Nucleic Acids Res. 49, 2583&#x2013;2597 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7969006</ArticleId><ArticleId IdType="pubmed">33621342</ArticleId></ArticleIdList></Reference><Reference><Citation>Deaton A. M., Bird A., CpG islands and the regulation of transcription. Genes Dev. 25, 1010&#x2013;1022 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3093116</ArticleId><ArticleId IdType="pubmed">21576262</ArticleId></ArticleIdList></Reference><Reference><Citation>Gyuricza I. G., Chick J. M., Keele G. R., Deighan A. G., Munger S. C., Korstanje R., Gygi S. P., Churchill G. A., Genome-wide transcript and protein analysis reveals distinct features of aging in the mouse heart. bioRxiv. 2020, 272260 (2020).</Citation></Reference><Reference><Citation>Takemon Y., Chick J. M., Gerdes Gyuricza I., Skelly D. A., Devuyst O., Gygi S. P., Churchill G. A., Korstanje R., Proteomic and transcriptomic profiling reveal different aspects of aging in the kidney. eLife 10, e62585 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8096428</ArticleId><ArticleId IdType="pubmed">33687326</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultz L. D., Lyons B. L., Burzenski L. M., Gott B., Samuels R., Schweitzer P. A., Dreger C., Herrmann H., Kalscheuer V., Olins A. L., Olins D. E., Sperling K., Hoffman K., Mutations at the mouse ichthyosis locus are within the lamin B receptor gene: A single gene model for human Pelger-Hu&#xeb;t anomaly. Hum. Mol. Genet. 12, 61&#x2013;69 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12490533</ArticleId></ArticleIdList></Reference><Reference><Citation>Solovei I., Wang A. S., Thanisch K., Schmidt C. S., Krebs S., Zwerger M., Cohen T. V., Devys D., Foisner R., Peichl L., Herrmann H., Blum H., Engelkamp D., Stewart C. L., Leonhardt H., Joffe B., LBR and lamin A/C sequentially tether peripheral heterochromatin and inversely regulate differentiation. Cell 152, 584&#x2013;598 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23374351</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonev B., Cavalli G., Organization and function of the 3D genome. Nat. Rev. Genet. 17, 661&#x2013;678 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27739532</ArticleId></ArticleIdList></Reference><Reference><Citation>van Steensel B., Belmont A. S., Lamina-associated domains: Links with chromosome architecture, heterochromatin, and gene repression. Cell 169, 780&#x2013;791 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5532494</ArticleId><ArticleId IdType="pubmed">28525751</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia Y., Vong J. S. L., Asafova A., Garvalov B. K., Caputo L., Cordero J., Singh A., Boettger T., G&#xfc;nther S., Fink L., Acker T., Barreto G., Seeger W., Braun T., Savai R., Dobreva G., Lamin B1 loss promotes lung cancer development and metastasis by epigenetic derepression of RET. J. Exp. Med. 216, 1377&#x2013;1395 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6547854</ArticleId><ArticleId IdType="pubmed">31015297</ArticleId></ArticleIdList></Reference><Reference><Citation>He J., Fu X., Zhang M., He F., Li W., Abdul M. M., Zhou J., Sun L., Chang C., Li Y., Liu H., Wu K., Babarinde I. A., Zhuang Q., Loh Y. H., Chen J., Esteban M. A., Hutchins A. P., Transposable elements are regulated by context-specific patterns of chromatin marks in mouse embryonic stem cells. Nat. Commun. 10, 34 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6318327</ArticleId><ArticleId IdType="pubmed">30604769</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguayo-Mazzucato C., Andle J., Lee T. B., Midha A., Talemal L., Chipashvili V., Hollister-Lock J., van Deursen J., Weir G., Bonner-Weir S., Acceleration of &#x3b2; cell aging determines diabetes and senolysis improves disease outcomes. Cell Metab. 30, 129&#x2013;142.e4 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6610720</ArticleId><ArticleId IdType="pubmed">31155496</ArticleId></ArticleIdList></Reference><Reference><Citation>Lieberman-Aiden E., Van Berkum N. L., Williams L., Imakaev M., Ragoczy T., Telling A., Amit I., Lajoie B. R., Sabo P. J., Dorschner M. O., Sandstrom R., Bernstein B., Bender M. A., Groudine M., Gnirke A., Stamatoyannopoulos J., Mirny L. A., Lander E. S., Dekker J., Comprehensive mapping of long-range interactions reveals folding principles of the human genome. Science 326, 289&#x2013;293 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2858594</ArticleId><ArticleId IdType="pubmed">19815776</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall I. M., Shankaranarayana G. D., Noma K.-I., Ayoub N., Cohen A., Grewal S. I. S., Establishment and maintenance of a heterochromatin domain. Science 297, 2232&#x2013;2237 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12215653</ArticleId></ArticleIdList></Reference><Reference><Citation>Padeken J., Heun P., Nucleolus and nuclear periphery: Velcro for heterochromatin. Curr. Opin. Cell Biol. 28, 54&#x2013;60 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24690547</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez-Jimenez C. P., Eling N., Chen H.-C., Vallejos C. A., Kolodziejczyk A. A., Connor F., Stojic L., Rayner T. F., Stubbington M. J. T., Teichmann S. A., De La Roche M., Marioni J. C., Odom D. T., Aging increases cell-to-cell transcriptional variability upon immune stimulation. Science 355, 1433&#x2013;1436 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5405862</ArticleId><ArticleId IdType="pubmed">28360329</ArticleId></ArticleIdList></Reference><Reference><Citation>Enge M., Arda H. E., Mignardi M., Beausang J., Bottino R., Kim S. K., Quake S. R., Single-cell analysis of human pancreas reveals transcriptional signatures of aging and somatic mutation patterns. Cell 171, 321&#x2013;330.e14 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6047899</ArticleId><ArticleId IdType="pubmed">28965763</ArticleId></ArticleIdList></Reference><Reference><Citation>Soreq L.; UK Brain Expression Consortium; North American Brain Expression Consortium, Rose J., Soreq E., Hardy J., Trabzuni D., Cookson M. R., Smith C., Ryten M., Patani R., Ule J., Major shifts in glial regional identity are a transcriptional hallmark of human brain aging. Cell Rep. 18, 557&#x2013;570 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5263238</ArticleId><ArticleId IdType="pubmed">28076797</ArticleId></ArticleIdList></Reference><Reference><Citation>Kowalczyk M. S., Tirosh I., Heckl D., Rao T. N., Dixit A., Haas B. J., Schneider R. K., Wagers A. J., Ebert B. L., Regev A., Single-cell RNA-seq reveals changes in cell cycle and differentiation programs upon aging of hematopoietic stem cells. Genome Res. 25, 1860&#x2013;1872 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4665007</ArticleId><ArticleId IdType="pubmed">26430063</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinsaft J. W., Edelberg J. M., Aging-associated changes in vascular activity: A potential link to geriatric cardiovascular disease. Am. J. Geriatr. Cardiol. 10, 348&#x2013;354 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11684920</ArticleId></ArticleIdList></Reference><Reference><Citation>Trayhurn P., Wood I. S., Signalling role of adipose tissue: Adipokines and inflammation in obesity. Biochem. Soc. Trans. 33, 1078&#x2013;1081 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16246049</ArticleId></ArticleIdList></Reference><Reference><Citation>Valdes A. M., Richards J. B., Gardner J. P., Swaminathan R., Kimura M., Xiaobin L., Aviv A., Spector T. D., Telomere length in leukocytes correlates with bone mineral density and is shorter in women with osteoporosis. Osteoporos. Int. 18, 1203&#x2013;1210 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17347788</ArticleId></ArticleIdList></Reference><Reference><Citation>Waldera Lupa D. M., Kalfalah F., Safferling K., Boukamp P., Poschmann G., Volpi E., G&#xf6;tz-R&#xf6;sch C., Bernerd F., Haag L., Huebenthal U., Fritsche E., Boege F., Grabe N., Tigges J., St&#xfc;hler K., Krutmann J., Characterization of skin aging-associated secreted proteins (SAASP) produced by dermal fibroblasts isolated from intrinsically aged human skin. J. Invest. Dermatol. 135, 1954&#x2013;1968 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25815425</ArticleId></ArticleIdList></Reference><Reference><Citation>Karasik D., Cohen-Zinder M., The genetic pleiotropy of musculoskeletal aging. Front. Physiol. 3, 303 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3429074</ArticleId><ArticleId IdType="pubmed">22934054</ArticleId></ArticleIdList></Reference><Reference><Citation>Childs B. G., Gluscevic M., Baker D. J., Laberge R. M., Marquess D., Dananberg J., Van Deursen J. M., Senescent cells: An emerging target for diseases of ageing. Nat. Rev. Drug Discov. 16, 718&#x2013;735 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5942225</ArticleId><ArticleId IdType="pubmed">28729727</ArticleId></ArticleIdList></Reference><Reference><Citation>Copp&#xe9; J. P., Patil C. K., Rodier F., Sun Y., Mu&#xf1;oz D. P., Goldstein J., Nelson P. S., Desprez P. Y., Campisi J., Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol. 6, e0060301 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2592359</ArticleId><ArticleId IdType="pubmed">19053174</ArticleId></ArticleIdList></Reference><Reference><Citation>Basisty N., Kale A., Jeon O. H., Kuehnemann C., Payne T., Rao C., Holtz A., Shah S., Sharma V., Ferrucci L., Campisi J., Schilling B., A proteomic atlas of senescence-associated secretomes for aging biomarker development. PLoS Biol. 18, e3000599 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6964821</ArticleId><ArticleId IdType="pubmed">31945054</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehallier B., Gate D., Schaum N., Nanasi T., Lee S. E., Yousef H., Moran Losada P., Berdnik D., Keller A., Verghese J., Sathyan S., Franceschi C., Milman S., Barzilai N., Wyss-Coray T., Undulating changes in human plasma proteome profiles across the lifespan. Nat. Med. 25, 1843&#x2013;1850 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7062043</ArticleId><ArticleId IdType="pubmed">31806903</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahadi S., Zhou W., Sch&#xfc;ssler-Fiorenza Rose S. M., Sailani M. R., Contrepois K., Avina M., Ashland M., Brunet A., Snyder M., Personal aging markers and ageotypes revealed by deep longitudinal profiling. Nat. Med. 26, 83&#x2013;90 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7301912</ArticleId><ArticleId IdType="pubmed">31932806</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka T., Biancotto A., Moaddel R., Moore A. Z., Gonzalez-Freire M., Aon M. A., Candia J., Zhang P., Cheung F., Fantoni G., Semba R. D., Ferrucci L., Plasma proteomic signature of age in healthy humans. Aging Cell 17, e12799 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6156492</ArticleId><ArticleId IdType="pubmed">29992704</ArticleId></ArticleIdList></Reference><Reference><Citation>Olivieri F., Prattichizzo F., Grillari J., Balistreri C. R., Cellular senescence and inflammaging in age-related diseases. Mediators Inflamm. 2018, 9076485 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5932453</ArticleId><ArticleId IdType="pubmed">29849499</ArticleId></ArticleIdList></Reference><Reference><Citation>Franceschi C., Garagnani P., Parini P., Giuliani C., Santoro A., Inflammaging: A new immune&#x2013;metabolic viewpoint for age-related diseases. Nat. Rev. Endocrinol. 14, 576&#x2013;590 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30046148</ArticleId></ArticleIdList></Reference><Reference><Citation>Sousa-Victor P., Neves J., Cedron-Craft W., Ventura P. B., Liao C. Y., Riley R. R., Soifer I., van Bruggen N., Kolumam G. A., Villeda S. A., Lamba D. A., Jasper H., MANF regulates metabolic and immune homeostasis in ageing and protects against liver damage. Nat. Metab. 1, 276&#x2013;290 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6727652</ArticleId><ArticleId IdType="pubmed">31489403</ArticleId></ArticleIdList></Reference><Reference><Citation>Upadhaya S., Sawai C. M., Papalexi E., Rashidfarrokhi A., Jang G., Chattopadhyay P., Satija R., Reizis B., Kinetics of adult hematopoietic stem cell differentiation in vivo. J. Exp. Med. 215, 2815&#x2013;2832 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6219744</ArticleId><ArticleId IdType="pubmed">30291161</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawai C. M., Babovic S., Upadhaya S., Knapp D. J. H. F., Lavin Y., Lau C. M., Goloborodko A., Feng J., Fujisaki J., Ding L., Mirny L. A., Merad M., Eaves C. J., Reizis B., Hematopoietic stem cells are the major source of multilineage hematopoiesis in adult animals. Immunity 45, 597&#x2013;609 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5054720</ArticleId><ArticleId IdType="pubmed">27590115</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanpain C., Stem cells: Skin regeneration and repair. Nature 464, 686&#x2013;687 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20360726</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung C. T., Coulombe P. A., Reed R. R., Contribution of olfactory neural stem cells to tissue maintenance and regeneration. Nat. Neurosci. 10, 720&#x2013;726 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17468753</ArticleId></ArticleIdList></Reference><Reference><Citation>Oates P. S., West A. R., Heme in intestinal epithelial cell turnover, differentiation, detoxification, inflammation, carcinogenesis, absorption and motility. World J. Gastroenterol. 12, 4281&#x2013;4295 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4087737</ArticleId><ArticleId IdType="pubmed">16865768</ArticleId></ArticleIdList></Reference><Reference><Citation>Franceschi C., Garagnani P., Morsiani C., Conte M., Santoro A., Grignolio A., Monti D., Capri M., Salvioli S., The continuum of aging and age-related diseases: Common mechanisms but different rates. Front. Med. 5, 61 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5890129</ArticleId><ArticleId IdType="pubmed">29662881</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaul E., Barron J., Age-related diseases and clinical and public health implications for the 85 years old and over population. Front. Public Heal. 5, 335 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5732407</ArticleId><ArticleId IdType="pubmed">29312916</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf3;pez-Ot&#xed;n C., Blasco M. A., Partridge L., Serrano M., Kroemer G., The hallmarks of aging. Cell 153, 1194&#x2013;1217 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3836174</ArticleId><ArticleId IdType="pubmed">23746838</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho D. H., Thienes C. P., Mahoney S. E., Analau E., Filippova G. N., Tapscott S. J., Antisense transcription and heterochromatin at the DM1 CTG repeats are constrained by CTCF. Mol. Cell 20, 483&#x2013;489 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16285929</ArticleId></ArticleIdList></Reference><Reference><Citation>Baumgart S., Glesel E., Singh G., Chen N., Reutlinger K., Zhang J., Billadeau D. D., Fernandez-Zapico M. E., Gress T. M., Singh S. K., Ellenrieder V., Restricted heterochromatin formation links NFATc2 repressor activity with growth promotion in pancreatic cancer. Gastroenterology 142, 388&#x2013;398.e7 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3626431</ArticleId><ArticleId IdType="pubmed">22079596</ArticleId></ArticleIdList></Reference><Reference><Citation>Regha K., Sloane M. A., Huang R., Pauler F. M., Warczok K. E., Melikant B., Radolf M., Martens J. H. A., Schotta G., Jenuwein T., Barlow D. P., Active and repressive chromatin are interspersed without spreading in an imprinted gene cluster in the mammalian genome. Mol. Cell 27, 353&#x2013;366 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2847180</ArticleId><ArticleId IdType="pubmed">17679087</ArticleId></ArticleIdList></Reference><Reference><Citation>Nielsen S. J., Schneider R., Bauer U.-M., Bannister A. J., Morrison A., O&#x2019;Carroll D., Firestein R., Cleary M., Jenuwein T., Herrera R. E., Kouzarides T., Rb targets histone H3 methylation and HP1 to promoters. Nature 412, 561&#x2013;565 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11484059</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan K. E., Reddy A. B. M., Dietzmann K., Suriano A. R., Kocieda V. P., Stewart M., Bhatia M., Epigenetic regulation of tumor necrosis factor alpha. Mol. Cell. Biol. 27, 5147&#x2013;5160 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1951949</ArticleId><ArticleId IdType="pubmed">17515611</ArticleId></ArticleIdList></Reference><Reference><Citation>Feiner B., Chase K. A., Melbourne J. K., Rosen C., Sharma R. P., Risperidone effects on heterochromatin: The role of kinase signaling. Clin. Exp. Immunol. 196, 67&#x2013;75 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6422669</ArticleId><ArticleId IdType="pubmed">30714144</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun L., Yu R., Dang W., Chromatin architectural changes during cellular senescence and aging. Genes 9, 211 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5924553</ArticleId><ArticleId IdType="pubmed">29659513</ArticleId></ArticleIdList></Reference><Reference><Citation>Kristiani L., Kim M., Kim Y., Role of the nuclear lamina in age-associated nuclear reorganization and inflammation. Cells 9, 718 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7140666</ArticleId><ArticleId IdType="pubmed">32183360</ArticleId></ArticleIdList></Reference><Reference><Citation>Satija R., Farrell J. A., Gennert D., Schier A. F., Regev A., Spatial reconstruction of single-cell gene expression data. Nat. Biotechnol. 33, 495&#x2013;502 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4430369</ArticleId><ArticleId IdType="pubmed">25867923</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayano M., Yang J.-H., Bonkowski M. S., Amorim J. A., Ross J. M., Coppotelli G., Griffin P. T., Chew Y. C., Guo W., Yang X., Vera D. L., Salfati E. L., Das A., Thakur S., Kane A. E., Mitchell S. J., Mohri Y., Nishimura E. K., Schaevitz L., Garg N., Balta A.-M., Rego M. A., Gregory-Ksander M., Jakobs T. C., Zhong L., Wakimoto H., Mostoslavsky R., Wagers A. J., Tsubota K., Bonasera S. J., Palmeira C. M., Seidman J. G., Seidman C. E., Wolf N. S., Kreiling J. A., Sedivy J. M., Murphy G. F., Oberdoerffer P., Ksander B. R., Rajman L. A., Sinclair D. A., DNA break-induced epigenetic drift as a cause of mammalian aging.bioRxiv, 808659 (2019).</Citation></Reference><Reference><Citation>Kimmel J. C., Penland L., Rubinstein N. D., Hendrickson D. G., Kelley D. R., Rosenthal A. Z., Murine single-cell RNA-seq reveals cell-identity- and tissue-specific trajectories of aging. Genome Res. 29, 2088&#x2013;2103 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6886498</ArticleId><ArticleId IdType="pubmed">31754020</ArticleId></ArticleIdList></Reference><Reference><Citation>Gardiner-Garden M., Frommer M., CpG islands in vertebrate genomes. J. Mol. Biol. 196, 261&#x2013;282 (1987).</Citation><ArticleIdList><ArticleId IdType="pubmed">3656447</ArticleId></ArticleIdList></Reference><Reference><Citation>Illingworth R. S., Gruenewald-Schneider U., Webb S., Kerr A. R. W., James K. D., Turner D. J., Smith C., Harrison D. J., Andrews R., Bird A. P., Orphan CpG islands identify numerous conserved promoters in the mammalian genome. PLOS Genet. 6, e1001134 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2944787</ArticleId><ArticleId IdType="pubmed">20885785</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Liu T., Meyer C. A., Eeckhoute J., Johnson D. S., Bernstein B. E., Nussbaum C., Myers R. M., Brown M., Li W., Shirley X. S., Model-based analysis of ChIP-Seq (MACS). Genome Biol. 9, R137 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2592715</ArticleId><ArticleId IdType="pubmed">18798982</ArticleId></ArticleIdList></Reference><Reference><Citation>Raghupathy N., Choi K., Vincent M. J., Beane G. L., Sheppard K. S., Munger S. C., Korstanje R., Pardo-Manual De Villena F., Churchill G. A., Hierarchical analysis of RNA-seq reads improves the accuracy of allele-specific expression. Bioinformatics 34, 2177&#x2013;2184 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6022640</ArticleId><ArticleId IdType="pubmed">29444201</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobin A., Davis C. A., Schlesinger F., Drenkow J., Zaleski C., Jha S., Batut P., Chaisson M., Gingeras T. R., STAR: Ultrafast universal RNA-seq aligner. Bioinformatics 29, 15&#x2013;21 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3530905</ArticleId><ArticleId IdType="pubmed">23104886</ArticleId></ArticleIdList></Reference><Reference><Citation>Love M. I., Huber W., Anders S., Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4302049</ArticleId><ArticleId IdType="pubmed">25516281</ArticleId></ArticleIdList></Reference><Reference><Citation>Uhl&#xe9;n M., Fagerberg L., Hallstr&#xf6;m B. M., Lindskog C., Oksvold P., Mardinoglu A., Sivertsson &#xc5;., Kampf C., Sj&#xf6;stedt E., Asplund A., Olsson I. M., Edlund K., Lundberg E., Navani S., Szigyarto C. A. K., Odeberg J., Djureinovic D., Takanen J. O., Hober S., Alm T., Edqvist P. H., Berling H., Tegel H., Mulder J., Rockberg J., Nilsson P., Schwenk J. M., Hamsten M., Von Feilitzen K., Forsberg M., Persson L., Johansson F., Zwahlen M., Von Heijne G., Nielsen J., Pont&#xe9;n F., Tissue-based map of the human proteome. Science 347, 1260419 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25613900</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherman B. T., Huang D. W., Tan Q., Guo Y., Bour S., Liu D., Stephens R., Baseler M. W., Lane C. H., Lempicki R. A., DAVID Knowledgebase: A gene-centered database integrating heterogeneous gene annotation resources to facilitate high-throughput gene functional analysis. BMC Bioinformatics. 8, 426 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2186358</ArticleId><ArticleId IdType="pubmed">17980028</ArticleId></ArticleIdList></Reference><Reference><Citation>D. R. Kuhn, R. N. Kacker, Y. Lei, G. Locke, P. Gallagher, Practical Combinatorial Testing (SP 800&#x2013;142, National Institute of Standards &amp; Technology, 2010).</Citation></Reference><Reference><Citation>Langmead B., Salzberg S. L., Fast gapped-read alignment with Bowtie 2. Nat. Methods 9, 357&#x2013;359 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3322381</ArticleId><ArticleId IdType="pubmed">22388286</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinz S., Benner C., Spann N., Bertolino E., Lin Y. C., Laslo P., Cheng J. X., Murre C., Singh H., Glass C. K., Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol. Cell 38, 576&#x2013;589 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2898526</ArticleId><ArticleId IdType="pubmed">20513432</ArticleId></ArticleIdList></Reference><Reference><Citation>Hounkpe B. W., Chenou F., de Lima F., de Paula E. V., HRT Atlas v1.0 database: Redefining human and mouse housekeeping genes and candidate reference transcripts by mining massive RNA-seq datasets. Nucleic Acids Res. 49, D947&#x2013;D955 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7778946</ArticleId><ArticleId IdType="pubmed">32663312</ArticleId></ArticleIdList></Reference><Reference><Citation>Harr J. C., Luperchio T. R., Wong X., Cohen E., Wheelan S. J., Reddy K. L., Directed targeting of chromatin to the nuclear lamina is mediated by chromatin state and A-type lamins. J. Cell Biol. 208, 33&#x2013;52 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4284222</ArticleId><ArticleId IdType="pubmed">25559185</ArticleId></ArticleIdList></Reference><Reference><Citation>McLeay R. C., Bailey T. L., Motif enrichment analysis: A unified framework and an evaluation on ChIP data. BMC Bioinformatics. 11, 165 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2868005</ArticleId><ArticleId IdType="pubmed">20356413</ArticleId></ArticleIdList></Reference><Reference><Citation>Beliveau B. J., Joyce E. F., Apostolopoulos N., Yilmaz F., Fonseka C. Y., McCole R. B., Chang Y., Li J. B., Senaratne T. N., Williams B. R., Rouillard J.-M., Wu C., Versatile design and synthesis platform for visualizing genomes with Oligopaint FISH probes. Proc. Natl. Acad. Sci. 109, 21301&#x2013;21306 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3535588</ArticleId><ArticleId IdType="pubmed">23236188</ArticleId></ArticleIdList></Reference><Reference><Citation>Eidet J. R., Pasovic L., Maria R., Jackson C. J., Utheim T. P., Objective assessment of changes in nuclear morphology and cell distribution following induction of apoptosis. Diagn. Pathol. 9, 92 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4048047</ArticleId><ArticleId IdType="pubmed">24885713</ArticleId></ArticleIdList></Reference><Reference><Citation>Iannuccelli E., Mompart F., Gellin J., Lahbib-Mansais Y., Yerle M., Boudier T., NEMO: A tool for analyzing gene and chromosome territory distributions from 3D-FISH experiments. Bioinformatics 26, 696&#x2013;697 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20080510</ArticleId></ArticleIdList></Reference><Reference><Citation>De Boer J., Andressoo J. O., De Wit J., Huijmans J., Beems R. B., Van Steeg H., Weeda G., Van der Horst G. T. J., Van Leeuwen W., Themmen A. P. N., Meradji M., Hoeijmakers J. H. J., Premature aging in mice deficient in DNA repair and transcription. Science 296, 1276&#x2013;1279 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">11950998</ArticleId></ArticleIdList></Reference><Reference><Citation>Dixon J. R., Selvaraj S., Yue F., Kim A., Li Y., Shen Y., Hu M., Liu J. S., Ren B., Topological domains in mammalian genomes identified by analysis of chromatin interactions. Nature 485, 376&#x2013;380 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3356448</ArticleId><ArticleId IdType="pubmed">22495300</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison D. E., Strong R., Sharp Z. D., Nelson J. F., Astle C. M., Flurkey K., Nadon N. L., Wilkinson J. E., Frenkel K., Carter C. S., Pahor M., Javors M. A., Fernandez E., Miller R. A., Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 460, 392&#x2013;395 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2786175</ArticleId><ArticleId IdType="pubmed">19587680</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">34916658</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>06</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>TREM2 interacts with TDP-43 and mediates microglial neuroprotection against TDP-43-related neurodegeneration.</ArticleTitle><Pagination><StartPage>26</StartPage><EndPage>38</EndPage><MedlinePgn>26-38</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41593-021-00975-6</ELocationID><Abstract><AbstractText>Triggering receptor expressed on myeloid cell 2 (TREM2) is linked to risk of neurodegenerative disease. However, the function of TREM2 in neurodegeneration is still not fully understood. Here, we investigated the role of microglial TREM2 in TAR DNA-binding protein 43 (TDP-43)-related neurodegeneration using virus-mediated and transgenic mouse models. We found that TREM2 deficiency impaired phagocytic clearance of pathological TDP-43 by microglia and enhanced neuronal damage and motor impairments. Mass cytometry analysis revealed that human TDP-43 (hTDP-43) induced a TREM2-dependent subpopulation of microglia with high CD11c expression and phagocytic ability. Using mass spectrometry (MS) and surface plasmon resonance (SPR) analysis, we further demonstrated an interaction between TDP-43 and TREM2 in vitro and in vivo as well as in human tissues from individuals with amyotrophic lateral sclerosis (ALS). We computationally identified regions within hTDP-43 that interact with TREM2. Our data highlight that TDP-43 is a possible ligand for microglial TREM2 and that this interaction mediates neuroprotection of microglia in TDP-43-related neurodegeneration.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s), under exclusive licence to Springer Nature America, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Xie</LastName><ForeName>Manling</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mayo Clinic Graduate School of Biomedical Sciences, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Liu</LastName><ForeName>Yong U</ForeName><Initials>YU</Initials><Identifier Source="ORCID">0000-0003-1278-7114</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, MN, USA. liuy6@foxmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory for Neuroscience in Health and Disease, Guangzhou First People's Hospital School of Medicine, South China University of Technology, Guangzhou, China. liuy6@foxmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Shunyi</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-7265-0801</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Lingxin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bosco</LastName><ForeName>Dale B</ForeName><Initials>DB</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pang</LastName><ForeName>Yuan-Ping</ForeName><Initials>YP</Initials><Identifier Source="ORCID">0000-0003-0838-2560</Identifier><AffiliationInfo><Affiliation>Computer-Aided Molecular Design Laboratory, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhong</LastName><ForeName>Jun</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-3148-4143</Identifier><AffiliationInfo><Affiliation>Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sheth</LastName><ForeName>Udit</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Mayo Clinic Graduate School of Biomedical Sciences, Rochester, MN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martens</LastName><ForeName>Yuka A</ForeName><Initials>YA</Initials><Identifier Source="ORCID">0000-0002-5194-4269</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Na</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-8648-9422</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Chia-Chen</ForeName><Initials>CC</Initials><Identifier Source="ORCID">0000-0001-7203-3926</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhuang</LastName><ForeName>Yongxian</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Liewei</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-3818-8531</Identifier><AffiliationInfo><Affiliation>Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dickson</LastName><ForeName>Dennis W</ForeName><Initials>DW</Initials><Identifier Source="ORCID">0000-0001-7189-7917</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mattson</LastName><ForeName>Mark P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bu</LastName><ForeName>Guojun</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-3491-1016</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Long-Jun</ForeName><Initials>LJ</Initials><Identifier Source="ORCID">0000-0001-8019-3380</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, MN, USA. wu.longjun@mayo.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA. wu.longjun@mayo.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Immunology, Mayo Clinic, Rochester, MN, USA. wu.longjun@mayo.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS110949</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG069701</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG066395</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AG064159</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS088627</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>12</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C578077">TDP-43 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498716">Trem2 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="Y">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="Y">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="Y">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000066829" MajorTopicYN="N">Neuroprotection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011971" MajorTopicYN="Y">Receptors, Immunologic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Competing interests. The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>12</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>11</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>6</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34916658</ArticleId><ArticleId IdType="mid">NIHMS1753734</ArticleId><ArticleId IdType="pmc">PMC8741737</ArticleId><ArticleId IdType="doi">10.1038/s41593-021-00975-6</ArticleId><ArticleId IdType="pii">10.1038/s41593-021-00975-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hickman S, Izzy S, Sen P, Morsett L &amp; El Khoury J Microglia in neurodegeneration. Nat Neurosci 21, 1359&#x2013;1369 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6817969</ArticleId><ArticleId IdType="pubmed">30258234</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulland TK &amp; Colonna M TREM2 - a key player in microglial biology and Alzheimer disease. Nat Rev Neurol 14, 667&#x2013;675 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30266932</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R, et al. TREM2 variants in Alzheimer&#x2019;s disease. N Engl J Med 368, 117&#x2013;127 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3631573</ArticleId><ArticleId IdType="pubmed">23150934</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T, et al. Variant of TREM2 associated with the risk of Alzheimer&#x2019;s disease. N Engl J Med 368, 107&#x2013;116 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677583</ArticleId><ArticleId IdType="pubmed">23150908</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer&#x2019;s disease model. Cell 160, 1061&#x2013;1071 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4477963</ArticleId><ArticleId IdType="pubmed">25728668</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y, et al. TREM2 Is a Receptor for beta-Amyloid that Mediates Microglial Function. Neuron 97, 1023&#x2013;1031 e1027 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5889092</ArticleId><ArticleId IdType="pubmed">29518356</ArticleId></ArticleIdList></Reference><Reference><Citation>Ou SH, Wu F, Harrich D, Garcia-Martinez LF &amp; Gaynor RB Cloning and characterization of a novel cellular protein, TDP-43, that binds to human immunodeficiency virus type 1 TAR DNA sequence motifs. J Virol 69, 3584&#x2013;3596 (1995).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC189073</ArticleId><ArticleId IdType="pubmed">7745706</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314, 130&#x2013;133 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Cairns NJ, et al. TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions. Am J Pathol 171, 227&#x2013;240 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1941578</ArticleId><ArticleId IdType="pubmed">17591968</ArticleId></ArticleIdList></Reference><Reference><Citation>Cady J, et al. TREM2 variant p.R47H as a risk factor for sporadic amyotrophic lateral sclerosis. JAMA Neurol 71, 449&#x2013;453 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4087113</ArticleId><ArticleId IdType="pubmed">24535663</ArticleId></ArticleIdList></Reference><Reference><Citation>Rayaprolu S, et al. TREM2 in neurodegeneration: evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson&#x2019;s disease. Mol Neurodegener 8, 19 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3691612</ArticleId><ArticleId IdType="pubmed">23800361</ArticleId></ArticleIdList></Reference><Reference><Citation>Krasemann S, et al. The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases. Immunity 47, 566&#x2013;581 e569 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5719893</ArticleId><ArticleId IdType="pubmed">28930663</ArticleId></ArticleIdList></Reference><Reference><Citation>Maniatis S, et al. Spatiotemporal dynamics of molecular pathology in amyotrophic lateral sclerosis. Science 364, 89&#x2013;93 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30948552</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker AK, et al. Functional recovery in new mouse models of ALS/FTLD after clearance of pathological cytoplasmic TDP-43. Acta Neuropathol 130, 643&#x2013;660 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5127391</ArticleId><ArticleId IdType="pubmed">26197969</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry VH, Nicoll JA &amp; Holmes C Microglia in neurodegenerative disease. Nat Rev Neurol 6, 193&#x2013;201 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20234358</ArticleId></ArticleIdList></Reference><Reference><Citation>Mrdjen D, et al. High-Dimensional Single-Cell Mapping of Central Nervous System Immune Cells Reveals Distinct Myeloid Subsets in Health, Aging, and Disease. Immunity 48, 380&#x2013;395 e386 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29426702</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H, et al. A Unique Microglia Type Associated with Restricting Development of Alzheimer&#x2019;s Disease. Cell 169, 1276&#x2013;1290 e1217 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Eyo UB, et al. P2Y12R-Dependent Translocation Mechanisms Gate the Changing Microglial Landscape. Cell Rep 23, 959&#x2013;966 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5965271</ArticleId><ArticleId IdType="pubmed">29694903</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiller KJ, et al. Microglia-mediated recovery from ALS-relevant motor neuron degeneration in a mouse model of TDP-43 proteinopathy. Nat Neurosci 21, 329&#x2013;340 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5857237</ArticleId><ArticleId IdType="pubmed">29463850</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinacker P, et al. TDP-43 in cerebrospinal fluid of patients with frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Arch Neurol 65, 1481&#x2013;1487 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2690860</ArticleId><ArticleId IdType="pubmed">19001167</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong J, et al. The interactome of a PTB domain-containing adapter protein, Odin, revealed by SILAC. J Proteomics 74, 294&#x2013;303 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3205450</ArticleId><ArticleId IdType="pubmed">21081186</ArticleId></ArticleIdList></Reference><Reference><Citation>Guenther EL, et al. Atomic structures of TDP-43 LCD segments and insights into reversible or pathogenic aggregation. Nat Struct Mol Biol 25, 463&#x2013;471 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5990464</ArticleId><ArticleId IdType="pubmed">29786080</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee EB, Lee VM &amp; Trojanowski JQ Gains or losses: molecular mechanisms of TDP43-mediated neurodegeneration. Nat Rev Neurosci 13, 38&#x2013;50 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3285250</ArticleId><ArticleId IdType="pubmed">22127299</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q, et al. Developmental Heterogeneity of Microglia and Brain Myeloid Cells Revealed by Deep Single-Cell RNA Sequencing. Neuron 101, 207&#x2013;223 e210 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6336504</ArticleId><ArticleId IdType="pubmed">30606613</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu YU, et al. Neuronal network activity controls microglial process surveillance in awake mice via norepinephrine signaling. Nat Neurosci 22, 1771&#x2013;1781 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6858573</ArticleId><ArticleId IdType="pubmed">31636449</ArticleId></ArticleIdList></Reference><Reference><Citation>Parhizkar S, et al. Loss of TREM2 function increases amyloid seeding but reduces plaque-associated ApoE. Nat Neurosci 22, 191&#x2013;204 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6417433</ArticleId><ArticleId IdType="pubmed">30617257</ArticleId></ArticleIdList></Reference><Reference><Citation>Leyns CEG, et al. TREM2 function impedes tau seeding in neuritic plaques. Nat Neurosci 22, 1217&#x2013;1222 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6660358</ArticleId><ArticleId IdType="pubmed">31235932</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee CYD, et al. Elevated TREM2 Gene Dosage Reprograms Microglia Responsivity and Ameliorates Pathological Phenotypes in Alzheimer&#x2019;s Disease Models. Neuron 97, 1032&#x2013;1048 e1035 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5927822</ArticleId><ArticleId IdType="pubmed">29518357</ArticleId></ArticleIdList></Reference><Reference><Citation>Konishi H &amp; Kiyama H Microglial TREM2/DAP12 Signaling: A Double-Edged Sword in Neural Diseases. Front Cell Neurosci 12, 206 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6087757</ArticleId><ArticleId IdType="pubmed">30127720</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazaheri F, et al. TREM2 deficiency impairs chemotaxis and microglial responses to neuronal injury. EMBO Rep 18, 1186&#x2013;1198 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5494532</ArticleId><ArticleId IdType="pubmed">28483841</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng H, et al. TREM2 Promotes Microglial Survival by Activating Wnt/beta-Catenin Pathway. J Neurosci 37, 1772&#x2013;1784 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5320608</ArticleId><ArticleId IdType="pubmed">28077724</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan Z, et al. Injured sensory neuron-derived CSF1 induces microglial proliferation and DAP12-dependent pain. Nat Neurosci 19, 94&#x2013;101 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4703328</ArticleId><ArticleId IdType="pubmed">26642091</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu N, et al. Spinal Microgliosis Due to Resident Microglial Proliferation Is Required for Pain Hypersensitivity after Peripheral Nerve Injury. Cell Rep 16, 605&#x2013;614 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4956495</ArticleId><ArticleId IdType="pubmed">27373153</ArticleId></ArticleIdList></Reference><Reference><Citation>Otero K, et al. Macrophage colony-stimulating factor induces the proliferation and survival of macrophages via a pathway involving DAP12 and beta-catenin. Nat Immunol 10, 734&#x2013;743 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4004764</ArticleId><ArticleId IdType="pubmed">19503107</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown GC &amp; Neher JJ Microglial phagocytosis of live neurons. Nat Rev Neurosci 15, 209&#x2013;216 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24646669</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu R, Shen Q, Xu P, Luo JJ &amp; Tang Y Phagocytosis of microglia in the central nervous system diseases. Mol Neurobiol 49, 1422&#x2013;1434 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4012154</ArticleId><ArticleId IdType="pubmed">24395130</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong S, et al. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science 352, 712&#x2013;716 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5094372</ArticleId><ArticleId IdType="pubmed">27033548</ArticleId></ArticleIdList></Reference><Reference><Citation>Koizumi S, et al. UDP acting at P2Y6 receptors is a mediator of microglial phagocytosis. Nature 446, 1091&#x2013;1095 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3464483</ArticleId><ArticleId IdType="pubmed">17410128</ArticleId></ArticleIdList></Reference><Reference><Citation>Tufail Y, et al. Phosphatidylserine Exposure Controls Viral Innate Immune Responses by Microglia. Neuron 93, 574&#x2013;586 e578 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5600182</ArticleId><ArticleId IdType="pubmed">28111081</ArticleId></ArticleIdList></Reference><Reference><Citation>Das R &amp; Chinnathambi S Microglial priming of antigen presentation and adaptive stimulation in Alzheimer&#x2019;s disease. Cell Mol Life Sci 76, 3681&#x2013;3694 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11105582</ArticleId><ArticleId IdType="pubmed">31093687</ArticleId></ArticleIdList></Reference><Reference><Citation>Harms AS, et al. MHCII is required for alpha-synuclein-induced activation of microglia, CD4 T cell proliferation, and dopaminergic neurodegeneration. J Neurosci 33, 9592&#x2013;9600 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3903980</ArticleId><ArticleId IdType="pubmed">23739956</ArticleId></ArticleIdList></Reference><Reference><Citation>Bulloch K, et al. CD11c/EYFP transgene illuminates a discrete network of dendritic cells within the embryonic, neonatal, adult, and injured mouse brain. J Comp Neurol 508, 687&#x2013;710 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18386786</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheean RK, et al. Association of Regulatory T-Cell Expansion With Progression of Amyotrophic Lateral Sclerosis: A Study of Humans and a Transgenic Mouse Model. JAMA Neurol 75, 681&#x2013;689 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5885208</ArticleId><ArticleId IdType="pubmed">29507931</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato-Hashimoto M, et al. Microglial SIRPalpha regulates the emergence of CD11c(+) microglia and demyelination damage in white matter. Elife 8 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6435324</ArticleId><ArticleId IdType="pubmed">30910011</ArticleId></ArticleIdList></Reference><Reference><Citation>Atagi Y, et al. Apolipoprotein E Is a Ligand for Triggering Receptor Expressed on Myeloid Cells 2 (TREM2). J Biol Chem 290, 26043&#x2013;26050 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4646257</ArticleId><ArticleId IdType="pubmed">26374899</ArticleId></ArticleIdList></Reference><Reference><Citation>Feiler MS, et al. TDP-43 is intercellularly transmitted across axon terminals. J Cell Biol 211, 897&#x2013;911 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4657165</ArticleId><ArticleId IdType="pubmed">26598621</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong L, et al. Soluble TREM2 ameliorates pathological phenotypes by modulating microglial functions in an Alzheimer&#x2019;s disease model. Nat Commun 10, 1365 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6433910</ArticleId><ArticleId IdType="pubmed">30911003</ArticleId></ArticleIdList></Reference><Reference><Citation>Kober DL, et al. Neurodegenerative disease mutations in TREM2 reveal a functional surface and distinct loss-of-function mechanisms. Elife 5 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5173322</ArticleId><ArticleId IdType="pubmed">27995897</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh FL, Wang Y, Tom I, Gonzalez LC &amp; Sheng M TREM2 Binds to Apolipoproteins, Including APOE and CLU/APOJ, and Thereby Facilitates Uptake of Amyloid-Beta by Microglia. Neuron 91, 328&#x2013;340 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27477018</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling JP, Pletnikova O, Troncoso JC &amp; Wong PC TDP-43 repression of nonconserved cryptic exons is compromised in ALS-FTD. Science 349, 650&#x2013;655 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4825810</ArticleId><ArticleId IdType="pubmed">26250685</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarkson BDS, Patel MS, LaFrance-Corey RG &amp; Howe CL Retrograde interferon-gamma signaling induces major histocompatibility class I expression in human-induced pluripotent stem cell-derived neurons. Ann Clin Transl Neurol 5, 172&#x2013;185 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5817842</ArticleId><ArticleId IdType="pubmed">29468178</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JY, Grunke SD, Levites Y, Golde TE &amp; Jankowsky JL Intracerebroventricular viral injection of the neonatal mouse brain for persistent and widespread neuronal transduction. J Vis Exp, 51863 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4199253</ArticleId><ArticleId IdType="pubmed">25286085</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng J, et al. Microglia and monocytes synergistically promote the transition from acute to chronic pain after nerve injury. Nat Commun 7, 12029 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4931235</ArticleId><ArticleId IdType="pubmed">27349690</ArticleId></ArticleIdList></Reference><Reference><Citation>Gittins R &amp; Harrison PJ Neuronal density, size and shape in the human anterior cingulate cortex: a comparison of Nissl and NeuN staining. Brain Res Bull 63, 155&#x2013;160 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15130705</ArticleId></ArticleIdList></Reference><Reference><Citation>Pang YP FF12MC: A revised AMBER forcefield and new protein simulation protocol. Proteins 84, 1490&#x2013;1516 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5129589</ArticleId><ArticleId IdType="pubmed">27348292</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorgensen WL, Chandreskhar J, Madura JD, Impey RW &amp; Klein ML Comparison of simple potential functions for simulating liquid water. J. Chem. Phys 79, 926&#x2013;935 (1983).</Citation></Reference><Reference><Citation>Pang Y-P Use of 1&#x2013;4 interaction scaling factors to control the conformational equilibrium between &#x3b1;-helix and &#x3b2;-strand. Biochem. Biophys. Res. Commun 457, 183&#x2013;186 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25543060</ArticleId></ArticleIdList></Reference><Reference><Citation>Larini L, Mannella R &amp; Leporini D Langevin stabilization of molecular-dynamics simulations of polymers by means of quasisymplectic algorithms. J Chem Phys 126, 104101 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17362055</ArticleId></ArticleIdList></Reference><Reference><Citation>Darden TA, York DM &amp; Pedersen LG Particle mesh Ewald: An N log(N) method for Ewald sums in large systems. J. Chem. Phys 98, 10089&#x2013;10092 (1993).</Citation></Reference><Reference><Citation>Pang YP Low-mass molecular dynamics simulation for configurational sampling enhancement: More evidence and theoretical explanation. Biochem Biophys Rep 4, 126&#x2013;133 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5668912</ArticleId><ArticleId IdType="pubmed">29124195</ArticleId></ArticleIdList></Reference><Reference><Citation>Joung IS &amp; Cheatham TE Determination of alkali and halide monovalent ion parameters for use in explicitly solvated biomolecular simulations. J. Phys. Chem. B 112, 9020&#x2013;9041 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2652252</ArticleId><ArticleId IdType="pubmed">18593145</ArticleId></ArticleIdList></Reference><Reference><Citation>Leyns CEG, et al. TREM2 function impedes tau seeding in neuritic plaques. Nat Neurosci (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6660358</ArticleId><ArticleId IdType="pubmed">31235932</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, et al. Neurotoxic microglia promote TDP-43 proteinopathy in progranulin deficiency. Nature 588, 459&#x2013;465 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7746606</ArticleId><ArticleId IdType="pubmed">32866962</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez-Riverol Y, et al. The PRIDE database and related tools and resources in 2019: improving support for quantification data. Nucleic Acids Res 47, D442&#x2013;D450 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6323896</ArticleId><ArticleId IdType="pubmed">30395289</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34928318</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>08</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>79</Volume><Issue>2</Issue><PubDate><Year>2022</Year><Month>Feb</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.</ArticleTitle><Pagination><StartPage>149</StartPage><EndPage>158</EndPage><MedlinePgn>149-158</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2021.4654</ELocationID><Abstract><AbstractText Label="IMPORTANCE">There is currently no consensus as to which biomarkers best predict longitudinal tau accumulation at different clinical stages of Alzheimer disease (AD).</AbstractText><AbstractText Label="OBJECTIVE">To describe longitudinal [18F]RO948 tau positron emission tomography (PET) findings across the clinical continuum of AD and determine which biomarker combinations showed the strongest associations with longitudinal tau PET and best optimized clinical trial enrichment.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">This longitudinal cohort study consecutively enrolled amyloid-&#x3b2; (A&#x3b2;)-negative cognitively unimpaired (CU) participants, A&#x3b2;-positive CU individuals, A&#x3b2;-positive individuals with mild cognitive impairment (MCI), and individuals with AD dementia between September 2017 and November 2020 from the Swedish BioFINDER-2 (discovery cohort) and BioFINDER-1 (validation cohort) studies.</AbstractText><AbstractText Label="EXPOSURES">Baseline plasma and cerebrospinal fluid A&#x3b2;42/A&#x3b2;40, tau phosphorylated at threonine-217 (p-tau217), p-tau181 and neurofilament light, magnetic resonance imaging, amyloid PET ([18F]flutemetamol), and tau PET ([18F]RO948 in the BioFINDER-2 study; [18F]flortaucipir in the BioFINDER-1 study).</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Baseline tau PET standardized uptake value ratio (SUVR) and annual percent change in tau PET SUVR across regions of interest derived using a data-driven approach combining clustering and event-based modeling. Regression models were used to examine associations between individual biomarkers and longitudinal tau PET and to identify which combinations best predicted longitudinal tau PET. These combinations were then entered in a power analysis to examine how their use as an enrichment strategy would affect sample size in a simulated clinical trial.</AbstractText><AbstractText Label="RESULTS">Of 343 participants, the mean (SD) age was 72.56 (7.24) years, and 157 (51.1%) were female. The clustering/event-based modeling-based approach identified 5 regions of interest (stages). In A&#x3b2;-positive CU individuals, the largest annual increase in tau PET SUVR was seen in stage I (entorhinal cortex, hippocampus, and amygdala; 4.04% [95% CI, 2.67%-5.32%]). In A&#x3b2;-positive individuals with MCI and with AD dementia, the greatest increases were seen in stages II (temporal cortical regions; 4.45% [95% CI, 3.41%-5.49%]) and IV (certain frontal regions; 5.22% [95% CI, 3.95%-6.49%]), respectively. In A&#x3b2;-negative CU individuals and those with MCI, modest change was seen in stage I (1.38% [95% CI, 0.78%-1.99%] and 1.80% [95% CI, 0.76%-2.84%], respectively). When looking at individual predictors and longitudinal tau PET in the stages that showed most change, plasma p-tau217 (R2&#x2009;=&#x2009;0.27, P&#x2009;&lt;&#x2009;.005), tau PET (stage I baseline SUVR; R2&#x2009;=&#x2009;0.13, P&#x2009;&lt;&#x2009;.05) and amyloid PET (R2&#x2009;=&#x2009;0.10, P&#x2009;&lt;&#x2009;.05) were significantly associated with longitudinal tau PET in stage I in A&#x3b2;-positive CU individuals. In A&#x3b2;-positive individuals with MCI, plasma p-tau217 (R2&#x2009;=&#x2009;0.24, P&#x2009;&lt;&#x2009;.005) and tau PET (stage II baseline SUVR; R2&#x2009;=&#x2009;0.44, P&#x2009;&lt;&#x2009;.001) were significantly associated with longitudinal tau PET in stage II. Findings were replicated in BioFINDER-1 using longitudinal [18F]flortaucipir. For the power analysis component, plasma p-tau217 with tau PET resulted in sample size reductions of 43% (95% CI, 34%-46%; P&#x2009;&lt;&#x2009;.005) in A&#x3b2;-positive CU individuals and of 68% (95% CI, 61%-73%; P&#x2009;&lt;&#x2009;.001) in A&#x3b2;-positive individuals with MCI.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">In trials using tau PET as the outcome, plasma p-tau217 with tau PET may prove optimal for enrichment in preclinical and prodromal AD. However, plasma p-tau217 was most important in preclinical AD, while tau PET was more important in prodromal AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Leuzy</LastName><ForeName>Antoine</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Ruben</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Sk&#xe5;ne University Hospital, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cullen</LastName><ForeName>Nicholas C</ForeName><Initials>NC</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strandberg</LastName><ForeName>Olof</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vogel</LastName><ForeName>Jacob W</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Penn/CHOP Lifespan Brain Institute, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Binette</LastName><ForeName>Alexa Pichet</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borroni</LastName><ForeName>Edilio</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>F. Hoffmann-La Roche Ltd, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Janelidze</LastName><ForeName>Shorena</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ohlsson</LastName><ForeName>Tomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Radiation Physics, Sk&#xe5;ne University Hospital, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>J&#xf6;gi</LastName><ForeName>Jonas</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Clinical Physiology and Nuclear Medicine, Sk&#xe5;ne University Hospital, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ossenkoppele</LastName><ForeName>Rik</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>VU University Medical Center, Neuroscience Campus Amsterdam, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palmqvist</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory Clinic, Sk&#xe5;ne University Hospital, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mattsson-Carlgren</LastName><ForeName>Niklas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Sk&#xe5;ne University Hospital, Lund, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wallenberg Centre for Molecular Medicine, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klein</LastName><ForeName>Gregory</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>F. Hoffmann-La Roche Ltd, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stomrud</LastName><ForeName>Erik</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>VU University Medical Center, Neuroscience Campus Amsterdam, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hansson</LastName><ForeName>Oskar</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory Clinic, Sk&#xe5;ne University Hospital, Lund, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002243">Carbolines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019275">Radiopharmaceuticals</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>J09QS3Z3WB</RegistryNumber><NameOfSubstance UI="C000591008">7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002243" MajorTopicYN="N">Carbolines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062706" MajorTopicYN="N">Prodromal Symptoms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019275" MajorTopicYN="N">Radiopharmaceuticals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="Y">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Palmqvist has served on scientific advisory boards and/or given lectures in symposia sponsored by F. Hoffmann-La Roche, Biogen, and Geras Solutions. Dr Klein reported being a shareholder of F. Hoffmann-La Roche as an employee outside the submitted work. Dr Hansson reported nonfinancial support from F. Hoffmann-La Roche and GE Healthcare during the conduct of the study; and grants from Swedish Research Council during the conduct of the study; personal fees from Biogen, Roche, Cerveau, and Siemens outside the submitted work; research support (for their institution) from AVID Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, GE Healthcare, Pfizer, and Roche; and has received consultancy/speaker fees from Roche, Genentech, Siemens, Biogen, Alzpath, and Cerveau. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>20</Day><Hour>12</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>12</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34928318</ArticleId><ArticleId IdType="pmc">PMC8689441</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2021.4654</ArticleId><ArticleId IdType="pii">2787209</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Duyckaerts C. Tau pathology in children and young adults: can you still be unconditionally Baptist? Acta Neuropathol. 2011;121(2):145-147. doi:10.1007/s00401-010-0794-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-010-0794-7</ArticleId><ArticleId IdType="pubmed">21225273</ArticleId></ArticleIdList></Reference><Reference><Citation>Duyckaerts C, Braak H, Brion JP, et al. . PART is part of Alzheimer disease. Acta Neuropathol. 2015;129(5):749-756. doi:10.1007/s00401-015-1390-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-015-1390-7</ArticleId><ArticleId IdType="pmc">PMC4405349</ArticleId><ArticleId IdType="pubmed">25628035</ArticleId></ArticleIdList></Reference><Reference><Citation>Ch&#xe9;telat G. Alzheimer disease: A&#x3b2;-independent processes-rethinking preclinical AD. Nat Rev Neurol. 2013;9(3):123-124. doi:10.1038/nrneurol.2013.21</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2013.21</ArticleId><ArticleId IdType="pmc">PMC3935395</ArticleId><ArticleId IdType="pubmed">23399647</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson O. Biomarkers for neurodegenerative diseases. Nat Med. 2021;27(6):954-963. doi:10.1038/s41591-021-01382-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01382-x</ArticleId><ArticleId IdType="pubmed">34083813</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Holtzman DM. Biomarker modeling of Alzheimer&#x2019;s disease. Neuron. 2013;80(6):1347-1358. doi:10.1016/j.neuron.2013.12.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.12.003</ArticleId><ArticleId IdType="pmc">PMC3928967</ArticleId><ArticleId IdType="pubmed">24360540</ArticleId></ArticleIdList></Reference><Reference><Citation>Spires-Jones TL, Hyman BT. The intersection of amyloid beta and tau at synapses in Alzheimer&#x2019;s disease. Neuron. 2014;82(4):756-771. doi:10.1016/j.neuron.2014.05.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.05.004</ArticleId><ArticleId IdType="pmc">PMC4135182</ArticleId><ArticleId IdType="pubmed">24853936</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Alafuzoff I, Bigio EH, et al. . Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol. 2012;71(5):362-381. doi:10.1097/NEN.0b013e31825018f7</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e31825018f7</ArticleId><ArticleId IdType="pmc">PMC3560290</ArticleId><ArticleId IdType="pubmed">22487856</ArticleId></ArticleIdList></Reference><Reference><Citation>Sintini I, Graff-Radford J, Senjem ML, et al. . Longitudinal neuroimaging biomarkers differ across Alzheimer&#x2019;s disease phenotypes. Brain. 2020;143(7):2281-2294. doi:10.1093/brain/awaa155</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa155</ArticleId><ArticleId IdType="pmc">PMC7363492</ArticleId><ArticleId IdType="pubmed">32572464</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison TM, Du R, Klencklen G, Baker SL, Jagust WJ. Distinct effects of beta-amyloid and tau on cortical thickness in cognitively healthy older adults. Alzheimers Dement. 2021;17(7):1085-1096.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8203764</ArticleId><ArticleId IdType="pubmed">33325068</ArticleId></ArticleIdList></Reference><Reference><Citation>Iaccarino L, La Joie R, Edwards L, et al. . Spatial relationships between molecular pathology and neurodegeneration in the Alzheimer&#x2019;s disease continuum. Cereb Cortex. 2021;31(1):1-14. doi:10.1093/cercor/bhaa184</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cercor/bhaa184</ArticleId><ArticleId IdType="pmc">PMC7727356</ArticleId><ArticleId IdType="pubmed">32808011</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R, Schonhaut DR, Sch&#xf6;ll M, et al. . Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer&#x2019;s disease. Brain. 2016;139(Pt 5):1551-1567. doi:10.1093/brain/aww027</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aww027</ArticleId><ArticleId IdType="pmc">PMC5006248</ArticleId><ArticleId IdType="pubmed">26962052</ArticleId></ArticleIdList></Reference><Reference><Citation>Bejanin A, Schonhaut DR, La Joie R, et al. . Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer&#x2019;s disease. Brain. 2017;140(12):3286-3300. doi:10.1093/brain/awx243</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awx243</ArticleId><ArticleId IdType="pmc">PMC5841139</ArticleId><ArticleId IdType="pubmed">29053874</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R, Smith R, Ohlsson T, et al. . Associations between tau, A&#x3b2;, and cortical thickness with cognition in Alzheimer disease. Neurology. 2019;92(6):e601-e612. doi:10.1212/WNL.0000000000006875</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000006875</ArticleId><ArticleId IdType="pmc">PMC6382060</ArticleId><ArticleId IdType="pubmed">30626656</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson KA, Schultz A, Betensky RA, et al. . Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol. 2016;79(1):110-119. doi:10.1002/ana.24546</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24546</ArticleId><ArticleId IdType="pmc">PMC4738026</ArticleId><ArticleId IdType="pubmed">26505746</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xf6;ll M, Lockhart SN, Schonhaut DR, et al. . PET imaging of tau deposition in the aging human brain. Neuron. 2016;89(5):971-982. doi:10.1016/j.neuron.2016.01.028</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.01.028</ArticleId><ArticleId IdType="pmc">PMC4779187</ArticleId><ArticleId IdType="pubmed">26938442</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowe VJ, Curran G, Fang P, et al. . An autoradiographic evaluation of AV-1451 Tau PET in dementia. Acta Neuropathol Commun. 2016;4(1):58. doi:10.1186/s40478-016-0315-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-016-0315-6</ArticleId><ArticleId IdType="pmc">PMC4906968</ArticleId><ArticleId IdType="pubmed">27296779</ArticleId></ArticleIdList></Reference><Reference><Citation>Marqui&#xe9; M, Normandin MD, Vanderburg CR, et al. . Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol. 2015;78(5):787-800. doi:10.1002/ana.24517</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24517</ArticleId><ArticleId IdType="pmc">PMC4900162</ArticleId><ArticleId IdType="pubmed">26344059</ArticleId></ArticleIdList></Reference><Reference><Citation>Sander K, Lashley T, Gami P, et al. . Characterization of tau positron emission tomography tracer [18F]AV-1451 binding to postmortem tissue in Alzheimer&#x2019;s disease, primary tauopathies, and other dementias. Alzheimers Dement. 2016;12(11):1116-1124. doi:10.1016/j.jalz.2016.01.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2016.01.003</ArticleId><ArticleId IdType="pubmed">26892233</ArticleId></ArticleIdList></Reference><Reference><Citation>Leuzy A, Chiotis K, Lemoine L, et al. . Tau PET imaging in neurodegenerative tauopathies-still a challenge. Mol Psychiatry. 2019;24(8):1112-1134. doi:10.1038/s41380-018-0342-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-018-0342-8</ArticleId><ArticleId IdType="pmc">PMC6756230</ArticleId><ArticleId IdType="pubmed">30635637</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison TM, La Joie R, Maass A, et al. . Longitudinal tau accumulation and atrophy in aging and Alzheimer disease. Ann Neurol. 2019;85(2):229-240. doi:10.1002/ana.25406</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25406</ArticleId><ArticleId IdType="pmc">PMC6579738</ArticleId><ArticleId IdType="pubmed">30597624</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho H, Choi JY, Lee HS, et al. . Progressive tau accumulation in Alzheimer disease: 2-year follow-up study. J Nucl Med. 2019;60(11):1611-1621. doi:10.2967/jnumed.118.221697</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.118.221697</ArticleId><ArticleId IdType="pmc">PMC6836867</ArticleId><ArticleId IdType="pubmed">30926651</ArticleId></ArticleIdList></Reference><Reference><Citation>Pontecorvo MJ, Devous MD, Kennedy I, et al. . A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer&#x2019;s disease dementia. Brain. 2019;142(6):1723-1735. doi:10.1093/brain/awz090</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz090</ArticleId><ArticleId IdType="pmc">PMC6536847</ArticleId><ArticleId IdType="pubmed">31009046</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanseeuw BJ, Betensky RA, Jacobs HIL, et al. . Association of amyloid and tau with cognition in preclinical Alzheimer disease: a longitudinal study. JAMA Neurol. 2019;76(8):915-924. doi:10.1001/jamaneurol.2019.1424</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2019.1424</ArticleId><ArticleId IdType="pmc">PMC6547132</ArticleId><ArticleId IdType="pubmed">31157827</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Wiste HJ, Schwarz CG, et al. . Longitudinal tau PET in ageing and Alzheimer&#x2019;s disease. Brain. 2018;141(5):1517-1528. doi:10.1093/brain/awy059</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awy059</ArticleId><ArticleId IdType="pmc">PMC5917767</ArticleId><ArticleId IdType="pubmed">29538647</ArticleId></ArticleIdList></Reference><Reference><Citation>Pascoal TA, Benedet AL, Tudorascu DL, et al. . Longitudinal 18F-MK-6240 tau tangles accumulation follows Braak stages. Brain. 2021;awab248. doi:10.1093/brain/awab248</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awab248</ArticleId><ArticleId IdType="pmc">PMC8677534</ArticleId><ArticleId IdType="pubmed">34515754</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho H, Choi JY, Hwang MS, et al. . In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum. Ann Neurol. 2016;80(2):247-258. doi:10.1002/ana.24711</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24711</ArticleId><ArticleId IdType="pubmed">27323247</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarz AJ, Yu P, Miller BB, et al. . Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages. Brain. 2016;139(Pt 5):1539-1550. doi:10.1093/brain/aww023</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aww023</ArticleId><ArticleId IdType="pubmed">26936940</ArticleId></ArticleIdList></Reference><Reference><Citation>Mintun MA, Lo AC, Duggan Evans C, et al. . Donanemab in early Alzheimer&#x2019;s disease. N Engl J Med. 2021;384(18):1691-1704. doi:10.1056/NEJMoa2100708</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2100708</ArticleId><ArticleId IdType="pubmed">33720637</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Bennett DA, Blennow K, et al. ; Contributors . NIA-AA research framework: toward a biological definition of Alzheimer&#x2019;s disease. Alzheimers Dement. 2018;14(4):535-562. doi:10.1016/j.jalz.2018.02.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.02.018</ArticleId><ArticleId IdType="pmc">PMC5958625</ArticleId><ArticleId IdType="pubmed">29653606</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Bennett DA, Blennow K, et al. . A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016;87(5):539-547. doi:10.1212/WNL.0000000000002923</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000002923</ArticleId><ArticleId IdType="pmc">PMC4970664</ArticleId><ArticleId IdType="pubmed">27371494</ArticleId></ArticleIdList></Reference><Reference><Citation>Leuzy A, Smith R, Ossenkoppele R, et al. . Diagnostic performance of RO948 F 18 tau positron emission tomography in the differentiation of Alzheimer disease from other neurodegenerative disorders. JAMA Neurol. 2020;77(8):955-965. doi:10.1001/jamaneurol.2020.0989</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2020.0989</ArticleId><ArticleId IdType="pmc">PMC7215644</ArticleId><ArticleId IdType="pubmed">32391858</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S, Janelidze S, Quiroz YT, et al. . Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA. 2020;324(8):772-781. doi:10.1001/jama.2020.12134</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12134</ArticleId><ArticleId IdType="pmc">PMC7388060</ArticleId><ArticleId IdType="pubmed">32722745</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Wiste HJ, Weigand SD, et al. . Defining imaging biomarker cut points for brain aging and Alzheimer&#x2019;s disease. Alzheimers Dement. 2017;13(3):205-216. doi:10.1016/j.jalz.2016.08.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2016.08.005</ArticleId><ArticleId IdType="pmc">PMC5344738</ArticleId><ArticleId IdType="pubmed">27697430</ArticleId></ArticleIdList></Reference><Reference><Citation>P&#xe9;rez-Grijalba V, Fandos N, Canudas J, et al. . Validation of immunoassay-based tools for the comprehensive quantification of A&#x3b2;40 and A&#x3b2;42 peptides in plasma. J Alzheimers Dis. 2016;54(2):751-762. doi:10.3233/JAD-160325</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-160325</ArticleId><ArticleId IdType="pmc">PMC5044780</ArticleId><ArticleId IdType="pubmed">27567833</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze S, Mattsson N, Palmqvist S, et al. . Plasma P-tau181 in Alzheimer&#x2019;s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer&#x2019;s dementia. Nat Med. 2020;26(3):379-386. doi:10.1038/s41591-020-0755-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0755-1</ArticleId><ArticleId IdType="pubmed">32123385</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze S, Stomrud E, Smith R, et al. . Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer&#x2019;s disease. Nat Commun. 2020;11(1):1683. doi:10.1038/s41467-020-15436-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-15436-0</ArticleId><ArticleId IdType="pmc">PMC7125218</ArticleId><ArticleId IdType="pubmed">32246036</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Cullen NC, Andreasson U, Zetterberg H, Blennow K. Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer disease. JAMA Neurol. 2019;76(7):791-799. doi:10.1001/jamaneurol.2019.0765</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2019.0765</ArticleId><ArticleId IdType="pmc">PMC6583067</ArticleId><ArticleId IdType="pubmed">31009028</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Hulle C, Jonaitis EM, Betthauser TJ, et al. . An examination of a novel multipanel of CSF biomarkers in the Alzheimer&#x2019;s disease clinical and pathological continuum. Alzheimers Dement. 2021;17(3):431-445.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8016695</ArticleId><ArticleId IdType="pubmed">33336877</ArticleId></ArticleIdList></Reference><Reference><Citation>Karikari TK, Pascoal TA, Ashton NJ, et al. . Blood phosphorylated tau 181 as a biomarker for Alzheimer&#x2019;s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 2020;19(5):422-433. doi:10.1016/S1474-4422(20)30071-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(20)30071-5</ArticleId><ArticleId IdType="pubmed">32333900</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Wiste HJ, Weigand SD, et al. . Different definitions of neurodegeneration produce similar amyloid/neurodegeneration biomarker group findings. Brain. 2015;138(Pt 12):3747-3759. doi:10.1093/brain/awv283</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awv283</ArticleId><ArticleId IdType="pmc">PMC4655341</ArticleId><ArticleId IdType="pubmed">26428666</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith R, Sch&#xf6;ll M, Leuzy A, et al. . Head-to-head comparison of tau positron emission tomography tracers [18F]flortaucipir and [18F]RO948. Eur J Nucl Med Mol Imaging. 2020;47(2):342-354. doi:10.1007/s00259-019-04496-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-019-04496-0</ArticleId><ArticleId IdType="pmc">PMC6974501</ArticleId><ArticleId IdType="pubmed">31612245</ArticleId></ArticleIdList></Reference><Reference><Citation>Rousset OG, Ma Y, Evans AC. Correction for partial volume effects in PET: principle and validation. J Nucl Med. 1998;39(5):904-911.</Citation><ArticleIdList><ArticleId IdType="pubmed">9591599</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Insel PS, Palmqvist S, et al. . Increased amyloidogenic APP processing in APOE &#x25b;4-negative individuals with cerebral &#x3b2;-amyloidosis. Nat Commun. 2016;7:10918. doi:10.1038/ncomms10918</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms10918</ArticleId><ArticleId IdType="pmc">PMC4786682</ArticleId><ArticleId IdType="pubmed">26948379</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourgeat P, Dor&#xe9; V, Fripp J, et al. ; AIBL research group . Implementing the centiloid transformation for 11C-PiB and &#x3b2;-amyloid 18F-PET tracers using CapAIBL. Neuroimage. 2018;183:387-393. doi:10.1016/j.neuroimage.2018.08.044</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2018.08.044</ArticleId><ArticleId IdType="pubmed">30130643</ArticleId></ArticleIdList></Reference><Reference><Citation>Young AL, Oxtoby NP, Daga P, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . A data-driven model of biomarker changes in sporadic Alzheimer&#x2019;s disease. Brain. 2014;137(Pt 9):2564-2577. doi:10.1093/brain/awu176</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awu176</ArticleId><ArticleId IdType="pmc">PMC4132648</ArticleId><ArticleId IdType="pubmed">25012224</ArticleId></ArticleIdList></Reference><Reference><Citation>Fonteijn HM, Modat M, Clarkson MJ, et al. . An event-based model for disease progression and its application in familial Alzheimer&#x2019;s disease and Huntington&#x2019;s disease. Neuroimage. 2012;60(3):1880-1889. doi:10.1016/j.neuroimage.2012.01.062</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2012.01.062</ArticleId><ArticleId IdType="pubmed">22281676</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogel JW, Iturria-Medina Y, Strandberg OT, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative; Swedish BioFinder Study . Spread of pathological tau proteins through communicating neurons in human Alzheimer&#x2019;s disease. Nat Commun. 2020;11(1):2612. doi:10.1038/s41467-020-15701-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-15701-2</ArticleId><ArticleId IdType="pmc">PMC7251068</ArticleId><ArticleId IdType="pubmed">32457389</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogel JW, Mattsson N, Iturria-Medina Y, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative; Swedish BioFINDER Study . Data-driven approaches for tau-PET imaging biomarkers in Alzheimer&#x2019;s disease. Hum Brain Mapp. 2019;40(2):638-651. doi:10.1002/hbm.24401</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hbm.24401</ArticleId><ArticleId IdType="pmc">PMC6865737</ArticleId><ArticleId IdType="pubmed">30368979</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellec P, Rosa-Neto P, Lyttelton OC, Benali H, Evans AC. Multi-level bootstrap analysis of stable clusters in resting-state fMRI. Neuroimage. 2010;51(3):1126-1139. doi:10.1016/j.neuroimage.2010.02.082</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2010.02.082</ArticleId><ArticleId IdType="pubmed">20226257</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 2006;112(4):389-404. doi:10.1007/s00401-006-0127-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-006-0127-z</ArticleId><ArticleId IdType="pmc">PMC3906709</ArticleId><ArticleId IdType="pubmed">16906426</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239-259. doi:10.1007/BF00308809</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00308809</ArticleId><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Thal DR, Ghebremedhin E, Del Tredici K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol. 2011;70(11):960-969. doi:10.1097/NEN.0b013e318232a379</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e318232a379</ArticleId><ArticleId IdType="pubmed">22002422</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie L, Wisse LEM, Pluta J, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Automated segmentation of medial temporal lobe subregions on in vivo T1-weighted MRI in early stages of Alzheimer&#x2019;s disease. Hum Brain Mapp. 2019;40(12):3431-3451. doi:10.1002/hbm.24607</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hbm.24607</ArticleId><ArticleId IdType="pmc">PMC6697377</ArticleId><ArticleId IdType="pubmed">31034738</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S, Janelidze S, Stomrud E, et al. . Performance of fully automated plasma assays as screening tests for Alzheimer disease-related &#x3b2;-amyloid status. JAMA Neurol. 2019;76(9):1060-1069. doi:10.1001/jamaneurol.2019.1632</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2019.1632</ArticleId><ArticleId IdType="pmc">PMC6593637</ArticleId><ArticleId IdType="pubmed">31233127</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze S, Teunissen CE, Zetterberg H, et al. . Head-to-head comparison of 8 plasma amyloid-&#x3b2; 42/40 assays in Alzheimer disease. JAMA Neurol. 2021. doi:10.1001/jamaneurol.2021.3180</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2021.3180</ArticleId><ArticleId IdType="pmc">PMC8453354</ArticleId><ArticleId IdType="pubmed">34542571</ArticleId></ArticleIdList></Reference><Reference><Citation>Akaike H. Likelihood of a model and information criteria. J Econometrics. 1981;16(1):3-14. doi:10.1016/0304-4076(81)90071-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0304-4076(81)90071-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnham KP, Anderson DR. Model Selection and Multimodel Inference. Springer; 2002.</Citation></Reference><Reference><Citation>Pontecorvo MJ, Devous MD Sr, Navitsky M, et al. ; 18F-AV-1451-A05 investigators . Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition. Brain. 2017;140(3):748-763. doi:10.1093/brain/aww334</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aww334</ArticleId><ArticleId IdType="pmc">PMC5382945</ArticleId><ArticleId IdType="pubmed">28077397</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowe VJ, Wiste HJ, Senjem ML, et al. . Widespread brain tau and its association with ageing, Braak stage and Alzheimer&#x2019;s dementia. Brain. 2018;141(1):271-287. doi:10.1093/brain/awx320</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awx320</ArticleId><ArticleId IdType="pmc">PMC5837250</ArticleId><ArticleId IdType="pubmed">29228201</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez JS, Becker JA, Jacobs HIL, et al. . The cortical origin and initial spread of medial temporal tauopathy in Alzheimer&#x2019;s disease assessed with positron emission tomography. Sci Transl Med. 2021;13(577):eabc0655. doi:10.1126/scitranslmed.abc0655</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abc0655</ArticleId><ArticleId IdType="pmc">PMC7978042</ArticleId><ArticleId IdType="pubmed">33472953</ArticleId></ArticleIdList></Reference><Reference><Citation>Insel PS, Mormino EC, Aisen PS, Thompson WK, Donohue MC. Neuroanatomical spread of amyloid &#x3b2; and tau in Alzheimer's disease: implications for primary prevention. Brain Commun. 2020;2(1):fcaa007. doi:10.1093/braincomms/fcaa007</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcaa007</ArticleId><ArticleId IdType="pmc">PMC7048875</ArticleId><ArticleId IdType="pubmed">32140682</ArticleId></ArticleIdList></Reference><Reference><Citation>Berron D, Vogel JW, Insel PS, et al. . Early stages of tau pathology and its associations with functional connectivity, atrophy and memory. Brain. 2021;144(9):2771-2783. doi:10.1093/brain/awab114</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awab114</ArticleId><ArticleId IdType="pmc">PMC8557349</ArticleId><ArticleId IdType="pubmed">33725124</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishnadas N, Dore V, Mulligan R, et al. . 18F-MK6240 longitudinal tau PET in ageing and Alzheimer's disease. J Nuclear Med. 2021;62(suppl 1):105.</Citation></Reference><Reference><Citation>de Calignon A, Polydoro M, Su&#xe1;rez-Calvet M, et al. . Propagation of tau pathology in a model of early Alzheimer&#x2019;s disease. Neuron. 2012;73(4):685-697. doi:10.1016/j.neuron.2011.11.033</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.11.033</ArticleId><ArticleId IdType="pmc">PMC3292759</ArticleId><ArticleId IdType="pubmed">22365544</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Drouet V, Wu JW, et al. . Trans-synaptic spread of tau pathology in vivo. PLoS One. 2012;7(2):e31302. doi:10.1371/journal.pone.0031302</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0031302</ArticleId><ArticleId IdType="pmc">PMC3270029</ArticleId><ArticleId IdType="pubmed">22312444</ArticleId></ArticleIdList></Reference><Reference><Citation>Crary JF, Trojanowski JQ, Schneider JA, et al. . Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol. 2014;128(6):755-766. doi:10.1007/s00401-014-1349-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-014-1349-0</ArticleId><ArticleId IdType="pmc">PMC4257842</ArticleId><ArticleId IdType="pubmed">25348064</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze S, Berron D, Smith R, et al. . Associations of plasma phospho-tau217 levels with tau positron emission tomography in early Alzheimer disease. JAMA Neurol. 2021;78(2):149-156. doi:10.1001/jamaneurol.2020.4201</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2020.4201</ArticleId><ArticleId IdType="pmc">PMC7653537</ArticleId><ArticleId IdType="pubmed">33165506</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson-Carlgren N, Janelidze S, Bateman RJ, et al. . Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau. EMBO Mol Med. 2021;13(6):e14022. doi:10.15252/emmm.202114022</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.202114022</ArticleId><ArticleId IdType="pmc">PMC8185545</ArticleId><ArticleId IdType="pubmed">33949133</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson-Carlgren N, Andersson E, Janelidze S, et al. . A&#x3b2; deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer&#x2019;s disease. Sci Adv. 2020;6(16):eaaz2387. doi:10.1126/sciadv.aaz2387</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.aaz2387</ArticleId><ArticleId IdType="pmc">PMC7159908</ArticleId><ArticleId IdType="pubmed">32426454</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Wiste HJ, Weigand SD, et al. . Predicting future rates of tau accumulation on PET. Brain. 2020;143(10):3136-3150. doi:10.1093/brain/awaa248</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa248</ArticleId><ArticleId IdType="pmc">PMC7586089</ArticleId><ArticleId IdType="pubmed">33094327</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato C, Barth&#xe9;lemy NR, Mawuenyega KG, et al. . Tau kinetics in neurons and the human central nervous system. Neuron. 2018;97(6):1284-1298.e7. doi:10.1016/j.neuron.2018.02.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2018.02.015</ArticleId><ArticleId IdType="pmc">PMC6137722</ArticleId><ArticleId IdType="pubmed">29566794</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashton NJ, Pascoal TA, Karikari TK, et al. . Plasma p-tau231: a new biomarker for incipient Alzheimer&#x2019;s disease pathology. Acta Neuropathol. 2021;141(5):709-724. doi:10.1007/s00401-021-02275-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-021-02275-6</ArticleId><ArticleId IdType="pmc">PMC8043944</ArticleId><ArticleId IdType="pubmed">33585983</ArticleId></ArticleIdList></Reference><Reference><Citation>Thijssen EH, La Joie R, Strom A, et al. ; Advancing Research and Treatment for Frontotemporal Lobar Degeneration investigators . Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer&#x2019;s disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. Lancet Neurol. 2021;20(9):739-752. doi:10.1016/S1474-4422(21)00214-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(21)00214-3</ArticleId><ArticleId IdType="pmc">PMC8711249</ArticleId><ArticleId IdType="pubmed">34418401</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoskin JL, Sabbagh MN, Al-Hasan Y, Decourt B. Tau immunotherapies for Alzheimer&#x2019;s disease. Expert Opin Investig Drugs. 2019;28(6):545-554. doi:10.1080/13543784.2019.1619694</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13543784.2019.1619694</ArticleId><ArticleId IdType="pmc">PMC7169377</ArticleId><ArticleId IdType="pubmed">31094578</ArticleId></ArticleIdList></Reference><Reference><Citation>American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders. 4th ed. American Psychiatric Association; 1994.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">34937781</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>06</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>98</Volume><Issue>9</Issue><PubDate><Year>2022</Year><Month>Mar</Month><Day>01</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Association of CSF A&#x3b2;<sub>38</sub> Levels With Risk of Alzheimer Disease-Related Decline.</ArticleTitle><Pagination><StartPage>e958</StartPage><EndPage>e967</EndPage><MedlinePgn>e958-e967</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0000000000013228</ELocationID><Abstract><AbstractText Label="BACKGROUND AND OBJECTIVE">Experimental studies suggest that the balance between short and long &#x3b2;-amyloid (A&#x3b2;) species might modulate the toxic effects of A&#x3b2; in Alzheimer disease (AD), but clinical evidence is lacking. We studied whether A&#x3b2;<sub>38</sub> levels in CSF relate to risk of AD dementia and cognitive decline.</AbstractText><AbstractText Label="METHODS">CSF A&#x3b2;<sub>38</sub> levels were measured in 656 individuals across 2 clinical cohorts: the Swedish BioFINDER study and the Alzheimer's Disease Neuroimaging Initiative (ADNI). Cox regression models were used to evaluate the association between baseline A&#x3b2;<sub>38</sub> levels and risk of AD dementia in AD biomarker-positive individuals (AD+; determined by CSF phosphorylated tau [P-tau]/A&#x3b2;<sub>42</sub> ratio) with subjective cognitive decline (SCD) or mild cognitive impairment (MCI). Linear mixed-effects models were used to evaluate the association between baseline A&#x3b2;<sub>38</sub> levels and cognitive decline as measured by the Mini-Mental State Examination (MMSE) in AD+ participants with SCD, MCI, or AD dementia.</AbstractText><AbstractText Label="RESULTS">In the BioFINDER cohort, high A&#x3b2;<sub>38</sub> levels were associated with slower decline in MMSE score (&#x3b2; = 0.30 points per SD, <i>p</i> = 0.001) and with lower risk of conversion to AD dementia (hazard ratio 0.83 per SD, <i>p</i> = 0.03). In the ADNI cohort, higher A&#x3b2;<sub>38</sub> levels were associated with less decline in MMSE score (&#x3b2; = 0.27, <i>p</i> = 0.01) but not risk of conversion to AD dementia (<i>p</i> = 0.66). A&#x3b2;<sub>38</sub> levels in both cohorts were significantly associated with both cognitive and clinical outcomes when further adjusted for CSF P-tau or CSF A&#x3b2;<sub>42</sub> levels.</AbstractText><AbstractText Label="DISCUSSION">Higher CSF A&#x3b2;<sub>38</sub> levels are associated with lower risk of AD-related changes in 2 independent clinical cohorts. These findings suggest that &#x3b3;-secretase modulators could be effective as disease-altering therapy.</AbstractText><AbstractText Label="TRIAL REGISTRATION INFORMATION">ClinicalTrials.gov Identifier: NCT03174938.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cullen</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>From the Clinical Memory Research Unit (N.C., S.J., S.P., E.S., N.M.-C., O.H.), Department of Clinical Sciences Malm&#xf6;, Faculty of Medicine, and Wallenberg Center for Molecular Medicine (N.M.-C.), Lund University; Memory Clinic (S.P., E.S., O.H.), Sk&#xe5;ne University Hospital, Malm&#xf6;; and Department of Neurology (N.M.-C.), Sk&#xe5;ne University Hospital, Lund, Sweden. nicholas.cullen@med.lu.se.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Janelidze</LastName><ForeName>Shorena</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>From the Clinical Memory Research Unit (N.C., S.J., S.P., E.S., N.M.-C., O.H.), Department of Clinical Sciences Malm&#xf6;, Faculty of Medicine, and Wallenberg Center for Molecular Medicine (N.M.-C.), Lund University; Memory Clinic (S.P., E.S., O.H.), Sk&#xe5;ne University Hospital, Malm&#xf6;; and Department of Neurology (N.M.-C.), Sk&#xe5;ne University Hospital, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palmqvist</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>From the Clinical Memory Research Unit (N.C., S.J., S.P., E.S., N.M.-C., O.H.), Department of Clinical Sciences Malm&#xf6;, Faculty of Medicine, and Wallenberg Center for Molecular Medicine (N.M.-C.), Lund University; Memory Clinic (S.P., E.S., O.H.), Sk&#xe5;ne University Hospital, Malm&#xf6;; and Department of Neurology (N.M.-C.), Sk&#xe5;ne University Hospital, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stomrud</LastName><ForeName>Erik</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>From the Clinical Memory Research Unit (N.C., S.J., S.P., E.S., N.M.-C., O.H.), Department of Clinical Sciences Malm&#xf6;, Faculty of Medicine, and Wallenberg Center for Molecular Medicine (N.M.-C.), Lund University; Memory Clinic (S.P., E.S., O.H.), Sk&#xe5;ne University Hospital, Malm&#xf6;; and Department of Neurology (N.M.-C.), Sk&#xe5;ne University Hospital, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mattsson-Carlgren</LastName><ForeName>Niklas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>From the Clinical Memory Research Unit (N.C., S.J., S.P., E.S., N.M.-C., O.H.), Department of Clinical Sciences Malm&#xf6;, Faculty of Medicine, and Wallenberg Center for Molecular Medicine (N.M.-C.), Lund University; Memory Clinic (S.P., E.S., O.H.), Sk&#xe5;ne University Hospital, Malm&#xf6;; and Department of Neurology (N.M.-C.), Sk&#xe5;ne University Hospital, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hansson</LastName><ForeName>Oskar</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>From the Clinical Memory Research Unit (N.C., S.J., S.P., E.S., N.M.-C., O.H.), Department of Clinical Sciences Malm&#xf6;, Faculty of Medicine, and Wallenberg Center for Molecular Medicine (N.M.-C.), Lund University; Memory Clinic (S.P., E.S., O.H.), Sk&#xe5;ne University Hospital, Malm&#xf6;; and Department of Neurology (N.M.-C.), Sk&#xe5;ne University Hospital, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Alzheimer&#x2019;s Disease Neuroimaging Initiative</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT03174938</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D000068397">Clinical Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>12</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="Y">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>5</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>12</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>23</Day><Hour>5</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>3</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34937781</ArticleId><ArticleId IdType="pmc">PMC8901176</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000013228</ArticleId><ArticleId IdType="pii">WNL.0000000000013228</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cummings JL, Morstorf T, Zhong K. Alzheimer's disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res Ther. 2014;6(4):37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4095696</ArticleId><ArticleId IdType="pubmed">25024750</ArticleId></ArticleIdList></Reference><Reference><Citation>Gauthier S, Albert M, Fox N, et al. . Why has therapy development for dementia failed in the last two decades? Alzheimers Dement. 2016;12(1):60-64.</Citation><ArticleIdList><ArticleId IdType="pubmed">26710325</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Alzheimer disease and aducanumab: adjusting our approach. Nat Rev Neurol. 2019;15(7):365-366.</Citation><ArticleIdList><ArticleId IdType="pubmed">31138932</ArticleId></ArticleIdList></Reference><Reference><Citation>Howard R, Liu KY. Questions EMERGE as Biogen claims aducanumab turnaround. Nat Rev Neurol. 2020;16(2):63-64.</Citation><ArticleIdList><ArticleId IdType="pubmed">31784690</ArticleId></ArticleIdList></Reference><Reference><Citation>Karran E, Mercken M, Strooper BD. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov. 2011;10(9):698-712.</Citation><ArticleIdList><ArticleId IdType="pubmed">21852788</ArticleId></ArticleIdList></Reference><Reference><Citation>Doody RS, Raman R, Farlow M, et al. . A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med. 2013;369(4):341-350.</Citation><ArticleIdList><ArticleId IdType="pubmed">23883379</ArticleId></ArticleIdList></Reference><Reference><Citation>Egan MF, Kost J, Tariot PN, et al. . Randomized trial of verubecestat for mild-to-moderate Alzheimer's disease. N Engl J Med. 2018;378(18):1691-1703.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6776074</ArticleId><ArticleId IdType="pubmed">29719179</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandenberghe R, Rinne JO, Boada M, et al. . Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials. Alzheimers Res Ther. 2016;8(1):18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4866415</ArticleId><ArticleId IdType="pubmed">27176461</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology TL. Solanezumab: too late in mild Alzheimer's disease? Lancet Neurol. 2017;16(2):97.</Citation><ArticleIdList><ArticleId IdType="pubmed">28102152</ArticleId></ArticleIdList></Reference><Reference><Citation>Wirths O, Zampar S. Emerging roles of N- and C-terminally truncated A&#x3b2; species in Alzheimer's disease. Expert Opin Ther Targets. 2019;23(12):991-1004.</Citation><ArticleIdList><ArticleId IdType="pubmed">31814468</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunys J, Valverde A, Checler F. Are N- and C-terminally truncated A&#x3b2; species key pathological triggers in Alzheimer's disease? J Biol Chem. 2018;293(40):15419-15428.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6177599</ArticleId><ArticleId IdType="pubmed">30143530</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar&#x2010;Singh S, Theuns J, Broeck BV, et al. . Mean age-of-onset of familial Alzheimer disease caused by presenilin mutations correlates with both increased A&#x3b2;42 and decreased A&#x3b2;40. Hum Mutat. 2006;27(7):686-695.</Citation><ArticleIdList><ArticleId IdType="pubmed">16752394</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia D, Watanabe H, Wu B, et al. . Presenilin-1 knockin mice reveal loss-of-function mechanism for familial Alzheimer's disease. Neuron. 2015;85(5):967-981.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4358812</ArticleId><ArticleId IdType="pubmed">25741723</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelleher RJ, Shen J. Genetics: gamma-secretase and human disease. Science. 2010;330(6007):1055-1056.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4556372</ArticleId><ArticleId IdType="pubmed">21097925</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore BD, Martin J, Mena Lde, et al. . Short A&#x3b2; peptides attenuate A&#x3b2;42 toxicity in vivo. J Exp Med. 2017;215(1):283-301.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5748850</ArticleId><ArticleId IdType="pubmed">29208777</ArticleId></ArticleIdList></Reference><Reference><Citation>Blain J-F, Bursavich MG, Freeman EA, et al. . Characterization of FRM-36143 as a new &#x3b3;-secretase modulator for the potential treatment of familial Alzheimer's disease. Alzheimers Res Ther. 2016;8(1):34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5004293</ArticleId><ArticleId IdType="pubmed">27572246</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S, Tideman P, Cullen N, et al. . Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures. Nat Med. 2021;27(6):1034-1042.</Citation><ArticleIdList><ArticleId IdType="pubmed">34031605</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen R. Mild cognitive impairment: current research and clinical implications. Semin Neurol. 2007;27(1):22-31.</Citation><ArticleIdList><ArticleId IdType="pubmed">17226738</ArticleId></ArticleIdList></Reference><Reference><Citation>Silverberg N, Elliott C, Ryan L, Masliah E, Hodes R. NIA commentary on the NIA-AA Research Framework: towards a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14(4):576-578.</Citation><ArticleIdList><ArticleId IdType="pubmed">29653608</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Aisen PS, Beckett LA, et al. . Alzheimer's Disease Neuroimaging Initiative (ADNI) clinical characterization. Neurology. 2010;74(3):201-209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2809036</ArticleId><ArticleId IdType="pubmed">20042704</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer&#x2019;s Disease Neuroimaging Initiative. Accessed March 1, 2020. adni.loni.usc.edu</Citation></Reference><Reference><Citation>Hansson O, Seibyl J, Stomrud E, et al. . CSF biomarkers of Alzheimer's disease concord with amyloid-&#x3b2; PET and predict clinical progression: a study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimers Dement. 2018;14(11):1470-1481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6119541</ArticleId><ArticleId IdType="pubmed">29499171</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapman KR, Bing-Canar H, Alosco ML, et al. . Mini Mental State Examination and Logical Memory scores for entry into Alzheimer's disease trials. Alzheimers Res Ther. 2016;8:9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4762168</ArticleId><ArticleId IdType="pubmed">26899835</ArticleId></ArticleIdList></Reference><Reference><Citation>Donohue MC, Sperling RA, Salmon DP, et al. . The Preclinical Alzheimer Cognitive Composite: measuring amyloid-related decline. JAMA Neurol. 2014;71(8):961-970.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4439182</ArticleId><ArticleId IdType="pubmed">24886908</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson RM, Hadjichrysanthou C, Evans S, Wong MM. Why do so many clinical trials of therapies for Alzheimer's disease fail? Lancet. 2017;390(10110):2327-2329.</Citation><ArticleIdList><ArticleId IdType="pubmed">29185425</ArticleId></ArticleIdList></Reference><Reference><Citation>Egan MF, Kost J, Voss T, et al. . Randomized trial of verubecestat for prodromal Alzheimer's disease. N Engl J Med. 2019;380(15):1408-1420.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6776078</ArticleId><ArticleId IdType="pubmed">30970186</ArticleId></ArticleIdList></Reference><Reference><Citation>Ricciarelli R, Fedele E. The amyloid cascade hypothesis in Alzheimer's disease: it's time to change our mind. Curr Neuropharmacol. 2017;15(6):926-935.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5652035</ArticleId><ArticleId IdType="pubmed">28093977</ArticleId></ArticleIdList></Reference><Reference><Citation>Weggen S, Beher D. Molecular consequences of amyloid precursor protein and presenilin mutations causing autosomal-dominant Alzheimer's disease. Alzheimers Res Ther. 2012;4(2):9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3334542</ArticleId><ArticleId IdType="pubmed">22494386</ArticleId></ArticleIdList></Reference><Reference><Citation>Crump CJ, Johnson DS, Li Y-M. Development and mechanism of &#x3b3;-secretase modulators for Alzheimer's disease. Biochemistry. 2013;52(19):3197-3216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3796170</ArticleId><ArticleId IdType="pubmed">23614767</ArticleId></ArticleIdList></Reference><Reference><Citation>Tate B, McKee TD, Loureiro RMB, et al. . Modulation of gamma-secretase for the treatment of Alzheimer's disease. Int J Alzheimers Dis. 2012;2012:210756.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3536039</ArticleId><ArticleId IdType="pubmed">23320246</ArticleId></ArticleIdList></Reference><Reference><Citation>Imbimbo BP, Panza F, Frisardi V, et al. . Therapeutic intervention for Alzheimer's disease with &#x3b3;-secretase inhibitors: still a viable option? Expert Opin Investig Drugs. 2011;20(3):325-341.</Citation><ArticleIdList><ArticleId IdType="pubmed">21222550</ArticleId></ArticleIdList></Reference><Reference><Citation>Kounnas MZ, Danks AM, Cheng S, et al. . Modulation of gamma-secretase reduces beta-amyloid deposition in a transgenic mouse model of Alzheimer's disease. Neuron. 2010;67(5):769-780.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2947312</ArticleId><ArticleId IdType="pubmed">20826309</ArticleId></ArticleIdList></Reference><Reference><Citation>Petit D, Hitzenberger M, Lismont S, et al. . Extracellular interface between APP and Nicastrin regulates A&#x3b2; length and response to &#x3b3;&#x2010;secretase modulators. EMBO J. 2019;38(12):e101494.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6576158</ArticleId><ArticleId IdType="pubmed">31109937</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze S, Zetterberg H, Mattsson N, et al. . CSF A&#x3b2;42/A&#x3b2;40 and A&#x3b2;42/A&#x3b2;38 ratios: better diagnostic markers of Alzheimer disease. Ann Clin Transl Neurol. 2016;3(3):154-165.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4774260</ArticleId><ArticleId IdType="pubmed">27042676</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahn JE, Liu R, Trapa P, et al. . Pharmacokinetic/pharmacodynamic (PK/pd) effects of PF-06648671, a novel gamma secretase modulator (GSM), following single and multiple dose administration in healthy volunteers. Alzheimers Dement. 2017;13:P601.</Citation></Reference><Reference><Citation>Ross J, Sharma S, Winston J, et al. . CHF5074 reduces biomarkers of neuroinflammation in patients with mild cognitive impairment: a 12-week, double-blind, placebo-controlled study. Curr Alzheimer Res. 2013;10(7):742-753.</Citation><ArticleIdList><ArticleId IdType="pubmed">23968157</ArticleId></ArticleIdList></Reference><Reference><Citation>Rynearson KD, Ponnusamy M, Prikhodko O, et al. . Preclinical validation of a potent &#x3b3;-secretase modulator for Alzheimer's disease prevention. J Exp Med. 2021;218(4):e20202560.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7931646</ArticleId><ArticleId IdType="pubmed">33651103</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehra R, Kepp KP. Understanding familial Alzheimer's disease: the fit-stay-trim mechanism of &#x3b3;-secretase. Wiley Interdiscip Rev Comput Mol Sci. Epub 10 Jun 2021.</Citation></Reference><Reference><Citation>Mehra R, Kepp KP. Computational prediction and molecular mechanism of &#x3b3;-secretase modulators. Eur J Pharm Sci. 2021;157:105626.</Citation><ArticleIdList><ArticleId IdType="pubmed">33115674</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang G, Zhou R, Guo X, Yan C, Lei J, Shi Y. Structural basis of &#x3b3;-secretase inhibition and modulation by small molecule drugs. Cell. 2021;184(2):521-533.e14.</Citation><ArticleIdList><ArticleId IdType="pubmed">33373587</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Benzinger TL, Berry S, et al. . The DIAN-TU Next Generation Alzheimer's Prevention Trial: adaptive design and disease progression model. Alzheimers Dement. 2017;13(1):8-19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5218895</ArticleId><ArticleId IdType="pubmed">27583651</ArticleId></ArticleIdList></Reference><Reference><Citation>Steiner H, Fukumori A, Tagami S, Okochi M. Making the final cut: pathogenic amyloid-&#x3b2; peptide generation by &#x3b3;-secretase. Cell Stress. 2018;2(11):292-310.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6551803</ArticleId><ArticleId IdType="pubmed">31225454</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia W, Wong ST, Hanlon E, Morin P. &#x3b3;-Secretase modulator in Alzheimer's disease: shifting the end. J Alzheimers Dis. 2012;31(4):685-696.</Citation><ArticleIdList><ArticleId IdType="pubmed">22710916</ArticleId></ArticleIdList></Reference><Reference><Citation>Cullen NC, Leuzy A, Janelidze S, et al. . Plasma biomarkers of Alzheimer's disease improve prediction of cognitive decline in cognitively unimpaired elderly populations. Nat Commun. 2021;12(1):3555.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8196018</ArticleId><ArticleId IdType="pubmed">34117234</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34961894</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>07</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-0533</ISSN><JournalIssue CitedMedium="Internet"><Volume>143</Volume><Issue>2</Issue><PubDate><Year>2022</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Acta neuropathologica</Title><ISOAbbreviation>Acta Neuropathol</ISOAbbreviation></Journal><ArticleTitle>CSF p-tau increase in response to A&#x3b2;-type and Danish-type cerebral amyloidosis and in the absence of neurofibrillary tangles.</ArticleTitle><Pagination><StartPage>287</StartPage><EndPage>290</EndPage><MedlinePgn>287-290</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00401-021-02400-5</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kaeser</LastName><ForeName>Stephan A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, 72076, T&#xfc;bingen, Germany. stephan.kaeser@uni-tuebingen.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>DZNE, German Center for Neurodegenerative Diseases, 72076, T&#xfc;bingen, Germany. stephan.kaeser@uni-tuebingen.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>H&#xe4;sler</LastName><ForeName>Lisa M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, 72076, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>DZNE, German Center for Neurodegenerative Diseases, 72076, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lambert</LastName><ForeName>Marius</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, 72076, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>DZNE, German Center for Neurodegenerative Diseases, 72076, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bergmann</LastName><ForeName>Carina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, 72076, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>DZNE, German Center for Neurodegenerative Diseases, 72076, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bottelbergs</LastName><ForeName>Astrid</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Neuroscience Department, Janssen Research and Development, Beerse, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Theunis</LastName><ForeName>Clara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Neuroscience Department, Janssen Research and Development, Beerse, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mercken</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Neuroscience Department, Janssen Research and Development, Beerse, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jucker</LastName><ForeName>Mathias</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-9045-1072</Identifier><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, 72076, T&#xfc;bingen, Germany. mathias.jucker@uni-tuebingen.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>DZNE, German Center for Neurodegenerative Diseases, 72076, T&#xfc;bingen, Germany. mathias.jucker@uni-tuebingen.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>12</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Acta Neuropathol</MedlineTA><NlmUniqueID>0412041</NlmUniqueID><ISSNLinking>0001-6322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C538248">Amyloid angiopathy</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016657" MajorTopicYN="N">Cerebral Amyloid Angiopathy</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003718" MajorTopicYN="N" Type="Geographic">Denmark</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>A.B., C.T. and M.M. were employees of Janssen Research and Development, LLC at the time the study was conducted. All the other authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>9</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>12</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>12</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>28</Day><Hour>6</Hour><Minute>38</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>12</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34961894</ArticleId><ArticleId IdType="pmc">PMC8742811</ArticleId><ArticleId IdType="doi">10.1007/s00401-021-02400-5</ArticleId><ArticleId IdType="pii">10.1007/s00401-021-02400-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Barthelemy NR, Li Y, Joseph-Mathurin N, Gordon BA, Hassenstab J, Benzinger TLS, et al. A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease. Nat Med. 2020;26:398&#x2013;407. doi: 10.1038/s41591-020-0781-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0781-z</ArticleId><ArticleId IdType="pmc">PMC7309367</ArticleId><ArticleId IdType="pubmed">32161412</ArticleId></ArticleIdList></Reference><Reference><Citation>Coomaraswamy J, Kilger E, Wolfing H, Sch&#xe4;fer C, Kaeser SA, Wegenast-Braun BM, et al. Modeling familial Danish dementia in mice supports the concept of the amyloid hypothesis of Alzheimer's disease. Proc Natl Acad Sci U S A. 2010;107:7969&#x2013;7974. doi: 10.1073/pnas.1001056107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1001056107</ArticleId><ArticleId IdType="pmc">PMC2867864</ArticleId><ArticleId IdType="pubmed">20385796</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson O. Biomarkers for neurodegenerative diseases. Nat Med. 2021;27:954&#x2013;963. doi: 10.1038/s41591-021-01382-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01382-x</ArticleId><ArticleId IdType="pubmed">34083813</ArticleId></ArticleIdList></Reference><Reference><Citation>Holton JL, Ghiso J, Lashley T, Rostagno A, Guerin CJ, Gibb G, et al. Regional distribution of amyloid-Bri deposition and its association with neurofibrillary degeneration in familial British dementia. Am J Pathol. 2001;158:515&#x2013;526. doi: 10.1016/S0002-9440(10)63993-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9440(10)63993-4</ArticleId><ArticleId IdType="pmc">PMC1850296</ArticleId><ArticleId IdType="pubmed">11159188</ArticleId></ArticleIdList></Reference><Reference><Citation>Holton JL, Lashley T, Ghiso J, Braendgaard H, Vidal R, Guerin CJ, et al. Familial Danish dementia: a novel form of cerebral amyloidosis associated with deposition of both amyloid-Dan and amyloid-beta. J Neuropathol Exp Neurol. 2002;61:254&#x2013;267. doi: 10.1093/jnen/61.3.254.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnen/61.3.254</ArticleId><ArticleId IdType="pubmed">11895040</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Bennett DA, Blennow K, Carrillo C, Feldman HH, Frisoni GB, et al. A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016;87:539&#x2013;547. doi: 10.1212/WNL.0000000000002923.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000002923</ArticleId><ArticleId IdType="pmc">PMC4970664</ArticleId><ArticleId IdType="pubmed">27371494</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze S, Stomrud E, Smith R, Palmqvist S, Mattsson N, Airey DC, et al. Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease. Nat Commun. 2020;11:1683. doi: 10.1038/s41467-020-15436-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-15436-0</ArticleId><ArticleId IdType="pmc">PMC7125218</ArticleId><ArticleId IdType="pubmed">32246036</ArticleId></ArticleIdList></Reference><Reference><Citation>Mintun MA, Lu M, Schade AE, Dage JL, Willis BA, Brooks DA et al (2021) TRAILBLAZER-ALZ study: amyloid clearance results in a rapid and sustained reduction in plasma P217tau levels. Presented at the Alzheimer's Association International Conference (AAIC), Denver, USA and Online, July 26&#x2013;30, 2021</Citation></Reference><Reference><Citation>Radde R, Bolmont T, Kaeser SA, Coomaraswamy J, Lindau D, Stoltze L, et al. Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep. 2006;7:940&#x2013;946. doi: 10.1038/sj.embor.7400784.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.embor.7400784</ArticleId><ArticleId IdType="pmc">PMC1559665</ArticleId><ArticleId IdType="pubmed">16906128</ArticleId></ArticleIdList></Reference><Reference><Citation>Schelle J, Hasler LM, Gopfert JC, Joos TO, Vanderstichele H, Stoops E, et al. Prevention of tau increase in cerebrospinal fluid of APP transgenic mice suggests downstream effect of BACE1 inhibition. Alzheimers Dement. 2017;13:701&#x2013;709. doi: 10.1016/j.jalz.2016.09.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2016.09.005</ArticleId><ArticleId IdType="pubmed">27750032</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, Zhang W, Yang Y, Murzin AG, Falcon B, Kotecha A, et al. Structure-based classification of tauopathies. Nature. 2021;598:359&#x2013;363. doi: 10.1038/s41586-021-03911-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03911-7</ArticleId><ArticleId IdType="pmc">PMC7611841</ArticleId><ArticleId IdType="pubmed">34588692</ArticleId></ArticleIdList></Reference><Reference><Citation>Triana-Baltzer G, Van Kolen K, Theunis C, Moughadam S, Slemmon R, Mercken M, et al. Development and validation of a high sensitivity assay for measuring p217 + tau in cerebrospinal fluid. J Alzheimer's Dis. 2020;77:1417&#x2013;1430. doi: 10.3233/JAD-200463.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-200463</ArticleId><ArticleId IdType="pmc">PMC7683057</ArticleId><ArticleId IdType="pubmed">32831201</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye L, Rasmussen J, Kaeser SA, Marzesco AM, Obermuller U, Mahler J, et al. Abeta seeding potency peaks in the early stages of cerebral beta-amyloidosis. EMBO Rep. 2017;18:1536&#x2013;1544. doi: 10.15252/embr.201744067.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embr.201744067</ArticleId><ArticleId IdType="pmc">PMC5579388</ArticleId><ArticleId IdType="pubmed">28701326</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34965419</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>15</Day></DateCompleted><DateRevised><Year>2022</Year><Month>02</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2211-1247</ISSN><JournalIssue CitedMedium="Internet"><Volume>37</Volume><Issue>13</Issue><PubDate><Year>2021</Year><Month>Dec</Month><Day>28</Day></PubDate></JournalIssue><Title>Cell reports</Title><ISOAbbreviation>Cell Rep</ISOAbbreviation></Journal><ArticleTitle>Alzheimer's vulnerable brain region relies on a distinct retromer core dedicated to endosomal recycling.</ArticleTitle><Pagination><StartPage>110182</StartPage><MedlinePgn>110182</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.celrep.2021.110182</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2211-1247(21)01682-X</ELocationID><Abstract><AbstractText>Whether and how the pathogenic disruptions in endosomal trafficking observed in Alzheimer's disease (AD) are linked to its anatomical vulnerability remain unknown. Here, we began addressing these questions by showing that neurons are enriched with a second retromer core, organized around VPS26b, differentially dedicated to endosomal recycling. Next, by imaging mouse models, we show that the trans-entorhinal cortex, a region most vulnerable to AD, is most susceptible to VPS26b depletion-a finding validated by electrophysiology, immunocytochemistry, and behavior. VPS26b was then found enriched in the trans-entorhinal cortex of human brains, where both VPS26b and the retromer-related receptor SORL1 were found deficient in AD. Finally, by regulating glutamate receptor and SORL1 recycling, we show that VPS26b can mediate regionally selective synaptic dysfunction and SORL1 deficiency. Together with the trans-entorhinal's unique network properties, hypothesized to impose a heavy demand on endosomal recycling, these results suggest a general mechanism that can explain AD's regional vulnerability.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Simoes</LastName><ForeName>Sabrina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, NY 10032, USA; Department of Neurology, Columbia University, New York, NY 10032, USA. Electronic address: sa2969@columbia.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Jia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, NY 10032, USA; Department of Psychiatry, Columbia University, New York, NY 10032, USA; The Mortimer B. Zuckerman Mind Brain Behavior Institute, Columbia University, New York, NY 10027, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buitrago</LastName><ForeName>Luna</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>The Robert F. Furchgott Center for Neural and Behavioral Science, Departments of Neurology and Physiology/Pharmacology, SUNY Downstate Medical Center, Brooklyn, NY 11203, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qureshi</LastName><ForeName>Yasir H</ForeName><Initials>YH</Initials><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feng</LastName><ForeName>Xinyang</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, NY 10032, USA; Department of Neurology, Columbia University, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kothiya</LastName><ForeName>Milankumar</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cortes</LastName><ForeName>Etty</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Vivek</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kannan</LastName><ForeName>Suvarnambiga</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Young-Hyun</ForeName><Initials>YH</Initials><AffiliationInfo><Affiliation>National Primate Research Center, Korea Research Institute of Bioscience &amp; Biotechnology, Daejeon, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Kyu-Tae</ForeName><Initials>KT</Initials><AffiliationInfo><Affiliation>National Primate Research Center, Korea Research Institute of Bioscience &amp; Biotechnology, Daejeon, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Alzheimer's Disease Neuroimaging Initiative</CollectiveName><AffiliationInfo><Affiliation>Membership of the Alzheimer's Disease Neuroimaging Initiative, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hussaini</LastName><ForeName>S Abid</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, NY 10032, USA; Pathology and Cell Biology, Columbia University, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moreno</LastName><ForeName>Herman</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>The Mortimer B. Zuckerman Mind Brain Behavior Institute, Columbia University, New York, NY 10027, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Paolo</LastName><ForeName>Gilbert</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, NY 10032, USA; Pathology and Cell Biology, Columbia University, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andersen</LastName><ForeName>Olav M</ForeName><Initials>OM</Initials><AffiliationInfo><Affiliation>Danish Research Institute of Translational Neuroscience (DANDRITE) Nordic-EMBL Partnership, Department of Biomedicine, Aarhus University, H&#xf8;gh-Guldbergs Gade 10, 8000 AarhusC, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Small</LastName><ForeName>Scott A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, NY 10032, USA; Department of Neurology, Columbia University, New York, NY 10032, USA. Electronic address: sas68@columbia.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG035015</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066462</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG034618</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG051556</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS056049</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Rep</MedlineTA><NlmUniqueID>101573691</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026502">LDL-Receptor Related Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026901">Membrane Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C102582">SORL1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498296">VPS26A protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D033921">Vesicular Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C089989">Vps26 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011992" MajorTopicYN="N">Endosomes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D026502" MajorTopicYN="N">LDL-Receptor Related Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D026901" MajorTopicYN="N">Membrane Transport Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059906" MajorTopicYN="N">Neuroimaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021381" MajorTopicYN="N">Protein Transport</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D033921" MajorTopicYN="N">Vesicular Transport Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">VPS26b</Keyword><Keyword MajorTopicYN="N">endosomal trafficking</Keyword><Keyword MajorTopicYN="N">retromer</Keyword><Keyword MajorTopicYN="N">trans-entorhinal cortex</Keyword></KeywordList><CoiStatement>Declaration of interests S.A.S. is a co-founder of Retromer Therapeutics, has equity in the company, and is a paid consultant to the company. In addition, S.A.S. has equity in Imij Technologies, an MRI-based company. G.D.P. is a full-time employee of Denali Therapeutics, Inc. O.M.A. has commercial interests in Retromer Therapeutics. Lastly, S.A.S., S.S., and Y.H.Q. are listed as co-inventors on Columbia University-owned patents that relate to retromer biomarkers and retromer drug discovery targets.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>11</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>11</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>12</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>29</Day><Hour>20</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>1</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34965419</ArticleId><ArticleId IdType="mid">NIHMS1767659</ArticleId><ArticleId IdType="pmc">PMC8792909</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2021.110182</ArticleId><ArticleId IdType="pii">S2211-1247(21)01682-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Adams JN, Maass A, Harrison TM, Baker SL, and Jagust WJ (2019). Cortical tau deposition follows patterns of entorhinal functional connectivity in aging. Elife 8, e49132.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6764824</ArticleId><ArticleId IdType="pubmed">31475904</ArticleId></ArticleIdList></Reference><Reference><Citation>Alamed J, Wilcock DM, Diamond DM, Gordon MN, and Morgan D (2006). Two-day radial-arm water maze learning and memory task; robust resolution of amyloid-related memory deficits in transgenic mice. Nat. Protoc 1, 1671&#x2013;1679.</Citation><ArticleIdList><ArticleId IdType="pubmed">17487150</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen OM, Bogh N, Landua AM, Ploen GG, Jensen AM, Monti G, Ulhon BP, Nyengaard JR, Jacobsen K, Jorgensen M, et al. (2021). In vivo evidence that SORL1, encoding the endosomal recycling receptor SORLA, can function as a casual gene in Alzheimer&#x2019;s Disease. bioRxiv. 10.1101/2021.07.13.452149.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.07.13.452149</ArticleId></ArticleIdList></Reference><Reference><Citation>Angulo SL, Henzi T, Neymotin SA, Suarez MD, Lytton WW, Schwaller B, and Moreno H (2020). Amyloid pathology-produced unexpected modifications of calcium homeostasis in hippocampal subicular dendrites 16, 251&#x2013;261.</Citation><ArticleIdList><ArticleId IdType="pubmed">31668966</ArticleId></ArticleIdList></Reference><Reference><Citation>Attar N, and Cullen PJ (2010). The retromer complex. Adv. Enzyme Regul 50,216&#x2013;236.</Citation><ArticleIdList><ArticleId IdType="pubmed">19900471</ArticleId></ArticleIdList></Reference><Reference><Citation>Avants BB, Tustison NJ, Song G, Cook PA, Klein A, and Gee JC (2011). A reproducible evaluation of ANTs similarity metric performance in brain image registration. Neuroimage 54, 2033&#x2013;2044.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3065962</ArticleId><ArticleId IdType="pubmed">20851191</ArticleId></ArticleIdList></Reference><Reference><Citation>Barker GR, and Warburton EC (2011). When is the hippocampus involved in recognition memory? J. Neurosci 31, 10721&#x2013;10731.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6622630</ArticleId><ArticleId IdType="pubmed">21775615</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Wen G, Morris JC, and Holtzman DM (2007). Fluctuations of CSF amyloid-beta levels: Implications for a diagnostic and therapeutic biomarker. Neurology 68, 666&#x2013;669.</Citation><ArticleIdList><ArticleId IdType="pubmed">17325273</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhalla A, Vetanovetz CP, Morel E, Chamoun Z, Di Paolo G, and Small SA (2012). The location and trafficking routes of the neuronal retromer and its role in amyloid precursor protein transport. Neurobiol. Dis 47, 126&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3589992</ArticleId><ArticleId IdType="pubmed">22516235</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolte S, and Cordelieres FP (2006). A guided tour into subcellular colocalization analysis in light microscopy. J. Microsc 224, 213&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pubmed">17210054</ArticleId></ArticleIdList></Reference><Reference><Citation>Bota M, Sporns O, and Swanson LW (2015). Architecture of the cerebral cortical association connectome underlying cognition. Proc. Natl. Acad. Sci. U S A 112, E2093&#x2013;E2101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4413280</ArticleId><ArticleId IdType="pubmed">25848037</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, and Braak E (1991). Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. (Berl) 82, 239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Bugarcic A, Zhe Y, Kerr MC, Griffin J, Collins BM, and Teasdale RD (2011). Vps26A and Vps26B subunits define distinct retromer complexes. Traffic 12, 1759&#x2013;1773.</Citation><ArticleIdList><ArticleId IdType="pubmed">21920005</ArticleId></ArticleIdList></Reference><Reference><Citation>Burd C, and Cullen PJ (2014). Retromer: A master conductor of endosome sorting. Cold Spring Harb. Perspect. Biol 6, a016774.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3941235</ArticleId><ArticleId IdType="pubmed">24492709</ArticleId></ArticleIdList></Reference><Reference><Citation>Cepeda-Prado E, Popp S, Khan U, Stefanov D, Rodriguez J, Menalled LB, Dow-Edwards D, Small SA, and Moreno H (2012). R6/2 Huntington&#x2019;s disease mice develop early and progressive abnormal brain metabolism and seizures. J. Neurosci 32, 6456&#x2013;6467.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3374973</ArticleId><ArticleId IdType="pubmed">22573668</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou N, Wu J, Bai Bingren J, Qiu A, and Chuang KH (2011). Robust automatic rodent brain extraction using 3-D pulse-coupled neural networks (PCNN). IEEE Trans. Image Process 20, 2554&#x2013;2564.</Citation><ArticleIdList><ArticleId IdType="pubmed">21411404</ArticleId></ArticleIdList></Reference><Reference><Citation>Choy RW, Park M, Temkin P, Herring BE, Marley A, Nicoll RA, and von Zastrow M (2014). Retromer mediates a discrete route of local membrane delivery to dendrites. Neuron 82, 55&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4029335</ArticleId><ArticleId IdType="pubmed">24698268</ArticleId></ArticleIdList></Reference><Reference><Citation>Criscuolo C, Fabiani C, Bonadonna C, Origlia N, and Domenici L (2015). BDNF prevents amyloid-dependent impairment of LTP in the entorhinal cortex by attenuating p38 MAPK phosphorylation. Neurobiol. Aging 36, 1303&#x2013;1309.</Citation><ArticleIdList><ArticleId IdType="pubmed">25554494</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehlers MD (2000). Reinsertion or degradation of AMPA receptors determined by activity-dependent endocytic sorting. Neuron 28, 511&#x2013;525.</Citation><ArticleIdList><ArticleId IdType="pubmed">11144360</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischl B, and Dale AM (2000). Measuring the thickness of the human cerebral cortex from magnetic resonance images. Proc. Natl. Acad. Sci. U S A 97, 11050&#x2013;11055.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27146</ArticleId><ArticleId IdType="pubmed">10984517</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischl B, Sereno MI, and Dale AM (1999). Cortical surface-based analysis. II: Inflation, flattening, and a surface-based coordinate system. Neuroimage 9, 195&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pubmed">9931269</ArticleId></ArticleIdList></Reference><Reference><Citation>Fjorback AW, Seaman M, Gustafsen C, Mehmedbasic A, Gokool S, Wu C, Militz D, Schmidt V, Madsen P, Nyengaard JR, et al. (2012). Retromer binds the FANSHY sorting motif in SorLA to regulate amyloid precursor protein sorting and processing. J. Neurosci 32, 1467&#x2013;1480.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6796259</ArticleId><ArticleId IdType="pubmed">22279231</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez-Isla T, Price JL, Mckeel DW Jr., Morris JC, Growdon JH, and Hyman BT (1996). Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer&#x2019;s disease. J. Neurosci 16, 4491&#x2013;4500.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578866</ArticleId><ArticleId IdType="pubmed">8699259</ArticleId></ArticleIdList></Reference><Reference><Citation>Holstege H, van der Lee SJ, Hulsman M, Wong TH, van Rooij JG, Weiss M, Louwersheimer E, Wolters FJ, Amin N, Uitterlinden AG, et al. (2017). Characterization of pathogenic SORL1 genetic variants for association with Alzheimer&#x2019;s disease: A clinical interpretation strategy. Eur. J. Hum. Genet 25, 973&#x2013;981.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5567154</ArticleId><ArticleId IdType="pubmed">28537274</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr., Bernstein MA, Fox NC, Thompson P, Alexander G, Harvey D, Borowski B, Britson PJ, J LW, Ward C, et al. (2008). The Alzheimer&#x2019;s disease neuroimaging initiative (ADNI): MRI methods. J. Magn. Reson. Imaging 27, 685&#x2013;691.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2544629</ArticleId><ArticleId IdType="pubmed">18302232</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Y, Mullaney KA, Peterhoff CM, Che S, Schmidt SD, Boyer-Boiteau A, Ginsberg SD, Cataldo AM, Mathews PM, and Nixon RA (2010). Alzheimer&#x2019;s-related endosome dysfunction in Down syndrome is Abeta-independent but requires APP and is reversed by BACE-1 inhibition. Proc. Natl. Acad. Sci. U S A 107, 1630&#x2013;1635.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2824382</ArticleId><ArticleId IdType="pubmed">20080541</ArticleId></ArticleIdList></Reference><Reference><Citation>Karch CM, and Goate AM (2015). Alzheimer&#x2019;s disease risk genes and mechanisms of disease pathogenesis. Biol. Psychiatry 77, 43&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4234692</ArticleId><ArticleId IdType="pubmed">24951455</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy MJ, and Ehlers MD (2011). Mechanisms and function of dendritic exocytosis. Neuron 69, 856&#x2013;875.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3073864</ArticleId><ArticleId IdType="pubmed">21382547</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerr MC, Bennetts JS, Simpson F, Thomas EC, Flegg C, Gleeson PA, Wicking C, and Teasdale RD (2005). A novel mammalian retromer component, Vps26B. Traffic 6, 991&#x2013;1001.</Citation><ArticleIdList><ArticleId IdType="pubmed">16190980</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan UA, Liu L, Provenzano FA, Berman DE, Profaci CP, Sloan R, Mayeux R, Duff KE, and Small SA (2014). Molecular drivers and cortical spread of lateral entorhinal cortex dysfunction in preclinical Alzheimer&#x2019;s disease. Nat. Neurosci 17, 304&#x2013;311.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4044925</ArticleId><ArticleId IdType="pubmed">24362760</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim E, Lee JW, Baek DC, Lee SR, Kim MS, Kim SH, Imakawa K, and Chang KT (2008). Identification of novel retromer complexes in the mouse testis. Biochem. Biophys. Res. Commun 375, 16&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">18656452</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim E, Lee Y, Lee HJ, Kim JS, Song BS, Huh JW, Lee SR, Kim SU, Kim SH, Hong Y, et al. (2010). Implication of mouse Vps26b-Vps29-Vps35 retromer complex in sortilin trafficking. Biochem. Biophys. Res. Commun 403, 167&#x2013;171.</Citation><ArticleIdList><ArticleId IdType="pubmed">21040701</ArticleId></ArticleIdList></Reference><Reference><Citation>Knupp A, Mishra S, Martinez R, Braggin JE, Szabo M, Kinoshita C, Hailey DW, Small SA, Jayadev S, and Young JE (2020). Depletion of the AD risk gene SORL1 selectively Impairs neuronal endosomal traffic independent of amyloidogenic APP processing. Cell Rep. 31, 107719.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7409533</ArticleId><ArticleId IdType="pubmed">32492427</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovtun O, Leneva N, Bykov YS, Ariotti N, Teasdale RD, Schaffer M, Engel BD, Owen DJ, Briggs JAG, and Collins BM (2018). Structure of the membrane-assembled retromer coat determined by cryo-electron tomography. Nature 561, 561&#x2013;564.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6173284</ArticleId><ArticleId IdType="pubmed">30224749</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwart D, Gregg A, Scheckel C, Murphy E, Paquet D, Duffield M, Fak J, Olsen O, Darnell R, and Tessier-Lavigne M (2019). A large panel of isogenic APP and PSEN1 mutant human iPSC Neurons reveals shared endosomal abnormalities mediated by APP beta-CTFs, not abeta. Neuron 104, 256&#x2013;270.e5.</Citation><ArticleIdList><ArticleId IdType="pubmed">31416668</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma L, Alonso A, and Dickson CT (2008). Differential induction of long-term potentiation in the horizontal versus columnar superficial connections to layer II cells of the entorhinal cortex. Neural Plast. 2008, 814815.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2442230</ArticleId><ArticleId IdType="pubmed">18604300</ArticleId></ArticleIdList></Reference><Reference><Citation>Mai J, Majtanik M, and Paxinos G (2015). Atlas of the Human Brain (Academic Press; ).</Citation></Reference><Reference><Citation>Maia LF, Kaeser SA, Reichwald J, Hruscha M, Martus P, Staufenbiel M, and Jucker M (2013). Changes in amyloid-beta and Tau in the cerebrospinal fluid of transgenic mice overexpressing amyloid precursor protein. Sci. Transl. Med 5, 194re2.</Citation><ArticleIdList><ArticleId IdType="pubmed">23863834</ArticleId></ArticleIdList></Reference><Reference><Citation>Mecozzi VJ, Berman DE, Simoes S, Vetanovetz C, Awal MR, Patel VM, Schneider RT, Petsko GA, Ringe D, and Small SA (2014). Pharmacological chaperones stabilize retromer to limit APP processing. Nat. Chem. Biol 10, 443&#x2013;449.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4076047</ArticleId><ArticleId IdType="pubmed">24747528</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirra SS, Heyman A, Mckeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, and Berg L (1991). The consortium to establish a registry for Alzheimer&#x2019;s disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer&#x2019;s disease. Neurology 41, 479&#x2013;486.</Citation><ArticleIdList><ArticleId IdType="pubmed">2011243</ArticleId></ArticleIdList></Reference><Reference><Citation>Morabito MV, Berman DE, Schneider RT, Zhang Y, Leibel RL, and Small SA (2014). Hyperleucinemia causes hippocampal retromer deficiency linking diabetes to Alzheimer&#x2019;s disease. Neurobiol. Dis 65, 188&#x2013;192.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4235335</ArticleId><ArticleId IdType="pubmed">24440570</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno H, Hua F, Brown T, and Small S (2006). Longitudinal mapping of mouse cerebral blood volume with MRI. NMR Biomed. 19, 535&#x2013;543.</Citation><ArticleIdList><ArticleId IdType="pubmed">16552789</ArticleId></ArticleIdList></Reference><Reference><Citation>Muhammad A, Flores I, Zhang H, Yu R, Staniszewski A, Planel E, Herman M, Ho L, Kreber R, Honig LS, et al. (2008). Retromer deficiency observed in Alzheimer&#x2019;s disease causes hippocampal dysfunction, neurodegeneration, and Abeta accumulation. Proc. Natl. Acad. Sci. U S A 105, 7327&#x2013;7332.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2386077</ArticleId><ArticleId IdType="pubmed">18480253</ArticleId></ArticleIdList></Reference><Reference><Citation>Nielsen MS, Gustafsen C, Madsen P, Nyengaard JR, Hermey G, Bakke O, Mari M, Schu P, Pohlmann R, Dennes A, and Petersen CM (2007). Sorting by the cytoplasmic domain of the amyloid precursor protein binding receptor SorLA. Mol. Cell. Biol 27, 6842&#x2013;6851.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2099242</ArticleId><ArticleId IdType="pubmed">17646382</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon RA (2005). Endosome function and dysfunction in Alzheimer&#x2019;s disease and other neurodegenerative diseases. Neurobiol. Aging 26, 373&#x2013;382.</Citation><ArticleIdList><ArticleId IdType="pubmed">15639316</ArticleId></ArticleIdList></Reference><Reference><Citation>Park M, Penick EC, Edwards JG, Kauer JA, and Ehlers MD (2004). Recycling endosomes supply AMPA receptors for LTP. Science 305,1972&#x2013;1975.</Citation><ArticleIdList><ArticleId IdType="pubmed">15448273</ArticleId></ArticleIdList></Reference><Reference><Citation>Pensalfini A, Kim S, Subbanna S, Bleiwas C, Goulbourne CN, Stavrides PH, Jiang Y, Lee JH, Darji S, Pawlik M, et al. (2020). Endosomal dysfunction induced by directly overactivating Rab5 recapitulates prodromal and neurodegenerative features of Alzheimer&#x2019;s disease. Cell Rep. 33,108420.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7714675</ArticleId><ArticleId IdType="pubmed">33238112</ArticleId></ArticleIdList></Reference><Reference><Citation>Qureshi YH, Berman DE, Klein RL, Patel VM, Simoes S, Kannan S, Cox R, Waksal SD, Stevens B, Petsko GA, and Small SA (2019). Retromer repletion with AAV9-VPS35 restores endosomal function in the mouse hippocampus. bioRxiv, 618496.</Citation></Reference><Reference><Citation>Qureshi YH, Patel VM, Kannan S, Waksal SD, Petsko GA, and Small SA (2020). Retromer combinatorials for gene-therapy across a spectrum of neurological diseases. bioRxiv. 10.1101/2020.09.03.282327.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.09.03.282327</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogaeva E, Meng Y, Lee JH, Gu Y, Kawarai T, Zou F, Katayama T, Baldwin CT, Cheng R, Hasegawa H, et al. (2007). The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat. Genet 39, 168&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2657343</ArticleId><ArticleId IdType="pubmed">17220890</ArticleId></ArticleIdList></Reference><Reference><Citation>Rojas R, van Vlijmen T, Mardones GA, Prabhu Y, Rojas AL, Mohammed S, Heck AJ, Raposo G, van der Sluijs P, and Bonifacino JS (2008). Regulation of retromer recruitment to endosomes by sequential action of Rab5 and Rab7. J. Cell Biol 183, 513&#x2013;526.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2575791</ArticleId><ArticleId IdType="pubmed">18981234</ArticleId></ArticleIdList></Reference><Reference><Citation>Rojas R, van Vlijmen T, Mardones GA, Prabhu Y, Rojas AL, Mohammed S, Heck AJR, Raposo G, van der Suijs P, and Bonifacino JS (2008). Regulation of retromer recruitment to endosomes by sequential action of Rab5 and Rab7. J Cell Biol. 183, 513&#x2013;526.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2575791</ArticleId><ArticleId IdType="pubmed">18981234</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabuncu MR, Yeo BTT, van Leemput K, Vercauteren T, and Golland P (2009). Asymmetric Image-Template Registration. Med. Image Comput. Comput. Assist. Interv 12, 565&#x2013;573.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2860756</ArticleId><ArticleId IdType="pubmed">20426033</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheltens P, de Strooper B, Kivipelto M, Holstege H, Chetelat G, Teunissen CE, Cummings J, and van der Flier WM (2021). Alzheimer&#x2019;s disease. Lancet 397, 1577&#x2013;1590.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8354300</ArticleId><ArticleId IdType="pubmed">33667416</ArticleId></ArticleIdList></Reference><Reference><Citation>Schobel SA, Chaudhury NH, Khan UA, Paniagua B, Styner MA, Asllani I, Inbar BP, Corcoran CM, Lieberman JA, Moore H, and Small SA (2013). Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver. Neuron 78, 81&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3966570</ArticleId><ArticleId IdType="pubmed">23583108</ArticleId></ArticleIdList></Reference><Reference><Citation>Seaman MN (2005). Recycle your receptors with retromer. Trends Cell Biol. 15, 68&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">15695093</ArticleId></ArticleIdList></Reference><Reference><Citation>Seaman MN (2012). The retromer complex - endosomal protein recycling and beyond. J. Cell Sci 125, 4693&#x2013;4702.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3517092</ArticleId><ArticleId IdType="pubmed">23148298</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ (2002). Alzheimer&#x2019;s disease is a synaptic failure. Science 298, 789&#x2013;791.</Citation><ArticleIdList><ArticleId IdType="pubmed">12399581</ArticleId></ArticleIdList></Reference><Reference><Citation>Simoes S, Neufeld JL, Triana-Baltzer G, Moughadam S, Chen EI, Kothiya M, Qureshi YH, Patel V, Honig LS, Kolb H, and Small SA (2020). Tau and other proteins found in Alzheimer&#x2019;s disease spinal fluid are linked to retromer-mediated endosomal traffic in mice and humans. Sci. Transl. Med 12,eaba6334.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7901670</ArticleId><ArticleId IdType="pubmed">33239387</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh V, Chertkow H, Lerch JP, Evans AC, Dorr AE, and Kabani NJ (2006). Spatial patterns of cortical thinning in mild cognitive impairment and Alzheimer&#x2019;s disease. Brain 129, 2885&#x2013;2893.</Citation><ArticleIdList><ArticleId IdType="pubmed">17008332</ArticleId></ArticleIdList></Reference><Reference><Citation>Small SA, and Gandy S (2006). Sorting through the cell biology of Alzheimer&#x2019;s disease: Intracellular pathways to pathogenesis. Neuron 52, 15&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4820242</ArticleId><ArticleId IdType="pubmed">17015224</ArticleId></ArticleIdList></Reference><Reference><Citation>Small SA, Kent K, Pierce A, Leung C, Kang MS, Okada H, Honig L, Vonsattel JP, and Kim TW (2005). Model-guided microarray implicates the retromer complex in Alzheimer&#x2019;s disease. Ann. Neurol 58, 909&#x2013;919.</Citation><ArticleIdList><ArticleId IdType="pubmed">16315276</ArticleId></ArticleIdList></Reference><Reference><Citation>Small SA, and Petsko GA (2015). Retromer in Alzheimer disease, Parkinson disease and other neurological disorders. Nat. Rev. Neurosci 16, 126&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pubmed">25669742</ArticleId></ArticleIdList></Reference><Reference><Citation>Small SA, Schobel SA, Buxton RB, Witter MP, and Barnes CA (2011). A pathophysiological framework of hippocampal dysfunction in ageing and disease. Nat. Rev. Neurosci 12, 585&#x2013;601.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312472</ArticleId><ArticleId IdType="pubmed">21897434</ArticleId></ArticleIdList></Reference><Reference><Citation>Small SA, Simoes-Spassov S, Mayeux R, and Petsko GA (2017). Endosomal traffic jams represent a pathogenic hub and therapeutic target in Alzheimer&#x2019;s disease. Trends Neurosci. 40, 592&#x2013;602.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5654621</ArticleId><ArticleId IdType="pubmed">28962801</ArticleId></ArticleIdList></Reference><Reference><Citation>Small SA, and Swanson LW (2019). A network explanation of Alzheimer&#x2019;s regional vulnerability. Cold Spring Harb. Symp. Quant Biol 83, 193&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pubmed">30642996</ArticleId></ArticleIdList></Reference><Reference><Citation>Temkin P, Morishita W, Goswami D, Arendt K, Chen L, and Malenka R (2017). The retromer supports AMPA receptor trafficking during LTP. Neuron 94, 74&#x2013;82.e5.</Citation><ArticleIdList><ArticleId IdType="pubmed">28384478</ArticleId></ArticleIdList></Reference><Reference><Citation>Thonberg H, Chiang HH, Lilius L, Forsell C, Lindstrom AK, Johansson C, Bjorkstrom J, Thordardottir S, Sleegers K, van Broeckhoven C, et al. (2017). Identification and description of three families with familial Alzheimer disease that segregate variants in the SORL1 gene. Acta Neuropathol. Commun 5, 43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5465543</ArticleId><ArticleId IdType="pubmed">28595629</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian Y, Tang F-L, Sun X, Wen L, Mei L, Tang B-S, and Xiong W-C (2015). VPS35-deficiency results in an impaired AMPA receptor trafficking and decreased dendritic spine maturation. Mol. Brain 8, 70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4628247</ArticleId><ArticleId IdType="pubmed">26521016</ArticleId></ArticleIdList></Reference><Reference><Citation>Truschel ST, Simoes S, Setty SR, Harper DC, Tenza D, Thomas PC, Herman KE, Sackett SD, Cowan DC, Theos AC, et al. (2009). ESCRT-I function is required for Tyrp1 transport from early endosomes to the melanosome limiting membrane. Traffic 10, 1318&#x2013;1336.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2747296</ArticleId><ArticleId IdType="pubmed">19624486</ArticleId></ArticleIdList></Reference><Reference><Citation>Vardarajan BN, Bruesegem SY, Harbour ME, St George-Hyslop P, Seaman MN, and Farrer LA (2012). Identification of Alzheimer disease-associated variants in genes that regulate retromer function. Neurobiol. Aging 33, 2231.e15&#x2013;e30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3391348</ArticleId><ArticleId IdType="pubmed">22673115</ArticleId></ArticleIdList></Reference><Reference><Citation>Vonsattel JP, Aizawa H, Ge P, Difiglia M, Mckee AC, Macdonald M, Gusella JF, Landwehrmeyer GB, Bird ED, Richardson EP Jr., et al. (1995). An improved approach to prepare human brains for research. J. Neuropathol. Exp. Neurol 54, 42&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">7815079</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z, Edwards JG, Riley N, Provance DW Jr., Karcher R, LI XD, Davison IG, Ikebe M, Mercer JA, Kauer JA, and Ehlers MD (2008). Myosin Vb mobilizes recycling endosomes and AMPA receptors for postsynaptic plasticity. Cell 135, 535&#x2013;548.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2585749</ArticleId><ArticleId IdType="pubmed">18984164</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson DI, Langston RF, Schlesiger MI, Wagner M, Watanabe S, and Ainge JA (2013). Lateral entorhinal cortex is critical for novel object-context recognition. Hippocampus 23, 352&#x2013;366.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3648979</ArticleId><ArticleId IdType="pubmed">23389958</ArticleId></ArticleIdList></Reference><Reference><Citation>Young JE, Fong LK, Frankowski H, Petsko GA, Small SA, and Goldstein LSB (2018). Stabilizing the retromer complex in a human stem cell model of Alzheimer&#x2019;s disease reduces TAU phosphorylation independently of amyloid precursor protein. Stem Cell Reports 10, 1046&#x2013;1058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5919412</ArticleId><ArticleId IdType="pubmed">29503090</ArticleId></ArticleIdList></Reference><Reference><Citation>Zamanillo D, Sprengel R, Hvalby O, Jensen V, Burnashev N, Rozov A, Kaiser KM, Koster HJ, Borchardt T, Worley P, et al. (1999). Importance of AMPA receptors for hippocampal synaptic plasticity but not for spatial learning. Science 284, 1805&#x2013;1811.</Citation><ArticleIdList><ArticleId IdType="pubmed">10364547</ArticleId></ArticleIdList></Reference><Reference><Citation>Zetterberg H (2017). Review: Tau in biofluids - relation to pathology, imaging and clinical features. Neuropathol. Appl. Neurobiol 43, 194&#x2013;199.</Citation><ArticleIdList><ArticleId IdType="pubmed">28054371</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34985969</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>06</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>626</Issue><PubDate><Year>2022</Year><Month>Jan</Month><Day>05</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>Distinct populations of highly potent TAU seed conformers in rapidly progressing Alzheimer's disease.</ArticleTitle><Pagination><StartPage>eabg0253</StartPage><MedlinePgn>eabg0253</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.abg0253</ELocationID><Abstract><AbstractText>Although genetic factors play a main role in determining the risk of developing Alzheimer&#x2019;s disease (AD), they do not explain extensive spectrum of clinicopathological phenotypes. Deposits of aggregated TAU proteins are one of the main predictors of cognitive decline in AD. We investigated the hypothesis that variabilities in AD progression could be due to diverse structural assemblies (strains) of TAU protein. Using sensitive biophysical methods in 40 patients with AD and markedly different disease durations, we identified populations of distinct TAU particles that differed in size, structural organization, and replication rate in vitro and in cell assay. The rapidly replicating, distinctly misfolded TAU conformers found in rapidly progressive AD were composed of ~80% misfolded four-repeat (4R) TAU and ~20% of misfolded 3R TAU isoform with the same conformational signatures. These biophysical observations suggest that distinctly misfolded population of 4R TAU conformers drive the rapid decline in AD and imply that effective therapeutic strategies might need to consider not a singular species but a cloud of differently misfolded TAU conformers.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Chae</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-0049-0807</Identifier><AffiliationInfo><Affiliation>Department of Pathology, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haldiman</LastName><ForeName>Tracy</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-9257-9149</Identifier><AffiliationInfo><Affiliation>Department of Pathology, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Sang-Gyun</ForeName><Initials>SG</Initials><Identifier Source="ORCID">0000-0002-6875-113X</Identifier><AffiliationInfo><Affiliation>Centre for Prions and Protein Folding Diseases, University of Alberta, Edmonton T6G 2M8, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hromadkova</LastName><ForeName>Lenka</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-4034-7212</Identifier><AffiliationInfo><Affiliation>Department of Pathology, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Zhuang Zhuang</ForeName><Initials>ZZ</Initials><Identifier Source="ORCID">0000-0001-9651-445X</Identifier><AffiliationInfo><Affiliation>Centre for Prions and Protein Folding Diseases, University of Alberta, Edmonton T6G 2M8, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Pathology, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Prion Disease Pathology Surveillance Center, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lissemore</LastName><ForeName>Frances</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0001-5250-8584</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lerner</LastName><ForeName>Alan</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-9447-6154</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Silva</LastName><ForeName>Rohan</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-5052-5775</Identifier><AffiliationInfo><Affiliation>Reta Lila Weston Institute of Neurological Studies and Department of Molecular Neuroscience, UCL Institute of Neurology, London WC1N 1PJ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>Mark L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Department of Pathology, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Prion Disease Pathology Surveillance Center, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Westaway</LastName><ForeName>David</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-1928-4616</Identifier><AffiliationInfo><Affiliation>Centre for Prions and Protein Folding Diseases, University of Alberta, Edmonton T6G 2M8, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Safar</LastName><ForeName>Jiri G</ForeName><Initials>JG</Initials><Identifier Source="ORCID">0000-0003-2209-0070</Identifier><AffiliationInfo><Affiliation>Department of Pathology, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G0501560</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>RF1 AG061797</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K-1212</GrantID><Acronym>PUK_</Acronym><Agency>Parkinson's UK</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/M02492X/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>RF1 AG058267</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>PS148962</GrantID><Agency>CIHR</Agency><Country>Canada</Country></Grant><Grant><GrantID>U01 AG016976</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>GER 163048</GrantID><Agency>CIHR</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>01</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020033">Protein Isoforms</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020033" MajorTopicYN="N">Protein Isoforms</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="Y">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing interests:</b> The authors declare that they have no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>1</Month><Day>5</Day><Hour>17</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>1</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>10</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34985969</ArticleId><ArticleId IdType="mid">NIHMS1840355</ArticleId><ArticleId IdType="pmc">PMC9549419</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.abg0253</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jun G, Ibrahim-Verbaas CA, Vronskaya M et al. A novel Alzheimer disease locus located near the gene encoding TAU protein. Mol. Psychiatry 21, 108&#x2013;117 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4573764</ArticleId><ArticleId IdType="pubmed">25778476</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunkle BW, Grenier-Boley B, Sims R et al. Genetic meta-analysis of diagnosed Alzheimer&#x2019;s disease identifies new risk loci and implicates A&#x3b2;, TAU, immunity and lipid processing. Nat. Genet 51, 414&#x2013;430 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6463297</ArticleId><ArticleId IdType="pubmed">30820047</ArticleId></ArticleIdList></Reference><Reference><Citation>Chitravas N, Jung RS, Kofskey DM, Blevins JE, Gambetti P, Leigh RJ, Cohen ML, Treatable neurological disorders misdiagnosed as Creutzfeldt-Jakob disease. Ann. Neurol 70, 437&#x2013;444 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3170496</ArticleId><ArticleId IdType="pubmed">21674591</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt C, Wolff M, Weitz M, Bartlau T, Korth C, Zerr I, Rapidly progressive Alzheimer disease. Arch. Neurol 68, 1124&#x2013;1130 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21911694</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt C, Redyk K, Meissner B, Krack L, von Ahsen N, Roeber S, Kretzschmar H, Zerr I, Clinical features of rapidly progressive Alzheimer&#x2019;s disease. Dement. Geriatr. Cogn. Disord 29, 371&#x2013;378 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">20453509</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt C, Artjomova S, Hoeschel M, Zerr I, CSF prion protein concentration and cognition in patients with Alzheimer disease. Prion 7, 229&#x2013;234 (2013)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3783108</ArticleId><ArticleId IdType="pubmed">23406922</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt C, Haik S, Satoh K, Rabano A, Martinez-Martin P, Roeber S, Brandel JP, Calero-Lara M, de Pedro-Cuesta J, Laplanche JL, Hauw JJ, Kretzschmar H, Zerr I, Rapidly progressive Alzheimer&#x2019;s disease: A multicenter update. J. Alzheimers Dis 30, 751&#x2013;756 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22460329</ArticleId></ArticleIdList></Reference><Reference><Citation>Pillai JA, Appleby BS, Safar J, Leverenz JB, Rapidly progressive Alzheimer&#x2019;s disease in two distinct autopsy cohorts. J. Alzheimers Dis 64, 973&#x2013;980 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6487475</ArticleId><ArticleId IdType="pubmed">29966195</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen ML, Kim C, Haldiman T, ElHag M, Mehndiratta P, Pichet T, Lissemore F, Shea M, Cohen Y, Chen W, Blevins J, Appleby BS, Surewicz K, Surewicz WK, Sajatovic M, Tatsuoka C, Zhang S, Mayo P, Butkiewicz M, Haines JL, Lerner AJ, Safar JG, Rapidly progressive Alzheimer&#x2019;s disease features distinct structures of amyloid-&#x3b2;. Brain 138, 1009&#x2013;1022 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5014074</ArticleId><ArticleId IdType="pubmed">25688081</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiang W, Yau WM, Lu JX, Collinge J, Tycko R, Structural variation in amyloid-&#x3b2; fibrils from Alzheimer&#x2019;s disease clinical subtypes. Nature 541, 217&#x2013;221 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5233555</ArticleId><ArticleId IdType="pubmed">28052060</ArticleId></ArticleIdList></Reference><Reference><Citation>Drummond E, Nayak S, Faustin A, Pires G, Hickman RA, Askenazi M, Cohen M, Haldiman T, Kim C, Han X, Shao Y, Safar JG, Ueberheide B, Wisniewski T, Proteomic differences in amyloid plaques in rapidly progressive and sporadic Alzheimer&#x2019;s disease. Acta Neuropathol. 133, 933&#x2013;954 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5503748</ArticleId><ArticleId IdType="pubmed">28258398</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallardo G, Holtzman DM, Amyloid-&#x3b2; and Tau at the crossroads of Alzheimer&#x2019;s disease. Adv. Exp. Med. Biol 1184, 187 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">32096039</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Del Tredici K, Evolutional aspects of Alzheimer&#x2019;s disease pathogenesis. J. Alzheimers Dis 33 (Suppl. 1), S155&#x2013;S161 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">22699850</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufman SK, Del Tredici K, Thomas TL, Braak H, Diamond MI, Tau seeding activity begins in the transentorhinal/entorhinal regions and anticipates phospho-TAU pathology in Alzheimer&#x2019;s disease and PART. Acta Neuropathol. 136, 57&#x2013;67 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6015098</ArticleId><ArticleId IdType="pubmed">29752551</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders DW, Kaufman SK, Holmes BB, Diamond MI, Prions and protein assemblies that convey biological information in health and disease. Neuron 89, 433&#x2013;448 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4748384</ArticleId><ArticleId IdType="pubmed">26844828</ArticleId></ArticleIdList></Reference><Reference><Citation>Caughey B, Baron GS, Chesebro B, Jeffrey M, Getting a grip on prions: Oligomers, amyloids, and pathological membrane interactions. Annu. Rev. Biochem 78, 177&#x2013;204 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2794486</ArticleId><ArticleId IdType="pubmed">19231987</ArticleId></ArticleIdList></Reference><Reference><Citation>Cobb NJ, Surewicz WK, Prion diseases and their biochemical mechanisms. Biochemistry 48, 2574&#x2013;2585 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2805067</ArticleId><ArticleId IdType="pubmed">19239250</ArticleId></ArticleIdList></Reference><Reference><Citation>Morales R, Abid K, Soto C, The prion strain phenomenon: Molecular basis and unprecedented features. Biochim. Biophys. Acta 1772, 681&#x2013;691 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2597801</ArticleId><ArticleId IdType="pubmed">17254754</ArticleId></ArticleIdList></Reference><Reference><Citation>Prusiner SB, in Principles of Molecular Medicine, Jameson JL, Ed. (Humana Press, 1998), pp. 927&#x2013;939.</Citation></Reference><Reference><Citation>Prusiner SB, Legname G, DeArmond SJ, Cohen FE, Safar J, Riesner D, Kaneko K, in Prion Biology and Diseases, Prusiner SB, Ed. (Cold Spring Harbor Laboratory Press, 2004), pp. 857&#x2013;920.</Citation></Reference><Reference><Citation>Barria MA, Mukherjee A, Gonzalez-Romero D, Morales R, Soto C, De novo generation of infectious prions in vitro produces a new disease phenotype. PLOS Pathog. 5, e1000421 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2675078</ArticleId><ArticleId IdType="pubmed">19436715</ArticleId></ArticleIdList></Reference><Reference><Citation>Castilla J, Saa P, Hetz C, Soto C, In vitro generation of infectious scrapie prions. Cell 121, 195&#x2013;206 (2005, 2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15851027</ArticleId></ArticleIdList></Reference><Reference><Citation>Deleault NR, Harris BT, Rees JR, Supattapone S, Formation of native prions from minimal components in vitro. Proc. Natl. Acad. Sci. U.S.A 104, 9741&#x2013;9746 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1887554</ArticleId><ArticleId IdType="pubmed">17535913</ArticleId></ArticleIdList></Reference><Reference><Citation>Geoghegan JC, Miller MB, Kwak AH, Harris BT, Supattapone S, Trans-dominant inhibition of prion propagation in vitro is not mediated by an accessory cofactor. PLOS Pathog. 5, e1000535 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2713408</ArticleId><ArticleId IdType="pubmed">19649330</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JI, Cali I, Surewicz K, Kong Q, Raymond GJ, Atarashi R, Race B, Qing L, Gambetti P, Caughey B, Surewicz WK, Mammalian prions generated from bacterially expressed prion protein in the absence of any mammalian cofactors. J. Biol. Chem 285, 14083&#x2013;14087 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2863186</ArticleId><ArticleId IdType="pubmed">20304915</ArticleId></ArticleIdList></Reference><Reference><Citation>Legname G, Baskakov IV, Nguyen H-OB, Riesner D, Cohen FE, DeArmond SJ, Prusiner SB, Synthetic mammalian prions. Science 305, 673&#x2013;676 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15286374</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang F, Wang X, Yuan CG, Ma J, Generating a prion with bacterially expressed recombinant prion protein. Science 327, 1132&#x2013;1135 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2893558</ArticleId><ArticleId IdType="pubmed">20110469</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim C, Xiao X, Chen S, Haldiman T, Smirnovas V, Kofskey D, Warren M, Surewicz K, Maurer NR, Kong Q, Surewicz W, Safar JG, Artificial strain of human prions created in vitro. Nat. Commun 9, 2166 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5986862</ArticleId><ArticleId IdType="pubmed">29867164</ArticleId></ArticleIdList></Reference><Reference><Citation>Wickner RB, [URE3] as an altered URE2 protein: Evidence for a prion analog in Saccharomyces cerevisiae. Science 264, 566&#x2013;569 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">7909170</ArticleId></ArticleIdList></Reference><Reference><Citation>Glover JR, Kowal AS, Schirmer EC, Patino MM, Liu J-J, Lindquist S, Self-seeded fibers formed by Sup35, the protein determinant of [PSI+], a heritable prion-like factor of S. cerevisiae. Cell 89, 811&#x2013;819 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9182769</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabir ME, Safar JG, Implications of prion adaptation and evolution paradigm for human neurodegenerative diseases. Prion 8, 111&#x2013;116 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7030914</ArticleId><ArticleId IdType="pubmed">24401672</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim C, Haldiman T, Surewicz K, Cohen Y, Chen W, Blevins J, Sy MS, Cohen M, Kong Q, Telling GC, Surewicz WK, Safar JG, Small protease sensitive oligomers of PrPSc in distinct human prions determine conversion rate of PrPC. PLOS Pathog. 8, e1002835 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3410855</ArticleId><ArticleId IdType="pubmed">22876179</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim C, Haldiman T, Cohen Y, Chen W, Blevins J, Sy MS, Cohen M, Safar JG, Protease-sensitive conformers in broad spectrum of distinct PrPSc structures in sporadic Creutzfeldt-Jakob disease are indicator of progression rate. PLOS Pathog. 7, e1002242 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3169556</ArticleId><ArticleId IdType="pubmed">21931554</ArticleId></ArticleIdList></Reference><Reference><Citation>Safar J, Wille H, Itri V, Groth D, Serban H, Torchia M, Cohen FE, Prusiner SB, Eight prion strains have PrPSc molecules with different conformations. Nat. Med 4, 1157&#x2013;1165 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9771749</ArticleId></ArticleIdList></Reference><Reference><Citation>Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, Mirra SS, Nelson PT, Schneider JA, Thal DR, Trojanowski JQ, Vinters HV, Hyman BT; National Institute on Aging; Alzheimer&#x2019;s Association, National Institute on Aging-Alzheimer&#x2019;s Association guidelines for the neuropathologic assessment of Alzheimer&#x2019;s disease: A practical approach. Acta Neuropathol. 123, 1&#x2013;11 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3268003</ArticleId><ArticleId IdType="pubmed">22101365</ArticleId></ArticleIdList></Reference><Reference><Citation>Geschwind MD, Shu H, Haman A, Sejvar JJ, Miller BL, Rapidly progressive dementia. Ann. Neurol 64, 97&#x2013;108 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2647859</ArticleId><ArticleId IdType="pubmed">18668637</ArticleId></ArticleIdList></Reference><Reference><Citation>Pillai JA, Bonner-Jackson A, Bekris LM, Safar J, Bena J, Leverenz JB, Highly elevated cerebrospinal fluid total Tau level reflects higher likelihood of non-amnestic subtype of Alzheimer&#x2019;s disease. J. Alzheimers Dis 70, 1051&#x2013;1058 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7086408</ArticleId><ArticleId IdType="pubmed">31306137</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt C, Karch A, Artjomova S, Hoeschel M, Zerr I, Pre-progression rates in Alzheimer&#x2019;s disease revisited. J. Alzheimers Dis 35, 451&#x2013;454 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23435410</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt C, Wolff M, von Ahsen N, Zerr I, Alzheimer&#x2019;s disease: Genetic polymorphisms and rate of decline. Dement. Geriatr. Cogn. Disord 33, 84&#x2013;89 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22414550</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen M, Appleby B, Safar JG, Distinct prion-like strains of amyloid beta implicated in phenotypic diversity of Alzheimer&#x2019;s disease. Prion 10, 9&#x2013;17 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4981201</ArticleId><ArticleId IdType="pubmed">26809345</ArticleId></ArticleIdList></Reference><Reference><Citation>Daude N, Kim C, Kang SG, Eskandari-Sedighi G, Haldiman T, Yang J, Fleck SC, Gomez-Cardona E, Han ZZ, Borrego-Ecija S, Wohlgemuth S, Julien O, Wille H, Molina-Porcel L, Gelpi E, Safar JG, Westaway D, Diverse, evolving conformer populations drive distinct phenotypes in frontotemporal lobar degeneration caused by the same MAPT-P301L mutation. Acta Neuropathol. 139, 1045&#x2013;1070 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7244472</ArticleId><ArticleId IdType="pubmed">32219515</ArticleId></ArticleIdList></Reference><Reference><Citation>Safar JG, Xiao X, Kabir ME, Chen S, Kim C, Haldiman T, Cohen Y, Chen W, Cohen ML, Surewicz WK, Structural determinants of phenotypic diversity and replication rate of human prions. PLOS Pathog. 11, e1004832 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4397081</ArticleId><ArticleId IdType="pubmed">25875953</ArticleId></ArticleIdList></Reference><Reference><Citation>Haldiman T, Kim C, Cohen Y, Chen W, Blevins J, Qing L, Cohen ML, Langeveld J, Telling GC, Kong Q, Safar JG, Co-existence of distinct prion types enables conformational evolution of human PrPSc by competitive selection. J. Biol. Chem 288, 29846&#x2013;29861 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3795283</ArticleId><ArticleId IdType="pubmed">23974118</ArticleId></ArticleIdList></Reference><Reference><Citation>Atarashi R, Moore RA, Sim VL, Hughson AG, Dorward DW, Onwubiko HA, Priola SA, Caughey B, Ultrasensitive detection of scrapie prion protein using seeded conversion of recombinant prion protein. Nat. Methods 4, 645&#x2013;650 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17643109</ArticleId></ArticleIdList></Reference><Reference><Citation>Puoti G, Bizzi A, Forloni G, Safar JG, Tagliavini F, Gambetti P, Sporadic human prion diseases: Molecular insights and diagnosis. Lancet Neurol. 11, 618&#x2013;628 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22710755</ArticleId></ArticleIdList></Reference><Reference><Citation>Safar JG, in Prions and Diseases, Zou W-Q, Gambetti P, Ed. (Springer Verlag, 2012), vol. 1.</Citation></Reference><Reference><Citation>Safar JG, Molecular pathogenesis of sporadic prion diseases in man. Prion 6, 108&#x2013;115 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3366352</ArticleId><ArticleId IdType="pubmed">22421210</ArticleId></ArticleIdList></Reference><Reference><Citation>Minjarez B, Valero Rustarazo ML, Sanchez del Pino MM, Gonz&#xe1;lez-Robles A, Sosa-Melgarejo JA, Luna-Mu&#xf1;oz J, Mena R, Luna-Arias JP, Identification of polypeptides in neurofibrillary tangles and total homogenates of brains with Alzheimer&#x2019;s disease by tandem mass spectrometry. J. Alzheimers Dis 34, 239&#x2013;262 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23229080</ArticleId></ArticleIdList></Reference><Reference><Citation>Bu&#xe9;e L, Troquier L, Burnouf S, Belarbi K, Van der Jeugd A, Ahmed T, Fernandez-Gomez F, Caillierez R, Grosjean ME, Begard S, Barbot B, Demeyer D, Obriot H, Brion I, Bu&#xe9;e-Scherrer V, Maurage CA, Balschun D, D&#x2019;Hooge R, Hamdane M, Blum D, Sergeant N, From TAU phosphorylation to TAU aggregation: What about neuronal death? Biochem. Soc. Trans 38, 967&#x2013;972 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20658986</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoothoff WH, Johnson GV, Tau phosphorylation: Physiological and pathological consequences. Biochim. Biophys. Acta 1739, 280&#x2013;297 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15615646</ArticleId></ArticleIdList></Reference><Reference><Citation>Irwin DJ, Cohen TJ, Grossman M, Arnold SE, McCarty-Wood E, Van Deerlin VM, Lee VM, Trojanowski JQ, Acetylated TAU neuropathology in sporadic and hereditary TAUopathies. Am. J. Pathol 183, 344&#x2013;351 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3730769</ArticleId><ArticleId IdType="pubmed">23885714</ArticleId></ArticleIdList></Reference><Reference><Citation>Min SW, Chen X, Tracy TE, Li Y, Zhou Y, Wang C, Shirakawa K, Minami SS, Defensor E, Mok SA, Sohn PD, Schilling B, Cong X, Ellerby L, Gibson BW, Johnson J, Krogan N, Shamloo M, Gestwicki J, Masliah E, Verdin E, Gan L, Critical role of acetylation in TAU-mediated neurodegeneration and cognitive deficits. Nat. Med 21, 1154&#x2013;1162 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4598295</ArticleId><ArticleId IdType="pubmed">26390242</ArticleId></ArticleIdList></Reference><Reference><Citation>Park S, Lee JH, Jeon JH, Lee MJ, Degradation or aggregation: The ramifications of post-translational modifications on TAU. BMB Rep. 51, 265&#x2013;273 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6033068</ArticleId><ArticleId IdType="pubmed">29661268</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs GG, Molecular pathology of neurodegenerative diseases: Principles and practice. J. Clin. Pathol 72, 725&#x2013;735 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31395625</ArticleId></ArticleIdList></Reference><Reference><Citation>Mays CE, van der Merwe J, Kim C, Haldiman T, McKenzie D, Safar JG, Westaway D, Prion infectivity plateaus and conversion to symptomatic disease originate from falling precursor levels and increased levels of oligomeric PrPSc species. J. Virol 89, 12418&#x2013;12426 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4665242</ArticleId><ArticleId IdType="pubmed">26423957</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeganathan S, von Bergen M, Brutlach H, Steinhoff HJ, Mandelkow E, Global hairpin folding of TAU in solution. Biochemistry 45, 2283&#x2013;2293 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16475817</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q, Wang F, Xiao X, Kim C, Bohon J, Kiselar J, Safar JG, Ma J, Surewicz WK, Structural attributes of mammalian prion infectivity: Insights from studies with synthetic prions. J. Biol. Chem 293, 18494&#x2013;18503 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6290147</ArticleId><ArticleId IdType="pubmed">30275016</ArticleId></ArticleIdList></Reference><Reference><Citation>Groveman BR, Orru CD, Hughson AG, Raymond LD, Zanusso G, Ghetti B, Campbell KJ, Safar J, Galasko D, Caughey B, Rapid and ultra-sensitive quantitation of disease-associated &#x3b1;-synuclein seeds in brain and cerebrospinal fluid by &#x3b1;Syn RT-QuIC. Acta Neuropathol. Commun 6, 7 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5806364</ArticleId><ArticleId IdType="pubmed">29422107</ArticleId></ArticleIdList></Reference><Reference><Citation>Foutz A, Appleby BS, Hamlin C, Liu X, Yang S, Cohen Y, Chen W, Blevins J, Fausett C, Wang H, Gambetti P, Zhang S, Hughson A, Tatsuoka C, Schonberger LB, Cohen ML, Caughey B, Safar JG, Diagnostic and prognostic value of human prion detection in cerebrospinal fluid. Ann. Neurol 81, 79&#x2013;92 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5266667</ArticleId><ArticleId IdType="pubmed">27893164</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeganathan S, von Bergen M, Mandelkow EM, Mandelkow E, The natively unfolded character of TAU and its aggregation to Alzheimer-like paired helical filaments. Biochemistry 47, 10526&#x2013;10539 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18783251</ArticleId></ArticleIdList></Reference><Reference><Citation>Daebel V, Chinnathambi S, Biernat J, Schwalbe M, Habenstein B, Loquet A, Akoury E, Tepper K, Muller H, Baldus M, Griesinger C, Zweckstetter M, Mandelkow E, Vijayan V, Lange A, &#x3b2;-Sheet core of tau paired helical filaments revealed by solid-state NMR. J. Am. Chem. Soc 134, 13982 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22862303</ArticleId></ArticleIdList></Reference><Reference><Citation>Taniguchi-Watanabe S, Arai T, Kametani F, Nonaka T, Masuda-Suzukake M, Tarutani A, Murayama S, Saito Y, Arima K, Yoshida M, Akiyama H, Robinson A, Mann DMA, Iwatsubo T, Hasegawa M, Biochemical classification of TAUopathies by immunoblot, protein sequence and mass spectrometric analyses of sarkosyl-insoluble and trypsin-resistant TAU. Acta Neuropathol. 131, 267&#x2013;280 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4713716</ArticleId><ArticleId IdType="pubmed">26538150</ArticleId></ArticleIdList></Reference><Reference><Citation>Orru CD, Wilham JM, Vascellari S, Hughson AG, Caughey B, New generation QuIC assays for prion seeding activity. Prion 6, 147&#x2013;152 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7082091</ArticleId><ArticleId IdType="pubmed">22421206</ArticleId></ArticleIdList></Reference><Reference><Citation>Oelschlegel AM, Weissmann C, Acquisition of drug resistance and dependence by prions. PLOS Pathog. 9, e1003158 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3567182</ArticleId><ArticleId IdType="pubmed">23408888</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Browning S, Mahal SP, Oelschlegel AM, Weissmann C, Darwinian evolution of prions in cell culture. Science 327, 869&#x2013;872 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2848070</ArticleId><ArticleId IdType="pubmed">20044542</ArticleId></ArticleIdList></Reference><Reference><Citation>Safarian S, Alimohammadi M, Saberi AA, Moosavi-Movahedi AA, A statistical mechanical deconvolution of the differential scanning calorimetric profiles of the thermal denaturation of cyanomethemoglobin. Protein J. 24, 175&#x2013;181 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16096723</ArticleId></ArticleIdList></Reference><Reference><Citation>Azuaga AI, Dobson CM, Mateo PL, Conejero-Lara F, Unfolding and aggregation during the thermal denaturation of streptokinase. Eur. J. Biochem 269, 4121&#x2013;4133 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12180989</ArticleId></ArticleIdList></Reference><Reference><Citation>Masters CL, Selkoe DJ, Biochemistry of amyloid &#x3b2;-protein and amyloid deposits in Alzheimer disease. Cold Spring Harb. Perspect. Med 2, a006262 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3367542</ArticleId><ArticleId IdType="pubmed">22675658</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirbaha H, Chen D, Morazova OA, Ruff KM, Sharma AM, Liu X, Goodarzi M, Pappu RV, Colby DW, Mirzaei H, Joachimiak LA, Diamond MI, Inert and seed-competent TAU monomers suggest structural origins of aggregation. eLife 7, e36584 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6039173</ArticleId><ArticleId IdType="pubmed">29988016</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma AM, Thomas TL, Woodard DR, Kashmer OM, Diamond MI, Tau monomer encodes strains. eLife 7, e37813 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6289568</ArticleId><ArticleId IdType="pubmed">30526844</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings J, Lee G, Ritter A, Sabbagh M, Zhong K, Alzheimer&#x2019;s disease drug development pipeline: 2019. Alzheimers Dement. 5, 272&#x2013;293 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6617248</ArticleId><ArticleId IdType="pubmed">31334330</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W, Falcon B, Murzin AG, Fan J, Crowther RA, Goedert M, Scheres SHW, Heparin-induced tau filaments are polymorphic and differ from those in Alzheimer&#x2019;s and Pick&#x2019;s diseases. eLife 8, e43584 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6375701</ArticleId><ArticleId IdType="pubmed">30720432</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcon B, Zivanov J, Zhang W, Murzin AG, Garringer HJ, Vidal R, Crowther RA, Newell KL, Ghetti B, Goedert M, Scheres SHW, Novel tau filament fold in chronic traumatic encephalopathy encloses hydrophobic molecules. Nature 568, 420&#x2013;423 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6472968</ArticleId><ArticleId IdType="pubmed">30894745</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Tau filaments in neurodegenerative diseases. FEBS Lett. 592, 2383&#x2013;2391 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29790176</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcon B, Zhang W, Schweighauser M, Murzin AG, Vidal R, Garringer HJ, Ghetti B, Scheres SHW, Goedert M, Tau filaments from multiple cases of sporadic and inherited Alzheimer&#x2019;s disease adopt a common fold. Acta Neuropathol. 136, 699&#x2013;708 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6208733</ArticleId><ArticleId IdType="pubmed">30276465</ArticleId></ArticleIdList></Reference><Reference><Citation>Wesseling H, Mair W, Kumar M, Schlaffner CN, Tang S, Beerepoot P, Fatou B, Guise AJ, Cheng L, Takeda S, Muntel J, Rotunno MS, Dujardin S, Davies P, Kosik KS, Miller BL, Berretta S, Hedreen JC, Grinberg LT, Seeley WW, Hyman BT, Steen H, Steen JA, Tau PTM profiles identify patient heterogeneity and stages of Alzheimer&#x2019;s disease. Cell 183, 1699&#x2013;1713.e13 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8168922</ArticleId><ArticleId IdType="pubmed">33188775</ArticleId></ArticleIdList></Reference><Reference><Citation>Dujardin S, Commins C, Lathuiliere A, Beerepoot P, Fernandes AR, Kamath TV, De Los Santos MB, Klickstein N, Corjuc DL, Corjuc BT, Dooley PM, Viode A, Oakley DH, Moore BD, Mullin K, Jean-Gilles D, Clark R, Atchison K, Moore R, Chibnik LB, Tanzi RE, Frosch MP, Serrano-Pozo A, Elwood F, Steen JA, Kennedy ME, Hyman BT, Tau molecular diversity contributes to clinical heterogeneity in Alzheimer&#x2019;s disease. Nat. Med 26, 1256&#x2013;1263 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7603860</ArticleId><ArticleId IdType="pubmed">32572268</ArticleId></ArticleIdList></Reference><Reference><Citation>Sepulveda-Falla D, Chavez-Gutierrez L, Portelius E, V&#xe9;lez JI, Dujardin S, Barrera-Ocampo A, Dinkel F, Hagel C, Puig B, Mastronardi C, Lopera F, Hyman BT, Blennow K, Arcos-Burgos M, de Strooper B, Glatzel M, A multifactorial model of pathology for age of onset heterogeneity in familial Alzheimer&#x2019;s disease. Acta Neuropathol. 141, 217&#x2013;233 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7847436</ArticleId><ArticleId IdType="pubmed">33319314</ArticleId></ArticleIdList></Reference><Reference><Citation>Siddiqi MK, Kim C, Haldiman T, Kacirova M, Wang B, Bohon J, Chance MR, Kiselar J, Safar JG, Structurally distinct external solvent-exposed domains drive replication of major human prions. PLOS Pathog. 17, e1009642 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8211289</ArticleId><ArticleId IdType="pubmed">34138981</ArticleId></ArticleIdList></Reference><Reference><Citation>Legname G, Nguyen H-OB, Peretz D, Cohen FE, DeArmond SJ, Prusiner SB, Continuum of prion protein structures enciphers a multitude of prion isolate-specified phenotypes. Proc. Natl. Acad. Sci. U.S.A 103, 19105&#x2013;19110 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1748184</ArticleId><ArticleId IdType="pubmed">17142317</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka M, Collins SR, Toyama BH, Weissman JS, The physical basis of how prion conformations determine strain phenotypes. Nature 442, 585&#x2013;589 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16810177</ArticleId></ArticleIdList></Reference><Reference><Citation>Paravastu AK, Leapman RD, Yau WM, Tycko R, Molecular structural basis for polymorphism in Alzheimer&#x2019;s beta-amyloid fibrils. Proc. Natl. Acad. Sci. U.S.A 105, 18349&#x2013;18354 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2587602</ArticleId><ArticleId IdType="pubmed">19015532</ArticleId></ArticleIdList></Reference><Reference><Citation>Michaels TCT, &#x161;ari&#x107; A, Habchi J, Chia S, Meisl G, Vendruscolo M, Dobson CM, Knowles TPJ, Chemical kinetics for bridging molecular mechanisms and macroscopic measurements of amyloid fibril formation. Annu. Rev. Phys. Chem 69, 273&#x2013;298 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29490200</ArticleId></ArticleIdList></Reference><Reference><Citation>Noble GP, Wang DW, Walsh DJ, Barone JR, Miller MB, Nishina KA, Li S, Supattapone S, A structural and functional comparison between infectious and non-Infectious autocatalytic recombinant PrP conformers. PLOS Pathog. 11, e1005017 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4488359</ArticleId><ArticleId IdType="pubmed">26125623</ArticleId></ArticleIdList></Reference><Reference><Citation>Deleault NR, Walsh DJ, Piro JR, Wang F, Wang X, Ma J, Rees JR, Supattapone S, Cofactor molecules maintain infectious conformation and restrict strain properties in purified prions. Proc. Natl. Acad. Sci. U.S.A 109, E1938&#x2013;E1946 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3396481</ArticleId><ArticleId IdType="pubmed">22711839</ArticleId></ArticleIdList></Reference><Reference><Citation>Deleault NR, Piro JR, Walsh DJ, Wang F, Ma J, Geoghegan JC, Supattapone S, Isolation of phosphatidylethanolamine as a solitary cofactor for prion formation in the absence of nucleic acids. Proc. Natl. Acad. Sci. U.S.A 109, 8546&#x2013;8551 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3365173</ArticleId><ArticleId IdType="pubmed">22586108</ArticleId></ArticleIdList></Reference><Reference><Citation>Aoyagi A, Condello C, St&#xf6;hr J, Yue W, Rivera BM, Lee JC, Woerman AL, Halliday G, van Duinen S, Ingelsson M, Lannfelt L, Graff C, Bird TD, Keene CD, Seeley WW, DeGrado WF, Prusiner SB, A&#x3b2; and tau prion-like activities decline with longevity in the Alzheimer&#x2019;s disease human brain. Sci. Transl. Med 11, eaat8462 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6640844</ArticleId><ArticleId IdType="pubmed">31043574</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang SG, Han ZZ, Daude N, McNamara E, Wohlgemuth S, Molina-Porcel L, Safar JG, Mok SA, Westaway D, Pathologic tau conformer ensembles induce dynamic, liquid-liquid phase separation events at the nuclear envelope. BMC Biol. 19, 199 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8428099</ArticleId><ArticleId IdType="pubmed">34503506</ArticleId></ArticleIdList></Reference><Reference><Citation>Tatsuoka C, Tseng H, Jaeger J, Varadi F, Smith MA, Yamada T, Smyth KA, Lerner AJ; The Alzheimer&#x2019;s Disease Neuroimaging Initiative, Modeling the heterogeneity in risk of progression to Alzheimer&#x2019;s disease across cognitive profiles in mild cognitive impairment. Alzheimers Res. Ther 5, 14 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3707057</ArticleId><ArticleId IdType="pubmed">23497709</ArticleId></ArticleIdList></Reference><Reference><Citation>Chien DT, Szardenings AK, Bahri S, Walsh JC, Mu F, Xia C, Shankle WR, Lerner AJ, Su MY, Elizarov A, Kolb HC, Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808. J. Alzheimers Dis 38, 171&#x2013;184 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">23948934</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr., Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH, The diagnosis of dementia due to Alzheimer&#x2019;s disease: Recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 7, 263&#x2013;269 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312024</ArticleId><ArticleId IdType="pubmed">21514250</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, Mirra SS, Nelson PT, Schneider JA, Thal DR, Thies B, Trojanowski JQ, Vinters HV, Montine TJ, National Institute on Aging-Alzheimer&#x2019;s Association guidelines for the neuropathologic assessment of Alzheimer&#x2019;s disease. Alzheimers Dement. 8, 1&#x2013;13 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3266529</ArticleId><ArticleId IdType="pubmed">22265587</ArticleId></ArticleIdList></Reference><Reference><Citation>Beekly DL, Ramos EM, Lee WW, Deitrich WD, Jacka ME, Wu J, Hubbard JL, Koepsell TD, Morris JC, Kukull WA; NIA Alzheimer&#x2019;s Disease Centers, The National Alzheimer&#x2019;s Coordinating Center (NACC) database: The Uniform Data Set. Alzheimer Dis. Assoc. Disord 21, 249&#x2013;258 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17804958</ArticleId></ArticleIdList></Reference><Reference><Citation>Parchi P, Zou W, Wang W, Brown P, Capellari S, Ghetti B, Kopp N, Schulz-Schaeffer WJ, Kretzschmar HA, Head MW, Ironside JW, Gambetti P, Chen SG, Genetic influence on the structural variations of the abnormal prion protein. Proc. Natl. Acad. Sci. U.S.A 97, 10168&#x2013;10172 (2000).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27779</ArticleId><ArticleId IdType="pubmed">10963679</ArticleId></ArticleIdList></Reference><Reference><Citation>Safar JG, Geschwind MD, Deering C, Didorenko S, Sattavat M, Sanchez H, Serban A, Vey M, Baron H, Giles K, Miller BL, DeArmond SJ, Prusiner SB, Diagnosis of human prion disease. Proc. Natl. Acad. Sci. U.S.A 102, 3501&#x2013;3501 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC552933</ArticleId><ArticleId IdType="pubmed">15741275</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanger F, Nicklen S, Coulson AR, DNA sequencing with chain-terminating inhibitors. Proc. Natl. Acad. Sci. U.S.A 74, 5463&#x2013;5467 (1977).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC431765</ArticleId><ArticleId IdType="pubmed">271968</ArticleId></ArticleIdList></Reference><Reference><Citation>Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, van Swieten JC, Seelaar H, Dopper EG, Onyike CU, Hillis AE, Josephs KA, Boeve BF, Kertesz A, Seeley WW, Rankin KP, Johnson JK, Gorno-Tempini ML, Rosen H, Prioleau-Latham CE, Lee A, Kipps CM, Lillo P, Piguet O, Rohrer JD, Rossor MN, Warren JD, Fox NC, Galasko D, Salmon DP, Black SE, Mesulam M, Weintraub S, Dickerson BC, Diehl-Schmid J, Pasquier F, Deramecourt V, Lebert F, Pijnenburg Y, Chow TW, Manes F, Grafman J, Cappa SF, Freedman M, Grossman M, Miller BL, Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 134, 2456&#x2013;2477 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3170532</ArticleId><ArticleId IdType="pubmed">21810890</ArticleId></ArticleIdList></Reference><Reference><Citation>Safar J, Prusiner SB, Chapter 29 Molecular studies of prion diseases. Prog. Brain Res 117 421&#x2013;434 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9932423</ArticleId></ArticleIdList></Reference><Reference><Citation>de Silva R, Lashley T, Gibb G, Hanger D, Hope A, Reid A, Bandopadhyay R, Utton M, Strand C, Jowett T, Khan N, Anderton B, Wood N, Holton J, Revesz T, Lees A, Pathological inclusion bodies in TAUopathies contain distinct complements of TAU with three or four microtubule-binding repeat domains as demonstrated by new specific monoclonal antibodies. Neuropathol. Appl. Neurobiol 29, 288&#x2013;302 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12787326</ArticleId></ArticleIdList></Reference><Reference><Citation>Luk KC, Song C, O&#x2019;Brien P, Stieber A, Branch JR, Brunden KR, Trojanowski JQ, Lee VM, Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc. Natl. Acad. Sci. U.S.A 106, 20051&#x2013;20056 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2785290</ArticleId><ArticleId IdType="pubmed">19892735</ArticleId></ArticleIdList></Reference><Reference><Citation>Safar JG, DeArmond SJ, Kociuba K, Deering C, Didorenko S, Bouzamondo-Bernstein E, Prusiner SB, Tremblay P, Prion clearance in bigenic mice. J. Gen. Virol 86, 2913&#x2013;2923 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16186247</ArticleId></ArticleIdList></Reference><Reference><Citation>Safar JG, Kellings K, Serban A, Groth D, Cleaver JE, Prusiner SB, Riesner D, Search for a prion-specific nucleic acid. J. Virol 79, 10796&#x2013;10806 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1182634</ArticleId><ArticleId IdType="pubmed">16051871</ArticleId></ArticleIdList></Reference><Reference><Citation>Dinkel PD, Siddiqua A, Huynh H, Shah M, Margittai M, Variations in filament conformation dictate seeding barrier between three- and four-repeat TAU. Biochemistry 50, 4330&#x2013;4336 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21510682</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee IS, Long JR, Prusiner SB, Safar JG, Selective precipitation of prions by polyoxometalate complexes. J. Am. Chem. Soc 127, 13802&#x2013;13803 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16201796</ArticleId></ArticleIdList></Reference><Reference><Citation>Safar JG, Wille H, Geschwind MD, Deering C, Latawiec D, Serban A, King DJ, Legname G, Weisgraber KH, Mahley RW, Miller BL, DeArmond SJ, Prusiner SB, Human prions and plasma lipoproteins. Proc. Natl. Acad. Sci. U.S.A 103, 11312&#x2013;11317 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1544083</ArticleId><ArticleId IdType="pubmed">16849426</ArticleId></ArticleIdList></Reference><Reference><Citation>Safar JG, Scott M, Monaghan J, Deering C, Didorenko S, Vergara J, Ball H, Legname G, Leclerc E, Solforosi L, Serban H, Groth D, Burton DR, Prusiner SB, Williamson RA, Measuring prions causing bovine spongiform encephalopathy or chronic wasting disease by immunoassays and transgenic mice. Nat. Biotechnol 20, 1147&#x2013;1150 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12389035</ArticleId></ArticleIdList></Reference><Reference><Citation>Mays CE, Kim C, Haldiman T, van der Merwe J, Lau A, Yang J, Grams J, Di Bari MA, Nonno R, Telling GC, Kong Q, Langeveld J, McKenzie D, Westaway D, Safar JG, Prion disease tempo determined by host-dependent substrate reduction. J. Clin. Invest 124, 847&#x2013;858 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3904628</ArticleId><ArticleId IdType="pubmed">24430187</ArticleId></ArticleIdList></Reference><Reference><Citation>Prusiner SB, Hadlow WJ, Eklund CM, Race RE, Cochran SP, Sedimentation characteristics of the scrapie agent from murine spleen and brain. Biochemistry 17, 4987&#x2013;4992 (1978).</Citation><ArticleIdList><ArticleId IdType="pubmed">214106</ArticleId></ArticleIdList></Reference><Reference><Citation>Steensgaard J, Humphries S, Spragg SP, in Preparative Centrifugation: A Practical Approach, Rickwood D, Ed. (IRL Press, 1992), pp. 187&#x2013;232.</Citation></Reference><Reference><Citation>Wille H, Prusiner SB, Ultrastructural studies on scrapie prion protein crystals obtained from reverse micellar solutions. Biophys. J 76, 1048&#x2013;1062 (1999).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1300055</ArticleId><ArticleId IdType="pubmed">9916037</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox BG, Blommel PG, Autoinduction of protein expression. Curr. Protoc. Protein Sci Chapter 5, Unit 5.23 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5602607</ArticleId><ArticleId IdType="pubmed">19365792</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraus A, Saijo E, Metrick II MA, Newell K, Sigurdson CJ, Zanusso G, Ghetti B, Caughey B, Seeding selectivity and ultrasensitive detection of tau aggregate conformers of Alzheimer disease. Acta Neuropathol. 137, 585&#x2013;598 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6426988</ArticleId><ArticleId IdType="pubmed">30570675</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders DW, Kaufman SK, DeVos SL, Sharma AM, Mirbaha H, Li A, Barker SJ, Foley AC, Thorpe JR, Serpell LC, Miller TM, Grinberg LT, Seeley WW, Diamond MI, Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron 82, 1271&#x2013;1288 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4171396</ArticleId><ArticleId IdType="pubmed">24857020</ArticleId></ArticleIdList></Reference><Reference><Citation>Collinge J, Clarke AR, A general model of prion strains and their pathogenicity. Science 318, 930&#x2013;936 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17991853</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34992268</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>23</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1718</ISSN><JournalIssue CitedMedium="Internet"><Volume>54</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Nature genetics</Title><ISOAbbreviation>Nat Genet</ISOAbbreviation></Journal><ArticleTitle>Genetic analysis of the human microglial transcriptome across brain regions, aging and disease pathologies.</ArticleTitle><Pagination><StartPage>4</StartPage><EndPage>17</EndPage><MedlinePgn>4-17</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41588-021-00976-y</ELocationID><Abstract><AbstractText>Microglia have emerged as important players in brain aging and pathology. To understand how genetic risk for neurological and psychiatric disorders is related to microglial function, large transcriptome studies are essential. Here we describe the transcriptome analysis of 255 primary human microglial samples isolated at autopsy from multiple brain regions of 100 individuals. We performed systematic analyses to investigate various aspects of microglial heterogeneities, including brain region and aging. We mapped expression and splicing quantitative trait loci and showed that many neurological disease susceptibility loci are mediated through gene expression or splicing in microglia. Fine-mapping of these loci nominated candidate causal variants that are within microglia-specific enhancers, finding associations with microglial expression of USP6NL for Alzheimer's disease and P2RY12 for Parkinson's disease. We have built the most comprehensive catalog to date of genetic effects on the microglial transcriptome and propose candidate functional variants in neurological and psychiatric disorders.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s), under exclusive licence to Springer Nature America, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Lopes</LastName><ForeName>Katia de Paiva</ForeName><Initials>KP</Initials><Identifier Source="ORCID">0000-0002-0240-0126</Identifier><AffiliationInfo><Affiliation>Nash Family Department of Neuroscience &amp; Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ronald M. Loeb Center for Alzheimer's Disease, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences &amp; Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Estelle and Daniel Maggin Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Snijders</LastName><ForeName>Gijsje J L</ForeName><Initials>GJL</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mental Illness Research, Education and Clinical Center, James J Peters VA Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Humphrey</LastName><ForeName>Jack</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Nash Family Department of Neuroscience &amp; Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ronald M. Loeb Center for Alzheimer's Disease, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences &amp; Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Estelle and Daniel Maggin Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Allan</LastName><ForeName>Amanda</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Nash Family Department of Neuroscience &amp; Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ronald M. Loeb Center for Alzheimer's Disease, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences &amp; Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Estelle and Daniel Maggin Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sneeboer</LastName><ForeName>Marjolein A M</ForeName><Initials>MAM</Initials><AffiliationInfo><Affiliation>Department of Translational Neuroscience, University Medical Center Utrecht Brain Center, Utrecht University, Utrecht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Navarro</LastName><ForeName>Elisa</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Nash Family Department of Neuroscience &amp; Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ronald M. Loeb Center for Alzheimer's Disease, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences &amp; Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Estelle and Daniel Maggin Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schilder</LastName><ForeName>Brian M</ForeName><Initials>BM</Initials><AffiliationInfo><Affiliation>Nash Family Department of Neuroscience &amp; Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ronald M. Loeb Center for Alzheimer's Disease, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences &amp; Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Estelle and Daniel Maggin Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vialle</LastName><ForeName>Ricardo A</ForeName><Initials>RA</Initials><Identifier Source="ORCID">0000-0003-3311-4197</Identifier><AffiliationInfo><Affiliation>Nash Family Department of Neuroscience &amp; Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ronald M. Loeb Center for Alzheimer's Disease, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences &amp; Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Estelle and Daniel Maggin Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parks</LastName><ForeName>Madison</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Nash Family Department of Neuroscience &amp; Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ronald M. Loeb Center for Alzheimer's Disease, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences &amp; Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Estelle and Daniel Maggin Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Missall</LastName><ForeName>Roy</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Zuiden</LastName><ForeName>Welmoed</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gigase</LastName><ForeName>Frederieke A J</ForeName><Initials>FAJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mental Illness Research, Education and Clinical Center, James J Peters VA Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>K&#xfc;bler</LastName><ForeName>Raphael</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-8448-1021</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Berlekom</LastName><ForeName>Amber Berdenis</ForeName><Initials>AB</Initials><AffiliationInfo><Affiliation>Department of Translational Neuroscience, University Medical Center Utrecht Brain Center, Utrecht University, Utrecht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hicks</LastName><ForeName>Emily M</ForeName><Initials>EM</Initials><Identifier Source="ORCID">0000-0001-9102-9244</Identifier><AffiliationInfo><Affiliation>Nash Family Department of Neuroscience &amp; Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ronald M. Loeb Center for Alzheimer's Disease, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences &amp; Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Estelle and Daniel Maggin Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>B&#x4e7;ttcher</LastName><ForeName>Chotima</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neuropsychiatry and Laboratory of Molecular Psychiatry, Charit&#xe9;-Universit&#xe4;tsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Priller</LastName><ForeName>Josef</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neuropsychiatry and Laboratory of Molecular Psychiatry, Charit&#xe9;-Universit&#xe4;tsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kahn</LastName><ForeName>Ren&#xe9; S</ForeName><Initials>RS</Initials><Identifier Source="ORCID">0000-0001-5909-8004</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mental Illness Research, Education and Clinical Center, James J Peters VA Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>de Witte</LastName><ForeName>Lot D</ForeName><Initials>LD</Initials><Identifier Source="ORCID">0000-0002-7235-9958</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA. lotje.dewitte@mssm.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mental Illness Research, Education and Clinical Center, James J Peters VA Medical Center, New York, NY, USA. lotje.dewitte@mssm.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Raj</LastName><ForeName>Towfique</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-9355-5704</Identifier><AffiliationInfo><Affiliation>Nash Family Department of Neuroscience &amp; Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. towfique.raj@mssm.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ronald M. Loeb Center for Alzheimer's Disease, Icahn School of Medicine at Mount Sinai, New York, NY, USA. towfique.raj@mssm.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences &amp; Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. towfique.raj@mssm.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Estelle and Daniel Maggin Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. towfique.raj@mssm.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG054005</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 AG055824</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS116006</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG068880</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG065926</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 OD026880</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AG063130</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>01</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Genet</MedlineTA><NlmUniqueID>9216904</NlmUniqueID><ISSNLinking>1061-4036</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2022 Apr;18(4):191-192. doi: 10.1038/s41582-022-00633-w.</RefSource><PMID Version="1">35228701</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001271" MajorTopicYN="N">Atlases as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066264" MajorTopicYN="N">Datasets as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018740" MajorTopicYN="N">Genetic Heterogeneity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D040641" MajorTopicYN="N">Quantitative Trait Loci</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012326" MajorTopicYN="N">RNA Splicing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059467" MajorTopicYN="N">Transcriptome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>12</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>10</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>1</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>1</Month><Day>7</Day><Hour>6</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>7</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34992268</ArticleId><ArticleId IdType="mid">NIHMS1749810</ArticleId><ArticleId IdType="pmc">PMC9245609</ArticleId><ArticleId IdType="doi">10.1038/s41588-021-00976-y</ArticleId><ArticleId IdType="pii">10.1038/s41588-021-00976-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Priller J. &amp; Prinz M. Targeting microglia in brain disorders. Science 365, 32&#x2013;33 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31273114</ArticleId></ArticleIdList></Reference><Reference><Citation>Ransohoff RM &amp; El Khoury J. Microglia in health and disease. Cold Spring Harb. Perspect. Biol 8, a020560 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4691795</ArticleId><ArticleId IdType="pubmed">26354893</ArticleId></ArticleIdList></Reference><Reference><Citation>Prinz M, Jung S. &amp; Priller J. Microglia biology: One century of evolving concepts. Cell 179, 292&#x2013;311 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31585077</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan Y-L, Yuan Y. &amp; Tian L. Microglial regional heterogeneity and its role in the brain. Mol. Psychiatry 25, 351&#x2013;367 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6974435</ArticleId><ArticleId IdType="pubmed">31772305</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Poel M. et al. Transcriptional profiling of human microglia reveals grey-white matter heterogeneity and multiple sclerosis-associated changes. Nat. Commun 10, 1139 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6416318</ArticleId><ArticleId IdType="pubmed">30867424</ArticleId></ArticleIdList></Reference><Reference><Citation>Grabert K. et al. Microglial brain region-dependent diversity and selective regional sensitivities to aging. Nat. Neurosci 19, 504&#x2013;516 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4768346</ArticleId><ArticleId IdType="pubmed">26780511</ArticleId></ArticleIdList></Reference><Reference><Citation>De Biase LM et al. Local cues establish and maintain region-specific phenotypes of basal ganglia microglia. Neuron 95, 341&#x2013;356.e6 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5754189</ArticleId><ArticleId IdType="pubmed">28689984</ArticleId></ArticleIdList></Reference><Reference><Citation>Soreq L. et al. Major shifts in glial regional identity are a transcriptional hallmark of human brain aging. Cell Rep. 18, 557&#x2013;570 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5263238</ArticleId><ArticleId IdType="pubmed">28076797</ArticleId></ArticleIdList></Reference><Reference><Citation>Masuda T. et al. Spatial and temporal heterogeneity of mouse and human microglia at single-cell resolution. Nature 566, 388&#x2013;392 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30760929</ArticleId></ArticleIdList></Reference><Reference><Citation>Olah M. et al. A transcriptomic atlas of aged human microglia. Nat. Commun 9, (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5803269</ArticleId><ArticleId IdType="pubmed">29416036</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathys H. et al. Single-cell transcriptomic analysis of Alzheimer&#x2019;s disease. Nature 570, 332&#x2013;337 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6865822</ArticleId><ArticleId IdType="pubmed">31042697</ArticleId></ArticleIdList></Reference><Reference><Citation>Mrdjen D. et al. High-dimensional single-cell mapping of central nervous system immune cells reveals distinct myeloid subsets in health, aging, and disease. Immunity 48, 599 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29562204</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammond TR et al. Single-cell RNA sequencing of microglia throughout the mouse lifespan and in the injured brain reveals complex cell-state changes. Immunity 50, 253&#x2013;271.e6 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6655561</ArticleId><ArticleId IdType="pubmed">30471926</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H. et al. A unique microglia type associated with restricting development of Alzheimer&#x2019;s disease. Cell 169, 1276&#x2013;1290.e17 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Masuda T. et al. Author Correction: Spatial and temporal heterogeneity of mouse and human microglia at single-cell resolution. Nature 568, E4 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30918409</ArticleId></ArticleIdList></Reference><Reference><Citation>Galatro TF et al. Transcriptomic analysis of purified human cortical microglia reveals age-associated changes. Nat. Neurosci 20, 1162&#x2013;1171 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28671693</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer PL et al. Microglia in degenerative neurological disease. Glia 7, 84&#x2013;92 (1993).</Citation><ArticleIdList><ArticleId IdType="pubmed">8423066</ArticleId></ArticleIdList></Reference><Reference><Citation>Kreutzberg GW Microglia: a sensor for pathological events in the CNS. Trends Neurosci. 19, 312&#x2013;318 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8843599</ArticleId></ArticleIdList></Reference><Reference><Citation>Tr&#xe9;panier MO, Hopperton KE, Mizrahi R, Mechawar N. &amp; Bazinet RP Postmortem evidence of cerebral inflammation in schizophrenia: a systematic review. Mol. Psychiatry 21, 1009&#x2013;1026 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4960446</ArticleId><ArticleId IdType="pubmed">27271499</ArticleId></ArticleIdList></Reference><Reference><Citation>Hopperton KE, Mohammad D, Tr&#xe9;panier MO, Giuliano V. &amp; Bazinet RP Markers of microglia in post-mortem brain samples from patients with Alzheimer&#x2019;s disease: a systematic review. Mol. Psychiatry 23, 177&#x2013;198 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5794890</ArticleId><ArticleId IdType="pubmed">29230021</ArticleId></ArticleIdList></Reference><Reference><Citation>Parikshak NN et al. Genome-wide changes in lncRNA, splicing, and regional gene expression patterns in autism. Nature 540, 423&#x2013;427 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7102905</ArticleId><ArticleId IdType="pubmed">27919067</ArticleId></ArticleIdList></Reference><Reference><Citation>Raj T. et al. Polarization of the effects of autoimmune and neurodegenerative risk alleles in leukocytes. Science 344, 519&#x2013;523 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4910825</ArticleId><ArticleId IdType="pubmed">24786080</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunkle BW et al. Genetic meta-analysis of diagnosed Alzheimer&#x2019;s disease identifies new risk loci and implicates A&#x3b2;, tau, immunity and lipid processing. Nat. Genet 51, 414&#x2013;430 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6463297</ArticleId><ArticleId IdType="pubmed">30820047</ArticleId></ArticleIdList></Reference><Reference><Citation>McCauley ME &amp; Baloh RH Inflammation in ALS/FTD pathogenesis. Acta Neuropathol. 137, 715&#x2013;730 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6482122</ArticleId><ArticleId IdType="pubmed">30465257</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandal MJ et al. Transcriptome-wide isoform-level dysregulation in ASD, schizophrenia, and bipolar disorder. Science 362, eaat8127 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6443102</ArticleId><ArticleId IdType="pubmed">30545856</ArticleId></ArticleIdList></Reference><Reference><Citation>Young Adam. M. H. et al. A map of transcriptional heterogeneity and regulatory variation in human microglia. Nat. Genetics 53, 861&#x2013;868 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7610960</ArticleId><ArticleId IdType="pubmed">34083789</ArticleId></ArticleIdList></Reference><Reference><Citation>Masuda T, Sankowski R, Staszewski O. &amp; Prinz M. Microglia heterogeneity in the single-cell era. Cell Rep. 30, 1271&#x2013;1281 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32023447</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YI et al. RNA splicing is a primary link between genetic variation and disease. Science 352, 600&#x2013;604 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5182069</ArticleId><ArticleId IdType="pubmed">27126046</ArticleId></ArticleIdList></Reference><Reference><Citation>Raj T. et al. CD33: increased inclusion of exon 2 implicates the Ig V-set domain in Alzheimer&#x2019;s disease susceptibility. Hum. Mol. Genet 23, 2729&#x2013;2736 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3990171</ArticleId><ArticleId IdType="pubmed">24381305</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffman GE &amp; Schadt EE variancePartition: interpreting drivers of variation in complex gene expression studies. BMC Bioinformatics 17, 483 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5123296</ArticleId><ArticleId IdType="pubmed">27884101</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffman GE &amp; Roussos P. dream: Powerful differential expression analysis for repeated measures designs. Bioinformatics (2020) doi:10.1093/bioinformatics/btaa687.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btaa687</ArticleId><ArticleId IdType="pmc">PMC8055218</ArticleId><ArticleId IdType="pubmed">32730587</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartigan JA &amp; Wong MA Algorithm AS 136: A K-means clustering algorithm. J. R. Stat. Soc. Ser. C. Appl. Stat 28, 100 (1979).</Citation></Reference><Reference><Citation>Srinivasan K. et al. Alzheimer&#x2019;s patient microglia exhibit enhanced aging and unique transcriptional activation. Cell Rep. 31, 107843 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7422733</ArticleId><ArticleId IdType="pubmed">32610143</ArticleId></ArticleIdList></Reference><Reference><Citation>Gosselin D. et al. An environment-dependent transcriptional network specifies human microglia identity. Science 356, eaal3222 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5858585</ArticleId><ArticleId IdType="pubmed">28546318</ArticleId></ArticleIdList></Reference><Reference><Citation>Stahl EA et al. Genome-wide association study identifies 30 loci associated with bipolar disorder. Nat. Genet 51, 793&#x2013;803 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6956732</ArticleId><ArticleId IdType="pubmed">31043756</ArticleId></ArticleIdList></Reference><Reference><Citation>Gusev A. et al. Transcriptome-wide association study of schizophrenia and chromatin activity yields mechanistic disease insights. Nat. Genet 50, 538&#x2013;548 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5942893</ArticleId><ArticleId IdType="pubmed">29632383</ArticleId></ArticleIdList></Reference><Reference><Citation>Raj T. et al. Integrative transcriptome analyses of the aging brain implicate altered splicing in Alzheimer&#x2019;s disease susceptibility. Nat. Genet 50, 1584&#x2013;1592 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6354244</ArticleId><ArticleId IdType="pubmed">30297968</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YI, Wong G, Humphrey J. &amp; Raj T. Prioritizing Parkinson&#x2019;s disease genes using population-scale transcriptomic data. Nat. Commun 10, 994 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6397174</ArticleId><ArticleId IdType="pubmed">30824768</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters MJ et al. The transcriptional landscape of age in human peripheral blood. Nat. Commun 6, 8570 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4639797</ArticleId><ArticleId IdType="pubmed">26490707</ArticleId></ArticleIdList></Reference><Reference><Citation>Urbut SM, Wang G, Carbonetto P. &amp; Stephens M. Flexible statistical methods for estimating and testing effects in genomic studies with multiple conditions. Nat. Genet 51, 187&#x2013;195 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6309609</ArticleId><ArticleId IdType="pubmed">30478440</ArticleId></ArticleIdList></Reference><Reference><Citation>Fairfax BP et al. Innate immune activity conditions the effect of regulatory variants upon monocyte gene expression. Science 343, 1246949 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4064786</ArticleId><ArticleId IdType="pubmed">24604202</ArticleId></ArticleIdList></Reference><Reference><Citation>Navarro E. et al. Dysregulation of mitochondrial and proteolysosomal genes in Parkinson&#x2019;s disease myeloid cells. Nat Aging 1, 850&#x2013;863 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8728893</ArticleId><ArticleId IdType="pubmed">35005630</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng B. et al. An xQTL map integrates the genetic architecture of the human brain&#x2019;s transcriptome and epigenome. Nat. Neurosci 20, 1418&#x2013;1426 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5785926</ArticleId><ArticleId IdType="pubmed">28869584</ArticleId></ArticleIdList></Reference><Reference><Citation>Storey JD The positive false discovery rate: a Bayesian interpretation and the q-value. Ann. Stat 31, 2013&#x2013;2035 (2003).</Citation></Reference><Reference><Citation>Han B. &amp; Eskin E. Random-effects model aimed at discovering associations in meta-analysis of genome-wide association studies. Am. J. Hum. Genet 88, 586&#x2013;598 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3146723</ArticleId><ArticleId IdType="pubmed">21565292</ArticleId></ArticleIdList></Reference><Reference><Citation>Marioni RE et al. GWAS on family history of Alzheimer&#x2019;s disease. Transl. Psychiatry 8, (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5959890</ArticleId><ArticleId IdType="pubmed">29777097</ArticleId></ArticleIdList></Reference><Reference><Citation>Giambartolomei C. et al. Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. PLoS Genet. 10, e1004383 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4022491</ArticleId><ArticleId IdType="pubmed">24830394</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert J-C et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer&#x2019;s disease. Nat. Genet 45, 1452&#x2013;1458 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3896259</ArticleId><ArticleId IdType="pubmed">24162737</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen IE et al. Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer&#x2019;s disease risk. Nat. Genet 51, 404&#x2013;413 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6836675</ArticleId><ArticleId IdType="pubmed">30617256</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalls MA et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson&#x2019;s disease: a meta-analysis of genome-wide association studies. Lancet Neurol. 18, 1091&#x2013;1102 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8422160</ArticleId><ArticleId IdType="pubmed">31701892</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. Nature 511, 421&#x2013;427 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4112379</ArticleId><ArticleId IdType="pubmed">25056061</ArticleId></ArticleIdList></Reference><Reference><Citation>International Multiple Sclerosis Genetics Consortium. Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Science 365, eaav7188 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7241648</ArticleId><ArticleId IdType="pubmed">31604244</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B. et al. Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer&#x2019;s disease. Cell 153, 707&#x2013;720 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677161</ArticleId><ArticleId IdType="pubmed">23622250</ArticleId></ArticleIdList></Reference><Reference><Citation>Desikan RS et al. Polygenic overlap between C-reactive protein, plasma lipids, and Alzheimer disease. Circulation 131, 2061&#x2013;2069 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4677995</ArticleId><ArticleId IdType="pubmed">25862742</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhernakova DV et al. Identification of context-dependent expression quantitative trait loci in whole blood. Nat. Genet 49, 139&#x2013;145 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">27918533</ArticleId></ArticleIdList></Reference><Reference><Citation>Nott A. et al. Brain cell type-specific enhancer-promoter interactome maps and disease-risk association. Science 366, 1134&#x2013;1139 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7028213</ArticleId><ArticleId IdType="pubmed">31727856</ArticleId></ArticleIdList></Reference><Reference><Citation>Grenn FP et al. The Parkinson&#x2019;s disease genome-wide association study locus browser. Mov. Disord 35, 2056&#x2013;2067 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7754106</ArticleId><ArticleId IdType="pubmed">32864809</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalls MA et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson&#x2019;s disease: a meta-analysis of genome-wide association studies. Lancet Neurol. 18, 1091&#x2013;1102 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8422160</ArticleId><ArticleId IdType="pubmed">31701892</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollingworth P. et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer&#x2019;s disease. Nat. Genet 43, 429&#x2013;435 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3084173</ArticleId><ArticleId IdType="pubmed">21460840</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xf6;ttcher C. et al. Human microglia regional heterogeneity and phenotypes determined by multiplexed single-cell mass cytometry. Nat. Neurosci 22, 78&#x2013;90 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30559476</ArticleId></ArticleIdList></Reference><Reference><Citation>Mittelbronn M, Dietz K, Schluesener HJ &amp; Meyermann R. Local distribution of microglia in the normal adult human central nervous system differs by up to one order of magnitude. Acta Neuropathol. 101, 249&#x2013;255 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11307625</ArticleId></ArticleIdList></Reference><Reference><Citation>Olah M. et al. Identification of a microglia phenotype supportive of remyelination. Glia 60, 306&#x2013;321 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22072381</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens B. et al. The classical complement cascade mediates CNS synapse elimination. Cell 131, 1164&#x2013;1178 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">18083105</ArticleId></ArticleIdList></Reference><Reference><Citation>Badimon A. et al. Negative feedback control of neuronal activity by microglia. Nature 586, 417&#x2013;423 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7577179</ArticleId><ArticleId IdType="pubmed">32999463</ArticleId></ArticleIdList></Reference><Reference><Citation>Savage JC et al. Nuclear receptors license phagocytosis by trem2+ myeloid cells in mouse models of Alzheimer&#x2019;s disease. J. Neurosci 35, 6532&#x2013;6543 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4405560</ArticleId><ArticleId IdType="pubmed">25904803</ArticleId></ArticleIdList></Reference><Reference><Citation>Courtney R. &amp; Landreth GE LXR regulation of brain cholesterol: From development to disease. Trends Endocrinol. Metab. 27, 404&#x2013;414 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4986614</ArticleId><ArticleId IdType="pubmed">27113081</ArticleId></ArticleIdList></Reference><Reference><Citation>Kao Y-C, Ho P-C, Tu Y-K, Jou I-M &amp; Tsai K-J Lipids and Alzheimer&#x2019;s disease. Int. J. Mol. Sci 21, 1505 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7073164</ArticleId><ArticleId IdType="pubmed">32098382</ArticleId></ArticleIdList></Reference><Reference><Citation>Proitsi P. et al. Alzheimer&#x2019;s disease susceptibility variants in the MS4A6A gene are associated with altered levels of MS4A6A expression in blood. Neurobiol. Aging 35, 279&#x2013;290 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24064185</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang K-L et al. A common haplotype lowers PU.1 expression in myeloid cells and delays onset of Alzheimer&#x2019;s disease. Nat. Neurosci 20, 1052&#x2013;1061 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5759334</ArticleId><ArticleId IdType="pubmed">28628103</ArticleId></ArticleIdList></Reference><Reference><Citation>Deming Y. et al. The MS4A gene cluster is a key modulator of soluble TREM2 and Alzheimer&#x2019;s disease risk. Sci. Transl. Med 11, eaau2291 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6697053</ArticleId><ArticleId IdType="pubmed">31413141</ArticleId></ArticleIdList></Reference><Reference><Citation>Novikova G. et al. Integration of Alzheimer&#x2019;s disease genetics and myeloid genomics identifies disease risk regulatory elements and genes. Nat. Commun 12, 1610 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7955030</ArticleId><ArticleId IdType="pubmed">33712570</ArticleId></ArticleIdList></Reference><Reference><Citation>Mildner A, Huang H, Radke J, Stenzel W. &amp; Priller J. P2Y12 receptor is expressed on human microglia under physiological conditions throughout development and is sensitive to neuroinflammatory diseases. Glia 65, 375&#x2013;387 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">27862351</ArticleId></ArticleIdList></Reference><Reference><Citation>T&#xf3;th A, Antal Z, Bereczki D. &amp; Sperl&#xe1;gh B. Purinergic signalling in Parkinson&#x2019;s disease: A multi-target system to combat neurodegeneration. Neurochem. Res 44, 2413&#x2013;2422 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6776560</ArticleId><ArticleId IdType="pubmed">31054067</ArticleId></ArticleIdList></Reference><Reference><Citation>van Wageningen TA et al. Regulation of microglial TMEM119 and P2RY12 immunoreactivity in multiple sclerosis white and grey matter lesions is dependent on their inflammatory environment. Acta Neuropathol. Commun 7, 206 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6907356</ArticleId><ArticleId IdType="pubmed">31829283</ArticleId></ArticleIdList></Reference><Reference><Citation>Haynes SE et al. The P2Y12 receptor regulates microglial activation by extracellular nucleotides. Nat. Neurosci 9, 1512&#x2013;1519 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17115040</ArticleId></ArticleIdList></Reference><Reference><Citation>Marsh SE et al. Single cell sequencing reveals glial specific responses to tissue processing &amp; enzymatic dissociation in mice and humans. bioRxiv (2020) doi:10.1101/2020.12.03.408542.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.12.03.408542</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattei D. et al. Enzymatic dissociation induces transcriptional and proteotype bias in brain cell populations. Int. J. Mol. Sci 21, 7944 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7663484</ArticleId><ArticleId IdType="pubmed">33114694</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MN et al. Common genetic variants modulate pathogen-sensing responses in human dendritic cells. Science 343, 1246980 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4124741</ArticleId><ArticleId IdType="pubmed">24604203</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramdhani S. et al. Tensor decomposition of stimulated monocyte and macrophage gene expression profiles identifies neurodegenerative disease-specific trans-eQTLs. PLoS Genet. 16, e1008549 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7018232</ArticleId><ArticleId IdType="pubmed">32012164</ArticleId></ArticleIdList></Reference><Reference><Citation>de Lange GM, Rademaker M, Boks MP &amp; Palmen SJMC Brain donation in psychiatry: results of a Dutch prospective donor program among psychiatric cohort participants. BMC Psychiatry 17, 347 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5651614</ArticleId><ArticleId IdType="pubmed">29058593</ArticleId></ArticleIdList></Reference><Reference><Citation>Melief J. et al. Characterizing primary human microglia: A comparative study with myeloid subsets and culture models. Glia 64, 1857&#x2013;1868 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27442614</ArticleId></ArticleIdList></Reference><Reference><Citation>Sneeboer MAM et al. Microglia in post-mortem brain tissue of patients with bipolar disorder are not immune activated. Transl. Psychiatry 9, 153 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6534632</ArticleId><ArticleId IdType="pubmed">31127084</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah H. PgmNr 1856: RAPiD&#x2014;an agile and dependable RNA-Seq framework. (ASHG, 2015).</Citation></Reference><Reference><Citation>Dobin A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15&#x2013;21 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3530905</ArticleId><ArticleId IdType="pubmed">23104886</ArticleId></ArticleIdList></Reference><Reference><Citation>Picard. http://broadinstitute.github.io/picard/.</Citation></Reference><Reference><Citation>Li B. &amp; Dewey CN RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics 12, 323 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3163565</ArticleId><ArticleId IdType="pubmed">21816040</ArticleId></ArticleIdList></Reference><Reference><Citation>Soneson C, Love MI &amp; Robinson MD Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences. F1000Res. 4, 1521 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4712774</ArticleId><ArticleId IdType="pubmed">26925227</ArticleId></ArticleIdList></Reference><Reference><Citation>1000 Genomes Project Consortium et al. A global reference for human genetic variation. Nature 526, 68&#x2013;74 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4750478</ArticleId><ArticleId IdType="pubmed">26432245</ArticleId></ArticleIdList></Reference><Reference><Citation>Boettger LM, Handsaker RE, Zody MC &amp; McCarroll SA Structural haplotypes and recent evolution of the human 17q21.31 region. Nat. Genet 44, 881&#x2013;885 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4020351</ArticleId><ArticleId IdType="pubmed">22751096</ArticleId></ArticleIdList></Reference><Reference><Citation>Allcock RJN et al. The MHC haplotype project: a resource for HLA-linked association studies. Tissue Antigens 59, 520&#x2013;521 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12445322</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H. Tabix: fast retrieval of sequence features from generic TAB-delimited files. Bioinformatics 27, 718&#x2013;719 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3042176</ArticleId><ArticleId IdType="pubmed">21208982</ArticleId></ArticleIdList></Reference><Reference><Citation>Schilder BM, Humphrey J. &amp; Raj T. echolocatoR: an automated end-to-end statistical and functional genomic fine-mapping pipeline. Bioinformatics (2021) doi:10.1093/bioinformatics/btab658.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btab658</ArticleId><ArticleId IdType="pmc">PMC10060715</ArticleId><ArticleId IdType="pubmed">34529038</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson MD, McCarthy DJ &amp; Smyth GK edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139&#x2013;140 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2796818</ArticleId><ArticleId IdType="pubmed">19910308</ArticleId></ArticleIdList></Reference><Reference><Citation>Law CW, Chen Y, Shi W. &amp; Smyth GK voom: Precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biol. 15, R29 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4053721</ArticleId><ArticleId IdType="pubmed">24485249</ArticleId></ArticleIdList></Reference><Reference><Citation>Love MI, Huber W. &amp; Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4302049</ArticleId><ArticleId IdType="pubmed">25516281</ArticleId></ArticleIdList></Reference><Reference><Citation>Patir A, Shih B, McColl BW &amp; Freeman TC A core transcriptional signature of human microglia: Derivation and utility in describing region-dependent alterations associated with Alzheimer&#x2019;s disease. Glia 67, 1240&#x2013;1253 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30758077</ArticleId></ArticleIdList></Reference><Reference><Citation>Manichaikul A. et al. Robust relationship inference in genome-wide association studies. Bioinformatics 26, 2867&#x2013;2873 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3025716</ArticleId><ArticleId IdType="pubmed">20926424</ArticleId></ArticleIdList></Reference><Reference><Citation>Fort A. et al. MBV: a method to solve sample mislabeling and detect technical bias in large combined genotype and sequencing assay datasets. Bioinformatics 33, 1895&#x2013;1897 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6044394</ArticleId><ArticleId IdType="pubmed">28186259</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang CC et al. Second-generation PLINK: rising to the challenge of larger and richer datasets. Gigascience 4, 7 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4342193</ArticleId><ArticleId IdType="pubmed">25722852</ArticleId></ArticleIdList></Reference><Reference><Citation>Das S. et al. Next-generation genotype imputation service and methods. Nat. Genet 48, 1284&#x2013;1287 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5157836</ArticleId><ArticleId IdType="pubmed">27571263</ArticleId></ArticleIdList></Reference><Reference><Citation>Loh P-R et al. Reference-based phasing using the Haplotype Reference Consortium panel. Nat. Genet 48, 1443&#x2013;1448 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5096458</ArticleId><ArticleId IdType="pubmed">27694958</ArticleId></ArticleIdList></Reference><Reference><Citation>Cingolani P. et al. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly (Austin) 6, 80&#x2013;92 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3679285</ArticleId><ArticleId IdType="pubmed">22728672</ArticleId></ArticleIdList></Reference><Reference><Citation>The GTEx Consortium. The GTEx Consortium atlas of genetic regulatory effects across human tissues. Science 369, 1318&#x2013;1330 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7737656</ArticleId><ArticleId IdType="pubmed">32913098</ArticleId></ArticleIdList></Reference><Reference><Citation>Stegle O, Parts L, Piipari M, Winn J. &amp; Durbin R. Using probabilistic estimation of expression residuals (PEER) to obtain increased power and interpretability of gene expression analyses. Nat. Protoc 7, 500&#x2013;507 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3398141</ArticleId><ArticleId IdType="pubmed">22343431</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor-Weiner A. et al. Scaling computational genomics to millions of individuals with GPUs. Genome Biol. 20, 228 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6823959</ArticleId><ArticleId IdType="pubmed">31675989</ArticleId></ArticleIdList></Reference><Reference><Citation>Cotto KC et al. RegTools: Integrated analysis of genomic and transcriptomic data for the discovery of splicing variants in cancer. bioRxiv (2018) doi:10.1101/436634.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/436634</ArticleId><ArticleId IdType="pmc">PMC10033906</ArticleId><ArticleId IdType="pubmed">36949070</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YI et al. Annotation-free quantification of RNA splicing using LeafCutter. Nat. Genet 50, 151&#x2013;158 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5742080</ArticleId><ArticleId IdType="pubmed">29229983</ArticleId></ArticleIdList></Reference><Reference><Citation>Stephens M. False discovery rates: a new deal. Biostatistics 18, 275&#x2013;294 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5379932</ArticleId><ArticleId IdType="pubmed">27756721</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">35019161</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>08</Day></DateCompleted><DateRevised><Year>2024</Year><Month>02</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1460-2075</ISSN><JournalIssue CitedMedium="Internet"><Volume>41</Volume><Issue>4</Issue><PubDate><Year>2022</Year><Month>Feb</Month><Day>15</Day></PubDate></JournalIssue><Title>The EMBO journal</Title><ISOAbbreviation>EMBO J</ISOAbbreviation></Journal><ArticleTitle>Loss of TREM2 rescues hyperactivation of microglia, but not lysosomal deficits and neurotoxicity in models of progranulin deficiency.</ArticleTitle><Pagination><StartPage>e109108</StartPage><MedlinePgn>e109108</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e109108</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.15252/embj.2021109108</ELocationID><Abstract><AbstractText>Haploinsufficiency of the progranulin (PGRN)-encoding gene (GRN) causes frontotemporal lobar degeneration (GRN-FTLD) and results in microglial hyperactivation, TREM2 activation, lysosomal dysfunction, and TDP-43 deposition. To understand the contribution of microglial hyperactivation to pathology, we used genetic and pharmacological approaches to suppress TREM2-dependent transition of microglia from a homeostatic to a disease-associated state. Trem2 deficiency in Grn KO mice reduced microglia hyperactivation. To explore antibody-mediated pharmacological modulation of TREM2-dependent microglial states, we identified antagonistic TREM2 antibodies. Treatment of macrophages from GRN-FTLD patients with these antibodies led to reduced TREM2 signaling due to its enhanced shedding. Furthermore, TREM2 antibody-treated PGRN-deficient microglia derived from human-induced pluripotent stem cells showed reduced microglial hyperactivation, TREM2 signaling, and phagocytic activity, but lysosomal dysfunction was not rescued. Similarly, lysosomal dysfunction, lipid dysregulation, and glucose hypometabolism of Grn KO mice were not rescued by TREM2 ablation. Synaptic loss and neurofilament light-chain (NfL) levels, a biomarker for neurodegeneration, were further elevated in the Grn/Trem2 KO cerebrospinal fluid (CSF). These findings suggest that TREM2-dependent microglia hyperactivation in models of GRN deficiency does not promote neurotoxicity, but rather neuroprotection.</AbstractText><CopyrightInformation>&#xa9; 2022 The Authors. Published under the terms of the CC BY NC ND 4.0 license.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Reifschneider</LastName><ForeName>Anika</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-9598-9373</Identifier><AffiliationInfo><Affiliation>Division of Metabolic Biochemistry, Faculty of Medicine, Biomedical Center (BMC), Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robinson</LastName><ForeName>Sophie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute for Stroke and Dementia Research, University Hospital Munich, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Lengerich</LastName><ForeName>Bettina</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Denali Therapeutics Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gn&#xf6;rich</LastName><ForeName>Johannes</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Nuclear Medicine, University Hospital, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Logan</LastName><ForeName>Todd</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Denali Therapeutics Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heindl</LastName><ForeName>Steffanie</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-3576-2702</Identifier><AffiliationInfo><Affiliation>Institute for Stroke and Dementia Research, University Hospital Munich, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vogt</LastName><ForeName>Miriam A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>ISAR Bioscience GmbH, Planegg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weidinger</LastName><ForeName>Endy</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Hospital, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Riedl</LastName><ForeName>Lina</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, School of Medicine, Technical University of Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wind</LastName><ForeName>Karin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Nuclear Medicine, University Hospital, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zatcepin</LastName><ForeName>Artem</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-0224-088X</Identifier><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Nuclear Medicine, University Hospital, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pes&#xe4;maa</LastName><ForeName>Ida</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haberl</LastName><ForeName>Sophie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>ISAR Bioscience GmbH, Planegg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nuscher</LastName><ForeName>Brigitte</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Division of Metabolic Biochemistry, Faculty of Medicine, Biomedical Center (BMC), Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kleinberger</LastName><ForeName>Gernot</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>ISAR Bioscience GmbH, Planegg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klimmt</LastName><ForeName>Julien</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-0781-6400</Identifier><AffiliationInfo><Affiliation>Institute for Stroke and Dementia Research, University Hospital Munich, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xf6;tzl</LastName><ForeName>Julia K</ForeName><Initials>JK</Initials><AffiliationInfo><Affiliation>Division of Metabolic Biochemistry, Faculty of Medicine, Biomedical Center (BMC), Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liesz</LastName><ForeName>Arthur</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-9069-2594</Identifier><AffiliationInfo><Affiliation>Institute for Stroke and Dementia Research, University Hospital Munich, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>B&#xfc;rger</LastName><ForeName>Katharina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Institute for Stroke and Dementia Research, University Hospital Munich, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brendel</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Nuclear Medicine, University Hospital, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levin</LastName><ForeName>Johannes</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Nuclear Medicine, University Hospital, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University Hospital, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diehl-Schmid</LastName><ForeName>Janine</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Hospital, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, School of Medicine, Technical University of Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suh</LastName><ForeName>Jung</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Denali Therapeutics Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Paolo</LastName><ForeName>Gilbert</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-1032-1265</Identifier><AffiliationInfo><Affiliation>Denali Therapeutics Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lewcock</LastName><ForeName>Joseph W</ForeName><Initials>JW</Initials><Identifier Source="ORCID">0000-0003-3012-7881</Identifier><AffiliationInfo><Affiliation>Denali Therapeutics Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Monroe</LastName><ForeName>Kathryn M</ForeName><Initials>KM</Initials><Identifier Source="ORCID">0000-0002-6901-1176</Identifier><AffiliationInfo><Affiliation>Denali Therapeutics Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paquet</LastName><ForeName>Dominik</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-2065-1639</Identifier><AffiliationInfo><Affiliation>Institute for Stroke and Dementia Research, University Hospital Munich, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Capell</LastName><ForeName>Anja</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-3118-911X</Identifier><AffiliationInfo><Affiliation>Division of Metabolic Biochemistry, Faculty of Medicine, Biomedical Center (BMC), Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haass</LastName><ForeName>Christian</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-4869-1627</Identifier><AffiliationInfo><Affiliation>Division of Metabolic Biochemistry, Faculty of Medicine, Biomedical Center (BMC), Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>01</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>EMBO J</MedlineTA><NlmUniqueID>8208664</NlmUniqueID><ISSNLinking>0261-4189</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000906">Antibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C120204">Grn protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000077153">Progranulins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498715">TREM2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498716">Trem2 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.2</RegistryNumber><NameOfSubstance UI="C000606896">SYK protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.2</RegistryNumber><NameOfSubstance UI="D000072377">Syk Kinase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000906" MajorTopicYN="N">Antibodies</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057174" MajorTopicYN="N">Frontotemporal Lobar Degeneration</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008247" MajorTopicYN="N">Lysosomes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009000" MajorTopicYN="N">Monocytes</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077153" MajorTopicYN="N">Progranulins</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="Y">deficiency</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072377" MajorTopicYN="N">Syk Kinase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">frontotemporal lobar degeneration</Keyword><Keyword MajorTopicYN="N">lysosomes</Keyword><Keyword MajorTopicYN="N">microglia</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">progranulin</Keyword></KeywordList><CoiStatement>CH collaborates with Denali Therapeutics, participated on one advisory board meeting of Biogen, and received a speaker honorarium from Novartis and Roche. CH is chief advisor of ISAR Bioscience. KMM, BVL, TL, JS, JWL, and GDP are employees and shareholders of Denali Therapeutics. DP is a scientific advisor of ISAR Bioscience. MB received speaker honoraria from GE healthcare, Roche, and LMI and is an advisor of LMI.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>12</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>12</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>1</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>1</Month><Day>12</Day><Hour>8</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>1</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35019161</ArticleId><ArticleId IdType="pmc">PMC8844989</ArticleId><ArticleId IdType="doi">10.15252/embj.2021109108</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abud EM, Ramirez RN, Martinez ES, Healy LM, Nguyen CHH, Newman SA, Yeromin AV, Scarfone VM, Marsh SE, Fimbres C et&#xa0;al (2017) iPSC&#x2010;derived human microglia&#x2010;like cells to study neurological diseases. Neuron 94: 278&#x2013;293.e9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5482419</ArticleId><ArticleId IdType="pubmed">28426964</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguzzi A, Haass C (2003) Games played by rogue proteins in prion disorders and Alzheimer's disease. Science 302: 814&#x2013;818</Citation><ArticleIdList><ArticleId IdType="pubmed">14593165</ArticleId></ArticleIdList></Reference><Reference><Citation>Almeida MR, Macario MC, Ramos L, Baldeiras I, Ribeiro MH, Santana I (2016) Portuguese family with the co&#x2010;occurrence of frontotemporal lobar degeneration and neuronal ceroid lipofuscinosis phenotypes due to progranulin gene mutation. Neurobiol Aging 41: 200 e201&#x2013;200 e205</Citation><ArticleIdList><ArticleId IdType="pubmed">27021778</ArticleId></ArticleIdList></Reference><Reference><Citation>Arrant AE, Roth JR, Boyle NR, Kashyap SN, Hoffmann MQ, Murchison CF, Ramos EM, Nana AL, Spina S, Grinberg LT et&#xa0;al (2019) Impaired beta&#x2010;glucocerebrosidase activity and processing in frontotemporal dementia due to progranulin mutations. Acta Neuropathol Commun 7: 218</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6929503</ArticleId><ArticleId IdType="pubmed">31870439</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker M, Mackenzie IR, Pickering&#x2010;Brown SM, Gass J, Rademakers R, Lindholm C, Snowden J, Adamson J, Sadovnick AD, Rollinson S et&#xa0;al (2006) Mutations in progranulin cause tau&#x2010;negative frontotemporal dementia linked to chromosome 17. Nature 442: 916&#x2013;919</Citation><ArticleIdList><ArticleId IdType="pubmed">16862116</ArticleId></ArticleIdList></Reference><Reference><Citation>Beel S, Moisse M, Damme M, De Muynck L, Robberecht W, Van Den Bosch L, Saftig P, Van Damme P (2017) Progranulin functions as a cathepsin D chaperone to stimulate axonal outgrowth in&#xa0;vivo. Hum Mol Genet 26: 2850&#x2013;2863</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5886064</ArticleId><ArticleId IdType="pubmed">28453791</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosch&#x2010;Queralt M, Cantuti&#x2010;Castelvetri L, Damkou A, Schifferer M, Schlepckow K, Alexopoulos I, Lutjohann D, Klose C, Vaculciakova L, Masuda T et&#xa0;al (2021) Diet&#x2010;dependent regulation of TGFbeta impairs reparative innate immune responses after demyelination. Nat Metab 3: 211&#x2013;227</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7610359</ArticleId><ArticleId IdType="pubmed">33619376</ArticleId></ArticleIdList></Reference><Reference><Citation>Brendel M, Probst F, Jaworska A, Overhoff F, Korzhova V, Albert NL, Beck R, Lindner S, Gildehaus F&#x2010;J, Baumann K et&#xa0;al (2016) Glial activation and glucose metabolism in a transgenic amyloid mouse model: a triple&#x2010;tracer PET study. J Nucl Med 57: 954&#x2013;960</Citation><ArticleIdList><ArticleId IdType="pubmed">26912428</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler VJ, Cortopassi WA, Argouarch AR, Ivry SL, Craik CS, Jacobson MP, Kao AW (2019a) Progranulin stimulates the in&#xa0;vitro maturation of pro&#x2010;cathepsin D at acidic pH. J Mol Biol 431: 1038&#x2013;1047</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6613950</ArticleId><ArticleId IdType="pubmed">30690031</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler VJ, Cortopassi WA, Gururaj S, Wang AL, Pierce OM, Jacobson MP, Kao AW (2019b) Multi&#x2010;granulin domain peptides bind to pro&#x2010;cathepsin D and stimulate its enzymatic activity more effectively than progranulin in&#xa0;vitro. Biochemistry 58: 2670&#x2013;2674</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6666309</ArticleId><ArticleId IdType="pubmed">31099551</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovsky O, Jedrychowski MP, Moore CS, Cialic R, Lanser AJ, Gabriely G, Koeglsperger T, Dake B, Wu PM, Doykan CE et&#xa0;al (2014) Identification of a unique TGF&#x2010;beta&#x2010;dependent molecular and functional signature in microglia. Nat Neurosci 17: 131&#x2013;143</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4066672</ArticleId><ArticleId IdType="pubmed">24316888</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Jian J, Hettinghouse A, Zhao X, Setchell KDR, Sun Y, Liu CJ (2018) Progranulin associates with hexosaminidase A and ameliorates GM2 ganglioside accumulation and lysosomal storage in Tay&#x2010;Sachs disease. J Mol Med 96: 1359&#x2013;1373</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6240367</ArticleId><ArticleId IdType="pubmed">30341570</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng Q, Danao J, Talreja S, Wen P, Yin J, Sun N, Li C&#x2010;M, Chui D, Tran D, Koirala S et&#xa0;al (2018) TREM2&#x2010;activating antibodies abrogate the negative pleiotropic effects of the Alzheimer's disease variant Trem 2(R47H) on murine myeloid cell function. J Biol Chem 293: 12620&#x2013;12633</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6093249</ArticleId><ArticleId IdType="pubmed">29599291</ArticleId></ArticleIdList></Reference><Reference><Citation>Cignarella F, Filipello F, Bollman B, Cantoni C, Locca A, Mikesell R, Manis M, Ibrahim A, Deng LI, Benitez BA et&#xa0;al (2020) TREM2 activation on microglia promotes myelin debris clearance and remyelination in a model of multiple sclerosis. Acta Neuropathol 140: 513&#x2013;534</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7498497</ArticleId><ArticleId IdType="pubmed">32772264</ArticleId></ArticleIdList></Reference><Reference><Citation>Colonna M, Wang Y (2016) TREM2 variants: new keys to decipher Alzheimer disease pathogenesis. Nat Rev Neurosci 17: 201&#x2013;207</Citation><ArticleIdList><ArticleId IdType="pubmed">26911435</ArticleId></ArticleIdList></Reference><Reference><Citation>Concordet JP, Haeussler M (2018) CRISPOR: intuitive guide selection for CRISPR/Cas9 genome editing experiments and screens. Nucleic Acids Res 46: W242&#x2013;W245</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6030908</ArticleId><ArticleId IdType="pubmed">29762716</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruts M, Gijselinck I, van der Zee J, Engelborghs S, Wils H, Pirici D, Rademakers R, Vandenberghe R, Dermaut B, Martin J&#x2010;J et&#xa0;al (2006) Null mutations in progranulin cause ubiquitin&#x2010;positive frontotemporal dementia linked to chromosome 17q21. Nature 442: 920&#x2013;924</Citation><ArticleIdList><ArticleId IdType="pubmed">16862115</ArticleId></ArticleIdList></Reference><Reference><Citation>Deczkowska A, Weiner A, Amit I (2020) The physiology, pathology, and potential therapeutic applications of the TREM2 signaling pathway. Cell 181: 1207&#x2013;1217</Citation><ArticleIdList><ArticleId IdType="pubmed">32531244</ArticleId></ArticleIdList></Reference><Reference><Citation>Deussing M, Blume T, Vomacka L, Mahler C, Focke C, Todica A, Unterrainer M, Albert NL, Lindner S, von Ungern&#x2010;Sternberg B et&#xa0;al (2018) Coupling between physiological TSPO expression in brain and myocardium allows stabilization of late&#x2010;phase cerebral [(18)F]GE180 PET quantification. NeuroImage 165: 83&#x2013;91</Citation><ArticleIdList><ArticleId IdType="pubmed">28988133</ArticleId></ArticleIdList></Reference><Reference><Citation>Efthymiou AG, Goate AM (2017) Late onset Alzheimer's disease genetics implicates microglial pathways in disease risk. Mol Neurodegener 12: 43</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5446752</ArticleId><ArticleId IdType="pubmed">28549481</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellwanger DC, Wang S, Brioschi S, Shao Z, Green L, Case R, Yoo D, Weishuhn D, Rathanaswami P, Bradley J et&#xa0;al (2021) Prior activation state shapes the microglia response to antihuman TREM2 in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 118: e2017742118</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7826333</ArticleId><ArticleId IdType="pubmed">33446504</ArticleId></ArticleIdList></Reference><Reference><Citation>Evers BM, Rodriguez&#x2010;Navas C, Tesla RJ, Prange&#x2010;Kiel J, Wasser CR, Yoo KS, McDonald J, Cenik B, Ravenscroft TA, Plattner F et&#xa0;al (2017) Lipidomic and transcriptomic basis of lysosomal dysfunction in progranulin deficiency. Cell Rep 20: 2565&#x2013;2574</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5757843</ArticleId><ArticleId IdType="pubmed">28903038</ArticleId></ArticleIdList></Reference><Reference><Citation>Ewers M, Franzmeier N, Su&#xe1;rez&#x2010;Calvet M, Morenas&#x2010;Rodriguez E, Caballero MAA, Kleinberger G, Piccio L, Cruchaga C, Deming Y, Dichgans M et&#xa0;al (2019) Increased soluble TREM2 in cerebrospinal fluid is associated with reduced cognitive and clinical decline in Alzheimer's disease. Sci Transl Med 10.1126/scitranslmed.aav6221</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aav6221</ArticleId><ArticleId IdType="pmc">PMC7050285</ArticleId><ArticleId IdType="pubmed">31462511</ArticleId></ArticleIdList></Reference><Reference><Citation>Fassler M, Rappaport MS, Cuno CB, George J (2021) Engagement of TREM2 by a novel monoclonal antibody induces activation of microglia and improves cognitive function in Alzheimer's disease models. J Neuroinflammation 18: 19</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7796541</ArticleId><ArticleId IdType="pubmed">33422057</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu J, Guo O, Zhen Z, Zhen J (2020) Essential functions of the transcription factor Npas4 in neural circuit development, plasticity, and diseases. Front Neurosci 14: 603373</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7736240</ArticleId><ArticleId IdType="pubmed">33335473</ArticleId></ArticleIdList></Reference><Reference><Citation>Gotzl JK, Brendel M, Werner G, Parhizkar S, Sebastian Monasor L, Kleinberger G, Colombo AV, Deussing M, Wagner M, Winkelmann J et&#xa0;al (2019) Opposite microglial activation stages upon loss of PGRN or TREM2 result in reduced cerebral glucose metabolism. EMBO Mol Med 11: 1&#x2013;15</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6554672</ArticleId><ArticleId IdType="pubmed">31122931</ArticleId></ArticleIdList></Reference><Reference><Citation>Gotzl JK, Colombo AV, Fellerer K, Reifschneider A, Werner G, Tahirovic S, Haass C, Capell A (2018) Early lysosomal maturation deficits in microglia triggers enhanced lysosomal activity in other brain cells of progranulin knockout mice. Mol Neurodegener 13: 48</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6123925</ArticleId><ArticleId IdType="pubmed">30180904</ArticleId></ArticleIdList></Reference><Reference><Citation>Gotzl JK, Lang CM, Haass C, Capell A (2016) Impaired protein degradation in FTLD and related disorders. Ageing Res Rev 32: 122&#x2013;139</Citation><ArticleIdList><ArticleId IdType="pubmed">27166223</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf6;tzl JK, Mori K, Damme M, Fellerer K, Tahirovic S, Kleinberger G, Janssens J, van der Zee J, Lang CM, Kremmer E et&#xa0;al (2014) Common pathobiochemical hallmarks of progranulin&#x2010;associated frontotemporal lobar degeneration and neuronal ceroid lipofuscinosis. Acta Neuropathol 127: 845&#x2013;860</Citation><ArticleIdList><ArticleId IdType="pubmed">24619111</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, Cruchaga C, Sassi C, Kauwe JS, Younkin S et&#xa0;al (2013) TREM2 variants in Alzheimer's disease. N Engl J Med 368: 117&#x2013;127</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3631573</ArticleId><ArticleId IdType="pubmed">23150934</ArticleId></ArticleIdList></Reference><Reference><Citation>Heindl S, Gesierich B, Benakis C, Llovera G, Duering M, Liesz A (2018) Automated morphological analysis of microglia after stroke. Front Cell Neurosci 12: 106</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5917008</ArticleId><ArticleId IdType="pubmed">29725290</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka MT, Kummer MP, Stutz A, Delekate A, Schwartz S, Vieira&#x2010;Saecker A, Griep A, Axt D, Remus A, Tzeng T&#x2010;C et&#xa0;al (2013) NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature 493: 674&#x2013;678</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3812809</ArticleId><ArticleId IdType="pubmed">23254930</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka MT, McManus RM, Latz E (2018) Inflammasome signalling in brain function and neurodegenerative disease. Nat Rev Neurosci 19: 610&#x2013;621</Citation><ArticleIdList><ArticleId IdType="pubmed">30206330</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong S, Beja&#x2010;Glasser VF, Nfonoyim BM, Frouin A, Li S, Ramakrishnan S, Merry KM, Shi Q, Rosenthal A, Barres BA et&#xa0;al (2016a) Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science 352: 712&#x2013;716</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5094372</ArticleId><ArticleId IdType="pubmed">27033548</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong S, Dissing&#x2010;Olesen L, Stevens B (2016b) New insights on the role of microglia in synaptic pruning in health and disease. Curr Opin Neurobiol 36: 128&#x2013;134</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5479435</ArticleId><ArticleId IdType="pubmed">26745839</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu F, Padukkavidana T, Vaegter CB, Brady OA, Zheng Y, Mackenzie IR, Feldman HH, Nykjaer A, Strittmatter SM (2010) Sortilin&#x2010;mediated endocytosis determines levels of the frontotemporal dementia protein, progranulin. Neuron 68: 654&#x2013;667</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2990962</ArticleId><ArticleId IdType="pubmed">21092856</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang M, Modeste E, Dammer E, Merino P, Taylor G, Duong DM, Deng Q, Holler CJ, Gearing M, Dickson D et&#xa0;al (2020) Network analysis of the progranulin&#x2010;deficient mouse brain proteome reveals pathogenic mechanisms shared in human frontotemporal dementia caused by GRN mutations. Acta Neuropathol Commun 8: 163</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7541308</ArticleId><ArticleId IdType="pubmed">33028409</ArticleId></ArticleIdList></Reference><Reference><Citation>Jadhav VS, Lin PBC, Pennington T, Di Prisco GV, Jannu AJ, Xu G, Moutinho M, Zhang J, Atwood BK, Puntambekar SS et&#xa0;al (2020) Trem2 Y38C mutation and loss of Trem2 impairs neuronal synapses in adult mice. Mol Neurodegener 15: 62</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7594478</ArticleId><ArticleId IdType="pubmed">33115519</ArticleId></ArticleIdList></Reference><Reference><Citation>Jian J, Zhao S, Tian Q&#x2010;Y, Liu H, Zhao Y, Chen W&#x2010;C, Grunig G, Torres PA, Wang BC, Zeng B et&#xa0;al (2016) Association between progranulin and gaucher disease. EBioMedicine 11: 127&#x2013;137</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5049935</ArticleId><ArticleId IdType="pubmed">27515686</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, Bjornsson S, Huttenlocher J, Levey AI, Lah JJ et&#xa0;al (2013) Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med 368: 107&#x2013;116</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677583</ArticleId><ArticleId IdType="pubmed">23150908</ArticleId></ArticleIdList></Reference><Reference><Citation>Kao AW, McKay A, Singh PP, Brunet A, Huang EJ (2017) Progranulin, lysosomal regulation and neurodegenerative disease. Nat Rev Neurosci 18: 325&#x2013;333</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6040832</ArticleId><ArticleId IdType="pubmed">28435163</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayasuga Y, Chiba S, Suzuki M, Kikusui T, Matsuwaki T, Yamanouchi K, Kotaki H, Horai R, Iwakura Y, Nishihara M (2007) Alteration of behavioural phenotype in mice by targeted disruption of the progranulin gene. Behav Brain Res 185: 110&#x2013;118</Citation><ArticleIdList><ArticleId IdType="pubmed">17764761</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren&#x2010;Shaul H, Spinrad A, Weiner A, Matcovitch&#x2010;Natan O, Dvir&#x2010;Szternfeld R, Ulland TK, David E, Baruch K, Lara&#x2010;Astaiso D, Toth B et&#xa0;al (2017) A Unique microglia type associated with restricting development of Alzheimer's disease. Cell 169: 1276&#x2013;1290.e17</Citation><ArticleIdList><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein ZA, Takahashi H, Ma M, Stagi M, Zhou M, Lam TT, Strittmatter SM (2017) Loss of TMEM106B ameliorates lysosomal and frontotemporal dementia&#x2010;related phenotypes in progranulin&#x2010;deficient mice. Neuron 95: 281&#x2013;296.e6</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5558861</ArticleId><ArticleId IdType="pubmed">28728022</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleinberger G, Brendel M, Mracsko E, Wefers B, Groeneweg L, Xiang X, Focke C, Deussing M, Suarez&#x2010;Calvet M, Mazaheri F et&#xa0;al (2017) The FTD&#x2010;like syndrome causing TREM2 T66M mutation impairs microglia function, brain perfusion, and glucose metabolism. EMBO J 36: 1837&#x2013;1853</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5494459</ArticleId><ArticleId IdType="pubmed">28559417</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleinberger G, Yamanishi Y, Su&#xe1;rez&#x2010;Calvet M, Czirr E, Lohmann E, Cuyvers E, Struyfs H, Pettkus N, Wenninger&#x2010;Weinzierl A, Mazaheri F et&#xa0;al (2014) TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Sci Transl Med 6: 243ra286</Citation><ArticleIdList><ArticleId IdType="pubmed">24990881</ArticleId></ArticleIdList></Reference><Reference><Citation>Krabbe G, Minami SS, Etchegaray JI, Taneja P, Djukic B, Davalos D, Le D, Lo I, Zhan L, Reichert MC et&#xa0;al (2017) Microglial NFkappaB&#x2010;TNFalpha hyperactivation induces obsessive&#x2010;compulsive behavior in mouse models of progranulin&#x2010;deficient frontotemporal dementia. Proc Natl Acad Sci USA 114: 5029&#x2013;5034</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5441749</ArticleId><ArticleId IdType="pubmed">28438992</ArticleId></ArticleIdList></Reference><Reference><Citation>Krasemann S, Madore C, Cialic R, Baufeld C, Calcagno N, El Fatimy R, Beckers L, O&#x2019;Loughlin E, Xu Y, Fanek Z et&#xa0;al (2017) The TREM2&#x2010;APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. Immunity 47: 566&#x2013;581.e9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5719893</ArticleId><ArticleId IdType="pubmed">28930663</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwart D, Paquet D, Teo S, Tessier&#x2010;Lavigne M (2017) Precise and efficient scarless genome editing in stem cells using CORRECT. Nat Protoc 12: 329&#x2013;354</Citation><ArticleIdList><ArticleId IdType="pubmed">28102837</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SH, Meilandt WJ, Xie L, Gandham VD, Ngu H, Barck KH, Rezzonico MG, Imperio J, Lalehzadeh G, Huntley MA et&#xa0;al (2021) Trem2 restrains the enhancement of tau accumulation and neurodegeneration by beta&#x2010;amyloid pathology. Neuron 109: 1283&#x2013;1301 e1286</Citation><ArticleIdList><ArticleId IdType="pubmed">33675684</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewcock JW, Schlepckow K, Di Paolo G, Tahirovic S, Monroe KM, Haass C (2020) Emerging microglia biology defines novel therapeutic approaches for Alzheimer's disease. Neuron 108: 801&#x2013;821</Citation><ArticleIdList><ArticleId IdType="pubmed">33096024</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim NK, Moestrup V, Zhang X, Wang WA, Moller A, Huang FD (2018) An improved method for collection of cerebrospinal fluid from anesthetized mice. J Vis Exp 10.3791/56774</Citation><ArticleIdList><ArticleId IdType="doi">10.3791/56774</ArticleId><ArticleId IdType="pmc">PMC5931779</ArticleId><ArticleId IdType="pubmed">29608146</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu B, Le KX, Park MA, Wang S, Belanger AP, Dubey S, Frost JL, Holton P, Reiser V, Jones PA et&#xa0;al (2015) In vivo detection of age&#x2010; and disease&#x2010;related increases in neuroinflammation by 18F&#x2010;GE180 TSPO MicroPET imaging in wild&#x2010;type and Alzheimer's transgenic mice. J Neurosci 35: 15716&#x2013;15730</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6705465</ArticleId><ArticleId IdType="pubmed">26609163</ArticleId></ArticleIdList></Reference><Reference><Citation>Logan T, Simon JS, Rana A, Cherf GM, Srivastava A, Davis SS, Yoon Low RL, Chiu C, Fang M, Huang F et&#xa0;al (2021) Rescue of a lysosomal storage disorder caused by BMP deficiency in Grn loss&#x2010;of&#x2010;function with a brain penetrant progranulin biologic. Cell 184: 4651&#x2013;4668.e25</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8489356</ArticleId><ArticleId IdType="pubmed">34450028</ArticleId></ArticleIdList></Reference><Reference><Citation>Lui H, Zhang J, Makinson S, Cahill M, Kelley K, Huang H&#x2010;Y, Shang Y, Oldham M, Martens L, Gao F et&#xa0;al (2016) Progranulin Deficiency Promotes Circuit&#x2010;Specific Synaptic Pruning By Microglia Via Complement Activation. Cell 165: 921&#x2013;935</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4860138</ArticleId><ArticleId IdType="pubmed">27114033</ArticleId></ArticleIdList></Reference><Reference><Citation>Marschallinger J, Iram T, Zardeneta M, Lee SE, Lehallier B, Haney MS, Pluvinage JV, Mathur V, Hahn O, Morgens DW et&#xa0;al (2020) Lipid&#x2010;droplet&#x2010;accumulating microglia represent a dysfunctional and proinflammatory state in the aging brain. Nat Neurosci 23: 194&#x2013;208</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7595134</ArticleId><ArticleId IdType="pubmed">31959936</ArticleId></ArticleIdList></Reference><Reference><Citation>Martens LH, Zhang J, Barmada SJ, Zhou P, Kamiya S, Sun B, Min S&#x2010;W, Gan LI, Finkbeiner S, Huang EJ et&#xa0;al (2012) Progranulin deficiency promotes neuroinflammation and neuron loss following toxin&#x2010;induced injury. J Clin Invest 122: 3955&#x2013;3959</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3484443</ArticleId><ArticleId IdType="pubmed">23041626</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazaheri F, Snaidero N, Kleinberger G, Madore C, Daria A, Werner G, Krasemann S, Capell A, Trumbach D, Wurst W et&#xa0;al (2017) TREM2 deficiency impairs chemotaxis and microglial responses to neuronal injury. EMBO Rep 18: 1186&#x2013;1198</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5494532</ArticleId><ArticleId IdType="pubmed">28483841</ArticleId></ArticleIdList></Reference><Reference><Citation>McQuade A, Coburn M, Tu CH, Hasselmann J, Davtyan H, Blurton&#x2010;Jones M (2018) Development and validation of a simplified method to generate human microglia from pluripotent stem cells. Mol Neurodegener 13: 67</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6303871</ArticleId><ArticleId IdType="pubmed">30577865</ArticleId></ArticleIdList></Reference><Reference><Citation>Meeter LH, Dopper EG, Jiskoot LC, Sanchez&#x2010;Valle R, Graff C, Benussi L, Ghidoni R, Pijnenburg YA, Borroni B, Galimberti D et&#xa0;al (2016) Neurofilament light chain: a biomarker for genetic frontotemporal dementia. Ann Clin Transl Neurol 3: 623&#x2013;636</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4999594</ArticleId><ArticleId IdType="pubmed">27606344</ArticleId></ArticleIdList></Reference><Reference><Citation>Meilandt WJ, Ngu H, Gogineni A, Lalehzadeh G, Lee SH, Srinivasan K, Imperio J, Wu T, Weber M, Kruse AJ et&#xa0;al (2020) Trem2 deletion reduces late&#x2010;stage amyloid plaque accumulation, elevates the Abeta42:Abeta40 ratio, and exacerbates axonal dystrophy and dendritic spine loss in the PS2APP Alzheimer's mouse model. J Neurosci 40: 1956&#x2013;1974</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7046459</ArticleId><ArticleId IdType="pubmed">31980586</ArticleId></ArticleIdList></Reference><Reference><Citation>Nugent AA, Lin K, van Lengerich B, Lianoglou S, Przybyla L, Davis SS, Llapashtica C, Wang J, Kim DJ, Xia D et&#xa0;al (2020) TREM2 regulates microglial cholesterol metabolism upon chronic phagocytic challenge. Neuron 105: 837&#x2013;854.e9</Citation><ArticleIdList><ArticleId IdType="pubmed">31902528</ArticleId></ArticleIdList></Reference><Reference><Citation>Overhoff F, Brendel M, Jaworska A, Korzhova V, Delker A, Probst F, Focke C, Gildehaus F&#x2010;J, Carlsen J, Baumann K et&#xa0;al (2016) Automated spatial brain normalization and hindbrain white matter reference tissue give improved [(18)F]&#x2010;Florbetaben PET quantitation in Alzheimer's model mice. Front Neurosci 10: 45</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4770021</ArticleId><ArticleId IdType="pubmed">26973442</ArticleId></ArticleIdList></Reference><Reference><Citation>Parhizkar S, Arzberger T, Brendel M, Kleinberger G, Deussing M, Focke C, Nuscher B, Xiong M, Ghasemigharagoz A, Katzmarski N et&#xa0;al (2019) Loss of TREM2 function increases amyloid seeding but reduces plaque&#x2010;associated ApoE. Nat Neurosci 22: 191&#x2013;204</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6417433</ArticleId><ArticleId IdType="pubmed">30617257</ArticleId></ArticleIdList></Reference><Reference><Citation>Paushter DH, Du H, Feng T, Hu F (2018) The lysosomal function of progranulin, a guardian against neurodegeneration. Acta Neuropathol 136: 1&#x2013;17</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6117207</ArticleId><ArticleId IdType="pubmed">29744576</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez&#x2010;Otano I, Larsen RS, Wesseling JF (2016) Emerging roles of GluN3&#x2010;containing NMDA receptors in the CNS. Nat Rev Neurosci 17: 623&#x2013;635</Citation><ArticleIdList><ArticleId IdType="pubmed">27558536</ArticleId></ArticleIdList></Reference><Reference><Citation>Preische O, Schultz SA, Apel A, Kuhle J, Kaeser SA, Barro C, Gr&#xe4;ber S, Kuder&#x2010;Buletta E, LaFougere C, Laske C et&#xa0;al (2019) Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease. Nat Med 25: 277&#x2013;283</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6367005</ArticleId><ArticleId IdType="pubmed">30664784</ArticleId></ArticleIdList></Reference><Reference><Citation>Price BR, Sudduth TL, Weekman EM, Johnson S, Hawthorne D, Woolums A, Wilcock DM (2020) Therapeutic Trem2 activation ameliorates amyloid&#x2010;beta deposition and improves cognition in the 5XFAD model of amyloid deposition. J Neuroinflammation 17: 238</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7427742</ArticleId><ArticleId IdType="pubmed">32795308</ArticleId></ArticleIdList></Reference><Reference><Citation>Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F (2013) Genome engineering using the CRISPR&#x2010;Cas9 system. Nat Protoc 8: 2281&#x2013;2308</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3969860</ArticleId><ArticleId IdType="pubmed">24157548</ArticleId></ArticleIdList></Reference><Reference><Citation>Ransohoff RM (2016) How neuroinflammation contributes to neurodegeneration. Science 353: 777&#x2013;783</Citation><ArticleIdList><ArticleId IdType="pubmed">27540165</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohrer JD, Woollacott IOC, Dick KM, Brotherhood E, Gordon E, Fellows A, Toombs J, Druyeh R, Cardoso MJ, Ourselin S et&#xa0;al (2016) Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia. Neurology 87: 1329&#x2013;1336</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5047041</ArticleId><ArticleId IdType="pubmed">27581216</ArticleId></ArticleIdList></Reference><Reference><Citation>Root J, Merino P, Nuckols A, Johnson M, Kukar T (2021) Lysosome dysfunction as a cause of neurodegenerative diseases: lessons from frontotemporal dementia and amyotrophic lateral sclerosis. Neurobiol Dis 154: 105360</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8113138</ArticleId><ArticleId IdType="pubmed">33812000</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlepckow K, Kleinberger G, Fukumori A, Feederle R, Lichtenthaler SF, Steiner H, Haass C (2017) An Alzheimer&#x2010;associated TREM2 variant occurs at the ADAM cleavage site and affects shedding and phagocytic function. EMBO Mol Med 9: 1356&#x2013;1365</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5623859</ArticleId><ArticleId IdType="pubmed">28855300</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlepckow K, Monroe KM, Kleinberger G, Cantuti&#x2010;Castelvetri L, Parhizkar S, Xia D, Willem M, Werner G, Pettkus N, Brunner B et&#xa0;al (2020) Enhancing protective microglial activities with a dual function TREM2 antibody to the stalk region. EMBO Mol Med 12: e11227</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7136959</ArticleId><ArticleId IdType="pubmed">32154671</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith K, Damiano J, Franceschetti S, Carpenter S, Canafoglia L, Morbin M, Rossi G, Pareyson D, Mole S, Staropoli J et&#xa0;al (2012) Strikingly different clinicopathological phenotypes determined by progranulin&#x2010;mutation dosage. Am J Hum Genet 90: 1102&#x2013;1107</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3370276</ArticleId><ArticleId IdType="pubmed">22608501</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiegel I, Mardinly AR, Gabel HW, Bazinet JE, Couch CH, Tzeng CP, Harmin DA, Greenberg ME (2014) Npas4 regulates excitatory&#x2010;inhibitory balance within neural circuits through cell&#x2010;type&#x2010;specific gene programs. Cell 157: 1216&#x2013;1229</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4089405</ArticleId><ArticleId IdType="pubmed">24855953</ArticleId></ArticleIdList></Reference><Reference><Citation>Steyer B, Bu Q, Cory E, Jiang K, Duong S, Sinha D, Steltzer S, Gamm D, Chang Q, Saha K (2018) Scarless genome editing of human pluripotent stem cells via transient puromycin selection. Stem Cell Rep 10: 642&#x2013;654</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5830934</ArticleId><ArticleId IdType="pubmed">29307579</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka Y, Suzuki G, Matsuwaki T, Hosokawa M, Serrano G, Beach TG, Yamanouchi K, Hasegawa M, Nishihara M (2017) Progranulin regulates lysosomal function and biogenesis through acidification of lysosomes. Hum Mol Genet 26: 969&#x2013;988</Citation><ArticleIdList><ArticleId IdType="pubmed">28073925</ArticleId></ArticleIdList></Reference><Reference><Citation>Thornton P, Sevalle J, Deery MJ, Fraser G, Zhou Y, Stahl S, Franssen EH, Dodd RB, Qamar S, Gomez Perez&#x2010;Nievas B et&#xa0;al (2017) TREM2 shedding by cleavage at the H157&#x2013;S158 bond is accelerated for the Alzheimer's disease&#x2010;associated H157Y variant. EMBO Mol Med 9: 1366&#x2013;1378</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5623839</ArticleId><ArticleId IdType="pubmed">28855301</ArticleId></ArticleIdList></Reference><Reference><Citation>Turnbull IR, Gilfillan S, Cella M, Aoshi T, Miller M, Piccio L, Hernandez M, Colonna M (2006) Cutting edge: TREM&#x2010;2 attenuates macrophage activation. J Immunol 177: 3520&#x2013;3524</Citation><ArticleIdList><ArticleId IdType="pubmed">16951310</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulrich JD, Finn MB, Wang Y, Shen A, Mahan TE, Jiang H, Stewart FR, Piccio L, Colonna M, Holtzman DM (2014) Altered microglial response to Abeta plaques in APPPS1&#x2010;21 mice heterozygous for TREM2. Mol Neurodegener 9: 20</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4049806</ArticleId><ArticleId IdType="pubmed">24893973</ArticleId></ArticleIdList></Reference><Reference><Citation>Valdez C, Wong YC, Schwake M, Bu G, Wszolek ZK, Krainc D (2017) Progranulin&#x2010;mediated deficiency of cathepsin D results in FTD and NCL&#x2010;like phenotypes in neurons derived from FTD patients. Hum Mol Genet 26: 4861&#x2013;4872</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5886207</ArticleId><ArticleId IdType="pubmed">29036611</ArticleId></ArticleIdList></Reference><Reference><Citation>Villa A, Gelosa P, Castiglioni L, Cimino M, Rizzi N, Pepe G, Lolli F, Marcello E, Sironi L, Vegeto E et&#xa0;al (2018) Sex&#x2010;specific features of microglia from adult mice. Cell Rep 23: 3501&#x2013;3511</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6024879</ArticleId><ArticleId IdType="pubmed">29924994</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, Mustafa M, Yuede CM, Salazar SV, Kong P, Long H, Ward M, Siddiqui O, Paul R, Gilfillan S et&#xa0;al (2020) Anti&#x2010;human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer's disease model. J Exp Med 10.1084/jem.20200785</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20200785</ArticleId><ArticleId IdType="pmc">PMC7478730</ArticleId><ArticleId IdType="pubmed">32579671</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Ulland TK, Ulrich JD, Song W, Tzaferis JA, Hole JT, Yuan P, Mahan TE, Shi Y, Gilfillan S et&#xa0;al (2016) TREM2&#x2010;mediated early microglial response limits diffusion and toxicity of amyloid plaques. J Exp Med 213: 667&#x2013;675</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4854736</ArticleId><ArticleId IdType="pubmed">27091843</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward ME, Chen R, Huang H&#x2010;Y, Ludwig C, Telpoukhovskaia M, Taubes A, Boudin H, Minami SS, Reichert M, Albrecht P et&#xa0;al (2017) Individuals with progranulin haploinsufficiency exhibit features of neuronal ceroid lipofuscinosis. Sci Transl Med 10.1126/scitranslmed.aah5642</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aah5642</ArticleId><ArticleId IdType="pmc">PMC5526610</ArticleId><ArticleId IdType="pubmed">28404863</ArticleId></ArticleIdList></Reference><Reference><Citation>Weisheit I, Kroeger JA, Malik R, Klimmt J, Crusius D, Dannert A, Dichgans M, Paquet D (2020) Detection of deleterious on&#x2010;target effects after HDR&#x2010;mediated CRISPR editing. Cell Rep 31: 107689</Citation><ArticleIdList><ArticleId IdType="pubmed">32460021</ArticleId></ArticleIdList></Reference><Reference><Citation>Weisheit I, Kroeger JA, Malik R, Wefers B, Lichtner P, Wurst W, Dichgans M, Paquet D (2021) Simple and reliable detection of CRISPR&#x2010;induced on&#x2010;target effects by qgPCR and SNP genotyping. Nat Protoc 16: 1714&#x2013;1739</Citation><ArticleIdList><ArticleId IdType="pubmed">33597771</ArticleId></ArticleIdList></Reference><Reference><Citation>Werner G, Damme M, Schludi M, Gnorich J, Wind K, Fellerer K, Wefers B, Wurst W, Edbauer D, Brendel M et&#xa0;al (2020) Loss of TMEM106B potentiates lysosomal and FTLD&#x2010;like pathology in progranulin&#x2010;deficient mice. EMBO Rep 21: e50241</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7534633</ArticleId><ArticleId IdType="pubmed">32929860</ArticleId></ArticleIdList></Reference><Reference><Citation>Woollacott IOC, Bocchetta M, Sudre CH, Ridha BH, Strand C, Courtney R, Ourselin S, Cardoso MJ, Warren JD, Rossor MN et&#xa0;al (2018) Pathological correlates of white matter hyperintensities in a case of progranulin mutation associated frontotemporal dementia. Neurocase 24: 166&#x2013;174</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6168954</ArticleId><ArticleId IdType="pubmed">30112957</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y, Shao W, Todd TW, Tong J, Yue M, Koga S, Castanedes&#x2010;Casey M, Librero AL, Lee CW, Mackenzie IR et&#xa0;al (2021) Microglial lysosome dysfunction contributes to white matter pathology and TDP&#x2010;43 proteinopathy in GRN&#x2010;associated FTD. Cell Rep 36: 109581</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8491969</ArticleId><ArticleId IdType="pubmed">34433069</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang X, Wind K, Wiedemann T, Blume T, Shi Y, Briel N, Beyer L, Biechele G, Eckenweber F, Zatcepin A et&#xa0;al (2021) Microglial activation states drive glucose uptake and FDG&#x2010;PET alterations in neurodegenerative diseases. Sci Transl Med 13: eabe5640</Citation><ArticleIdList><ArticleId IdType="pubmed">34644146</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan P, Condello C, Keene CD, Wang Y, Bird TD, Paul SM, Luo W, Colonna M, Baddeley D, Grutzendler J (2016) TREM2 haplodeficiency in mice and humans impairs the microglia barrier function leading to decreased amyloid compaction and severe axonal dystrophy. Neuron 92: 252&#x2013;264</Citation><ArticleIdList><ArticleId IdType="pubmed">27710785</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, Velmeshev D, Hashimoto K, Huang Y&#x2010;H, Hofmann JW, Shi X, Chen J, Leidal AM, Dishart JG, Cahill MK et&#xa0;al (2020) Neurotoxic microglia promote TDP&#x2010;43 proteinopathy in progranulin deficiency. Nature 588: 459&#x2013;465</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7746606</ArticleId><ArticleId IdType="pubmed">32866962</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X, Paushter DH, Feng T, Pardon CM, Mendoza CS, Hu F (2017) Regulation of cathepsin D activity by the FTLD protein progranulin. Acta Neuropathol 134: 151&#x2013;153</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5568051</ArticleId><ArticleId IdType="pubmed">28493053</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X, Paushter DH, Pagan MD, Kim D, Nunez Santos M, Lieberman RL, Overkleeft HS, Sun Y, Smolka MB, Hu F (2019) Progranulin deficiency leads to reduced glucocerebrosidase activity. PLoS One 14: e0212382</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6619604</ArticleId><ArticleId IdType="pubmed">31291241</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X, Sun L, Bastos de Oliveira F, Qi X, Brown WJ, Smolka MB, Sun Y, Hu F (2015) Prosaposin facilitates sortilin&#x2010;independent lysosomal trafficking of progranulin. J Cell Biol 210: 991&#x2013;1002</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4576858</ArticleId><ArticleId IdType="pubmed">26370502</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35020407</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>06</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>627</Issue><PubDate><Year>2022</Year><Month>Jan</Month><Day>12</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>The PET tracer [<sup>11</sup>C]MK-6884 quantifies M4 muscarinic receptor in rhesus monkeys and patients with Alzheimer's disease.</ArticleTitle><Pagination><StartPage>eabg3684</StartPage><MedlinePgn>eabg3684</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.abg3684</ELocationID><Abstract><AbstractText>Positron emission tomography (PET) ligands play an important role in the development of therapeutics by serving as target engagement or pharmacodynamic biomarkers. Here, we describe the discovery and translation of the PET tracer [<sup>11</sup>C]MK-6884 from rhesus monkeys to patients with Alzheimer&#x2019;s disease (AD). [<sup>3</sup>H]MK-6884/[<sup>11</sup>C]MK-6884 binds with high binding affinity and good selectivity to an allosteric site on M4 muscarinic cholinergic receptors (M4Rs) in vitro and shows a regional distribution in the brain consistent with M4R localization in vivo. The tracer demonstrates target engagement of positive allosteric modulators of the M4R (M4 PAMs) through competitive binding interactions. [<sup>11</sup>C]MK-6884 binding is enhanced in vitro by the orthosteric M4R agonist carbachol and indirectly in vivo by the acetylcholinesterase inhibitor donepezil in rhesus monkeys and healthy volunteers, consistent with its pharmacology as a highly cooperative M4 PAM. PET imaging of [<sup>11</sup>C]MK-6884 in patients with AD identified substantial regional differences quantified as nondisplaceable binding potential (BP<sub>ND</sub>) of [<sup>11</sup>C]MK-6884. These results suggest that [<sup>11</sup>C]MK-6884 is a useful target engagement biomarker for M4 PAMs but may also act as a sensitive probe of neuropathological changes in the brains of patients with AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Wenping</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0003-2887-0481</Identifier><AffiliationInfo><Affiliation>MRL, Merck &amp; Co. Inc., Kenilworth, NJ 07033, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yuchuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>MRL, Merck &amp; Co. Inc., Kenilworth, NJ 07033, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lohith</LastName><ForeName>Talakad G</ForeName><Initials>TG</Initials><AffiliationInfo><Affiliation>MRL, Merck &amp; Co. Inc., Kenilworth, NJ 07033, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeng</LastName><ForeName>Zhizhen</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>MRL, Merck &amp; Co. Inc., Kenilworth, NJ 07033, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tong</LastName><ForeName>Ling</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-3302-8184</Identifier><AffiliationInfo><Affiliation>MRL, Merck &amp; Co. Inc., Kenilworth, NJ 07033, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mazzola</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>MRL, Merck &amp; Co. Inc., Kenilworth, NJ 07033, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Riffel</LastName><ForeName>Kerry</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>MRL, Merck &amp; Co. Inc., Kenilworth, NJ 07033, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Patricia</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-3341-1343</Identifier><AffiliationInfo><Affiliation>MRL, Merck &amp; Co. Inc., Kenilworth, NJ 07033, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Purcell</LastName><ForeName>Mona</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-1339-3611</Identifier><AffiliationInfo><Affiliation>MRL, Merck &amp; Co. Inc., Kenilworth, NJ 07033, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holahan</LastName><ForeName>Marie</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-7514-6176</Identifier><AffiliationInfo><Affiliation>MRL, Merck &amp; Co. Inc., Kenilworth, NJ 07033, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haley</LastName><ForeName>Hyking</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-6705-2276</Identifier><AffiliationInfo><Affiliation>MRL, Merck &amp; Co. Inc., Kenilworth, NJ 07033, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gantert</LastName><ForeName>Liza</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-5042-8932</Identifier><AffiliationInfo><Affiliation>MRL, Merck &amp; Co. Inc., Kenilworth, NJ 07033, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hesk</LastName><ForeName>David</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-4059-4168</Identifier><AffiliationInfo><Affiliation>MRL, Merck &amp; Co. Inc., Kenilworth, NJ 07033, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ren</LastName><ForeName>Sumei</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-5163-0489</Identifier><AffiliationInfo><Affiliation>MRL, Merck &amp; Co. Inc., Kenilworth, NJ 07033, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morrow</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>MRL, Merck &amp; Co. Inc., Kenilworth, NJ 07033, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uslaner</LastName><ForeName>Jason</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>MRL, Merck &amp; Co. Inc., Kenilworth, NJ 07033, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Struyk</LastName><ForeName>Arie</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-0189-1004</Identifier><AffiliationInfo><Affiliation>MRL, Merck &amp; Co. Inc., Kenilworth, NJ 07033, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wai</LastName><ForeName>Jenny Miu-Chun</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>MRL, Merck &amp; Co. Inc., Kenilworth, NJ 07033, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rudd</LastName><ForeName>Michael T</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>MRL, Merck &amp; Co. Inc., Kenilworth, NJ 07033, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tellers</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>MRL, Merck &amp; Co. Inc., Kenilworth, NJ 07033, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McAvoy</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-1917-5797</Identifier><AffiliationInfo><Affiliation>MRL, Merck &amp; Co. Inc., Kenilworth, NJ 07033, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bormans</LastName><ForeName>Guy</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-0335-7190</Identifier><AffiliationInfo><Affiliation>Laboratory for Radiopharmaceutical Research, KU Leuven, 3001 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koole</LastName><ForeName>Michel</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-5862-640X</Identifier><AffiliationInfo><Affiliation>Nuclear Medicine and Molecular Imaging, KU Leuven and University Hospital Leuven, 3001 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Laere</LastName><ForeName>Koen</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-5200-7245</Identifier><AffiliationInfo><Affiliation>Nuclear Medicine and Molecular Imaging, KU Leuven and University Hospital Leuven, 3001 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Serdons</LastName><ForeName>Kim</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Nuclear Medicine and Molecular Imaging, KU Leuven and University Hospital Leuven, 3001 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Hoon</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Center for Clinical Pharmacology, KU Leuven, 3001 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Declercq</LastName><ForeName>Ruben</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Translational Pharmacology Europe, MSD (Europe) Inc., 1200 Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Lepeleire</LastName><ForeName>Inge</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Translational Pharmacology Europe, MSD (Europe) Inc., 1200 Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pascual</LastName><ForeName>Maria B</ForeName><Initials>MB</Initials><Identifier Source="ORCID">0000-0002-4467-7406</Identifier><AffiliationInfo><Affiliation>Nantz National Alzheimer Center, Houston Methodist Neurological Institute, Houston, TX 77030, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Weill Cornell Medicine, New York, NY 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zanotti-Fregonara</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Nantz National Alzheimer Center, Houston Methodist Neurological Institute, Houston, TX 77030, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Weill Cornell Medicine, New York, NY 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Meixiang</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-2098-1833</Identifier><AffiliationInfo><Affiliation>Nantz National Alzheimer Center, Houston Methodist Neurological Institute, Houston, TX 77030, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Weill Cornell Medicine, New York, NY 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arbones</LastName><ForeName>Victoria</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-4591-6990</Identifier><AffiliationInfo><Affiliation>Nantz National Alzheimer Center, Houston Methodist Neurological Institute, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masdeu</LastName><ForeName>Joseph C</ForeName><Initials>JC</Initials><Identifier Source="ORCID">0000-0001-9955-6954</Identifier><AffiliationInfo><Affiliation>Nantz National Alzheimer Center, Houston Methodist Neurological Institute, Houston, TX 77030, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Weill Cornell Medicine, New York, NY 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Amy</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-8860-1921</Identifier><AffiliationInfo><Affiliation>MRL, Merck &amp; Co. Inc., Kenilworth, NJ 07033, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hussain</LastName><ForeName>Azher</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-4436-6648</Identifier><AffiliationInfo><Affiliation>MRL, Merck &amp; Co. Inc., Kenilworth, NJ 07033, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bueters</LastName><ForeName>Tjerk</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>MRL, Merck &amp; Co. Inc., Kenilworth, NJ 07033, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anderson</LastName><ForeName>Matt S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>MRL, Merck &amp; Co. Inc., Kenilworth, NJ 07033, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hostetler</LastName><ForeName>Eric D</ForeName><Initials>ED</Initials><AffiliationInfo><Affiliation>MRL, Merck &amp; Co. Inc., Kenilworth, NJ 07033, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Basile</LastName><ForeName>Anthony S</ForeName><Initials>AS</Initials><Identifier Source="ORCID">0000-0003-3100-6555</Identifier><AffiliationInfo><Affiliation>MRL, Merck &amp; Co. Inc., Kenilworth, NJ 07033, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>01</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011976">Receptors, Muscarinic</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.1.7</RegistryNumber><NameOfSubstance UI="D000110">Acetylcholinesterase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000110" MajorTopicYN="N">Acetylcholinesterase</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008253" MajorTopicYN="N">Macaca mulatta</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011976" MajorTopicYN="N">Receptors, Muscarinic</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>1</Month><Day>12</Day><Hour>17</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>1</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35020407</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.abg3684</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35022652</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>25</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1460-2156</ISSN><JournalIssue CitedMedium="Internet"><Volume>145</Volume><Issue>10</Issue><PubDate><Year>2022</Year><Month>Oct</Month><Day>21</Day></PubDate></JournalIssue><Title>Brain : a journal of neurology</Title><ISOAbbreviation>Brain</ISOAbbreviation></Journal><ArticleTitle>Genetically identical twins show comparable tau PET load and spatial distribution.</ArticleTitle><Pagination><StartPage>3571</StartPage><EndPage>3581</EndPage><MedlinePgn>3571-3581</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/brain/awac004</ELocationID><Abstract><AbstractText>Tau accumulation starts during the preclinical phase of Alzheimer's disease and is closely associated with cognitive decline. For preventive purposes, it is important to identify factors associated with tau accumulation and spread. Studying genetically identical twin-pairs may give insight into genetic and environmental contributions to tau pathology, as similarities in identical twin-pairs largely result from genetic factors, while differences in identical twin-pairs can largely be attributed to non-shared, environmental factors. This study aimed to examine similarities and dissimilarities in a cohort of genetically identical older twin-pairs in (i) tau load; and (ii) spatial distribution of tau, measured with 18F-flortaucipir PET. We selected 78 genetically identical twins (39 pairs; average age 73 &#xb1; 6 years), enriched for amyloid-&#x3b2; pathology and APOE &#x3b5;4 carriership, who underwent dynamic 18F-flortaucipir PET. We extracted binding potentials (BPND) in entorhinal, temporal, widespread neocortical and global regions, and examined within-pair similarities in BPND using age and sex corrected intra-class correlations. Furthermore, we tested whether twin-pairs showed a more similar spatial 18F-flortaucipir distribution compared to non-twin pairs, and whether the participant's co-twin could be identified solely based on the spatial 18F-flortaucipir distribution. Last, we explored whether environmental (e.g. physical activity, obesity) factors could explain observed differences in twins of a pair in 18F-flortaucipir BPND. On visual inspection, Alzheimer's disease-like 18F-flortaucipir PET patterns were observed, and although we mainly identified similarities in twin-pairs, some pairs showed strong dissimilarities. 18F-flortaucipir BPND was correlated in twins in the entorhinal (r = 0.40; P = 0.01), neocortical (r = 0.59; P &lt; 0.01) and global (r = 0.56; P &lt; 0.01) regions, but not in the temporal region (r = 0.20; P = 0.10). The 18F-flortaucipir distribution pattern was significantly more similar between twins of the same pair [mean r = 0.27; standard deviation (SD) = 0.09] than between non-twin pairings of participants (mean r = 0.01; SD = 0.10) (P &lt; 0.01), also after correcting for proxies of off-target binding. Based on the spatial 18F-flortaucipir distribution, we could identify with an accuracy of 86% which twins belonged to the same pair. Finally, within-pair differences in 18F-flortaucipir BPND were associated with within-pair differences in depressive symptoms (0.37 &lt; &#x3b2; &lt; 0.56), physical activity (-0.41 &lt; &#x3b2; &lt; -0.42) and social activity (-0.32 &lt; &#x3b2; &lt; -0.36) (all P &lt; 0.05). Overall, identical twin-pairs were comparable in tau load and spatial distribution, highlighting the important role of genetic factors in the accumulation and spreading of tau pathology. Considering also the presence of dissimilarities in tau pathology in identical twin-pairs, our results additionally support a role for (potentially modifiable) environmental factors in the onset of Alzheimer's disease pathological processes, which may be of interest for future prevention strategies.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2022. Published by Oxford University Press on behalf of the Guarantors of Brain.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Coomans</LastName><ForeName>Emma M</ForeName><Initials>EM</Initials><Identifier Source="ORCID">0000-0002-4289-9101</Identifier><AffiliationInfo><Affiliation>Department of Radiology and Nuclear Medicine, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tomassen</LastName><ForeName>Jori</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ossenkoppele</LastName><ForeName>Rik</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Golla</LastName><ForeName>Sandeep S V</ForeName><Initials>SSV</Initials><AffiliationInfo><Affiliation>Department of Radiology and Nuclear Medicine, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>den Hollander</LastName><ForeName>Marijke</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Radiology and Nuclear Medicine, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Collij</LastName><ForeName>Lyduine E</ForeName><Initials>LE</Initials><Identifier Source="ORCID">0000-0002-2902-2268</Identifier><AffiliationInfo><Affiliation>Department of Radiology and Nuclear Medicine, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weltings</LastName><ForeName>Emma</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Radiology and Nuclear Medicine, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Landen</LastName><ForeName>Sophie M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wolters</LastName><ForeName>Emma E</ForeName><Initials>EE</Initials><AffiliationInfo><Affiliation>Department of Radiology and Nuclear Medicine, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Windhorst</LastName><ForeName>Albert D</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>Department of Radiology and Nuclear Medicine, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barkhof</LastName><ForeName>Frederik</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Radiology and Nuclear Medicine, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UCL Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Geus</LastName><ForeName>Eco J C</ForeName><Initials>EJC</Initials><AffiliationInfo><Affiliation>Department of Biological Psychology, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scheltens</LastName><ForeName>Philip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Visser</LastName><ForeName>Pieter Jelle</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Alzheimer Center Limburg, School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurobiology, Care Sciences and Society, Division of Neurogeriatrics, Karolinska Institutet, StockholmSweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Berckel</LastName><ForeName>Bart N M</ForeName><Initials>BNM</Initials><AffiliationInfo><Affiliation>Department of Radiology and Nuclear Medicine, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>den Braber</LastName><ForeName>Anouk</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biological Psychology, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D018486">Twin Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Brain</MedlineTA><NlmUniqueID>0372537</NlmUniqueID><ISSNLinking>0006-8950</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014430" MajorTopicYN="N">Twins, Monozygotic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">PET</Keyword><Keyword MajorTopicYN="N">genetics</Keyword><Keyword MajorTopicYN="N">tau</Keyword><Keyword MajorTopicYN="N">twins</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>9</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>11</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>11</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>1</Month><Day>13</Day><Hour>6</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>1</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35022652</ArticleId><ArticleId IdType="pmc">PMC9586544</ArticleId><ArticleId IdType="doi">10.1093/brain/awac004</ArticleId><ArticleId IdType="pii">6504924</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sperling RA, Aisen PS, Beckett LA, et al. . Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):280&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3220946</ArticleId><ArticleId IdType="pubmed">21514248</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen WJ, Ossenkoppele R, Knol DL, et al. . Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA. 2015;313(19):1924&#x2013;1938.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4486209</ArticleId><ArticleId IdType="pubmed">25988462</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack C Jr, Holtzman DM. Biomarker modeling of Alzheimer's disease. Neuron. 2013;80(6):1347&#x2013;1358.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3928967</ArticleId><ArticleId IdType="pubmed">24360540</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison TM, La Joie R, Maass A, et al. . Longitudinal tau accumulation and atrophy in aging and alzheimer disease. Ann Neurol. 2019;85(2):229&#x2013;240.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6579738</ArticleId><ArticleId IdType="pubmed">30597624</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehmann M, Ghosh PM, Madison C, et al. . Diverging patterns of amyloid deposition and hypometabolism in clinical variants of probable Alzheimer's disease. Brain. 2013;136(Pt 3):844&#x2013;858.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3580269</ArticleId><ArticleId IdType="pubmed">23358601</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson KA, Schultz A, Betensky RA, et al. . Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol. 2016;79(1):110&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4738026</ArticleId><ArticleId IdType="pubmed">26505746</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogel JW, Young AL, Oxtoby NP, et al. . Four distinct trajectories of tau deposition identified in Alzheimer's disease. Nat Med. 2021;27(5):871&#x2013;881.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8686688</ArticleId><ArticleId IdType="pubmed">33927414</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol Aging. 1995;16(3):271&#x2013;278; discussion 278&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">7566337</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho H, Choi JY, Hwang MS, et al. . In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum. Ann Neurol. 2016;80(2):247&#x2013;258.</Citation><ArticleIdList><ArticleId IdType="pubmed">27323247</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xf6;ll M, Lockhart SN, Schonhaut DR, et al. . PET Imaging of tau deposition in the aging human brain. Neuron. 2016;89(5):971&#x2013;982.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4779187</ArticleId><ArticleId IdType="pubmed">26938442</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarz AJ, Yu P, Miller BB, et al. . Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages. Brain. 2016;139(Pt 5):1539&#x2013;1550.</Citation><ArticleIdList><ArticleId IdType="pubmed">26936940</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogel JW, Iturria-Medina Y, Strandberg OT, et al. . Spread of pathological tau proteins through communicating neurons in human Alzheimer's disease. Nat Commun. 2020;11(1):2612.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7251068</ArticleId><ArticleId IdType="pubmed">32457389</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R, Schonhaut DR, Sch&#xf6;ll M, et al. . Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. Brain. 2016;139(Pt 5):1551&#x2013;1567.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5006248</ArticleId><ArticleId IdType="pubmed">26962052</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanseeuw BJ, Betensky RA, Jacobs HIL, et al. . Association of amyloid and tau with cognition in preclinical Alzheimer disease: A longitudinal study. JAMA Neurol. 2019;76:915.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6547132</ArticleId><ArticleId IdType="pubmed">31157827</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R, Smith R, Ohlsson T, et al. . Associations between tau, A&#x3b2;, and cortical thickness with cognition in Alzheimer disease. Neurology. 2019;92(6):e601&#x2013;e612.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6382060</ArticleId><ArticleId IdType="pubmed">30626656</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison TM, Du R, Klencklen G, Baker SL, Jagust WJ. Distinct effects of beta-amyloid and tau on cortical thickness in cognitively healthy older adults. Alzheimers Dement. 2020;17:1085&#x2013;1096.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8203764</ArticleId><ArticleId IdType="pubmed">33325068</ArticleId></ArticleIdList></Reference><Reference><Citation>Aschenbrenner AJ, Gordon BA, Benzinger TLS, Morris JC, Hassenstab JJ. Influence of tau PET, amyloid PET, and hippocampal volume on cognition in Alzheimer disease. Neurology. 2018;91(9):e859&#x2013;e866.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6133625</ArticleId><ArticleId IdType="pubmed">30068637</ArticleId></ArticleIdList></Reference><Reference><Citation>Bejanin A, Schonhaut DR, La Joie R, et al. . Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease. Brain. 2017;140(12):3286&#x2013;3300.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5841139</ArticleId><ArticleId IdType="pubmed">29053874</ArticleId></ArticleIdList></Reference><Reference><Citation>Visser D, Wolters EE, Verfaillie SCJ, et al. . Tau pathology and relative cerebral blood flow are independently associated with cognition in Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2020;47(13):3165&#x2013;3175.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7680306</ArticleId><ArticleId IdType="pubmed">32462397</ArticleId></ArticleIdList></Reference><Reference><Citation>Maass A, Lockhart SN, Harrison TM, et al. . Entorhinal tau pathology, episodic memory decline, and neurodegeneration in aging. J Neurosci. 2018;38(3):530&#x2013;543.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5777108</ArticleId><ArticleId IdType="pubmed">29192126</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowe VJ, Bruinsma TJ, Wiste HJ, et al. . Cross-sectional associations of tau-PET signal with cognition in cognitively unimpaired adults. Neurology. 2019;93(1):e29&#x2013;e39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6659005</ArticleId><ArticleId IdType="pubmed">31147421</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Mormino EC, Schultz AP, et al. . The impact of amyloid-beta and tau on prospective cognitive decline in older individuals. Ann Neurol. 2019;85(2):181&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6402593</ArticleId><ArticleId IdType="pubmed">30549303</ArticleId></ArticleIdList></Reference><Reference><Citation>Kremen WS, Prom-Wormley E, Panizzon MS, et al. . Genetic and environmental influences on the size of specific brain regions in midlife: the VETSA MRI study. Neuroimage. 2010;49(2):1213&#x2013;1223.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3397915</ArticleId><ArticleId IdType="pubmed">19786105</ArticleId></ArticleIdList></Reference><Reference><Citation>Posthuma D, de Geus EJ, Neale MC, et al. . Multivariate genetic analysis of brain structure in an extended twin design. Behav Genet. 2000;30(4):311&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">11206086</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatz M, Reynolds CA, Fratiglioni L, et al. . Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry. 2006;63(2):168&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pubmed">16461860</ArticleId></ArticleIdList></Reference><Reference><Citation>Konijnenberg E, Carter SF, Ten Kate M, et al. . The EMIF-AD PreclinAD study: study design and baseline cohort overview. Alzheimers Res Ther. 2018;10(1):75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6091034</ArticleId><ArticleId IdType="pubmed">30075734</ArticleId></ArticleIdList></Reference><Reference><Citation>Collij LE, Konijnenberg E, Reimand J, et al. . Assessing amyloid pathology in cognitively normal subjects using (18)F-flutemetamol PET: Comparing visual reads and quantitative methods. J Nucl Med. 2019;60(4):541&#x2013;547.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6448465</ArticleId><ArticleId IdType="pubmed">30315145</ArticleId></ArticleIdList></Reference><Reference><Citation>Collij LE, Heeman F, Salvado G, et al. . Multitracer model for staging cortical amyloid deposition using PET imaging. Neurology. 2020;95(11):e1538&#x2013;e1553.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7713745</ArticleId><ArticleId IdType="pubmed">32675080</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The clinical dementia rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412&#x2013;2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Heyman A, Mohs RC, et al. . The consortium to establish a registry for Alzheimer's disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology. 1989;39(9):1159&#x2013;1165.</Citation><ArticleIdList><ArticleId IdType="pubmed">2771064</ArticleId></ArticleIdList></Reference><Reference><Citation>Yesavage JA, Brink TL, Rose TL, et al. . Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res. 1982;17(1):37&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">7183759</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuncel H, Visser D, Yaqub M, et al. . Effect of shortening the scan duration on quantitative accuracy of (18)F-flortaucipir studies. Mol Imaging Biol. 2021;23:604&#x2013;613.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8277654</ArticleId><ArticleId IdType="pubmed">33496930</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammers A, Allom R, Koepp MJ, et al. . Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe. Hum Brain Mapp. 2003;19(4):224&#x2013;247.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6871794</ArticleId><ArticleId IdType="pubmed">12874777</ArticleId></ArticleIdList></Reference><Reference><Citation>Svarer C, Madsen K, Hasselbalch SG, et al. . MR-based automatic delineation of volumes of interest in human brain PET images using probability maps. Neuroimage. 2005;24(4):969&#x2013;979.</Citation><ArticleIdList><ArticleId IdType="pubmed">15670674</ArticleId></ArticleIdList></Reference><Reference><Citation>Golla SSV, Wolters EE, Timmers T, et al. . Parametric methods for (18)F-flortaucipir PET. J Cereb Blood Flow Metab. 2020;40(2):365&#x2013;373.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7044757</ArticleId><ArticleId IdType="pubmed">30569813</ArticleId></ArticleIdList></Reference><Reference><Citation>Golla SSV, Lubberink M, van Berckel BNM, Lammertsma AA, Boellaard R. Partial volume correction of brain PET studies using iterative deconvolution in combination with HYPR denoising. EJNMMI Res. 2017;7(1):36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5400775</ArticleId><ArticleId IdType="pubmed">28432674</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R, Rabinovici GD, Smith R, et al. . Discriminative accuracy of 18F-flortaucipir positron emission tomography for alzheimer disease vs other neurodegenerative disorders. JAMA. 2018;320(11):1151&#x2013;1162.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6233630</ArticleId><ArticleId IdType="pubmed">30326496</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolters EE, Golla SSV, Timmers T, et al. . A novel partial volume correction method for accurate quantification of (18)F- flortaucipir in the hippocampus. EJNMMI Res. 2018;8(1):79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6093830</ArticleId><ArticleId IdType="pubmed">30112620</ArticleId></ArticleIdList></Reference><Reference><Citation>Oldfield RC. The assessment and analysis of handedness: the Edinburgh inventory. Neuropsychologia. 1971;9(1):97&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pubmed">5146491</ArticleId></ArticleIdList></Reference><Reference><Citation>Konijnenberg E, Tomassen J, den Braber A, et al. . Onset of preclinical Alzheimer disease in monozygotic twins. Ann Neurol. 2021;89:987&#x2013;1000.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8251701</ArticleId><ArticleId IdType="pubmed">33583080</ArticleId></ArticleIdList></Reference><Reference><Citation>Livingston G, Huntley J, Sommerlad A, et al. . Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020;396(10248):413&#x2013;446.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7392084</ArticleId><ArticleId IdType="pubmed">32738937</ArticleId></ArticleIdList></Reference><Reference><Citation>Smits C, Theo Goverts S, Festen JM. The digits-in-noise test: assessing auditory speech recognition abilities in noise. J Acoust Soc Am. 2013;133(3):1693&#x2013;1706.</Citation><ArticleIdList><ArticleId IdType="pubmed">23464039</ArticleId></ArticleIdList></Reference><Reference><Citation>Washburn RA, Smith KW, Jette AM, Janney CA. The physical activity scale for the elderly (PASE): development and evaluation. J Clin Epidemiol. 1993;46(2):153&#x2013;162.</Citation><ArticleIdList><ArticleId IdType="pubmed">8437031</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker SL, Harrison TM, Maass A, La Joie R, Jagust WJ. Effect of off-target binding on (18)F-flortaucipir variability in healthy controls across the life span. J Nucl Med. 2019;60(10):1444&#x2013;1451.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6785795</ArticleId><ArticleId IdType="pubmed">30877180</ArticleId></ArticleIdList></Reference><Reference><Citation>De Moor MHM, Boomsma DI, Stubbe JH, Willemsen G, de Geus EJ. Testing causality in the association between regular exercise and symptoms of anxiety and depression. Arch Gen Psychiatry. 2008;65(8):897&#x2013;905.</Citation><ArticleIdList><ArticleId IdType="pubmed">18678794</ArticleId></ArticleIdList></Reference><Reference><Citation>Brickell KL, Leverenz JB, Steinbart EJ, et al. . Clinicopathological concordance and discordance in three monozygotic twin pairs with familial Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2007;78(10):1050&#x2013;1055.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2117553</ArticleId><ArticleId IdType="pubmed">17615170</ArticleId></ArticleIdList></Reference><Reference><Citation>Iacono D, Volkman I, Nennesmo I, et al. . Neuropathologic assessment of dementia markers in identical and fraternal twins. Brain Pathol. 2014;24(4):317&#x2013;333.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4065212</ArticleId><ArticleId IdType="pubmed">24450926</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett RE, DeVos SL, Dujardin S, et al. . Enhanced tau aggregation in the presence of amyloid beta. Am J Pathol. 2017;187(7):1601&#x2013;1612.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5500829</ArticleId><ArticleId IdType="pubmed">28500862</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolters EE, Ossenkoppele R, Verfaillie SCJ, et al. . Regional (18)F-flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2020;47(12):2866&#x2013;2878.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7567681</ArticleId><ArticleId IdType="pubmed">32291510</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R, Iaccarino L, Schonhaut DR, et al. . Tau covariance patterns in Alzheimer's disease patients match intrinsic connectivity networks in the healthy brain. Neuroimage Clin. 2019;23:101848.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6510968</ArticleId><ArticleId IdType="pubmed">31077982</ArticleId></ArticleIdList></Reference><Reference><Citation>Cope TE, Rittman T, Borchert RJ, et al. . Tau burden and the functional connectome in Alzheimer's disease and progressive supranuclear palsy. Brain. 2018;141(2):550&#x2013;567.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5837359</ArticleId><ArticleId IdType="pubmed">29293892</ArticleId></ArticleIdList></Reference><Reference><Citation>Franzmeier N, Rubinski A, Neitzel J, et al. . Functional connectivity associated with tau levels in ageing. Alzheimer's, and small vessel disease. Brain. 2019;142(4):1093&#x2013;1107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6439332</ArticleId><ArticleId IdType="pubmed">30770704</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobs HIL, Hedden T, Schultz AP, et al. . Structural tract alterations predict downstream tau accumulation in amyloid-positive older individuals. Nat Neurosci. 2018;21(3):424&#x2013;431.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5857215</ArticleId><ArticleId IdType="pubmed">29403032</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmitt JE, Neale MC, Fassassi B, et al. . The dynamic role of genetics on cortical patterning during childhood and adolescence. Proc Natl Acad Sci USA. 2014;111(18):6774&#x2013;6779.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4020057</ArticleId><ArticleId IdType="pubmed">24753564</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnatkeviciute A, Fulcher BD, Oldham S, et al. . Genetic influences on hub connectivity of the human connectome. Nat Commun. 2021;12(1):4237.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8271018</ArticleId><ArticleId IdType="pubmed">34244483</ArticleId></ArticleIdList></Reference><Reference><Citation>Arenaza-Urquijo EM, Vemuri P. Resistance vs resilience to Alzheimer disease: Clarifying terminology for preclinical studies. Neurology. 2018;90(15):695&#x2013;703.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5894932</ArticleId><ArticleId IdType="pubmed">29592885</ArticleId></ArticleIdList></Reference><Reference><Citation>Okonkwo OC, Schultz SA, Oh JM, et al. . Physical activity attenuates age-related biomarker alterations in preclinical AD. Neurology. 2014;83(19):1753&#x2013;1760.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4239838</ArticleId><ArticleId IdType="pubmed">25298312</ArticleId></ArticleIdList></Reference><Reference><Citation>Schreiber S, Vogel J, Schwimmer HD, Marks SM, Schreiber F, Jagust W. Impact of lifestyle dimensions on brain pathology and cognition. Neurobiol Aging. 2016;40:164&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4792130</ArticleId><ArticleId IdType="pubmed">26973116</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35025652</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>19</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>375</Volume><Issue>6577</Issue><PubDate><Year>2022</Year><Month>Jan</Month><Day>14</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>A molecular view of human amyloid-&#x3b2; folds.</ArticleTitle><Pagination><StartPage>147</StartPage><EndPage>148</EndPage><MedlinePgn>147-148</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/science.abn5428</ELocationID><Abstract><AbstractText>Structures of amyloid-&#x3b2; fibrils suggest Alzheimer&#x2019;s disease&#x2013;modifying strategies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Willem</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Biomedical Center (BMC), Division of Metabolic Biochemistry, Faculty of Medicine, Ludwig Maximilians University Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>F&#xe4;ndrich</LastName><ForeName>Marcus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Protein Biochemistry, Ulm University, Ulm, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MC_U105184291</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_UP_1201/25</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Science. 2022 Jan 14;375(6577):167-172. doi: 10.1126/science.abm7285.</RefSource><PMID Version="1">35025654</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="Y">Amyloid beta-Peptides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>1</Month><Day>13</Day><Hour>17</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35025652</ArticleId><ArticleId IdType="doi">10.1126/science.abn5428</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">35045281</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>14</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2211-1247</ISSN><JournalIssue CitedMedium="Internet"><Volume>38</Volume><Issue>3</Issue><PubDate><Year>2022</Year><Month>Jan</Month><Day>18</Day></PubDate></JournalIssue><Title>Cell reports</Title><ISOAbbreviation>Cell Rep</ISOAbbreviation></Journal><ArticleTitle>The neuronal retromer can regulate both neuronal and microglial phenotypes of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>110262</StartPage><MedlinePgn>110262</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.celrep.2021.110262</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2211-1247(21)01774-5</ELocationID><Abstract><AbstractText>Disruption of retromer-dependent endosomal trafficking is considered pathogenic in late-onset Alzheimer's disease (AD). Here, to investigate this disruption in the intact brain, we turn to a genetic mouse model where the retromer core protein VPS35 is depleted in hippocampal neurons, and then we replete VPS35 using an optimized viral vector protocol. The VPS35 depletion-repletion studies strengthen the causal link between the neuronal retromer and AD-associated neuronal phenotypes, including the acceleration of amyloid precursor protein cleavage and the loss of synaptic glutamate receptors. Moreover, the studies show that the neuronal retromer can regulate a distinct, dystrophic, microglia morphology, phenotypic of hippocampal microglia in AD. Finally, the neuronal and, in part, the microglia responses to VPS35 depletion were found to occur independent of tau. Showing that the neuronal retromer can regulate AD-associated pathologies in two of AD's principal cell types strengthens the link, and clarifies the mechanism, between endosomal trafficking and late-onset sporadic AD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 The Author(s). Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Qureshi</LastName><ForeName>Yasir H</ForeName><Initials>YH</Initials><AffiliationInfo><Affiliation>Departments of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berman</LastName><ForeName>Diego E</ForeName><Initials>DE</Initials><AffiliationInfo><Affiliation>Departments of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marsh</LastName><ForeName>Samuel E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Boston Children's Hospital, F.M. Kirby Neurobiology Center, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klein</LastName><ForeName>Ronald L</ForeName><Initials>RL</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Toxicology and Neuroscience, Louisiana State University Health Sciences Center, Shreveport, LA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Vivek M</ForeName><Initials>VM</Initials><AffiliationInfo><Affiliation>Departments of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simoes</LastName><ForeName>Sabrina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Departments of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kannan</LastName><ForeName>Suvarnambiga</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Departments of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petsko</LastName><ForeName>Gregory A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stevens</LastName><ForeName>Beth</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Boston Children's Hospital, F.M. Kirby Neurobiology Center, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA; Howard Hughes Medical Institute, Boston Children's Hospital, Boston, MA, USA. Electronic address: beth.stevens@childrens.harvard.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Small</LastName><ForeName>Scott A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Departments of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, NY, USA. Electronic address: sas68@columbia.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG066462</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG008702</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 HD105351</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Rep</MedlineTA><NlmUniqueID>101573691</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D033921">Vesicular Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C101274">Vps35 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011992" MajorTopicYN="N">Endosomes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021381" MajorTopicYN="N">Protein Transport</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D033921" MajorTopicYN="N">Vesicular Transport Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">SORL1</Keyword><Keyword MajorTopicYN="N">VPS35</Keyword><Keyword MajorTopicYN="N">astrocytes</Keyword><Keyword MajorTopicYN="N">endosomal trafficking</Keyword><Keyword MajorTopicYN="N">gene therapy</Keyword><Keyword MajorTopicYN="N">late-onset AD</Keyword><Keyword MajorTopicYN="N">microglia</Keyword><Keyword MajorTopicYN="N">mouse models</Keyword><Keyword MajorTopicYN="N">retromer</Keyword></KeywordList><CoiStatement>Declaration of interests S.A.S., G.A.P., and B.S. are on the Scientific Advisory Board of Retromer Therapeutics; G.A.P. is also on the Scientific Advisory Boards of MeiraGTx, AnnovisBio, Amicus Therapeutics, and Proclara Biosciences. B.S. is also on the advisory board of Annexon Biosciences and Neumora. Y.H.Q. is consulting for Retromer Therapeutics. Last, S.A.S., G.A.P., and Y.H.Q. are co-inventors on patent &#x201c;Stabilization of retromer for the treatment of Alzheimer's disease and other neurodegenerative disorders&#x201d; owned by Columbia University. S.A.S., S.S., and Y.H.Q. are co-inventors on patent &#x201c;Precision targeted retromer therapeutics for the treatment of neurodegenerative diseases and disorders&#x201d; owned by Columbia University.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>3</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>9</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>12</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>1</Month><Day>19</Day><Hour>20</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>1</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>2</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35045281</ArticleId><ArticleId IdType="mid">NIHMS1772775</ArticleId><ArticleId IdType="pmc">PMC8830374</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2021.110262</ArticleId><ArticleId IdType="pii">S2211-1247(21)01774-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alzheimer A (1906). &#xdc;ber eine eigenartige Erkrankung der Hirnrinde. &#x201c;A Characteristic Disease of the Cerebral Cortex&#x201d;. Neurologisches Centralblatt 25, 1134.</Citation></Reference><Reference><Citation>Alzheimer A (1907). &#xdc;ber eine eigenartige Erkrankung der Hirnrinde., 64, 146&#x2013;148. Allgemeine Zeitschrift fur Psychiatrie und Psychisch-gerichtliche Medizin 64, 146&#x2013;148.</Citation><ArticleIdList><ArticleId IdType="pubmed">8713166</ArticleId></ArticleIdList></Reference><Reference><Citation>Andorfer C, Kress Y, Espinoza M, De Silva R, Tucker KL, Barde YA, Duff K, and Davies P (2003). Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J. Neurochem. 86, 582&#x2013;590.</Citation><ArticleIdList><ArticleId IdType="pubmed">12859672</ArticleId></ArticleIdList></Reference><Reference><Citation>Aschauer DF, Kreuz S, and Rumpel S (2013). Analysis of transduction efficiency, tropism and axonal transport of AAV serotypes 1, 2, 5, 6, 8 and 9 in the mouse brain. PLoS One 8, e76310.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3785459</ArticleId><ArticleId IdType="pubmed">24086725</ArticleId></ArticleIdList></Reference><Reference><Citation>Barthelemy NR, LI Y, Joseph-Mathurin N, Gordon BA, Hassenstab J, Benzinger TLS, Buckles V, Fagan AM, Perrin RJ, Goate AM, et al. (2020). A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer&#x2019;s disease. Nat. Med. 26, 398&#x2013;407.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7309367</ArticleId><ArticleId IdType="pubmed">32161412</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazan NG, Marcheselli VL, and Cole-Edwards K (2005). Brain response to injury and neurodegeneration: endogenous neuroprotective signaling. Ann. N. Y Acad. Sci. 1053, 137&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pubmed">16179516</ArticleId></ArticleIdList></Reference><Reference><Citation>Benes P, Vetvicka V, and Fusek M (2008). Cathepsin D&#x2013;many functions of one aspartic protease. Crit. Rev. Oncol. Hematol. 68, 12&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2635020</ArticleId><ArticleId IdType="pubmed">18396408</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhalla A, Vetanovetz CP, Morel E, Chamoun Z, Di Paolo G, and Small SA (2012). The location and trafficking routes of the neuronal retromer and its role in amyloid precursor protein transport. Neurobiol. Dis. 47, 126&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3589992</ArticleId><ArticleId IdType="pubmed">22516235</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown RW, and Chirala R (1995). Utility of microwave-citrate antigen retrieval in diagnostic immunohistochemistry. Mod. Pathol. 8, 515&#x2013;520.</Citation><ArticleIdList><ArticleId IdType="pubmed">7675770</ArticleId></ArticleIdList></Reference><Reference><Citation>Buccitelli C, and Selbach M (2020). mRNAs, proteins and the emerging principles of gene expression control. Nat. Rev. Genet. 21, 630&#x2013;644.</Citation><ArticleIdList><ArticleId IdType="pubmed">32709985</ArticleId></ArticleIdList></Reference><Reference><Citation>Burd C, and Cullen PJ (2014). Retromer: a master conductor of endosome sorting. Cold Spring Harb Perspect. Biol. 6, a016774.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3941235</ArticleId><ArticleId IdType="pubmed">24492709</ArticleId></ArticleIdList></Reference><Reference><Citation>Carosi JM, Denton D, Kumar S, and Sargeant TJ (2021). Retromer dysfunction at the nexus of tauopathies. Cell Death Differ 28, 884&#x2013;899.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7937680</ArticleId><ArticleId IdType="pubmed">33473181</ArticleId></ArticleIdList></Reference><Reference><Citation>Carosi JM, Hein LK, Van Den Hurk M, Adams R, Milky B, Singh S, Bardy C, Denton D, Kumar S, and Sargeant TJ (2020). Retromer regulates the lysosomal clearance of MAPT/tau. Autophagy 17, 1&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8496733</ArticleId><ArticleId IdType="pubmed">32960680</ArticleId></ArticleIdList></Reference><Reference><Citation>Castle MJ, Turunen HT, Vandenberghe LH, and Wolfe JH (2016). Controlling AAV tropism in the nervous system with natural and engineered capsids. Methods Mol. Biol. 1382, 133&#x2013;149.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4993104</ArticleId><ArticleId IdType="pubmed">26611584</ArticleId></ArticleIdList></Reference><Reference><Citation>Cataldo AM, Peterhoff CM, Troncoso JC, Gomez-Isla T, Hyman BT, and Nixon RA (2000). Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer&#x2019;s disease and Down syndrome: differential effects of APOE genotype and presenilin mutations. Am. J. Pathol. 157, 277&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850219</ArticleId><ArticleId IdType="pubmed">10880397</ArticleId></ArticleIdList></Reference><Reference><Citation>Cetin A, Komai S, Eliava M, Seeburg PH, and Osten P (2007). Stereotaxic gene delivery in the rodent brain. Nat. Protoc. 1, 3166&#x2013;3173.</Citation><ArticleIdList><ArticleId IdType="pubmed">17406580</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, and Colonna M (2021). Microglia in Alzheimer&#x2019;s disease at single-cell level. Are there common patterns in humans and mice? J. Exp. Med. 218, e20202717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8302448</ArticleId><ArticleId IdType="pubmed">34292312</ArticleId></ArticleIdList></Reference><Reference><Citation>Christensen SK, Narimatsu Y, Simoes S, Goth C, Vaegter CB, Small SA, Cahalan MD, and Andersen OM (2020). Endosomal trafficking is required for glycosylation and normal maturation of the Alzheimer&#x2019;s-associated protein sorLA. bioRxiv. 10.1101/2020.07.12.199885.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.07.12.199885</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciron C, Desmaris N, Colle MA, Raoul S, Joussemet B, Verot L, Ausseil J, Froissart R, Roux F, Cherel Y, et al. (2006). Gene therapy of the brain in the dog model of Hurler&#x2019;s syndrome. Ann. Neurol. 60, 204&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pubmed">16718701</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies DS, Ma J, Jegathees T, and Goldsbury C (2017). Microglia show altered morphology and reduced arborization in human brain during aging and Alzheimer&#x2019;s disease. Brain Pathol. 27, 795&#x2013;808.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8029278</ArticleId><ArticleId IdType="pubmed">27862631</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B, and Karran E (2016). The cellular phase of Alzheimer&#x2019;s disease. Cell 164, 603&#x2013;615.</Citation><ArticleIdList><ArticleId IdType="pubmed">26871627</ArticleId></ArticleIdList></Reference><Reference><Citation>Deczkowska A, Keren-Shaul H, Weiner A, Colonna M, Schwartz M, and Amit I (2018). Disease-associated microglia: a universal immune sensor of neurodegeneration. Cell 173, 1073&#x2013;1081.</Citation><ArticleIdList><ArticleId IdType="pubmed">29775591</ArticleId></ArticleIdList></Reference><Reference><Citation>Eaton SL, Roche SL, Llavero Hurtado M, Oldknow KJ, Farquharson C, Gillingwater TH, and Wishart TM (2013). Total protein analysis as a reliable loading control for quantitative fluorescent Western blotting. PLoS One 8, e72457.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3758299</ArticleId><ArticleId IdType="pubmed">24023619</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira TA, Blackman AV, Oyrer J, Jayabal S, Chung AJ, Watt AJ, Sj&#xf6;str&#xf6;m PJ, and Van Meyel DJ (2014). Neuronal morphometry directly from bitmap images. Nat. Methods 11, 982&#x2013;984.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5271921</ArticleId><ArticleId IdType="pubmed">25264773</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu H, Possenti A, Freer R, Nakano Y, Villegas NCH, Tang M, Cauhy PVM, Lassus BA, Chen S, Fowler SL, et al. (2019). A tau homeostasis signature is linked with the cellular and regional vulnerability of excitatory neurons to tau pathology. Nat. Neurosci. 22, 47&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6330709</ArticleId><ArticleId IdType="pubmed">30559469</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao GP, Alvira MR, Wang L, Calcedo R, Johnston J, and Wilson JM (2002). Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc. Natl. Acad. Sci. U S A. 99, 11854&#x2013;11859.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC129358</ArticleId><ArticleId IdType="pubmed">12192090</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghorbani M, Mohamadpour AH, Mehri S, Abnous K, and Hassanzadeh-Khayyat M (2014). Proteomics screening of molecular targets of granulocyte colony stimulating factor in the mouse brain and PC12 cell line. Life Sci. 108, 44&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">24831556</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammond TR, Marsh SE, and Stevens B (2019). Immune signaling in neurodegeneration. Immunity 50, 955&#x2013;974.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6822103</ArticleId><ArticleId IdType="pubmed">30995509</ArticleId></ArticleIdList></Reference><Reference><Citation>Han J, Goldstein LA, Hou W, Watkins SC, and Rabinowich H (2021). Involvement of CASP9 (caspase 9) in IGF2R/CI-MPR endosomal transport. Autophagy 17, 1393&#x2013;1409.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8204962</ArticleId><ArticleId IdType="pubmed">32397873</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen DV, Hanson JE, and Sheng M (2018). Microglia in Alzheimer&#x2019;s disease. J. Cell Biol 217, 459&#x2013;472.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5800817</ArticleId><ArticleId IdType="pubmed">29196460</ArticleId></ArticleIdList></Reference><Reference><Citation>Heindl S, Gesierich B, Benakis C, Llovera G, Duering M, and Liesz A (2018). Automated morphological analysis of microglia after stroke. Front Cell Neurosci 12, 106.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5917008</ArticleId><ArticleId IdType="pubmed">29725290</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickman S, Izzy S, Sen P, Morsett L, and El Khoury J (2018). Microglia in neurodegeneration. Nat. Neurosci. 21, 1359&#x2013;1369.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6817969</ArticleId><ArticleId IdType="pubmed">30258234</ArticleId></ArticleIdList></Reference><Reference><Citation>Hinderer C, Bell P, Vite CH, Louboutin JP, Grant R, Bote E, Yu H, Pukenas B, Hurst R, and Wilson JM (2014). Widespread gene transfer in the central nervous system of cynomolgus macaques following delivery of AAV9 into the cisterna magna. Mol. Ther. Methods Clin. Dev. 1, 14051.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4448732</ArticleId><ArticleId IdType="pubmed">26052519</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong S, Beja-Glasser VF, Nfonoyim BM, Frouin A, LI S, Ramakrishnan S, Merry KM, Shi Q, Rosenthal A, Barres BA, et al. (2016a). Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science 352, 712&#x2013;716.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5094372</ArticleId><ArticleId IdType="pubmed">27033548</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong S, Dissing-Olesen L, and Stevens B (2016b). New insights on the role of microglia in synaptic pruning in health and disease. Curr. Opin. Neurobiol. 36, 128&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5479435</ArticleId><ArticleId IdType="pubmed">26745839</ArticleId></ArticleIdList></Reference><Reference><Citation>Hudry E, Martin C, Gandhi S, Gyorgy B, Scheffer DI, MU D, Merkel SF, Mingozzi F, Fitzpatrick Z, Dimant H, et al. (2016). Exosome-associated AAV vector as a robust and convenient neuroscience tool. Gene Ther. 23, 380&#x2013;392.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4824662</ArticleId><ArticleId IdType="pubmed">26836117</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Y, Mullaney KA, Peterhoff CM, Che S, Schmidt SD, Boyer-Boiteau A, Ginsberg SD, Cataldo AM, Mathews PM, and Nixon RA (2010). Alzheimer&#x2019;s-related endosome dysfunction in Down syndrome is Abeta-independent but requires APP and is reversed by BACE-1 inhibition. Proc. Natl. Acad. Sci. U S A. 107, 1630&#x2013;1635.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2824382</ArticleId><ArticleId IdType="pubmed">20080541</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanai K, Nunoya T, Shibuya K, Nakamura T, and Tajima M (1998). Variations in effectiveness of antigen retrieval pretreatments for diagnostic immunohistochemistry. Res. Vet. Sci. 64, 57&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">9557807</ArticleId></ArticleIdList></Reference><Reference><Citation>Karch CM, and Goate AM (2015). Alzheimer&#x2019;s disease risk genes and mechanisms of disease pathogenesis. Biol. Psychiatry 77, 43&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4234692</ArticleId><ArticleId IdType="pubmed">24951455</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H, Spinrad A, Weiner A, Matcovitch-Natan O, Dvir-Szternfeld R, Ulland TK, David E, Baruch K, Lara-Astaiso D, Toth B, et al. (2017). A unique microglia type Associated with restricting development of Alzheimer&#x2019;s disease. Cell 169, 1276&#x2013;1290.e17.</Citation><ArticleIdList><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirby ED, Kuwahara AA, Messer RL, and Wyss-Coray T (2015). Adult hippocampal neural stem and progenitor cells regulate the neurogenic niche by secreting VEGF. P.N.A.S. USA 112, 4128&#x2013;4133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4386397</ArticleId><ArticleId IdType="pubmed">25775598</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein RL, Hamby ME, Gong Y, Hirko AC, Wang S, Hughes JA, King MA, and Meyer EM (2002). Dose and promoter effects of adeno-associated viral vector for green fluorescent protein expression in the rat brain. Exp. Neurol. 176, 66&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">12093083</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovtun O, Leneva N, Bykov YS, Ariotti N, Teasdale RD, Schaffer M, Engel BD, Owen DJ, Briggs JAG, and Collins BM (2018). Structure of the membrane-assembled retromer coat determined by cryo-electron tomography. Nature 561, 561&#x2013;564.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6173284</ArticleId><ArticleId IdType="pubmed">30224749</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwart D, Gregg A, Scheckel C, Murphy E, Paquet D, Duffield M, Fak J, Olsen O, Darnell R, and Tessier-Lavigne M (2019). A large panel of isogenic APP and PSEN1 mutant human iPSC neurons reveals shared endosomal abnormalities mediated by APP beta-CTFs, not abeta. Neuron 104, 256&#x2013;270.</Citation><ArticleIdList><ArticleId IdType="pubmed">31416668</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauritzen I, Pardossi-Piquard R, Bauer C, Brigham E, Abraham JD, Ranaldi S, Fraser P, St-George-Hyslop P, Le Thuc O, Espin V, et al. (2012). The &#x3b2;-secretase-derived C-terminal fragment of &#x3b2;APP, C99, but not A&#x3b2;, is a key contributor to early intraneuronal lesions in triple-transgenic mouse hippocampus. J. Neurosci. 32, 16243&#x2013;16255.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5019353</ArticleId><ArticleId IdType="pubmed">23152608</ArticleId></ArticleIdList></Reference><Reference><Citation>Li JG, Chiu J, and Pratico D (2019a). Full recovery of the Alzheimer&#x2019;s disease phenotype by gain of function of vacuolar protein sorting 35. Mol. Psychiatry 25, 2630&#x2013;2640.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6685773</ArticleId><ArticleId IdType="pubmed">30733594</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q, Cheng Z, Zhou L, Darmanis S, Neff NF, Okamoto J, Gulati G, Bennett ML, Sun LO, Clarke LE, et al. (2019b). Developmental heterogeneity of microglia and brain myeloid cells revealed by deep single-cell RNA sequencing. Neuron 101, 207&#x2013;223.e10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6336504</ArticleId><ArticleId IdType="pubmed">30606613</ArticleId></ArticleIdList></Reference><Reference><Citation>Maccarrone G, Bonfiglio JJ, Silberstein S, Turck CW, and Martins-De-Souza D (2017). Characterization of a protein interactome by Co-immunoprecipitation and shotgun mass spectrometry. Methods Mol. Biol. 1546, 223&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">27896772</ArticleId></ArticleIdList></Reference><Reference><Citation>Mastakov MY, Baer K, Symes CW, Leichtlein CB, Kotin RM, and During MJ (2002). Immunological aspects of recombinant adeno-associated virus delivery to the mammalian brain. J. Virol. 76, 8446&#x2013;8454.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC155154</ArticleId><ArticleId IdType="pubmed">12134047</ArticleId></ArticleIdList></Reference><Reference><Citation>Mecozzi VJ, Berman DE, Simoes S, Vetanovetz C, Awal MR, Patel VM, Schneider RT, Petsko GA, Ringe D, and SMALL SA (2014). Pharmacological chaperones stabilize retromer to limit APP processing. Nat. Chem. Biol. 10, 443&#x2013;449.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4076047</ArticleId><ArticleId IdType="pubmed">24747528</ArticleId></ArticleIdList></Reference><Reference><Citation>Merezhko M, Brunello CA, Yan X, Vihinen H, Jokitalo E, Uronen RL, and Huttunen HJ (2018). Secretion of tau via an unconventional non-vesicular mechanism. Cell Rep 25, 2027&#x2013;2035 e4.</Citation><ArticleIdList><ArticleId IdType="pubmed">30463001</ArticleId></ArticleIdList></Reference><Reference><Citation>Mingozzi F, and High KA (2013). Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood 122, 23&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3701904</ArticleId><ArticleId IdType="pubmed">23596044</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishra S, Knupp A, Szabo M, Kinoshita C, Hailey DW, Wang Y, and Young JE (2021). The Alzheimer&#x2019;s gene SORL1 is a key regulator of endosomal recycling in human neurons. bioRxiv. 10.1101/2021.07.26.453861.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.07.26.453861</ArticleId><ArticleId IdType="pmc">PMC8885486</ArticleId><ArticleId IdType="pubmed">35226190</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrison HW, and Filosa JA (2013). A quantitative spatiotemporal analysis of microglia morphology during ischemic stroke and reperfusion. J. Neuroinflammation 10, 4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3570327</ArticleId><ArticleId IdType="pubmed">23311642</ArticleId></ArticleIdList></Reference><Reference><Citation>Navarro V, Sanchez-Mejias E, Jimenez S, Munoz-Castro C, Sanchez-Varo R, Davila JC, Vizuete M, Gutierrez A, and Vitorica J (2018). Microglia in Alzheimer&#x2019;s disease: activated, dysfunctional or degenerative. Front Aging Neurosci. 10, 140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5958192</ArticleId><ArticleId IdType="pubmed">29867449</ArticleId></ArticleIdList></Reference><Reference><Citation>Niklas J, Melnyk A, Yuan Y, and Heinzle E (2011). Selective permeabilization for the high-throughput measurement of compartmented enzyme activities in mammalian cells. Anal. Biochem. 416, 218&#x2013;227.</Citation><ArticleIdList><ArticleId IdType="pubmed">21683676</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon RA (2005). Endosome function and dysfunction in Alzheimer&#x2019;s disease and other neurodegenerative diseases. Neurobiol. Aging 26, 373&#x2013;382.</Citation><ArticleIdList><ArticleId IdType="pubmed">15639316</ArticleId></ArticleIdList></Reference><Reference><Citation>Pellicer EM, and Sundblad A (1994). [Antigen retrieval by microwave oven with buffer of citric acid]. Medicina (B Aires) 54, 129&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pubmed">7997128</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez BA, Shutterly A, Chan YK, Byrne BJ, and Corti M (2020). Management of neuroinflammatory responses to AAV-mediated gene therapies for neurodegenerative diseases. Brain Sci. 10, 119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7071492</ArticleId><ArticleId IdType="pubmed">32098339</ArticleId></ArticleIdList></Reference><Reference><Citation>Pluvinage JV, and Wyss-Coray T (2017). Microglial barriers to viral gene delivery. Neuron 93, 468&#x2013;470.</Citation><ArticleIdList><ArticleId IdType="pubmed">28182900</ArticleId></ArticleIdList></Reference><Reference><Citation>Qu W, Yuan B, Liu J, Liu Q, Zhang X, Cui R, Yang W, and Li B (2021). Emerging role of AMPA receptor subunit GluA1 in synaptic plasticity: implications for Alzheimer&#x2019;s disease. Cell Prolif 54, e12959.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7791177</ArticleId><ArticleId IdType="pubmed">33188547</ArticleId></ArticleIdList></Reference><Reference><Citation>Qureshi YH, Patel VM, Berman DE, Kothiya MJ, Neufeld JL, Vardarajan B, Tang M, Reyes-Dumeyer D, Lantigua R, Medrano M, et al. (2018). An Alzheimer&#x2019;s linked loss-of-function CLN5 variant impairs Cathepsin D maturation consistent with a retromer trafficking defect. Mol. Cell Biol 38, e00011&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6168984</ArticleId><ArticleId IdType="pubmed">30037983</ArticleId></ArticleIdList></Reference><Reference><Citation>Ransohoff RM (2016). How neuroinflammation contributes to neurodegeneration. Science 353, 777&#x2013;783.</Citation><ArticleIdList><ArticleId IdType="pubmed">27540165</ArticleId></ArticleIdList></Reference><Reference><Citation>Rojas R, Van Vlijmen T, Mardones GA, Prabhu Y, Rojas AL, Mohammed S, Heck AJ, Raposo G, Van Der Sluijs P, and Bonifacino JS (2008). Regulation of retromer recruitment to endosomes by sequential action of Rab5 and Rab7. J. Cell Biol 183, 513&#x2013;526.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2575791</ArticleId><ArticleId IdType="pubmed">18981234</ArticleId></ArticleIdList></Reference><Reference><Citation>Salter MW, and Stevens B (2017). Microglia emerge as central players in brain disease. Nat. Med. 23, 1018&#x2013;1027.</Citation><ArticleIdList><ArticleId IdType="pubmed">28886007</ArticleId></ArticleIdList></Reference><Reference><Citation>Samaranch L, Salegio EA, San Sebastian W, Kells AP, Foust KD, Bringas JR, Lamarre C, Forsayeth J, Kaspar BK, and Bankiewicz KS (2012). Adeno-associated virus serotype 9 transduction in the central nervous system of nonhuman primates. Hum. Gene Ther. 23, 382&#x2013;389.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3327605</ArticleId><ArticleId IdType="pubmed">22201473</ArticleId></ArticleIdList></Reference><Reference><Citation>Samaranch L, Sebastian WS, Kells AP, Salegio EA, Heller G, Bringas JR, Pivirotto P, Dearmond S, Forsayeth J, and Bankiewicz KS (2014). AAV9-mediated expression of a non-self protein in nonhuman primate central nervous system triggers widespread neuroinflammation driven by antigen-presenting cell transduction. Mol. Ther. 22, 329&#x2013;337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3918916</ArticleId><ArticleId IdType="pubmed">24419081</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuster DJ, Dykstra JA, Riedl MS, Kitto KF, Belur l.R., Mcivor RS, Elde RP, Fairbanks CA, and Vulchanova L (2014). Biodistribution of adeno-associated virus serotype 9 (AAV9) vector after intrathecal and intravenous delivery in mouse. Front Neuroanat. 8, 42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4051274</ArticleId><ArticleId IdType="pubmed">24959122</ArticleId></ArticleIdList></Reference><Reference><Citation>Seaman MN (2005). Recycle your receptors with retromer. Trends Cell Biol 15, 68&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">15695093</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ (2002). Alzheimer&#x2019;s disease is a synaptic failure. Science 298, 789&#x2013;791.</Citation><ArticleIdList><ArticleId IdType="pubmed">12399581</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahidehpour RK, Higdon RE, Crawford NG, Neltner JH, Ighodaro ET, Patel E, Price D, Nelson PT, and Bachstetter AD (2021). Dystrophic microglia are associated with neurodegenerative disease and not healthy aging in the human brain. Neurobiol. Aging 99, 19&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8293930</ArticleId><ArticleId IdType="pubmed">33422891</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi SR, Chaiwun B, Young L, Cote RJ, and Taylor CR (1993). Antigen retrieval technique utilizing citrate buffer or urea solution for immunohistochemical demonstration of androgen receptor in formalin-fixed paraffin sections. J. Histochem. Cytochem. 41, 1599&#x2013;1604.</Citation><ArticleIdList><ArticleId IdType="pubmed">7691930</ArticleId></ArticleIdList></Reference><Reference><Citation>Sholl DA (1953). Dendritic organization in the neurons of the visual and motor cortices of the cat. J. Anat. 87, 387&#x2013;406.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1244622</ArticleId><ArticleId IdType="pubmed">13117757</ArticleId></ArticleIdList></Reference><Reference><Citation>Simoes S, Neufeld JL, Triana-Baltzer G, Moughadam S, Chen EI, Kothiya M, Qureshi YH, Patel V, Honig LS, Kolb H, and Small SA (2020). Tau and other proteins found in Alzheimer&#x2019;s disease spinal fluid are linked to retromer-mediated endosomal traffic in mice and humans. Sci. Transl Med. 12, eaba6334.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7901670</ArticleId><ArticleId IdType="pubmed">33239387</ArticleId></ArticleIdList></Reference><Reference><Citation>Sipe GO, Lowery RL, Tremblay M, Kelly EA, Lamantia CE, and Majewska AK (2016). Microglial P2Y12 is necessary for synaptic plasticity in mouse visual cortex. Nat. Commun. 7, 10905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4786684</ArticleId><ArticleId IdType="pubmed">26948129</ArticleId></ArticleIdList></Reference><Reference><Citation>Small SA, and Petsko GA (2015). Retromer in Alzheimer disease, Parkinson disease and other neurological disorders. Nat. Rev. Neurosci. 16, 126&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pubmed">25669742</ArticleId></ArticleIdList></Reference><Reference><Citation>Small SA, and Petsko GA (2020). Endosomal recycling reconciles the Alzheimer&#x2019;s disease paradox. Sci. Transl Med. 12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8025181</ArticleId><ArticleId IdType="pubmed">33268506</ArticleId></ArticleIdList></Reference><Reference><Citation>Small SA, Simoes-Spassov S, Mayeux R, and Petsko GA (2017). Endosomal traffic jams represent a pathogenic hub and therapeutic target in Alzheimer&#x2019;s disease. Trends Neurosci. 40, 592&#x2013;602.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5654621</ArticleId><ArticleId IdType="pubmed">28962801</ArticleId></ArticleIdList></Reference><Reference><Citation>Song WM, and Colonna M (2018). The identity and function of microglia in neurodegeneration. Nat. Immunol. 19, 1048&#x2013;1058.</Citation><ArticleIdList><ArticleId IdType="pubmed">30250185</ArticleId></ArticleIdList></Reference><Reference><Citation>Streit WJ, Braak H, Xue QS, and Bechmann I (2009). Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer&#x2019;s disease. Acta Neuropathol. 118, 475&#x2013;485.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2737117</ArticleId><ArticleId IdType="pubmed">19513731</ArticleId></ArticleIdList></Reference><Reference><Citation>Streit WJ, Khoshbouei H, and Bechmann I (2020). Dystrophic microglia in late-onset Alzheimer&#x2019;s disease. Glia 68, 845&#x2013;854.</Citation><ArticleIdList><ArticleId IdType="pubmed">31922322</ArticleId></ArticleIdList></Reference><Reference><Citation>Takatori S, Wang W, Iguchi A, and Tomita T (2019). Genetic risk factors for alzheimer disease: emerging roles of microglia in disease pathomechanisms. In Reviews on Biomarker Studies in Psychiatric and Neurodegenerative Disorders, GUEST PC, ed. (Cham: Springer International Publishing; ), pp. 83&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pubmed">30747419</ArticleId></ArticleIdList></Reference><Reference><Citation>Temkin P, Morishita W, Goswami D, Arendt K, Chen L, and Malenka R (2017). The retromer supports AMPA receptor trafficking during LTP. Neuron 94, 74&#x2013;82 e5.</Citation><ArticleIdList><ArticleId IdType="pubmed">28384478</ArticleId></ArticleIdList></Reference><Reference><Citation>Thonberg H, Chiang HH, Lilius L, Forsell C, Lindstr&#xf6;m AK, Johansson C, Bj&#xf6;rkstr&#xf6;m J, Thordardottir S, Sleegers K, Van Broeckhoven C, et al. (2017). Identification and description of three families with familial Alzheimer disease that segregate variants in the SORL1 gene. Acta Neuropathol. Commun. 5, 43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5465543</ArticleId><ArticleId IdType="pubmed">28595629</ArticleId></ArticleIdList></Reference><Reference><Citation>Tischer J, Krueger M, Mueller W, Staszewski O, Prinz M, Streit WJ, and Bechmann I (2016). Inhomogeneous distribution of Iba-1 characterizes microglial pathology in Alzheimer&#x2019;s disease. Glia 64, 1562&#x2013;1572.</Citation><ArticleIdList><ArticleId IdType="pubmed">27404378</ArticleId></ArticleIdList></Reference><Reference><Citation>Vagnozzi AN, Li JG, Chiu J, Razmpour R, Warfield R, Ramirez SH, and Pratico D (2019). VPS35 regulates tau phosphorylation and neuropathology in tauopathy. Mol. Psychiatry 6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6949432</ArticleId><ArticleId IdType="pubmed">31289348</ArticleId></ArticleIdList></Reference><Reference><Citation>Wakabayashi K, Narisawa-Saito M, Iwakura Y, Arai T, Ikeda K, Takahashi H, and Nawa H (1999). Phenotypic down-regulation of glutamate receptor subunit GluR1 in Alzheimer&#x2019;s disease. Neurobiol. Aging 20, 287&#x2013;295.</Citation><ArticleIdList><ArticleId IdType="pubmed">10588576</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang DB, Dayton RD, Henning PP, Cain CD, Zhao LR, Schrott LM, Orchard EA, Knight DS, and Klein RL (2010). Expansive gene transfer in the rat CNS rapidly produces amyotrophic lateral sclerosis relevant sequelae when TDP-43 is overexpressed. Mol. Ther. 18, 2064&#x2013;2074.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2997590</ArticleId><ArticleId IdType="pubmed">20877346</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen L, Tang FL, Hong Y, Luo SW, Wang CL, He W, Shen C, Jung JU, Xiong F, Lee DH, et al. (2011). VPS35 haploinsufficiency increases Alzheimer&#x2019;s disease neuropathology. J. Cell Biol 195, 765&#x2013;779.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3257571</ArticleId><ArticleId IdType="pubmed">22105352</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilton DK, Dissing-Olesen L, and Stevens B (2019). Neuron-glia signaling in synapse elimination. Annu. Rev. Neurosci. 42, 107&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pubmed">31283900</ArticleId></ArticleIdList></Reference><Reference><Citation>Wittenberg GM, and Tsien JZ (2002). An emerging molecular and cellular framework for memory processing by the hippocampus. Trends Neurosci. 25, 501&#x2013;505.</Citation><ArticleIdList><ArticleId IdType="pubmed">12220877</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasuda RP, Ikonomovic MD, Sheffield R, Rubin RT, Wolfe BB, and Armstrong DM (1995). Reduction of AMPA-selective glutamate receptor subunits in the entorhinal cortex of patients with Alzheimer&#x2019;s disease pathology: a biochemical study. Brain Res. 678, 161&#x2013;167.</Citation><ArticleIdList><ArticleId IdType="pubmed">7542540</ArticleId></ArticleIdList></Reference><Reference><Citation>Young JE, Fong LK, Frankowski H, Petsko GA, Small SA, and Goldstein LSB (2018). Stabilizing the retromer complex in a human stem cell model of Alzheimer&#x2019;s disease reduces TAU phosphorylation independently of amyloid precursor protein. Stem Cell Rep. 10, 1046&#x2013;1058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5919412</ArticleId><ArticleId IdType="pubmed">29503090</ArticleId></ArticleIdList></Reference><Reference><Citation>Zetterberg H (2017). Review: tau in biofluids - relation to pathology, imaging and clinical features. Neuropathol. Appl. Neurobiol. 43, 194&#x2013;199.</Citation><ArticleIdList><ArticleId IdType="pubmed">28054371</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Chen K, Sloan SA, Bennett ML, Scholze AR, O&#x2019;keeffe S, Phatnani HP, Guarnieri P, Caneda C, Ruderisch N, et al. (2014). An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J. Neurosci. 34, 11929&#x2013;11947.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4152602</ArticleId><ArticleId IdType="pubmed">25186741</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Sloan SA, Clarke LE, Caneda C, Plaza CA, Blumenthal PD, Vogel H, Steinberg GK, Edwards MS, Li G, et al. (2016). Purification and characterization of progenitor and mature human astrocytes reveals transcriptional and functional differences with mouse. Neuron 89, 37&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4707064</ArticleId><ArticleId IdType="pubmed">26687838</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35072712</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>79</Volume><Issue>3</Issue><PubDate><Year>2022</Year><Month>Mar</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Association of Ischemic Stroke Incidence, Severity, and Recurrence With Dementia in the Atherosclerosis Risk in Communities Cohort Study.</ArticleTitle><Pagination><StartPage>271</StartPage><EndPage>280</EndPage><MedlinePgn>271-280</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2021.5080</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Ischemic stroke is associated with increased risk of dementia, but the association of stroke severity and recurrence with risk of impaired cognition is not well known.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To examine the risk of dementia after incident ischemic stroke and assess how it differed by stroke severity and recurrence.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">The Atherosclerosis Risk in Communities (ARIC) study is an ongoing prospective cohort of 15&#x202f;792 community-dwelling individuals from 4 US states (Mississippi, Maryland, Minnesota, and North Carolina). Among them, 15&#x202f;379 participants free of stroke and dementia at baseline (1987 to 1989) were monitored through 2019. Data were analyzed from April to October 2021. Associations between dementia and time-varying ischemic stroke incidence, frequency, and severity were studied across an average of 4.4 visits over a median follow-up of 25.5 years with Cox proportional hazards models adjusted for sociodemographic characteristics, apolipoprotein E, and vascular risk factors.</AbstractText><AbstractText Label="EXPOSURES" NlmCategory="METHODS">Incident and recurrent ischemic strokes were classified by expert review of hospital records, with severity defined by the National Institutes of Health Stroke Scale (NIHSS; minor, &#x2264;5; mild, 6-10; moderate, 11-15; and severe, &#x2265;16).</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="METHODS">Dementia cases adjudicated through expert review of in-person evaluations, informant interviews, telephone assessments, hospitalization codes, and death certificates. In participants with stroke, dementia events in the first year after stroke were not counted.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">At baseline, the mean (SD) age of participants was 54.1 (5.8) years, and 8485 of 15&#x202f;379 participants (55.2%) were women. A total of 4110 participants (26.7%) were Black and 11&#x202f;269 (73.3%) were White. A total of 1378 ischemic strokes (1155 incident) and 2860 dementia cases were diagnosed 1 year or more after incident stroke in participants with stroke, or at any point after baseline in participants without stroke, were identified through December 31, 2019. NIHSS scores were available for 1184 of 1378 ischemic strokes (85.9%). Risk of dementia increased with both the number and severity of strokes. Compared with no stroke, risk of dementia by adjusted hazard ratio was 1.76 (95% CI, 1.49-2.00) for 1 minor to mild stroke, 3.47 (95% CI, 2.23-5.40) for 1 moderate to severe stroke, 3.48 (95% CI, 2.54-4.76) for 2 or more minor to mild strokes, and 6.68 (95% CI, 3.77-11.83) for 2 or more moderate to severe strokes.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">In this study, risk of dementia significantly increased after ischemic stroke, independent of vascular risk factors. Results suggest a dose-response association of stroke severity and recurrence with risk of dementia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Koton</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Nursing, The Stanley Steyer School of Health Professions, Tel Aviv University, Tel Aviv, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, Johns Hopkins University School of Public Health, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pike</LastName><ForeName>James Russell</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, University of North Carolina, Chapel Hill.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johansen</LastName><ForeName>Michelle</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knopman</LastName><ForeName>David S</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lakshminarayan</LastName><ForeName>Kamakshi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mosley</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Mississippi Medical Center, Jackson.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patole</LastName><ForeName>Shalom</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Johns Hopkins University School of Public Health, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosamond</LastName><ForeName>Wayne D</ForeName><Initials>WD</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, University of North Carolina, Chapel Hill.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Andrea L C</ForeName><Initials>ALC</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharrett</LastName><ForeName>A Richey</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Johns Hopkins University School of Public Health, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wruck</LastName><ForeName>Lisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Duke Clinical Research Institute, Durham, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coresh</LastName><ForeName>Josef</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Johns Hopkins University School of Public Health, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gottesman</LastName><ForeName>Rebecca F</ForeName><Initials>RF</Initials><AffiliationInfo><Affiliation>Stroke Branch, National Institute of Neurological Disorders and Stroke Intramural Research Program, National Institutes of Health, Bethesda, Maryland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01 HL096812</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 AG052573</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201700001I</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL096902</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201700005I</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL096899</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201700003I</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL096814</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL096917</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201700004I</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 NS112459</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201700002I</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL070825</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D050197" MajorTopicYN="Y">Atherosclerosis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="Y">Dementia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000083242" MajorTopicYN="Y">Ischemic Stroke</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020521" MajorTopicYN="Y">Stroke</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Pike reported grants from National Institutes of Health during the conduct of the study. Dr Johansen reported grants from National Institute of Neurological Disorders and Stroke Mentored Patient-Oriented Research Career Development Award (K23) outside the submitted work. Dr Knopman reported grants from Biogen and Lilly outside the submitted work; serves on a data safety monitoring board for the Dominantly Inherited Alzheimer Network (DIAN) study; serves on a data safety monitoring board for Biogen but receives no personal compensation; is funded as a site principal investigator by the University of Southern California; has served as a consultant for Roche, Samus Therapeutics, Third Rock, and Alzeca Biosciences but receives no personal compensation; and receives funding from the National Institutes of Health. Dr Lakshminarayan reported grants from the National Institutes of Health University of North Carolina subaward and grants from the National Institutes of Health during the conduct of the study. Dr Mosley reported grants from the National Institutes of Health during the conduct of the study. Dr Coresh reported grants from the National Institutes of Health during the conduct of the study. Dr Gottesman reported formerly serving as Associate Editor of the <i>Journal of the American Academy of Neurology</i> outside the submitted work. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>1</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>1</Month><Day>24</Day><Hour>12</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>1</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35072712</ArticleId><ArticleId IdType="pmc">PMC8787684</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2021.5080</ArticleId><ArticleId IdType="pii">2787973</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>De Ronchi D, Palmer K, Pioggiosi P, et al. . The combined effect of age, education, and stroke on dementia and cognitive impairment no dementia in the elderly. Dement Geriatr Cogn Disord. 2007;24(4):266-273. doi:10.1159/000107102</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000107102</ArticleId><ArticleId IdType="pubmed">17700023</ArticleId></ArticleIdList></Reference><Reference><Citation>Mijajlovi&#x107; MD, Pavlovi&#x107; A, Brainin M, et al. . Post-stroke dementia&#x2014;a comprehensive review. BMC Med. 2017;15(1):11. doi:10.1186/s12916-017-0779-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-017-0779-7</ArticleId><ArticleId IdType="pmc">PMC5241961</ArticleId><ArticleId IdType="pubmed">28095900</ArticleId></ArticleIdList></Reference><Reference><Citation>Pendlebury ST, Rothwell PM; Oxford Vascular Study . Incidence and prevalence of dementia associated with transient ischaemic attack and stroke: analysis of the population-based Oxford Vascular Study. Lancet Neurol. 2019;18(3):248-258. doi:10.1016/S1474-4422(18)30442-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30442-3</ArticleId><ArticleId IdType="pmc">PMC6390174</ArticleId><ArticleId IdType="pubmed">30784556</ArticleId></ArticleIdList></Reference><Reference><Citation>Pendlebury ST, Chen PJ, Welch SJ, et al. ; Oxford Vascular Study . Methodological factors in determining risk of dementia after transient ischemic attack and stroke: (II) effect of attrition on follow-up. Stroke. 2015;46(6):1494-1500. doi:10.1161/STROKEAHA.115.009065</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/STROKEAHA.115.009065</ArticleId><ArticleId IdType="pmc">PMC5117256</ArticleId><ArticleId IdType="pubmed">25953366</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottesman RF, Hillis AE. Predictors and assessment of cognitive dysfunction resulting from ischaemic stroke. Lancet Neurol. 2010;9(9):895-905. doi:10.1016/S1474-4422(10)70164-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70164-2</ArticleId><ArticleId IdType="pmc">PMC3592203</ArticleId><ArticleId IdType="pubmed">20723846</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottesman RF, Albert MS, Alonso A, et al. . Associations between midlife vascular risk factors and 25-year incident dementia in the Atherosclerosis Risk in Communities (ARIC) cohort. JAMA Neurol. 2017;74(10):1246-1254. doi:10.1001/jamaneurol.2017.1658</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2017.1658</ArticleId><ArticleId IdType="pmc">PMC5710244</ArticleId><ArticleId IdType="pubmed">28783817</ArticleId></ArticleIdList></Reference><Reference><Citation>Callisaya ML, Purvis T, Lawler K, Brodtmann A, Cadilhac DA, Kilkenny MF. Dementia is associated with poorer quality of care and outcomes after stroke: an observational study. J Gerontol A Biol Sci Med Sci. 2021;76(5):851-858. doi:10.1093/gerona/glaa139</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/gerona/glaa139</ArticleId><ArticleId IdType="pubmed">32498086</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnellan C, Werring D. Cognitive impairment before and after intracerebral haemorrhage: a systematic review. Neurol Sci. 2020;41(3):509-527. doi:10.1007/s10072-019-04150-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-019-04150-5</ArticleId><ArticleId IdType="pubmed">31802344</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman DS, Gottesman RF, Sharrett AR, et al. . Mild cognitive impairment and dementia prevalence: the Atherosclerosis Risk in Communities Neurocognitive Study (ARIC-NCS). Alzheimers Dement (Amst). 2016;2:1-11. doi:10.1016/j.dadm.2015.12.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dadm.2015.12.002</ArticleId><ArticleId IdType="pmc">PMC4772876</ArticleId><ArticleId IdType="pubmed">26949733</ArticleId></ArticleIdList></Reference><Reference><Citation>The ARIC investigators . The Atherosclerosis Risk in Communities (ARIC) study: design and objectives. Am J Epidemiol. 1989;129(4):687-702. doi:10.1093/oxfordjournals.aje.a115184</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/oxfordjournals.aje.a115184</ArticleId><ArticleId IdType="pubmed">2646917</ArticleId></ArticleIdList></Reference><Reference><Citation>Koton S, Schneider AL, Rosamond WD, et al. . Stroke incidence and mortality trends in US communities, 1987 to 2011. JAMA. 2014;312(3):259-268. doi:10.1001/jama.2014.7692</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2014.7692</ArticleId><ArticleId IdType="pubmed">25027141</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosamond WD, Folsom AR, Chambless LE, et al. . Stroke incidence and survival among middle-aged adults: 9-year follow-up of the Atherosclerosis Risk in Communities (ARIC) cohort. Stroke. 1999;30(4):736-743. doi:10.1161/01.STR.30.4.736</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.STR.30.4.736</ArticleId><ArticleId IdType="pubmed">10187871</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruban A, Daya N, Schneider ALC, et al. . Liver enzymes and risk of stroke: the Atherosclerosis Risk in Communities (ARIC) study. J Stroke. 2020;22(3):357-368. doi:10.5853/jos.2020.00290</Citation><ArticleIdList><ArticleId IdType="doi">10.5853/jos.2020.00290</ArticleId><ArticleId IdType="pmc">PMC7568972</ArticleId><ArticleId IdType="pubmed">33053951</ArticleId></ArticleIdList></Reference><Reference><Citation>Gross AL, Power MC, Albert MS, et al. . Application of latent variable methods to the study of cognitive decline when tests change over time. Epidemiology. 2015;26(6):878-887. doi:10.1097/EDE.0000000000000379</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/EDE.0000000000000379</ArticleId><ArticleId IdType="pmc">PMC4819068</ArticleId><ArticleId IdType="pubmed">26414855</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman DS, Gottesman RF, Sharrett AR, et al. . Midlife vascular risk factors and midlife cognitive status in relation to prevalence of mild cognitive impairment and dementia in later life: the Atherosclerosis Risk in Communities study. Alzheimers Dement. 2018;14(11):1406-1415. doi:10.1016/j.jalz.2018.03.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.03.011</ArticleId><ArticleId IdType="pmc">PMC6231996</ArticleId><ArticleId IdType="pubmed">29763593</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindsell CJ, Alwell K, Moomaw CJ, et al. . Validity of a retrospective National Institutes of Health Stroke Scale scoring methodology in patients with severe stroke. J Stroke Cerebrovasc Dis. 2005;14(6):281-283. doi:10.1016/j.jstrokecerebrovasdis.2005.08.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jstrokecerebrovasdis.2005.08.004</ArticleId><ArticleId IdType="pubmed">17904038</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams LS, Yilmaz EY, Lopez-Yunez AM. Retrospective assessment of initial stroke severity with the NIH Stroke Scale. Stroke. 2000;31(4):858-862. doi:10.1161/01.STR.31.4.858</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.STR.31.4.858</ArticleId><ArticleId IdType="pubmed">10753988</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman DS, Ryberg S. A verbal memory test with high predictive accuracy for dementia of the Alzheimer type. Arch Neurol. 1989;46(2):141-145. doi:10.1001/archneur.1989.00520380041011</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.1989.00520380041011</ArticleId><ArticleId IdType="pubmed">2916953</ArticleId></ArticleIdList></Reference><Reference><Citation>Benton A., Hamsher K. Multilingual Aphasia Examination. University of Iowa; 1976.</Citation></Reference><Reference><Citation>Wechsler, D. Wechsler Memory Scale-Revised. Psychological Corporation; 1987.</Citation></Reference><Reference><Citation>Simon R, Makuch RW. A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non-responder bias. Stat Med. 1984;3(1):35-44. doi:10.1002/sim.4780030106</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.4780030106</ArticleId><ArticleId IdType="pubmed">6729287</ArticleId></ArticleIdList></Reference><Reference><Citation>Benichou J. A review of adjusted estimators of attributable risk. Stat Methods Med Res. 2001;10(3):195-216. doi:10.1177/096228020101000303</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/096228020101000303</ArticleId><ArticleId IdType="pubmed">11446148</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox DR. Regression models and life-tables. J R Stat Soc Ser A Stat Soc. 1972;34(2):187-202. http://www.jstor.org/stable/2985181</Citation></Reference><Reference><Citation>Fine JP, Gray RJ. A Proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496-509. doi:10.1080/01621459.1999.10474144</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/01621459.1999.10474144</ArticleId></ArticleIdList></Reference><Reference><Citation>Enders CK, Keller BT, Levy R. A fully conditional specification approach to multilevel imputation of categorical and continuous variables. Psychol Methods. 2018;23(2):298-317. doi:10.1037/met0000148</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/met0000148</ArticleId><ArticleId IdType="pubmed">28557466</ArticleId></ArticleIdList></Reference><Reference><Citation>von Hippel PT. How many imputations do you need? a two-stage calculation using a quadratic rule. Sociol Methods Res. 2020;49(3):699-718. doi:10.1177/0049124117747303</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0049124117747303</ArticleId><ArticleId IdType="pmc">PMC11361408</ArticleId><ArticleId IdType="pubmed">39211325</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine DA, Galecki AT, Langa KM, et al. . Trajectory of cognitive decline after incident stroke. JAMA. 2015;314(1):41-51. doi:10.1001/jama.2015.6968</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2015.6968</ArticleId><ArticleId IdType="pmc">PMC4655087</ArticleId><ArticleId IdType="pubmed">26151265</ArticleId></ArticleIdList></Reference><Reference><Citation>Censori B, Manara O, Agostinis C, et al. . Dementia after first stroke. Stroke. 1996;27(7):1205-1210. doi:10.1161/01.STR.27.7.1205</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.STR.27.7.1205</ArticleId><ArticleId IdType="pubmed">8685929</ArticleId></ArticleIdList></Reference><Reference><Citation>Desmond DW, Moroney JT, Paik MC, et al. . Frequency and clinical determinants of dementia after ischemic stroke. Neurology. 2000;54(5):1124-1131. doi:10.1212/WNL.54.5.1124</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.54.5.1124</ArticleId><ArticleId IdType="pubmed">10720286</ArticleId></ArticleIdList></Reference><Reference><Citation>Liman TG, Heuschmann PU, Endres M, Fl&#xf6;el A, Schwab S, Kolominsky-Rabas PL. Changes in cognitive function over 3 years after first-ever stroke and predictors of cognitive impairment and long-term cognitive stability: the Erlangen Stroke Project. Dement Geriatr Cogn Disord. 2011;31(4):291-299. doi:10.1159/000327358</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000327358</ArticleId><ArticleId IdType="pubmed">21502760</ArticleId></ArticleIdList></Reference><Reference><Citation>Douiri A, Rudd AG, Wolfe CD. Prevalence of poststroke cognitive impairment: South London Stroke Register 1995-2010. Stroke. 2013;44(1):138-145. doi:10.1161/STROKEAHA.112.670844</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/STROKEAHA.112.670844</ArticleId><ArticleId IdType="pubmed">23150656</ArticleId></ArticleIdList></Reference><Reference><Citation>Portegies ML, Wolters FJ, Hofman A, Ikram MK, Koudstaal PJ, Ikram MA. Prestroke vascular pathology and the risk of recurrent stroke and poststroke dementia. Stroke. 2016;47(8):2119-2122. doi:10.1161/STROKEAHA.116.014094</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/STROKEAHA.116.014094</ArticleId><ArticleId IdType="pubmed">27418596</ArticleId></ArticleIdList></Reference><Reference><Citation>Ihle-Hansen H, Thommessen B, Fagerland MW, et al. . Multifactorial vascular risk factor intervention to prevent cognitive impairment after stroke and TIA: a 12-month randomized controlled trial. Int J Stroke. 2014;9(7):932-938. doi:10.1111/j.1747-4949.2012.00928.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1747-4949.2012.00928.x</ArticleId><ArticleId IdType="pubmed">23205666</ArticleId></ArticleIdList></Reference><Reference><Citation>Rist PM, Chalmers J, Arima H, et al. . Baseline cognitive function, recurrent stroke, and risk of dementia in patients with stroke. Stroke. 2013;44(7):1790-1795. doi:10.1161/STROKEAHA.111.680728</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/STROKEAHA.111.680728</ArticleId><ArticleId IdType="pmc">PMC3695012</ArticleId><ArticleId IdType="pubmed">23686974</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xe9;non H, Durieu I, Guerouaou D, Lebert F, Pasquier F, Leys D. Poststroke dementia: incidence and relationship to prestroke cognitive decline. Neurology. 2001;57(7):1216-1222. doi:10.1212/WNL.57.7.1216</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.57.7.1216</ArticleId><ArticleId IdType="pubmed">11591838</ArticleId></ArticleIdList></Reference><Reference><Citation>Nys GM, van Zandvoort MJ, de Kort PL, Jansen BP, de Haan EH, Kappelle LJ. Cognitive disorders in acute stroke: prevalence and clinical determinants. Cerebrovasc Dis. 2007;23(5-6):408-416. doi:10.1159/000101464</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000101464</ArticleId><ArticleId IdType="pubmed">17406110</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin JH, Lin RT, Tai CT, Hsieh CL, Hsiao SF, Liu CK. Prediction of poststroke dementia. Neurology. 2003;61(3):343-348. doi:10.1212/01.WNL.0000078891.27052.10</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000078891.27052.10</ArticleId><ArticleId IdType="pubmed">12913195</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou DH, Wang JY, Li J, Deng J, Gao C, Chen M. Study on frequency and predictors of dementia after ischemic stroke: the Chongqing stroke study. J Neurol. 2004;251(4):421-427. doi:10.1007/s00415-004-0337-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-004-0337-z</ArticleId><ArticleId IdType="pubmed">15083286</ArticleId></ArticleIdList></Reference><Reference><Citation>Viticchi G, Falsetti L, Plutino A, Bartolini M, Buratti L, Silvestrini M. Sex influence in ischemic stroke severity and outcome among metabolically unhealthy overweight patients. J Neurol Sci. 2020;416:116955. doi:10.1016/j.jns.2020.116955</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2020.116955</ArticleId><ArticleId IdType="pubmed">32540509</ArticleId></ArticleIdList></Reference><Reference><Citation>Appelros P, Nydevik I, Seiger A, Ter&#xe9;nt A. Predictors of severe stroke: influence of preexisting dementia and cardiac disorders. Stroke. 2002;33(10):2357-2362. doi:10.1161/01.STR.0000030318.99727.FA</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.STR.0000030318.99727.FA</ArticleId><ArticleId IdType="pubmed">12364721</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung SH, Ebaid D, Kramer S, et al. . Pre-stroke physical activity and admission stroke severity: a systematic review. Int J Stroke. 2021:16(9):1009-1018. doi:10.1177/1747493021995271</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1747493021995271</ArticleId><ArticleId IdType="pubmed">33527883</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleindorfer D, Lindsell C, Alwell KA, et al. . Patients living in impoverished areas have more severe ischemic strokes. Stroke. 2012;43(8):2055-2059. doi:10.1161/STROKEAHA.111.649608</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/STROKEAHA.111.649608</ArticleId><ArticleId IdType="pmc">PMC3432858</ArticleId><ArticleId IdType="pubmed">22773557</ArticleId></ArticleIdList></Reference><Reference><Citation>Vivanco-Hidalgo RM, Avellaneda-Gomez C, Dadvand P, et al. . Association of residential air pollution, noise, and greenspace with initial ischemic stroke severity. Environ Res. 2019;179(Pt A):108725. doi:10.1016/j.envres.2019.108725</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.envres.2019.108725</ArticleId><ArticleId IdType="pubmed">31539843</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xe9;jot Y, Duloquin G, Crespy V, et al. . Influence of preexisting cognitive impairment on clinical severity of ischemic stroke: the Dijon Stroke Registry. Stroke. 2020;51(6):1667-1673. doi:10.1161/STROKEAHA.119.028845</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/STROKEAHA.119.028845</ArticleId><ArticleId IdType="pubmed">32397931</ArticleId></ArticleIdList></Reference><Reference><Citation>Helenius J, Goddeau RP Jr, Moonis M, Henninger N. Impact of leukoaraiosis burden on hemispheric lateralization of the National Institutes of Health Stroke Scale deficit in acute ischemic stroke. Stroke. 2016;47(1):24-30. doi:10.1161/STROKEAHA.115.011771</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/STROKEAHA.115.011771</ArticleId><ArticleId IdType="pubmed">26556825</ArticleId></ArticleIdList></Reference><Reference><Citation>Helenius J, Henninger N. Leukoaraiosis burden significantly modulates the association between infarct volume and National Institutes of Health Stroke Scale in ischemic stroke. Stroke. 2015;46(7):1857-1863. doi:10.1161/STROKEAHA.115.009258</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/STROKEAHA.115.009258</ArticleId><ArticleId IdType="pubmed">25999386</ArticleId></ArticleIdList></Reference><Reference><Citation>Koton S, Schneider ALC, Windham BG, Mosley TH, Gottesman RF, Coresh J. Microvascular brain disease progression and risk of stroke: the ARIC study. Stroke. 2020;51(11):3264-3270. doi:10.1161/STROKEAHA.120.030063</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/STROKEAHA.120.030063</ArticleId><ArticleId IdType="pmc">PMC7769118</ArticleId><ArticleId IdType="pubmed">32998653</ArticleId></ArticleIdList></Reference><Reference><Citation>Koton S, Sang Y, Schneider ALC, Rosamond WD, Gottesman RF, Coresh J. Trends in stroke incidence rates in older US adults: an update from the Atherosclerosis Risk in Communities (ARIC) cohort study. JAMA Neurol. 2020;77(1):109-113. doi:10.1001/jamaneurol.2019.3258</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2019.3258</ArticleId><ArticleId IdType="pmc">PMC6777233</ArticleId><ArticleId IdType="pubmed">31566685</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35065037</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>21</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1474-4465</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>2</Issue><PubDate><Year>2022</Year><Month>Feb</Month></PubDate></JournalIssue><Title>The Lancet. Neurology</Title><ISOAbbreviation>Lancet Neurol</ISOAbbreviation></Journal><ArticleTitle>Variant-dependent heterogeneity in amyloid &#x3b2; burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study.</ArticleTitle><Pagination><StartPage>140</StartPage><EndPage>152</EndPage><MedlinePgn>140-152</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1474-4422(21)00375-6</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1474-4422(21)00375-6</ELocationID><Abstract><AbstractText Label="BACKGROUND">Insights gained from studying individuals with autosomal dominant Alzheimer's disease have broadly influenced mechanistic hypotheses, biomarker development, and clinical trials in both sporadic and dominantly inherited Alzheimer's disease. Although pathogenic variants causing autosomal dominant Alzheimer's disease are highly penetrant, there is substantial heterogeneity in levels of amyloid &#x3b2; (A&#x3b2;) between individuals. We aimed to examine whether this heterogeneity is related to disease progression and to investigate the association with mutation location within PSEN1, PSEN2, or APP.</AbstractText><AbstractText Label="METHODS">We did cross-sectional and longitudinal analyses of data from the Dominantly Inherited Alzheimer's Network (DIAN) observational study, which enrols individuals from families affected by autosomal dominant Alzheimer's disease. 340 participants in the DIAN study who were aged 18 years or older, had a history of autosomal dominant Alzheimer's disease in their family, and who were enrolled between September, 2008, and June, 2019, were included in our analysis. 206 participants were carriers of pathogenic mutations in PSEN1, PSEN2, or APP, and 134 were non-carriers. 62 unique pathogenic variants were identified in the cohort and were grouped in two ways. First, we sorted variants in PSEN1, PSEN2, or APP by the affected protein domain. Second, we divided PSEN1 variants according to position before or after codon 200. We examined variant-dependent variability in A&#x3b2; biomarkers, specifically Pittsburgh-Compound-B PET (PiB-PET) signal, levels of CSF A&#x3b2;1-42 (A&#x3b2;42), and levels of A&#x3b2;1-40 (A&#x3b2;40).</AbstractText><AbstractText Label="FINDINGS">Cortical and striatal PiB-PET signal showed striking variant-dependent variability using both grouping approaches (p&lt;0&#xb7;0001), despite similar progression on the clinical dementia rating (p&gt;0&#xb7;7), and CSF A&#x3b2;42 levels (codon-based grouping: p=0&#xb7;49; domain-based grouping: p=0&#xb7;095). Longitudinal PiB-PET signal also varied across codon-based groups, mirroring cross-sectional analyses.</AbstractText><AbstractText Label="INTERPRETATION">Autosomal dominant Alzheimer's disease pathogenic variants showed highly differential temporal and regional patterns of PiB-PET signal, despite similar functional progression. These findings suggest that although increased PiB-PET signal is generally seen in autosomal dominant Alzheimer's disease, higher levels of PiB-PET signal at an individual level might not reflect more severe or more advanced disease. Our results have high relevance for ongoing clinical trials in autosomal dominant Alzheimer's disease, including those using A&#x3b2; PET as a surrogate marker of disease progression. Additionally, and pertinent to both sporadic and autosomal dominant Alzheimer's disease, our results suggest that CSF and PET measures of A&#x3b2; levels are not interchangeable and might reflect different A&#x3b2;-driven pathobiological processes.</AbstractText><AbstractText Label="FUNDING">National Institute on Aging, Doris Duke Charitable Foundation, German Center for Neurodegenerative Diseases, Japanese Agency for Medical Research and Development.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chhatwal</LastName><ForeName>Jasmeer P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Department of Neurology, Harvard Medical School, Boston, MA, USA; Massachusetts General Hospital, Boston, MA, USA; Brigham and Women's Hospital, Boston, MA, USA. Electronic address: chhatwal.jasmeer@mgh.harvard.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schultz</LastName><ForeName>Stephanie A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Harvard Medical School, Boston, MA, USA; Massachusetts General Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McDade</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University in St Louis, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schultz</LastName><ForeName>Aaron P</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>Department of Neurology, Harvard Medical School, Boston, MA, USA; Massachusetts General Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Lei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology, Harvard Medical School, Boston, MA, USA; Brigham and Women's Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hanseeuw</LastName><ForeName>Bernard J</ForeName><Initials>BJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Harvard Medical School, Boston, MA, USA; Massachusetts General Hospital, Boston, MA, USA; Universit&#xe9; Catholique de Louvain, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joseph-Mathurin</LastName><ForeName>Nelly</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Mallinckrodt Institute of Radiology, Washington University in St Louis, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feldman</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Mallinckrodt Institute of Radiology, Washington University in St Louis, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fitzpatrick</LastName><ForeName>Colleen D</ForeName><Initials>CD</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital, Boston, MA, USA; Brigham and Women's Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sparks</LastName><ForeName>Kathryn P</ForeName><Initials>KP</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levin</LastName><ForeName>Johannes</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Ludwig-Maximilians Universit&#xe4;t M&#xfc;nchen, Munich, Germany; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany; German Center for Neurodegenerative Diseases, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berman</LastName><ForeName>Sarah B</ForeName><Initials>SB</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Pittsburgh, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Renton</LastName><ForeName>Alan E</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Esposito</LastName><ForeName>Bianca T</ForeName><Initials>BT</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fernandez</LastName><ForeName>Maria Vitoria</ForeName><Initials>MV</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University in St Louis, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sung</LastName><ForeName>Yun Ju</ForeName><Initials>YJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University in St Louis, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Jae Hong</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klunk</LastName><ForeName>William E</ForeName><Initials>WE</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Pittsburgh, Pittsburgh, PA, USA; Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hofmann</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Disease, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Noble</LastName><ForeName>James M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Columbia University Irving Medical Center, Department of Neurology, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graff-Radford</LastName><ForeName>Neill</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Mayo Clinic, Department of Neurology, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mori</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Osaka City University, Sumiyoshi Ward, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salloway</LastName><ForeName>Steven M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Butler Hospital, Memory and Aging Program, Brown University Alpert Medical School, Providence, RI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masters</LastName><ForeName>Colin L</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>The University of Melbourne, Melbourne, VIC, Australia; Florey Institute, Melbourne, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martins</LastName><ForeName>Ralph</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Macquarie University, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karch</LastName><ForeName>Celeste M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University in St Louis, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiong</LastName><ForeName>Chengjie</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Biostatistics, Washington University in St Louis, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cruchaga</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University in St Louis, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perrin</LastName><ForeName>Richard J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Pathology, Washington University in St Louis, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gordon</LastName><ForeName>Brian A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Mallinckrodt Institute of Radiology, Washington University in St Louis, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benzinger</LastName><ForeName>Tammie L S</ForeName><Initials>TLS</Initials><AffiliationInfo><Affiliation>Mallinckrodt Institute of Radiology, Washington University in St Louis, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fox</LastName><ForeName>Nick C</ForeName><Initials>NC</Initials><AffiliationInfo><Affiliation>UCL Queen Square Institute of Neurology, Dementia Research Centre, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schofield</LastName><ForeName>Peter R</ForeName><Initials>PR</Initials><AffiliationInfo><Affiliation>Neuroscience Research Australia, Sydney, NSW, Australia; School of Medical Sciences, University of New South Wales, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fagan</LastName><ForeName>Anne M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University in St Louis, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goate</LastName><ForeName>Alison M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University in St Louis, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bateman</LastName><ForeName>Randall J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University in St Louis, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Keith A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Harvard Medical School, Boston, MA, USA; Massachusetts General Hospital, Boston, MA, USA; Brigham and Women's Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Harvard Medical School, Boston, MA, USA; Massachusetts General Hospital, Boston, MA, USA; Brigham and Women's Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Dominantly Inherited Alzheimer's Network Investigators</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG066444</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG053474</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UF1 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AG049087</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 OD025214</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG071865</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062421</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG036694</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Neurol</MedlineTA><NlmUniqueID>101139309</NlmUniqueID><ISSNLinking>1474-4422</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Neurol. 2022 Feb;21(2):105-106. doi: 10.1016/S1474-4422(21)00461-0.</RefSource><PMID Version="1">35065027</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="Y">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006579" MajorTopicYN="N">Heterozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Declaration of interests JPC has served on medical advisory boards for Otsuka Pharmaceuticals and Humana Healthcare, outside of the submitted work. APS has served on medical advisory boards for Janssen Pharmaceuticals and Biogen, outside of the submitted work. SMS reports consulting to Eisai, Novartis, Genentech, F Hoffmann-La Roche, Gemvax, Avid Radiopharmaceuticals, and Eli Lilly, outside of the submitted work. SMS also serves on steering committees for major biomarker and clinical trials and consortia such as the Alzheimer's Disease Neuroimaging Initiative, the Dominantly Inherited Alzheimer Network (DIAN), Alzheimer's Clinical Trial Consortium, Global Alzheimer's Platform- Network, and Longitudinal Early-onset Alzheimer's disease study, and is a project arm leader for the Dominantly Inherited Alzheimer's Network-Treatment Unit (DIAN-TU) study, outside of the submitted work. WEK is a co-inventor of Pittsburgh-Compound-B (PiB) and, as such, has a financial interest in a license agreement held by GE Healthcare and the University of Pittsburgh (PA, USA) based on the PiB-PET technology used in this manuscript. GE Healthcare provided no grant support for this study and had no role in the design or interpretation of results or preparation of this manuscript. AMF has received research funding from the National Institutes of Health and National Institute on Aging, Biogen, Centene, Fujirebio, and Roche Diagnostics, outside of the submitted work. AMF is a member of the scientific advisory boards for Roche Diagnostics, Genentech, and AbbVie, and also consults for Araclon and Grifols, DiademRes, DiamiR, and Otsuka Pharmaceuticals, outside of the submitted work. RJB has equity ownership interest in C2N Diagnostics and receives royalty income based on technology (ie, stable isotope labelling kinetics and a blood plasma assay) licensed by Washington University (WA, USA) to C2N Diagnostics. RJB receives income from C2N Diagnostics for serving on the scientific advisory board. Washington University, with RJB as co-inventor, has submitted the US non-provisional patent application &#x201c;Cerebrospinal fluid (CSF) tau rate of phosphorylation measurement to define stages of Alzheimer's disease and monitor brain kinases/phosphatases activity.&#x201d; RJB has received honoraria from Janssen and Pfizer as a speaker, and from Merck and Pfizer as an advisory board member. RJB has been an invited speaker, advisory board member, and consultant for F Hoffman La Roche, an invited speaker and consultant for AC Immune and Janssen, and a consultant for Amgen and Eisai, outside of the submitted work. AMG has consulted for Eisai, Biogen, Pfizer, AbbVie, Cognition Therapeutics, and GSK, outside of the submitted work. AMG also served on the Scientific Advisory Board of Denali Therapeutics (from 2015 to 2018), outside of the submitted work. RAS and KAJ are involved in public-private partnership clinical trials sponsored by the National Institutes of Health and Eli Lilly, which owns the distribution rights to flortaucipir, but they do not have any personal financial relationship with Eli Lilly. NG-R reports grants from Biogen, Abbvie, and Lilly, outside of the submitted work. All other authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>2</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>10</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>10</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>1</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>1</Month><Day>22</Day><Hour>20</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>2</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35065037</ArticleId><ArticleId IdType="mid">NIHMS1775138</ArticleId><ArticleId IdType="pmc">PMC8956209</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(21)00375-6</ArticleId><ArticleId IdType="pii">S1474-4422(21)00375-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ryman DC, Acosta-Baena N, Aisen PS, et al. Symptom onset in autosomal dominant Alzheimer disease: A systematic review and meta-analysis. Neurology 2014; 83(3): 253&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4117367</ArticleId><ArticleId IdType="pubmed">24928124</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Xiong C, Benzinger TLS, et al. Clinical and Biomarker Changes in Dominantly Inherited Alzheimer&#x2019;s Disease. The New England journal of medicine 2012; 367(9): 795&#x2013;804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3474597</ArticleId><ArticleId IdType="pubmed">22784036</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Quiroz YT, Fleisher AS, et al. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer&#x2019;s disease in the presenilin 1 E280A kindred: a case-control study. The Lancet Neurology 2012; 11(12): 1048&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4181671</ArticleId><ArticleId IdType="pubmed">23137948</ArticleId></ArticleIdList></Reference><Reference><Citation>Borchelt DR, Thinakaran G, Eckman CB, et al. Familial Alzheimer&#x2019;s Disease&#x2013;Linked Presenilin 1 Variants Elevate A&#x3b2;1&#x2013;42/1&#x2013;40 Ratio In Vitro and In Vivo. Neuron 1996; 17(5): 1005&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">8938131</ArticleId></ArticleIdList></Reference><Reference><Citation>Paterson RW, Gabelle A, Lucey BP, et al. SILK studies - capturing the turnover of proteins linked to neurodegenerative diseases. Nat Rev Neurol 2019; 15(7): 419&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6876864</ArticleId><ArticleId IdType="pubmed">31222062</ArticleId></ArticleIdList></Reference><Reference><Citation>Potter R, Patterson BW, Elbert DL, et al. Increased in Vivo Amyloid- 42 Production, Exchange, and Loss in Presenilin Mutation Carriers. Science Translational Medicine 2013; 5(189): 189ra77-ra77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3838868</ArticleId><ArticleId IdType="pubmed">23761040</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer&#x2019;s disease at 25 years. EMBO Molecular Medicine 2016; 8(6): 595&#x2013;608.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4888851</ArticleId><ArticleId IdType="pubmed">27025652</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun L, Zhou R, Yang G, Shi Y. Analysis of 138 pathogenic mutations in presenilin-1 on the in vitro production of A&#x3b2;42 and A&#x3b2;40 peptides by &#x3b3;-secretase. Proceedings of the National Academy of Sciences of the United States of America 2016: 201618657.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5278480</ArticleId><ArticleId IdType="pubmed">27930341</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheuner D, Eckman C, Jensen M, et al. Secreted amyloid &#x3b2;&#x2013;protein similar to that in the senile plaques of Alzheimer&#x2019;s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer&#x2019;s disease. Nature Medicine 1996; 2(8): 864&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">8705854</ArticleId></ArticleIdList></Reference><Reference><Citation>Bentahir M, Nyabi O, Verhamme J, et al. Presenilin clinical mutations can affect gamma-secretase activity by different mechanisms. Journal of Neurochemistry 2006; 96(3): 732&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">16405513</ArticleId></ArticleIdList></Reference><Reference><Citation>Ch&#xe1;vez-Guti&#xe9;rrez L, Bammens L, Benilova I, et al. The mechanism of &#x3b3;-Secretase dysfunction in familial Alzheimer disease. The EMBO Journal 2012; 31(10): 2261&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3364747</ArticleId><ArticleId IdType="pubmed">22505025</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe MS. Dysfunctional &#x3b3;-Secretase in Familial Alzheimer&#x2019;s Disease. Neurochemical Research 2019; 44(1): 5&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6592691</ArticleId><ArticleId IdType="pubmed">29619615</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, Blazey TM, Snyder AZ, et al. Partial volume correction in quantitative amyloid imaging. Neuroimage 2015; 107: 55&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4300252</ArticleId><ArticleId IdType="pubmed">25485714</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann DMA, Pickering-Brown SM, Takeuchi A, Iwatsubo T. Amyloid Angiopathy and Variability in Amyloid &#x3b2; Deposition Is Determined by Mutation Position in Presenilin-1-Linked Alzheimer&#x2019;s Disease. 2001; 158(6): 2165&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1891993</ArticleId><ArticleId IdType="pubmed">11395394</ArticleId></ArticleIdList></Reference><Reference><Citation>Ringman JM, Monsell S, Ng DW, et al. Neuropathology of Autosomal Dominant Alzheimer Disease in the National Alzheimer Coordinating Center Database. 2016; 75(3): 284&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4934612</ArticleId><ArticleId IdType="pubmed">26888304</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Price JC, Mathis CA, et al. Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. Journal of Neuroscience 2007; 27(23): 6174&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3265970</ArticleId><ArticleId IdType="pubmed">17553989</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, Ataka S, Mizuno T, et al. High Striatal Amyloid &#x3b2;-Peptide Deposition Across Different Autosomal Alzheimer Disease Mutation Types. Archives of Neurology 2009; 66(12): 1537&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">20008660</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen AD, McDade E, Christian B, et al. Early striatal amyloid deposition distinguishes Down syndrome and autosomal dominant Alzheimer&#x2019;s disease from late-onset amyloid deposition. Alzheimer&#x2019;s &amp; Dementia 2018; 14(6): 743&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5994364</ArticleId><ArticleId IdType="pubmed">29477284</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Connor A, Pannee J, Poole T, et al. Plasma A&#x3b2; ratios in autosomal dominant Alzheimer&#x2019;s disease: the influence of genotype. Cold Spring Harbor Laboratory; 2021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8634092</ArticleId><ArticleId IdType="pubmed">33892504</ArticleId></ArticleIdList></Reference><Reference><Citation>Swanson C, Kanekiyo M, Kaplow J, et al. Plasma A&#x3b2; 42:40 Ratio Tracks with Changes in Brain Amyloid PET SUVr in the Core and Open Label Extension of the Phase 2 Proof of Concept Study BAN2401-G000&#x2013;201 Following Treatment with Lecanemab in Subjects with Early Alzheimer&#x2019;s Disease. Alzheimer&#x2019;s Association International Conference, Denver, USA 2021.</Citation></Reference><Reference><Citation>Jack CR Jr., Bennett DA, Blennow K, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer&#x2019;s disease. Alzheimers Dement 2018; 14(4): 535&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5958625</ArticleId><ArticleId IdType="pubmed">29653606</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia D, Watanabe H, Wu B, et al. Presenilin-1 Knockin Mice Reveal Loss-of-Function Mechanism for Familial Alzheimer&#x2019;s Disease. Neuron 2015; 85(5): 967&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4358812</ArticleId><ArticleId IdType="pubmed">25741723</ArticleId></ArticleIdList></Reference><Reference><Citation>Tu H, Nelson O, Bezprozvanny A, et al. Presenilins Form ER Ca2+ Leak Channels, a Function Disrupted by Familial Alzheimer&#x2019;s Disease-Linked Mutations. Cell 2006; 126(5): 981&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3241869</ArticleId><ArticleId IdType="pubmed">16959576</ArticleId></ArticleIdList></Reference><Reference><Citation>Maarouf CL, Daugs ID, Spina S, et al. Histopathological and molecular heterogeneity among individuals with dementia associated with Presenilin mutations. Molecular Neurodegeneration 2008; 3(1): 20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2600784</ArticleId><ArticleId IdType="pubmed">19021905</ArticleId></ArticleIdList></Reference><Reference><Citation>Miravalle L, Calero M, Takao M, Roher AE, Ghetti B, Vidal R. Amino-Terminally Truncated A&#x3b2; Peptide Species Are the Main Component of Cotton Wool Plaques&#x2020;. Biochemistry 2005; 44(32): 10810&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">16086583</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann DMA, Takeuchi A, Sato S, et al. Cases of Alzheimer&#x2019;s disease due to deletion of exon 9 of the presenilin-1 gene show an unusual but characteristic &#x3b2;-amyloid pathology known as &#x2018;cotton wool&#x2019; plaques. Neuropathology and Applied Neurobiology 2001; 27(3): 189&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">11489138</ArticleId></ArticleIdList></Reference><Reference><Citation>Scholl M, Wall A, Thordardottir S, et al. Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers. Neurology 2012; 79(3): 229&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">22700814</ArticleId></ArticleIdList></Reference><Reference><Citation>Nilsberth C, Westlind-Danielsson A, Eckman CB, et al. The &#x2018;Arctic&#x2019; APP mutation (E693G) causes Alzheimer&#x2019;s disease by enhanced A&#x3b2; protofibril formation. Nature Neuroscience 2001; 4(9): 887&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">11528419</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu S, Gordon BA, Hornbeck R, et al. Discovery and validation of autosomal dominant Alzheimer&#x2019;s disease mutations. Alzheimers Res Ther 2018; 10(1): 67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6052673</ArticleId><ArticleId IdType="pubmed">30021643</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruchaga C, Del-Aguila JL, Saef B, et al. Polygenic risk score of sporadic late-onset Alzheimer&#x2019;s disease reveals a shared architecture with the familial and early-onset forms. Alzheimer&#x2019;s &amp; Dementia : the Journal of the Alzheimer&#x2019;s Association 2018; 14(2): 205&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5803427</ArticleId><ArticleId IdType="pubmed">28943286</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">35063084</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>09</Day></DateCompleted><DateRevised><Year>2022</Year><Month>05</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4172</ISSN><JournalIssue CitedMedium="Internet"><Volume>185</Volume><Issue>4</Issue><PubDate><Year>2022</Year><Month>Feb</Month><Day>17</Day></PubDate></JournalIssue><Title>Cell</Title><ISOAbbreviation>Cell</ISOAbbreviation></Journal><ArticleTitle>Tau interactome maps synaptic and mitochondrial processes associated with neurodegeneration.</ArticleTitle><Pagination><StartPage>712</StartPage><EndPage>728.e14</EndPage><MedlinePgn>712-728.e14</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cell.2021.12.041</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0092-8674(21)01563-4</ELocationID><Abstract><AbstractText>Tau (MAPT) drives neuronal dysfunction in Alzheimer disease (AD) and other tauopathies. To dissect the underlying mechanisms, we combined an engineered ascorbic acid peroxidase (APEX) approach with quantitative affinity purification mass spectrometry (AP-MS) followed by proximity ligation assay (PLA) to characterize Tau interactomes modified by neuronal activity and mutations that cause frontotemporal dementia (FTD) in human induced pluripotent stem cell (iPSC)-derived neurons. We established interactions of Tau with presynaptic vesicle proteins during activity-dependent Tau secretion and mapped the Tau-binding sites to the cytosolic domains of integral synaptic vesicle proteins. We showed that FTD mutations impair bioenergetics and markedly diminished Tau's interaction with mitochondria proteins, which were downregulated in&#xa0;AD brains of multiple cohorts and correlated with disease severity. These multimodal and dynamic Tau interactomes with exquisite spatial resolution shed light on Tau's role in neuronal function and disease and highlight potential therapeutic targets to block Tau-mediated pathogenesis.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 The Author(s). Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tracy</LastName><ForeName>Tara E</ForeName><Initials>TE</Initials><AffiliationInfo><Affiliation>Gladstone Institutes, San Francisco, CA 94158, USA; Buck Institute for Research on Aging, Novato, CA 94945, USA. Electronic address: ttracy@buckinstitute.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madero-P&#xe9;rez</LastName><ForeName>Jesus</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Helen and Robert Appel Alzheimer Disease Research Institute, Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY 10021, USA. Electronic address: jem4002@med.cornell.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swaney</LastName><ForeName>Danielle L</ForeName><Initials>DL</Initials><AffiliationInfo><Affiliation>Gladstone Institutes, San Francisco, CA 94158, USA; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, CA 94158, USA; Quantitative Biosciences Institute (QBI), University of California, San Francisco, San Francisco, CA 94158, USA. Electronic address: danielle.swaney@gladstone.ucsf.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Timothy S</ForeName><Initials>TS</Initials><AffiliationInfo><Affiliation>Department of Neurology, Movement Disorders Program and Program in Neurogenetics, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moritz</LastName><ForeName>Michelle</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cellular and Molecular Pharmacology, University of California, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Konrad</LastName><ForeName>Csaba</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ward</LastName><ForeName>Michael E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Gladstone Institutes, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stevenson</LastName><ForeName>Erica</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Gladstone Institutes, San Francisco, CA 94158, USA; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, CA 94158, USA; Quantitative Biosciences Institute (QBI), University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>H&#xfc;ttenhain</LastName><ForeName>Ruth</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Gladstone Institutes, San Francisco, CA 94158, USA; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, CA 94158, USA; Quantitative Biosciences Institute (QBI), University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kauwe</LastName><ForeName>Grant</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Buck Institute for Research on Aging, Novato, CA 94945, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mercedes</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Helen and Robert Appel Alzheimer Disease Research Institute, Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY 10021, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sweetland-Martin</LastName><ForeName>Lauren</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Helen and Robert Appel Alzheimer Disease Research Institute, Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY 10021, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Xu</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Gladstone Institutes, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mok</LastName><ForeName>Sue-Ann</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, University of Alberta, Edmonton, AB T6G 2R3, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Man Ying</ForeName><Initials>MY</Initials><AffiliationInfo><Affiliation>Helen and Robert Appel Alzheimer Disease Research Institute, Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY 10021, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Telpoukhovskaia</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Gladstone Institutes, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Min</LastName><ForeName>Sang-Won</ForeName><Initials>SW</Initials><AffiliationInfo><Affiliation>Gladstone Institutes, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Chao</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Gladstone Institutes, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sohn</LastName><ForeName>Peter Dongmin</ForeName><Initials>PD</Initials><AffiliationInfo><Affiliation>Gladstone Institutes, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Jordie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Gladstone Institutes, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Yungui</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Gladstone Institutes, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Wenjie</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Helen and Robert Appel Alzheimer Disease Research Institute, Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY 10021, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trojanowski</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials><AffiliationInfo><Affiliation>Center for Neurodegenerative Disease Research, School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Virginia M Y</ForeName><Initials>VMY</Initials><AffiliationInfo><Affiliation>Center for Neurodegenerative Disease Research, School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gong</LastName><ForeName>Shiaoching</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Helen and Robert Appel Alzheimer Disease Research Institute, Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY 10021, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manfredi</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coppola</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurology, Movement Disorders Program and Program in Neurogenetics, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA; Department of Psychiatry, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA 90095, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krogan</LastName><ForeName>Nevan J</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>Gladstone Institutes, San Francisco, CA 94158, USA; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, CA 94158, USA; Quantitative Biosciences Institute (QBI), University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geschwind</LastName><ForeName>Daniel H</ForeName><Initials>DH</Initials><AffiliationInfo><Affiliation>Department of Neurology, Movement Disorders Program and Program in Neurogenetics, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA; Department of Human Genetics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA; Institute of Precision Health, University of California, Los Angeles, Los Angeles, CA 90095, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gan</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Helen and Robert Appel Alzheimer Disease Research Institute, Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY 10021, USA. Electronic address: lig2033@med.cornell.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U54 NS100717</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R25 NS065723</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG057862</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG054214</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG064239</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 NS072026</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG019610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>01</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell</MedlineTA><NlmUniqueID>0413066</NlmUniqueID><ISSNLinking>0092-8674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000596">Amino Acids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050505">Mutant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Trends Neurosci. 2022 May;45(5):339-341. doi: 10.1016/j.tins.2022.02.004.</RefSource><PMID Version="1">35232606</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000596" MajorTopicYN="N">Amino Acids</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019921" MajorTopicYN="N">Biotinylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002467" MajorTopicYN="N">Cell Nucleus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004734" MajorTopicYN="N">Energy Metabolism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057026" MajorTopicYN="N">Induced Pluripotent Stem Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050505" MajorTopicYN="N">Mutant Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072417" MajorTopicYN="N">Protein Domains</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060066" MajorTopicYN="Y">Protein Interaction Maps</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D040901" MajorTopicYN="N">Proteomics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013347" MajorTopicYN="N">Subcellular Fractions</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">APEX</Keyword><Keyword MajorTopicYN="N">Tau</Keyword><Keyword MajorTopicYN="N">Tau secretion</Keyword><Keyword MajorTopicYN="N">affinity purification mass spectrometry</Keyword><Keyword MajorTopicYN="N">interactome</Keyword><Keyword MajorTopicYN="N">mitochondria</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">protein-protein interaction</Keyword><Keyword MajorTopicYN="N">synapse</Keyword><Keyword MajorTopicYN="N">tauopathies</Keyword></KeywordList><CoiStatement>Declaration of interests L.G. is a founder of Aeton Therapeutics. N.J.K. received research support from Vir Biotechnology and F. Hoffmann-La Roche; has consulting agreements with the Icahn School of Medicine at Mount Sinai, New York, Maze Therapeutics, and Interline Therapeutics; is a shareholder in Tenaya Therapeutics, Maze Therapeutics, and Interline Therapeutics; and is a financially compensated Scientific Advisory Board Member for GEn1E Life sciences.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>6</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>10</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>12</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>1</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>1</Month><Day>22</Day><Hour>5</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>2</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35063084</ArticleId><ArticleId IdType="mid">NIHMS1775332</ArticleId><ArticleId IdType="pmc">PMC8857049</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2021.12.041</ArticleId><ArticleId IdType="pii">S0092-8674(21)01563-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alonso AD, Grundke-Iqbal I, Barra HS, and Iqbal K (1997). Abnormal phosphorylation of tau and the mechanism of Alzheimer neurofibrillary degeneration: sequestration of microtubule-associated proteins 1 and 2 and the disassembly of microtubules by the abnormal tau. Proc. Natl. Acad. Sci. USA 94, 298&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC19321</ArticleId><ArticleId IdType="pubmed">8990203</ArticleId></ArticleIdList></Reference><Reference><Citation>Amadoro G, Corsetti V, Atlante A, Florenzano F, Capsoni S, Bussani R, Mercanti D, and Calissano P (2012). Interaction between NH(2)-tau fragment and Abeta in Alzheimer&#x2019;s disease mitochondria contributes to the synaptic deterioration. Neurobiol. Aging 33, 833, e1&#x2013;833.25.</Citation><ArticleIdList><ArticleId IdType="pubmed">21958963</ArticleId></ArticleIdList></Reference><Reference><Citation>Bardai FH, Wang L, Mutreja Y, Yenjerla M, Gamblin TC, and Feany MB (2018). A conserved cytoskeletal signaling cascade mediates neurotoxicity of FTDP-17 tau mutations in vivo. J. Neurosci. 38, 108&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5761430</ArticleId><ArticleId IdType="pubmed">29138281</ArticleId></ArticleIdList></Reference><Reference><Citation>Belizaire R, Komanduri C, Wooten K, Chen M, Thaller C, and Janz R (2004). Characterization of synaptogyrin 3 as a new synaptic vesicle protein. J. Comp. Neurol. 470, 266&#x2013;281.</Citation><ArticleIdList><ArticleId IdType="pubmed">14755516</ArticleId></ArticleIdList></Reference><Reference><Citation>Benussi L, Ghidoni R, Paterlini A, Nicosia F, Alberici AC, Signorini S, Barbiero L, and Binetti G (2005). Interaction between tau and alpha-synuclein proteins is impaired in the presence of P301L tau mutation. Exp. Cell Res. 308, 78&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">15904919</ArticleId></ArticleIdList></Reference><Reference><Citation>Berk JM, Tifft KE, and Wilson KL (2013). The nuclear envelope LEM-domain protein emerin. Nucleus 4, 298&#x2013;314.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3810338</ArticleId><ArticleId IdType="pubmed">23873439</ArticleId></ArticleIdList></Reference><Reference><Citation>Biederer T, and S&#xfc;dhof TC (2000). Mints as adaptors. Direct binding to neurexins and recruitment of munc18. J. Biol. Chem. 275, 39803&#x2013;39806.</Citation><ArticleIdList><ArticleId IdType="pubmed">11036064</ArticleId></ArticleIdList></Reference><Reference><Citation>Bindea G, Mlecnik B, Hackl H, Charoentong P, Tosolini M, Kirilovsky A, Fridman WH, Pag&#xe8; s F, Trajanoski Z, and Galon J (2009). ClueGO: a cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics Oxf. Engl. 25, 1091&#x2013;1093.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2666812</ArticleId><ArticleId IdType="pubmed">19237447</ArticleId></ArticleIdList></Reference><Reference><Citation>Brand MD, and Nicholls DG (2011). Assessing mitochondrial dysfunction in cells. Biochem. J. 435, 297&#x2013;312.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3076726</ArticleId><ArticleId IdType="pubmed">21726199</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang CW, Shao E, and Mucke L (2021). Tau: enabler of diverse brain disorders and target of rapidly evolving therapeutic strategies. Science 371, eabb8255.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8118650</ArticleId><ArticleId IdType="pubmed">33632820</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi H, Kim HJ, Yang J, Chae S, Lee W, Chung S, Kim J, Choi H, Song H, Lee CK, et al. (2020). Acetylation changes tau interactome to degrade tau in Alzheimer&#x2019;s disease animal and organoid models. Aging Cell 19, e13081.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6974726</ArticleId><ArticleId IdType="pubmed">31763743</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox J, and Mann M (2008). MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol. 26, 1367&#x2013;1372.</Citation><ArticleIdList><ArticleId IdType="pubmed">19029910</ArticleId></ArticleIdList></Reference><Reference><Citation>David DC, Hauptmann S, Scherping I, Schuessel K, Keil U, Rizzu P, Ravid R, Dr&#xf6;se S, Brandt U, M&#xfc;ller WE, et al. (2005). Proteomic and functional analyses reveal a mitochondrial dysfunction in P301L tau transgenic mice. J. Biol. Chem. 280, 23802&#x2013;23814.</Citation><ArticleIdList><ArticleId IdType="pubmed">15831501</ArticleId></ArticleIdList></Reference><Reference><Citation>David DC, Layfield R, Serpell L, Narain Y, Goedert M, and Spillantini MG (2002). Proteasomal degradation of Tau protein. J. Neurochem. 83, 176&#x2013;185.</Citation><ArticleIdList><ArticleId IdType="pubmed">12358741</ArticleId></ArticleIdList></Reference><Reference><Citation>DuBoff B, G&#xf6;tz J, and Feany MB (2012). Tau promotes neurodegeneration via DRP1 mislocalization in vivo. Neuron 75, 618&#x2013;632.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3428596</ArticleId><ArticleId IdType="pubmed">22920254</ArticleId></ArticleIdList></Reference><Reference><Citation>Dulubova I, Khvotchev M, Liu S, Huryeva I, S&#xfc;dhof TC, and Rizo J (2007). Munc18&#x2013;1 binds directly to the neuronal SNARE complex. Proc. Natl. Acad. Sci. USA 104, 2697&#x2013;2702.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1815244</ArticleId><ArticleId IdType="pubmed">17301226</ArticleId></ArticleIdList></Reference><Reference><Citation>Efron B, and Gong G (1983). A leisurely look at the bootstrap, the jackknife, and cross-validation. Am. Stat. 37, 36&#x2013;48.</Citation></Reference><Reference><Citation>Eftekharzadeh B, Daigle JG, Kapinos LE, Coyne A, Schiantarelli J, Carlomagno Y, Cook C, Miller SJ, Dujardin S, Amaral AS, et al. (2018). Tau protein disrupts nucleocytoplasmic transport in Alzheimer&#x2019;s disease. Neuron 99, 925&#x2013;940.e7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6240334</ArticleId><ArticleId IdType="pubmed">30189209</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehrlich M, Hallmann AL, Reinhardt P, Ara&#xfa;zo-Bravo MJ, Korr S, R&#xf6;pke A, Psathaki OE, Ehling P, Meuth SG, Oblak AL, et al. (2015). Distinct neurodegenerative changes in an induced pluripotent stem cell model of frontotemporal dementia linked to mutant Tau protein. Stem Cell Rep 5, 83&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4618448</ArticleId><ArticleId IdType="pubmed">26143746</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans HT, Benetatos J, van Roijen M, Bodea LG, and G&#xf6;tz J (2019). Decreased synthesis of ribosomal proteins in tauopathy revealed by non-canonical amino acid labelling. EMBO J 38, e101174.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6600635</ArticleId><ArticleId IdType="pubmed">31268600</ArticleId></ArticleIdList></Reference><Reference><Citation>Fong H, Wang C, Knoferle J, Walker D, Balestra ME, Tong LM, Leung L, Ring KL, Seeley WW, Karydas A, et al. (2013). Genetic correction of tauopathy phenotypes in neurons derived from human induced pluripotent stem cells. Stem Cell Rep 1, 226&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3849235</ArticleId><ArticleId IdType="pubmed">24319659</ArticleId></ArticleIdList></Reference><Reference><Citation>Frandemiche ML, De Seranno S, Rush T, Borel E, Elie A, Arnal I, Lant&#xe9; F, and Buisson A (2014). Activity-dependent Tau protein translocation to excitatory synapse is disrupted by exposure to amyloid-beta oligomers. J. Neurosci. 34, 6084&#x2013;6097.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6608293</ArticleId><ArticleId IdType="pubmed">24760868</ArticleId></ArticleIdList></Reference><Reference><Citation>Giasson BI, Forman MS, Higuchi M, Golbe LI, Graves CL, Kotzbauer PT, Trojanowski JQ, and Lee VM (2003). Initiation and synergistic fibrillization of tau and alpha-synuclein. Science 300, 636&#x2013;640.</Citation><ArticleIdList><ArticleId IdType="pubmed">12714745</ArticleId></ArticleIdList></Reference><Reference><Citation>Guix FX, Corbett GT, Cha DJ, Mustapic M, Liu W, Mengel D, Chen Z, Aikawa E, Young-Pearse T, Kapogiannis D, et al. (2018). Detection of aggregation-competent tau in neuron-derived extracellular vesicles. Int. J. Mol. Sci. 19, 663.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5877524</ArticleId><ArticleId IdType="pubmed">29495441</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunawardana CG, Mehrabian M, Wang X, Mueller I, Lubambo IB, Jonkman JE, Wang H, and Schmitt-Ulms G (2015). The human tau interactome: binding to the ribonucleoproteome, and impaired binding of the proline-to-leucine mutant at Position 301 (P301L) to chaperones and the proteasome. Mol. Cell. Proteomics 14, 3000&#x2013;3014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4638042</ArticleId><ArticleId IdType="pubmed">26269332</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagestedt T, Lichtenberg B, Wille H, Mandelkow EM, and Mandelkow E (1989). Tau protein becomes long and stiff upon phosphorylation: correlation between paracrystalline structure and degree of phosphorylation. J. Cell Biol. 109, 1643&#x2013;1651.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2115827</ArticleId><ArticleId IdType="pubmed">2507554</ArticleId></ArticleIdList></Reference><Reference><Citation>Helm MS, Dankovich TM, Mandad S, Rammner B, J&#xe4;hne S, Salimi V, Koerbs C, Leibrandt R, Urlaub H, Schikorski T, and Rizzoli SO (2021). A large-scale nanoscopy and biochemistry analysis of postsynaptic dendritic spines. Nat. Neurosci. 24, 1151&#x2013;1162.</Citation><ArticleIdList><ArticleId IdType="pubmed">34168338</ArticleId></ArticleIdList></Reference><Reference><Citation>Hodes RJ, and Buckholtz N (2016). Accelerating medicines partnership: Alzheimer&#x2019;s disease (AMP-AD) knowledge portal Aids Alzheimer&#x2019;s drug discovery through open data sharing. Expert Opin. Ther. Targets 20, 389&#x2013;391.</Citation><ArticleIdList><ArticleId IdType="pubmed">26853544</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoover BR, Reed MN, Su J, Penrod RD, Kotilinek LA, Grant MK, Pitstick R, Carlson GA, Lanier LM, Yuan LL, et al. (2010). Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron 68, 1067&#x2013;1081.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3026458</ArticleId><ArticleId IdType="pubmed">21172610</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung V, Zou P, Rhee HW, Udeshi ND, Cracan V, Svinkina T, Carr SA, Mootha VK, and Ting AY (2014). Proteomic mapping of the human mitochondrial intermembrane space in live cells via ratiometric APEX tagging. Mol. Cell 55, 332&#x2013;341.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4743503</ArticleId><ArticleId IdType="pubmed">25002142</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishihara T, Hong M, Zhang B, Nakagawa Y, Lee MK, Trojanowski JQ, and Lee VM (1999). Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform. Neuron 24, 751&#x2013;762.</Citation><ArticleIdList><ArticleId IdType="pubmed">10595524</ArticleId></ArticleIdList></Reference><Reference><Citation>Ittner LM, Fath T, Ke YD, Bi M, van Eersel J, Li KM, Gunning P, and G&#xf6;tz J (2008). Parkinsonism and impaired axonal transport in a mouse model of frontotemporal dementia. Proc. Natl. Acad. Sci. USA 105, 15997&#x2013;16002.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2572931</ArticleId><ArticleId IdType="pubmed">18832465</ArticleId></ArticleIdList></Reference><Reference><Citation>Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, W&#xf6;lfing H, Chieng BC, Christie MJ, Napier IA, et al. (2010). Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer&#x2019;s disease mouse models. Cell 142, 387&#x2013;397.</Citation><ArticleIdList><ArticleId IdType="pubmed">20655099</ArticleId></ArticleIdList></Reference><Reference><Citation>Ittner LM, Ke YD, and G&#xf6;tz J (2009). Phosphorylated Tau interacts with c-Jun N-terminal kinase-interacting protein 1 (JIP1) in Alzheimer disease. J. Biol. Chem. 284, 20909&#x2013;20916.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2742856</ArticleId><ArticleId IdType="pubmed">19491104</ArticleId></ArticleIdList></Reference><Reference><Citation>Jha S, Shibata E, and Dutta A (2008). Human Rvb1/Tip49 is required for the histone acetyltransferase activity of Tip60/NuA4 and for the downregulation of phosphorylation on H2AX after DNA damage. Mol. Cell. Biol. 28, 2690&#x2013;2700.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2293106</ArticleId><ArticleId IdType="pubmed">18285460</ArticleId></ArticleIdList></Reference><Reference><Citation>J&#xf3;nsson ZO, Jha S, Wohlschlegel JA, and Dutta A (2004). Rvb1p/Rvb2p recruit Arp5p and assemble a functional Ino80 chromatin remodeling complex. Mol. Cell 16, 465&#x2013;477.</Citation><ArticleIdList><ArticleId IdType="pubmed">15525518</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam SS, Martell JD, Kamer KJ, Deerinck TJ, Ellisman MH, Mootha VK, and Ting AY (2015). Directed evolution of APEX2 for electron microscopy and proximity labeling. Nat. Methods 12, 51&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4296904</ArticleId><ArticleId IdType="pubmed">25419960</ArticleId></ArticleIdList></Reference><Reference><Citation>Langfelder P, and Horvath S (2007). Eigengene networks for studying the relationships between co-expression modules. BMC Syst. Biol. 1, 54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2267703</ArticleId><ArticleId IdType="pubmed">18031580</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SJ, Matsuura Y, Liu SM, and Stewart M (2005). Structural basis for nuclear import complex dissociation by RanGTP. Nature 435, 693&#x2013;696.</Citation><ArticleIdList><ArticleId IdType="pubmed">15864302</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Kumar Y, Zempel H, Mandelkow EM, Biernat J, and Mandelkow E (2011). Novel diffusion barrier for axonal retention of Tau in neurons and its failure in neurodegeneration. EMBO J 30, 4825&#x2013;4837.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3243615</ArticleId><ArticleId IdType="pubmed">22009197</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C, Song X, Nisbet R, and G&#xf6;tz J (2016). Co-immunoprecipitation with tau isoform-specific antibodies reveals distinct protein interactions and highlights a putative role for 2N tau in disease. J. Biol. Chem. 291, 8173&#x2013;8188.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4825019</ArticleId><ArticleId IdType="pubmed">26861879</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu F, Iqbal K, Grundke-Iqbal I, Rossie S, and Gong CX (2005). Dephosphorylation of tau by protein phosphatase 5: impairment in Alzheimer&#x2019;s disease. J. Biol. Chem. 280, 1790&#x2013;1796.</Citation><ArticleIdList><ArticleId IdType="pubmed">15546861</ArticleId></ArticleIdList></Reference><Reference><Citation>Lobingier BT, H&#xfc;ttenhain R, Eichel K, Miller KB, Ting AY, von Zastrow M, and Krogan NJ (2017). An approach to spatiotemporally resolve protein interaction networks in living cells. Cell 169, 350&#x2013;360.e12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5616215</ArticleId><ArticleId IdType="pubmed">28388416</ArticleId></ArticleIdList></Reference><Reference><Citation>Logsdon BA, Perumal TM, Swarup V, Wang M, Funk C, Gaiteri C, Allen M, Wang X, Dammer E, Srivastava G, et al. (2019). Meta-analysis of the human brain transcriptome identifies heterogeneity across human AD coexpression modules robust to sample collection and methodological approach. bioRxiv. https://www.biorxiv.org/content/10.1101/510420v1.abstract.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/510420v1.abstract</ArticleId></ArticleIdList></Reference><Reference><Citation>Loh KH, Stawski PS, Draycott AS, Udeshi ND, Lehrman EK, Wilton DK, Svinkina T, Deerinck TJ, Ellisman MH, Stevens B, et al. (2016). Proteomic analysis of unbounded cellular compartments: synaptic clefts. Cell 166, 1295&#x2013;1307.e21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5167540</ArticleId><ArticleId IdType="pubmed">27565350</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsui T, Jiang P, Nakano S, Sakamaki Y, Yamamoto H, and Mizushima N (2018). Autophagosomal YKT6 is required for fusion with lysosomes independently of syntaxin 17. J. Cell Biol. 217, 2633&#x2013;2645.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6080929</ArticleId><ArticleId IdType="pubmed">29789439</ArticleId></ArticleIdList></Reference><Reference><Citation>Maziuk BF, Apicco DJ, Cruz AL, Jiang L, Ash PEA, da Rocha EL, Zhang C, Yu WH, Leszyk J, Abisambra JF, et al. (2018). RNA binding proteins co-localize with small tau inclusions in tauopathy. Acta Neuropathol. Commun. 6, 71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6069705</ArticleId><ArticleId IdType="pubmed">30068389</ArticleId></ArticleIdList></Reference><Reference><Citation>McInnes J, Wierda K, Snellinx A, Bounti L, Wang YC, Stancu IC, Ap&#xf3;stolo N, Gevaert K, Dewachter I, Spires-Jones TL, et al. (2018). Synaptogyrin-3 mediates presynaptic dysfunction induced by tau. Neuron 97, 823&#x2013;835.e8.</Citation><ArticleIdList><ArticleId IdType="pubmed">29398363</ArticleId></ArticleIdList></Reference><Reference><Citation>Meier S, Bell M, Lyons DN, Rodriguez-Rivera J, Ingram A, Fontaine SN, Mechas E, Chen J, Wolozin B, LeVine H 3rd., et al. (2016). Pathological tau promotes neuronal damage by impairing ribosomal function and decreasing protein synthesis. J. Neurosci. 36, 1001&#x2013;1007.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4719006</ArticleId><ArticleId IdType="pubmed">26791227</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyaoka Y, Chan AH, Judge LM, Yoo J, Huang M, Nguyen TD, Lizarraga PP, So PL, and Conklin BR (2014). Isolation of single-base genome-edited human iPS cells without antibiotic selection. Nat. Methods 11, 291&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4063274</ArticleId><ArticleId IdType="pubmed">24509632</ArticleId></ArticleIdList></Reference><Reference><Citation>Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E, Ridderstr&#xe5;le M, Laurila E, et al. (2003). PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 34, 267&#x2013;273.</Citation><ArticleIdList><ArticleId IdType="pubmed">12808457</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris M, Maeda S, Vossel K, and Mucke L (2011). The many faces of tau. Neuron 70, 410&#x2013;426.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3319390</ArticleId><ArticleId IdType="pubmed">21555069</ArticleId></ArticleIdList></Reference><Reference><Citation>Myeku N, Clelland CL, Emrani S, Kukushkin NV, Yu WH, Goldberg AL, and Duff KE (2016). Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling. Nat. Med. 22, 46&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4787271</ArticleId><ArticleId IdType="pubmed">26692334</ArticleId></ArticleIdList></Reference><Reference><Citation>Pearson ES (1931). The test of significance for the correlation coefficient. J. Am. Stat. Assoc. 26, 128&#x2013;134.</Citation></Reference><Reference><Citation>Pooler AM, Phillips EC, Lau DH, Noble W, and Hanger DP (2013). Physiological release of endogenous tau is stimulated by neuronal activity. EMBO Rep 14, 389&#x2013;394.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3615658</ArticleId><ArticleId IdType="pubmed">23412472</ArticleId></ArticleIdList></Reference><Reference><Citation>R Core Team (2019). R: A Language and Environment for Statistical Computing (R Foundation for Statistical Computing; ).</Citation></Reference><Reference><Citation>Rhee HW, Zou P, Udeshi ND, Martell JD, Mootha VK, Carr SA, and Ting AY (2013). Proteomic mapping of mitochondria in living cells via spatially restricted enzymatic tagging. Science 339, 1328&#x2013;1331.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3916822</ArticleId><ArticleId IdType="pubmed">23371551</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruben GC, Iqbal K, Grundke-Iqbal I, Wisniewski HM, Ciardelli TL, and Johnson JE Jr. (1991). The microtubule-associated protein tau forms a triple-stranded left-hand helical polymer. J. Biol. Chem. 266, 22019&#x2013;22027.</Citation><ArticleIdList><ArticleId IdType="pubmed">1939223</ArticleId></ArticleIdList></Reference><Reference><Citation>Santarella RA, Skiniotis G, Goldie KN, Tittmann P, Gross H, Mandelkow EM, Mandelkow E, and Hoenger A (2004). Surface-decoration of microtubules by human tau. J. Mol. Biol. 339, 539&#x2013;553.</Citation><ArticleIdList><ArticleId IdType="pubmed">15147841</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoch KM, DeVos SL, Miller RL, Chun SJ, Norrbom M, Wozniak DF, Dawson HN, Bennett CF, Rigo F, and Miller TM (2016). Increased 4R-tau induces pathological changes in a human-tau mouse model. Neuron 90, 941&#x2013;947.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5040069</ArticleId><ArticleId IdType="pubmed">27210553</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulz KL, Eckert A, Rhein V, Mai S, Haase W, Reichert AS, Jendrach M, M&#xfc;ller WE, and Leuner K (2012). A new link to mitochondrial impairment in tauopathies. Mol. Neurobiol. 46, 205&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">22847631</ArticleId></ArticleIdList></Reference><Reference><Citation>Seyfried NT, Dammer EB, Swarup V, Nandakumar D, Duong DM, Yin L, Deng Q, Nguyen T, Hales CM, Wingo T, et al. (2017). A multi-network approach identifies protein-specific co-expression in asymptomatic and symptomatic Alzheimer&#x2019;s disease. Cell Syst 4, 60&#x2013;72.e4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5269514</ArticleId><ArticleId IdType="pubmed">27989508</ArticleId></ArticleIdList></Reference><Reference><Citation>Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, and Ideker T (2003). Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 13, 2498&#x2013;2504.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC403769</ArticleId><ArticleId IdType="pubmed">14597658</ArticleId></ArticleIdList></Reference><Reference><Citation>Silverstein AM, Galigniana MD, Chen MS, Owens-Grillo JK, Chinkers M, and Pratt WB (1997). Protein phosphatase 5 is a major component of glucocorticoid receptor.hsp90 complexes with properties of an FK506-binding immunophilin. J. Biol. Chem. 272, 16224&#x2013;16230.</Citation><ArticleIdList><ArticleId IdType="pubmed">9195923</ArticleId></ArticleIdList></Reference><Reference><Citation>Sohn PD, Huang CT, Yan R, Fan L, Tracy TE, Camargo CM, Montgomery KM, Arhar T, Mok SA, Freilich R, et al. (2019). Pathogenic tau impairs axon initial segment plasticity and excitability homeostasis. Neuron 104, 458&#x2013;470.e5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6880876</ArticleId><ArticleId IdType="pubmed">31542321</ArticleId></ArticleIdList></Reference><Reference><Citation>Sohn PD, Tracy TE, Son HI, Zhou Y, Leite RE, Miller BL, Seeley WW, Grinberg LT, and Gan L (2016). Acetylated tau destabilizes the cytoskeleton in the axon initial segment and is mislocalized to the somatodendritic compartment. Mol. Neurodegener. 11, 47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4928318</ArticleId><ArticleId IdType="pubmed">27356871</ArticleId></ArticleIdList></Reference><Reference><Citation>Sokolow S, Henkins KM, Bilousova T, Gonzalez B, Vinters HV, Miller CA, Cornwell L, Poon WW, and Gylys KH (2015). Pre-synaptic C-terminal truncated tau is released from cortical synapses in Alzheimer&#x2019;s disease. J. Neurochem. 133, 368&#x2013;379.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4397171</ArticleId><ArticleId IdType="pubmed">25393609</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al. (2005). Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545&#x2013;15550.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1239896</ArticleId><ArticleId IdType="pubmed">16199517</ArticleId></ArticleIdList></Reference><Reference><Citation>Swarup V, Chang TS, Duong DM, Dammer EB, Dai J, Lah JJ, Johnson ECB, Seyfried NT, Levey AI, and Geschwind DH (2020). Identification of conserved proteomic networks in neurodegenerative dementia. Cell Rep 31, 107807.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8221021</ArticleId><ArticleId IdType="pubmed">32579933</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor IR, Ahmad A, Wu T, Nordhues BA, Bhullar A, Gestwicki JE, and Zuiderweg ERP (2018). The disorderly conduct of Hsc70 and its interaction with the Alzheimer&#x2019;s-related Tau protein. J. Biol. Chem. 293, 10796&#x2013;10809.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6036187</ArticleId><ArticleId IdType="pubmed">29764935</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson AD, Scaglione KM, Prensner J, Gillies AT, Chinnaiyan A, Paulson HL, Jinwal UK, Dickey CA, and Gestwicki JE (2012). Analysis of the tau-associated proteome reveals that exchange of Hsp70 for Hsp90 is involved in tau degradation. ACS Chem. Biol. 7, 1677&#x2013;1686.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3477299</ArticleId><ArticleId IdType="pubmed">22769591</ArticleId></ArticleIdList></Reference><Reference><Citation>Tracy TE, Sohn PD, Minami SS, Wang C, Min SW, Li Y, Zhou Y, Le D, Lo I, Ponnusamy R, et al. (2016). Acetylated tau obstructs KIBRA-mediated signaling in synaptic plasticity and promotes Tauopathy-related memory loss. Neuron 90, 245&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4859346</ArticleId><ArticleId IdType="pubmed">27041503</ArticleId></ArticleIdList></Reference><Reference><Citation>Udeshi ND, Pedram K, Svinkina T, Fereshetian S, Myers SA, Aygun O, Krug K, Clauser K, Ryan D, Ast T, et al. (2017). Antibodies to biotin enable large-scale detection of biotinylation sites on proteins. Nat. Methods 14, 1167&#x2013;1170.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8954634</ArticleId><ArticleId IdType="pubmed">29039416</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanderweyde T, Apicco DJ, Youmans-Kidder K, Ash PEA, Cook C, Lummertz da Rocha E, Jansen-West K, Frame AA, Citro A, Leszyk JD, et al. (2016). Interaction of tau with the RNA-Binding Protein TIA1 Regulates tau Pathophysiology and Toxicity. Cell Rep 15, 1455&#x2013;1466.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5325702</ArticleId><ArticleId IdType="pubmed">27160897</ArticleId></ArticleIdList></Reference><Reference><Citation>Vizca&#xed;no JA, Csordas A, del-Toro N, Dianes JA, Griss J, Lavidas I, Mayer G, Perez-Riverol Y, Reisinger F, Ternent T, et al. (2016). 2016 update of the PRIDE database and its related tools. Nucleic Acids Res 44, D447&#x2013;D456.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4702828</ArticleId><ArticleId IdType="pubmed">26527722</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogel JW, Iturria-Medina Y, Strandberg OT, Smith R, Levitis E, Evans AC, and Hansson O; Alzheimer&#x2019;s Disease Neuroimaging Initiative, and Swedish BioFinder Study (2020). Spread of pathological tau proteins through communicating neurons in human Alzheimer&#x2019;s disease. Nat. Commun. 11, 2612.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7251068</ArticleId><ArticleId IdType="pubmed">32457389</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C, Ward ME, Chen R, Liu K, Tracy TE, Chen X, Xie M, Sohn PD, Ludwig C, Meyer-Franke A, et al. (2017a). Scalable production of iPSC-derived human neurons to identify tau-lowering compounds by high-content screening. Stem Cell Rep 9, 1221&#x2013;1233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5639430</ArticleId><ArticleId IdType="pubmed">28966121</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang P, Joberty G, Buist A, Vanoosthuyse A, Stancu IC, Vasconcelos B, Pierrot N, Faelth-Savitski M, Kienlen-Campard P, Octave JN, et al. (2017b). Tau interactome mapping based identification of Otub1 as Tau deubiquitinase involved in accumulation of pathological Tau forms in vitro and in vivo. Acta neuropathol 133, 731&#x2013;749.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5390007</ArticleId><ArticleId IdType="pubmed">28083634</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Williams D, M&#xfc;ller I, Lemieux M, Dukart R, Maia IBL, Wang H, Woerman AL, and Schmitt-Ulms G (2019). Tau interactome analyses in CRISPR-Cas9 engineered neuronal cells reveal ATPase-dependent binding of wild-type but not P301L Tau to non-muscle myosins. Sci. Rep. 9, 16238.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6838314</ArticleId><ArticleId IdType="pubmed">31700063</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Balaji V, Kaniyappan S, Kr&#xfc;ger L, Irsen S, Tepper K, Chandupatla R, Maetzler W, Schneider A, Mandelkow E, et al. (2017c). The release and trans-synaptic transmission of Tau via exosomes. Mol. Neurodegener. 12, 5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5237256</ArticleId><ArticleId IdType="pubmed">28086931</ArticleId></ArticleIdList></Reference><Reference><Citation>Weickert S, Wawrzyniuk M, John LH, R&#xfc;diger SGD, and Drescher M (2020). The mechanism of Hsp90-induced oligomerizaton of Tau. Sci. Adv. 6, eaax6999.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7069708</ArticleId><ArticleId IdType="pubmed">32201713</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcoxon F (1945). Individual comparisons by ranking methods. Biom. Bull. 1, 80&#x2013;83.</Citation></Reference><Reference><Citation>Wu JW, Hussaini SA, Bastille IM, Rodriguez GA, Mrejeru A, Rilett K, Sanders DW, Cook C, Fu H, Boonen RA, et al. (2016). Neuronal activity enhances tau propagation and tau pathology in vivo. Nat. Neurosci. 19, 1085&#x2013;1092.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4961585</ArticleId><ArticleId IdType="pubmed">27322420</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada K, Holth JK, Liao F, Stewart FR, Mahan TE, Jiang H, Cirrito JR, Patel TK, Hochgr&#xe4;fe K, Mandelkow EM, et al. (2014). Neuronal activity regulates extracellular tau in vivo. J. Exp. Med. 211, 387&#x2013;393.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3949564</ArticleId><ArticleId IdType="pubmed">24534188</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TC, Maeda J, Suhara T, Trojanowski JQ, and Lee VM (2007). Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53, 337&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pubmed">17270732</ArticleId></ArticleIdList></Reference><Reference><Citation>Zachariae U, and Grubm&#xfc;ller H (2008). Importin-beta: structural and dynamic determinants of a molecular spring. Structure 16, 906&#x2013;915.</Citation><ArticleIdList><ArticleId IdType="pubmed">18547523</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B, and Horvath S (2005). A general framework for weighted gene co-expression network analysis. Stat. Appl. Genet. Mol. Biol. 4, Article 17.</Citation><ArticleIdList><ArticleId IdType="pubmed">16646834</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Pak C, Han Y, Ahlenius H, Zhang Z, Chanda S, Marro S, Patzke C, Acuna C, Covy J, et al. (2013). Rapid single-step induction of functional neurons from human pluripotent stem cells. Neuron 78, 785&#x2013;798.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3751803</ArticleId><ArticleId IdType="pubmed">23764284</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng X, Boyer L, Jin M, Mertens J, Kim Y, Ma L, Ma L, Hamm M, Gage FH, and Hunter T (2016). Metabolic reprogramming during neuronal differentiation from aerobic glycolysis to neuronal oxidative phosphorylation. eLife 5, e13374.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4963198</ArticleId><ArticleId IdType="pubmed">27282387</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou L, McInnes J, Wierda K, Holt M, Herrmann AG, Jackson RJ, Wang YC, Swerts J, Beyens J, Miskiewicz K, et al. (2017). Tau association with synaptic vesicles causes presynaptic dysfunction. Nat. Commun. 8, 15295.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5437271</ArticleId><ArticleId IdType="pubmed">28492240</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35099509</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>20</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>79</Volume><Issue>3</Issue><PubDate><Year>2022</Year><Month>Mar</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum.</ArticleTitle><Pagination><StartPage>228</StartPage><EndPage>243</EndPage><MedlinePgn>228-243</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2021.5216</ELocationID><Abstract><AbstractText Label="IMPORTANCE">One characteristic histopathological event in Alzheimer disease (AD) is cerebral amyloid aggregation, which can be detected by biomarkers in cerebrospinal fluid (CSF) and on positron emission tomography (PET) scans. Prevalence estimates of amyloid pathology are important for health care planning and clinical trial design.</AbstractText><AbstractText Label="OBJECTIVE">To estimate the prevalence of amyloid abnormality in persons with normal cognition, subjective cognitive decline, mild cognitive impairment, or clinical AD dementia and to examine the potential implications of cutoff methods, biomarker modality (CSF or PET), age, sex, APOE genotype, educational level, geographical region, and dementia severity for these estimates.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">This cross-sectional, individual-participant pooled study included participants from 85 Amyloid Biomarker Study cohorts. Data collection was performed from January 1, 2013, to December 31, 2020. Participants had normal cognition, subjective cognitive decline, mild cognitive impairment, or clinical AD dementia. Normal cognition and subjective cognitive decline were defined by normal scores on cognitive tests, with the presence of cognitive complaints defining subjective cognitive decline. Mild cognitive impairment and clinical AD dementia were diagnosed according to published criteria.</AbstractText><AbstractText Label="EXPOSURES">Alzheimer disease biomarkers detected on PET or in CSF.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Amyloid measurements were dichotomized as normal or abnormal using cohort-provided cutoffs for CSF or PET or by visual reading for PET. Adjusted data-driven cutoffs for abnormal amyloid were calculated using gaussian mixture modeling. Prevalence of amyloid abnormality was estimated according to age, sex, cognitive status, biomarker modality, APOE carrier status, educational level, geographical location, and dementia severity using generalized estimating equations.</AbstractText><AbstractText Label="RESULTS">Among the 19&#x202f;097 participants (mean [SD] age, 69.1 [9.8] years; 10&#x202f;148 women [53.1%]) included, 10&#x202f;139 (53.1%) underwent an amyloid PET scan and 8958 (46.9%) had an amyloid CSF measurement. Using cohort-provided cutoffs, amyloid abnormality prevalences were similar to 2015 estimates for individuals without dementia and were similar across PET- and CSF-based estimates (24%; 95% CI, 21%-28%) in participants with normal cognition, 27% (95% CI, 21%-33%) in participants with subjective cognitive decline, and 51% (95% CI, 46%-56%) in participants with mild cognitive impairment, whereas for clinical AD dementia the estimates were higher for PET than CSF (87% vs 79%; mean difference, 8%; 95% CI, 0%-16%; P&#x2009;=&#x2009;.04). Gaussian mixture modeling-based cutoffs for amyloid measures on PET scans were similar to cohort-provided cutoffs and were not adjusted. Adjusted CSF cutoffs resulted in a 10% higher amyloid abnormality prevalence than PET-based estimates in persons with normal cognition (mean difference, 9%; 95% CI, 3%-15%; P&#x2009;=&#x2009;.004), subjective cognitive decline (9%; 95% CI, 3%-15%; P&#x2009;=&#x2009;.005), and mild cognitive impairment (10%; 95% CI, 3%-17%; P&#x2009;=&#x2009;.004), whereas the estimates were comparable in persons with clinical AD dementia (mean difference, 4%; 95% CI, -2% to 9%; P&#x2009;=&#x2009;.18).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">This study found that CSF-based estimates using adjusted data-driven cutoffs were up to 10% higher than PET-based estimates in people without dementia, whereas the results were similar among people with dementia. This finding suggests that preclinical and prodromal AD may be more prevalent than previously estimated, which has important implications for clinical trial recruitment strategies and health care planning policies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jansen</LastName><ForeName>Willemijn J</ForeName><Initials>WJ</Initials><AffiliationInfo><Affiliation>Alzheimer Centre Limburg, Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Maastricht, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Banner Alzheimer's Institute, Phoenix, Arizona.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Janssen</LastName><ForeName>Olin</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Alzheimer Centre Limburg, Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Maastricht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tijms</LastName><ForeName>Betty M</ForeName><Initials>BM</Initials><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam University Medical Center (UMC), Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vos</LastName><ForeName>Stephanie J B</ForeName><Initials>SJB</Initials><AffiliationInfo><Affiliation>Alzheimer Centre Limburg, Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Maastricht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ossenkoppele</LastName><ForeName>Rik</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam University Medical Center (UMC), Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences, Malm&#xf6;, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Visser</LastName><ForeName>Pieter Jelle</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Alzheimer Centre Limburg, Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Maastricht, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam University Medical Center (UMC), Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Amyloid Biomarker Study Group</CollectiveName></Author><Author ValidYN="Y"><LastName>Aarsland</LastName><ForeName>Dag</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Division for Neurogeriatrics, Karolinska Institutet, Huddinge, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Age-Related Medicine, Stavanger University Hospital, Stavanger, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alcolea</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Altomare</LastName><ForeName>Daniele</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Laboratory Alzheimer's Neuroimaging and Epidemiology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Fatebenefratelli, Brescia, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>von Arnim</LastName><ForeName>Christine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Geriatrics, University of Goettingen Medical School, Goettingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinic for Neurogeriatrics and Neurological Rehabilitation, University and Rehabilitation Hospital Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baiardi</LastName><ForeName>Simone</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Experimental Diagnostic and Specialty Medicine (DIMES), University of Bologna, Bologna, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baldeiras</LastName><ForeName>Ines</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Center for Neuroscience and Cell Biology (CIBB), University of Coimbra, Coimbra, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology Department and Laboratory of Neurochemistry, Centro Hospitalar e Universit&#xe1;rio de Coimbra, Praceta Professor Mota Pinto, Coimbra, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, University of Coimbra, Azinhaga de Santa Comba, Coimbra, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barthel</LastName><ForeName>Henryk</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, University Hospital of Leipzig, Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bateman</LastName><ForeName>Randall J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Neurology and the Alzheimer's Disease Research Center, Washington University School of Medicine in St Louis, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Berckel</LastName><ForeName>Bart</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Binette</LastName><ForeName>Alexa Pichet</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Faculty of Medicine, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Douglas Mental Health University Institute, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Department of Neuroscience and Physiology, Sahlgren's University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boada</LastName><ForeName>Merce</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Research Center and Memory Clinic of Fundaci&#xf3; Alzheimer Centre Educacional, Institut Catal&#xe0; de Neuroci&#xe8;ncies Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boecker</LastName><ForeName>Henning</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Deutsches Zentrum f&#xfc;r Neurodegenerative Erkrankungen e.V. (DZNE), Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bottlaender</LastName><ForeName>Michel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Universit&#xe9; Paris-Saclay, Service Hospitalier Fr&#xe9;d&#xe9;ric Joliot (CEA), French National Centre for Scientific Research (CNRS), Institut National de la Sant&#xe9; et de la Recherche M&#xe9;dicale (INSERM), BioMaps, Service Hospitalier Frederic Joliot, Orsay, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>den Braber</LastName><ForeName>Anouk</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Alzheimer Centre Amsterdam, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brooks</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Translational and Clinical Research Institute, University of Newcastle upon Tyne, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Nuclear Medicine, Positron Emission Tomography Centre, Aarhus University, Aarhus, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Brain Sciences, Imperial College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Buchem</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Hospital Leiden, Leiden, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Camus</LastName><ForeName>Vincent</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Unite Mixte de Recherche, INSERM U930, French National Centre for Scientific Research (CNRS) ERL, Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carill</LastName><ForeName>Jose Manuel</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Nuclear Medicine Department, University Hospital Marqu&#xe9;s de Valdecilla, Molecular Imaging, Instituto de Investigaci&#xf3;n Sanitaria Valdecilla (IDIVAL), University of Cantabria, Santander, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cerman</LastName><ForeName>Jiri</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Kewei</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Banner Alzheimer's Institute, Phoenix, Arizona.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ch&#xe9;telat</LastName><ForeName>Ga&#xeb;l</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Normandie University, University of Caen Normandie (UNICAEN), INSERM, U1237, Physiopathology and Imaging of Neurological Disorders (PhIND), Institut Blood and Brain at Caen-Normandie, Cyceron, Caen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chipi</LastName><ForeName>Elena</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Centro Disturbi della Memoria, Laboratorio di Neurochimica Clinica, Clinica Neurologica, Universit&#xe0; di Perugia, Perugia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>Ann D</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daniels</LastName><ForeName>Alisha</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine in St Louis, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Delarue</LastName><ForeName>Marion</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Normandie University, University of Caen Normandie (UNICAEN), INSERM, U1237, Physiopathology and Imaging of Neurological Disorders (PhIND), Institut Blood and Brain at Caen-Normandie, Cyceron, Caen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Didic</LastName><ForeName>Mira</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Assistance Publique H&#xf4;pitaux de Marseille (AP-HM), Timone, Service de Neurologie et Neuropsychologie, H&#xf4;pital Timone Adultes, Marseille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Aix Marseille Univ, INSERM, Institut de Neurosciences des Syst&#xe8;mes (INS), Marseille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Drzezga</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Deutsches Zentrum f&#xfc;r Neurodegenerative Erkrankungen e.V. (DZNE), Bonn, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Nuclear Medicine, University Hospital of Cologne, Cologne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dubois</LastName><ForeName>Bruno</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurology, Institut de la M&#xe9;moire et de la Maladie d'Alzheimer, Centre de R&#xe9;f&#xe9;rence D&#xe9;mences Rares, H&#xf4;pital de la Piti&#xe9;-Salp&#xea;tri&#xe8;re, Assistance Publique-H&#xf4;pitaux de Paris (AP-HP), Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eckerstr&#xf6;m</LastName><ForeName>Marie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ekblad</LastName><ForeName>Laura L</ForeName><Initials>LL</Initials><AffiliationInfo><Affiliation>Turku PET Centre, University of Turku, Turku, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Engelborghs</LastName><ForeName>Sebastiaan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Reference Center for Biological Markers of Dementia (BIODEM), University of Antwerp, Antwerp, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Neurosciences, Vrije Universiteit Brussel, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Epelbaum</LastName><ForeName>St&#xe9;phane</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Institut de la M&#xe9;moire et de la Maladie d'Alzheimer, Centre de R&#xe9;f&#xe9;rence D&#xe9;mences Rares, H&#xf4;pital de la Piti&#xe9;-Salp&#xea;tri&#xe8;re, Assistance Publique-H&#xf4;pitaux de Paris (AP-HP), Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fagan</LastName><ForeName>Anne M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Neurology and the Alzheimer's Disease Research Center, Washington University School of Medicine in St Louis, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>Yong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fladby</LastName><ForeName>Tormod</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Akershus University Hospital, Lorenskog, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fleisher</LastName><ForeName>Adam S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis, Indiana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van der Flier</LastName><ForeName>Wiesje M</ForeName><Initials>WM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Alzheimer Centre Amsterdam, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>F&#xf6;rster</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, Klinikum rechts der Isar, Technische Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Nuclear Medicine, Klinikum Bayreuth, Bayreuth, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fortea</LastName><ForeName>Juan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frederiksen</LastName><ForeName>Kristian Steen</ForeName><Initials>KS</Initials><AffiliationInfo><Affiliation>Danish Dementia Research Center, Department of Neurology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Freund-Levi</LastName><ForeName>Yvonne</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>School of Medical Sciences, &#xd6;rebro University, &#xd6;rebro, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurobiology, Care Sciences and Society, Division of Clinical Geriatrics, Karolinska Institutet Center for Alzheimer Research, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Old Age Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frings</LastName><ForeName>Lars</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frisoni</LastName><ForeName>Giovanni B</ForeName><Initials>GB</Initials><AffiliationInfo><Affiliation>Memory Clinic, University Hospitals and University of Geneva, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fr&#xf6;hlich</LastName><ForeName>Lutz</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Geriatric Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gabryelewicz</LastName><ForeName>Tomasz</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Disorders, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gertz</LastName><ForeName>Hermann-Josef</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Klinik und Poliklinik f&#xfc;r Psychiatrie und Psychotherapie, Universit&#xe4;tsklinikum Leipzig, Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gill</LastName><ForeName>Kiran Dip</ForeName><Initials>KD</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Postgraduate Institute of Medical Education and Research, Chandigarh, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gkatzima</LastName><ForeName>Olymbia</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Greek Association of Alzheimer's Disease and Related Disorders, Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xf3;mez-Tortosa</LastName><ForeName>Estrella</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurology, Fundaci&#xf3;n Jim&#xe9;nez D&#xed;az, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grimmer</LastName><ForeName>Timo</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technical University of Munich, School of Medicine, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guedj</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Aix Marseille University, AP-HM, CNRS, Centrale Marseille, Institut Fresnel, Timone Hospital, Centre Europ&#xe9;en de Recherche en Imagerie M&#xe9;dicale (CERIMED), Nuclear Medicine Department, Marseille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Habeck</LastName><ForeName>Christian G</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>Department of Neurology, Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hampel</LastName><ForeName>Harald</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Sorbonne University, Clinical Research Group no. 21, Alzheimer Precision Medicine, AP-HP, Piti&#xe9;-Salp&#xea;tri&#xe8;re Hospital, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Handels</LastName><ForeName>Ron</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Alzheimer Centre Limburg, Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Maastricht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hansson</LastName><ForeName>Oskar</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences, Malm&#xf6;, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hausner</LastName><ForeName>Lucrezia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Universit&#xe4;t Heidelberg, Abteilung Gerontopsychiatrie, Zentralinstitut f&#xfc;r Seelische Gesundheit Mannheim, Mannheim, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hellwig</LastName><ForeName>Sabine</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heneka</LastName><ForeName>Michael T</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital of Bonn, Bonn, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herukka</LastName><ForeName>Sanna-Kaisa</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>Institute of Clinical Medicine-Neurology, University of Eastern Finland, Kuopio, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurocenter, Neurology, Kuopio University Hospital, Kuopio, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hildebrandt</LastName><ForeName>Helmut</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Klinikum Bremen-Ost, University of Oldenburg, Institute of Psychology, Oldenburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hodges</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Brain and Mind Centre, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hort</LastName><ForeName>Jakub</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Chin-Chang</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Chang Gung Memorial Foundation-Linkou, Taoyuan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iriondo</LastName><ForeName>Ane Juaristi</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Center for Research and Advanced Therapies, Centro de Investigaci&#xf3;n y Ciencias Avanzadas-Alzheimer Foundation, Donostia-San Sebastian, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Itoh</LastName><ForeName>Yoshiaki</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Osaka City University Graduate School of Medicine, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ivanoiu</LastName><ForeName>Adrian</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Cliniques Universitaires Saint-Luc, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jagust</LastName><ForeName>William J</ForeName><Initials>WJ</Initials><AffiliationInfo><Affiliation>Helen Wills Neuroscience Institute, University of California, Berkeley, Berkeley.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Molecular Biophysics and Integrated Bioimaging, Lawrence Berkeley National Laboratory, Berkeley, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jessen</LastName><ForeName>Frank</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Medical Faculty, University of Cologne, Cologne, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>DZNE, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johannsen</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Memory Disorder Unit, Copenhagen University Hospital, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Keith A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Department of Radiology, Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kandimalla</LastName><ForeName>Ramesh</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Postgraduate Institute of Medical Education and Research, Chandigarh, India.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiation Oncology, Emory University, Atlanta, Georgia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Applied Biology, Council of Scientific and Industrial Research (CSIR)-Indian Institute of Chemical Technology, Uppal Road, Tarnaka, Hyderabad, Telangana State, India.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry, Kakatiya Medical College/Mahatma Gandhi Memorial Hospital, Warangal, Telangana State, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kapaki</LastName><ForeName>Elisabeth N</ForeName><Initials>EN</Initials><AffiliationInfo><Affiliation>National and Kapodistrian University of Athens, School of Medicine, 1st Department of Neurology, Eginition Hospital, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kern</LastName><ForeName>Silke</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Neuropsychiatric Epidemiology Unit, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kilander</LastName><ForeName>Lena</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Public Health and Caring Sciences/Geriatrics, Uppsala University, Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klimkowicz-Mrowiec</LastName><ForeName>Aleksandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine and Gerontology, Faculty of Medicine, Jagiellonian University Medical College, Krakow, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klunk</LastName><ForeName>William E</ForeName><Initials>WE</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of Pittsburgh, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koglin</LastName><ForeName>Norman</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Life Molecular Imaging GmbH, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kornhuber</LastName><ForeName>Johannes</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, University Hospital, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kramberger</LastName><ForeName>Milica G</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Medical Centre Ljubljana, Ljubljana, Slovenia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuo</LastName><ForeName>Hung-Chou</ForeName><Initials>HC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Chang Gung Memorial Hospital at Linkou Medical Center, Chang Gung University College of Medicine, Taoyuan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Laere</LastName><ForeName>Koen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Nuclear Medicine and Molecular Imaging, University Hospitals Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Imaging and Pathology, Katholieke Universiteit Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Landau</LastName><ForeName>Susan M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Helen Wills Neuroscience Institute, University of California, Berkeley, Berkeley.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Landeau</LastName><ForeName>Brigitte</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Normandie University, University of Caen Normandie (UNICAEN), INSERM, U1237, Physiopathology and Imaging of Neurological Disorders (PhIND), Institut Blood and Brain at Caen-Normandie, Cyceron, Caen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Dong Young</ForeName><Initials>DY</Initials><AffiliationInfo><Affiliation>Department of Neuropsychiatry, Seoul National University Hospital, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Leon</LastName><ForeName>Mony</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Brain Health Imaging Institute, Department of Radiology, Weill Cornell Medicine, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leyton</LastName><ForeName>Cristian E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>School of Psychology, Faculty of Science, The University of Sydney, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Kun-Ju</ForeName><Initials>KJ</Initials><AffiliationInfo><Affiliation>Healthy Aging Research Center and Department of Medical Imaging and Radiological Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Nuclear Medicine and Molecular Imaging Center, Linkou Chang Gung Memorial Hospital, Guishan, Taoyuan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lle&#xf3;</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xf6;wenmark</LastName><ForeName>Malin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Memory Clinic, Department of Geriatrics, Uppsala University Hospital, Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madsen</LastName><ForeName>Karine</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Neurobiology Research Unit, Copenhagen University Hospital, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maier</LastName><ForeName>Wolfgang</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Diseases and Geriatric Psychiatry, University of Bonn, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marcusson</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Acute Internal Medicine and Geriatrics, Department of Health, Medicine and Caring Sciences, Link&#xf6;ping University, Link&#xf6;ping, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marqui&#xe9;</LastName><ForeName>Marta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Research Center and Memory Clinic of Fundaci&#xf3; Alzheimer Centre Educacional, Institut Catal&#xe0; de Neuroci&#xe8;ncies Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martinez-Lage</LastName><ForeName>Pablo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Center for Research and Advanced Therapies, CITA-Alzheimer Foundation, Donostia-San Sebastian, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maserejian</LastName><ForeName>Nancy</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Biogen, Cambridge, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mattsson</LastName><ForeName>Niklas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences, Malm&#xf6;, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Mendon&#xe7;a</LastName><ForeName>Alexandre</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Lisboa, Lisboa, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meyer</LastName><ForeName>Philipp T</ForeName><Initials>PT</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Bruce L</ForeName><Initials>BL</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Minatani</LastName><ForeName>Shinobu</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Osaka City University Graduate School of Medicine, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mintun</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Avid Radiopharmaceuticals, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mok</LastName><ForeName>Vincent C T</ForeName><Initials>VCT</Initials><AffiliationInfo><Affiliation>Division of Neurology, Department of Medicine and Therapeutics, Prince of Wales Hospital, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Margaret K.L. Cheung Research Centre for Management of Parkinsonism, Gerald Choa Neuroscience Centre, Lui Che Woo Institute of Innovative Medicine, The Chinese University of Hong Kong, Hong Kong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>BrainNow Research Institute, Guangdong Province, Shenzhen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Molinuevo</LastName><ForeName>Jose Luis</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease and Other Cognitive Disorders Unit, Institut d'Investigacions Biom&#xe8;diques August Pi i Sunyer (IDIBAPS), Clinic University Hospital, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morbelli</LastName><ForeName>Silvia Daniela</ForeName><Initials>SD</Initials><AffiliationInfo><Affiliation>Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ospedale Policlinico San Martino, IRCCS, Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Neurology and the Alzheimer's Disease Research Center, Washington University School of Medicine in St Louis, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mroczko</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurodegeneration Diagnostics, Medical University of Bia&#x142;ystok, Bia&#x142;ystok, Poland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemical Diagnostics, University Hospital of Bia&#x142;ystok, Bia&#x142;ystok, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Na</LastName><ForeName>Duk L</ForeName><Initials>DL</Initials><AffiliationInfo><Affiliation>Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Center, Samsung Medical Center, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Newberg</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Myrna Brind Center of Integrative Medicine, Thomas Jefferson University and Hospital, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nobili</LastName><ForeName>Flavio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DINOGMI), University of Genoa, Genoa, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ospedale Policlinico San Martino, IRCCS, Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nordberg</LastName><ForeName>Agneta</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Division for Neurogeriatrics, Karolinska Institutet, Huddinge, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Age-Related Medicine, Stavanger University Hospital, Stavanger, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olde Rikkert</LastName><ForeName>Marcel G M</ForeName><Initials>MGM</Initials><AffiliationInfo><Affiliation>Radboudumc Alzheimer Centre, Radboud University Medical Center, Nijmegen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Oliveira</LastName><ForeName>Catarina Resende</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>Center for Neuroscience and Cell Biology (CIBB), University of Coimbra, Coimbra, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olivieri</LastName><ForeName>Pauline</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurology of Memory and Language, Groupe Hospitalier Universitaire Paris Psychiatry and Neurosciences, H&#xf4;pital Sainte Anne, F-75014, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universit&#xe9; de Paris, Paris, Universit&#xe9; Paris-Saclay, BioMaps, CEA, CNRS, INSERM, Orsay, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Orellana</LastName><ForeName>Adela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Research Center and Memory Clinic of Fundaci&#xf3; Alzheimer Centre Educacional, Institut Catal&#xe0; de Neuroci&#xe8;ncies Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paraskevas</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>National and Kapodistrian University of Athens, School of Medicine, 1st Department of Neurology, Eginition Hospital, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parchi</LastName><ForeName>Piero</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Istituto delle Scienze Neurologiche di Bologna, IRCCS, Bologna, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>DIMES, University of Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pardini</LastName><ForeName>Matteo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>DINOGMI, University of Genoa, Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parnetti</LastName><ForeName>Lucilla</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Centro Disturbi della Memoria, Laboratorio di Neurochimica Clinica, Clinica Neurologica, Universit&#xe0; di Perugia, Perugia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peters</LastName><ForeName>Oliver</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Klinik f&#xfc;r Psychiatrie und Psychotherapie, Charit&#xe9; Universit&#xe4;tsmedizin Berlin-CBF, Berlin, Deutschland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poirier</LastName><ForeName>Judes</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Studies on Prevention of Alzheimer's Disease (StOP-AD) Centre, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Popp</LastName><ForeName>Julius</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Geriatric Psychiatry, University Hospital of Psychiatry Z&#xfc;rich and University of Z&#xfc;rich, Z&#xfc;rich, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Old Age Psychiatry, Department of Psychiatry, University Hospital of Lausanne and University of Lausanne, Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prabhakar</LastName><ForeName>Sudesh</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Nehru Hospital, Postgraduate Institute of Medical Education and Research, Chandigarh, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rabinovici</LastName><ForeName>Gil D</ForeName><Initials>GD</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramakers</LastName><ForeName>Inez H</ForeName><Initials>IH</Initials><AffiliationInfo><Affiliation>Alzheimer Centre Limburg, Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Maastricht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rami</LastName><ForeName>Lorena</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Cl&#xed;nic of Barcelona, IDIBAPS, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reiman</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Banner Alzheimer's Institute, Phoenix, Arizona.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rinne</LastName><ForeName>Juha O</ForeName><Initials>JO</Initials><AffiliationInfo><Affiliation>Turku PET Centre, Turku, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodrigue</LastName><ForeName>Karen M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Center for Vital Longevity, School of Behavioral and Brain Sciences, The University of Texas at Dallas, Dallas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodr&#xed;guez-Rodriguez</LastName><ForeName>Eloy</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Neurology Department, Hospital Universitario Marqu&#xe9;s de Valdecilla and IDIVAL, Santander, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roe</LastName><ForeName>Catherine M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Neurology and the Alzheimer's Disease Research Center, Washington University School of Medicine in St Louis, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosa-Neto</LastName><ForeName>Pedro</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Studies on Prevention of Alzheimer's Disease (StOP-AD) Centre, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosen</LastName><ForeName>Howard J</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rot</LastName><ForeName>Uros</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Neurology, Medical Center, Zaloska 7, Ljubljana, Slovenia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rowe</LastName><ForeName>Christopher C</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Department of Molecular Imaging, Austin Health, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Florey Department of Neuroscience, University of Melbourne, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>R&#xfc;ther</LastName><ForeName>Eckart</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, University Medical Center, Georg-August University, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruiz</LastName><ForeName>Agust&#xed;n</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Research Center and Memory Clinic of Fundaci&#xf3; Alzheimer Centre Educacional, Institut Catal&#xe0; de Neuroci&#xe8;ncies Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sabri</LastName><ForeName>Osama</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, University Hospital of Leipzig, Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sakhardande</LastName><ForeName>Jayant</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Cognitive Neuroscience Division, Department of Neurology and the Taub Institute, Columbia University, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S&#xe1;nchez-Juan</LastName><ForeName>Pascual</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Service of Neurology, University Hospital Marqu&#xe9;s de Valdecilla-IDIVAL, CIBERNED, Santander, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sando</LastName><ForeName>Sigrid Botne</ForeName><Initials>SB</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University Hospital of Trondheim, Trondheim, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santana</LastName><ForeName>Isabel</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Center for Neuroscience and Cell Biology (CIBB), University of Coimbra, Coimbra, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology Department and Laboratory of Neurochemistry, Centro Hospitalar e Universit&#xe1;rio de Coimbra, Praceta Professor Mota Pinto, Coimbra, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, University of Coimbra, Azinhaga de Santa Comba, Coimbra, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sarazin</LastName><ForeName>Marie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology of Memory and Language, Groupe Hospitalier Universitaire Paris Psychiatry and Neurosciences, H&#xf4;pital Sainte Anne, F-75014, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universit&#xe9; de Paris, Paris, Universit&#xe9; Paris-Saclay, BioMaps, CEA, CNRS, INSERM, Orsay, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scheltens</LastName><ForeName>Philip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurology, Alzheimer Centre Amsterdam, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schr&#xf6;der</LastName><ForeName>Johannes</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Section for Geriatric Psychiatry, University of Heidelberg, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Selnes</LastName><ForeName>Per</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurology, Akershus University Hospital, Lorenskog, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seo</LastName><ForeName>Sang Won</ForeName><Initials>SW</Initials><AffiliationInfo><Affiliation>Department of Neurology, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silva</LastName><ForeName>Dina</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Lisboa, Lisboa, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Skoog</LastName><ForeName>Ingmar</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Neuropsychiatric Epidemiology Unit, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Snyder</LastName><ForeName>Peter J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, The University of Rhode Island, Kingston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soininen</LastName><ForeName>Hilkka</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurocenter, Department of Neurology, Kuopio University Hospital, Kuopio, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sollberger</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Memory Clinic, University Department of Geriatric Medicine, Felix Platter-Hospital, Basel, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University Hospital Basel, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Aging Brain Study, Department of Neurology, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spiru</LastName><ForeName>Luisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Geriatrics, Gerontology and Old Age Psychiatry Clinical Department, Carol Davila University of Medicine and Pharmacy-Elias, Emergency Clinical Hospital, Bucharest, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory Clinic and Longevity Medicine, Ana Aslan International Foundation, Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stern</LastName><ForeName>Yaakov</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Cognitive Neuroscience Division, Department of Neurology and the Taub Institute, Columbia University, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stomrud</LastName><ForeName>Erik</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences, Malm&#xf6;, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takeda</LastName><ForeName>Akitoshi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Osaka City University Graduate School of Medicine, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teichmann</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Institut de la M&#xe9;moire et de la Maladie d'Alzheimer, Centre de R&#xe9;f&#xe9;rence D&#xe9;mences Rares, H&#xf4;pital de la Piti&#xe9;-Salp&#xea;tri&#xe8;re, Assistance Publique-H&#xf4;pitaux de Paris (AP-HP), Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre de R&#xe9;f&#xe9;rence D&#xe9;mences Rares, Piti&#xe9;-Salp&#xea;tri&#xe8;re University Hospital, AP-HP, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teunissen</LastName><ForeName>Charlotte E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Department of Neurology, Alzheimer Centre Amsterdam, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Louisa I</ForeName><Initials>LI</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Human Behavior, Alpert Medical School of Brown University, Providence, Rhode Island.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tomassen</LastName><ForeName>Jori</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Alzheimer Centre Amsterdam, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsolaki</LastName><ForeName>Magda</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Aristotle University of Thessaloniki, Memory and Dementia Center, 3rd Department of Neurology, George Papanicolau General Hospital of Thessaloniki, Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vandenberghe</LastName><ForeName>Rik</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Laboratory for Cognitive Neurology, Department of Neurosciences, University of Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology Department, University Hospitals Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verbeek</LastName><ForeName>Marcel M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Departments of Neurology and Laboratory Medicine, Radboud University Medical Center, Donders Institute for Brain, Cognition and Behaviour, Radboud Alzheimer Centre, Nijmegen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verhey</LastName><ForeName>Frans R J</ForeName><Initials>FRJ</Initials><AffiliationInfo><Affiliation>Alzheimer Centre Limburg, Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Maastricht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Villemagne</LastName><ForeName>Victor</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Molecular Imaging, Austin Health, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Molecular Biomarkers in Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Villeneuve</LastName><ForeName>Sylvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Faculty of Medicine, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Douglas Mental Health University Institute, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>McConnell Brain Imaging Centre, Montreal Neurological Institute, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vogelgsang</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Translational Neuroscience Laboratory, McLean Hospital, Harvard Medical School, Belmont, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Waldemar</LastName><ForeName>Gunhild</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Danish Dementia Research Center, Department of Neurology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wallin</LastName><ForeName>Anders</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Neuropsychiatric Epidemiology Unit, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wallin</LastName><ForeName>&#xc5;sa K</ForeName><Initials>&#xc5;K</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences, Malm&#xf6;, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wiltfang</LastName><ForeName>Jens</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, University Medical Center G&#xf6;ttingen, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Neurology, Department of Neurodegeneration and Hertie-Institute for Clinical Brain Research, University of Tuebingen, Tuebingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wolk</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yen</LastName><ForeName>Tzu-Chen</ForeName><Initials>TC</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine and Molecular Imaging Center, Linkou Chang Gung Memorial Hospital, Guishan, Taoyuan, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Healthy Aging Research Center and Department of Medical Imaging and Radiological Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zboch</LastName><ForeName>Marzena</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Research-Scientific-Didactic Centre of Dementia-Related Diseases in Scinawa, Medical University of Wroclaw, Wroclaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Neuropsychiatric Epidemiology Unit, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, University College London (UCL) Queen Square Institute of Neurology, Queen Square, London, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute, London, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS104147</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG031581</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G84/6523</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P30 AG062422</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG036694</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058227">Amyloidogenic Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2022 Mar 1;79(3):225-227. doi: 10.1001/jamaneurol.2021.5225.</RefSource><PMID Version="1">35099511</PMID></CommentsCorrections><CommentsCorrections RefType="ErratumIn"><RefSource>JAMA Neurol. 2022 Mar 1;79(3):313. doi: 10.1001/jamaneurol.2022.0265.</RefSource><PMID Version="1">35285880</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058227" MajorTopicYN="N">Amyloidogenic Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000686" MajorTopicYN="Y">Amyloidosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="Y">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>2</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>1</Month><Day>31</Day><Hour>12</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>6</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35099509</ArticleId><ArticleId IdType="mid">NIHMS2077955</ArticleId><ArticleId IdType="pmc">PMC12138908</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2021.5216</ArticleId><ArticleId IdType="pii">2788270</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jack CR Jr, Bennett DA, Blennow K, et al.; Contributors. NIA-AA research framework: toward a biological definition of Alzheimer&#x2019;s disease. Alzheimers Dement. 2018;14(4):535&#x2013;562. doi:10.1016/j.jalz.2018.02.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.02.018</ArticleId><ArticleId IdType="pmc">PMC5958625</ArticleId><ArticleId IdType="pubmed">29653606</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheltens P, De Strooper B, Kivipelto M, et al. Alzheimer&#x2019;s disease. Lancet. 2021;397(10284):1577&#x2013;1590. doi:10.1016/S0140-6736(20)32205-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32205-4</ArticleId><ArticleId IdType="pmc">PMC8354300</ArticleId><ArticleId IdType="pubmed">33667416</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldman HH, Haas M, Gandy S, et al.; One Mind for Research and the New York Academy of Sciences. Alzheimer&#x2019;s disease research and development: a call for a new research roadmap. Ann N Y Acad Sci. 2014;1313:1&#x2013;16. doi:10.1111/nyas.12424</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nyas.12424</ArticleId><ArticleId IdType="pubmed">24754377</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Langbaum JB, Tariot PN, et al. CAP&#x2013;advancing the evaluation of preclinical Alzheimer disease treatments. Nat Rev Neurol. 2016;12(1):56&#x2013;61. doi:10.1038/nrneurol.2015.177</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2015.177</ArticleId><ArticleId IdType="pmc">PMC4847536</ArticleId><ArticleId IdType="pubmed">26416539</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Rentz DM, Johnson KA, et al. The A4 study: stopping AD before symptoms begin? Sci Transl Med. 2014;6(228):228fs13. doi:10.1126/scitranslmed.3007941</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3007941</ArticleId><ArticleId IdType="pmc">PMC4049292</ArticleId><ArticleId IdType="pubmed">24648338</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen WJ, Ossenkoppele R, Knol DL, et al.; Amyloid Biomarker Study Group. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA. 2015;313(19):1924&#x2013;1938. doi:10.1001/jama.2015.4668</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2015.4668</ArticleId><ArticleId IdType="pmc">PMC4486209</ArticleId><ArticleId IdType="pubmed">25988462</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R, Jansen WJ, Rabinovici GD, et al.; Amyloid PET Study Group. Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. JAMA. 2015;313(19):1939&#x2013;1949. doi:10.1001/jama.2015.4669</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2015.4669</ArticleId><ArticleId IdType="pmc">PMC4517678</ArticleId><ArticleId IdType="pubmed">25988463</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Andreasson U, Persson S, et al. The Alzheimer&#x2019;s Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement. 2011;7(4):386&#x2013;395.e6. doi:10.1016/j.jalz.2011.05.2243</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2011.05.2243</ArticleId><ArticleId IdType="pmc">PMC3710290</ArticleId><ArticleId IdType="pubmed">21784349</ArticleId></ArticleIdList></Reference><Reference><Citation>Vos SJ, Visser PJ, Verhey F, et al. Variability of CSF Alzheimer&#x2019;s disease biomarkers: implications for clinical practice. PLoS One. 2014;9(6):e100784. doi:10.1371/journal.pone.0100784</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0100784</ArticleId><ArticleId IdType="pmc">PMC4069102</ArticleId><ArticleId IdType="pubmed">24959687</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois B, Villain N, Frisoni GB, et al. Clinical diagnosis of Alzheimer&#x2019;s disease: recommendations of the International Working Group. Lancet Neurol. 2021;20(6):484&#x2013;496. doi:10.1016/S1474-4422(21)00066-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(21)00066-1</ArticleId><ArticleId IdType="pmc">PMC8339877</ArticleId><ArticleId IdType="pubmed">33933186</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindler SE, Sutphen CL, Teunissen C, et al. Upward drift in cerebrospinal fluid amyloid &#x3b2; 42 assay values for more than 10 years. Alzheimers Dement. 2018;14(1):62&#x2013;70. doi:10.1016/j.jalz.2017.06.2264</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2017.06.2264</ArticleId><ArticleId IdType="pmc">PMC5750131</ArticleId><ArticleId IdType="pubmed">28710906</ArticleId></ArticleIdList></Reference><Reference><Citation>Tijms BM, Willemse EAJ, Zwan MD, et al. Unbiased approach to counteract upward drift in cerebrospinal fluid amyloid-&#x3b2; 1&#x2013;42 analysis results. Clin Chem. 2018;64(3):576&#x2013;585. doi:10.1373/clinchem.2017.281055</Citation><ArticleIdList><ArticleId IdType="doi">10.1373/clinchem.2017.281055</ArticleId><ArticleId IdType="pubmed">29208658</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertens D, Tijms BM, Scheltens P, Teunissen CE, Visser PJ. Unbiased estimates of cerebrospinal fluid &#x3b2;-amyloid 1&#x2013;42 cutoffs in a large memory clinic population. Alzheimers Res Ther. 2017;9(1):8. doi:10.1186/s13195-016-0233-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-016-0233-7</ArticleId><ArticleId IdType="pmc">PMC5307885</ArticleId><ArticleId IdType="pubmed">28193256</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256(3):183&#x2013;194. doi:10.1111/j.1365-2796.2004.01388.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2796.2004.01388.x</ArticleId><ArticleId IdType="pubmed">15324362</ArticleId></ArticleIdList></Reference><Reference><Citation>Winblad B, Palmer K, Kivipelto M, et al. Mild cognitive impairment&#x2013;beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med. 2004;256(3):240&#x2013;246. doi:10.1111/j.1365-2796.2004.01380.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2796.2004.01380.x</ArticleId><ArticleId IdType="pubmed">15324367</ArticleId></ArticleIdList></Reference><Reference><Citation>De Meyer G, Shapiro F, Vanderstichele H, et al.; Alzheimer&#x2019;s Disease Neuroimaging Initiative. Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol. 2010;67(8):949&#x2013;956. doi:10.1001/archneurol.2010.179</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2010.179</ArticleId><ArticleId IdType="pmc">PMC2963067</ArticleId><ArticleId IdType="pubmed">20697045</ArticleId></ArticleIdList></Reference><Reference><Citation>Hubbard AE, Ahern J, Fleischer NL, et al. To GEE or not to GEE: comparing population average and mixed models for estimating the associations between neighborhood risk factors and health. Epidemiology. 2010;21(4):467&#x2013;474. doi:10.1097/EDE.0b013e3181caeb90</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/EDE.0b013e3181caeb90</ArticleId><ArticleId IdType="pubmed">20220526</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S, Mattsson N, Hansson O; Alzheimer&#x2019;s Disease Neuroimaging Initiative. Cerebrospinal fluid analysis detects cerebral amyloid-&#x3b2; accumulation earlier than positron emission tomography. Brain. 2016;139(pt 4):1226&#x2013;1236. doi:10.1093/brain/aww015</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aww015</ArticleId><ArticleId IdType="pmc">PMC4806222</ArticleId><ArticleId IdType="pubmed">26936941</ArticleId></ArticleIdList></Reference><Reference><Citation>Reimand J, de Wilde A, Teunissen CE, et al. PET and CSF amyloid-&#x3b2; status are differently predicted by patient features: information from discordant cases. Alzheimers Res Ther. 2019;11(1):100. doi:10.1186/s13195-019-0561-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-019-0561-5</ArticleId><ArticleId IdType="pmc">PMC6898919</ArticleId><ArticleId IdType="pubmed">31810489</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewczuk P, Riederer P, O&#x2019;Bryant SE, et al.; Members of the WFSBP Task Force Working on this Topic: Peter Riederer, Carla Gallo, Dimitrios Kapogiannis, Andrea Lopez Mato, Florence Thibaut. Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: an update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. World J Biol Psychiatry. 2018;19(4):244&#x2013;328. doi:10.1080/15622975.2017.1375556</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15622975.2017.1375556</ArticleId><ArticleId IdType="pmc">PMC5916324</ArticleId><ArticleId IdType="pubmed">29076399</ArticleId></ArticleIdList></Reference><Reference><Citation>Reimand J, Collij L, Scheltens P, Bouwman F, Ossenkoppele R; Alzheimer&#x2019;s Disease Neuroimaging Initiative. Association of amyloid-&#x3b2; CSF/PET discordance and tau load 5 years later. Neurology. 2020;95(19):e2648&#x2013;e2657. doi:10.1212/WNL.0000000000010739</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000010739</ArticleId><ArticleId IdType="pmc">PMC7963352</ArticleId><ArticleId IdType="pubmed">32913020</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson KA, Sperling RA, Gidicsin CM, et al.; AV45-A11 study group. Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer&#x2019;s disease dementia, mild cognitive impairment, and normal aging. Alzheimers Dement. 2013;9(5, suppl):S72&#x2013;S83. doi:10.1016/j.jalz.2012.10.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2012.10.007</ArticleId><ArticleId IdType="pmc">PMC3800236</ArticleId><ArticleId IdType="pubmed">23375563</ArticleId></ArticleIdList></Reference><Reference><Citation>Bucci M, Savitcheva I, Farrar G, et al. A multisite analysis of the concordance between visual image interpretation and quantitative analysis of [18F]flutemetamol amyloid PET images. Eur J Nucl Med Mol Imaging. 2021;48(7):2183&#x2013;2199. doi:10.1007/s00259-021-05311-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-021-05311-5</ArticleId><ArticleId IdType="pmc">PMC8175298</ArticleId><ArticleId IdType="pubmed">33844055</ArticleId></ArticleIdList></Reference><Reference><Citation>Sala A, Nordberg A, Rodriguez-Vieitez E; Alzheimer&#x2019;s Disease Neuroimaging Initiative. Longitudinal pathways of cerebrospinal fluid and positron emission tomography biomarkers of amyloid-&#x3b2; positivity. Mol Psychiatry. Published online December 11, 2020. doi:10.1038/s41380-020-00950-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-020-00950-w</ArticleId><ArticleId IdType="pmc">PMC8758501</ArticleId><ArticleId IdType="pubmed">33303945</ArticleId></ArticleIdList></Reference><Reference><Citation>Ch&#xe9;telat G, Arbizu J, Barthel H, et al. Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer&#x2019;s disease and other dementias. Lancet Neurol. 2020;19(11):951&#x2013;962. doi:10.1016/S1474-4422(20)30314-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(20)30314-8</ArticleId><ArticleId IdType="pubmed">33098804</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau SM, Lu M, Joshi AD, et al.; Alzheimer&#x2019;s Disease Neuroimaging Initiative. Comparing positron emission tomography imaging and cerebrospinal fluid measurements of &#x3b2;-amyloid. Ann Neurol. 2013;74(6):826&#x2013;836. doi:10.1002/ana.23908</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.23908</ArticleId><ArticleId IdType="pmc">PMC3748164</ArticleId><ArticleId IdType="pubmed">23536396</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts RO, Aakre JA, Kremers WK, et al. Prevalence and outcomes of amyloid positivity among persons without dementia in a longitudinal, population-based setting. JAMA Neurol. 2018;75 (8):970&#x2013;979. doi:10.1001/jamaneurol.2018.0629</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2018.0629</ArticleId><ArticleId IdType="pmc">PMC6142936</ArticleId><ArticleId IdType="pubmed">29710225</ArticleId></ArticleIdList></Reference><Reference><Citation>Mielke MM, Wiste HJ, Weigand SD, et al. Indicators of amyloid burden in a population-based study of cognitively normal elderly. Neurology. 2012;79(15):1570&#x2013;1577. doi:10.1212/WNL.0b013e31826e2696</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e31826e2696</ArticleId><ArticleId IdType="pmc">PMC3475629</ArticleId><ArticleId IdType="pubmed">22972644</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Roe CM, Xiong C, et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol. 2010;67(1):122&#x2013;131. doi:10.1002/ana.21843</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21843</ArticleId><ArticleId IdType="pmc">PMC2830375</ArticleId><ArticleId IdType="pubmed">20186853</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe CC, Ellis KA, Rimajova M, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging. 2010;31(8):1275&#x2013;1283. doi:10.1016/j.neurobiolaging.2010.04.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2010.04.007</ArticleId><ArticleId IdType="pubmed">20472326</ArticleId></ArticleIdList></Reference><Reference><Citation>Safieh M, Korczyn AD, Michaelson DM. ApoE4: an emerging therapeutic target for Alzheimer&#x2019;s disease. BMC Med. 2019;17(1):64. doi:10.1186/s12916-019-1299-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-019-1299-4</ArticleId><ArticleId IdType="pmc">PMC6425600</ArticleId><ArticleId IdType="pubmed">30890171</ArticleId></ArticleIdList></Reference><Reference><Citation>Insel PS, Hansson O, Mattsson-Carlgren N. Association between apolipoprotein E &#x3b5;2 vs &#x3b5;4, age, and &#x3b2;-amyloid in adults without cognitive impairment. JAMA Neurol. 2021;78(2):229&#x2013;235. doi:10.1001/jamaneurol.2020.3780</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2020.3780</ArticleId><ArticleId IdType="pmc">PMC7551211</ArticleId><ArticleId IdType="pubmed">33044487</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Wiste HJ, Weigand SD, et al. Age, sex, and APOE &#x3b5;4 effects on memory, brain structure, and &#x3b2;-amyloid across the adult life span. JAMA Neurol. 2015;72(5):511&#x2013;519. doi:10.1001/jamaneurol.2014.4821</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.4821</ArticleId><ArticleId IdType="pmc">PMC4428984</ArticleId><ArticleId IdType="pubmed">25775353</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern Y Cognitive reserve and Alzheimer disease. Alzheimer Dis Assoc Disord. 2006;20(3, suppl 2):S69&#x2013;S74. doi:10.1097/00002093-200607001-00010</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00002093-200607001-00010</ArticleId><ArticleId IdType="pubmed">16917199</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen WJ, Ossenkoppele R, Tijms BM, et al.; Amyloid Biomarker Study Group. Association of cerebral amyloid-&#x3b2; aggregation with cognitive functioning in persons without dementia. JAMA Psychiatry. 2018;75(1):84&#x2013;95. doi:10.1001/jamapsychiatry.2017.3391</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapsychiatry.2017.3391</ArticleId><ArticleId IdType="pmc">PMC5786156</ArticleId><ArticleId IdType="pubmed">29188296</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Wiste HJ, Lesnick TG, et al. Brain &#x3b2;-amyloid load approaches a plateau. Neurology. 2013;80(10):890&#x2013;896. doi:10.1212/WNL.0b013e3182840bbe</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3182840bbe</ArticleId><ArticleId IdType="pmc">PMC3653215</ArticleId><ArticleId IdType="pubmed">23446680</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas D, Radji S, Benedetti A. Systematic review of methods for individual patient data meta-analysis with binary outcomes. BMC Med Res Methodol. 2014;14:79. doi:10.1186/1471-2288-14-79</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2288-14-79</ArticleId><ArticleId IdType="pmc">PMC4074845</ArticleId><ArticleId IdType="pubmed">24943877</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35099506</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>20</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>79</Volume><Issue>3</Issue><PubDate><Year>2022</Year><Month>Mar</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Association of BDNF Val66Met With Tau Hyperphosphorylation and Cognition in Dominantly Inherited Alzheimer Disease.</ArticleTitle><Pagination><StartPage>261</StartPage><EndPage>270</EndPage><MedlinePgn>261-270</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2021.5181</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Allelic variation in the brain-derived neurotrophic factor (BDNF) Val66Met polymorphism moderates increases in cerebrospinal fluid (CSF) levels of tau and phosphorylated tau 181 (p-tau181), measured using immunoassay, and cognitive decline in presymptomatic dominantly inherited Alzheimer disease (DIAD). Advances in mass spectrometry show that CSF tau phosphorylation occupancy at threonine 181 and 217 (p-tau181/tau181, p-tau217/tau217) increases with initial &#x3b2;-amyloid (A&#x3b2;) aggregation, while phosphorylation occupancy at threonine 205 (p-tau205/tau205) and level of total tau increase when brain atrophy and clinical symptoms become evident.</AbstractText><AbstractText Label="OBJECTIVE">To determine whether site-specific tau phosphorylation occupancy (ratio of phosphorylated to unphosphorylated tau) is associated with BDNF Val66Met in presymptomatic and symptomatic DIAD.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">This cross-sectional cohort study included participants from the Dominantly Inherited Alzheimer Network (DIAN) and A&#x3b2;-positive cognitively normal older adults in the Alzheimer's Disease Neuroimaging Initiative (ADNI). Data were collected from 2009 through 2018 at multicenter clinical sites in the United States, United Kingdom, and Australia, with no follow-up. DIAN participants provided a CSF sample and completed clinical and cognitive assessments. Data analysis was conducted between March 2020 and March 2021.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Mass spectrometry analysis was used to determine site-specific tau phosphorylation level; tau levels were also measured using immunoassay. Episodic memory and global cognitive composites were computed.</AbstractText><AbstractText Label="RESULTS">Of 374 study participants, 144 were mutation noncarriers, 156 were presymptomatic mutation carriers, and 74 were symptomatic carriers. Of the 527 participants in the network, 153 were excluded because their CSF sample, BDNF status, or both were unavailable. Also included were 125 A&#x3b2;-positive cognitively normal older adults in the ADNI. The mean (SD) age of DIAD participants was 38.7 (10.9) years; 43% were women. The mean (SD) age of participants with preclinical sporadic AD was 74.8 (5.6) years; 52% were women. In presymptomatic mutation carriers, compared with Val66 homozygotes, Met66 carriers showed significantly poorer episodic memory (d&#x2009;=&#x2009;0.62; 95% CI, 0.28-0.95), lower hippocampal volume (d&#x2009;=&#x2009;0.40; 95% CI, 0.09-0.71), and higher p-tau217/tau217 (d&#x2009;=&#x2009;0.64; 95% CI, 0.30-0.97), p-tau181/tau181 (d&#x2009;=&#x2009;0.65; 95% CI, 0.32-0.99), and mass spectrometry total tau (d&#x2009;=&#x2009;0.43; 95% CI, 0.10-0.76). In symptomatic mutation carriers, Met66 carriers showed significantly poorer global cognition (d&#x2009;=&#x2009;1.17; 95% CI, 0.65-1.66) and higher p-tau217/tau217 (d&#x2009;=&#x2009;0.53; 95% CI, 0.05-1.01), mass spectrometry total tau (d&#x2009;=&#x2009;0.78; 95% CI, 0.28-1.25), and p-tau205/tau205 (d&#x2009;=&#x2009;0.97; 95% CI, 0.46-1.45), when compared with Val66 homozygotes. In preclinical sporadic AD, Met66 carriers showed poorer episodic memory (d&#x2009;=&#x2009;0.39; 95% CI, 0.00-0.77) and higher total tau (d&#x2009;=&#x2009;0.45; 95% CI, 0.07-0.84) and p-tau181 (d&#x2009;=&#x2009;0.46; 95% CI, 0.07-0.85).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">In DIAD, clinical disease stage and BDNF Met66 were associated with cognitive impairment and levels of site-specific tau phosphorylation. This suggests that pharmacological strategies designed to increase neurotrophic support in the presymptomatic stages of AD may be beneficial.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Yen Ying</ForeName><Initials>YY</Initials><AffiliationInfo><Affiliation>Turner Institute for Brain and Mental Health, School of Psychological Sciences, Monash University, Clayton, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maruff</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Turner Institute for Brain and Mental Health, School of Psychological Sciences, Monash University, Clayton, Victoria, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cogstate Ltd, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barth&#xe9;lemy</LastName><ForeName>Nicolas R</ForeName><Initials>NR</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine in St Louis, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goate</LastName><ForeName>Alison</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hassenstab</LastName><ForeName>Jason</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine in St Louis, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sato</LastName><ForeName>Chihiro</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine in St Louis, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fagan</LastName><ForeName>Anne M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine in St Louis, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benzinger</LastName><ForeName>Tammie L S</ForeName><Initials>TLS</Initials><AffiliationInfo><Affiliation>Department of Radiology, Washington University School of Medicine in St Louis, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiong</LastName><ForeName>Chengjie</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Biostatistics, Washington University School of Medicine in St Louis, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cruchaga</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine in St Louis, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levin</LastName><ForeName>Johannes</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farlow</LastName><ForeName>Martin R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Department of Neurology, Indiana University, Indianapolis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graff-Radford</LastName><ForeName>Neill R</ForeName><Initials>NR</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic Jacksonville, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laske</LastName><ForeName>Christoph</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Section for Dementia Research, Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, Department of Psychiatry and Psychotherapy, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masters</LastName><ForeName>Colin L</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salloway</LastName><ForeName>Stephen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Butler Hospital, Providence, Rhode Island.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Warren Alpert Medical School of Brown University, Providence, Rhode Island.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schofield</LastName><ForeName>Peter R</ForeName><Initials>PR</Initials><AffiliationInfo><Affiliation>Neuroscience Research Australia, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medical Sciences, University of New South Wales, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine in St Louis, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bateman</LastName><ForeName>Randall J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine in St Louis, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McDade</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine in St Louis, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Dominantly Inherited Alzheimer Network</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U19 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG021886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019208">Brain-Derived Neurotrophic Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>2ZD004190S</RegistryNumber><NameOfSubstance UI="D013912">Threonine</NameOfSubstance></Chemical><Chemical><RegistryNumber>7171WSG8A2</RegistryNumber><NameOfSubstance UI="C579455">BDNF protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>JAMA Neurol. 2022 Mar 1;79(3):313. doi: 10.1001/jamaneurol.2022.0335.</RefSource><PMID Version="1">35285879</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019208" MajorTopicYN="N">Brain-Derived Neurotrophic Factor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013912" MajorTopicYN="N">Threonine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Barth&#xe9;lemy reported a patent pending for cerebrospinal fluid (CSF) tau rate of phosphorylation measurement to define stages of Alzheimer disease and monitor brain kinases/phosphatases activity and a patent pending for novel tau isoforms to predict onset of symptoms and dementia in Alzheimer disease. Dr Goate reported grants from NIH DIAN during conduct of the study and personal fees from consulting or scientific advisory board work for Genentech, AbbVie, UK DRI, Vlaams Instituut voor Biotechnologie (VIB), and Queensland Brain Institute outside the submitted work. Dr Hassenstab reported personal fees from Roche, Eisai, and Parabon Nanolabs outside the submitted work. Dr Fagan reported grants from NIH during the conduct of the study, grants from Centene outside the submitted work, personal fees as a board member for Roche Diagnostics and Diadem outside the submitted work, and consultant fees from DiamiR and Siemens Healthcare Diagnostics, Inc, outside the submitted work. Dr Benzinger reported radiopharmaceutical support from Avid Radiopharmaceuticals, Cerveau, and Life Molecular Imaging; serving on consulting, speakers bureau, and advisory boards for Siemens, Eisai, and Biogen; and serving as an investigator in clinical trials sponsored by Lilly, Roche, Johnson &amp; Johnson, Biogen, and Eisai. Dr Cruchaga reported research support from Biogen, Eisai, Alector, and Parabon and being a member of the advisory boards of Vivid Genetics, Halia Therapeutics, and ADx Healthcare. Dr Levin reported grants from the German Center for Neurodegenerative Diseases (DZNE) during the conduct of the study and the following fees outside the submitted work: compensation from MODAG as part-time chief medical officer; speaker fees from Bayer Vital, Biogen, and Roche; consulting fees from Axon Neuroscience; author fees from Thieme Medical Publishers and W. Kohlhammer; and nonfinancial support from AbbVie. Dr Graff-Radford reported grants from NIH DIAN during the conduct of the study and having taken part in multicenter studies funded by Lilly, Biogen, and AbbVie. Dr Salloway reported grants, personal fees, and nonfinancial support from Biogen; grants and personal fees from Eisai; personal fees and nonfinancial support from Avid; personal fees and nonfinancial support from Novartis; personal fees from Genentech; grants from Lilly; and personal fees and nonfinancial support from Roche, all outside the submitted work. Dr Schofield reported grants from NIH and an anonymous foundation paid through Washington University and grants from Roth Charitable Foundation during the conduct of the study. Dr Morris reported grants from NIH during the conduct of the study. Dr Bateman reported receiving income from C2N Diagnostics for serving on the scientific advisory board and grants from National Institute on Aging (NIA, UFAG032438) during the conduct of the study; funding and nonfinancial support for the DIAN-TU-001 Trial and royalties, funding, and nonfinancial support from members of the DIAN-TU Pharma Consortium, NfL Consortium, and Tau SILK Consortium, which include Avid Radiopharmaceuticals, Janssen, Hoffman La-Roche/Genentech Consulting, Lilly, Eisai Consulting, Biogen, AbbVie, and Bristol Myers Squibb; and personal fees from Amgen Consulting outside the submitted work. Dr McDade reported grants from NIA during the conduct of the study. Drs Barth&#xe9;lemy, Bateman, and McDade are co-inventors of the technology &#x201c;Methods of diagnosing AD with phosphorylation changes,&#x201d; licensed by Washington University to C2N Diagnostics. Washington University holds 5% equity in C2N. Through these relationships, Washington University and Drs Barth&#xe9;lemy, Bateman, and McDade are entitled to receive royalties from the license agreement with C2N. No other disclosures were reported.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Chhatwal</LastName><ForeName>Jasmeer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fitzpatrick</LastName><ForeName>Colleen</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bodge</LastName><ForeName>Courtney</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Salloway</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>De La Cruz</LastName><ForeName>Chrismary</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goldman</LastName><ForeName>Jill</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mejia</LastName><ForeName>Arlene</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Neimeyer</LastName><ForeName>Katie</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Noble</LastName><ForeName>James</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gardener</LastName><ForeName>Samantha</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martins</LastName><ForeName>Ralph</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sohrabi</LastName><ForeName>Hamid</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Taddei</LastName><ForeName>Kevin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carter</LastName><ForeName>Kathleen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duong</LastName><ForeName>Duc</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Erik</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Levey</LastName><ForeName>Allan</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ping</LastName><ForeName>Lingyan</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Seyfried</LastName><ForeName>Nick</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gr&#xe4;ber-Sultan</LastName><ForeName>Susanne</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>H&#xe4;sler</LastName><ForeName>Lisa</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hofmann</LastName><ForeName>Anna</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jucker</LastName><ForeName>Mathias</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>K&#xe4;ser</LastName><ForeName>Stephan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kuder-Buletta</LastName><ForeName>Elke</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Laske</LastName><ForeName>Christoph</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Preische</LastName><ForeName>Oliver</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Diffenbacher</LastName><ForeName>Anna</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Igor</LastName><ForeName>Yakushev</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Levin</LastName><ForeName>Johannes</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>V&#xf6;glein</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oberm&#xfc;ller</LastName><ForeName>Ulricke</ForeName><Initials>U</Initials></Investigator><Investigator ValidYN="Y"><LastName>Esposito</LastName><ForeName>Bianca</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goate</LastName><ForeName>Alison</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Renton</LastName><ForeName>Alan</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brosch</LastName><ForeName>Jared</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Buck</LastName><ForeName>Jill</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Farlow</LastName><ForeName>Marty</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ghetti</LastName><ForeName>Bernardino</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Allegri</LastName><ForeName>Ricardo</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chrem</LastName><ForeName>Patricio</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Egido</LastName><ForeName>Noelia</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Haass</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morenas-Rodriguez</LastName><ForeName>Estrella</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nuscher</LastName><ForeName>Brigitte</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Day</LastName><ForeName>Gregory S</ForeName><Initials>GS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Graff-Radford</LastName><ForeName>Neill</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Graham</LastName><ForeName>Morgan</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stephens</LastName><ForeName>Sochenda</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jack</LastName><ForeName>Clifford</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bechara</LastName><ForeName>Jacob</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brooks</LastName><ForeName>William Bill</ForeName><Initials>WB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schofield</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Araki</LastName><ForeName>Aki</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ikeuchi</LastName><ForeName>Takeshi</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kasuga</LastName><ForeName>Kensaku</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ishii</LastName><ForeName>Kenji</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fujii</LastName><ForeName>Hisako</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Senda</LastName><ForeName>Michio</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shimada</LastName><ForeName>Hiroyuki</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ihara</LastName><ForeName>Ryoko</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nagamatsu</LastName><ForeName>Akemi</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Niimi</LastName><ForeName>Yoshiki</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Douglas</LastName><ForeName>Jane</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fox</LastName><ForeName>Nick</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grilo</LastName><ForeName>Miguel</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mummery</LastName><ForeName>Cath</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>O'Connor</LastName><ForeName>Antoinette</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Masters</LastName><ForeName>Colin</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koeppe</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Berman</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goldberg</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ikonomovic</LastName><ForeName>Snezana</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Klunk</LastName><ForeName>William Bill</ForeName><Initials>WB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lopez</LastName><ForeName>Oscar</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mountz</LastName><ForeName>James</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nadkarni</LastName><ForeName>Neelesh</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Patira</LastName><ForeName>Riddhi</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Lori</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Snitz</LastName><ForeName>Beth</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thompson</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weamer</LastName><ForeName>Elise</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mason</LastName><ForeName>Neal Scott</ForeName><Initials>NS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chui</LastName><ForeName>Helena</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ringman</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Adams</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barthelemy</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bateman</LastName><ForeName>Randall</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Benzinger</LastName><ForeName>Tammie</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brandon</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Buckles</LastName><ForeName>Virginia</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cash</LastName><ForeName>Lisa</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chen</LastName><ForeName>Charlie</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chua</LastName><ForeName>Jasmin</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cruchaga</LastName><ForeName>Carlos</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Denner</LastName><ForeName>Darcy</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dincer</LastName><ForeName>Aylin</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Donahue</LastName><ForeName>Tamara</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fagan</LastName><ForeName>Anne</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Feldman</LastName><ForeName>Becca</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Flores</LastName><ForeName>Shaney</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Franklin</LastName><ForeName>Erin</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Friedrichsen</LastName><ForeName>Nelly</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gonzalez</LastName><ForeName>Alyssa</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gordon</LastName><ForeName>Brian</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gray</LastName><ForeName>Julia</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gremminger</LastName><ForeName>Emily</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Groves</LastName><ForeName>Alex</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hassenstab</LastName><ForeName>Jason</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hellm</LastName><ForeName>Cortaiga</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Herries</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hoechst-Swisher</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hornbeck</LastName><ForeName>Russ</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jerome</LastName><ForeName>Gina</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Karch</LastName><ForeName>Celeste</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Keefe</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koudelis</LastName><ForeName>Deb</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Li</LastName><ForeName>Yan</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marsh</LastName><ForeName>Jacob</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martinez</LastName><ForeName>Rita</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mawuenyega</LastName><ForeName>Kwasi</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>McCullough</LastName><ForeName>Austin</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>McDade</LastName><ForeName>Eric</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morris</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Norton</LastName><ForeName>Joanne</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Perrin</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shady</LastName><ForeName>Kristine</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sigurdson</LastName><ForeName>Wendy</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wang</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wang</LastName><ForeName>Qing</ForeName><Initials>Q</Initials></Investigator><Investigator ValidYN="Y"><LastName>Xiong</LastName><ForeName>Chengjie</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Xu</LastName><ForeName>Jinbin</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Xu</LastName><ForeName>Xiong</ForeName><Initials>X</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>2</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>1</Month><Day>31</Day><Hour>12</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>1</Month><Day>31</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35099506</ArticleId><ArticleId IdType="pmc">PMC8804973</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2021.5181</ArticleId><ArticleId IdType="pii">2788271</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bateman RJ, Xiong C, Benzinger TLS, et al. ; Dominantly Inherited Alzheimer Network . Clinical and biomarker changes in dominantly inherited Alzheimer&#x2019;s disease. N Engl J Med. 2012;367(9):795-804. doi:10.1056/NEJMoa1202753</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1202753</ArticleId><ArticleId IdType="pmc">PMC3474597</ArticleId><ArticleId IdType="pubmed">22784036</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryman DC, Acosta-Baena N, Aisen PS, et al. ; Dominantly Inherited Alzheimer Network . Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. Neurology. 2014;83(3):253-260. doi:10.1212/WNL.0000000000000596</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000000596</ArticleId><ArticleId IdType="pmc">PMC4117367</ArticleId><ArticleId IdType="pubmed">24928124</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang CW, Shao E, Mucke L. Tau: enabler of diverse brain disorders and target of rapidly evolving therapeutic strategies. Science. 2021;371(6532):eabb8255. doi:10.1126/science.abb8255</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abb8255</ArticleId><ArticleId IdType="pmc">PMC8118650</ArticleId><ArticleId IdType="pubmed">33632820</ArticleId></ArticleIdList></Reference><Reference><Citation>Fahnestock M. Brain-derived neurotrophic factor: the link between amyloid-&#x3b2; and memory loss. Future Neurol. 2011;6:627-639. doi:10.2217/fnl.11.44</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/fnl.11.44</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosa E, Mahendram S, Ke YD, Ittner LM, Ginsberg SD, Fahnestock M. Tau downregulates BDNF expression in animal and cellular models of Alzheimer&#x2019;s disease. Neurobiol Aging. 2016;48:135-142. doi:10.1016/j.neurobiolaging.2016.08.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2016.08.020</ArticleId><ArticleId IdType="pmc">PMC5159317</ArticleId><ArticleId IdType="pubmed">27676333</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim YY, Hassenstab J, Goate A, et al. ; Dominantly Inherited Alzheimer Network . Effect of BDNFVal66Met on disease markers in dominantly inherited Alzheimer&#x2019;s disease. Ann Neurol. 2018;84(3):424-435. doi:10.1002/ana.25299</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25299</ArticleId><ArticleId IdType="pmc">PMC6153076</ArticleId><ArticleId IdType="pubmed">30014553</ArticleId></ArticleIdList></Reference><Reference><Citation>Franzmeier N, Ren J, Damm A, et al. . The BDNFVal66Met SNP modulates the association between beta-amyloid and hippocampal disconnection in Alzheimer&#x2019;s disease. Mol Psychiatry. 2021;26(2):614-628.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6754794</ArticleId><ArticleId IdType="pubmed">30899092</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim YY, Villemagne VL, Laws SM, et al. ; Australian Imaging, Biomarkers and Lifestyle (AIBL) Research Group . BDNF Val66Met, A&#x3b2; amyloid, and cognitive decline in preclinical Alzheimer&#x2019;s disease. Neurobiol Aging. 2013;34(11):2457-2464. doi:10.1016/j.neurobiolaging.2013.05.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2013.05.006</ArticleId><ArticleId IdType="pubmed">23769397</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon BA, Blazey TM, Christensen J, et al. . Tau PET in autosomal dominant Alzheimer&#x2019;s disease: relationship with cognition, dementia and other biomarkers. Brain. 2019;142(4):1063-1076. doi:10.1093/brain/awz019</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz019</ArticleId><ArticleId IdType="pmc">PMC6439328</ArticleId><ArticleId IdType="pubmed">30753379</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson-Carlgren N, Andersson E, Janelidze S, et al. . A&#x3b2; deposition is associated with increases in soluble and phosphorylated tau that precede a positive tau PET in Alzheimer&#x2019;s disease. Sci Adv. 2020;6(16):eaaz2387. doi:10.1126/sciadv.aaz2387</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.aaz2387</ArticleId><ArticleId IdType="pmc">PMC7159908</ArticleId><ArticleId IdType="pubmed">32426454</ArticleId></ArticleIdList></Reference><Reference><Citation>Barth&#xe9;lemy NR, Li Y, Joseph-Mathurin N, et al. ; Dominantly Inherited Alzheimer Network . A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer&#x2019;s disease. Nat Med. 2020;26(3):398-407. doi:10.1038/s41591-020-0781-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0781-z</ArticleId><ArticleId IdType="pmc">PMC7309367</ArticleId><ArticleId IdType="pubmed">32161412</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon BA, Blazey TM, Su Y, et al. . Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer&#x2019;s disease: a longitudinal study. Lancet Neurol. 2018;17(3):241-250. doi:10.1016/S1474-4422(18)30028-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30028-0</ArticleId><ArticleId IdType="pmc">PMC5816717</ArticleId><ArticleId IdType="pubmed">29397305</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg L, Miller JP, Storandt M, et al. . Mild senile dementia of the Alzheimer type: 2. Longitudinal assessment. Ann Neurol. 1988;23(5):477-484. doi:10.1002/ana.410230509</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410230509</ArticleId><ArticleId IdType="pubmed">3389756</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412-2414. doi:10.1212/WNL.43.11.2412-a</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.43.11.2412-a</ArticleId><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-mental state&#x201d;: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-198. doi:10.1016/0022-3956(75)90026-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-3956(75)90026-6</ArticleId><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Burke WJ, Roccaforte WH, Wengel SP. The short form of the Geriatric Depression Scale: a comparison with the 30-item form. J Geriatr Psychiatry Neurol. 1991;4(3):173-178. doi:10.1177/089198879100400310</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/089198879100400310</ArticleId><ArticleId IdType="pubmed">1953971</ArticleId></ArticleIdList></Reference><Reference><Citation>Storandt M, Balota DA, Aschenbrenner AJ, Morris JC. Clinical and psychological characteristics of the initial cohort of the Dominantly Inherited Alzheimer Network (DIAN). Neuropsychology. 2014;28(1):19-29. doi:10.1037/neu0000030</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/neu0000030</ArticleId><ArticleId IdType="pmc">PMC3877741</ArticleId><ArticleId IdType="pubmed">24219606</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim YY, Hassenstab J, Cruchaga C, et al. ; Dominantly Inherited Alzheimer Network . BDNF Val66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimer&#x2019;s disease. Brain. 2016;139(pt 10):2766-2777. doi:10.1093/brain/aww200</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aww200</ArticleId><ArticleId IdType="pmc">PMC5815565</ArticleId><ArticleId IdType="pubmed">27521573</ArticleId></ArticleIdList></Reference><Reference><Citation>Crane PK, Carle A, Gibbons LE, et al. . Development and assessment of a composite score for memory in the Alzheimer's Disease Neuroimaging Initiative (ADNI). Brain Imaging Behav. 2012;6(4):502-516. doi:10.1007/s11682-012-9186-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11682-012-9186-z</ArticleId><ArticleId IdType="pmc">PMC3806057</ArticleId><ArticleId IdType="pubmed">22782295</ArticleId></ArticleIdList></Reference><Reference><Citation>Barth&#xe9;lemy NR, Fenaille F, Hirtz C, et al. . Tau protein quantification in human cerebrospinal fluid by targeted mass spectrometry at high sequence coverage provides insights into its primary structure heterogeneity. J Proteome Res. 2016;15(2):667-676. doi:10.1021/acs.jproteome.5b01001</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jproteome.5b01001</ArticleId><ArticleId IdType="pubmed">26742856</ArticleId></ArticleIdList></Reference><Reference><Citation>Talbot C, Lendon C, Craddock N, Shears S, Morris JC, Goate A. Protection against Alzheimer&#x2019;s disease with apoE epsilon 2. Lancet. 1994;343(8910):1432-1433. doi:10.1016/S0140-6736(94)92557-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(94)92557-7</ArticleId><ArticleId IdType="pubmed">7910910</ArticleId></ArticleIdList></Reference><Reference><Citation>Benzinger TL, Blazey T, Jack CR Jr, et al. . Regional variability of imaging biomarkers in autosomal dominant Alzheimer&#x2019;s disease. Proc Natl Acad Sci U S A. 2013;110(47):E4502-E4509. doi:10.1073/pnas.1317918110</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1317918110</ArticleId><ArticleId IdType="pmc">PMC3839740</ArticleId><ArticleId IdType="pubmed">24194552</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, Blazey TM, Snyder AZ, et al. ; Dominantly Inherited Alzheimer Network . Partial volume correction in quantitative amyloid imaging. Neuroimage. 2015;107:55-64. doi:10.1016/j.neuroimage.2014.11.058</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2014.11.058</ArticleId><ArticleId IdType="pmc">PMC4300252</ArticleId><ArticleId IdType="pubmed">25485714</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramanan VK, Castillo AM, Knopman DS, et al. . Association of apolipoprotein e &#x25b;4, educational level, and sex with tau deposition and tau-mediated metabolic dysfunction in older adults. JAMA Netw Open. 2019;2(10):e1913909. doi:10.1001/jamanetworkopen.2019.13909</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2019.13909</ArticleId><ArticleId IdType="pmc">PMC6820045</ArticleId><ArticleId IdType="pubmed">31642932</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckley RF, Mormino EC, Rabin JS, et al. . Sex differences in the association of global amyloid and regional tau deposition measured by positron emission tomography in clinically normal older adults. JAMA Neurol. 2019;76(5):542-551. doi:10.1001/jamaneurol.2018.4693</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2018.4693</ArticleId><ArticleId IdType="pmc">PMC6515599</ArticleId><ArticleId IdType="pubmed">30715078</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Lawrence Erlbaum Associates; 1988.</Citation></Reference><Reference><Citation>Lim YY, Villemagne VL, Laws SM, et al. ; Australian Imaging, Biomarkers and Lifestyle (AIBL) Research Group . BDNF Val66Met, A&#x3b2; amyloid, and cognitive decline in preclinical Alzheimer&#x2019;s disease. Neurobiol Aging. 2013;34(11):2457-2464. doi:10.1016/j.neurobiolaging.2013.05.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2013.05.006</ArticleId><ArticleId IdType="pubmed">23769397</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim YY, Villemagne VL, Laws SM, et al. ; AIBL Research Group . Effect of BDNF Val66Met on memory decline and hippocampal atrophy in prodromal Alzheimer&#x2019;s disease: a preliminary study. PLoS One. 2014;9(1):e86498. doi:10.1371/journal.pone.0086498</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0086498</ArticleId><ArticleId IdType="pmc">PMC3903533</ArticleId><ArticleId IdType="pubmed">24475133</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim YY, Laws SM, Perin S, et al. ; AIBL Research Group . BDNF VAL66MET polymorphism and memory decline across the spectrum of Alzheimer&#x2019;s disease. Genes Brain Behav. 2021;20(5):e12724. doi:10.1111/gbb.12724</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/gbb.12724</ArticleId><ArticleId IdType="pubmed">33369083</ArticleId></ArticleIdList></Reference><Reference><Citation>McDade E, Wang G, Gordon BA, et al. ; Dominantly Inherited Alzheimer Network . Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease. Neurology. 2018;91(14):e1295-e1306. doi:10.1212/WNL.0000000000006277</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000006277</ArticleId><ArticleId IdType="pmc">PMC6177272</ArticleId><ArticleId IdType="pubmed">30217935</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Xiong C, Jasielec MS, et al. ; Dominantly Inherited Alzheimer Network . Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer&#x2019;s disease. Sci Transl Med. 2014;6(226):226ra30. doi:10.1126/scitranslmed.3007901</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3007901</ArticleId><ArticleId IdType="pmc">PMC4038930</ArticleId><ArticleId IdType="pubmed">24598588</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu B, Nagappan G, Guan X, Nathan PJ, Wren P. BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases. Nat Rev Neurosci. 2013;14(6):401-416. doi:10.1038/nrn3505</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn3505</ArticleId><ArticleId IdType="pubmed">23674053</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, Yao H, Xu Y, et al. . Therapeutic potential of a TrkB agonistic antibody for Alzheimer&#x2019;s disease. Theranostics. 2020;10(15):6854-6874. doi:10.7150/thno.44165</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/thno.44165</ArticleId><ArticleId IdType="pmc">PMC7295064</ArticleId><ArticleId IdType="pubmed">32550908</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35102691</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>18</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1552-5279</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>11</Issue><PubDate><Year>2022</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Alzheimer's &amp; dementia : the journal of the Alzheimer's Association</Title><ISOAbbreviation>Alzheimers Dement</ISOAbbreviation></Journal><ArticleTitle>Assessment of hearing and vision impairment in cohort studies collecting cognitive data in older adults.</ArticleTitle><Pagination><StartPage>2243</StartPage><EndPage>2251</EndPage><MedlinePgn>2243-2251</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/alz.12575</ELocationID><Abstract><AbstractText Label="INTRODUCTION">There are no standard practices for considering sensory impairment in studies measuring cognitive function among older adults. Exclusion of participants with impairments may inaccurately estimate the prevalence of cognitive impairment and dementia.</AbstractText><AbstractText Label="METHODS">We surveyed prospective cohort studies measuring cognitive function in older adults, determined the proportion that excluded participants based on sensory impairment and the proportion that assessed each type of sensory impairment, and described the methods of sensory assessment.</AbstractText><AbstractText Label="RESULTS">Investigators/staff from 85 (of 192 cohorts) responded; 6 (7%) excluded participants with severe impairment; 80 (94%) measured hearing and/or vision impairment, while 5 (6%) measured neither. Thirty-two (38%) cohorts assessed hearing objectively and 45 (53%) assessed vision objectively.</AbstractText><AbstractText Label="DISCUSSION">Findings indicate variation in methods used to assess sensory impairment, with potential implications for resource allocation. To ensure equitable inclusion of study participants, consensus is needed on best practices standardized protocols for assessment and accommodations of sensory impairment.</AbstractText><CopyrightInformation>&#xa9; 2022 the Alzheimer's Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Chelsea</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-9942-9955</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nagarajan</LastName><ForeName>Niranjani</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Assi</LastName><ForeName>Lama</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Cochlear Center for Hearing and Public Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Kening</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Cochlear Center for Hearing and Public Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Powell</LastName><ForeName>Danielle S</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>Cochlear Center for Hearing and Public Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pedersen</LastName><ForeName>Emily</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Cochlear Center for Hearing and Public Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosman</LastName><ForeName>Lori</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Welch Medical Library, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Villavisanis</LastName><ForeName>Dillan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carlson</LastName><ForeName>Michelle C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swenor</LastName><ForeName>Bonnielin K</ForeName><Initials>BK</Initials><AffiliationInfo><Affiliation>Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cochlear Center for Hearing and Public Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Disability Health Research Center, Johns Hopkins University, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deal</LastName><ForeName>Jennifer A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Cochlear Center for Hearing and Public Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Disability Health Research Center, Johns Hopkins University, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG055404</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AG060243</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UG1 EY020522</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG052640</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG054693</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG066153</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066587</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG066576</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>02</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Alzheimers Dement</MedlineTA><NlmUniqueID>101231978</NlmUniqueID><ISSNLinking>1552-5260</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D034381" MajorTopicYN="Y">Hearing Loss</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014786" MajorTopicYN="N">Vision Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006309" MajorTopicYN="N">Hearing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="Y">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cognitive impairment</Keyword><Keyword MajorTopicYN="N">dementia</Keyword><Keyword MajorTopicYN="N">hearing loss</Keyword><Keyword MajorTopicYN="N">older adults</Keyword><Keyword MajorTopicYN="N">sensory impairment</Keyword><Keyword MajorTopicYN="N">vision loss</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>11</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>6</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>12</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>2</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>2</Month><Day>1</Day><Hour>6</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>11</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35102691</ArticleId><ArticleId IdType="mid">NIHMS1765895</ArticleId><ArticleId IdType="pmc">PMC9339590</ArticleId><ArticleId IdType="doi">10.1002/alz.12575</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lin FR, Niparko JK, Ferrucci L. Hearing loss prevalence in the United States. Arch Intern Med. 2011. Nov 14;171(20):1851&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3564588</ArticleId><ArticleId IdType="pubmed">22083573</ArticleId></ArticleIdList></Reference><Reference><Citation>Swenor BK, Ramulu PY, Willis JR, Friedman D, Lin FR. The prevalence of concurrent hearing and vision impairment in the United States. JAMA Intern Med. 2013. Feb 25;173(4):312&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3875214</ArticleId><ArticleId IdType="pubmed">23338042</ArticleId></ArticleIdList></Reference><Reference><Citation>Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020. Aug 8;396(10248):413&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7392084</ArticleId><ArticleId IdType="pubmed">32738937</ArticleId></ArticleIdList></Reference><Reference><Citation>Loughrey DG, Kelly ME, Kelley GA, Brennan S, Lawlor BA. Association of Age-Related Hearing Loss With Cognitive Function, Cognitive Impairment, and Dementia: A Systematic Review and Meta-analysis. JAMA Otolaryngol Head Neck Surg. 2018. Feb 1;144(2):115&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5824986</ArticleId><ArticleId IdType="pubmed">29222544</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen SP, Bhattacharya J, Pershing S. Association of Vision Loss With Cognition in Older Adults. JAMA Ophthalmol. 2017. Sep 1;135(9):963&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5710542</ArticleId><ArticleId IdType="pubmed">28817745</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng DD, Swenor BK, Christ SL, West SK, Lam BL, Lee DJ. Longitudinal Associations Between Visual Impairment and Cognitive Functioning: The Salisbury Eye Evaluation Study. JAMA Ophthalmol. 2018. Sep 1;136(9):989&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6142982</ArticleId><ArticleId IdType="pubmed">29955805</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann D, Robinski M, Mau W, Girndt M. Cognitive Testing in Patients with CKD: The Problem of Missing Cases. Clin J Am Soc Nephrol. 2017. Mar 7;12(3):391&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5338701</ArticleId><ArticleId IdType="pubmed">28148556</ArticleId></ArticleIdList></Reference><Reference><Citation>Deal JA, Gross AL, Sharrett AR, Abraham AG, Coresh J, Carlson M, Griswold M, Mosley T, Power MC, Ramulu P, Reed NS, Lin FR, Swenor BK. Hearing impairment and missing cognitive test scores in a population-based study of older adults: The Atherosclerosis Risk in Communities neurocognitive study. Alzheimers Dement. 2021. Apr 12. doi: 10.1002/alz.12339. Epub ahead of print.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.12339</ArticleId><ArticleId IdType="pubmed">33844443</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitson HE, Cronin-Golomb A, Cruickshanks KJ, Gilmore GC, Owsley C, Peelle JE, et al. American Geriatrics Society and National Institute on Aging Bench-to-Bedside Conference: Sensory Impairment and Cognitive Decline in Older Adults. J Am Geriatr Soc. 2018. Nov;66(11):2052&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6410371</ArticleId><ArticleId IdType="pubmed">30248173</ArticleId></ArticleIdList></Reference><Reference><Citation>Pirozzo S, Papinczak T, Glasziou P. Whispered voice test for screening for hearing impairment in adults and children: systematic review. BMJ. 2003. Oct 25;327(7421):967.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC259166</ArticleId><ArticleId IdType="pubmed">14576249</ArticleId></ArticleIdList></Reference><Reference><Citation>Torres-Russotto D, Landau WM, Harding GW, Bohne BA, Sun K, Sinatra PM. Calibrated finger rub auditory screening test (CALFRAST). Neurology. 2009. May 5;72(18):1595&#x2013;600.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677516</ArticleId><ArticleId IdType="pubmed">19414727</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker JJ, Cleveland LM, Davis JL, Seales JS. Audiometry screening and interpretation. Am Fam Physician. 2013. Jan 1;87(1):41&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">23317024</ArticleId></ArticleIdList></Reference><Reference><Citation>Bailey IL, Lovie JE. New design principles for visual acuity letter charts. Am J Optom Physiol Opt. 1976. Nov;53(11):740&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">998716</ArticleId></ArticleIdList></Reference><Reference><Citation>Lovie-Kitchin JE. Validity and reliability of visual acuity measurements. Ophthalmic Physiol Opt. 1988;8(4):363&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">3253626</ArticleId></ArticleIdList></Reference><Reference><Citation>Legge GE, Ross JA, Luebker A, LaMay JM. Psychophysics of reading. VIII. The Minnesota Low-Vision Reading Test. Optom Vis Sci. 1989. Dec;66(12):843&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">2626251</ArticleId></ArticleIdList></Reference><Reference><Citation>Pelli DG, Robson JG, Wilkins AJ. The design of a new letter chart for measuring contrast sensitivity. Clinical Vision Sciences. 1988;2(3):187&#x2013;199.</Citation></Reference><Reference><Citation>Gaasterland DE, Ederer F, Sullivan EK, Caprioli J. Advanced Glaucoma Intervention Study. 2. Visual field test scoring and reliability. Ophthalmology. 1994. Aug;101(8):1445&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">7741836</ArticleId></ArticleIdList></Reference><Reference><Citation>Beigi RH, Krubiner C, Jamieson DJ, Lyerly AD, Hughes B, Riley L, et al. The need for inclusion of pregnant women in COVID-19 vaccine trials. Vaccine. 2021. Feb 5;39(6):868&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7798437</ArticleId><ArticleId IdType="pubmed">33446385</ArticleId></ArticleIdList></Reference><Reference><Citation>Tun PA, McCoy S, Wingfield A. Aging, hearing acuity, and the attentional costs of effortful listening. Psychol Aging. 2009. Sep;24(3):761&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2773464</ArticleId><ArticleId IdType="pubmed">19739934</ArticleId></ArticleIdList></Reference><Reference><Citation>Galvin JE, Roe CM, Powlishta KK, Coats MA, Muich SJ, Grant E, et al. The AD8: a brief informant interview to detect dementia. Neurology. 2005. Aug 23;65(4):559&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">16116116</ArticleId></ArticleIdList></Reference><Reference><Citation>Deal JA, Goman AM, Albert MS, Arnold ML, Burgard S, Chisolm T, et al. Hearing treatment for reducing cognitive decline: Design and methods of the Aging and Cognitive Health Evaluation in Elders randomized controlled trial. Alzheimers Dement (N Y). 2018;4:499&#x2013;507.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6197326</ArticleId><ArticleId IdType="pubmed">30364572</ArticleId></ArticleIdList></Reference><Reference><Citation>The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators. Am J Epidemiol. 1989. Apr;129(4):687&#x2013;702.</Citation><ArticleIdList><ArticleId IdType="pubmed">2646917</ArticleId></ArticleIdList></Reference><Reference><Citation>Verbrugge LM, Jette AM. The disablement process. Soc Sci Med. 1994. Jan;38(1):1&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">8146699</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamil RJ, Genther DJ, Lin FR. Factors associated with the accuracy of subjective assessments of hearing impairment. Ear Hear. 2015. Jan;36(1):164&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4272625</ArticleId><ArticleId IdType="pubmed">25158982</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Gasim M, Munoz B, West SK, Scott AW. Associations between self-rated vision score, vision tests, and self-reported visual function in the Salisbury Eye Evaluation Study. Invest Ophthalmol Vis Sci. 2013;54(9):6439&#x2013;6445. Published 2013 Sep 27. doi:10.1167/iovs.12-11461</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.12-11461</ArticleId><ArticleId IdType="pmc">PMC4590654</ArticleId><ArticleId IdType="pubmed">23812494</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35115731</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>15</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>2</Issue><PubDate><Year>2022</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Large-scale deep multi-layer analysis of Alzheimer's disease brain reveals strong proteomic disease-related changes not observed at the RNA level.</ArticleTitle><Pagination><StartPage>213</StartPage><EndPage>225</EndPage><MedlinePgn>213-225</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41593-021-00999-y</ELocationID><Abstract><AbstractText>The biological processes that are disrupted in the Alzheimer's disease (AD) brain remain incompletely understood. In this study, we analyzed the proteomes of more than 1,000 brain tissues to reveal new AD-related protein co-expression modules that were highly preserved across cohorts and brain regions. Nearly half of the protein co-expression modules, including modules significantly altered in AD, were not observed in RNA networks from the same cohorts and brain regions, highlighting the proteopathic nature of AD. Two such AD-associated modules unique to the proteomic network included a module related to MAPK signaling and metabolism and a module related to the matrisome. The matrisome module was influenced by the APOE &#x3b5;4 allele but was not related to the rate of cognitive decline after adjustment for neuropathology. By contrast, the MAPK/metabolism module was strongly associated with the rate of cognitive decline. Disease-associated modules unique to the proteome are sources of promising therapeutic targets and biomarkers for AD.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Johnson</LastName><ForeName>Erik C B</ForeName><Initials>ECB</Initials><Identifier Source="ORCID">0000-0002-0604-2944</Identifier><AffiliationInfo><Affiliation>Goizueta Alzheimer's Disease Research Center, Emory University School of Medicine, Atlanta, GA, USA. erik.c.b.johnson@emory.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA. erik.c.b.johnson@emory.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Carter</LastName><ForeName>E Kathleen</ForeName><Initials>EK</Initials><AffiliationInfo><Affiliation>Goizueta Alzheimer's Disease Research Center, Emory University School of Medicine, Atlanta, GA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Dammer</LastName><ForeName>Eric B</ForeName><Initials>EB</Initials><Identifier Source="ORCID">0000-0003-2947-7606</Identifier><AffiliationInfo><Affiliation>Goizueta Alzheimer's Disease Research Center, Emory University School of Medicine, Atlanta, GA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry, Emory University School of Medicine, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duong</LastName><ForeName>Duc M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Goizueta Alzheimer's Disease Research Center, Emory University School of Medicine, Atlanta, GA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry, Emory University School of Medicine, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gerasimov</LastName><ForeName>Ekaterina S</ForeName><Initials>ES</Initials><Identifier Source="ORCID">0000-0002-3986-352X</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yue</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Genetics, Emory University School of Medicine, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Jiaqi</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-3480-3234</Identifier><AffiliationInfo><Affiliation>Department of Genetics, Emory University School of Medicine, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Betarbet</LastName><ForeName>Ranjita</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-4792-8952</Identifier><AffiliationInfo><Affiliation>Goizueta Alzheimer's Disease Research Center, Emory University School of Medicine, Atlanta, GA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ping</LastName><ForeName>Lingyan</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Goizueta Alzheimer's Disease Research Center, Emory University School of Medicine, Atlanta, GA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry, Emory University School of Medicine, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yin</LastName><ForeName>Luming</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Emory University School of Medicine, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Serrano</LastName><ForeName>Geidy E</ForeName><Initials>GE</Initials><AffiliationInfo><Affiliation>Banner Sun Health Research Institute, Sun City, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beach</LastName><ForeName>Thomas G</ForeName><Initials>TG</Initials><AffiliationInfo><Affiliation>Banner Sun Health Research Institute, Sun City, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Junmin</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-0472-7648</Identifier><AffiliationInfo><Affiliation>Departments of Structural Biology and Developmental Neurobiology, St. Jude Children's Research Hospital, Memphis, TN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Proteomics and Metabolomics, St. Jude Children's Research Hospital, Memphis, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Jager</LastName><ForeName>Philip L</ForeName><Initials>PL</Initials><Identifier Source="ORCID">0000-0002-8057-2505</Identifier><AffiliationInfo><Affiliation>Center for Translational &amp; Computational Neuroimmunology, Department of Neurology, Taub Institute, Columbia University Irving Medical Center, New York Presbyterian Hospital, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haroutunian</LastName><ForeName>Vahram</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0001-5860-2512</Identifier><AffiliationInfo><Affiliation>Departments of Psychiatry and Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>James J. Peters VA Medical Center MIRECC, Bronx, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Bin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Mount Sinai Center for Transformative Disease Modeling, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaiteri</LastName><ForeName>Chris</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gearing</LastName><ForeName>Marla</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Goizueta Alzheimer's Disease Research Center, Emory University School of Medicine, Atlanta, GA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wingo</LastName><ForeName>Thomas S</ForeName><Initials>TS</Initials><Identifier Source="ORCID">0000-0002-7679-6282</Identifier><AffiliationInfo><Affiliation>Goizueta Alzheimer's Disease Research Center, Emory University School of Medicine, Atlanta, GA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics, Emory University School of Medicine, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wingo</LastName><ForeName>Aliza P</ForeName><Initials>AP</Initials><Identifier Source="ORCID">0000-0002-6360-6726</Identifier><AffiliationInfo><Affiliation>Goizueta Alzheimer's Disease Research Center, Emory University School of Medicine, Atlanta, GA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Emory University School of Medicine, Atlanta, GA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Mental Health, Atlanta VA Medical Center, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lah</LastName><ForeName>James J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Goizueta Alzheimer's Disease Research Center, Emory University School of Medicine, Atlanta, GA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levey</LastName><ForeName>Allan I</ForeName><Initials>AI</Initials><Identifier Source="ORCID">0000-0002-3153-502X</Identifier><AffiliationInfo><Affiliation>Goizueta Alzheimer's Disease Research Center, Emory University School of Medicine, Atlanta, GA, USA. alevey@emory.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA. alevey@emory.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seyfried</LastName><ForeName>Nicholas T</ForeName><Initials>NT</Initials><Identifier Source="ORCID">0000-0002-4507-624X</Identifier><AffiliationInfo><Affiliation>Goizueta Alzheimer's Disease Research Center, Emory University School of Medicine, Atlanta, GA, USA. nseyfri@emory.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA. nseyfri@emory.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry, Emory University School of Medicine, Atlanta, GA, USA. nseyfri@emory.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG072975</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 AG065187</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>IK4 BX005219</GrantID><Acronym>BX</Acronym><Agency>BLRD VA</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066511</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG061356</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG053960</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG059319</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG061357</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG025688</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 AG068604</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 NS072026</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG019610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066514</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG057470</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG015819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 AG054345</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG057471</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG061800</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG062181</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG057440</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG056533</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG046170</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG072980</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 AG062633</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG057911</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>02</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020543">Proteome</NameOfSubstance></Chemical><Chemical><RegistryNumber>63231-63-0</RegistryNumber><NameOfSubstance UI="D012313">RNA</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2022 May;18(5):255-256. doi: 10.1038/s41582-022-00648-3.</RefSource><PMID Version="1">35301457</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="Y">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020543" MajorTopicYN="N">Proteome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D040901" MajorTopicYN="N">Proteomics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012313" MajorTopicYN="N">RNA</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>3</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>12</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>2</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>2</Month><Day>4</Day><Hour>5</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>2</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35115731</ArticleId><ArticleId IdType="mid">NIHMS1763213</ArticleId><ArticleId IdType="pmc">PMC8825285</ArticleId><ArticleId IdType="doi">10.1038/s41593-021-00999-y</ArticleId><ArticleId IdType="pii">10.1038/s41593-021-00999-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Karch CM, Goate AM. Alzheimer&#x2019;s disease risk genes and mechanisms of disease pathogenesis. Biol. Psychiatry. 2015;77:43&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4234692</ArticleId><ArticleId IdType="pubmed">24951455</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang HS, et al. Genetics of gene expression in the aging human brain reveal TDP-43 proteinopathy pathophysiology. Neuron. 2020;107:496&#x2013;508.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7416464</ArticleId><ArticleId IdType="pubmed">32526197</ArticleId></ArticleIdList></Reference><Reference><Citation>Ting L, Rad R, Gygi SP, Haas W. MS3 eliminates ratio distortion in isobaric multiplexed quantitative proteomics. Nat. Methods. 2011;8:937&#x2013;940.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3205343</ArticleId><ArticleId IdType="pubmed">21963607</ArticleId></ArticleIdList></Reference><Reference><Citation>Rauniyar N, Yates JR., 3rd Isobaric labeling-based relative quantification in shotgun proteomics. J. Proteome Res. 2014;13:5293&#x2013;5309.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4261935</ArticleId><ArticleId IdType="pubmed">25337643</ArticleId></ArticleIdList></Reference><Reference><Citation>Ping L, et al. Global quantitative analysis of the human brain proteome and phosphoproteome in Alzheimer&#x2019;s disease. Sci. Data. 2020;7:315.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7522715</ArticleId><ArticleId IdType="pubmed">32985496</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson ECB, et al. Deep proteomic network analysis of Alzheimer&#x2019;s disease brain reveals alterations in RNA binding proteins and RNA splicing associated with disease. Mol. Neurodegener. 2018;13:52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6172707</ArticleId><ArticleId IdType="pubmed">30286791</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson ECB, et al. Large-scale proteomic analysis of Alzheimer&#x2019;s disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation. Nat. Med. 2020;26:769&#x2013;780.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7405761</ArticleId><ArticleId IdType="pubmed">32284590</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, et al. The Rush Memory and Aging Project: study design and baseline characteristics of the study cohort. Neuroepidemiology. 2005;25:163&#x2013;175.</Citation><ArticleIdList><ArticleId IdType="pubmed">16103727</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Arvanitakis Z, Wilson RS. Overview and findings from the Religious Orders Study. Curr. Alzheimer Res. 2012;9:628&#x2013;645.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3409291</ArticleId><ArticleId IdType="pubmed">22471860</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, et al. Overview and findings from the Rush Memory and Aging Project. Curr. Alzheimer Res. 2012;9:646&#x2013;663.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3439198</ArticleId><ArticleId IdType="pubmed">22471867</ArticleId></ArticleIdList></Reference><Reference><Citation>Beach TG, et al. Arizona study of aging and neurodegenerative disorders and brain and body donation program. Neuropathology. 2015;35:354&#x2013;389.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4593391</ArticleId><ArticleId IdType="pubmed">25619230</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirra SS, et al. The Consortium to Establish a Registry for Alzheimer&#x2019;s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer&#x2019;s disease. Neurology. 1991;41:479&#x2013;486.</Citation><ArticleIdList><ArticleId IdType="pubmed">2011243</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 2006;112:389&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3906709</ArticleId><ArticleId IdType="pubmed">16906426</ArticleId></ArticleIdList></Reference><Reference><Citation>Montine TJ, et al. National Institute on Aging&#x2013;Alzheimer&#x2019;s Association guidelines for the neuropathologic assessment of Alzheimer&#x2019;s disease: a practical approach. Acta Neuropathol. 2012;123:1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3268003</ArticleId><ArticleId IdType="pubmed">22101365</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr., et al. NIA-AA Research Framework: toward a biological definition of Alzheimer&#x2019;s disease. Alzheimers Dement. 2018;14:535&#x2013;562.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5958625</ArticleId><ArticleId IdType="pubmed">29653606</ArticleId></ArticleIdList></Reference><Reference><Citation>Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics. 2008;9:559.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2631488</ArticleId><ArticleId IdType="pubmed">19114008</ArticleId></ArticleIdList></Reference><Reference><Citation>Choobdar S, et al. Assessment of network module identification across complex diseases. Nat. Methods. 2019;16:843&#x2013;852.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6719725</ArticleId><ArticleId IdType="pubmed">31471613</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomasoni M, et al. MONET: a toolbox integrating top-performing methods for network modularization. Bioinformatics. 2020;36:3920&#x2013;3921.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7320625</ArticleId><ArticleId IdType="pubmed">32271874</ArticleId></ArticleIdList></Reference><Reference><Citation>Hynes RO, Naba A. Overview of the matrisome&#x2014;an inventory of extracellular matrix constituents and functions. Cold Spring Harb. Perspect. Biol. 2012;4:a004903.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3249625</ArticleId><ArticleId IdType="pubmed">21937732</ArticleId></ArticleIdList></Reference><Reference><Citation>Naba A, et al. The matrisome: in silico definition and in vivo characterization by proteomics of normal and tumor extracellular matrices. Mol. Cell Proteom. 2012;11:014647.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3322572</ArticleId><ArticleId IdType="pubmed">22159717</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai B, et al. Deep multilayer brain proteomics identifies molecular networks in Alzheimer&#x2019;s disease progression. Neuron. 2020;105:975&#x2013;991.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7318843</ArticleId><ArticleId IdType="pubmed">31926610</ArticleId></ArticleIdList></Reference><Reference><Citation>Ping L, et al. Global quantitative analysis of the human brain proteome in Alzheimer&#x2019;s and Parkinson&#x2019;s disease. Sci. Data. 2018;5:180036.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5848788</ArticleId><ArticleId IdType="pubmed">29533394</ArticleId></ArticleIdList></Reference><Reference><Citation>Langfelder P, Luo R, Oldham MC, Horvath S. Is my network module preserved and reproducible? PLoS Comput. Biol. 2011;7:e1001057.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3024255</ArticleId><ArticleId IdType="pubmed">21283776</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Thal DR, Ghebremedhin E, Del Tredici K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J. Neuropathol. Exp. Neurol. 2011;70:960&#x2013;969.</Citation><ArticleIdList><ArticleId IdType="pubmed">22002422</ArticleId></ArticleIdList></Reference><Reference><Citation>Uribe C, et al. Cortical atrophy patterns in early Parkinson&#x2019;s disease patients using hierarchical cluster analysis. Parkinsonism Relat. Disord. 2018;50:3&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">29449187</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorges M, et al. Longitudinal brain atrophy distribution in advanced Parkinson&#x2019;s disease: what makes the difference in &#x2018;cognitive status&#x2019; converters? Hum. Brain Mapp. 2020;41:1416&#x2013;1434.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7267933</ArticleId><ArticleId IdType="pubmed">31789477</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B, et al. Proteogenomic characterization of human colon and rectal cancer. Nature. 2014;513:382&#x2013;387.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4249766</ArticleId><ArticleId IdType="pubmed">25043054</ArticleId></ArticleIdList></Reference><Reference><Citation>Mertins P, et al. Proteogenomics connects somatic mutations to signalling in breast cancer. Nature. 2016;534:55&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5102256</ArticleId><ArticleId IdType="pubmed">27251275</ArticleId></ArticleIdList></Reference><Reference><Citation>Drummond E, et al. Proteomic differences in amyloid plaques in rapidly progressive and sporadic Alzheimer&#x2019;s disease. Acta Neuropathol. 2017;133:933&#x2013;954.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5503748</ArticleId><ArticleId IdType="pubmed">28258398</ArticleId></ArticleIdList></Reference><Reference><Citation>Drummond E, et al. Phosphorylated tau interactome in the human Alzheimer&#x2019;s disease brain. Brain. 2020;143:2803&#x2013;2817.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7526722</ArticleId><ArticleId IdType="pubmed">32812023</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruggink KA, et al. Dickkopf-related protein 3 is a potential A&#x3b2;-associated protein in Alzheimer&#x2019;s disease. J. Neurochem. 2015;134:1152&#x2013;1162.</Citation><ArticleIdList><ArticleId IdType="pubmed">26119087</ArticleId></ArticleIdList></Reference><Reference><Citation>Esteve P, et al. Elevated levels of secreted-frizzled-related-protein 1 contribute to Alzheimer&#x2019;s disease pathogenesis. Nat. Neurosci. 2019;22:1258&#x2013;1268.</Citation><ArticleIdList><ArticleId IdType="pubmed">31308530</ArticleId></ArticleIdList></Reference><Reference><Citation>Wisniewski T, et al. HB-GAM is a cytokine present in Alzheimer&#x2019;s and Down&#x2019;s syndrome lesions. Neuroreport. 1996;7:667&#x2013;671.</Citation><ArticleIdList><ArticleId IdType="pubmed">8730853</ArticleId></ArticleIdList></Reference><Reference><Citation>Lassmann H, et al. Synaptic pathology in Alzheimer&#x2019;s disease: immunological data for markers of synaptic and large dense-core vesicles. Neuroscience. 1992;46:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">1594095</ArticleId></ArticleIdList></Reference><Reference><Citation>Chalmers KA, Love S. Neurofibrillary tangles may interfere with Smad 2/3 signaling in neurons. J. Neuropathol. Exp. Neurol. 2007;66:158&#x2013;167.</Citation><ArticleIdList><ArticleId IdType="pubmed">17279001</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer PL, Kawamata T, Walker DG. Distribution of clusterin in Alzheimer brain tissue. Brain Res. 1992;579:337&#x2013;341.</Citation><ArticleIdList><ArticleId IdType="pubmed">1378350</ArticleId></ArticleIdList></Reference><Reference><Citation>Hondius DC, et al. Proteomics analysis identifies new markers associated with capillary cerebral amyloid angiopathy in Alzheimer&#x2019;s disease. Acta Neuropathol. Commun. 2018;6:46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5985582</ArticleId><ArticleId IdType="pubmed">29860944</ArticleId></ArticleIdList></Reference><Reference><Citation>de Leeuw CA, Mooij JM, Heskes T, Posthuma D. MAGMA: generalized gene-set analysis of GWAS data. PLoS Comput. Biol. 2015;11:e1004219.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4401657</ArticleId><ArticleId IdType="pubmed">25885710</ArticleId></ArticleIdList></Reference><Reference><Citation>Seyfried NT, et al. A multi-network approach identifies protein-specific co-expression in asymptomatic and symptomatic Alzheimer&#x2019;s disease. Cell Syst. 2017;4:60&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5269514</ArticleId><ArticleId IdType="pubmed">27989508</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu L, et al. Cortical proteins associated with cognitive resilience in community-dwelling older persons. JAMA Psychiatry. 2020;77:1172&#x2013;1180.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7330835</ArticleId><ArticleId IdType="pubmed">32609320</ArticleId></ArticleIdList></Reference><Reference><Citation>Higginbotham, L. et al. Integrated proteomics reveals brain-based cerebrospinal fluid biomarkers in asymptomatic and symptomatic Alzheimer&#x2019;s disease. Sci. Adv.6, eaaz9360 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7577712</ArticleId><ArticleId IdType="pubmed">33087358</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamauchi Y, et al. Role of the N- and C-terminal domains in binding of apolipoprotein E isoforms to heparan sulfate and dermatan sulfate: a surface plasmon resonance study. Biochemistry. 2008;47:6702&#x2013;6710.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2844924</ArticleId><ArticleId IdType="pubmed">18507396</ArticleId></ArticleIdList></Reference><Reference><Citation>Arboleda-Velasquez JF, et al. Resistance to autosomal dominant Alzheimer&#x2019;s disease in an APOE3 Christchurch homozygote: a case report. Nat. Med. 2019;25:1680&#x2013;1683.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6898984</ArticleId><ArticleId IdType="pubmed">31686034</ArticleId></ArticleIdList></Reference><Reference><Citation>Uren A, et al. Secreted frizzled-related protein-1 binds directly to Wingless and is a biphasic modulator of Wnt signaling. J. Biol. Chem. 2000;275:4374&#x2013;4382.</Citation><ArticleIdList><ArticleId IdType="pubmed">10660608</ArticleId></ArticleIdList></Reference><Reference><Citation>Esteve P, et al. SFRPs act as negative modulators of ADAM10 to regulate retinal neurogenesis. Nat. Neurosci. 2011;14:562&#x2013;569.</Citation><ArticleIdList><ArticleId IdType="pubmed">21478884</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou M, et al. Targeted mass spectrometry to quantify brain-derived cerebrospinal fluid biomarkers in Alzheimer&#x2019;s disease. Clin. Proteom. 2020;17:19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7257173</ArticleId><ArticleId IdType="pubmed">32514259</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulland TK, et al. TREM2 maintains microglial metabolic fitness in Alzheimer&#x2019;s disease. Cell. 2017;170:649&#x2013;663.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5573224</ArticleId><ArticleId IdType="pubmed">28802038</ArticleId></ArticleIdList></Reference><Reference><Citation>Minhas PS, et al. Restoring metabolism of myeloid cells reverses cognitive decline in ageing. Nature. 2021;590:122&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8274816</ArticleId><ArticleId IdType="pubmed">33473210</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, et al. Religious Orders Study and Rush Memory and Aging Project. J. Alzheimers Dis. 2018;64:S161&#x2013;S189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6380522</ArticleId><ArticleId IdType="pubmed">29865057</ArticleId></ArticleIdList></Reference><Reference><Citation>Ince PG, Lowe J, Shaw PJ. Amyotrophic lateral sclerosis: current issues in classification, pathogenesis and molecular pathology. Neuropathol. Appl. Neurobiol. 1998;24:104&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pubmed">9634206</ArticleId></ArticleIdList></Reference><Reference><Citation>Balsis S, Benge JF, Lowe DA, Geraci L, Doody RS. How do scores on the ADAS-Cog, MMSE, and CDR-SOB correspond? Clin. Neuropsychol. 2015;29:1002&#x2013;1009.</Citation><ArticleIdList><ArticleId IdType="pubmed">26617181</ArticleId></ArticleIdList></Reference><Reference><Citation>Pichler P, et al. Peptide labeling with isobaric tags yields higher identification rates using iTRAQ 4-plex compared to TMT 6-plex and iTRAQ 8-plex on LTQ Orbitrap. Anal. Chem. 2010;82:6549&#x2013;6558.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3093924</ArticleId><ArticleId IdType="pubmed">20593797</ArticleId></ArticleIdList></Reference><Reference><Citation>Mertins P, et al. Reproducible workflow for multiplexed deep-scale proteome and phosphoproteome analysis of tumor tissues by liquid chromatography&#x2013;mass spectrometry. Nat. Protoc. 2018;13:1632&#x2013;1661.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6211289</ArticleId><ArticleId IdType="pubmed">29988108</ArticleId></ArticleIdList></Reference><Reference><Citation>Wingo TS, et al. Integrating next-generation genomic sequencing and mass spectrometry to estimate allele-specific protein abundance in human brain. J. Proteome Res. 2017;16:3336&#x2013;3347.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5698003</ArticleId><ArticleId IdType="pubmed">28691493</ArticleId></ArticleIdList></Reference><Reference><Citation>Tukey, J. W. Exploratory Data Analysis (Addison-Wesley, 1977).</Citation></Reference><Reference><Citation>Oldham MC, et al. Functional organization of the transcriptome in human brain. Nat. Neurosci. 2008;11:1271&#x2013;1282.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2756411</ArticleId><ArticleId IdType="pubmed">18849986</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen KD, Irizarry RA, Wu Z. Removing technical variability in RNA-seq data using conditional quantile normalization. Biostatistics. 2012;13:204&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3297825</ArticleId><ArticleId IdType="pubmed">22285995</ArticleId></ArticleIdList></Reference><Reference><Citation>Sieberts SK, et al. Large eQTL meta-analysis reveals differing patterns between cerebral cortical and cerebellar brain regions. Sci. Data. 2020;7:340.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7550587</ArticleId><ArticleId IdType="pubmed">33046718</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie ME, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43:e47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4402510</ArticleId><ArticleId IdType="pubmed">25605792</ArticleId></ArticleIdList></Reference><Reference><Citation>Law CW, Chen Y, Shi W, Smyth GK. voom: precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biol. 2014;15:R29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4053721</ArticleId><ArticleId IdType="pubmed">24485249</ArticleId></ArticleIdList></Reference><Reference><Citation>Hotelling H. Analysis of a complex of statistical variables into principal components. J. Educ. Psychol. 1933;24:417&#x2013;441.</Citation></Reference><Reference><Citation>Pearson K. On lines and planes of closest fit to systems of points in space. Philos. Mag. 1901;2:559&#x2013;572.</Citation></Reference><Reference><Citation>Miller JA, Woltjer RL, Goodenbour JM, Horvath S, Geschwind DH. Genes and pathways underlying regional and cell type changes in Alzheimer&#x2019;s disease. Genome Med. 2013;5:48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3706780</ArticleId><ArticleId IdType="pubmed">23705665</ArticleId></ArticleIdList></Reference><Reference><Citation>Newman ME. Fast algorithm for detecting community structure in networks. Phys. Rev. E Stat. Nonlin. Soft Matter Phys. 2004;69:066133.</Citation><ArticleIdList><ArticleId IdType="pubmed">15244693</ArticleId></ArticleIdList></Reference><Reference><Citation>Arenas A, Fernandez A, Gomez S. Analysis of the structure of complex networks at different resolution levels. New J. Phys. 2008;10:053039.</Citation></Reference><Reference><Citation>McKenzie AT, et al. Multiscale network modeling of oligodendrocytes reveals molecular components of myelin dysregulation in Alzheimer&#x2019;s disease. Mol. Neurodegener. 2017;12:82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5674813</ArticleId><ArticleId IdType="pubmed">29110684</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma K, et al. Cell type- and brain region-resolved mouse brain proteome. Nat. Neurosci. 2015;18:1819&#x2013;1831.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7116867</ArticleId><ArticleId IdType="pubmed">26523646</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, et al. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J. Neurosci. 2014;34:11929&#x2013;11947.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4152602</ArticleId><ArticleId IdType="pubmed">25186741</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunkle BW, et al. Genetic meta-analysis of diagnosed Alzheimer&#x2019;s disease identifies new risk loci and implicates A&#x3b2;, tau, immunity and lipid processing. Nat. Genet. 2019;51:414&#x2013;430.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6463297</ArticleId><ArticleId IdType="pubmed">30820047</ArticleId></ArticleIdList></Reference><Reference><Citation>De Jager PL, et al. A multi-omic atlas of the human frontal cortex for aging and Alzheimer&#x2019;s disease research. Sci. Data. 2018;5:180142.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6080491</ArticleId><ArticleId IdType="pubmed">30084846</ArticleId></ArticleIdList></Reference><Reference><Citation>Wingo AP, et al. Integrating human brain proteomes with genome-wide association data implicates new proteins in Alzheimer&#x2019;s disease pathogenesis. Nat. Genet. 2021;53:143&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8130821</ArticleId><ArticleId IdType="pubmed">33510477</ArticleId></ArticleIdList></Reference><Reference><Citation>Manichaikul A, et al. Robust relationship inference in genome-wide association studies. Bioinformatics. 2010;26:2867&#x2013;2873.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3025716</ArticleId><ArticleId IdType="pubmed">20926424</ArticleId></ArticleIdList></Reference><Reference><Citation>Genomes Project C, et al. An integrated map of genetic variation from 1,092 human genomes. Nature. 2012;491:56&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3498066</ArticleId><ArticleId IdType="pubmed">23128226</ArticleId></ArticleIdList></Reference><Reference><Citation>Das S, et al. Next-generation genotype imputation service and methods. Nat. Genet. 2016;48:1284&#x2013;1287.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5157836</ArticleId><ArticleId IdType="pubmed">27571263</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, et al. Late-life depression is not associated with dementia-related pathology. Neuropsychology. 2016;30:135&#x2013;142.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4740262</ArticleId><ArticleId IdType="pubmed">26237627</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyle PA, et al. Person-specific contribution of neuropathologies to cognitive loss in old age. Ann. Neurol. 2018;83:74&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5876116</ArticleId><ArticleId IdType="pubmed">29244218</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamini Y, Yekutieli D. The control of the false discovery rate in multiple testing under dependency. Ann. Stat. 2001;29:1165&#x2013;1188.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35142047</PMID><DateCompleted><Year>2023</Year><Month>10</Month><Day>23</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1552-5279</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>10</Issue><PubDate><Year>2023</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Alzheimer's &amp; dementia : the journal of the Alzheimer's Association</Title><ISOAbbreviation>Alzheimers Dement</ISOAbbreviation></Journal><ArticleTitle>Association between CSF biomarkers of Alzheimer's disease and neuropsychiatric symptoms: Mayo Clinic Study of Aging.</ArticleTitle><Pagination><StartPage>4498</StartPage><EndPage>4506</EndPage><MedlinePgn>4498-4506</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/alz.12557</ELocationID><Abstract><AbstractText Label="INTRODUCTION">We examined the association between cerebrospinal fluid (CSF)-derived biomarkers of Alzheimer's disease and neuropsychiatric symptoms (NPS) in older non-demented adults.</AbstractText><AbstractText Label="METHODS">We included 784 persons (699 cognitively unimpaired, 85 with mild cognitive impairment) aged &#x2265; 50 years who underwent CSF amyloid beta (A&#x3b2;42), hyperphosphorylated tau 181 (p-tau), and total tau (t-tau) as well as NPS assessment using Beck Depression and Anxiety Inventories (BDI-II, BAI), and Neuropsychiatric Inventory Questionnaire (NPI-Q).</AbstractText><AbstractText Label="RESULTS">Lower CSF A&#x3b2;42, and higher t-tau/A&#x3b2;42 and p-tau/A&#x3b2;42 ratios were associated with BDI-II and BAI total scores, clinical depression (BDI-II &#x2265; 13), and clinical anxiety (BAI &#x2265; 10), as well as NPI-Q-assessed anxiety, apathy, and nighttime behavior.</AbstractText><AbstractText Label="DISCUSSION">CSF A&#x3b2;42, t-tau/A&#x3b2;42, and p-tau/A&#x3b2;42 ratios were associated with NPS in community-dwelling individuals free of dementia. If confirmed by a longitudinal cohort study, the findings have clinical relevance of taking into account the NPS status of individuals with abnormal CSF biomarkers.</AbstractText><CopyrightInformation>&#xa9; 2021 The Authors. Alzheimer's &amp; Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Krell-Roesch</LastName><ForeName>Janina</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Sports and Sports Science, Karlsruhe Institute of Technology, Karlsruhe, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rakusa</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University Medical Centre Maribor, Maribor, Slovenia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Syrjanen</LastName><ForeName>Jeremy A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Harten</LastName><ForeName>Argonde C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Alzheimer Center, Department of Neurology, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lowe</LastName><ForeName>Val J</ForeName><Initials>VJ</Initials><AffiliationInfo><Affiliation>Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jack</LastName><ForeName>Clifford R</ForeName><Initials>CR</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kremers</LastName><ForeName>Walter K</ForeName><Initials>WK</Initials><AffiliationInfo><Affiliation>Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knopman</LastName><ForeName>David S</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stokin</LastName><ForeName>Gorazd B</ForeName><Initials>GB</Initials><AffiliationInfo><Affiliation>International Clinical Research Center, St. Anne's Hospital, Brno, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vassilaki</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geda</LastName><ForeName>Yonas E</ForeName><Initials>YE</Initials><Identifier Source="ORCID">0000-0003-1187-7230</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Barrow Neurological Institute, Phoenix, Arizona, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K01 MH068351</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG041851</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG069453</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG034676</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG072980</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG011378</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R33 AG058738</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG057708</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG019610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG006786</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS097495</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062677</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>02</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Alzheimers Dement</MedlineTA><NlmUniqueID>101231978</NlmUniqueID><ISSNLinking>1552-5260</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="Y">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">CSF amyloid beta 42</Keyword><Keyword MajorTopicYN="N">CSF phosphorylated tau</Keyword><Keyword MajorTopicYN="N">CSF total tau</Keyword><Keyword MajorTopicYN="N">cerebrospinal fluid biomarkers</Keyword><Keyword MajorTopicYN="N">neuropsychiatric symptoms</Keyword><Keyword MajorTopicYN="N">non-demented</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>6</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>12</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>11</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>23</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>2</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>2</Month><Day>10</Day><Hour>5</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35142047</ArticleId><ArticleId IdType="mid">NIHMS1921089</ArticleId><ArticleId IdType="pmc">PMC10433790</ArticleId><ArticleId IdType="doi">10.1002/alz.12557</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Banning LCP, Ramakers I, Deckers K, Verhey FRJ, Aalten P. Affective symptoms and AT(N) biomarkers in mild cognitive impairment and Alzheimer&#x2019;s disease: A systematic literature review. Neurosci Biobehav Rev. 2019;107:346&#x2013;359.</Citation><ArticleIdList><ArticleId IdType="pubmed">31525387</ArticleId></ArticleIdList></Reference><Reference><Citation>Geda YE, Schneider LS, Gitlin LN, et al. Neuropsychiatric symptoms in Alzheimer&#x2019;s disease: past progress and anticipation of the future. Alzheimers Dement. 2013;9(5):602&#x2013;608.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3766403</ArticleId><ArticleId IdType="pubmed">23562430</ArticleId></ArticleIdList></Reference><Reference><Citation>Apostolova LG, Cummings JL. Neuropsychiatric manifestations in mild cognitive impairment: a systematic review of the literature. Dementia &amp; Geriatric Cognitive Disorders. 2008;25(2):115&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pubmed">18087152</ArticleId></ArticleIdList></Reference><Reference><Citation>Geda YE, Roberts RO, Knopman DS, et al. Prevalence of neuropsychiatric symptoms in mild cognitive impairment and normal cognitive aging: population-based study. Archives of General Psychiatry. 2008;65(10):1193&#x2013;1198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2575648</ArticleId><ArticleId IdType="pubmed">18838636</ArticleId></ArticleIdList></Reference><Reference><Citation>Geda YE, Krell-Roesch J, Sambuchi N, Michel BF. Neuropsychiatric Symptoms and Neuroimaging Biomarkers in Alzheimer Disease: &#x201c;Which is the Cart and Which is the Horse?&#x201d;. Am J Geriatr Psychiatry. 2017;25(7):694&#x2013;696.</Citation><ArticleIdList><ArticleId IdType="pubmed">28392189</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters ME, Lyketsos CG. Beyond memory: a focus on the other neuropsychiatric symptoms of dementia. Am J Geriatr Psychiatry. 2015;23(2):115&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4293074</ArticleId><ArticleId IdType="pubmed">25575934</ArticleId></ArticleIdList></Reference><Reference><Citation>Tommasi NS, Gonzalez C, Briggs D, et al. Affective symptoms and regional cerebral tau burden in early-stage Alzheimer&#x2019;s disease. Int J Geriatr Psychiatry. 2021;36(7):1050&#x2013;1058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8187284</ArticleId><ArticleId IdType="pubmed">33682933</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasuno F, Minami H, Hattori H, Alzheimer&#x2019;s Disease Neuroimaging I. Relationship between neuropsychiatric symptoms and Alzheimer&#x2019;s disease pathology: An in vivo positron emission tomography study. Int J Geriatr Psychiatry. 2021;36(4):598&#x2013;605.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7933053</ArticleId><ArticleId IdType="pubmed">33165946</ArticleId></ArticleIdList></Reference><Reference><Citation>Tissot C, Therriault J, Pascoal TA, et al. Association between regional tau pathology and neuropsychiatric symptoms in aging and dementia due to Alzheimer&#x2019;s disease. Alzheimers Dement (N Y). 2021;7(1):e12154.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8012244</ArticleId><ArticleId IdType="pubmed">33816761</ArticleId></ArticleIdList></Reference><Reference><Citation>Miao R, Chen HY, Gill S, et al. Plasma beta-Amyloid in Mild Behavioural Impairment - Neuropsychiatric Symptoms on the Alzheimer&#x2019;s Continuum. J Geriatr Psychiatry Neurol. 2021:8919887211016068.</Citation><ArticleIdList><ArticleId IdType="pubmed">34036829</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee GJ, Lu PH, Hua X, et al. Depressive symptoms in mild cognitive impairment predict greater atrophy in Alzheimer&#x2019;s disease-related regions. Biol Psychiatry. 2012;71(9):814&#x2013;821.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3322258</ArticleId><ArticleId IdType="pubmed">22322105</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramakers IH, Verhey FR, Scheltens P, et al. Anxiety is related to Alzheimer cerebrospinal fluid markers in subjects with mild cognitive impairment. Psychol Med. 2013;43(5):911&#x2013;920.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4104501</ArticleId><ArticleId IdType="pubmed">22954311</ArticleId></ArticleIdList></Reference><Reference><Citation>Nathan PJ, Lim YY, Abbott R, et al. Association between CSF biomarkers, hippocampal volume and cognitive function in patients with amnestic mild cognitive impairment (MCI). Neurobiol Aging. 2017;53:1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">28189924</ArticleId></ArticleIdList></Reference><Reference><Citation>Reijs BLR, Vos SJB, Soininen H, et al. Association Between Later Life Lifestyle Factors and Alzheimer&#x2019;s Disease Biomarkers in Non-Demented Individuals: A Longitudinal Descriptive Cohort Study. J Alzheimers Dis. 2017;60(4):1387&#x2013;1395.</Citation><ArticleIdList><ArticleId IdType="pubmed">29036813</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold SE, Xie SX, Leung YY, et al. Plasma biomarkers of depressive symptoms in older adults. Transl Psychiatry. 2012;2:e65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3309547</ArticleId><ArticleId IdType="pubmed">22832727</ArticleId></ArticleIdList></Reference><Reference><Citation>Donovan NJ, Wadsworth LP, Lorius N, et al. Regional cortical thinning predicts worsening apathy and hallucinations across the Alzheimer disease spectrum. Am J Geriatr Psychiatry. 2014;22(11):1168&#x2013;1179.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3960369</ArticleId><ArticleId IdType="pubmed">23890751</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo HC, Yen HC, Huang CC, Hsu WC, Wei HJ, Lin CL. Cerebrospinal fluid biomarkers for neuropsychological symptoms in early stage of late-onset Alzheimer&#x2019;s disease. Int J Neurosci. 2015;125(10):747&#x2013;754.</Citation><ArticleIdList><ArticleId IdType="pubmed">25290083</ArticleId></ArticleIdList></Reference><Reference><Citation>Scaricamazza E, Colonna I, Sancesario GM, et al. Neuropsychiatric symptoms differently affect mild cognitive impairment and Alzheimer&#x2019;s disease patients: a retrospective observational study. Neurol Sci. 2019;40(7):1377&#x2013;1382.</Citation><ArticleIdList><ArticleId IdType="pubmed">30903419</ArticleId></ArticleIdList></Reference><Reference><Citation>Banning LCP, Ramakers I, Kohler S, et al. The Association Between Biomarkers and Neuropsychiatric Symptoms Across the Alzheimer&#x2019;s Disease Spectrum. Am J Geriatr Psychiatry. 2020; 28(7):735&#x2013;744.</Citation><ArticleIdList><ArticleId IdType="pubmed">32088096</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts RO, Geda YE, Knopman DS, et al. The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology. 2008;30(1):58&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2821441</ArticleId><ArticleId IdType="pubmed">18259084</ArticleId></ArticleIdList></Reference><Reference><Citation>Rey A L&#x2019;examen clinique en psychologie. Paris: Presses Universitaires de France; 1964.</Citation></Reference><Reference><Citation>Wechsler D Wechsler Memory Scale-Revised. New York: The Psychological Corporation; 1987.</Citation></Reference><Reference><Citation>Kaplan E, Goodglass H, Weintraub S. Boston Naming Test. 2nd ed. Philadelphia: Lippincott Williams &amp; Wilkins; 2001.</Citation></Reference><Reference><Citation>Lucas JA, Ivnik RJ, Smith GE, et al. Mayo&#x2019;s Older Americans Normative Studies: category fluency norms. J Clin Exp Neuropsychol. 1998;20(2):194&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pubmed">9777473</ArticleId></ArticleIdList></Reference><Reference><Citation>Wechsler D Wechsler Adult Intelligence Scale-Revised. New York: Psychological Corporation; 1981.</Citation></Reference><Reference><Citation>Reitan RM. Validity of the Trail Making Test as an indicator of organic brain damage. Perceptual and Motor Skills. 1958;8(3):271&#x2013;276.</Citation></Reference><Reference><Citation>Ivnik R, Malec J, Smith G, et al. Mayo&#x2019;s Older Americans Normative Studies: WAIS-R, WMS-R, and AVLT norms for ages 56 through 97. Clin Neuropsychol. 1992;6(Supplement):1&#x2013;104.</Citation></Reference><Reference><Citation>Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256(3):183&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pubmed">15324362</ArticleId></ArticleIdList></Reference><Reference><Citation>Winblad B, Palmer K, Kivipelto M, et al. Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. Journal of Internal Medicine. 2004;256(3):240&#x2013;246.</Citation><ArticleIdList><ArticleId IdType="pubmed">15324367</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Harten AC, Wiste HJ, Weigand SD, et al. CSF biomarkers in Olmsted County: Evidence of 2 subclasses and associations with demographics. Neurology. 2020;95(3):e256&#x2013;e267.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7455353</ArticleId><ArticleId IdType="pubmed">32591471</ArticleId></ArticleIdList></Reference><Reference><Citation>Beck AT, Steer RA, Brown GK. Manual for Beck Depression Inventory-II (BDI-II). San Antonio: Psychology Corporation; 2001.</Citation></Reference><Reference><Citation>Beck AT, Steer RA. BAI, Beck Anxiety Inventory: Manual. San Antonio: Psychological Corp. : Harcourt Brace Jovanovich; 1990.</Citation></Reference><Reference><Citation>Kaufer DI, Cummings JL, Ketchel P, et al. Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. Journal of Neuropsychiatry and Clinical Neurosciences. 2000;12(2):233&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pubmed">11001602</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrington KD, Lim YY, Gould E, Maruff P. Amyloid-beta and depression in healthy older adults: A systematic review. Aust N Z J Psychiatry. 2015;49(1):36&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">25414381</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzales MM, Insel PS, Nelson C, et al. Chronic depressive symptomatology and CSF amyloid beta and tau levels in mild cognitive impairment. Int J Geriatr Psychiatry. 2018;33(10):1305&#x2013;1311.</Citation><ArticleIdList><ArticleId IdType="pubmed">29953668</ArticleId></ArticleIdList></Reference><Reference><Citation>Showraki A, Murari G, Ismail Z, et al. Cerebrospinal Fluid Correlates of Neuropsychiatric Symptoms in Patients with Alzheimer&#x2019;s Disease/Mild Cognitive Impairment: A Systematic Review. J Alzheimers Dis. 2019;71(2):477&#x2013;501.</Citation><ArticleIdList><ArticleId IdType="pubmed">31424398</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Luehmann M, Spires-Jones TL, Prada C, et al. Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer&#x2019;s disease. Nature. 2008;451(7179):720&#x2013;724.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3264491</ArticleId><ArticleId IdType="pubmed">18256671</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang JE, Lim MM, Bateman RJ, et al. Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science. 2009;326(5955):1005&#x2013;1007.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2789838</ArticleId><ArticleId IdType="pubmed">19779148</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Caccamo A, Shepherd JD, et al. Triple-transgenic model of Alzheimer&#x2019;s disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron. 2003;39(3):409&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">12895417</ArticleId></ArticleIdList></Reference><Reference><Citation>Bierer LM, Hof PR, Purohit DP, et al. Neocortical neurofibrillary tangles correlate with dementia severity in Alzheimer&#x2019;s disease. Arch Neurol. 1995;52(1):81&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">7826280</ArticleId></ArticleIdList></Reference><Reference><Citation>Buerger K, Ewers M, Pirttila T, et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer&#x2019;s disease. Brain. 2006;129(Pt 11):3035&#x2013;3041.</Citation><ArticleIdList><ArticleId IdType="pubmed">17012293</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JC, Kim SJ, Hong S, Kim Y. Diagnosis of Alzheimer&#x2019;s disease utilizing amyloid and tau as fluid biomarkers. Exp Mol Med. 2019;51(5):1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6509326</ArticleId><ArticleId IdType="pubmed">31073121</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie C, Smailagic N, Noel-Storr AH, Ukoumunne O, Ladds EC, Martin S. CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer&#x2019;s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev. 2017;3:CD010803.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6464349</ArticleId><ArticleId IdType="pubmed">28328043</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson O, Seibyl J, Stomrud E, et al. CSF biomarkers of Alzheimer&#x2019;s disease concord with amyloid-beta PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimers Dement. 2018;14(11):1470&#x2013;1481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6119541</ArticleId><ArticleId IdType="pubmed">29499171</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Lonneborg A, Boccardi M, Blennow K, Hansson O, Geneva Task Force for the Roadmap of Alzheimer&#x2019;s B. Clinical validity of cerebrospinal fluid Abeta42, tau, and phospho-tau as biomarkers for Alzheimer&#x2019;s disease in the context of a structured 5-phase development framework. Neurobiol Aging. 2017;52:196&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pubmed">28317649</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang MJ, Yi S, Han JY, et al. Analysis of Cerebrospinal Fluid and [11C]PIB PET Biomarkers for Alzheimer&#x2019;s Disease with Updated Protocols. J Alzheimers Dis. 2016;52(4):1403&#x2013;1413.</Citation><ArticleIdList><ArticleId IdType="pubmed">27163824</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Shaw LM, Xiong C, et al. Comparison of analytical platforms for cerebrospinal fluid measures of beta-amyloid 1&#x2013;42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology. Arch Neurol. 2011;68(9):1137&#x2013;1144.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3154969</ArticleId><ArticleId IdType="pubmed">21555603</ArticleId></ArticleIdList></Reference><Reference><Citation>Krell-Roesch J, Lowe VJ, Neureiter J, et al. Depressive and anxiety symptoms and cortical amyloid deposition among cognitively normal elderly persons: the Mayo Clinic Study of Aging. Int Psychogeriatr. 2018;30(2):245&#x2013;251.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5815897</ArticleId><ArticleId IdType="pubmed">29198244</ArticleId></ArticleIdList></Reference><Reference><Citation>Ismail Z, Aguera-Ortiz L, Brodaty H, et al. The Mild Behavioral Impairment Checklist (MBI-C): A Rating Scale for Neuropsychiatric Symptoms in Pre-Dementia Populations. J Alzheimers Dis. 2017;56(3):929&#x2013;938.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5652315</ArticleId><ArticleId IdType="pubmed">28059789</ArticleId></ArticleIdList></Reference><Reference><Citation>Lussier FZ, Pascoal TA, Chamoun M, et al. Mild behavioral impairment is associated with beta-amyloid but not tau or neurodegeneration in cognitively intact elderly individuals. Alzheimers Dement. 2020;16(1):192&#x2013;199.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7041633</ArticleId><ArticleId IdType="pubmed">31914223</ArticleId></ArticleIdList></Reference><Reference><Citation>Johansson M, Stomrud E, Insel PS, et al. Mild behavioral impairment and its relation to tau pathology in preclinical Alzheimer&#x2019;s disease. Transl Psychiatry. 2021;11(1):76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7838407</ArticleId><ArticleId IdType="pubmed">33500386</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35171209</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>08</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6238</ISSN><JournalIssue CitedMedium="Internet"><Volume>79</Volume><Issue>4</Issue><PubDate><Year>2022</Year><Month>Apr</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA psychiatry</Title><ISOAbbreviation>JAMA Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Longitudinal Associations of Mental Disorders With Dementia: 30-Year Analysis of 1.7 Million New Zealand Citizens.</ArticleTitle><Pagination><StartPage>333</StartPage><EndPage>340</EndPage><MedlinePgn>333-340</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamapsychiatry.2021.4377</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Mental disorders are an underappreciated category of modifiable risk factors for dementia. Developing an evidence base about the link between mental disorders and dementia risk requires studies that use large, representative samples, consider the full range of psychiatric conditions, ascertain mental disorders from early life, use long follow-ups, and distinguish between Alzheimer disease and related dementias.</AbstractText><AbstractText Label="OBJECTIVE">To test whether mental disorders antedate dementia across 3 decades of observation.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">This population-based administrative register study of mental disorders and Alzheimer disease and related dementias included all individuals born in New Zealand between 1928 and 1967 who resided in the country for any time during the 30-year observation period between July 1988 and June 2018. Data were from the New Zealand Integrated Data Infrastructure, a collection of whole-of-population administrative data sources linked at the individual level. Data were analyzed from October 2020 to November 2021.</AbstractText><AbstractText Label="EXPOSURES">Diagnoses of mental disorders were ascertained from public-hospital records.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Diagnoses of dementia were ascertained from public-hospital records, mortality records, and pharmaceutical records.</AbstractText><AbstractText Label="RESULTS">Of 1&#x202f;711&#x202f;386 included individuals, 866&#x202f;301 (50.6%) were male, and individuals were aged 21 to 60 years at baseline. Relative to individuals without a mental disorder, those with a mental disorder were at increased risk of developing subsequent dementia (relative risk [RR], 4.24; 95% CI, 4.07-4.42; hazard ratio, 6.49; 95% CI, 6.25-6.73). Among individuals with dementia, those with a mental disorder developed dementia a mean of 5.60 years (95% CI, 5.31-5.90) earlier than those without a mental disorder. Associations held across sex and age and after accounting for preexisting chronic physical diseases and socioeconomic deprivation. Associations were present across different types of mental disorders and self-harm behavior (RRs ranged from 2.93 [95% CI, 2.66-3.21] for neurotic disorders to 6.20 [95% CI, 5.67-6.78] for psychotic disorders), and were evident for Alzheimer disease (RR, 2.76; 95% CI, 2.45-3.11) and all other dementias (RR, 5.85; 95% CI, 5.58-6.13).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">In this study, mental disorders were associated with the onset of dementia in the population. Ameliorating mental disorders in early life might also ameliorate neurodegenerative conditions and extend quality of life in old age.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Richmond-Rakerd</LastName><ForeName>Leah S</ForeName><Initials>LS</Initials><AffiliationInfo><Affiliation>Department of Psychology, University of Michigan, Ann Arbor.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Souza</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Centre of Methods and Policy Application in the Social Sciences (COMPASS), University of Auckland, Auckland, New Zealand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Social Sciences, University of Auckland, Auckland, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Milne</LastName><ForeName>Barry J</ForeName><Initials>BJ</Initials><AffiliationInfo><Affiliation>Centre of Methods and Policy Application in the Social Sciences (COMPASS), University of Auckland, Auckland, New Zealand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Social Sciences, University of Auckland, Auckland, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caspi</LastName><ForeName>Avshalom</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Psychology and Neuroscience, Duke University, Durham, North Carolina.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, North Carolina.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Genomic and Computational Biology, Duke University, Durham, North Carolina.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Psychiatry, Psychology, and Neuroscience, King's College London, London, England.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Promenta Center, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moffitt</LastName><ForeName>Terrie E</ForeName><Initials>TE</Initials><AffiliationInfo><Affiliation>Department of Psychology and Neuroscience, Duke University, Durham, North Carolina.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, North Carolina.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Genomic and Computational Biology, Duke University, Durham, North Carolina.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Psychiatry, Psychology, and Neuroscience, King's College London, London, England.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Promenta Center, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MR/P005918/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 AG069939</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Psychiatry</MedlineTA><NlmUniqueID>101589550</NlmUniqueID><ISSNLinking>2168-622X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="Y">Mental Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009520" MajorTopicYN="N" Type="Geographic">New Zealand</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="Y">Psychotic Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Milne has received grants from the New Zealand Ministry of Business, Innovation and Employment during the conduct of the study. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>2</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>2</Month><Day>16</Day><Hour>12</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>2</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35171209</ArticleId><ArticleId IdType="pmc">PMC8851362</ArticleId><ArticleId IdType="doi">10.1001/jamapsychiatry.2021.4377</ArticleId><ArticleId IdType="pii">2789298</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Global action plan on the public health response to dementia, 2017-2025. World Health Organization. Published 2017. Accessed January 11, 2022. https://apps.who.int/iris/bitstream/handle/10665/259615/9789241513487-eng.pdf?sequence=1</Citation></Reference><Reference><Citation>Liang JH, Lu L, Li JY, et al. . Contributions of modifiable risk factors to dementia incidence: a bayesian network analysis. J Am Med Dir Assoc. 2020;21(11):1592-1599.e13. doi:10.1016/j.jamda.2020.04.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jamda.2020.04.006</ArticleId><ArticleId IdType="pubmed">32563753</ArticleId></ArticleIdList></Reference><Reference><Citation>Livingston G, Huntley J, Sommerlad A, et al. . Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020;396(10248):413-446. doi:10.1016/S0140-6736(20)30367-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30367-6</ArticleId><ArticleId IdType="pmc">PMC7392084</ArticleId><ArticleId IdType="pubmed">32738937</ArticleId></ArticleIdList></Reference><Reference><Citation>National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Health Sciences Policy; Committee on Preventing Dementia and Cognitive Impairment . Preventing Cognitive Decline and Dementia: a Way Forward. Downey A, Stroud C, Landis S, Leshner AI, eds. National Academies Press; 2017.</Citation><ArticleIdList><ArticleId IdType="pubmed">28650595</ArticleId></ArticleIdList></Reference><Reference><Citation>Vos SJB, van Boxtel MPJ, Schiepers OJG, et al. . Modifiable risk factors for prevention of dementia in midlife, late life and the oldest-old: validation of the LIBRA index. J Alzheimers Dis. 2017;58(2):537-547. doi:10.3233/JAD-161208</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-161208</ArticleId><ArticleId IdType="pubmed">28453475</ArticleId></ArticleIdList></Reference><Reference><Citation>Baumgart M, Snyder HM, Carrillo MC, Fazio S, Kim H, Johns H. Summary of the evidence on modifiable risk factors for cognitive decline and dementia: a population-based perspective. Alzheimers Dement. 2015;11(6):718-726. doi:10.1016/j.jalz.2015.05.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2015.05.016</ArticleId><ArticleId IdType="pubmed">26045020</ArticleId></ArticleIdList></Reference><Reference><Citation>Moffitt TE, Caspi A. Psychiatry&#x2019;s opportunity to prevent the rising burden of age-related disease. JAMA Psychiatry. 2019;76(5):461-462. doi:10.1001/jamapsychiatry.2019.0037</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapsychiatry.2019.0037</ArticleId><ArticleId IdType="pmc">PMC8327353</ArticleId><ArticleId IdType="pubmed">30916735</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker E, Orellana Rios CL, Lahmann C, R&#xfc;cker G, Bauer J, Boeker M. Anxiety as a risk factor of Alzheimer&#x2019;s disease and vascular dementia. Br J Psychiatry. 2018;213(5):654-660. doi:10.1192/bjp.2018.173</Citation><ArticleIdList><ArticleId IdType="doi">10.1192/bjp.2018.173</ArticleId><ArticleId IdType="pubmed">30339108</ArticleId></ArticleIdList></Reference><Reference><Citation>Gimson A, Schlosser M, Huntley JD, Marchant NL. Support for midlife anxiety diagnosis as an independent risk factor for dementia: a systematic review. BMJ Open. 2018;8(4):e019399. doi:10.1136/bmjopen-2017-019399</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2017-019399</ArticleId><ArticleId IdType="pmc">PMC5969723</ArticleId><ArticleId IdType="pubmed">29712690</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai L, Huang J. Schizophrenia and risk of dementia: a meta-analysis study. Neuropsychiatr Dis Treat. 2018;14:2047-2055. doi:10.2147/NDT.S172933</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/NDT.S172933</ArticleId><ArticleId IdType="pmc">PMC6095111</ArticleId><ArticleId IdType="pubmed">30147318</ArticleId></ArticleIdList></Reference><Reference><Citation>Velosa J, Delgado A, Finger E, Berk M, Kapczinski F, de Azevedo Cardoso T. Risk of dementia in bipolar disorder and the interplay of lithium: a systematic review and meta-analyses. Acta Psychiatr Scand. 2020;141(6):510-521. doi:10.1111/acps.13153</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/acps.13153</ArticleId><ArticleId IdType="pubmed">31954065</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmquist S, Nordstr&#xf6;m A, Nordstr&#xf6;m P. The association of depression with subsequent dementia diagnosis: a Swedish nationwide cohort study from 1964 to 2016. PLOS Med. 2020;17(1):e1003016. doi:10.1371/journal.pmed.1003016</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1003016</ArticleId><ArticleId IdType="pmc">PMC6952081</ArticleId><ArticleId IdType="pubmed">31917808</ArticleId></ArticleIdList></Reference><Reference><Citation>Plana-Ripoll O, Pedersen CB, Holtz Y, et al. . Exploring comorbidity within mental disorders among a Danish national population. JAMA Psychiatry. 2019;76(3):259-270. doi:10.1001/jamapsychiatry.2018.3658</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapsychiatry.2018.3658</ArticleId><ArticleId IdType="pmc">PMC6439836</ArticleId><ArticleId IdType="pubmed">30649197</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper B, Holmes C. Previous psychiatric history as a risk factor for late-life dementia: a population-based case-control study. Age Ageing. 1998;27(2):181-188. doi:10.1093/ageing/27.2.181</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ageing/27.2.181</ArticleId><ArticleId IdType="pubmed">16296677</ArticleId></ArticleIdList></Reference><Reference><Citation>Zilkens RR, Bruce DG, Duke J, Spilsbury K, Semmens JB. Severe psychiatric disorders in mid-life and risk of dementia in late life (age 65-84 years): a population based case-control study. Curr Alzheimer Res. 2014;11(7):681-693. doi:10.2174/1567205011666140812115004</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1567205011666140812115004</ArticleId><ArticleId IdType="pmc">PMC4153082</ArticleId><ArticleId IdType="pubmed">25115541</ArticleId></ArticleIdList></Reference><Reference><Citation>Kessing LV, S&#xf8;nderg&#xe5;rd L, Forman JL, Andersen PK. Antidepressants and dementia. J Affect Disord. 2009;117(1-2):24-29. doi:10.1016/j.jad.2008.11.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2008.11.020</ArticleId><ArticleId IdType="pubmed">19138799</ArticleId></ArticleIdList></Reference><Reference><Citation>Leigh-Hunt N, Bagguley D, Bash K, et al. . An overview of systematic reviews on the public health consequences of social isolation and loneliness. Public Health. 2017;152:157-171. doi:10.1016/j.puhe.2017.07.035</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.puhe.2017.07.035</ArticleId><ArticleId IdType="pubmed">28915435</ArticleId></ArticleIdList></Reference><Reference><Citation>Seblova D, Fischer M, Fors S, et al. . Does prolonged education causally affect dementia risk when adult socioeconomic status is not altered? a Swedish natural experiment in 1.3 million individuals. Am J Epidemiol. 2021;190(5):817-826. doi:10.1093/aje/kwaa255</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwaa255</ArticleId><ArticleId IdType="pubmed">33226079</ArticleId></ArticleIdList></Reference><Reference><Citation>Vermeulen-Smit E, Ten Have M, Van Laar M, De Graaf R. Clustering of health risk behaviours and the relationship with mental disorders. J Affect Disord. 2015;171:111-119. doi:10.1016/j.jad.2014.09.031</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2014.09.031</ArticleId><ArticleId IdType="pubmed">25303027</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnett JH, Salmond CH, Jones PB, Sahakian BJ. Cognitive reserve in neuropsychiatry. Psychol Med. 2006;36(8):1053-1064. doi:10.1017/S0033291706007501</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0033291706007501</ArticleId><ArticleId IdType="pubmed">16854246</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett S, Grant MM, Aldred S. Oxidative stress in vascular dementia and Alzheimer&#x2019;s disease: a common pathology. J Alzheimers Dis. 2009;17(2):245-257. doi:10.3233/JAD-2009-1041</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2009-1041</ArticleId><ArticleId IdType="pubmed">19221412</ArticleId></ArticleIdList></Reference><Reference><Citation>Clancy U, Gilmartin D, Jochems ACC, Knox L, Doubal FN, Wardlaw JM. Neuropsychiatric symptoms associated with cerebral small vessel disease: a systematic review and meta-analysis. Lancet Psychiatry. 2021;8(3):225-236. doi:10.1016/S2215-0366(20)30431-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2215-0366(20)30431-4</ArticleId><ArticleId IdType="pubmed">33539776</ArticleId></ArticleIdList></Reference><Reference><Citation>Lutz MW, Sprague D, Barrera J, Chiba-Falek O. Shared genetic etiology underlying Alzheimer&#x2019;s disease and major depressive disorder. Transl Psychiatry. 2020;10(1):88. doi:10.1038/s41398-020-0769-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41398-020-0769-y</ArticleId><ArticleId IdType="pmc">PMC7062839</ArticleId><ArticleId IdType="pubmed">32152295</ArticleId></ArticleIdList></Reference><Reference><Citation>Salim S. Oxidative stress and psychological disorders. Curr Neuropharmacol. 2014;12(2):140-147. doi:10.2174/1570159X11666131120230309</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1570159X11666131120230309</ArticleId><ArticleId IdType="pmc">PMC3964745</ArticleId><ArticleId IdType="pubmed">24669208</ArticleId></ArticleIdList></Reference><Reference><Citation>Watson A, Joyce E. Cognitive reserve and neuropsychiatric disorders. Curr Opin Behav Sci. 2015;4:142-146. doi:10.1016/j.cobeha.2015.05.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cobeha.2015.05.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Milne BJ, Atkinson J, Blakely T, et al. . Data resource profile: the New Zealand Integrated Data Infrastructure (IDI). Int J Epidemiol. 2019;48(3):677-677e. doi:10.1093/ije/dyz014</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyz014</ArticleId><ArticleId IdType="pubmed">30793742</ArticleId></ArticleIdList></Reference><Reference><Citation>Stats New Zealand. Integrated data infrastructure. Accessed July 7, 2021. https://www.stats.govt.nz/integrated-data/integrated-data-infrastructure</Citation></Reference><Reference><Citation>Stats NZ. Integrated Data Infrastructure extension: privacy impact assessment. 3rd ed. Accessed November 10, 2021. http://infoshare.stats.govt.nz/browse_for_stats/snapshots-of-nz/ integrated-data-infrastructure/keep-data-safe/privacy-impact-assessments/privacy-impact-assessmentextension- idi-oct-15.aspx#gsc.tab=0</Citation></Reference><Reference><Citation>Baker MG, Barnard LT, Kvalsvig A, et al. . Increasing incidence of serious infectious diseases and inequalities in New Zealand: a national epidemiological study. Lancet. 2012;379(9821):1112-1119. doi:10.1016/S0140-6736(11)61780-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(11)61780-7</ArticleId><ArticleId IdType="pubmed">22353263</ArticleId></ArticleIdList></Reference><Reference><Citation>Richmond-Rakerd LS, D&#x2019;Souza S, Milne BJ, Caspi A, Moffitt TE. Longitudinal associations of mental disorders with physical diseases and mortality among 2.3 million New Zealand citizens. JAMA Netw Open. 2021;4(1):e2033448. doi:10.1001/jamanetworkopen.2020.33448</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2020.33448</ArticleId><ArticleId IdType="pmc">PMC7807295</ArticleId><ArticleId IdType="pubmed">33439264</ArticleId></ArticleIdList></Reference><Reference><Citation>Walesby KE, Exeter DJ, Gibb S, Wood PC, Starr JM, Russ TC. Prevalence and geographical variation of dementia in New Zealand from 2012 to 2015: brief report utilising routinely collected data within the Integrated Data Infrastructure. Australas J Ageing. 2020;39(3):297-304. doi:10.1111/ajag.12790</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ajag.12790</ArticleId><ArticleId IdType="pubmed">32394527</ArticleId></ArticleIdList></Reference><Reference><Citation>VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the E-value. Ann Intern Med. 2017;167(4):268-274. doi:10.7326/M16-2607</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M16-2607</ArticleId><ArticleId IdType="pubmed">28693043</ArticleId></ArticleIdList></Reference><Reference><Citation>Belloy ME, Napolioni V, Greicius MD. A quarter century of APOE and Alzheimer&#x2019;s disease: progress to date and the path forward. Neuron. 2019;101(5):820-838. doi:10.1016/j.neuron.2019.01.056</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2019.01.056</ArticleId><ArticleId IdType="pmc">PMC6407643</ArticleId><ArticleId IdType="pubmed">30844401</ArticleId></ArticleIdList></Reference><Reference><Citation>Beurel E, Toups M, Nemeroff CB. The bidirectional relationship of depression and inflammation: double trouble. Neuron. 2020;107(2):234-256. doi:10.1016/j.neuron.2020.06.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2020.06.002</ArticleId><ArticleId IdType="pmc">PMC7381373</ArticleId><ArticleId IdType="pubmed">32553197</ArticleId></ArticleIdList></Reference><Reference><Citation>Rehm J, Hasan OSM, Black SE, Shield KD, Schwarzinger M. Alcohol use and dementia: a systematic scoping review. Alzheimers Res Ther. 2019;11(1):1. doi:10.1186/s13195-018-0453-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-018-0453-0</ArticleId><ArticleId IdType="pmc">PMC6320619</ArticleId><ArticleId IdType="pubmed">30611304</ArticleId></ArticleIdList></Reference><Reference><Citation>Harvey PD, Rosenthal JB. Cognitive and functional deficits in people with schizophrenia: evidence for accelerated or exaggerated aging? Schizophr Res. 2018;196:14-21. doi:10.1016/j.schres.2017.05.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.schres.2017.05.009</ArticleId><ArticleId IdType="pubmed">28506706</ArticleId></ArticleIdList></Reference><Reference><Citation>Brommelhoff JA, Gatz M, Johansson B, McArdle JJ, Fratiglioni L, Pedersen NL. Depression as a risk factor or prodromal feature for dementia? findings in a population-based sample of Swedish twins. Psychol Aging. 2009;24(2):373-384. doi:10.1037/a0015713</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/a0015713</ArticleId><ArticleId IdType="pmc">PMC2713179</ArticleId><ArticleId IdType="pubmed">19485655</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang W, Li X, Pan K-Y, et al. . Association of life-course depression with the risk of dementia in late life: a nationwide twin study. Alzheimers Dement. 2021;17(8):1383-1390. doi:10.1002/alz.12303</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.12303</ArticleId><ArticleId IdType="pubmed">33656267</ArticleId></ArticleIdList></Reference><Reference><Citation>World Alzheimer Report 2019: attitudes to dementia. Alzheimer's Disease International. Published online September 20, 2019. Accessed July 6, 2021. https://www.alzint.org/resource/world-alzheimer-report-2019/</Citation></Reference><Reference><Citation>Musiek ES, Morris JC. Possible consequences of the approval of a disease-modifying therapy for Alzheimer disease. JAMA Neurol. 2021;78(2):141-142. doi:10.1001/jamaneurol.2020.4478</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2020.4478</ArticleId><ArticleId IdType="pubmed">33252672</ArticleId></ArticleIdList></Reference><Reference><Citation>Powell T. What a bad day science had. The Hastings Center. Published June 8, 2021. Accessed July 6, 2021. https://www.thehastingscenter.org/what-a-bad-day-science-had/</Citation></Reference><Reference><Citation>Hendriks S, Peetoom K, Bakker C, et al. ; Young-Onset Dementia Epidemiology Study Group . Global prevalence of young-onset dementia: a systematic review and meta-analysis. JAMA Neurol. 2021;78(9):1080-1090. doi:10.1001/jamaneurol.2021.2161</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2021.2161</ArticleId><ArticleId IdType="pmc">PMC8290331</ArticleId><ArticleId IdType="pubmed">34279544</ArticleId></ArticleIdList></Reference><Reference><Citation>da Silva J, Gon&#xe7;alves-Pereira M, Xavier M, Mukaetova-Ladinska EB. Affective disorders and risk of developing dementia: systematic review. Br J Psychiatry. 2013;202(3):177-186. doi:10.1192/bjp.bp.111.101931</Citation><ArticleIdList><ArticleId IdType="doi">10.1192/bjp.bp.111.101931</ArticleId><ArticleId IdType="pubmed">23457181</ArticleId></ArticleIdList></Reference><Reference><Citation>Ribe AR, Laursen TM, Charles M, et al. . Long-term risk of dementia in persons with schizophrenia: a Danish population-based cohort study. JAMA Psychiatry. 2015;72(11):1095-1101. doi:10.1001/jamapsychiatry.2015.1546</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapsychiatry.2015.1546</ArticleId><ArticleId IdType="pubmed">26444987</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohn R, Saxena S, Levav I, Saraceno B. The treatment gap in mental health care. Bull World Health Organ. 2004;82(11):858-866.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2623050</ArticleId><ArticleId IdType="pubmed">15640922</ArticleId></ArticleIdList></Reference><Reference><Citation>Kazdin AE. Annual Research Review: expanding mental health services through novel models of intervention delivery. J Child Psychol Psychiatry. 2019;60(4):455-472. doi:10.1111/jcpp.12937</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcpp.12937</ArticleId><ArticleId IdType="pubmed">29900543</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">35212707</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>09</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1540-9538</ISSN><JournalIssue CitedMedium="Internet"><Volume>219</Volume><Issue>3</Issue><PubDate><Year>2022</Year><Month>Mar</Month><Day>07</Day></PubDate></JournalIssue><Title>The Journal of experimental medicine</Title><ISOAbbreviation>J Exp Med</ISOAbbreviation></Journal><ArticleTitle>Glymphatic system clears extracellular tau and protects from tau aggregation and neurodegeneration.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e20211275</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1084/jem.20211275</ELocationID><Abstract><AbstractText>Accumulation of tau has been implicated in various neurodegenerative diseases termed tauopathies. Tau is a microtubule-associated protein but is also actively released into the extracellular fluids including brain interstitial fluid and cerebrospinal fluid (CSF). However, it remains elusive whether clearance of extracellular tau impacts tau-associated neurodegeneration. Here, we show that aquaporin-4 (AQP4), a major driver of the glymphatic clearance system, facilitates the elimination of extracellular tau from the brain to CSF and subsequently to deep cervical lymph nodes. Strikingly, deletion of AQP4 not only elevated tau in CSF but also markedly exacerbated phosphorylated tau deposition and the associated neurodegeneration in the brains of transgenic mice expressing P301S mutant tau. The current study identified the clearance pathway of extracellular tau in the central nervous system, suggesting that glymphatic clearance of extracellular tau is a novel regulatory mechanism whose impairment contributes to tau aggregation and neurodegeneration.</AbstractText><CopyrightInformation>&#xa9; 2022 Ishida et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Ishida</LastName><ForeName>Kazuhisa</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-5120-4586</Identifier><AffiliationInfo><Affiliation>Department of Neuropathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Yamada</LastName><ForeName>Kaoru</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0003-3696-0604</Identifier><AffiliationInfo><Affiliation>Department of Neuropathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nishiyama</LastName><ForeName>Risa</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-7379-6324</Identifier><AffiliationInfo><Affiliation>Department of Neuropathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hashimoto</LastName><ForeName>Tadafumi</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-5442-4800</Identifier><AffiliationInfo><Affiliation>Department of Neuropathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Innovative Dementia Prevention, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nishida</LastName><ForeName>Itaru</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0003-2484-7356</Identifier><AffiliationInfo><Affiliation>Department of Neuropathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abe</LastName><ForeName>Yoichiro</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0001-6163-8794</Identifier><AffiliationInfo><Affiliation>Department of Pharmacology, Keio University School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Keio University Global Research Institute, Center for Water Biology and Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yasui</LastName><ForeName>Masato</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-5481-1779</Identifier><AffiliationInfo><Affiliation>Department of Pharmacology, Keio University School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Keio University Global Research Institute, Center for Water Biology and Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iwatsubo</LastName><ForeName>Takeshi</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-1160-8129</Identifier><AffiliationInfo><Affiliation>Department of Neuropathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>02</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Exp Med</MedlineTA><NlmUniqueID>2985109R</NlmUniqueID><ISSNLinking>0022-1007</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C496031">Aqp4 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051401">Aquaporin 4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C558298">Mapt protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050505">Mutant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051401" MajorTopicYN="N">Aquaporin 4</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045604" MajorTopicYN="N">Extracellular Fluid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077502" MajorTopicYN="N">Glymphatic System</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050505" MajorTopicYN="N">Mutant Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066263" MajorTopicYN="N">Protein Aggregation, Pathological</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Disclosures: K. Yamada reported &#x201c;part of the study was supported by a collaborative grant from NIPRO Co.&#x201d; No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>6</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>12</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>1</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>2</Month><Day>25</Day><Hour>12</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>2</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>8</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35212707</ArticleId><ArticleId IdType="pmc">PMC8932543</ArticleId><ArticleId IdType="doi">10.1084/jem.20211275</ArticleId><ArticleId IdType="pii">213037</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abe, Y., Ikegawa N., Yoshida K., Muramatsu K., Hattori S., Kawai K., Murakami M., Tanaka T., Goda W., Goto M., et al. . 2020. Behavioral and electrophysiological evidence for a neuroprotective role of aquaporin-4 in the 5xFAD transgenic mice model. Acta Neuropathol. Commun. 8:67. 10.1186/s40478-020-00936-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-020-00936-3</ArticleId><ArticleId IdType="pmc">PMC7218576</ArticleId><ArticleId IdType="pubmed">32398151</ArticleId></ArticleIdList></Reference><Reference><Citation>Aoyagi, H., Hasegawa M., and Tamaoka A.. 2007. Fibrillogenic nuclei composed of P301L mutant tau induce elongation of P301L tau but not wild-type tau. J. Biol. Chem. 282:20309&#x2013;20318. 10.1074/jbc.M611876200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M611876200</ArticleId><ArticleId IdType="pubmed">17526496</ArticleId></ArticleIdList></Reference><Reference><Citation>Aspelund, A., Antila S., Proulx S.T., Karlsen T.V., Karaman S., Detmar M., Wiig H., and Alitalo K.. 2015. A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules. J. Exp. Med. 212:991&#x2013;999. 10.1084/jem.20142290</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20142290</ArticleId><ArticleId IdType="pmc">PMC4493418</ArticleId><ArticleId IdType="pubmed">26077718</ArticleId></ArticleIdList></Reference><Reference><Citation>Barth&#xe9;lemy, N.R., Horie K., Sato C., and Bateman R.J.. 2020a. Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer&#x2019;s disease. J. Exp. Med. 217:1&#x2013;12:e20200861. 10.1084/JEM.20200861</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/JEM.20200861</ArticleId><ArticleId IdType="pmc">PMC7596823</ArticleId><ArticleId IdType="pubmed">32725127</ArticleId></ArticleIdList></Reference><Reference><Citation>Barth&#xe9;lemy, N.R., Li Y., Joseph-Mathurin N., Gordon B.A., Hassenstab J., Benzinger T.L.S., Buckles V., Fagan A.M., Perrin R.J., Goate A.M., et al. 2020b. A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer&#x2019;s disease. Nat. Med. 26:398&#x2013;407. 10.1038/s41591-020-0781-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0781-z</ArticleId><ArticleId IdType="pmc">PMC7309367</ArticleId><ArticleId IdType="pubmed">32161412</ArticleId></ArticleIdList></Reference><Reference><Citation>Burfeind, K.G., Murchison C.F., Westaway S.K., Simon M.J., Erten-Lyons D., Kaye J.A., Quinn J.F., and Iliff J.J.. 2017. The effects of noncoding aquaporin-4 single-nucleotide polymorphisms on cognition and functional progression of Alzheimer&#x2019;s disease. Alzheimers Dement. 3:348&#x2013;359. 10.1016/J.TRCI.2017.05.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.TRCI.2017.05.001</ArticleId><ArticleId IdType="pmc">PMC5651426</ArticleId><ArticleId IdType="pubmed">29067342</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao, X., Xu H., Feng W., Su D., and Xiao M.. 2018. Deletion of aquaporin-4 aggravates brain pathology after blocking of the meningeal lymphatic drainage. Brain Res. Bull. 143:83&#x2013;96. 10.1016/j.brainresbull.2018.10.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainresbull.2018.10.007</ArticleId><ArticleId IdType="pubmed">30347264</ArticleId></ArticleIdList></Reference><Reference><Citation>Clavaguera, F., Bolmont T., Crowther R.A., Abramowski D., Frank S., Probst A., Fraser G., Stalder A.K., Beibel M., Staufenbiel M., et al. . 2009. Transmission and spreading of tauopathy in transgenic mouse brain. Nat. Cell Biol. 11:909&#x2013;913. 10.1038/ncb1901</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncb1901</ArticleId><ArticleId IdType="pmc">PMC2726961</ArticleId><ArticleId IdType="pubmed">19503072</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper, J.M., Lathuiliere A., Migliorini M., Arai A.L., Wani M.M., Dujardin S., Muratoglu S.C., Hyman B.T., and Strickland D.K.. 2021. Regulation of tau internalization, degradation, and seeding by LRP1 reveals multiple pathways for tau catabolism. J. Biol. Chem. 296:100715. 10.1016/j.jbc.2021.100715</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbc.2021.100715</ArticleId><ArticleId IdType="pmc">PMC8164048</ArticleId><ArticleId IdType="pubmed">33930462</ArticleId></ArticleIdList></Reference><Reference><Citation>Eide, P.K., Vatnehol S.A.S., Emblem K.E., and Ringstad G.. 2018. Magnetic resonance imaging provides evidence of glymphatic drainage from human brain to cervical lymph nodes. Sci. Rep. 8:7194&#x2013;7210. 10.1038/s41598-018-25666-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-25666-4</ArticleId><ArticleId IdType="pmc">PMC5940793</ArticleId><ArticleId IdType="pubmed">29740121</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost, B., Jacks R.L., and Diamond M.I.. 2009. Propagation of tau misfolding from the outside to the inside of a cell. J. Biol. Chem. 284:12845&#x2013;12852. 10.1074/jbc.M808759200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M808759200</ArticleId><ArticleId IdType="pmc">PMC2676015</ArticleId><ArticleId IdType="pubmed">19282288</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison, I.F., Ismail O., Machhada A., Colgan N., Ohene Y., Nahavandi P., Ahmed Z., Fisher A., Meftah S., Murray T.K., et al. . 2020. Impaired glymphatic function and clearance of tau in an Alzheimer&#x2019;s disease model. Brain. 143:2576&#x2013;2593. 10.1093/brain/awaa179</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa179</ArticleId><ArticleId IdType="pmc">PMC7447521</ArticleId><ArticleId IdType="pubmed">32705145</ArticleId></ArticleIdList></Reference><Reference><Citation>Holth, J.K., Fritschi S.K., Wang C., Pedersen N.P., Cirrito J.R., Mahan T.E., Finn M.B., Manis M., Geerling J.C., Fuller P.M., et al. . 2019. The sleep-wake cycle regulates brain interstitial fluid tau in mice and CSF tau in humans. Science. 363:880&#x2013;884. 10.1126/science.aav2546</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aav2546</ArticleId><ArticleId IdType="pmc">PMC6410369</ArticleId><ArticleId IdType="pubmed">30679382</ArticleId></ArticleIdList></Reference><Reference><Citation>Iba, M., Guo J.L., McBride J.D., Zhang B., Trojanowski J.Q., and Lee V.M.-Y.. 2013. Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer&#x2019;s-like tauopathy. J. Neurosci. 33:1024&#x2013;1037. 10.1523/JNEUROSCI.2642-12.2013</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2642-12.2013</ArticleId><ArticleId IdType="pmc">PMC3575082</ArticleId><ArticleId IdType="pubmed">23325240</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikeshima-Kataoka, H., Abe Y., Abe T., and Yasui M.. 2013. Immunological function of aquaporin-4 in stab-wounded mouse brain in concert with a pro-inflammatory cytokine inducer, osteopontin. Mol. Cell. Neurosci. 56:65&#x2013;75. 10.1016/j.mcn.2013.02.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2013.02.002</ArticleId><ArticleId IdType="pubmed">23428384</ArticleId></ArticleIdList></Reference><Reference><Citation>Iliff, J.J., Chen M.J., Plog B.A., Zeppenfeld D.M., Soltero M., Yang L., Singh I., Deane R., and Nedergaard M.. 2014. Impairment of glymphatic pathway function promotes tau pathology after traumatic brain injury. J. Neurosci. 34:16180&#x2013;16193. 10.1523/JNEUROSCI.3020-14.2014</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3020-14.2014</ArticleId><ArticleId IdType="pmc">PMC4252540</ArticleId><ArticleId IdType="pubmed">25471560</ArticleId></ArticleIdList></Reference><Reference><Citation>Iliff, J.J., Wang M., Liao Y., Plogg B.A., Peng W., Gundersen G.A., Benveniste H., Vates G.E., Deane R., Goldman S.A., et al. . 2012. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid. Sci. Transl. Med. 4:147ra111. 10.1126/scitranslmed.3003748</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3003748</ArticleId><ArticleId IdType="pmc">PMC3551275</ArticleId><ArticleId IdType="pubmed">22896675</ArticleId></ArticleIdList></Reference><Reference><Citation>Iliff, J.J., Wang M., Zeppenfeld D.M., Venkataraman A., Plog B.A., Liao Y., Deane R., and Nedergaard M.. 2013. Cerebral arterial pulsation drives paravascular CSF-interstitial fluid exchange in the murine brain. J. Neurosci. 33:18190&#x2013;18199. 10.1523/JNEUROSCI.1592-13.2013</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1592-13.2013</ArticleId><ArticleId IdType="pmc">PMC3866416</ArticleId><ArticleId IdType="pubmed">24227727</ArticleId></ArticleIdList></Reference><Reference><Citation>Kfoury, N., Holmes B.B., Jiang H., Holtzman D.M., and Diamond M.I.. 2012. Trans-cellular propagation of tau aggregation by fibrillar species. J. Biol. Chem. 287:19440&#x2013;19451. 10.1074/jbc.M112.346072</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.346072</ArticleId><ArticleId IdType="pmc">PMC3365982</ArticleId><ArticleId IdType="pubmed">22461630</ArticleId></ArticleIdList></Reference><Reference><Citation>Kress, B.T., Iliff J.J., Xia M., Wang M., Wei Bs H.S., Zeppenfeld D., Xie L., Kang H., Xu Q., Liew J.A., et al. . 2014. Impairment of paravascular clearance pathways in the aging brain. Ann. Neurol. 76:845&#x2013;861. 10.1002/ana.24271</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24271</ArticleId><ArticleId IdType="pmc">PMC4245362</ArticleId><ArticleId IdType="pubmed">25204284</ArticleId></ArticleIdList></Reference><Reference><Citation>Louveau, A., Smirnov I., Keyes T.J., Eccles J.D., Rouhani S.J., Peske J.D., Derecki N.C., Castle D., Mandell J.W., Lee K.S., et al. . 2015. Structural and functional features of central nervous system lymphatic vessels. Nature. 523:337&#x2013;341. 10.1038/nature14432</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature14432</ArticleId><ArticleId IdType="pmc">PMC4506234</ArticleId><ArticleId IdType="pubmed">26030524</ArticleId></ArticleIdList></Reference><Reference><Citation>Da Mesquita, S., Louveau A., Vaccari A., Smirnov I., Cornelison R.C., Kingsmore K.M., Contarino C., Onengut-Gumuscu S., Farber E., Raper D., et al. . 2018. Functional aspects of meningeal lymphatics in ageing and Alzheimer&#x2019;s disease. Nature. 560:185&#x2013;191. 10.1038/s41586-018-0368-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-018-0368-8</ArticleId><ArticleId IdType="pmc">PMC6085146</ArticleId><ArticleId IdType="pubmed">30046111</ArticleId></ArticleIdList></Reference><Reference><Citation>Mestre, H., Hablitz L.M., Xavier A.L.R., Feng W., Zou W., Pu T., Monai H., Murlidharan G., Rivera R.M.C., Simon M.J., et al. . 2018. Aquaporin-4-dependent glymphatic solute transport in the rodent brain. Elife. 7:1&#x2013;31:e40070. 10.7554/eLife.40070</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.40070</ArticleId><ArticleId IdType="pmc">PMC6307855</ArticleId><ArticleId IdType="pubmed">30561329</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel, T.K., Habimana-Griffin L., Gao X., Xu B., Achilefu S., Alitalo K., McKee C.A., Sheehan P.W., Musiek E.S., Xiong C., et al. . 2019. Dural lymphatics regulate clearance of extracellular tau from the CNS. Mol. Neurodegener. 14:11&#x2013;19. 10.1186/s13024-019-0312-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-019-0312-x</ArticleId><ArticleId IdType="pmc">PMC6391770</ArticleId><ArticleId IdType="pubmed">30813965</ArticleId></ArticleIdList></Reference><Reference><Citation>Pooler, A.M., Phillips E.C., Lau D.H.W., Noble W., and Hanger D.P.. 2013. Physiological release of endogenous tau is stimulated by neuronal activity. EMBO Rep. 14:389&#x2013;394. 10.1038/embor.2013.15</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/embor.2013.15</ArticleId><ArticleId IdType="pmc">PMC3615658</ArticleId><ArticleId IdType="pubmed">23412472</ArticleId></ArticleIdList></Reference><Reference><Citation>Rauch, J.N., Luna G., Guzman E., Audouard M., Challis C., Sibih Y.E., Leshuk C., Hernandez I., Wegmann S., Hyman B.T., et al. . 2020. LRP1 is a master regulator of tau uptake and spread. Nature. 580:381&#x2013;385. 10.1038/s41586-020-2156-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2156-5</ArticleId><ArticleId IdType="pmc">PMC7687380</ArticleId><ArticleId IdType="pubmed">32296178</ArticleId></ArticleIdList></Reference><Reference><Citation>Ringstad, G., Valnes L.M., Dale A.M., Pripp A.H., Vatnehol S.S, Emblem K.E., Mardal K.A., and Eide P.K.. 2018. Brain-wide glymphatic enhancement and clearance in humans assessed with MRI. JCI Insight. 3:e121537. 10.1172/jci.insight.121537</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.121537</ArticleId><ArticleId IdType="pmc">PMC6124518</ArticleId><ArticleId IdType="pubmed">29997300</ArticleId></ArticleIdList></Reference><Reference><Citation>Ringstad, G., Vatnehol S.A.S., and Eide P.K.. 2017. Glymphatic MRI in idiopathic normal pressure hydrocephalus. Brain. 140:2691&#x2013;2705. 10.1093/brain/awx191</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awx191</ArticleId><ArticleId IdType="pmc">PMC5841149</ArticleId><ArticleId IdType="pubmed">28969373</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato, C., Barth&#xe9;lemy N.R., Mawuenyega K.G., Patterson B.W., Gordon B.A., Jockel-Balsarotti J., Sullivan M., Crisp M.J., Kasten T., Kirmess K.M., et al. . 2018. Tau kinetics in neurons and the human central nervous system. Neuron. 97:1284&#x2013;1298.e7. 10.1016/j.neuron.2018.02.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2018.02.015</ArticleId><ArticleId IdType="pmc">PMC6137722</ArticleId><ArticleId IdType="pubmed">29566794</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka, Y., Yamada K., Satake K., Nishida I., Heuberger M., Kuwahara T., and Iwatsubo T.. 2019. Seeding activity-based detection uncovers the different release mechanisms of seed-competent tau versus inert tau via lysosomal exocytosis. Front. Neurosci. 13:1258&#x2013;1267. 10.3389/fnins.2019.01258</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.01258</ArticleId><ArticleId IdType="pmc">PMC6881304</ArticleId><ArticleId IdType="pubmed">31824253</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, J., Jin W.S., Le Bu X., Zeng F., Huang Z.L., Li W.W., Shen L.L., Zhuang Z.Q., Fang Y., Sun B.L., et al. . 2018. Physiological clearance of tau in the periphery and its therapeutic potential for tauopathies. Acta Neuropathol. 136:525&#x2013;536. 10.1007/s00401-018-1891-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-1891-2</ArticleId><ArticleId IdType="pubmed">30074071</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu, J.W., Hussaini S.A., Bastille I.M., Rodriguez G.A., Mrejeru A., Rilett K., Sanders D.W., Cook C., Fu H., Boonen R.A.C.M., et al. . 2016. Neuronal activity enhances tau propagation and tau pathology in vivo. Nat. Neurosci. 19:1085&#x2013;1092. 10.1038/nn.4328</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4328</ArticleId><ArticleId IdType="pmc">PMC4961585</ArticleId><ArticleId IdType="pubmed">27322420</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie, L., Kang H., Xu Q., Chen M.J., Liao Y., Thiyagarajan M., J. O&#x2019;Donnell, Christensen D.J., Nicholson C., Iliff J.J., et al. . 2013. Sleep drives metabolite clearance from the adult brain. Science. 342:373&#x2013;377. 10.1126/science.1241224</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1241224</ArticleId><ArticleId IdType="pmc">PMC3880190</ArticleId><ArticleId IdType="pubmed">24136970</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu, Z., Xiao N., Chen Y., Huang H., Marshall C., Gao J., Cai Z., Wu T., Hu G., and Xiao M.. 2015. Deletion of aquaporin-4 in APP/PS1 mice exacerbates brain A&#x3b2; accumulation and memory deficits. Mol. Neurodegener. 10:58. 10.1186/s13024-015-0056-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-015-0056-1</ArticleId><ArticleId IdType="pmc">PMC4631089</ArticleId><ArticleId IdType="pubmed">26526066</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada, K., Cirrito J.R., Stewart F.R., Jiang H., Finn M.B., Holmes B.B., Binder L.I., Mandelkow E.-M., Diamond M.I., Lee V.M.-Y., and Holtzman D.M.. 2011. In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice. J. Neurosci. 31:13110&#x2013;13117. 10.1523/JNEUROSCI.2569-11.2011</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2569-11.2011</ArticleId><ArticleId IdType="pmc">PMC4299126</ArticleId><ArticleId IdType="pubmed">21917794</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada, K., Holth J.K., Liao F., Stewart F.R., Mahan T.E., Jiang H., Cirrito J.R., Patel T.K., Hochgr&#xe4;fe K., Mandelkow E.-M., and Holtzman D.M.. 2014. Neuronal activity regulates extracellular tau in vivo. J. Exp. Med. 211:387&#x2013;393. 10.1084/jem.20131685</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20131685</ArticleId><ArticleId IdType="pmc">PMC3949564</ArticleId><ArticleId IdType="pubmed">24534188</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada, K., Patel T.K., Hochgr&#xe4;fe K., Mahan T.E., Jiang H., Stewart F.R., Mandelkow E.-M., and Holtzman D.M.. 2015. Analysis of in vivo turnover of tau in a mouse model of tauopathy. Mol. Neurodegener. 10:55. 10.1186/s13024-015-0052-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-015-0052-5</ArticleId><ArticleId IdType="pmc">PMC4621881</ArticleId><ArticleId IdType="pubmed">26502977</ArticleId></ArticleIdList></Reference><Reference><Citation>Yanamandra, K., Kfoury N., Jiang H., Mahan T.E., Ma S., Maloney S.E., Wozniak D.F., Diamond M.I., and Holtzman D.M.. 2013. Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron. 80:402&#x2013;414. 10.1016/j.neuron.2013.07.046</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.07.046</ArticleId><ArticleId IdType="pmc">PMC3924573</ArticleId><ArticleId IdType="pubmed">24075978</ArticleId></ArticleIdList></Reference><Reference><Citation>Yanamandra, K., Patel T.K., Jiang H., Schindler S., Ulrich J.D., Boxer A.L., Miller B.L., Kerwin D.R., Gallardo G., Stewart F., et al. . 2017. Anti-tau antibody administration increases plasma tau in transgenic mice and patients with tauopathy. Sci. Transl. Med. 9:eaal2029. 10.1126/scitranslmed.aal2029</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aal2029</ArticleId><ArticleId IdType="pmc">PMC5727571</ArticleId><ArticleId IdType="pubmed">28424326</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshiyama, Y., Higuchi M., Zhang B., Huang S.M., Iwata N., Saido T.C., Maeda J., Suhara T., Trojanowski J.Q., and Lee V.M.Y.. 2007. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron. 53:337&#x2013;351. 10.1016/j.neuron.2007.01.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2007.01.010</ArticleId><ArticleId IdType="pubmed">17270732</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeppenfeld, D.M., Simon M., Haswell J.D., D&#x2019;Abreo D., Murchison C., Quinn J.F., Grafe M.R., Woltjer R.L., Kaye J., and Iliff J.J.. 2017. Association of perivascular localization of aquaporin-4 with cognition and Alzheimer disease in aging brains. JAMA Neurol. 74:91. 10.1001/jamaneurol.2016.4370</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2016.4370</ArticleId><ArticleId IdType="pubmed">27893874</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35228700</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>3</Issue><PubDate><Year>2022</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Long-term diazepam treatment enhances microglial spine engulfment and impairs cognitive performance via the mitochondrial 18&#x2009;kDa translocator protein (TSPO).</ArticleTitle><Pagination><StartPage>317</StartPage><EndPage>329</EndPage><MedlinePgn>317-329</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41593-022-01013-9</ELocationID><Abstract><AbstractText>Benzodiazepines are widely administered drugs to treat anxiety and insomnia. In addition to tolerance development and abuse liability, their chronic use may cause cognitive impairment and increase the risk for dementia. However, the mechanism by which benzodiazepines might contribute to persistent cognitive decline remains unknown. Here we report that diazepam, a widely prescribed benzodiazepine, impairs the structural plasticity of dendritic spines, causing cognitive impairment in mice. Diazepam induces these deficits via the mitochondrial 18&#x2009;kDa translocator protein (TSPO), rather than classical &#x3b3;-aminobutyric acid type A receptors, which alters microglial morphology, and phagocytosis of synaptic material. Collectively, our findings demonstrate a mechanism by which TSPO ligands alter synaptic plasticity and, as a consequence, cause cognitive impairment.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s), under exclusive licence to Springer Nature America, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Yuan</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0001-6135-1830</Identifier><AffiliationInfo><Affiliation>Center for Neuropathology, Ludwig Maximilian University of Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Medical Research School, Ludwig Maximilian University of Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cui</LastName><ForeName>Mochen</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center for Neuropathology, Ludwig Maximilian University of Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Medical Research School, Ludwig Maximilian University of Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ochs</LastName><ForeName>Katharina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Center for Neuropathology, Ludwig Maximilian University of Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brendel</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-9247-2843</Identifier><AffiliationInfo><Affiliation>Department of Nuclear Medicine, University Hospital of Munich, Ludwig Maximilian University of Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Str&#xfc;bing</LastName><ForeName>Felix L</ForeName><Initials>FL</Initials><Identifier Source="ORCID">0000-0002-9436-6294</Identifier><AffiliationInfo><Affiliation>Center for Neuropathology, Ludwig Maximilian University of Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Briel</LastName><ForeName>Nils</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-4349-3277</Identifier><AffiliationInfo><Affiliation>Center for Neuropathology, Ludwig Maximilian University of Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Medical Research School, Ludwig Maximilian University of Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eckenweber</LastName><ForeName>Florian</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, University Hospital of Munich, Ludwig Maximilian University of Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zou</LastName><ForeName>Chengyu</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Center for Neuropathology, Ludwig Maximilian University of Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Interdisciplinary Research Center on Biology and Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Banati</LastName><ForeName>Richard B</ForeName><Initials>RB</Initials><Identifier Source="ORCID">0000-0003-3558-597X</Identifier><AffiliationInfo><Affiliation>Australian Nuclear Science and Technology Organisation (ANSTO), Sydney NSW, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Brain and Mind Centre, Medical Imaging Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Guo-Jun</ForeName><Initials>GJ</Initials><Identifier Source="ORCID">0000-0002-4278-8372</Identifier><AffiliationInfo><Affiliation>Australian Nuclear Science and Technology Organisation (ANSTO), Sydney NSW, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Brain and Mind Centre, Medical Imaging Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Middleton</LastName><ForeName>Ryan J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Australian Nuclear Science and Technology Organisation (ANSTO), Sydney NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rupprecht</LastName><ForeName>Rainer</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, University of Regensburg, Regensburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rudolph</LastName><ForeName>Uwe</ForeName><Initials>U</Initials><Identifier Source="ORCID">0000-0001-9396-4746</Identifier><AffiliationInfo><Affiliation>Department of Comparative Biosciences, College of Veterinary Medicine, and Carl R. Woese Institute for Genomic Biology, University of Illinois at Urbana-Champaign, Urbana, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeilhofer</LastName><ForeName>Hanns Ulrich</ForeName><Initials>HU</Initials><Identifier Source="ORCID">0000-0001-6954-4629</Identifier><AffiliationInfo><Affiliation>Institute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology (ETH) Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rammes</LastName><ForeName>Gerhard</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Intensive Care Medicine, Klinikum rechts der Isar, Technische Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Herms</LastName><ForeName>Jochen</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-6201-1042</Identifier><AffiliationInfo><Affiliation>Center for Neuropathology, Ludwig Maximilian University of Munich, Munich, Germany. jochen.herms@dzne.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Germany. jochen.herms@dzne.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), Munich, Germany. jochen.herms@dzne.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Dorostkar</LastName><ForeName>Mario M</ForeName><Initials>MM</Initials><Identifier Source="ORCID">0000-0001-8037-4907</Identifier><AffiliationInfo><Affiliation>Center for Neuropathology, Ludwig Maximilian University of Munich, Munich, Germany. mario.dorostkar@med.uni-muenchen.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Germany. mario.dorostkar@med.uni-muenchen.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>02</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C463819">Bzrp protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D024101">Mitochondrial Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018079">Receptors, GABA</NameOfSubstance></Chemical><Chemical><RegistryNumber>12794-10-4</RegistryNumber><NameOfSubstance UI="D001569">Benzodiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>Q3JTX2Q7TU</RegistryNumber><NameOfSubstance UI="D003975">Diazepam</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001569" MajorTopicYN="N">Benzodiazepines</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003975" MajorTopicYN="Y">Diazepam</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="Y">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024101" MajorTopicYN="N">Mitochondrial Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018079" MajorTopicYN="N">Receptors, GABA</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>10</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>1</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>1</Day><Hour>5</Hour><Minute>56</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35228700</ArticleId><ArticleId IdType="doi">10.1038/s41593-022-01013-9</ArticleId><ArticleId IdType="pii">10.1038/s41593-022-01013-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rudolph, U. &amp; Knoflach, F. Beyond classical benzodiazepines: novel therapeutic potential of GABA<sub>A</sub> receptor subtypes. Nat. Rev. Drug Discov. 10, 685&#x2013;697 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">3375401</ArticleId><ArticleId IdType="doi">10.1038/nrd3502</ArticleId></ArticleIdList></Reference><Reference><Citation>Rupprecht, R. et al. Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders. Nat. Rev. Drug Discov. 9, 971&#x2013;988 (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd3295</ArticleId></ArticleIdList></Reference><Reference><Citation>Papadopoulos, V. et al. Translocator protein (18 kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol. Sci. 27, 402&#x2013;409 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16822554</ArticleId><ArticleId IdType="doi">10.1016/j.tips.2006.06.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, G.-J. et al. Functional gains in energy and cell metabolism after TSPO gene insertion. Cell Cycle 16, 436&#x2013;447 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28103132</ArticleId><ArticleId IdType="pmc">5351937</ArticleId><ArticleId IdType="doi">10.1080/15384101.2017.1281477</ArticleId></ArticleIdList></Reference><Reference><Citation>Gut, P., Zweckstetter, M. &amp; Banati, R. B. Lost in translocation: the functions of the 18-kD translocator protein. Trends Endocrinol. Metab. 26, 349&#x2013;356 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26026242</ArticleId><ArticleId IdType="pmc">5654500</ArticleId><ArticleId IdType="doi">10.1016/j.tem.2015.04.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Barker, M. J., Greenwood, K. M., Jackson, M. &amp; Crowe, S. F. Cognitive effects of long-term benzodiazepine use. CNS Drugs 18, 37&#x2013;48 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">14731058</ArticleId><ArticleId IdType="doi">10.2165/00023210-200418010-00004</ArticleId></ArticleIdList></Reference><Reference><Citation>Arolfo, M. P. &amp; Brioni, J. D. Diazepam impairs place learning in the Morris water maze. Behav. Neural Biol. 55, 131&#x2013;136 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">1996944</ArticleId><ArticleId IdType="doi">10.1016/0163-1047(91)80133-Y</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallacher, J. et al. Benzodiazepine use and risk of dementia: evidence from the Caerphilly Prospective Study (CaPS). J. Epidemiol. Community Health 66, 869&#x2013;873 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22034632</ArticleId><ArticleId IdType="doi">10.1136/jech-2011-200314</ArticleId></ArticleIdList></Reference><Reference><Citation>de Gage, S. B. et al. Benzodiazepine use and risk of Alzheimer&#x2019;s disease: case&#x2013;control study. BMJ 349, g5205 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.g5205</ArticleId></ArticleIdList></Reference><Reference><Citation>Penninkilampi, R. &amp; Eslick, G. D. A systematic review and meta-analysis of the risk of dementia associated with benzodiazepine use, after controlling for protopathic bias. CNS Drugs 32, 485&#x2013;497 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29926372</ArticleId><ArticleId IdType="doi">10.1007/s40263-018-0535-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Gray, S. L. et al. Benzodiazepine use and risk of incident dementia or cognitive decline: prospective population based study. BMJ 352, i90 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26837813</ArticleId><ArticleId IdType="pmc">4737849</ArticleId><ArticleId IdType="doi">10.1136/bmj.i90</ArticleId></ArticleIdList></Reference><Reference><Citation>Bi&#xe9;try, F. A., Pfeil, A. M., Reich, O., Schwenkglenks, M. &amp; Meier, C. R. Benzodiazepine use and risk of developing Alzheimer&#x2019;s disease: a case&#x2013;control study based on Swiss claims data. CNS Drugs 31, 245&#x2013;251 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28078633</ArticleId><ArticleId IdType="doi">10.1007/s40263-016-0404-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasai, H., Fukuda, M., Watanabe, S., Hayashi-Takagi, A. &amp; Noguchi, J. Structural dynamics of dendritic spines in memory and cognition. Trends Neurosci. 33, 121&#x2013;129 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20138375</ArticleId><ArticleId IdType="doi">10.1016/j.tins.2010.01.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou, C. et al. Neuroinflammation impairs adaptive structural plasticity of dendritic spines in a preclinical model of Alzheimer&#x2019;s disease. Acta Neuropathol. 131, 235&#x2013;246 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26724934</ArticleId><ArticleId IdType="pmc">4713725</ArticleId><ArticleId IdType="doi">10.1007/s00401-015-1527-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo, Y., Lin, A., Chang, P. &amp; Gan, W.-B. Development of long-term dendritic spine stability in diverse regions of cerebral cortex. Neuron 46, 181&#x2013;189 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15848798</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2005.04.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Grutzendler, J., Kasthuri, N. &amp; Gan, W.-B. Long-term dendritic spine stability in the adult cortex. Nature 420, 812&#x2013;816 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12490949</ArticleId><ArticleId IdType="doi">10.1038/nature01276</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng, G. et al. Imaging neuronal subsets in transgenic mice expressing multiple spectral variants of GFP. Neuron 28, 41&#x2013;51 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">11086982</ArticleId><ArticleId IdType="doi">10.1016/S0896-6273(00)00084-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudolph, U. et al. Benzodiazepine actions mediated by specific &#x3b3;-aminobutyric acid<sub>A</sub> receptor subtypes. Nature 401, 796&#x2013;800 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10548105</ArticleId><ArticleId IdType="doi">10.1038/44579</ArticleId></ArticleIdList></Reference><Reference><Citation>Richter, L. et al. Diazepam-bound GABA<sub>A</sub> receptor models identify new benzodiazepine binding-site ligands. Nat. Chem. Biol. 8, 455&#x2013;464 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">3368153</ArticleId><ArticleId IdType="doi">10.1038/nchembio.917</ArticleId></ArticleIdList></Reference><Reference><Citation>Ralvenius, W. T., Benke, D., Acuna, M. A., Rudolph, U. &amp; Zeilhofer, H. U. Analgesia and unwanted benzodiazepine effects in point-mutated mice expressing only one benzodiazepine-sensitive GABA<sub>A</sub> receptor subtype. Nat. Commun. 6, 6803 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25865415</ArticleId><ArticleId IdType="pmc">4829939</ArticleId><ArticleId IdType="doi">10.1038/ncomms7803</ArticleId></ArticleIdList></Reference><Reference><Citation>Sohal, V. S., Zhang, F., Yizhar, O. &amp; Deisseroth, K. Parvalbumin neurons and gamma rhythms enhance cortical circuit performance. Nature 459, 698&#x2013;702 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19396159</ArticleId><ArticleId IdType="pmc">3969859</ArticleId><ArticleId IdType="doi">10.1038/nature07991</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu, H., Gan, J. &amp; Jonas, P. Fast-spiking, parvalbumin<sup>+</sup> GABAergic interneurons: from cellular design to microcircuit function. Science 345, 1255263 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25082707</ArticleId><ArticleId IdType="doi">10.1126/science.1255263</ArticleId></ArticleIdList></Reference><Reference><Citation>Pritchett, D. B. &amp; Seeburg, P. H. &#x3b3;&#x2010;Aminobutyric acid<sub>A</sub> receptor &#x3b1;<sub>5</sub>&#x2010;subunit creates novel type II benzodiazepine receptor pharmacology. J. Neurochem. 54, 1802&#x2013;1804 (1990).</Citation><ArticleIdList><ArticleId IdType="pubmed">2157817</ArticleId><ArticleId IdType="doi">10.1111/j.1471-4159.1990.tb01237.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Romeo, E. et al. 2-Aryl-3-indoleacetamides (FGIN-1): a new class of potent and specific ligands for the mitochondrial DBI receptor (MDR). J. Pharmacol. Exp. Ther. 262, 971&#x2013;978 (1992).</Citation><ArticleIdList><ArticleId IdType="pubmed">1326631</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf6;w, K. et al. Molecular and neuronal substrate for the selective attenuation of anxiety. Science 290, 131&#x2013;134 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">11021797</ArticleId><ArticleId IdType="doi">10.1126/science.290.5489.131</ArticleId></ArticleIdList></Reference><Reference><Citation>Crestani, F. et al. Trace fear conditioning involves hippocampal &#x3b1;<sub>5</sub> GABA<sub>A</sub> receptors. Proc. Natl Acad. Sci. USA 99, 8980&#x2013;8985 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12084936</ArticleId><ArticleId IdType="pmc">124409</ArticleId><ArticleId IdType="doi">10.1073/pnas.142288699</ArticleId></ArticleIdList></Reference><Reference><Citation>Banati, R. B. et al. Positron emission tomography and functional characterization of a complete PBR/TSPO knockout. Nat. Commun. 5, 5452 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25406832</ArticleId><ArticleId IdType="doi">10.1038/ncomms6452</ArticleId></ArticleIdList></Reference><Reference><Citation>Brendel, M. et al. Glial activation and glucose metabolism in a transgenic amyloid mouse model: a triple-tracer PET study. J. Nucl. Med. 57, 954&#x2013;960 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26912428</ArticleId><ArticleId IdType="doi">10.2967/jnumed.115.167858</ArticleId></ArticleIdList></Reference><Reference><Citation>Kreisl, W. C. et al. In vivo radioligand binding to translocator protein correlates with severity of Alzheimer&#x2019;s disease. Brain 136, 2228&#x2013;2238 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23775979</ArticleId><ArticleId IdType="pmc">3692038</ArticleId><ArticleId IdType="doi">10.1093/brain/awt145</ArticleId></ArticleIdList></Reference><Reference><Citation>Cagnin, A. et al. In-vivo measurement of activated microglia in dementia. Lancet 358, 461&#x2013;467 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11513911</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(01)05625-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf, L. et al. Enhancing neurosteroid synthesis&#x2014;relationship to the pharmacology of translocator protein (18 kDa)(TSPO) ligands and benzodiazepines. Pharmacopsychiatry 48, 72&#x2013;77 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25654303</ArticleId><ArticleId IdType="doi">10.1055/s-0035-1558003</ArticleId></ArticleIdList></Reference><Reference><Citation>Salter, M. W. &amp; Stevens, B. Microglia emerge as central players in brain disease. Nat. Med. 23, 1018&#x2013;1027 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28886007</ArticleId><ArticleId IdType="doi">10.1038/nm.4397</ArticleId></ArticleIdList></Reference><Reference><Citation>Wake, H., Moorhouse, A. J., Miyamoto, A. &amp; Nabekura, J. Microglia: actively surveying and shaping neuronal circuit structure and function. Trends Neurosci. 36, 209&#x2013;217 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23260014</ArticleId><ArticleId IdType="doi">10.1016/j.tins.2012.11.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong, S. et al. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science 352, 712&#x2013;716 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27033548</ArticleId><ArticleId IdType="pmc">5094372</ArticleId><ArticleId IdType="doi">10.1126/science.aad8373</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung, W.-S., Welsh, C. A., Barres, B. A. &amp; Stevens, B. Do glia drive synaptic and cognitive impairment in disease? Nat. Neurosci. 18, 1539&#x2013;1545 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26505565</ArticleId><ArticleId IdType="pmc">4739631</ArticleId><ArticleId IdType="doi">10.1038/nn.4142</ArticleId></ArticleIdList></Reference><Reference><Citation>Elmore, M. R. et al. Colony-stimulating factor 1 receptor signaling is necessary for microglia viability, unmasking a microglia progenitor cell in the adult brain. Neuron 82, 380&#x2013;397 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24742461</ArticleId><ArticleId IdType="pmc">4161285</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2014.02.040</ArticleId></ArticleIdList></Reference><Reference><Citation>Paolicelli, R. C. et al. Synaptic pruning by microglia is necessary for normal brain development. Science 333, 1456&#x2013;1458 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21778362</ArticleId><ArticleId IdType="doi">10.1126/science.1202529</ArticleId></ArticleIdList></Reference><Reference><Citation>Neniskyte, U. &amp; Gross, C. T. Errant gardeners: glial-cell-dependent synaptic pruning and neurodevelopmental disorders. Nat. Rev. Neurosci. 18, 658&#x2013;670 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28931944</ArticleId><ArticleId IdType="doi">10.1038/nrn.2017.110</ArticleId></ArticleIdList></Reference><Reference><Citation>Dejanovic, B. et al. Changes in the synaptic proteome in tauopathy and rescue of tau-induced synapse loss by C1q antibodies. Neuron 100, 1322&#x2013;1336 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30392797</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2018.10.014</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, Y. U. et al. Neuronal network activity controls microglial process surveillance in awake mice via norepinephrine signaling. Nat. Neurosci. 22, 1771&#x2013;1781 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31636449</ArticleId><ArticleId IdType="pmc">6858573</ArticleId><ArticleId IdType="doi">10.1038/s41593-019-0511-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Umpierre, A. D. &amp; Wu, L. J. How microglia sense and regulate neuronal activity. Glia 69, 1637&#x2013;1653 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33369790</ArticleId><ArticleId IdType="doi">10.1002/glia.23961</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, Y., Zhou, X.-h, Meranus, D. H., Wang, L. &amp; Kukull, W. A. Benzodiazepine use and cognitive decline in elderly with normal cognition. Alzheimer Dis. Assoc. Disord. 30, 113&#x2013;117 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">4670597</ArticleId><ArticleId IdType="doi">10.1097/WAD.0000000000000099</ArticleId></ArticleIdList></Reference><Reference><Citation>Pariente, A., de Gage, S. B., Moore, N. &amp; B&#xe9;gaud, B. The benzodiazepine&#x2013;dementia disorders link: current state of knowledge. CNS Drugs 30, 1&#x2013;7 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26715389</ArticleId><ArticleId IdType="doi">10.1007/s40263-015-0305-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Filipello, F. et al. The microglial innate immune receptor TREM2 is required for synapse elimination and normal brain connectivity. Immunity 48, 979&#x2013;991 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29752066</ArticleId><ArticleId IdType="doi">10.1016/j.immuni.2018.04.016</ArticleId></ArticleIdList></Reference><Reference><Citation>Paolicelli, R. C. et al. TDP-43 depletion in microglia promotes amyloid clearance but also induces synapse loss. Neuron 95, 297&#x2013;308 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28669544</ArticleId><ArticleId IdType="pmc">5519492</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2017.05.037</ArticleId></ArticleIdList></Reference><Reference><Citation>Lechin, F. et al. Peripheral blood immunological parameters in long-term benzodiazepine users. Clin. Neuropharmacol. 17, 63&#x2013;72 (1994).</Citation></Reference><Reference><Citation>Covelli, V. et al. Effects of benzodiazepines on the immune system. Acta Neurologica 13, 418&#x2013;423 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">1776530</ArticleId></ArticleIdList></Reference><Reference><Citation>Colasanti, A. et al. Bipolar disorder is associated with the rs6971 polymorphism in the gene encoding 18 kDa translocator protein (TSPO). Psychoneuroendocrinology 38, 2826&#x2013;2829 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23942012</ArticleId><ArticleId IdType="pmc">3820042</ArticleId><ArticleId IdType="doi">10.1016/j.psyneuen.2013.07.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung, S. et al. Analysis of fractalkine receptor CX<sub>3</sub>CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. Mol. Cell. Biol. 20, 4106&#x2013;4114 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10805752</ArticleId><ArticleId IdType="pmc">85780</ArticleId><ArticleId IdType="doi">10.1128/MCB.20.11.4106-4114.2000</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuhrmann, M., Mitteregger, G., Kretzschmar, H. &amp; Herms, J. Dendritic pathology in prion disease starts at the synaptic spine. J. Neurosci. 27, 6224&#x2013;6233 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17553995</ArticleId><ArticleId IdType="pmc">6672160</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.5062-06.2007</ArticleId></ArticleIdList></Reference><Reference><Citation>Mrsic-Flogel, T. D. et al. Homeostatic regulation of eye-specific responses in visual cortex during ocular dominance plasticity. Neuron 54, 961&#x2013;972 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17582335</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2007.05.028</ArticleId></ArticleIdList></Reference><Reference><Citation>Deussing, M. et al. Coupling between physiological TSPO expression in brain and myocardium allows stabilization of late-phase cerebral [<sup>18</sup>F]GE180 PET quantification. Neuroimage 165, 83&#x2013;91 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">28988133</ArticleId><ArticleId IdType="doi">10.1016/j.neuroimage.2017.10.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleinberger, G. et al. The FTD&#x2010;like syndrome causing TREM2 T66M mutation impairs microglia function, brain perfusion, and glucose metabolism. EMBO J. 36, 1837&#x2013;1853 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28559417</ArticleId><ArticleId IdType="pmc">5494459</ArticleId><ArticleId IdType="doi">10.15252/embj.201796516</ArticleId></ArticleIdList></Reference><Reference><Citation>Leger, M. et al. Object recognition test in mice. Nat. Protoc. 8, 2531&#x2013;2537 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2013.155</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35247328</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>19</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4172</ISSN><JournalIssue CitedMedium="Internet"><Volume>185</Volume><Issue>8</Issue><PubDate><Year>2022</Year><Month>Apr</Month><Day>14</Day></PubDate></JournalIssue><Title>Cell</Title><ISOAbbreviation>Cell</ISOAbbreviation></Journal><ArticleTitle>Homotypic fibrillization of TMEM106B across diverse neurodegenerative diseases.</ArticleTitle><Pagination><StartPage>1346</StartPage><EndPage>1355.e15</EndPage><MedlinePgn>1346-1355.e15</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cell.2022.02.026</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0092-8674(22)00259-8</ELocationID><Abstract><AbstractText>Misfolding and aggregation of disease-specific proteins, resulting in the formation of filamentous cellular inclusions, is a hallmark of neurodegenerative disease with characteristic filament structures, or conformers, defining each proteinopathy. Here we show that a previously unsolved amyloid fibril composed of a 135 amino acid C-terminal fragment of TMEM106B is a common finding in distinct human neurodegenerative diseases, including cases characterized by abnormal aggregation of TDP-43, tau, or &#x3b1;-synuclein protein. A combination of cryoelectron microscopy and mass spectrometry was used to solve the structures of TMEM106B fibrils at a resolution of 2.7&#xa0;&#xc5; from postmortem human brain tissue afflicted with frontotemporal lobar degeneration with TDP-43 pathology (FTLD-TDP, n&#xa0;= 8), progressive supranuclear palsy (PSP, n&#xa0;= 2), or dementia with Lewy bodies (DLB, n&#xa0;= 1). The commonality of abundant amyloid fibrils composed of TMEM106B, a lysosomal/endosomal protein, to a broad range of debilitating human disorders indicates a shared fibrillization pathway that may initiate or accelerate neurodegeneration.</AbstractText><CopyrightInformation>Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Mortimer B. Zuckerman Mind Brain Behavior Institute, Columbia University, New York, NY 10027, USA; Department of Biochemistry and Molecular Biophysics, Columbia University, New York, NY 10032, USA; Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, 630 West 168th Street, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiang</LastName><ForeName>Xinyu</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Mortimer B. Zuckerman Mind Brain Behavior Institute, Columbia University, New York, NY 10027, USA; Department of Biochemistry and Molecular Biophysics, Columbia University, New York, NY 10032, USA; Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, 630 West 168th Street, New York, NY 10032, USA; Department of Structural Biology, Stanford University School of Medicine, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Mortimer B. Zuckerman Mind Brain Behavior Institute, Columbia University, New York, NY 10027, USA; Department of Biochemistry and Molecular Biophysics, Columbia University, New York, NY 10032, USA; Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, 630 West 168th Street, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Carolyn</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Mortimer B. Zuckerman Mind Brain Behavior Institute, Columbia University, New York, NY 10027, USA; Department of Biochemistry and Molecular Biophysics, Columbia University, New York, NY 10032, USA; Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, 630 West 168th Street, New York, NY 10032, USA; Department of Microbiology &amp; Immunology, Columbia University, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arakhamia</LastName><ForeName>Tamta</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Mortimer B. Zuckerman Mind Brain Behavior Institute, Columbia University, New York, NY 10027, USA; Department of Biochemistry and Molecular Biophysics, Columbia University, New York, NY 10032, USA; Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, 630 West 168th Street, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simjanoska</LastName><ForeName>Marija</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Mortimer B. Zuckerman Mind Brain Behavior Institute, Columbia University, New York, NY 10027, USA; Department of Biochemistry and Molecular Biophysics, Columbia University, New York, NY 10032, USA; Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, 630 West 168th Street, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Chi</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biophysics, Columbia University, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carlomagno</LastName><ForeName>Yari</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Guoan</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Proteomics and Metabolomics Core Facility, Weill Cornell Medicine, New York, NY 10021, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dhingra</LastName><ForeName>Shikhar</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Mortimer B. Zuckerman Mind Brain Behavior Institute, Columbia University, New York, NY 10027, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thierry</LastName><ForeName>Manon</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Centre for Cognitive Neurology, Department of Neurology, New York University School of Medicine, New York, NY 10016, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perneel</LastName><ForeName>Jolien</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Applied and Translational Neurogenomics, VIB Center for Molecular Neurology, VIB, Antwerp, Belgium; Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heeman</LastName><ForeName>Bavo</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Applied and Translational Neurogenomics, VIB Center for Molecular Neurology, VIB, Antwerp, Belgium; Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Forgrave</LastName><ForeName>Lauren M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC V6T 2B5, Canada; Department of Pathology and Laboratory Medicine, St. Paul's Hospital, Providence Health Care, Vancouver, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeTure</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeMarco</LastName><ForeName>Mari L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC V6T 2B5, Canada; Department of Pathology and Laboratory Medicine, St. Paul's Hospital, Providence Health Care, Vancouver, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cook</LastName><ForeName>Casey N</ForeName><Initials>CN</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rademakers</LastName><ForeName>Rosa</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Applied and Translational Neurogenomics, VIB Center for Molecular Neurology, VIB, Antwerp, Belgium; Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dickson</LastName><ForeName>Dennis W</ForeName><Initials>DW</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petrucelli</LastName><ForeName>Leonard</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stowell</LastName><ForeName>Michael H B</ForeName><Initials>MHB</Initials><AffiliationInfo><Affiliation>Department of Molecular, Cellular and Developmental Biology, University of Colorado Boulder, Boulder, CO 80309, USA. Electronic address: stowellm@colorado.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mackenzie</LastName><ForeName>Ian R A</ForeName><Initials>IRA</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC V6T 2B5, Canada. Electronic address: ian.mackenzie@vch.ca.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fitzpatrick</LastName><ForeName>Anthony W P</ForeName><Initials>AWP</Initials><AffiliationInfo><Affiliation>Mortimer B. Zuckerman Mind Brain Behavior Institute, Columbia University, New York, NY 10027, USA; Department of Biochemistry and Molecular Biophysics, Columbia University, New York, NY 10032, USA; Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, 630 West 168th Street, New York, NY 10032, USA. Electronic address: anthony.fitzpatrick@columbia.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG063780</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 NS110438</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>74580</GrantID><Agency>CIHR</Agency><Country>Canada</Country></Grant><Grant><GrantID>U54 NS110435</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG061829</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>03</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell</MedlineTA><NlmUniqueID>0413066</NlmUniqueID><ISSNLinking>0092-8674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C556915">TMEM106B protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Cell. 2022 Apr 14;185(8):1290-1292. doi: 10.1016/j.cell.2022.03.032.</RefSource><PMID Version="1">35427496</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020285" MajorTopicYN="N">Cryoelectron Microscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="Y">Membrane Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="Y">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">DLB</Keyword><Keyword MajorTopicYN="N">FTLD-TDP</Keyword><Keyword MajorTopicYN="N">PSP</Keyword><Keyword MajorTopicYN="N">TMEM106B</Keyword><Keyword MajorTopicYN="N">amyloid fibrils</Keyword><Keyword MajorTopicYN="N">cryo-EM</Keyword><Keyword MajorTopicYN="N">endosome</Keyword><Keyword MajorTopicYN="N">lysosome</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">proteolysis</Keyword></KeywordList><CoiStatement>Declaration of interests The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>1</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>2</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>2</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>5</Day><Hour>20</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>4</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35247328</ArticleId><ArticleId IdType="mid">NIHMS1784277</ArticleId><ArticleId IdType="pmc">PMC9018563</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2022.02.026</ArticleId><ArticleId IdType="pii">S0092-8674(22)00259-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Afonine PV, Poon BK, Read RJ, Sobolev OV, Terwilliger TC, Urzhumtsev A, and Adams PD (2018). Real-space refinement in PHENIX for cryo-EM and crystallography. Acta Crystallogr D Struct Biol 74, 531&#x2013;544.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6096492</ArticleId><ArticleId IdType="pubmed">29872004</ArticleId></ArticleIdList></Reference><Reference><Citation>Arakhamia T, Lee CE, Carlomagno Y, Duong DM, Kundinger SR, Wang K, Williams D, DeTure M, Dickson DW, Cook CN, et al. (2020). Posttranslational Modifications Mediate the Structural Diversity of Tauopathy Strains. Cell 180, 633&#x2013;644.e612.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7491959</ArticleId><ArticleId IdType="pubmed">32032505</ArticleId></ArticleIdList></Reference><Reference><Citation>Arseni D, Hasegawa M, Murzin AG, Kametani F, Arai M, Yoshida M, and Ryskeldi-Falcon B (2022). Structure of pathological TDP-43 filaments from ALS with FTLD. Nature
601, 139&#x2013;143. atom2svg.pygist.github.com/biochem-fan/026ec2f191fee9285424d12fc2b84ce7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7612255</ArticleId><ArticleId IdType="pubmed">34880495</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker M, Mackenzie IR, Pickering-Brown SM, Gass J, Rademakers R, Lindholm C, Snowden J, Adamson J, Sadovnick AD, Rollinson S, et al. (2006). Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 442, 916&#x2013;919.</Citation><ArticleIdList><ArticleId IdType="pubmed">16862116</ArticleId></ArticleIdList></Reference><Reference><Citation>Brady OA, Zhou X, and Hu F (2014). Regulated intramembrane proteolysis of the frontotemporal lobar degeneration risk factor, TMEM106B, by signal peptide peptidase-like 2a (SPPL2a). J Biol Chem 289, 19670&#x2013;19680.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4094077</ArticleId><ArticleId IdType="pubmed">24872421</ArticleId></ArticleIdList></Reference><Reference><Citation>Brier MR, Gordon B, Friedrichsen K, McCarthy J, Stern A, Christensen J, Owen C, Aldea P, Su Y, Hassenstab J, et al. (2016). Tau and A&#x3b2; imaging, CSF measures, and cognition in Alzheimer&#x2019;s disease. Sci Transl Med 8, 338ra366.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5267531</ArticleId><ArticleId IdType="pubmed">27169802</ArticleId></ArticleIdList></Reference><Reference><Citation>Busch JI, Martinez-Lage M, Ashbridge E, Grossman M, Van Deerlin VM, Hu F, Lee VM, Trojanowski JQ, and Chen-Plotkin AS (2013). Expression of TMEM106B, the frontotemporal lobar degeneration-associated protein, in normal and diseased human brain. Acta Neuropathol Commun 1, 36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3893524</ArticleId><ArticleId IdType="pubmed">24252750</ArticleId></ArticleIdList></Reference><Reference><Citation>Cairns NJ, Bigio EH, Mackenzie IR, Neumann M, Lee VM, Hatanpaa KJ, White CL 3rd, Schneider JA, Grinberg LT, Halliday G, et al. (2007). Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol 114, 5&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2827877</ArticleId><ArticleId IdType="pubmed">17579875</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlomagno Y, Manne S, DeTure M, Prudencio M, Zhang YJ, Hanna Al-Shaikh R, Dunmore JA, Daughrity LM, Song Y, Castanedes-Casey M, et al. (2021). The AD tau core spontaneously self-assembles and recruits full-length tau to filaments. Cell Rep 34, 108843.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8094113</ArticleId><ArticleId IdType="pubmed">33730588</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatterjee P, Pedrini S, Stoops E, Goozee K, Villemagne VL, Asih PR, Verberk IMW, Dave P, Taddei K, Sohrabi HR, et al. (2021). Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer&#x2019;s disease. Translational Psychiatry 11, 27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7801513</ArticleId><ArticleId IdType="pubmed">33431793</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen VB, Arendall WB 3rd, Headd JJ, Keedy DA, Immormino RM, Kapral GJ, Murray LW, Richardson JS, and Richardson DC (2010). MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr D Biol Crystallogr 66, 12&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2803126</ArticleId><ArticleId IdType="pubmed">20057044</ArticleId></ArticleIdList></Reference><Reference><Citation>Chojnowski G, Simpkin AJ, Leonardo DA, Seifert-Davila W, Vivas-Ruiz DE, Keegan RM, and Rigden DJ (2022). findMySequence: a neural-network-based approach for identification of unknown proteins in X-ray crystallography and cryo-EM. IUCrJ 9, 86&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8733886</ArticleId><ArticleId IdType="pubmed">35059213</ArticleId></ArticleIdList></Reference><Reference><Citation>Cianfrocco MA, W. M, Youn C, Wagner R, Leschziner AE (2017). COSMIC2: A Science Gateway for Cryo-Electron Microscopy Structure Determination. Practice &amp; Experience in Advanced Research Computing 2, 1&#x2013;5.</Citation></Reference><Reference><Citation>Cox J, and Mann M (2008). MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nature Biotechnology 26, 1367&#x2013;1372.</Citation><ArticleIdList><ArticleId IdType="pubmed">19029910</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, Nicholson AM, Finch NA, Flynn H, Adamson J, et al. (2011). Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 72, 245&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Emsley P, Lohkamp B, Scott WG, and Cowtan K (2010). Features and development of Coot. Acta Crystallogr D Biol Crystallogr 66, 486&#x2013;501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2852313</ArticleId><ArticleId IdType="pubmed">20383002</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcon B, Zhang W, Murzin AG, Murshudov G, Garringer HJ, Vidal R, Crowther RA, Ghetti B, Scheres SHW, and Goedert M (2018). Structures of filaments from Pick&#x2019;s disease reveal a novel tau protein fold. Nature 561, 137&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6204212</ArticleId><ArticleId IdType="pubmed">30158706</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcon B, Zivanov J, Zhang W, Murzin AG, Garringer HJ, Vidal R, Crowther RA, Newell KL, Ghetti B, Goedert M, et al. (2019). Novel tau filament fold in chronic traumatic encephalopathy encloses hydrophobic molecules. Nature 568, 420&#x2013;423.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6472968</ArticleId><ArticleId IdType="pubmed">30894745</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng T, Lacrampe A, and Hu F (2021). Physiological and pathological functions of TMEM106B: a gene associated with brain aging and multiple brain disorders. Acta Neuropathol 141, 327&#x2013;339.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8049516</ArticleId><ArticleId IdType="pubmed">33386471</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng T, Sheng RR, Sol&#xe9;-Dom&#xe8;nech S, Ullah M, Zhou X, Mendoza CS, Enriquez LCM, Katz II, Paushter DH, Sullivan PM, et al. (2020). A role of the frontotemporal lobar degeneration risk factor TMEM106B in myelination. Brain 143, 2255&#x2013;2271.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7363491</ArticleId><ArticleId IdType="pubmed">32572497</ArticleId></ArticleIdList></Reference><Reference><Citation>Finch N, Carrasquillo MM, Baker M, Rutherford NJ, Coppola G, Dejesus-Hernandez M, Crook R, Hunter T, Ghidoni R, Benussi L, et al. (2011). TMEM106B regulates progranulin levels and the penetrance of FTLD in GRN mutation carriers. Neurology 76, 467&#x2013;474.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3034409</ArticleId><ArticleId IdType="pubmed">21178100</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzpatrick AW, and Saibil HR (2019). Cryo-EM of amyloid fibrils and cellular aggregates. Curr Opin Struct Biol 58, 34&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6778506</ArticleId><ArticleId IdType="pubmed">31200186</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzpatrick AWP, Debelouchina GT, Bayro MJ, Clare DK, Caporini MA, Bajaj VS, Jaroniec CP, Wang L, Ladizhansky V, M&#xfc;ller SA, et al. (2013). Atomic structure and hierarchical assembly of a cross-&#x3b2; amyloid fibril. P Natl Acad Sci USA 110, 5468&#x2013;5473.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3619355</ArticleId><ArticleId IdType="pubmed">23513222</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzpatrick AWP, Falcon B, He S, Murzin AG, Murshudov G, Garringer HJ, Crowther RA, Ghetti B, Goedert M, and Scheres SHW (2017). Cryo-EM structures of tau filaments from Alzheimer&#x2019;s disease. Nature 547, 185&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5552202</ArticleId><ArticleId IdType="pubmed">28678775</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatton C, Ghanem SS, Koss DJ, Abdi IY, Gibbons E, Guerreiro R, Bras J, Consortium, I.D.G., Walker L, Gelpi E, et al. (2022). Prion-like &#x3b1;-synuclein pathology in the brain of infants with Krabbe disease. Brain.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9128812</ArticleId><ArticleId IdType="pubmed">34999780</ArticleId></ArticleIdList></Reference><Reference><Citation>He S, and Scheres SHW (2017). Helical reconstruction in RELION. Journal of Structural Biology 198, 163&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5479445</ArticleId><ArticleId IdType="pubmed">28193500</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho CM, Li X, Lai M, Terwilliger TC, Beck JR, Wohlschlegel J, Goldberg DE, Fitzpatrick AWP, and Zhou ZH (2020). Bottom-up structural proteomics: cryoEM of protein complexes enriched from the cellular milieu. Nat Methods 17, 79&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7494424</ArticleId><ArticleId IdType="pubmed">31768063</ArticleId></ArticleIdList></Reference><Reference><Citation>Hortschansky P, Christopeit T, Schroeckh V, and F&#xe4;ndrich M (2005). Thermodynamic analysis of the aggregation propensity of oxidized Alzheimer&#x2019;s beta-amyloid variants. Protein Sci 14, 2915&#x2013;2918.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2253225</ArticleId><ArticleId IdType="pubmed">16199659</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang S, and Bhaskar K (2020). Degradation and Transmission of Tau by Autophagic-Endolysosomal Networks and Potential Therapeutic Targets for Tauopathy. Front Mol Neurosci 13, 586731.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7596180</ArticleId><ArticleId IdType="pubmed">33177989</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang YX, Cao Q, Sawaya MR, Abskharon R, Ge P, DeTure M, Dickson DW, Fu JY, Ogorzalek Loo RR, Loo JA, et al. (2022). Amyloid fibrils in frontotemporal lobar degeneration with TDP-43 inclusions are composed of TMEM106B, rather than TDP-43. bioRxiv, 2022.2001.2031.478523.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9844993</ArticleId><ArticleId IdType="pubmed">35344984</ArticleId></ArticleIdList></Reference><Reference><Citation>Jucker M, and Walker LC (2013). Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature 501, 45&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3963807</ArticleId><ArticleId IdType="pubmed">24005412</ArticleId></ArticleIdList></Reference><Reference><Citation>Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, Tunyasuvunakool K, Bates R, &#x17d;&#xed;dek A, Potapenko A, et al. (2021). Highly accurate protein structure prediction with AlphaFold. Nature 596, 583&#x2013;589.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8371605</ArticleId><ArticleId IdType="pubmed">34265844</ArticleId></ArticleIdList></Reference><Reference><Citation>Kametani F, Yoshida M, Matsubara T, Murayama S, Saito Y, Kawakami I, Onaya M, Tanaka H, Kakita A, Robinson AC, et al. (2020). Comparison of Common and Disease-Specific Post-translational Modifications of Pathological Tau Associated With a Wide Range of Tauopathies. Front Neurosci 14, 581936.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7672045</ArticleId><ArticleId IdType="pubmed">33250706</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim DE, Chivian D, and Baker D (2004). Protein structure prediction and analysis using the Robetta server. Nucleic Acids Res 32, W526&#x2013;W531.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC441606</ArticleId><ArticleId IdType="pubmed">15215442</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang CM, Fellerer K, Schwenk BM, Kuhn PH, Kremmer E, Edbauer D, Capell A, and Haass C (2012). Membrane orientation and subcellular localization of transmembrane protein 106B (TMEM106B), a major risk factor for frontotemporal lobar degeneration. J Biol Chem 287, 19355&#x2013;19365.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3365973</ArticleId><ArticleId IdType="pubmed">22511793</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee VM, Goedert M, and Trojanowski JQ (2001). Neurodegenerative tauopathies. Annu Rev Neurosci 24, 1121&#x2013;1159.</Citation><ArticleIdList><ArticleId IdType="pubmed">11520930</ArticleId></ArticleIdList></Reference><Reference><Citation>Li F, Leier A, Liu Q, Wang Y, Xiang D, Akutsu T, Webb GI, Smith AI, Marquez-Lago T, Li J, et al. (2020). Procleave: Predicting Protease-specific Substrate Cleavage Sites by Combining Sequence and Structural Information. Genomics Proteomics Bioinformatics 18, 52&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7393547</ArticleId><ArticleId IdType="pubmed">32413515</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xfc;ningschr&#xf6;r P, Werner G, Stroobants S, Kakuta S, Dombert B, Sinske D, Wanner R, L&#xfc;llmann-Rauch R, Wefers B, Wurst W, et al. (2020). The FTLD Risk Factor TMEM106B Regulates the Transport of Lysosomes at the Axon Initial Segment of Motoneurons. Cell Rep 30, 3506&#x2013;3519.e3506.</Citation><ArticleIdList><ArticleId IdType="pubmed">32160553</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Neumann M, Baborie A, Sampathu DM, Du Plessis D, Jaros E, Perry RH, Trojanowski JQ, Mann DM, and Lee VM (2011). A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol 122, 111&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3285143</ArticleId><ArticleId IdType="pubmed">21644037</ArticleId></ArticleIdList></Reference><Reference><Citation>Monaco A, and Fraldi A (2020). Protein Aggregation and Dysfunction of Autophagy-Lysosomal Pathway: A Vicious Cycle in Lysosomal Storage Diseases. Front Mol Neurosci 13, 37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7079699</ArticleId><ArticleId IdType="pubmed">32218723</ArticleId></ArticleIdList></Reference><Reference><Citation>Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, Mirra SS, et al. (2012). National Institute on Aging-Alzheimer&#x2019;s Association guidelines for the neuropathologic assessment of Alzheimer&#x2019;s disease: a practical approach. Acta Neuropathol 123, 1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3268003</ArticleId><ArticleId IdType="pubmed">22101365</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholson AM, Finch NA, Wojtas A, Baker MC, Perkerson RB 3rd, Castanedes-Casey M, Rousseau L, Benussi L, Binetti G, Ghidoni R, et al. (2013). TMEM106B p.T185S regulates TMEM106B protein levels: implications for frontotemporal dementia. J Neurochem 126, 781&#x2013;791.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3766501</ArticleId><ArticleId IdType="pubmed">23742080</ArticleId></ArticleIdList></Reference><Reference><Citation>Petkova AT, Leapman RD, Guo Z, Yau WM, Mattson MP, and Tycko R (2005). Self-propagating, molecular-level polymorphism in Alzheimer&#x2019;s beta-amyloid fibrils. Science 307, 262&#x2013;265.</Citation><ArticleIdList><ArticleId IdType="pubmed">15653506</ArticleId></ArticleIdList></Reference><Reference><Citation>Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, and Ferrin TE (2004). UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem 25, 1605&#x2013;1612.</Citation><ArticleIdList><ArticleId IdType="pubmed">15264254</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfab J, Phan NM, and Si D (2021). DeepTracer for fast de novo cryo-EM protein structure modeling and special studies on CoV-related complexes. Proc Natl Acad Sci U S A 118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7812826</ArticleId><ArticleId IdType="pubmed">33361332</ArticleId></ArticleIdList></Reference><Reference><Citation>Rademakers R, Nicholson AM, Ren Y, Koga S, Nguyen HP, Brooks M, Qiao W, Quicksall ZS, Matchett B, Perkerson RB, et al. (2021). Loss of Tmem106b leads to cerebellum Purkinje cell death and motor deficits. Brain Pathol 31, e12945.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8412084</ArticleId><ArticleId IdType="pubmed">33709463</ArticleId></ArticleIdList></Reference><Reference><Citation>Rawlings ND, Barrett AJ, Thomas PD, Huang X, Bateman A, and Finn RD (2017). The MEROPS database of proteolytic enzymes, their substrates and inhibitors in 2017 and a comparison with peptidases in the PANTHER database. Nucleic Acids Res 46, D624&#x2013;D632.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5753285</ArticleId><ArticleId IdType="pubmed">29145643</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez-Garcia R, Gomez-Blanco J, Cuervo A, Carazo JM, Sorzano COS, and Vargas J (2021). DeepEMhancer: a deep learning solution for cryo-EM volume post-processing. Communications Biology 4, 874.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8282847</ArticleId><ArticleId IdType="pubmed">34267316</ArticleId></ArticleIdList></Reference><Reference><Citation>Schweighauser M, Arseni D, Huang M, L&#xf6;vestam S, Shi Y, Yang Y, Zhang W, Kotecha A, Garringer HJ, Vidal R, et al. (2021). Age-Dependent Formation of TMEM106B Amyloid Filaments in Human Brain. bioRxiv, 2021.2011.2009.467923.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9095482</ArticleId><ArticleId IdType="pubmed">35344985</ArticleId></ArticleIdList></Reference><Reference><Citation>Schweighauser M, Shi Y, Tarutani A, Kametani F, Murzin AG, Ghetti B, Matsubara T, Tomita T, Ando T, Hasegawa K, et al. (2020). Structures of &#x3b1;-synuclein filaments from multiple system atrophy. Nature 585, 464&#x2013;469.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7116528</ArticleId><ArticleId IdType="pubmed">32461689</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwenk BM, Lang CM, Hogl S, Tahirovic S, Orozco D, Rentzsch K, Lichtenthaler SF, Hoogenraad CC, Capell A, Haass C, et al. (2014). The FTLD risk factor TMEM106B and MAP6 control dendritic trafficking of lysosomes. Embo j 33, 450&#x2013;467.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3989627</ArticleId><ArticleId IdType="pubmed">24357581</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, Zhang W, Yang Y, Murzin AG, Falcon B, Kotecha A, van Beers M, Tarutani A, Kametani F, Garringer HJ, et al. (2021). Structure-based classification of tauopathies. Nature 598, 359&#x2013;363.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7611841</ArticleId><ArticleId IdType="pubmed">34588692</ArticleId></ArticleIdList></Reference><Reference><Citation>Smirnovas V, Winter R, Funck T, and Dzwolak W (2005). Thermodynamic Properties Underlying the &#x3b1;-Helix-to-&#x3b2;-Sheet Transition, Aggregation, and Amyloidogenesis of Polylysine as Probed by Calorimetry, Densimetry, and Ultrasound Velocimetry. The Journal of Physical Chemistry B 109, 19043&#x2013;19045.</Citation><ArticleIdList><ArticleId IdType="pubmed">16853453</ArticleId></ArticleIdList></Reference><Reference><Citation>Sormanni P, Aprile FA, and Vendruscolo M (2015). The CamSol method of rational design of protein mutants with enhanced solubility. J Mol Biol 427, 478&#x2013;490.</Citation><ArticleIdList><ArticleId IdType="pubmed">25451785</ArticleId></ArticleIdList></Reference><Reference><Citation>Stagi M, Klein ZA, Gould TJ, Bewersdorf J, and Strittmatter SM (2014). Lysosome size, motility and stress response regulated by fronto-temporal dementia modifier TMEM106B. Mol Cell Neurosci 61, 226&#x2013;240.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4145808</ArticleId><ArticleId IdType="pubmed">25066864</ArticleId></ArticleIdList></Reference><Reference><Citation>Stroobants S, D&#x2019;Hooge R, and Damme M (2021). Aged Tmem106b knockout mice display gait deficits in coincidence with Purkinje cell loss and only limited signs of non-motor dysfunction. Brain Pathol 31, 223&#x2013;238.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8018119</ArticleId><ArticleId IdType="pubmed">33016371</ArticleId></ArticleIdList></Reference><Reference><Citation>van Daalen KR, Reijneveld JF, and Bovenschen N (2020). Modulation of Inflammation by Extracellular Granzyme A. Frontiers in Immunology 11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7248576</ArticleId><ArticleId IdType="pubmed">32508827</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Deerlin VM, Sleiman PM, Martinez-Lage M, Chen-Plotkin A, Wang LS, Graff-Radford NR, Dickson DW, Rademakers R, Boeve BF, Grossman M, et al. (2010). Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet 42, 234&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2828525</ArticleId><ArticleId IdType="pubmed">20154673</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Zee J, Van Langenhove T, Kleinberger G, Sleegers K, Engelborghs S, Vandenberghe R, Santens P, Van den Broeck M, Joris G, Brys J, et al. (2011). TMEM106B is associated with frontotemporal lobar degeneration in a clinically diagnosed patient cohort. Brain 134, 808&#x2013;815.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3044834</ArticleId><ArticleId IdType="pubmed">21354975</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J, Anishchenko I, Park H, Peng Z, Ovchinnikov S, and Baker D (2020). Improved protein structure prediction using predicted interresidue orientations. Proceedings of the National Academy of Sciences 117, 1496&#x2013;1503.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6983395</ArticleId><ArticleId IdType="pubmed">31896580</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K (2016). Gctf: Real-time CTF determination and correction. J Struct Biol 193, 1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4711343</ArticleId><ArticleId IdType="pubmed">26592709</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W, Falcon B, Murzin AG, Fan J, Crowther RA, Goedert M, and Scheres SH (2019). Heparin-induced tau filaments are polymorphic and differ from those in Alzheimer&#x2019;s and Pick&#x2019;s diseases. Elife 8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6375701</ArticleId><ArticleId IdType="pubmed">30720432</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W, Tarutani A, Newell KL, Murzin AG, Matsubara T, Falcon B, Vidal R, Garringer HJ, Shi Y, Ikeuchi T, et al. (2020). Novel tau filament fold in corticobasal degeneration. Nature 580, 283&#x2013;287.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7148158</ArticleId><ArticleId IdType="pubmed">32050258</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng SQ, Palovcak E, Armache J-P, Verba KA, Cheng Y, and Agard DA (2017). MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. Nature Methods 14, 331&#x2013;332.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5494038</ArticleId><ArticleId IdType="pubmed">28250466</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X, Brooks M, Jiang P, Koga S, Zuberi AR, Baker MC, Parsons TM, Castanedes-Casey M, Phillips V, Librero AL, et al. (2020). Loss of Tmem106b exacerbates FTLD pathologies and causes motor deficits in progranulin-deficient mice. EMBO Rep 21, e50197.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7534638</ArticleId><ArticleId IdType="pubmed">32761777</ArticleId></ArticleIdList></Reference><Reference><Citation>Zivanov J, Nakane T, Forsberg BO, Kimanius D, Hagen WJ, Lindahl E, and Scheres SH (2018). New tools for automated high-resolution cryo-EM structure determination in RELION-3. Elife 7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6250425</ArticleId><ArticleId IdType="pubmed">30412051</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35255491</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>29</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>604</Volume><Issue>7907</Issue><PubDate><Year>2022</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>SARS-CoV-2 is associated with changes in brain structure in UK Biobank.</ArticleTitle><Pagination><StartPage>697</StartPage><EndPage>707</EndPage><MedlinePgn>697-707</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41586-022-04569-5</ELocationID><Abstract><AbstractText>There is strong evidence of brain-related abnormalities in COVID-19<sup>1-13</sup>. However, it remains unknown whether the impact of SARS-CoV-2 infection can be detected in milder cases, and whether this can reveal possible mechanisms contributing to brain pathology. Here we investigated brain changes in 785 participants of UK Biobank (aged 51-81 years) who were imaged twice&#xa0;using magnetic resonance imaging, including 401 cases who tested positive for infection with SARS-CoV-2 between their two scans-with 141 days on average separating their diagnosis and the second scan-as well as 384 controls. The availability of pre-infection imaging data reduces the likelihood of pre-existing risk factors being misinterpreted as disease effects. We identified significant longitudinal effects when comparing the two groups, including (1) a greater reduction in grey matter thickness and tissue contrast in the orbitofrontal cortex and parahippocampal gyrus; (2) greater changes in markers of tissue damage in regions that are functionally connected to the primary olfactory cortex; and (3) a greater reduction in global brain size&#xa0;in the SARS-CoV-2 cases. The participants who were infected with SARS-CoV-2 also showed on average a greater cognitive decline between the two time points. Importantly, these imaging and cognitive longitudinal effects were still observed after excluding the 15 patients who had been hospitalised. These mainly limbic brain imaging results may be the in vivo hallmarks of a degenerative spread of the disease through olfactory pathways, of neuroinflammatory events, or of the loss of sensory input due to anosmia. Whether this deleterious effect can be partially reversed, or whether these effects will persist in the long term, remains to be investigated with additional follow-up.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Douaud</LastName><ForeName>Gwena&#xeb;lle</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-1981-391X</Identifier><AffiliationInfo><Affiliation>FMRIB Centre, Wellcome Centre for Integrative Neuroimaging (WIN), Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK. gwenaelle.douaud@ndcn.ox.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Soojin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>FMRIB Centre, Wellcome Centre for Integrative Neuroimaging (WIN), Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alfaro-Almagro</LastName><ForeName>Fidel</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>FMRIB Centre, Wellcome Centre for Integrative Neuroimaging (WIN), Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arthofer</LastName><ForeName>Christoph</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-1474-9963</Identifier><AffiliationInfo><Affiliation>FMRIB Centre, Wellcome Centre for Integrative Neuroimaging (WIN), Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Chaoyue</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-9402-1563</Identifier><AffiliationInfo><Affiliation>FMRIB Centre, Wellcome Centre for Integrative Neuroimaging (WIN), Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCarthy</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>FMRIB Centre, Wellcome Centre for Integrative Neuroimaging (WIN), Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lange</LastName><ForeName>Frederik</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-1736-7162</Identifier><AffiliationInfo><Affiliation>FMRIB Centre, Wellcome Centre for Integrative Neuroimaging (WIN), Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andersson</LastName><ForeName>Jesper L R</ForeName><Initials>JLR</Initials><AffiliationInfo><Affiliation>FMRIB Centre, Wellcome Centre for Integrative Neuroimaging (WIN), Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Griffanti</LastName><ForeName>Ludovica</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>FMRIB Centre, Wellcome Centre for Integrative Neuroimaging (WIN), Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>OHBA, Wellcome Centre for Integrative Neuroimaging (WIN), Department of Psychiatry, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duff</LastName><ForeName>Eugene</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>FMRIB Centre, Wellcome Centre for Integrative Neuroimaging (WIN), Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Paediatrics, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jbabdi</LastName><ForeName>Saad</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>FMRIB Centre, Wellcome Centre for Integrative Neuroimaging (WIN), Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taschler</LastName><ForeName>Bernd</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0001-6574-4789</Identifier><AffiliationInfo><Affiliation>FMRIB Centre, Wellcome Centre for Integrative Neuroimaging (WIN), Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keating</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Ear Institute, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Winkler</LastName><ForeName>Anderson M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Collins</LastName><ForeName>Rory</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Nuffield Department of Population Health, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matthews</LastName><ForeName>Paul M</ForeName><Initials>PM</Initials><Identifier Source="ORCID">0000-0002-1619-8328</Identifier><AffiliationInfo><Affiliation>UK Dementia Research Institute and Department of Brain Sciences, Imperial College, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Allen</LastName><ForeName>Naomi</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Nuffield Department of Population Health, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Karla L</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>FMRIB Centre, Wellcome Centre for Integrative Neuroimaging (WIN), Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nichols</LastName><ForeName>Thomas E</ForeName><Initials>TE</Initials><Identifier Source="ORCID">0000-0002-4516-5103</Identifier><AffiliationInfo><Affiliation>Big Data Institute, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Stephen M</ForeName><Initials>SM</Initials><Identifier Source="ORCID">0000-0001-8166-069X</Identifier><AffiliationInfo><Affiliation>FMRIB Centre, Wellcome Centre for Integrative Neuroimaging (WIN), Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MR/T033371/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_QA137853</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>ZIA MH002781</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/K006673/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_PC_17228</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>ZIA MH002782</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/S034978/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_PC_15067</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_PC_17223</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>CH/1996001/9454</GrantID><Acronym>BHF_</Acronym><Agency>British Heart Foundation</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_PC_12027</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>203139/Z/16/Z</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>215573/Z/19/Z</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_EX_G0801669</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_PC_21051</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_U137686854</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_PC_12029</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0300622</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_PC_12028</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_PC_18026</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>03</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="UpdateOf"><RefSource>medRxiv. 2022 Mar 02:2021.06.11.21258690. doi: 10.1101/2021.06.11.21258690.</RefSource><PMID Version="1">34189535</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2022 Apr;604(7907):633-634. doi: 10.1038/d41586-022-00503-x.</RefSource><PMID Version="1">35260835</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2022 Jun;18(6):321-322. doi: 10.1038/s41582-022-00661-6.</RefSource><PMID Version="1">35449462</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2022 Jun;606(7915):631-632. doi: 10.1038/d41586-022-01589-z.</RefSource><PMID Version="1">35681006</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Signal Transduct Target Ther. 2022 Jul 11;7(1):230. doi: 10.1038/s41392-022-01072-1.</RefSource><PMID Version="1">35817774</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018070" MajorTopicYN="N">Biological Specimen Banks</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="Y">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012903" MajorTopicYN="N">Smell</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006113" MajorTopicYN="N" Type="Geographic">United Kingdom</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>R.C. has been seconded from the University of Oxford as chief executive and principal investigator of UK Biobank, which is a charitable company. N.A. is chief scientist for UK Biobank. P.M.M. acknowledges consultancy fees from Novartis and Biogen; he has received recent honoraria or speakers&#x2019; honoraria and research or educational funds from Novartis, Bristol Myers Squibb and Biogen. P.M.M. serves as the honorary chair of the UK Biobank Imaging Working Group and as an unpaid member of the UK Biobank Steering Committee; he is chair of the UKRI Medical Research Council Neurosciences and Mental Health Board.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>8</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>2</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>7</Day><Hour>20</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>3</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35255491</ArticleId><ArticleId IdType="pmc">PMC9046077</ArticleId><ArticleId IdType="doi">10.1038/s41586-022-04569-5</ArticleId><ArticleId IdType="pii">10.1038/s41586-022-04569-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Paterson RW, et al. The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings. Brain. 2020;143:3104&#x2013;3120.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7454352</ArticleId><ArticleId IdType="pubmed">32637987</ArticleId></ArticleIdList></Reference><Reference><Citation>de Erausquin GA, et al. The chronic neuropsychiatric sequelae of COVID-19: the need for a prospective study of viral impact on brain functioning. Alzheimers Dement. 2021;17:1056&#x2013;1065.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10431934</ArticleId><ArticleId IdType="pubmed">33399270</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang AC, et al. Dysregulation of brain and choroid plexus cell types in severe COVID-19. Nature. 2021;595:565&#x2013;571.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8400927</ArticleId><ArticleId IdType="pubmed">34153974</ArticleId></ArticleIdList></Reference><Reference><Citation>Deleidi M, Isacson O. Viral and inflammatory triggers of neurodegenerative diseases. Sci. Transl. Med. 2012;4:121ps123.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3982831</ArticleId><ArticleId IdType="pubmed">22344685</ArticleId></ArticleIdList></Reference><Reference><Citation>Butowt R, Meunier N, Bryche B, von Bartheld CS. The olfactory nerve is not a likely route to brain infection in COVID-19: a critical review of data from humans and animal models. Acta Neuropathol. 2021;141:809&#x2013;822.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8075028</ArticleId><ArticleId IdType="pubmed">33903954</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry. 2021;8:416&#x2013;427.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8023694</ArticleId><ArticleId IdType="pubmed">33836148</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M, Luciano S, Geddes JR, Harrison PJ. Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA. Lancet Psychiatry. 2021;8:130&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7820108</ArticleId><ArticleId IdType="pubmed">33181098</ArticleId></ArticleIdList></Reference><Reference><Citation>Helms J, et al. Neurologic features in severe SARS-CoV-2 infection. N. Engl. J. Med. 2020;382:2268&#x2013;2270.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7179967</ArticleId><ArticleId IdType="pubmed">32294339</ArticleId></ArticleIdList></Reference><Reference><Citation>Manca R, De Marco M, Ince P. G., Venneri A. Heterogeneity in regional damage detected by neuroimaging and neuropathological studies in older adults with COVID-19: a cognitive-neuroscience systematic review to inform the long-term impact of the virus on neurocognitive trajectories. Front. Aging Neurosci. 2021;13:646908.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8209297</ArticleId><ArticleId IdType="pubmed">34149394</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukerji SS, Solomon IH. What can we learn from brain autopsies in COVID-19? Neurosci. Lett. 2021;742:135528.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7687409</ArticleId><ArticleId IdType="pubmed">33248159</ArticleId></ArticleIdList></Reference><Reference><Citation>Meinhardt J, et al. Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19. Nat. Neurosci. 2021;24:168&#x2013;175.</Citation><ArticleIdList><ArticleId IdType="pubmed">33257876</ArticleId></ArticleIdList></Reference><Reference><Citation>Puelles VG, et al. Multiorgan and renal tropism of SARS-CoV-2. N. Engl. J. Med. 2020;383:590&#x2013;592.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7240771</ArticleId><ArticleId IdType="pubmed">32402155</ArticleId></ArticleIdList></Reference><Reference><Citation>Matschke J, et al. Neuropathology of patients with COVID-19 in Germany: a post-mortem case series. Lancet Neurol. 2020;19:919&#x2013;929.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7535629</ArticleId><ArticleId IdType="pubmed">33031735</ArticleId></ArticleIdList></Reference><Reference><Citation>Chertow, D. et al. SARS-CoV-2 infection and persistence throughout the human body and brain. Preprint at Research Square10.21203/rs.3.rs-1139035/v1 (2021).</Citation></Reference><Reference><Citation>Philippens, I. H. C. H. M. et al. SARS-CoV-2 causes brain inflammation and induces Lewy body formation in macaques. Preprint at bioRxiv10.1101/2021.02.23.432474 (2021).</Citation></Reference><Reference><Citation>Lechien JR, et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur. Arch. Otorhinolaryngol. 2020;277:2251&#x2013;2261.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7134551</ArticleId><ArticleId IdType="pubmed">32253535</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper KW, et al. COVID-19 and the chemical senses: supporting players take center stage. Neuron. 2020;107:219&#x2013;233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7328585</ArticleId><ArticleId IdType="pubmed">32640192</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosp JA, et al. Cognitive impairment and altered cerebral glucose metabolism in the subacute stage of COVID-19. Brain. 2021;144:1263&#x2013;1276.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8083602</ArticleId><ArticleId IdType="pubmed">33822001</ArticleId></ArticleIdList></Reference><Reference><Citation>Postma EM, Smeets PAM, Boek WM, Boesveldt S. Investigating morphological changes in the brain in relation to etiology and duration of olfactory dysfunction with voxel-based morphometry. Sci. Rep. 2021;11:12704.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8209212</ArticleId><ArticleId IdType="pubmed">34135435</ArticleId></ArticleIdList></Reference><Reference><Citation>Butowt R, Bilinska K. SARS-CoV-2: olfaction, brain infection, and the urgent need for clinical samples allowing earlier virus detection. ACS Chem. Neurosci. 2020;11:1200&#x2013;1203.</Citation><ArticleIdList><ArticleId IdType="pubmed">32283006</ArticleId></ArticleIdList></Reference><Reference><Citation>Netland J, Meyerholz DK, Moore S, Cassell M, Perlman S. Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2. J. Virol. 2008;82:7264&#x2013;7275.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2493326</ArticleId><ArticleId IdType="pubmed">18495771</ArticleId></ArticleIdList></Reference><Reference><Citation>Brann DH, et al. Non-neuronal expression of SARS-CoV-2 entry genes in the olfactory system suggests mechanisms underlying COVID-19-associated anosmia. Sci. Adv. 2020;6:eabc5801.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10715684</ArticleId><ArticleId IdType="pubmed">32937591</ArticleId></ArticleIdList></Reference><Reference><Citation>Carmichael ST, Clugnet MC, Price JL. Central olfactory connections in the macaque monkey. J. Comp. Neurol. 1994;346:403&#x2013;434.</Citation><ArticleIdList><ArticleId IdType="pubmed">7527806</ArticleId></ArticleIdList></Reference><Reference><Citation>Palouzier-Paulignan B, et al. Olfaction under metabolic influences. Chem. Senses. 2012;37:769&#x2013;797.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3529618</ArticleId><ArticleId IdType="pubmed">22832483</ArticleId></ArticleIdList></Reference><Reference><Citation>Guedj E, et al. 18F-FDG brain PET hypometabolism in post-SARS-CoV-2 infection: substrate for persistent/delayed disorders? Eur. J. Nucl. Med. Mol. Imaging. 2021;48:592&#x2013;595.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7391029</ArticleId><ArticleId IdType="pubmed">32728799</ArticleId></ArticleIdList></Reference><Reference><Citation>Raman B, et al. Medium-term effects of SARS-CoV-2 infection on multiple vital organs, exercise capacity, cognition, quality of life and mental health, post-hospital discharge. EClinicalMedicine. 2021;31:100683.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7808914</ArticleId><ArticleId IdType="pubmed">33490928</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffanti L, et al. Adapting the UK Biobank brain imaging protocol and analysis pipeline for the C-MORE multi-organ study of COVID-19 survivors. Front. Neurol. 2021;12:753284.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8586081</ArticleId><ArticleId IdType="pubmed">34777224</ArticleId></ArticleIdList></Reference><Reference><Citation>Reichert JL, Schopf V. Olfactory loss and regain: lessons for neuroplasticity. Neuroscientist. 2018;24:22&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">28459173</ArticleId></ArticleIdList></Reference><Reference><Citation>Han P, et al. Olfactory brain gray matter volume reduction in patients with chronic rhinosinusitis. Int. Forum Allergy Rhinol. 2017;7:551&#x2013;556.</Citation><ArticleIdList><ArticleId IdType="pubmed">28383208</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou G, Lane G, Cooper SL, Kahnt T, Zelano C. Characterizing functional pathways of the human olfactory system. eLife. 2019;8:e47177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6656430</ArticleId><ArticleId IdType="pubmed">31339489</ArticleId></ArticleIdList></Reference><Reference><Citation>Fraser MA, et al. Longitudinal trajectories of hippocampal volume in middle to older age community dwelling individuals. Neurobiol. Aging. 2021;97:97&#x2013;105.</Citation><ArticleIdList><ArticleId IdType="pubmed">33190123</ArticleId></ArticleIdList></Reference><Reference><Citation>Ronnlund M, Nyberg L, Backman L, Nilsson LG. Stability, growth, and decline in adult life span development of declarative memory: cross-sectional and longitudinal data from a population-based study. Psychol. Aging. 2005;20:3&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">15769210</ArticleId></ArticleIdList></Reference><Reference><Citation>Vidal-Pineiro D, et al. Individual variations in &#x2018;brain age&#x2019; relate to early-life factors more than to longitudinal brain change. eLife. 2021;10:e69995.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8580481</ArticleId><ArticleId IdType="pubmed">34756163</ArticleId></ArticleIdList></Reference><Reference><Citation>Diana RA, Yonelinas AP, Ranganath C. Imaging recollection and familiarity in the medial temporal lobe: a three-component model. Trends Cogn. Sci. 2007;11:379&#x2013;386.</Citation><ArticleIdList><ArticleId IdType="pubmed">17707683</ArticleId></ArticleIdList></Reference><Reference><Citation>Staresina BP, Duncan KD, Davachi L. Perirhinal and parahippocampal cortices differentially contribute to later recollection of object- and scene-related event details. J. Neurosci. 2011;31:8739&#x2013;8747.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3128497</ArticleId><ArticleId IdType="pubmed">21677158</ArticleId></ArticleIdList></Reference><Reference><Citation>Naya Y, Suzuki WA. Integrating what and when across the primate medial temporal lobe. Science. 2011;333:773&#x2013;776.</Citation><ArticleIdList><ArticleId IdType="pubmed">21817056</ArticleId></ArticleIdList></Reference><Reference><Citation>Doty RL. Olfaction: smell of change in the air. Cerebrum. 2017;2017:cer-10-17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6132042</ArticleId><ArticleId IdType="pubmed">30210659</ArticleId></ArticleIdList></Reference><Reference><Citation>Avery JA, et al. Taste quality representation in the human brain. J. Neurosci. 2020;40:1042&#x2013;1052.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6989007</ArticleId><ArticleId IdType="pubmed">31836661</ArticleId></ArticleIdList></Reference><Reference><Citation>Chikazoe J, Lee DH, Kriegeskorte N, Anderson AK. Distinct representations of basic taste qualities in human gustatory cortex. Nat. Commun. 2019;10:1048.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6401093</ArticleId><ArticleId IdType="pubmed">30837463</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferdon S, Murphy C. The cerebellum and olfaction in the aging brain: a functional magnetic resonance imaging study. Neuroimage. 2003;20:12&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">14527566</ArticleId></ArticleIdList></Reference><Reference><Citation>Kas A, et al. The cerebral network of COVID-19-related encephalopathy: a longitudinal voxel-based 18F-FDG-PET study. Eur. J. Nucl. Med. Mol. Imaging. 2021;48:2543&#x2013;2557.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7810428</ArticleId><ArticleId IdType="pubmed">33452633</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin Y, et al. Long-term microstructure and cerebral blood flow changes in patients recovered from COVID-19 without neurological manifestations. J. Clin. Invest. 2021;131:e147329.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8262559</ArticleId><ArticleId IdType="pubmed">33630760</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai ST, Lu MK, San S, Tsai CH. The neurologic manifestations of coronavirus disease 2019 pandemic: a systemic review. Front. Neurol. 2020;11:498.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7248254</ArticleId><ArticleId IdType="pubmed">32574246</ArticleId></ArticleIdList></Reference><Reference><Citation>Han P, Musch M, Abolmaali N, Hummel T. Improved odor identification ability and increased regional gray matter volume after olfactory training in patients with idiopathic olfactory loss. iPerception. 2021;12:20416695211005811.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8073728</ArticleId><ArticleId IdType="pubmed">33996020</ArticleId></ArticleIdList></Reference><Reference><Citation>Blazhenets G, et al. Slow but evident recovery from neocortical dysfunction and cognitive impairment in a series of chronic COVID-19 patients. J. Nucl. Med. 2021;62:910&#x2013;915.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8882885</ArticleId><ArticleId IdType="pubmed">33789937</ArticleId></ArticleIdList></Reference><Reference><Citation>Douaud G, et al. DTI measures in crossing-fibre areas: increased diffusion anisotropy reveals early white matter alteration in MCI and mild Alzheimer&#x2019;s disease. Neuroimage. 2011;55:880&#x2013;890.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7116583</ArticleId><ArticleId IdType="pubmed">21182970</ArticleId></ArticleIdList></Reference><Reference><Citation>Douaud G, et al. Preventing Alzheimer&#x2019;s disease-related gray matter atrophy by B-vitamin treatment. Proc. Natl Acad. Sci. USA. 2013;110:9523&#x2013;9528.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677457</ArticleId><ArticleId IdType="pubmed">23690582</ArticleId></ArticleIdList></Reference><Reference><Citation>Fawns-Ritchie C, Deary IJ. Reliability and validity of the UK Biobank cognitive tests. PLoS ONE. 2020;15:e0231627.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7170235</ArticleId><ArticleId IdType="pubmed">32310977</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahlberg R, Adli M, Bschor T, Kienast T. Age effects on trail making test during acute depressive and manic episode. Int. J. Neurosci. 2008;118:1347&#x2013;1356.</Citation><ArticleIdList><ArticleId IdType="pubmed">18698515</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahurin RK, et al. Trail making test errors and executive function in schizophrenia and depression. Clin. Neuropsychol. 2006;20:271&#x2013;288.</Citation><ArticleIdList><ArticleId IdType="pubmed">16690547</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashendorf L, et al. Trail making test errors in normal aging, mild cognitive impairment, and dementia. Arch. Clin. Neuropsychol. 2008;23:129&#x2013;137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2693196</ArticleId><ArticleId IdType="pubmed">18178372</ArticleId></ArticleIdList></Reference><Reference><Citation>Sobel N, et al. Odorant-induced and sniff-induced activation in the cerebellum of the human. J. Neurosci. 1998;18:8990&#x2013;9001.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6793565</ArticleId><ArticleId IdType="pubmed">9787004</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowland MJ, et al. Early brain injury and cognitive impairment after aneurysmal subarachnoid haemorrhage. Sci. Rep. 2021;11:23245.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8636506</ArticleId><ArticleId IdType="pubmed">34853362</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao S, et al. Rapid vigilance and episodic memory decrements in COVID-19 survivors. Brain Commun. 2022;4:fcab295.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8807287</ArticleId><ArticleId IdType="pubmed">35128398</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka MT, Kummer MP, Latz E. Innate immune activation in neurodegenerative disease. Nat. Rev. Immunol. 2014;14:463&#x2013;477.</Citation><ArticleIdList><ArticleId IdType="pubmed">24962261</ArticleId></ArticleIdList></Reference><Reference><Citation>Deeks JJ, et al. Antibody tests for identification of current and past infection with SARS-CoV-2. Cochrane Database Syst. Rev. 2020;6:CD013652.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7387103</ArticleId><ArticleId IdType="pubmed">32584464</ArticleId></ArticleIdList></Reference><Reference><Citation>Salat DH, et al. Thinning of the cerebral cortex in aging. Cereb. Cortex. 2004;14:721&#x2013;730.</Citation><ArticleIdList><ArticleId IdType="pubmed">15054051</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao L, et al. Age-related differences in brain morphology and the modifiers in middle-aged and older adults. Cereb. Cortex. 2019;29:4169&#x2013;4193.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6931275</ArticleId><ArticleId IdType="pubmed">30535294</ArticleId></ArticleIdList></Reference><Reference><Citation>Elliott LT, et al. Genome-wide association studies of brain imaging phenotypes in UK Biobank. Nature. 2018;562:210&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6786974</ArticleId><ArticleId IdType="pubmed">30305740</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller KL, et al. Multimodal population brain imaging in the UK Biobank prospective epidemiological study. Nat. Neurosci. 2016;19:1523&#x2013;1536.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5086094</ArticleId><ArticleId IdType="pubmed">27643430</ArticleId></ArticleIdList></Reference><Reference><Citation>Alfaro-Almagro F, et al. Image processing and quality control for the first 10,000 brain imaging datasets from UK Biobank. Neuroimage. 2018;166:400&#x2013;424.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5770339</ArticleId><ArticleId IdType="pubmed">29079522</ArticleId></ArticleIdList></Reference><Reference><Citation>Littlejohns TJ, et al. The UK Biobank imaging enhancement of 100,000 participants: rationale, data collection, management and future directions. Nat. Commun. 2020;11:2624.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7250878</ArticleId><ArticleId IdType="pubmed">32457287</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith SM, et al. An expanded set of genome-wide association studies of brain imaging phenotypes in UK Biobank. Nat. Neurosci. 2021;24:737&#x2013;745.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7610742</ArticleId><ArticleId IdType="pubmed">33875891</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, C. et al. Phenotypic and genetic associations of quantitative magnetic susceptibility in UK Biobank brain imaging. Preprint at bioRxiv10.1101/2021.06.28.450248 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9174052</ArticleId><ArticleId IdType="pubmed">35606419</ArticleId></ArticleIdList></Reference><Reference><Citation>Pauli WM, Nili AN, Tyszka JM. A high-resolution probabilistic in vivo atlas of human subcortical brain nuclei. Sci. Data. 2018;5:180063.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5903366</ArticleId><ArticleId IdType="pubmed">29664465</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffanti L, et al. BIANCA (Brain Intensity AbNormality Classification Algorithm): a new tool for automated segmentation of white matter hyperintensities. Neuroimage. 2016;141:191&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5035138</ArticleId><ArticleId IdType="pubmed">27402600</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C, et al. Methods for quantitative susceptibility and R2* mapping in whole post-mortem brains at 7T applied to amyotrophic lateral sclerosis. Neuroimage. 2020;222:117216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7775972</ArticleId><ArticleId IdType="pubmed">32745677</ArticleId></ArticleIdList></Reference><Reference><Citation>Iglesias JE, et al. A probabilistic atlas of the human thalamic nuclei combining ex vivo MRI and histology. Neuroimage. 2018;183:314&#x2013;326.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6215335</ArticleId><ArticleId IdType="pubmed">30121337</ArticleId></ArticleIdList></Reference><Reference><Citation>Iglesias JE, et al. Bayesian longitudinal segmentation of hippocampal substructures in brain MRI using subject-specific atlases. Neuroimage. 2016;141:542&#x2013;555.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5026967</ArticleId><ArticleId IdType="pubmed">27426838</ArticleId></ArticleIdList></Reference><Reference><Citation>Iglesias JE, et al. Bayesian segmentation of brainstem structures in MRI. Neuroimage. 2015;113:184&#x2013;195.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4434226</ArticleId><ArticleId IdType="pubmed">25776214</ArticleId></ArticleIdList></Reference><Reference><Citation>Saygin ZM, et al. High-resolution magnetic resonance imaging reveals nuclei of the human amygdala: manual segmentation to automatic atlas. Neuroimage. 2017;155:370&#x2013;382.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5557007</ArticleId><ArticleId IdType="pubmed">28479476</ArticleId></ArticleIdList></Reference><Reference><Citation>Neudorfer C, et al. A high-resolution in vivo magnetic resonance imaging atlas of the human hypothalamic region. Sci. Data. 2020;7:305.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7492465</ArticleId><ArticleId IdType="pubmed">32934244</ArticleId></ArticleIdList></Reference><Reference><Citation>Alfaro-Almagro F, et al. Confound modelling in UK Biobank brain imaging. Neuroimage. 2021;224:117002.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7610719</ArticleId><ArticleId IdType="pubmed">32502668</ArticleId></ArticleIdList></Reference><Reference><Citation>Vickers AJ. The use of percentage change from baseline as an outcome in a controlled trial is statistically inefficient: a simulation study. BMC Med. Res. Methodol. 2001;1:6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC34605</ArticleId><ArticleId IdType="pubmed">11459516</ArticleId></ArticleIdList></Reference><Reference><Citation>Papst I, et al. Age-dependence of healthcare interventions for COVID-19 in Ontario, Canada. BMC Public Health. 2021;21:706.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8040357</ArticleId><ArticleId IdType="pubmed">33845807</ArticleId></ArticleIdList></Reference><Reference><Citation>Levin AT, et al. Assessing the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications. Eur. J. Epidemiol. 2020;35:1123&#x2013;1138.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7721859</ArticleId><ArticleId IdType="pubmed">33289900</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35278341</PMID><DateCompleted><Year>2023</Year><Month>01</Month><Day>17</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1552-5279</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Alzheimer's &amp; dementia : the journal of the Alzheimer's Association</Title><ISOAbbreviation>Alzheimers Dement</ISOAbbreviation></Journal><ArticleTitle>Identification of the A&#x3b2;37/42 peptide ratio in CSF as an improved A&#x3b2; biomarker for Alzheimer's disease.</ArticleTitle><Pagination><StartPage>79</StartPage><EndPage>96</EndPage><MedlinePgn>79-96</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/alz.12646</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Identifying CSF-based biomarkers for the &#x3b2;-amyloidosis that initiates Alzheimer's disease (AD) could provide inexpensive and dynamic tests to distinguish AD from normal aging and predict future cognitive decline.</AbstractText><AbstractText Label="METHODS">We developed immunoassays specifically detecting all C-terminal variants of secreted amyloid &#x3b2;-protein and identified a novel biomarker, the A&#x3b2; 37/42 ratio, that outperforms the canonical A&#x3b2;42/40 ratio as a means to evaluate the &#x3b3;-secretase activity and brain A&#x3b2; accumulation.</AbstractText><AbstractText Label="RESULTS">We show that A&#x3b2; 37/42 can distinguish physiological and pathological status in (1) presenilin-1 mutant vs wild-type cultured cells, (2) AD vs control brain tissue, and (3) AD versus cognitively normal (CN) subjects in CSF, where 37/42 (AUC 0.9622) outperformed 42/40 (AUC 0.8651) in distinguishing CN from AD.</AbstractText><AbstractText Label="DISCUSSION">We conclude that the A&#x3b2; 37/42 ratio sensitively detects presenilin/&#x3b3;-secretase dysfunction and better distinguishes CN from AD than A&#x3b2;42/40 in CSF. Measuring this novel ratio alongside promising phospho-tau analytes may provide highly discriminatory fluid biomarkers for AD.</AbstractText><CopyrightInformation>&#xa9; 2022 the Alzheimer's Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Lei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lauro</LastName><ForeName>Bianca M</ForeName><Initials>BM</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Amy</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Hyo</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhattarai</LastName><ForeName>Sanjay</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medicinal Chemistry, University of Kansas, Lawrence, Kansas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wolfe</LastName><ForeName>Michael S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Medicinal Chemistry, University of Kansas, Lawrence, Kansas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karch</LastName><ForeName>Celeste M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University in St. Louis, St. Louis, Missouri, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurologic Disorders, St. Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Young-Pearse</LastName><ForeName>Tracy</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Dominantly Inherited Alzheimer Network (DIAN)</CollectiveName></Author><Author ValidYN="Y"><LastName>Selkoe</LastName><ForeName>Dennis J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG072975</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG046152</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG015379</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG032984</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG006173</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R03 AG063046</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG071865</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG006173</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG030146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG055909</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG036836</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG015819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 NS117446</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>03</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Alzheimers Dement</MedlineTA><NlmUniqueID>101231978</NlmUniqueID><ISSNLinking>1552-5260</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="Y">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">CSF biomarkers</Keyword><Keyword MajorTopicYN="N">amyloid &#x3b2;-protein</Keyword></KeywordList><CoiStatement>Declaration of Interests. DJS is a director and consultant of Prothena Biosciences. The other authors declare no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>2</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>11</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>2</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>12</Day><Hour>17</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35278341</ArticleId><ArticleId IdType="mid">NIHMS1802899</ArticleId><ArticleId IdType="pmc">PMC9464800</ArticleId><ArticleId IdType="doi">10.1002/alz.12646</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Edbauer D, Winkler E, Regula JT, Pesold B, Steiner H, Haass C. Reconstitution of &#x3b3;-secretase activity. Nature cell biology 2003; 5: 486&#x2013;488.</Citation><ArticleIdList><ArticleId IdType="pubmed">12679784</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimberly WT, LaVoie MJ, Ostaszewski BL, Ye W, Wolfe MS, Selkoe DJ. Gamma-secretase is a membrane protein complex comprised of presenilin, nicastrin, Aph-1, and Pen-2. Proc Natl Acad Sci U S A 2003; 100: 6382&#x2013;6387.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC164455</ArticleId><ArticleId IdType="pubmed">12740439</ArticleId></ArticleIdList></Reference><Reference><Citation>Takasugi N, Tomita T, Hayashi I, Tsuruoka M, Niimura M, Takahashi Y et al. The role of presenilin cofactors in the &#x3b3;-secretase complex. Nature 2003; 422: 438&#x2013;441.</Citation><ArticleIdList><ArticleId IdType="pubmed">12660785</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe MS, Xia W, Ostaszewski BL, Diehl TS, Kimberly WT, Selkoe DJ. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and &#x3b3;-secretase activity. Nature 1999; 398: 513&#x2013;517.</Citation><ArticleIdList><ArticleId IdType="pubmed">10206644</ArticleId></ArticleIdList></Reference><Reference><Citation>Haapasalo A, Kovacs DM. The many substrates of presenilin/&#x3b3;-secretase. J Alzheimers Dis 2011; 25: 3&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3281584</ArticleId><ArticleId IdType="pubmed">21335653</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen AC, Kim S, Shepardson N, Patel S, Hong S, Selkoe DJ. Physical and functional interaction between the &#x3b1;- and &#x3b3;-secretases: A new model of regulated intramembrane proteolysis. J Cell Biol 2015; 211: 1157&#x2013;1176.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4687875</ArticleId><ArticleId IdType="pubmed">26694839</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Ding L, Rovere M, Wolfe MS, Selkoe DJ. A cellular complex of BACE1 and &#x3b3;-secretase sequentially generates A&#x3b2; from its full-length precursor. Journal of Cell Biology 2019; 218: 644&#x2013;663.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6363461</ArticleId><ArticleId IdType="pubmed">30626721</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolduc DM, Montagna DR, Seghers MC, Wolfe MS, Selkoe DJ. The amyloid-beta forming tripeptide cleavage mechanism of &#x3b3;-secretase. Elife 2016; 5: e17578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5134833</ArticleId><ArticleId IdType="pubmed">27580372</ArticleId></ArticleIdList></Reference><Reference><Citation>Kakuda N, Shoji M, Arai H, Furukawa K, Ikeuchi T, Akazawa K et al. Altered &#x3b3;-secretase activity in mild cognitive impairment and Alzheimer&#x2019;s disease. EMBO molecular medicine 2012; 4: 344&#x2013;352.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3376855</ArticleId><ArticleId IdType="pubmed">22354516</ArticleId></ArticleIdList></Reference><Reference><Citation>Takami M, Nagashima Y, Sano Y, Ishihara S, Morishima-Kawashima M, Funamoto S et al. &#x3b3;-Secretase: successive tripeptide and tetrapeptide release from the transmembrane domain of &#x3b2;-carboxyl terminal fragment. Journal of Neuroscience 2009; 29: 13042&#x2013;13052.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6665297</ArticleId><ArticleId IdType="pubmed">19828817</ArticleId></ArticleIdList></Reference><Reference><Citation>Reinert J, Richard BC, Klafki HW, Friedrich B, Bayer TA, Wiltfang J et al. Deposition of C-terminally truncated A&#x3b2; species A&#x3b2;37 and A&#x3b2;39 in Alzheimer&#x2019;s disease and transgenic mouse models. Acta Neuropathologica Communications 2016; 4:</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4784385</ArticleId><ArticleId IdType="pubmed">26955942</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiltfang J, Esselmann H, Bibl M, Smirnov A, Otto M, Paul S et al. Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1&#x2013;37/38/39 in addition to 1&#x2013;40/42 in Alzheimer&#x2019;s disease and in patients with chronic neuroinflammation. J Neurochem 2002; 81: 481&#x2013;496.</Citation><ArticleIdList><ArticleId IdType="pubmed">12065657</ArticleId></ArticleIdList></Reference><Reference><Citation>Bibl M, Esselmann H, Mollenhauer B, Weniger G, Welge V, Liess M et al. Blood-based neurochemical diagnosis of vascular dementia: A pilot study. Journal of neurochemistry 2007; 103: 467&#x2013;474.</Citation><ArticleIdList><ArticleId IdType="pubmed">17662050</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xf6;glund K, Hansson O, Buchhave P, Zetterberg H, Lewczuk P, Londos E et al. Prediction of Alzheimer&#x2019;s disease using a cerebrospinal fluid pattern of C-terminally truncated &#x3b2;-amyloid peptides. Neurodegenerative diseases 2008; 5: 268&#x2013;276.</Citation><ArticleIdList><ArticleId IdType="pubmed">18309230</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewczuk P, Esselmann H, Bibl M, Paul S, Svitek J, Miertschischk J et al. Electrophoretic separation of amyloid &#x3b2; peptides in plasma. Electrophoresis 2004; 25: 3336&#x2013;3343.</Citation><ArticleIdList><ArticleId IdType="pubmed">15490456</ArticleId></ArticleIdList></Reference><Reference><Citation>Pannee J, T&#xf6;rnqvist U, Westerlund A, Ingelsson M, Lannfelt L, Brinkmalm G et al. The amyloid-&#x3b2; degradation pattern in plasma&#x2014;a possible tool for clinical trials in Alzheimer&#x2019;s disease. Neuroscience letters 2014; 573: 7&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">24796810</ArticleId></ArticleIdList></Reference><Reference><Citation>Portelius E, Andreasson U, Ringman JM, Buerger K, Daborg J, Buchhave P et al. Distinct cerebrospinal fluid amyloid &#x3b2; peptide signatures in sporadic and PSEN1 A431E-associated familial Alzheimer&#x2019;s disease. Molecular Neurodegeneration 2010; 5: 2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2818651</ArticleId><ArticleId IdType="pubmed">20145736</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai X-c, Yan C, Yang G, Lu P, Ma D, Sun L et al. An atomic structure of human &#x3b3;-secretase. Nature 2015; 525: 212&#x2013;217.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4568306</ArticleId><ArticleId IdType="pubmed">26280335</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou R, Yang G, Guo X, Zhou Q, Lei J, Shi Y. Recognition of the amyloid precursor protein by human &#x3b3;-secretase. Science 2019; 363:</Citation><ArticleIdList><ArticleId IdType="pubmed">30630874</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Lauro BM, Wolfe MS, Selkoe DJ. Hydrophilic loop 1 of Presenilin-1 and the APP GxxxG transmembrane motif regulate &#x3b3;-secretase function in generating Alzheimer-causing A&#x3b2; peptides. J Biol Chem 2021; 296: 100393.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7961089</ArticleId><ArticleId IdType="pubmed">33571524</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Roberts RO, Knopman DS, Geda YE, Cha RH, Pankratz VS et al. Prevalence of mild cognitive impairment is higher in men: The Mayo Clinic Study of Aging. Neurology 2010; 75: 889&#x2013;897.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2938972</ArticleId><ArticleId IdType="pubmed">20820000</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts RO, Geda YE, Knopman DS, Cha RH, Pankratz VS, Boeve BF et al. The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology 2008; 30: 58&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2821441</ArticleId><ArticleId IdType="pubmed">18259084</ArticleId></ArticleIdList></Reference><Reference><Citation>St Sauver JL, Grossardt BR, Yawn BP, Melton III LJ, Pankratz JJ, Brue SM et al. Data resource profile: the Rochester Epidemiology Project (REP) medical records-linkage system. International journal of epidemiology 2012; 41: 1614&#x2013;1624.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3535751</ArticleId><ArticleId IdType="pubmed">23159830</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Pak C, Han Y, Ahlenius H, Zhang Z, Chanda S et al. Rapid single-step induction of functional neurons from human pluripotent stem cells. Neuron 2013; 78: 785&#x2013;798.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3751803</ArticleId><ArticleId IdType="pubmed">23764284</ArticleId></ArticleIdList></Reference><Reference><Citation>Muratore CR, Zhou C, Liao M, Fernandez MA, Taylor WM, Lagomarsino VN et al. Cell-type Dependent Alzheimer&#x2019;s Disease Phenotypes: Probing the Biology of Selective Neuronal Vulnerability. Stem Cell Reports 2017; 9: 1868&#x2013;1884.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5785690</ArticleId><ArticleId IdType="pubmed">29153990</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Buchman AS, Boyle PA, Barnes LL, Wilson RS, Schneider JA. Religious orders study and rush memory and aging project. Journal of Alzheimer&#x2019;s Disease 2018; 64: S161&#x2013;S189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6380522</ArticleId><ArticleId IdType="pubmed">29865057</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitamoto TKJS, Ogomori K, Tateishi J, Prusiner SB. Formic acid pretreatment enhances immunostaining of cerebral and systemic amyloids. Laboratory investigation; a journal of technical methods and pathology 1987; 57: 230&#x2013;236.</Citation><ArticleIdList><ArticleId IdType="pubmed">2441141</ArticleId></ArticleIdList></Reference><Reference><Citation>J&#xe4;kel L, Boche D, Nicoll JAR, Verbeek MM. A&#x3b2;43 in human Alzheimer&#x2019;s disease: effects of active A&#x3b2;42 immunization. Acta Neuropathol Commun 2019; 7: 141.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6717966</ArticleId><ArticleId IdType="pubmed">31477180</ArticleId></ArticleIdList></Reference><Reference><Citation>Borchelt DR, Thinakaran G, Eckman CB, Lee MK, Davenport F, Ratovitsky T et al. Familial Alzheimer&#x2019;s disease&#x2013;linked presenilin 1 variants elevate A&#x3b2;1&#x2013;42/1&#x2013;40 ratio in vitro and in vivo. Neuron 1996; 17: 1005&#x2013;1013.</Citation><ArticleIdList><ArticleId IdType="pubmed">8938131</ArticleId></ArticleIdList></Reference><Reference><Citation>Citron M, Westaway D, Xia W, Carlson G, Diehl T, Levesque G et al. Mutant presenilins of Alzheimer&#x2019;s disease increase production of 42-residue amyloid &#x3b2;-protein in both transfected cells and transgenic mice. Nature medicine 1997; 3: 67&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">8986743</ArticleId></ArticleIdList></Reference><Reference><Citation>Citron M, Eckman CB, Diehl TS, Corcoran C, Ostaszewski BL, Xia W et al. Additive effects of PS1 and APP mutations on secretion of the 42-residue amyloid &#x3b2;-protein. Neurobiology of disease 1998; 5: 107&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pubmed">9746908</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N et al. Secreted amyloid &#x3b2;&#x2013;protein similar to that in the senile plaques of Alzheimer&#x2019;s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer&#x2019;s disease. Nature medicine 1996; 2: 864&#x2013;870.</Citation><ArticleIdList><ArticleId IdType="pubmed">8705854</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun L, Zhou R, Yang G, Shi Y. Analysis of 138 pathogenic mutations in presenilin-1 on the in vitro production of A&#x3b2;42 and A&#x3b2;40 peptides by &#x3b3;-secretase. Proceedings of the National Academy of Sciences 2017; 114: E476&#x2013;E485.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5278480</ArticleId><ArticleId IdType="pubmed">27930341</ArticleId></ArticleIdList></Reference><Reference><Citation>Okochi M, Tagami S, Yanagida K, Takami M, Kodama TS, Mori K et al. &#x3b3;-secretase modulators and presenilin 1 mutants act differently on presenilin/&#x3b3;-secretase function to cleave A&#x3b2;42 and A&#x3b2;43. Cell Rep 2013; 3: 42&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">23291095</ArticleId></ArticleIdList></Reference><Reference><Citation>Ch&#xe1;vez-Guti&#xe9;rrez L, Bammens L, Benilova I, Vandersteen A, Benurwar M, Borgers M et al. The mechanism of &#x3b3;-secretase dysfunction in familial Alzheimer disease. The EMBO journal 2012; 31: 2261&#x2013;2274.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3364747</ArticleId><ArticleId IdType="pubmed">22505025</ArticleId></ArticleIdList></Reference><Reference><Citation>Karch CM, Hern&#xe1;ndez D, Wang J-C, Marsh J, Hewitt AW, Hsu S et al. Human fibroblast and stem cell resource from the Dominantly Inherited Alzheimer Network. Alzheimer&#x2019;s research &amp; therapy 2018; 10: 1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6060509</ArticleId><ArticleId IdType="pubmed">30045758</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagomarsino VN, Pearse II RV, Liu L, Hsieh Y-C, Fernandez MA, Vinton EA et al. Stem cell-derived neurons reflect features of protein networks, neuropathology, and cognitive outcome of their aged human donors. Neuron 2021;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8571042</ArticleId><ArticleId IdType="pubmed">34473944</ArticleId></ArticleIdList></Reference><Reference><Citation>Agholme L, Clarin M, Gkanatsiou E, Kettunen P, Chebli J, Brinkmalm G et al. Low-dose &#x3b3;-secretase inhibition increases secretion of A&#x3b2; peptides and intracellular oligomeric A&#x3b2;. Molecular and Cellular Neuroscience 2017; 85: 211&#x2013;219.</Citation><ArticleIdList><ArticleId IdType="pubmed">29104140</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore BD, Martin J, de Mena L, Sanchez J, Cruz PE, Ceballos-Diaz C et al. Short A&#x3b2; peptides attenuate A&#x3b2;42 toxicity in vivo. Journal of Experimental Medicine 2018; 215: 283&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5748850</ArticleId><ArticleId IdType="pubmed">29208777</ArticleId></ArticleIdList></Reference><Reference><Citation>Kounnas MZ, Danks AM, Cheng S, Tyree C, Ackerman E, Zhang X et al. Modulation of &#x3b3;-secretase reduces &#x3b2;-amyloid deposition in a transgenic mouse model of Alzheimer&#x2019;s disease. Neuron 2010; 67: 769&#x2013;780.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2947312</ArticleId><ArticleId IdType="pubmed">20826309</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhattarai S, Liu L, Wolfe MS. Discovery of aryl aminothiazole &#x3b3;-secretase modulators with novel effects on amyloid &#x3b2;-peptide production. bioRxiv 2021;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9759287</ArticleId><ArticleId IdType="pubmed">34767913</ArticleId></ArticleIdList></Reference><Reference><Citation>Kakuda N, Yamaguchi H, Akazawa K, Hata S, Suzuki T, Hatsuta H et al. &#x3b3;-Secretase activity is associated with Braak Senile Plaque stages. Am J Pathol 2020;</Citation><ArticleIdList><ArticleId IdType="pubmed">32201261</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura M, Nakamura S-i, Kimura N, Liu L, Suzuki T, Tooyama I. Age-related modulation of &#x3b3;-secretase activity in non-human primate brains. Journal of Neurochemistry 2012; 123: 21&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">22817324</ArticleId></ArticleIdList></Reference><Reference><Citation>Szaruga M, Veugelen S, Benurwar M, Lismont S, Sepulveda-Falla D, Lleo A et al. Qualitative changes in human &#x3b3;-secretase underlie familial Alzheimer&#x2019;s disease. Journal of Experimental Medicine 2015; 212: 2003&#x2013;2013.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4647268</ArticleId><ArticleId IdType="pubmed">26481686</ArticleId></ArticleIdList></Reference><Reference><Citation>Kakuda N, Miyasaka T, Iwasaki N, Nirasawa T, Wada-Kakuda S, Takahashi-Fujigasaki J et al. Distinct deposition of amyloid-&#x3b2; species in brains with Alzheimer&#x2019;s disease pathology visualized with MALDI imaging mass spectrometry. Acta neuropathologica communications 2017; 5: 1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5641992</ArticleId><ArticleId IdType="pubmed">29037261</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S, Janelidze S, Stomrud E, Zetterberg H, Karl J, Zink K et al. Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease-Related &#x3b2;-Amyloid Status. JAMA Neurol 2019;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6593637</ArticleId><ArticleId IdType="pubmed">31233127</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindler SE, Bollinger JG, Ovod V, Mawuenyega KG, Li Y, Gordon BA et al. High-precision plasma &#x3b2;-amyloid 42/40 predicts current and future brain amyloidosis. Neurology 2019; 10.1212/WNL.0000000000008081.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000008081</ArticleId><ArticleId IdType="pmc">PMC6946467</ArticleId><ArticleId IdType="pubmed">31371569</ArticleId></ArticleIdList></Reference><Reference><Citation>West T, Kirmess KM, Meyer MR, Holubasch MS, Knapik SS, Hu Y et al. A blood-based diagnostic test incorporating plasma A&#x3b2;42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis. Molecular neurodegeneration 2021; 16: 1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8088704</ArticleId><ArticleId IdType="pubmed">33933117</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze S, Pannee J, Mikulskis A, Chiao P, Zetterberg H, Blennow K et al. Concordance Between Different Amyloid Immunoassays and Visual Amyloid Positron Emission Tomographic Assessment. JAMA Neurol 2017; 74: 1492&#x2013;1501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5822196</ArticleId><ArticleId IdType="pubmed">29114726</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze S, Zetterberg H, Mattsson N, Palmqvist S, Vanderstichele H, Lindberg O et al. CSF A&#x3b2;42/A&#x3b2;40 and A&#x3b2;42/A&#x3b2;38 ratios: better diagnostic markers of Alzheimer disease. Annals of clinical and translational neurology 2016; 3: 154&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4774260</ArticleId><ArticleId IdType="pubmed">27042676</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S, Mattsson N, Hansson O, Initiative ADN. Cerebrospinal fluid analysis detects cerebral amyloid-&#x3b2; accumulation earlier than positron emission tomography. Brain 2016; 139: 1226&#x2013;1236.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4806222</ArticleId><ArticleId IdType="pubmed">26936941</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35296861</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>15</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>603</Volume><Issue>7902</Issue><PubDate><Year>2022</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Reproducible brain-wide association studies require thousands of individuals.</ArticleTitle><Pagination><StartPage>654</StartPage><EndPage>660</EndPage><MedlinePgn>654-660</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41586-022-04492-9</ELocationID><Abstract><AbstractText>Magnetic resonance imaging (MRI) has transformed our understanding of the human brain through well-replicated mapping of abilities to specific structures (for example, lesion studies) and functions<sup>1-3</sup> (for example, task functional MRI (fMRI)). Mental health research and care have yet to realize similar advances from MRI. A primary challenge has been replicating associations between inter-individual differences in brain structure&#xa0;or&#xa0;function and complex cognitive or mental health phenotypes (brain-wide association studies (BWAS)). Such BWAS have typically relied on sample sizes appropriate for classical brain mapping<sup>4</sup> (the median neuroimaging study sample size is about 25), but potentially too small for capturing reproducible brain-behavioural phenotype associations<sup>5,6</sup>. Here we used three of the largest neuroimaging datasets currently available-with a total sample size of around 50,000 individuals-to quantify BWAS effect sizes and reproducibility as a function of sample size. BWAS associations were smaller than previously thought, resulting in statistically underpowered studies, inflated effect sizes and replication failures at typical sample sizes. As sample sizes grew into the thousands, replication rates began to improve and effect size inflation decreased. More robust BWAS effects were detected for functional MRI (versus structural), cognitive tests (versus mental health questionnaires) and multivariate methods (versus univariate). Smaller than expected brain-phenotype associations and variability across population subsamples can explain widespread BWAS replication failures. In contrast to non-BWAS approaches with larger effects (for example, lesions, interventions and within-person), BWAS reproducibility requires samples with thousands of individuals.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s), under exclusive licence to Springer Nature Limited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Marek</LastName><ForeName>Scott</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-0032-9052</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, St Louis, MO, USA. smarek@wustl.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Tervo-Clemmens</LastName><ForeName>Brenden</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-9557-1126</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. btervo-clemmens@mgh.harvard.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychology, University of Pittsburgh, Pittsburgh, PA, USA. btervo-clemmens@mgh.harvard.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calabro</LastName><ForeName>Finnegan J</ForeName><Initials>FJ</Initials><Identifier Source="ORCID">0000-0002-8092-3942</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Bioengineering, University of Pittsburgh, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montez</LastName><ForeName>David F</ForeName><Initials>DF</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kay</LastName><ForeName>Benjamin P</ForeName><Initials>BP</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hatoum</LastName><ForeName>Alexander S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Donohue</LastName><ForeName>Meghan Rose</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Foran</LastName><ForeName>William</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Ryland L</ForeName><Initials>RL</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hendrickson</LastName><ForeName>Timothy J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>University of Minnesota Informatics Institute, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malone</LastName><ForeName>Stephen M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Department of Psychology, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kandala</LastName><ForeName>Sridhar</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feczko</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Masonic Institute for the Developing Brain, University of Minnesota Medical School, Minneapolis, MN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, University of Minnesota Medical School, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miranda-Dominguez</LastName><ForeName>Oscar</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Masonic Institute for the Developing Brain, University of Minnesota Medical School, Minneapolis, MN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, University of Minnesota Medical School, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graham</LastName><ForeName>Alice M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Oregon Health and Science University, Portland, OR, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Earl</LastName><ForeName>Eric A</ForeName><Initials>EA</Initials><Identifier Source="ORCID">0000-0001-5512-0083</Identifier><AffiliationInfo><Affiliation>Masonic Institute for the Developing Brain, University of Minnesota Medical School, Minneapolis, MN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Oregon Health and Science University, Portland, OR, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perrone</LastName><ForeName>Anders J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Masonic Institute for the Developing Brain, University of Minnesota Medical School, Minneapolis, MN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Oregon Health and Science University, Portland, OR, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cordova</LastName><ForeName>Michaela</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Oregon Health and Science University, Portland, OR, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doyle</LastName><ForeName>Olivia</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0003-3957-2949</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Oregon Health and Science University, Portland, OR, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moore</LastName><ForeName>Lucille A</ForeName><Initials>LA</Initials><Identifier Source="ORCID">0000-0002-7665-2713</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Oregon Health and Science University, Portland, OR, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Conan</LastName><ForeName>Gregory M</ForeName><Initials>GM</Initials><AffiliationInfo><Affiliation>Masonic Institute for the Developing Brain, University of Minnesota Medical School, Minneapolis, MN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Oregon Health and Science University, Portland, OR, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uriarte</LastName><ForeName>Johnny</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Oregon Health and Science University, Portland, OR, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Snider</LastName><ForeName>Kathy</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Oregon Health and Science University, Portland, OR, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lynch</LastName><ForeName>Benjamin J</ForeName><Initials>BJ</Initials><Identifier Source="ORCID">0000-0001-7310-2022</Identifier><AffiliationInfo><Affiliation>Masonic Institute for the Developing Brain, University of Minnesota Medical School, Minneapolis, MN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Minnesota Supercomputing Institute, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilgenbusch</LastName><ForeName>James C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Masonic Institute for the Developing Brain, University of Minnesota Medical School, Minneapolis, MN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Minnesota Supercomputing Institute, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pengo</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>University of Minnesota Informatics Institute, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tam</LastName><ForeName>Angela</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-6752-5707</Identifier><AffiliationInfo><Affiliation>Department of Electrical and Computer Engineering, National University of Singapore, Singapore, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Sleep and Cognition, National University of Singapore, Singapore, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Translational MR Research, National University of Singapore, Singapore, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>N.1 Institute for Health, Institute for Digital Medicine, National University of Singapore, Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Jianzhong</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Electrical and Computer Engineering, National University of Singapore, Singapore, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Sleep and Cognition, National University of Singapore, Singapore, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Translational MR Research, National University of Singapore, Singapore, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>N.1 Institute for Health, Institute for Digital Medicine, National University of Singapore, Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Newbold</LastName><ForeName>Dillan J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Annie</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seider</LastName><ForeName>Nicole A</ForeName><Initials>NA</Initials><Identifier Source="ORCID">0000-0003-1511-1515</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van</LastName><ForeName>Andrew N</ForeName><Initials>AN</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Engineering, Washington University in St Louis, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Metoki</LastName><ForeName>Athanasia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chauvin</LastName><ForeName>Roselyne J</ForeName><Initials>RJ</Initials><Identifier Source="ORCID">0000-0001-5786-4705</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laumann</LastName><ForeName>Timothy O</ForeName><Initials>TO</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greene</LastName><ForeName>Deanna J</ForeName><Initials>DJ</Initials><Identifier Source="ORCID">0000-0002-0739-7771</Identifier><AffiliationInfo><Affiliation>Department of Cognitive Science, University of California San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petersen</LastName><ForeName>Steven E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Engineering, Washington University in St Louis, St Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurological Surgery, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychological and Brain Sciences, Washington University in St Louis, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garavan</LastName><ForeName>Hugh</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Vermont, Burlington, VT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Wesley K</ForeName><Initials>WK</Initials><AffiliationInfo><Affiliation>Division of Biostatistics, University of California San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nichols</LastName><ForeName>Thomas E</ForeName><Initials>TE</Initials><Identifier Source="ORCID">0000-0002-4516-5103</Identifier><AffiliationInfo><Affiliation>Oxford Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, Nuffield Department of Population Health, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yeo</LastName><ForeName>B T Thomas</ForeName><Initials>BTT</Initials><AffiliationInfo><Affiliation>Department of Electrical and Computer Engineering, National University of Singapore, Singapore, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Sleep and Cognition, National University of Singapore, Singapore, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Translational MR Research, National University of Singapore, Singapore, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>N.1 Institute for Health, Institute for Digital Medicine, National University of Singapore, Singapore, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Integrative Sciences and Engineering Programme, National University of Singapore, Singapore, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Charlestown, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barch</LastName><ForeName>Deanna M</ForeName><Initials>DM</Initials><Identifier Source="ORCID">0000-0003-1693-8506</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychological and Brain Sciences, Washington University in St Louis, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luna</LastName><ForeName>Beatriz</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Psychology, University of Pittsburgh, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fair</LastName><ForeName>Damien A</ForeName><Initials>DA</Initials><Identifier Source="ORCID">0000-0001-8602-393X</Identifier><AffiliationInfo><Affiliation>Masonic Institute for the Developing Brain, University of Minnesota Medical School, Minneapolis, MN, USA. faird@umn.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, University of Minnesota Medical School, Minneapolis, MN, USA. faird@umn.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Child Development, University of Minnesota Medical School, Minneapolis, MN, USA. faird@umn.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dosenbach</LastName><ForeName>Nico U F</ForeName><Initials>NUF</Initials><Identifier Source="ORCID">0000-0002-6876-7078</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St Louis, MO, USA. ndosenbach@wustl.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Engineering, Washington University in St Louis, St Louis, MO, USA. ndosenbach@wustl.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology, Washington University School of Medicine, St Louis, MO, USA. ndosenbach@wustl.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Occupational Therapy, Washington University School of Medicine, St Louis, MO, USA. ndosenbach@wustl.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Washington University School of Medicine, St Louis, MO, USA. ndosenbach@wustl.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K12 DA043490</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 DA041147</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 DA041120</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UE5 NS090978</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AA026919</GrantID><Acronym>AA</Acronym><Agency>NIAAA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 NS123345</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 DA041123</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 DA041117</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 DA041148</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F31 NS110332</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 HD103525</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R25 NS090978</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 NS088590</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 NS022343</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MC_QA137853</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>U01 DA041093</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 DA051038</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 MH100019</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 DA041134</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 DA041022</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 MH104592</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K99 MH121518</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 DA041156</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 DA041025</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R25 MH112473</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 MH125023</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH096773</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 DA050989</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 MH091657</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 DA041089</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 DA050988</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 DA041106</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 DA007261</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 DA041028</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 DA041048</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 NS115672</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_PC_17228</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R44 MH121276</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH115357</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R44 MH122066</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R44 MH124567</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002345</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 DA041174</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R00 MH121518</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>03</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2022 Mar;603(7903):777-778. doi: 10.1038/d41586-022-00767-3.</RefSource><PMID Version="1">35301503</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2022 Apr;604(7905):230-231. doi: 10.1038/d41586-022-00971-1.</RefSource><PMID Version="1">35388158</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Neuron. 2022 May 4;110(9):1446-1449. doi: 10.1016/j.neuron.2022.04.018.</RefSource><PMID Version="1">35512638</PMID></CommentsCorrections><CommentsCorrections RefType="ErratumIn"><RefSource>Nature. 2022 May;605(7911):E11. doi: 10.1038/s41586-022-04692-3.</RefSource><PMID Version="1">35534626</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>AJR Am J Roentgenol. 2023 Jan;220(1):149. doi: 10.2214/AJR.22.28026.</RefSource><PMID Version="1">35674354</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Neurosci. 2022 Jul;25(7):835-837. doi: 10.1038/s41593-022-01110-9.</RefSource><PMID Version="1">35710985</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Med. 2022 Aug 12;3(8):526-531. doi: 10.1016/j.medj.2022.07.002.</RefSource><PMID Version="1">35963233</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2022 Aug;608(7924):647. doi: 10.1038/d41586-022-02283-w.</RefSource><PMID Version="1">36002501</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2023 Mar;615(7951):E8-E12. doi: 10.1038/s41586-023-05746-w.</RefSource><PMID Version="1">36890374</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2023 Mar;615(7951):E4-E7. doi: 10.1038/s41586-023-05745-x.</RefSource><PMID Version="1">36890392</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="Y">Brain</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="Y">Brain Mapping</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066264" MajorTopicYN="N">Datasets as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="Y">Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059906" MajorTopicYN="N">Neuroimaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>E.A.E., D.A.F and N.U.F.D. have a financial interest in NOUS Imaging Inc. and may financially benefit if the company is successful in marketing FIRMM motion-monitoring software products. O.M.-D., E.A.E., A.N.V., D.A.F. and N.U.F.D. may receive royalty income based on FIRMM technology developed at Washington University School of Medicine and Oregon Health and Sciences University and licensed to NOUS Imaging Inc. D.A.F. and N.U.F.D. are co-founders of NOUS Imaging Inc. and E.A.E. is a former employee of NOUS Imaging. These potential conflicts of interest have been reviewed and are managed by Washington University School of Medicine, Oregon Health and Sciences University and the University of Minnesota. The other authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>8</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>1</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>17</Day><Hour>5</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>3</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35296861</ArticleId><ArticleId IdType="mid">NIHMS1793416</ArticleId><ArticleId IdType="pmc">PMC8991999</ArticleId><ArticleId IdType="doi">10.1038/s41586-022-04492-9</ArticleId><ArticleId IdType="pii">10.1038/s41586-022-04492-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Raichle ME, et al. A default mode of brain function. Proc. Natl Acad. Sci. USA. 2001;98:676&#x2013;682. doi: 10.1073/pnas.98.2.676.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.98.2.676</ArticleId><ArticleId IdType="pmc">PMC14647</ArticleId><ArticleId IdType="pubmed">11209064</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner AD, et al. Building memories: remembering and forgetting of verbal experiences as predicted by brain activity. Science. 1998;281:1188&#x2013;1191. doi: 10.1126/science.281.5380.1188.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.281.5380.1188</ArticleId><ArticleId IdType="pubmed">9712582</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, et al. Detection of cortical activation during averaged single trials of a cognitive task using functional magnetic resonance imaging. Proc. Natl Acad. Sci. USA. 1996;93:14878&#x2013;14883. doi: 10.1073/pnas.93.25.14878.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.93.25.14878</ArticleId><ArticleId IdType="pmc">PMC26230</ArticleId><ArticleId IdType="pubmed">8962149</ArticleId></ArticleIdList></Reference><Reference><Citation>Szucs D, Ioannidis JP. Sample size evolution in neuroimaging research: an evaluation of highly-cited studies (1990-2012) and of latest practices (2017-2018) in high-impact journals. Neuroimage. 2020;221:117164. doi: 10.1016/j.neuroimage.2020.117164.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2020.117164</ArticleId><ArticleId IdType="pubmed">32679253</ArticleId></ArticleIdList></Reference><Reference><Citation>Button KS, et al. Power failure: why small sample size undermines the reliability of neuroscience. Nat. Rev. Neurosci. 2013;14:365&#x2013;376. doi: 10.1038/nrn3475.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn3475</ArticleId><ArticleId IdType="pubmed">23571845</ArticleId></ArticleIdList></Reference><Reference><Citation>Yarkoni T. Big correlations in little studies: inflated fMRI correlations reflect low statistical power&#x2014;Commentary on Vul et al. (2009) Perspect. Psychol. Sci. 2009;4:294&#x2013;298. doi: 10.1111/j.1745-6924.2009.01127.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1745-6924.2009.01127.x</ArticleId><ArticleId IdType="pubmed">26158966</ArticleId></ArticleIdList></Reference><Reference><Citation>Poldrack RA, et al. Scanning the horizon: towards transparent and reproducible neuroimaging research. Nat. Rev. Neurosci. 2017;18:115&#x2013;126. doi: 10.1038/nrn.2016.167.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn.2016.167</ArticleId><ArticleId IdType="pmc">PMC6910649</ArticleId><ArticleId IdType="pubmed">28053326</ArticleId></ArticleIdList></Reference><Reference><Citation>Masouleh SK, Eickhoff SB, Hoffstaedter F, Genon S, Alzheimer&#x2019;s Disease Neuroimaging Initiative Empirical examination of the replicability of associations between brain structure and psychological variables. eLife. 2019;8:e43464. doi: 10.7554/eLife.43464.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.43464</ArticleId><ArticleId IdType="pmc">PMC6483597</ArticleId><ArticleId IdType="pubmed">30864950</ArticleId></ArticleIdList></Reference><Reference><Citation>Dinga R, et al. Evaluating the evidence for biotypes of depression: Methodological replication and extension of Drysdale et al. (2017) Neuroimage Clin. 2019;22:101796. doi: 10.1016/j.nicl.2019.101796.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nicl.2019.101796</ArticleId><ArticleId IdType="pmc">PMC6543446</ArticleId><ArticleId IdType="pubmed">30935858</ArticleId></ArticleIdList></Reference><Reference><Citation>Boekel W, et al. A purely confirmatory replication study of structural brain&#x2013;behavior correlations. Cortex. 2015;66:115&#x2013;133. doi: 10.1016/j.cortex.2014.11.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cortex.2014.11.019</ArticleId><ArticleId IdType="pubmed">25684445</ArticleId></ArticleIdList></Reference><Reference><Citation>Nosek, B. A., Cohoon, J., Kidwell, M. &amp; Spies, J. R. Estimating the reproducibility of psychological science. Preprint at 10.31219/osf.io/447b3 (2016).</Citation></Reference><Reference><Citation>Visscher PM, et al. 10 years of GWAS discovery: biology, function, and translation. Am. J. Hum. Genet. 2017;101:5&#x2013;22. doi: 10.1016/j.ajhg.2017.06.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2017.06.005</ArticleId><ArticleId IdType="pmc">PMC5501872</ArticleId><ArticleId IdType="pubmed">28686856</ArticleId></ArticleIdList></Reference><Reference><Citation>Begley CG, Ellis LM. Drug development: raise standards for preclinical cancer research. Nature. 2012;483:531&#x2013;533. doi: 10.1038/483531a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/483531a</ArticleId><ArticleId IdType="pubmed">22460880</ArticleId></ArticleIdList></Reference><Reference><Citation>Botvinik-Nezer R, et al. Variability in the analysis of a single neuroimaging dataset by many teams. Nature. 2020;582:84&#x2013;88. doi: 10.1038/s41586-020-2314-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2314-9</ArticleId><ArticleId IdType="pmc">PMC7771346</ArticleId><ArticleId IdType="pubmed">32483374</ArticleId></ArticleIdList></Reference><Reference><Citation>Nuzzo R. Scientific method: Statistical errors. Nature. 2014;506:150&#x2013;152. doi: 10.1038/506150a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/506150a</ArticleId><ArticleId IdType="pubmed">24522584</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawkins DM. The problem of overfitting. J. Chem. Inf. Comput. Sci. 2004;44:1&#x2013;12. doi: 10.1021/ci0342472.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ci0342472</ArticleId><ArticleId IdType="pubmed">14741005</ArticleId></ArticleIdList></Reference><Reference><Citation>Bishop D. How scientists can stop fooling themselves over statistics. Nature. 2020;584:9. doi: 10.1038/d41586-020-02275-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-020-02275-8</ArticleId><ArticleId IdType="pubmed">32747780</ArticleId></ArticleIdList></Reference><Reference><Citation>Munaf&#xf2; MR, et al. A manifesto for reproducible science. Nat. Hum. Behav. 2017;1:0021. doi: 10.1038/s41562-016-0021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41562-016-0021</ArticleId><ArticleId IdType="pmc">PMC7610724</ArticleId><ArticleId IdType="pubmed">33954258</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xf6;nbrodt FD, Perugini M. At what sample size do correlations stabilize? J. Res. Pers. 2013;47:609&#x2013;612. doi: 10.1016/j.jrp.2013.05.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jrp.2013.05.009</ArticleId></ArticleIdList></Reference><Reference><Citation>Varoquaux G. Cross-validation failure: small sample sizes lead to large error bars. Neuroimage. 2018;180:68&#x2013;77. doi: 10.1016/j.neuroimage.2017.06.061.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2017.06.061</ArticleId><ArticleId IdType="pubmed">28655633</ArticleId></ArticleIdList></Reference><Reference><Citation>Yarkoni T. Big correlations in little studies: Inflated fMRI correlations reflect low statistical power&#x2014;Commentary on Vul et al. (2009) Perspect. Psychol. Sci. 2009;4:294&#x2013;298. doi: 10.1111/j.1745-6924.2009.01127.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1745-6924.2009.01127.x</ArticleId><ArticleId IdType="pubmed">26158966</ArticleId></ArticleIdList></Reference><Reference><Citation>Button KS, et al. Confidence and precision increase with high statistical power. Nat. Rev. Neurosci. 2013;14:585&#x2013;586. doi: 10.1038/nrn3475-c4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn3475-c4</ArticleId><ArticleId IdType="pubmed">23820778</ArticleId></ArticleIdList></Reference><Reference><Citation>Casey BJ, et al. The Adolescent Brain Cognitive Development (ABCD) study: imaging acquisition across 21 sites. Dev. Cogn. Neurosci. 2018;32:43&#x2013;54. doi: 10.1016/j.dcn.2018.03.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dcn.2018.03.001</ArticleId><ArticleId IdType="pmc">PMC5999559</ArticleId><ArticleId IdType="pubmed">29567376</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Essen DC, et al. The WU-Minn Human Connectome Project: an overview. NeuroImage. 2013;80:62&#x2013;79. doi: 10.1016/j.neuroimage.2013.05.041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2013.05.041</ArticleId><ArticleId IdType="pmc">PMC3724347</ArticleId><ArticleId IdType="pubmed">23684880</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudlow C, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. 2015;12:e1001779. doi: 10.1371/journal.pmed.1001779.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1001779</ArticleId><ArticleId IdType="pmc">PMC4380465</ArticleId><ArticleId IdType="pubmed">25826379</ArticleId></ArticleIdList></Reference><Reference><Citation>Greene AS, Gao S, Scheinost D, Constable RT. Task-induced brain state manipulation improves prediction of individual traits. Nat. Commun. 2018;9:2807. doi: 10.1038/s41467-018-04920-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-04920-3</ArticleId><ArticleId IdType="pmc">PMC6052101</ArticleId><ArticleId IdType="pubmed">30022026</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaarani B, et al. Baseline brain function in the preadolescents of the ABCD Study. Nat. Neurosci. 2021;24:1176&#x2013;1186. doi: 10.1038/s41593-021-00867-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-021-00867-9</ArticleId><ArticleId IdType="pmc">PMC8947197</ArticleId><ArticleId IdType="pubmed">34099922</ArticleId></ArticleIdList></Reference><Reference><Citation>Heaton RK, et al. Reliability and validity of composite scores from the NIH Toolbox Cognition Battery in adults. J. Int. Neuropsychol. Soc. 2014;20:588&#x2013;598. doi: 10.1017/S1355617714000241.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S1355617714000241</ArticleId><ArticleId IdType="pmc">PMC4103963</ArticleId><ArticleId IdType="pubmed">24960398</ArticleId></ArticleIdList></Reference><Reference><Citation>Achenbach, T. M. &amp; Rescorla, L. Manual for the ASEBA School-age Forms &amp; Profiles: An Integrated System of Multi-informant Assessment (ASEBA, 2001).</Citation></Reference><Reference><Citation>Kharabian Masouleh S, et al. Influence of processing pipeline on cortical thickness measurement. Cereb. Cortex. 2020;30:5014&#x2013;5027. doi: 10.1093/cercor/bhaa097.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cercor/bhaa097</ArticleId><ArticleId IdType="pmc">PMC7391418</ArticleId><ArticleId IdType="pubmed">32377664</ArticleId></ArticleIdList></Reference><Reference><Citation>Erdfelder E, Faul F, Buchner A. GPOWER: A general power analysis program. Behav. Res. Methods Instrum. Comput. 1996;28:1&#x2013;11. doi: 10.3758/BF03203630.</Citation><ArticleIdList><ArticleId IdType="doi">10.3758/BF03203630</ArticleId></ArticleIdList></Reference><Reference><Citation>Ioannidis JPA, Munaf&#xf2; MR, Fusar-Poli P, Nosek BA, David SP. Publication and other reporting biases in cognitive sciences: detection, prevalence, and prevention. Trends Cogn. Sci. 2014;18:235&#x2013;241. doi: 10.1016/j.tics.2014.02.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tics.2014.02.010</ArticleId><ArticleId IdType="pmc">PMC4078993</ArticleId><ArticleId IdType="pubmed">24656991</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon EM, et al. Precision functional mapping of individual human brains. Neuron. 2017;95:791&#x2013;807.e7. doi: 10.1016/j.neuron.2017.07.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2017.07.011</ArticleId><ArticleId IdType="pmc">PMC5576360</ArticleId><ArticleId IdType="pubmed">28757305</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciric R, et al. Benchmarking of participant-level confound regression strategies for the control of motion artifact in studies of functional connectivity. NeuroImage. 2017;154:174&#x2013;187. doi: 10.1016/j.neuroimage.2017.03.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2017.03.020</ArticleId><ArticleId IdType="pmc">PMC5483393</ArticleId><ArticleId IdType="pubmed">28302591</ArticleId></ArticleIdList></Reference><Reference><Citation>Dosenbach NUF, et al. Real-time motion analytics during brain MRI improve data quality and reduce costs. Neuroimage. 2017;161:80&#x2013;93. doi: 10.1016/j.neuroimage.2017.08.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2017.08.025</ArticleId><ArticleId IdType="pmc">PMC5731481</ArticleId><ArticleId IdType="pubmed">28803940</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanwisher N, Stanley D, Harris A. The fusiform face area is selective for faces not animals. NeuroReport. 1999;10:183&#x2013;187. doi: 10.1097/00001756-199901180-00035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00001756-199901180-00035</ArticleId><ArticleId IdType="pubmed">10094159</ArticleId></ArticleIdList></Reference><Reference><Citation>Pritschet L, et al. Functional reorganization of brain networks across the human menstrual cycle. Neuroimage. 2020;220:117091. doi: 10.1016/j.neuroimage.2020.117091.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2020.117091</ArticleId><ArticleId IdType="pubmed">32621974</ArticleId></ArticleIdList></Reference><Reference><Citation>Laumann TO, et al. Brain network reorganisation in an adolescent after bilateral perinatal strokes. Lancet Neurol. 2021;20:255&#x2013;256. doi: 10.1016/S1474-4422(21)00062-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(21)00062-4</ArticleId><ArticleId IdType="pubmed">33743230</ArticleId></ArticleIdList></Reference><Reference><Citation>Kay KN, Naselaris T, Prenger RJ, Gallant JL. Identifying natural images from human brain activity. Nature. 2008;452:352&#x2013;355. doi: 10.1038/nature06713.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature06713</ArticleId><ArticleId IdType="pmc">PMC3556484</ArticleId><ArticleId IdType="pubmed">18322462</ArticleId></ArticleIdList></Reference><Reference><Citation>Newbold DJ, et al. Plasticity and spontaneous activity pulses in disused human brain circuits. Neuron. 2020;107:580&#x2013;589.e6. doi: 10.1016/j.neuron.2020.05.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2020.05.007</ArticleId><ArticleId IdType="pmc">PMC7419711</ArticleId><ArticleId IdType="pubmed">32778224</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith SM, Nichols TE. Statistical challenges in &#x2018;big data&#x2019; human neuroimaging. Neuron. 2018;97:263&#x2013;268. doi: 10.1016/j.neuron.2017.12.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2017.12.018</ArticleId><ArticleId IdType="pubmed">29346749</ArticleId></ArticleIdList></Reference><Reference><Citation>Border R, et al. No support for historical candidate gene or candidate gene-by-interaction hypotheses for major depression across multiple large samples. Am. J. Psychiatry. 2019;176:376&#x2013;387. doi: 10.1176/appi.ajp.2018.18070881.</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/appi.ajp.2018.18070881</ArticleId><ArticleId IdType="pmc">PMC6548317</ArticleId><ArticleId IdType="pubmed">30845820</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JJ, et al. Gene discovery and polygenic prediction from a genome-wide association study of educational attainment in 1.1 million individuals. Nat. Genet. 2018;50:1112&#x2013;1121. doi: 10.1038/s41588-018-0147-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-018-0147-3</ArticleId><ArticleId IdType="pmc">PMC6393768</ArticleId><ArticleId IdType="pubmed">30038396</ArticleId></ArticleIdList></Reference><Reference><Citation>Kundu P, Inati SJ, Evans JW, Luh W-M, Bandettini PA. Differentiating BOLD and non-BOLD signals in fMRI time series using multi-echo EPI. Neuroimage. 2012;60:1759&#x2013;1770. doi: 10.1016/j.neuroimage.2011.12.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2011.12.028</ArticleId><ArticleId IdType="pmc">PMC3350785</ArticleId><ArticleId IdType="pubmed">22209809</ArticleId></ArticleIdList></Reference><Reference><Citation>Vizioli L, et al. Lowering the thermal noise barrier in functional brain mapping with magnetic resonance imaging. Nat. Commun. 2021;12:5181. doi: 10.1038/s41467-021-25431-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-25431-8</ArticleId><ArticleId IdType="pmc">PMC8405721</ArticleId><ArticleId IdType="pubmed">34462435</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiffman S, Stone AA, Hufford MR. Ecological momentary assessment. Ann. Rev. Clin. Psychol. 2008;4:1&#x2013;32. doi: 10.1146/annurev.clinpsy.3.022806.091415.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.clinpsy.3.022806.091415</ArticleId><ArticleId IdType="pubmed">18509902</ArticleId></ArticleIdList></Reference><Reference><Citation>NOT-OD-07-088: policy for sharing of data obtained in NIH supported or conducted genome-wide association studies (GWAS). National Institutes of Healthhttps://grants.nih.gov/grants/guide/notice-files/NOT-OD-07-088.html (2007).</Citation></Reference><Reference><Citation>Buzs&#xe1;ki G. The brain&#x2013;cognitive behavior problem: a retrospective. eNeuro. 2020;7:ENEURO.0069&#x2013;20.2020. doi: 10.1523/ENEURO.0069-20.2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/ENEURO.0069-20.2020</ArticleId><ArticleId IdType="pmc">PMC7415918</ArticleId><ArticleId IdType="pubmed">32769166</ArticleId></ArticleIdList></Reference><Reference><Citation>Errington TM, Denis A, Perfito N, Iorns E, Nosek BA. Challenges for assessing replicability in preclinical cancer biology. eLife. 2021;10:e67995. doi: 10.7554/eLife.67995.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.67995</ArticleId><ArticleId IdType="pmc">PMC8651289</ArticleId><ArticleId IdType="pubmed">34874008</ArticleId></ArticleIdList></Reference><Reference><Citation>Patil P, Peng RD, Leek JT. What should researchers expect when they replicate studies? A statistical view of replicability in psychological science. Perspect. Psychol. Sci. 2016;11:539&#x2013;544. doi: 10.1177/1745691616646366.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1745691616646366</ArticleId><ArticleId IdType="pmc">PMC4968573</ArticleId><ArticleId IdType="pubmed">27474140</ArticleId></ArticleIdList></Reference><Reference><Citation>Feczko, E. et al. Adolescent Brain Cognitive Development (ABCD) community MRI collection and utilities. Preprint at 10.1101/2021.07.09.451638 (2021).</Citation></Reference><Reference><Citation>Volkow ND, et al. The conception of the ABCD Study: from substance use to a broad NIH collaboration. Dev. Cogn. Neurosci. 2018;32:4&#x2013;7. doi: 10.1016/j.dcn.2017.10.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dcn.2017.10.002</ArticleId><ArticleId IdType="pmc">PMC5893417</ArticleId><ArticleId IdType="pubmed">29051027</ArticleId></ArticleIdList></Reference><Reference><Citation>Power JD, Barnes KA, Snyder AZ, Schlaggar BL, Petersen SE. Spurious but systematic correlations in functional connectivity MRI networks arise from subject motion. Neuroimage. 2012;59:2142&#x2013;2154. doi: 10.1016/j.neuroimage.2011.10.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2011.10.018</ArticleId><ArticleId IdType="pmc">PMC3254728</ArticleId><ArticleId IdType="pubmed">22019881</ArticleId></ArticleIdList></Reference><Reference><Citation>Fair DA, et al. Correction of respiratory artifacts in MRI head motion estimates. Neuroimage. 2020;208:116400. doi: 10.1016/j.neuroimage.2019.116400.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2019.116400</ArticleId><ArticleId IdType="pmc">PMC7307712</ArticleId><ArticleId IdType="pubmed">31778819</ArticleId></ArticleIdList></Reference><Reference><Citation>Glasser MF, et al. The minimal preprocessing pipelines for the Human Connectome Project. Neuroimage. 2013;80:105&#x2013;124. doi: 10.1016/j.neuroimage.2013.04.127.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2013.04.127</ArticleId><ArticleId IdType="pmc">PMC3720813</ArticleId><ArticleId IdType="pubmed">23668970</ArticleId></ArticleIdList></Reference><Reference><Citation>Avants BB, et al. A reproducible evaluation of ANTs similarity metric performance in brain image registration. Neuroimage. 2011;54:2033&#x2013;2044. doi: 10.1016/j.neuroimage.2010.09.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2010.09.025</ArticleId><ArticleId IdType="pmc">PMC3065962</ArticleId><ArticleId IdType="pubmed">20851191</ArticleId></ArticleIdList></Reference><Reference><Citation>Dale AM, Fischl B, Sereno MI. Cortical surface-based analysis. NeuroImage. 1999;9:179&#x2013;194. doi: 10.1006/nimg.1998.0395.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/nimg.1998.0395</ArticleId><ArticleId IdType="pubmed">9931268</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenkinson M, Beckmann CF, Behrens TEJ, Woolrich MW, Smith SM. FSL. Neuroimage. 2012;62:782&#x2013;790. doi: 10.1016/j.neuroimage.2011.09.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2011.09.015</ArticleId><ArticleId IdType="pubmed">21979382</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcus DS, et al. Informatics and data mining tools and strategies for the human connectome project. Front. Neuroinform. 2011;5:4. doi: 10.3389/fninf.2011.00004.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fninf.2011.00004</ArticleId><ArticleId IdType="pmc">PMC3127103</ArticleId><ArticleId IdType="pubmed">21743807</ArticleId></ArticleIdList></Reference><Reference><Citation>Hallquist MN, Hwang K, Luna B. The nuisance of nuisance regression: spectral misspecification in a common approach to resting-state fMRI preprocessing reintroduces noise and obscures functional connectivity. Neuroimage. 2013;82:208&#x2013;225. doi: 10.1016/j.neuroimage.2013.05.116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2013.05.116</ArticleId><ArticleId IdType="pmc">PMC3759585</ArticleId><ArticleId IdType="pubmed">23747457</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon EM, et al. Generation and evaluation of a cortical area parcellation from resting-state correlations. Cereb. Cortex. 2016;26:288&#x2013;303. doi: 10.1093/cercor/bhu239.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cercor/bhu239</ArticleId><ArticleId IdType="pmc">PMC4677978</ArticleId><ArticleId IdType="pubmed">25316338</ArticleId></ArticleIdList></Reference><Reference><Citation>Seitzman BA, et al. A set of functionally-defined brain regions with improved representation of the subcortex and cerebellum. Neuroimage. 2020;206:116290. doi: 10.1016/j.neuroimage.2019.116290.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2019.116290</ArticleId><ArticleId IdType="pmc">PMC6981071</ArticleId><ArticleId IdType="pubmed">31634545</ArticleId></ArticleIdList></Reference><Reference><Citation>Marek S, et al. Identifying reproducible individual differences in childhood functional brain networks: an ABCD Study. Dev. Cogn. Neurosci. 2019;40:100706. doi: 10.1016/j.dcn.2019.100706.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dcn.2019.100706</ArticleId><ArticleId IdType="pmc">PMC6927479</ArticleId><ArticleId IdType="pubmed">31614255</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith SM, et al. A positive-negative mode of population covariation links brain connectivity, demographics and behavior. Nat. Neurosci. 2015;18:1565&#x2013;1567. doi: 10.1038/nn.4125.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4125</ArticleId><ArticleId IdType="pmc">PMC4625579</ArticleId><ArticleId IdType="pubmed">26414616</ArticleId></ArticleIdList></Reference><Reference><Citation>Barch DM, et al. Demographic, physical and mental health assessments in the adolescent brain and cognitive development study: rationale and description. Dev. Cogn. Neurosci. 2018;32:55&#x2013;66. doi: 10.1016/j.dcn.2017.10.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dcn.2017.10.010</ArticleId><ArticleId IdType="pmc">PMC5934320</ArticleId><ArticleId IdType="pubmed">29113758</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothman, K. Modern Epidemiology (Lippincott Williams &amp; Wilkins, 2016).</Citation></Reference><Reference><Citation>Gratton C, et al. Functional brain networks are dominated by stable group and individual factors, not cognitive or daily variation. Neuron. 2018;98:439&#x2013;452.e5. doi: 10.1016/j.neuron.2018.03.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2018.03.035</ArticleId><ArticleId IdType="pmc">PMC5912345</ArticleId><ArticleId IdType="pubmed">29673485</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Essen DC, et al. The Human Connectome Project: a data acquisition perspective. Neuroimage. 2012;62:2222&#x2013;2231. doi: 10.1016/j.neuroimage.2012.02.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2012.02.018</ArticleId><ArticleId IdType="pmc">PMC3606888</ArticleId><ArticleId IdType="pubmed">22366334</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller KL, et al. Multimodal population brain imaging in the UK Biobank prospective epidemiological study. Nat. Neurosci. 2016;19:1523&#x2013;1536. doi: 10.1038/nn.4393.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4393</ArticleId><ArticleId IdType="pmc">PMC5086094</ArticleId><ArticleId IdType="pubmed">27643430</ArticleId></ArticleIdList></Reference><Reference><Citation>Littlejohns TJ, et al. The UK Biobank imaging enhancement of 100,000 participants: raitonale, data collection, management and future directions. Nat. Commun. 2020;11:2624. doi: 10.1038/s41467-020-15948-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-15948-9</ArticleId><ArticleId IdType="pmc">PMC7250878</ArticleId><ArticleId IdType="pubmed">32457287</ArticleId></ArticleIdList></Reference><Reference><Citation>Barch DM, et al. Function in the human connectome: task-fMRI and individual differences in behavior. Neuroimage. 2013;80:169&#x2013;189. doi: 10.1016/j.neuroimage.2013.05.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2013.05.033</ArticleId><ArticleId IdType="pmc">PMC4011498</ArticleId><ArticleId IdType="pubmed">23684877</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35305339</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>04</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1474-4465</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>4</Issue><PubDate><Year>2022</Year><Month>Apr</Month></PubDate></JournalIssue><Title>The Lancet. Neurology</Title><ISOAbbreviation>Lancet Neurol</ISOAbbreviation></Journal><ArticleTitle>Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer's disease: a longitudinal observational study.</ArticleTitle><Pagination><StartPage>329</StartPage><EndPage>341</EndPage><MedlinePgn>329-341</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1474-4422(22)00027-8</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1474-4422(22)00027-8</ELocationID><Abstract><AbstractText Label="BACKGROUND">Therapeutic modulation of TREM2-dependent microglial function might provide an additional strategy to slow the progression of Alzheimer's disease. Although studies in animal models suggest that TREM2 is protective against Alzheimer's pathology, its effect on tau pathology and its potential beneficial role in people with Alzheimer's disease is still unclear. Our aim was to study associations between the dynamics of soluble TREM2, as a biomarker of TREM2 signalling, and amyloid &#x3b2; (A&#x3b2;) deposition, tau-related pathology, neuroimaging markers, and cognitive decline, during the progression of autosomal dominant Alzheimer's disease.</AbstractText><AbstractText Label="METHODS">We did a longitudinal analysis of data from the Dominantly Inherited Alzheimer Network (DIAN) observational study, which includes families with a history of autosomal dominant Alzheimer's disease. Participants aged over 18 years who were enrolled in DIAN between Jan 1, 2009, and July 31, 2019, were categorised as either carriers of pathogenic variants in PSEN1, PSEN2, and APP genes (n=155) or non-carriers (n=93). We measured amounts of cleaved soluble TREM2 using a novel immunoassay in CSF samples obtained every 2 years from participants who were asymptomatic (Clinical Dementia Rating [CDR]=0) and annually for those who were symptomatic (CDR&gt;0). CSF concentrations of A&#x3b2;40, A&#x3b2;42, total tau (t-tau), and tau phosphorylated on threonine 181 (p-tau) were measured by validated immunoassays. Predefined neuroimaging measurements were total cortical uptake of Pittsburgh compound B PET (PiB-PET), cortical thickness in the precuneus ascertained by MRI, and hippocampal volume determined by MRI. Cognition was measured using a validated cognitive composite (including DIAN word list test, logical memory delayed recall, digit symbol coding test [total score], and minimental status examination). We based our statistical analysis on univariate and bivariate linear mixed effects models.</AbstractText><AbstractText Label="FINDINGS">In carriers of pathogenic variants, a high amyloid burden at baseline, represented by low CSF A&#x3b2;42 (&#x3b2;=-4&#xb7;28&#x2008;&#xd7;&#x2008;10<sup>-2</sup> [SE 0&#xb7;013], p=0&#xb7;0012), but not high cortical uptake in PiB-PET (&#x3b2;=-5&#xb7;51&#x2008;&#xd7;&#x2008;10<sup>-3</sup> [0&#xb7;011], p=0&#xb7;63), was the only predictor of an augmented annual rate of subsequent increase in soluble TREM2. Augmented annual rates of increase in soluble TREM2 were associated with a diminished rate of decrease in amyloid deposition, as measured by A&#x3b2;42 in CSF (r=0&#xb7;56 [0&#xb7;22], p=0&#xb7;011), in presymptomatic carriers of pathogenic variants, and with diminished annual rate of increase in PiB-PET (r=-0&#xb7;67 [0&#xb7;25], p=0&#xb7;0060) in symptomatic carriers of pathogenic variants. Presymptomatic carriers of pathogenic variants with annual rates of increase in soluble TREM2 lower than the median showed a correlation between enhanced annual rates of increase in p-tau in CSF and augmented annual rates of increase in PiB-PET signal (r=0&#xb7;45 [0&#xb7;21], p=0&#xb7;035), that was not observed in those with rates of increase in soluble TREM2 higher than the median. Furthermore, presymptomatic carriers of pathogenic variants with rates of increase in soluble TREM2 above or below the median had opposite associations between A&#x3b2;42 in CSF and PiB-PET uptake when assessed longitudinally. Augmented annual rates of increase in soluble TREM2 in presymptomatic carriers of pathogenic variants correlated with decreased cortical shrinkage in the precuneus (r=0&#xb7;46 [0&#xb7;22]), p=0&#xb7;040) and diminished cognitive decline (r=0&#xb7;67 [0&#xb7;22], p=0&#xb7;0020).</AbstractText><AbstractText Label="INTERPRETATION">Our findings in autosomal dominant Alzheimer's disease position the TREM2 response within the amyloid cascade immediately after the first pathological changes in A&#x3b2; aggregation and further support the role of TREM2 on A&#x3b2; plaque deposition and compaction. Furthermore, these findings underpin a beneficial effect of TREM2 on A&#x3b2; deposition, A&#x3b2;-dependent tau pathology, cortical shrinkage, and cognitive decline. Soluble TREM2 could, therefore, be a key marker for clinical trial design and interpretation. Efforts to develop TREM2-boosting therapies are ongoing.</AbstractText><AbstractText Label="FUNDING">German Research Foundation, US National Institutes of Health.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Morenas-Rodr&#xed;guez</LastName><ForeName>Estrella</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases, Munich, Germany; Metabolic Biochemistry, Biomedical Center, Faculty of Medicine, Ludwig-Maximilians University, Munich, Germany. Electronic address: estrella.morenas.rodriguez@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Biostatistics, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nuscher</LastName><ForeName>Brigitte</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases, Munich, Germany; Metabolic Biochemistry, Biomedical Center, Faculty of Medicine, Ludwig-Maximilians University, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Franzmeier</LastName><ForeName>Nicolai</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Institute for Stroke and Dementia Research, Klinikum der Universit&#xe4;t M&#xfc;nchen, Ludwig-Maximilians University, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiong</LastName><ForeName>Chengjie</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Biostatistics, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Su&#xe1;rez-Calvet</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Barcelona&#x3b2;eta Brain Research Center, Pasqual Maragall Foundation, Barcelona, Spain; Servei de Neurologia, Hospital del Mar Medical Research Institute, Barcelona, Spain; Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Fragilidad y Envejecimiento Saludable, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fagan</LastName><ForeName>Anne M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schultz</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Mallinckrodt Institute of Radiology, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gordon</LastName><ForeName>Brian A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Mallinckrodt Institute of Radiology, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benzinger</LastName><ForeName>Tammie L S</ForeName><Initials>TLS</Initials><AffiliationInfo><Affiliation>Mallinckrodt Institute of Radiology, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hassenstab</LastName><ForeName>Jason</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McDade</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feederle</LastName><ForeName>Regina</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases, Munich, Germany; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany; Institute for Diabetes and Obesity, Monoclonal Antibody Core Facility, Helmholtz Center, Munich, Germany; German Research Center for Environmental Health, Neuherberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karch</LastName><ForeName>Celeste M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schlepckow</LastName><ForeName>Kai</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases, Munich, Germany; Metabolic Biochemistry, Biomedical Center, Faculty of Medicine, Ludwig-Maximilians University, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kleinberger</LastName><ForeName>Gernot</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases, Munich, Germany; Metabolic Biochemistry, Biomedical Center, Faculty of Medicine, Ludwig-Maximilians University, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nellgard</LastName><ForeName>Bengt</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Intensive Care, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden; Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>V&#xf6;glein</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases, Munich, Germany; Department of Neurology, University Hospital of Munich, Ludwig-Maximilians University, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden; Department of Neurodegenerative Disease, UCL Queens Square Institute of Neurology, University College London, London, UK; UK Dementia Research Institute, University College London, London, UK; Hong Kong Center for Neurodegenerative Diseases, Hong Kong Special Administrative Region, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ewers</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases, Munich, Germany; Institute for Stroke and Dementia Research, Klinikum der Universit&#xe4;t M&#xfc;nchen, Ludwig-Maximilians University, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jucker</LastName><ForeName>Mathias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases, T&#xfc;bingen, Germany; Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levin</LastName><ForeName>Johannes</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases, Munich, Germany; Department of Neurology, University Hospital of Munich, Ludwig-Maximilians University, Munich, Germany; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bateman</LastName><ForeName>Randall J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haass</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases, Munich, Germany; Metabolic Biochemistry, Biomedical Center, Faculty of Medicine, Ludwig-Maximilians University, Munich, Germany; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Dominantly Inherited Alzheimer Network</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG062421</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG058501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG068398</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UF1 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 OD025214</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Neurol</MedlineTA><NlmUniqueID>101139309</NlmUniqueID><ISSNLinking>1474-4422</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498715">TREM2 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Neurol. 2022 Apr;21(4):297-298. doi: 10.1016/S1474-4422(22)00087-4.</RefSource><PMID Version="1">35305329</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2022 May;18(5):251. doi: 10.1038/s41582-022-00658-1.</RefSource><PMID Version="1">35396358</PMID></CommentsCorrections><CommentsCorrections RefType="ErratumIn"><RefSource>Lancet Neurol. 2022 May;21(5):e5. doi: 10.1016/S1474-4422(22)00140-5.</RefSource><PMID Version="1">35429484</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="Y">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="Y">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Declaration of interests HZ has served at scientific advisory boards for Alector, Eisai, Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics, Nervgen, AZTherapies, and CogRx, and has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, and Biogen. MS-C has served as a consultant and at advisory boards for Roche Diagnostics International and has given lectures in symposia sponsored by Roche Diagnostics, Sociedad Limitada Unipersonal, and Roche Farma, Sociedad An&#xf3;nima. AMF participates in the scientific advisory boards for Roche Diagnostics, Genentech, and DiamiR, and collaborates as a consultant for DiamiR and Siemens Healthcare Diagnostics. TLSB collaborates with Biogen and Siemens as a consultant and participates in the Advisory board of Eisai and Biogen. JH collaborates as a consultant for Roche and Parabon Nanolabs, and participates in the Advisory board of Eisai, CaringBridge, and WallE. EM collaborates as a consultant for Eli Lilly, has received funding for attending meetings from the Alzheimer Association and Foundation Alzheimer, and participates in the Data Safety Monitoring Board of Eli Lilly, Alector, and in the Advisory Board of Fondation Alzheimer, and Alzmend. KS received royalties for co-developing the therapeutic anti-TREM2 mouse antibody 4D9. JCM has served as consultant for Barcelona Beta Brain Research Center, TS Srinivasan Advisory Board (Chennai, India), has received honoraria for lectures given at Montefiori Grand Rounds (NY, USA) and Tetra-Institute Alzheimer Disease Research Center Seminar Series, and participates in the Advisory Boards of Cure Alzheimer's Fund Research Strategy Council and Leads Advisory Board (IN, USA). KB collaborates as a consultant for Abcam, Axon, BioArctic, Biogen, Japanese Organization for Medical Device Development and Shimadzu, Lilly, MagQu, Pharmatrophix, Prothena, Roche Diagnostics, and Siemens Healthineers, has received honoraria for lectures from Grupo de Estudos de Envelhecimento Cerebral e Dem&#xea;ncia and Roche Diagnostics, and IFCC and SNIBE, has served at data monitoring committees for Julius Clinical and Novartis, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, which is a part of Gothenburg University Ventures Incubator programme. JL participates as a consultant in Axon Neuroscience and Biogen, has received honoraria for lectures given by Bayer Vital and Roche, support for attending meetings by AbbVie and Biogen, and has participated in the Advisory board of Axon Neuroscience. JL has also received author fees from Thieme medical publishers, W Kohlhammer GmbH medical publishers, and a compensation for duty as part-time chief marketing officer by MODAG GmbH. RJB collaborates as a consultant with Eisai, Amgen, and Hoffman La-Roche, has received travel support from Hoffman La-Roche, and participates in the C2N Diagnostics Scientific Advisory board. RJB also serves as principal investigator of the Dominantly Inherited Alzheimer's Network-Treatment Unit (DIAN-TU), which is supported by the Alzheimer's Association, GHR Foundation, an anonymous organisation, and the DIAN-TU Pharma Consortium (active members include Eli Lilly and Company, Avid Radiopharmaceuticals, F Hoffman-La Roche, Genentech, Biogen, Eisai, and Janssen. Previous members include Abbvie, Amgen, AstraZeneca, Forum, Mithridion, Novartis, Pfizer, Sanofi, and United Neuroscience). In addition, in-kind support has been received from CogState and Signant Health. CH collaborates with Denali Therapeutics, and has participated on one advisory board meeting of Biogen. CH is also chief advisor of ISAR Bioscience and a member of the scientific advisory board of AviadoBio. CH has received honoraria for lectures at Weill Cornell Medicine, Sheikh Hamdan Webinar Series, Washington University, Eisai, and UT Southwestern Medical Center, and participates in the US Patent Application (number 16/319,373).</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Adams</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Allegri</LastName><ForeName>Ricardo</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Araki</LastName><ForeName>Aki</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barthelemy</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bechara</LastName><ForeName>Jacob</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Berman</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bodge</LastName><ForeName>Courtney</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brandon</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brooks</LastName><ForeName>William Bill</ForeName><Initials>WB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brosch</LastName><ForeName>Jared</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Buck</LastName><ForeName>Jill</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Buckles</LastName><ForeName>Virginia</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carter</LastName><ForeName>Kathleen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cash</LastName><ForeName>Lisa</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chen</LastName><ForeName>Charlie</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chhatwal</LastName><ForeName>Jasmeer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chrem</LastName><ForeName>Patricio</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chua</LastName><ForeName>Jasmin</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chui</LastName><ForeName>Helena</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cruchaga</LastName><ForeName>Carlos</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Day</LastName><ForeName>Gregory S</ForeName><Initials>GS</Initials></Investigator><Investigator ValidYN="Y"><LastName>De La Cruz</LastName><ForeName>Chrismary</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Denner</LastName><ForeName>Darcy</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Diffenbacher</LastName><ForeName>Anna</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dincer</LastName><ForeName>Aylin</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Donahue</LastName><ForeName>Tamara</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Douglas</LastName><ForeName>Jane</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duong</LastName><ForeName>Duc</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Egido</LastName><ForeName>Noelia</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Esposito</LastName><ForeName>Bianca</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Farlow</LastName><ForeName>Marty</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Feldman</LastName><ForeName>Becca</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fitzpatrick</LastName><ForeName>Colleen</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Flores</LastName><ForeName>Shaney</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fox</LastName><ForeName>Nick</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Franklin</LastName><ForeName>Erin</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Friedrichsen</LastName><ForeName>Nelly</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fujii</LastName><ForeName>Hisako</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gardener</LastName><ForeName>Samantha</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ghetti</LastName><ForeName>Bernardino</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goate</LastName><ForeName>Alison</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goldberg</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goldman</LastName><ForeName>Jill</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gonzalez</LastName><ForeName>Alyssa</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gr&#xe4;ber-Sultan</LastName><ForeName>Susanne</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Graff-Radford</LastName><ForeName>Neill</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Graham</LastName><ForeName>Morgan</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gray</LastName><ForeName>Julia</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gremminger</LastName><ForeName>Emily</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grilo</LastName><ForeName>Miguel</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Groves</LastName><ForeName>Alex</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>H&#xe4;sler</LastName><ForeName>Lisa</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hellm</LastName><ForeName>Cortaiga</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Herries</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hoechst-Swisher</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hofmann</LastName><ForeName>Anna</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hornbeck</LastName><ForeName>Russ</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Igor</LastName><ForeName>Yakushev</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ihara</LastName><ForeName>Ryoko</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ikeuchi</LastName><ForeName>Takeshi</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ikonomovic</LastName><ForeName>Snezana</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ishii</LastName><ForeName>Kenji</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jack</LastName><ForeName>Clifford</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jerome</LastName><ForeName>Gina</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Erik</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>K&#xe4;ser</LastName><ForeName>Stephan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kasuga</LastName><ForeName>Kensaku</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Keefe</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Klunk</LastName><ForeName>William Bill</ForeName><Initials>WB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koeppe</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koudelis</LastName><ForeName>Deb</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kuder-Buletta</LastName><ForeName>Elke</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Laske</LastName><ForeName>Christoph</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Levey</LastName><ForeName>Allan</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lopez</LastName><ForeName>Oscar</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marsh</LastName><ForeName>Jacob</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martinez</LastName><ForeName>Rita</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martins</LastName><ForeName>Ralph</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mason</LastName><ForeName>Neal Scott</ForeName><Initials>NS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Masters</LastName><ForeName>Colin</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mawuenyega</LastName><ForeName>Kwasi</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>McCullough</LastName><ForeName>Austin</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mejia</LastName><ForeName>Arlene</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>MountzMD</LastName><ForeName>James</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mummery</LastName><ForeName>Cath</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nadkarni</LastName><ForeName>Neelesh</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nagamatsu</LastName><ForeName>Akemi</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Neimeyer</LastName><ForeName>Katie</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Niimi</LastName><ForeName>Yoshiki</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Noble</LastName><ForeName>James</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Norton</LastName><ForeName>Joanne</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nuscher</LastName><ForeName>Brigitte</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>O'Connor</LastName><ForeName>Antoinette</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oberm&#xfc;ller</LastName><ForeName>Ulricke</ForeName><Initials>U</Initials></Investigator><Investigator ValidYN="Y"><LastName>Patira</LastName><ForeName>Riddhi</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Perrin</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ping</LastName><ForeName>Lingyan</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Preische</LastName><ForeName>Oliver</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Renton</LastName><ForeName>Alan</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ringman</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Salloway</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schofield</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Senda</LastName><ForeName>Michio</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Seyfried</LastName><ForeName>Nick</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shady</LastName><ForeName>Kristine</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shimada</LastName><ForeName>Hiroyuki</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sigurdson</LastName><ForeName>Wendy</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Lori</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Snitz</LastName><ForeName>Beth</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sohrabi</LastName><ForeName>Hamid</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stephens</LastName><ForeName>Sochenda</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Taddei</LastName><ForeName>Kevin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thompson</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wang</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wang</LastName><ForeName>Qing</ForeName><Initials>Q</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weamer</LastName><ForeName>Elise</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Xu</LastName><ForeName>Jinbin</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Xu</LastName><ForeName>Xiong</ForeName><Initials>X</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>10</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>1</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>1</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>19</Day><Hour>20</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>4</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35305339</ArticleId><ArticleId IdType="pmc">PMC8926925</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(22)00027-8</ArticleId><ArticleId IdType="pii">S1474-4422(22)00027-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Heneka MT, Kummer MP, Stutz A, et al. NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature. 2013;493:674&#x2013;678.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3812809</ArticleId><ArticleId IdType="pubmed">23254930</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H, Spinrad A, Weiner A, et al. A unique microglia type associated with restricting development of Alzheimer's disease. Cell. 2017;169:1276&#x2013;1290.e17.</Citation><ArticleIdList><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R, Wojtas A, Bras J, et al. TREM2 variants in Alzheimer's disease. N Engl J Med. 2013;368:117&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3631573</ArticleId><ArticleId IdType="pubmed">23150934</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleinberger G, Yamanishi Y, Su&#xe1;rez-Calvet M, et al. TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Sci Transl Med. 2014;6</Citation><ArticleIdList><ArticleId IdType="pubmed">24990881</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazaheri F, Snaidero N, Kleinberger G, et al. TREM2 deficiency impairs chemotaxis and microglial responses to neuronal injury. EMBO Rep. 2017;18:1186&#x2013;1198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5494532</ArticleId><ArticleId IdType="pubmed">28483841</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewcock JW, Schlepckow K, Di Paolo G, Tahirovic S, Monroe KM, Haass C. Emerging microglia biology defines novel therapeutic approaches for Alzheimer's disease. Neuron. 2020;108:801&#x2013;821.</Citation><ArticleIdList><ArticleId IdType="pubmed">33096024</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlepckow K, Kleinberger G, Fukumori A, et al. An Alzheimer-associated TREM2 variant occurs at the ADAM cleavage site and affects shedding and phagocytic function. EMBO Mol Med. 2017;9:1356&#x2013;1365.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5623859</ArticleId><ArticleId IdType="pubmed">28855300</ArticleId></ArticleIdList></Reference><Reference><Citation>Su&#xe1;rez-Calvet M, Araque Caballero MA, Kleinberger G, et al. Early changes in CSF sTREM2 in dominantly inherited Alzheimer's disease occur after amyloid deposition and neuronal injury. Sci Transl Med. 2016;8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5385711</ArticleId><ArticleId IdType="pubmed">27974666</ArticleId></ArticleIdList></Reference><Reference><Citation>Su&#xe1;rez-Calvet M, Kleinberger G, Araque Caballero MA, et al. sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers. EMBO Mol Med. 2016;8:466&#x2013;476.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5120370</ArticleId><ArticleId IdType="pubmed">26941262</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccio L, Deming Y, Del-&#xc1;guila JL, et al. Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status. Acta Neuropathol. 2016;131:925&#x2013;933.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4867123</ArticleId><ArticleId IdType="pubmed">26754641</ArticleId></ArticleIdList></Reference><Reference><Citation>Deming Y, Filipello F, Cignarella F, et al. The MS4A gene cluster is a key modulator of soluble TREM2 and Alzheimer's disease risk. Sci Transl Med. 2019;11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6697053</ArticleId><ArticleId IdType="pubmed">31413141</ArticleId></ArticleIdList></Reference><Reference><Citation>Ewers M, Biechele G, Su&#xe1;rez-Calvet M, et al. Higher CSF sTREM2 and microglia activation are associated with slower rates of beta-amyloid accumulation. EMBO Mol Med. 2020;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7507349</ArticleId><ArticleId IdType="pubmed">32790063</ArticleId></ArticleIdList></Reference><Reference><Citation>Ewers M, Franzmeier N, Su&#xe1;rez-Calvet M, et al. Increased soluble TREM2 in cerebrospinal fluid is associated with reduced cognitive and clinical decline in Alzheimer's disease. Sci Transl Med. 2019;11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7050285</ArticleId><ArticleId IdType="pubmed">31462511</ArticleId></ArticleIdList></Reference><Reference><Citation>Pascoal TA, Benedet AL, Ashton NJ, et al. Microglial activation and tau propagate jointly across Braak stages. Nat Med. 2021;27:1592&#x2013;1599.</Citation><ArticleIdList><ArticleId IdType="pubmed">34446931</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang PF, Hu H, Tan L, Yu JT. Microglia biomarkers in Alzheimer's disease. Mol Neurobiol. 2021;58:3388&#x2013;3404.</Citation><ArticleIdList><ArticleId IdType="pubmed">33713018</ArticleId></ArticleIdList></Reference><Reference><Citation>Edwin TH, Henjum K, Nilsson LNG, et al. A high cerebrospinal fluid soluble TREM2 level is associated with slow clinical progression of Alzheimer's disease. Alzheimers Dement (Amst) 2020;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7720866</ArticleId><ArticleId IdType="pubmed">33313376</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcon C, Mont&#xe9;-Rubio GC, Grau-Rivera O, et al. CSF glial biomarkers YKL40 and sTREM2 are associated with longitudinal volume and diffusivity changes in cognitively unimpaired individuals. Neuroimage Clin. 2019;23</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6458453</ArticleId><ArticleId IdType="pubmed">30978656</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z, Shen X, Pan W. Longitudinal analysis is more powerful than cross-sectional analysis in detecting genetic association with neuroimaging phenotypes. PLoS One. 2014;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4123854</ArticleId><ArticleId IdType="pubmed">25098835</ArticleId></ArticleIdList></Reference><Reference><Citation>McDade E, Wang G, Gordon BA, et al. Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease. Neurology. 2018;91:e1295&#x2013;e1306.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6177272</ArticleId><ArticleId IdType="pubmed">30217935</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmitz TW, Soreq H, Poirier J, Spreng RN. Longitudinal basal forebrain degeneration interacts with TREM2/C3 biomarkers of inflammation in presymptomatic Alzheimer's disease. J Neurosci. 2020;40:1931&#x2013;1942.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7046458</ArticleId><ArticleId IdType="pubmed">31915256</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartl M, Dakna M, Galasko D, et al. Biomarkers of neurodegeneration and glial activation validated in Alzheimer's disease assessed in longitudinal cerebrospinal fluid samples of Parkinson's disease. PLoS One. 2021;16</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8496858</ArticleId><ArticleId IdType="pubmed">34618817</ArticleId></ArticleIdList></Reference><Reference><Citation>Parhizkar S, Arzberger T, Brendel M, et al. Loss of TREM2 function increases amyloid seeding but reduces plaque-associated ApoE. Nat Neurosci. 2019;22:191&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6417433</ArticleId><ArticleId IdType="pubmed">30617257</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon BA, Blazey TM, Su Y, et al. Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study. Lancet Neurol. 2018;17:241&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5816717</ArticleId><ArticleId IdType="pubmed">29397305</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012;367:795&#x2013;804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3474597</ArticleId><ArticleId IdType="pubmed">22784036</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsubuki S, Takaki Y, Saido TC. Dutch, Flemish, Italian, and Arctic mutations of APP and resistance of Abeta to physiologically relevant proteolytic degradation. Lancet. 2003;361:1957&#x2013;1958.</Citation><ArticleIdList><ArticleId IdType="pubmed">12801742</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43:2412&#x2013;2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Su&#xe1;rez-Calvet M, Morenas-Rodr&#xed;guez E, Kleinberger G, et al. Early increase of CSF sTREM2 in Alzheimer's disease is associated with tau related-neurodegeneration but not with amyloid-&#x3b2; pathology. Mol Neurodegener. 2019;14:1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6327425</ArticleId><ArticleId IdType="pubmed">30630532</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Benzinger TL, Berry S, et al. The DIAN-TU Next Generation Alzheimer's prevention trial: adaptive design and disease progression model. Alzheimers Dement. 2017;13:8&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5218895</ArticleId><ArticleId IdType="pubmed">27583651</ArticleId></ArticleIdList></Reference><Reference><Citation>Fieuws S, Verbeke G. Joint modelling of multivariate longitudinal profiles: pitfalls of the random-effects approach. Stat Med. 2004;23:3093&#x2013;3104.</Citation><ArticleIdList><ArticleId IdType="pubmed">15449333</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo J, Gao F, Liu J, et al. Statistical estimation and comparison of group-specific bivariate correlation coefficients in family-type clustered studies. J Appl Stat. 2021 doi: 10.1080/02664763.2021.1899141. published online March.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/02664763.2021.1899141</ArticleId><ArticleId IdType="pmc">PMC9225315</ArticleId><ArticleId IdType="pubmed">35755087</ArticleId></ArticleIdList></Reference><Reference><Citation>Uhlmann RE, Rother C, Rasmussen J, et al. Acute targeting of pre-amyloid seeds in transgenic mice reduces Alzheimer-like pathology later in life. Nat Neurosci. 2020;23:1580&#x2013;1588.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7783656</ArticleId><ArticleId IdType="pubmed">33199898</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y, Happonen KE, Burrola PG, et al. Microglia use TAM receptors to detect and engulf amyloid &#x3b2; plaques. Nat Immunol. 2021;22:586&#x2013;594.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8102389</ArticleId><ArticleId IdType="pubmed">33859405</ArticleId></ArticleIdList></Reference><Reference><Citation>Meilandt WJ, Ngu H, Gogineni A, et al. Trem2 deletion reduces late-stage amyloid plaque accumulation, elevates the A&#x3b2;42:A&#x3b2;40 ratio, and exacerbates axonal dystrophy and dendritic spine loss in the PS2APP Alzheimer's mouse model. J Neurosci. 2020;40:1956&#x2013;1974.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7046459</ArticleId><ArticleId IdType="pubmed">31980586</ArticleId></ArticleIdList></Reference><Reference><Citation>Toledo JB, Bjerke M, Da X, et al. Nonlinear association between cerebrospinal fluid and florbetapir F-18 &#x3b2;-amyloid measures across the spectrum of Alzheimer disease. JAMA Neurol. 2015;72:571&#x2013;581.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5642905</ArticleId><ArticleId IdType="pubmed">25822737</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SH, Meilandt WJ, Xie L, et al. Trem2 restrains the enhancement of tau accumulation and neurodegeneration by &#x3b2;-amyloid pathology. Neuron. 2021;109:1283&#x2013;1301. e6.</Citation><ArticleIdList><ArticleId IdType="pubmed">33675684</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunkle BW, Grenier-Boley B, Sims R, et al. Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates A&#x3b2;, tau, immunity and lipid processing. Nat Genet. 2019;51:414&#x2013;430.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6463297</ArticleId><ArticleId IdType="pubmed">30820047</ArticleId></ArticleIdList></Reference><Reference><Citation>Small SA, Petsko GA. Endosomal recycling reconciles the Alzheimer's disease paradox. Sci Transl Med. 2020;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8025181</ArticleId><ArticleId IdType="pubmed">33268506</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35310497</PMID><DateRevised><Year>2024</Year><Month>08</Month><Day>24</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2041-6520</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>8</Issue><PubDate><Year>2022</Year><Month>Feb</Month><Day>23</Day></PubDate></JournalIssue><Title>Chemical science</Title><ISOAbbreviation>Chem Sci</ISOAbbreviation></Journal><ArticleTitle>Amyloid-&#x3b2; peptide 37, 38 and 40 individually and cooperatively inhibit amyloid-&#x3b2; 42 aggregation.</ArticleTitle><Pagination><StartPage>2423</StartPage><EndPage>2439</EndPage><MedlinePgn>2423-2439</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1039/d1sc02990h</ELocationID><Abstract><AbstractText>The pathology of Alzheimer's disease is connected to the aggregation of &#x3b2;-amyloid (A&#x3b2;) peptide, which <i>in vivo</i> exists as a number of length-variants. Truncations and extensions are found at both the N- and C-termini, relative to the most commonly studied 40- and 42-residue alloforms. Here, we investigate the aggregation of two physiologically abundant alloforms, A&#x3b2;<sub>37</sub> and A&#x3b2;<sub>38</sub>, as pure peptides and in mixtures with A&#x3b2;<sub>40</sub> and A&#x3b2;<sub>42</sub>. A variety of molar ratios were applied in quaternary mixtures to investigate whether a certain ratio is maximally inhibiting of the more toxic alloform A&#x3b2;<sub>42</sub>. Through kinetic analysis, we show that both A&#x3b2;<sub>37</sub> and A&#x3b2;<sub>38</sub> self-assemble through an autocatalytic secondary nucleation reaction to form fibrillar &#x3b2;-sheet-rich aggregates, albeit on a longer timescale than A&#x3b2;<sub>40</sub> or A&#x3b2;<sub>42</sub>. Additionally, we show that the shorter alloforms co-aggregate with A&#x3b2;<sub>40</sub>, affecting both the kinetics of aggregation and the resulting fibrillar ultrastructure. In contrast, neither A&#x3b2;<sub>37</sub> nor A&#x3b2;<sub>38</sub> forms co-aggregates with A&#x3b2;<sub>42</sub>; however, both short alloforms reduce the rate of A&#x3b2;<sub>42</sub> aggregation in a concentration-dependent manner. Finally, we show that the aggregation of A&#x3b2;<sub>42</sub> is more significantly impeded by a combination of A&#x3b2;<sub>37</sub>, A&#x3b2;<sub>38</sub>, and A&#x3b2;<sub>40</sub> than by any of these alloforms independently. These results demonstrate that the aggregation of any given A&#x3b2; alloform is significantly perturbed by the presence of other alloforms, particularly in heterogeneous mixtures, such as is found in the extracellular fluid of the brain.</AbstractText><CopyrightInformation>This journal is &#xa9; The Royal Society of Chemistry.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Braun</LastName><ForeName>Gabriel A</ForeName><Initials>GA</Initials><Identifier Source="ORCID">0000-0002-9105-5757</Identifier><AffiliationInfo><Affiliation>Biochemistry and Structural Biology, Lund University Lund Sweden sara.linse@biochemistry.lu.se.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dear</LastName><ForeName>Alexander J</ForeName><Initials>AJ</Initials><Identifier Source="ORCID">0000-0003-3055-607X</Identifier><AffiliationInfo><Affiliation>Biochemistry and Structural Biology, Lund University Lund Sweden sara.linse@biochemistry.lu.se.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cell Biology, Harvard Medical School Boston MA USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Paulson School of Engineering and Applied Science, Harvard University Cambridge MA USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Chemistry, University of Cambridge Cambridge UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanagavarapu</LastName><ForeName>Kalyani</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Biochemistry and Structural Biology, Lund University Lund Sweden sara.linse@biochemistry.lu.se.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg M&#xf6;lndal Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital M&#xf6;lndal Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology Queen Square London UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute at UCL London UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Linse</LastName><ForeName>Sara</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-9629-7109</Identifier><AffiliationInfo><Affiliation>Biochemistry and Structural Biology, Lund University Lund Sweden sara.linse@biochemistry.lu.se.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>02</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Chem Sci</MedlineTA><NlmUniqueID>101545951</NlmUniqueID><ISSNLinking>2041-6520</ISSNLinking></MedlineJournalInfo><CoiStatement>H. Z. has served at scientific advisory boards for Eisai, Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics, Nervgen, AZTherapies and CogRx, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>6</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>1</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>21</Day><Hour>9</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>22</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>2</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35310497</ArticleId><ArticleId IdType="pmc">PMC8864715</ArticleId><ArticleId IdType="doi">10.1039/d1sc02990h</ArticleId><ArticleId IdType="pii">d1sc02990h</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lane C. A. Hardy J. Schott J. M. Eur. J. Neurol. 2018;25:59&#x2013;70. doi: 10.1111/ene.13439.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.13439</ArticleId><ArticleId IdType="pubmed">28872215</ArticleId></ArticleIdList></Reference><Reference><Citation>Developing therapeutics for Alzheimer's disease: progress and challenges, ed., M. S. Wolfe, Elsevier/AP, Academic Press is an imprint of Elsevier, Amsterdam; Boston, 2016</Citation></Reference><Reference><Citation>Reiss A. B. Arain H. A. Stecker M. M. Siegart N. M. Kasselman L. J. Rev. Neurosci. 2018;29:613&#x2013;627.</Citation><ArticleIdList><ArticleId IdType="pubmed">29447116</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings J. L. Tong G. Ballard C. J. Alzheimer's Dis. 2019;67:779&#x2013;794.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6398562</ArticleId><ArticleId IdType="pubmed">30689575</ArticleId></ArticleIdList></Reference><Reference><Citation>Sevigny J. Chiao P. Bussi&#xe8;re T. Weinreb P. H. Williams L. Maier M. Dunstan R. Salloway S. Chen T. Ling Y. O'Gorman J. Qian F. Arastu M. Li M. Chollate S. Brennan M. S. Quintero-Monzon O. Scannevin R. H. Arnold H. M. Engber T. Rhodes K. Ferrero J. Hang Y. Mikulskis A. Grimm J. Hock C. Nitsch R. M. Sandrock A. Nature. 2016;537:50&#x2013;56. doi: 10.1038/nature19323.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature19323</ArticleId><ArticleId IdType="pubmed">27582220</ArticleId></ArticleIdList></Reference><Reference><Citation>Haeberlein S. B., Presented in part at the 12th Clinical Trials on Alzheimer's Disease (CTAD) Congress, San Diego, CA, 2019</Citation></Reference><Reference><Citation>Linse S. Scheidt T. Bernfur K. Vendruscolo M. Dobson C. M. Cohen S. I. A. Sileikis E. Lundqvist M. Qian F. O&#x2019;Malley T. Bussiere T. Weinreb P. H. Xu C. K. Meisl G. Devenish S. R. A. Knowles T. P. J. Hansson O. Nat. Struct. Mol. Biol. 2020;27:1125&#x2013;1133. doi: 10.1038/s41594-020-0505-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41594-020-0505-6</ArticleId><ArticleId IdType="pubmed">32989305</ArticleId></ArticleIdList></Reference><Reference><Citation>
&#x201c;FDA Grants Accelerated Approval for Alzheimer's Drug.&#x201d; June 2021. https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-alzheimers-drug. Accessed October 2021</Citation></Reference><Reference><Citation>Hardy J. Allsop D. Trends Pharmacol. Sci. 1991;12:383&#x2013;388. doi: 10.1016/0165-6147(91)90609-V.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0165-6147(91)90609-V</ArticleId><ArticleId IdType="pubmed">1763432</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J. Higgins G. Science. 1992;256:184&#x2013;185. doi: 10.1126/science.1566067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1566067</ArticleId><ArticleId IdType="pubmed">1566067</ArticleId></ArticleIdList></Reference><Reference><Citation>Cline E. N. Bicca M. A. Viola K. L. Klein W. L. J. Alzheimer's Dis. 2018;64:S567&#x2013;S610.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6004937</ArticleId><ArticleId IdType="pubmed">29843241</ArticleId></ArticleIdList></Reference><Reference><Citation>Iadanza M. G. Jackson M. P. Hewitt E. W. Ranson N. A. Radford S. E. Nat. Rev. Mol. Cell Biol. 2018;19:755&#x2013;773. doi: 10.1038/s41580-018-0060-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41580-018-0060-8</ArticleId><ArticleId IdType="pubmed">30237470</ArticleId></ArticleIdList></Reference><Reference><Citation>Linse S. Biophys. Rev. 2017;9:329&#x2013;338. doi: 10.1007/s12551-017-0289-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12551-017-0289-z</ArticleId><ArticleId IdType="pmc">PMC5578932</ArticleId><ArticleId IdType="pubmed">28812278</ArticleId></ArticleIdList></Reference><Reference><Citation>T&#xf6;rnquist M. Michaels T. C. T. Sanagavarapu K. Yang X. Meisl G. Cohen S. I. A. Knowles T. P. J. Linse S. Chem. Commun. 2018;54:8667&#x2013;8684. doi: 10.1039/C8CC02204F.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/C8CC02204F</ArticleId><ArticleId IdType="pubmed">29978862</ArticleId></ArticleIdList></Reference><Reference><Citation>Ransohoff R. M. Science. 2016;353:777&#x2013;783. doi: 10.1126/science.aag2590.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aag2590</ArticleId><ArticleId IdType="pubmed">27540165</ArticleId></ArticleIdList></Reference><Reference><Citation>Calsolaro V. Edison P. Alzheimer's Dementia. 2016;12:719&#x2013;732. doi: 10.1016/j.jalz.2016.02.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2016.02.010</ArticleId><ArticleId IdType="pubmed">27179961</ArticleId></ArticleIdList></Reference><Reference><Citation>Kametani F. Hasegawa M. Front. Neurosci. 2018;12:25. doi: 10.3389/fnins.2018.00025.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2018.00025</ArticleId><ArticleId IdType="pmc">PMC5797629</ArticleId><ArticleId IdType="pubmed">29440986</ArticleId></ArticleIdList></Reference><Reference><Citation>Bloom G. S. JAMA Neurol. 2014;71:505. doi: 10.1001/jamaneurol.2013.5847.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2013.5847</ArticleId><ArticleId IdType="pubmed">24493463</ArticleId></ArticleIdList></Reference><Reference><Citation>Gouras G. K. Olsson T. T. Hansson O. Neurotherapeutics. 2015;12:3&#x2013;11. doi: 10.1007/s13311-014-0313-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-014-0313-y</ArticleId><ArticleId IdType="pmc">PMC4322079</ArticleId><ArticleId IdType="pubmed">25371168</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe D. J. Hardy J. EMBO Mol. Med. 2016;8:595&#x2013;608. doi: 10.15252/emmm.201606210.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201606210</ArticleId><ArticleId IdType="pmc">PMC4888851</ArticleId><ArticleId IdType="pubmed">27025652</ArticleId></ArticleIdList></Reference><Reference><Citation>Arosio P. Vendruscolo M. Dobson C. M. Knowles T. P. J. Trends Pharmacol. Sci. 2014;35:127&#x2013;135. doi: 10.1016/j.tips.2013.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tips.2013.12.005</ArticleId><ArticleId IdType="pubmed">24560688</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y. Thompson R. Zhang H. Xu H. Mol. Brain. 2011;4:3. doi: 10.1186/1756-6606-4-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1756-6606-4-3</ArticleId><ArticleId IdType="pmc">PMC3022812</ArticleId><ArticleId IdType="pubmed">21214928</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C. Kaether C. Thinakaran G. Sisodia S. Cold Spring Harbor Perspect. Med. 2012;2:a006270.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3331683</ArticleId><ArticleId IdType="pubmed">22553493</ArticleId></ArticleIdList></Reference><Reference><Citation>Mawuenyega K. G. Kasten T. Sigurdson W. Bateman R. J. Anal. Biochem. 2013;440:56&#x2013;62. doi: 10.1016/j.ab.2013.04.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ab.2013.04.031</ArticleId><ArticleId IdType="pmc">PMC3749773</ArticleId><ArticleId IdType="pubmed">23714261</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaneko N. Yamamoto R. Sato T.-A. Tanaka K. Proc. Jpn. Acad., Ser. B. 2014;90:104&#x2013;117. doi: 10.2183/pjab.90.104.</Citation><ArticleIdList><ArticleId IdType="doi">10.2183/pjab.90.104</ArticleId><ArticleId IdType="pmc">PMC3997810</ArticleId><ArticleId IdType="pubmed">24621957</ArticleId></ArticleIdList></Reference><Reference><Citation>Reinert J. Richard B. C. Klafki H. W. Friedrich B. Bayer T. A. Wiltfang J. Kovacs G. G. Ingelsson M. Lannfelt L. Paetau A. Bergquist J. Wirths O. Acta Neuropathol. Commun. 2016;4:24. doi: 10.1186/s40478-016-0294-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-016-0294-7</ArticleId><ArticleId IdType="pmc">PMC4784385</ArticleId><ArticleId IdType="pubmed">26955942</ArticleId></ArticleIdList></Reference><Reference><Citation>Brinkmalm G. Hong W. Wang Z. Liu W. O'Malley T. T. Sun X. Frosch M. P. Selkoe D. J. Portelius E. Zetterberg H. Blennow K. Walsh D. M. Brain. 2019;142:1441&#x2013;1457. doi: 10.1093/brain/awz066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz066</ArticleId><ArticleId IdType="pmc">PMC6487330</ArticleId><ArticleId IdType="pubmed">31032851</ArticleId></ArticleIdList></Reference><Reference><Citation>Bibl M. Mollenhauer B. Esselmann H. Lewczuk P. Klafki H.-W. Sparbier K. Smirnov A. Cepek L. Trenkwalder C. R&#xfc;ther E. Kornhuber J. Otto M. Wiltfang J. Brain. 2006;129:1177&#x2013;1187. doi: 10.1093/brain/awl063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awl063</ArticleId><ArticleId IdType="pmc">PMC5403412</ArticleId><ArticleId IdType="pubmed">16600985</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiltfang J. Esselmann H. Bibl M. Smirnov A. Otto M. Paul S. Schmidt B. Klafki H.-W. Maler M. Dyrks T. Bienert M. Beyermann M. R&#xfc;ther E. Kornhuber J. J. Neurochem. 2002;81:481&#x2013;496. doi: 10.1046/j.1471-4159.2002.00818.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.2002.00818.x</ArticleId><ArticleId IdType="pubmed">12065657</ArticleId></ArticleIdList></Reference><Reference><Citation>Galasko D. Chang L. Motter R. Clark C. M. Kaye J. Knopman D. Thomas R. Kholodenko D. Schenk D. Lieberburg I. Miller B. Green R. Basherad R. Kertiles L. Boss M. A. Seubert P. Arch. Neurol. 1998;55:937. doi: 10.1001/archneur.55.7.937.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.55.7.937</ArticleId><ArticleId IdType="pubmed">9678311</ArticleId></ArticleIdList></Reference><Reference><Citation>Spies P. E. Verbeek M. M. van Groen T. Claassen J. A. H. R. Front. Biosci., Landmark Ed. 2012;17:2024&#x2013;2034. doi: 10.2741/4035.</Citation><ArticleIdList><ArticleId IdType="doi">10.2741/4035</ArticleId><ArticleId IdType="pubmed">22652762</ArticleId></ArticleIdList></Reference><Reference><Citation>Zampar S. Klafki H. W. Sritharen K. Bayer T. A. Wiltfang J. Rostagno A. Ghiso J. Miles L. A. Wirths O. Neuropathol. Appl. Neurobiol. 2020;46:673&#x2013;685. doi: 10.1111/nan.12637.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nan.12637</ArticleId><ArticleId IdType="pmc">PMC8082844</ArticleId><ArticleId IdType="pubmed">32497293</ArticleId></ArticleIdList></Reference><Reference><Citation>Szczepankiewicz O. Linse B. Meisl G. Thulin E. Frohm B. Sala Frigerio C. Colvin M. T. Jacavone A. C. Griffin R. G. Knowles T. Walsh D. M. Linse S. J. Am. Chem. Soc. 2015;137:14673&#x2013;14685. doi: 10.1021/jacs.5b07849.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jacs.5b07849</ArticleId><ArticleId IdType="pmc">PMC5412961</ArticleId><ArticleId IdType="pubmed">26535489</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiffert T. Meisl G. Flagmeier P. De S. Dunning C. J. R. Frohm B. Zetterberg H. Blennow K. Portelius E. Klenerman D. Dobson C. M. Knowles T. P. J. Linse S. ACS Chem. Neurosci. 2019;10:2374&#x2013;2384. doi: 10.1021/acschemneuro.8b00676.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschemneuro.8b00676</ArticleId><ArticleId IdType="pubmed">30793584</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy M. P. LeVine H. J. Alzheimer's Dis. 2010;19:311&#x2013;323.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2813509</ArticleId><ArticleId IdType="pubmed">20061647</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandersteen A. Hubin E. Sarroukh R. De Baets G. Schymkowitz J. Rousseau F. Subramaniam V. Raussens V. Wenschuh H. Wildemann D. Broersen K. FEBS Lett. 2012;586:4088&#x2013;4093. doi: 10.1016/j.febslet.2012.10.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.febslet.2012.10.022</ArticleId><ArticleId IdType="pubmed">23103738</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen S. I. A. Linse S. Luheshi L. M. Hellstrand E. White D. A. Rajah L. Otzen D. E. Vendruscolo M. Dobson C. M. Knowles T. P. J. Proc. Natl. Acad. Sci. U. S. A. 2013;110:9758&#x2013;9763. doi: 10.1073/pnas.1218402110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1218402110</ArticleId><ArticleId IdType="pmc">PMC3683769</ArticleId><ArticleId IdType="pubmed">23703910</ArticleId></ArticleIdList></Reference><Reference><Citation>Meisl G. Yang X. Hellstrand E. Frohm B. Kirkegaard J. B. Cohen S. I. A. Dobson C. M. Linse S. Knowles T. P. J. Proc. Natl. Acad. Sci. U. S. A. 2014;111:9384&#x2013;9389. doi: 10.1073/pnas.1401564111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1401564111</ArticleId><ArticleId IdType="pmc">PMC4084462</ArticleId><ArticleId IdType="pubmed">24938782</ArticleId></ArticleIdList></Reference><Reference><Citation>Abelein A. Jarvet J. Barth A. Gr&#xe4;slund A. Danielsson J. J. Am. Chem. Soc. 2016;138:6893&#x2013;6902. doi: 10.1021/jacs.6b04511.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jacs.6b04511</ArticleId><ArticleId IdType="pubmed">27171340</ArticleId></ArticleIdList></Reference><Reference><Citation>Meisl G. Yang X. Dobson C. M. Linse S. Knowles T. P. J. Chem. Sci. 2017;8:4352&#x2013;4362. doi: 10.1039/C7SC00215G.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/C7SC00215G</ArticleId><ArticleId IdType="pmc">PMC5580342</ArticleId><ArticleId IdType="pubmed">28979758</ArticleId></ArticleIdList></Reference><Reference><Citation>Meisl G. Yang X. Frohm B. Knowles T. P. J. Linse S. Sci. Rep. 2016;6:18728. doi: 10.1038/srep18728.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep18728</ArticleId><ArticleId IdType="pmc">PMC4725935</ArticleId><ArticleId IdType="pubmed">26758487</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabat&#xe9; R. Espargar&#xf3; A. Barbosa-Barros L. Ventura S. Estelrich J. Biochimie. 2012;94:1730&#x2013;1738. doi: 10.1016/j.biochi.2012.03.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biochi.2012.03.027</ArticleId><ArticleId IdType="pubmed">22542639</ArticleId></ArticleIdList></Reference><Reference><Citation>Srivastava A. K. Pittman J. M. Zerweck J. Venkata B. S. Moore P. C. Sachleben J. R. Meredith S. C. Protein Sci. 2019;28:1567&#x2013;1581.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6699094</ArticleId><ArticleId IdType="pubmed">31276610</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabaleiro-Lago C. Quinlan-Pluck F. Lynch I. Lindman S. Minogue A. M. Thulin E. Walsh D. M. Dawson K. A. Linse S. J. Am. Chem. Soc. 2008;130:15437&#x2013;15443. doi: 10.1021/ja8041806.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ja8041806</ArticleId><ArticleId IdType="pubmed">18954050</ArticleId></ArticleIdList></Reference><Reference><Citation>Ezzat K. Pernemalm M. P&#xe5;lsson S. Roberts T. C. J&#xe4;rver P. Dondalska A. Bestas B. Sobkowiak M. J. Lev&#xe4;nen B. Sk&#xf6;ld M. Thompson E. A. Saher O. Kari O. K. Lajunen T. Sverremark Ekstr&#xf6;m E. Nilsson C. Ishchenko Y. Malm T. Wood M. J. A. Power U. F. Masich S. Lind&#xe9;n A. Sandberg J. K. Lehti&#xf6; J. Spetz A.-L. EL Andaloussi S. Nat. Commun. 2019;10:2331. doi: 10.1038/s41467-019-10192-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-10192-2</ArticleId><ArticleId IdType="pmc">PMC6536551</ArticleId><ArticleId IdType="pubmed">31133680</ArticleId></ArticleIdList></Reference><Reference><Citation>Padayachee E. R. Zetterberg H. Portelius E. Bor&#xe9;n J. Molinuevo J. L. Andreasen N. Cukalevski R. Linse S. Blennow K. Andreasson U. Brain Res. 2016;1651:11&#x2013;16. doi: 10.1016/j.brainres.2016.09.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2016.09.022</ArticleId><ArticleId IdType="pmc">PMC5090044</ArticleId><ArticleId IdType="pubmed">27653981</ArticleId></ArticleIdList></Reference><Reference><Citation>Frankel R. T&#xf6;rnquist M. Meisl G. Hansson O. Andreasson U. Zetterberg H. Blennow K. Frohm B. Cedervall T. Knowles T. P. J. Leiding T. Linse S. Commun. Biol. 2019;2:365. doi: 10.1038/s42003-019-0612-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-019-0612-2</ArticleId><ArticleId IdType="pmc">PMC6783456</ArticleId><ArticleId IdType="pubmed">31602414</ArticleId></ArticleIdList></Reference><Reference><Citation>Cukalevski R. Yang X. Meisl G. Weininger U. Bernfur K. Frohm B. Knowles T. P. J. Linse S. Chem. Sci. 2015;6:4215&#x2013;4233. doi: 10.1039/C4SC02517B.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/C4SC02517B</ArticleId><ArticleId IdType="pmc">PMC5707514</ArticleId><ArticleId IdType="pubmed">29218188</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore B. D. Martin J. de Mena L. Sanchez J. Cruz P. E. Ceballos-Diaz C. Ladd T. B. Ran Y. Levites Y. Kukar T. L. Kurian J. J. McKenna R. Koo E. H. Borchelt D. R. Janus C. Rincon-Limas D. Fernandez-Funez P. Golde T. E. J. Exp. Med. 2018;215:283&#x2013;301. doi: 10.1084/jem.20170600.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20170600</ArticleId><ArticleId IdType="pmc">PMC5748850</ArticleId><ArticleId IdType="pubmed">29208777</ArticleId></ArticleIdList></Reference><Reference><Citation>Quartey M. O. Nyarko J. N. K. Maley J. M. Barnes J. R. Bolanos M. A. C. Heistad R. M. Knudsen K. J. Pennington P. R. Buttigieg J. De Carvalho C. E. Leary S. C. Parsons M. P. Mousseau D. D. Sci. Rep. 2021;11:431. doi: 10.1038/s41598-020-80164-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-80164-w</ArticleId><ArticleId IdType="pmc">PMC7801637</ArticleId><ArticleId IdType="pubmed">33432101</ArticleId></ArticleIdList></Reference><Reference><Citation>Portelius E. Andreasson U. Ringman J. M. Buerger K. Daborg J. Buchhave P. Hansson O. Harmsen A. Gustavsson M. K. Hanse E. Galasko D. Hampel H. Blennow K. Zetterberg H. Mol. Neurodegener. 2010;5:2. doi: 10.1186/1750-1326-5-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-5-2</ArticleId><ArticleId IdType="pmc">PMC2818651</ArticleId><ArticleId IdType="pubmed">20145736</ArticleId></ArticleIdList></Reference><Reference><Citation>Portelius E. Van Broeck B. Andreasson U. Gustavsson M. K. Mercken M. Zetterberg H. Borghys H. Blennow K. J. Alzheimer's Dis. 2010;21:1005&#x2013;1012.</Citation><ArticleIdList><ArticleId IdType="pubmed">20634579</ArticleId></ArticleIdList></Reference><Reference><Citation>Michaels T. C. T. &#x160;ari&#x107; A. Curk S. Bernfur K. Arosio P. Meisl G. Dear A. J. Cohen S. I. A. Dobson C. M. Vendruscolo M. Linse S. Knowles T. P. J. Nat. Chem. 2020;12:445&#x2013;451. doi: 10.1038/s41557-020-0452-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41557-020-0452-1</ArticleId><ArticleId IdType="pmc">PMC7616962</ArticleId><ArticleId IdType="pubmed">32284577</ArticleId></ArticleIdList></Reference><Reference><Citation>Jan A. Gokce O. Luthi-Carter R. Lashuel H. A. J. Biol. Chem. 2008;283:28176&#x2013;28189. doi: 10.1074/jbc.M803159200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M803159200</ArticleId><ArticleId IdType="pmc">PMC2661389</ArticleId><ArticleId IdType="pubmed">18694930</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray M. M. Bernstein S. L. Nyugen V. Condron M. M. Teplow D. B. Bowers M. T. J. Am. Chem. Soc. 2009;131:6316&#x2013;6317. doi: 10.1021/ja8092604.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ja8092604</ArticleId><ArticleId IdType="pmc">PMC2697393</ArticleId><ArticleId IdType="pubmed">19385598</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolder S. G. Sagis L. M. C. Venema P. van der Linden E. Langmuir. 2007;23:4144&#x2013;4147. doi: 10.1021/la063048k.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/la063048k</ArticleId><ArticleId IdType="pubmed">17341102</ArticleId></ArticleIdList></Reference><Reference><Citation>Silvers R. Colvin M. T. Frederick K. K. Jacavone A. C. Lindquist S. Linse S. Griffin R. G. Biochemistry. 2017;56:4850&#x2013;4859. doi: 10.1021/acs.biochem.7b00729.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.biochem.7b00729</ArticleId><ArticleId IdType="pmc">PMC8254419</ArticleId><ArticleId IdType="pubmed">28792214</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh D. M. Thulin E. Minogue A. M. Gustavsson N. Pang E. Teplow D. B. Linse S. FEBS J. 2009;276:1266&#x2013;1281. doi: 10.1111/j.1742-4658.2008.06862.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1742-4658.2008.06862.x</ArticleId><ArticleId IdType="pmc">PMC2702495</ArticleId><ArticleId IdType="pubmed">19175671</ArticleId></ArticleIdList></Reference><Reference><Citation>Meisl G. Kirkegaard J. B. Arosio P. Michaels T. C. T. Vendruscolo M. Dobson C. M. Linse S. Knowles T. P. J. Nat. Protoc. 2016;11:252&#x2013;272. doi: 10.1038/nprot.2016.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2016.010</ArticleId><ArticleId IdType="pubmed">26741409</ArticleId></ArticleIdList></Reference><Reference><Citation>Meisl G., Michaels T. C. T., Linse S. and Knowles T. P. J., in Amyloid Proteins, ed. E. M. Sigurdsson, M. Calero and M. Gasset, Springer New York, New York, NY, 2018, vol. 1779, pp. 181&#x2013;196</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Meisl G. Rajah L. Cohen S. A. I. Pfammatter M. &#x160;ari&#x107; A. Hellstrand E. Buell A. K. Aguzzi A. Linse S. Vendruscolo M. Dobson C. M. Knowles T. P. J. Chem. Sci. 2017;8:7087&#x2013;7097. doi: 10.1039/C7SC01965C.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/C7SC01965C</ArticleId><ArticleId IdType="pmc">PMC5637470</ArticleId><ArticleId IdType="pubmed">29147538</ArticleId></ArticleIdList></Reference><Reference><Citation>Dear A. J. Meisl G. Michaels T. C. T. Zimmermann M. R. Linse S. Knowles T. P. J. J. Chem. Phys. 2020;152:045101. doi: 10.1063/1.5133635.</Citation><ArticleIdList><ArticleId IdType="doi">10.1063/1.5133635</ArticleId><ArticleId IdType="pmc">PMC7377910</ArticleId><ArticleId IdType="pubmed">32007046</ArticleId></ArticleIdList></Reference><Reference><Citation>Munke A. Persson J. Weiffert T. De Genst E. Meisl G. Arosio P. Carnerup A. Dobson C. M. Vendruscolo M. Knowles T. P. J. Linse S. Proc. Natl. Acad. Sci. U. S. A. 2017;114:6444&#x2013;6449. doi: 10.1073/pnas.1700407114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1700407114</ArticleId><ArticleId IdType="pmc">PMC5488933</ArticleId><ArticleId IdType="pubmed">28584111</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarell C. J. Stockley P. G. Radford S. E. Prion. 2013;7:359&#x2013;368. doi: 10.4161/pri.26415.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/pri.26415</ArticleId><ArticleId IdType="pmc">PMC4134340</ArticleId><ArticleId IdType="pubmed">24025483</ArticleId></ArticleIdList></Reference><Reference><Citation>Ivanova M. I. Lin Y. Lee Y.-H. Zheng J. Ramamoorthy A. Biophys. Chem. 2021;269:106507. doi: 10.1016/j.bpc.2020.106507.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bpc.2020.106507</ArticleId><ArticleId IdType="pmc">PMC10317075</ArticleId><ArticleId IdType="pubmed">33254009</ArticleId></ArticleIdList></Reference><Reference><Citation>Chia S. Flagmeier P. Habchi J. Lattanzi V. Linse S. Dobson C. M. Knowles T. P. J. Vendruscolo M. Proc. Natl. Acad. Sci. U. S. A. 2017;114:8005&#x2013;8010. doi: 10.1073/pnas.1700239114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1700239114</ArticleId><ArticleId IdType="pmc">PMC5544282</ArticleId><ArticleId IdType="pubmed">28698377</ArticleId></ArticleIdList></Reference><Reference><Citation>Bondarev S. Antonets K. Kajava A. Nizhnikov A. Zhouravleva G. Int. J. Mol. Sci. 2018;19:2292. doi: 10.3390/ijms19082292.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms19082292</ArticleId><ArticleId IdType="pmc">PMC6121665</ArticleId><ArticleId IdType="pubmed">30081572</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasecke F. Niyangoda C. Borjas G. Pan J. Matthews G. Muschol M. Hoyer W. Angew. Chem., Int. Ed. 2021;60:3016&#x2013;3021. doi: 10.1002/anie.202010098.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/anie.202010098</ArticleId><ArticleId IdType="pmc">PMC7898819</ArticleId><ArticleId IdType="pubmed">33095508</ArticleId></ArticleIdList></Reference><Reference><Citation>Kessler J. C. Rochet J.-C. Lansbury P. T. Biochemistry. 2003;42:672&#x2013;678. doi: 10.1021/bi020429y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi020429y</ArticleId><ArticleId IdType="pubmed">12534279</ArticleId></ArticleIdList></Reference><Reference><Citation>Abeln S. Frenkel D. PLoS Comput. Biol. 2008;4:e1000241. doi: 10.1371/journal.pcbi.1000241.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pcbi.1000241</ArticleId><ArticleId IdType="pmc">PMC2588114</ArticleId><ArticleId IdType="pubmed">19096500</ArticleId></ArticleIdList></Reference><Reference><Citation>Arber C. Toombs J. Lovejoy C. Ryan N. S. Paterson R. W. Willumsen N. Gkanatsiou E. Portelius E. Blennow K. Heslegrave A. Schott J. M. Hardy J. Lashley T. Fox N. C. Zetterberg H. Wray S. Mol. Psychiatry. 2020;25:2919&#x2013;2931. doi: 10.1038/s41380-019-0410-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-019-0410-8</ArticleId><ArticleId IdType="pmc">PMC7577860</ArticleId><ArticleId IdType="pubmed">30980041</ArticleId></ArticleIdList></Reference><Reference><Citation>Mekala S. Nelson G. Li Y.-M. RSC Med. Chem. 2020;11:1003&#x2013;1022. doi: 10.1039/D0MD00196A.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/D0MD00196A</ArticleId><ArticleId IdType="pmc">PMC7513388</ArticleId><ArticleId IdType="pubmed">33479693</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe M. S. Molecules. 2021;26:388. doi: 10.3390/molecules26020388.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules26020388</ArticleId><ArticleId IdType="pmc">PMC7828430</ArticleId><ArticleId IdType="pubmed">33450968</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang G. Zhou R. Guo X. Yan C. Lei J. Shi Y. Cell. 2021;184:521&#x2013;533.e14. doi: 10.1016/j.cell.2020.11.049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.11.049</ArticleId><ArticleId IdType="pubmed">33373587</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35332321</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>18</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1545-9985</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>4</Issue><PubDate><Year>2022</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Nature structural &amp; molecular biology</Title><ISOAbbreviation>Nat Struct Mol Biol</ISOAbbreviation></Journal><ArticleTitle>Tau modification by the norepinephrine metabolite DOPEGAL stimulates its pathology and propagation.</ArticleTitle><Pagination><StartPage>292</StartPage><EndPage>305</EndPage><MedlinePgn>292-305</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41594-022-00745-3</ELocationID><Abstract><AbstractText>The noradrenergic locus ceruleus (LC) is the first site of detectable tau pathology in Alzheimer's disease (AD), but the mechanisms underlying the selective vulnerability of the LC in AD have not been completely identified. In the present study, we show that DOPEGAL, a monoamine oxidase A (MAO-A) metabolite of norepinephrine (NE), reacts directly with the primary amine on the Lys353 residue of tau to stimulate its aggregation and facilitate its propagation. Inhibition of MAO-A or mutation of the Lys353 residue to arginine (Lys353Arg) decreases tau Lys353-DOPEGAL levels and diminishes tau pathology spreading. Wild-type tau preformed fibrils (PFFs) trigger Lys353-DOPEGAL formation, tau pathology propagation and cognitive impairment in MAPT transgenic mice, all of which are attenuated with PFFs made from the Lys353Arg mutant. Thus, the selective vulnerability of LC neurons in AD may be explained, in part, by NE oxidation via MAO-A into DOPEGAL, which covalently modifies tau and accelerates its aggregation, toxicity and propagation.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s), under exclusive licence to Springer Nature America, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Seong Su</ForeName><Initials>SS</Initials><Identifier Source="ORCID">0000-0002-2517-9962</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meng</LastName><ForeName>Lanxia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology, Renmin Hospital of Wuhan University, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xingyu</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Neurology, Renmin Hospital of Wuhan University, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Zhiping</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Departments of Structural Biology and Developmental Neurobiology, St. Jude Children's Research Hospital, Memphis, TN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Proteomics and Metabolomics, St. Jude Children's Research Hospital, Memphis, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mancieri</LastName><ForeName>Ariana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Departments of Structural Biology and Developmental Neurobiology, St. Jude Children's Research Hospital, Memphis, TN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Proteomics and Metabolomics, St. Jude Children's Research Hospital, Memphis, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Boer</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Departments of Structural Biology and Developmental Neurobiology, St. Jude Children's Research Hospital, Memphis, TN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Proteomics and Metabolomics, St. Jude Children's Research Hospital, Memphis, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Xia</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weinshenker</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Human Genetics, Emory University School of Medicine, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Junmin</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-0472-7648</Identifier><AffiliationInfo><Affiliation>Departments of Structural Biology and Developmental Neurobiology, St. Jude Children's Research Hospital, Memphis, TN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Proteomics and Metabolomics, St. Jude Children's Research Hospital, Memphis, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Zhentao</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0001-6708-1472</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Renmin Hospital of Wuhan University, Wuhan, China. zhentaozhang@whu.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ye</LastName><ForeName>Keqiang</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA. kq.ye@siat.ac.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Life and Health Sciences, Shenzhen Institute of Advanced Technology, Shenzhen, China. kq.ye@siat.ac.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Brain Cognition and Brain Disease Institute, Shenzhen Institute of Advanced Technology, Shenzhen, China. kq.ye@siat.ac.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 NS055077</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG061175</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002378</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>03</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Struct Mol Biol</MedlineTA><NlmUniqueID>101186374</NlmUniqueID><ISSNLinking>1545-9985</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000715615">dopegal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.4.3.4</RegistryNumber><NameOfSubstance UI="D008995">Monoamine Oxidase</NameOfSubstance></Chemical><Chemical><RegistryNumber>GO1N1ZPR3B</RegistryNumber><NameOfSubstance UI="D000079">Acetaldehyde</NameOfSubstance></Chemical><Chemical><RegistryNumber>X4W3ENH1CV</RegistryNumber><NameOfSubstance UI="D009638">Norepinephrine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000079" MajorTopicYN="N">Acetaldehyde</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008125" MajorTopicYN="N">Locus Coeruleus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008995" MajorTopicYN="N">Monoamine Oxidase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009638" MajorTopicYN="Y">Norepinephrine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Competing Interests. The authors have declared that no conflict of interests exists.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>2</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>25</Day><Hour>5</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>10</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35332321</ArticleId><ArticleId IdType="mid">NIHMS1787080</ArticleId><ArticleId IdType="pmc">PMC9018606</ArticleId><ArticleId IdType="doi">10.1038/s41594-022-00745-3</ArticleId><ArticleId IdType="pii">10.1038/s41594-022-00745-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Grundke-Iqbal I et al. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A 83, 4913&#x2013;7 (1986).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC323854</ArticleId><ArticleId IdType="pubmed">3088567</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H &amp; Braak E Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82, 239&#x2013;59 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Arriagada PV, Growdon JH, Hedley-Whyte ET &amp; Hyman BT Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer&#x2019;s disease. Neurology 42, 631&#x2013;9 (1992).</Citation><ArticleIdList><ArticleId IdType="pubmed">1549228</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho H et al. Tau PET in Alzheimer disease and mild cognitive impairment. Neurology 87, 375&#x2013;83 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27358341</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinshenker D Functional consequences of locus coeruleus degeneration in Alzheimer&#x2019;s disease. Curr Alzheimer Res 5, 342&#x2013;5 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18537547</ArticleId></ArticleIdList></Reference><Reference><Citation>Chalermpalanupap T et al. Targeting norepinephrine in mild cognitive impairment and Alzheimer&#x2019;s disease. Alzheimers Res Ther 5, 21 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3706916</ArticleId><ArticleId IdType="pubmed">23634965</ArticleId></ArticleIdList></Reference><Reference><Citation>Rorabaugh JM et al. Chemogenetic locus coeruleus activation restores reversal learning in a rat model of Alzheimer&#x2019;s disease. Brain 140, 3023&#x2013;3038 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5841201</ArticleId><ArticleId IdType="pubmed">29053824</ArticleId></ArticleIdList></Reference><Reference><Citation>Ressler KJ &amp; Nemeroff CB Role of norepinephrine in the pathophysiology and treatment of mood disorders. Biol Psychiatry 46, 1219&#x2013;33 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10560027</ArticleId></ArticleIdList></Reference><Reference><Citation>Sara SJ The locus coeruleus and noradrenergic modulation of cognition. Nat Rev Neurosci 10, 211&#x2013;23 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19190638</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrmann N, Lanct?T KL &amp; Khan LR The role of norepinephrine in the behavioral and psychological symptoms of dementia. Journal of Neuropsychiatry &amp; Clinical Neurosciences 16, 261 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15377733</ArticleId></ArticleIdList></Reference><Reference><Citation>Theofilas P, Dunlop S, Heinsen H &amp; Grinberg LT Turning on the Light Within: Subcortical Nuclei of the Isodentritic Core and their Role in Alzheimer&#x2019;s Disease Pathogenesis. J Alzheimers Dis 46, 17&#x2013;34 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4550582</ArticleId><ArticleId IdType="pubmed">25720408</ArticleId></ArticleIdList></Reference><Reference><Citation>Theofilas P et al. Locus coeruleus volume and cell population changes during Alzheimer&#x2019;s disease progression: A stereological study in human postmortem brains with potential implication for early-stage biomarker discovery. Alzheimers Dement 13, 236&#x2013;246 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5298942</ArticleId><ArticleId IdType="pubmed">27513978</ArticleId></ArticleIdList></Reference><Reference><Citation>R&#xfc;b U et al. The Brainstem Tau Cytoskeletal Pathology of Alzheimer&#x2019;s Disease: A Brief Historical Overview and Description of its Anatomical Distribution Pattern, Evolutional Features, Pathogenetic and Clinical Relevance. Curr Alzheimer Res 13, 1178&#x2013;97 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27264543</ArticleId></ArticleIdList></Reference><Reference><Citation>Chalermpalanupap T, Schroeder JP, Rorabaugh JM, Liles LC &amp; Lah JJ Locus Coeruleus Ablation Exacerbates Cognitive Deficits, Neuropathology, and Lethality in P301S Tau Transgenic Mice. 38, 74&#x2013;92 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5761438</ArticleId><ArticleId IdType="pubmed">29133432</ArticleId></ArticleIdList></Reference><Reference><Citation>Wischik CM, Harrington CR &amp; Storey JM Tau-aggregation inhibitor therapy for Alzheimer&#x2019;s disease. Biochem Pharmacol 88, 529&#x2013;39 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24361915</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly SC et al. Locus coeruleus cellular and molecular pathology during the progression of Alzheimer&#x2019;s disease. Acta Neuropathol Commun 5, 8 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5251221</ArticleId><ArticleId IdType="pubmed">28109312</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattammal MB, Strong R, Lakshmi VM, Chung HD &amp; Stephenson AH Prostaglandin H synthetase-mediated metabolism of dopamine: implication for Parkinson&#x2019;s disease. J Neurochem 64, 1645&#x2013;54 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">7891092</ArticleId></ArticleIdList></Reference><Reference><Citation>Burke WJ 3,4-dihydroxyphenylacetaldehyde: a potential target for neuroprotective therapy in Parkinson&#x2019;s disease. Curr Drug Targets CNS Neurol Disord 2, 143&#x2013;8 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12769806</ArticleId></ArticleIdList></Reference><Reference><Citation>Li SW, Lin TS, Minteer S &amp; Burke WJ 3,4-Dihydroxyphenylacetaldehyde and hydrogen peroxide generate a hydroxyl radical: possible role in Parkinson&#x2019;s disease pathogenesis. Brain Res Mol Brain Res 93, 1&#x2013;7 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11532332</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisenhofer G, Kopin IJ &amp; Goldstein DS Catecholamine metabolism: a contemporary view with implications for physiology and medicine. Pharmacol Rev 56, 331&#x2013;49 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15317907</ArticleId></ArticleIdList></Reference><Reference><Citation>Burke WJ et al. Accumulation of 3,4-dihydroxyphenylglycolaldehyde, the neurotoxic monoamine oxidase A metabolite of norepinephrine, in locus ceruleus cell bodies in Alzheimer&#x2019;s disease: mechanism of neuron death. Brain Res 816, 633&#x2013;7 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">9878889</ArticleId></ArticleIdList></Reference><Reference><Citation>Burke WJ et al. Neurotoxicity of MAO metabolites of catecholamine neurotransmitters: role in neurodegenerative diseases. Neurotoxicology 25, 101&#x2013;15 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">14697885</ArticleId></ArticleIdList></Reference><Reference><Citation>Burke WJ, Kristal BS, Yu BP, Li SW &amp; Lin TS Norepinephrine transmitter metabolite generates free radicals and activates mitochondrial permeability transition: a mechanism for DOPEGAL-induced apoptosis. Brain Res 787, 328&#x2013;32 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9518674</ArticleId></ArticleIdList></Reference><Reference><Citation>Kristal BS et al. Selective dopaminergic vulnerability: 3,4-dihydroxyphenylacetaldehyde targets mitochondria. Free Radic Biol Med 30, 924&#x2013;31 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11295535</ArticleId></ArticleIdList></Reference><Reference><Citation>Burke WJ, Schmitt CA, Gillespie KN &amp; Li SW Norepinephrine transmitter metabolite is a selective cell death messenger in differentiated rat pheochromocytoma cells. Brain Res 722, 232&#x2013;5 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8813375</ArticleId></ArticleIdList></Reference><Reference><Citation>Burke WJ et al. Catecholamine monoamine oxidase a metabolite in adrenergic neurons is cytotoxic in vivo. Brain Res 891, 218&#x2013;27 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11164826</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z et al. Cleavage of tau by asparagine endopeptidase mediates the neurofibrillary pathology in Alzheimer&#x2019;s disease. Nat Med 20, 1254&#x2013;62 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4224595</ArticleId><ArticleId IdType="pubmed">25326800</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z et al. Delta-secretase cleaves amyloid precursor protein and regulates the pathogenesis in Alzheimer&#x2019;s disease. Nat Commun 6, 8762 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4659940</ArticleId><ArticleId IdType="pubmed">26549211</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang SS et al. &#x3b1;-Synuclein stimulation of monoamine oxidase-B and legumain protease mediates the pathology of Parkinson&#x2019;s disease. Embo j 37(2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6003650</ArticleId><ArticleId IdType="pubmed">29769405</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang SS et al. Norepinephrine metabolite DOPEGAL activates AEP and pathological Tau aggregation in locus coeruleus. J Clin Invest 130, 422&#x2013;437 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6934194</ArticleId><ArticleId IdType="pubmed">31793911</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang SS et al. ApoE4 inhibition of VMAT2 in the locus coeruleus exacerbates Tau pathology in Alzheimer&#x2019;s disease. Acta Neuropathol (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8217363</ArticleId><ArticleId IdType="pubmed">33895869</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook C et al. Acetylation of the KXGS motifs in tau is a critical determinant in modulation of tau aggregation and clearance. Hum Mol Genet 23, 104&#x2013;16 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3857946</ArticleId><ArticleId IdType="pubmed">23962722</ArticleId></ArticleIdList></Reference><Reference><Citation>Leuzy A et al. Longitudinal tau and metabolic PET imaging in relation to novel CSF tau measures in Alzheimer&#x2019;s disease. Eur J Nucl Med Mol Imaging 46, 1152&#x2013;1163 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6451715</ArticleId><ArticleId IdType="pubmed">30610252</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K et al. Cerebrospinal fluid tau fragment correlates with tau PET: a candidate biomarker for tangle pathology. Brain 143, 650&#x2013;660 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7009597</ArticleId><ArticleId IdType="pubmed">31834365</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z et al. Asparagine endopeptidase cleaves &#x3b1;-synuclein and mediates pathologic activities in Parkinson&#x2019;s disease. Nat Struct Mol Biol 24, 632&#x2013;642 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5871868</ArticleId><ArticleId IdType="pubmed">28671665</ArticleId></ArticleIdList></Reference><Reference><Citation>Sayre LM, Smith MA &amp; Perry G Chemistry and biochemistry of oxidative stress in neurodegenerative disease. Curr Med Chem 8, 721&#x2013;38 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11375746</ArticleId></ArticleIdList></Reference><Reference><Citation>Marchitti SA, Deitrich RA &amp; Vasiliou V Neurotoxicity and metabolism of the catecholamine-derived 3,4-dihydroxyphenylacetaldehyde and 3,4-dihydroxyphenylglycolaldehyde: the role of aldehyde dehydrogenase. Pharmacol Rev 59, 125&#x2013;50 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17379813</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuma DJ, Donohue TM Jr., Medina VA &amp; Sorrell MF Enhancement of acetaldehyde-protein adduct formation by L-ascorbate. Arch Biochem Biophys 234, 377&#x2013;81 (1984).</Citation><ArticleIdList><ArticleId IdType="pubmed">6093697</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng Y &amp; Bai F The Association of Tau With Mitochondrial Dysfunction in Alzheimer&#x2019;s Disease. Front Neurosci 12, 163 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5874499</ArticleId><ArticleId IdType="pubmed">29623026</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandelkow EM, Stamer K, Vogel R, Thies E &amp; Mandelkow E Clogging of axons by tau, inhibition of axonal traffic and starvation of synapses. Neurobiol Aging 24, 1079&#x2013;85 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">14643379</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y et al. Tau accumulation impairs mitophagy via increasing mitochondrial membrane potential and reducing mitochondrial Parkin. Oncotarget 7, 17356&#x2013;68 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4951217</ArticleId><ArticleId IdType="pubmed">26943044</ArticleId></ArticleIdList></Reference><Reference><Citation>Li XC et al. Human wild-type full-length tau accumulation disrupts mitochondrial dynamics and the functions via increasing mitofusins. Sci Rep 6, 24756 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4838862</ArticleId><ArticleId IdType="pubmed">27099072</ArticleId></ArticleIdList></Reference><Reference><Citation>Jucker M &amp; Walker LC Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders. Ann Neurol 70, 532&#x2013;40 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3203752</ArticleId><ArticleId IdType="pubmed">22028219</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibbons GS, Lee VMY &amp; Trojanowski JQ Mechanisms of Cell-to-Cell Transmission of Pathological Tau: A Review. JAMA Neurol 76, 101&#x2013;108 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6382549</ArticleId><ArticleId IdType="pubmed">30193298</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell BJ, Malvankar MM, Tallon C &amp; Slusher BS Sowing the Seeds of Discovery: Tau-Propagation Models of Alzheimer&#x2019;s Disease. ACS Chem Neurosci 11, 3499&#x2013;3509 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7992042</ArticleId><ArticleId IdType="pubmed">33050700</ArticleId></ArticleIdList></Reference><Reference><Citation>Asai H et al. Depletion of microglia and inhibition of exosome synthesis halt tau propagation. Nat Neurosci 18, 1584&#x2013;93 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4694577</ArticleId><ArticleId IdType="pubmed">26436904</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegmann S et al. Removing endogenous tau does not prevent tau propagation yet reduces its neurotoxicity. EMBO J 34, 3028&#x2013;41 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4687785</ArticleId><ArticleId IdType="pubmed">26538322</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka MT et al. Locus ceruleus degeneration promotes Alzheimer pathogenesis in amyloid precursor protein 23 transgenic mice. J Neurosci 26, 1343&#x2013;54 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6675491</ArticleId><ArticleId IdType="pubmed">16452658</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammerschmidt T et al. Selective loss of noradrenaline exacerbates early cognitive dysfunction and synaptic deficits in APP/PS1 mice. Biol Psychiatry 73, 454&#x2013;63 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4712953</ArticleId><ArticleId IdType="pubmed">22883210</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinshenker D Long Road to Ruin: Noradrenergic Dysfunction in Neurodegenerative Disease. Trends Neurosci 41, 211&#x2013;223 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5878728</ArticleId><ArticleId IdType="pubmed">29475564</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka MT et al. Locus ceruleus controls Alzheimer&#x2019;s disease pathology by modulating microglial functions through norepinephrine. Proc Natl Acad Sci U S A 107, 6058&#x2013;63 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2851853</ArticleId><ArticleId IdType="pubmed">20231476</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu K et al. High-Throughput Profiling of Proteome and Posttranslational Modifications by 16-Plex TMT Labeling and Mass Spectrometry. Methods Mol Biol 2228, 205&#x2013;224 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8458009</ArticleId><ArticleId IdType="pubmed">33950493</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma B et al. PEAKS: powerful software for peptide de novo sequencing by tandem mass spectrometry. Rapid Commun Mass Spectrom 17, 2337&#x2013;42 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">14558135</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu K et al. High-Throughput Profiling of Proteome and Posttranslational Modifications by 16-Plex TMT Labeling and Mass Spectrometry. Methods Mol Biol 2228, 205&#x2013;224 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8458009</ArticleId><ArticleId IdType="pubmed">33950493</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma B et al. PEAKS: powerful software for peptide de novo sequencing by tandem mass spectrometry. Rapid Commun Mass Spectrom 17, 2337&#x2013;42 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">14558135</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35333573</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2375-2548</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>12</Issue><PubDate><Year>2022</Year><Month>Mar</Month><Day>25</Day></PubDate></JournalIssue><Title>Science advances</Title><ISOAbbreviation>Sci Adv</ISOAbbreviation></Journal><ArticleTitle>pH regulates potassium conductance and drives a constitutive proton current in human TMEM175.</ArticleTitle><Pagination><StartPage>eabm1568</StartPage><MedlinePgn>eabm1568</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">eabm1568</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1126/sciadv.abm1568</ELocationID><Abstract><AbstractText>Human TMEM175, a noncanonical potassium (K<sup>+</sup>) channel in endolysosomes, contributes to their pH stability and is implicated in the pathogenesis of Parkinson's disease (PD). Structurally, the TMEM175 family exhibits an architecture distinct from canonical potassium channels, as it lacks the typical TVGYG selectivity filter. Here, we show that human TMEM175 not only exhibits pH-dependent structural changes that reduce K<sup>+</sup> permeation at acidic pH but also displays proton permeation. TMEM175 constitutively conducts K<sup>+</sup> at pH 7.4 but displays reduced K<sup>+</sup> permeation at lower pH. In contrast, proton current through TMEM175 increases with decreasing pH because of the increased proton gradient. Molecular dynamics simulation, structure-based mutagenesis, and electrophysiological analysis suggest that K<sup>+</sup> ions and protons share the same permeation pathway. The M393T variant of human TMEM175 associated with PD shows reduced function in both K<sup>+</sup> and proton permeation. Together, our structural and electrophysiological analysis reveals a mechanism of TMEM175 regulation by pH.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Wang</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0001-7577-456X</Identifier><AffiliationInfo><Affiliation>Departments of Otolaryngology and Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Chen</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-7212-4588</Identifier><AffiliationInfo><Affiliation>Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Longfei</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-7788-2123</Identifier><AffiliationInfo><Affiliation>Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rawson</LastName><ForeName>Shaun</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-2973-2630</Identifier><AffiliationInfo><Affiliation>Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Wen Jun</ForeName><Initials>WJ</Initials><Identifier Source="ORCID">0000-0002-3982-9305</Identifier><AffiliationInfo><Affiliation>Department of Chemistry, University of Southern California, Los Angeles, CA 90089, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nist-Lund</LastName><ForeName>Carl</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-0224-7387</Identifier><AffiliationInfo><Affiliation>Departments of Otolaryngology and Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Jason</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-3036-9928</Identifier><AffiliationInfo><Affiliation>Departments of Otolaryngology and Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Zhangfei</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Biological Chemistry and Pharmacology, The Ohio State University, Columbus, OH 43210, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xia</LastName><ForeName>Shiyu</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holt</LastName><ForeName>Jeffrey R</ForeName><Initials>JR</Initials><Identifier Source="ORCID">0000-0002-7182-8011</Identifier><AffiliationInfo><Affiliation>Departments of Otolaryngology and Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Hao</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-7281-8579</Identifier><AffiliationInfo><Affiliation>Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fu</LastName><ForeName>Tian-Min</ForeName><Initials>TM</Initials><Identifier Source="ORCID">0000-0002-6281-1752</Identifier><AffiliationInfo><Affiliation>Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biological Chemistry and Pharmacology, The Ohio State University, Columbus, OH 43210, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P41 GM103310</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 HD105351</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DC013521</GrantID><Acronym>DC</Acronym><Agency>NIDCD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 HL066987</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>03</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Adv</MedlineTA><NlmUniqueID>101653440</NlmUniqueID><ISSNLinking>2375-2548</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>25</Day><Hour>17</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>26</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>3</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35333573</ArticleId><ArticleId IdType="pmc">PMC8956256</ArticleId><ArticleId IdType="doi">10.1126/sciadv.abm1568</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lawrence R. E., Zoncu R., The lysosome as a cellular centre for signalling, metabolism and quality control. Nat. Cell Biol. 21, 133&#x2013;142 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30602725</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu H., Ren D., Lysosomal physiology. Annu. Rev. Physiol. 77, 57&#x2013;80 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4524569</ArticleId><ArticleId IdType="pubmed">25668017</ArticleId></ArticleIdList></Reference><Reference><Citation>Cang C., Aranda K., Seo Y. J., Gasnier B., Ren D., TMEM175 is an organelle K+ channel regulating lysosomal function. Cell 162, 1101&#x2013;1112 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26317472</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalls M. A., Pankratz N., Lill C. M., Do C. B., Hernandez D. G., Saad M., De Stefano A. L., Kara E., Bras J., Sharma M., Schulte C., Keller M. F., Arepalli S., Letson C., Edsall C., Stefansson H., Liu X., Pliner H., Lee J. H., Cheng R.; International Parkinson&#x2019;s Disease Genomics Consortium (IPDGC); Parkinson&#x2019;s Study Group (PSG) Parkinson&#x2019;s Research: The Organized GENetics Initiative (PROGENI); 23andMe; GenePD; NeuroGenetics Research Consortium (NGRC); Hussman Institute of Human Genomics (HIHG); The Ashkenazi Jewish Dataset Investigator; Cohorts for Health and Aging Research in Genetic Epidemiology (CHARGE); North American Brain Expression Consortium (NABEC); United Kingdom Brain Expression Consortium (UKBEC); Greek Parkinson&#x2019;s Disease Consortium; Alzheimer Genetic Analysis Group, Ikram M. A., Ioannidis J. P. A., Hadjigeorgiou G. M., Bis J. C., Martinez M., Perlmutter J. S., Goate A., Marder K., Fiske B., Sutherland M., Xiromerisiou G., Myers R. H., Clark L. N., Stefansson K., Hardy J. A., Heutink P., Chen H., Wood N. W., Houlden H., Payami H., Brice A., Scott W. K., Gasser T., Bertram L., Eriksson N., Foroud T., Singleton A. B., Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson&#x2019;s disease. Nat. Genet. 46, 989&#x2013;993 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4146673</ArticleId><ArticleId IdType="pubmed">25064009</ArticleId></ArticleIdList></Reference><Reference><Citation>Jinn S., Drolet R. E., Cramer P. E., Wong A. H. K., Toolan D. M., Gretzula C. A., Voleti B., Vassileva G., Disa J., Tadin-Strapps M., Stone D. J., TMEM175 deficiency impairs lysosomal and mitochondrial function and increases &#x3b1;-synuclein aggregation. Proc. Natl. Acad. Sci. U.S.A. 114, 2389&#x2013;2394 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5338534</ArticleId><ArticleId IdType="pubmed">28193887</ArticleId></ArticleIdList></Reference><Reference><Citation>Jinn S., Blauwendraat C., Toolan D., Gretzula C. A., Drolet R. E., Smith S., Nalls M. A., Marcus J., Singleton A. B., Stone D. J., Functionalization of the TMEM175 p.M393T variant as a risk factor for Parkinson disease. Hum. Mol. Genet. 28, 3244&#x2013;3254 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6859430</ArticleId><ArticleId IdType="pubmed">31261387</ArticleId></ArticleIdList></Reference><Reference><Citation>Krohn L., &#xd6;zt&#xfc;rk T. N., Vanderperre B., Ouled Amar Bencheikh B., Ruskey J. A., Laurent S. B., Spiegelman D., Postuma R. B., Arnulf I., Hu M. T. M., Dauvilliers Y., H&#xf6;gl B., Stefani A., Monaca C. C., Plazzi G., Antelmi E., Ferini-Strambi L., Heidbreder A., Rudakou U., Cochen de Cock V., Young P., Wolf P., Oliva P., Zhang X. K., Greenbaum L., Liong C., Gagnon J. F., Desautels A., Hassin-Baer S., Montplaisir J. Y., Dupr&#xe9; N., Rouleau G. A., Fon E. A., Trempe J. F., Lamoureux G., Alcalay R. N., Gan-Or Z., Genetic, structural, and functional evidence link TMEM175 to synucleinopathies. Ann. Neurol. 87, 139&#x2013;153 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31658403</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu X. C., Cao L., Tan M. S., Jiang T., Wang H. F., Lu H., Tan C. C., Zhang W., Tan L., Yu J. T., Association of Parkinson&#x2019;s disease GWAS-linked loci with Alzheimer&#x2019;s disease in Han Chinese. Mol. Neurobiol. 54, 308&#x2013;318 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">26738859</ArticleId></ArticleIdList></Reference><Reference><Citation>Jing C. C., Luo X. G., Cui H. G., Li F. R., Li P., Jiang E. Z., Ren Y., Pang H., Screening of polymorphisms located in the FGF20 and TMEM175 genes in North Chinese Parkinson&#x2019;s disease patients. Genet. Mol. Res. 14, 13679&#x2013;13687 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26535683</ArticleId></ArticleIdList></Reference><Reference><Citation>Blauwendraat C., Heilbron K., Vallerga C. L., Bandres-Ciga S., von Coelln R., Pihlstr&#xf8;m L., Sim&#xf3;n-S&#xe1;nchez J., Schulte C., Sharma M., Krohn L., Siitonen A., Iwaki H., Leonard H., Noyce A. J., Tan M., Gibbs J. R., Hernandez D. G., Scholz S. W., Jankovic J., Shulman L. M., Lesage S., Corvol J. C., Brice A., van Hilten J. J., Marinus J.; The 23andMe Research Team, Eerola-Rautio J., Tienari P., Majamaa K., Toft M., Grosset D. G., Gasser T., Heutink P., Shulman J. M., Wood N., Hardy J., Morris H. R., Hinds D. A., Gratten J., Visscher P. M., Gan-Or Z., Nalls M. A., Singleton A. B.; for the International Parkinson&#x2019;s Disease Genomics Consortium (IPDGC) , Parkinson&#x2019;s disease age at onset genome-wide association study: Defining heritability, genetic loci, and &#x3b1;-synuclein mechanisms. Mov. Disord. 34, 866&#x2013;875 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6579628</ArticleId><ArticleId IdType="pubmed">30957308</ArticleId></ArticleIdList></Reference><Reference><Citation>Senkevich K., Gan-Or Z., Autophagy lysosomal pathway dysfunction in Parkinson&#x2019;s disease; evidence from human genetics. Parkinsonism Relat. Disord. 73, 60&#x2013;71 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31761667</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark L. N., Ross B. M., Wang Y., Mejia-Santana H., Harris J., Louis E. D., Cote L. J., Andrews H., Fahn S., Waters C., Ford B., Frucht S., Ottman R., Marder K., Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease. Neurology 69, 1270&#x2013;1277 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3624967</ArticleId><ArticleId IdType="pubmed">17875915</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee C., Guo J., Zeng W., Kim S., She J., Cang C., Ren D., Jiang Y., The lysosomal potassium channel TMEM175 adopts a novel tetrameric architecture. Nature 547, 472&#x2013;475 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5901963</ArticleId><ArticleId IdType="pubmed">28723891</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunner J. D., Jakob R. P., Schulze T., Neldner Y., Moroni A., Thiel G., Maier T., Schenck S., Structural basis for ion selectivity in TMEM175 K+ channels. eLife 9, e53683 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7176437</ArticleId><ArticleId IdType="pubmed">32267231</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh S., Paknejad N., Hite R. K., Gating and selectivity mechanisms for the lysosomal K+ channel TMEM175. eLife 9, e53430 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7141809</ArticleId><ArticleId IdType="pubmed">32228865</ArticleId></ArticleIdList></Reference><Reference><Citation>Wie J., Liu Z., Song H., Tropea T. F., Yang L., Wang H., Liang Y., Cang C., Aranda K., Lohmann J., Yang J., Lu B., Chen-Plotkin A. S., Luk K. C., Ren D., A growth-factor-activated lysosomal K+ channel regulates Parkinson&#x2019;s pathology. Nature 592, E10 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7979525</ArticleId><ArticleId IdType="pubmed">33505021</ArticleId></ArticleIdList></Reference><Reference><Citation>Karatas M., Dogan S., Spahiu E., A&#x161;i&#x107; A., Be&#x161;i&#x107; L., Turan Y., Enzyme kinetics and inhibition parameters of human leukocyte glucosylceramidase. Heliyon 6, e05191 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7609449</ArticleId><ArticleId IdType="pubmed">33163670</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramsey I. S., Mokrab Y., Carvacho I., Sands Z. A., Sansom M. S. P., Clapham D. E., An aqueous H+ permeation pathway in the voltage-gated proton channel Hv1. Nat. Struct. Mol. Biol. 17, 869&#x2013;875 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4035905</ArticleId><ArticleId IdType="pubmed">20543828</ArticleId></ArticleIdList></Reference><Reference><Citation>DeCoursey T. E., Voltage-gated proton channels: Molecular biology, physiology, and pathophysiology of the H(V) family. Physiol. Rev. 93, 599&#x2013;652 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677779</ArticleId><ArticleId IdType="pubmed">23589829</ArticleId></ArticleIdList></Reference><Reference><Citation>Saotome K., Teng B., Tsui C. C. (. A.)., Lee W. H., Tu Y. H., Kaplan J. P., Sansom M. S. P., Liman E. R., Ward A. B., Structures of the otopetrin proton channels Otop1 and Otop3. Nat. Struct. Mol. Biol. 26, 518&#x2013;525 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6564688</ArticleId><ArticleId IdType="pubmed">31160780</ArticleId></ArticleIdList></Reference><Reference><Citation>Tu Y. H., Cooper A. J., Teng B., Chang R. B., Artiga D. J., Turner H. N., Mulhall E. M., Ye W., Smith A. D., Liman E. R., An evolutionarily conserved gene family encodes proton-selective ion channels. Science 359, 1047&#x2013;1050 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5845439</ArticleId><ArticleId IdType="pubmed">29371428</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu F., Chamberlin A., Watkins B. M., Ionescu A., Perez M. E., Barro-Soria R., Gonz&#xe1;lez C., Noskov S. Y., Larsson H. P., Molecular mechanism of Zn2+ inhibition of a voltage-gated proton channel. Proc. Natl. Acad. Sci. U.S.A. 113, E5962&#x2013;E5971 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5056077</ArticleId><ArticleId IdType="pubmed">27647906</ArticleId></ArticleIdList></Reference><Reference><Citation>Cang C., Bekele B., Ren D., The voltage-gated sodium channel TPC1 confers endolysosomal excitability. Nat. Chem. Biol. 10, 463&#x2013;469 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24776928</ArticleId></ArticleIdList></Reference><Reference><Citation>Goehring A., Lee C. H., Wang K. H., Michel J. C., Claxton D. P., Baconguis I., Althoff T., Fischer S., Garcia K. C., Gouaux E., Screening and large-scale expression of membrane proteins in mammalian cells for structural studies. Nat. Protoc. 9, 2574&#x2013;2585 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4291175</ArticleId><ArticleId IdType="pubmed">25299155</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng S. Q., Palovcak E., Armache J.-P., Verba K. A., Cheng Y., Agard D. A., MotionCor2: Anisotropic correction of beam-induced motion for improved cryo-electron microscopy. Nat. Methods 14, 331&#x2013;332 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5494038</ArticleId><ArticleId IdType="pubmed">28250466</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohou A., Grigorieff N., CTFFIND4: Fast and accurate defocus estimation from electron micrographs. J. Struct. Biol. 192, 216&#x2013;221 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6760662</ArticleId><ArticleId IdType="pubmed">26278980</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner T., Merino F., Stabrin M., Moriya T., Antoni C., Apelbaum A., Hagel P., Sitsel O., Raisch T., Prumbaum D., Quentin D., Roderer D., Tacke S., Siebolds B., Schubert E., Shaikh T. R., Lill P., Gatsogiannis C., Raunser S., SPHIRE-crYOLO is a fast and accurate fully automated particle picker for cryo-EM. Commun. Biol. 2, 218 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6584505</ArticleId><ArticleId IdType="pubmed">31240256</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheres S. H. W., RELION: Implementation of a Bayesian approach to cryo-EM structure determination. J. Struct. Biol. 180, 519&#x2013;530 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3690530</ArticleId><ArticleId IdType="pubmed">23000701</ArticleId></ArticleIdList></Reference><Reference><Citation>Zivanov J., Nakane T., Scheres S. H. W., A Bayesian approach to beam-induced motion correction in cryo-EM single-particle analysis. IUCrJ 6, 5&#x2013;17 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6327179</ArticleId><ArticleId IdType="pubmed">30713699</ArticleId></ArticleIdList></Reference><Reference><Citation>Punjani A., Rubinstein J. L., Fleet D. J., Brubaker M. A., cryoSPARC: Algorithms for rapid unsupervised cryo-EM structure determination. Nat. Methods 14, 290&#x2013;296 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28165473</ArticleId></ArticleIdList></Reference><Reference><Citation>Zivanov J., Nakane T., Scheres S. H. W., Estimation of high-order aberrations and anisotropic magnification from cryo-EM data sets in RELION-3.1. IUCrJ 7, 253&#x2013;267 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7055373</ArticleId><ArticleId IdType="pubmed">32148853</ArticleId></ArticleIdList></Reference><Reference><Citation>Morin A., Eisenbraun B., Key J., Sanschagrin P. C., Timony M. A., Ottaviano M., Sliz P., Collaboration gets the most out of software. eLife 2, e01456 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3771563</ArticleId><ArticleId IdType="pubmed">24040512</ArticleId></ArticleIdList></Reference><Reference><Citation>Biasini M., Bienert S., Waterhouse A., Arnold K., Studer G., Schmidt T., Kiefer F., Cassarino T. G., Bertoni M., Bordoli L., Schwede T., SWISS-MODEL: Modelling protein tertiary and quaternary structure using evolutionary information. Nucleic Acids Res. 42, W252&#x2013;W258 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4086089</ArticleId><ArticleId IdType="pubmed">24782522</ArticleId></ArticleIdList></Reference><Reference><Citation>Pettersen E. F., Goddard T. D., Huang C. C., Couch G. S., Greenblatt D. M., Meng E. C., Ferrin T. E., UCSF Chimera&#x2014;A visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605&#x2013;1612 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15264254</ArticleId></ArticleIdList></Reference><Reference><Citation>Emsley P., Cowtan K., Coot: Model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126&#x2013;2132 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15572765</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams P. D., Afonine P. V., Bunk&#xf3;czi G., Chen V. B., Davis I. W., Echols N., Headd J. J., Hung L. W., Kapral G. J., Grosse-Kunstleve R. W., McCoy A. J., Moriarty N. W., Oeffner R., Read R. J., Richardson D. C., Richardson J. S., Terwilliger T. C., Zwart P. H., PHENIX: A comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66, 213&#x2013;221 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2815670</ArticleId><ArticleId IdType="pubmed">20124702</ArticleId></ArticleIdList></Reference><Reference><Citation>W. L. DeLano, The PyMOL Molecular Graphics System (2002).</Citation></Reference><Reference><Citation>Fiser A., Sali A., Modeller: Generation and refinement of homology-based protein structure models. Methods Enzymol. 374, 461&#x2013;491 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">14696385</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang J., Rauscher S., Nawrocki G., Ran T., Feig M., de Groot B. L., Grubm&#xfc;ller H., MacKerell A. D. Jr., CHARMM36m: An improved force field for folded and intrinsically disordered proteins. Nat. Methods 14, 71&#x2013;73 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5199616</ArticleId><ArticleId IdType="pubmed">27819658</ArticleId></ArticleIdList></Reference><Reference><Citation>Jo S., Kim T., Iyer V. G., Im W., CHARMM-GUI: A web-based graphical user interface for CHARMM. J. Comput. Chem. 29, 1859&#x2013;1865 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18351591</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Der Spoel D., Lindahl E., Hess B., Groenhof G., Mark A. E., Berendsen H. J. C., GROMACS: Fast, flexible, and free. J. Comput. Chem. 26, 1701&#x2013;1718 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16211538</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng W., Yang J. W., Beauchamp E., Cai R., Hussein S., Hofmann L., Li Q., Flockerzi V., Berthiaume L. G., Tang J., Chen X. Z., Regulation of TRPP3 channel function by N-terminal domain palmitoylation and phosphorylation. J. Biol. Chem. 291, 25678&#x2013;25691 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5207264</ArticleId><ArticleId IdType="pubmed">27754867</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng W., Yang X., Hu R., Cai R., Hofmann L., Wang Z., Hu Q., Liu X., Bulkley D., Yu Y., Tang J., Flockerzi V., Cao Y., Cao E., Chen X. Z., Hydrophobic pore gates regulate ion permeation in polycystic kidney disease 2 and 2L1 channels. Nat. Commun. 9, 2302 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5998024</ArticleId><ArticleId IdType="pubmed">29899465</ArticleId></ArticleIdList></Reference><Reference><Citation>Smart O. S., Neduvelil J. G., Wang X., Wallace B. A., Sansom M. S. P., HOLE: A program for the analysis of the pore dimensions of ion channel structural models. J. Mol. Graph. 14, 354&#x2013;360 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">9195488</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35344985</PMID><DateCompleted><Year>2022</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>605</Volume><Issue>7909</Issue><PubDate><Year>2022</Year><Month>May</Month></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Age-dependent formation of TMEM106B amyloid filaments in human brains.</ArticleTitle><Pagination><StartPage>310</StartPage><EndPage>314</EndPage><MedlinePgn>310-314</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41586-022-04650-z</ELocationID><Abstract><AbstractText>Many age-dependent neurodegenerative diseases, such as Alzheimer's and Parkinson's, are characterized by abundant inclusions of amyloid filaments. Filamentous inclusions of the proteins tau, amyloid-&#x3b2;, &#x3b1;-synuclein and transactive response DNA-binding protein (TARDBP; also known as TDP-43) are the most common<sup>1,2</sup>. Here we used structure determination by cryogenic electron microscopy to show that residues 120-254 of the lysosomal type II transmembrane protein 106B (TMEM106B) also form amyloid filaments in human brains. We determined the structures of TMEM106B filaments from a number of brain regions of 22 individuals with abundant amyloid deposits, including those resulting from sporadic and inherited tauopathies, amyloid-&#x3b2; amyloidoses, synucleinopathies and TDP-43 proteinopathies, as well as from the frontal cortex of 3 individuals with normal neurology and no or only a few amyloid deposits. We observed three TMEM106B folds, with no clear relationships between folds and diseases. TMEM106B filaments correlated with the presence of a 29-kDa sarkosyl-insoluble fragment and globular cytoplasmic inclusions, as detected by an antibody specific to the carboxy-terminal region of TMEM106B. The identification of TMEM106B filaments in the brains of older, but not younger, individuals with normal neurology indicates that they form in an age-dependent manner.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Schweighauser</LastName><ForeName>Manuel</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-1848-1610</Identifier><AffiliationInfo><Affiliation>Medical Research Council Laboratory of Molecular Biology, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Arseni</LastName><ForeName>Diana</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-7585-288X</Identifier><AffiliationInfo><Affiliation>Medical Research Council Laboratory of Molecular Biology, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Bacioglu</LastName><ForeName>Mehtap</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-0304-7026</Identifier><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Huang</LastName><ForeName>Melissa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Medical Research Council Laboratory of Molecular Biology, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>L&#xf6;vestam</LastName><ForeName>Sofia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Medical Research Council Laboratory of Molecular Biology, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Shi</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0003-1579-7561</Identifier><AffiliationInfo><Affiliation>Medical Research Council Laboratory of Molecular Biology, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Yang</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0003-2238-6437</Identifier><AffiliationInfo><Affiliation>Medical Research Council Laboratory of Molecular Biology, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Wenjuan</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0002-3011-9956</Identifier><AffiliationInfo><Affiliation>Medical Research Council Laboratory of Molecular Biology, Cambridge, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Research Council Prion Unit, Institute of Prion Diseases, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kotecha</LastName><ForeName>Abhay</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-4480-5439</Identifier><AffiliationInfo><Affiliation>Thermo Fisher Scientific, Eindhoven, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garringer</LastName><ForeName>Holly J</ForeName><Initials>HJ</Initials><Identifier Source="ORCID">0000-0002-1899-7676</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vidal</LastName><ForeName>Ruben</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hallinan</LastName><ForeName>Grace I</ForeName><Initials>GI</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Newell</LastName><ForeName>Kathy L</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tarutani</LastName><ForeName>Airi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Brain and Neurosciences, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murayama</LastName><ForeName>Shigeo</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Molecular Research Center for Children's Mental Development, United Graduate School of Child Development, University of Osaka, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miyazaki</LastName><ForeName>Masayuki</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saito</LastName><ForeName>Yuko</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neuropathology, Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoshida</LastName><ForeName>Mari</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Medical Science of Aging, Aichi Medical University, Nagakute, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hasegawa</LastName><ForeName>Kazuko</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Neurology, Sagamihara National Hospital, Sagamihara, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lashley</LastName><ForeName>Tammaryn</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease and Queen Square Brain Bank for Neurological Disorders, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Revesz</LastName><ForeName>Tamas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease and Queen Square Brain Bank for Neurological Disorders, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kovacs</LastName><ForeName>Gabor G</ForeName><Initials>GG</Initials><Identifier Source="ORCID">0000-0003-3841-5511</Identifier><AffiliationInfo><Affiliation>Tanz Centre for Research in Neurodegenerative Diseases and Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Neurology, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Swieten</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Erasmus Medical Centre, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takao</LastName><ForeName>Masaki</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Clinical Laboratory, National Center of Neurology and Psychiatry, National Center Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Mihara Memorial Hospital, Isesaki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hasegawa</LastName><ForeName>Masato</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-7415-8159</Identifier><AffiliationInfo><Affiliation>Department of Brain and Neurosciences, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghetti</LastName><ForeName>Bernardino</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-1842-8019</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spillantini</LastName><ForeName>Maria Grazia</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryskeldi-Falcon</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-8176-2618</Identifier><AffiliationInfo><Affiliation>Medical Research Council Laboratory of Molecular Biology, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murzin</LastName><ForeName>Alexey G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>Medical Research Council Laboratory of Molecular Biology, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goedert</LastName><ForeName>Michel</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-5214-7886</Identifier><AffiliationInfo><Affiliation>Medical Research Council Laboratory of Molecular Biology, Cambridge, UK. mg@mrc-lmb.cam.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scheres</LastName><ForeName>Sjors H W</ForeName><Initials>SHW</Initials><Identifier Source="ORCID">0000-0002-0462-6540</Identifier><AffiliationInfo><Affiliation>Medical Research Council Laboratory of Molecular Biology, Cambridge, UK. scheres@mrc-lmb.cam.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MC_UP_1201/25</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P30 AG010133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MC_U105184291</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_UP_1202/5</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>RF1 AG071177</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG072976</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 NS110437</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MC_UP_A025_1013</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>03</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C556915">TMEM106B protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="Y">Aging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="Y">Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000686" MajorTopicYN="Y">Amyloidosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="Y">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="Y">Membrane Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="Y">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>11</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>28</Day><Hour>20</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>3</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35344985</ArticleId><ArticleId IdType="pmc">PMC9095482</ArticleId><ArticleId IdType="doi">10.1038/s41586-022-04650-z</ArticleId><ArticleId IdType="pii">10.1038/s41586-022-04650-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Goedert M. Alzheimer&#x2019;s and Parkinson&#x2019;s diseases: the prion concept in relation to assembled A&#x3b2;, tau and &#x3b1;-synuclein. Science. 2015;349:1255555.</Citation><ArticleIdList><ArticleId IdType="pubmed">26250687</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng C, Trojanowski J. Q., Lee V. M.-Y. Protein transmission in neurodegenerative disease. Nat. Rev. Neurol. 2020;16:199&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9242841</ArticleId><ArticleId IdType="pubmed">32203399</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholson A, Rademakers R. What we know about TMEM106B in neurodegeneration. Acta Neuropathol. 2016;132:639&#x2013;651.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5074873</ArticleId><ArticleId IdType="pubmed">27543298</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng T, Lacrampe A, Hu F. Physiological and pathological functions of TMEM106B: a gene associated with brain aging and multiple brain disorders. Acta Neuropathol. 2021;141:327&#x2013;339.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8049516</ArticleId><ArticleId IdType="pubmed">33386471</ArticleId></ArticleIdList></Reference><Reference><Citation>Uhl&#xe9;n M, et al. Tissue-based map of the human proteome. Science. 2015;347:1260419.</Citation><ArticleIdList><ArticleId IdType="pubmed">25613900</ArticleId></ArticleIdList></Reference><Reference><Citation>Brady OA, Zheng Y, Murphy K, Huang M, Hu F. The frontotemporal lobar degeneration risk factor, TMEM106B, regulates lysosomal morphology and function. Hum. Mol. Genet. 2013;22:685&#x2013;695.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3554197</ArticleId><ArticleId IdType="pubmed">23136129</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Deerlin VM, et al. Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat. Genet. 2010;42:234&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2828525</ArticleId><ArticleId IdType="pubmed">20154673</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruchaga C, et al. TMEM106B gene polymorphism is associated with age at onset in granulin mutation carriers and plasma granulin protein levels. Arch. Neurol. 2011;68:581&#x2013;586.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3090529</ArticleId><ArticleId IdType="pubmed">21220649</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholson AM, et al. TMEM106B p.T185S regulates TMEM106B protein levels: implications for frontotemporal dementia. J. Neurochem. 2013;126:781&#x2013;791.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3766501</ArticleId><ArticleId IdType="pubmed">23742080</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen-Plotkin AS, et al. TMEM106B, the risk gene for frontotemporal dementia, is regulated by microRNA-132/212 cluster and affects progranulin pathways. J. Neurosci. 2012;32:11213&#x2013;11227.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3446826</ArticleId><ArticleId IdType="pubmed">22895706</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhinn H, Abeliovich A. Differential aging analysis in human cerebral cortex identifies variants in TMEM106B and GRN that regulate aging phenotypes. Cell Syst. 2017;4:404&#x2013;415.</Citation><ArticleIdList><ArticleId IdType="pubmed">28330615</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z, et al. The TMEM106B FTLD-protective variant, rs1990621, is also associated with increased neuronal proportion. Acta Neuropathol. 2020;139:45&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6942643</ArticleId><ArticleId IdType="pubmed">31456032</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzpatrick AWP, et al. Cryo-EM structures of tau filaments from Alzheimer&#x2019;s disease. Nature. 2017;547:185&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5552202</ArticleId><ArticleId IdType="pubmed">28678775</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcon B, et al. Structures of filaments from Pick&#x2019;s disease reveal a novel tau protein fold. Nature. 2018;561:137&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6204212</ArticleId><ArticleId IdType="pubmed">30158706</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcon B, et al. Novel tau filament fold in chronic traumatic encephalopathy encloses hydrophobic molecules. Nature. 2019;568:420&#x2013;423.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6472968</ArticleId><ArticleId IdType="pubmed">30894745</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W, et al. Novel tau filament fold in corticobasal degeneration. Nature. 2020;580:283&#x2013;287.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7148158</ArticleId><ArticleId IdType="pubmed">32050258</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, et al. Structure-based classification of tauopathies. Nature. 2021;598:359&#x2013;363.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7611841</ArticleId><ArticleId IdType="pubmed">34588692</ArticleId></ArticleIdList></Reference><Reference><Citation>Schweighauser M, et al. Structures of &#x3b1;-synuclein filaments from multiple system atrophy. Nature. 2020;585:464&#x2013;469.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7116528</ArticleId><ArticleId IdType="pubmed">32461689</ArticleId></ArticleIdList></Reference><Reference><Citation>Kollmer M, et al. Cryo-EM structure and polymorphism of A&#x3b2; amyloid fibrils purified from Alzheimer&#x2019;s brain tissue. Nat. Commun. 2019;10:4760.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6820800</ArticleId><ArticleId IdType="pubmed">31664019</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, et al. Cryo-EM structures of amyloid-&#x3b2; 42 filaments from human brains. Science. 2022;375:167&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7612234</ArticleId><ArticleId IdType="pubmed">35025654</ArticleId></ArticleIdList></Reference><Reference><Citation>Arseni D, et al. Structure of pathological TDP-43 filaments from ALS with FTLD. Nature. 2022;601:139&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7612255</ArticleId><ArticleId IdType="pubmed">34880495</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarutani A, Arai T, Murayama S, Hisanaga S-I, Hasegawa M. Potent prion-like behaviors of pathogenic &#x3b1;-synuclein and evaluation of inactivation methods. Acta Neuropathol. Commun. 2018;6:29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5907316</ArticleId><ArticleId IdType="pubmed">29669601</ArticleId></ArticleIdList></Reference><Reference><Citation>Tunyasuvunakool K, et al. Highly accurate protein structure prediction for the human proteome. Nature. 2021;596:590&#x2013;596.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8387240</ArticleId><ArticleId IdType="pubmed">34293799</ArticleId></ArticleIdList></Reference><Reference><Citation>Takao M, et al. Early-onset dementia with Lewy bodies. Brain Pathol. 2004;14:137&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8095855</ArticleId><ArticleId IdType="pubmed">15193026</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung T, Bader N, Grune T. Lipofuscin: formation, distribution, and metabolic consequences. Ann. N. Y. Acad. Sci. 2007;1119:97&#x2013;111.</Citation><ArticleIdList><ArticleId IdType="pubmed">18056959</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon RA. The role of autophagy in neurodegenerative disease. Nat. Med. 2013;19:983&#x2013;997.</Citation><ArticleIdList><ArticleId IdType="pubmed">23921753</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenberg SG, Davies P. A preparation of Alzheimer paired helical filaments that displays distinct tau proteins by polyacrylamide gel electrophoresis. Proc. Natl Acad. Sci. USA. 1990;87:5827&#x2013;5831.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC54421</ArticleId><ArticleId IdType="pubmed">2116006</ArticleId></ArticleIdList></Reference><Reference><Citation>Taniguchi-Watanabe S, et al. Biochemical classification of tauopathies by immunoblot, protein sequence and mass spectrometric analyses of sarkosyl-insoluble and trypsin-resistant tau. Acta Neuropathol. 2016;131:267&#x2013;280.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Satoh J, et al. TMEM106B expression is reduced in Alzheimer&#x2019;s disease brains. Alzheimers Res. Ther. 2014;6:17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4055042</ArticleId><ArticleId IdType="pubmed">24684749</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a-Nafr&#xed;a J, Watson JF, Greger IH. IVA cloning: a single-tube universal cloning system exploiting bacterial in vivo assembly. Sci. Rep. 2016;6:27459.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4893743</ArticleId><ArticleId IdType="pubmed">27264908</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheres SHW. Amyloid structure determination in RELION-3.1. Acta Crystallogr. 2020;D76:94&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7008511</ArticleId><ArticleId IdType="pubmed">32038040</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohou A, Grigorieff N. CTFFIND4: fast and accurate defocus estimation from electron micrographs. J. Struct. Biol. 2015;192:216&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6760662</ArticleId><ArticleId IdType="pubmed">26278980</ArticleId></ArticleIdList></Reference><Reference><Citation>He S, Scheres SHW. Helical reconstruction in RELION. J. Struct. Biol. 2017;198:163&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5479445</ArticleId><ArticleId IdType="pubmed">28193500</ArticleId></ArticleIdList></Reference><Reference><Citation>Zivanov J, et al. New tools for automated high-resolution cryo-EM structure determination in RELION-3. eLife. 2018;7:e42166.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6250425</ArticleId><ArticleId IdType="pubmed">30412051</ArticleId></ArticleIdList></Reference><Reference><Citation>Zivanov J, Nakane T, Scheres SHW. A Bayesian approach to beam-induced motion correction in cryo-EM single-particle analysis. IUCrJ. 2019;6:5&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6327179</ArticleId><ArticleId IdType="pubmed">30713699</ArticleId></ArticleIdList></Reference><Reference><Citation>Zivanov J, Nakane T, Scheres SHW. Estimation of high-order aberrations and anisotropic magnification from cryo-EM data sets in RELION-3.1. IUCrJ. 2020;7:253&#x2013;267.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7055373</ArticleId><ArticleId IdType="pubmed">32148853</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S, et al. High-resolution noise substitution to measure overfitting and validate resolution in 3D structure determination by single particle electron cryomicroscopy. Ultramicroscopy. 2013;135:24&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3834153</ArticleId><ArticleId IdType="pubmed">23872039</ArticleId></ArticleIdList></Reference><Reference><Citation>de Castro, et al. ScanProsite: detection of PROSITE signature matches and ProRule-associated functional and structural residues in proteins. Nucleic Acids Res. 2006;34:W362&#x2013;W365.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1538847</ArticleId><ArticleId IdType="pubmed">16845026</ArticleId></ArticleIdList></Reference><Reference><Citation>Casa&#xf1;al A, Lohkamp B, Emsley P. Current developments in Coot for macromolecular model building of electron cryo-microscopy and crystallographic data. Protein Sci. 2020;29:1069&#x2013;1078.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7096722</ArticleId><ArticleId IdType="pubmed">31730249</ArticleId></ArticleIdList></Reference><Reference><Citation>Croll TI. ISOLDE: a physically realistic environment for model building into low-resolution electron-density maps. Acta Crystallogr. 2018;D74:519&#x2013;530.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6096486</ArticleId><ArticleId IdType="pubmed">29872003</ArticleId></ArticleIdList></Reference><Reference><Citation>Busch JI, et al. Expression of TMEM106B, the frontotemporal lobar degeneration-associated protein, in normal and diseased human brain. Acta Neuropathol. Commun. 2013;1:36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3893524</ArticleId><ArticleId IdType="pubmed">24252750</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35344984</PMID><DateCompleted><Year>2022</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>605</Volume><Issue>7909</Issue><PubDate><Year>2022</Year><Month>May</Month></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Amyloid fibrils in FTLD-TDP are composed of TMEM106B and not TDP-43.</ArticleTitle><Pagination><StartPage>304</StartPage><EndPage>309</EndPage><MedlinePgn>304-309</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41586-022-04670-9</ELocationID><Abstract><AbstractText>Frontotemporal lobar degeneration (FTLD) is the third most common neurodegenerative condition after Alzheimer's and Parkinson's diseases<sup>1</sup>. FTLD typically presents in 45 to 64 year olds with behavioural changes or progressive decline of language skills<sup>2</sup>. The subtype FTLD-TDP is characterized by certain clinical symptoms and pathological neuronal inclusions with TAR DNA-binding protein (TDP-43) immunoreactivity<sup>3</sup>. Here we extracted amyloid fibrils from brains of four patients representing four of the five FTLD-TDP subclasses, and determined their structures by cryo-electron microscopy. Unexpectedly, all amyloid fibrils examined were composed of a 135-residue carboxy-terminal fragment of transmembrane protein 106B (TMEM106B), a lysosomal membrane protein previously implicated as a genetic risk factor for FTLD-TDP<sup>4</sup>. In addition to TMEM106B fibrils, we detected abundant non-fibrillar aggregated TDP-43 by immunogold labelling. Our observations confirm that FTLD-TDP is associated with amyloid fibrils, and that the fibrils are formed by TMEM106B rather than TDP-43.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s), under exclusive licence to Springer Nature Limited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Jiang</LastName><ForeName>Yi Xiao</ForeName><Initials>YX</Initials><AffiliationInfo><Affiliation>Departments of Chemistry and Biochemistry and Biological Chemistry, UCLA-DOE Institute, and Molecular Biology Institute, UCLA, Los Angeles, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Howard Hughes Medical Institute, UCLA, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Cao</LastName><ForeName>Qin</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Departments of Chemistry and Biochemistry and Biological Chemistry, UCLA-DOE Institute, and Molecular Biology Institute, UCLA, Los Angeles, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Howard Hughes Medical Institute, UCLA, Los Angeles, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders, Ministry of Education, Shanghai Jiao Tong University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sawaya</LastName><ForeName>Michael R</ForeName><Initials>MR</Initials><Identifier Source="ORCID">0000-0003-0874-9043</Identifier><AffiliationInfo><Affiliation>Departments of Chemistry and Biochemistry and Biological Chemistry, UCLA-DOE Institute, and Molecular Biology Institute, UCLA, Los Angeles, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Howard Hughes Medical Institute, UCLA, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abskharon</LastName><ForeName>Romany</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Departments of Chemistry and Biochemistry and Biological Chemistry, UCLA-DOE Institute, and Molecular Biology Institute, UCLA, Los Angeles, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Howard Hughes Medical Institute, UCLA, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ge</LastName><ForeName>Peng</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-2661-8226</Identifier><AffiliationInfo><Affiliation>Departments of Chemistry and Biochemistry and Biological Chemistry, UCLA-DOE Institute, and Molecular Biology Institute, UCLA, Los Angeles, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Howard Hughes Medical Institute, UCLA, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeTure</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dickson</LastName><ForeName>Dennis W</ForeName><Initials>DW</Initials><Identifier Source="ORCID">0000-0001-7189-7917</Identifier><AffiliationInfo><Affiliation>Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fu</LastName><ForeName>Janine Y</ForeName><Initials>JY</Initials><Identifier Source="ORCID">0000-0002-8854-041X</Identifier><AffiliationInfo><Affiliation>Departments of Chemistry and Biochemistry and Biological Chemistry, UCLA-DOE Institute, and Molecular Biology Institute, UCLA, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ogorzalek Loo</LastName><ForeName>Rachel R</ForeName><Initials>RR</Initials><Identifier Source="ORCID">0000-0002-0580-2833</Identifier><AffiliationInfo><Affiliation>Departments of Chemistry and Biochemistry and Biological Chemistry, UCLA-DOE Institute, and Molecular Biology Institute, UCLA, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loo</LastName><ForeName>Joseph A</ForeName><Initials>JA</Initials><Identifier Source="ORCID">0000-0001-9989-1437</Identifier><AffiliationInfo><Affiliation>Departments of Chemistry and Biochemistry and Biological Chemistry, UCLA-DOE Institute, and Molecular Biology Institute, UCLA, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eisenberg</LastName><ForeName>David S</ForeName><Initials>DS</Initials><Identifier Source="ORCID">0000-0003-2432-5419</Identifier><AffiliationInfo><Affiliation>Departments of Chemistry and Biochemistry and Biological Chemistry, UCLA-DOE Institute, and Molecular Biology Institute, UCLA, Los Angeles, CA, USA. david@mbi.ucla.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Howard Hughes Medical Institute, UCLA, Los Angeles, CA, USA. david@mbi.ucla.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG048120</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG063911</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM103479</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 OD018111</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM007185</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003949</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 RR023057</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG048120</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 AG070895</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 NS084974</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG070895</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062677</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>03</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598624">TARDBP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C556915">TMEM106B protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="Y">Amyloid</DescriptorName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020285" MajorTopicYN="N">Cryoelectron Microscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="Y">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057174" MajorTopicYN="Y">Frontotemporal Lobar Degeneration</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="Y">Membrane Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="Y">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Competing Interest. D.S.E. is an advisor and equity shareholder in ADRx, Inc. The remaining authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>9</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>28</Day><Hour>20</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>1</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35344984</ArticleId><ArticleId IdType="mid">NIHMS1858738</ArticleId><ArticleId IdType="pmc">PMC9844993</ArticleId><ArticleId IdType="doi">10.1038/s41586-022-04670-9</ArticleId><ArticleId IdType="pii">10.1038/s41586-022-04670-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mohandas E &amp; Rajmohan V Frontotemporal dementia: An updated overview. Indian J. Psychiatry 51, S65&#x2013;S69 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3038533</ArticleId><ArticleId IdType="pubmed">21416021</ArticleId></ArticleIdList></Reference><Reference><Citation>Neary D et al. Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria. Neurology 51, 1546&#x2013;1554 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9855500</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M et al. Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis. Science 314, 130&#x2013;133 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Deerlin VM et al. Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat. Genet 42, 234&#x2013;239 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2828525</ArticleId><ArticleId IdType="pubmed">20154673</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiti F &amp; Dobson CM Protein Misfolding, Amyloid Formation, and Human Disease: A Summary of Progress Over the Last Decade. Annu. Rev. Biochem 86, 27&#x2013;68 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28498720</ArticleId></ArticleIdList></Reference><Reference><Citation>Benson MD et al. Amyloid nomenclature 2020: update and recommendations by the International Society of Amyloidosis (ISA) nomenclature committee. Amyloid Int. J. Exp. Clin. Investig. Off. J. Int. Soc. Amyloidosis 27, 217&#x2013;222 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33100054</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisenberg D &amp; Jucker M The amyloid state of proteins in human diseases. Cell 148, 1188&#x2013;1203 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3353745</ArticleId><ArticleId IdType="pubmed">22424229</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzpatrick AWP et al. Cryo-EM structures of tau filaments from Alzheimer&#x2019;s disease. Nature 547, 185&#x2013;190 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5552202</ArticleId><ArticleId IdType="pubmed">28678775</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcon B et al. Structures of filaments from Pick&#x2019;s disease reveal a novel tau protein fold. Nature 561, 137&#x2013;140 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6204212</ArticleId><ArticleId IdType="pubmed">30158706</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcon B et al. Novel tau filament fold in chronic traumatic encephalopathy encloses hydrophobic molecules. Nature 568, 420&#x2013;423 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6472968</ArticleId><ArticleId IdType="pubmed">30894745</ArticleId></ArticleIdList></Reference><Reference><Citation>Kollmer M et al. Cryo-EM structure and polymorphism of A&#x3b2; amyloid fibrils purified from Alzheimer&#x2019;s brain tissue. Nat. Commun 10, 4760 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6820800</ArticleId><ArticleId IdType="pubmed">31664019</ArticleId></ArticleIdList></Reference><Reference><Citation>Schweighauser M et al. Structures of &#x3b1;-synuclein filaments from multiple system atrophy. Nature 585, 464&#x2013;469 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7116528</ArticleId><ArticleId IdType="pubmed">32461689</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W et al. Novel tau filament fold in corticobasal degeneration. Nature 580, 283&#x2013;287 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7148158</ArticleId><ArticleId IdType="pubmed">32050258</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratnavalli E, Brayne C, Dawson K &amp; Hodges JR The prevalence of frontotemporal dementia. Neurology 58, 1615&#x2013;1621 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12058088</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldman JS et al. Frontotemporal Dementia:: Genetics and Genetic Counseling Dilemmas. The Neurologist 10, 227&#x2013;234 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15335440</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IRA et al. A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol. (Berl.) 122, 111&#x2013;113 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3285143</ArticleId><ArticleId IdType="pubmed">21644037</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee EB et al. Expansion of the classification of FTLD-TDP: distinct pathology associated with rapidly progressive frontotemporal degeneration. Acta Neuropathol. (Berl.) 134, 65&#x2013;78 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5521959</ArticleId><ArticleId IdType="pubmed">28130640</ArticleId></ArticleIdList></Reference><Reference><Citation>Lashley T, Rohrer JD, Mead S &amp; Revesz T Review: An update on clinical, genetic and pathological aspects of frontotemporal lobar degenerations. Neuropathol. Appl. Neurobiol 41, 858&#x2013;881 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26041104</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa M et al. Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Ann. Neurol 64, 60&#x2013;70 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2674108</ArticleId><ArticleId IdType="pubmed">18546284</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu R-C, Wang H, Tan M-S, Yu J-T &amp; Tan L TMEM106B and APOE polymorphisms interact to confer risk for late-onset Alzheimer&#x2019;s disease in Han Chinese. J. Neural Transm. Vienna Austria 1996 121, 283&#x2013;287 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24166182</ArticleId></ArticleIdList></Reference><Reference><Citation>Rutherford NJ et al. TMEM106B risk variant is implicated in the pathologic presentation of Alzheimer disease. Neurology 79, 717&#x2013;718 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3467659</ArticleId><ArticleId IdType="pubmed">22855871</ArticleId></ArticleIdList></Reference><Reference><Citation>Vass R et al. Risk genotypes at TMEM106B are associated with cognitive impairment in amyotrophic lateral sclerosis. Acta Neuropathol. (Berl.) 121, 373&#x2013;380 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3095217</ArticleId><ArticleId IdType="pubmed">21104415</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang CM et al. Membrane orientation and subcellular localization of transmembrane protein 106B (TMEM106B), a major risk factor for frontotemporal lobar degeneration. J. Biol. Chem 287, 19355&#x2013;19365 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3365973</ArticleId><ArticleId IdType="pubmed">22511793</ArticleId></ArticleIdList></Reference><Reference><Citation>Brady OA, Zhou X &amp; Hu F Regulated Intramembrane Proteolysis of the Frontotemporal Lobar Degeneration Risk Factor, TMEM106B, by Signal Peptide Peptidase-like 2a (SPPL2a). J. Biol. Chem 289, 19670&#x2013;19680 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4094077</ArticleId><ArticleId IdType="pubmed">24872421</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawaya MR, Hughes MP, Rodriguez JA, Riek R &amp; Eisenberg DS The expanding amyloid family: Structure, stability, function, and pathogenesis. Cell 184, 4857&#x2013;4873 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8772536</ArticleId><ArticleId IdType="pubmed">34534463</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y et al. Structure-based classification of tauopathies. Nature 598, 359&#x2013;363 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7611841</ArticleId><ArticleId IdType="pubmed">34588692</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruchaga C et al. Association of TMEM106B gene polymorphism with age at onset in granulin mutation carriers and plasma granulin protein levels. Arch. Neurol 68, 581&#x2013;586 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3090529</ArticleId><ArticleId IdType="pubmed">21220649</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholson AM et al. TMEM106B p.T185S regulates TMEM106B protein levels: implications for frontotemporal dementia. J. Neurochem 126, 781&#x2013;791 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3766501</ArticleId><ArticleId IdType="pubmed">23742080</ArticleId></ArticleIdList></Reference><Reference><Citation>Inukai Y et al. Abnormal phosphorylation of Ser409/410 of TDP-43 in FTLD-U and ALS. FEBS Lett. 582, 2899&#x2013;2904 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18656473</ArticleId></ArticleIdList></Reference><Reference><Citation>Laferri&#xe8;re F et al. TDP-43 extracted from frontotemporal lobar degeneration subject brains displays distinct aggregate assemblies and neurotoxic effects reflecting disease progression rates. Nat. Neurosci 22, 65 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30559480</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314, 130&#x2013;133 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Brien RJ &amp; Wong PC Amyloid Precursor Protein Processing and Alzheimer&#x2019;s Disease. Annu. Rev. Neurosci 34, 185&#x2013;204 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3174086</ArticleId><ArticleId IdType="pubmed">21456963</ArticleId></ArticleIdList></Reference><Reference><Citation>Nonaka T et al. Prion-like properties of pathological TDP-43 aggregates from diseased brains. Cell Rep. 4, 124&#x2013;134 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23831027</ArticleId></ArticleIdList></Reference><Reference><Citation>Arseni D et al. Structure of pathological TDP-43 filaments from ALS with FTLD. Nature 601, 139&#x2013;143 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7612255</ArticleId><ArticleId IdType="pubmed">34880495</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt M et al. Cryo-EM structure of a transthyretin-derived amyloid fibril from a patient with hereditary ATTR amyloidosis. Nat. Commun 10, 5008 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6825171</ArticleId><ArticleId IdType="pubmed">31676763</ArticleId></ArticleIdList></Reference><Reference><Citation>Suloway C et al. Automated molecular microscopy: the new Leginon system. J. Struct. Biol 151, 41&#x2013;60 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15890530</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohou A &amp; Grigorieff N CTFFIND4: Fast and accurate defocus estimation from electron micrographs. J. Struct. Biol 192, 216&#x2013;221 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6760662</ArticleId><ArticleId IdType="pubmed">26278980</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner T et al. Two particle-picking procedures for filamentous proteins: SPHIRE-crYOLO filament mode and SPHIRE-STRIPER. Acta Crystallogr. Sect. Struct. Biol 76, 613&#x2013;620 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7336381</ArticleId><ArticleId IdType="pubmed">32627734</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang G et al. EMAN2: an extensible image processing suite for electron microscopy. J. Struct. Biol 157, 38&#x2013;46 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">16859925</ArticleId></ArticleIdList></Reference><Reference><Citation>He S &amp; Scheres SHW Helical reconstruction in RELION. J. Struct. Biol 198, 163&#x2013;176 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5479445</ArticleId><ArticleId IdType="pubmed">28193500</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheres SHW RELION: Implementation of a Bayesian approach to cryo-EM structure determination. J. Struct. Biol 180, 519&#x2013;530 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3690530</ArticleId><ArticleId IdType="pubmed">23000701</ArticleId></ArticleIdList></Reference><Reference><Citation>Emsley P, Lohkamp B, Scott WG &amp; Cowtan K Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr 66, 486&#x2013;501 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2852313</ArticleId><ArticleId IdType="pubmed">20383002</ArticleId></ArticleIdList></Reference><Reference><Citation>Terwilliger TC Automated side-chain model building and sequence assignment by template matching. Acta Crystallogr. D Biol. Crystallogr 59, 45&#x2013;49 (2003).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2745879</ArticleId><ArticleId IdType="pubmed">12499538</ArticleId></ArticleIdList></Reference><Reference><Citation>Afonine PV et al. Real-space refinement in PHENIX for cryo-EM and crystallography. Acta Crystallogr. Sect. Struct. Biol 74, 531&#x2013;544 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6096492</ArticleId><ArticleId IdType="pubmed">29872004</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen VB et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. D Biol. Crystallogr 66, 12&#x2013;21 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2803126</ArticleId><ArticleId IdType="pubmed">20057044</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams CJ et al. MolProbity: More and better reference data for improved all-atom structure validation. Protein Sci. Publ. Protein Soc 27, 293&#x2013;315 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5734394</ArticleId><ArticleId IdType="pubmed">29067766</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Q, Boyer DR, Sawaya MR, Ge P &amp; Eisenberg DS Cryo-EM structure and inhibitor design of human IAPP (amylin) fibrils. Nat. Struct. Mol. Biol 27, 653&#x2013;659 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8579859</ArticleId><ArticleId IdType="pubmed">32541896</ArticleId></ArticleIdList></Reference><Reference><Citation>Thevis M, Ogorzalek Loo RR &amp; Loo JA In-Gel Derivatization of Proteins for Cysteine-Specific Cleavages and their Analysis by Mass Spectrometry. J. Proteome Res 2, 163&#x2013;172 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12716130</ArticleId></ArticleIdList></Reference><Reference><Citation>McConnell SA et al. Protein Labeling via a Specific Lysine-Isopeptide Bond Using the Pilin Polymerizing Sortase from Corynebacterium diphtheriae. J. Am. Chem. Soc 140, 8420&#x2013;8423 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6230430</ArticleId><ArticleId IdType="pubmed">29927249</ArticleId></ArticleIdList></Reference><Reference><Citation>Rappsilber J, Mann M &amp; Ishihama Y Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips. Nat. Protoc 2, 1896&#x2013;1906 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17703201</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35365805</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>07</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5578</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>6</Issue><PubDate><Year>2022</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Molecular psychiatry</Title><ISOAbbreviation>Mol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>A&#x3b2; profiles generated by Alzheimer's disease causing PSEN1 variants determine the pathogenicity of the mutation and predict age at disease onset.</ArticleTitle><Pagination><StartPage>2821</StartPage><EndPage>2832</EndPage><MedlinePgn>2821-2832</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41380-022-01518-6</ELocationID><Abstract><AbstractText>Familial Alzheimer's disease (FAD), caused by mutations in Presenilin (PSEN1/2) and Amyloid Precursor Protein (APP) genes, is associated with an early age at onset (AAO) of symptoms. AAO is relatively consistent within families and between carriers of the same mutations, but differs markedly between individuals carrying different mutations. Gaining a mechanistic understanding of why certain mutations manifest several decades earlier than others is extremely important in elucidating the foundations of pathogenesis and AAO. Pathogenic mutations affect the protease (PSEN/&#x3b3;-secretase) and the substrate (APP) that generate amyloid &#x3b2; (A&#x3b2;) peptides. Altered A&#x3b2; metabolism has long been associated with AD pathogenesis, with absolute or relative increases in A&#x3b2;42 levels most commonly implicated in the disease development. However, analyses addressing the relationships between these A&#x3b2;42 increments and AAO are inconsistent. Here, we investigated this central aspect of AD pathophysiology via comprehensive analysis of 25 FAD-linked A&#x3b2; profiles. Hypothesis- and data-driven approaches demonstrate linear correlations between mutation-driven alterations in A&#x3b2; profiles and AAO. In addition, our studies show that the A&#x3b2; (37&#x2009;+&#x2009;38&#x2009;+&#x2009;40)&#x2009;/&#x2009;(42&#x2009;+&#x2009;43) ratio offers predictive value in the assessment of 'unclear' PSEN1 variants. Of note, the analysis of PSEN1 variants presenting additionally with spastic paraparesis, indicates that a different mechanism underlies the aetiology of this distinct clinical phenotype. This study thus delivers valuable assays for fundamental, clinical and genetic research as well as supports therapeutic interventions aimed at shifting A&#x3b2; profiles towards shorter A&#x3b2; peptides.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Petit</LastName><ForeName>Dieter</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-5721-8041</Identifier><AffiliationInfo><Affiliation>VIB-KU Leuven Center for Brain &amp; Disease Research, Herestraat 49 box 602, 3000, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosciences, Leuven Brain Institute, KU Leuven, Herestraat 49 box 602, 3000, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Fern&#xe1;ndez</LastName><ForeName>Sara Guti&#xe9;rrez</ForeName><Initials>SG</Initials><Identifier Source="ORCID">0000-0002-7479-0768</Identifier><AffiliationInfo><Affiliation>VIB-KU Leuven Center for Brain &amp; Disease Research, Herestraat 49 box 602, 3000, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosciences, Leuven Brain Institute, KU Leuven, Herestraat 49 box 602, 3000, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zoltowska</LastName><ForeName>Katarzyna Marta</ForeName><Initials>KM</Initials><Identifier Source="ORCID">0000-0001-5853-3465</Identifier><AffiliationInfo><Affiliation>VIB-KU Leuven Center for Brain &amp; Disease Research, Herestraat 49 box 602, 3000, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosciences, Leuven Brain Institute, KU Leuven, Herestraat 49 box 602, 3000, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Enzlein</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-1789-4090</Identifier><AffiliationInfo><Affiliation>VIB-KU Leuven Center for Brain &amp; Disease Research, Herestraat 49 box 602, 3000, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosciences, Leuven Brain Institute, KU Leuven, Herestraat 49 box 602, 3000, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Mass Spectrometry and Optical Spectroscopy (CeMOS), Mannheim University of Applied Sciences, Paul-Wittsack Str. 10, 68163, Mannheim, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Natalie S</ForeName><Initials>NS</Initials><AffiliationInfo><Affiliation>UK Dementia Research Institute at UCL, Queen Square, WC1N 3BG, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, Queen Square, WC1N 3BG, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Connor</LastName><ForeName>Antoinette</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-4467-128X</Identifier><AffiliationInfo><Affiliation>UK Dementia Research Institute at UCL, Queen Square, WC1N 3BG, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, Queen Square, WC1N 3BG, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Szaruga</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>VIB-KU Leuven Center for Brain &amp; Disease Research, Herestraat 49 box 602, 3000, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosciences, Leuven Brain Institute, KU Leuven, Herestraat 49 box 602, 3000, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hill</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>VIB-KU Leuven Center for Brain &amp; Disease Research, Herestraat 49 box 602, 3000, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosciences, Leuven Brain Institute, KU Leuven, Herestraat 49 box 602, 3000, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vandenberghe</LastName><ForeName>Rik</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Laboratory for Cognitive Neurology, Department of Neurosciences, KU Leuven, Herestraat 49 box 1027, 3000, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology Department, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fox</LastName><ForeName>Nick C</ForeName><Initials>NC</Initials><AffiliationInfo><Affiliation>UK Dementia Research Institute at UCL, Queen Square, WC1N 3BG, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, Queen Square, WC1N 3BG, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ch&#xe1;vez-Guti&#xe9;rrez</LastName><ForeName>Luc&#xed;a</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-8239-559X</Identifier><AffiliationInfo><Affiliation>VIB-KU Leuven Center for Brain &amp; Disease Research, Herestraat 49 box 602, 3000, Leuven, Belgium. lucia.chavezgutierrez@kuleuven.be.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosciences, Leuven Brain Institute, KU Leuven, Herestraat 49 box 602, 3000, Leuven, Belgium. lucia.chavezgutierrez@kuleuven.be.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>439</GrantID><Acronym>ALZS_</Acronym><Agency>Alzheimer's Society</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>EP-D-18-001</GrantID><Acronym>EPA</Acronym><Agency>EPA</Agency><Country>United States</Country></Grant><Grant><GrantID>G0900421</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>DH_</Acronym><Agency>Department of Health</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>04</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Psychiatry</MedlineTA><NlmUniqueID>9607835</NlmUniqueID><ISSNLinking>1359-4184</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="Y">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>DP, SGF, KMZ, TE, NSR, AO&#x2019;C, MS, EH, RV and LCG declare no competing interests. NCF reports consultancy for Roche, Biogen and Ionis and serving on a Data Safety Monitoring Board for Biogen.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>7</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>2</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>2</Day><Hour>5</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>4</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35365805</ArticleId><ArticleId IdType="mid">EMS143802</ArticleId><ArticleId IdType="pmc">PMC9156411</ArticleId><ArticleId IdType="doi">10.1038/s41380-022-01518-6</ArticleId><ArticleId IdType="pii">10.1038/s41380-022-01518-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>De Strooper B, Karran E. The cellular phase of Alzheimer&#x2019;s disease. Cell. 2016;164:603&#x2013;15. doi: 10.1016/j.cell.2015.12.056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2015.12.056</ArticleId><ArticleId IdType="pubmed">26871627</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer&#x2019;s disease at 25 years. EMBO Mol Med. 2016;8:1&#x2013;14.. doi: 10.15252/emmm.201606210.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201606210</ArticleId><ArticleId IdType="pmc">PMC4888851</ArticleId><ArticleId IdType="pubmed">27025652</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan NS, Nicholas JM, Weston PSJ, Liang Y, Lashley T, Guerreiro R, et al. Clinical phenotype and genetic associations in autosomal dominant familial Alzheimer&#x2019;s disease: a case series. Lancet Neurol. 2016;15:1326&#x2013;35. doi: 10.1016/S1474-4422(16)30193-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(16)30193-4</ArticleId><ArticleId IdType="pubmed">27777022</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B, Saftig P, Craessaerts K, Vanderstichele H, Guhde G, Annaert W, et al. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature. 1998;391:387&#x2013;90. doi: 10.1038/34910.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/34910</ArticleId><ArticleId IdType="pubmed">9450754</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe MS, Xia W, Ostaszewski BL, Diehl TS, Kimberly WT, Selkoe DJ. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature. 1999;398:513&#x2013;7. doi: 10.1038/19077.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/19077</ArticleId><ArticleId IdType="pubmed">10206644</ArticleId></ArticleIdList></Reference><Reference><Citation>Steiner H, Duff K, Capell A, Romig H, Grim MG, Lincoln S, et al. A loss of function mutation of presenilin-2 interferes with amyloid &#x3b2; -peptide production and notch signaling. J Biol Chem. 1999;274:28669&#x2013;73. doi: 10.1074/jbc.274.40.28669.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.274.40.28669</ArticleId><ArticleId IdType="pubmed">10497236</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu G, Nishimura M, Arawaka S, Levitan D, Zhang L, Tandon A, et al. Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and betaAPP processing. Nature. 2000;407:48&#x2013;54. doi: 10.1038/35024009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35024009</ArticleId><ArticleId IdType="pubmed">10993067</ArticleId></ArticleIdList></Reference><Reference><Citation>Francis R, McGrath G, Zhang J, Ruddy DA, Sym M, Apfeld J, et al. aph-1 and pen-2 are required for Notch pathway signaling, &#x3b3;-secretase cleavage of &#x3b2;APP, and presenilin protein accumulation. Dev Cell. 2002;3:85&#x2013;97. doi: 10.1016/S1534-5807(02)00189-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1534-5807(02)00189-2</ArticleId><ArticleId IdType="pubmed">12110170</ArticleId></ArticleIdList></Reference><Reference><Citation>Goutte C, Tsunozaki M, Hale VA, Priess JR. APH-1 is a multipass membrane protein essential for the Notch signaling pathway in Caenorhabditis elegans embryos. Proc Natl Acad Sci USA. 2002;99:775&#x2013;9. doi: 10.1073/pnas.022523499.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.022523499</ArticleId><ArticleId IdType="pmc">PMC117381</ArticleId><ArticleId IdType="pubmed">11792846</ArticleId></ArticleIdList></Reference><Reference><Citation>Takami M, Nagashima Y, Sano Y, Ishihara S, Morishima-Kawashima M, Funamoto S, et al. gamma-Secretase: successive tripeptide and tetrapeptide release from the transmembrane domain of beta-carboxyl terminal fragment. J Neurosci. 2009;29:13042&#x2013;52. doi: 10.1523/JNEUROSCI.2362-09.2009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2362-09.2009</ArticleId><ArticleId IdType="pmc">PMC6665297</ArticleId><ArticleId IdType="pubmed">19828817</ArticleId></ArticleIdList></Reference><Reference><Citation>Duff K, Eckmant C, Zehr C, Yu X, Cristian-Mihail P, Perez-tur J, et al. Increased amyloid-A&#x3b2;42(43) in brains of mice expressing mutant presenilin 1. Nature. 1996;383:710&#x2013;3. doi: 10.1038/383710a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/383710a0</ArticleId><ArticleId IdType="pubmed">8878479</ArticleId></ArticleIdList></Reference><Reference><Citation>Borchelt DR, Thinakaran G, Eckman CB, Lee MK, Davenport F, Ratovitsky T, et al. Familial Alzheimer&#x2019;s disease&#x2013;linked presenilin 1 variants elevate A&#x3b2; 1&#x2013;42/1&#x2013;40 ratio in vitro and in vivo. Neuron. 1996;17:1005&#x2013;13. doi: 10.1016/S0896-6273(00)80230-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(00)80230-5</ArticleId><ArticleId IdType="pubmed">8938131</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, et al. Secreted amyloid &#x3b2; protein similar to that in the senile plaques of Alzheimer&#x2019;s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer&#x2019;s disease. Nat Med. 1996;2:925&#x2013;8.. doi: 10.1038/nm0896-864.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm0896-864</ArticleId><ArticleId IdType="pubmed">8705854</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann DMA, Iwatsubo T, Cairns TNJ, Lantos PL, Nochlin D, Prihar G, et al. Amyloid beta protein (Abeta) deposition in chromosome 14-linked Alzheimer&#x2019; s Disease: Predominance of Abeta42(43) Am Neurol Assoc. 1996;40:149&#x2013;56. doi: 10.1002/ana.410400205.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410400205</ArticleId><ArticleId IdType="pubmed">8773595</ArticleId></ArticleIdList></Reference><Reference><Citation>Citron M, Westaway D, Xia W, Carlson G, Diehl T, Levesque G, et al. Mutant presenilins of Alzheimer&#x2019;s disease increase production of 42-residue amyloid &#x3b2;-protein in both transfected cells and transgenic mice. Nat Med. 1997;3:67&#x2013;72. doi: 10.1038/nm0197-67.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm0197-67</ArticleId><ArticleId IdType="pubmed">8986743</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomita T, Maruyama K, Saido TC, Kume H, Shinozaki K, Tokuhiro S, et al. The presenilin 2 mutation (N141I) linked to familial Alzheimer disease (Volga German families) increases the secretion of amyloid beta protein ending at the 42nd (or 43rd) residue. Proc Natl Acad Sci USA. 1997;94:2025&#x2013;30. doi: 10.1073/pnas.94.5.2025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.94.5.2025</ArticleId><ArticleId IdType="pmc">PMC20036</ArticleId><ArticleId IdType="pubmed">9050898</ArticleId></ArticleIdList></Reference><Reference><Citation>Murayama O, Tomita T, Nihonmatsu N, Murayama M, Sun X, Honda T, et al. Enhancement of amyloid &#x3b2; 42 secretion by 28 different presenilin 1 mutations of familial Alzheimer&#x2019;s disease. Neurosci Lett. 1999;265:61&#x2013;3. doi: 10.1016/S0304-3940(99)00187-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0304-3940(99)00187-1</ArticleId><ArticleId IdType="pubmed">10327206</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar-singh S, Theuns J, Van BroeckB, Pirici D, Vennekens K, Corsmit E, et al. Mean age-of-onset of familial alzheimer disease caused by presenilin mutations correlates with both increased A&#x3b2;42 and decreased A&#x3b2;40. Hum Mutat. 2006;27:686&#x2013;95. doi: 10.1002/humu.20336.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.20336</ArticleId><ArticleId IdType="pubmed">16752394</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia D, Watanabe H, Wu B, Lee SH, Li Y, Tsvetkov E, et al. Presenilin-1 knockin mice reveal loss-of-function mechanism for familial alzheimer&#x2019;s disease. Neuron. 2015;85:967&#x2013;81. doi: 10.1016/j.neuron.2015.02.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2015.02.010</ArticleId><ArticleId IdType="pmc">PMC4358812</ArticleId><ArticleId IdType="pubmed">25741723</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu S, Pimenova AA, Hayes K, Villa JA, Rosene MJ, Jere M, et al. Systematic validation of variants of unknown significance in APP, PSEN1 and PSEN2. Neurobiol Dis. 2020;139:104817. doi: 10.1016/j.nbd.2020.104817.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2020.104817</ArticleId><ArticleId IdType="pmc">PMC7236786</ArticleId><ArticleId IdType="pubmed">32087291</ArticleId></ArticleIdList></Reference><Reference><Citation>Potter R, Patterson BW, Elbert DL, Ovod V, Kasten T, Sigurdson W, et al. Increased in vivo amyloid- 42 production, exchange, and loss in presenilin mutation carriers. Sci Transl Med. 2013;5:189ra77. doi: 10.1126/scitranslmed.3005615.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3005615</ArticleId><ArticleId IdType="pmc">PMC3838868</ArticleId><ArticleId IdType="pubmed">23761040</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta ND, Refolo LM, Eckman C, Sanders S, Yager D, Perez-Tur J, et al. Increased A&#x3b2;42(43) from cell lines expressing presenilin 1 mutations. Ann Neurol. 1998;43:256&#x2013;8. doi: 10.1002/ana.410430217.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410430217</ArticleId><ArticleId IdType="pubmed">9485068</ArticleId></ArticleIdList></Reference><Reference><Citation>Duering M, Grimm MOW, Grimm HS, Schr J, Hartmann T. Mean age of onset in familial Alzheimer&#x2019;s disease is determined by amyloid beta 42. Neurobiol Aging. 2005;26:785&#x2013;8. doi: 10.1016/j.neurobiolaging.2004.08.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2004.08.002</ArticleId><ArticleId IdType="pubmed">15718035</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun L, Zhou R, Yang G, Shi Y. Analysis of 138 pathogenic mutations in presenilin-1 on the in vitro production of A&#x3b2;42 and A&#x3b2;40 peptides by &#x3b3;-secretase. Proc Natl Acad Sci USA. 2017;114:E476&#x2013;85..</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5278480</ArticleId><ArticleId IdType="pubmed">27930341</ArticleId></ArticleIdList></Reference><Reference><Citation>Ch&#xe1;vez-Guti&#xe9;rrez L, Bammens L, Benilova I, Vandersteen A, Benurwar M, Borgers M, et al. The mechanism of &#x3b3;-Secretase dysfunction in familial Alzheimer disease. EMBO J. 2012;31:2261&#x2013;74. doi: 10.1038/emboj.2012.79.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emboj.2012.79</ArticleId><ArticleId IdType="pmc">PMC3364747</ArticleId><ArticleId IdType="pubmed">22505025</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez MA, Klutkowski JA, Freret T, Wolfe MS. Alzheimer presenilin-1 mutations dramatically reduce trimming of long amyloid &#x3b2;-peptides (A&#x3b2;) by &#x3b3;-secretase to increase 42-to-40-residue A&#x3b2;. J Biol Chem. 2014;289:31043&#x2013;52. doi: 10.1074/jbc.M114.581165.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M114.581165</ArticleId><ArticleId IdType="pmc">PMC4223309</ArticleId><ArticleId IdType="pubmed">25239621</ArticleId></ArticleIdList></Reference><Reference><Citation>Veugelen S, Saito T, Saido TCTC, Ch&#xe1;vez-Guti&#xe9;rrez L, De Strooper B, Ch&#xe1;vez-Gutierrez L, et al. Familial Alzheimer&#x2019;s disease mutations in presenilin generate amyloidogenic A&#x3b2; peptide seeds. Neuron. 2016;90:410&#x2013;6. doi: 10.1016/j.neuron.2016.03.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.03.010</ArticleId><ArticleId IdType="pubmed">27100199</ArticleId></ArticleIdList></Reference><Reference><Citation>Kretner B, Trambauer J, Fukumori A, Mielke J, Kuhn P, Kremmer E, et al. Generation and deposition of A&#x3b2;43 by the virtually inactive presenilin&#x2010;1 L435F mutant contradicts the presenilin loss&#x2010;of&#x2010;function hypothesis of Alzheimer&#x2019;s disease. EMBO Mol Med. 2016;8:458&#x2013;65. doi: 10.15252/emmm.201505952.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201505952</ArticleId><ArticleId IdType="pmc">PMC5119496</ArticleId><ArticleId IdType="pubmed">26988102</ArticleId></ArticleIdList></Reference><Reference><Citation>Szaruga M, Munteanu B, Lismont S, Veugelen S, Horr&#xe9; K, Mercken M, et al. Alzheimer&#x2019;s-causing mutations shift A&#x3b2; length by destabilizing &#x3b3;-secretase-A&#x3b2;n interactions. Cell. 2017;170:443&#x2013;56.e14. doi: 10.1016/j.cell.2017.07.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.07.004</ArticleId><ArticleId IdType="pubmed">28753424</ArticleId></ArticleIdList></Reference><Reference><Citation>Devkota S, Williams TD, Wolfe MS. Familial Alzheimer s disease mutations in amyloid protein precursor alter proteolysis by &#x3b3;-secretase to increase amyloid &#x3b2;-peptides of &#x2265;45 residues. J Biol Chem. 2021;296:100281. doi: 10.1016/j.jbc.2021.100281.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbc.2021.100281</ArticleId><ArticleId IdType="pmc">PMC7948801</ArticleId><ArticleId IdType="pubmed">33450230</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Connor A, Pannee J, Poole T, Arber C, Portelius E, Swift IJ, et al. Plasma amyloid-&#x3b2; ratios in autosomal dominant Alzheimer&#x2019;s disease: the influence of genotype. Brain. 2021;144:2964&#x2013;70. doi: 10.1093/brain/awab166.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awab166</ArticleId><ArticleId IdType="pmc">PMC8634092</ArticleId><ArticleId IdType="pubmed">33892504</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi-Takahara Y, Morishima-Kawashima M, Tanimura Y, Dolios G, Hirotani N, Horikoshi Y, et al. Longer forms of amyloid-&#x3b2; protein: implications for the mechanism of intramembrane cleavage by &#x3b3;-secretase. J Neurosci. 2005;25:436&#x2013;45. doi: 10.1523/JNEUROSCI.1575-04.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1575-04.2005</ArticleId><ArticleId IdType="pmc">PMC6725472</ArticleId><ArticleId IdType="pubmed">15647487</ArticleId></ArticleIdList></Reference><Reference><Citation>Yagishita S, Morishima-Kawashima M, Ishiura S, Ihara Y. A&#x3b2;46 is processed to A&#x3b2;40 and A&#x3b2;43, but not to A&#x3b2;42, in the low density membrane domains. J Biol Chem. 2008;283:733&#x2013;8. doi: 10.1074/jbc.M707103200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M707103200</ArticleId><ArticleId IdType="pubmed">18024430</ArticleId></ArticleIdList></Reference><Reference><Citation>Dimitrov M, Alattia JR, Lemmin T, Lehal R, Fligier A, Houacine J, et al. Alzheimer&#x2019;s disease mutations in APP but not &#x3b3;-secretase modulators affect epsilon-cleavage-dependent AICD production. Nat Commun. 2013;4:2246. doi: 10.1038/ncomms3246.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms3246</ArticleId><ArticleId IdType="pubmed">23907250</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim YE, Cho H, Kim HJ, Na DL, Seo SW, Ki CS. PSEN1 variants in Korean patients with clinically suspicious early-onset familial Alzheimer&#x2019;s disease. Sci Rep. 2020;10:4&#x2013;10.. doi: 10.1038/s41598-019-56343-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-56343-9</ArticleId><ArticleId IdType="pmc">PMC7044324</ArticleId><ArticleId IdType="pubmed">32103039</ArticleId></ArticleIdList></Reference><Reference><Citation>Dumanchin C, Tournier I, Martin C, Didic M, Belliard S, Carlander B, et al. Biological effects of four PSEN1 gene mutations causing Alzheimer disease with spastic paraparesis and cotton wool plaques. Hum Mutat. 2006;27:1063. doi: 10.1002/humu.9458.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.9458</ArticleId><ArticleId IdType="pubmed">16941492</ArticleId></ArticleIdList></Reference><Reference><Citation>Chelban V, Breza M, Szaruga M, Vandrovcova J, Murphy D, Lee C, et al. Spastic paraplegia preceding PSEN1 &#x2010;related familial Alzheimer&#x2019;s disease. Alzheimer&#x2019;s Dement Diagnosis. Assess Dis Monit. 2021;13:e12186.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8088589</ArticleId><ArticleId IdType="pubmed">33969176</ArticleId></ArticleIdList></Reference><Reference><Citation>Petit D, Hitzenberger M, Lismont S, Zoltowska KM, Ryan NS, Mercken M, et al. Extracellular interface between APP and Nicastrin regulates A&#x3b2; length and response to &#x3b3;&#x2010;secretase modulators. EMBO J. 2019;38:e101494. doi: 10.15252/embj.2019101494.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.2019101494</ArticleId><ArticleId IdType="pmc">PMC6576158</ArticleId><ArticleId IdType="pubmed">31109937</ArticleId></ArticleIdList></Reference><Reference><Citation>V&#xe9;lez JI, Lopera F, Patel HR, Johar AS, Chuah A, Tob&#xf3;n C, et al. APOE*E2 allele delays age of onset in PSEN1 E280A Alzheimer&#x2019;s disease. Mol Psychiatry. 2016;21:916&#x2013;24. doi: 10.1038/mp.2015.177.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2015.177</ArticleId><ArticleId IdType="pmc">PMC5414071</ArticleId><ArticleId IdType="pubmed">26619808</ArticleId></ArticleIdList></Reference><Reference><Citation>Acx H, Ch&#xe1;vez-Guti&#xe9;rrez L, Serneels L, Lismont S, Benurwar M, Elad N, et al. Signature amyloid beta profiles are produced by different gamma-secretase complexes. J Biol Chem. 2014;289:4346&#x2013;55. doi: 10.1074/jbc.M113.530907.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M113.530907</ArticleId><ArticleId IdType="pmc">PMC3924297</ArticleId><ArticleId IdType="pubmed">24338474</ArticleId></ArticleIdList></Reference><Reference><Citation>Sannerud R, Esselens C, Ejsmont P, Mattera R, Rochin L, Tharkeshwar AK, et al. Restricted location of PSEN2/&#x3b3;-secretase determines substrate specificity and generates an intracellular A&#x3b2; pool. Cell. 2016;166:193&#x2013;208. doi: 10.1016/j.cell.2016.05.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2016.05.020</ArticleId><ArticleId IdType="pmc">PMC7439524</ArticleId><ArticleId IdType="pubmed">27293189</ArticleId></ArticleIdList></Reference><Reference><Citation>Borgeg&#xe5;rd T, Gustavsson S, Nilsson C, Parpal S, Klintenberg R, Berg A-L, et al. Alzheimer&#x2019;s disease: presenilin 2-sparing &#x3b3;-secretase inhibition is a tolerable A&#x3b2; peptide-lowering strategy. J Neurosci. 2012;32:17297&#x2013;305. doi: 10.1523/JNEUROSCI.1451-12.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1451-12.2012</ArticleId><ArticleId IdType="pmc">PMC6621836</ArticleId><ArticleId IdType="pubmed">23197721</ArticleId></ArticleIdList></Reference><Reference><Citation>Herreman A, Hartmann D, Annaert W, Saftig P, Craessaerts K, Serneels L, et al. Presenilin 2 deficiency causes a mild pulmonary phenotype and no changes in amyloid precursor protein processing but enhances the embryonic lethal phenotype of presenilin 1 deficiency. Proc Natl Acad Sci USA. 1999;96:11872&#x2013;7. doi: 10.1073/pnas.96.21.11872.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.96.21.11872</ArticleId><ArticleId IdType="pmc">PMC18379</ArticleId><ArticleId IdType="pubmed">10518543</ArticleId></ArticleIdList></Reference><Reference><Citation>Szaruga M, Veugelen S, Benurwar M, Lismont S, Sepulveda-Falla D, Lleo A, et al. Qualitative changes in human &#x3b3;-secretase underlie familial Alzheimer&#x2019;s disease. J Exp Med. 2015;212:2003&#x2013;13. doi: 10.1084/jem.20150892.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20150892</ArticleId><ArticleId IdType="pmc">PMC4647268</ArticleId><ArticleId IdType="pubmed">26481686</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker ES, Martinez M, Brunkan AL, Goate A. Presenilin 2 familial Alzheimer&#x2019; s disease mutations result in partial loss of function and dramatic changes in A&#x3b2;42/40 ratios. J Neurochem. 2005;92:294&#x2013;301. doi: 10.1111/j.1471-4159.2004.02858.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2004.02858.x</ArticleId><ArticleId IdType="pubmed">15663477</ArticleId></ArticleIdList></Reference><Reference><Citation>De Jonghe C, Esselens C, Kumar-singh S, Craessaerts K, Serneels S, Checler F, et al. Pathogenic APP mutations near the &#x3b3;-secretase cleavage site differentially affect A&#x3b2; secretion and APP C-terminal fragment stability. Hum Mol Genet. 2001;10:1665&#x2013;71. doi: 10.1093/hmg/10.16.1665.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/10.16.1665</ArticleId><ArticleId IdType="pubmed">11487570</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S, Mao A, Bhattacharya S, Robertson N, Grisshammer R, Tate CG, et al. How do short chain nonionic detergents destabilize G-protein-coupled receptors? J Am Chem Soc. 2016;138:15425&#x2013;33. doi: 10.1021/jacs.6b08742.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jacs.6b08742</ArticleId><ArticleId IdType="pmc">PMC5148649</ArticleId><ArticleId IdType="pubmed">27792324</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang N, Kepp KP. A&#x3b2;42/A&#x3b2;40 ratios of presenilin 1 mutations correlate with clinical onset of Alzheimer&#x2019;s Disease. J Alzheimer&#x2019;s Dis. 2018;66:939&#x2013;45. doi: 10.3233/JAD-180829.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-180829</ArticleId><ArticleId IdType="pubmed">30412504</ArticleId></ArticleIdList></Reference><Reference><Citation>Murrell J, Ghetti B, Cochran E, Macias-Islas MA, Medina L, Varpetian A, et al. The A431E mutation in PSEN1 causing Familial Alzheimer&#x2019;s Disease originating in Jalisco State, Mexico: an additional fifteen families. Neurogenetics. 2006;7:277&#x2013;9. doi: 10.1007/s10048-006-0053-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10048-006-0053-1</ArticleId><ArticleId IdType="pmc">PMC3378247</ArticleId><ArticleId IdType="pubmed">16897084</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsubara-Tsutsui M, Yasuda M, Yamagata H, Nomura T, Taguchi K, Kohara K, et al. Molecular evidence of presenilin 1 mutation in familial early onset dementia. Am J Med Genet. 2002;114:292&#x2013;8. doi: 10.1002/ajmg.10250.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajmg.10250</ArticleId><ArticleId IdType="pubmed">11920851</ArticleId></ArticleIdList></Reference><Reference><Citation>Arber C, Toombs J, Lovejoy C, Ryan NS, Paterson RW, Willumsen N, et al. Familial Alzheimer&#x2019;s disease patient-derived neurons reveal distinct mutation-specific effects on amyloid beta. Mol Psychiatry. 2020;25:2919&#x2013;31. doi: 10.1038/s41380-019-0410-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-019-0410-8</ArticleId><ArticleId IdType="pmc">PMC7577860</ArticleId><ArticleId IdType="pubmed">30980041</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder E, Saunders AM, Risch N, Strittmatter W, Schmechel D, Gaskell P, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet. 1994;7:180&#x2013;4. doi: 10.1038/ng0694-180.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng0694-180</ArticleId><ArticleId IdType="pubmed">7920638</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrano-Pozo A, Qian J, Monsell SE, Betensky RA, Hyman BT. APOE&#x3b5;2 is associated with milder clinical and pathological Alzheimer disease. Ann Neurol. 2015;77:917&#x2013;29. doi: 10.1002/ana.24369.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24369</ArticleId><ArticleId IdType="pmc">PMC4447539</ArticleId><ArticleId IdType="pubmed">25623662</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Arboleda-Velasquez JF, Quiroz YT, Huentelman MJ, Beach TG, Caselli RJ, et al. Exceptionally low likelihood of Alzheimer&#x2019;s dementia in APOE2 homozygotes from a 5,000-person neuropathological study. Nat Commun. 2020;11:667. doi: 10.1038/s41467-019-14279-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-14279-8</ArticleId><ArticleId IdType="pmc">PMC6997393</ArticleId><ArticleId IdType="pubmed">32015339</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito T, Suemoto T, Brouwers N, Sleegers K, Funamoto S, Mihira N, et al. Potent amyloidogenicity and pathogenicity of A&#x3b2;43. Nat Neurosci. 2011;14:1023&#x2013;32. doi: 10.1038/nn.2858.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2858</ArticleId><ArticleId IdType="pubmed">21725313</ArticleId></ArticleIdList></Reference><Reference><Citation>Trambauer J, Rodr&#xed;guez Sarmiento RM, Fukumori A, Feederle R, Baumann K, Steiner H. A&#x3b2;43&#x2010;producing PS 1 FAD mutants cause altered substrate interactions and respond to &#x3b3;&#x2010;secretase modulation. EMBO Rep. 2020;21:1&#x2013;13.. doi: 10.15252/embr.201947996.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embr.201947996</ArticleId><ArticleId IdType="pmc">PMC6945062</ArticleId><ArticleId IdType="pubmed">31762188</ArticleId></ArticleIdList></Reference><Reference><Citation>Raux G, Gantier R, Thomas-Anterion C, Boulliat J, Verpillat P, Hannequin D, et al. Dementia with prominent frontotemporal features associated with L113P presenilin 1 mutation. Neurology. 2000;55:1577&#x2013;9. doi: 10.1212/WNL.55.10.1577.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.55.10.1577</ArticleId><ArticleId IdType="pubmed">11094121</ArticleId></ArticleIdList></Reference><Reference><Citation>The Lund and Manchester Groups. Clinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups. J Neurol Neurosurg Psychiatry. 1994;57:416&#x2013;8. doi: 10.1136/jnnp.57.4.416.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.57.4.416</ArticleId><ArticleId IdType="pmc">PMC1072868</ArticleId><ArticleId IdType="pubmed">8163988</ArticleId></ArticleIdList></Reference><Reference><Citation>Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998;51:1546&#x2013;54. doi: 10.1212/WNL.51.6.1546.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.51.6.1546</ArticleId><ArticleId IdType="pubmed">9855500</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergmans BA, De Strooper B. &#x3b3;-secretases: from cell biology to therapeutic strategies. Lancet Neurol. 2010;9:215&#x2013;26. doi: 10.1016/S1474-4422(09)70332-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(09)70332-1</ArticleId><ArticleId IdType="pubmed">20129170</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernardi L, Tomaino C, Anfossi M, Gallo M, Geracitano S, Costanzo A, et al. Novel PSEN1 and PGRN mutations in early-onset familial frontotemporal dementia. Neurobiol Aging. 2009;30:1825&#x2013;33. doi: 10.1016/j.neurobiolaging.2008.01.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2008.01.005</ArticleId><ArticleId IdType="pubmed">18314228</ArticleId></ArticleIdList></Reference><Reference><Citation>Koriath C, Kenny J, Adamson G, Druyeh R, Taylor W, Beck J, et al. Predictors for a dementia gene mutation based on gene-panel next-generation sequencing of a large dementia referral series. Mol Psychiatry. 2020;25:3399&#x2013;412. doi: 10.1038/s41380-018-0224-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-018-0224-0</ArticleId><ArticleId IdType="pmc">PMC6330090</ArticleId><ArticleId IdType="pubmed">30279455</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanoisel&#xe9;e HM, Nicolas G, Wallon D, Rovelet-Lecrux A, Lacour M, Rousseau S, et al. APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: a genetic screening study of familial and sporadic cases. PLoS Med. 2017;14:e1002270. doi: 10.1371/journal.pmed.1002270.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1002270</ArticleId><ArticleId IdType="pmc">PMC5370101</ArticleId><ArticleId IdType="pubmed">28350801</ArticleId></ArticleIdList></Reference><Reference><Citation>Herreman A, Serneels L, Annaert W, Collen D, Schoonjans L, De Strooper B. Total inactivation of &#x3b3;-secretase activity in presenilin-deficient embryonic stem cells. Nat Cell Biol. 2000;2:461&#x2013;2. doi: 10.1038/35017105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35017105</ArticleId><ArticleId IdType="pubmed">10878813</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryman DC, Aisen PS, Bird T, Danek A, Fox NC, Goate A, et al. Symptom onset in autosomal dominant Alzheimer disease a systematic review and meta-analysis. J Neurol. 2014;83:253&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4117367</ArticleId><ArticleId IdType="pubmed">24928124</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35377391</PMID><DateCompleted><Year>2022</Year><Month>05</Month><Day>11</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>79</Volume><Issue>5</Issue><PubDate><Year>2022</Year><Month>May</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Subcortical Neuronal Correlates of Sleep in Neurodegenerative Diseases.</ArticleTitle><Pagination><StartPage>498</StartPage><EndPage>508</EndPage><MedlinePgn>498-508</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2022.0429</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Sleep disturbance is common among patients with neurodegenerative diseases. Examining the subcortical neuronal correlates of sleep disturbances is important to understanding the early-stage sleep neurodegenerative phenomena.</AbstractText><AbstractText Label="OBJECTIVES">To examine the correlation between the number of important subcortical wake-promoting neurons and clinical sleep phenotypes in patients with Alzheimer disease (AD) or progressive supranuclear palsy (PSP).</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">This longitudinal cohort study enrolled 33 patients with AD, 20 patients with PSP, and 32 healthy individuals from the Memory and Aging Center of the University of California, San Francisco, between August 22, 2008, and December 31, 2020. Participants received electroencephalographic and polysomnographic sleep assessments. Postmortem neuronal analyses of brainstem hypothalamic wake-promoting neurons were performed and were included in the clinicopathological correlation analysis. No eligible participants were excluded from the study.</AbstractText><AbstractText Label="EXPOSURES">Electroencephalographic and polysomnographic assessment of sleep and postmortem immunohistological stereological analysis of 3 wake-promoting nuclei (noradrenergic locus coeruleus [LC], orexinergic lateral hypothalamic area [LHA], and histaminergic tuberomammillary nucleus [TMN]).</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Nocturnal sleep variables, including total sleep time, sleep maintenance, rapid eye movement (REM) latency, and time spent in REM sleep and stages 1, 2, and 3 of non-REM (NREM1, NREM2, and NREM3, respectively) sleep, and wake after sleep onset. Neurotransmitter, tau, and total neuronal counts of LC, LHA, and TMN.</AbstractText><AbstractText Label="RESULTS">Among 19 patients included in the clinicopathological correlation analysis, the mean (SD) age at death was 70.53 (7.75) years; 10 patients (52.6%) were female; and all patients were White. After adjusting for primary diagnosis, age, sex, and time between sleep analyses and death, greater numbers of LHA and TMN neurons were correlated with decreased homeostatic sleep drive, as observed by less total sleep time (LHA: r&#x2009;=&#x2009;-0.63; P&#x2009;=&#x2009;.009; TMN: r&#x2009;=&#x2009;-0.62; P&#x2009;=&#x2009;.008), lower sleep maintenance (LHA: r&#x2009;=&#x2009;-0.85; P&#x2009;&lt;&#x2009;.001; TMN: r&#x2009;=&#x2009;-0.78; P&#x2009;&lt;&#x2009;.001), and greater percentage of wake after sleep onset (LHA: r&#x2009;=&#x2009;0.85; P&#x2009;&lt;&#x2009;.001; TMN: r&#x2009;=&#x2009;0.78; P&#x2009;&lt;&#x2009;.001). In addition, greater numbers of LHA and TMN neurons were correlated with less NREM2 sleep (LHA: r&#x2009;=&#x2009;-0.76; P&#x2009;&lt;&#x2009;.001; TMN: r&#x2009;=&#x2009;-0.73; P&#x2009;&lt;&#x2009;.001). A greater number of TMN neurons was also correlated with less REM sleep (r&#x2009;=&#x2009;-0.61; P&#x2009;=&#x2009;.01). A greater number of LC neurons was mainly correlated with less total sleep time (r&#x2009;=&#x2009;-0.68; P&#x2009;=&#x2009;.008) and greater REM latency (r&#x2009;=&#x2009;0.71; P&#x2009;=&#x2009;.006). The AD-predominant group had significantly greater sleep drive, including higher total sleep time (mean [SD], 0.49 [1.18] vs -1.09 [1.37]; P&#x2009;=&#x2009;.03), higher sleep maintenance (mean [SD], 0.18 [1.22] vs -1.53 [1.78]; P&#x2009;=&#x2009;.02), and lower percentage of wake after sleep onset during sleep period time (mean [SD], -0.18 [1.20] vs 1.49 [1.72]; P&#x2009;=&#x2009;.02) than the PSP-predominant group based on unbiased k-means clustering and principal component analyses.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">In this cohort study, subcortical wake-promoting neurons were significantly correlated with sleep phenotypes in patients with AD and PSP, suggesting that the loss of wake-promoting neurons among patients with neurodegenerative conditions may disturb the control of sleep-wake homeostasis. These findings suggest that the subcortical system is a primary mechanism associated with sleep disturbances in the early stages of neurodegenerative diseases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Oh</LastName><ForeName>Jun Y</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, University of California, San Francisco, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walsh</LastName><ForeName>Christine M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ranasinghe</LastName><ForeName>Kamalini</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mladinov</LastName><ForeName>Mihovil</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pereira</LastName><ForeName>Felipe L</ForeName><Initials>FL</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petersen</LastName><ForeName>Cathrine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Falg&#xe0;s</LastName><ForeName>Neus</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Global Brain Health Institute, University of California, San Francisco, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yack</LastName><ForeName>Leslie</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Stress and Health Research Program, Department of Mental Health, San Francisco VA Medical Center, San Francisco, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lamore</LastName><ForeName>Tia</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nasar</LastName><ForeName>Rakin</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lew</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Song</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Metzler</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Stress and Health Research Program, Department of Mental Health, San Francisco VA Medical Center, San Francisco, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coppola</LastName><ForeName>Quentin</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pandher</LastName><ForeName>Natalie</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Le</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heuer</LastName><ForeName>Hilary W</ForeName><Initials>HW</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heinsen</LastName><ForeName>Helmut</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Wurzburg, Wurzburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spina</LastName><ForeName>Salvatore</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seeley</LastName><ForeName>William W</ForeName><Initials>WW</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kramer</LastName><ForeName>Joel</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rabinovici</LastName><ForeName>Gil D</ForeName><Initials>GD</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boxer</LastName><ForeName>Adam L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Bruce L</ForeName><Initials>BL</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Global Brain Health Institute, University of California, San Francisco, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vossel</LastName><ForeName>Keith</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California, Los Angeles, Los Angeles.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neylan</LastName><ForeName>Thomas C</ForeName><Initials>TC</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Stress and Health Research Program, Department of Mental Health, San Francisco VA Medical Center, San Francisco, California.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, University of California, San Francisco, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grinberg</LastName><ForeName>Lea T</ForeName><Initials>LT</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Global Brain Health Institute, University of California, San Francisco, San Francisco.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, University of Sao Paulo Medical School, Sao Paulo, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, University of California, San Francisco, San Francisco.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K24 AG053435</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG038791</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG063911</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG060477</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG032289</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062422</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG019724</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 NS092089</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 AG052648</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG064314</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012890" MajorTopicYN="N">Sleep</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012893" MajorTopicYN="Y">Sleep Wake Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014851" MajorTopicYN="N">Wakefulness</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Yack reported receiving personal fees from the University of California, San Francisco, during the conduct of the study. Dr Coppola reported receiving grants from the National Institute on Aging, the Rainwater Charitable Foundation, and the Tau Consortium, during the conduct of the study. Dr Pandher reported receiving grants from the National Institutes of Health (NIH), the Rainwater Charitable Foundation, and the Tau Consortium during the conduct of the study. Dr Spina reported receiving consulting fees from Acsel Health, Precision Xtract, and Techspert.io outside the submitted work. Dr Rabinovici reported receiving grants from the NIH during the conduct of the study; grants from the Alzheimer's Association, the American College of Radiology, Genentech, and the NIH; personal fees from Eisai, Eli Lilly and Company, Genentech, Johnson &amp; Johnson, and Roche; and being employed as an associate editor of <i>JAMA Neurology</i> outside the submitted work. Dr Boxer reported receiving grants from the NIH and the Rainwater Charitable Foundation during the conduct of the study; grants from Biogen, Eisai, and Regeneron Pharmaceuticals; personal fees from Denali Therapeutics, GlaxoSmithKline, Humana, Oligomerix, Oscotec, Roche, Transposon Therapeutics, and Wave Life Sciences; nonfinancial support from Eli Lilly and Company and Novartis; and owning stock options in Alector, Arvinas, AZTherapies, and TrueBinding outside the submitted work. Dr Miller reported receiving grants from the NIH; serving as an advisor for the Arizona Alzheimer's Disease Center, the Association for Frontotemporal Degeneration, the Bluefield Project to Cure FTD, the Buck Institute for Research on Aging, the John Douglas French Alzheimer&#x2019;s Foundation, the Larry L. Hillblom Foundation, the Massachusetts Alzheimer&#x2019;s Disease Research Center, the National Institute for Health Research Cambridge Biomedical Research Centre (and its subunit, the Biomedical Research Unit in Dementia), Stanford University, the Tau Consortium, the University of Southern California, and the University of Washington; serving as a director or codirector of the Bluefield Project to Cure FTD, the Global Brain Health Institute, and the Tau Consortium; and being employed as affiliated faculty at the Institute for Neurodegenerative Diseases outside the submitted work. Dr Vossel reported receiving grants from the Alzheimer's Association, the John Douglas French Alzheimer's Foundation, the NIH, and the S.D. Bechtel, Jr. Foundation during the conduct of the study. Dr Grinberg reported receiving grants from the NIH and the Rainwater Charitable Foundation during the conduct of the study and personal fees from CuraSen Therapeutics and the Simons Foundation outside the submitted work. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>4</Day><Hour>12</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>4</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35377391</ArticleId><ArticleId IdType="pmc">PMC8981071</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2022.0429</ArticleId><ArticleId IdType="pii">2790494</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ehrenberg AJ, Suemoto CK, de Paula Fran&#xe7;a Resende E, et al. . Neuropathologic correlates of psychiatric symptoms in Alzheimer&#x2019;s disease. J Alzheimers Dis. 2018;66(1):115-126. doi:10.3233/JAD-180688</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-180688</ArticleId><ArticleId IdType="pmc">PMC6381997</ArticleId><ArticleId IdType="pubmed">30223398</ArticleId></ArticleIdList></Reference><Reference><Citation>Spira AP, An Y, Wu MN, et al. . Excessive daytime sleepiness and napping in cognitively normal adults: associations with subsequent amyloid deposition measured by PiB PET. Sleep. 2018;41(10). doi:10.1093/sleep/zsy152</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/sleep/zsy152</ArticleId><ArticleId IdType="pmc">PMC6187104</ArticleId><ArticleId IdType="pubmed">30192978</ArticleId></ArticleIdList></Reference><Reference><Citation>Leng Y, Redline S, Stone KL, Ancoli-Israel S, Yaffe K. Objective napping, cognitive decline, and risk of cognitive impairment in older men. Alzheimers Dement. 2019;15(8):1039-1047. doi:10.1016/j.jalz.2019.04.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2019.04.009</ArticleId><ArticleId IdType="pmc">PMC6699896</ArticleId><ArticleId IdType="pubmed">31227429</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsapanou A, Gu Y, Manly J, et al. . Daytime sleepiness and sleep inadequacy as risk factors for dementia. Dement Geriatr Cogn Dis Extra. 2015;5(2):286-295. doi:10.1159/000431311</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000431311</ArticleId><ArticleId IdType="pmc">PMC4521063</ArticleId><ArticleId IdType="pubmed">26273244</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh CM, Ruoff L, Walker K, et al. . Sleepless night and day, the plight of progressive supranuclear palsy. Sleep. 2017;40(11):zsx154. doi:10.1093/sleep/zsx154</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/sleep/zsx154</ArticleId><ArticleId IdType="pmc">PMC6251530</ArticleId><ArticleId IdType="pubmed">29029214</ArticleId></ArticleIdList></Reference><Reference><Citation>Musiek ES, Xiong DD, Holtzman DM. Sleep, circadian rhythms, and the pathogenesis of Alzheimer disease. Exp Mol Med. 2015;47(3):e148. doi:10.1038/emm.2014.121</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emm.2014.121</ArticleId><ArticleId IdType="pmc">PMC4351409</ArticleId><ArticleId IdType="pubmed">25766617</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterniczuk R, Theou O, Rusak B, Rockwood K. Sleep disturbance is associated with incident dementia and mortality. Curr Alzheimer Res. 2013;10(7):767-775. doi:10.2174/15672050113109990134</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/15672050113109990134</ArticleId><ArticleId IdType="pubmed">23905991</ArticleId></ArticleIdList></Reference><Reference><Citation>Hahn EA, Wang HX, Andel R, Fratiglioni L. A change in sleep pattern may predict Alzheimer disease. Am J Geriatr Psychiatry. 2014;22(11):1262-1271. doi:10.1016/j.jagp.2013.04.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jagp.2013.04.015</ArticleId><ArticleId IdType="pubmed">23954041</ArticleId></ArticleIdList></Reference><Reference><Citation>Musiek ES, Holtzman DM. Mechanisms linking circadian clocks, sleep, and neurodegeneration. Science. 2016;354(6315):1004-1008. doi:10.1126/science.aah4968</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aah4968</ArticleId><ArticleId IdType="pmc">PMC5219881</ArticleId><ArticleId IdType="pubmed">27885006</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie L, Kang H, Xu Q, et al. . Sleep drives metabolite clearance from the adult brain. Science. 2013;342(6156):373-377. doi:10.1126/science.1241224</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1241224</ArticleId><ArticleId IdType="pmc">PMC3880190</ArticleId><ArticleId IdType="pubmed">24136970</ArticleId></ArticleIdList></Reference><Reference><Citation>Holth JK, Fritschi SK, Wang C, et al. . The sleep-wake cycle regulates brain interstitial fluid tau in mice and CSF tau in humans. Science. 2019;363(6429):880-884. doi:10.1126/science.aav2546</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aav2546</ArticleId><ArticleId IdType="pmc">PMC6410369</ArticleId><ArticleId IdType="pubmed">30679382</ArticleId></ArticleIdList></Reference><Reference><Citation>Barth&#xe9;lemy NR, Liu H, Lu W, Kotzbauer PT, Bateman RJ, Lucey BP. Sleep deprivation affects tau phosphorylation in human cerebrospinal fluid. Ann Neurol. 2020;87(5):700-709. doi:10.1002/ana.25702</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25702</ArticleId><ArticleId IdType="pmc">PMC7289061</ArticleId><ArticleId IdType="pubmed">32057125</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang JE, Lim MM, Bateman RJ, et al. . Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science. 2009;326(5955):1005-1007. doi:10.1126/science.1180962</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1180962</ArticleId><ArticleId IdType="pmc">PMC2789838</ArticleId><ArticleId IdType="pubmed">19779148</ArticleId></ArticleIdList></Reference><Reference><Citation>Roh JH, Huang Y, Bero AW, et al. . Disruption of the sleep-wake cycle and diurnal fluctuation of &#x3b2;-amyloid in mice with Alzheimer&#x2019;s disease pathology. Sci Transl Med. 2012;4(150):150ra122. doi:10.1126/scitranslmed.3004291</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3004291</ArticleId><ArticleId IdType="pmc">PMC3654377</ArticleId><ArticleId IdType="pubmed">22956200</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C, Holtzman DM. Bidirectional relationship between sleep and Alzheimer&#x2019;s disease: role of amyloid, tau, and other factors. Neuropsychopharmacology. 2020;45(1):104-120. doi:10.1038/s41386-019-0478-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41386-019-0478-5</ArticleId><ArticleId IdType="pmc">PMC6879647</ArticleId><ArticleId IdType="pubmed">31408876</ArticleId></ArticleIdList></Reference><Reference><Citation>Falg&#xe0;s N, Walsh CM, Neylan TC, Grinberg LT. Deepen into sleep and wake patterns across Alzheimer&#x2019;s disease phenotypes. Alzheimers Dement. 2021;17(8):1403-1406. doi:10.1002/alz.12304</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.12304</ArticleId><ArticleId IdType="pmc">PMC8364869</ArticleId><ArticleId IdType="pubmed">33710762</ArticleId></ArticleIdList></Reference><Reference><Citation>Ju YES, McLeland JS, Toedebusch CD, et al. . Sleep quality and preclinical Alzheimer disease. JAMA Neurol. 2013;70(5):587-593. doi:10.1001/jamaneurol.2013.2334</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2013.2334</ArticleId><ArticleId IdType="pmc">PMC3676720</ArticleId><ArticleId IdType="pubmed">23479184</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucey BP. It&#x2019;s complicated: the relationship between sleep and Alzheimer&#x2019;s disease in humans. Neurobiol Dis. 2020;144:105031. doi:10.1016/j.nbd.2020.105031</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2020.105031</ArticleId><ArticleId IdType="pmc">PMC7484285</ArticleId><ArticleId IdType="pubmed">32738506</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh J, Eser RA, Ehrenberg AJ, et al. . Profound degeneration of wake-promoting neurons in Alzheimer&#x2019;s disease. Alzheimers Dement. 2019;15(10):1253-1263. doi:10.1016/j.jalz.2019.06.3916</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2019.06.3916</ArticleId><ArticleId IdType="pmc">PMC6801040</ArticleId><ArticleId IdType="pubmed">31416793</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobs HIL, Becker JA, Kwong K, et al. . In vivo and neuropathology data support locus coeruleus integrity as indicator of Alzheimer&#x2019;s disease pathology and cognitive decline. Sci Transl Med. 2021;13(612):eabj2511. doi:10.1126/scitranslmed.abj2511</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abj2511</ArticleId><ArticleId IdType="pmc">PMC8641759</ArticleId><ArticleId IdType="pubmed">34550726</ArticleId></ArticleIdList></Reference><Reference><Citation>Theofilas P, Ehrenberg AJ, Dunlop S, et al. . Locus coeruleus volume and cell population changes during Alzheimer&#x2019;s disease progression: a stereological study in human postmortem brains with potential implication for early-stage biomarker discovery. Alzheimers Dement. 2017;13(3):236-246. doi:10.1016/j.jalz.2016.06.2362</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2016.06.2362</ArticleId><ArticleId IdType="pmc">PMC5298942</ArticleId><ArticleId IdType="pubmed">27513978</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehrenberg AJ, Nguy AK, Theofilas P, et al. . Quantifying the accretion of hyperphosphorylated tau in the locus coeruleus and dorsal raphe nucleus: the pathological building blocks of early Alzheimer&#x2019;s disease. Neuropathol Appl Neurobiol. 2017;43(5):393-408. doi:10.1111/nan.12387</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nan.12387</ArticleId><ArticleId IdType="pmc">PMC5642282</ArticleId><ArticleId IdType="pubmed">28117917</ArticleId></ArticleIdList></Reference><Reference><Citation>Vossel KA, Ranasinghe KG, Beagle AJ, et al. . Incidence and impact of subclinical epileptiform activity in Alzheimer&#x2019;s disease. Ann Neurol. 2016;80(6):858-870. doi:10.1002/ana.24794</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24794</ArticleId><ArticleId IdType="pmc">PMC5177487</ArticleId><ArticleId IdType="pubmed">27696483</ArticleId></ArticleIdList></Reference><Reference><Citation>Litvan I, Agid Y, Calne D, et al. . Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology. 1996;47(1):1-9. doi:10.1212/WNL.47.1.1</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.47.1.1</ArticleId><ArticleId IdType="pubmed">8710059</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT, Phelps CH, Beach TG, et al. . National Institute on Aging&#x2013;Alzheimer&#x2019;s Association guidelines for the neuropathologic assessment of Alzheimer&#x2019;s disease. Alzheimers Dement. 2012;8(1):1-13. doi:10.1016/j.jalz.2011.10.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2011.10.007</ArticleId><ArticleId IdType="pmc">PMC3266529</ArticleId><ArticleId IdType="pubmed">22265587</ArticleId></ArticleIdList></Reference><Reference><Citation>Suemoto CK, Ferretti-Rebustini REL, Rodriguez RD, et al. . Neuropathological diagnoses and clinical correlates in older adults in Brazil: a cross-sectional study. PLoS Med. 2017;14(3):e1002267. doi:10.1371/journal.pmed.1002267</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1002267</ArticleId><ArticleId IdType="pmc">PMC5369698</ArticleId><ArticleId IdType="pubmed">28350821</ArticleId></ArticleIdList></Reference><Reference><Citation>Cairns NJ, Bigio EH, Mackenzie IRA, et al. ; Consortium for Frontotemporal Lobar Degeneration . Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol. 2007;114(1):5-22. doi:10.1007/s00401-007-0237-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-007-0237-2</ArticleId><ArticleId IdType="pmc">PMC2827877</ArticleId><ArticleId IdType="pubmed">17579875</ArticleId></ArticleIdList></Reference><Reference><Citation>Iber C; American Academy of Sleep Medicine. The AASM Manual for the Scoring of Sleep and Associated Events: Rules, Terminology and Technical Specifications. American Academy of Sleep Medicine; 2007.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>West MJ, Slomianka L, Gundersen HJ. Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator. Anat Rec. 1991;231(4):482-497. doi:10.1002/ar.1092310411</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ar.1092310411</ArticleId><ArticleId IdType="pubmed">1793176</ArticleId></ArticleIdList></Reference><Reference><Citation>Steele JC, Richardson JC, Olszewski J. Progressive supranuclear palsy. a heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol. 1964;10:333-359. doi:10.1001/archneur.1964.00460160003001</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.1964.00460160003001</ArticleId><ArticleId IdType="pubmed">14107684</ArticleId></ArticleIdList></Reference><Reference><Citation>Peter-Derex L, Yammine P, Bastuji H, Croisile B. Sleep and Alzheimer&#x2019;s disease. Sleep Med Rev. 2015;19:29-38. doi:10.1016/j.smrv.2014.03.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.smrv.2014.03.007</ArticleId><ArticleId IdType="pubmed">24846773</ArticleId></ArticleIdList></Reference><Reference><Citation>Iranzo A. Sleep in neurodegenerative diseases. Sleep Med Clin. 2016;11(1):1-18. doi:10.1016/j.jsmc.2015.10.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsmc.2015.10.011</ArticleId><ArticleId IdType="pubmed">26972029</ArticleId></ArticleIdList></Reference><Reference><Citation>Stratmann K, Heinsen H, Korf HW, et al. . Precortical phase of Alzheimer&#x2019;s disease (AD)&#x2013;related tau cytoskeletal pathology. Brain Pathol. 2016;26(3):371-386. doi:10.1111/bpa.12289</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bpa.12289</ArticleId><ArticleId IdType="pmc">PMC4720581</ArticleId><ArticleId IdType="pubmed">26193084</ArticleId></ArticleIdList></Reference><Reference><Citation>Irwin DJ. Tauopathies as clinicopathological entities. Parkinsonism Relat Disord. 2016;22(suppl 1):S29-S33. doi:10.1016/j.parkreldis.2015.09.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.parkreldis.2015.09.020</ArticleId><ArticleId IdType="pmc">PMC4662611</ArticleId><ArticleId IdType="pubmed">26382841</ArticleId></ArticleIdList></Reference><Reference><Citation>Scammell TE, Arrigoni E, Lipton JO. Neural circuitry of wakefulness and sleep. Neuron. 2017;93(4):747-765. doi:10.1016/j.neuron.2017.01.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2017.01.014</ArticleId><ArticleId IdType="pmc">PMC5325713</ArticleId><ArticleId IdType="pubmed">28231463</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh J, Petersen C, Walsh CM, Bittencourt JC, Neylan TC, Grinberg LT. The role of co-neurotransmitters in sleep and wake regulation. Mol Psychiatry. 2019;24(9):1284-1295. doi:10.1038/s41380-018-0291-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-018-0291-2</ArticleId><ArticleId IdType="pmc">PMC6491268</ArticleId><ArticleId IdType="pubmed">30377299</ArticleId></ArticleIdList></Reference><Reference><Citation>Saper CB, Fuller PM. Wake-sleep circuitry: an overview. Curr Opin Neurobiol. 2017;44:186-192. doi:10.1016/j.conb.2017.03.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.conb.2017.03.021</ArticleId><ArticleId IdType="pmc">PMC5531075</ArticleId><ArticleId IdType="pubmed">28577468</ArticleId></ArticleIdList></Reference><Reference><Citation>McKillop LE, Vyazovskiy VV. Sleep and ageing: from human studies to rodent models. Curr Opin Physiol. 2020;15:210-216. doi:10.1016/j.cophys.2020.03.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cophys.2020.03.004</ArticleId><ArticleId IdType="pmc">PMC7255885</ArticleId><ArticleId IdType="pubmed">32467862</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucey BP, McCullough A, Landsness EC, et al. . Reduced non&#x2013;rapid eye movement sleep is associated with tau pathology in early Alzheimer&#x2019;s disease. Sci Transl Med. 2019;11(474):eaau6550. doi:10.1126/scitranslmed.aau6550</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aau6550</ArticleId><ArticleId IdType="pmc">PMC6342564</ArticleId><ArticleId IdType="pubmed">30626715</ArticleId></ArticleIdList></Reference><Reference><Citation>Mander BA, Marks SM, Vogel JW, et al. . &#x3b2;-amyloid disrupts human NREM slow waves and related hippocampus-dependent memory consolidation. Nat Neurosci. 2015;18(7):1051-1057. doi:10.1038/nn.4035</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4035</ArticleId><ArticleId IdType="pmc">PMC4482795</ArticleId><ArticleId IdType="pubmed">26030850</ArticleId></ArticleIdList></Reference><Reference><Citation>Liguori C, Romigi A, Nuccetelli M, et al. . Orexinergic system dysregulation, sleep impairment, and cognitive decline in Alzheimer disease. JAMA Neurol. 2014;71(12):1498-1505. doi:10.1001/jamaneurol.2014.2510</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.2510</ArticleId><ArticleId IdType="pubmed">25322206</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim ASP, Ellison BA, Wang JL, et al. . Sleep is related to neuron numbers in the ventrolateral preoptic/intermediate nucleus in older adults with and without Alzheimer&#x2019;s disease. Brain. 2014;137(Pt 10):2847-2861. doi:10.1093/brain/awu222</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awu222</ArticleId><ArticleId IdType="pmc">PMC4163039</ArticleId><ArticleId IdType="pubmed">25142380</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang JL, Lim AS, Chiang WY, et al. . Suprachiasmatic neuron numbers and rest-activity circadian rhythms in older humans. Ann Neurol. 2015;78(2):317-322. doi:10.1002/ana.24432</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24432</ArticleId><ArticleId IdType="pmc">PMC4515161</ArticleId><ArticleId IdType="pubmed">25921596</ArticleId></ArticleIdList></Reference><Reference><Citation>Lew CH, Petersen C, Neylan TC, Grinberg LT. Tau-driven degeneration of sleep- and wake-regulating neurons in Alzheimer&#x2019;s disease. Sleep Med Rev. 2021;60:101541. doi:10.1016/j.smrv.2021.101541</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.smrv.2021.101541</ArticleId><ArticleId IdType="pmc">PMC8862638</ArticleId><ArticleId IdType="pubmed">34500400</ArticleId></ArticleIdList></Reference><Reference><Citation>Mladinov M, Oh JY, Petersen C, et al. . Specific pattern of melanin-concentrating hormone (MCH) neuron degeneration in Alzheimer&#x2019;s disease and possible clinical implications. medRxiv. Preprint posted online January 29, 2021. doi:10.1101/2021.01.27.21250608</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.01.27.21250608</ArticleId></ArticleIdList></Reference><Reference><Citation>Leng Y, Musiek ES, Hu K, Cappuccio FP, Yaffe K. Association between circadian rhythms and neurodegenerative diseases. Lancet Neurol. 2019;18(3):307-318. doi:10.1016/S1474-4422(18)30461-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30461-7</ArticleId><ArticleId IdType="pmc">PMC6426656</ArticleId><ArticleId IdType="pubmed">30784558</ArticleId></ArticleIdList></Reference><Reference><Citation>De Pablo-Fernandez E, Courtney R, Warner TT, Holton JL. A histologic study of the circadian system in Parkinson disease, multiple system atrophy, and progressive supranuclear palsy. JAMA Neurol. 2018;75(8):1008-1012. doi:10.1001/jamaneurol.2018.0640</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2018.0640</ArticleId><ArticleId IdType="pmc">PMC6142937</ArticleId><ArticleId IdType="pubmed">29710120</ArticleId></ArticleIdList></Reference><Reference><Citation>Lukic MJ, Kurz C, Respondek G, et al. ; Barcelona Brain Bank Collaborative Group, the MDS-Endorsed PSP Study Group . Copathology in progressive supranuclear palsy: does it matter? Mov Disord. 2020;35(6):984-993. doi:10.1002/mds.28011</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.28011</ArticleId><ArticleId IdType="pubmed">32125724</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35379992</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>14</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1718</ISSN><JournalIssue CitedMedium="Internet"><Volume>54</Volume><Issue>4</Issue><PubDate><Year>2022</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Nature genetics</Title><ISOAbbreviation>Nat Genet</ISOAbbreviation></Journal><ArticleTitle>New insights into the genetic etiology of Alzheimer's disease and related dementias.</ArticleTitle><Pagination><StartPage>412</StartPage><EndPage>436</EndPage><MedlinePgn>412-436</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41588-022-01024-z</ELocationID><Abstract><AbstractText>Characterization of the genetic landscape of Alzheimer's disease (AD) and related dementias (ADD) provides a unique opportunity for a better understanding of the associated pathophysiological processes. We performed a two-stage genome-wide association study totaling 111,326 clinically diagnosed/'proxy' AD cases and 677,663 controls. We found 75 risk loci, of which 42 were new at the time of analysis. Pathway enrichment analyses confirmed the involvement of amyloid/tau pathways and highlighted microglia implication. Gene prioritization in the new loci identified 31 genes that were suggestive of new genetically associated processes, including the tumor necrosis factor alpha pathway through the linear ubiquitin chain assembly complex. We also built a new genetic risk score associated with the risk of future AD/dementia or progression from mild cognitive impairment to AD/dementia. The improvement in prediction led to a 1.6- to 1.9-fold increase in AD risk from the lowest to the highest decile, in addition to effects of age and the APOE &#x3b5;4 allele.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Bellenguez</LastName><ForeName>C&#xe9;line</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-1240-7874</Identifier><AffiliationInfo><Affiliation>Universit&#xe9; de Lille, INSERM, CHU Lille, Institut Pasteur Lille, U1167-RID-AGE, Facteurs de risque et d&#xe9;terminants mol&#xe9;culaires des maladies li&#xe9;es au vieillissement, Lille, France. celine.bellenguez@pasteur-lille.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>K&#xfc;&#xe7;&#xfc;kali</LastName><ForeName>Fahri</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-3835-9639</Identifier><AffiliationInfo><Affiliation>Complex Genetics of Alzheimer's Disease Group, VIB Center for Molecular Neurology, VIB, Antwerp, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Neurogenetics, Institute Born - Bunge, Antwerp, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Jansen</LastName><ForeName>Iris E</ForeName><Initials>IE</Initials><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Complex Trait Genetics, Center for Neurogenomics and Cognitive Research, Amsterdam Neuroscience, Vrije University, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Kleineidam</LastName><ForeName>Luca</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital Bonn, Bonn, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Neurogenetics and Molecular Psychiatry, Department of Psychiatry and Psychotherapy, University of Cologne, Medical Faculty, Cologne, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE Bonn), Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Moreno-Grau</LastName><ForeName>Sonia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Research Center and Memory Clinic Fundaci&#xf3; ACE, Institut Catal&#xe0; de Neuroci&#xe8;ncies Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Amin</LastName><ForeName>Najaf</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-8944-1771</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology, Erasmus MC, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Nuffield Department of Population Health, Oxford University, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Naj</LastName><ForeName>Adam C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology, and Informatics, Penn Neurodegeneration Genomics Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Campos-Martin</LastName><ForeName>Rafael</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of Neurogenetics and Molecular Psychiatry, Department of Psychiatry and Psychotherapy, University of Cologne, Medical Faculty, Cologne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grenier-Boley</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Universit&#xe9; de Lille, INSERM, CHU Lille, Institut Pasteur Lille, U1167-RID-AGE, Facteurs de risque et d&#xe9;terminants mol&#xe9;culaires des maladies li&#xe9;es au vieillissement, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andrade</LastName><ForeName>Victor</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital Bonn, Bonn, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Neurogenetics and Molecular Psychiatry, Department of Psychiatry and Psychotherapy, University of Cologne, Medical Faculty, Cologne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holmans</LastName><ForeName>Peter A</ForeName><Initials>PA</Initials><Identifier Source="ORCID">0000-0003-0870-9412</Identifier><AffiliationInfo><Affiliation>MRC Centre for Neuropsychiatric Genetics and Genomics, Division of Psychological Medicine and Clinical Neuroscience, School of Medicine, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boland</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>CEA, Centre National de Recherche en G&#xe9;nomique Humaine, Universit&#xe9; Paris-Saclay, Evry, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Damotte</LastName><ForeName>Vincent</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Universit&#xe9; de Lille, INSERM, CHU Lille, Institut Pasteur Lille, U1167-RID-AGE, Facteurs de risque et d&#xe9;terminants mol&#xe9;culaires des maladies li&#xe9;es au vieillissement, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Lee</LastName><ForeName>Sven J</ForeName><Initials>SJ</Initials><Identifier Source="ORCID">0000-0003-1606-8643</Identifier><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Section Genomics of Neurodegenerative Diseases and Aging, Department of Human Genetics Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Costa</LastName><ForeName>Marcos R</ForeName><Initials>MR</Initials><Identifier Source="ORCID">0000-0002-4928-2163</Identifier><AffiliationInfo><Affiliation>Universit&#xe9; de Lille, INSERM, CHU Lille, Institut Pasteur Lille, U1167-RID-AGE, Facteurs de risque et d&#xe9;terminants mol&#xe9;culaires des maladies li&#xe9;es au vieillissement, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Brain Institute, Federal University of Rio Grande do Norte, Natal, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuulasmaa</LastName><ForeName>Teemu</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-1795-7314</Identifier><AffiliationInfo><Affiliation>Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Qiong</ForeName><Initials>Q</Initials><Identifier Source="ORCID">0000-0002-3658-1375</Identifier><AffiliationInfo><Affiliation>Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Framingham Heart Study, Framingham, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Rojas</LastName><ForeName>Itziar</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-2148-381X</Identifier><AffiliationInfo><Affiliation>Research Center and Memory Clinic Fundaci&#xf3; ACE, Institut Catal&#xe0; de Neuroci&#xe8;ncies Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bis</LastName><ForeName>Joshua C</ForeName><Initials>JC</Initials><Identifier Source="ORCID">0000-0002-3409-1110</Identifier><AffiliationInfo><Affiliation>Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yaqub</LastName><ForeName>Amber</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-3579-8054</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology, Erasmus MC, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prokic</LastName><ForeName>Ivana</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-0370-1473</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology, Erasmus MC, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chapuis</LastName><ForeName>Julien</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-5802-2857</Identifier><AffiliationInfo><Affiliation>Universit&#xe9; de Lille, INSERM, CHU Lille, Institut Pasteur Lille, U1167-RID-AGE, Facteurs de risque et d&#xe9;terminants mol&#xe9;culaires des maladies li&#xe9;es au vieillissement, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmad</LastName><ForeName>Shahzad</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-8658-3790</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology, Erasmus MC, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>LACDR, Leiden, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giedraitis</LastName><ForeName>Vilmantas</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0003-3423-2021</Identifier><AffiliationInfo><Affiliation>Department of Public Health and Carins Sciences/Geriatrics, Uppsala University, Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aarsland</LastName><ForeName>Dag</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Centre of Age-Related Medicine, Stavanger University Hospital, Stavanger, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Psychiatry, Psychology &amp; Neuroscience, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garcia-Gonzalez</LastName><ForeName>Pablo</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-0125-5403</Identifier><AffiliationInfo><Affiliation>Research Center and Memory Clinic Fundaci&#xf3; ACE, Institut Catal&#xe0; de Neuroci&#xe8;ncies Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdelnour</LastName><ForeName>Carla</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Research Center and Memory Clinic Fundaci&#xf3; ACE, Institut Catal&#xe0; de Neuroci&#xe8;ncies Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alarc&#xf3;n-Mart&#xed;n</LastName><ForeName>Emilio</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Research Center and Memory Clinic Fundaci&#xf3; ACE, Institut Catal&#xe0; de Neuroci&#xe8;ncies Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery, Biochemistry and Molecular Biology, School of Medicine, University of M&#xe1;laga, M&#xe1;laga, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alcolea</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-3819-3245</Identifier><AffiliationInfo><Affiliation>CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, II B Sant Pau, Hospital de la Santa Creu i Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alegret</LastName><ForeName>Montserrat</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Research Center and Memory Clinic Fundaci&#xf3; ACE, Institut Catal&#xe0; de Neuroci&#xe8;ncies Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alvarez</LastName><ForeName>Ignacio</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-8537-3935</Identifier><AffiliationInfo><Affiliation>Fundaci&#xf3; Doc&#xe8;ncia i Recerca M&#xfa;tuaTerrassa and Movement Disorders Unit, Department of Neurology, University Hospital M&#xfa;tuaTerrassa, Terrassa, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory Disorders Unit, Department of Neurology, Hospital Universitari Mutua de Terrassa, Terrassa, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>&#xc1;lvarez</LastName><ForeName>Victoria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Laboratorio de Gen&#xe9;tica, Hospital Universitario Central de Asturias, Oviedo, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Servicio de Neurolog&#xed;a, Hospital Universitario Central de Asturias- Oviedo and Instituto de Investigaci&#xf3;n Biosanitaria del Principado de Asturias, Oviedo, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Armstrong</LastName><ForeName>Nicola J</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>Centre for Healthy Brain Ageing, School of Psychiatry, Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsolaki</LastName><ForeName>Anthoula</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-5563-7776</Identifier><AffiliationInfo><Affiliation>First Department of Neurology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Alzheimer Hellas, Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ant&#xfa;nez</LastName><ForeName>Carmen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Unidad de Demencias, Hospital Cl&#xed;nico Universitario Virgen de la Arrixaca, Murcia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Appollonio</LastName><ForeName>Ildebrando</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>School of Medicine and Surgery, University of Milano-Bicocca, Milano, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology Unit, San Gerardo Hospital, Monza, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arcaro</LastName><ForeName>Marina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Fondazione IRCCS Ca'Granda, Ospedale Policlinico, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Archetti</LastName><ForeName>Silvana</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Laboratory Diagnostics, III Laboratory of Analysis, Brescia Hospital, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pastor</LastName><ForeName>Alfonso Arias</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Unitat Trastorns Cognitius, Hospital Universitari Santa Maria de Lleida, Lleida, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institut de Recerca Biomedica de Lleida (IRBLLeida), Lleida, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arosio</LastName><ForeName>Beatrice</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Geriatic Unit, Fondazione C&#xe0; Granda, IRCCS Ospedale Maggiore Policlinico, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Athanasiu</LastName><ForeName>Lavinia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>NORMENT Centre, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bailly</LastName><ForeName>Henri</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>EA 4468, Universit&#xe9; de Paris, APHP, H&#xf4;pital Broca, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Banaj</LastName><ForeName>Nerisa</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Laboratory of Neuropsychiatry, Department of Clinical and Behavioral Neurology, IRCCS Santa Lucia Foundation, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baquero</LastName><ForeName>Miquel</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-6861-1831</Identifier><AffiliationInfo><Affiliation>Servei de Neurologia, Hospital Universitari i Polit&#xe8;cnic La Fe, Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barral</LastName><ForeName>Sandra</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Taub Institute on Alzheimer's Disease and the Aging Brain, Department of Neurology, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unit of Neurology, University of Parma and AOU, Parma, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinic of Neurology, UH 'Alexandrovska', Medical University - Sofia, Sofia, Bulgaria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beiser</LastName><ForeName>Alexa</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Boston University and the NHLBI's Framingham Heart Study, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pastor</LastName><ForeName>Ana Bel&#xe9;n</ForeName><Initials>AB</Initials><Identifier Source="ORCID">0000-0001-9637-4688</Identifier><AffiliationInfo><Affiliation>CIEN Foundation/Queen Sofia Foundation Alzheimer Center, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Below</LastName><ForeName>Jennifer E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Vanderbilt Brain Institute, Vanderbilt University, Nashville, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benchek</LastName><ForeName>Penelope</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Cleveland Institute for Computational Biology, Case Western Reserve University, Cleveland, OH, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benussi</LastName><ForeName>Luisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Molecular Markers Laboratory, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berr</LastName><ForeName>Claudine</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-5254-7655</Identifier><AffiliationInfo><Affiliation>Neuropsychiatry: Epidemiological and Clinical Research, PSNREC, Universit&#xe9; de Montpellier, INSERM U1061, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Besse</LastName><ForeName>C&#xe9;line</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>CEA, Centre National de Recherche en G&#xe9;nomique Humaine, Universit&#xe9; Paris-Saclay, Evry, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bessi</LastName><ForeName>Valentina</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-6176-3584</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Binetti</LastName><ForeName>Giuliano</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Molecular Markers Laboratory, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>MAC - Memory Clinic, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bizarro</LastName><ForeName>Alessandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Geriatrics Unit, Fondazione Policlinico A. Gemelli IRCCS, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blesa</LastName><ForeName>Rafael</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, II B Sant Pau, Hospital de la Santa Creu i Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boada</LastName><ForeName>Merc&#xe8;</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-2617-3009</Identifier><AffiliationInfo><Affiliation>Research Center and Memory Clinic Fundaci&#xf3; ACE, Institut Catal&#xe0; de Neuroci&#xe8;ncies Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boerwinkle</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Human Genetics Center, School of Public Health, University of Texas Health Science Center at Houston, Houston, TX, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borroni</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Centre for Neurodegenerative Disorders, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boschi</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neuroscience "Rita Levi Montalcini", University of Torino, Torino, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boss&#xf9;</LastName><ForeName>Paola</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-1432-0078</Identifier><AffiliationInfo><Affiliation>Experimental Neuro-psychobiology Laboratory, Department of Clinical and Behavioral Neurology, IRCCS Santa Lucia Foundation, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Br&#xe5;then</LastName><ForeName>Geir</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-3224-7983</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Clinical Neurophysiology, University Hospital of Trondheim, Trondheim, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuromedicine and Movement Science, Norwegian University of Science and Technology, Trondheim, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bressler</LastName><ForeName>Jan</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-6578-4772</Identifier><AffiliationInfo><Affiliation>Human Genetics Center, School of Public Health, University of Texas Health Science Center at Houston, Houston, TX, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Public Health, University of Texas Health Science Center at Houston, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bresner</LastName><ForeName>Catherine</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-2673-9762</Identifier><AffiliationInfo><Affiliation>MRC Centre for Neuropsychiatric Genetics and Genomics, Division of Psychological Medicine and Clinical Neuroscience, School of Medicine, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brodaty</LastName><ForeName>Henry</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-9487-6617</Identifier><AffiliationInfo><Affiliation>Centre for Healthy Brain Ageing, School of Psychiatry, Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dementia Centre for Research Collaboration, School of Psychiatry, University of New South Wales, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brookes</LastName><ForeName>Keeley J</ForeName><Initials>KJ</Initials><Identifier Source="ORCID">0000-0003-2427-2513</Identifier><AffiliationInfo><Affiliation>Biosciences, School of Science and Technology, Nottingham Trent University, Nottingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brusco</LastName><ForeName>Luis Ignacio</ForeName><Initials>LI</Initials><AffiliationInfo><Affiliation>Centro de Neuropsiquiatr&#xed;a y Neurolog&#xed;a de la Conducta (CENECON), Facultad de Medicina, Universidad de Buenos Aires (UBA), C.A.B.A., Buenos Aires, Argentina.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departamento Ciencias Fisiol&#xf3;gicas UAII, Facultad de Medicina, UBA, C.A.B.A., Buenos Aires, Argentina.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hospital Interzonal General de Agudos Eva Per&#xf3;n, San Mart&#xed;n, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buiza-Rueda</LastName><ForeName>Dolores</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Erasmus MC, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>B&#xfb;rger</LastName><ForeName>Katharina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Institute for Stroke and Dementia Research, Klinikum der Universit&#xe4;t M&#xfc;nchen, Ludwig Maximilians Universit&#xe4;t (LMU), Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE, Munich), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burholt</LastName><ForeName>Vanessa</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-6789-127X</Identifier><AffiliationInfo><Affiliation>Faculty of Medical &amp; Health Sciences, University of Auckland, Auckland, New Zealand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wales Centre for Ageing &amp; Dementia Research, Swansea University, Wales, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bush</LastName><ForeName>William S</ForeName><Initials>WS</Initials><Identifier Source="ORCID">0000-0002-9729-6519</Identifier><AffiliationInfo><Affiliation>Department of Population &amp; Quantitative Health Sciences, Case Western Reserve University, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calero</LastName><ForeName>Miguel</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-5366-3324</Identifier><AffiliationInfo><Affiliation>Research Center and Memory Clinic Fundaci&#xf3; ACE, Institut Catal&#xe0; de Neuroci&#xe8;ncies Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIEN Foundation/Queen Sofia Foundation Alzheimer Center, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UFIEC, Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cantwell</LastName><ForeName>Laura B</ForeName><Initials>LB</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chene</LastName><ForeName>Genevi&#xe8;ve</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>INSERM, Bordeaux Population Health Research Center, UMR 1219, ISPED, CIC 1401-EC, Universit&#xe9; de Bordeaux, Bordeaux, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pole Sant&#xe9; Publique, CHU de Bordeaux, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Jaeyoon</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-6431-9454</Identifier><AffiliationInfo><Affiliation>Medicine Biomedical Genetics Boston University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cuccaro</LastName><ForeName>Michael L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Dr. John T. Macdonald Foundation Department of Human Genetics, University of Miami, Miami, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carracedo</LastName><ForeName>&#xc1;ngel</ForeName><Initials>&#xc1;</Initials><AffiliationInfo><Affiliation>Grupo de Medicina Xen&#xf3;mica, Centro Nacional de Genotipado (CEGEN-PRB3-ISCIII), Universidade de Santiago de Compostela, Santiago de Compostela, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fundaci&#xf3;n P&#xfa;blica Galega de Medicina Xen&#xf3;mica- CIBERER-IDIS, University of Santiago de Compostela, Santiago de Compostela, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cecchetti</LastName><ForeName>Roberta</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institute of Gerontology and Geriatrics, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cervera-Carles</LastName><ForeName>Laura</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-2286-200X</Identifier><AffiliationInfo><Affiliation>CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, II B Sant Pau, Hospital de la Santa Creu i Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Charbonnier</LastName><ForeName>Camille</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Genetics and CNR-MAJ, Normandie University, UNIROUEN, INSERM U1245, CHU Rouen, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Hung-Hsin</ForeName><Initials>HH</Initials><AffiliationInfo><Affiliation>Division of Genetic Medicine, Vanderbilt University, Nashville, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chillotti</LastName><ForeName>Caterina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Unit of Clinical Pharmacology, University Hospital of Cagliari, Cagliari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ciccone</LastName><ForeName>Simona</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Geriatic Unit, Fondazione C&#xe0; Granda, IRCCS Ospedale Maggiore Policlinico, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Claassen</LastName><ForeName>Jurgen A H R</ForeName><Initials>JAHR</Initials><AffiliationInfo><Affiliation>Radboudumc Alzheimer Center, Department of Geriatrics, Radboud University Medical Center, Nijmegen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clark</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute for Regenerative Medicine, University of Z&#xfc;rich, Schlieren, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Conti</LastName><ForeName>Elisa</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>School of Medicine and Surgery, University of Milano-Bicocca, Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corma-G&#xf3;mez</LastName><ForeName>Ana&#xef;s</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Unidad Cl&#xed;nica de Enfermedades Infecciosas y Microbiolog&#xed;a, Hospital Universitario de Valme, Sevilla, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Costantini</LastName><ForeName>Emanuele</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-1096-8221</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Catholic University of Sacred Heart, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Custodero</LastName><ForeName>Carlo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>University of Bari, "A. Moro", Bary, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daian</LastName><ForeName>Delphine</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>CEA, Centre National de Recherche en G&#xe9;nomique Humaine, Universit&#xe9; Paris-Saclay, Evry, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dalmasso</LastName><ForeName>Maria Carolina</ForeName><Initials>MC</Initials><Identifier Source="ORCID">0000-0002-4901-9955</Identifier><AffiliationInfo><Affiliation>Division of Neurogenetics and Molecular Psychiatry, Department of Psychiatry and Psychotherapy, University of Cologne, Medical Faculty, Cologne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daniele</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Catholic University of Sacred Heart, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dardiotis</LastName><ForeName>Efthimios</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>School of Medicine, University of Thessaly, Larissa, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dartigues</LastName><ForeName>Jean-Fran&#xe7;ois</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Bordeaux Population Health Research Center, University Bordeaux, INSERM, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Deyn</LastName><ForeName>Peter Paul</ForeName><Initials>PP</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Medical Center Groningen, Groningen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Paiva Lopes</LastName><ForeName>Katia</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-0240-0126</Identifier><AffiliationInfo><Affiliation>Ronald M. Loeb Center for Alzheimer's Disease, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences &amp; Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Estelle and Daniel Maggin Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Witte</LastName><ForeName>Lot D</ForeName><Initials>LD</Initials><Identifier Source="ORCID">0000-0002-7235-9958</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Debette</LastName><ForeName>St&#xe9;phanie</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-8675-7968</Identifier><AffiliationInfo><Affiliation>Bordeaux Population Health Research Center, University Bordeaux, INSERM, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deckert</LastName><ForeName>J&#xfc;rgen</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Psychosomatics and Psychotherapy, Center of Mental Health, University Hospital, Wuerzburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Del Ser</LastName><ForeName>Teodoro</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-9806-7083</Identifier><AffiliationInfo><Affiliation>CIEN Foundation/Queen Sofia Foundation Alzheimer Center, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Denning</LastName><ForeName>Nicola</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>UKDRI@ Cardiff, School of Medicine, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeStefano</LastName><ForeName>Anita</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Boston University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dichgans</LastName><ForeName>Martin</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-0654-387X</Identifier><AffiliationInfo><Affiliation>Institute for Stroke and Dementia Research, Klinikum der Universit&#xe4;t M&#xfc;nchen, Ludwig Maximilians Universit&#xe4;t (LMU), Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diehl-Schmid</LastName><ForeName>Janine</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-7745-1382</Identifier><AffiliationInfo><Affiliation>Klinikum rechts der Isar, Department of Psychiatry and Psychotherapy, Technical University of Munich, School of Medicine, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diez-Fairen</LastName><ForeName>M&#xf3;nica</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-1882-0309</Identifier><AffiliationInfo><Affiliation>Fundaci&#xf3; Doc&#xe8;ncia i Recerca M&#xfa;tuaTerrassa and Movement Disorders Unit, Department of Neurology, University Hospital M&#xfa;tuaTerrassa, Terrassa, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory Disorders Unit, Department of Neurology, Hospital Universitari Mutua de Terrassa, Terrassa, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rossi</LastName><ForeName>Paolo Dionigi</ForeName><Initials>PD</Initials><AffiliationInfo><Affiliation>Geriatic Unit, Fondazione C&#xe0; Granda, IRCCS Ospedale Maggiore Policlinico, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Djurovic</LastName><ForeName>Srdjan</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-8140-8061</Identifier><AffiliationInfo><Affiliation>NORMENT Centre, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duron</LastName><ForeName>Emmanuelle</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>EA 4468, Universit&#xe9; de Paris, APHP, H&#xf4;pital Broca, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D&#xfc;zel</LastName><ForeName>Emrah</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Institute of Cognitive Neurology and Dementia Research (IKND), Otto-Von-Guericke University, Magdeburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dufouil</LastName><ForeName>Carole</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-2442-4476</Identifier><AffiliationInfo><Affiliation>INSERM, Bordeaux Population Health Research Center, UMR 1219, ISPED, CIC 1401-EC, Universit&#xe9; de Bordeaux, Bordeaux, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pole Sant&#xe9; Publique, CHU de Bordeaux, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eiriksdottir</LastName><ForeName>Gudny</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Icelandic Heart Association, Kopovagur, Iceland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Engelborghs</LastName><ForeName>Sebastiaan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center for Neurosciences, Vrije Universiteit Brussel (VUB), Brussels, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Reference Center for Biological Markers of Dementia (BIODEM), Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, UZ Brussel, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Escott-Price</LastName><ForeName>Valentina</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0003-1784-5483</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UKDRI@ Cardiff, School of Medicine, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Espinosa</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Research Center and Memory Clinic Fundaci&#xf3; ACE, Institut Catal&#xe0; de Neuroci&#xe8;ncies Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ewers</LastName><ForeName>Michael</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-5231-1714</Identifier><AffiliationInfo><Affiliation>Institute for Stroke and Dementia Research, Klinikum der Universit&#xe4;t M&#xfc;nchen, Ludwig Maximilians Universit&#xe4;t (LMU), Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE, Munich), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Faber</LastName><ForeName>Kelley M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Department of Medical and Molecular Genetics, Indiana University, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fabrizio</LastName><ForeName>Tagliavini</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-1039-7315</Identifier><AffiliationInfo><Affiliation>Fondazione IRCCS, Istituto Neurologico Carlo Besta, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nielsen</LastName><ForeName>Sune Fallgaard</ForeName><Initials>SF</Initials><AffiliationInfo><Affiliation>Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Herlev, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fardo</LastName><ForeName>David W</ForeName><Initials>DW</Initials><AffiliationInfo><Affiliation>Sanders-Brown Center on Aging, Department of Biostatistics, University of Kentucky, Lexington, KY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farotti</LastName><ForeName>Lucia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Centre for Memory Disturbances, Lab of Clinical Neurochemistry, Section of Neurology, University of Perugia, Perugia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fenoglio</LastName><ForeName>Chiara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>University of Milan, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fern&#xe1;ndez-Fuertes</LastName><ForeName>Marta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Unidad Cl&#xed;nica de Enfermedades Infecciosas y Microbiolog&#xed;a, Hospital Universitario de Valme, Sevilla, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferrari</LastName><ForeName>Raffaele</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Laboratory of Neurogenetics, Department of Internal Medicine, Texas Tech University Health Science Center, Lubbock, TX, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Reta Lila Weston Research Laboratories, Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferreira</LastName><ForeName>Catarina B</ForeName><Initials>CB</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Lisbon, Lisbon, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferri</LastName><ForeName>Evelyn</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Geriatic Unit, Fondazione C&#xe0; Granda, IRCCS Ospedale Maggiore Policlinico, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fin</LastName><ForeName>Bertrand</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>CEA, Centre National de Recherche en G&#xe9;nomique Humaine, Universit&#xe9; Paris-Saclay, Evry, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fischer</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Social Medicine Center East- Donauspital, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fladby</LastName><ForeName>Tormod</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-9984-9797</Identifier><AffiliationInfo><Affiliation>Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flie&#xdf;bach</LastName><ForeName>Klaus</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Neurogenetics and Molecular Psychiatry, Department of Psychiatry and Psychotherapy, University of Cologne, Medical Faculty, Cologne, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE Bonn), Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fongang</LastName><ForeName>Bernard</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Glenn Biggs Institute for Alzheimer's &amp; Neurodegenerative Diseases, University of Texas Health Sciences Center, San Antonio, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fornage</LastName><ForeName>Myriam</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-0677-8158</Identifier><AffiliationInfo><Affiliation>Department of Neuromedicine and Movement Science, Norwegian University of Science and Technology, Trondheim, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Public Health, University of Texas Health Science Center at Houston, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fortea</LastName><ForeName>Juan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, II B Sant Pau, Hospital de la Santa Creu i Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Foroud</LastName><ForeName>Tatiana M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Department of Medical and Molecular Genetics, Indiana University, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fostinelli</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Molecular Markers Laboratory, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fox</LastName><ForeName>Nick C</ForeName><Initials>NC</Initials><Identifier Source="ORCID">0000-0002-6660-657X</Identifier><AffiliationInfo><Affiliation>Dementia Research Centre, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Franco-Mac&#xed;as</LastName><ForeName>Emlio</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Unidad de Demencias, Servicio de Neurolog&#xed;a y Neurofisiolog&#xed;a. Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Roc&#xed;o/CSIC/Universidad de Sevilla, Seville, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bullido</LastName><ForeName>Mar&#xed;a J</ForeName><Initials>MJ</Initials><Identifier Source="ORCID">0000-0002-6477-1117</Identifier><AffiliationInfo><Affiliation>CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto de Investigacion Sanitaria 'Hospital la Paz' (IdIPaz), Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Biolog&#xed;a Molecular Severo Ochoa (UAM-CSIC), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frank-Garc&#xed;a</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto de Investigacion Sanitaria 'Hospital la Paz' (IdIPaz), Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hospital Universitario la Paz, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Froelich</LastName><ForeName>Lutz</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-1494-0813</Identifier><AffiliationInfo><Affiliation>Department of Geriatric Psychiatry, Central Institute for Mental Health, Mannheim, University of Heidelberg, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fulton-Howard</LastName><ForeName>Brian</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Ronald M. Loeb Center for Alzheimer's Disease Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galimberti</LastName><ForeName>Daniela</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-9284-5953</Identifier><AffiliationInfo><Affiliation>Fondazione IRCCS Ca'Granda, Ospedale Policlinico, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Milan, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xed;a-Alberca</LastName><ForeName>Jose Maria</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0003-2951-6644</Identifier><AffiliationInfo><Affiliation>CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Alzheimer Research Center &amp; Memory Clinic, Andalusian Institute for Neuroscience, M&#xe1;laga, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xed;a-Gonz&#xe1;lez</LastName><ForeName>Pablo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Research Center and Memory Clinic Fundaci&#xf3; ACE, Institut Catal&#xe0; de Neuroci&#xe8;ncies Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garcia-Madrona</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Hospital Universitario Ramon y Cajal, IRYCIS, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garcia-Ribas</LastName><ForeName>Guillermo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Hospital Universitario Ramon y Cajal, IRYCIS, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghidoni</LastName><ForeName>Roberta</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Molecular Markers Laboratory, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giegling</LastName><ForeName>Ina</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giorgio</LastName><ForeName>Giaccone</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Fondazione IRCCS, Istituto Neurologico Carlo Besta, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goate</LastName><ForeName>Alison M</ForeName><Initials>AM</Initials><Identifier Source="ORCID">0000-0002-0576-2472</Identifier><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Ronald M. Loeb Center for Alzheimer's Disease Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldhardt</LastName><ForeName>Oliver</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Klinikum rechts der Isar, Department of Psychiatry and Psychotherapy, Technical University of Munich, School of Medicine, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gomez-Fonseca</LastName><ForeName>Duber</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology, and Informatics Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonz&#xe1;lez-P&#xe9;rez</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-9771-5982</Identifier><AffiliationInfo><Affiliation>CAEBI, Centro Andaluz de Estudios Bioinform&#xe1;ticos, Sevilla, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graff</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Center for Alzheimer Research, Department NVS, Division of Neurogeriatrics, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unit for Hereditary Dementias, Karolinska University Hospital-Solna, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grande</LastName><ForeName>Giulia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm University, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Green</LastName><ForeName>Emma</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-8687-5590</Identifier><AffiliationInfo><Affiliation>Institute of Public Health, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grimmer</LastName><ForeName>Timo</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Klinikum rechts der Isar, Department of Psychiatry and Psychotherapy, Technical University of Munich, School of Medicine, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gr&#xfc;nblatt</LastName><ForeName>Edna</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-8505-7265</Identifier><AffiliationInfo><Affiliation>Department of Child and Adolescent Psychiatry and Psychotherapy, University Hospital of Psychiatry Zurich, University of Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Center Zurich, University of Zurich and ETH Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zurich Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grunin</LastName><ForeName>Michelle</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gudnason</LastName><ForeName>Vilmundur</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0001-5696-0084</Identifier><AffiliationInfo><Affiliation>Icelandic Heart Association, Faculty of Medicine, University of Iceland, Reykjavik, Iceland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guetta-Baranes</LastName><ForeName>Tamar</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Human Genetics, School of Life Sciences, Life Sciences Building, University Park, University of Nottingham, Nottingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haapasalo</LastName><ForeName>Annakaisa</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-0959-2957</Identifier><AffiliationInfo><Affiliation>AI Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hadjigeorgiou</LastName><ForeName>Georgios</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurology, Medical School, University of Cyprus, Nicosia, Cyprus.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haines</LastName><ForeName>Jonathan L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Department of Population &amp; Quantitative Health Sciences, Case Western Reserve University, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamilton-Nelson</LastName><ForeName>Kara L</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>The John P. Hussman Institute for Human Genomics, University of Miami, Miami, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hampel</LastName><ForeName>Harald</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>GRC 21, Alzheimer Precision Medicine Initiative (APMI), Sorbonne University, AP-HP, Piti&#xe9;-Salp&#xea;tri&#xe8;re Hospital, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hanon</LastName><ForeName>Olivier</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>EA 4468, Universit&#xe9; de Paris, APHP, H&#xf4;pital Broca, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hardy</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Reta Lila Weston Research Laboratories, Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hartmann</LastName><ForeName>Annette M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hausner</LastName><ForeName>Lucrezia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Geriatric Psychiatry, Central Institute for Mental Health, Mannheim, University of Heidelberg, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harwood</LastName><ForeName>Janet</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-3225-0069</Identifier><AffiliationInfo><Affiliation>MRC Centre for Neuropsychiatric Genetics and Genomics, Division of Psychological Medicine and Clinical Neuroscience, School of Medicine, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heilmann-Heimbach</LastName><ForeName>Stefanie</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-1057-465X</Identifier><AffiliationInfo><Affiliation>Institute of Human Genetics, University of Bonn, School of Medicine &amp; University Hospital Bonn, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Helisalmi</LastName><ForeName>Seppo</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Clinical Medicine, Neurology, University of Eastern, Kuopio, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Clinical Medicine, Internal Medicine, University of Eastern Finland, Kuopio, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heneka</LastName><ForeName>Michael T</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital Bonn, Bonn, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE Bonn), Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hern&#xe1;ndez</LastName><ForeName>Isabel</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Research Center and Memory Clinic Fundaci&#xf3; ACE, Institut Catal&#xe0; de Neuroci&#xe8;ncies Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herrmann</LastName><ForeName>Martin J</ForeName><Initials>MJ</Initials><Identifier Source="ORCID">0000-0001-9970-2122</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Psychosomatics and Psychotherapy, Center of Mental Health, University Hospital, Wuerzburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoffmann</LastName><ForeName>Per</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institute of Human Genetics, University of Bonn, School of Medicine &amp; University Hospital Bonn, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holmes</LastName><ForeName>Clive</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Clinical and Experimental Science, Faculty of Medicine, University of Southampton, Southampton, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holstege</LastName><ForeName>Henne</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-7688-3087</Identifier><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Section Genomics of Neurodegenerative Diseases and Aging, Department of Human Genetics Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vilas</LastName><ForeName>Raquel Huerto</ForeName><Initials>RH</Initials><AffiliationInfo><Affiliation>Unitat Trastorns Cognitius, Hospital Universitari Santa Maria de Lleida, Lleida, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institut de Recerca Biomedica de Lleida (IRBLLeida), Lleida, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hulsman</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Section Genomics of Neurodegenerative Diseases and Aging, Department of Human Genetics Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Humphrey</LastName><ForeName>Jack</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Ronald M. Loeb Center for Alzheimer's Disease, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences &amp; Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Estelle and Daniel Maggin Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Nash Family Department of Neuroscience &amp; Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Biessels</LastName><ForeName>Geert Jan</ForeName><Initials>GJ</Initials><Identifier Source="ORCID">0000-0001-6862-2496</Identifier><AffiliationInfo><Affiliation>Department of Neurology, UMC Utrecht Brain Center, Utrecht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jian</LastName><ForeName>Xueqiu</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0002-0313-6494</Identifier><AffiliationInfo><Affiliation>Glenn Biggs Institute for Alzheimer's &amp; Neurodegenerative Diseases, University of Texas Health Sciences Center, San Antonio, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johansson</LastName><ForeName>Charlotte</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-5351-1950</Identifier><AffiliationInfo><Affiliation>Center for Alzheimer Research, Department NVS, Division of Neurogeriatrics, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jun</LastName><ForeName>Gyungah R</ForeName><Initials>GR</Initials><Identifier Source="ORCID">0000-0002-3230-8697</Identifier><AffiliationInfo><Affiliation>Medicine Biomedical Genetics Boston University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kastumata</LastName><ForeName>Yuriko</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-0188-8094</Identifier><AffiliationInfo><Affiliation>Biostatistics, University of Kentucky College of Public Health, Lexington, KY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kauwe</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biology, Brigham Young University, Provo, UT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kehoe</LastName><ForeName>Patrick G</ForeName><Initials>PG</Initials><Identifier Source="ORCID">0000-0002-7542-1139</Identifier><AffiliationInfo><Affiliation>Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kilander</LastName><ForeName>Lena</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>St&#xe5;hlbom</LastName><ForeName>Anne Kinhult</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>Center for Alzheimer Research, Department NVS, Division of Neurogeriatrics, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kivipelto</LastName><ForeName>Miia</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Clinical Geriatrics, Center for Alzheimer Research, Care Sciences and Society (NVS), Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroepidemiology and Ageing Research Unit, School of Public Health, Imperial College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research &amp; Development, UnitStockholms Sjukhem, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koivisto</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Clinical Medicine, Neurology, University of Eastern, Kuopio, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Kuopio University Hospital, Kuopio, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosciences, University of Helsinki and Department of Geriatrics, Helsinki University Hospital, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kornhuber</LastName><ForeName>Johannes</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-8096-3987</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, Universit&#xe4;tsklinikum Erlangen, and Friedrich-Alexander Universit&#xe4;t Erlangen-N&#xfc;rnberg, Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kosmidis</LastName><ForeName>Mary H</ForeName><Initials>MH</Initials><Identifier Source="ORCID">0000-0001-8790-1220</Identifier><AffiliationInfo><Affiliation>Laboratory of Cognitive Neuroscience, School of Psychology, Aristotle University of Thessaloniki, Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kukull</LastName><ForeName>Walter A</ForeName><Initials>WA</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuksa</LastName><ForeName>Pavel P</ForeName><Initials>PP</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kunkle</LastName><ForeName>Brian W</ForeName><Initials>BW</Initials><AffiliationInfo><Affiliation>Department of Neurology, Medical School, University of Cyprus, Nicosia, Cyprus.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuzma</LastName><ForeName>Amanda B</ForeName><Initials>AB</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lage</LastName><ForeName>Carmen</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-1703-121X</Identifier><AffiliationInfo><Affiliation>CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology Service, Marqu&#xe9;s de Valdecilla University Hospital (University of Cantabria and IDIVAL), Santander, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laukka</LastName><ForeName>Erika J</ForeName><Initials>EJ</Initials><AffiliationInfo><Affiliation>Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm University, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Stockholm Gerontology Research Center, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Launer</LastName><ForeName>Lenore</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-3238-7612</Identifier><AffiliationInfo><Affiliation>Laboratory of Epidemiology, Demography, and Biometry, National Institute of Aging, The National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Intramural Research Program/National Institute on Aging/National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lauria</LastName><ForeName>Alessandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Geriatrics Unit, Fondazione Policlinico A. Gemelli IRCCS, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Chien-Yueh</ForeName><Initials>CY</Initials><Identifier Source="ORCID">0000-0002-4304-974X</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lehtisalo</LastName><ForeName>Jenni</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Clinical Medicine, Neurology, University of Eastern, Kuopio, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Public Health Promotion Unit, Finnish Institute for Health and Welfare, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lerch</LastName><ForeName>Ondrej</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Memory Clinic, Department of Neurology, Charles University, 2nd Faculty of Medicine and Motol University Hospital, Praha, Czechia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>International Clinical Research Center, St. Anne's University Hospital Brno, Brno, Czechia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lle&#xf3;</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-2568-5478</Identifier><AffiliationInfo><Affiliation>CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, II B Sant Pau, Hospital de la Santa Creu i Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Longstreth</LastName><ForeName>William</ForeName><Initials>W</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Departments of Neurology and Epidemiology, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lopez</LastName><ForeName>Oscar</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0002-8546-8256</Identifier><AffiliationInfo><Affiliation>Framingham Heart Study, Framingham, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Munain</LastName><ForeName>Adolfo Lopez</ForeName><Initials>AL</Initials><Identifier Source="ORCID">0000-0002-9509-4032</Identifier><AffiliationInfo><Affiliation>CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Hospital Universitario Donostia, OSAKIDETZA-Servicio Vasco de Salud, San Sebastian, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Love</LastName><ForeName>Seth</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xf6;wemark</LastName><ForeName>Malin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luckcuck</LastName><ForeName>Lauren</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>MRC Centre for Neuropsychiatric Genetics and Genomics, Division of Psychological Medicine and Clinical Neuroscience, School of Medicine, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lunetta</LastName><ForeName>Kathryn L</ForeName><Initials>KL</Initials><Identifier Source="ORCID">0000-0002-9268-810X</Identifier><AffiliationInfo><Affiliation>Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Yiyi</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-3609-8877</Identifier><AffiliationInfo><Affiliation>Section Genomics of Neurodegenerative Diseases and Aging, Department of Human Genetics Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mac&#xed;as</LastName><ForeName>Juan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Unidad Cl&#xed;nica de Enfermedades Infecciosas y Microbiolog&#xed;a, Hospital Universitario de Valme, Sevilla, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>MacLeod</LastName><ForeName>Catherine A</ForeName><Initials>CA</Initials><Identifier Source="ORCID">0000-0002-9314-7380</Identifier><AffiliationInfo><Affiliation>School of Health Sciences, Bangor University, Bangor, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maier</LastName><ForeName>Wolfgang</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital Bonn, Bonn, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE Bonn), Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mangialasche</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Division of Clinical Geriatrics, Center for Alzheimer Research, Care Sciences and Society (NVS), Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spallazzi</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Unit of Neurology, University of Parma and AOU, Parma, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marqui&#xe9;</LastName><ForeName>Marta</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-0660-0950</Identifier><AffiliationInfo><Affiliation>Research Center and Memory Clinic Fundaci&#xf3; ACE, Institut Catal&#xe0; de Neuroci&#xe8;ncies Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marshall</LastName><ForeName>Rachel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>MRC Centre for Neuropsychiatric Genetics and Genomics, Division of Psychological Medicine and Clinical Neuroscience, School of Medicine, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Eden R</ForeName><Initials>ER</Initials><AffiliationInfo><Affiliation>The John P. Hussman Institute for Human Genomics, University of Miami, Miami, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montes</LastName><ForeName>Angel Mart&#xed;n</ForeName><Initials>AM</Initials><Identifier Source="ORCID">0000-0002-1694-786X</Identifier><AffiliationInfo><Affiliation>CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto de Investigacion Sanitaria 'Hospital la Paz' (IdIPaz), Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hospital Universitario la Paz, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodr&#xed;guez</LastName><ForeName>Carmen Mart&#xed;nez</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Servicio de Neurolog&#xed;a, Hospital Universitario Central de Asturias- Oviedo and Instituto de Investigaci&#xf3;n Biosanitaria del Principado de Asturias, Oviedo, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masullo</LastName><ForeName>Carlo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute of Neurology, Catholic University of the Sacred Heart, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mayeux</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Taub Institute on Alzheimer's Disease and the Aging Brain, Department of Neurology, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Gertrude H. Sergievsky Center, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mead</LastName><ForeName>Simon</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-4326-1468</Identifier><AffiliationInfo><Affiliation>MRC Prion Unit at UCL, UCL Institute of Prion Diseases, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mecocci</LastName><ForeName>Patrizia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institute of Gerontology and Geriatrics, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Medina</LastName><ForeName>Miguel</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-7016-5340</Identifier><AffiliationInfo><Affiliation>CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIEN Foundation/Queen Sofia Foundation Alzheimer Center, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meggy</LastName><ForeName>Alun</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>UKDRI@ Cardiff, School of Medicine, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mehrabian</LastName><ForeName>Shima</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Clinic of Neurology, UH 'Alexandrovska', Medical University - Sofia, Sofia, Bulgaria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mendoza</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Alzheimer Research Center &amp; Memory Clinic, Andalusian Institute for Neuroscience, M&#xe1;laga, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Men&#xe9;ndez-Gonz&#xe1;lez</LastName><ForeName>Manuel</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-5218-0774</Identifier><AffiliationInfo><Affiliation>Servicio de Neurolog&#xed;a, Hospital Universitario Central de Asturias- Oviedo and Instituto de Investigaci&#xf3;n Biosanitaria del Principado de Asturias, Oviedo, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mir</LastName><ForeName>Pablo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unidad de Trastornos del Movimiento, Servicio de Neurolog&#xed;a y Neurofisiolog&#xed;a. Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Roc&#xed;o/CSIC/Universidad de Sevilla, Seville, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moebus</LastName><ForeName>Susanne</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute for Urban Public Health, University Hospital of University Duisburg-Essen, Essen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mol</LastName><ForeName>Merel</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-2533-2530</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Erasmus MC, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Molina-Porcel</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Neurological Tissue Bank of the Biobanc-Hospital Clinic-IDIBAPS, Institut d'Investigacions Biom&#xe8;diques August Pi i Sunyer, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Department, Hospital Clinic, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montrreal</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Research Center and Memory Clinic Fundaci&#xf3; ACE, Institut Catal&#xe0; de Neuroci&#xe8;ncies Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morelli</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Laboratory of Brain Aging and Neurodegeneration, FIL-CONICET, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moreno</LastName><ForeName>Fermin</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Hospital Universitario Donostia, OSAKIDETZA-Servicio Vasco de Salud, San Sebastian, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morgan</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-8217-2396</Identifier><AffiliationInfo><Affiliation>Human Genetics, School of Life Sciences, University of Nottingham, Nottingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mosley</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Memory Impairment and Neurodegenerative Dementia (MIND) Center, University of Mississippi Medical Center, Jackson, MS, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>N&#xf6;then</LastName><ForeName>Markus M</ForeName><Initials>MM</Initials><Identifier Source="ORCID">0000-0002-8770-2464</Identifier><AffiliationInfo><Affiliation>Institute of Human Genetics, University of Bonn, School of Medicine &amp; University Hospital Bonn, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muchnik</LastName><ForeName>Carolina</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-1542-3706</Identifier><AffiliationInfo><Affiliation>Centro de Neuropsiquiatr&#xed;a y Neurolog&#xed;a de la Conducta (CENECON), Facultad de Medicina, Universidad de Buenos Aires (UBA), C.A.B.A., Buenos Aires, Argentina.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratorio de Bioqu&#xed;mica Molecular, Facultad de Medicina, Instituto de Investigaciones M&#xe9;dicas A. Lanari, UBA, C.A.B.A, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mukherjee</LastName><ForeName>Shubhabrata</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nacmias</LastName><ForeName>Benedetta</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0001-9338-9040</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ngandu</LastName><ForeName>Tiia</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Public Health Promotion Unit, Finnish Institute for Health and Welfare, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nicolas</LastName><ForeName>Gael</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-9391-7800</Identifier><AffiliationInfo><Affiliation>Department of Genetics and CNR-MAJ, Normandie University, UNIROUEN, INSERM U1245, CHU Rouen, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nordestgaard</LastName><ForeName>B&#xf8;rge G</ForeName><Initials>BG</Initials><Identifier Source="ORCID">0000-0002-1954-7220</Identifier><AffiliationInfo><Affiliation>Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Herlev, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olaso</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>CEA, Centre National de Recherche en G&#xe9;nomique Humaine, Universit&#xe9; Paris-Saclay, Evry, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Orellana</LastName><ForeName>Adelina</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Research Center and Memory Clinic Fundaci&#xf3; ACE, Institut Catal&#xe0; de Neuroci&#xe8;ncies Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Orsini</LastName><ForeName>Michela</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Catholic University of Sacred Heart, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ortega</LastName><ForeName>Gemma</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Research Center and Memory Clinic Fundaci&#xf3; ACE, Institut Catal&#xe0; de Neuroci&#xe8;ncies Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Padovani</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paolo</LastName><ForeName>Caffarra</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>DIMEC, University of Parma, Parma, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Papenberg</LastName><ForeName>Goran</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm University, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parnetti</LastName><ForeName>Lucilla</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Centre for Memory Disturbances, Lab of Clinical Neurochemistry, Section of Neurology, University of Perugia, Perugia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pasquier</LastName><ForeName>Florence</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0001-9880-9788</Identifier><AffiliationInfo><Affiliation>Resources and Research Memory Center (MRRC) of Distalz, LicendUniversity of Lille, INSERM, CHU Lille, UMR1172, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pastor</LastName><ForeName>Pau</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-7493-8777</Identifier><AffiliationInfo><Affiliation>Fundaci&#xf3; Doc&#xe8;ncia i Recerca M&#xfa;tuaTerrassa and Movement Disorders Unit, Department of Neurology, University Hospital M&#xfa;tuaTerrassa, Terrassa, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory Disorders Unit, Department of Neurology, Hospital Universitari Mutua de Terrassa, Terrassa, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peloso</LastName><ForeName>Gina</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-5355-8636</Identifier><AffiliationInfo><Affiliation>Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Boston University and the NHLBI's Framingham Heart Study, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>P&#xe9;rez-Cord&#xf3;n</LastName><ForeName>Alba</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-6028-0791</Identifier><AffiliationInfo><Affiliation>Research Center and Memory Clinic Fundaci&#xf3; ACE, Institut Catal&#xe0; de Neuroci&#xe8;ncies Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>P&#xe9;rez-Tur</LastName><ForeName>Jordi</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-9111-1712</Identifier><AffiliationInfo><Affiliation>CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institut de Biomedicina de Val&#xe8;ncia-CSIC CIBERNED, Val&#xe8;ncia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unitat Mixta de de Neurolog&#xed;a y Gen&#xe9;tica, Institut d'Investigaci&#xf3; Sanit&#xe0;ria La Fe, Val&#xe8;ncia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pericard</LastName><ForeName>Pierre</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-8167-6448</Identifier><AffiliationInfo><Affiliation>US 41-UMS 2014-PLBS, bilille, Universit&#xe9; de Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peters</LastName><ForeName>Oliver</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Institute of Psychiatry and Psychotherapy, Charit&#xe9;-Universit&#xe4;tsmedizin Berlin, Freie Universit&#xe4;t Berlin, Humboldt-Universit&#xe4;t Zu Berlin, and Berlin Institute of Health, Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pijnenburg</LastName><ForeName>Yolande A L</ForeName><Initials>YAL</Initials><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pineda</LastName><ForeName>Juan A</ForeName><Initials>JA</Initials><Identifier Source="ORCID">0000-0002-3751-0296</Identifier><AffiliationInfo><Affiliation>Unidad Cl&#xed;nica de Enfermedades Infecciosas y Microbiolog&#xed;a, Hospital Universitario de Valme, Sevilla, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pi&#xf1;ol-Ripoll</LastName><ForeName>Gerard</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Unitat Trastorns Cognitius, Hospital Universitari Santa Maria de Lleida, Lleida, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institut de Recerca Biomedica de Lleida (IRBLLeida), Lleida, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pisanu</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-9151-4319</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Sciences, University of Cagliari, Cagliari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Polak</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Psychosomatics and Psychotherapy, Center of Mental Health, University Hospital, Wuerzburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Popp</LastName><ForeName>Julius</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>CHUV, Old Age Psychiatry, Department of Psychiatry, Lausanne, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Old Age Psychiatry, Department of Psychiatry, Lausanne University Hospital, Lausanne, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Geriatric Psychiatry, University Hospital of Psychiatry Z&#xfc;rich, Z&#xfc;rich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Posthuma</LastName><ForeName>Danielle</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-7582-2365</Identifier><AffiliationInfo><Affiliation>Department of Complex Trait Genetics, Center for Neurogenomics and Cognitive Research, Amsterdam Neuroscience, Vrije University, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Priller</LastName><ForeName>Josef</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuropsychiatry and Laboratory of Molecular Psychiatry, Charit&#xe9;, Charit&#xe9;platz 1, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Puerta</LastName><ForeName>Raquel</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-1191-5893</Identifier><AffiliationInfo><Affiliation>Research Center and Memory Clinic Fundaci&#xf3; ACE, Institut Catal&#xe0; de Neuroci&#xe8;ncies Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quenez</LastName><ForeName>Olivier</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0002-8273-8505</Identifier><AffiliationInfo><Affiliation>Department of Genetics and CNR-MAJ, Normandie University, UNIROUEN, INSERM U1245, CHU Rouen, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quintela</LastName><ForeName>In&#xe9;s</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Grupo de Medicina Xen&#xf3;mica, Centro Nacional de Genotipado (CEGEN-PRB3-ISCIII), Universidade de Santiago de Compostela, Santiago de Compostela, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thomassen</LastName><ForeName>Jesper Qvist</ForeName><Initials>JQ</Initials><Identifier Source="ORCID">0000-0003-3484-9531</Identifier><AffiliationInfo><Affiliation>Department of Clinical Biochemistry, Rigshospitalet, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>R&#xe1;bano</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIEN Foundation/Queen Sofia Foundation Alzheimer Center, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rainero</LastName><ForeName>Innocenzo</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Centre for Neurodegenerative Disorders, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rajabli</LastName><ForeName>Farid</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>The John P. Hussman Institute for Human Genomics, University of Miami, Miami, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramakers</LastName><ForeName>Inez</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Psychiatry &amp; Neuropsychologie, Maastricht University, Alzheimer Center Limburg, Maastricht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Real</LastName><ForeName>Luis M</ForeName><Initials>LM</Initials><Identifier Source="ORCID">0000-0003-4932-7429</Identifier><AffiliationInfo><Affiliation>Unidad Cl&#xed;nica de Enfermedades Infecciosas y Microbiolog&#xed;a, Hospital Universitario de Valme, Sevilla, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Depatamento de Especialidades Quir&#xfa;rgicas Bioqu&#xed;mica e Inmunolog&#xed;a, Facultad de Medicina, Universidad de M&#xe1;laga, M&#xe1;laga, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reinders</LastName><ForeName>Marcel J T</ForeName><Initials>MJT</Initials><Identifier Source="ORCID">0000-0002-1148-1562</Identifier><AffiliationInfo><Affiliation>Delft Bioinformatics Lab, Delft University of Technology, Delft, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reitz</LastName><ForeName>Christiane</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-8757-7889</Identifier><AffiliationInfo><Affiliation>Gertrude H. Sergievsky Center, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Delft Bioinformatics Lab, Delft University of Technology, Delft, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Taub Institute, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reyes-Dumeyer</LastName><ForeName>Dolly</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Taub Institute, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ridge</LastName><ForeName>Perry</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Bioinformatics, College of Life Sciences, Brigham Young University, Provo, UT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Riedel-Heller</LastName><ForeName>Steffi</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-4321-6090</Identifier><AffiliationInfo><Affiliation>Institute of Social Medicine, Occupational Health and Public Health, University of Leipzig, Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Riederer</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Center of Mental Health, Clinic and Policlinic of Psychiatry, Psychosomatics and Psychotherapy, University Hospital of W&#xfc;rzburg, Wuerzburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roberto</LastName><ForeName>Natalia</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Research Center and Memory Clinic Fundaci&#xf3; ACE, Institut Catal&#xe0; de Neuroci&#xe8;ncies Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodriguez-Rodriguez</LastName><ForeName>Eloy</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-7742-677X</Identifier><AffiliationInfo><Affiliation>CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology Service, Marqu&#xe9;s de Valdecilla University Hospital (University of Cantabria and IDIVAL), Santander, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rongve</LastName><ForeName>Arvid</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-0476-4134</Identifier><AffiliationInfo><Affiliation>Department of Research and Innovation, Helse Fonna, Haugesund Hospital, Haugesund, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Clinical Medicine (K1), The University of Bergen, Bergen, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Allende</LastName><ForeName>Irene Rosas</ForeName><Initials>IR</Initials><AffiliationInfo><Affiliation>Laboratorio de Gen&#xe9;tica, Hospital Universitario Central de Asturias, Oviedo, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Servicio de Neurolog&#xed;a, Hospital Universitario Central de Asturias- Oviedo and Instituto de Investigaci&#xf3;n Biosanitaria del Principado de Asturias, Oviedo, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosende-Roca</LastName><ForeName>Mait&#xe9;e</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Research Center and Memory Clinic Fundaci&#xf3; ACE, Institut Catal&#xe0; de Neuroci&#xe8;ncies Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Royo</LastName><ForeName>Jose Luis</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Departamento de Especialidades Quir&#xfa;rgicas, Bioqu&#xed;micas e Inmunolog&#xed;a, School of Medicine, University of M&#xe1;laga, M&#xe1;laga, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rubino</LastName><ForeName>Elisa</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neuroscience and Mental Health, AOU Citt&#xe0; della Salute e della Scienza di Torino, Torino, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rujescu</LastName><ForeName>Dan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S&#xe1;ez</LastName><ForeName>Mar&#xed;a Eugenia</ForeName><Initials>ME</Initials><Identifier Source="ORCID">0000-0001-9299-2534</Identifier><AffiliationInfo><Affiliation>CAEBI, Centro Andaluz de Estudios Bioinform&#xe1;ticos, Sevilla, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sakka</LastName><ForeName>Paraskevi</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Athens Association of Alzheimer's Disease and Related Disorders, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saltvedt</LastName><ForeName>Ingvild</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-7897-9808</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Clinical Neurophysiology, University Hospital of Trondheim, Trondheim, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Geriatrics, St. Olav's Hospital, Trondheim University Hospital, Trondheim, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanabria</LastName><ForeName>&#xc1;ngela</ForeName><Initials>&#xc1;</Initials><AffiliationInfo><Affiliation>Research Center and Memory Clinic Fundaci&#xf3; ACE, Institut Catal&#xe0; de Neuroci&#xe8;ncies Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S&#xe1;nchez-Arjona</LastName><ForeName>Mar&#xed;a Bernal</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>Unidad de Demencias, Servicio de Neurolog&#xed;a y Neurofisiolog&#xed;a. Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Roc&#xed;o/CSIC/Universidad de Sevilla, Seville, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanchez-Garcia</LastName><ForeName>Florentino</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Immunology, Hospital Universitario Doctor Negr&#xed;n, Las Palmas de Gran Canaria, Las Palmas, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Juan</LastName><ForeName>Pascual S&#xe1;nchez</ForeName><Initials>PS</Initials><Identifier Source="ORCID">0000-0002-6081-8037</Identifier><AffiliationInfo><Affiliation>CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology Service, Marqu&#xe9;s de Valdecilla University Hospital (University of Cantabria and IDIVAL), Santander, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S&#xe1;nchez-Valle</LastName><ForeName>Raquel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Neurology Department-Hospital Cl&#xed;nic, IDIBAPS, Universitat de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sando</LastName><ForeName>Sigrid B</ForeName><Initials>SB</Initials><AffiliationInfo><Affiliation>Experimental Neuro-psychobiology Laboratory, Department of Clinical and Behavioral Neurology, IRCCS Santa Lucia Foundation, Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology and Clinical Neurophysiology, University Hospital of Trondheim, Trondheim, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sarnowski</LastName><ForeName>Chlo&#xe9;</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-6090-7099</Identifier><AffiliationInfo><Affiliation>Human Genetics Center, School of Public Health, University of Texas Health Science Center at Houston, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Satizabal</LastName><ForeName>Claudia L</ForeName><Initials>CL</Initials><Identifier Source="ORCID">0000-0002-1115-4430</Identifier><AffiliationInfo><Affiliation>Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Boston University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Glenn Biggs Institute for Alzheimer's &amp; Neurodegenerative Diseases, University of Texas Health Sciences Center, San Antonio, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scamosci</LastName><ForeName>Michela</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Gerontology and Geriatrics, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scarmeas</LastName><ForeName>Nikolaos</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Taub Institute on Alzheimer's Disease and the Aging Brain, Department of Neurology, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>First Department of Neurology, Aiginition Hospital, National and Kapodistrian University of Athens, Medical School, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scarpini</LastName><ForeName>Elio</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Fondazione IRCCS Ca'Granda, Ospedale Policlinico, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Milan, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scheltens</LastName><ForeName>Philip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scherbaum</LastName><ForeName>Norbert</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>LVR-Hospital Essen, Department of Psychiatry and Psychotherapy, Medical Faculty, University of Duisburg-Essen, Essen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scherer</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Primary Medical Care, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmid</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE Bonn), Bonn, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Medical Biometry, Informatics and Epidemiology, University Hospital of Bonn, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Anja</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital Bonn, Bonn, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE Bonn), Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schott</LastName><ForeName>Jonathan M</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0003-2059-024X</Identifier><AffiliationInfo><Affiliation>Dementia Research Centre, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Selb&#xe6;k</LastName><ForeName>Geir</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-6511-8219</Identifier><AffiliationInfo><Affiliation>Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Geriatric Medicine, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seripa</LastName><ForeName>Davide</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Laboratory for Advanced Hematological Diagnostics, Department of Hematology and Stem Cell Transplant, Vito Fazzi Hospital, Lecce, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Serrano</LastName><ForeName>Manuel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Diabetes y Enfermedades Metab&#xf3;licas Asociadas, CIBERDEM, Hospital Cl&#xed;nico San Carlos, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sha</LastName><ForeName>Jin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology, and Informatics, Penn Neurodegeneration Genomics Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shadrin</LastName><ForeName>Alexey A</ForeName><Initials>AA</Initials><Identifier Source="ORCID">0000-0002-7467-250X</Identifier><AffiliationInfo><Affiliation>NORMENT Centre, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Skrobot</LastName><ForeName>Olivia</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Slifer</LastName><ForeName>Susan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>The John P. Hussman Institute for Human Genomics, University of Miami, Miami, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Snijders</LastName><ForeName>Gijsje J L</ForeName><Initials>GJL</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soininen</LastName><ForeName>Hilkka</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-2785-9937</Identifier><AffiliationInfo><Affiliation>Institute of Clinical Medicine, Neurology, University of Eastern, Kuopio, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Solfrizzi</LastName><ForeName>Vincenzo</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-8524-0315</Identifier><AffiliationInfo><Affiliation>University of Bari, "A. Moro", Bary, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Solomon</LastName><ForeName>Alina</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Clinical Medicine, Neurology, University of Eastern, Kuopio, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Clinical Geriatrics, Center for Alzheimer Research, Care Sciences and Society (NVS), Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Yeunjoo</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-7452-3731</Identifier><AffiliationInfo><Affiliation>Department of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sorbi</LastName><ForeName>Sandro</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sotolongo-Grau</LastName><ForeName>Oscar</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0002-9679-0670</Identifier><AffiliationInfo><Affiliation>Research Center and Memory Clinic Fundaci&#xf3; ACE, Institut Catal&#xe0; de Neuroci&#xe8;ncies Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spalletta</LastName><ForeName>Gianfranco</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-7432-4249</Identifier><AffiliationInfo><Affiliation>Laboratory of Neuropsychiatry, Department of Clinical and Behavioral Neurology, IRCCS Santa Lucia Foundation, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spottke</LastName><ForeName>Annika</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE Bonn), Bonn, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of Bonn, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Squassina</LastName><ForeName>Alessio</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-7415-7607</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Section of Neuroscience and Clinical Pharmacology, University of Cagliari, Cagliari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stordal</LastName><ForeName>Eystein</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-2443-7923</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Namsos Hospital, Namsos, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tartan</LastName><ForeName>Juan Pablo</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Research Center and Memory Clinic Fundaci&#xf3; ACE, Institut Catal&#xe0; de Neuroci&#xe8;ncies Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>T&#xe1;rraga</LastName><ForeName>Llu&#xed;s</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Research Center and Memory Clinic Fundaci&#xf3; ACE, Institut Catal&#xe0; de Neuroci&#xe8;ncies Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tes&#xed;</LastName><ForeName>Niccolo</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Section Genomics of Neurodegenerative Diseases and Aging, Department of Human Genetics Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thalamuthu</LastName><ForeName>Anbupalam</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centre for Healthy Brain Ageing, School of Psychiatry, Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thomas</LastName><ForeName>Tegos</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>First Department of Neurology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Alzheimer Hellas, Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tosto</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-7075-8245</Identifier><AffiliationInfo><Affiliation>Taub Institute on Alzheimer's Disease and the Aging Brain, Department of Neurology, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Traykov</LastName><ForeName>Latchezar</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Clinic of Neurology, UH 'Alexandrovska', Medical University - Sofia, Sofia, Bulgaria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tremolizzo</LastName><ForeName>Lucio</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>School of Medicine and Surgery, University of Milano-Bicocca, Milano, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology Unit, San Gerardo Hospital, Monza, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tybj&#xe6;rg-Hansen</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Biochemistry, Rigshospitalet, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uitterlinden</LastName><ForeName>Andre</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-7276-3387</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine and Biostatistics, Erasmus MC, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ullgren</LastName><ForeName>Abbe</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Center for Alzheimer Research, Department NVS, Division of Neurogeriatrics, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ulstein</LastName><ForeName>Ingun</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Geriatric Medicine, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valero</LastName><ForeName>Sergi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Research Center and Memory Clinic Fundaci&#xf3; ACE, Institut Catal&#xe0; de Neuroci&#xe8;ncies Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valladares</LastName><ForeName>Otto</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0001-8055-2187</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Broeckhoven</LastName><ForeName>Christine Van</ForeName><Initials>CV</Initials><Identifier Source="ORCID">0000-0003-0183-7665</Identifier><AffiliationInfo><Affiliation>Complex Genetics of Alzheimer's Disease Group, VIB Center for Molecular Neurology, VIB, Antwerp, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Neurogenetics, Institute Born - Bunge, Antwerp, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurodegenerative Brain Diseases Group, VIB Center for Molecular Neurology, VIB, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vance</LastName><ForeName>Jeffery</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Dr. John T. Macdonald Foundation Department of Human Genetics, University of Miami, Miami, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vardarajan</LastName><ForeName>Badri N</ForeName><Initials>BN</Initials><AffiliationInfo><Affiliation>Taub Institute on Alzheimer's Disease and the Aging Brain, Department of Neurology, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Lugt</LastName><ForeName>Aad</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, ErasmusMC, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dongen</LastName><ForeName>Jasper Van</ForeName><Initials>JV</Initials><AffiliationInfo><Affiliation>Complex Genetics of Alzheimer's Disease Group, VIB Center for Molecular Neurology, VIB, Antwerp, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Neurogenetics, Institute Born - Bunge, Antwerp, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Rooij</LastName><ForeName>Jeroen</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Erasmus MC, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, ErasmusMC, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Swieten</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Erasmus MC, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vandenberghe</LastName><ForeName>Rik</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Laboratory for Cognitive Neurology, Department of Neurosciences, University of Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology Department, University Hospitals Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verhey</LastName><ForeName>Frans</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Psychiatry &amp; Neuropsychologie, Maastricht University, Alzheimer Center Limburg, Maastricht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vidal</LastName><ForeName>Jean-S&#xe9;bastien</ForeName><Initials>JS</Initials><Identifier Source="ORCID">0000-0001-6770-0720</Identifier><AffiliationInfo><Affiliation>EA 4468, Universit&#xe9; de Paris, APHP, H&#xf4;pital Broca, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vogelgsang</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-9326-8193</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, University Medical Center Goettingen, Goettingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Harvard Medical School, McLean Hospital, Belmont, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vyhnalek</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Memory Clinic, Department of Neurology, Charles University, 2nd Faculty of Medicine and Motol University Hospital, Praha, Czechia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>International Clinical Research Center, St. Anne's University Hospital Brno, Brno, Czechia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wagner</LastName><ForeName>Michael</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-2589-6440</Identifier><AffiliationInfo><Affiliation>Department of Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital Bonn, Bonn, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE Bonn), Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wallon</LastName><ForeName>David</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-2634-7198</Identifier><AffiliationInfo><Affiliation>Department of Neurology and CNR-MAJ, F 76000, Normandy Center for Genomic and Personalized Medicine, Normandie University, UNIROUEN, INSERM U1245, CHU Rouen, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Li-San</ForeName><Initials>LS</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Ruiqi</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weinhold</LastName><ForeName>Leonie</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute of Medical Biometry, Informatics and Epidemiology, University Hospital of Bonn, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wiltfang</LastName><ForeName>Jens</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-1492-5330</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, University Medical Center Goettingen, Goettingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Goettingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Science Department, iBiMED, Aveiro, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Windle</LastName><ForeName>Gill</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>School of Health Sciences, Bangor University, Bangor, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Woods</LastName><ForeName>Bob</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-6781-651X</Identifier><AffiliationInfo><Affiliation>School of Health Sciences, Bangor University, Bangor, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yannakoulia</LastName><ForeName>Mary</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-2171-7337</Identifier><AffiliationInfo><Affiliation>Department of Nutrition and Diatetics, Harokopio University, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zare</LastName><ForeName>Habil</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-5902-6238</Identifier><AffiliationInfo><Affiliation>Glenn Biggs Institute for Alzheimer's &amp; Neurodegenerative Diseases, University of Texas Health Sciences Center, San Antonio, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xiaoling</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0001-8237-1857</Identifier><AffiliationInfo><Affiliation>Department of Medicine (Biomedical Genetics), Boston University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Congcong</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Medicine (Biomedical Genetics), Boston University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zulaica</LastName><ForeName>Miren</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurosciences Area, Instituto Biodonostia, San Sebastian, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>EADB</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>GR@ACE</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>DEGESCO</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>EADI</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>GERAD</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>Demgene</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>FinnGen</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>ADGC</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>CHARGE</CollectiveName></Author><Author ValidYN="Y"><LastName>Farrer</LastName><ForeName>Lindsay A</ForeName><Initials>LA</Initials><Identifier Source="ORCID">0000-0001-5533-4225</Identifier><AffiliationInfo><Affiliation>Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medicine Biomedical Genetics Boston University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Boston University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Psaty</LastName><ForeName>Bruce M</ForeName><Initials>BM</Initials><Identifier Source="ORCID">0000-0002-7278-2190</Identifier><AffiliationInfo><Affiliation>Framingham Heart Study, Framingham, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Health Service, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghanbari</LastName><ForeName>Mohsen</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-9476-7143</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology, Erasmus MC, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raj</LastName><ForeName>Towfique</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-9355-5704</Identifier><AffiliationInfo><Affiliation>Ronald M. Loeb Center for Alzheimer's Disease, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences &amp; Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Estelle and Daniel Maggin Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Nash Family Department of Neuroscience &amp; Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sachdev</LastName><ForeName>Perminder</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-9595-3220</Identifier><AffiliationInfo><Affiliation>Centre for Healthy Brain Ageing, School of Psychiatry, Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mather</LastName><ForeName>Karen</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0003-4143-8941</Identifier><AffiliationInfo><Affiliation>Centre for Healthy Brain Ageing, School of Psychiatry, Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jessen</LastName><ForeName>Frank</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital Bonn, Bonn, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE Bonn), Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ikram</LastName><ForeName>M Arfan</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0003-0372-8585</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology, Erasmus MC, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Mendon&#xe7;a</LastName><ForeName>Alexandre</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Lisbon, Lisbon, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hort</LastName><ForeName>Jakub</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Intramural Research Program/National Institute on Aging/National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory Clinic, Department of Neurology, Charles University, 2nd Faculty of Medicine and Motol University Hospital, Praha, Czechia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsolaki</LastName><ForeName>Magda</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-2072-8010</Identifier><AffiliationInfo><Affiliation>First Department of Neurology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Alzheimer Hellas, Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pericak-Vance</LastName><ForeName>Margaret A</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0001-7283-8804</Identifier><AffiliationInfo><Affiliation>AI Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amouyel</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-9088-234X</Identifier><AffiliationInfo><Affiliation>Universit&#xe9; de Lille, INSERM, CHU Lille, Institut Pasteur Lille, U1167-RID-AGE, Facteurs de risque et d&#xe9;terminants mol&#xe9;culaires des maladies li&#xe9;es au vieillissement, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Julie</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-4069-0259</Identifier><AffiliationInfo><Affiliation>MRC Centre for Neuropsychiatric Genetics and Genomics, Division of Psychological Medicine and Clinical Neuroscience, School of Medicine, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UKDRI@ Cardiff, School of Medicine, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frikke-Schmidt</LastName><ForeName>Ruth</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-4084-5027</Identifier><AffiliationInfo><Affiliation>Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Biochemistry, Rigshospitalet, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clarimon</LastName><ForeName>Jordi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, II B Sant Pau, Hospital de la Santa Creu i Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deleuze</LastName><ForeName>Jean-Fran&#xe7;ois</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>CEA, Centre National de Recherche en G&#xe9;nomique Humaine, Universit&#xe9; Paris-Saclay, Evry, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rossi</LastName><ForeName>Giacomina</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Fondazione IRCCS, Istituto Neurologico Carlo Besta, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seshadri</LastName><ForeName>Sudha</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-6135-2622</Identifier><AffiliationInfo><Affiliation>Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Boston University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Glenn Biggs Institute for Alzheimer's &amp; Neurodegenerative Diseases, University of Texas Health Sciences Center, San Antonio, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andreassen</LastName><ForeName>Ole A</ForeName><Initials>OA</Initials><Identifier Source="ORCID">0000-0002-4461-3568</Identifier><AffiliationInfo><Affiliation>NORMENT Centre, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ingelsson</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Public Health and Carins Sciences/Geriatrics, Uppsala University, Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Hiltunen</LastName><ForeName>Mikko</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Brain Institute, Federal University of Rio Grande do Norte, Natal, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Sleegers</LastName><ForeName>Kristel</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-0283-2332</Identifier><AffiliationInfo><Affiliation>Complex Genetics of Alzheimer's Disease Group, VIB Center for Molecular Neurology, VIB, Antwerp, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Neurogenetics, Institute Born - Bunge, Antwerp, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Schellenberg</LastName><ForeName>Gerard D</ForeName><Initials>GD</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>van Duijn</LastName><ForeName>Cornelia M</ForeName><Initials>CM</Initials><Identifier Source="ORCID">0000-0002-2374-9204</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology, Erasmus MC, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Nuffield Department of Population Health, Oxford University, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Sims</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-3885-1199</Identifier><AffiliationInfo><Affiliation>MRC Centre for Neuropsychiatric Genetics and Genomics, Division of Psychological Medicine and Clinical Neuroscience, School of Medicine, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>van der Flier</LastName><ForeName>Wiesje M</ForeName><Initials>WM</Initials><Identifier Source="ORCID">0000-0001-8766-6224</Identifier><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Ruiz</LastName><ForeName>Agust&#xed;n</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Research Center and Memory Clinic Fundaci&#xf3; ACE, Institut Catal&#xe0; de Neuroci&#xe8;ncies Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Ramirez</LastName><ForeName>Alfredo</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-4991-763X</Identifier><AffiliationInfo><Affiliation>Department of Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital Bonn, Bonn, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Neurogenetics and Molecular Psychiatry, Department of Psychiatry and Psychotherapy, University of Cologne, Medical Faculty, Cologne, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE Bonn), Bonn, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Glenn Biggs Institute for Alzheimer's &amp; Neurodegenerative Diseases, University of Texas Health Sciences Center, San Antonio, TX, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Lambert</LastName><ForeName>Jean-Charles</ForeName><Initials>JC</Initials><Identifier Source="ORCID">0000-0003-0829-7817</Identifier><AffiliationInfo><Affiliation>Universit&#xe9; de Lille, INSERM, CHU Lille, Institut Pasteur Lille, U1167-RID-AGE, Facteurs de risque et d&#xe9;terminants mol&#xe9;culaires des maladies li&#xe9;es au vieillissement, Lille, France. Jean-Charles.Lambert@pasteur-lille.fr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS080820</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG013854</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG053760</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066444</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 AG065463</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/R024804/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>UL1 TR001445</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01HC85080</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G0801418/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 AG022374</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG023501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL103612</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 AG057191</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG046152</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HG006375</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG058654</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS017950</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RC2 AG036528</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/L023784/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 AG054005</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG028377</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 AG054076</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>ALCHALABI-DOBSON/APR14/829-791</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/N029402/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P50 AG005142</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG059421</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG035137</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG062622</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG009029</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201800001C</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG021886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG031581</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG009956</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL080295</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066511</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG072122</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 EY007157</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201200036C</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG017586</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066512</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G0701075</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>U01 AG061356</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K99 AG066849</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RC2 AG036650</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG019085</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL130114</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 AG055824</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG032984</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG013616</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG030146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P20 MD000546</GrantID><Acronym>MD</Acronym><Agency>NIMHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>75N92021D00006</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG008702</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017173</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 RR029893</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>HHMI</Acronym><Agency>Howard Hughes Medical Institute</Agency><Country>United States</Country></Grant><Grant><GrantID>G0300429</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>DH_</Acronym><Agency>Department of Health</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>U01 AG016976</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 NS039764</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG008051</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG013846</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG056270</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RC2 AG036502</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG072980</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL087652</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/L501517/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>N01HC85082</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/K013041/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 AG028786</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>KL2 RR024151</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG049607</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G0902227</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P50 AG005136</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG012300</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AG063130</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG059319</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL105756</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062422</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG037985</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201500001I</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F99 AG073565</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG012101</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG023651</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 DK066134</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016573</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G0601022</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>N01HC55222</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 DK063491</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066462</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01HC85083</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG008017</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG042437</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG041689</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG019724</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/L501529/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>N01HC85079</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066530</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG033193</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 ES030285</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG036042</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG058589</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG032990</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG026395</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01HC85086</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG025688</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG015473</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG066597</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066509</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01HC25195</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RC2 AG036547</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG002219</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG041797</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005144</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG010491</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MC_PC_17112</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>U01 AG006781</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066546</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG033040</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005138</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG048927</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG057473</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG037212</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG052409</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG068880</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG021547</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG041232</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG019757</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG020688</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG022018</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG046139</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG072977</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG020098</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG062418</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS118146</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 NS072026</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG030653</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027944</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UH2 NS100605</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG061872</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG025259</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003949</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG057519</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062715</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HG004610</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG072976</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010129</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG046161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG011101</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016582</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG048015</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG041718</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG025711</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/T04604X/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>HHSN268200800007C</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG019610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG061351</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/L023784/2</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P30 AG072972</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01HC85081</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/L010305/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 AG023629</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066514</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G9901400</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P30 AG028383</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG017216</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UKDRI-2002</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0901254</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P50 AG033514</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS059873</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG018023</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG006786</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG068753</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG036836</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG072979</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG015819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG026916</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG049505</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>04</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Genet</MedlineTA><NlmUniqueID>9216904</NlmUniqueID><ISSNLinking>1061-4036</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2022 Jul;18(7):387-388. doi: 10.1038/s41582-022-00678-x.</RefSource><PMID Version="1">35624172</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Neurol. 2022 Aug;21(8):676-677. doi: 10.1016/S1474-4422(22)00234-4.</RefSource><PMID Version="1">35697056</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="Y">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>H. Hampel is an employee of Eisai. The present article was initiated and prepared as part of his academic position at Sorbonne University (Paris, France), and it reflects entirely and exclusively his own opinion. He serves as Senior Associate Editor for the <i>Alzheimers &amp; Dementia</i> journal and has not received any fees or honoraria since May 2019. Before May 2019, H. Hampel received lecture fees from Servier, Biogen and Roche; research grants from Pfizer, Avid and MSD Avenir (paid to the institution); travel funding from Eisai, Functional Neuromodulation, Axovant, Eli Lilly and Company, Takeda, Zinfandel Pharmaceuticals, GE Healthcare and Oryzon Genomics; and consultancy fees from Qynapse, Jung Diagnostics, Cytox, Axovant, Anavex, Takeda, Zinfandel Pharmaceuticals, GE Healthcare, Oryzon Genomics and Functional Neuromodulation. He served as a scientific advisory board member for Functional Neuromodulation, Axovant, Eisai, Eli Lilly and Company, Cytox, GE Healthcare, Takeda and Zinfandel, Oryzon Genomics and Roche Diagnostics. The remaining authors declare no competing interests</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Laczo</LastName><ForeName>Jan</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Matoska</LastName><ForeName>Vaclav</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Serpente</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Assogna</LastName><ForeName>Francesca</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Piras</LastName><ForeName>Fabrizio</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Piras</LastName><ForeName>Federica</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ciullo</LastName><ForeName>Valentina</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shofany</LastName><ForeName>Jacob</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ferrarese</LastName><ForeName>Carlo</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Andreoni</LastName><ForeName>Simona</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sala</LastName><ForeName>Gessica</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zoia</LastName><ForeName>Chiara Paola</ForeName><Initials>CP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zompo</LastName><ForeName>Maria Del</ForeName><Initials>MD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Benussi</LastName><ForeName>Alberto</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bastiani</LastName><ForeName>Patrizia</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Takalo</LastName><ForeName>Mari</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Natunen</LastName><ForeName>Teemu</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Laatikainen</LastName><ForeName>Tiina</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tuomilehto</LastName><ForeName>Jaakko</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Antikainen</LastName><ForeName>Riitta</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Strandberg</LastName><ForeName>Timo</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lindstr&#xf6;m</LastName><ForeName>Jaana</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Peltonen</LastName><ForeName>Markku</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Abraham</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Al-Chalabi</LastName><ForeName>Ammar</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bass</LastName><ForeName>Nicholas J</ForeName><Initials>NJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brayne</LastName><ForeName>Carol</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brown</LastName><ForeName>Kristelle S</ForeName><Initials>KS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Collinge</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Craig</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Deloukas</LastName><ForeName>Pangiotis</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fox</LastName><ForeName>Nick</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gerrish</LastName><ForeName>Amy</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gill</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gwilliam</LastName><ForeName>Rhian</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harold</LastName><ForeName>Denise</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hollingworth</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnston</LastName><ForeName>Jarret A</ForeName><Initials>JA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jones</LastName><ForeName>Lesley</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lawlor</LastName><ForeName>Brian</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Livingston</LastName><ForeName>Gill</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lovestone</LastName><ForeName>Simon</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lupton</LastName><ForeName>Michelle</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lynch</LastName><ForeName>Aoibhinn</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mann</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>McGuinness</LastName><ForeName>Bernadette</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>McQuillin</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>O'Donovan</LastName><ForeName>Michael C</ForeName><Initials>MC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Owen</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Passmore</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Powell</LastName><ForeName>John F</ForeName><Initials>JF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Proitsi</LastName><ForeName>Petra</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rossor</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shaw</LastName><ForeName>Christopher E</ForeName><Initials>CE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>A David</ForeName><Initials>AD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gurling</LastName><ForeName>Hugh</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Todd</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mummery</LastName><ForeName>Catherine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ryan</LastName><ForeName>Nathalie</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lacidogna</LastName><ForeName>Giordano</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Adarmes-G&#xf3;mez</LastName><ForeName>Ad</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maule&#xf3;n</LastName><ForeName>Ana</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pancho</LastName><ForeName>Ana</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gailhajenet</LastName><ForeName>Anna</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lafuente</LastName><ForeName>Asunci&#xf3;n</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Macias-Garc&#xed;a</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mart&#xed;n</LastName><ForeName>Elvira</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pelej&#xe0;</LastName><ForeName>Esther</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carrillo</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Merl&#xed;n</LastName><ForeName>Isabel Sastre</ForeName><Initials>IS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garrote-Espina</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vargas</LastName><ForeName>Liliana</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carrion-Claro</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mar&#xed;n</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Labrador</LastName><ForeName>Ma</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Buendia</LastName><ForeName>Mar</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alonso</LastName><ForeName>Mar&#xed;a Dolores</ForeName><Initials>MD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guitart</LastName><ForeName>Marina</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moreno</LastName><ForeName>Mariona</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ibarria</LastName><ForeName>Marta</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Peri&#xf1;&#xe1;n</LastName><ForeName>Mt</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aguilera</LastName><ForeName>Nuria</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>G&#xf3;mez-Garre</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ca&#xf1;abate</LastName><ForeName>Pilar</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Escuela</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pineda-S&#xe1;nchez</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vigo-Ortega</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jes&#xfa;s</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Preckler</LastName><ForeName>Silvia</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rodrigo-Herrero</LastName><ForeName>Silvia</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Diego</LastName><ForeName>Susana</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vacca</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roveta</LastName><ForeName>Fausto</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Salvadori</LastName><ForeName>Nicola</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chipi</LastName><ForeName>Elena</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boecker</LastName><ForeName>Henning</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Laske</LastName><ForeName>Christoph</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Perneczky</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anastasiou</LastName><ForeName>Costas</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Janowitz</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Malik</LastName><ForeName>Rainer</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anastasiou</LastName><ForeName>Anna</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Parveen</LastName><ForeName>Kayenat</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lage</LastName><ForeName>Carmen</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>L&#xf3;pez-Garc&#xed;a</LastName><ForeName>Sara</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Antonell</LastName><ForeName>Anna</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mihova</LastName><ForeName>Kalina Yonkova</ForeName><Initials>KY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Belezhanska</LastName><ForeName>Diyana</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weber</LastName><ForeName>Heike</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kochen</LastName><ForeName>Silvia</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Solis</LastName><ForeName>Patricia</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Medel</LastName><ForeName>Nancy</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lisso</LastName><ForeName>Julieta</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sevillano</LastName><ForeName>Zulma</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Politis</LastName><ForeName>Daniel G</ForeName><Initials>DG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cores</LastName><ForeName>Valeria</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cuesta</LastName><ForeName>Carolina</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ortiz</LastName><ForeName>Cecilia</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bacha</LastName><ForeName>Juan Ignacio</ForeName><Initials>JI</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rios</LastName><ForeName>Mario</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saenz</LastName><ForeName>Aldo</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Abalos</LastName><ForeName>Mariana Sanchez</ForeName><Initials>MS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kohler</LastName><ForeName>Eduardo</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Palacio</LastName><ForeName>Dana Lis</ForeName><Initials>DL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Etchepareborda</LastName><ForeName>Ignacio</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kohler</LastName><ForeName>Matias</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Novack</LastName><ForeName>Gisela</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Prestia</LastName><ForeName>Federico Ariel</ForeName><Initials>FA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Galeano</LastName><ForeName>Pablo</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Casta&#xf1;o</LastName><ForeName>Eduardo M</ForeName><Initials>EM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Germani</LastName><ForeName>Sandra</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Toso</LastName><ForeName>Carlos Reyes</ForeName><Initials>CR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rojo</LastName><ForeName>Matias</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ingino</LastName><ForeName>Carlos</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mangone</LastName><ForeName>Carlos</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rubinsztein</LastName><ForeName>David C</ForeName><Initials>DC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Teipel</LastName><ForeName>Stefan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fievet</LastName><ForeName>Nathalie</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Deramerourt</LastName><ForeName>Vincent</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Forsell</LastName><ForeName>Charlotte</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thonberg</LastName><ForeName>H&#xe5;kan</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bjerke</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roeck</LastName><ForeName>Ellen De</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mart&#xed;nez-Larrad</LastName><ForeName>Mar&#xed;a Teresa</ForeName><Initials>MT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Olivar</LastName><ForeName>Natividad</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aguilera</LastName><ForeName>Nuria</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cano</LastName><ForeName>Amanda</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ca&#xf1;abate</LastName><ForeName>Pilar</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Macias</LastName><ForeName>Juan</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maro&#xf1;as</LastName><ForeName>Olalla</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nu&#xf1;ez-Llaves</LastName><ForeName>Ra&#xfa;l</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oliv&#xe9;</LastName><ForeName>Cl&#xe0;udia</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pelej&#xe1;</LastName><ForeName>Ester</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Adarmes-G&#xf3;mez</LastName><ForeName>Astrid D</ForeName><Initials>AD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alonso</LastName><ForeName>Mar&#xed;a Dolores</ForeName><Initials>MD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Amer-Ferrer</LastName><ForeName>Guillermo</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Antequera</LastName><ForeName>Martirio</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burguera</LastName><ForeName>Juan Andr&#xe9;s</ForeName><Initials>JA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carrillo</LastName><ForeName>F&#xe1;tima</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carri&#xf3;n-Claro</LastName><ForeName>Mario</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Casajeros</LastName><ForeName>Mar&#xed;a Jos&#xe9;</ForeName><Initials>MJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martinez de Pancorbo</LastName><ForeName>Marian</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Escuela</LastName><ForeName>Roc&#xed;o</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garrote-Espina</LastName><ForeName>Lorena</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>G&#xf3;mez-Garre</LastName><ForeName>Pilar</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hevilla</LastName><ForeName>Saray</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jes&#xfa;s</LastName><ForeName>Silvia</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Espinosa</LastName><ForeName>Miguel Angel Labrador</ForeName><Initials>MAL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Legaz</LastName><ForeName>Agustina</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>L&#xf3;pez-Garc&#xed;a</LastName><ForeName>Sara</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Macias-Garc&#xed;a</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Manzanares</LastName><ForeName>Salvadora</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mar&#xed;n</LastName><ForeName>Marta</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mar&#xed;n-Mu&#xf1;oz</LastName><ForeName>Juan</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mar&#xed;n</LastName><ForeName>Tamara</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mart&#xed;nez</LastName><ForeName>Bego&#xf1;a</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mart&#xed;nez</LastName><ForeName>Victoriana</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mart&#xed;nez-Lage &#xc1;lvarez</LastName><ForeName>Pablo</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Iriarte</LastName><ForeName>Maite Mendioroz</ForeName><Initials>MM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Peri&#xf1;&#xe1;n-Tocino</LastName><ForeName>Mar&#xed;a Teresa</ForeName><Initials>MT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pineda-S&#xe1;nchez</LastName><ForeName>Roc&#xed;o</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Real de As&#xfa;a</LastName><ForeName>Diego</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rodrigo</LastName><ForeName>Silvia</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sastre</LastName><ForeName>Isabel</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vicente</LastName><ForeName>Maria Pilar</ForeName><Initials>MP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vigo-Ortega</LastName><ForeName>Rosario</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vivancos</LastName><ForeName>Liliana</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Epelbaum</LastName><ForeName>Jacques</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hannequin</LastName><ForeName>Didier</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Campion</LastName><ForeName>Dominique</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Deramecourt</LastName><ForeName>Vincent</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tzourio</LastName><ForeName>Christophe</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brice</LastName><ForeName>Alexis</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dubois</LastName><ForeName>Bruno</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Williams</LastName><ForeName>Amy</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thomas</LastName><ForeName>Charlene</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Davies</LastName><ForeName>Chloe</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nash</LastName><ForeName>William</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dowzell</LastName><ForeName>Kimberley</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morales</LastName><ForeName>Atahualpa Castillo</ForeName><Initials>AC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bernardo-Harrington</LastName><ForeName>Mateus</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Turton</LastName><ForeName>James</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lord</LastName><ForeName>Jenny</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brown</LastName><ForeName>Kristelle</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vardy</LastName><ForeName>Emma</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fisher</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Warren</LastName><ForeName>Jason D</ForeName><Initials>JD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rossor</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ryan</LastName><ForeName>Natalie S</ForeName><Initials>NS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guerreiro</LastName><ForeName>Rita</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Uphill</LastName><ForeName>James</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bass</LastName><ForeName>Nick</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heun</LastName><ForeName>Reinhard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>K&#xf6;lsch</LastName><ForeName>Heike</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sch&#xfc;rmann</LastName><ForeName>Britta</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lacour</LastName><ForeName>Andr&#xe9;</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Herold</LastName><ForeName>Christine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnston</LastName><ForeName>Janet A</ForeName><Initials>JA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Passmore</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Powell</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Patel</LastName><ForeName>Yogen</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hodges</LastName><ForeName>Angela</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Becker</LastName><ForeName>Tim</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Warden</LastName><ForeName>Donald</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wilcock</LastName><ForeName>Gordon</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clarke</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Deloukas</LastName><ForeName>Panagiotis</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ben-Shlomo</LastName><ForeName>Yoav</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hooper</LastName><ForeName>Nigel M</ForeName><Initials>NM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pickering-Brown</LastName><ForeName>Stuart</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sussams</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Warner</LastName><ForeName>Nick</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bayer</LastName><ForeName>Anthony</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heuser</LastName><ForeName>Isabella</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Drichel</LastName><ForeName>Dmitriy</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Klopp</LastName><ForeName>Norman</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mayhaus</LastName><ForeName>Manuel</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Riemenschneider</LastName><ForeName>Matthias</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pinchler</LastName><ForeName>Sabrina</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Feulner</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gu</LastName><ForeName>Wei</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>van den Bussche</LastName><ForeName>Hendrik</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>H&#xfc;ll</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fr&#xf6;lich</LastName><ForeName>Lutz</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wichmann</LastName><ForeName>H-Erich</ForeName><Initials>HE</Initials></Investigator><Investigator ValidYN="Y"><LastName>J&#xf6;ckel</LastName><ForeName>Karl-Heinz</ForeName><Initials>KH</Initials></Investigator><Investigator ValidYN="Y"><LastName>O'Donovan</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Owen</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bahrami</LastName><ForeName>Shahram</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bosnes</LastName><ForeName>Ingunn</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Selnes</LastName><ForeName>Per</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bergh</LastName><ForeName>Sverre</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Palotie</LastName><ForeName>Aarno</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Daly</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jacob</LastName><ForeName>Howard</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Matakidou</LastName><ForeName>Athena</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Runz</LastName><ForeName>Heiko</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>John</LastName><ForeName>Sally</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Plenge</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>McCarthy</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hunkapiller</LastName><ForeName>Julie</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ehm</LastName><ForeName>Meg</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Waterworth</LastName><ForeName>Dawn</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fox</LastName><ForeName>Caroline</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Malarstig</LastName><ForeName>Anders</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Klinger</LastName><ForeName>Kathy</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Call</LastName><ForeName>Kathy</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Behrens</LastName><ForeName>Tim</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Loerch</LastName><ForeName>Patrick</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>M&#xe4;kel&#xe4;</LastName><ForeName>Tomi</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kaprio</LastName><ForeName>Jaakko</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Virolainen</LastName><ForeName>Petri</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pulkki</LastName><ForeName>Kari</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kilpi</LastName><ForeName>Terhi</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Perola</LastName><ForeName>Markus</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Partanen</LastName><ForeName>Jukka</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pitk&#xe4;ranta</LastName><ForeName>Anne</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kaarteenaho</LastName><ForeName>Riitta</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vainio</LastName><ForeName>Seppo</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Turpeinen</LastName><ForeName>Miia</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Serpi</LastName><ForeName>Raisa</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Laitinen</LastName><ForeName>Tarja</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>M&#xe4;kel&#xe4;</LastName><ForeName>Johanna</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kosma</LastName><ForeName>Veli-Matti</ForeName><Initials>VM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kujala</LastName><ForeName>Urho</ForeName><Initials>U</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tuovila</LastName><ForeName>Outi</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hendolin</LastName><ForeName>Minna</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pakkanen</LastName><ForeName>Raimo</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Waring</LastName><ForeName>Jeff</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Riley-Gillis</LastName><ForeName>Bridget</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Liu</LastName><ForeName>Jimmy</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Biswas</LastName><ForeName>Shameek</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Diogo</LastName><ForeName>Dorothee</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marshall</LastName><ForeName>Catherine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hu</LastName><ForeName>Xinli</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gossel</LastName><ForeName>Matthias</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Graham</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cummings</LastName><ForeName>Beryl</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ripatti</LastName><ForeName>Samuli</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schleutker</LastName><ForeName>Johanna</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arvas</LastName><ForeName>Mikko</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carp&#xe9;n</LastName><ForeName>Olli</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hinttala</LastName><ForeName>Reetta</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kettunen</LastName><ForeName>Johannes</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mannermaa</LastName><ForeName>Arto</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Laukkanen</LastName><ForeName>Jari</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Julkunen</LastName><ForeName>Valtteri</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Remes</LastName><ForeName>Anne</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>K&#xe4;lvi&#xe4;inen</LastName><ForeName>Reetta</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Peltola</LastName><ForeName>Jukka</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tienari</LastName><ForeName>Pentti</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rinne</LastName><ForeName>Juha</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ziemann</LastName><ForeName>Adam</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Waring</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Esmaeeli</LastName><ForeName>Sahar</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smaoui</LastName><ForeName>Nizar</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lehtonen</LastName><ForeName>Anne</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eaton</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lahdenper&#xe4;</LastName><ForeName>Sanni</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Adelsberg</LastName><ForeName>Janet</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Michon</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kerchner</LastName><ForeName>Geoff</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bowers</LastName><ForeName>Natalie</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Teng</LastName><ForeName>Edmond</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eicher</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mehta</LastName><ForeName>Vinay</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gormley</LastName><ForeName>Padhraig</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Linden</LastName><ForeName>Kari</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Whelan</LastName><ForeName>Christopher</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Xu</LastName><ForeName>Fanli</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pulford</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>F&#xe4;rkkil&#xe4;</LastName><ForeName>Martti</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pikkarainen</LastName><ForeName>Sampsa</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jussila</LastName><ForeName>Airi</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blomster</LastName><ForeName>Timo</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kiviniemi</LastName><ForeName>Mikko</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Voutilainen</LastName><ForeName>Markku</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Georgantas</LastName><ForeName>Bob</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heap</LastName><ForeName>Graham</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rahimov</LastName><ForeName>Fedik</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Usiskin</LastName><ForeName>Keith</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lu</LastName><ForeName>Tim</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oh</LastName><ForeName>Danny</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kalpala</LastName><ForeName>Kirsi</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miller</LastName><ForeName>Melissa</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>McCarthy</LastName><ForeName>Linda</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eklund</LastName><ForeName>Kari</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Palom&#xe4;ki</LastName><ForeName>Antti</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Isom&#xe4;ki</LastName><ForeName>Pia</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Piril&#xe4;</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kaipiainen-Sepp&#xe4;nen</LastName><ForeName>Oili</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Huhtakangas</LastName><ForeName>Johanna</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lertratanakul</LastName><ForeName>Apinya</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hochfeld</LastName><ForeName>Marla</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bing</LastName><ForeName>Nan</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gordillo</LastName><ForeName>Jorge Esparza</ForeName><Initials>JE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mars</LastName><ForeName>Nina</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pelkonen</LastName><ForeName>Margit</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kauppi</LastName><ForeName>Paula</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kankaanranta</LastName><ForeName>Hannu</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harju</LastName><ForeName>Terttu</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Close</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Greenberg</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chen</LastName><ForeName>Hubert</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Betts</LastName><ForeName>Jo</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ghosh</LastName><ForeName>Soumitra</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Salomaa</LastName><ForeName>Veikko</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Niiranen</LastName><ForeName>Teemu</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Juonala</LastName><ForeName>Markus</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mets&#xe4;rinne</LastName><ForeName>Kaj</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>K&#xe4;h&#xf6;nen</LastName><ForeName>Mika</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Junttila</LastName><ForeName>Juhani</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Laakso</LastName><ForeName>Markku</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pihlajam&#xe4;ki</LastName><ForeName>Jussi</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sinisalo</LastName><ForeName>Juha</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Taskinen</LastName><ForeName>Marja-Riitta</ForeName><Initials>MR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tuomi</LastName><ForeName>Tiinamaija</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Challis</LastName><ForeName>Ben</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Peterson</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chu</LastName><ForeName>Audrey</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Parkkinen</LastName><ForeName>Jaakko</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Muslin</LastName><ForeName>Anthony</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Joensuu</LastName><ForeName>Heikki</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Meretoja</LastName><ForeName>Tuomo</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aaltonen</LastName><ForeName>Lauri</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mattson</LastName><ForeName>Johanna</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Auranen</LastName><ForeName>Annika</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Karihtala</LastName><ForeName>Peeter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kauppila</LastName><ForeName>Saila</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Auvinen</LastName><ForeName>P&#xe4;ivi</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Elenius</LastName><ForeName>Klaus</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Popovic</LastName><ForeName>Relja</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schutzman</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Loboda</LastName><ForeName>Andrey</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chhibber</LastName><ForeName>Aparna</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lehtonen</LastName><ForeName>Heli</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>McDonough</LastName><ForeName>Stefan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Crohns</LastName><ForeName>Marika</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kulkarni</LastName><ForeName>Diptee</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kaarniranta</LastName><ForeName>Kai</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Turunen</LastName><ForeName>Joni A</ForeName><Initials>JA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ollila</LastName><ForeName>Terhi</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Seitsonen</LastName><ForeName>Sanna</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Uusitalo</LastName><ForeName>Hannu</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aaltonen</LastName><ForeName>Vesa</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Uusitalo-J&#xe4;rvinen</LastName><ForeName>Hannele</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Luodonp&#xe4;&#xe4;</LastName><ForeName>Marja</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hautala</LastName><ForeName>Nina</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Loomis</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Strauss</LastName><ForeName>Erich</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chen</LastName><ForeName>Hao</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Podgornaia</LastName><ForeName>Anna</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hoffman</LastName><ForeName>Joshua</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tasanen</LastName><ForeName>Kaisa</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Huilaja</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hannula-Jouppi</LastName><ForeName>Katariina</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Salmi</LastName><ForeName>Teea</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Peltonen</LastName><ForeName>Sirkku</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koulu</LastName><ForeName>Leena</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harvima</LastName><ForeName>Ilkka</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wu</LastName><ForeName>Ying</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Choy</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pussinen</LastName><ForeName>Pirkko</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Salminen</LastName><ForeName>Aino</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Salo</LastName><ForeName>Tuula</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rice</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nieminen</LastName><ForeName>Pekka</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Palotie</LastName><ForeName>Ulla</ForeName><Initials>U</Initials></Investigator><Investigator ValidYN="Y"><LastName>Siponen</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Suominen</LastName><ForeName>Liisa</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>M&#xe4;ntyl&#xe4;</LastName><ForeName>P&#xe4;ivi</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gursoy</LastName><ForeName>Ulvi</ForeName><Initials>U</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anttonen</LastName><ForeName>Vuokko</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sipil&#xe4;</LastName><ForeName>Kirsi</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Davis</LastName><ForeName>Justin Wade</ForeName><Initials>JW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quarless</LastName><ForeName>Danjuma</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petrovski</LastName><ForeName>Slav&#xe9;</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wigmore</LastName><ForeName>Eleonor</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chen</LastName><ForeName>Chia-Yen</ForeName><Initials>CY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bronson</LastName><ForeName>Paola</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tsai</LastName><ForeName>Ellen</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Huang</LastName><ForeName>Yunfeng</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maranville</LastName><ForeName>Joseph</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shaikho</LastName><ForeName>Elmutaz</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mohammed</LastName><ForeName>Elhaj</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wadhawan</LastName><ForeName>Samir</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kvikstad</LastName><ForeName>Erika</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Caliskan</LastName><ForeName>Minal</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chang</LastName><ForeName>Diana</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bhangale</LastName><ForeName>Tushar</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pendergrass</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Holzinger</LastName><ForeName>Emily</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chen</LastName><ForeName>Xing</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hedman</LastName><ForeName>&#xc5;sa</ForeName><Initials>&#xc5;</Initials></Investigator><Investigator ValidYN="Y"><LastName>King</LastName><ForeName>Karen S</ForeName><Initials>KS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wang</LastName><ForeName>Clarence</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Xu</LastName><ForeName>Ethan</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Auge</LastName><ForeName>Franck</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chatelain</LastName><ForeName>Clement</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rajpal</LastName><ForeName>Deepak</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Liu</LastName><ForeName>Dongyu</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Call</LastName><ForeName>Katherine</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Xia</LastName><ForeName>Tai-He</ForeName><Initials>TH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brauer</LastName><ForeName>Matt</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kurki</LastName><ForeName>Mitja</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Karjalainen</LastName><ForeName>Juha</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Havulinna</LastName><ForeName>Aki</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jalanko</LastName><ForeName>Anu</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Palta</LastName><ForeName>Priit</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Della Briotta Parolo</LastName><ForeName>Pietro</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhou</LastName><ForeName>Wei</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lemmel&#xe4;</LastName><ForeName>Susanna</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rivas</LastName><ForeName>Manuel</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harju</LastName><ForeName>Jarmo</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lehisto</LastName><ForeName>Arto</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ganna</LastName><ForeName>Andrea</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Llorens</LastName><ForeName>Vincent</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Laivuori</LastName><ForeName>Hannele</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>R&#xfc;eger</LastName><ForeName>Sina</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Niemi</LastName><ForeName>Mari E</ForeName><Initials>ME</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tukiainen</LastName><ForeName>Taru</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reeve</LastName><ForeName>Mary Pat</ForeName><Initials>MP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heyne</LastName><ForeName>Henrike</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Palin</LastName><ForeName>Kimmo</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garcia-Tabuenca</LastName><ForeName>Javier</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Siirtola</LastName><ForeName>Harri</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kiiskinen</LastName><ForeName>Tuomo</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>Jiwoo</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tsuo</LastName><ForeName>Kristin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Elliott</LastName><ForeName>Amanda</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kristiansson</LastName><ForeName>Kati</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hyv&#xe4;rinen</LastName><ForeName>Kati</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ritari</LastName><ForeName>Jarmo</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koskinen</LastName><ForeName>Miika</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pylk&#xe4;s</LastName><ForeName>Katri</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kalaoja</LastName><ForeName>Marita</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Karjalainen</LastName><ForeName>Minna</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mantere</LastName><ForeName>Tuomo</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kangasniemi</LastName><ForeName>Eeva</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heikkinen</LastName><ForeName>Sami</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Laakkonen</LastName><ForeName>Eija</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sipeky</LastName><ForeName>Csilla</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heron</LastName><ForeName>Samuel</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Karlsson</LastName><ForeName>Antti</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jambulingam</LastName><ForeName>Dhanaprakash</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rathinakannan</LastName><ForeName>Venkat Subramaniam</ForeName><Initials>VS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kajanne</LastName><ForeName>Risto</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aavikko</LastName><ForeName>Mervi</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jim&#xe9;nez</LastName><ForeName>Manuel Gonz&#xe1;lez</ForeName><Initials>MG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Della Briotta Parola</LastName><ForeName>Pietro</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lehist&#xf6;</LastName><ForeName>Arto</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kanai</LastName><ForeName>Masahiro</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kaunisto</LastName><ForeName>Mari</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kilpel&#xe4;inen</LastName><ForeName>Elina</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sipil&#xe4;</LastName><ForeName>Timo P</ForeName><Initials>TP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brein</LastName><ForeName>Georg</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Awaisa</LastName><ForeName>Ghazal</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shcherban</LastName><ForeName>Anastasia</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Donner</LastName><ForeName>Kati</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Loukola</LastName><ForeName>Anu</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Laiho</LastName><ForeName>P&#xe4;ivi</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sistonen</LastName><ForeName>Tuuli</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kaiharju</LastName><ForeName>Essi</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Laukkanen</LastName><ForeName>Markku</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>J&#xe4;rvensivu</LastName><ForeName>Elina</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>L&#xe4;hteenm&#xe4;ki</LastName><ForeName>Sini</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>M&#xe4;nnikk&#xf6;</LastName><ForeName>Lotta</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wong</LastName><ForeName>Regis</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mattsson</LastName><ForeName>Hannele</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hiekkalinna</LastName><ForeName>Tero</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paajanen</LastName><ForeName>Teemu</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>P&#xe4;rn</LastName><ForeName>Kalle</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gracia-Tabuenca</LastName><ForeName>Javier</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Abner</LastName><ForeName>Erin</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Adams</LastName><ForeName>Perrie M</ForeName><Initials>PM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aguirre</LastName><ForeName>Alyssa</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Albert</LastName><ForeName>Marilyn S</ForeName><Initials>MS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Albin</LastName><ForeName>Roger L</ForeName><Initials>RL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Allen</LastName><ForeName>Mariet</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alvarez</LastName><ForeName>Lisa</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Apostolova</LastName><ForeName>Liana G</ForeName><Initials>LG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arnold</LastName><ForeName>Steven E</ForeName><Initials>SE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Asthana</LastName><ForeName>Sanjay</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Atwood</LastName><ForeName>Craig S</ForeName><Initials>CS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ayres</LastName><ForeName>Gayle</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Baldwin</LastName><ForeName>Clinton T</ForeName><Initials>CT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barber</LastName><ForeName>Robert C</ForeName><Initials>RC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barnes</LastName><ForeName>Lisa L</ForeName><Initials>LL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barral</LastName><ForeName>Sandra</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beach</LastName><ForeName>Thomas G</ForeName><Initials>TG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Becker</LastName><ForeName>James T</ForeName><Initials>JT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beecham</LastName><ForeName>Gary W</ForeName><Initials>GW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beekly</LastName><ForeName>Duane</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Below</LastName><ForeName>Jennifer E</ForeName><Initials>JE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Benchek</LastName><ForeName>Penelope</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Benitez</LastName><ForeName>Bruno A</ForeName><Initials>BA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bennett</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bertelson</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Margaret</LastName><ForeName>Flanagan E</ForeName><Initials>FE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bird</LastName><ForeName>Thomas D</ForeName><Initials>TD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blacker</LastName><ForeName>Deborah</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boeve</LastName><ForeName>Bradley F</ForeName><Initials>BF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bowen</LastName><ForeName>James D</ForeName><Initials>JD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boxer</LastName><ForeName>Adam</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brewer</LastName><ForeName>James</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burke</LastName><ForeName>James R</ForeName><Initials>JR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burns</LastName><ForeName>Jeffrey M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bush</LastName><ForeName>Will S</ForeName><Initials>WS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Buxbaum</LastName><ForeName>Joseph D</ForeName><Initials>JD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cairns</LastName><ForeName>Nigel J</ForeName><Initials>NJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cao</LastName><ForeName>Chuanhai</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carlson</LastName><ForeName>Christopher S</ForeName><Initials>CS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carlsson</LastName><ForeName>Cynthia M</ForeName><Initials>CM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carney</LastName><ForeName>Regina M</ForeName><Initials>RM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carrasquillo</LastName><ForeName>Minerva M</ForeName><Initials>MM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chasse</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chesselet</LastName><ForeName>Marie-Francoise</ForeName><Initials>MF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chesi</LastName><ForeName>Alessandra</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chin</LastName><ForeName>Nathaniel A</ForeName><Initials>NA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chui</LastName><ForeName>Helena C</ForeName><Initials>HC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chung</LastName><ForeName>Jaeyoon</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Craft</LastName><ForeName>Suzanne</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Crane</LastName><ForeName>Paul K</ForeName><Initials>PK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cribbs</LastName><ForeName>David H</ForeName><Initials>DH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Crocco</LastName><ForeName>Elizabeth A</ForeName><Initials>EA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cruchaga</LastName><ForeName>Carlos</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cuccaro</LastName><ForeName>Michael L</ForeName><Initials>ML</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cullum</LastName><ForeName>Munro</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Darby</LastName><ForeName>Eveleen</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Davis</LastName><ForeName>Barbara</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>De Jager</LastName><ForeName>Philip L</ForeName><Initials>PL</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeCarli</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeToledo</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dick</LastName><ForeName>Malcolm</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dickson</LastName><ForeName>Dennis W</ForeName><Initials>DW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dombroski</LastName><ForeName>Beth A</ForeName><Initials>BA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doody</LastName><ForeName>Rachelle S</ForeName><Initials>RS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duara</LastName><ForeName>Ranjan</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ertekin-Taner</LastName><ForeName>Nil&#xfc;fer</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Evans</LastName><ForeName>Denis A</ForeName><Initials>DA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fairchild</LastName><ForeName>Thomas J</ForeName><Initials>TJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fallon</LastName><ForeName>Kenneth B</ForeName><Initials>KB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Farlow</LastName><ForeName>Martin R</ForeName><Initials>MR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Farrell</LastName><ForeName>John J</ForeName><Initials>JJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fernandez-Hernandez</LastName><ForeName>Victoria</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ferris</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frosch</LastName><ForeName>Matthew P</ForeName><Initials>MP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fulton-Howard</LastName><ForeName>Brian</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Galasko</LastName><ForeName>Douglas R</ForeName><Initials>DR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gamboa</LastName><ForeName>Adriana</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gearing</LastName><ForeName>Marla</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Geschwind</LastName><ForeName>Daniel H</ForeName><Initials>DH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ghetti</LastName><ForeName>Bernardino</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gilbert</LastName><ForeName>John R</ForeName><Initials>JR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grabowski</LastName><ForeName>Thomas J</ForeName><Initials>TJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Graff-Radford</LastName><ForeName>Neill R</ForeName><Initials>NR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grant</LastName><ForeName>Struan F A</ForeName><Initials>SFA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Green</LastName><ForeName>Robert C</ForeName><Initials>RC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Growdon</LastName><ForeName>John H</ForeName><Initials>JH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Haines</LastName><ForeName>Jonathan L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hakonarson</LastName><ForeName>Hakon</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hall</LastName><ForeName>James</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hamilton</LastName><ForeName>Ronald L</ForeName><Initials>RL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harari</LastName><ForeName>Oscar</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harrell</LastName><ForeName>Lindy E</ForeName><Initials>LE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Haut</LastName><ForeName>Jacob</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Head</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Henderson</LastName><ForeName>Victor W</ForeName><Initials>VW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hernandez</LastName><ForeName>Michelle</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hohman</LastName><ForeName>Timothy</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Honig</LastName><ForeName>Lawrence S</ForeName><Initials>LS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Huebinger</LastName><ForeName>Ryan M</ForeName><Initials>RM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Huentelman</LastName><ForeName>Matthew J</ForeName><Initials>MJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hulette</LastName><ForeName>Christine M</ForeName><Initials>CM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hyman</LastName><ForeName>Bradley T</ForeName><Initials>BT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hynan</LastName><ForeName>Linda S</ForeName><Initials>LS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ibanez</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jarvik</LastName><ForeName>Gail P</ForeName><Initials>GP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jayadev</LastName><ForeName>Suman</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jin</LastName><ForeName>Lee-Way</ForeName><Initials>LW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Kim</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Leigh</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kamboh</LastName><ForeName>M Ilyas</ForeName><Initials>MI</Initials></Investigator><Investigator ValidYN="Y"><LastName>Karydas</LastName><ForeName>Anna M</ForeName><Initials>AM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Katz</LastName><ForeName>Mindy J</ForeName><Initials>MJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kaye</LastName><ForeName>Jeffrey A</ForeName><Initials>JA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Keene</LastName><ForeName>C Dirk</ForeName><Initials>CD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Khaleeq</LastName><ForeName>Aisha</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kim</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Knebl</LastName><ForeName>Janice</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kowall</LastName><ForeName>Neil W</ForeName><Initials>NW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kramer</LastName><ForeName>Joel H</ForeName><Initials>JH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kuksa</LastName><ForeName>Pavel P</ForeName><Initials>PP</Initials></Investigator><Investigator ValidYN="Y"><LastName>LaFerla</LastName><ForeName>Frank M</ForeName><Initials>FM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lah</LastName><ForeName>James J</ForeName><Initials>JJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Larson</LastName><ForeName>Eric B</ForeName><Initials>EB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>Chien-Yueh</ForeName><Initials>CY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>Edward B</ForeName><Initials>EB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lerner</LastName><ForeName>Alan</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leung</LastName><ForeName>Yuk Yee</ForeName><Initials>YY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leverenz</LastName><ForeName>James B</ForeName><Initials>JB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Levey</LastName><ForeName>Allan I</ForeName><Initials>AI</Initials></Investigator><Investigator ValidYN="Y"><LastName>Li</LastName><ForeName>Mingyao</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lieberman</LastName><ForeName>Andrew P</ForeName><Initials>AP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lipton</LastName><ForeName>Richard B</ForeName><Initials>RB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Logue</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lyketsos</LastName><ForeName>Constantine G</ForeName><Initials>CG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Malamon</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mains</LastName><ForeName>Douglas</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marson</LastName><ForeName>Daniel C</ForeName><Initials>DC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martiniuk</LastName><ForeName>Frank</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mash</LastName><ForeName>Deborah C</ForeName><Initials>DC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Masliah</LastName><ForeName>Eliezer</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Massman</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Masurkar</LastName><ForeName>Arjun</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>McCormick</LastName><ForeName>Wayne C</ForeName><Initials>WC</Initials></Investigator><Investigator ValidYN="Y"><LastName>McCurry</LastName><ForeName>Susan M</ForeName><Initials>SM</Initials></Investigator><Investigator ValidYN="Y"><LastName>McDavid</LastName><ForeName>Andrew N</ForeName><Initials>AN</Initials></Investigator><Investigator ValidYN="Y"><LastName>McDonough</LastName><ForeName>Stefan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>McKee</LastName><ForeName>Ann C</ForeName><Initials>AC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mesulam</LastName><ForeName>Marsel</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mez</LastName><ForeName>Jesse</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miller</LastName><ForeName>Bruce L</ForeName><Initials>BL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miller</LastName><ForeName>Carol A</ForeName><Initials>CA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miller</LastName><ForeName>Joshua W</ForeName><Initials>JW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Montine</LastName><ForeName>Thomas J</ForeName><Initials>TJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Monuki</LastName><ForeName>Edwin S</ForeName><Initials>ES</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Myers</LastName><ForeName>Amanda J</ForeName><Initials>AJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Trung</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>O'Bryant</LastName><ForeName>Sid</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Olichney</LastName><ForeName>John M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ory</LastName><ForeName>Marcia</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Palmer</LastName><ForeName>Raymond</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Parisi</LastName><ForeName>Joseph E</ForeName><Initials>JE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paulson</LastName><ForeName>Henry L</ForeName><Initials>HL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pavlik</LastName><ForeName>Valory</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paydarfar</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Perez</LastName><ForeName>Victoria</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Peskind</LastName><ForeName>Elaine</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald C</ForeName><Initials>RC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Phillips-Cremins</LastName><ForeName>Jennifer E</ForeName><Initials>JE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pierce</LastName><ForeName>Aimee</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Polk</LastName><ForeName>Marsha</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Poon</LastName><ForeName>Wayne W</ForeName><Initials>WW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Potter</LastName><ForeName>Huntington</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Qu</LastName><ForeName>Liming</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quiceno</LastName><ForeName>Mary</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quinn</LastName><ForeName>Joseph F</ForeName><Initials>JF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Raj</LastName><ForeName>Ashok</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Raskind</LastName><ForeName>Murray</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reiman</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reisberg</LastName><ForeName>Barry</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reisch</LastName><ForeName>Joan S</ForeName><Initials>JS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ringman</LastName><ForeName>John M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roberson</LastName><ForeName>Erik D</ForeName><Initials>ED</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rodriguear</LastName><ForeName>Monica</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rogaeva</LastName><ForeName>Ekaterina</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosen</LastName><ForeName>Howard J</ForeName><Initials>HJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosenberg</LastName><ForeName>Roger N</ForeName><Initials>RN</Initials></Investigator><Investigator ValidYN="Y"><LastName>Royall</LastName><ForeName>Donald R</ForeName><Initials>DR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sager</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sano</LastName><ForeName>Mary</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saykin</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schneider</LastName><ForeName>Julie A</ForeName><Initials>JA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schneider</LastName><ForeName>Lon S</ForeName><Initials>LS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Seeley</LastName><ForeName>William W</ForeName><Initials>WW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Slifer</LastName><ForeName>Susan H</ForeName><Initials>SH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Small</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Amanda G</ForeName><Initials>AG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Janet P</ForeName><Initials>JP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Song</LastName><ForeName>Yeunjoo E</ForeName><Initials>YE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sonnen</LastName><ForeName>Joshua A</ForeName><Initials>JA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spina</LastName><ForeName>Salvatore</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>George-Hyslop</LastName><ForeName>Peter St</ForeName><Initials>PS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stern</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stevens</LastName><ForeName>Alan B</ForeName><Initials>AB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Strittmatter</LastName><ForeName>Stephen M</ForeName><Initials>SM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sultzer</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Swerdlow</LastName><ForeName>Russell H</ForeName><Initials>RH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tanzi</LastName><ForeName>Rudolph E</ForeName><Initials>RE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tilson</LastName><ForeName>Jeffrey L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trojanowski</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Troncoso</LastName><ForeName>Juan C</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tsuang</LastName><ForeName>Debby W</ForeName><Initials>DW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Valladares</LastName><ForeName>Otto</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Van Deerlin</LastName><ForeName>Vivianna M</ForeName><Initials>VM</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Eldik</LastName><ForeName>Linda J</ForeName><Initials>LJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vassar</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vinters</LastName><ForeName>Harry V</ForeName><Initials>HV</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vonsattel</LastName><ForeName>Jean-Paul</ForeName><Initials>JP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weintraub</LastName><ForeName>Sandra</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Welsh-Bohmer</LastName><ForeName>Kathleen A</ForeName><Initials>KA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Whitehead</LastName><ForeName>Patrice L</ForeName><Initials>PL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wijsman</LastName><ForeName>Ellen M</ForeName><Initials>EM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wilhelmsen</LastName><ForeName>Kirk C</ForeName><Initials>KC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Williams</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Williamson</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wilms</LastName><ForeName>Henrik</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wingo</LastName><ForeName>Thomas S</ForeName><Initials>TS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wisniewski</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Woltjer</LastName><ForeName>Randall L</ForeName><Initials>RL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Woon</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wright</LastName><ForeName>Clinton B</ForeName><Initials>CB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wu</LastName><ForeName>Chuang-Kuo</ForeName><Initials>CK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Younkin</LastName><ForeName>Steven G</ForeName><Initials>SG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yu</LastName><ForeName>Chang-En</ForeName><Initials>CE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yu</LastName><ForeName>Lei</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yuanchao</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhao</LastName><ForeName>Yi</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhu</LastName><ForeName>Xiongwei</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>Adams</LastName><ForeName>Hieab</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Akinyemi</LastName><ForeName>Rufus O</ForeName><Initials>RO</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ali</LastName><ForeName>Muhammad</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Armstrong</LastName><ForeName>Nicola</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aparicio</LastName><ForeName>Hugo J</ForeName><Initials>HJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bahadori</LastName><ForeName>Maryam</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Becker</LastName><ForeName>James T</ForeName><Initials>JT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Breteler</LastName><ForeName>Monique</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chasman</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chauhan</LastName><ForeName>Ganesh</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Comic</LastName><ForeName>Hata</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cox</LastName><ForeName>Simon</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cupples</LastName><ForeName>Adrienne L</ForeName><Initials>AL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Davies</LastName><ForeName>Gail</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeCarli</LastName><ForeName>Charles S</ForeName><Initials>CS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duperron</LastName><ForeName>Marie-Gabrielle</ForeName><Initials>MG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dupuis</LastName><ForeName>Jos&#xe9;e</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Evans</LastName><ForeName>Tavia</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fan</LastName><ForeName>Frank</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fitzpatrick</LastName><ForeName>Annette</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fohner</LastName><ForeName>Alison E</ForeName><Initials>AE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ganguli</LastName><ForeName>Mary</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Geerlings</LastName><ForeName>Mirjam</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Glatt</LastName><ForeName>Stephen J</ForeName><Initials>SJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gonzalez</LastName><ForeName>Hector M</ForeName><Initials>HM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goss</LastName><ForeName>Monica</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grabe</LastName><ForeName>Hans</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Habes</LastName><ForeName>Mohamad</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heckbert</LastName><ForeName>Susan R</ForeName><Initials>SR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hofer</LastName><ForeName>Edith</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hong</LastName><ForeName>Elliot</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hughes</LastName><ForeName>Timothy</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kautz</LastName><ForeName>Tiffany F</ForeName><Initials>TF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Knol</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kremen</LastName><ForeName>William</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lacaze</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lahti</LastName><ForeName>Jari</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grand</LastName><ForeName>Quentin Le</ForeName><Initials>QL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Litkowski</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Li</LastName><ForeName>Shuo</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Liu</LastName><ForeName>Dan</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Liu</LastName><ForeName>Xuan</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>Loitfelder</LastName><ForeName>Marisa</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Manning</LastName><ForeName>Alisa</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maillard</LastName><ForeName>Pauline</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marioni</LastName><ForeName>Riccardo</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mazoyer</LastName><ForeName>Bernard</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Lent</LastName><ForeName>Debora Melo</ForeName><Initials>DM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mei</LastName><ForeName>Hao</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mishra</LastName><ForeName>Aniket</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nyquist</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>O'Connell</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Patel</LastName><ForeName>Yash</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paus</LastName><ForeName>Tomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pausova</LastName><ForeName>Zdenka</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Raikkonen-Talvitie</LastName><ForeName>Katri</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Riaz</LastName><ForeName>Moeen</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rich</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rotter</LastName><ForeName>Jerome</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Romero</LastName><ForeName>Jose</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roshchupkin</LastName><ForeName>Gena</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saba</LastName><ForeName>Yasaman</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sargurupremraj</LastName><ForeName>Murali</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schmidt</LastName><ForeName>Helena</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schmidt</LastName><ForeName>Reinhold</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shulman</LastName><ForeName>Joshua M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sekhar</LastName><ForeName>Hema</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rajula</LastName><ForeName>Reddy</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shin</LastName><ForeName>Jean</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Simino</LastName><ForeName>Jeannette</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sliz</LastName><ForeName>Eeva</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Teumer</LastName><ForeName>Alexander</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thomas</LastName><ForeName>Alvin</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tin</LastName><ForeName>Adrienne</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tucker-Drob</LastName><ForeName>Elliot</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vojinovic</LastName><ForeName>Dina</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wang</LastName><ForeName>Yanbing</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weinstein</LastName><ForeName>Galit</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Williams</LastName><ForeName>Dylan</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wittfeld</LastName><ForeName>Katharina</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yanek</LastName><ForeName>Lisa</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yang</LastName><ForeName>Yunju</ForeName><Initials>Y</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>6</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>1</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>5</Day><Hour>5</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>4</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35379992</ArticleId><ArticleId IdType="pmc">PMC9005347</ArticleId><ArticleId IdType="doi">10.1038/s41588-022-01024-z</ArticleId><ArticleId IdType="pii">10.1038/s41588-022-01024-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gatz M, et al. Role of genes and environments for explaining Alzheimer disease. Arch. Gen. Psychiatry. 2006;63:168&#x2013;174. doi: 10.1001/archpsyc.63.2.168.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archpsyc.63.2.168</ArticleId><ArticleId IdType="pubmed">16461860</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellenguez C, Grenier-Boley B, Lambert JC. Genetics of Alzheimer&#x2019;s disease: where we are, and where we are going. Curr. Opin. Neurobiol. 2020;61:40&#x2013;48. doi: 10.1016/j.conb.2019.11.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.conb.2019.11.024</ArticleId><ArticleId IdType="pubmed">31863938</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen IE, et al. Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer&#x2019;s disease risk. Nat. Genet. 2019;51:404&#x2013;413. doi: 10.1038/s41588-018-0311-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-018-0311-9</ArticleId><ArticleId IdType="pmc">PMC6836675</ArticleId><ArticleId IdType="pubmed">30617256</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang CC, et al. Second-generation PLINK: rising to the challenge of larger and richer datasets. Gigascience. 2015;4:7. doi: 10.1186/s13742-015-0047-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13742-015-0047-8</ArticleId><ArticleId IdType="pmc">PMC4342193</ArticleId><ArticleId IdType="pubmed">25722852</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunkle BW, et al. Genetic meta-analysis of diagnosed Alzheimer&#x2019;s disease identifies new risk loci and implicates A&#x3b2;, tau, immunity and lipid processing. Nat. Genet. 2019;51:414&#x2013;430. doi: 10.1038/s41588-019-0358-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-019-0358-2</ArticleId><ArticleId IdType="pmc">PMC6463297</ArticleId><ArticleId IdType="pubmed">30820047</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer&#x2019;s disease. Nat. Genet. 2013;45:1452&#x2013;1458. doi: 10.1038/ng.2802.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.2802</ArticleId><ArticleId IdType="pmc">PMC3896259</ArticleId><ArticleId IdType="pubmed">24162737</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu JZ, Erlich Y, Pickrell JK. Case-control association mapping by proxy using family history of disease. Nat. Genet. 2017;49:325&#x2013;331. doi: 10.1038/ng.3766.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3766</ArticleId><ArticleId IdType="pubmed">28092683</ArticleId></ArticleIdList></Reference><Reference><Citation>Marioni RE, et al. GWAS on family history of Alzheimer&#x2019;s disease. Transl. Psychiatry. 2018;8:99. doi: 10.1038/s41398-018-0150-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41398-018-0150-6</ArticleId><ArticleId IdType="pmc">PMC5959890</ArticleId><ArticleId IdType="pubmed">29777097</ArticleId></ArticleIdList></Reference><Reference><Citation>Sims R, et al. Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer&#x2019;s disease. Nat. Genet. 2017;49:1373&#x2013;1384. doi: 10.1038/ng.3916.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3916</ArticleId><ArticleId IdType="pmc">PMC5669039</ArticleId><ArticleId IdType="pubmed">28714976</ArticleId></ArticleIdList></Reference><Reference><Citation>Jun G, et al. A novel Alzheimer disease locus located near the gene encoding tau protein. Mol. Psychiatry. 2016;21:108&#x2013;117. doi: 10.1038/mp.2015.23.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2015.23</ArticleId><ArticleId IdType="pmc">PMC4573764</ArticleId><ArticleId IdType="pubmed">25778476</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartzentruber J, et al. Genome-wide meta-analysis, fine-mapping and integrative prioritization implicate new Alzheimer&#x2019;s disease risk genes. Nat. Genet. 2021;53:392&#x2013;402. doi: 10.1038/s41588-020-00776-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-020-00776-w</ArticleId><ArticleId IdType="pmc">PMC7610386</ArticleId><ArticleId IdType="pubmed">33589840</ArticleId></ArticleIdList></Reference><Reference><Citation>de Rojas I, et al. Common variants in Alzheimer&#x2019;s disease and risk stratification by polygenic risk scores. Nat. Commun. 2021;12:3417. doi: 10.1038/s41467-021-22491-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-22491-8</ArticleId><ArticleId IdType="pmc">PMC8184987</ArticleId><ArticleId IdType="pubmed">34099642</ArticleId></ArticleIdList></Reference><Reference><Citation>Wightman DP, et al. A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer&#x2019;s disease. Nat. Genet. 2021;53:1276&#x2013;1282. doi: 10.1038/s41588-021-00921-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-021-00921-z</ArticleId><ArticleId IdType="pmc">PMC10243600</ArticleId><ArticleId IdType="pubmed">34493870</ArticleId></ArticleIdList></Reference><Reference><Citation>Skene NG, et al. Genetic identification of brain cell types underlying schizophrenia. Nat. Genet. 2018;50:825&#x2013;833. doi: 10.1038/s41588-018-0129-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-018-0129-5</ArticleId><ArticleId IdType="pmc">PMC6477180</ArticleId><ArticleId IdType="pubmed">29785013</ArticleId></ArticleIdList></Reference><Reference><Citation>de Leeuw CA, Stringer S, Dekkers IA, Heskes T, Posthuma D. Conditional and interaction gene-set analysis reveals novel functional pathways for blood pressure. Nat. Commun. 2018;9:3768. doi: 10.1038/s41467-018-06022-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-06022-6</ArticleId><ArticleId IdType="pmc">PMC6138636</ArticleId><ArticleId IdType="pubmed">30218068</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Kaether C, Thinakaran G, Sisodia S. Trafficking and proteolytic processing of APP. Cold Spring Harb. Perspect. Med. 2012;2:a006270. doi: 10.1101/cshperspect.a006270.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a006270</ArticleId><ArticleId IdType="pmc">PMC3331683</ArticleId><ArticleId IdType="pubmed">22553493</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapuis J, et al. Genome-wide, high-content siRNA screening identifies the Alzheimer&#x2019;s genetic risk factor FERMT2 as a major modulator of APP metabolism. Acta Neuropathol. 2017;133:955&#x2013;966. doi: 10.1007/s00401-016-1652-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-016-1652-z</ArticleId><ArticleId IdType="pmc">PMC5427165</ArticleId><ArticleId IdType="pubmed">27933404</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleynen A, et al. Expressed fusion gene landscape and its impact in multiple myeloma. Nat. Commun. 2017;8:1893. doi: 10.1038/s41467-017-00638-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-00638-w</ArticleId><ArticleId IdType="pmc">PMC5711960</ArticleId><ArticleId IdType="pubmed">29196615</ArticleId></ArticleIdList></Reference><Reference><Citation>Szklarczyk D, et al. STRING v11: Protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47:D607&#x2013;D613. doi: 10.1093/nar/gky1131.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gky1131</ArticleId><ArticleId IdType="pmc">PMC6323986</ArticleId><ArticleId IdType="pubmed">30476243</ArticleId></ArticleIdList></Reference><Reference><Citation>Spit M, Rieser E, Walczak H. Linear ubiquitination at a glance. J. Cell Sci. 2019;132:jcs208512. doi: 10.1242/jcs.208512.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.208512</ArticleId><ArticleId IdType="pubmed">30659056</ArticleId></ArticleIdList></Reference><Reference><Citation>Pencina MJ, D&#x2019;Agostino RB, Pencina KM, Janssens ACJW, Greenland P. Interpreting incremental value of markers added to risk prediction models. Am. J. Epidemiol. 2012;176:473&#x2013;481. doi: 10.1093/aje/kws207.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kws207</ArticleId><ArticleId IdType="pmc">PMC3530349</ArticleId><ArticleId IdType="pubmed">22875755</ArticleId></ArticleIdList></Reference><Reference><Citation>Dourlen P, Chapuis J, Lambert J-C. Using high-throughput animal or cell-based models to functionally characterize GWAS signals. Curr. Genet. Med. Rep. 2018;6:107&#x2013;115. doi: 10.1007/s40142-018-0141-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40142-018-0141-1</ArticleId><ArticleId IdType="pmc">PMC6096908</ArticleId><ArticleId IdType="pubmed">30147999</ArticleId></ArticleIdList></Reference><Reference><Citation>Dourlen P, Kilinc D, Malmanche N, Chapuis J, Lambert JC. The new genetic landscape of Alzheimer&#x2019;s disease: from amyloid cascade to genetically driven synaptic failure hypothesis? Acta Neuropathol. 2019;138:221&#x2013;236. doi: 10.1007/s00401-019-02004-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-019-02004-0</ArticleId><ArticleId IdType="pmc">PMC6660578</ArticleId><ArticleId IdType="pubmed">30982098</ArticleId></ArticleIdList></Reference><Reference><Citation>Deuss M, Reiss K, Hartmann D. Part-time &#x3b1;-secretases: the functional biology of ADAM 9, 10 and 17. Curr. Alzheimer Res. 2008;5:187&#x2013;201. doi: 10.2174/156720508783954686.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156720508783954686</ArticleId><ArticleId IdType="pubmed">18393804</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim T, et al. Human LilrB2 is a &#x3b2;-amyloid receptor and its murine homolog PirB regulates synaptic plasticity in an Alzheimer&#x2019;s model. Science. 2013;341:1399&#x2013;1404. doi: 10.1126/science.1242077.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1242077</ArticleId><ArticleId IdType="pmc">PMC3853120</ArticleId><ArticleId IdType="pubmed">24052308</ArticleId></ArticleIdList></Reference><Reference><Citation>Salminen A, Kaarniranta K. Siglec receptors and hiding plaques in Alzheimer&#x2019;s disease. J. Mol. Med. 2009;87:697&#x2013;701. doi: 10.1007/s00109-009-0472-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00109-009-0472-1</ArticleId><ArticleId IdType="pubmed">19390836</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodgers MA, et al. The linear ubiquitin assembly complex (LUBAC) is essential for NLRP3 inflammasome activation. J. Exp. Med. 2014;211:1333&#x2013;1347. doi: 10.1084/jem.20132486.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20132486</ArticleId><ArticleId IdType="pmc">PMC4076580</ArticleId><ArticleId IdType="pubmed">24958845</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwai K. LUBAC-mediated linear ubiquitination: a crucial regulator of immune signaling. Proc. Jpn. Acad. Ser. B Phys. Biol. Sci. 2021;97:120&#x2013;133. doi: 10.2183/pjab.97.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.2183/pjab.97.007</ArticleId><ArticleId IdType="pmc">PMC8019854</ArticleId><ArticleId IdType="pubmed">33692228</ArticleId></ArticleIdList></Reference><Reference><Citation>Venegas C, et al. Microglia-derived ASC specks crossseed amyloid-&#x3b2; in Alzheimer&#x2019;s disease. Nature. 2017;552:355&#x2013;361. doi: 10.1038/nature25158.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature25158</ArticleId><ArticleId IdType="pubmed">29293211</ArticleId></ArticleIdList></Reference><Reference><Citation>Ising C, et al. NLRP3 inflammasome activation drives tau pathology. Nature. 2019;575:669&#x2013;673. doi: 10.1038/s41586-019-1769-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-1769-z</ArticleId><ArticleId IdType="pmc">PMC7324015</ArticleId><ArticleId IdType="pubmed">31748742</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakayama Y, et al. Linear polyubiquitin chain modification of TDP-43-positive neuronal cytoplasmic inclusions in amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol. 2020;79:256&#x2013;265. doi: 10.1093/jnen/nlz135.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnen/nlz135</ArticleId><ArticleId IdType="pubmed">31951008</ArticleId></ArticleIdList></Reference><Reference><Citation>Black RA, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-&#x2205; from cells. Nature. 1997;385:729&#x2013;733. doi: 10.1038/385729a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/385729a0</ArticleId><ArticleId IdType="pubmed">9034190</ArticleId></ArticleIdList></Reference><Reference><Citation>Verstrepen L, Carpentier I, Verhelst K, Beyaert R. ABINs: A20 binding inhibitors of NF-&#x3ba;B and apoptosis signaling. Biochem. Pharmacol. 2009;78:105&#x2013;114. doi: 10.1016/j.bcp.2009.02.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bcp.2009.02.009</ArticleId><ArticleId IdType="pubmed">19464428</ArticleId></ArticleIdList></Reference><Reference><Citation>Spitz C, et al. Non-canonical Shedding of TNF&#x3b1; by SPPL2a is determined by the conformational flexibility of its transmembrane helix. iScience. 2020;23:101775. doi: 10.1016/j.isci.2020.101775.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2020.101775</ArticleId><ArticleId IdType="pmc">PMC7689174</ArticleId><ArticleId IdType="pubmed">33294784</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang W, et al. The growth factor progranulin binds to tnf receptors and is therapeutic against inflammatory arthritis in mice. Science. 2011;332:478&#x2013;484. doi: 10.1126/science.1199214.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1199214</ArticleId><ArticleId IdType="pmc">PMC3104397</ArticleId><ArticleId IdType="pubmed">21393509</ArticleId></ArticleIdList></Reference><Reference><Citation>He P, et al. Deletion of tumor necrosis factor death receptor inhibits amyloid &#x3b2; generation and prevents learning and memory deficits in Alzheimer&#x2019;s mice. J. Cell Biol. 2007;178:829&#x2013;841. doi: 10.1083/jcb.200705042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.200705042</ArticleId><ArticleId IdType="pmc">PMC2064547</ArticleId><ArticleId IdType="pubmed">17724122</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi JQ, et al. Anti-TNF-&#x3b1; reduces amyloid plaques and tau phosphorylation and induces CD11c-positive dendritic-like cell in the APP/PS1 transgenic mouse brains. Brain Res. 2011;1368:239&#x2013;247. doi: 10.1016/j.brainres.2010.10.053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2010.10.053</ArticleId><ArticleId IdType="pubmed">20971085</ArticleId></ArticleIdList></Reference><Reference><Citation>Bezbradica JS, Coll RC, Schroder K. Sterile signals generate weaker and delayed macrophage NLRP3 inflammasome responses relative to microbial signals. Cell. Mol. Immunol. 2017;14:118&#x2013;126. doi: 10.1038/cmi.2016.11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cmi.2016.11</ArticleId><ArticleId IdType="pmc">PMC5214936</ArticleId><ArticleId IdType="pubmed">26996064</ArticleId></ArticleIdList></Reference><Reference><Citation>Decourt B, Lahiri DK, Sabbagh MN. Targeting tumor necrosis factor alpha for Alzheimer&#x2019;s disease. Curr. Alzheimer Res. 2016;14:412&#x2013;425. doi: 10.2174/1567205013666160930110551.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1567205013666160930110551</ArticleId><ArticleId IdType="pmc">PMC5328927</ArticleId><ArticleId IdType="pubmed">27697064</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B, Karran E. The cellular phase of Alzheimer&#x2019;s disease. Cell. 2016;164:603&#x2013;615. doi: 10.1016/j.cell.2015.12.056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2015.12.056</ArticleId><ArticleId IdType="pubmed">26871627</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong K, et al. TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer. J. Clin. Invest. 2018;128:2500&#x2013;2518. doi: 10.1172/JCI96148.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI96148</ArticleId><ArticleId IdType="pmc">PMC5983340</ArticleId><ArticleId IdType="pubmed">29613856</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhinn H, Abeliovich A. Differential aging analysis in human cerebral cortex identifies variants in TMEM106B and GRN that regulate aging phenotypes. Cell Syst. 2017;4:404&#x2013;415. doi: 10.1016/j.cels.2017.02.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cels.2017.02.009</ArticleId><ArticleId IdType="pubmed">28330615</ArticleId></ArticleIdList></Reference><Reference><Citation>Vass R, et al. Risk genotypes at TMEM106B are associated with cognitive impairment in amyotrophic lateral sclerosis. Acta Neuropathol. 2011;121:373&#x2013;380. doi: 10.1007/s00401-010-0782-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-010-0782-y</ArticleId><ArticleId IdType="pmc">PMC3095217</ArticleId><ArticleId IdType="pubmed">21104415</ArticleId></ArticleIdList></Reference><Reference><Citation>Baizabal-Carvallo JF, Jankovic J. Parkinsonism, movement disorders and genetics in frontotemporal dementia. Nat. Rev. Neurol. 2016;12:175&#x2013;185. doi: 10.1038/nrneurol.2016.14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2016.14</ArticleId><ArticleId IdType="pubmed">26891767</ArticleId></ArticleIdList></Reference><Reference><Citation>Tropea TF, et al. TMEM106B Effect on cognition in Parkinson disease and frontotemporal dementia. Ann. Neurol. 2019;85:801&#x2013;811. doi: 10.1002/ana.25486.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25486</ArticleId><ArticleId IdType="pmc">PMC6953172</ArticleId><ArticleId IdType="pubmed">30973966</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendsaikhan A, Tooyama I, Walker DG. Microglial progranulin: involvement in Alzheimer&#x2019;s disease and neurodegenerative diseases. Cells. 2019;8:230. doi: 10.3390/cells8030230.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells8030230</ArticleId><ArticleId IdType="pmc">PMC6468562</ArticleId><ArticleId IdType="pubmed">30862089</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z, et al. The TMEM106B FTLD-protective variant, rs1990621, is also associated with increased neuronal proportion. Acta Neuropathol. 2020;139:45&#x2013;61. doi: 10.1007/s00401-019-02066-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-019-02066-0</ArticleId><ArticleId IdType="pmc">PMC6942643</ArticleId><ArticleId IdType="pubmed">31456032</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang HS, et al. Genetics of gene expression in the aging human brain reveal TDP-43 proteinopathy pathophysiology. Neuron. 2020;107:496&#x2013;508.e6. doi: 10.1016/j.neuron.2020.05.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2020.05.010</ArticleId><ArticleId IdType="pmc">PMC7416464</ArticleId><ArticleId IdType="pubmed">32526197</ArticleId></ArticleIdList></Reference><Reference><Citation>Paushter DH, Du H, Feng T, Hu F. The lysosomal function of progranulin, a guardian against neurodegeneration. Acta Neuropathol. 2018;136:1&#x2013;17. doi: 10.1007/s00401-018-1861-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-1861-8</ArticleId><ArticleId IdType="pmc">PMC6117207</ArticleId><ArticleId IdType="pubmed">29744576</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng T, Lacrampe A, Hu F. Physiological and pathological functions of TMEM106B: a gene associated with brain aging and multiple brain disorders. Acta Neuropathol. 2021;141:327&#x2013;339. doi: 10.1007/s00401-020-02246-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-020-02246-3</ArticleId><ArticleId IdType="pmc">PMC8049516</ArticleId><ArticleId IdType="pubmed">33386471</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacour A, et al. Genome-wide significant risk factors for Alzheimer&#x2019;s disease: role in progression to dementia due to Alzheimer&#x2019;s disease among subjects with mild cognitive impairment. Mol. Psychiatry. 2017;22:153&#x2013;160. doi: 10.1038/mp.2016.18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2016.18</ArticleId><ArticleId IdType="pmc">PMC5414086</ArticleId><ArticleId IdType="pubmed">26976043</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q, et al. Risk prediction of late-onset Alzheimer&#x2019;s disease implies an oligogenic architecture. Nat. Commun. 2020;11:1&#x2013;11. doi: 10.1038/s41467-019-13993-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-13993-7</ArticleId><ArticleId IdType="pmc">PMC7511365</ArticleId><ArticleId IdType="pubmed">32968074</ArticleId></ArticleIdList></Reference><Reference><Citation>Holstege H, et al. Exome sequencing identifies novel AD-associated genes. medRxiv. 2020;18:24.</Citation></Reference><Reference><Citation>Psaty BM, et al. Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium design of prospective meta-analyses of genome-wide association studies from 5 cohorts. Circulation: Cardiovasc. Genet. 2009;2:73&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2875693</ArticleId><ArticleId IdType="pubmed">20031568</ArticleId></ArticleIdList></Reference><Reference><Citation>Naj AC, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer&#x2019;s disease. Nat. Genet. 2011;43:436&#x2013;441. doi: 10.1038/ng.801.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.801</ArticleId><ArticleId IdType="pmc">PMC3090745</ArticleId><ArticleId IdType="pubmed">21460841</ArticleId></ArticleIdList></Reference><Reference><Citation>Jun G, et al. Meta-analysis confirms CR1, CLU, and PICALM as Alzheimer disease risk loci and reveals interactions with APOE genotypes. Arch. Neurol. 2010;67:1473&#x2013;1484. doi: 10.1001/archneurol.2010.201.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2010.201</ArticleId><ArticleId IdType="pmc">PMC3048805</ArticleId><ArticleId IdType="pubmed">20697030</ArticleId></ArticleIdList></Reference><Reference><Citation>Taliun D, et al. Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program. Nature. 2021;590:290&#x2013;299. doi: 10.1038/s41586-021-03205-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03205-y</ArticleId><ArticleId IdType="pmc">PMC7875770</ArticleId><ArticleId IdType="pubmed">33568819</ArticleId></ArticleIdList></Reference><Reference><Citation>Das S, et al. Next-generation genotype imputation service and methods. Nat. Genet. 2016;48:1284&#x2013;1287. doi: 10.1038/ng.3656.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3656</ArticleId><ArticleId IdType="pmc">PMC5157836</ArticleId><ArticleId IdType="pubmed">27571263</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarthy S, et al. A reference panel of 64,976 haplotypes for genotype imputation. Nat. Genet. 2016;48:1279&#x2013;1283. doi: 10.1038/ng.3643.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3643</ArticleId><ArticleId IdType="pmc">PMC5388176</ArticleId><ArticleId IdType="pubmed">27548312</ArticleId></ArticleIdList></Reference><Reference><Citation>Marchini J, Howie B, Myers S, McVean G, Donnelly P. A new multipoint method for genome-wide association studies by imputation of genotypes. Nat. Genet. 2007;39:906&#x2013;913. doi: 10.1038/ng2088.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng2088</ArticleId><ArticleId IdType="pubmed">17572673</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou W, et al. Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies. Nat. Genet. 2018;50:1335&#x2013;1341. doi: 10.1038/s41588-018-0184-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-018-0184-y</ArticleId><ArticleId IdType="pmc">PMC6119127</ArticleId><ArticleId IdType="pubmed">30104761</ArticleId></ArticleIdList></Reference><Reference><Citation>Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics. 2010;26:2190&#x2013;2191. doi: 10.1093/bioinformatics/btq340.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btq340</ArticleId><ArticleId IdType="pmc">PMC2922887</ArticleId><ArticleId IdType="pubmed">20616382</ArticleId></ArticleIdList></Reference><Reference><Citation>Aulchenko YS, Ripke S, Isaacs A, van Duijn CM. GenABEL: an R library for genome-wide association analysis. Bioinformatics. 2007;23:1294&#x2013;1296. doi: 10.1093/bioinformatics/btm108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btm108</ArticleId><ArticleId IdType="pubmed">17384015</ArticleId></ArticleIdList></Reference><Reference><Citation>Bulik-Sullivan B, et al. LD score regression distinguishes confounding from polygenicity in genome-wide association studies. Nat. Genet. 2015;47:291&#x2013;295. doi: 10.1038/ng.3211.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3211</ArticleId><ArticleId IdType="pmc">PMC4495769</ArticleId><ArticleId IdType="pubmed">25642630</ArticleId></ArticleIdList></Reference><Reference><Citation>de Leeuw CA, Mooij JM, Heskes T, Posthuma D. MAGMA: generalized gene-set analysis of GWAS data. PLoS Comput. Biol. 2015;11:e1004219. doi: 10.1371/journal.pcbi.1004219.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pcbi.1004219</ArticleId><ArticleId IdType="pmc">PMC4401657</ArticleId><ArticleId IdType="pubmed">25885710</ArticleId></ArticleIdList></Reference><Reference><Citation>Yurko R, Roeder K, Devlin B, G&#x2019;Sell M. H&#x2010;MAGMA, inheriting a shaky statistical foundation, yields excess false positives. Ann. Hum. Genet. 2021;85:97&#x2013;100. doi: 10.1111/ahg.12412.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ahg.12412</ArticleId><ArticleId IdType="pubmed">33372276</ArticleId></ArticleIdList></Reference><Reference><Citation>De Leeuw CA, Neale BM, Heskes T, Posthuma D. The statistical properties of gene-set analysis. Nat. Rev. Genet. 2016;17:353&#x2013;364. doi: 10.1038/nrg.2016.29.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrg.2016.29</ArticleId><ArticleId IdType="pubmed">27070863</ArticleId></ArticleIdList></Reference><Reference><Citation>Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc. Natl Acad. Sci. U. S. A. 2003;100:9440&#x2013;9445. doi: 10.1073/pnas.1530509100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1530509100</ArticleId><ArticleId IdType="pmc">PMC170937</ArticleId><ArticleId IdType="pubmed">12883005</ArticleId></ArticleIdList></Reference><Reference><Citation>Coelho, D. M., L. I. da Cruz Carvalho, Melo-de-Farias, A. R., Lambert, J.-C. &amp; Costa, M. R. Differential transcript usage unravels gene expression alterations in Alzheimer&#x2019;s disease human brains. NPJ Aging Mech. Dis. 7, 2 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7782705</ArticleId><ArticleId IdType="pubmed">33398016</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler A, Hoffman P, Smibert P, Papalexi E, Satija R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. 2018;36:411&#x2013;420. doi: 10.1038/nbt.4096.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.4096</ArticleId><ArticleId IdType="pmc">PMC6700744</ArticleId><ArticleId IdType="pubmed">29608179</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen M, et al. Human whole genome genotype and transcriptome data for Alzheimer&#x2019;s and other neurodegenerative diseases. Sci. Data. 2016;3:160089. doi: 10.1038/sdata.2016.89.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sdata.2016.89</ArticleId><ArticleId IdType="pmc">PMC5058336</ArticleId><ArticleId IdType="pubmed">27727239</ArticleId></ArticleIdList></Reference><Reference><Citation>Mostafavi S, et al. A molecular network of the aging human brain provides insights into the pathology and cognitive decline of Alzheimer&#x2019;s disease. Nat. Neurosci. 2018;21:811&#x2013;819. doi: 10.1038/s41593-018-0154-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0154-9</ArticleId><ArticleId IdType="pmc">PMC6599633</ArticleId><ArticleId IdType="pubmed">29802388</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, et al. Religious orders study and rush memory and aging project. J. Alzheimer&#x2019;s Dis. 2018;64:S161&#x2013;S189. doi: 10.3233/JAD-179939.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-179939</ArticleId><ArticleId IdType="pmc">PMC6380522</ArticleId><ArticleId IdType="pubmed">29865057</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M, et al. The Mount Sinai cohort of large-scale genomic, transcriptomic and proteomic data in Alzheimer&#x2019;s disease. Sci. Data. 2018;5:180185. doi: 10.1038/sdata.2018.185.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sdata.2018.185</ArticleId><ArticleId IdType="pmc">PMC6132187</ArticleId><ArticleId IdType="pubmed">30204156</ArticleId></ArticleIdList></Reference><Reference><Citation>GTEx Consortium The GTEx Consortium atlas of genetic regulatory effects across human tissues. Science. 2020;369:1318&#x2013;1330. doi: 10.1126/science.aaz1776.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaz1776</ArticleId><ArticleId IdType="pmc">PMC7737656</ArticleId><ArticleId IdType="pubmed">32913098</ArticleId></ArticleIdList></Reference><Reference><Citation>De, K. et al. Atlas of genetic effects in human microglia transcriptome across brain regions, aging and disease pathologies. Preprint at bioRxiv10.1101/2020.10.27.356113 (2020).</Citation></Reference><Reference><Citation>Alasoo K, et al. Shared genetic effects on chromatin and gene expression indicate a role for enhancer priming in immune response. Nat. Genet. 2018;50:424&#x2013;431. doi: 10.1038/s41588-018-0046-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-018-0046-7</ArticleId><ArticleId IdType="pmc">PMC6548559</ArticleId><ArticleId IdType="pubmed">29379200</ArticleId></ArticleIdList></Reference><Reference><Citation>N&#xe9;d&#xe9;lec Y, et al. Genetic ancestry and natural selection drive population differences in immune responses to pathogens. Cell. 2016;167:657&#x2013;669.e21. doi: 10.1016/j.cell.2016.09.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2016.09.025</ArticleId><ArticleId IdType="pubmed">27768889</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L, et al. Genetic drivers of epigenetic and transcriptional variation in human immune cells. Cell. 2016;167:1398&#x2013;1414.e24. doi: 10.1016/j.cell.2016.10.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2016.10.026</ArticleId><ArticleId IdType="pmc">PMC5119954</ArticleId><ArticleId IdType="pubmed">27863251</ArticleId></ArticleIdList></Reference><Reference><Citation>Momozawa Y, et al. IBD risk loci are enriched in multigenic regulatory modules encompassing putative causative genes. Nat. Commun. 2018;9:2427. doi: 10.1038/s41467-018-04365-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-04365-8</ArticleId><ArticleId IdType="pmc">PMC6013502</ArticleId><ArticleId IdType="pubmed">29930244</ArticleId></ArticleIdList></Reference><Reference><Citation>Fairfax BP, et al. Innate immune activity conditions the effect of regulatory variants upon monocyte gene expression. Sci. (80-.). 2014;343:1246949. doi: 10.1126/science.1246949.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1246949</ArticleId><ArticleId IdType="pmc">PMC4064786</ArticleId><ArticleId IdType="pubmed">24604202</ArticleId></ArticleIdList></Reference><Reference><Citation>Quach H, et al. Genetic adaptation and neandertal admixture shaped the immune system of human populations. Cell. 2016;167:643&#x2013;656.e17. doi: 10.1016/j.cell.2016.09.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2016.09.024</ArticleId><ArticleId IdType="pmc">PMC5075285</ArticleId><ArticleId IdType="pubmed">27768888</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerimov, N. et al. eQTL catalogue: a compendium of uniformly processed human gene expression and splicing QTLs. Preprint at bioRxiv10.1101/2020.01.29.924266 (2020).</Citation></Reference><Reference><Citation>Wingo AP, et al. Integrating human brain proteomes with genome-wide association data implicates new proteins in Alzheimer&#x2019;s disease pathogenesis. Nat. Genet. 2021;53:143&#x2013;146. doi: 10.1038/s41588-020-00773-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-020-00773-z</ArticleId><ArticleId IdType="pmc">PMC8130821</ArticleId><ArticleId IdType="pubmed">33510477</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng B, et al. An xQTL map integrates the genetic architecture of the human brain&#x2019;s transcriptome and epigenome. Nat. Neurosci. 2017;20:1418&#x2013;1426. doi: 10.1038/nn.4632.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4632</ArticleId><ArticleId IdType="pmc">PMC5785926</ArticleId><ArticleId IdType="pubmed">28869584</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbeira AN, et al. Exploiting the GTEx resources to decipher the mechanisms at GWAS loci. Genome Biol. 2021;22:49. doi: 10.1186/s13059-020-02252-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-020-02252-4</ArticleId><ArticleId IdType="pmc">PMC7836161</ArticleId><ArticleId IdType="pubmed">33499903</ArticleId></ArticleIdList></Reference><Reference><Citation>Edgar RD, Jones MJ, Meaney MJ, Turecki G, Kobor MS. BECon: a tool for interpreting DNA methylation findings from blood in the context of brain. Transl. Psychiatry. 2017;7:e1187. doi: 10.1038/tp.2017.171.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/tp.2017.171</ArticleId><ArticleId IdType="pmc">PMC5611738</ArticleId><ArticleId IdType="pubmed">28763057</ArticleId></ArticleIdList></Reference><Reference><Citation>Freytag V, et al. Genetic estimators of DNA methylation provide insights into the molecular basis of polygenic traits. Transl. Psychiatry. 2018;8:31. doi: 10.1038/s41398-017-0070-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41398-017-0070-x</ArticleId><ArticleId IdType="pmc">PMC5802460</ArticleId><ArticleId IdType="pubmed">29382824</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbeira AN, et al. Exploring the phenotypic consequences of tissue specific gene expression variation inferred from GWAS summary statistics. Nat. Commun. 2018;9:1825. doi: 10.1038/s41467-018-03621-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-03621-1</ArticleId><ArticleId IdType="pmc">PMC5940825</ArticleId><ArticleId IdType="pubmed">29739930</ArticleId></ArticleIdList></Reference><Reference><Citation>Chouraki V, et al. Evaluation of a genetic risk score to improve risk prediction for Alzheimer&#x2019;s disease. J. Alzheimers Dis. 2016;53:921&#x2013;932. doi: 10.3233/JAD-150749.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-150749</ArticleId><ArticleId IdType="pmc">PMC5036102</ArticleId><ArticleId IdType="pubmed">27340842</ArticleId></ArticleIdList></Reference><Reference><Citation>Steyerberg EW, et al. Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology. 2010;21:128&#x2013;138. doi: 10.1097/EDE.0b013e3181c30fb2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/EDE.0b013e3181c30fb2</ArticleId><ArticleId IdType="pmc">PMC3575184</ArticleId><ArticleId IdType="pubmed">20010215</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrell FE, Califf RM, Pryor DB, Lee KL, Rosati RA. Evaluating the yield of medical tests. JAMA. 1982;247:2543&#x2013;2546. doi: 10.1001/jama.1982.03320430047030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.1982.03320430047030</ArticleId><ArticleId IdType="pubmed">7069920</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerds TA, Kattan MW, Schumacher M, Yu C. Estimating a time-dependentconcordance index for survival prediction models with covariate dependent censoring. Stat. Med. 2013;32:2173&#x2013;2184. doi: 10.1002/sim.5681.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.5681</ArticleId><ArticleId IdType="pubmed">23172755</ArticleId></ArticleIdList></Reference><Reference><Citation>Pencina MJ, D&#x2019;Agostino RB, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat. Med. 2011;30:11&#x2013;21. doi: 10.1002/sim.4085.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.4085</ArticleId><ArticleId IdType="pmc">PMC3341973</ArticleId><ArticleId IdType="pubmed">21204120</ArticleId></ArticleIdList></Reference><Reference><Citation>Kattan MW, Gerds TA. The index of prediction accuracy: an intuitive measure useful for evaluating risk prediction models. Diagnostic Progn. Res. 2018;2:7. doi: 10.1186/s41512-018-0029-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s41512-018-0029-2</ArticleId><ArticleId IdType="pmc">PMC6460739</ArticleId><ArticleId IdType="pubmed">31093557</ArticleId></ArticleIdList></Reference><Reference><Citation>Viechtbauer W. Conducting meta-analyses in R with the metafor. J. Stat. Softw. 2010;36:1&#x2013;48. doi: 10.18637/jss.v036.i03.</Citation><ArticleIdList><ArticleId IdType="doi">10.18637/jss.v036.i03</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozenne B, S&#xf8;rensen AL, Scheike T, Torp-Pedersen C, Gerds T. riskRegression: predicting the risk of an event using Cox regression models. R. J. 2017;9:440&#x2013;460. doi: 10.32614/RJ-2017-062.</Citation><ArticleIdList><ArticleId IdType="doi">10.32614/RJ-2017-062</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35381189</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>06</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>110</Volume><Issue>11</Issue><PubDate><Year>2022</Year><Month>Jun</Month><Day>01</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Astrocytes and oligodendrocytes undergo subtype-specific transcriptional changes in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>1788</StartPage><EndPage>1805.e10</EndPage><MedlinePgn>1788-1805.e10</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2022.03.008</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0896-6273(22)00244-6</ELocationID><Abstract><AbstractText>Resolving glial contributions to Alzheimer's disease (AD) is necessary because changes in neuronal function, such as reduced synaptic density, altered electrophysiological properties, and degeneration, are not entirely cell autonomous. To improve understanding of transcriptomic heterogeneity in glia during AD, we used single-nuclei RNA sequencing (snRNA-seq) to characterize astrocytes and oligodendrocytes from apolipoprotein (APOE) &#x190;2/3 human AD and age- and genotype-matched non-symptomatic (NS) brains. We enriched astrocytes before sequencing and characterized pathology from the same location as the sequenced material. We characterized baseline heterogeneity in both astrocytes and oligodendrocytes and identified global and subtype-specific transcriptomic changes between AD and NS astrocytes and oligodendrocytes. We also took advantage of recent human and mouse spatial transcriptomics resources to localize heterogeneous astrocyte subtypes to specific regions in the healthy and inflamed brain. Finally, we integrated our data with published AD snRNA-seq datasets, highlighting the power of combining datasets to resolve previously unidentifiable astrocyte subpopulations.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sadick</LastName><ForeName>Jessica S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Neuroscience Institute, NYU Grossman School of Medicine, New York, NY 10016, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Dea</LastName><ForeName>Michael R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Neuroscience Institute, NYU Grossman School of Medicine, New York, NY 10016, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hasel</LastName><ForeName>Philip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Neuroscience Institute, NYU Grossman School of Medicine, New York, NY 10016, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dykstra</LastName><ForeName>Taitea</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Neuroscience Institute, NYU Grossman School of Medicine, New York, NY 10016, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Faustin</LastName><ForeName>Arline</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Center for Cognitive Neurology, NYU Grossman School of Medicine, New York, NY 10016, USA; Department of Pathology, NYU Langone Health, New York, NY 10016, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liddelow</LastName><ForeName>Shane A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Neuroscience Institute, NYU Grossman School of Medicine, New York, NY 10016, USA; Department of Neuroscience and Physiology, NYU Grossman School of Medicine, New York, NY 10016, USA; Department of Ophthalmology, NYU Grossman School of Medicine, New York, NY 10016, USA; Parekh Center for Interdisciplinary Neurology, NYU Grossman School of Medicine, New York, NY 10016, USA. Electronic address: shane.liddelow@nyulangone.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG008051</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066512</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG052909</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>04</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012342">RNA, Small Nuclear</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="Y">Astrocytes</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009457" MajorTopicYN="N">Neuroglia</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009836" MajorTopicYN="N">Oligodendroglia</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012342" MajorTopicYN="N">RNA, Small Nuclear</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059467" MajorTopicYN="N">Transcriptome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">astrocyte</Keyword><Keyword MajorTopicYN="N">dataset integration</Keyword><Keyword MajorTopicYN="N">glia</Keyword><Keyword MajorTopicYN="N">heterogeneity</Keyword><Keyword MajorTopicYN="N">inflammation</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">oligodendrocyte</Keyword><Keyword MajorTopicYN="N">single-nuclei sequencing</Keyword><Keyword MajorTopicYN="N">spatial transcriptomics</Keyword></KeywordList><CoiStatement>Declarations of interests S.A.L. is a founder of AstronauTx Ltd and a member of its scientific advisory board. All other authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>3</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>1</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>5</Day><Hour>20</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>6</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35381189</ArticleId><ArticleId IdType="mid">NIHMS1795138</ArticleId><ArticleId IdType="pmc">PMC9167747</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2022.03.008</ArticleId><ArticleId IdType="pii">S0896-6273(22)00244-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Amezquita RA, Lun ATL, Becht E, Carey VJ, Carpp LN, Geistlinger L, Marini F, Rue-Albrecht K, Risso D, Soneson C, et al. (2020). Orchestrating single-cell analysis with Bioconductor. Nat Methods 17, 137&#x2013;145. 10.1038/s41592-019-0654-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41592-019-0654-x</ArticleId><ArticleId IdType="pmc">PMC7358058</ArticleId><ArticleId IdType="pubmed">31792435</ArticleId></ArticleIdList></Reference><Reference><Citation>Ando K, Uemura K, Kuzuya A, Maesako M, Asada-Utsugi M, Kubota M, Aoyagi N, Yoshioka K, Okawa K, Inoue H, et al. (2011). N-cadherin regulates p38 MAPK signaling via association with JNK-associated leucine zipper protein: implications for neurodegeneration in Alzheimer disease. J Biol Chem 286, 7619&#x2013;7628. 10.1074/jbc.M110.158477.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110.158477</ArticleId><ArticleId IdType="pmc">PMC3045016</ArticleId><ArticleId IdType="pubmed">21177868</ArticleId></ArticleIdList></Reference><Reference><Citation>Argaw AT, Asp L, Zhang J, Navrazhina K, Pham T, Mariani JN, Mahase S, Dutta DJ, Seto J, Kramer EG, et al. (2012). Astrocyte-derived VEGF-A drives blood-brain barrier disruption in CNS inflammatory disease. J Clin Invest 122, 2454&#x2013;2468. 10.1172/JCI60842.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI60842</ArticleId><ArticleId IdType="pmc">PMC3386814</ArticleId><ArticleId IdType="pubmed">22653056</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer&#x2019;s Association (2021). 2021 Alzheimer&#x2019;s disease facts and figures. Alzheimers Dement 17, 327&#x2013;406. 10.1002/alz.12328.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.12328</ArticleId><ArticleId IdType="pubmed">33756057</ArticleId></ArticleIdList></Reference><Reference><Citation>Bankhead P, Loughrey MB, Fernandez JA, Dombrowski Y, McArt DG, Dunne PD, McQuaid S, Gray RT, Murray LJ, Coleman HG, et al. (2017). QuPath: Open source software for digital pathology image analysis. Sci Rep 7, 16878. 10.1038/s41598-017-17204-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-17204-5</ArticleId><ArticleId IdType="pmc">PMC5715110</ArticleId><ArticleId IdType="pubmed">29203879</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbar L, Jain T, Zimmer M, Kruglikov I, Sadick JS, Wang M, Kalpana K, Rose IVL, Burstein SR, Rusielewicz T, et al. (2020). CD49f Is a Novel Marker of Functional and Reactive Human iPSC-Derived Astrocytes. Neuron 107, 436&#x2013;453. 10.1016/j.neuron.2020.05.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2020.05.014</ArticleId><ArticleId IdType="pmc">PMC8274549</ArticleId><ArticleId IdType="pubmed">32485136</ArticleId></ArticleIdList></Reference><Reference><Citation>Bayraktar OA, Bartels T, Holmqvist S, Kleshchevnikov V, Martirosyan A, Polioudakis D, Ben Haim L, Young AMH, Batiuk MY, Prakash K, et al. (2020). Astrocyte layers in the mammalian cerebral cortex revealed by a single-cell in situ transcriptomic map. Nature Neuroscience 23, 500&#x2013;509.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7116562</ArticleId><ArticleId IdType="pubmed">32203496</ArticleId></ArticleIdList></Reference><Reference><Citation>Boisvert MM, Erikson GA, Shokhirev MN, and Allen NJ (2018). The Aging Astrocyte Transcriptome from Multiple Regions of the Mouse Brain. Cell Rep 22, 269&#x2013;285. 10.1016/j.celrep.2017.12.039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2017.12.039</ArticleId><ArticleId IdType="pmc">PMC5783200</ArticleId><ArticleId IdType="pubmed">29298427</ArticleId></ArticleIdList></Reference><Reference><Citation>Boswell-Smith V, Spina D, and Page CP (2006). Phosphodiesterase inhibitors. Br J Pharmacol 147 Suppl 1, S252&#x2013;257. 10.1038/sj.bjp.0706495.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.bjp.0706495</ArticleId><ArticleId IdType="pmc">PMC1760738</ArticleId><ArticleId IdType="pubmed">16402111</ArticleId></ArticleIdList></Reference><Reference><Citation>Boutros T, Chevet E, and Metrakos P (2008). Mitogen-activated protein (MAP) kinase/MAP kinase phosphatase regulation: roles in cell growth, death, and cancer. Pharmacol Rev 60, 261310. 10.1124/pr.107.00106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/pr.107.00106</ArticleId><ArticleId IdType="pubmed">18922965</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Y, Xu H, Zhu Y, Shi MJ, Wei L, Zhang J, Cheng S, Shi Y, Tong H, Kang L, et al. (2019). ADAMTS13 maintains cerebrovascular integrity to ameliorate Alzheimer-like pathology. PLoS Biol 17, e3000313. 10.1371/journal.pbio.3000313.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.3000313</ArticleId><ArticleId IdType="pmc">PMC6588259</ArticleId><ArticleId IdType="pubmed">31185010</ArticleId></ArticleIdList></Reference><Reference><Citation>Carter SF, Scholl M, Almkvist O, Wall A, Engler H, Langstrom B, and Nordberg A (2012). Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG. Journal of Nuclear Medicine 53, 37&#x2013;46. 10.2967/jnumed.110.087031.</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.110.087031</ArticleId><ArticleId IdType="pubmed">22213821</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang RY, Etheridge N, Dodd PR, and Nouwens AS (2014). Targeted quantitative analysis of synaptic proteins in Alzheimer&#x2019;s disease brain. Neurochem Int 75, 66&#x2013;75. 10.1016/j.neuint.2014.05.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuint.2014.05.011</ArticleId><ArticleId IdType="pubmed">24893329</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarke LE, Liddelow SA, Chakraborty C, Munch AE, Heiman M, and Barres BA (2018). Normal aging induces A1-like astrocyte reactivity. Proc Natl Acad Sci U S A 115, E1896&#x2013;E1905. 10.1073/pnas.1800165115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1800165115</ArticleId><ArticleId IdType="pmc">PMC5828643</ArticleId><ArticleId IdType="pubmed">29437957</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins LM, O&#x2019;Keeffe GW, Long-Smith CM, Wyatt SL, Sullivan AM, Toulouse A, and Nolan YM (2013). Mitogen-activated protein kinase phosphatase (MKP)-1 as a neuroprotective agent: promotion of the morphological development of midbrain dopaminergic neurons. Neuromolecular Med 15, 435&#x2013;446. 10.1007/s12017-013-8230-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12017-013-8230-5</ArticleId><ArticleId IdType="pubmed">23584919</ArticleId></ArticleIdList></Reference><Reference><Citation>Counts SE, and Mufson EJ (2017). Regulator of Cell Cycle (RGCC) Expression During the Progression of Alzheimer&#x2019;s Disease. Cell Transplant 26, 693&#x2013;702. 10.3727/096368916X694184.</Citation><ArticleIdList><ArticleId IdType="doi">10.3727/096368916X694184</ArticleId><ArticleId IdType="pmc">PMC5661221</ArticleId><ArticleId IdType="pubmed">27938491</ArticleId></ArticleIdList></Reference><Reference><Citation>Crowell HL, Soneson C, Germain P-L, Calini D, Collin L, Raposo C, Malhotra D, and Robinson MD (2019). muscat detects subpopulation-specific state transitions from multisample multi-condition single-cell transcriptomics data. Nat Commun 10, 6077. 10.1038/S41467-020-19894-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/S41467-020-19894-4</ArticleId><ArticleId IdType="pmc">PMC7705760</ArticleId><ArticleId IdType="pubmed">33257685</ArticleId></ArticleIdList></Reference><Reference><Citation>de la Torre JC (2004). Is Alzheimer&#x2019;s disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. The Lancet Neurology 3, 184&#x2013;190. 10.1016/s1474-4422(04)00683-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1474-4422(04)00683-0</ArticleId><ArticleId IdType="pubmed">14980533</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B, and Karran E (2016). The cellular phase of Alzheimer&#x2019;s disease. Cell 164, 603&#x2013;615. 10.1016/j.cell.2015.12.056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2015.12.056</ArticleId><ArticleId IdType="pubmed">26871627</ArticleId></ArticleIdList></Reference><Reference><Citation>Del-Aguila JL, Li Z, Dube U, Mihindukulasuriya KA, Budde JP, Fernandez MV, Ibanez L, Bradley J, Wang F, Bergmann K, et al. (2019). A single-nuclei RNA sequencing study of Mendelian and sporadic AD in the human brain. Alzheimers Res Ther 11, 71. 10.1186/s13195-019-0524-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-019-0524-x</ArticleId><ArticleId IdType="pmc">PMC6689177</ArticleId><ArticleId IdType="pubmed">31399126</ArticleId></ArticleIdList></Reference><Reference><Citation>Diaz-Castro B, Gangwani MR, Yu X, Coppola G, and Khakh BS (2019). Astrocyte molecular signatures in Huntington&#x2019;s disease. Science Translational Medicine 11.</Citation><ArticleIdList><ArticleId IdType="pubmed">31619545</ArticleId></ArticleIdList></Reference><Reference><Citation>Dimas P, Montani L, Pereira JA, Moreno D, Trotzmuller M, Gerber J, Semenkovich CF, Kofeler HC, and Suter U (2019). CNS myelination and remyelination depend on fatty acid synthesis by oligodendrocytes. Elife 8. 10.7554/eLife.44702.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.44702</ArticleId><ArticleId IdType="pmc">PMC6504237</ArticleId><ArticleId IdType="pubmed">31063129</ArticleId></ArticleIdList></Reference><Reference><Citation>Durinck S, Spellman PT, Birney E, and Huber W (2009). Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt. Nat Protoc 4, 1184&#x2013;1191. 10.1038/nprot.2009.97.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2009.97</ArticleId><ArticleId IdType="pmc">PMC3159387</ArticleId><ArticleId IdType="pubmed">19617889</ArticleId></ArticleIdList></Reference><Reference><Citation>Farkas E, and Luiten PGM (2001). Cerebral microvascular pathology in aging and Alzheimer&#x2019;s disease. Progress in Neurobiology 64, 575&#x2013;611.</Citation><ArticleIdList><ArticleId IdType="pubmed">11311463</ArticleId></ArticleIdList></Reference><Reference><Citation>Funfschilling U, Supplie LM, Mahad D, Boretius S, Saab AS, Edgar J, Brinkmann BG, Kassmann CM, Tzvetanova ID, Mobius W, et al. (2012). Glycolytic oligodendrocytes maintain myelin and long-term axonal integrity. Nature 485, 517&#x2013;521. 10.1038/nature11007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature11007</ArticleId><ArticleId IdType="pmc">PMC3613737</ArticleId><ArticleId IdType="pubmed">22622581</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerrits E, Brouwer N, Kooistra SM, Woodbury ME, Vermeiren Y, Lambourne M, Mulder J, Kummer M, Moller T, Biber K, et al. (2021). Distinct amyloid-beta and tau-associated microglia profiles in Alzheimer&#x2019;s disease. Acta Neuropathol. 10.1007/s00401-021-02263-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-021-02263-w</ArticleId><ArticleId IdType="pmc">PMC8043951</ArticleId><ArticleId IdType="pubmed">33609158</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginsberg SD, Che S, Counts SE, and Mufson EJ (2006). Single cell gene expression profiling Alzheimer&#x2019;s disease. NeuroRx 3, 302&#x2013;318.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3593387</ArticleId><ArticleId IdType="pubmed">16815214</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldberg TE, Huey ED, and Devanand DP (2020). Association of APOE e2 genotype with Alzheimer&#x2019;s and non-Alzheimer&#x2019;s neurodegenerative pathologies. Nat Commun 11, 4727. 10.1038/S41467-020-18198-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/S41467-020-18198-x</ArticleId><ArticleId IdType="pmc">PMC7501268</ArticleId><ArticleId IdType="pubmed">32948752</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez-Reyes RE, Nava-Mesa MO, Vargas-Sanchez K, Ariza-Salamanca D, and Mora-Munoz L (2017). Involvement of astrocytes in Alzheimer&#x2019;s disease from a neuroinflammatory and oxidative stress perspective. Frontiers in Molecular Neuroscience 10 (427). 10.3389/fnmol.2017.00427.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2017.00427</ArticleId><ArticleId IdType="pmc">PMC5742194</ArticleId><ArticleId IdType="pubmed">29311817</ArticleId></ArticleIdList></Reference><Reference><Citation>Grubman A, Chew G, Ouyang JF, Sun G, Choo XY, McLean C, Simmons RK, Buckberry S, Vargas-Landin DB, Poppe D, et al. (2019). A single-cell atlas of entorhinal cortex from individuals with Alzheimer&#x2019;s disease reveals cell-type-specific gene expression regulation. Nat Neurosci 22, 2087&#x2013;2097. 10.1038/s41593-019-0539-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-019-0539-4</ArticleId><ArticleId IdType="pubmed">31768052</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu Z, Eils R, and Schlesner M (2016). Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics 32, 2847&#x2013;2849. 10.1093/bioinformatics/btw313.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btw313</ArticleId><ArticleId IdType="pubmed">27207943</ArticleId></ArticleIdList></Reference><Reference><Citation>Guttenplan KA, Weigel MK, Adler DI, Couthouis J, Liddelow SA, Gitler AD, and Barres BA (2020). Knockout of reactive astrocyte activating factors slows disease progression in an ALS mouse model. Nat Commun 11, 3753. 10.1038/s41467-020-17514-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-17514-9</ArticleId><ArticleId IdType="pmc">PMC7385161</ArticleId><ArticleId IdType="pubmed">32719333</ArticleId></ArticleIdList></Reference><Reference><Citation>Guttenplan KA, Weigel MK, Prakash P, Wijewardhane PR, Hasel P, Rufen-Blanchette U, Munch AE, Blum JA, Fine J, Neal MC, et al. (2021). Neurotoxic reactive astrocytes induce cell death via saturated lipids. Nature. 10.1038/s41586-021-03960-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03960-y</ArticleId><ArticleId IdType="pubmed">34616039</ArticleId></ArticleIdList></Reference><Reference><Citation>Hafemeister C, and Satija R (2019). Normalization and variance stabilization of single-cell RNA-seq data using regularized negative binomial regression. Genome Biol 20, 296. 10.1186/s13059-019-1874-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-019-1874-1</ArticleId><ArticleId IdType="pmc">PMC6927181</ArticleId><ArticleId IdType="pubmed">31870423</ArticleId></ArticleIdList></Reference><Reference><Citation>Hao Y, Hao S, Andersen-Nissen E, Mauck WM 3rd, Zheng S, Butler A, Lee MJ, Wilk AJ, Darby C, Zager M, et al. (2021). Integrated analysis of multimodal single-cell data. Cell 184, 3573&#x2013;3587 e3529. 10.1016/j.cell.2021.04.048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.04.048</ArticleId><ArticleId IdType="pmc">PMC8238499</ArticleId><ArticleId IdType="pubmed">34062119</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasel P, Rose IVL, Sadick JS, Kim RD, and Liddelow SA (2021). Neuroinflammatory astrocyte subtypes in the mouse brain. Nat Neurosci 24, 1475&#x2013;1487. 10.1038/s41593-021-00905-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-021-00905-6</ArticleId><ArticleId IdType="pubmed">34413515</ArticleId></ArticleIdList></Reference><Reference><Citation>Hattori T, Shimizu S, Koyama Y, Yamada K, Kuwahara R, Kumamoto N, Matsuzaki S, Ito A, Katayama T, and Tohyama M (2010). DISC1 regulates N-cadherin and &#x3b2;1-integrin expression in neurons. Molecular Psychiatry 15, 778&#x2013;778. 10.1038/mp.2010.83.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2010.83</ArticleId><ArticleId IdType="pubmed">20479754</ArticleId></ArticleIdList></Reference><Reference><Citation>Hodge RD, Bakken TE, Miller JA, Smith KA, Barkan ER, Graybuck LT, Close JL, Long B, Johansen N, Penn O, et al. (2019). Conserved cell types with divergent features in human versus mouse cortex. Nature 573, 61&#x2013;68. 10.1038/s41586-019-1506-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-1506-7</ArticleId><ArticleId IdType="pmc">PMC6919571</ArticleId><ArticleId IdType="pubmed">31435019</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong S, Beja-Glasser VF, Nfonoyim BM, Frouin A, Li S, Ramakrishnan S, Merry KM, Shi Q, Rosenthal A, Barres BA, et al. (2016). Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science 352, 712&#x2013;716. 10.1126/science.aad8373.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aad8373</ArticleId><ArticleId IdType="pmc">PMC5094372</ArticleId><ArticleId IdType="pubmed">27033548</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Z, Zhao J, Wang W, Zhou J, and Zhang J (2020). Depletion of LncRNA NEAT1 Rescues Mitochondrial Dysfunction Through NEDD4L-Dependent PINK1 Degradation in Animal Models of Alzheimer&#x2019;s Disease. Front Cell Neurosci 14, 28. 10.3389/fncel.2020.00028.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2020.00028</ArticleId><ArticleId IdType="pmc">PMC7043103</ArticleId><ArticleId IdType="pubmed">32140098</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang HY, Wek SA, McGrath BC, Lu D, Hai T, Harding HP, Wang X, Ron D, Cavener DR, and Wek RC (2004). Activating transcription factor 3 is integral to the eukaryotic initiation factor 2 kinase stress response. Mol Cell Biol 24, 1365&#x2013;1377. 10.1128/mcb.24.3.1365-1377.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mcb.24.3.1365-1377.2004</ArticleId><ArticleId IdType="pmc">PMC321431</ArticleId><ArticleId IdType="pubmed">14729979</ArticleId></ArticleIdList></Reference><Reference><Citation>Kay M (2021). ggdist: Visualizations of Distributions and Uncertainty. DOI: 10.5281/zenodo.3879620.</Citation><ArticleIdList><ArticleId IdType="doi">10.5281/zenodo.3879620</ArticleId><ArticleId IdType="pubmed">37883271</ArticleId></ArticleIdList></Reference><Reference><Citation>Kedmi M, and Orr-Urtreger A (2007). Expression changes in mouse brains following nicotine-induced seizures: the modulation of transcription factor networks. Physiol Genomics 30, 242&#x2013;252. 10.1152/physiolgenomics.00288.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physiolgenomics.00288.2006</ArticleId><ArticleId IdType="pubmed">17456735</ArticleId></ArticleIdList></Reference><Reference><Citation>Kilinc D (2018). The Emerging Role of Mechanics in Synapse Formation and Plasticity. Front Cell Neurosci 12, 483. 10.3389/fncel.2018.00483.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2018.00483</ArticleId><ArticleId IdType="pmc">PMC6291423</ArticleId><ArticleId IdType="pubmed">30574071</ArticleId></ArticleIdList></Reference><Reference><Citation>Komarova NL, and Thalhauser CJ (2011). High degree of heterogeneity in Alzheimer&#x2019;s disease progression patterns. PLoS Comput Biol 7, e1002251. 10.1371/journal.pcbi.1002251.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pcbi.1002251</ArticleId><ArticleId IdType="pmc">PMC3207941</ArticleId><ArticleId IdType="pubmed">22072952</ArticleId></ArticleIdList></Reference><Reference><Citation>Korsunsky I, Millard N, Fan J, Slowikowski K, Zhang F, Wei K, Baglaenko Y, Brenner M, Loh PR, and Raychaudhuri S (2019). Fast, sensitive and accurate integration of single-cell data with Harmony. Nat Methods 16, 1289&#x2013;1296. 10.1038/s41592-019-0619-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41592-019-0619-0</ArticleId><ArticleId IdType="pmc">PMC6884693</ArticleId><ArticleId IdType="pubmed">31740819</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau SF, Cao H, Fu AKY, and Ip NY (2020). Single-nucleus transcriptome analysis reveals dysregulation of angiogenic endothelial cells and neuroprotective glia in Alzheimer&#x2019;s disease. Proc Natl Acad Sci U S A 117, 25800&#x2013;25809. 10.1073/pnas.2008762117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2008762117</ArticleId><ArticleId IdType="pmc">PMC7568283</ArticleId><ArticleId IdType="pubmed">32989152</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S, Viqar F, Zimmerman ME, Narkhede A, Tosto G, Benzinger TL, Marcus DS, Fagan AM, Goate A, Fox NC, et al. (2016). White matter hyperintensities are a core feature of Alzheimer&#x2019;s disease: Evidence from the dominantly inherited Alzheimer network. Ann Neurol 79, 929&#x2013;939. 10.1002/ana.24647.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24647</ArticleId><ArticleId IdType="pmc">PMC4884146</ArticleId><ArticleId IdType="pubmed">27016429</ArticleId></ArticleIdList></Reference><Reference><Citation>Leng K, Li E, Eser R, Piergies A, Sit R, Tan M, Neff N, Li SH, Rodriguez RD, Suemoto CK, et al. (2021). Molecular characterization of selectively vulnerable neurons in Alzheimer&#x2019;s disease. Nat Neurosci. 10.1038/s41593-020-00764-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-020-00764-7</ArticleId><ArticleId IdType="pmc">PMC7854528</ArticleId><ArticleId IdType="pubmed">33432193</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewandowski NM, Ju S, Verbitsky M, Ross B, Geddie ML, Rockenstein E, Adame A, Muhammad A, Vonsattel JP, Ringe D, et al. (2010). Polyamine pathway contributes to the pathogenesis of Parkinson disease. Proc Natl Acad Sci U S A 107, 16970&#x2013;16975. 10.1073/pnas.1011751107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1011751107</ArticleId><ArticleId IdType="pmc">PMC2947879</ArticleId><ArticleId IdType="pubmed">20837543</ArticleId></ArticleIdList></Reference><Reference><Citation>Lian H, Litvinchuk A, Chiang AC, Aithmitti N, Jankowsky JL, and Zheng H (2016). Astrocyte-Microglia Cross Talk through Complement Activation Modulates Amyloid Pathology in Mouse Models of Alzheimer&#x2019;s Disease. J Neurosci 36, 577&#x2013;589. 10.1523/JNeUrOSCI.2117-15.2016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNeUrOSCI.2117-15.2016</ArticleId><ArticleId IdType="pmc">PMC4710776</ArticleId><ArticleId IdType="pubmed">26758846</ArticleId></ArticleIdList></Reference><Reference><Citation>Liddelow SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L, Bennett ML, Munch AE, Chung WS, Peterson TC, et al. (2017). Neurotoxic reactive astrocytes are induced by activated microglia. Nature 541, 481&#x2013;487. 10.1038/nature21029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature21029</ArticleId><ArticleId IdType="pmc">PMC5404890</ArticleId><ArticleId IdType="pubmed">28099414</ArticleId></ArticleIdList></Reference><Reference><Citation>Lie E, Li Y, Kim R, and Kim E (2018). SALM/Lrfn Family Synaptic Adhesion Molecules. Front Mol Neurosci 11, 105. 10.3389/fnmol.2018.00105.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2018.00105</ArticleId><ArticleId IdType="pmc">PMC5895706</ArticleId><ArticleId IdType="pubmed">29674953</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorente-Gea L, Garcia B, Martin C, Quiros L, and Fernandez-Vega I (2017). Heparan sulfate proteoglycans and heparanases in Alzheimer&#x2019;s disease: current outlook and potential therapeutic targets. Neural Regeneration Research 12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5514864</ArticleId><ArticleId IdType="pubmed">28761422</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathys H, Davila-Velderrain J, Peng Z, Gao F, Mohammadi S, Young JZ, Menon M, He L, Abdurrob F, Jiang X, et al. (2019). Single-cell transcriptomic analysis of Alzheimer&#x2019;s disease. Nature. 10.1038/s41586-019-1195-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-1195-2</ArticleId><ArticleId IdType="pmc">PMC6865822</ArticleId><ArticleId IdType="pubmed">31042697</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Schott JM, Hardy J, Turner MR, and Zetterberg H (2016). Selective vulnerability in neurodegeneration: insights from clinical variants of Alzheimer&#x2019;s disease. J Neurol Neurosurg Psychiatry 87, 1000&#x2013;1004. 10.1136/jnnp-2015-311321.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2015-311321</ArticleId><ArticleId IdType="pubmed">26746185</ArticleId></ArticleIdList></Reference><Reference><Citation>Maynard KR, Collado-Torres L, Weber LM, Uytingco C, Barry BK, Williams SR, Catallini JL 2nd, Tran MN, Besich Z, Tippani M, et al. (2021). Transcriptome-scale spatial gene expression in the human dorsolateral prefrontal cortex. Nat Neurosci 24, 425&#x2013;436. 10.1038/S41593-020-00787-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/S41593-020-00787-0</ArticleId><ArticleId IdType="pmc">PMC8095368</ArticleId><ArticleId IdType="pubmed">33558695</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohamed LA, Keller JN, and Kaddoumi A (2016). Role of P-glycoprotein in mediating rivastigmine effect on amyloid-beta brain load and related pathology in Alzheimer&#x2019;s disease mouse model. Biochimica et Biophysica Acta 1862, 778&#x2013;787. 10.1016/j.bbadis.2016.01.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2016.01.013</ArticleId><ArticleId IdType="pmc">PMC4788561</ArticleId><ArticleId IdType="pubmed">26780497</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray ME, Graff-Radford NR, Ross OA, Petersen RC, Duara R, and Dickson DW (2011). Neuropathologically defined subtypes of Alzheimer&#x2019;s disease with distinct clinical characteristics: a retrospective study. The Lancet Neurology 10, 785&#x2013;796. 10.1016/s1474-4422(11)70156-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1474-4422(11)70156-9</ArticleId><ArticleId IdType="pmc">PMC3175379</ArticleId><ArticleId IdType="pubmed">21802369</ArticleId></ArticleIdList></Reference><Reference><Citation>Nedergaard M, Ransom B, and Goldman SA (2003). New roles for astrocytes: redefining the functional architecture of the brain. Trends Neurosci 26, 523&#x2013;530. 10.1016/j.tins.2003.08.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2003.08.008</ArticleId><ArticleId IdType="pubmed">14522144</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Pious NM, Jicha GA, Wilcock DM, Fardo DW, Estus S, and Rebeck GW (2013). APOE-e2 and APOE-e4 Correlate With Increased Amyloid Accumulation in Cerebral Vasculature. J Neuropathol Exp Neurol 72, 708&#x2013;715.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3715146</ArticleId><ArticleId IdType="pubmed">23771217</ArticleId></ArticleIdList></Reference><Reference><Citation>Nott A, Holtman IR, Coufal NG, Schlachetzki JCM, Yu M, Hu R, Han CZ, Pena M, Xiao J, Wu Y, et al. (2019). Brain cell type-specific enhancer-promoter interactome maps and disease-risk association. Science 366, 1134&#x2013;1139.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7028213</ArticleId><ArticleId IdType="pubmed">31727856</ArticleId></ArticleIdList></Reference><Reference><Citation>Nunes-Xavier CE, Zaldumbide L, Aurtenetxe O, Lopez-Almaraz R, Lopez JI, and Pulido R (2019). Dual-Specificity Phosphatases in Neuroblastoma Cell Growth and Differentiation. Int J Mol Sci 20. 10.3390/ijms20051170.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20051170</ArticleId><ArticleId IdType="pmc">PMC6429076</ArticleId><ArticleId IdType="pubmed">30866462</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Callaghan P, Sandwall E, Li JP, Yu H, Ravid R, Guan ZZ, van Kuppevelt TH, Nilsson LN, Ingelsson M, Hyman BT, et al. (2008). Heparan sulfate accumulation with Abeta deposits in Alzheimer&#x2019;s disease and Tg2576 mice is contributed by glial cells. Brain Pathol 18, 548&#x2013;561. 10.1111/j.1750-3639.2008.00152.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1750-3639.2008.00152.x</ArticleId><ArticleId IdType="pmc">PMC2856073</ArticleId><ArticleId IdType="pubmed">18422760</ArticleId></ArticleIdList></Reference><Reference><Citation>Owen JB, Di Domenico F, Sultana R, Perluigi M, Cini C, Pierce WM, and Butterfield DA (2009). Proteomics-determined differences in the concanavalin-A-fractionated proteome of hippocampus and inferior parietal lobule in subjects with Alzheimer&#x2019;s disease and mild cognitive impairment: implications for progression of AD. Journal of Proteome Research 8, 471&#x2013;482. 10.1021/pr800667a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/pr800667a</ArticleId><ArticleId IdType="pmc">PMC2658606</ArticleId><ArticleId IdType="pubmed">19072283</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardo B, Spangler A, Weber LM, Hicks SC, Jaffe AE, Martinowich K, Maynard KR, and Collado-Torres L (2021). spatialLIBD: an R/Bioconductor package to visualize spatially-resolved transcriptomics data. bioRxiv, 2021.2004.2029.440149. 10.1101/2021.04.29.440149.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.04.29.440149</ArticleId><ArticleId IdType="pmc">PMC9188087</ArticleId><ArticleId IdType="pubmed">35689177</ArticleId></ArticleIdList></Reference><Reference><Citation>Paton CM, and Ntambi JM (2009). Biochemical and physiological function of stearoyl-CoA desaturase. Am J Physiol Endocrinol Metab 297, E28&#x2013;37. 10.1152/ajpendo.90897.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpendo.90897.2008</ArticleId><ArticleId IdType="pmc">PMC2711665</ArticleId><ArticleId IdType="pubmed">19066317</ArticleId></ArticleIdList></Reference><Reference><Citation>Prickaerts J, Heckman PRA, and Blokland A (2017). Investigational phosphodiesterase inhibitors in phase I and phase II clinical trials for Alzheimer&#x2019;s disease. Expert Opin Investig Drugs 26, 1033&#x2013;1048. 10.1080/13543784.2017.1364360.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13543784.2017.1364360</ArticleId><ArticleId IdType="pubmed">28772081</ArticleId></ArticleIdList></Reference><Reference><Citation>Radanovic M, Ramos F, Pereira S, Stella F, Aprahamian I, Ferreira LK, Forlenza OV, and Busatto GF (2013). White matter abnormalities associated with Alzheimer&#x2019;s disease and mild cognitive impairment: a critical review of MRI studies. Expert Review in Neurotherapeutics 13, 483&#x2013;493.</Citation><ArticleIdList><ArticleId IdType="pubmed">23621306</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramsay L, Quille ML, Orset C, de la Grange P, Rousselet E, Ferec C, Le Gac G, Genin E, and Timsit S (2019). Blood transcriptomic biomarker as a surrogate of ischemic brain gene expression. Ann Clin Transl Neurol 6, 1681&#x2013;1695. 10.1002/acn3.50861.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.50861</ArticleId><ArticleId IdType="pmc">PMC6764628</ArticleId><ArticleId IdType="pubmed">31400065</ArticleId></ArticleIdList></Reference><Reference><Citation>Refolo LM, Malester B, LaFrancois J, Bryant-Thomas T, Wang R, Tint GS, Sambamurti K, Duff K, and Pappolla MA (2000). Hypercholesterolemia accelerates the Alzheimer&#x2019;s amyloid pathology in a transgenic mouse model. Neurobiol Dis 7, 321&#x2013;331. 10.1006/nbdi.2000.0304.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/nbdi.2000.0304</ArticleId><ArticleId IdType="pubmed">10964604</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Arboleda-Velasquez JF, Quiroz YT, Huentelman MJ, Beach TG, Caselli RJ, Chen Y, Su Y, Myers AJ, Hardy J, et al. (2020). Exceptionally low likelihood of Alzheimer&#x2019;s dementia in APOE2 homozygotes from a 5,000-person neuropathological study. Nat Commun 11, 667. 10.1038/s41467-019-14279-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-14279-8</ArticleId><ArticleId IdType="pmc">PMC6997393</ArticleId><ArticleId IdType="pubmed">32015339</ArticleId></ArticleIdList></Reference><Reference><Citation>Risso D, Perraudeau F, Gribkova S, Dudoit S, and Vert JP (2018). A general and flexible method for signal extraction from single-cell RNA-seq data. Nat Commun 9, 284. 10.1038/S41467-017-02554-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/S41467-017-02554-5</ArticleId><ArticleId IdType="pmc">PMC5773593</ArticleId><ArticleId IdType="pubmed">29348443</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson MD, McCarthy DJ, and Smyth GK (2010). edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139&#x2013;140. 10.1093/bioinformatics/btp616.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btp616</ArticleId><ArticleId IdType="pmc">PMC2796818</ArticleId><ArticleId IdType="pubmed">19910308</ArticleId></ArticleIdList></Reference><Reference><Citation>Saab AS, Tzvetavona ID, Trevisiol A, Baltan S, Dibaj P, Kusch K, Mobius W, Goetze B, Jahn HM, Huang W, et al. (2016). Oligodendroglial NMDA Receptors Regulate Glucose Import and Axonal Energy Metabolism. Neuron 91, 119&#x2013;132. 10.1016/j.neuron.2016.05.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.05.016</ArticleId><ArticleId IdType="pmc">PMC9084537</ArticleId><ArticleId IdType="pubmed">27292539</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadick JS, and Liddelow SA (2019). Don&#x2019;t forget astrocytes when targeting Alzheimer&#x2019;s disease. British Journal of Pharmacology. 10.1111/bph.14568.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.14568</ArticleId><ArticleId IdType="pmc">PMC6715613</ArticleId><ArticleId IdType="pubmed">30636042</ArticleId></ArticleIdList></Reference><Reference><Citation>Saher G, Brugger B, Lappe-Siefke C, Mobius W, Tozawa R, Wehr MC, Wieland F, Ishibashi S, and Nave KA (2005). High cholesterol level is essential for myelin membrane growth. Nat Neurosci 8, 468&#x2013;475. 10.1038/nn1426.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn1426</ArticleId><ArticleId IdType="pubmed">15793579</ArticleId></ArticleIdList></Reference><Reference><Citation>Saher G, Quintes S, and Nave KA (2011). Cholesterol: a novel regulatory role in myelin formation. Neuroscientist 17, 79&#x2013;93. 10.1177/1073858410373835.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1073858410373835</ArticleId><ArticleId IdType="pubmed">21343408</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B, et al. (2012). Fiji: an open-source platform for biological-image analysis. Nat Methods 9, 676&#x2013;682. 10.1038/nmeth.2019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.2019</ArticleId><ArticleId IdType="pmc">PMC3855844</ArticleId><ArticleId IdType="pubmed">22743772</ArticleId></ArticleIdList></Reference><Reference><Citation>Schipper HM, Bennett DA, Liberman A, Bienias JL, Schneider JA, Kelly J, and Arvanitakis Z (2006). Glial heme oxygenase-1 expression in Alzheimer disease and mild cognitive impairment. Neurobiology of Aging 27, 252&#x2013;261. 10.1016/j.neurobiolaging.2005.01.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2005.01.016</ArticleId><ArticleId IdType="pubmed">16399210</ArticleId></ArticleIdList></Reference><Reference><Citation>Schnadelbach O, Ozen I, Blaschuk OW, Meyer RL, and Fawcett JW (2001). N-cadherin is involved in axon-oligodendrocyte contact and myelination. Mol Cell Neurosci 17, 1084&#x2013;1093. 10.1006/mcne.2001.0961.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/mcne.2001.0961</ArticleId><ArticleId IdType="pubmed">11414796</ArticleId></ArticleIdList></Reference><Reference><Citation>Shepardson NE, Shankar GM, and Selkoe DJ (2011). Cholesterol level and statin use in Alzheimer disease: I. Review of epidemiological and preclinical studies. Arch Neurol 68, 1239&#x2013;1244. 10.1001/archneurol.2011.203.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2011.203</ArticleId><ArticleId IdType="pmc">PMC3211071</ArticleId><ArticleId IdType="pubmed">21987540</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, Yamada K, Liddelow SA, Smith ST, Zhao L, Luo W, Tsai RM, Spina S, Grinberg LT, Rojas JC, et al. (2017). ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature 549, 523&#x2013;527. 10.1038/nature24016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature24016</ArticleId><ArticleId IdType="pmc">PMC5641217</ArticleId><ArticleId IdType="pubmed">28959956</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith HL, Freeman OJ, Butcher AJ, Holmqvist S, Humoud I, Schatzl T, Hughes DT, Verity NC, Swinden DP, Hayes J, et al. (2020). Astrocyte Unfolded Protein Response Induces a Specific Reactivity State that Causes Non-Cell-Autonomous Neuronal Degeneration. Neuron 105, 855&#x2013;866 e855. 10.1016/j.neuron.2019.12.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2019.12.014</ArticleId><ArticleId IdType="pmc">PMC7054837</ArticleId><ArticleId IdType="pubmed">31924446</ArticleId></ArticleIdList></Reference><Reference><Citation>Stogsdill JA, Ramirez J, Liu D, Kim YH, Baldwin KT, Enustun E, Ejikeme T, Ji RR, and Eroglu C (2017). Astrocytic neuroligins control astrocyte morphogenesis and synaptogenesis. Nature 551, 192&#x2013;197. 10.1038/nature24638.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature24638</ArticleId><ArticleId IdType="pmc">PMC5796651</ArticleId><ArticleId IdType="pubmed">29120426</ArticleId></ArticleIdList></Reference><Reference><Citation>Stuart T, Butler A, Hoffman P, Hafemeister C, Papalexi E, Mauck WM 3rd, Hao Y, Stoeckius M, Smibert P, and Satija R (2019). Comprehensive Integration of Single-Cell Data. Cell 177, 1888&#x2013;1902 e1821. 10.1016/j.cell.2019.05.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2019.05.031</ArticleId><ArticleId IdType="pmc">PMC6687398</ArticleId><ArticleId IdType="pubmed">31178118</ArticleId></ArticleIdList></Reference><Reference><Citation>Syed YA, Baer A, Hofer MP, Gonzalez GA, Rundle J, Myrta S, Huang JK, Zhao C, Rossner MJ, Trotter MW, et al. (2013). Inhibition of phosphodiesterase-4 promotes oligodendrocyte precursor cell differentiation and enhances CNS remyelination. EMBO Mol Med 5, 1918&#x2013;1934. 10.1002/emmm.201303123.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/emmm.201303123</ArticleId><ArticleId IdType="pmc">PMC3914530</ArticleId><ArticleId IdType="pubmed">24293318</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor DM, Moser R, Regulier E, Breuillaud L, Dixon M, Beesen AA, Elliston L, Silva Santos Mde F, Kim J, Jones L, et al. (2013). MAP kinase phosphatase 1 (MKP-1/DUSP1) is neuroprotective in Huntington&#x2019;s disease via additive effects of JNK and p38 inhibition. J Neurosci 33, 2313&#x2013;2325. 10.1523/JNEUROSCI.4965-11.2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4965-11.2013</ArticleId><ArticleId IdType="pmc">PMC3711389</ArticleId><ArticleId IdType="pubmed">23392662</ArticleId></ArticleIdList></Reference><Reference><Citation>Teaktong T, Graham A, Court J, Perry R, Jaros E, Johnson M, Hall R, and Perry E (2003). Alzheimer&#x2019;s disease is associated with a selective increase in alpha7 nicotinic acetylcholine receptor immunoreactivity in astrocytes. Glia 41, 207&#x2013;211. 10.1002/glia.10132.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.10132</ArticleId><ArticleId IdType="pubmed">12509811</ArticleId></ArticleIdList></Reference><Reference><Citation>Tirosh I, Izar B, Prakadan SM, Wadsworth MH 2nd, Treacy D, Trombetta JJ, Rotem A, Rodman C, Lian C, Murphy G, et al. (2016). Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science 352, 189&#x2013;196. 10.1126/science.aad0501.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aad0501</ArticleId><ArticleId IdType="pmc">PMC4944528</ArticleId><ArticleId IdType="pubmed">27124452</ArticleId></ArticleIdList></Reference><Reference><Citation>Vidal R, Frangione B, Rostagno A, Mead S, Revesz T, Plant G, and Ghiso J (1999). A stop-codon mutation in the BRI gene associated with familial British dementia. Nature 399, 776&#x2013;781.</Citation><ArticleIdList><ArticleId IdType="pubmed">10391242</ArticleId></ArticleIdList></Reference><Reference><Citation>Viswanathan A, and Greenberg SM (2011). Cerebral amyloid angiopathy in the elderly. Annals of Neurology 70, 871&#x2013;880. 10.1002/ana.22516.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.22516</ArticleId><ArticleId IdType="pmc">PMC4004372</ArticleId><ArticleId IdType="pubmed">22190361</ArticleId></ArticleIdList></Reference><Reference><Citation>von Bartheld CS, Bahney J, and Herculano-Houzel S (2016). The search for true numbers of neurons and glial cells in the human brain: A review of 150 years of cell counting. J Comp Neurol 524, 3865&#x2013;3895. 10.1002/cne.24040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cne.24040</ArticleId><ArticleId IdType="pmc">PMC5063692</ArticleId><ArticleId IdType="pubmed">27187682</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu T, Dejanovic B, Gandham VD, Gogineni A, Edmonds R, Schauer S, Srinivasan K, Huntley MA, Wang Y, Wang TM, et al. (2019). Complement C3 Is Activated in Human AD Brain and Is Required for Neurodegeneration in Mouse Models of Amyloidosis and Tauopathy. Cell Rep 28, 2111&#x2013;2123 e2116. 10.1016/j.celrep.2019.07.060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2019.07.060</ArticleId><ArticleId IdType="pubmed">31433986</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y, Li Z, Huang YY, Wu D, and Luo HB (2018). Novel Phosphodiesterase Inhibitors for Cognitive Improvement in Alzheimer&#x2019;s Disease. J Med Chem 61, 5467&#x2013;5483. 10.1021/acs.jmedchem.7b01370.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.7b01370</ArticleId><ArticleId IdType="pubmed">29363967</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Z, Zhao L, Chen X, Cheng X, and Zhang Y (2015). Galantamine attenuates amyloid-beta deposition and astrocyte activation in APP/PS1 transgenic mice. Experimental Gerontology 72, 244&#x2013;250. 10.1016/j.exger.2015.10.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.exger.2015.10.015</ArticleId><ArticleId IdType="pubmed">26521029</ArticleId></ArticleIdList></Reference><Reference><Citation>Yip CM, Elton EA, Darabie AA, Morrison MR, and McLaurin J (2001). Cholesterol, a modulator of membrane-associated Abeta-fibrillogenesis and neurotoxicity. J Mol Biol 311, 723&#x2013;734. 10.1006/jmbi.2001.4881.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/jmbi.2001.4881</ArticleId><ArticleId IdType="pubmed">11518526</ArticleId></ArticleIdList></Reference><Reference><Citation>Yue C, and Jing N (2015). The promise of stem cells in the therapy of Alzheimer&#x2019;s disease. Transl Neurogegener 4, 8. 10.1186/s40035-015-0029-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40035-015-0029-x</ArticleId><ArticleId IdType="pmc">PMC4423588</ArticleId><ArticleId IdType="pubmed">25954503</ArticleId></ArticleIdList></Reference><Reference><Citation>Zamanian JL, Xu L, Foo LC, Nouri N, Zhou L, Giffard RG, and Barres BA (2012). Genomic analysis of reactive astrogliosis. J Neurosci 32, 6391&#x2013;6410. 10.1523/JNEUROSCI.6221-11.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.6221-11.2012</ArticleId><ArticleId IdType="pmc">PMC3480225</ArticleId><ArticleId IdType="pubmed">22553043</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Sloan SA, Clarke LE, Caneda C, Plaza CA, Blumenthal PD, Vogel H, Steinberg GK, Edwards MS, Li G, et al. (2016). Purification and Characterization of Progenitor and Mature Human Astrocytes Reveals Transcriptional and Functional Differences with Mouse. Neuron 89, 37&#x2013;53. 10.1016/j.neuron.2015.11.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2015.11.013</ArticleId><ArticleId IdType="pmc">PMC4707064</ArticleId><ArticleId IdType="pubmed">26687838</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang ZG, Zhang L, Jiang Q, Zhang R, Davies K, Powers C, van Bruggen N, and Chopp M (2000). VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain. Journal of Clinical Investigation 106, 829&#x2013;838.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC517814</ArticleId><ArticleId IdType="pubmed">11018070</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong L, Xie YZ, Cao TT, Wang Z, Wang T, Li X, Shen RC, Xu H, Bu G, and Chen XF (2016). A rapid and cost-effective method for genotyping apolipoprotein E gene polymorphism. Mol Neurodegener 11, 2. 10.1186/s13024-016-0069-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-016-0069-4</ArticleId><ArticleId IdType="pmc">PMC4710020</ArticleId><ArticleId IdType="pubmed">26754117</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Song WM, Andhey PS, Swain A, Levy T, Miller KR, Poliani PL, Cominelli M, Grover S, Gilfillan S, et al. (2020). Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer&#x2019;s disease. Nat Med 26, 131&#x2013;142. 10.1038/s41591-019-0695-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-019-0695-9</ArticleId><ArticleId IdType="pmc">PMC6980793</ArticleId><ArticleId IdType="pubmed">31932797</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35379994</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>08</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>4</Issue><PubDate><Year>2022</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Exome sequencing of individuals with Huntington's disease implicates FAN1 nuclease activity in slowing CAG expansion and disease onset.</ArticleTitle><Pagination><StartPage>446</StartPage><EndPage>457</EndPage><MedlinePgn>446-457</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41593-022-01033-5</ELocationID><Abstract><AbstractText>The age at onset of motor symptoms in Huntington's disease (HD) is driven by HTT CAG repeat length but modified by other genes. In this study, we used exome sequencing of 683 patients with HD with extremes of onset or phenotype relative to CAG length to identify rare variants associated with clinical effect. We discovered damaging coding variants in candidate modifier genes identified in previous genome-wide association studies associated with altered HD onset or severity. Variants in FAN1 clustered in its DNA-binding and nuclease domains and were associated predominantly with earlier-onset HD. Nuclease activities of purified variants in vitro correlated with residual age at motor onset of HD. Mutating endogenous FAN1 to a nuclease-inactive form in an induced pluripotent stem cell model of HD led to rates of CAG expansion similar to those observed with complete FAN1 knockout. Together, these data implicate FAN1 nuclease activity in slowing somatic repeat expansion and hence onset of HD.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>McAllister</LastName><ForeName>Branduff</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0001-6308-2136</Identifier><AffiliationInfo><Affiliation>Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Donaldson</LastName><ForeName>Jasmine</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-6699-0674</Identifier><AffiliationInfo><Affiliation>Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Binda</LastName><ForeName>Caroline S</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Powell</LastName><ForeName>Sophie</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-6507-6079</Identifier><AffiliationInfo><Affiliation>Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chughtai</LastName><ForeName>Uroosa</ForeName><Initials>U</Initials><Identifier Source="ORCID">0000-0001-8110-7114</Identifier><AffiliationInfo><Affiliation>Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Edwards</LastName><ForeName>Gareth</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stone</LastName><ForeName>Joseph</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-0767-385X</Identifier><AffiliationInfo><Affiliation>Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lobanov</LastName><ForeName>Sergey</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-3126-1903</Identifier><AffiliationInfo><Affiliation>Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elliston</LastName><ForeName>Linda</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuhmacher</LastName><ForeName>Laura-Nadine</ForeName><Initials>LN</Initials><AffiliationInfo><Affiliation>Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rees</LastName><ForeName>Elliott</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Menzies</LastName><ForeName>Georgina</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-6600-6507</Identifier><AffiliationInfo><Affiliation>School of Biosciences, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ciosi</LastName><ForeName>Marc</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-7663-4080</Identifier><AffiliationInfo><Affiliation>Institute of Molecular, Cell and Systems Biology, University of Glasgow, Glasgow, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maxwell</LastName><ForeName>Alastair</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Molecular, Cell and Systems Biology, University of Glasgow, Glasgow, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chao</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Molecular Neurogenetics Unit, Center for Genomic Medicine, Massachusetts General Hospital and Department of Neurology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hong</LastName><ForeName>Eun Pyo</ForeName><Initials>EP</Initials><Identifier Source="ORCID">0000-0001-7789-686X</Identifier><AffiliationInfo><Affiliation>Molecular Neurogenetics Unit, Center for Genomic Medicine, Massachusetts General Hospital and Department of Neurology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lucente</LastName><ForeName>Diane</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Molecular Neurogenetics Unit, Center for Genomic Medicine, Massachusetts General Hospital and Department of Neurology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wheeler</LastName><ForeName>Vanessa</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Molecular Neurogenetics Unit, Center for Genomic Medicine, Massachusetts General Hospital and Department of Neurology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Jong-Min</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0001-5799-0787</Identifier><AffiliationInfo><Affiliation>Molecular Neurogenetics Unit, Center for Genomic Medicine, Massachusetts General Hospital and Department of Neurology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical and Population Genetics Program, Broad Institute, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>MacDonald</LastName><ForeName>Marcy E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Molecular Neurogenetics Unit, Center for Genomic Medicine, Massachusetts General Hospital and Department of Neurology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical and Population Genetics Program, Broad Institute, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Long</LastName><ForeName>Jeffrey D</ForeName><Initials>JD</Initials><Identifier Source="ORCID">0000-0001-7181-9652</Identifier><AffiliationInfo><Affiliation>Departments of Psychiatry and Biostatistics, University of Iowa, Iowa City, IA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aylward</LastName><ForeName>Elizabeth H</ForeName><Initials>EH</Initials><AffiliationInfo><Affiliation>Seattle Children's Research Institute, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Landwehrmeyer</LastName><ForeName>G Bernhard</ForeName><Initials>GB</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosser</LastName><ForeName>Anne E</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>Brain Repair Group, Schools of Medicine and Biosciences, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience and Mental Health Research Institute, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>REGISTRY Investigators of the European Huntington&#x2019;s disease network</CollectiveName></Author><Author ValidYN="Y"><LastName>Paulsen</LastName><ForeName>Jane S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>University of Wisconsin, Madison, WI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>PREDICT-HD Investigators of the Huntington Study Group</CollectiveName></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Nigel M</ForeName><Initials>NM</Initials><AffiliationInfo><Affiliation>Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gusella</LastName><ForeName>James F</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Molecular Neurogenetics Unit, Center for Genomic Medicine, Massachusetts General Hospital and Department of Neurology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical and Population Genetics Program, Broad Institute, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Monckton</LastName><ForeName>Darren G</ForeName><Initials>DG</Initials><Identifier Source="ORCID">0000-0002-8298-8264</Identifier><AffiliationInfo><Affiliation>Institute of Molecular, Cell and Systems Biology, University of Glasgow, Glasgow, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Allen</LastName><ForeName>Nicholas D</ForeName><Initials>ND</Initials><Identifier Source="ORCID">0000-0003-4009-186X</Identifier><AffiliationInfo><Affiliation>School of Biosciences, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holmans</LastName><ForeName>Peter</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-0870-9412</Identifier><AffiliationInfo><Affiliation>Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Lesley</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-3007-4612</Identifier><AffiliationInfo><Affiliation>Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK. jonesl1@cardiff.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute at Cardiff, Cardiff University, Cardiff, UK. jonesl1@cardiff.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Massey</LastName><ForeName>Thomas H</ForeName><Initials>TH</Initials><Identifier Source="ORCID">0000-0002-9804-2131</Identifier><AffiliationInfo><Affiliation>Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK. masseyt1@cardiff.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MR/P001629/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>U01 NS082079</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>109088/Z/15A</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 NS040068</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS091161</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS049206</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS105709</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_EX_MR/N50192X/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/L010305/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>04</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000071058">Huntingtin Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064251">Multifunctional Enzymes</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.-</RegistryNumber><NameOfSubstance UI="D004706">Endodeoxyribonucleases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.-</RegistryNumber><NameOfSubstance UI="D005090">Exodeoxyribonucleases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.-</RegistryNumber><NameOfSubstance UI="C551063">FAN1 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004706" MajorTopicYN="Y">Endodeoxyribonucleases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005090" MajorTopicYN="Y">Exodeoxyribonucleases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059472" MajorTopicYN="N">Exome</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071058" MajorTopicYN="N">Huntingtin Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006816" MajorTopicYN="Y">Huntington Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064251" MajorTopicYN="N">Multifunctional Enzymes</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019680" MajorTopicYN="Y">Trinucleotide Repeat Expansion</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073359" MajorTopicYN="N">Exome Sequencing</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>V.C.W. is a scientific advisory board member of Triplet Therapeutics, a company developing new therapeutic approaches to address triplet repeat disorders such Huntington&#x2019;s disease and myotonic dystrophy. V.C.W.&#x2019;s financial interests in Triplet Therapeutics were reviewed and are managed by Massachusetts General Hospital and Mass General Brigham in accordance with their conflict of interest policies. V.C.W. is also a scientific advisory board member of LoQus23 Therapeutics and has provided paid consulting services to Alnylam. J.-M.L. is on the scientific advisory board of GenEdit. J.D.L. is a paid advisory board member for F. Hoffmann-La Roche and uniQure biopharma and is a paid consultant for Vaccinex, Wave Life Sciences, Genentech, Triplet Therapeutics and PTC Therapeutics. E.H.A. serves on a Data Safety Monitoring Board for Roche. G.B.L. has provided consulting services, advisory board functions, clinical trial services and/or lectures for Allergan, Alnylam, Amarin, AOP Orphan Pharmaceuticals, Bayer Pharma, the CHDI Foundation, GlaxoSmithKline, F. Hoffmann-La Roche, Ipsen, Isis Pharma, Lundbeck, Neurosearch, Medesis, Medivation, Medtronic, NeuraMetrix, Novartis, Pfizer, Prana Biotechnology, Sangamo/Shire, Siena Biotech, Temmler Pharma and Teva Pharmaceuticals. G.B.L. has also received research grant support from the CHDI Foundation, the Bundesministerium f&#xfc;r Bildung und Forschung, the Deutsche Forschungsgemeinschaft and the European Commission (EU-FP7, JPND). His study site in Ulm has received compensation in the context of the observational Enroll-HD Study from Teva, Isis, F. Hoffmann-Roche and the Gossweiler Foundation. He receives royalties from Oxford University Press and is employed by the State of Baden-W&#xfc;rttemberg at the University of Ulm. A.E.R. is chair of the European Huntington&#x2019;s Disease Network executive committee and is the global PI for Triplet Therapeutics. J.S.P. has provided consulting services, advisory board functions and clinical trial services for Acadia, F. Hoffman-La Roche, Wave Life Sciences and the CHDI Foundation. J.F.G. is a scientific advisory board member and has a financial interest in Triplet Therapeutics. His National Institutes of Health-funded project is using genetic and genomic approaches to uncover other genes that significantly influence when diagnosable symptoms emerge and how rapidly they worsen in Huntington&#x2019;s disease. The company is developing new therapeutic approaches to address triplet repeat disorders, such Huntington&#x2019;s disease, myotonic dystrophy and spinocerebellar ataxias. His interests were reviewed and are managed by Massachusetts General Hospital and Mass General Brigham in accordance with their conflict of interest policies. J.F.G. has also been a consultant for Wave Life Sciences. Within the last 5 years, D.G.M. has been a scientific consultant and/or received honoraria/stock options/research contracts from AMO Pharma, Charles River Laboratories, LoQus23, Small Molecule RNA, Triplet Therapeutics and Vertex Pharmaceuticals. L.J. is a member of the scientific advisory boards of LoQus23 Therapeutics and Triplet Therapeutics. T.H.M. is an associate member of the scientific advisory board of LoQus23 Therapeutics. B.M., J.D., C.S.B., S.P., U.C., G.E., J.S., S.L., L.E., L.-N.S., E.R., G.M., M.C., A.M., M.J.C., E.P.H., D.L., M.E.M., N.M.W., N.D.A. and P.H. have nothing to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>5</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>2</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>5</Day><Hour>5</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>4</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35379994</ArticleId><ArticleId IdType="pmc">PMC8986535</ArticleId><ArticleId IdType="doi">10.1038/s41593-022-01033-5</ArticleId><ArticleId IdType="pii">10.1038/s41593-022-01033-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>McAllister B, et al. Timing and impact of psychiatric, cognitive, and motor abnormalities in Huntington disease. Neurology. 2021;96:e2395&#x2013;e2406.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8166441</ArticleId><ArticleId IdType="pubmed">33766994</ArticleId></ArticleIdList></Reference><Reference><Citation>Bates GP, et al. Huntington disease. Nat. Rev. Dis. Prim. 2015;1:15005.</Citation><ArticleIdList><ArticleId IdType="pubmed">27188817</ArticleId></ArticleIdList></Reference><Reference><Citation>A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington&#x2019;s disease chromosomes. The Huntington&#x2019;s Disease Collaborative Research Group. Cell72, 971&#x2013;983 (1993).</Citation><ArticleIdList><ArticleId IdType="pubmed">8458085</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrew SE, et al. The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington&#x2019;s disease. Nat. Genet. 1993;4:398&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="pubmed">8401589</ArticleId></ArticleIdList></Reference><Reference><Citation>Duyao M, et al. Trinucleotide repeat length instability and age of onset in Huntington&#x2019;s disease. Nat. Genet. 1993;4:387&#x2013;392.</Citation><ArticleIdList><ArticleId IdType="pubmed">8401587</ArticleId></ArticleIdList></Reference><Reference><Citation>Snell RG, et al. Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington&#x2019;s disease. Nat. Genet. 1993;4:393&#x2013;397.</Citation><ArticleIdList><ArticleId IdType="pubmed">8401588</ArticleId></ArticleIdList></Reference><Reference><Citation>Wexler NS, et al. Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington&#x2019;s disease age of onset. Proc. Natl Acad. Sci. USA. 2004;101:3498&#x2013;3503.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC373491</ArticleId><ArticleId IdType="pubmed">14993615</ArticleId></ArticleIdList></Reference><Reference><Citation>GeM-HD Consortium. CAG repeat not polyglutamine length determines timing of Huntington&#x2019;s disease onset. Cell. 2019;178:887&#x2013;900.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6700281</ArticleId><ArticleId IdType="pubmed">31398342</ArticleId></ArticleIdList></Reference><Reference><Citation>Moss DJH, et al. Identification of genetic variants associated with Huntington&#x2019;s disease progression: a genome-wide association study. Lancet Neurol. 2017;16:701&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pubmed">28642124</ArticleId></ArticleIdList></Reference><Reference><Citation>GeM-HD Consortium. Identification of genetic factors that modify clinical onset of Huntington&#x2019;s disease. Cell. 2015;162:516&#x2013;526.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4524551</ArticleId><ArticleId IdType="pubmed">26232222</ArticleId></ArticleIdList></Reference><Reference><Citation>MacKay C, et al. Identification of KIAA1018/FAN1, a DNA repair nuclease recruited to DNA damage by monoubiquitinated FANCD2. Cell. 2010;142:65&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3710700</ArticleId><ArticleId IdType="pubmed">20603015</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciosi M, et al. A genetic association study of glutamine-encoding DNA sequence structures, somatic CAG expansion, and DNA repair gene variants, with Huntington disease clinical outcomes. EBioMedicine. 2019;48:568&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6838430</ArticleId><ArticleId IdType="pubmed">31607598</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright GEB, et al. Length of uninterrupted CAG, independent of polyglutamine size, results in increased somatic instability, hastening onset of Huntington disease. Am. J. Hum. Genet. 2019;104:1116&#x2013;1126.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6556907</ArticleId><ArticleId IdType="pubmed">31104771</ArticleId></ArticleIdList></Reference><Reference><Citation>Shelbourne PF, et al. Triplet repeat mutation length gains correlate with cell-type specific vulnerability in Huntington disease brain. Hum. Mol. Genet. 2007;16:1133&#x2013;1142.</Citation><ArticleIdList><ArticleId IdType="pubmed">17409200</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonitel R, et al. DNA instability in postmitotic neurons. Proc. Natl Acad. Sci. USA. 2008;105:3467&#x2013;3472.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2265187</ArticleId><ArticleId IdType="pubmed">18299573</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovalenko M, et al. Msh2 acts in medium-spiny striatal neurons as an enhancer of CAG instability and mutant huntingtin phenotypes in Huntington&#x2019;s disease knock-in mice. PLoS ONE. 2012;7:e44273.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3436885</ArticleId><ArticleId IdType="pubmed">22970194</ArticleId></ArticleIdList></Reference><Reference><Citation>Swami M, et al. Somatic expansion of the Huntington&#x2019;s disease CAG repeat in the brain is associated with an earlier age of disease onset. Hum. Mol. Genet. 2009;18:3039&#x2013;3047.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2714728</ArticleId><ArticleId IdType="pubmed">19465745</ArticleId></ArticleIdList></Reference><Reference><Citation>Dragileva E, et al. Intergenerational and striatal CAG repeat instability in Huntington&#x2019;s disease knock-in mice involve different DNA repair genes. Neurobiol. Dis. 2009;33:37&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2811282</ArticleId><ArticleId IdType="pubmed">18930147</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto RM, et al. Mismatch repair genes Mlh1 and Mlh3 modify CAG instability in Huntington&#x2019;s disease mice: genome-wide and candidate approaches. PLoS Genet. 2013;9:e1003930.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3814320</ArticleId><ArticleId IdType="pubmed">24204323</ArticleId></ArticleIdList></Reference><Reference><Citation>Loupe JM, et al. Promotion of somatic CAG repeat expansion by Fan1 knock-out in Huntington&#x2019;s disease knock-in mice is blocked by Mlh1 knock-out. Hum. Mol. Genet. 2020;29:3044&#x2013;3053.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7645713</ArticleId><ArticleId IdType="pubmed">32876667</ArticleId></ArticleIdList></Reference><Reference><Citation>Maurano MT, et al. Systematic localization of common disease-associated variation in regulatory DNA. Science. 2012;337:1190&#x2013;1195.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3771521</ArticleId><ArticleId IdType="pubmed">22955828</ArticleId></ArticleIdList></Reference><Reference><Citation>Visscher PM, et al. 10 years of GWAS discovery: biology, function, and translation. Am. J. Hum. Genet. 2017;101:5&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5501872</ArticleId><ArticleId IdType="pubmed">28686856</ArticleId></ArticleIdList></Reference><Reference><Citation>Rees E, et al. De novo mutations identified by exome sequencing implicate rare missense variants in SLC6A1 in schizophrenia. Nat. Neurosci. 2020;23:179&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7007300</ArticleId><ArticleId IdType="pubmed">31932766</ArticleId></ArticleIdList></Reference><Reference><Citation>Raghavan NS, et al. Whole-exome sequencing in 20,197 persons for rare variants in Alzheimer&#x2019;s disease. Ann. Clin. Transl. Neurol. 2018;5:832&#x2013;842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6043775</ArticleId><ArticleId IdType="pubmed">30009200</ArticleId></ArticleIdList></Reference><Reference><Citation>van Rheenen W, et al. Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. Nat. Genet. 2016;48:1043&#x2013;1048.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5556360</ArticleId><ArticleId IdType="pubmed">27455348</ArticleId></ArticleIdList></Reference><Reference><Citation>Langbehn DR, Brinkman RR, Falush D, Paulsen JS, Hayden MR. A new model for prediction of the age of onset and penetrance for Huntington&#x2019;s disease based on CAG length. Clin. Genet. 2004;65:267&#x2013;277.</Citation><ArticleIdList><ArticleId IdType="pubmed">15025718</ArticleId></ArticleIdList></Reference><Reference><Citation>Paulsen JS, et al. Detection of Huntington&#x2019;s disease decades before diagnosis: the Predict-HD study. J. Neurol. Neurosurg. Psychiatry. 2008;79:874&#x2013;880.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2569211</ArticleId><ArticleId IdType="pubmed">18096682</ArticleId></ArticleIdList></Reference><Reference><Citation>Goold R, et al. FAN1 modifies Huntington&#x2019;s disease progression by stabilizing the expanded HTT CAG repeat. Hum. Mol. Genet. 2019;28:650&#x2013;661.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6360275</ArticleId><ArticleId IdType="pubmed">30358836</ArticleId></ArticleIdList></Reference><Reference><Citation>Goold R, et al. FAN1 controls mismatch repair complex assembly via MLH1 retention to stabilize CAG repeat expansion in Huntington&#x2019;s disease. Cell Rep. 2021;36:109649.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8424649</ArticleId><ArticleId IdType="pubmed">34469738</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim K-H, et al. Genetic and functional analyses point to FAN1 as the source of multiple Huntington disease modifier effects. Am. J. Hum. Genet. 2020;107:96&#x2013;110.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7332667</ArticleId><ArticleId IdType="pubmed">32589923</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastarache L, et al. Phenotype risk scores identify patients with unrecognized Mendelian disease patterns. Science. 2018;359:1233&#x2013;1239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5959723</ArticleId><ArticleId IdType="pubmed">29590070</ArticleId></ArticleIdList></Reference><Reference><Citation>iPSC HD. Consortium. Induced pluripotent stem cells from patients with Huntington&#x2019;s disease show CAG-repeat-expansion-associated phenotypes. Cell Stem Cell. 2012;11:264&#x2013;278.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3804072</ArticleId><ArticleId IdType="pubmed">22748968</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattis VB, et al. HD iPSC-derived neural progenitors accumulate in culture and are susceptible to BDNF withdrawal due to glutamate toxicity. Hum. Mol. Genet. 2015;24:3257&#x2013;3271.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4424959</ArticleId><ArticleId IdType="pubmed">25740845</ArticleId></ArticleIdList></Reference><Reference><Citation>Kratz K, et al. Deficiency of FANCD2-associated nuclease KIAA1018/FAN1 sensitizes cells to interstrand crosslinking agents . Cell. 2010;142:77&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">20603016</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu T, Ghosal G, Yuan J, Chen J, Huang J. FAN1 acts with FANCI-FANCD2 to promote DNA interstrand cross-link repair. Science. 2010;329:693&#x2013;696.</Citation><ArticleIdList><ArticleId IdType="pubmed">20671156</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy L, et al. Dramatic tissue-specific mutation length increases are an early molecular event in Huntington disease pathogenesis. Hum. Mol. Genet. 2003;12:3359&#x2013;3367.</Citation><ArticleIdList><ArticleId IdType="pubmed">14570710</ArticleId></ArticleIdList></Reference><Reference><Citation>Flower M, et al. MSH3 modifies somatic instability and disease severity in Huntington&#x2019;s and myotonic dystrophy type 1. Brain. 2019;142:1876&#x2013;1886.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6598626</ArticleId><ArticleId IdType="pubmed">31216018</ArticleId></ArticleIdList></Reference><Reference><Citation>Panigrahi GB, Slean MM, Simard JP, Gileadi O, Pearson CE. Isolated short CTG/CAG DNA slip-outs are repaired efficiently by hMutS&#x3b2;, but clustered slip-outs are poorly repaired. Proc. Natl Acad. Sci. USA. 2010;107:12593&#x2013;12598.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2906547</ArticleId><ArticleId IdType="pubmed">20571119</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao X-N, et al. Muts&#x3b2; generates both expansions and contractions in a mouse model of the Fragile X-associated disorders. Hum. Mol. Genet. 2015;24:7087&#x2013;7096.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4654059</ArticleId><ArticleId IdType="pubmed">26420841</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller CJ, Kim G-Y, Zhao X, Usdin K. All three mammalian MutL complexes are required for repeat expansion in a mouse cell model of the Fragile X-related disorders. PLoS Genet. 2020;16:e1008902.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7347238</ArticleId><ArticleId IdType="pubmed">32589669</ArticleId></ArticleIdList></Reference><Reference><Citation>R&#xe4;schle M, Marra G, Nystr&#xf6;m-Lahti M, Sch&#xe4;r P, Jiricny J. Identification of hMutL&#x3b2;, a heterodimer of hMLH1 and hPMS1. J. Biol. Chem. 1999;274:32368&#x2013;32375.</Citation><ArticleIdList><ArticleId IdType="pubmed">10542278</ArticleId></ArticleIdList></Reference><Reference><Citation>Karczewski KJ, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2020;581:434&#x2013;443.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7334197</ArticleId><ArticleId IdType="pubmed">32461654</ArticleId></ArticleIdList></Reference><Reference><Citation>Smogorzewska A, et al. A genetic screen identifies FAN1, a Fanconi anemia-associated nuclease necessary for DNA interstrand crosslink repair. Mol. Cell. 2010;39:36&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2919743</ArticleId><ArticleId IdType="pubmed">20603073</ArticleId></ArticleIdList></Reference><Reference><Citation>Lachaud C, et al. Karyomegalic interstitial nephritis and DNA damage-induced polyploidy in Fan1 nuclease-defective knock-in mice. Genes Dev. 2016;30:639&#x2013;644.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4803050</ArticleId><ArticleId IdType="pubmed">26980188</ArticleId></ArticleIdList></Reference><Reference><Citation>Cannavo E, Gerrits B, Marra G, Schlapbach R, Jiricny J. Characterization of the interactome of the human MutL homologues MLH1, PMS1, and PMS2. J. Biol. Chem. 2007;282:2976&#x2013;2986.</Citation><ArticleIdList><ArticleId IdType="pubmed">17148452</ArticleId></ArticleIdList></Reference><Reference><Citation>Porro A, et al. FAN1&#x2013;MLH1 interaction affects repair of DNA interstrand cross-links and slipped-CAG/CTG repeats. Sci. Adv. 2021;7:eabf7906.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8324060</ArticleId><ArticleId IdType="pubmed">34330701</ArticleId></ArticleIdList></Reference><Reference><Citation>Bettencourt C, et al. DNA repair pathways underlie a common genetic mechanism modulating onset in polyglutamine diseases. Ann. Neurol. 2016;79:983&#x2013;990.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4914895</ArticleId><ArticleId IdType="pubmed">27044000</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao X-N, Usdin K. FAN1 protects against repeat expansions in a Fragile X mouse model. DNA Repair (Amst). 2018;69:1&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6119480</ArticleId><ArticleId IdType="pubmed">29990673</ArticleId></ArticleIdList></Reference><Reference><Citation>Marouli E, et al. Rare and low-frequency coding variants alter human adult height. Nature. 2017;542:186&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5302847</ArticleId><ArticleId IdType="pubmed">28146470</ArticleId></ArticleIdList></Reference><Reference><Citation>Chao MJ, et al. Population-specific genetic modification of Huntington&#x2019;s disease in Venezuela. PLoS Genet. 2018;14:e1007274.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5965898</ArticleId><ArticleId IdType="pubmed">29750799</ArticleId></ArticleIdList></Reference><Reference><Citation>UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Res. 2019;47:D506&#x2013;D515.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6323992</ArticleId><ArticleId IdType="pubmed">30395287</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin H, Cho Y. Structural and functional relationships of FAN1. DNA Repair (Amst). 2017;56:135&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pubmed">28623094</ArticleId></ArticleIdList></Reference><Reference><Citation>Orth M, et al. Observing Huntington&#x2019;s disease: the European Huntington&#x2019;s Disease Network&#x2019;s REGISTRY. PLoS Curr. 2010;2:RRN1184.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2947793</ArticleId><ArticleId IdType="pubmed">20890398</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleveland, W., Grosse, E. &amp; Shyu, W. Local regression models. In: Statistical Models in S, Chapter 8 (Chapman and Hall/CRC, 1991).</Citation></Reference><Reference><Citation>Zhang Y, et al. Indexing disease progression at study entry with individuals at-risk for Huntington disease. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2011;156B:751&#x2013;763.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3174494</ArticleId><ArticleId IdType="pubmed">21858921</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishwaran H, Kogalur UB, Blackstone EH, Lauer MS. Random survival forests. Ann. Appl. Stat. 2008;2:841&#x2013;860.</Citation></Reference><Reference><Citation>Royston P, Parmar MKB. Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome. BMC Med. Res. Methodol. 2013;13:152.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3922847</ArticleId><ArticleId IdType="pubmed">24314264</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciosi, M. et al. Library preparation and MiSeq sequencing for the genotyping-by-sequencing of the Huntington disease HTT exon one trinucleotide repeat and the quantification of somatic mosaicism. Protocol Exchange. 10.1038/protex.2018.089 (2018).</Citation></Reference><Reference><Citation>Milne I, et al. Using Tablet for visual exploration of second-generation sequencing data. Brief. Bioinform. 2013;14:193&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pubmed">22445902</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics. 2009;25:2078&#x2013;2079.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2723002</ArticleId><ArticleId IdType="pubmed">19505943</ArticleId></ArticleIdList></Reference><Reference><Citation>Gnirke A, et al. Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing. Nat. Biotechnol. 2009;27:182&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2663421</ArticleId><ArticleId IdType="pubmed">19182786</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher S, et al. A scalable, fully automated process for construction of sequence-ready human exome targeted capture libraries. Genome Biol. 2011;12:R1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3091298</ArticleId><ArticleId IdType="pubmed">21205303</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang R, et al. Mechanism of DNA interstrand cross-link processing by repair nuclease FAN1. Science. 2014;346:1127&#x2013;1130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4285437</ArticleId><ArticleId IdType="pubmed">25430771</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao T, et al. Importance of homo-dimerization of Fanconi-associated nuclease 1 in DNA flap cleavage. DNA Repair (Amst). 2018;64:53&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7105229</ArticleId><ArticleId IdType="pubmed">29518739</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang L, Wang K. Identification of copy number variants from SNP arrays using PennCNV. Methods Mol. Biol. 2018;1833:1&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">30039360</ArticleId></ArticleIdList></Reference><Reference><Citation>Telezhkin V, et al. Forced cell cycle exit and modulation of GABAA, CREB, and GSK3&#x3b2; signaling promote functional maturation of induced pluripotent stem cell-derived neurons. Am. J. Physiol. Cell Physiol. 2016;310:C520&#x2013;C541.</Citation><ArticleIdList><ArticleId IdType="pubmed">26718628</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith-Geater C, et al. Aberrant development corrected in adult-onset Huntington&#x2019;s disease iPSC-derived neuronal cultures via WNT signaling modulation. Stem Cell Rep. 2020;14:406&#x2013;419.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7066322</ArticleId><ArticleId IdType="pubmed">32109367</ArticleId></ArticleIdList></Reference><Reference><Citation>Covarrubias-Pazaran G, Diaz-Garcia L, Schlautman B, Salazar W, Zalapa J. Fragman: an R package for fragment analysis. BMC Genet. 2016;17:62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4839125</ArticleId><ArticleId IdType="pubmed">27098093</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J-M, et al. A novel approach to investigate tissue-specific trinucleotide repeat instability. BMC Syst. Biol. 2010;4:29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2856555</ArticleId><ArticleId IdType="pubmed">20302627</ArticleId></ArticleIdList></Reference><Reference><Citation>DePristo MA, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat. Genet. 2011;43:491&#x2013;498.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3083463</ArticleId><ArticleId IdType="pubmed">21478889</ArticleId></ArticleIdList></Reference><Reference><Citation>Van der Auwera GA, et al. From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline. Curr. Protoc. Bioinformatics. 2013;43:11.10.1&#x2013;11.10.33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4243306</ArticleId><ArticleId IdType="pubmed">25431634</ArticleId></ArticleIdList></Reference><Reference><Citation>McKenna A, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20:1297&#x2013;1303.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2928508</ArticleId><ArticleId IdType="pubmed">20644199</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, Durbin R. Fast and accurate short read alignment with Burrows&#x2013;Wheeler transform. Bioinformatics. 2009;25:1754&#x2013;1760.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2705234</ArticleId><ArticleId IdType="pubmed">19451168</ArticleId></ArticleIdList></Reference><Reference><Citation>Poplin, R. et al. Scaling accurate genetic variant discovery to tens of thousands of samples. Preprint at https://www.biorxiv.org/content/10.1101/201178v3 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/201178v3</ArticleId></ArticleIdList></Reference><Reference><Citation>Jun G, et al. Detecting and estimating contamination of human DNA samples in sequencing and array-based genotype data. Am. J. Hum. Genet. 2012;91:839&#x2013;848.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3487130</ArticleId><ArticleId IdType="pubmed">23103226</ArticleId></ArticleIdList></Reference><Reference><Citation>Lek M, et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature. 2016;536:285&#x2013;291.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5018207</ArticleId><ArticleId IdType="pubmed">27535533</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedersen BS, Quinlan AR. Who&#x2019;s who? Detecting and resolving sample anomalies in human DNA sequencing studies with Peddy. Am. J. Hum. Genet. 2017;100:406&#x2013;413.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5339084</ArticleId><ArticleId IdType="pubmed">28190455</ArticleId></ArticleIdList></Reference><Reference><Citation>1000 Genomes Project Consortium. A global reference for human genetic variation. Nature. 2015;526:68&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4750478</ArticleId><ArticleId IdType="pubmed">26432245</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X, Jian X, Boerwinkle E. dbNSFP: a lightweight database of human nonsynonymous SNPs and their functional predictions. Hum. Mutat. 2011;32:894&#x2013;899.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3145015</ArticleId><ArticleId IdType="pubmed">21520341</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X, Wu C, Li C, Boerwinkle E. dbNSFP v3.0: a one-stop database of functional predictions and annotations for human nonsynonymous and splice-site SNVs. Hum. Mutat. 2016;37:235&#x2013;241.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4752381</ArticleId><ArticleId IdType="pubmed">26555599</ArticleId></ArticleIdList></Reference><Reference><Citation>McLaren W, et al. The Ensembl Variant Effect Predictor. Genome Biol. 2016;17:122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4893825</ArticleId><ArticleId IdType="pubmed">27268795</ArticleId></ArticleIdList></Reference><Reference><Citation>Kircher M, et al. A general framework for estimating the relative pathogenicity of human genetic variants. Nat. Genet. 2014;46:310&#x2013;315.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3992975</ArticleId><ArticleId IdType="pubmed">24487276</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S, et al. Optimal unified approach for rare-variant association testing with application to small-sample case&#x2013;control whole-exome sequencing studies. Am. J. Hum. Genet. 2012;91:224&#x2013;237.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3415556</ArticleId><ArticleId IdType="pubmed">22863193</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu MC, et al. Rare-variant association testing for sequencing data with the sequence kernel association test. Am. J. Hum. Genet. 2011;89:82&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3135811</ArticleId><ArticleId IdType="pubmed">21737059</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">35426173</PMID><DateCompleted><Year>2022</Year><Month>07</Month><Day>22</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1531-8257</ISSN><JournalIssue CitedMedium="Internet"><Volume>37</Volume><Issue>7</Issue><PubDate><Year>2022</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov Disord</ISOAbbreviation></Journal><ArticleTitle>A Randomized First-in-Human Study With UB-312, a UBITh&#xae; &#x3b1;-Synuclein Peptide Vaccine.</ArticleTitle><Pagination><StartPage>1416</StartPage><EndPage>1424</EndPage><MedlinePgn>1416-1424</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mds.29016</ELocationID><Abstract><AbstractText Label="BACKGROUND">&#x3b1;-Synuclein (&#x3b1;Syn) is believed to play a central role in Parkinson's disease (PD) neuropathology and is considered a target for disease modification. UB-312 is a synthetic &#x3b1;Syn peptide conjugated to a T helper peptide and is expected to induce antibodies specifically against oligomeric and fibrillar &#x3b1;Syn, making UB-312 a potential immunotherapeutic for synucleopathies.</AbstractText><AbstractText Label="OBJECTIVE">To investigate the safety, tolerability, and immunogenicity of UB-312 vaccination in healthy participants and to determine a safe and immunologically optimal dose for the first-in-patient study.</AbstractText><AbstractText Label="METHODS">Fifty eligible healthy participants were enrolled in a 44-week, randomized, placebo-controlled, double-blind study. Participants in seven cohorts were randomized to three intramuscular UB-312 or placebo injections at weeks 1, 5, and 13 (doses ranging between 40 and 2000&#x2009;&#x3bc;g). Safety and tolerability were assessed by adverse events, clinical laboratory, vital signs, electrocardiograms, and neurological and physical examinations. Immunogenicity was assessed by measuring serum and cerebrospinal fluid (CSF) anti-&#x3b1;Syn antibody concentrations.</AbstractText><AbstractText Label="RESULTS">Twenty-three participants received all three vaccinations of UB-312. Most adverse events were mild, transient, and self-resolving. Common treatment-emergent adverse events included headache, nasopharyngitis, vaccination-site pain, lumbar puncture-site pain, and fatigue. UB-312 induced dose- and time-dependent antibody production. Antibodies were detectable in serum and CSF of all participants receiving the 300/300/300&#x2009;&#x3bc;g UB-312 dose regimen. The average CSF/serum ratio was 0.2%.</AbstractText><AbstractText Label="CONCLUSIONS">UB-312 was generally safe, well tolerated, and induced anti-&#x3b1;Syn antibodies in serum and CSF of healthy participants. The 100 and 300&#x2009;&#x3bc;g doses are selected for further evaluation in participants with PD. &#xa9; 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.</AbstractText><CopyrightInformation>&#xa9; 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Hui Jing</ForeName><Initials>HJ</Initials><Identifier Source="ORCID">0000-0003-0662-9670</Identifier><AffiliationInfo><Affiliation>Vaxxinity Inc., Dallas, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thijssen</LastName><ForeName>Eva</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-3907-072X</Identifier><AffiliationInfo><Affiliation>Centre for Human Drug Research, Leiden, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Leiden University Medical Centre, Leiden, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Brummelen</LastName><ForeName>Emilie</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Centre for Human Drug Research, Leiden, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Plas</LastName><ForeName>Johan L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Centre for Human Drug Research, Leiden, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Leiden University Medical Centre, Leiden, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Radanovic</LastName><ForeName>Igor</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Centre for Human Drug Research, Leiden, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moerland</LastName><ForeName>Matthijs</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Centre for Human Drug Research, Leiden, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsieh</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Vaxxinity Inc., Dallas, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Groeneveld</LastName><ForeName>Geert Jan</ForeName><Initials>GJ</Initials><AffiliationInfo><Affiliation>Centre for Human Drug Research, Leiden, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Leiden University Medical Centre, Leiden, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dodart</LastName><ForeName>Jean-Cosme</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Vaxxinity Inc., Dallas, Texas, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>04</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010455">Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D022223">Vaccines, Subunit</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010146" MajorTopicYN="N">Pain</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="Y">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D022223" MajorTopicYN="N">Vaccines, Subunit</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="Y">alpha-Synuclein</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Parkinson's disease</Keyword><Keyword MajorTopicYN="N">active immunotherapy</Keyword><Keyword MajorTopicYN="N">first-in-human</Keyword><Keyword MajorTopicYN="N">vaccine</Keyword><Keyword MajorTopicYN="N">&#x3b1;-synuclein</Keyword></KeywordList><CoiStatement>H.J.Y. and J.&#x2010;C.D. are employees and hold stocks in Vaxxinity.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>3</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>8</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>15</Day><Hour>5</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>10</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35426173</ArticleId><ArticleId IdType="pmc">PMC9545051</ArticleId><ArticleId IdType="doi">10.1002/mds.29016</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Yang W, Hamilton JL, Kopil C, Beck JC, Tanner CM, Albin RL, et al. Current and projected future economic burden of Parkinson's disease in the U.S. NPJ Parkinsons Dis 2020;6:1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7347582</ArticleId><ArticleId IdType="pubmed">32665974</ArticleId></ArticleIdList></Reference><Reference><Citation>Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, et al. Parkinson disease. Nat Rev Dis Primer 2017;3:17013</Citation><ArticleIdList><ArticleId IdType="pubmed">28332488</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartels T, Choi JG, Selkoe DJ. &#x3b1;&#x2010;Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 2011;477:107&#x2013;110. 10.1038/nature10324</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature10324</ArticleId><ArticleId IdType="pmc">PMC3166366</ArticleId><ArticleId IdType="pubmed">21841800</ArticleId></ArticleIdList></Reference><Reference><Citation>
Valdinocci D, Radford RAW, Siow SM, Chung RS, Pountney DL. Potential modes of intercellular &#x3b1;&#x2010;synuclein transmission. Int J Mol Sci
2017;18:469
http://europepmc.org/abstract/MED/28241427
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5344001</ArticleId><ArticleId IdType="pubmed">28241427</ArticleId></ArticleIdList></Reference><Reference><Citation>Melki R. How the shapes of seeds can influence pathology. Neurobiol Dis 2018;109:201&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pubmed">28363800</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefanis L, Kholodilov N, Rideout HJ, Burke RE, Greene LA. Synuclein&#x2010;1 is selectively up&#x2010;regulated in response to nerve growth factor treatment in PC12 cells: synuclein induction by NGF. J Neurochem 2001;76:1165&#x2013;1176.</Citation><ArticleIdList><ArticleId IdType="pubmed">11181836</ArticleId></ArticleIdList></Reference><Reference><Citation>Luk KC, Kehm VM, Zhang B, O'Brien P, Trojanowski JQ, Lee VMY. Intracerebral inoculation of pathological &#x3b1;&#x2010;synuclein initiates a rapidly progressive neurodegenerative &#x3b1;&#x2010;synucleinopathy in mice. J Exp Med 2012;209:975&#x2013;986. 10.1038/nature10324</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature10324</ArticleId><ArticleId IdType="pmc">PMC3348112</ArticleId><ArticleId IdType="pubmed">22508839</ArticleId></ArticleIdList></Reference><Reference><Citation>Schenk DB, Koller M, Ness DK, Griffith SG, Grundman M, Zago W, et al. First&#x2010;in&#x2010;human assessment of PRX002, an anti&#x2013;&#x3b1;&#x2010;synuclein monoclonal antibody, in healthy volunteers. Mov Disord 2017;32:211&#x2013;218.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5324684</ArticleId><ArticleId IdType="pubmed">27886407</ArticleId></ArticleIdList></Reference><Reference><Citation>Volc D, Poewe W, Kutzelnigg A, L&#xfc;hrs P, Thun&#x2010;Hohenstein C, Schneeberger A, et al. Safety and immunogenicity of the &#x3b1;&#x2010;synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single&#x2010;blinded, phase 1 trial. Lancet Neurol 2020;19:591&#x2013;600.</Citation><ArticleIdList><ArticleId IdType="pubmed">32562684</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuchimanchi M, Monine M, Kandadi Muralidharan K, Woodward C, Penner N. Phase II dose selection for alpha synuclein&#x2013;targeting antibody cinpanemab (BIIB054) based on target protein binding levels in the brain. CPT Pharmacometrics Syst Pharmacol 2020;9:515&#x2013;522.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7499191</ArticleId><ArticleId IdType="pubmed">32613752</ArticleId></ArticleIdList></Reference><Reference><Citation>Brys M, Fanning L, Hung S, Ellenbogen A, Penner N, Yang M, et al. Randomized phase I clinical trial of anti&#x2010;&#x3b1;&#x2010;synuclein antibody BIIB054. Mov Disord 2019;34:1154&#x2013;1163.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6771554</ArticleId><ArticleId IdType="pubmed">31211448</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasinezumab slows progression on measures of Parkinson's disease in phase 2 study. Prothena Corporation plc. Accesed August 9, 2021.</Citation></Reference><Reference><Citation>Wang CY, Finstad CL, Walfield AM, Sia C, Sokoll KK, Chang T&#x2010;Y, et al. Site&#x2010;specific UBITh&#xae; amyloid&#x2010;&#x3b2; vaccine for immunotherapy of Alzheimer's disease. Vaccine 2007;25:3041&#x2013;3052. 10.1016/j.vaccine.2007.01.031</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2007.01.031</ArticleId><ArticleId IdType="pubmed">17287052</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang CY, Wang P&#x2010;N, Chiu M&#x2010;J, Finstad CL, Lin F, Lynn S, et al. UB&#x2010;311, a novel UBITh&#xae; amyloid &#x3b2; peptide vaccine for mild Alzheimer's disease. Alzheimers Dement 2017;3:262&#x2013;272.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5651432</ArticleId><ArticleId IdType="pubmed">29067332</ArticleId></ArticleIdList></Reference><Reference><Citation>
United Neuroscience Ltd
(2020). A Randomized, Double&#x2010;blind, Placebo&#x2010;controlled, 3&#x2010;arm Parallel&#x2010;group, Multicenter, Phase IIa Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of UBITh&#xae; AD Immunotherapeutic Vaccine (UB&#x2010;311) in Patients with Mild Alzheimer's Disease. clinicaltrials.gov; (Report No. NCT02551809). https://clinicaltrials.gov/ct2/show/NCT02551809
</Citation></Reference><Reference><Citation>
United Neuroscience Ltd
. (2021). 
An Extension Study of a Phase IIa Study in Patients with Mild Alzheimer's Disease to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of UBITh&#xae; AD Immunotherapeutic Vaccine (UB&#x2010;311)
. clinicaltrials.gov; (Report No: NCT03531710). https://clinicaltrials.gov/ct2/show/NCT03531710
</Citation></Reference><Reference><Citation>Nimmo JT, Verma A, Dodart J&#x2010;C, Wang CY, Savistchenko J, Melki R, et al. Novel antibodies detect additional &#x3b1;&#x2010;synuclein pathology in synucleinopathies: potential development for immunotherapy. Alzheimers Res Ther 2020;12:159</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7702704</ArticleId><ArticleId IdType="pubmed">33256825</ArticleId></ArticleIdList></Reference><Reference><Citation>Nimmo JT, Smith H, Wang CY, Teeling JL, Nicoll JAR, Verma A, et al. Immunisation with UB&#x2010;312 in the Thy1SNCA mouse prevents motor performance deficits and oligomeric &#x3b1;&#x2010;synuclein accumulation in the brain and gut. Acta Neuropathol (Berl) 2021;143(1):55&#x2013;73. 10.1007/s00401-021-02381-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-021-02381-5</ArticleId><ArticleId IdType="pmc">PMC8732825</ArticleId><ArticleId IdType="pubmed">34741635</ArticleId></ArticleIdList></Reference><Reference><Citation>Meissner WG, Traon AP&#x2010;L, Foubert&#x2010;Samier A, Galabova G, Galitzky M, Kutzelnigg A, et al. A phase 1 randomized trial of specific active &#x3b1;&#x2010;synuclein immunotherapies PD01A and PD03A in multiple system atrophy. Mov Disord 2020;35:1957&#x2013;1965.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7754431</ArticleId><ArticleId IdType="pubmed">32882100</ArticleId></ArticleIdList></Reference><Reference><Citation>Bode C, Zhao G, Steinhagen F, Kinjo T, Klinman DM. CpG DNA as a vaccine adjuvant. Expert Rev Vaccines 2011;10:499&#x2013;511.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3108434</ArticleId><ArticleId IdType="pubmed">21506647</ArticleId></ArticleIdList></Reference><Reference><Citation>Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez&#x2010;Domingo J, Hwang S&#x2010;J, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med 2015;372:2087&#x2013;2096.</Citation><ArticleIdList><ArticleId IdType="pubmed">25916341</ArticleId></ArticleIdList></Reference><Reference><Citation>
Adjuvants and vaccines | Vaccine Safety. CDC
. 2020. Accesed April 16, 2021. https://www.cdc.gov/vaccinesafety/concerns/adjuvants.html
</Citation></Reference><Reference><Citation>Scheiermann J, Klinman DM. Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer. Vaccine 2014;32:6377&#x2013;6389.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4252359</ArticleId><ArticleId IdType="pubmed">24975812</ArticleId></ArticleIdList></Reference><Reference><Citation>Talaat KR, Halsey NA, Cox AB, Coles CL, Durbin AP, Ramakrishnan A, et al. Rapid changes in serum cytokines and chemokines in response to inactivated influenza vaccination. Influenza Other Respir Viruses 2018;12:202&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5820426</ArticleId><ArticleId IdType="pubmed">28991404</ArticleId></ArticleIdList></Reference><Reference><Citation>Christian LM, Porter K, Karlsson E, Schultz&#x2010;Cherry S. Proinflammatory cytokine responses correspond with subjective side effects after influenza virus vaccination. Vaccine 2015;33:3360&#x2013;3366.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4467994</ArticleId><ArticleId IdType="pubmed">26027906</ArticleId></ArticleIdList></Reference><Reference><Citation>
Jankovic J, Goodman I, Safirstein B, Marmon TK, Schenk DB, Koller M, et al. Safety and tolerability of multiple ascending doses of PRX002/RG7935, an anti&#x2013;&#x3b1;&#x2010;synuclein monoclonal antibody, in patients with Parkinson disease: a randomized clinical trial. JAMA Neurol
2018;75:1206&#x2013;1214. http://jamanetwork.com/journals/jamaneurology/fullarticle/2685097
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6233845</ArticleId><ArticleId IdType="pubmed">29913017</ArticleId></ArticleIdList></Reference><Reference><Citation>Jan A, Gon&#xe7;alves NP, Vaegter CB, Jensen PH, Ferreira N. The prion&#x2010;like spreading of alpha&#x2010;synuclein in Parkinson's disease: update on models and hypotheses. Int J Mol Sci 2021;22:8338</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8347623</ArticleId><ArticleId IdType="pubmed">34361100</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefanis L, Emmanouilidou E, Pantazopoulou M, Kirik D, Vekrellis K, Tofaris GK. How is alpha&#x2010;synuclein cleared from the cell? J Neurochem 2019;150:577&#x2013;590.</Citation><ArticleIdList><ArticleId IdType="pubmed">31069800</ArticleId></ArticleIdList></Reference><Reference><Citation>Hijaz BA, Volpicelli&#x2010;Daley LA. Initiation and propagation of &#x3b1;&#x2010;synuclein aggregation in the nervous system. Mol Neurodegener 2020;15:19</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7060612</ArticleId><ArticleId IdType="pubmed">32143659</ArticleId></ArticleIdList></Reference><Reference><Citation>Upcott M, Chaprov KD, Buchman VL. Toward a disease&#x2010;modifying therapy of alpha&#x2010;synucleinopathies: new molecules and new approaches came into the limelight. Molecules 2021;26:7351</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8658846</ArticleId><ArticleId IdType="pubmed">34885933</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon EH, Tennagels S, Gold R, Gerwert K, Beyer L, T&#xf6;nges L. Update on CSF biomarkers in Parkinson's disease. Biomolecules 2022;12:329</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8869235</ArticleId><ArticleId IdType="pubmed">35204829</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35435938</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>15</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>79</Volume><Issue>6</Issue><PubDate><Year>2022</Year><Month>Jun</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Divergent Cortical Tau Positron Emission Tomography Patterns Among Patients With Preclinical Alzheimer Disease.</ArticleTitle><Pagination><StartPage>592</StartPage><EndPage>603</EndPage><MedlinePgn>592-603</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2022.0676</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Characterization of early tau deposition in individuals with preclinical Alzheimer disease (AD) is critical for prevention trials that aim to select individuals at risk for AD and halt the progression of disease.</AbstractText><AbstractText Label="OBJECTIVE">To evaluate the prevalence of cortical tau positron emission tomography (PET) heterogeneity in a large cohort of clinically unimpaired older adults with elevated &#x3b2;-amyloid (A+).</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">This cross-sectional study examined prerandomized tau PET, amyloid PET, structural magnetic resonance imaging, demographic, and cognitive data from the Anti-Amyloid Treatment in Asymptomatic AD (A4) Study from April 2014 to December 2017. Follow-up analyses used observational tau PET data from the Alzheimer's Disease Neuroimaging Initiative (ADNI), the Harvard Aging Brain Study (HABS), and the Wisconsin Registry for Alzheimer's Prevention and the Wisconsin Alzheimer's Disease Research Center (together hereinafter referred to as Wisconsin) to evaluate consistency. Participants were clinically unimpaired at the study visit closest to the tau PET scan and had available amyloid and tau PET data (A4 Study, n&#x2009;=&#x2009;447; ADNI, n&#x2009;=&#x2009;433; HABS, n&#x2009;=&#x2009;190; and Wisconsin, n&#x2009;=&#x2009;328). No participants who met eligibility criteria were excluded. Data were analyzed from May 11, 2021, to January 25, 2022.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Individuals with preclinical AD with heterogeneous cortical tau PET patterns (A+T cortical+) were identified by examining asymmetrical cortical tau signal and disproportionate cortical tau signal relative to medial temporal lobe (MTL) tau. Voxelwise tau patterns, amyloid, neurodegeneration, cognition, and demographic characteristics were examined.</AbstractText><AbstractText Label="RESULTS">The 447 A4 participants (A+ group, 392; and normal &#x3b2;-amyloid group, 55), with a mean (SD) age of 71.8 (4.8) years, included 239 women (54%). A total of 36 individuals in the A+ group (9% of the A+ group) exhibited heterogeneous cortical tau patterns and were further categorized into 3 subtypes: asymmetrical left, precuneus dominant, and asymmetrical right. A total of 116 individuals in the A+ group (30% of the A+ group) showed elevated MTL tau (A+T MTL+). Individuals in the A+T cortical+ group were younger than those in the A+T MTL+ group (t61.867&#x2009;=&#x2009;-2.597; P&#x2009;=&#x2009;.03). Across the A+T cortical+ and A+T MTL+ groups, increased regional tau was associated with reduced hippocampal volume and MTL thickness but not with cortical thickness. Memory scores were comparable between the A+T cortical+ and A+T MTL+ groups, whereas executive functioning scores were lower for the A+T cortical+ group than for the A+T MTL+ group. The prevalence of the A+T cortical+ group and tau patterns within the A+T cortical+ group were consistent in ADNI, HABS, and Wisconsin.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">This study suggests that early tau deposition may follow multiple trajectories during preclinical AD and may involve several cortical regions. Staging procedures, especially those based on neuropathology, that assume a uniform trajectory across individuals are insufficient for disease monitoring with tau imaging.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Young</LastName><ForeName>Christina B</ForeName><Initials>CB</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Winer</LastName><ForeName>Joseph R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Younes</LastName><ForeName>Kyan</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cody</LastName><ForeName>Karly A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Betthauser</LastName><ForeName>Tobey J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Sterling C</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wisconsin Alzheimer's Institute, University of Wisconsin School of Medicine and Public Health, Madison.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schultz</LastName><ForeName>Aaron</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greicius</LastName><ForeName>Michael D</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cobos</LastName><ForeName>Inma</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Pathology, Stanford University School of Medicine, Stanford, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poston</LastName><ForeName>Kathleen L</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mormino</LastName><ForeName>Elizabeth C</ForeName><Initials>EC</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Alzheimer&#x2019;s Disease Neuroimaging Initiative and the Harvard Aging Brain Study</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>F32 AG074625</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066515</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG063689</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000686" MajorTopicYN="Y">Amyloidosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="Y">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Young reported receiving grants from the Alzheimer&#x2019;s Association during the conduct of the study. Ms Cody reported receiving grants from the National Institutes of Health (NIH) during the conduct of the study. Dr Johnson reported receiving grants from the NIH during the conduct of the study; and personal fees from Roche Diagnostics outside the submitted work. Dr Schultz reported receiving grants from the NIH during the conduct of the study; and personal fees from NervGen, Qynapse, Biogen, and Janssen outside the submitted work. Dr Sperling reported receiving grants from the National Institute on Aging and the Alzheimer&#x2019;s Association during the conduct of the study; and personal fees from AC Immune, Janssen, Genentech, Ionis, NerGen, Shionogi, and Oligmerix outside the submitted work. Dr Greicius reported receiving grants from the NIH during the conduct of the study. Dr Poston reported receiving grants from the NIH/National Institute of Neurological Disorders and Stroke during the conduct of the study; and grants from MJFF, Alzheimer&#x2019;s Drug Discovery Foundation, and Lewy Body Dementia Association outside the submitted work. Dr Mormino reported receiving grants from the NIH during the conduct of the study; and personal fees from Eli Lilly, Roche, and NeuroTrack; and grants from the Alzheimer&#x2019;s Association outside the submitted work. No other disclosures were reported.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Weiner</LastName><ForeName>Michael W</ForeName><Initials>MW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aisen</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jack</LastName><ForeName>Clifford R</ForeName><Initials>CR</Initials><Suffix>Jr</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Jagust</LastName><ForeName>William</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trojanowki</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Toga</LastName><ForeName>Arthur W</ForeName><Initials>AW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beckett</LastName><ForeName>Laurel</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Green</LastName><ForeName>Robert C</ForeName><Initials>RC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saykin</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Perrin</LastName><ForeName>Richard J</ForeName><Initials>RJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shaw</LastName><ForeName>Leslie M</ForeName><Initials>LM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Khachaturian</LastName><ForeName>Zaven</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carrillo</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Potter</LastName><ForeName>William</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barnes</LastName><ForeName>Lisa</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bernard</LastName><ForeName>Marie</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gonzalez</LastName><ForeName>Hector</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ho</LastName><ForeName>Carole</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hsiao</LastName><ForeName>John K</ForeName><Initials>JK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jackson</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Masliah</LastName><ForeName>Eliezer</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Masterman</LastName><ForeName>Donna</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Okonkwo</LastName><ForeName>Ozioma</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ryan</LastName><ForeName>Laurie</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Silverberg</LastName><ForeName>Nina</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fleisher</LastName><ForeName>Adam</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sacrey</LastName><ForeName>Diana T</ForeName><Initials>DT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fockler</LastName><ForeName>Juliet</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Conti</LastName><ForeName>Cat</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Veitch</LastName><ForeName>Dallas</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Neuhaus</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jin</LastName><ForeName>Chengshi</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nosheny</LastName><ForeName>Rachel</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ashford</LastName><ForeName>Mariam</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Flenniken</LastName><ForeName>Derek</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kormos</LastName><ForeName>Adrienne</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Montine</LastName><ForeName>Tom</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rafii</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Raman</LastName><ForeName>Rema</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jimenez</LastName><ForeName>Gustavo</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Donohue</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gessert</LastName><ForeName>Devon</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Salazar</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zimmerman</LastName><ForeName>Caileigh</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cabrera</LastName><ForeName>Yuliana</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Walter</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miller</LastName><ForeName>Garrett</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Coker</LastName><ForeName>Godfrey</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clanton</LastName><ForeName>Taylor</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hergesheimer</LastName><ForeName>Lindsey</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Adegoke</LastName><ForeName>Olusegun</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mahboubi</LastName><ForeName>Payam</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moore</LastName><ForeName>Shelley</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pizzola</LastName><ForeName>Jeremy</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shaffer</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harvey</LastName><ForeName>Danielle</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Forghanian-Arani</LastName><ForeName>Arvin</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Borowski</LastName><ForeName>Bret</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ward</LastName><ForeName>Chad</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schwarz</LastName><ForeName>Christopher</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jones</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gunter</LastName><ForeName>Jeff</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kantarci</LastName><ForeName>Kejal</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Senjem</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vemuri</LastName><ForeName>Prashanthi</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reid</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fox</LastName><ForeName>Nick C</ForeName><Initials>NC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Malone</LastName><ForeName>Ian</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thompson</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thomopoulos</LastName><ForeName>Sophia I</ForeName><Initials>SI</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nir</LastName><ForeName>Talia M</ForeName><Initials>TM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jahanshad</LastName><ForeName>Neda</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeCarli</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Knaack</LastName><ForeName>Alexander</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fletcher</LastName><ForeName>Evan</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tosun-Turgut</LastName><ForeName>Duygu</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chen</LastName><ForeName>Stephanie R</ForeName><Initials>SR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Choe</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Crawford</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yuschkevich</LastName><ForeName>Paul A</ForeName><Initials>PA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Das</LastName><ForeName>Sandhitsu</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koeppe</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reiman</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chen</LastName><ForeName>Kewei</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mathis</LastName><ForeName>Chet</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Landau</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cairns</LastName><ForeName>Nigel J</ForeName><Initials>NJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Householder</LastName><ForeName>Erin</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Franklin</LastName><ForeName>Erin</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bernhardt</LastName><ForeName>Haley</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Taylor-Reinwald</LastName><ForeName>Lisa</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Korecka</LastName><ForeName>Magdalena</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Figurski</LastName><ForeName>Michal</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Neu</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nho</LastName><ForeName>Kwangsik</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Risacher</LastName><ForeName>Shannon L</ForeName><Initials>SL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Apostolova</LastName><ForeName>Liana G</ForeName><Initials>LG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shen</LastName><ForeName>Li</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Foroud</LastName><ForeName>Tatiana M</ForeName><Initials>TM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nudelman</LastName><ForeName>Kelly</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Faber</LastName><ForeName>Kelley</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wilmes</LastName><ForeName>Kristi</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thal</LastName><ForeName>Leon</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Keith A</ForeName><Initials>KA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa A</ForeName><Initials>RA</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>18</Day><Hour>12</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>4</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35435938</ArticleId><ArticleId IdType="pmc">PMC9016616</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2022.0676</ArticleId><ArticleId IdType="pii">2790807</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Johnson KA, Schultz A, Betensky RA, et al. . Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol. 2016;79(1):110-119. doi:10.1002/ana.24546</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24546</ArticleId><ArticleId IdType="pmc">PMC4738026</ArticleId><ArticleId IdType="pubmed">26505746</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowe VJ, Bruinsma TJ, Wiste HJ, et al. . Cross-sectional associations of tau-PET signal with cognition in cognitively unimpaired adults. Neurology. 2019;93(1):e29-e39. doi:10.1212/WNL.0000000000007728</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000007728</ArticleId><ArticleId IdType="pmc">PMC6659005</ArticleId><ArticleId IdType="pubmed">31147421</ArticleId></ArticleIdList></Reference><Reference><Citation>Betthauser TJ, Koscik RL, Jonaitis EM, et al. . Amyloid and tau imaging biomarkers explain cognitive decline from late middle-age. Brain. 2020;143(1):320-335. doi:10.1093/brain/awz378</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz378</ArticleId><ArticleId IdType="pmc">PMC6935717</ArticleId><ArticleId IdType="pubmed">31886494</ArticleId></ArticleIdList></Reference><Reference><Citation>Maass A, Landau S, Baker SL, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer&#x2019;s disease. Neuroimage. 2017;157:448-463. doi:10.1016/j.neuroimage.2017.05.058</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2017.05.058</ArticleId><ArticleId IdType="pmc">PMC5814575</ArticleId><ArticleId IdType="pubmed">28587897</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Alafuzoff I, Bigio EH, et al. . Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol. 2012;71(5):362-381. doi:10.1097/NEN.0b013e31825018f7</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e31825018f7</ArticleId><ArticleId IdType="pmc">PMC3560290</ArticleId><ArticleId IdType="pubmed">22487856</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239-259. doi:10.1007/BF00308809</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00308809</ArticleId><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT, Phelps CH, Beach TG, et al. . National Institute on Aging&#x2013;Alzheimer&#x2019;s Association guidelines for the neuropathologic assessment of Alzheimer&#x2019;s disease. Alzheimers Dement. 2012;8(1):1-13. doi:10.1016/j.jalz.2011.10.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2011.10.007</ArticleId><ArticleId IdType="pmc">PMC3266529</ArticleId><ArticleId IdType="pubmed">22265587</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitwell JL, Dickson DW, Murray ME, et al. . Neuroimaging correlates of pathologically-defined atypical Alzheimer&#x2019;s disease. Lancet Neurol. 2012;11(10):868-877. doi:10.1016/S1474-4422(12)70200-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(12)70200-4</ArticleId><ArticleId IdType="pmc">PMC3490201</ArticleId><ArticleId IdType="pubmed">22951070</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray ME, Graff-Radford NR, Ross OA, Petersen RC, Duara R, Dickson DW. Neuropathologically defined subtypes of Alzheimer&#x2019;s disease with distinct clinical characteristics: a retrospective study. Lancet Neurol. 2011;10(9):785-796. doi:10.1016/S1474-4422(11)70156-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(11)70156-9</ArticleId><ArticleId IdType="pmc">PMC3175379</ArticleId><ArticleId IdType="pubmed">21802369</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen C, Nolan AL, de Paula Fran&#xe7;a Resende E, et al. . Alzheimer&#x2019;s disease clinical variants show distinct regional patterns of neurofibrillary tangle accumulation. Acta Neuropathol. 2019;138(4):597-612. doi:10.1007/s00401-019-02036-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-019-02036-6</ArticleId><ArticleId IdType="pmc">PMC7012374</ArticleId><ArticleId IdType="pubmed">31250152</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R, Schonhaut DR, Sch&#xf6;ll M, et al. . Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer&#x2019;s disease. Brain. 2016;139(pt 5):1551-1567. doi:10.1093/brain/aww027</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aww027</ArticleId><ArticleId IdType="pmc">PMC5006248</ArticleId><ArticleId IdType="pubmed">26962052</ArticleId></ArticleIdList></Reference><Reference><Citation>La Joie R, Visani AV, Lesman-Segev OH, et al. . Association of APOE4 and clinical variability in Alzheimer disease with the pattern of tau- and amyloid-PET. Neurology. 2021;96(5):e650-e661. doi:10.1212/WNL.0000000000011270</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000011270</ArticleId><ArticleId IdType="pmc">PMC7884991</ArticleId><ArticleId IdType="pubmed">33262228</ArticleId></ArticleIdList></Reference><Reference><Citation>Sintini I, Martin PR, Graff-Radford J, et al. . Longitudinal tau-PET uptake and atrophy in atypical Alzheimer&#x2019;s disease. Neuroimage Clin. 2019;23:101823. doi:10.1016/j.nicl.2019.101823</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nicl.2019.101823</ArticleId><ArticleId IdType="pmc">PMC6475765</ArticleId><ArticleId IdType="pubmed">31004914</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips JS, Das SR, McMillan CT, et al. . Tau PET imaging predicts cognition in atypical variants of Alzheimer&#x2019;s disease. Hum Brain Mapp. 2018;39(2):691-708. doi:10.1002/hbm.23874</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hbm.23874</ArticleId><ArticleId IdType="pmc">PMC5764792</ArticleId><ArticleId IdType="pubmed">29105977</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasrallah IM, Chen YJ, Hsieh MK, et al. . 18F-flortaucipir PET/MRI correlations in nonamnestic and amnestic variants of Alzheimer disease. J Nucl Med. 2018;59(2):299-306. doi:10.2967/jnumed.117.194282</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.117.194282</ArticleId><ArticleId IdType="pmc">PMC6348438</ArticleId><ArticleId IdType="pubmed">28747523</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R, Leuzy A, Cho H, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative; PREVENT-AD research group . The impact of demographic, clinical, genetic, and imaging variables on tau PET status. Eur J Nucl Med Mol Imaging. 2021;48(7):2245-2258. doi:10.1007/s00259-020-05099-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-020-05099-w</ArticleId><ArticleId IdType="pmc">PMC8131404</ArticleId><ArticleId IdType="pubmed">33215319</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowe VJ, Wiste HJ, Senjem ML, et al. . Widespread brain tau and its association with ageing, Braak stage and Alzheimer&#x2019;s dementia. Brain. 2018;141(1):271-287. doi:10.1093/brain/awx320</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awx320</ArticleId><ArticleId IdType="pmc">PMC5837250</ArticleId><ArticleId IdType="pubmed">29228201</ArticleId></ArticleIdList></Reference><Reference><Citation>Koedam ELGE, Lauffer V, van der Vlies AE, van der Flier WM, Scheltens P, Pijnenburg YAL. Early-versus late-onset Alzheimer&#x2019;s disease: more than age alone. J Alzheimers Dis. 2010;19(4):1401-1408. doi:10.3233/JAD-2010-1337</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2010-1337</ArticleId><ArticleId IdType="pubmed">20061618</ArticleId></ArticleIdList></Reference><Reference><Citation>Graff-Radford J, Yong KXX, Apostolova LG, et al. . New insights into atypical Alzheimer&#x2019;s disease in the era of biomarkers. Lancet Neurol. 2021;20(3):222-234. doi:10.1016/S1474-4422(20)30440-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(20)30440-3</ArticleId><ArticleId IdType="pmc">PMC8056394</ArticleId><ArticleId IdType="pubmed">33609479</ArticleId></ArticleIdList></Reference><Reference><Citation>The A4 Study. Accessed March 8, 2022. https://a4study.org/</Citation></Reference><Reference><Citation>Sperling RA, Donohue MC, Raman R, et al. ; A4 Study Team. Association of factors with elevated amyloid burden in clinically normal older individuals. JAMA Neurol. 2020;77(6):735-745. doi:10.1001/jamaneurol.2020.0387</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2020.0387</ArticleId><ArticleId IdType="pmc">PMC7136861</ArticleId><ArticleId IdType="pubmed">32250387</ArticleId></ArticleIdList></Reference><Reference><Citation>Dagley A, LaPoint M, Huijbers W, et al. . Harvard Aging Brain Study: dataset and accessibility. Neuroimage. 2017;144(pt B):255-258. doi:10.1016/j.neuroimage.2015.03.069</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2015.03.069</ArticleId><ArticleId IdType="pmc">PMC4592689</ArticleId><ArticleId IdType="pubmed">25843019</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson SC, Koscik RL, Jonaitis EM, et al. . The Wisconsin Registry for Alzheimer&#x2019;s Prevention: a review of findings and current directions. Alzheimers Dement (Amst). 2017;10:130-142. doi:10.1016/j.dadm.2017.11.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dadm.2017.11.007</ArticleId><ArticleId IdType="pmc">PMC5755749</ArticleId><ArticleId IdType="pubmed">29322089</ArticleId></ArticleIdList></Reference><Reference><Citation>Crutch SJ, Schott JM, Rabinovici GD, et al. ; Alzheimer&#x2019;s Association ISTAART Atypical Alzheimer&#x2019;s Disease and Associated Syndromes Professional Interest Area . Consensus classification of posterior cortical atrophy. Alzheimers Dement. 2017;13(8):870-884. doi:10.1016/j.jalz.2017.01.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2017.01.014</ArticleId><ArticleId IdType="pmc">PMC5788455</ArticleId><ArticleId IdType="pubmed">28259709</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorno-Tempini ML, Hillis AE, Weintraub S, et al. . Classification of primary progressive aphasia and its variants. Neurology. 2011;76(11):1006-1014. doi:10.1212/WNL.0b013e31821103e6</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e31821103e6</ArticleId><ArticleId IdType="pmc">PMC3059138</ArticleId><ArticleId IdType="pubmed">21325651</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward JH. Hierarchical grouping to optimize an objective function. J Am Stat Assoc. 1963;58(301):236-244. doi:10.1080/01621459.1963.10500845</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/01621459.1963.10500845</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xf6;ll M, Lockhart SN, Schonhaut DR, et al. . PET imaging of tau deposition in the aging human brain. Neuron. 2016;89(5):971-982. doi:10.1016/j.neuron.2016.01.028</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.01.028</ArticleId><ArticleId IdType="pmc">PMC4779187</ArticleId><ArticleId IdType="pubmed">26938442</ArticleId></ArticleIdList></Reference><Reference><Citation>Vemuri P, Lowe VJ, Knopman DS, et al. . Tau-PET uptake: regional variation in average SUVR and impact of amyloid deposition. Alzheimers Dement (Amst). 2016;6:21-30. doi:10.1016/j.dadm.2016.12.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dadm.2016.12.010</ArticleId><ArticleId IdType="pmc">PMC5257031</ArticleId><ArticleId IdType="pubmed">28138510</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Mormino EC, Schultz AP, et al. . The impact of amyloid&#x3b2; and tau on prospective cognitive decline in older individuals. Ann Neurol. 2019;85(2):181-193. doi:10.1002/ana.25395</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25395</ArticleId><ArticleId IdType="pmc">PMC6402593</ArticleId><ArticleId IdType="pubmed">30549303</ArticleId></ArticleIdList></Reference><Reference><Citation>Dwivedi AK, Mallawaarachchi I, Alvarado LA. Analysis of small sample size studies using nonparametric bootstrap test with pooled resampling method. Stat Med. 2017;36(14):2187-2205. doi:10.1002/sim.7263</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.7263</ArticleId><ArticleId IdType="pubmed">28276584</ArticleId></ArticleIdList></Reference><Reference><Citation>Mintun MA, Lo AC, Duggan Evans C, et al. . Donanemab in early Alzheimer&#x2019;s disease. N Engl J Med. 2021;384(18):1691-1704. doi:10.1056/NEJMoa2100708</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2100708</ArticleId><ArticleId IdType="pubmed">33720637</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormino EC. The relevance of beta-amyloid on markers of Alzheimer&#x2019;s disease in clinically normal individuals and factors that influence these associations. Neuropsychol Rev. 2014;24(3):300-312. doi:10.1007/s11065-014-9267-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11065-014-9267-4</ArticleId><ArticleId IdType="pmc">PMC4313873</ArticleId><ArticleId IdType="pubmed">25108368</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogel JW, Young AL, Oxtoby NP, et al. . Four distinct trajectories of tau deposition identified in Alzheimer&#x2019;s disease. Nat Med. 2021;27(5):871-881. doi:10.1038/s41591-021-01309-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01309-6</ArticleId><ArticleId IdType="pmc">PMC8686688</ArticleId><ArticleId IdType="pubmed">33927414</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez JS, Becker JA, Jacobs HIL, et al. . The cortical origin and initial spread of medial temporal tauopathy in Alzheimer&#x2019;s disease assessed with positron emission tomography. Sci Transl Med. 2021;13(577):eabc0655. doi:10.1126/scitranslmed.abc0655</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abc0655</ArticleId><ArticleId IdType="pmc">PMC7978042</ArticleId><ArticleId IdType="pubmed">33472953</ArticleId></ArticleIdList></Reference><Reference><Citation>Groot C, Yeo BTT, Vogel JW, et al. . Latent atrophy factors related to phenotypical variants of posterior cortical atrophy. Neurology. 2020;95(12):e1672-e1685. doi:10.1212/WNL.0000000000010362</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000010362</ArticleId><ArticleId IdType="pmc">PMC7713727</ArticleId><ArticleId IdType="pubmed">32675078</ArticleId></ArticleIdList></Reference><Reference><Citation>Day GS, Gordon BA, Jackson K, et al. . Tau PET binding distinguishes patients with early-stage posterior cortical atrophy from amnestic Alzheimer disease dementia. Alzheimer Dis Assoc Disord. 2017;31(2):87-93. doi:10.1097/WAD.0000000000000196</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WAD.0000000000000196</ArticleId><ArticleId IdType="pmc">PMC5443698</ArticleId><ArticleId IdType="pubmed">28394771</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez JS, Hanseeuw BJ, Lopera F, et al. . Longitudinal amyloid and tau accumulation in autosomal dominant Alzheimer&#x2019;s disease: findings from the Colombia-Boston (COLBOS) Biomarker Study. Alzheimers Res Ther. 2021;13(1):27. doi:10.1186/s13195-020-00765-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-020-00765-5</ArticleId><ArticleId IdType="pmc">PMC7811244</ArticleId><ArticleId IdType="pubmed">33451357</ArticleId></ArticleIdList></Reference><Reference><Citation>Meisl G, Hidari E, Allinson K, et al. . In vivo rate-determining steps of tau seed accumulation in Alzheimer&#x2019;s disease. Sci Adv. 2021;7(44):eabh1448. doi:10.1126/sciadv.abh1448</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.abh1448</ArticleId><ArticleId IdType="pmc">PMC8555892</ArticleId><ArticleId IdType="pubmed">34714685</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Knopman DS, Jagust WJ, et al. . Tracking pathophysiological processes in Alzheimer&#x2019;s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12(2):207-216. doi:10.1016/S1474-4422(12)70291-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(12)70291-0</ArticleId><ArticleId IdType="pmc">PMC3622225</ArticleId><ArticleId IdType="pubmed">23332364</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira D, Nordberg A, Westman E. Biological subtypes of Alzheimer disease: a systematic review and meta-analysis. Neurology. 2020;94(10):436-448. doi:10.1212/WNL.0000000000009058</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000009058</ArticleId><ArticleId IdType="pmc">PMC7238917</ArticleId><ArticleId IdType="pubmed">32047067</ArticleId></ArticleIdList></Reference><Reference><Citation>Bejanin A, Schonhaut DR, La Joie R, et al. . Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer&#x2019;s disease. Brain. 2017;140(12):3286-3300. doi:10.1093/brain/awx243</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awx243</ArticleId><ArticleId IdType="pmc">PMC5841139</ArticleId><ArticleId IdType="pubmed">29053874</ArticleId></ArticleIdList></Reference><Reference><Citation>Maass A, Lockhart SN, Harrison TM, et al. . Entorhinal tau pathology, episodic memory decline, and neurodegeneration in aging. J Neurosci. 2018;38(3):530-543. doi:10.1523/JNEUROSCI.2028-17.2017</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2028-17.2017</ArticleId><ArticleId IdType="pmc">PMC5777108</ArticleId><ArticleId IdType="pubmed">29192126</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker JE, Lim YY, Pietrzak RH, et al. . Cognitive impairment and decline in cognitively normal older adults with high amyloid-&#x3b2;: a meta-analysis. Alzheimers Dement (Amst). 2016;6:108-121. doi:10.1016/j.dadm.2016.09.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dadm.2016.09.002</ArticleId><ArticleId IdType="pmc">PMC5315443</ArticleId><ArticleId IdType="pubmed">28239636</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith R, Sch&#xf6;ll M, Widner H, et al. . In vivo retention of 18F-AV-1451 in corticobasal syndrome. Neurology. 2017;89(8):845-853. doi:10.1212/WNL.0000000000004264</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004264</ArticleId><ArticleId IdType="pmc">PMC5580862</ArticleId><ArticleId IdType="pubmed">28754841</ArticleId></ArticleIdList></Reference><Reference><Citation>Utianski RL, Whitwell JL, Schwarz CG, et al. . Tau-PET imaging with [18F]AV-1451 in primary progressive apraxia of speech. Cortex. 2018;99:358-374. doi:10.1016/j.cortex.2017.12.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cortex.2017.12.021</ArticleId><ArticleId IdType="pmc">PMC5800944</ArticleId><ArticleId IdType="pubmed">29353121</ArticleId></ArticleIdList></Reference><Reference><Citation>Schonhaut DR, McMillan CT, Spina S, et al. . 18F-flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: a multicenter study. Ann Neurol. 2017;82(4):622-634. doi:10.1002/ana.25060</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25060</ArticleId><ArticleId IdType="pmc">PMC5665658</ArticleId><ArticleId IdType="pubmed">28980714</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleisher AS, Pontecorvo MJ, Devous MD Sr, et al. ; A16 Study Investigators . Positron emission tomography imaging with [18F]flortaucipir and postmortem assessment of Alzheimer disease neuropathologic changes. JAMA Neurol. 2020;77(7):829-839. doi:10.1001/jamaneurol.2020.0528</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2020.0528</ArticleId><ArticleId IdType="pmc">PMC7186920</ArticleId><ArticleId IdType="pubmed">32338734</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35438743</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>21</Day></DateCompleted><DateRevised><Year>2022</Year><Month>05</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3598</ISSN><JournalIssue CitedMedium="Internet"><Volume>327</Volume><Issue>15</Issue><PubDate><Year>2022</Year><Month>Apr</Month><Day>19</Day></PubDate></JournalIssue><Title>JAMA</Title><ISOAbbreviation>JAMA</ISOAbbreviation></Journal><ArticleTitle>Association of Race and Ethnicity With Dementia.</ArticleTitle><Pagination><StartPage>1454</StartPage><EndPage>1455</EndPage><MedlinePgn>1454-1455</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jama.2022.4473</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yeo</LastName><ForeName>Gwen</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Stanford University School of Medicine, Stanford, California.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA</MedlineTA><NlmUniqueID>7501160</NlmUniqueID><ISSNLinking>0098-7484</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>JAMA. 2022 Apr 19;327(15):1488-1495. doi: 10.1001/jama.2022.3550.</RefSource><PMID Version="1">35438728</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="Y">Dementia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005006" MajorTopicYN="N">Ethnicity</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044469" MajorTopicYN="N">Racial Groups</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012959" MajorTopicYN="N">Socioeconomic Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>19</Day><Hour>12</Hour><Minute>38</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35438743</ArticleId><ArticleId IdType="doi">10.1001/jama.2022.4473</ArticleId><ArticleId IdType="pii">2791243</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35438728</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>21</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3598</ISSN><JournalIssue CitedMedium="Internet"><Volume>327</Volume><Issue>15</Issue><PubDate><Year>2022</Year><Month>Apr</Month><Day>19</Day></PubDate></JournalIssue><Title>JAMA</Title><ISOAbbreviation>JAMA</ISOAbbreviation></Journal><ArticleTitle>Association of Race and Ethnicity With Incidence of Dementia Among Older Adults.</ArticleTitle><Pagination><StartPage>1488</StartPage><EndPage>1495</EndPage><MedlinePgn>1488-1495</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jama.2022.3550</ELocationID><Abstract><AbstractText Label="IMPORTANCE">The racial and ethnic diversity of the US, including among patients receiving their care at the Veterans Health Administration (VHA), is increasing. Dementia is a significant public health challenge and may have greater incidence among older adults from underrepresented racial and ethnic minority groups.</AbstractText><AbstractText Label="OBJECTIVE">To determine dementia incidence across 5 racial and ethnic groups and by US geographical region within a large, diverse, national cohort of older veterans who received care in the largest integrated health care system in the US.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">Retrospective cohort study within the VHA of a random sample (5% sample selected for each fiscal year) of 1&#x202f;869&#x202f;090 participants aged 55 years or older evaluated from October 1, 1999, to September 30, 2019 (the date of final follow-up).</AbstractText><AbstractText Label="EXPOSURES">Self-reported racial and ethnic data were obtained from the National Patient Care Database. US region was determined using Centers for Disease Control and Prevention (CDC) regions from residential zip codes.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Incident diagnosis of dementia (9th and 10th editions of the International Classification of Diseases). Fine-Gray proportional hazards models were used to examine time to diagnosis, with age as the time scale and accounting for competing risk of death.</AbstractText><AbstractText Label="RESULTS">Among the 1&#x202f;869&#x202f;090 study participants (mean age, 69.4 [SD, 7.9] years; 42&#x202f;870 women [2%]; 6865 American Indian or Alaska Native [0.4%], 9391 Asian [0.5%], 176&#x202f;795 Black [9.5%], 20&#x202f;663 Hispanic [1.0%], and 1&#x202f;655&#x202f;376 White [88.6%]), 13% received a diagnosis of dementia over a mean follow-up of 10.1 years. Age-adjusted incidence of dementia per 1000 person-years was 14.2 (95% CI, 13.3-15.1) for American Indian or Alaska Native participants, 12.4 (95% CI, 11.7-13.1) for Asian participants, 19.4 (95% CI, 19.2-19.6) for Black participants, 20.7 (95% CI, 20.1-21.3) for Hispanic participants, and 11.5 (95% CI, 11.4-11.6) for White participants. Compared with White participants, the fully adjusted hazard ratios were 1.05 (95% CI, 0.98-1.13) for American Indian or Alaska Native participants, 1.20 (95% CI, 1.13-1.28) for Asian participants, 1.54 (95% CI, 1.51-1.57) for Black participants, and 1.92 (95% CI, 1.82-2.02) for Hispanic participants. Across most US regions, age-adjusted dementia incidence rates were highest for Black and Hispanic participants, with rates similar among American Indian or Alaska Native, Asian, and White participants.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">Among older adults who received care at VHA medical centers, there were significant differences in dementia incidence based on race and ethnicity. Further research is needed to understand the mechanisms responsible for these differences.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kornblith</LastName><ForeName>Erica</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>San Francisco Veterans Affairs Health Care System, San Francisco, California.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bahorik</LastName><ForeName>Amber</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, University of California, San Francisco.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Northern California Institute for Research and Education, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boscardin</LastName><ForeName>W John</ForeName><Initials>WJ</Initials><AffiliationInfo><Affiliation>San Francisco Veterans Affairs Health Care System, San Francisco, California.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xia</LastName><ForeName>Feng</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>San Francisco Veterans Affairs Health Care System, San Francisco, California.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Northern California Institute for Research and Education, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barnes</LastName><ForeName>Deborah E</ForeName><Initials>DE</Initials><AffiliationInfo><Affiliation>San Francisco Veterans Affairs Health Care System, San Francisco, California.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, University of California, San Francisco.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yaffe</LastName><ForeName>Kristine</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>San Francisco Veterans Affairs Health Care System, San Francisco, California.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, University of California, San Francisco.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Northern California Institute for Research and Education, San Francisco.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>IK2 RX003073</GrantID><Acronym>RX</Acronym><Agency>RRD VA</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 AG031155</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R35 AG071916</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA</MedlineTA><NlmUniqueID>7501160</NlmUniqueID><ISSNLinking>0098-7484</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA. 2022 Apr 19;327(15):1454-1455. doi: 10.1001/jama.2022.4473.</RefSource><PMID Version="1">35438743</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="Y">Dementia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005006" MajorTopicYN="N">Ethnicity</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008913" MajorTopicYN="N">Minority Groups</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044469" MajorTopicYN="N">Racial Groups</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014728" MajorTopicYN="Y">Veterans</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000081324" MajorTopicYN="N">Veterans Health Services</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Yaffe reported receiving grant R35AG071916 from the National Institute on Aging (NIA) during the conduct of the study; serving on the data and safety monitoring boards for several National Institutes of Health&#x2013;sponsored studies; and receiving personal fees for serving on the data and safety monitoring boards of Eli Lilly and Alector and for serving as a member of the Beeson scientific advisory board. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>19</Day><Hour>12</Hour><Minute>38</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>10</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35438728</ArticleId><ArticleId IdType="pmc">PMC9020215</ArticleId><ArticleId IdType="doi">10.1001/jama.2022.3550</ArticleId><ArticleId IdType="pii">2791223</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Katz MJ, Lipton RB, Hall CB, et al. . Age-specific and sex-specific prevalence and incidence of mild cognitive impairment, dementia, and Alzheimer dementia in blacks and whites: a report from the Einstein Aging Study. Alzheimer Dis Assoc Disord. 2012;26(4):335-343. doi:10.1097/WAD.0b013e31823dbcfc</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WAD.0b013e31823dbcfc</ArticleId><ArticleId IdType="pmc">PMC3334445</ArticleId><ArticleId IdType="pubmed">22156756</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta KM, Yeo GW. Systematic review of dementia prevalence and incidence in United States race/ethnic populations. Alzheimers Dement. 2017;13(1):72-83. doi:10.1016/j.jalz.2016.06.2360</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2016.06.2360</ArticleId><ArticleId IdType="pubmed">27599209</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzpatrick AL, Kuller LH, Ives DG, et al. . Incidence and prevalence of dementia in the Cardiovascular Health Study. J Am Geriatr Soc. 2004;52(2):195-204. doi:10.1111/j.1532-5415.2004.52058.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1532-5415.2004.52058.x</ArticleId><ArticleId IdType="pubmed">14728627</ArticleId></ArticleIdList></Reference><Reference><Citation>Plassman BL, Langa KM, Fisher GG, et al. . Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology. 2007;29(1-2):125-132. doi:10.1159/000109998</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000109998</ArticleId><ArticleId IdType="pmc">PMC2705925</ArticleId><ArticleId IdType="pubmed">17975326</ArticleId></ArticleIdList></Reference><Reference><Citation>Moon H, Badana ANS, Hwang S-Y, Sears JS, Haley WE. Dementia prevalence in older adults: variation by race/ethnicity and immigrant status. Am J Geriatr Psychiatry. 2019;27(3):241-250. doi:10.1016/j.jagp.2018.11.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jagp.2018.11.003</ArticleId><ArticleId IdType="pubmed">30573327</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayeda ER, Glymour MM, Quesenberry CP, Whitmer RA. Inequalities in dementia incidence between six racial and ethnic groups over 14 years. Alzheimers Dement. 2016;12(3):216-224. doi:10.1016/j.jalz.2015.12.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2015.12.007</ArticleId><ArticleId IdType="pmc">PMC4969071</ArticleId><ArticleId IdType="pubmed">26874595</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaffe K, Falvey C, Harris TB, et al. ; Health ABC Study . Effect of socioeconomic disparities on incidence of dementia among biracial older adults: prospective study. BMJ. 2013;347:f7051. doi:10.1136/bmj.f7051</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.f7051</ArticleId><ArticleId IdType="pmc">PMC3898154</ArticleId><ArticleId IdType="pubmed">24355614</ArticleId></ArticleIdList></Reference><Reference><Citation>Chin AL, Negash S, Hamilton R. Diversity and disparity in dementia: the impact of ethnoracial differences in Alzheimer disease. Alzheimer Dis Assoc Disord. 2011;25(3):187-195. doi:10.1097/WAD.0b013e318211c6c9</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WAD.0b013e318211c6c9</ArticleId><ArticleId IdType="pmc">PMC3396146</ArticleId><ArticleId IdType="pubmed">21399486</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaffe K, Vittinghoff E, Lindquist K, et al. . Posttraumatic stress disorder and risk of dementia among US veterans. Arch Gen Psychiatry. 2010;67(6):608-613. doi:10.1001/archgenpsychiatry.2010.61</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archgenpsychiatry.2010.61</ArticleId><ArticleId IdType="pmc">PMC2933793</ArticleId><ArticleId IdType="pubmed">20530010</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes DE, Kaup A, Kirby KA, Byers AL, Diaz-Arrastia R, Yaffe K. Traumatic brain injury and risk of dementia in older veterans. Neurology. 2014;83(4):312-319. doi:10.1212/WNL.0000000000000616</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000000616</ArticleId><ArticleId IdType="pmc">PMC4115602</ArticleId><ArticleId IdType="pubmed">24966406</ArticleId></ArticleIdList></Reference><Reference><Citation>Veitch DP, Friedl KE, Weiner MW. Military risk factors for cognitive decline, dementia and Alzheimer&#x2019;s disease. Curr Alzheimer Res. 2013;10(9):907-930. doi:10.2174/15672050113109990142</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/15672050113109990142</ArticleId><ArticleId IdType="pubmed">23906002</ArticleId></ArticleIdList></Reference><Reference><Citation>Hinojosa R. Cardiovascular disease among United States military veterans: evidence of a waning healthy soldier effect using the National Health Interview Survey. Chronic Illn. 2020;16(1):55-68. doi:10.1177/1742395318785237</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1742395318785237</ArticleId><ArticleId IdType="pubmed">29940779</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker LE, Poltavskiy E, Janak JC, Beyer CA, Stewart IJ, Howard JT. US military service and racial/ethnic differences in cardiovascular disease: an analysis of the 2011-2016 Behavioral Risk Factor Surveillance System. Ethn Dis. 2019;29(3):451-462. doi:10.18865/ed.29.3.451</Citation><ArticleIdList><ArticleId IdType="doi">10.18865/ed.29.3.451</ArticleId><ArticleId IdType="pmc">PMC6645722</ArticleId><ArticleId IdType="pubmed">31367165</ArticleId></ArticleIdList></Reference><Reference><Citation>Baicker K, Chandra A, Skinner JS. Geographic variation in health care and the problem of measuring racial disparities. Perspect Biol Med. 2005;48(1)(suppl):S42-S53. doi:10.1353/pbm.2005.0020</Citation><ArticleIdList><ArticleId IdType="doi">10.1353/pbm.2005.0020</ArticleId><ArticleId IdType="pubmed">15842086</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasnain-Wynia R, Baker DW, Nerenz D, et al. . Disparities in health care are driven by where minority patients seek care: examination of the hospital quality alliance measures. Arch Intern Med. 2007;167(12):1233-1239. doi:10.1001/archinte.167.12.1233</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinte.167.12.1233</ArticleId><ArticleId IdType="pubmed">17592095</ArticleId></ArticleIdList></Reference><Reference><Citation>National Center for Chronic Disease Prevention and Health Promotion Regions . Centers for Disease Control and Prevention. Accessed March 18, 2022. https://www.cdc.gov/chronicdisease/index.htm</Citation></Reference><Reference><Citation>US Department of Veterans Affairs . VHA dementia steering committee recommendations for dementia care in the VHA healthcare system 2016. Published September 2016. Accessed September 3, 2019. https://www.va.gov/GERIATRICS/docs/VHA_DSC_RECOMMENDATIONS_SEPT_2016_9-12-16.pdf</Citation></Reference><Reference><Citation>Wei MY, Luster JE, Chan C-L, Min L. Comprehensive review of ICD-9 code accuracies to measure multimorbidity in administrative data. BMC Health Serv Res. 2020;20(1):489. doi:10.1186/s12913-020-05207-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12913-020-05207-4</ArticleId><ArticleId IdType="pmc">PMC7268621</ArticleId><ArticleId IdType="pubmed">32487087</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujiyoshi A, Jacobs DR Jr, Alonso A, Luchsinger JA, Rapp SR, Duprez DA. Validity of death certificate and hospital discharge ICD codes for dementia diagnosis: the Multi Ethnic Study of Atherosclerosis. Alzheimer Dis Assoc Disord. 2017;31(2):168-172. doi:10.1097/WAD.0000000000000164</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WAD.0000000000000164</ArticleId><ArticleId IdType="pmc">PMC5418097</ArticleId><ArticleId IdType="pubmed">27819846</ArticleId></ArticleIdList></Reference><Reference><Citation>Beiser A, D&#x2019;Agostino RB Sr, Seshadri S, Sullivan LM, Wolf PA. Computing estimates of incidence, including lifetime risk: Alzheimer&#x2019;s disease in the Framingham Study. The Practical Incidence Estimators (PIE) macro. Stat Med. 2000;19(11-12):1495-1522. doi:10.1002/(SICI)1097-0258(20000615/30)19:11/12&lt;1495::AID-SIM441&gt;3.0.CO;2-E</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1097-0258(20000615/30)19:11/12&lt;1495::AID-SIM441&gt;3.0.CO;2-E</ArticleId><ArticleId IdType="pubmed">10844714</ArticleId></ArticleIdList></Reference><Reference><Citation>VA Office of Health Equity . VA national veteran health equity report: distribution of race/ethnicity among veteran VHA patients, FY13. Published 2016. Accessed June 10, 2021. https://vha-healthequity.shinyapps.io/NVHER_Shiny/</Citation></Reference><Reference><Citation>Weiner MF, Hynan LS, Beekly D, Koepsell TD, Kukull WA. Comparison of Alzheimer&#x2019;s disease in American Indians, whites, and African Americans. Alzheimers Dement. 2007;3(3):211-216. doi:10.1016/j.jalz.2007.04.376</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2007.04.376</ArticleId><ArticleId IdType="pubmed">19595940</ArticleId></ArticleIdList></Reference><Reference><Citation>National Congress of American Indians. Demographics. Accessed August 24, 2021. https://www.ncai.org/about-tribes/demographics</Citation></Reference><Reference><Citation>National Indian Council on Aging, Inc . American Indian Veterans have highest record of military service. Published November 8, 2019. Accessed August 12, 2021. https://www.nicoa.org/american-indian-veterans-have-highest-record-of-military-service/</Citation></Reference><Reference><Citation>Hendrie HC, Hall KS, Pillay N, et al. . Alzheimer&#x2019;s disease is rare in Cree. Int Psychogeriatr. 1993;5(1):5-14. doi:10.1017/S1041610293001358</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S1041610293001358</ArticleId><ArticleId IdType="pubmed">8499574</ArticleId></ArticleIdList></Reference><Reference><Citation>Jervis LL, Manson SM. American Indians/Alaska natives and dementia. Alzheimer Dis Assoc Disord. 2002;16(suppl 2):S89-S95. doi:10.1097/00002093-200200002-00011</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00002093-200200002-00011</ArticleId><ArticleId IdType="pubmed">12351922</ArticleId></ArticleIdList></Reference><Reference><Citation>Warren LA, Shi Q, Young K, Borenstein A, Martiniuk A. Prevalence and incidence of dementia among indigenous populations: a systematic review. Int Psychogeriatr. 2015;27(12):1959-1970. doi:10.1017/S1041610215000861</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S1041610215000861</ArticleId><ArticleId IdType="pubmed">26088474</ArticleId></ArticleIdList></Reference><Reference><Citation>Carty CL, Noonan C, Muller C, et al. . Risk factors for Alzheimer&#x2019;s disease and related dementia diagnoses in American Indians. Ethn Dis. 2020;30(4):671-680. doi:10.18865/ed.30.4.671</Citation><ArticleIdList><ArticleId IdType="doi">10.18865/ed.30.4.671</ArticleId><ArticleId IdType="pmc">PMC7518528</ArticleId><ArticleId IdType="pubmed">32989367</ArticleId></ArticleIdList></Reference><Reference><Citation>Spencer KL, Grace M. Social foundations of health care inequality and treatment bias. Annu Rev Sociol. 2016;42:101-120. doi:10.1146/annurev-soc-081715-074226</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-soc-081715-074226</ArticleId></ArticleIdList></Reference><Reference><Citation>Eliacin J, Cunningham B, Partin MR, et al. . Veterans affairs providers&#x2019; beliefs about the contributors to and responsibility for reducing racial and ethnic health care disparities. Health Equity. 2019;3(1):436-448. doi:10.1089/heq.2019.0018</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/heq.2019.0018</ArticleId><ArticleId IdType="pmc">PMC6707034</ArticleId><ArticleId IdType="pubmed">31448354</ArticleId></ArticleIdList></Reference><Reference><Citation>Fyffe DC, Mukherjee S, Barnes LL, Manly JJ, Bennett DA, Crane PK. Explaining differences in episodic memory performance among older African Americans and Whites: the roles of factors related to cognitive reserve and test bias. J Int Neuropsychol Soc. 2011;17(4):625-638. doi:10.1017/S1355617711000476</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S1355617711000476</ArticleId><ArticleId IdType="pmc">PMC3496282</ArticleId><ArticleId IdType="pubmed">23131601</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyatt SB, Williams DR, Calvin R, Henderson FC, Walker ER, Winters K. Racism and cardiovascular disease in African Americans. Am J Med Sci. 2003;325(6):315-331. doi:10.1097/00000441-200306000-00003</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00000441-200306000-00003</ArticleId><ArticleId IdType="pubmed">12811228</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang M-X, Cross P, Andrews H, et al. . Incidence of AD in African-Americans, Caribbean Hispanics, and Caucasians in northern Manhattan. Neurology. 2001;56(1):49-56. doi:10.1212/WNL.56.1.49</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.56.1.49</ArticleId><ArticleId IdType="pubmed">11148235</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes LL, Leurgans S, Aggarwal NT, et al. . Mixed pathology is more likely in black than white decedents with Alzheimer dementia. Neurology. 2015;85(6):528-534. doi:10.1212/WNL.0000000000001834</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000001834</ArticleId><ArticleId IdType="pmc">PMC4540250</ArticleId><ArticleId IdType="pubmed">26180136</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaffe K, Lwi SJ, Hoang TD, et al. . Military-related risk factors in female veterans and risk of dementia. Neurology. 2019;92(3):e205-e211. doi:10.1212/WNL.0000000000006778</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000006778</ArticleId><ArticleId IdType="pmc">PMC6340384</ArticleId><ArticleId IdType="pubmed">30541865</ArticleId></ArticleIdList></Reference><Reference><Citation>Rooks RN, Simonsick EM, Klesges LM, Newman AB, Ayonayon HN, Harris TB. Racial disparities in health care access and cardiovascular disease indicators in Black and White older adults in the Health ABC Study. J Aging Health. 2008;20(6):599-614. doi:10.1177/0898264308321023</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0898264308321023</ArticleId><ArticleId IdType="pmc">PMC2733332</ArticleId><ArticleId IdType="pubmed">18625758</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilsanz P, Mayeda ER, Glymour MM, Quesenberry CP, Whitmer RA. Association between birth in a high stroke mortality state, race, and risk of dementia. JAMA Neurol. 2017;74(9):1056-1062. doi:10.1001/jamaneurol.2017.1553</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2017.1553</ArticleId><ArticleId IdType="pmc">PMC5691590</ArticleId><ArticleId IdType="pubmed">28759663</ArticleId></ArticleIdList></Reference><Reference><Citation>Guland B, Wilder D, Lantigua R, et al. . Differences in rates of dementia between ethno-racial groups. In: Racial and Ethnic Differences in the Health of Older Americans. National Academies Press; 1997.</Citation><ArticleIdList><ArticleId IdType="pubmed">23115810</ArticleId></ArticleIdList></Reference><Reference><Citation>Javier SJ, Troszak LK, Shimada SL, et al. . Racial and ethnic disparities in use of a personal health record by veterans living with HIV. J Am Med Inform Assoc. 2019;26(8-9):696-702. doi:10.1093/jamia/ocz024</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocz024</ArticleId><ArticleId IdType="pmc">PMC7647203</ArticleId><ArticleId IdType="pubmed">30924875</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen AY, Schrag NM, Halpern M, Stewart A, Ward EM. Health insurance and stage at diagnosis of laryngeal cancer: does insurance type predict stage at diagnosis? Arch Otolaryngol Head Neck Surg. 2007;133(8):784-790. doi:10.1001/archotol.133.8.784</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archotol.133.8.784</ArticleId><ArticleId IdType="pubmed">17709617</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">35438230</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>08</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1469-3178</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>6</Issue><PubDate><Year>2022</Year><Month>Jun</Month><Day>07</Day></PubDate></JournalIssue><Title>EMBO reports</Title><ISOAbbreviation>EMBO Rep</ISOAbbreviation></Journal><ArticleTitle>Gel-like inclusions of C-terminal fragments of TDP-43 sequester stalled proteasomes in neurons.</ArticleTitle><Pagination><StartPage>e53890</StartPage><MedlinePgn>e53890</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e53890</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.15252/embr.202153890</ELocationID><Abstract><AbstractText>Aggregation of the multifunctional RNA-binding protein TDP-43 defines large subgroups of amyotrophic lateral sclerosis and frontotemporal dementia and correlates with neurodegeneration in both diseases. In disease, characteristic C-terminal fragments of ~25&#x2009;kDa ("TDP-25") accumulate in cytoplasmic inclusions. Here, we analyze gain-of-function mechanisms of TDP-25 combining cryo-electron tomography, proteomics, and functional assays. In neurons, cytoplasmic TDP-25 inclusions are amorphous, and photobleaching experiments reveal gel-like biophysical properties that are less dynamic than nuclear TDP-43. Compared with full-length TDP-43, the TDP-25 interactome is depleted of low-complexity domain proteins. TDP-25 inclusions are enriched in 26S proteasomes adopting exclusively substrate-processing conformations, suggesting that inclusions sequester proteasomes, which are largely stalled and no longer undergo the cyclic conformational changes required for proteolytic activity. Reporter assays confirm that TDP-25 impairs proteostasis, and this inhibitory function is enhanced by ALS-causing TDP-43 mutations. These findings support a patho-physiological relevance of proteasome dysfunction in ALS/FTD.</AbstractText><CopyrightInformation>&#xa9; 2022 The Authors. Published under the terms of the CC BY 4.0 license.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Riemenschneider</LastName><ForeName>Henrick</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Guo</LastName><ForeName>Qiang</ForeName><Initials>Q</Initials><Identifier Source="ORCID">0000-0003-3520-5439</Identifier><AffiliationInfo><Affiliation>Department of Molecular Structural Biology, Max Planck Institute of Biochemistry, Martinsried, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>State Key Laboratory of Protein and Plant Gene Research, School of Life Sciences and Peking-Tsinghua Center for Life Sciences, Peking University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bader</LastName><ForeName>Jakob</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-6575-0609</Identifier><AffiliationInfo><Affiliation>Department of Proteomics and Signal Transduction, Max Planck Institute for Biochemistry, Martinsried, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frottin</LastName><ForeName>Fr&#xe9;d&#xe9;ric</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-2756-7838</Identifier><AffiliationInfo><Affiliation>Department of Cellular Biochemistry, Max Planck Institute for Biochemistry, Martinsried, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Integrative Biology of the Cell (I2BC), Universit&#xe9; Paris-Saclay, CEA, CNRS, Gif-sur-Yvette, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farny</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kleinberger</LastName><ForeName>Gernot</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haass</LastName><ForeName>Christian</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-4869-1627</Identifier><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Chair of Metabolic Biochemistry, Faculty of Medicine, Biomedical Center (BMC), Ludwig-Maximilians-Universit&#xe4;t Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster of Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mann</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-1292-4799</Identifier><AffiliationInfo><Affiliation>Department of Proteomics and Signal Transduction, Max Planck Institute for Biochemistry, Martinsried, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hartl</LastName><ForeName>F Ulrich</ForeName><Initials>FU</Initials><Identifier Source="ORCID">0000-0002-7941-135X</Identifier><AffiliationInfo><Affiliation>Department of Cellular Biochemistry, Max Planck Institute for Biochemistry, Martinsried, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster of Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baumeister</LastName><ForeName>Wolfgang</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Molecular Structural Biology, Max Planck Institute of Biochemistry, Martinsried, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hipp</LastName><ForeName>Mark S</ForeName><Initials>MS</Initials><Identifier Source="ORCID">0000-0002-0497-3016</Identifier><AffiliationInfo><Affiliation>Department of Cellular Biochemistry, Max Planck Institute for Biochemistry, Martinsried, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Sciences of Cells and Systems, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine and Health Sciences, Carl von Ossietzky University Oldenburg, Oldenburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meissner</LastName><ForeName>Felix</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0003-1000-7989</Identifier><AffiliationInfo><Affiliation>Department of Proteomics and Signal Transduction, Max Planck Institute for Biochemistry, Martinsried, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Systems Immunology and Proteomics, Medical Faculty, Institute of Innate Immunity, University of Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fern&#xe1;ndez-Busnadiego</LastName><ForeName>Rub&#xe9;n</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-8366-7622</Identifier><AffiliationInfo><Affiliation>Department of Molecular Structural Biology, Max Planck Institute of Biochemistry, Martinsried, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Neuropathology, University Medical Center G&#xf6;ttingen, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cluster of Excellence "Multiscale Bioimaging: from Molecular Machines to Networks of Excitable Cells" (MBExC), University of G&#xf6;ttingen, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Edbauer</LastName><ForeName>Dieter</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-7186-4653</Identifier><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster of Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate School of Systemic Neurosciences (GSN), Ludwig-Maximilians-University Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>04</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>EMBO Rep</MedlineTA><NlmUniqueID>100963049</NlmUniqueID><ISSNLinking>1469-221X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598624">TARDBP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C574535">TDP-25 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.25.1</RegistryNumber><NameOfSubstance UI="D046988">Proteasome Endopeptidase Complex</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>EMBO Rep. 2024 Jul;25(7):3161. doi: 10.1038/s44319-024-00163-0.</RefSource><PMID Version="1">38849674</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="Y">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002479" MajorTopicYN="N">Inclusion Bodies</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="Y">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="Y">Peptide Fragments</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D046988" MajorTopicYN="N">Proteasome Endopeptidase Complex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">TDP-43</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">phase separation</Keyword><Keyword MajorTopicYN="N">proteasome</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>3</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>8</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>19</Day><Hour>8</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>4</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35438230</ArticleId><ArticleId IdType="pmc">PMC9171420</ArticleId><ArticleId IdType="doi">10.15252/embr.202153890</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arseni D, Hasegawa M, Murzin AG, Kametani F, Arai M, Yoshida M, Ryskeldi&#x2010;Falcon B (2022) Structure of pathological TDP&#x2010;43 filaments from ALS with FTLD. Nature 601: 139&#x2013;143</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7612255</ArticleId><ArticleId IdType="pubmed">34880495</ArticleId></ArticleIdList></Reference><Reference><Citation>Asano S, Fukuda Y, Beck F, Aufderheide A, F&#xf6;rster F, Danev R, Baumeister W (2015) Proteasomes. A molecular census of 26S proteasomes in intact neurons. Science 347: 439&#x2013;442</Citation><ArticleIdList><ArticleId IdType="pubmed">25613890</ArticleId></ArticleIdList></Reference><Reference><Citation>Babinchak WM, Haider R, Dumm BK, Sarkar P, Surewicz K, Choi JK, Surewicz WK (2019) The role of liquid&#x2010;liquid phase separation in aggregation of the TDP&#x2010;43 low&#x2010;complexity domain. J Biol Chem 294: 6306&#x2013;6317</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6484124</ArticleId><ArticleId IdType="pubmed">30814253</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauerlein FJB, Fernandez&#x2010;Busnadiego R, Baumeister W (2020) Investigating the structure of neurotoxic protein aggregates inside cells. Trends Cell Biol 30: 951&#x2013;966</Citation><ArticleIdList><ArticleId IdType="pubmed">32981805</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xe4;uerlein FJB, Saha I, Mishra A, Kalemanov M, Mart&#xed;nez&#x2010;S&#xe1;nchez A, Klein R, Dudanova I, Hipp MS, Hartl FU, Baumeister W et al (2017) In situ architecture and cellular interactions of PolyQ inclusions. Cell 171: 179&#x2013;187.e10</Citation><ArticleIdList><ArticleId IdType="pubmed">28890085</ArticleId></ArticleIdList></Reference><Reference><Citation>Bax M, McKenna J, Do&#x2010;Ha D, Stevens CH, Higginbottom S, Balez R, Cabral&#x2010;da&#x2010;Silva MEC, Farrawell NE, Engel M, Poronnik P et al (2019) The ubiquitin proteasome system is a key regulator of pluripotent stem cell survival and motor neuron differentiation. Cells 8: 581</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6627164</ArticleId><ArticleId IdType="pubmed">31200561</ArticleId></ArticleIdList></Reference><Reference><Citation>Bett JS, Cook C, Petrucelli L, Bates GP (2009) The ubiquitin&#x2010;proteasome reporter GFPu does not accumulate in neurons of the R6/2 transgenic mouse model of Huntington's disease. PLoS One 4: e5128</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2662425</ArticleId><ArticleId IdType="pubmed">19352500</ArticleId></ArticleIdList></Reference><Reference><Citation>Bharat TA, Scheres SH (2016) Resolving macromolecular structures from electron cryo&#x2010;tomography data using subtomogram averaging in RELION. Nat Protoc 11: 2054&#x2013;2065</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5215819</ArticleId><ArticleId IdType="pubmed">27685097</ArticleId></ArticleIdList></Reference><Reference><Citation>Blokhuis AM, Koppers M, Groen EJN, van den Heuvel DMA, Dini Modigliani S, Anink JJ, Fumoto K, van Diggelen F, Snelting A, Sodaar P et al (2016) Comparative interactomics analysis of different ALS&#x2010;associated proteins identifies converging molecular pathways. Acta Neuropathol 132: 175&#x2013;196</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4947123</ArticleId><ArticleId IdType="pubmed">27164932</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Q, Boyer DR, Sawaya MR, Ge P, Eisenberg DS (2019) Cryo&#x2010;EM structures of four polymorphic TDP&#x2010;43 amyloid cores. Nat Struct Mol Biol 26: 619&#x2013;627</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7047951</ArticleId><ArticleId IdType="pubmed">31235914</ArticleId></ArticleIdList></Reference><Reference><Citation>Cassel JA, Reitz AB (2013) Ubiquilin&#x2010;2 (UBQLN2) binds with high affinity to the C&#x2010;terminal region of TDP&#x2010;43 and modulates TDP&#x2010;43 levels in H4 cells: characterization of inhibition by nucleic acids and 4&#x2010;aminoquinolines. Biochim Biophys Acta 1834: 964&#x2013;971</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3960997</ArticleId><ArticleId IdType="pubmed">23541532</ArticleId></ArticleIdList></Reference><Reference><Citation>Chien HM, Lee CC, Huang JJ (2021) The different faces of the TDP&#x2010;43 low&#x2010;complexity domain: the formation of liquid droplets and amyloid fibrils. Int J Mol Sci 22: 8213</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8348237</ArticleId><ArticleId IdType="pubmed">34360978</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou C&#x2010;C, Zhang YI, Umoh ME, Vaughan SW, Lorenzini I, Liu F, Sayegh M, Donlin&#x2010;Asp PG, Chen YH, Duong DM et al (2018) TDP&#x2010;43 pathology disrupts nuclear pore complexes and nucleocytoplasmic transport in ALS/FTD. Nat Neurosci 21: 228&#x2013;239</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5800968</ArticleId><ArticleId IdType="pubmed">29311743</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins GA, Goldberg AL (2017) The logic of the 26S proteasome. Cell 169: 792&#x2013;806</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5609836</ArticleId><ArticleId IdType="pubmed">28525752</ArticleId></ArticleIdList></Reference><Reference><Citation>Conicella AE, Zerze GH, Mittal J, Fawzi NL (2016) ALS mutations disrupt phase separation mediated by alpha&#x2010;helical structure in the TDP&#x2010;43 low&#x2010;complexity C&#x2010;terminal domain. Structure 24: 1537&#x2013;1549</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5014597</ArticleId><ArticleId IdType="pubmed">27545621</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox J, Hein MY, Luber CA, Paron I, Nagaraj N, Mann M (2014) Accurate proteome&#x2010;wide label&#x2010;free quantification by delayed normalization and maximal peptide ratio extraction, termed MaxLFQ. Mol Cell Proteomics 13: 2513&#x2013;2526</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4159666</ArticleId><ArticleId IdType="pubmed">24942700</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox J, Mann M (2008) MaxQuant enables high peptide identification rates, individualized p.p.b.&#x2010;range mass accuracies and proteome&#x2010;wide protein quantification. Nat Biotechnol 26: 1367&#x2013;1372</Citation><ArticleIdList><ArticleId IdType="pubmed">19029910</ArticleId></ArticleIdList></Reference><Reference><Citation>Creekmore BC, Chang YW, Lee EB (2021) The Cryo&#x2010;EM effect: structural biology of neurodegenerative disease aggregates. J Neuropathol Exp Neurol 80: 514&#x2013;529</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8177849</ArticleId><ArticleId IdType="pubmed">33970243</ArticleId></ArticleIdList></Reference><Reference><Citation>Dantuma NP, Lindsten K, Glas R, Jellne M, Masucci MG (2000) Short&#x2010;lived green fluorescent proteins for quantifying ubiquitin/proteasome&#x2010;dependent proteolysis in living cells. Nat Biotechnol 18: 538&#x2013;543</Citation><ArticleIdList><ArticleId IdType="pubmed">10802622</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng H&#x2010;X, Chen W, Hong S&#x2010;T, Boycott KM, Gorrie GH, Siddique N, Yang YI, Fecto F, Shi Y, Zhai H et al (2011) Mutations in UBQLN2 cause dominant X&#x2010;linked juvenile and adult&#x2010;onset ALS and ALS/dementia. Nature 477: 211&#x2013;215</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3169705</ArticleId><ArticleId IdType="pubmed">21857683</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisenberg D, Jucker M (2012) The amyloid state of proteins in human diseases. Cell 148: 1188&#x2013;1203</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3353745</ArticleId><ArticleId IdType="pubmed">22424229</ArticleId></ArticleIdList></Reference><Reference><Citation>Feneberg E, Gordon D, Thompson AG, Finelli MJ, Dafinca R, Candalija A, Charles PD, M&#xe4;ger I, Wood MJ, Fischer R et al (2020) An ALS&#x2010;linked mutation in TDP&#x2010;43 disrupts normal protein interactions in the motor neuron response to oxidative stress. Neurobiol Dis 144: 105050</Citation><ArticleIdList><ArticleId IdType="pubmed">32800996</ArticleId></ArticleIdList></Reference><Reference><Citation>Freibaum BD, Chitta RK, High AA, Taylor JP (2010) Global analysis of TDP&#x2010;43 interacting proteins reveals strong association with RNA splicing and translation machinery. J Proteome Res 9: 1104&#x2013;1120</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2897173</ArticleId><ArticleId IdType="pubmed">20020773</ArticleId></ArticleIdList></Reference><Reference><Citation>Frottin F, Schueder F, Tiwary S, Gupta R, Korner R, Schlichthaerle T, Cox J, Jungmann R, Hartl FU, Hipp MS (2019) The nucleolus functions as a phase&#x2010;separated protein quality control compartment. Science 365: 342&#x2013;347</Citation><ArticleIdList><ArticleId IdType="pubmed">31296649</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao FB, Almeida S, Lopez&#x2010;Gonzalez R (2017) Dysregulated molecular pathways in amyotrophic lateral sclerosis&#x2010;frontotemporal dementia spectrum disorder. EMBO J 36: 2931&#x2013;2950</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5641681</ArticleId><ArticleId IdType="pubmed">28916614</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasset&#x2010;Rosa F, Lu S, Yu H, Chen C, Melamed Z, Guo L, Shorter J, Da Cruz S, Cleveland DW (2019) Cytoplasmic TDP&#x2010;43 de&#x2010;mixing independent of stress granules drives inhibition of nuclear import, loss of nuclear TDP&#x2010;43, and cell death. Neuron 102: 339&#x2013;357.e7</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6548321</ArticleId><ArticleId IdType="pubmed">30853299</ArticleId></ArticleIdList></Reference><Reference><Citation>Gitcho MA, Strider J, Carter D, Taylor&#x2010;Reinwald L, Forman MS, Goate AM, Cairns NJ (2009) VCP mutations causing frontotemporal lobar degeneration disrupt localization of TDP&#x2010;43 and induce cell death. J Biol Chem 284: 12384&#x2013;12398</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2673306</ArticleId><ArticleId IdType="pubmed">19237541</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomes E, Shorter J (2019) The molecular language of membraneless organelles. J Biol Chem 294: 7115&#x2013;7127</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6509512</ArticleId><ArticleId IdType="pubmed">30045872</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottlieb CD, Thompson ACS, Ordureau A, Harper JW, Kopito RR (2019) Acute unfolding of a single protein immediately stimulates recruitment of ubiquitin protein ligase E3C (UBE3C) to 26S proteasomes. J Biol Chem 294: 16511&#x2013;16524</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6851344</ArticleId><ArticleId IdType="pubmed">31375563</ArticleId></ArticleIdList></Reference><Reference><Citation>Guenther EL, Cao Q, Trinh H, Lu J, Sawaya MR, Cascio D, Boyer DR, Rodriguez JA, Hughes MP, Eisenberg DS (2018) Atomic structures of TDP&#x2010;43 LCD segments and insights into reversible or pathogenic aggregation. Nat Struct Mol Biol 25: 463&#x2013;471</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5990464</ArticleId><ArticleId IdType="pubmed">29786080</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Q, Lehmer C, Mart&#xed;nez&#x2010;S&#xe1;nchez A, Rudack T, Beck F, Hartmann H, P&#xe9;rez&#x2010;Berlanga M, Frottin F, Hipp MS, Hartl FU et al (2018) In situ structure of neuronal C9orf72 Poly&#x2010;GA aggregates reveals proteasome recruitment. Cell 172: 696&#x2013;705.e12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6035389</ArticleId><ArticleId IdType="pubmed">29398115</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartmann H, Hornburg D, Czuppa M, Bader J, Michaelsen M, Farny D, Arzberger T, Mann M, Meissner F, Edbauer D (2018) Proteomics and C9orf72 neuropathology identify ribosomes as poly&#x2010;GR/PR interactors driving toxicity. Life Sci Alliance 1: e201800070</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6238541</ArticleId><ArticleId IdType="pubmed">30456350</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa M, Arai T, Nonaka T, Kametani F, Yoshida M, Hashizume Y, Beach TG, Buratti E, Baralle F, Morita M et al (2008) Phosphorylated TDP&#x2010;43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Ann Neurol 64: 60&#x2013;70</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2674108</ArticleId><ArticleId IdType="pubmed">18546284</ArticleId></ArticleIdList></Reference><Reference><Citation>Hipp MS, Kasturi P, Hartl FU (2019) The proteostasis network and its decline in ageing. Nat Rev Mol Cell Biol 20: 421&#x2013;435</Citation><ArticleIdList><ArticleId IdType="pubmed">30733602</ArticleId></ArticleIdList></Reference><Reference><Citation>Hrabe T, Chen Y, Pfeffer S, Cuellar LK, Mangold AV, Forster F (2012) PyTom: a python&#x2010;based toolbox for localization of macromolecules in cryo&#x2010;electron tomograms and subtomogram analysis. J Struct Biol 178: 177&#x2013;188</Citation><ArticleIdList><ArticleId IdType="pubmed">22193517</ArticleId></ArticleIdList></Reference><Reference><Citation>Igaz LM, Kwong LK, Xu Y, Truax AC, Uryu K, Neumann M, Clark CM, Elman LB, Miller BL, Grossman M et al (2008) Enrichment of C&#x2010;terminal fragments in TAR DNA&#x2010;binding protein&#x2010;43 cytoplasmic inclusions in brain but not in spinal cord of frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Am J Pathol 173: 182&#x2013;194</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2438296</ArticleId><ArticleId IdType="pubmed">18535185</ArticleId></ArticleIdList></Reference><Reference><Citation>Jain S, Wheeler JR, Walters RW, Agrawal A, Barsic A, Parker R (2016) ATPase&#x2010;modulated stress granules contain a diverse proteome and substructure. Cell 164: 487&#x2013;498</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4733397</ArticleId><ArticleId IdType="pubmed">26777405</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato M, Han T, Xie S, Shi K, Du X, Wu L, Mirzaei H, Goldsmith E, Longgood J, Pei J et al (2012) Cell&#x2010;free formation of RNA granules: low complexity sequence domains form dynamic fibers within hydrogels. Cell 149: 753&#x2013;767</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6347373</ArticleId><ArticleId IdType="pubmed">22579281</ArticleId></ArticleIdList></Reference><Reference><Citation>Kremer JR, Mastronarde DN, McIntosh JR (1996) Computer visualization of three&#x2010;dimensional image data using IMOD. J Struct Biol 116: 71&#x2013;76</Citation><ArticleIdList><ArticleId IdType="pubmed">8742726</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulak NA, Pichler G, Paron I, Nagaraj N, Mann M (2014) Minimal, encapsulated proteomic&#x2010;sample processing applied to copy&#x2010;number estimation in eukaryotic cells. Nat Methods 11: 319&#x2013;324</Citation><ArticleIdList><ArticleId IdType="pubmed">24487582</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q, Babinchak WM, Surewicz WK (2021) Cryo&#x2010;EM structure of amyloid fibrils formed by the entire low complexity domain of TDP&#x2010;43. Nat Commun 12: 1620</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7955110</ArticleId><ArticleId IdType="pubmed">33712624</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling SC, Albuquerque CP, Han JS, Lagier&#x2010;Tourenne C, Tokunaga S, Zhou H, Cleveland DW (2010) ALS&#x2010;associated mutations in TDP&#x2010;43 increase its stability and promote TDP&#x2010;43 complexes with FUS/TLS. Proc Natl Acad Sci U S A 107: 13318&#x2013;13323</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2922163</ArticleId><ArticleId IdType="pubmed">20624952</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Arzberger T, Kremmer E, Troost D, Lorenzl S, Mori K, Weng S&#x2010;M, Haass C, Kretzschmar HA, Edbauer D et al (2013) Dipeptide repeat protein pathology in C9ORF72 mutation cases: clinico&#x2010;pathological correlations. Acta Neuropathol 126: 859&#x2013;879</Citation><ArticleIdList><ArticleId IdType="pubmed">24096617</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann JR, Gleixner AM, Mauna JC, Gomes E, DeChellis&#x2010;Marks MR, Needham PG, Copley KE, Hurtle B, Portz B, Pyles NJ et al (2019) RNA binding antagonizes neurotoxic phase transitions of TDP&#x2010;43. Neuron 102: 321&#x2013;338.e8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6472983</ArticleId><ArticleId IdType="pubmed">30826182</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin EW, Mittag T (2018) Relationship of sequence and phase separation in protein low&#x2010;complexity regions. Biochemistry 57: 2478&#x2013;2487</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6476794</ArticleId><ArticleId IdType="pubmed">29517898</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez&#x2010;Sanchez A, Garcia I, Asano S, Lucic V, Fernandez JJ (2014) Robust membrane detection based on tensor voting for electron tomography. J Struct Biol 186: 49&#x2013;61</Citation><ArticleIdList><ArticleId IdType="pubmed">24625523</ArticleId></ArticleIdList></Reference><Reference><Citation>Mastronarde DN (2005) Automated electron microscope tomography using robust prediction of specimen movements. J Struct Biol 152: 36&#x2013;51</Citation><ArticleIdList><ArticleId IdType="pubmed">16182563</ArticleId></ArticleIdList></Reference><Reference><Citation>May S, Hornburg D, Schludi MH, Arzberger T, Rentzsch K, Schwenk BM, Gr&#xe4;sser FA, Mori K, Kremmer E, Banzhaf&#x2010;Strathmann J et al (2014) C9orf72 FTLD/ALS&#x2010;associated Gly&#x2010;Ala dipeptide repeat proteins cause neuronal toxicity and Unc119 sequestration. Acta Neuropathol 128: 485&#x2013;503</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4159571</ArticleId><ArticleId IdType="pubmed">25120191</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray DT, Kato M, Lin Y, Thurber KR, Hung I, McKnight SL, Tycko R (2017) Structure of FUS protein fibrils and its relevance to self&#x2010;assembly and phase separation of low&#x2010;complexity domains. Cell 171: 615&#x2013;627.e16</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5650524</ArticleId><ArticleId IdType="pubmed">28942918</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark CM et al (2006) Ubiquitinated TDP&#x2010;43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314: 130&#x2013;133</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Nickell S, Forster F, Linaroudis A, Net WD, Beck F, Hegerl R, Baumeister W, Plitzko JM (2005) TOM software toolbox: acquisition and analysis for electron tomography. J Struct Biol 149: 227&#x2013;234</Citation><ArticleIdList><ArticleId IdType="pubmed">15721576</ArticleId></ArticleIdList></Reference><Reference><Citation>Oates ME, Romero P, Ishida T, Ghalwash M, Mizianty MJ, Xue B, Dosztanyi Z, Uversky VN, Obradovic Z, Kurgan L et al (2013) D(2)P(2): database of disordered protein predictions. Nucleic Acids Res 41: D508&#x2013;D516</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3531159</ArticleId><ArticleId IdType="pubmed">23203878</ArticleId></ArticleIdList></Reference><Reference><Citation>Olzscha H, Schermann SM, Woerner AC, Pinkert S, Hecht MH, Tartaglia GG, Vendruscolo M, Hayer&#x2010;Hartl M, Hartl FU, Vabulas RM (2011) Amyloid&#x2010;like aggregates sequester numerous metastable proteins with essential cellular functions. Cell 144: 67&#x2013;78</Citation><ArticleIdList><ArticleId IdType="pubmed">21215370</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel A, Lee H, Jawerth L, Maharana S, Jahnel M, Hein M, Stoynov S, Mahamid J, Saha S, Franzmann T et al (2015) A liquid&#x2010;to&#x2010;solid phase transition of the ALS protein FUS accelerated by disease mutation. Cell 162: 1066&#x2013;1077</Citation><ArticleIdList><ArticleId IdType="pubmed">26317470</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasad A, Bharathi V, Sivalingam V, Girdhar A, Patel BK (2019) Molecular mechanisms of TDP&#x2010;43 misfolding and pathology in amyotrophic lateral sclerosis. Front Mol Neurosci 12: 25</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6382748</ArticleId><ArticleId IdType="pubmed">30837838</ArticleId></ArticleIdList></Reference><Reference><Citation>Qamar S, Wang G, Randle SJ, Ruggeri FS, Varela JA, Lin JQ, Phillips EC, Miyashita A, Williams D, Strohl F et al (2018) FUS phase separation is modulated by a molecular chaperone and methylation of arginine cation&#x2010;pi interactions. Cell 173: 720&#x2013;734.e715</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5927716</ArticleId><ArticleId IdType="pubmed">29677515</ArticleId></ArticleIdList></Reference><Reference><Citation>Rapsomaniki MA, Kotsantis P, Symeonidou IE, Giakoumakis NN, Taraviras S, Lygerou Z (2012) easyFRAP: an interactive, easy&#x2010;to&#x2010;use tool for qualitative and quantitative analysis of FRAP data. Bioinformatics 28: 1800&#x2013;1801</Citation><ArticleIdList><ArticleId IdType="pubmed">22543368</ArticleId></ArticleIdList></Reference><Reference><Citation>Riera&#x2010;Tur I, Sch&#xe4;fer T, Hornburg D, Mishra A, Fern&#xe1;ndez&#x2010;Mosquera L, Feigenbutz D, Auer P, Mann M, Baumeister W, Klein R et al (2021) Amyloid&#x2010;like aggregates cause lysosomal defects in neurons via gain&#x2010;of&#x2010;function toxicity. bioRxiv. 10.1101/2019.12.16.877431 [PREPRINT]</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2019.12.16.877431</ArticleId><ArticleId IdType="pmc">PMC8711852</ArticleId><ArticleId IdType="pubmed">34933920</ArticleId></ArticleIdList></Reference><Reference><Citation>Rigort A, Bauerlein FJ, Villa E, Eibauer M, Laugks T, Baumeister W, Plitzko JM (2012) Focused ion beam micromachining of eukaryotic cells for cryoelectron tomography. Proc Natl Acad Sci U S A 109: 4449&#x2013;4454</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3311327</ArticleId><ArticleId IdType="pubmed">22392984</ArticleId></ArticleIdList></Reference><Reference><Citation>Scotter EL, Vance C, Nishimura AL, Lee YB, Chen HJ, Urwin H, Sardone V, Mitchell JC, Rogelj B, Rubinsztein DC et al (2014) Differential roles of the ubiquitin proteasome system and autophagy in the clearance of soluble and aggregated TDP&#x2010;43 species. J Cell Sci 127: 1263&#x2013;1278</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3953816</ArticleId><ArticleId IdType="pubmed">24424030</ArticleId></ArticleIdList></Reference><Reference><Citation>Tashiro Y, Urushitani M, Inoue H, Koike M, Uchiyama Y, Komatsu M, Tanaka K, Yamazaki M, Abe M, Misawa H et al (2012) Motor neuron&#x2010;specific disruption of proteasomes, but not autophagy, replicates amyotrophic lateral sclerosis. J Biol Chem 287: 42984&#x2013;42994</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3522293</ArticleId><ArticleId IdType="pubmed">23095749</ArticleId></ArticleIdList></Reference><Reference><Citation>Trinkaus VA, Riera&#x2010;Tur I, Martinez&#x2010;Sanchez A, Bauerlein FJB, Guo Q, Arzberger T, Baumeister W, Dudanova I, Hipp MS, Hartl FU et al (2021) In situ architecture of neuronal alpha&#x2010;Synuclein inclusions. Nat Commun 12: 2110</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8046968</ArticleId><ArticleId IdType="pubmed">33854052</ArticleId></ArticleIdList></Reference><Reference><Citation>Tusher VG, Tibshirani R, Chu G (2001) Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 98: 5116&#x2013;5121</Citation><ArticleIdList><ArticleId IdType="pmc">PMC33173</ArticleId><ArticleId IdType="pubmed">11309499</ArticleId></ArticleIdList></Reference><Reference><Citation>Tyanova S, Temu T, Sinitcyn P, Carlson A, Hein MY, Geiger T, Mann M, Cox J (2016) The Perseus computational platform for comprehensive analysis of (prote)omics data. Nat Methods 13: 731&#x2013;740</Citation><ArticleIdList><ArticleId IdType="pubmed">27348712</ArticleId></ArticleIdList></Reference><Reference><Citation>Tziortzouda P, Van Den Bosch L, Hirth F (2021) Triad of TDP43 control in neurodegeneration: autoregulation, localization and aggregation. Nat Rev Neurosci 22: 197&#x2013;208</Citation><ArticleIdList><ArticleId IdType="pubmed">33654312</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogler TO, Wheeler JR, Nguyen ED, Hughes MP, Britson KA, Lester E, Rao B, Betta ND, Whitney ON, Ewachiw TE et al (2018) TDP&#x2010;43 and RNA form amyloid&#x2010;like myo&#x2010;granules in regenerating muscle. Nature 563: 508&#x2013;513</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6324568</ArticleId><ArticleId IdType="pubmed">30464263</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker AK, Tripathy K, Restrepo CR, Ge G, Xu Y, Kwong LK, Trojanowski JQ, Lee VM (2015) An insoluble frontotemporal lobar degeneration&#x2010;associated TDP&#x2010;43 C&#x2010;terminal fragment causes neurodegeneration and hippocampus pathology in transgenic mice. Hum Mol Genet 24: 7241&#x2013;7254</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5007600</ArticleId><ArticleId IdType="pubmed">26476406</ArticleId></ArticleIdList></Reference><Reference><Citation>Watabe K, Kato Y, Sakuma M, Murata M, Niida&#x2010;Kawaguchi M, Takemura T, Hanagata N, Tada M, Kakita A, Shibata N (2020) Praja1 RING&#x2010;finger E3 ubiquitin ligase suppresses neuronal cytoplasmic TDP&#x2010;43 aggregate formation. Neuropathology 40: 570&#x2013;586</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7818255</ArticleId><ArticleId IdType="pubmed">32686212</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu G, Wang LG, Han Y, He QY (2012) clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 16: 284&#x2013;287</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3339379</ArticleId><ArticleId IdType="pubmed">22455463</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu H, Lu S, Gasior K, Singh D, Vazquez&#x2010;Sanchez S, Tapia O, Toprani D, Beccari MS, Yates JR, Da Cruz S et al (2021) HSP70 chaperones RNA&#x2010;free TDP&#x2010;43 into anisotropic intranuclear liquid spherical shells. Science 371: eabb4309</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8286096</ArticleId><ArticleId IdType="pubmed">33335017</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y&#x2010;J, Xu Y&#x2010;F, Cook C, Gendron TF, Roettges P, Link CD, Lin W&#x2010;L, Tong J, Castanedes&#x2010;Casey M, Ash P et al (2009) Aberrant cleavage of TDP&#x2010;43 enhances aggregation and cellular toxicity. Proc Natl Acad Sci U S A 106: 7607&#x2013;7612</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2671323</ArticleId><ArticleId IdType="pubmed">19383787</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng SQ, Palovcak E, Armache JP, Verba KA, Cheng Y, Agard DA (2017) MotionCor2: anisotropic correction of beam&#x2010;induced motion for improved cryo&#x2010;electron microscopy. Nat Methods 14: 331&#x2013;332</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5494038</ArticleId><ArticleId IdType="pubmed">28250466</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35441134</PMID><DateRevised><Year>2022</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2632-1297</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>2</Issue><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Brain communications</Title><ISOAbbreviation>Brain Commun</ISOAbbreviation></Journal><ArticleTitle>&#x3b2;-Amyloid discordance of cerebrospinal fluid and positron emission tomography imaging shows distinct spatial tau patterns.</ArticleTitle><Pagination><StartPage>fcac084</StartPage><MedlinePgn>fcac084</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">fcac084</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/braincomms/fcac084</ELocationID><Abstract><AbstractText>Extracellular &#x3b2;-amyloid plaques and intracellular neurofibrillary tau tangles are the primary hallmarks of Alzheimer's disease. &#x3b2;-Amyloid pathology can be directly quantified by positron emission tomography imaging or indirectly by measuring the decrease of cerebrospinal fluid &#x3b2;-amyloid<sub>42</sub>/&#x3b2;-amyloid<sub>40</sub> ratio. Although these two &#x3b2;-amyloid biomarkers may be considered interchangeable, they sometimes show discordance, particularly in early stage of Alzheimer's disease. Individuals with cerebrospinal fluid &#x3b2;-amyloid positive only or &#x3b2;-amyloid positron emission tomography positive only may be at early amyloidosis stage compared to those who are cerebrospinal fluid &#x3b2;-amyloid negative and &#x3b2;-amyloid positron emission tomography negative orcerebrospinal fluid &#x3b2;-amyloid positive and &#x3b2;-amyloid positron emission tomography positive. Besides, &#x3b2;-amyloid pathology may play an initiating role in Alzheimer's disease onset, leading to subsequent tau increases. However, it is still unclear whether individuals with different &#x3b2;-amyloid pathways have distinct spatial patterns of cortical tau tangles in early amyloidosis stage. In this study, we analyzed 238 cognitively unimpaired and 77 mild cognitive impairment individuals with concurrent (interval of acquisition &lt;1 year) <sup>18</sup>F-flortaucipir tau positron emission tomography, &#x3b2;-amyloid (<sup>18</sup>F-florbetapir or <sup>18</sup>F-florbetaben) positron emission tomography and cerebrospinal fluid &#x3b2;-amyloid<sub>42</sub> and &#x3b2;-amyloid<sub>40</sub> and cerebrospinal fluid p-Tau<sub>181</sub> and divided them into four different cerebrospinal fluid/positron emission tomography groups based on the abnormal status of cerebrospinal fluid &#x3b2;-amyloid<sub>42</sub>/&#x3b2;-amyloid<sub>40</sub> (cerebrospinal fluid&#xb1;) and &#x3b2;-amyloid positron emission tomography (&#xb1;). We determined the cortical regions with significant tau elevations of different cerebrospinal fluid/positron emission tomography groups and investigated the region-wise and voxel-wise associations of tau positron emission tomography images with cerebrospinal fluid &#x3b2;-amyloid<sub>42</sub>/&#x3b2;-amyloid<sub>40</sub>, &#x3b2;-amyloid positron emission tomography and cerebrospinal fluid p-Tau/&#x3b2;-amyloid<sub>40</sub> in early (cerebrospinal fluid positive/positron emission tomography negative and cerebrospinal fluid negative/positron emission tomography positive) and late (cerebrospinal fluid positive/positron emission tomography positive) amyloidosis stages. By compared to the cerebrospinal fluid negative/positron emission tomography negative individuals (Ref) without evidence of tau increase measured by cerebrospinal fluid or positron emission tomography, cerebrospinal fluid positive/positron emission tomography negative individuals showed higher tau in entorhinal but not in Braak<sub>III/IV</sub> and Braak<sub>V/VI</sub>, whereas cerebrospinal fluid negative/positron emission tomography positive individuals had significant tau elevations in Braak<sub>V/VI</sub> but not in entorhinal and Braak<sub>III/IV</sub>. In contrast, cerebrospinal fluid positive/positron emission tomography positive individuals showed significant tau increases in all the cortical regions than the Ref group. The voxel-wise analyses provided further evidence that lower cerebrospinal fluid &#x3b2;-amyloid<sub>42</sub>/&#x3b2;-amyloid<sub>40</sub> was associated with higher tau in entorhinal, whilst higher &#x3b2;-amyloid positron emission tomography was related to higher tau in Braak<sub>V/VI</sub> regions in early amyloidosis stage. Both lower cerebrospinal fluid &#x3b2;-amyloid<sub>42</sub>/&#x3b2;-amyloid<sub>40</sub> and higher &#x3b2;-amyloid positron emission tomography were correlated with tau aggregation in all the Braak stages regions in late amyloidosis stage. These findings provide novel insights into the spatial patterns of cortical tau tangles in different amyloidosis stages of Alzheimer's disease, suggesting cerebrospinal fluid &#x3b2;-amyloid and &#x3b2;-amyloid positron emission tomography discordant groups may have distinct characteristics of cortical tau tangles in early amyloidosis stage.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2022. Published by Oxford University Press on behalf of the Guarantors of Brain.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Chenyang</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute of Biomedical Engineering, Shenzhen Bay Laboratory, Shenzhen 518132, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Qingyong</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Chinese Academy of Sciences-Shenzhen Hospital, Shenzhen 518107, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Siwei</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Biomedical Engineering, Shenzhen Bay Laboratory, Shenzhen 518132, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Zhicheng</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Institute of Chemical Biology, Shenzhen Bay Laboratory, Shenzhen 518132, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fu</LastName><ForeName>Liping</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, China-Japan Friendship Hospital, 2 Yinghuayuan Dongjie, Beijing 100029, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Qiyu</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Institute of Biomedical Engineering, Shenzhen Bay Laboratory, Shenzhen 518132, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital &amp; Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen 518116, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Hongbo</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-3671-0445</Identifier><AffiliationInfo><Affiliation>Department of Neurosurgery, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Tengfei</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-2982-0865</Identifier><AffiliationInfo><Affiliation>Institute of Biomedical Engineering, Shenzhen Bay Laboratory, Shenzhen 518132, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Biomedical Engineering, Peking University Shenzhen Graduate School, Shenzhen 518055, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Alzheimer&#x2019;s Disease Neuroimaging Initiative</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>03</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Brain Commun</MedlineTA><NlmUniqueID>101755125</NlmUniqueID><ISSNLinking>2632-1297</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">Tau</Keyword><Keyword MajorTopicYN="N">cerebrospinal fluid</Keyword><Keyword MajorTopicYN="N">positron emission tomography imaging</Keyword><Keyword MajorTopicYN="N">&#x3b2;-amyloid</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>10</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>12</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>20</Day><Hour>5</Hour><Minute>56</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>21</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>3</Month><Day>31</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35441134</ArticleId><ArticleId IdType="pmc">PMC9014538</ArticleId><ArticleId IdType="doi">10.1093/braincomms/fcac084</ArticleId><ArticleId IdType="pii">fcac084</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>McKhann GM, Knopman DS, Chertkow H, et al. . The diagnosis of dementia due to Alzheimer&#x2019;s disease: Recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimer&#x2019;s Dement 2011;7(3):263&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312024</ArticleId><ArticleId IdType="pubmed">21514250</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Bennett DA, Blennow K, et al. . NIA-AA research framework: Toward a biological definition of Alzheimer&#x2019;s disease. Alzheimer&#x2019;s Dement 2018;14(4):535&#x2013;562.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5958625</ArticleId><ArticleId IdType="pubmed">29653606</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo T, Korman D, Baker SL, Landau SM, Jagust WJ. Longitudinal cognitive and biomarker measurements support a unidirectional pathway in Alzheimer&#x2019;s disease pathophysiology. Biol Psychiatry 2021;89(8):786&#x2013;794.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9682985</ArticleId><ArticleId IdType="pubmed">32919611</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo T, Brendel M, Grimmer T, Rominger A, Yakushev I. Predicting regional pattern of longitudinal &#x3b2;-amyloid accumulation by baseline PET. J Nucl Med 2017;58(4):639&#x2013;645.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5373505</ArticleId><ArticleId IdType="pubmed">27754901</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo T, Dukart J, Brendel M, Rominger A, Grimmer T, Yakushev I. Rate of &#x3b2;-amyloid accumulation varies with baseline amyloid burden: Implications for anti-amyloid drug trials. Alzheimer&#x2019;s Dement 2018;14(11):1387&#x2013;1396.</Citation><ArticleIdList><ArticleId IdType="pubmed">30420035</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo T, Landau SM, Jagust WJ. Detecting earlier stages of amyloid deposition using PET in cognitively normal elderly adults. Neurology 2020;94(14):e1512&#x2013;e1524.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7251521</ArticleId><ArticleId IdType="pubmed">32188766</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo T, Shaw LM, Trojanowski JQ, Jagust WJ, Landau SM. Association of CSF A&#x3b2;, amyloid PET, and cognition in cognitively unimpaired elderly adults. Neurology 2020;95(15):e2075&#x2013;e2085.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7713747</ArticleId><ArticleId IdType="pubmed">32759202</ArticleId></ArticleIdList></Reference><Reference><Citation>Pannee J, Portelius E, Minthon L, et al. . Reference measurement procedure for CSF amyloid beta (A&#x3b2;)1-42 and the CSF A&#x3b2;1-42/A&#x3b2;1-40 ratio &#x2013; a cross-validation study against amyloid PET. J Neurochem 2016;139(4):651&#x2013;658.</Citation><ArticleIdList><ArticleId IdType="pubmed">27579672</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze S, Zetterberg H, Mattsson N, et al. . CSF A&#x3b2;42/A&#x3b2;40 and A&#x3b2;42/A&#x3b2;38 ratios: Better diagnostic markers of Alzheimer disease. Ann Clin Transl Neurol 2016;3(3):154&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4774260</ArticleId><ArticleId IdType="pubmed">27042676</ArticleId></ArticleIdList></Reference><Reference><Citation>Reimand J, de Wilde A, Teunissen CE, et al. . PET and CSF amyloid-&#x3b2; status are differently predicted by patient features: Information from discordant cases. Alzheimers Res Ther 2019;11(1):100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6898919</ArticleId><ArticleId IdType="pubmed">31810489</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S, Mattsson N, Hansson O. Cerebrospinal fluid analysis detects cerebral amyloid-&#x3b2; accumulation earlier than positron emission tomography. Brain 2016;139(4):1226&#x2013;1236.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4806222</ArticleId><ArticleId IdType="pubmed">26936941</ArticleId></ArticleIdList></Reference><Reference><Citation>Reimand J, Boon BDC, Collij LE, et al. . Amyloid-&#x3b2; PET and CSF in an autopsy-confirmed cohort. Ann Clin Transl Neurol 2020;7(11):2150&#x2013;2160.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7664271</ArticleId><ArticleId IdType="pubmed">33080124</ArticleId></ArticleIdList></Reference><Reference><Citation>Leuzy A, Chiotis K, Hasselbalch SG, et al. . Pittsburgh compound B imaging and cerebrospinal fluid amyloid-&#x3b2; in a multicentre European memory clinic study. Brain 2016;139(9):2540&#x2013;2553.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4995359</ArticleId><ArticleId IdType="pubmed">27401520</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewczuk P, Matzen A, Blennow K, et al. . Cerebrospinal fluid A&#x3b2;42/40 corresponds better than A&#x3b2;42 to amyloid PET in Alzheimer&#x2019;s disease. J Alzheimer&#x2019;s Dis 2017;55(2):813&#x2013;822.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5147502</ArticleId><ArticleId IdType="pubmed">27792012</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze S, Pannee J, Mikulskis A, et al. . Concordance between different amyloid immunoassays and visual amyloid positron emission tomographic assessment. JAMA Neurol 2017;74(12):1492&#x2013;1501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5822196</ArticleId><ArticleId IdType="pubmed">29114726</ArticleId></ArticleIdList></Reference><Reference><Citation>Niemantsverdriet E, Ottoy J, Somers C, et al. . The cerebrospinal fluid A&#x3b2;1&#x2013;42/A&#x3b2;1&#x2013;40 ratio improves concordance with amyloid-PET for diagnosing Alzheimer&#x2019;s disease in a clinical setting. J Alzheimer&#x2019;s Dis 2017;60(2):561&#x2013;576.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5611891</ArticleId><ArticleId IdType="pubmed">28869470</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindler SE, Gray JD, Gordon BA, et al. . Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging. Alzheimer&#x2019;s Dement 2018;14(11):1460&#x2013;1469.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6119652</ArticleId><ArticleId IdType="pubmed">29501462</ArticleId></ArticleIdList></Reference><Reference><Citation>Adamczuk K, Schaeverbeke J, Vanderstichele HMJ, et al. . Diagnostic value of cerebrospinal fluid A&#x3b2; ratios in preclinical Alzheimer&#x2019;s disease. Alzheimers Res Ther 2015;7(1):75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4683859</ArticleId><ArticleId IdType="pubmed">26677842</ArticleId></ArticleIdList></Reference><Reference><Citation>Doecke JD, Ward L, Burnham SC, et al. . Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging. Alzheimers Res Ther 2020;12(1):36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7110644</ArticleId><ArticleId IdType="pubmed">32234072</ArticleId></ArticleIdList></Reference><Reference><Citation>de Wilde A, Reimand J, Teunissen CE, et al. . Discordant amyloid-&#x3b2; PET and CSF biomarkers and its clinical consequences. Alzheimers Res Ther 2019;11(1):78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6739952</ArticleId><ArticleId IdType="pubmed">31511058</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcolea D, Pegueroles J, Mu&#xf1;oz L, et al. . Agreement of amyloid PET and CSF biomarkers for Alzheimer&#x2019;s disease on Lumipulse. Ann Clin Transl Neurol 2019;6(9):1815&#x2013;1824.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6764494</ArticleId><ArticleId IdType="pubmed">31464088</ArticleId></ArticleIdList></Reference><Reference><Citation>Sala A, Nordberg A, Rodriguez-Vieitez E. Longitudinal pathways of cerebrospinal fluid and positron emission tomography biomarkers of amyloid-&#x3b2; positivity. Mol Psychiatry 2021;26(10):5864&#x2013;5874.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8758501</ArticleId><ArticleId IdType="pubmed">33303945</ArticleId></ArticleIdList></Reference><Reference><Citation>Zwan MD, Rinne JO, Hasselbalch SG, et al. . Use of amyloid-PET to determine cutpoints for CSF markers. Neurology 2016;86(1):50&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4731290</ArticleId><ArticleId IdType="pubmed">26468410</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Insel PS, Donohue M, et al. . Independent information from cerebrospinal fluid amyloid-&#x3b2; and florbetapir imaging in Alzheimer&#x2019;s disease. Brain 2015;138(3):772&#x2013;783.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4339769</ArticleId><ArticleId IdType="pubmed">25541191</ArticleId></ArticleIdList></Reference><Reference><Citation>Toledo JB, Bjerke M, Da X, et al. . Nonlinear association between Cerebrospinal fluid and florbetapir F-18 &#x3b2;-amyloid measures across the spectrum of Alzheimer disease. JAMA Neurol 2015;72(5):571&#x2013;581.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5642905</ArticleId><ArticleId IdType="pubmed">25822737</ArticleId></ArticleIdList></Reference><Reference><Citation>Vos SJB, Gordon BA, Su Y, et al. . NIA-AA staging of preclinical Alzheimer disease: Discordance and concordance of CSF and imaging biomarkers. Neurobiol Aging 2016;44:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4913039</ArticleId><ArticleId IdType="pubmed">27318129</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson O, Seibyl J, Stomrud E, et al. . CSF biomarkers of Alzheimer&#x2019;s disease concord with amyloid-&#x3b2; PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimer&#x2019;s Dement 2018;14(11):1470&#x2013;1481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6119541</ArticleId><ArticleId IdType="pubmed">29499171</ArticleId></ArticleIdList></Reference><Reference><Citation>Koivunen J, Pirttil&#xe4; T, Kemppainen N, et al. . PET amyloid ligand [11C]PIB uptake and cerebrospinal fluid &#x3b2;-amyloid in mild cognitive impairment. Dement Geriatr Cogn Disord 2008;26(4):378&#x2013;383.</Citation><ArticleIdList><ArticleId IdType="pubmed">18931497</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Mintun MA, Shah AR, et al. . Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer&#x2019;s disease. EMBO Mol Med 2009;1(8-9):371&#x2013;380.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2806678</ArticleId><ArticleId IdType="pubmed">20049742</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau SM, Lu M, Joshi AD, et al. . Comparing positron emission tomography imaging and cerebrospinal fluid measurements of &#x3b2;-amyloid. Ann Neurol 2013;74(6):826&#x2013;836.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3748164</ArticleId><ArticleId IdType="pubmed">23536396</ArticleId></ArticleIdList></Reference><Reference><Citation>Zwan M, van Harten A, Ossenkoppele R, et al. . Concordance between cerebrospinal fluid biomarkers and [11C]PIB PET in a memory clinic cohort. J Alzheimer&#x2019;s Dis 2014;41(3):801&#x2013;807.</Citation><ArticleIdList><ArticleId IdType="pubmed">24705549</ArticleId></ArticleIdList></Reference><Reference><Citation>Reimand J, Collij L, Scheltens P, Bouwman F, Ossenkoppele R. Association of amyloid-&#x3b2; CSF/PET discordance and tau load 5 years later. Neurology 2020;95(19):e2648&#x2013;e2657.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7963352</ArticleId><ArticleId IdType="pubmed">32913020</ArticleId></ArticleIdList></Reference><Reference><Citation>Leal SL, Lockhart SN, Maass A, Bell RK, Jagust WJ. Subthreshold amyloid predicts tau deposition in aging. J Neurosci 2018;38(19):4482&#x2013;4489.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5943976</ArticleId><ArticleId IdType="pubmed">29686045</ArticleId></ArticleIdList></Reference><Reference><Citation>Tosun D, Landau S, Aisen PS, et al. . Association between tau deposition and antecedent amyloid-&#x3b2; accumulation rates in normal and early symptomatic individuals. Brain 2017;140(5):1499&#x2013;1512.</Citation><ArticleIdList><ArticleId IdType="pubmed">28334939</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanseeuw BJ, Betensky RA, Jacobs HIL, et al. . Association of amyloid and tau with cognition in preclinical Alzheimer disease. JAMA Neurol 2019;76(8):915.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6547132</ArticleId><ArticleId IdType="pubmed">31157827</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo T, Korman D, La Joie R, et al. . Normalization of CSF pTau measurement by A&#x3b2;40 improves its performance as a biomarker of Alzheimer&#x2019;s disease. Alzheimers Res Ther 2020;12(1):97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7429887</ArticleId><ArticleId IdType="pubmed">32799929</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman DS, Lundt ES, Therneau TM, et al. . Association of initial &#x3b2;-Amyloid levels with subsequent flortaucipir positron emission tomography changes in persons without cognitive impairment. JAMA Neurol 2021;78(2):217.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7573795</ArticleId><ArticleId IdType="pubmed">33074304</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82(4):239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xf6;ll M, Lockhart SN, Schonhaut DR, et al. . PET imaging of tau deposition in the aging human brain. Neuron 2016;89(5):971&#x2013;982.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4779187</ArticleId><ArticleId IdType="pubmed">26938442</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez JS, Becker JA, Jacobs HIL, et al. . The cortical origin and initial spread of medial temporal tauopathy in Alzheimer&#x2019;s disease assessed with positron emission tomography. Sci Transl Med 2021;13(577):eabc0655.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7978042</ArticleId><ArticleId IdType="pubmed">33472953</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho H, Choi JY, Hwang MS, et al. . In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum. Ann Neurol 2016;80(2):247&#x2013;258.</Citation><ArticleIdList><ArticleId IdType="pubmed">27323247</ArticleId></ArticleIdList></Reference><Reference><Citation>Dor&#xe9; V, Krishnadas N, Bourgeat P, et al. . Relationship between amyloid and tau levels and its impact on tau spreading. Eur J Nucl Med Mol Imaging 2021;48(7):2225&#x2013;2232.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8175299</ArticleId><ArticleId IdType="pubmed">33495928</ArticleId></ArticleIdList></Reference><Reference><Citation>Pascoal TA, Therriault J, Benedet AL, et al. . 18F-MK-6240 PET for early and late detection of neurofibrillary tangles. Brain 2020;143(9):2818&#x2013;2830.</Citation><ArticleIdList><ArticleId IdType="pubmed">32671408</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Wiste HJ, Weigand SD, et al. . Defining imaging biomarker cut points for brain aging and Alzheimer&#x2019;s disease. Alzheimer&#x2019;s Dement 2017;13(3):205&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5344738</ArticleId><ArticleId IdType="pubmed">27697430</ArticleId></ArticleIdList></Reference><Reference><Citation>Desikan RS, S&#xe9;gonne F, Fischl B, et al. . An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage 2006;31(3):968&#x2013;980.</Citation><ArticleIdList><ArticleId IdType="pubmed">16530430</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau SM, Fero A, Baker SL, et al. . Measurement of longitudinal &#x3b2;-amyloid change with 18F-florbetapir PET and standardized uptake value ratios. J Nucl Med 2015;56(4):567&#x2013;574.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5313473</ArticleId><ArticleId IdType="pubmed">25745095</ArticleId></ArticleIdList></Reference><Reference><Citation>Maass A, Landau S, Baker SL, et al. . Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer&#x2019;s disease. Neuroimage 2017;157:448&#x2013;463.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5814575</ArticleId><ArticleId IdType="pubmed">28587897</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen AD, Landau SM, Snitz BE, Klunk WE, Blennow K, Zetterberg H. Fluid and PET biomarkers for amyloid pathology in Alzheimer&#x2019;s disease. Mol Cell Neurosci 2019;97(7):3&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">30537535</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson-Carlgren N, Andersson E, Janelidze S, et al. . A&#x3b2; deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer&#x2019;s disease. Sci Adv 2020;6(16):eaaz2387.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159908</ArticleId><ArticleId IdType="pubmed">32426454</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer P-F, Pichet Binette A, Gonneaud J, Breitner JCS, Villeneuve S. Characterization of Alzheimer disease biomarker discrepancies using cerebrospinal fluid phosphorylated Tau and AV1451 positron emission tomography. JAMA Neurol 2020;77(4):508.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6990861</ArticleId><ArticleId IdType="pubmed">31961372</ArticleId></ArticleIdList></Reference><Reference><Citation>Day GS, Gordon BA, Perrin RJ, et al. . In vivo [18F]-AV-1451 tau-PET imaging in sporadic Creutzfeldt-Jakob disease. Neurology 2018;90(10):e896&#x2013;e906.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5863493</ArticleId><ArticleId IdType="pubmed">29438042</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleisher AS, Pontecorvo MJ, Devous MD, et al. . Positron emission tomography imaging with [18F]flortaucipir and postmortem assessment of Alzheimer disease neuropathologic changes. JAMA Neurol 2020;77(7):829.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7186920</ArticleId><ArticleId IdType="pubmed">32338734</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen CD, Holden TR, Gordon BA, et al. . Ante- and postmortem tau in autosomal dominant and late-onset Alzheimer&#x2019;s disease. Ann Clin Transl Neurol 2020;7(12):2475&#x2013;2480.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7732239</ArticleId><ArticleId IdType="pubmed">33150749</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S, Sch&#xf6;ll M, Strandberg O, et al. . Earliest accumulation of &#x3b2;-amyloid occurs within the default-mode network and concurrently affects brain connectivity. Nat Commun 2017;8(1):1214.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5663717</ArticleId><ArticleId IdType="pubmed">29089479</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Wiste HJ, Schwarz CG, et al. . Longitudinal tau PET in ageing and Alzheimer&#x2019;s disease. Brain 2018;141(5):1517&#x2013;1528.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5917767</ArticleId><ArticleId IdType="pubmed">29538647</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Wiste HJ, Therneau TM, et al. . Associations of Amyloid, Tau, and Neurodegeneration biomarker profiles with rates of memory decline among individuals without dementia. JAMA 2019;321(23):2316.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6582267</ArticleId><ArticleId IdType="pubmed">31211344</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Wiste HJ, Botha H, et al. . The bivariate distribution of amyloid-&#x3b2; and tau: Relationship with established neurocognitive clinical syndromes. Brain 2019;142(10):3230&#x2013;3242.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6763736</ArticleId><ArticleId IdType="pubmed">31501889</ArticleId></ArticleIdList></Reference><Reference><Citation>Park J-C, Han S-H, Yi D, et al. . Plasma tau/amyloid-&#x3b2;1&#x2013;42 ratio predicts brain tau deposition and neurodegeneration in Alzheimer&#x2019;s disease. Brain 2019;142(3):771&#x2013;786.</Citation><ArticleIdList><ArticleId IdType="pubmed">30668647</ArticleId></ArticleIdList></Reference><Reference><Citation>Graff-Radford J, Arenaza-Urquijo EM, Knopman DS, et al. . White matter hyperintensities: Relationship to amyloid and tau burden. Brain 2019;142(8):2483&#x2013;2491.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6658846</ArticleId><ArticleId IdType="pubmed">31199475</ArticleId></ArticleIdList></Reference><Reference><Citation>Botha H, Mantyh WG, Graff-Radford J, et al. . Tau-negative amnestic dementia masquerading as Alzheimer disease dementia. Neurology 2018;90(11):e940&#x2013;e946.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5858947</ArticleId><ArticleId IdType="pubmed">29438037</ArticleId></ArticleIdList></Reference><Reference><Citation>Dujardin S, Commins C, Lathuiliere A, et al. . Tau molecular diversity contributes to clinical heterogeneity in Alzheimer&#x2019;s disease. Nat Med 2020;26(8):1256&#x2013;1263.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7603860</ArticleId><ArticleId IdType="pubmed">32572268</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogel JW, Young AL, Oxtoby NP, et al. . Four distinct trajectories of tau deposition identified in Alzheimer&#x2019;s disease. Nat Med 2021;27(5):871&#x2013;881.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8686688</ArticleId><ArticleId IdType="pubmed">33927414</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R, Lyoo CH, Sudre CH, et al. . Distinct tau PET patterns in atrophy-defined subtypes of Alzheimer&#x2019;s disease. Alzheimer&#x2019;s Dement 2020;16(2):335&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7012375</ArticleId><ArticleId IdType="pubmed">31672482</ArticleId></ArticleIdList></Reference><Reference><Citation>Therriault J, Pascoal TA, Savard M, et al. . Topographic distribution of Amyloid-&#x3b2;, Tau, and Atrophy in patients with behavioral/dysexecutive Alzheimer disease. Neurology 2021;96(1):e81&#x2013;e92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7884976</ArticleId><ArticleId IdType="pubmed">33093220</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35443153</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>20</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>110</Volume><Issue>12</Issue><PubDate><Year>2022</Year><Month>Jun</Month><Day>15</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Regional A&#x3b2;-tau interactions promote onset and acceleration of Alzheimer's disease tau spreading.</ArticleTitle><Pagination><StartPage>1932</StartPage><EndPage>1943.e5</EndPage><MedlinePgn>1932-1943.e5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2022.03.034</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0896-6273(22)00305-1</ELocationID><Abstract><AbstractText>Amyloid-beta and tau are key molecules in the pathogenesis of Alzheimer's disease, but it remains unclear how these proteins interact to promote disease. Here, by combining cross-sectional and longitudinal molecular imaging and network connectivity analyses in living humans, we identified two amyloid-beta/tau interactions associated with the onset and propagation of tau spreading. First, we show that the lateral entorhinal cortex, an early site of tau neurofibrillary tangle formation, is subject to remote, connectivity-mediated amyloid-beta/tau interactions linked to initial tau spreading. Second, we identify the inferior temporal gyrus as the region featuring the greatest local amyloid-beta/tau interactions and a connectivity profile well suited to accelerate tau propagation. Taken together, our data address long-standing questions regarding the topographical dissimilarity between early amyloid-beta and tau deposition.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Wha Jin</ForeName><Initials>WJ</Initials><AffiliationInfo><Affiliation>School of Biomedical Engineering, Korea University, Seoul 02841, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Jesse A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA 94143, USA; Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA 94143, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Hye Ryun</ForeName><Initials>HR</Initials><AffiliationInfo><Affiliation>School of Biomedical Engineering, Korea University, Seoul 02841, South Korea; Global Health Technology Research Center, College of Health Science, Korea University, Seoul 02841, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>La Joie</LastName><ForeName>Renaud</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA 94143, USA; Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA 94143, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cho</LastName><ForeName>Hanna</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Gangnam Severance Hospital, Seoul 06273, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lyoo</LastName><ForeName>Chul Hyoung</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Department of Neurology, Gangnam Severance Hospital, Seoul 06273, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rabinovici</LastName><ForeName>Gil D</ForeName><Initials>GD</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA 94143, USA; Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA 94143, USA; Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA 94143, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seong</LastName><ForeName>Joon-Kyung</ForeName><Initials>JK</Initials><AffiliationInfo><Affiliation>School of Biomedical Engineering, Korea University, Seoul 02841, South Korea; Department of Artificial Intelligence, Korea University, Seoul 02841, South Korea. Electronic address: jkseong@korea.ac.kr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seeley</LastName><ForeName>William W</ForeName><Initials>WW</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA 94143, USA; Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA 94143, USA; Department of Pathology, University of California, San Francisco, San Francisco, CA 94143, USA. Electronic address: bill.seeley@ucsf.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Alzheimer&#x2019;s Disease Neuroimaging Initiative</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062422</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG019724</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K99 AG065501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG055698</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>04</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2022 Jun;18(6):318. doi: 10.1038/s41582-022-00667-0.</RefSource><PMID Version="1">35508634</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000054" MajorTopicYN="N">Acceleration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">DTI</Keyword><Keyword MajorTopicYN="N">PET</Keyword><Keyword MajorTopicYN="N">amyloid-beta</Keyword><Keyword MajorTopicYN="N">connectome</Keyword><Keyword MajorTopicYN="N">tau</Keyword></KeywordList><CoiStatement>Declaration of interests W.W.S. received compensation as a lecturer for Corcept Therapeutics and as a consultant for Guidepoint Global Consulting and GLG Council. G.D.R. receives research support from the National Institutes of Health, Alzheimer&#x2019;s Association, American College of Radiology, Rainwater Charitable Foundation, gift from Edward and Pearl Fein, Avid Radiopharmaceuticals, Eli Lilly, Life Molecular Imaging, GE Healthcare, and Genentech. He has served as a consultant for Axon Neurosciences, Eisai, GE Healthcare, Merck, Genentech, and Roche. He serves on a data safety monitoring board for Johnson &amp; Johnson. He is an Associate Editor for JAMA Neurology. A subset of the authors has filed provisional patent no. 63/085,749 in the U.S. based on this work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>11</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>2</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>20</Day><Hour>20</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>6</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35443153</ArticleId><ArticleId IdType="mid">NIHMS1801172</ArticleId><ArticleId IdType="pmc">PMC9233123</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2022.03.034</ArticleId><ArticleId IdType="pii">S0896-6273(22)00305-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>AIZENSTEIN HJ, NEBES RD, SAXTON JA, PRICE JC, MATHIS CA, TSOPELAS ND, ZIOLKO SK, JAMES JA, SNITZ BE, HOUCK PR, BI W, COHEN AD, LOPRESTI BJ, DEKOSKY ST, HALLIGAN EM &amp; KLUNK WE 2008. Frequent Amyloid Deposition Without Significant Cognitive Impairment Among the Elderly. Archives of Neurology, 65, 1509&#x2013;1517.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2636844</ArticleId><ArticleId IdType="pubmed">19001171</ArticleId></ArticleIdList></Reference><Reference><Citation>ALBERT MS, DEKOSKY ST, DICKSON D, DUBOIS B, FELDMAN HH, FOX NC, GAMST A, HOLTZMAN DM, JAGUST WJ, PETERSEN RC, SNYDER PJ, CARRILLO MC, THIES B &amp; PHELPS CH 2011. The diagnosis of mild cognitive impairment due to Alzheimer&#x2019;s disease: Recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's &amp; Dementia, 7, 270&#x2013;279.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312027</ArticleId><ArticleId IdType="pubmed">21514249</ArticleId></ArticleIdList></Reference><Reference><Citation>BAEK MS, CHO H, LEE HS, CHOI JY, LEE JH, RYU YH, LEE MS &amp; LYOO CH 2020. Temporal trajectories of in vivo tau and amyloid-&#x3b2; accumulation in Alzheimer&#x2019;s disease. European Journal of Nuclear Medicine and Molecular Imaging, 47, 2879&#x2013;2886.</Citation><ArticleIdList><ArticleId IdType="pubmed">32350558</ArticleId></ArticleIdList></Reference><Reference><Citation>BEAULIEU C 2002. The basis of anisotropic water diffusion in the nervous system &#x2013; a technical review. NMR in Biomedicine, 15, 435&#x2013;455.</Citation><ArticleIdList><ArticleId IdType="pubmed">12489094</ArticleId></ArticleIdList></Reference><Reference><Citation>BENJAMINI Y &amp; HOCHBERG Y 1995. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society. Series B (Methodological), 57, 289&#x2013;300.</Citation></Reference><Reference><Citation>BRAAK H, ALAFUZOFF I, ARZBERGER T, KRETZSCHMAR H &amp; DEL TREDICI K 2006. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathologica, 112, 389&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3906709</ArticleId><ArticleId IdType="pubmed">16906426</ArticleId></ArticleIdList></Reference><Reference><Citation>BRAAK H &amp; BRAAK E 1991. Neuropathological staging of Alzheimer-related changes. Acta Neuropathologica, 82, 239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>BRAAK H &amp; DEL TREDICI K 2011. Alzheimer's pathogenesis: is there neuron-to-neuron propagation? Acta Neuropathologica, 121, 589&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">21516512</ArticleId></ArticleIdList></Reference><Reference><Citation>BROWN JA, DENG J, NEUHAUS J, SIBLE IJ, SIAS AC, LEE SE, KORNAK J, MARX GA, KARYDAS AM, SPINA S, GRINBERG LT, COPPOLA G, GESCHWIND DH, KRAMER JH, GORNO-TEMPINI ML, MILLER BL, ROSEN HJ &amp; SEELEY WW 2019. Patient-Tailored, Connectivity-Based Forecasts of Spreading Brain Atrophy. Neuron, 104, 856&#x2013;868.e5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7012373</ArticleId><ArticleId IdType="pubmed">31623919</ArticleId></ArticleIdList></Reference><Reference><Citation>CHO H, CHOI JY, HWANG MS, KIM YJ, LEE HM, LEE HS, LEE JH, RYU YH, LEE MS &amp; LYOO CH 2016. In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum. Annals of Neurology, 80, 247&#x2013;258.</Citation><ArticleIdList><ArticleId IdType="pubmed">27323247</ArticleId></ArticleIdList></Reference><Reference><Citation>CHO H, CHOI JY, LEE HS, LEE JH, RYU YH, LEE MS, JACK CR &amp; LYOO CH 2019. Progressive Tau Accumulation in Alzheimer Disease: 2-Year Follow-up Study. Journal of Nuclear Medicine, 60, 1611&#x2013;1621.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6836867</ArticleId><ArticleId IdType="pubmed">30926651</ArticleId></ArticleIdList></Reference><Reference><Citation>CHOI JY, CHO H, AHN SJ, LEE JH, RYU YH, LEE MS &amp; LYOO CH 2018. Off-Target 18F-AV-1451 Binding in the Basal Ganglia Correlates with Age-Related Iron Accumulation. Journal of Nuclear Medicine, 59, 117&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pubmed">28775201</ArticleId></ArticleIdList></Reference><Reference><Citation>CLAVAGUERA F, AKATSU H, FRASER G, CROWTHER RA, FRANK S, HENCH J, PROBST A, WINKLER DT, REICHWALD J, STAUFENBIEL M, GHETTI B, GOEDERT M &amp; TOLNAY M 2013. Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Proc Natl Acad Sci U S A, 110, 9535&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677441</ArticleId><ArticleId IdType="pubmed">23690619</ArticleId></ArticleIdList></Reference><Reference><Citation>CRARY JF, TROJANOWSKI JQ, SCHNEIDER JA, ABISAMBRA JF, ABNER EL, ALAFUZOFF I, ARNOLD SE, ATTEMS J, BEACH TG, BIGIO EH, CAIRNS NJ, DICKSON DW, GEARING M, GRINBERG LT, HOF PR, HYMAN BT, JELLINGER K, JICHA GA, KOVACS GG, KNOPMAN DS, KOFLER J, KUKULL WA, MACKENZIE IR, MASLIAH E, MCKEE A, MONTINE TJ, MURRAY ME, NELTNER JH, SANTA-MARIA I, SEELEY WW, SERRANO-POZO A, SHELANSKI ML, STEIN T, TAKAO M, THAL DR, TOLEDO JB, TRONCOSO JC, VONSATTEL JP, WHITE CL 3RD, WISNIEWSKI T, WOLTJER RL, YAMADA M &amp; NELSON PT 2014. Primary age-related tauopathy (PART):a common pathology associated with human aging. Acta neuropathologica, 128, 755&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4257842</ArticleId><ArticleId IdType="pubmed">25348064</ArticleId></ArticleIdList></Reference><Reference><Citation>CUMMINGS J &amp; SALLOWAY S 2021. Aducanumab: Appropriate use recommendations. Alzheimer's &amp; Dementia, n/a.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8792094</ArticleId><ArticleId IdType="pubmed">34314093</ArticleId></ArticleIdList></Reference><Reference><Citation>DAS SR, XIE L, WISSE LEM, ITTYERAH R, TUSTISON NJ, DICKERSON BC, YUSHKEVICH PA &amp; WOLK DA 2018. Longitudinal and cross-sectional structural magnetic resonance imaging correlates of AV-1451 uptake. Neurobiology of Aging, 66, 49&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5924615</ArticleId><ArticleId IdType="pubmed">29518752</ArticleId></ArticleIdList></Reference><Reference><Citation>EWING-COBBS L, HASAN KM, PRASAD MR, KRAMER L &amp; BACHEVALIER J 2006. Corpus callosum diffusion anisotropy correlates with neuropsychological outcomes in twins disconcordant for traumatic brain injury. AJNR. American journal of neuroradiology, 27, 879&#x2013;881.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1868391</ArticleId><ArticleId IdType="pubmed">16611782</ArticleId></ArticleIdList></Reference><Reference><Citation>FAN L, LI H, ZHUO J, ZHANG Y, WANG J, CHEN L, YANG Z, CHU C, XIE S, LAIRD AR, FOX PT, EICKHOFF SB, YU C &amp; JIANG T 2016. The Human Brainnetome Atlas: A New Brain Atlas Based on Connectional Architecture. Cerebral Cortex, 26, 3508&#x2013;3526.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4961028</ArticleId><ArticleId IdType="pubmed">27230218</ArticleId></ArticleIdList></Reference><Reference><Citation>FRANZMEIER N, NEITZEL J, RUBINSKI A, SMITH R, STRANDBERG O, OSSENKOPPELE R, HANSSON O, EWERS M &amp; ALZHEIMER'S DISEASE NEUROIMAGING I. 2020. Functional brain architecture is associated with the rate of tau accumulation in Alzheimer's disease. Nat Commun, 11, 347.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6969065</ArticleId><ArticleId IdType="pubmed">31953405</ArticleId></ArticleIdList></Reference><Reference><Citation>GOLD BT, POWELL DK, XUAN L, JIANG Y &amp; HARDY PA 2007. Speed of lexical decision correlates with diffusion anisotropy in left parietal and frontal white matter: evidence from diffusion tensor imaging. Neuropsychologia, 45, 2439&#x2013;2446.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2965058</ArticleId><ArticleId IdType="pubmed">17509627</ArticleId></ArticleIdList></Reference><Reference><Citation>GROTHE MJ, BARTHEL H, SEPULCRE J, DYRBA M, SABRI O &amp; TEIPEL SJ 2017. In vivo staging of regional amyloid deposition. Neurology, 89, 2031.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5711511</ArticleId><ArticleId IdType="pubmed">29046362</ArticleId></ArticleIdList></Reference><Reference><Citation>HE Z, GUO JL, MCBRIDE JD, NARASIMHAN S, KIM H, CHANGOLKAR L, ZHANG B, GATHAGAN RJ, YUE C, DENGLER C, STIEBER A, NITLA M, COULTER DA, ABEL T, BRUNDEN KR, TROJANOWSKI JQ &amp; LEE VM 2018. Amyloid-beta plaques enhance Alzheimer's brain tau-seeded pathologies by facilitating neuritic plaque tau aggregation. Nat Med, 24, 29&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5760353</ArticleId><ArticleId IdType="pubmed">29200205</ArticleId></ArticleIdList></Reference><Reference><Citation>HOAGLIN DC, MOSTELLER F &amp; TUKEY JW 2000. Understanding robust and exploratory data analysis.</Citation></Reference><Reference><Citation>HYMAN BT, DAMASIO AR, VAN HOESEN GW &amp; BARNES CL 1984. Alzheimer's disease: cell-specific pathology isolates the hippocampal formation. Science, 298, 83&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">6474172</ArticleId></ArticleIdList></Reference><Reference><Citation>INDRAYAN A &amp; MALHOTRA RK 2017. Medical biostatistics, CRC Press.</Citation></Reference><Reference><Citation>ITURRIA-MEDINA Y, SOTERO RC, TOUSSAINT PJ, EVANS AC &amp; ALZHEIMER'S DISEASE NEUROIMAGING, I. 2014. Epidemic spreading model to characterize misfolded proteins propagation in aging and associated neurodegenerative disorders. PLoS computational biology, 10, e1003956&#x2013;e1003956.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4238950</ArticleId><ArticleId IdType="pubmed">25412207</ArticleId></ArticleIdList></Reference><Reference><Citation>JACK CR, KNOPMAN DS, JAGUST WJ, SHAW LM, AISEN PS, WEINER MW, PETERSEN RC &amp; TROJANOWSKI JQ 2010. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. The Lancet Neurology, 9, 119&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2819840</ArticleId><ArticleId IdType="pubmed">20083042</ArticleId></ArticleIdList></Reference><Reference><Citation>JACK CR, PETERSEN RC, XU YC, WARING SC, O'BRIEN PC, TANGALOS EG, SMITH GE, IVNIK RJ &amp; KOKMEN E 1997. Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease. Neurology, 49, 786&#x2013;794.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2730601</ArticleId><ArticleId IdType="pubmed">9305341</ArticleId></ArticleIdList></Reference><Reference><Citation>JAGUST W 2018. Imaging the evolution and pathophysiology of Alzheimer disease. Nature Reviews Neuroscience, 19, 687&#x2013;700.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7032048</ArticleId><ArticleId IdType="pubmed">30266970</ArticleId></ArticleIdList></Reference><Reference><Citation>JAGUST WJ, LANDAU SM, KOEPPE RA, REIMAN EM, CHEN K, MATHIS CA, PRICE JC, FOSTER NL &amp; WANG AY 2015. The Alzheimer's Disease Neuroimaging Initiative 2 PET Core: 2015. Alzheimer's &amp; dementia : the journal of the Alzheimer's Association, 11, 757&#x2013;771.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4510459</ArticleId><ArticleId IdType="pubmed">26194311</ArticleId></ArticleIdList></Reference><Reference><Citation>JOHNSON KA, SCHULTZ A, BETENSKY RA, BECKER JA, SEPULCRE J, RENTZ D, MORMINO E, CHHATWAL J, AMARIGLIO R, PAPP K, MARSHALL G, ALBERS M, MAURO S, PEPIN L, ALVERIO J, JUDGE K, PHILIOSSAINT M, SHOUP T, YOKELL D, DICKERSON B, GOMEZ-ISLA T, HYMAN B, VASDEV N &amp; SPERLING R 2016. Tau positron emission tomographic imaging in aging and early Alzheimer disease. Annals of Neurology, 79, 110&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4738026</ArticleId><ArticleId IdType="pubmed">26505746</ArticleId></ArticleIdList></Reference><Reference><Citation>JOSHI AD, PONTECORVO MJ, CLARK CM, CARPENTER AP, JENNINGS DL, SADOWSKY CH, ADLER LP, KOVNAT KD, SEIBYL JP, ARORA A, SAHA K, BURNS JD, LOWREY MJ, MINTUN MA, SKOVRONSKY DM &amp; INVESTIGATORS T. F. F. S. 2012. Performance Characteristics of Amyloid PET with Florbetapir F 18 in Patients with Alzheimer's Disease and Cognitively Normal Subjects. 53, 378&#x2013;384.</Citation><ArticleIdList><ArticleId IdType="pubmed">22331215</ArticleId></ArticleIdList></Reference><Reference><Citation>KIM EJ, HWANG JL, GAUS SE, NANA AL, DENG J, BROWN JA, SPINA S, LEE MJ, RAMOS EM, GRINBERG LT, KRAMER JH, BOXER AL, GORNO-TEMPINI ML, ROSEN HJ, MILLER BL &amp; SEELEY WW 2019. Evidence of corticofugal tau spreading in patients with frontotemporal dementia. Acta Neuropathol.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7012377</ArticleId><ArticleId IdType="pubmed">31542807</ArticleId></ArticleIdList></Reference><Reference><Citation>LA JOIE R, PERROTIN A, BARR&#xeb; L, HOMMET C, M&#xeb;ZENGE F, IBAZIZENE M, CAMUS V, ABBAS A, LANDEAU B &amp; GUILLOTEAU D 2012. Region-specific hierarchy between atrophy, hypometabolism, and &#x3b2;-amyloid (A&#x3b2;) load in Alzheimer's disease dementia. Journal of Neuroscience, 32, 16265&#x2013;16273.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6794030</ArticleId><ArticleId IdType="pubmed">23152610</ArticleId></ArticleIdList></Reference><Reference><Citation>LEMOINE L, LEUZY A, CHIOTIS K, RODRIGUEZ-VIEITEZ E &amp; NORDBERG A 2018. Tau positron emission tomography imaging in tauopathies: The added hurdle of off-target binding. Alzheimer's &amp; Dementia: Diagnosis, Assessment &amp; Disease Monitoring, 10,232&#x2013;236.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5956931</ArticleId><ArticleId IdType="pubmed">29780868</ArticleId></ArticleIdList></Reference><Reference><Citation>LEUZY A, CHIOTIS K, LEMOINE L, GILLBERG P-G, ALMKVIST O, RODRIGUEZ-VIEITEZ E &amp; NORDBERG A 2019. Tau PET imaging in neurodegenerative tauopathies&#x2014;still a challenge. Molecular Psychiatry, 24, 1112&#x2013;1134.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6756230</ArticleId><ArticleId IdType="pubmed">30635637</ArticleId></ArticleIdList></Reference><Reference><Citation>LIU L, DROUET V, WU JW, WITTER MP, SMALL SA, CLELLAND C &amp; DUFF K 2012. Trans-synaptic spread of tau pathology in vivo. PLoS One, 7, e31302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3270029</ArticleId><ArticleId IdType="pubmed">22312444</ArticleId></ArticleIdList></Reference><Reference><Citation>LOCKHART SN, AYAKTA N, WINER JR, LA JOIE R, RABINOVICI GD &amp; JAGUST WJ 2017. Elevated (18)F-AV-1451 PET tracer uptake detected in incidental imaging findings. Neurology, 88, 1095&#x2013;1097.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5384840</ArticleId><ArticleId IdType="pubmed">28188303</ArticleId></ArticleIdList></Reference><Reference><Citation>MAASS A, LANDAU S, BAKER SL, HORNG A, LOCKHART SN, LA JOIE R, RABINOVICI GD &amp; JAGUST WJ 2017. Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease. NeuroImage, 157, 448&#x2013;463.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5814575</ArticleId><ArticleId IdType="pubmed">28587897</ArticleId></ArticleIdList></Reference><Reference><Citation>MAIER-HEIN KH, NEHER PF, HOUDE J-C, C&#xf6;T&#xeb; M-A, GARYFALLIDIS E, ZHONG J, CHAMBERLAND M, YEH F-C, LIN Y-C, JI Q, REDDICK WE, GLASS JO, CHEN DQ, FENG Y, GAO C, WU Y, MA J, HE R, LI Q, WESTIN C-F, DESLAURIERS-GAUTHIER S, GONZ&#xe3;LEZ JOO, PAQUETTE M, ST-JEAN S, GIRARD G, RHEAULT F, SIDHU J, TAX CMW, GUO F, MESRI HY, D&#xe3;VID S, FROELING M, HEEMSKERK AM, LEEMANS A, BOR&#xeb; A, PINSARD B, BEDETTI C, DESROSIERS M, BRAMBATI S, DOYON J, SARICA A, VASTA R, CERASA A, QUATTRONE A, YEATMAN J, KHAN AR, HODGES W, ALEXANDER S, ROMASCANO D, BARAKOVIC M, AUR&#xef;A A, ESTEBAN O, LEMKADDEM A, THIRAN J-P, CETINGUL HE, ODRY BL, MAILHE B, NADAR MS, PIZZAGALLI F, PRASAD G, VILLALON-REINA JE, GALVIS J, THOMPSON PM, REQUEJO FDS, LAGUNA PL, LACERDA LM, BARRETT R, DELL&#x2019;ACQUA F, CATANI M, PETIT L, CARUYER E, DADUCCI A, DYRBY TB, HOLLAND-LETZ T, HILGETAG CC, STIELTJES B &amp; DESCOTEAUX M 2017. The challenge of mapping the human connectome based on diffusion tractography. Nature Communications, 8, 1349.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5677006</ArticleId><ArticleId IdType="pubmed">29116093</ArticleId></ArticleIdList></Reference><Reference><Citation>MCDADE E, WANG G, GORDON BA, HASSENSTAB J, BENZINGER TLS, BUCKLES V, FAGAN AM, HOLTZMAN DM, CAIRNS NJ, GOATE AM, MARCUS DS, MORRIS JC, PAUMIER K, XIONG C, ALLEGRI R, BERMAN SB, KLUNK W, NOBLE J, RINGMAN J, GHETTI B, FARLOW M, SPERLING RA, CHHATWAL J, SALLOWAY S, GRAFF-RADFORD NR, SCHOFIELD PR, MASTERS C, ROSSOR MN, FOX NC, LEVIN J, JUCKER M, BATEMAN RJ &amp; DOMINANTLY INHERITED ALZHEIMER N 2018. Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease. Neurology, 91, e1295&#x2013;e1306.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6177272</ArticleId><ArticleId IdType="pubmed">30217935</ArticleId></ArticleIdList></Reference><Reference><Citation>MCKHANN GM, KNOPMAN DS, CHERTKOW H, HYMAN BT, JACK CR, KAWAS CH, KLUNK WE, KOROSHETZ WJ, MANLY JJ, MAYEUX R, MOHS RC, MORRIS JC, ROSSOR MN, SCHELTENS P, CARRILLO MC, THIES B, WEINTRAUB S &amp; PHELPS CH 2011. The diagnosis of dementia due to Alzheimer&#x2019;s disease: Recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's &amp; Dementia, 7, 263&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312024</ArticleId><ArticleId IdType="pubmed">21514250</ArticleId></ArticleIdList></Reference><Reference><Citation>MINTUN MA, LO AC, DUGGAN EVANS C, WESSELS AM, ARDAYFIO PA, ANDERSEN SW, SHCHERBININ S, SPARKS J, SIMS JR, BRYS M, APOSTOLOVA LG, SALLOWAY SP &amp; SKOVRONSKY DM 2021. Donanemab in Early Alzheimer&#x2019;s Disease. New England Journal of Medicine, 384, 1691&#x2013;1704.</Citation><ArticleIdList><ArticleId IdType="pubmed">33720637</ArticleId></ArticleIdList></Reference><Reference><Citation>MUSIEK ES &amp; HOLTZMAN DM 2012. Origins of Alzheimer's disease: reconciling cerebrospinal fluid biomarker and neuropathology data regarding the temporal sequence of amyloid-beta and tau involvement. Current Opinion in Neurology, 25, 715&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3682920</ArticleId><ArticleId IdType="pubmed">23041958</ArticleId></ArticleIdList></Reference><Reference><Citation>OSSENKOPPELE R, IACCARINO L, SCHONHAUT DR, BROWN JA, LA JOIE R, O'NEIL JP, JANABI M, BAKER SL, KRAMER JH, GORNO-TEMPINI ML, MILLER BL, ROSEN HJ, SEELEY WW, JAGUST WJ &amp; RABINOVICI GD 2019. Tau covariance patterns in Alzheimer's disease patients match intrinsic connectivity networks in the healthy brain. Nenroimage Clin, 23, 101848.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6510968</ArticleId><ArticleId IdType="pubmed">31077982</ArticleId></ArticleIdList></Reference><Reference><Citation>OSSENKOPPELE R, PIJNENBURG YA, PERRY DC, COHN-SHEEHY BI, SCHELTENS NM, VOGEL JW, KRAMER JH, VAN DER VLIES AE, JOIE RL &amp; ROSEN HJ 2015. The behavioural/dysexecutive variant of Alzheimer&#x2019;s disease: clinical, neuroimaging and pathological features. Brain, 138, 2732&#x2013;2749.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4623840</ArticleId><ArticleId IdType="pubmed">26141491</ArticleId></ArticleIdList></Reference><Reference><Citation>PETERSEN RC, AISEN PS, BECKETT LA, DONOHUE MC, GAMST AC, HARVEY DJ, JACK CR JR., JAGUST WJ, SHAW LM, TOGA AW, TROJANOWSKI JQ &amp; WEINER MW 2010. Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology, 74, 201&#x2013;209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2809036</ArticleId><ArticleId IdType="pubmed">20042704</ArticleId></ArticleIdList></Reference><Reference><Citation>RAJ A, KUCEYESKI A &amp; WEINER M 2012. A Network Diffusion Model of Disease Progression in Dementia. Neuron, 73, 1204&#x2013;1215.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3623298</ArticleId><ArticleId IdType="pubmed">22445347</ArticleId></ArticleIdList></Reference><Reference><Citation>RAJ A, LOCASTRO E, KUCEYESKI A, TOSUN D, RELKIN N, WEINER M &amp; FOR THE ALZHEIMER'S DISEASE NEUROIMAGING, I. 2015. Network Diffusion Model of Progression Predicts Longitudinal Patterns of Atrophy and Metabolism in Alzheimer's Disease. Cell Rep.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5747552</ArticleId><ArticleId IdType="pubmed">25600871</ArticleId></ArticleIdList></Reference><Reference><Citation>SANCHEZ JS, BECKER JA, JACOBS HIL, HANSEEUW BJ, JIANG S, SCHULTZ AP, PROPERZI MJ, KATZ SR, BEISER A, SATIZABAL CL, O&#x2019;DONNELL A, DECARLI C, KILLIANY R, EL FAKHRI G, NORMANDIN MD, G&#xf5;MEZ-ISLA T, QUIROZ YT, RENTZ DM, SPERLING RA, SESHADRI S, AUGUSTINACK J, PRICE JC &amp; JOHNSON KA 2021a. The cortical origin and initial spread of medial temporal tauopathy in Alzheimer&#x2019;s disease assessed with positron emission tomography. Science Translational Medicine, 13, eabc0655.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7978042</ArticleId><ArticleId IdType="pubmed">33472953</ArticleId></ArticleIdList></Reference><Reference><Citation>SANCHEZ JS, HANSEEUW BJ, LOPERA F, SPERLING RA, BAENA A, BOCANEGRA Y, AGUILLON D, GUZM&#xe3;N-V&#xeb;LEZ E, PARDILLA-DELGADO E, RAMIREZ-GOMEZ L, VILA-CASTELAR C, MARTINEZ JE, FOX-FULLER JT, RAMOS C, OCHOA-ESCUDERO M, ALVAREZ S, JACOBS HIL, SCHULTZ AP, GATCHEL JR, BECKER JA, KATZ SR, MAYBLYUM DV, PRICE JC, REIMAN EM, JOHNSON KA &amp; QUIROZ YT 2021b. Longitudinal amyloid and tau accumulation in autosomal dominant Alzheimer&#x2019;s disease: findings from the Colombia-Boston (COLBOS) biomarker study. Alzheimer's Research &amp; Therapy, 13, 27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7811244</ArticleId><ArticleId IdType="pubmed">33451357</ArticleId></ArticleIdList></Reference><Reference><Citation>SCOTT MR, HAMPTON OL, BUCKLEY RF, CHHATWAL JP, HANSEEUW BJ, JACOBS HIL, PROPERZI MJ, SANCHEZ JS, JOHNSON KA, SPERLING RA &amp; SCHULTZ AP 2020. Inferior temporal tau is associated with accelerated prospective cortical thinning in clinically normal older adults. NeuroImage, 220, 116991.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7572623</ArticleId><ArticleId IdType="pubmed">32512123</ArticleId></ArticleIdList></Reference><Reference><Citation>SEPULCRE J, GROTHE MJ, D'OLEIRE UQUILLAS F, ORTIZ-TERAN L, DIEZ I, YANG HS, JACOBS HIL, HANSEEUW BJ, LI Q, EL-FAKHRI G, SPERLING RA &amp; JOHNSON KA 2018. Neurogenetic contributions to amyloid beta and tau spreading in the human cortex. Nat Med, 24, 1910&#x2013;1918.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6518398</ArticleId><ArticleId IdType="pubmed">30374196</ArticleId></ArticleIdList></Reference><Reference><Citation>THAL DR, R&#xfe;B U, ORANTES M &amp; BRAAK H 2002. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology, 58, 1791&#x2013;800.</Citation><ArticleIdList><ArticleId IdType="pubmed">12084879</ArticleId></ArticleIdList></Reference><Reference><Citation>TSAI RM, BEJANIN A, LESMAN-SEGEV O, LAJOIE R, VISANI A, BOURAKOVA V, O&#x2019;NEIL JP, JANABI M, BAKER S, LEE SE, PERRY DC, BAJOREK L, KARYDAS A, SPINA S, GRINBERG LT, SEELEY WW, RAMOS EM, COPPOLA G, GORNO-TEMPINI ML, MILLER BL, ROSEN HJ, JAGUST W, BOXER AL &amp; RABINOVICI GD 2019. 18F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes. Alzheimer's Research &amp; Therapy, 11, 13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6357510</ArticleId><ArticleId IdType="pubmed">30704514</ArticleId></ArticleIdList></Reference><Reference><Citation>VAN DEN HEUVEL MP &amp; SPORNS O 2011. Rich-Club Organization of the Human Connectome. The Journal of Neuroscience, 31, 15775.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6623027</ArticleId><ArticleId IdType="pubmed">22049421</ArticleId></ArticleIdList></Reference><Reference><Citation>VOGEL JW, ITURRIA-MEDINA Y, STRANDBERG OT, SMITH R, LEVITIS E, EVANS AC, HANSSON O, ALZHEIMER'S DISEASE NEUROIMAGING I. &amp; SWEDISH BIOFINDER S 2020. Spread of pathological tau proteins through communicating neurons in human Alzheimer's disease. Nat Commun, 11, 2612.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7251068</ArticleId><ArticleId IdType="pubmed">32457389</ArticleId></ArticleIdList></Reference><Reference><Citation>VOGEL JW, YOUNG AL, OXTOBY NP, SMITH R, OSSENKOPPELE R, STRANDBERG OT, LA JOIE R, AKSMAN LM, GROTHE MJ, ITURRIA-MEDINA Y, WEINER M, AISEN P, PETERSEN R, JACK CR, JAGUST W, TROJANOWKI JQ, TOGA AW, BECKETT L, GREEN RC, SAYKIN AJ, MORRIS J, SHAW LM, LIU E, MONTINE T, THOMAS RG, DONOHUE M, WALTER S, GESSERT D, SATHER T, JIMINEZ G, HARVEY D, BERNSTEIN M, FOX N, THOMPSON P, SCHUFF N, DECARLI C, BOROWSKI B, GUNTER J, SENJEM M, VEMURI P, JONES D, KANTARCI K, WARD C, KOEPPE RA, FOSTER N, REIMAN EM, CHEN K, MATHIS C, LANDAU S, CAIRNS NJ, HOUSEHOLDER E, REINWALD LT, LEE V, KORECKA M, FIGURSKI M, CRAWFORD K, NEU S, FOROUD TM, POTKIN S, SHEN L, KELLEY F, KIM S, NHO K, KACHATURIAN Z, FRANK R, SNYDER PJ, MOLCHAN S, KAYE J, QUINN J, LIND B, CARTER R, DOLEN S, SCHNEIDER LS, PAWLUCZYK S, BECCERA M, TEODORO L, SPANN BM, BREWER J, VANDERSWAG H, FLEISHER A, HEIDEBRINK JL, LORD JL, MASON SS, ALBERS CS, KNOPMAN D, JOHNSON K, DOODY RS, MEYER JV, CHOWDHURY M, ROUNTREE S, DANG M, STERN Y, HONIG LS, BELL KL, ANCES B, MORRIS JC, CARROLL M, LEON S, MINTUN MA, SCHNEIDER S, et al. 2021. Four distinct trajectories of tau deposition identified in Alzheimer&#x2019;s disease. Nature Medicine, 27, 871&#x2013;881.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8686688</ArticleId><ArticleId IdType="pubmed">33927414</ArticleId></ArticleIdList></Reference><Reference><Citation>WANG R, BENNER T, SORENSEN AG &amp; WEDEEN VJ Diffusion toolkit: a software package for diffusion imaging data processing and tractography. Proc Intl Soc Mag Reson Med, 2007. Berlin.</Citation></Reference><Reference><Citation>WATERS J 2010. The concentration of soluble extracellular amyloid-&#x3b2; protein in acute brain slices from CRND8 mice. PloS one, 5, e15709&#x2013;e15709.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3012091</ArticleId><ArticleId IdType="pubmed">21209950</ArticleId></ArticleIdList></Reference><Reference><Citation>WILSON RJ 1979. Introduction to graph theory, Pearson Education India.</Citation></Reference><Reference><Citation>WOLK DA, DICKERSON BC &amp; THE ALZHEIMER&#x2019;S DISEASE NEUROIMAGING, I. 2010. Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional&#x2013;executive network function in Alzheimer&#x2019;s disease. Proceedings of the National Academy of Sciences, 107, 10256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2890481</ArticleId><ArticleId IdType="pubmed">20479234</ArticleId></ArticleIdList></Reference><Reference><Citation>WOOK YOO S, HAN CE, SHIN JS, WON SEO S, NA DL, KAISER M, JEONG Y &amp; SEONG J-K 2015. A Network Flow-based Analysis of Cognitive Reserve in Normal Ageing and Alzheimer&#x2019;s Disease. Scientific Reports, 5, 10057.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4438712</ArticleId><ArticleId IdType="pubmed">25992968</ArticleId></ArticleIdList></Reference><Reference><Citation>ZHOU J, GENNATAS, EFSTATHIOS D, KRAMER, JOEL H, MILLER, BRUCE L &amp; SEELEY, WILLIAM W. 2012. Predicting Regional Neurodegeneration from the Healthy Brain Functional Connectome. Neuron, 73, 1216&#x2013;1227.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3361461</ArticleId><ArticleId IdType="pubmed">22445348</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35444284</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>29</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>604</Volume><Issue>7907</Issue><PubDate><Year>2022</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Somatic genomic changes in single Alzheimer's disease neurons.</ArticleTitle><Pagination><StartPage>714</StartPage><EndPage>722</EndPage><MedlinePgn>714-722</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41586-022-04640-1</ELocationID><Abstract><AbstractText>Dementia in Alzheimer's disease progresses alongside neurodegeneration<sup>1-4</sup>, but the specific events that cause neuronal dysfunction and death remain poorly understood. During normal ageing, neurons progressively accumulate somatic mutations<sup>5</sup> at rates similar to those of dividing cells<sup>6,7</sup> which suggests that genetic factors, environmental exposures or disease states might influence this accumulation<sup>5</sup>. Here we analysed single-cell whole-genome sequencing data from 319 neurons from the prefrontal cortex and hippocampus of individuals with Alzheimer's disease and neurotypical control individuals. We found that somatic DNA alterations increase in individuals with Alzheimer's disease, with distinct molecular patterns. Normal neurons accumulate mutations primarily in an age-related pattern (signature A), which closely resembles 'clock-like' mutational signatures that have been previously described in healthy and cancerous cells<sup>6-10</sup>. In neurons affected by Alzheimer's disease, additional DNA alterations are driven by distinct processes (signature C) that highlight C&gt;A and other specific nucleotide changes. These changes potentially implicate nucleotide oxidation<sup>4,11</sup>, which we show is increased in Alzheimer's-disease-affected neurons in situ. Expressed genes exhibit signature-specific damage, and mutations show a transcriptional strand bias, which suggests that transcription-coupled nucleotide excision repair has a role in the generation of mutations. The alterations in Alzheimer's disease affect coding exons and are predicted to create dysfunctional genetic knockout cells and proteostatic stress. Our results suggest that known pathogenic mechanisms in Alzheimer's disease may lead to genomic damage to neurons that can progressively impair function. The aberrant accumulation of DNA alterations in neurodegeneration provides insight into the cascade of molecular and cellular events that occurs in the development of Alzheimer's disease.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s), under exclusive licence to Springer Nature Limited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Miller</LastName><ForeName>Michael B</ForeName><Initials>MB</Initials><Identifier Source="ORCID">0000-0002-6205-3314</Identifier><AffiliationInfo><Affiliation>Division of Neuropathology, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Genetics and Genomics, Manton Center for Orphan Diseases, Boston Children's Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Broad Institute of MIT and Harvard, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Huang</LastName><ForeName>August Yue</ForeName><Initials>AY</Initials><Identifier Source="ORCID">0000-0002-0416-2854</Identifier><AffiliationInfo><Affiliation>Division of Genetics and Genomics, Manton Center for Orphan Diseases, Boston Children's Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Broad Institute of MIT and Harvard, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Junho</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Genetics and Genomics, Manton Center for Orphan Diseases, Boston Children's Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Broad Institute of MIT and Harvard, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biological Sciences, Sungkyunkwan University, Suwon, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Zinan</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Division of Genetics and Genomics, Manton Center for Orphan Diseases, Boston Children's Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kirkham</LastName><ForeName>Samantha L</ForeName><Initials>SL</Initials><Identifier Source="ORCID">0000-0002-5444-6636</Identifier><AffiliationInfo><Affiliation>Division of Genetics and Genomics, Manton Center for Orphan Diseases, Boston Children's Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maury</LastName><ForeName>Eduardo A</ForeName><Initials>EA</Initials><Identifier Source="ORCID">0000-0002-2211-8611</Identifier><AffiliationInfo><Affiliation>Division of Genetics and Genomics, Manton Center for Orphan Diseases, Boston Children's Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Broad Institute of MIT and Harvard, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Bioinformatics and Integrative Genomics Program, Harvard-MIT MD-PhD Program, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ziegenfuss</LastName><ForeName>Jennifer S</ForeName><Initials>JS</Initials><Identifier Source="ORCID">0000-0002-3828-0381</Identifier><AffiliationInfo><Affiliation>Department of Molecular, Cell and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reed</LastName><ForeName>Hannah C</ForeName><Initials>HC</Initials><AffiliationInfo><Affiliation>Division of Genetics and Genomics, Manton Center for Orphan Diseases, Boston Children's Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Allegheny College, Meadville, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neil</LastName><ForeName>Jennifer E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Division of Genetics and Genomics, Manton Center for Orphan Diseases, Boston Children's Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Howard Hughes Medical Institute, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rento</LastName><ForeName>Lariza</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-9361-441X</Identifier><AffiliationInfo><Affiliation>Division of Genetics and Genomics, Manton Center for Orphan Diseases, Boston Children's Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Howard Hughes Medical Institute, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryu</LastName><ForeName>Steven C</ForeName><Initials>SC</Initials><Identifier Source="ORCID">0000-0003-0620-9609</Identifier><AffiliationInfo><Affiliation>Division of Genetics and Genomics, Manton Center for Orphan Diseases, Boston Children's Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Chanthia C</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Division of Genetics and Genomics, Manton Center for Orphan Diseases, Boston Children's Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luquette</LastName><ForeName>Lovelace J</ForeName><Initials>LJ</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ames</LastName><ForeName>Heather M</ForeName><Initials>HM</Initials><Identifier Source="ORCID">0000-0002-5868-7672</Identifier><AffiliationInfo><Affiliation>Department of Pathology, University of Maryland School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oakley</LastName><ForeName>Derek H</ForeName><Initials>DH</Initials><AffiliationInfo><Affiliation>Department of Pathology, Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frosch</LastName><ForeName>Matthew P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Department of Pathology, Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hyman</LastName><ForeName>Bradley T</ForeName><Initials>BT</Initials><Identifier Source="ORCID">0000-0002-7959-9401</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lodato</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0003-4175-1073</Identifier><AffiliationInfo><Affiliation>Division of Genetics and Genomics, Manton Center for Orphan Diseases, Boston Children's Hospital, Boston, MA, USA. michael.lodato@umassmed.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Harvard Medical School, Boston, MA, USA. michael.lodato@umassmed.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular, Cell and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, MA, USA. michael.lodato@umassmed.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Eunjung Alice</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Division of Genetics and Genomics, Manton Center for Orphan Diseases, Boston Children's Hospital, Boston, MA, USA. ealice.lee@childrens.harvard.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Broad Institute of MIT and Harvard, Cambridge, MA, USA. ealice.lee@childrens.harvard.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Harvard Medical School, Boston, MA, USA. ealice.lee@childrens.harvard.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walsh</LastName><ForeName>Christopher A</ForeName><Initials>CA</Initials><Identifier Source="ORCID">0000-0002-0156-2238</Identifier><AffiliationInfo><Affiliation>Division of Genetics and Genomics, Manton Center for Orphan Diseases, Boston Children's Hospital, Boston, MA, USA. christopher.walsh@childrens.harvard.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Broad Institute of MIT and Harvard, Cambridge, MA, USA. christopher.walsh@childrens.harvard.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Harvard Medical School, Boston, MA, USA. christopher.walsh@childrens.harvard.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Howard Hughes Medical Institute, Boston, MA, USA. christopher.walsh@childrens.harvard.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Harvard Medical School, Boston, MA, USA. christopher.walsh@childrens.harvard.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Acronym>HHMI</Acronym><Agency>Howard Hughes Medical Institute</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 AG065502</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG051791</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS032457</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R00 AG054748</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 HD105351</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 HL007627</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062421</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DP2 AG072437</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 HG002295</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM007753</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG070921</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T15 LM007098</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>04</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009711">Nucleotides</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-49-2</RegistryNumber><NameOfSubstance UI="D004247">DNA</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004247" MajorTopicYN="N">DNA</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005091" MajorTopicYN="N">Exons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D023281" MajorTopicYN="N">Genomics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059645" MajorTopicYN="N">Mutation Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="Y">Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009711" MajorTopicYN="N">Nucleotides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017397" MajorTopicYN="N">Prefrontal Cortex</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073336" MajorTopicYN="N">Whole Genome Sequencing</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing interests</b> C.A.W. is a paid consultant (cash, no equity) to Third Rock Ventures and Flagship Pioneering (cash, no equity) and is on the Clinical Advisory Board (cash and equity) of Maze Therapeutics. No research support is received. These companies did not fund and had no role in the conception or performance of this research project. The remaining authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>6</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>21</Day><Hour>5</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>10</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35444284</ArticleId><ArticleId IdType="mid">NIHMS1826063</ArticleId><ArticleId IdType="pmc">PMC9357465</ArticleId><ArticleId IdType="doi">10.1038/s41586-022-04640-1</ArticleId><ArticleId IdType="pii">10.1038/s41586-022-04640-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Selkoe DJ &amp; Hardy J The amyloid hypothesis of Alzheimer&#x2019;s disease at 25 years. EMBO Mol. Med 8, 595&#x2013;608 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4888851</ArticleId><ArticleId IdType="pubmed">27025652</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT et al. National Institute on Aging&#x2013;Alzheimer&#x2019;s Association guidelines for the neuropathologic assessment of Alzheimer&#x2019;s disease. Alzheimers Dement 8, 1&#x2013;13 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3266529</ArticleId><ArticleId IdType="pubmed">22265587</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H &amp; Braak E Staging of Alzheimer&#x2019;s disease-related neurofibrillary changes. Neurobiol. Aging 16, 271&#x2013;278 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">7566337</ArticleId></ArticleIdList></Reference><Reference><Citation>Gabbita SP, Lovell MA &amp; Markesbery WR Increased nuclear DNA oxidation in the brain in Alzheimer&#x2019;s disease. J. Neurochem 71, 2034&#x2013;2040 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9798928</ArticleId></ArticleIdList></Reference><Reference><Citation>Lodato MA et al. Aging and neurodegeneration are associated with increased mutations in single human neurons. Science 359, 555&#x2013;559 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5831169</ArticleId><ArticleId IdType="pubmed">29217584</ArticleId></ArticleIdList></Reference><Reference><Citation>Blokzijl F et al. Tissue-specific mutation accumulation in human adult stem cells during life. Nature 538, 260&#x2013;264 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5536223</ArticleId><ArticleId IdType="pubmed">27698416</ArticleId></ArticleIdList></Reference><Reference><Citation>Osorio FG et al. Somatic mutations reveal lineage relationships and age-related mutagenesis in human hematopoiesis. Cell Rep 25, 2308&#x2013;2316 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6289083</ArticleId><ArticleId IdType="pubmed">30485801</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexandrov LB et al. Signatures of mutational processes in human cancer. Nature 500, 415&#x2013;421 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3776390</ArticleId><ArticleId IdType="pubmed">23945592</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexandrov LB et al. Clock-like mutational processes in human somatic cells. Nat. Genet 47, 1402&#x2013;1407 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4783858</ArticleId><ArticleId IdType="pubmed">26551669</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexandrov LB et al. The repertoire of mutational signatures in human cancer. Nature 578, 94&#x2013;101 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7054213</ArticleId><ArticleId IdType="pubmed">32025018</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu T et al. REST and stress resistance in ageing and Alzheimer&#x2019;s disease. Nature 507, 448&#x2013;454 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4110979</ArticleId><ArticleId IdType="pubmed">24670762</ArticleId></ArticleIdList></Reference><Reference><Citation>Genovese G et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N. Engl. J. Med 371, 2477&#x2013;2487 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4290021</ArticleId><ArticleId IdType="pubmed">25426838</ArticleId></ArticleIdList></Reference><Reference><Citation>Martincorena I et al. Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin. Science 348, 880&#x2013;886 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4471149</ArticleId><ArticleId IdType="pubmed">25999502</ArticleId></ArticleIdList></Reference><Reference><Citation>Martincorena I et al. Somatic mutant clones colonize the human esophagus with age. Science 362, 911&#x2013;917 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6298579</ArticleId><ArticleId IdType="pubmed">30337457</ArticleId></ArticleIdList></Reference><Reference><Citation>Lodato MA et al. Somatic mutation in single human neurons tracks developmental and transcriptional history. Science 350, 94&#x2013;98 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4664477</ArticleId><ArticleId IdType="pubmed">26430121</ArticleId></ArticleIdList></Reference><Reference><Citation>Hazen JL et al. The complete genome sequences, unique mutational spectra, and developmental potency of adult neurons revealed by cloning. Neuron 89, 1223&#x2013;1236 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4795965</ArticleId><ArticleId IdType="pubmed">26948891</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhagwat AS et al. Strand-biased cytosine deamination at the replication fork causes cytosine to thymine mutations in Escherichia coli. Proc. Natl Acad. Sci. USA 113, 2176&#x2013;2181 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4776466</ArticleId><ArticleId IdType="pubmed">26839411</ArticleId></ArticleIdList></Reference><Reference><Citation>Kucab JE et al. A compendium of mutational signatures of environmental agents. Cell 177, 821&#x2013;836 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6506336</ArticleId><ArticleId IdType="pubmed">30982602</ArticleId></ArticleIdList></Reference><Reference><Citation>Sala Frigerio C et al. On the identification of low allele frequency mosaic mutations in the brains of Alzheimer&#x2019;s disease patients. Alzheimers Dement 11, 1265&#x2013;1276 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25937274</ArticleId></ArticleIdList></Reference><Reference><Citation>Abascal F et al. Somatic mutation landscapes at single-molecule resolution. Nature 593, 405&#x2013;410 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33911282</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu H et al. A tau homeostasis signature is linked with the cellular and regional vulnerability of excitatory neurons to tau pathology. Nat. Neurosci 22, 47&#x2013;56 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6330709</ArticleId><ArticleId IdType="pubmed">30559469</ArticleId></ArticleIdList></Reference><Reference><Citation>Leng K et al. Molecular characterization of selectively vulnerable neurons in Alzheimer&#x2019;s disease. Nat. Neurosci 24, 276&#x2013;287 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7854528</ArticleId><ArticleId IdType="pubmed">33432193</ArticleId></ArticleIdList></Reference><Reference><Citation>Bohrson CL et al. Linked-read analysis identifies mutations in single-cell DNA-sequencing data. Nat. Genet 51, 749&#x2013;754 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6900933</ArticleId><ArticleId IdType="pubmed">30886424</ArticleId></ArticleIdList></Reference><Reference><Citation>Petljak M et al. Characterizing mutational signatures in human cancer cell lines reveals episodic APOBEC mutagenesis. Cell 176, 1282&#x2013;1294 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6424819</ArticleId><ArticleId IdType="pubmed">30849372</ArticleId></ArticleIdList></Reference><Reference><Citation>Xing D, Tan L, Chang C-H, Li H &amp; Xie XS Accurate SNV detection in single cells by transposon-based whole-genome amplification of complementary strands. Proc. Natl Acad. Sci. USA 118, e2013106118 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7923680</ArticleId><ArticleId IdType="pubmed">33593904</ArticleId></ArticleIdList></Reference><Reference><Citation>Madabhushi R et al. Activity-induced DNA breaks govern the expression of neuronal early-response genes. Cell 161, 1592&#x2013;1605 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4886855</ArticleId><ArticleId IdType="pubmed">26052046</ArticleId></ArticleIdList></Reference><Reference><Citation>Min S et al. Absence of coding somatic single nucleotide variants within well-known candidate genes in late-onset sporadic Alzheimer&#x2019;s disease based on the analysis of multi-omics data. Neurobiol. Aging 108, 207&#x2013;209 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9832973</ArticleId><ArticleId IdType="pubmed">34392980</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MH et al. Somatic APP gene recombination in Alzheimer&#x2019;s disease and normal neurons. Nature 563, 639&#x2013;645 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6391999</ArticleId><ArticleId IdType="pubmed">30464338</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J et al. APP gene copy number changes reflect exogenous contamination. Nature 584, E20&#x2013;E28 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7704338</ArticleId><ArticleId IdType="pubmed">32814883</ArticleId></ArticleIdList></Reference><Reference><Citation>Jager M et al. Deficiency of nucleotide excision repair is associated with mutational signature observed in cancer. Genome Res 29, 1067&#x2013;1077 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6633256</ArticleId><ArticleId IdType="pubmed">31221724</ArticleId></ArticleIdList></Reference><Reference><Citation>Mecocci P, MacGarvey U &amp; Beal MF Oxidative damage to mitochondrial DNA is increased in Alzheimer&#x2019;s disease. Ann. Neurol 36, 747&#x2013;751 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">7979220</ArticleId></ArticleIdList></Reference><Reference><Citation>Chun H et al. Severe reactive astrocytes precipitate pathological hallmarks of Alzheimer&#x2019;s disease via H O &#x2212; production. Nat. Neurosci 23, 1555&#x2013;1566 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33199896</ArticleId></ArticleIdList></Reference><Reference><Citation>Pao PC et al. HDAC1 modulates OGG1-initiated oxidative DNA damage repair in the aging brain and Alzheimer&#x2019;s disease. Nat. Commun 11, 2484 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7235043</ArticleId><ArticleId IdType="pubmed">32424276</ArticleId></ArticleIdList></Reference><Reference><Citation>Nouspikel T &amp; Hanawalt PC Terminally differentiated human neurons repair transcribed genes but display attenuated global DNA repair and modulation of repair gene expression. Mol. Cell. Biol 20, 1562&#x2013;1570 (2000).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC85340</ArticleId><ArticleId IdType="pubmed">10669734</ArticleId></ArticleIdList></Reference><Reference><Citation>Seplyarskiy VB et al. Error-prone bypass of DNA lesions during lagging-strand replication is a common source of germline and cancer mutations. Nat. Genet 51, 36&#x2013;41 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6317876</ArticleId><ArticleId IdType="pubmed">30510240</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang JC, Svoboda DL, Reardon JT &amp; Sancar A Human nucleotide excision nuclease removes thymine dimers from DNA by incising the 22nd phosphodiester bond 5&#x2032; and the 6th phosphodiester bond 3&#x2032; to the photodimer . Proc. Natl Acad. Sci. USA 89, 3664&#x2013;3668 (1992).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC48929</ArticleId><ArticleId IdType="pubmed">1314396</ArticleId></ArticleIdList></Reference><Reference><Citation>Gate D et al. Clonally expanded CD8 T cells patrol the cerebrospinal fluid in Alzheimer&#x2019;s disease. Nature 577, 399&#x2013;404 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7445078</ArticleId><ArticleId IdType="pubmed">31915375</ArticleId></ArticleIdList></Reference><Reference><Citation>Soheili-Nezhad S, van der Linden RJ, Olde Rikkert M, Sprooten E &amp; Poelmans G Long genes are more frequently affected by somatic mutations and show reduced expression in Alzheimer&#x2019;s disease: Implications for disease etiology. Alzheimers Dement 17, 489&#x2013;499 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8048495</ArticleId><ArticleId IdType="pubmed">33075204</ArticleId></ArticleIdList></Reference><Reference><Citation>Crabtree GR Our fragile intellect. Part I. Trends Genet 29, 1&#x2013;3 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23153596</ArticleId></ArticleIdList></Reference><Reference><Citation>Fragola G et al. Deletion of topoisomerase 1 in excitatory neurons causes genomic instability and early onset neurodegeneration. Nat. Commun 11, 1962 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7181881</ArticleId><ArticleId IdType="pubmed">32327659</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez-Pena V et al. Accurate genomic variant detection in single cells with primary template-directed amplification. Proc. Natl Acad. Sci. USA 118, e2024176118 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8214697</ArticleId><ArticleId IdType="pubmed">34099548</ArticleId></ArticleIdList></Reference><Reference><Citation>Luquette LJ et al. Ultraspecific somatic SNV and indel detection in single neurons using primary template-directed amplification Preprint at bioRxiv 10.1101/2021.04.30.442032 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.04.30.442032</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaur U et al. Reactive oxygen species, redox signaling and neuroinflammation in Alzheimer&#x2019;s disease: the NF-&#x3ba;B connection. Curr. Top. Med. Chem 15, 446&#x2013;457 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25620241</ArticleId></ArticleIdList></Reference><Reference><Citation>Butterfield DA, Castegna A, Lauderback CM &amp; Drake J Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer&#x2019;s disease brain contribute to neuronal death. Neurobiol. Aging 23, 655&#x2013;664 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12392766</ArticleId></ArticleIdList></Reference><Reference><Citation>David DC et al. Proteomic and functional analyses reveal a mitochondrial dysfunction in P301L tau transgenic mice. J. Biol. Chem 280, 23802&#x2013;23814 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15831501</ArticleId></ArticleIdList></Reference><Reference><Citation>Khurana V et al. A neuroprotective role for the DNA damage checkpoint in tauopathy. Aging Cell 11, 360&#x2013;362 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22181010</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakofsky CJ et al. Repair of multiple simultaneous double-strand breaks causes bursts of genome-wide clustered hypermutation. PLoS Biol 17, e3000464 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6786661</ArticleId><ArticleId IdType="pubmed">31568516</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandrekar-Colucci S &amp; Landreth GE Microglia and inflammation in Alzheimer&#x2019;s disease. CNS Neurol. Disord. Drug Targets 9, 156&#x2013;167 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3653290</ArticleId><ArticleId IdType="pubmed">20205644</ArticleId></ArticleIdList></Reference><Reference><Citation>Rottkamp CA et al. Redox-active iron mediates amyloid-beta toxicity. Free Radic. Biol. Med 30, 447&#x2013;450 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11182300</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang AY et al. Parallel RNA and DNA analysis after deep sequencing (PRDD-seq) reveals cell type-specific lineage patterns in human brain. Proc. Natl Acad. Sci. USA 117, 13886&#x2013;13895 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7322034</ArticleId><ArticleId IdType="pubmed">32522880</ArticleId></ArticleIdList></Reference><Reference><Citation>Dean FB, Nelson JR, Giesler TL &amp; Lasken RS Rapid amplification of plasmid and phage DNA using Phi 29 DNA polymerase and multiply-primed rolling circle amplification. Genome Res 11, 1095&#x2013;1099 (2001).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC311129</ArticleId><ArticleId IdType="pubmed">11381035</ArticleId></ArticleIdList></Reference><Reference><Citation>Evrony GD et al. Single-neuron sequencing analysis of L1 retrotransposition and somatic mutation in the human brain. Cell 151, 483&#x2013;496 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3567441</ArticleId><ArticleId IdType="pubmed">23101622</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng GXY et al. Massively parallel digital transcriptional profiling of single cells. Nat. Commun 8, 14049 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5241818</ArticleId><ArticleId IdType="pubmed">28091601</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan J et al. Characterizing transcriptional heterogeneity through pathway and gene set overdispersion analysis. Nat. Methods 13, 241&#x2013;244 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4772672</ArticleId><ArticleId IdType="pubmed">26780092</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong X et al. Accurate identification of single-nucleotide variants in whole-genome-amplified single cells. Nat. Methods 14, 491&#x2013;493 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5408311</ArticleId><ArticleId IdType="pubmed">28319112</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H &amp; Durbin R Fast and accurate short read alignment with Burrows&#x2013;Wheeler transform. Bioinformatics 25, 1754&#x2013;1760 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2705234</ArticleId><ArticleId IdType="pubmed">19451168</ArticleId></ArticleIdList></Reference><Reference><Citation>McKenna A et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 20, 1297&#x2013;1303 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2928508</ArticleId><ArticleId IdType="pubmed">20644199</ArticleId></ArticleIdList></Reference><Reference><Citation>Keogh MJ et al. High prevalence of focal and multi-focal somatic genetic variants in the human brain. Nat. Commun 9, 4257 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6189186</ArticleId><ArticleId IdType="pubmed">30323172</ArticleId></ArticleIdList></Reference><Reference><Citation>Park JS et al. Brain somatic mutations observed in Alzheimer&#x2019;s disease associated with aging and dysregulation of tau phosphorylation. Nat. Commun 10, 3090 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6626023</ArticleId><ArticleId IdType="pubmed">31300647</ArticleId></ArticleIdList></Reference><Reference><Citation>Luquette LJ, Bohrson CL, Sherman MA &amp; Park PJ Identification of somatic mutations in single cell DNA-seq using a spatial model of allelic imbalance. Nat. Commun 10, 3908 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6715686</ArticleId><ArticleId IdType="pubmed">31467286</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai X et al. Single-cell, genome-wide sequencing identifies clonal somatic copy-number variation in the human brain. Cell Rep 8, 1280&#x2013;1289 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4272008</ArticleId><ArticleId IdType="pubmed">25159146</ArticleId></ArticleIdList></Reference><Reference><Citation>Baslan T et al. Genome-wide copy number analysis of single cells. Nat. Protoc 7, 1024&#x2013;1041 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5069701</ArticleId><ArticleId IdType="pubmed">22555242</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexandrov LB, Nik-Zainal S, Wedge DC, Campbell PJ &amp; Stratton MR Deciphering signatures of mutational processes operative in human cancer. Cell Rep 3, 246&#x2013;259 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3588146</ArticleId><ArticleId IdType="pubmed">23318258</ArticleId></ArticleIdList></Reference><Reference><Citation>Blokzijl F, Janssen R, van Boxtel R &amp; Cuppen E MutationalPatterns: comprehensive genome-wide analysis of mutational processes. Genome Med 10, 33 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5922316</ArticleId><ArticleId IdType="pubmed">29695279</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J et al. Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors. Nat. Genet 48, 600&#x2013;606 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4936490</ArticleId><ArticleId IdType="pubmed">27111033</ArticleId></ArticleIdList></Reference><Reference><Citation>Bates D, M&#xe4;chler M, Bolker B &amp; Walker S Fitting linear mixed-effects models using lme4. J. Stat. Softw 67, 1&#x2013;48 (2015).</Citation></Reference><Reference><Citation>Kuznetsova A, Brockhoff PB &amp; Christensen RHB lmerTest Package: tests in linear mixed effects models. J. Stat. Softw 82, 1&#x2013;26 (2017).</Citation></Reference><Reference><Citation>Consortium GT et al. Genetic effects on gene expression across human tissues. Nature 550, 204&#x2013;213 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5776756</ArticleId><ArticleId IdType="pubmed">29022597</ArticleId></ArticleIdList></Reference><Reference><Citation>Love MI, Huber W &amp; Anders S Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15, 550 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4302049</ArticleId><ArticleId IdType="pubmed">25516281</ArticleId></ArticleIdList></Reference><Reference><Citation>Young MD, Wakefield MJ, Smyth GK &amp; Oshlack A Gene ontology analysis for RNA-seq: accounting for selection bias. Genome Biol 11, R14 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2872874</ArticleId><ArticleId IdType="pubmed">20132535</ArticleId></ArticleIdList></Reference><Reference><Citation>Green P et al. Transcription-associated mutational asymmetry in mammalian evolution. Nat. Genet 33, 514&#x2013;517 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12612582</ArticleId></ArticleIdList></Reference><Reference><Citation>Polak P &amp; Arndt PF Transcription induces strand-specific mutations at the 5&#x2032; end of human genes. Genome Res 18, 1216&#x2013;1223 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2493432</ArticleId><ArticleId IdType="pubmed">18463301</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang K, Li M &amp; Hakonarson H ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res 38, e164 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2938201</ArticleId><ArticleId IdType="pubmed">20601685</ArticleId></ArticleIdList></Reference><Reference><Citation>Lek M et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature 536, 285&#x2013;291 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5018207</ArticleId><ArticleId IdType="pubmed">27535533</ArticleId></ArticleIdList></Reference><Reference><Citation>Coppede F &amp; Migliore L DNA damage and repair in Alzheimer&#x2019;s disease. Curr. Alzheimer Res 6, 36&#x2013;47 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19199873</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoang ML et al. Genome-wide quantification of rare somatic mutations in normal human tissues using massively parallel sequencing. Proc. Natl Acad. Sci. USA 113, 9846&#x2013;9851 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5024639</ArticleId><ArticleId IdType="pubmed">27528664</ArticleId></ArticleIdList></Reference><Reference><Citation>Franco I et al. Somatic mutagenesis in satellite cells associates with human skeletal muscle aging. Nat. Commun 9, 800 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5824957</ArticleId><ArticleId IdType="pubmed">29476074</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L et al. Single-cell whole-genome sequencing reveals the functional landscape of somatic mutations in B lymphocytes across the human lifespan. Proc. Natl Acad. Sci. USA 116, 9014&#x2013;9019 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6500118</ArticleId><ArticleId IdType="pubmed">30992375</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee-Six H et al. The landscape of somatic mutation in normal colorectal epithelial cells. Nature 574, 532&#x2013;537 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31645730</ArticleId></ArticleIdList></Reference><Reference><Citation>Franco I et al. Whole genome DNA sequencing provides an atlas of somatic mutagenesis in healthy human cells and identifies a tumor-prone cell type. Genome Biol 20, 285 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6918713</ArticleId><ArticleId IdType="pubmed">31849330</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunet JP, Tamayo P, Golub TR &amp; Mesirov JP Metagenes and molecular pattern discovery using matrix factorization. Proc. Natl Acad. Sci. USA 101, 4164&#x2013;4169 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC384712</ArticleId><ArticleId IdType="pubmed">15016911</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">35450967</PMID><DateCompleted><Year>2022</Year><Month>07</Month><Day>20</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>99</Volume><Issue>3</Issue><PubDate><Year>2022</Year><Month>Jul</Month><Day>19</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Effect of Race on Prediction of Brain Amyloidosis by Plasma A&#x3b2;42/A&#x3b2;40, Phosphorylated Tau, and Neurofilament Light.</ArticleTitle><Pagination><StartPage>e245</StartPage><EndPage>e257</EndPage><MedlinePgn>e245-e257</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0000000000200358</ELocationID><Abstract><AbstractText Label="BACKGROUND AND OBJECTIVES">To evaluate whether plasma biomarkers of amyloid (A&#x3b2;42/A&#x3b2;40), tau (p-tau181 and p-tau231), and neuroaxonal injury (neurofilament light chain [NfL]) detect brain amyloidosis consistently across racial groups.</AbstractText><AbstractText Label="METHODS">Individuals enrolled in studies of memory and aging who self-identified as African American (AA) were matched 1:1 to self-identified non-Hispanic White (NHW) individuals by age, <i>APOE</i> &#x3b5;4 carrier status, and cognitive status. Each participant underwent blood and CSF collection, and amyloid PET was performed in 103 participants (68%). Plasma A&#x3b2;42/A&#x3b2;40 was measured by a high-performance immunoprecipitation-mass spectrometry assay. Plasma p-tau181, p-tau231, and NfL were measured by Simoa immunoassays. CSF A&#x3b2;42/A&#x3b2;40 and amyloid PET status were used as primary and secondary reference standards of brain amyloidosis, respectively.</AbstractText><AbstractText Label="RESULTS">There were 76 matched pairs of AA and NHW participants (n = 152 total). For both AA and NHW groups, the median age was 68.4 years, 42% were <i>APOE</i> &#x3b5;4 carriers, and 91% were cognitively normal. AA were less likely than NHW participants to have brain amyloidosis by CSF A&#x3b2;42/A&#x3b2;40 (22% vs 43% positive; <i>p</i> = 0.003). The receiver operating characteristic area under the curve of CSF A&#x3b2;42/A&#x3b2;40 status with the plasma biomarkers was as follows: A&#x3b2;42/A&#x3b2;40, 0.86 (95% CI 0.79-0.92); p-tau181, 0.76 (0.68-0.84); p-tau231, 0.69 (0.60-0.78); and NfL, 0.64 (0.55-0.73). In models predicting CSF A&#x3b2;42/A&#x3b2;40 status with plasma A&#x3b2;42/A&#x3b2;40 that included covariates (age, sex, <i>APOE</i> &#x3b5;4 carrier status, race, and cognitive status), race did not affect the probability of CSF A&#x3b2;42/A&#x3b2;40 positivity. In similar models based on plasma p-tau181, p-tau231, or NfL, AA participants had a lower probability of CSF A&#x3b2;42/A&#x3b2;40 positivity (odds ratio 0.31 [95% CI 0.13-0.73], 0.30 [0.13-0.71], and 0.27 [0.12-0.64], respectively). Models of amyloid PET status yielded similar findings.</AbstractText><AbstractText Label="DISCUSSION">Models predicting brain amyloidosis using a high-performance plasma A&#x3b2;42/A&#x3b2;40 assay may provide an accurate and consistent measure of brain amyloidosis across AA and NHW groups, but models based on plasma p-tau181, p-tau231, and NfL may perform inconsistently and could result in disproportionate misdiagnosis of AA individuals.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schindler</LastName><ForeName>Suzanne E</ForeName><Initials>SE</Initials><Identifier Source="ORCID">0000-0003-1020-6347</Identifier><AffiliationInfo><Affiliation>From the Department of Neurology (S.E.S., R.L.H., Y.L., B.S., K.L.M., D.B., A.M.F., J.B.-B., R.J.B., J.C.M), Knight Alzheimer Disease Research Center (S.E.S., R.L.H., Y.L., B.S., K.L.M., D.B., A.M.F., B.A.G., T.L.S.B., J.B.-B., R.J.B., C.X., J.C.M.), Hope Center for Neurological Disorders (A.M.F.), Mallinckrodt Institute of Radiology (B.A.G., T.L.S.B.), and Division of Biostatistics (C.X.), Washington University School of Medicine, St. Louis, MO; Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry (T.K.K., N.J.A., H.Z., K.B.), Institute of Neuroscience and Physiology, University of Gothenburg, M&#xf6;lndal, Sweden; Department of Psychiatry (T.K.K.), University of Pittsburgh, PA; Wallenberg Centre for Molecular and Translational Medicine (N.J.A.), University of Gothenburg, Sweden; Institute of Psychiatry, Psychology and Neuroscience (N.J.A.), Maurice Wohl Institute Clinical Neuroscience Institute, King's College London,; NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation (N.J.A.), London, UK; C2N Diagnostics (K.E.Y., T.W., M.R.M., K.M.K.), St. Louis, MO; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, London,; UK Dementia Research Institute at UCL (H.Z.), London, UK; and Hong Kong Center for Neurodegenerative Diseases (H.Z.), China. schindler.s.e@wustl.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karikari</LastName><ForeName>Thomas K</ForeName><Initials>TK</Initials><Identifier Source="ORCID">0000-0003-1422-4358</Identifier><AffiliationInfo><Affiliation>From the Department of Neurology (S.E.S., R.L.H., Y.L., B.S., K.L.M., D.B., A.M.F., J.B.-B., R.J.B., J.C.M), Knight Alzheimer Disease Research Center (S.E.S., R.L.H., Y.L., B.S., K.L.M., D.B., A.M.F., B.A.G., T.L.S.B., J.B.-B., R.J.B., C.X., J.C.M.), Hope Center for Neurological Disorders (A.M.F.), Mallinckrodt Institute of Radiology (B.A.G., T.L.S.B.), and Division of Biostatistics (C.X.), Washington University School of Medicine, St. Louis, MO; Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry (T.K.K., N.J.A., H.Z., K.B.), Institute of Neuroscience and Physiology, University of Gothenburg, M&#xf6;lndal, Sweden; Department of Psychiatry (T.K.K.), University of Pittsburgh, PA; Wallenberg Centre for Molecular and Translational Medicine (N.J.A.), University of Gothenburg, Sweden; Institute of Psychiatry, Psychology and Neuroscience (N.J.A.), Maurice Wohl Institute Clinical Neuroscience Institute, King's College London,; NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation (N.J.A.), London, UK; C2N Diagnostics (K.E.Y., T.W., M.R.M., K.M.K.), St. Louis, MO; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, London,; UK Dementia Research Institute at UCL (H.Z.), London, UK; and Hong Kong Center for Neurodegenerative Diseases (H.Z.), China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ashton</LastName><ForeName>Nicholas J</ForeName><Initials>NJ</Initials><Identifier Source="ORCID">0000-0002-3579-8804</Identifier><AffiliationInfo><Affiliation>From the Department of Neurology (S.E.S., R.L.H., Y.L., B.S., K.L.M., D.B., A.M.F., J.B.-B., R.J.B., J.C.M), Knight Alzheimer Disease Research Center (S.E.S., R.L.H., Y.L., B.S., K.L.M., D.B., A.M.F., B.A.G., T.L.S.B., J.B.-B., R.J.B., C.X., J.C.M.), Hope Center for Neurological Disorders (A.M.F.), Mallinckrodt Institute of Radiology (B.A.G., T.L.S.B.), and Division of Biostatistics (C.X.), Washington University School of Medicine, St. Louis, MO; Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry (T.K.K., N.J.A., H.Z., K.B.), Institute of Neuroscience and Physiology, University of Gothenburg, M&#xf6;lndal, Sweden; Department of Psychiatry (T.K.K.), University of Pittsburgh, PA; Wallenberg Centre for Molecular and Translational Medicine (N.J.A.), University of Gothenburg, Sweden; Institute of Psychiatry, Psychology and Neuroscience (N.J.A.), Maurice Wohl Institute Clinical Neuroscience Institute, King's College London,; NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation (N.J.A.), London, UK; C2N Diagnostics (K.E.Y., T.W., M.R.M., K.M.K.), St. Louis, MO; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, London,; UK Dementia Research Institute at UCL (H.Z.), London, UK; and Hong Kong Center for Neurodegenerative Diseases (H.Z.), China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henson</LastName><ForeName>Rachel L</ForeName><Initials>RL</Initials><Identifier Source="ORCID">0000-0002-0664-0629</Identifier><AffiliationInfo><Affiliation>From the Department of Neurology (S.E.S., R.L.H., Y.L., B.S., K.L.M., D.B., A.M.F., J.B.-B., R.J.B., J.C.M), Knight Alzheimer Disease Research Center (S.E.S., R.L.H., Y.L., B.S., K.L.M., D.B., A.M.F., B.A.G., T.L.S.B., J.B.-B., R.J.B., C.X., J.C.M.), Hope Center for Neurological Disorders (A.M.F.), Mallinckrodt Institute of Radiology (B.A.G., T.L.S.B.), and Division of Biostatistics (C.X.), Washington University School of Medicine, St. Louis, MO; Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry (T.K.K., N.J.A., H.Z., K.B.), Institute of Neuroscience and Physiology, University of Gothenburg, M&#xf6;lndal, Sweden; Department of Psychiatry (T.K.K.), University of Pittsburgh, PA; Wallenberg Centre for Molecular and Translational Medicine (N.J.A.), University of Gothenburg, Sweden; Institute of Psychiatry, Psychology and Neuroscience (N.J.A.), Maurice Wohl Institute Clinical Neuroscience Institute, King's College London,; NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation (N.J.A.), London, UK; C2N Diagnostics (K.E.Y., T.W., M.R.M., K.M.K.), St. Louis, MO; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, London,; UK Dementia Research Institute at UCL (H.Z.), London, UK; and Hong Kong Center for Neurodegenerative Diseases (H.Z.), China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yarasheski</LastName><ForeName>Kevin E</ForeName><Initials>KE</Initials><Identifier Source="ORCID">0000-0001-5436-2451</Identifier><AffiliationInfo><Affiliation>From the Department of Neurology (S.E.S., R.L.H., Y.L., B.S., K.L.M., D.B., A.M.F., J.B.-B., R.J.B., J.C.M), Knight Alzheimer Disease Research Center (S.E.S., R.L.H., Y.L., B.S., K.L.M., D.B., A.M.F., B.A.G., T.L.S.B., J.B.-B., R.J.B., C.X., J.C.M.), Hope Center for Neurological Disorders (A.M.F.), Mallinckrodt Institute of Radiology (B.A.G., T.L.S.B.), and Division of Biostatistics (C.X.), Washington University School of Medicine, St. Louis, MO; Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry (T.K.K., N.J.A., H.Z., K.B.), Institute of Neuroscience and Physiology, University of Gothenburg, M&#xf6;lndal, Sweden; Department of Psychiatry (T.K.K.), University of Pittsburgh, PA; Wallenberg Centre for Molecular and Translational Medicine (N.J.A.), University of Gothenburg, Sweden; Institute of Psychiatry, Psychology and Neuroscience (N.J.A.), Maurice Wohl Institute Clinical Neuroscience Institute, King's College London,; NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation (N.J.A.), London, UK; C2N Diagnostics (K.E.Y., T.W., M.R.M., K.M.K.), St. Louis, MO; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, London,; UK Dementia Research Institute at UCL (H.Z.), London, UK; and Hong Kong Center for Neurodegenerative Diseases (H.Z.), China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>West</LastName><ForeName>Tim</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-3267-8249</Identifier><AffiliationInfo><Affiliation>From the Department of Neurology (S.E.S., R.L.H., Y.L., B.S., K.L.M., D.B., A.M.F., J.B.-B., R.J.B., J.C.M), Knight Alzheimer Disease Research Center (S.E.S., R.L.H., Y.L., B.S., K.L.M., D.B., A.M.F., B.A.G., T.L.S.B., J.B.-B., R.J.B., C.X., J.C.M.), Hope Center for Neurological Disorders (A.M.F.), Mallinckrodt Institute of Radiology (B.A.G., T.L.S.B.), and Division of Biostatistics (C.X.), Washington University School of Medicine, St. Louis, MO; Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry (T.K.K., N.J.A., H.Z., K.B.), Institute of Neuroscience and Physiology, University of Gothenburg, M&#xf6;lndal, Sweden; Department of Psychiatry (T.K.K.), University of Pittsburgh, PA; Wallenberg Centre for Molecular and Translational Medicine (N.J.A.), University of Gothenburg, Sweden; Institute of Psychiatry, Psychology and Neuroscience (N.J.A.), Maurice Wohl Institute Clinical Neuroscience Institute, King's College London,; NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation (N.J.A.), London, UK; C2N Diagnostics (K.E.Y., T.W., M.R.M., K.M.K.), St. Louis, MO; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, London,; UK Dementia Research Institute at UCL (H.Z.), London, UK; and Hong Kong Center for Neurodegenerative Diseases (H.Z.), China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meyer</LastName><ForeName>Mathew R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (S.E.S., R.L.H., Y.L., B.S., K.L.M., D.B., A.M.F., J.B.-B., R.J.B., J.C.M), Knight Alzheimer Disease Research Center (S.E.S., R.L.H., Y.L., B.S., K.L.M., D.B., A.M.F., B.A.G., T.L.S.B., J.B.-B., R.J.B., C.X., J.C.M.), Hope Center for Neurological Disorders (A.M.F.), Mallinckrodt Institute of Radiology (B.A.G., T.L.S.B.), and Division of Biostatistics (C.X.), Washington University School of Medicine, St. Louis, MO; Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry (T.K.K., N.J.A., H.Z., K.B.), Institute of Neuroscience and Physiology, University of Gothenburg, M&#xf6;lndal, Sweden; Department of Psychiatry (T.K.K.), University of Pittsburgh, PA; Wallenberg Centre for Molecular and Translational Medicine (N.J.A.), University of Gothenburg, Sweden; Institute of Psychiatry, Psychology and Neuroscience (N.J.A.), Maurice Wohl Institute Clinical Neuroscience Institute, King's College London,; NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation (N.J.A.), London, UK; C2N Diagnostics (K.E.Y., T.W., M.R.M., K.M.K.), St. Louis, MO; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, London,; UK Dementia Research Institute at UCL (H.Z.), London, UK; and Hong Kong Center for Neurodegenerative Diseases (H.Z.), China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kirmess</LastName><ForeName>Kristopher M</ForeName><Initials>KM</Initials><Identifier Source="ORCID">0000-0002-0306-323X</Identifier><AffiliationInfo><Affiliation>From the Department of Neurology (S.E.S., R.L.H., Y.L., B.S., K.L.M., D.B., A.M.F., J.B.-B., R.J.B., J.C.M), Knight Alzheimer Disease Research Center (S.E.S., R.L.H., Y.L., B.S., K.L.M., D.B., A.M.F., B.A.G., T.L.S.B., J.B.-B., R.J.B., C.X., J.C.M.), Hope Center for Neurological Disorders (A.M.F.), Mallinckrodt Institute of Radiology (B.A.G., T.L.S.B.), and Division of Biostatistics (C.X.), Washington University School of Medicine, St. Louis, MO; Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry (T.K.K., N.J.A., H.Z., K.B.), Institute of Neuroscience and Physiology, University of Gothenburg, M&#xf6;lndal, Sweden; Department of Psychiatry (T.K.K.), University of Pittsburgh, PA; Wallenberg Centre for Molecular and Translational Medicine (N.J.A.), University of Gothenburg, Sweden; Institute of Psychiatry, Psychology and Neuroscience (N.J.A.), Maurice Wohl Institute Clinical Neuroscience Institute, King's College London,; NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation (N.J.A.), London, UK; C2N Diagnostics (K.E.Y., T.W., M.R.M., K.M.K.), St. Louis, MO; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, London,; UK Dementia Research Institute at UCL (H.Z.), London, UK; and Hong Kong Center for Neurodegenerative Diseases (H.Z.), China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (S.E.S., R.L.H., Y.L., B.S., K.L.M., D.B., A.M.F., J.B.-B., R.J.B., J.C.M), Knight Alzheimer Disease Research Center (S.E.S., R.L.H., Y.L., B.S., K.L.M., D.B., A.M.F., B.A.G., T.L.S.B., J.B.-B., R.J.B., C.X., J.C.M.), Hope Center for Neurological Disorders (A.M.F.), Mallinckrodt Institute of Radiology (B.A.G., T.L.S.B.), and Division of Biostatistics (C.X.), Washington University School of Medicine, St. Louis, MO; Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry (T.K.K., N.J.A., H.Z., K.B.), Institute of Neuroscience and Physiology, University of Gothenburg, M&#xf6;lndal, Sweden; Department of Psychiatry (T.K.K.), University of Pittsburgh, PA; Wallenberg Centre for Molecular and Translational Medicine (N.J.A.), University of Gothenburg, Sweden; Institute of Psychiatry, Psychology and Neuroscience (N.J.A.), Maurice Wohl Institute Clinical Neuroscience Institute, King's College London,; NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation (N.J.A.), London, UK; C2N Diagnostics (K.E.Y., T.W., M.R.M., K.M.K.), St. Louis, MO; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, London,; UK Dementia Research Institute at UCL (H.Z.), London, UK; and Hong Kong Center for Neurodegenerative Diseases (H.Z.), China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saef</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (S.E.S., R.L.H., Y.L., B.S., K.L.M., D.B., A.M.F., J.B.-B., R.J.B., J.C.M), Knight Alzheimer Disease Research Center (S.E.S., R.L.H., Y.L., B.S., K.L.M., D.B., A.M.F., B.A.G., T.L.S.B., J.B.-B., R.J.B., C.X., J.C.M.), Hope Center for Neurological Disorders (A.M.F.), Mallinckrodt Institute of Radiology (B.A.G., T.L.S.B.), and Division of Biostatistics (C.X.), Washington University School of Medicine, St. Louis, MO; Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry (T.K.K., N.J.A., H.Z., K.B.), Institute of Neuroscience and Physiology, University of Gothenburg, M&#xf6;lndal, Sweden; Department of Psychiatry (T.K.K.), University of Pittsburgh, PA; Wallenberg Centre for Molecular and Translational Medicine (N.J.A.), University of Gothenburg, Sweden; Institute of Psychiatry, Psychology and Neuroscience (N.J.A.), Maurice Wohl Institute Clinical Neuroscience Institute, King's College London,; NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation (N.J.A.), London, UK; C2N Diagnostics (K.E.Y., T.W., M.R.M., K.M.K.), St. Louis, MO; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, London,; UK Dementia Research Institute at UCL (H.Z.), London, UK; and Hong Kong Center for Neurodegenerative Diseases (H.Z.), China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moulder</LastName><ForeName>Krista L</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (S.E.S., R.L.H., Y.L., B.S., K.L.M., D.B., A.M.F., J.B.-B., R.J.B., J.C.M), Knight Alzheimer Disease Research Center (S.E.S., R.L.H., Y.L., B.S., K.L.M., D.B., A.M.F., B.A.G., T.L.S.B., J.B.-B., R.J.B., C.X., J.C.M.), Hope Center for Neurological Disorders (A.M.F.), Mallinckrodt Institute of Radiology (B.A.G., T.L.S.B.), and Division of Biostatistics (C.X.), Washington University School of Medicine, St. Louis, MO; Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry (T.K.K., N.J.A., H.Z., K.B.), Institute of Neuroscience and Physiology, University of Gothenburg, M&#xf6;lndal, Sweden; Department of Psychiatry (T.K.K.), University of Pittsburgh, PA; Wallenberg Centre for Molecular and Translational Medicine (N.J.A.), University of Gothenburg, Sweden; Institute of Psychiatry, Psychology and Neuroscience (N.J.A.), Maurice Wohl Institute Clinical Neuroscience Institute, King's College London,; NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation (N.J.A.), London, UK; C2N Diagnostics (K.E.Y., T.W., M.R.M., K.M.K.), St. Louis, MO; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, London,; UK Dementia Research Institute at UCL (H.Z.), London, UK; and Hong Kong Center for Neurodegenerative Diseases (H.Z.), China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bradford</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (S.E.S., R.L.H., Y.L., B.S., K.L.M., D.B., A.M.F., J.B.-B., R.J.B., J.C.M), Knight Alzheimer Disease Research Center (S.E.S., R.L.H., Y.L., B.S., K.L.M., D.B., A.M.F., B.A.G., T.L.S.B., J.B.-B., R.J.B., C.X., J.C.M.), Hope Center for Neurological Disorders (A.M.F.), Mallinckrodt Institute of Radiology (B.A.G., T.L.S.B.), and Division of Biostatistics (C.X.), Washington University School of Medicine, St. Louis, MO; Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry (T.K.K., N.J.A., H.Z., K.B.), Institute of Neuroscience and Physiology, University of Gothenburg, M&#xf6;lndal, Sweden; Department of Psychiatry (T.K.K.), University of Pittsburgh, PA; Wallenberg Centre for Molecular and Translational Medicine (N.J.A.), University of Gothenburg, Sweden; Institute of Psychiatry, Psychology and Neuroscience (N.J.A.), Maurice Wohl Institute Clinical Neuroscience Institute, King's College London,; NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation (N.J.A.), London, UK; C2N Diagnostics (K.E.Y., T.W., M.R.M., K.M.K.), St. Louis, MO; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, London,; UK Dementia Research Institute at UCL (H.Z.), London, UK; and Hong Kong Center for Neurodegenerative Diseases (H.Z.), China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fagan</LastName><ForeName>Anne M</ForeName><Initials>AM</Initials><Identifier Source="ORCID">0000-0002-5383-0214</Identifier><AffiliationInfo><Affiliation>From the Department of Neurology (S.E.S., R.L.H., Y.L., B.S., K.L.M., D.B., A.M.F., J.B.-B., R.J.B., J.C.M), Knight Alzheimer Disease Research Center (S.E.S., R.L.H., Y.L., B.S., K.L.M., D.B., A.M.F., B.A.G., T.L.S.B., J.B.-B., R.J.B., C.X., J.C.M.), Hope Center for Neurological Disorders (A.M.F.), Mallinckrodt Institute of Radiology (B.A.G., T.L.S.B.), and Division of Biostatistics (C.X.), Washington University School of Medicine, St. Louis, MO; Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry (T.K.K., N.J.A., H.Z., K.B.), Institute of Neuroscience and Physiology, University of Gothenburg, M&#xf6;lndal, Sweden; Department of Psychiatry (T.K.K.), University of Pittsburgh, PA; Wallenberg Centre for Molecular and Translational Medicine (N.J.A.), University of Gothenburg, Sweden; Institute of Psychiatry, Psychology and Neuroscience (N.J.A.), Maurice Wohl Institute Clinical Neuroscience Institute, King's College London,; NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation (N.J.A.), London, UK; C2N Diagnostics (K.E.Y., T.W., M.R.M., K.M.K.), St. Louis, MO; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, London,; UK Dementia Research Institute at UCL (H.Z.), London, UK; and Hong Kong Center for Neurodegenerative Diseases (H.Z.), China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gordon</LastName><ForeName>Brian A</ForeName><Initials>BA</Initials><Identifier Source="ORCID">0000-0003-2109-2955</Identifier><AffiliationInfo><Affiliation>From the Department of Neurology (S.E.S., R.L.H., Y.L., B.S., K.L.M., D.B., A.M.F., J.B.-B., R.J.B., J.C.M), Knight Alzheimer Disease Research Center (S.E.S., R.L.H., Y.L., B.S., K.L.M., D.B., A.M.F., B.A.G., T.L.S.B., J.B.-B., R.J.B., C.X., J.C.M.), Hope Center for Neurological Disorders (A.M.F.), Mallinckrodt Institute of Radiology (B.A.G., T.L.S.B.), and Division of Biostatistics (C.X.), Washington University School of Medicine, St. Louis, MO; Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry (T.K.K., N.J.A., H.Z., K.B.), Institute of Neuroscience and Physiology, University of Gothenburg, M&#xf6;lndal, Sweden; Department of Psychiatry (T.K.K.), University of Pittsburgh, PA; Wallenberg Centre for Molecular and Translational Medicine (N.J.A.), University of Gothenburg, Sweden; Institute of Psychiatry, Psychology and Neuroscience (N.J.A.), Maurice Wohl Institute Clinical Neuroscience Institute, King's College London,; NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation (N.J.A.), London, UK; C2N Diagnostics (K.E.Y., T.W., M.R.M., K.M.K.), St. Louis, MO; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, London,; UK Dementia Research Institute at UCL (H.Z.), London, UK; and Hong Kong Center for Neurodegenerative Diseases (H.Z.), China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benzinger</LastName><ForeName>Tammie L S</ForeName><Initials>TLS</Initials><Identifier Source="ORCID">0000-0002-8114-0552</Identifier><AffiliationInfo><Affiliation>From the Department of Neurology (S.E.S., R.L.H., Y.L., B.S., K.L.M., D.B., A.M.F., J.B.-B., R.J.B., J.C.M), Knight Alzheimer Disease Research Center (S.E.S., R.L.H., Y.L., B.S., K.L.M., D.B., A.M.F., B.A.G., T.L.S.B., J.B.-B., R.J.B., C.X., J.C.M.), Hope Center for Neurological Disorders (A.M.F.), Mallinckrodt Institute of Radiology (B.A.G., T.L.S.B.), and Division of Biostatistics (C.X.), Washington University School of Medicine, St. Louis, MO; Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry (T.K.K., N.J.A., H.Z., K.B.), Institute of Neuroscience and Physiology, University of Gothenburg, M&#xf6;lndal, Sweden; Department of Psychiatry (T.K.K.), University of Pittsburgh, PA; Wallenberg Centre for Molecular and Translational Medicine (N.J.A.), University of Gothenburg, Sweden; Institute of Psychiatry, Psychology and Neuroscience (N.J.A.), Maurice Wohl Institute Clinical Neuroscience Institute, King's College London,; NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation (N.J.A.), London, UK; C2N Diagnostics (K.E.Y., T.W., M.R.M., K.M.K.), St. Louis, MO; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, London,; UK Dementia Research Institute at UCL (H.Z.), London, UK; and Hong Kong Center for Neurodegenerative Diseases (H.Z.), China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Balls-Berry</LastName><ForeName>Joyce</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-3497-1115</Identifier><AffiliationInfo><Affiliation>From the Department of Neurology (S.E.S., R.L.H., Y.L., B.S., K.L.M., D.B., A.M.F., J.B.-B., R.J.B., J.C.M), Knight Alzheimer Disease Research Center (S.E.S., R.L.H., Y.L., B.S., K.L.M., D.B., A.M.F., B.A.G., T.L.S.B., J.B.-B., R.J.B., C.X., J.C.M.), Hope Center for Neurological Disorders (A.M.F.), Mallinckrodt Institute of Radiology (B.A.G., T.L.S.B.), and Division of Biostatistics (C.X.), Washington University School of Medicine, St. Louis, MO; Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry (T.K.K., N.J.A., H.Z., K.B.), Institute of Neuroscience and Physiology, University of Gothenburg, M&#xf6;lndal, Sweden; Department of Psychiatry (T.K.K.), University of Pittsburgh, PA; Wallenberg Centre for Molecular and Translational Medicine (N.J.A.), University of Gothenburg, Sweden; Institute of Psychiatry, Psychology and Neuroscience (N.J.A.), Maurice Wohl Institute Clinical Neuroscience Institute, King's College London,; NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation (N.J.A.), London, UK; C2N Diagnostics (K.E.Y., T.W., M.R.M., K.M.K.), St. Louis, MO; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, London,; UK Dementia Research Institute at UCL (H.Z.), London, UK; and Hong Kong Center for Neurodegenerative Diseases (H.Z.), China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bateman</LastName><ForeName>Randall J</ForeName><Initials>RJ</Initials><Identifier Source="ORCID">0000-0002-7729-1702</Identifier><AffiliationInfo><Affiliation>From the Department of Neurology (S.E.S., R.L.H., Y.L., B.S., K.L.M., D.B., A.M.F., J.B.-B., R.J.B., J.C.M), Knight Alzheimer Disease Research Center (S.E.S., R.L.H., Y.L., B.S., K.L.M., D.B., A.M.F., B.A.G., T.L.S.B., J.B.-B., R.J.B., C.X., J.C.M.), Hope Center for Neurological Disorders (A.M.F.), Mallinckrodt Institute of Radiology (B.A.G., T.L.S.B.), and Division of Biostatistics (C.X.), Washington University School of Medicine, St. Louis, MO; Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry (T.K.K., N.J.A., H.Z., K.B.), Institute of Neuroscience and Physiology, University of Gothenburg, M&#xf6;lndal, Sweden; Department of Psychiatry (T.K.K.), University of Pittsburgh, PA; Wallenberg Centre for Molecular and Translational Medicine (N.J.A.), University of Gothenburg, Sweden; Institute of Psychiatry, Psychology and Neuroscience (N.J.A.), Maurice Wohl Institute Clinical Neuroscience Institute, King's College London,; NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation (N.J.A.), London, UK; C2N Diagnostics (K.E.Y., T.W., M.R.M., K.M.K.), St. Louis, MO; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, London,; UK Dementia Research Institute at UCL (H.Z.), London, UK; and Hong Kong Center for Neurodegenerative Diseases (H.Z.), China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiong</LastName><ForeName>Chengjie</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (S.E.S., R.L.H., Y.L., B.S., K.L.M., D.B., A.M.F., J.B.-B., R.J.B., J.C.M), Knight Alzheimer Disease Research Center (S.E.S., R.L.H., Y.L., B.S., K.L.M., D.B., A.M.F., B.A.G., T.L.S.B., J.B.-B., R.J.B., C.X., J.C.M.), Hope Center for Neurological Disorders (A.M.F.), Mallinckrodt Institute of Radiology (B.A.G., T.L.S.B.), and Division of Biostatistics (C.X.), Washington University School of Medicine, St. Louis, MO; Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry (T.K.K., N.J.A., H.Z., K.B.), Institute of Neuroscience and Physiology, University of Gothenburg, M&#xf6;lndal, Sweden; Department of Psychiatry (T.K.K.), University of Pittsburgh, PA; Wallenberg Centre for Molecular and Translational Medicine (N.J.A.), University of Gothenburg, Sweden; Institute of Psychiatry, Psychology and Neuroscience (N.J.A.), Maurice Wohl Institute Clinical Neuroscience Institute, King's College London,; NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation (N.J.A.), London, UK; C2N Diagnostics (K.E.Y., T.W., M.R.M., K.M.K.), St. Louis, MO; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, London,; UK Dementia Research Institute at UCL (H.Z.), London, UK; and Hong Kong Center for Neurodegenerative Diseases (H.Z.), China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-4671-6763</Identifier><AffiliationInfo><Affiliation>From the Department of Neurology (S.E.S., R.L.H., Y.L., B.S., K.L.M., D.B., A.M.F., J.B.-B., R.J.B., J.C.M), Knight Alzheimer Disease Research Center (S.E.S., R.L.H., Y.L., B.S., K.L.M., D.B., A.M.F., B.A.G., T.L.S.B., J.B.-B., R.J.B., C.X., J.C.M.), Hope Center for Neurological Disorders (A.M.F.), Mallinckrodt Institute of Radiology (B.A.G., T.L.S.B.), and Division of Biostatistics (C.X.), Washington University School of Medicine, St. Louis, MO; Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry (T.K.K., N.J.A., H.Z., K.B.), Institute of Neuroscience and Physiology, University of Gothenburg, M&#xf6;lndal, Sweden; Department of Psychiatry (T.K.K.), University of Pittsburgh, PA; Wallenberg Centre for Molecular and Translational Medicine (N.J.A.), University of Gothenburg, Sweden; Institute of Psychiatry, Psychology and Neuroscience (N.J.A.), Maurice Wohl Institute Clinical Neuroscience Institute, King's College London,; NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation (N.J.A.), London, UK; C2N Diagnostics (K.E.Y., T.W., M.R.M., K.M.K.), St. Louis, MO; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, London,; UK Dementia Research Institute at UCL (H.Z.), London, UK; and Hong Kong Center for Neurodegenerative Diseases (H.Z.), China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-1890-4193</Identifier><AffiliationInfo><Affiliation>From the Department of Neurology (S.E.S., R.L.H., Y.L., B.S., K.L.M., D.B., A.M.F., J.B.-B., R.J.B., J.C.M), Knight Alzheimer Disease Research Center (S.E.S., R.L.H., Y.L., B.S., K.L.M., D.B., A.M.F., B.A.G., T.L.S.B., J.B.-B., R.J.B., C.X., J.C.M.), Hope Center for Neurological Disorders (A.M.F.), Mallinckrodt Institute of Radiology (B.A.G., T.L.S.B.), and Division of Biostatistics (C.X.), Washington University School of Medicine, St. Louis, MO; Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry (T.K.K., N.J.A., H.Z., K.B.), Institute of Neuroscience and Physiology, University of Gothenburg, M&#xf6;lndal, Sweden; Department of Psychiatry (T.K.K.), University of Pittsburgh, PA; Wallenberg Centre for Molecular and Translational Medicine (N.J.A.), University of Gothenburg, Sweden; Institute of Psychiatry, Psychology and Neuroscience (N.J.A.), Maurice Wohl Institute Clinical Neuroscience Institute, King's College London,; NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation (N.J.A.), London, UK; C2N Diagnostics (K.E.Y., T.W., M.R.M., K.M.K.), St. Louis, MO; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, London,; UK Dementia Research Institute at UCL (H.Z.), London, UK; and Hong Kong Center for Neurodegenerative Diseases (H.Z.), China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials><Identifier Source="ORCID">0000-0001-9820-5618</Identifier><AffiliationInfo><Affiliation>From the Department of Neurology (S.E.S., R.L.H., Y.L., B.S., K.L.M., D.B., A.M.F., J.B.-B., R.J.B., J.C.M), Knight Alzheimer Disease Research Center (S.E.S., R.L.H., Y.L., B.S., K.L.M., D.B., A.M.F., B.A.G., T.L.S.B., J.B.-B., R.J.B., C.X., J.C.M.), Hope Center for Neurological Disorders (A.M.F.), Mallinckrodt Institute of Radiology (B.A.G., T.L.S.B.), and Division of Biostatistics (C.X.), Washington University School of Medicine, St. Louis, MO; Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry (T.K.K., N.J.A., H.Z., K.B.), Institute of Neuroscience and Physiology, University of Gothenburg, M&#xf6;lndal, Sweden; Department of Psychiatry (T.K.K.), University of Pittsburgh, PA; Wallenberg Centre for Molecular and Translational Medicine (N.J.A.), University of Gothenburg, Sweden; Institute of Psychiatry, Psychology and Neuroscience (N.J.A.), Maurice Wohl Institute Clinical Neuroscience Institute, King's College London,; NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation (N.J.A.), London, UK; C2N Diagnostics (K.E.Y., T.W., M.R.M., K.M.K.), St. Louis, MO; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, London,; UK Dementia Research Institute at UCL (H.Z.), London, UK; and Hong Kong Center for Neurodegenerative Diseases (H.Z.), China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG070941</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG053474</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AG053426</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 OD025214</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002345</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066444</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG067505</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG053550</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>04</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C078592">amyloid beta-protein (1-40)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000686" MajorTopicYN="Y">Amyloidosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007382" MajorTopicYN="N">Intermediate Filaments</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>9</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>2</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>22</Day><Hour>7</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>7</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35450967</ArticleId><ArticleId IdType="pmc">PMC9302933</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000200358</ArticleId><ArticleId IdType="pii">WNL.0000000000200358</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Johnson KA, Minoshima S, Bohnen NI, et al. . Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. Alzheimers Dement. 2013;9:e1-16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3733252</ArticleId><ArticleId IdType="pubmed">23360977</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw LM, Arias J, Blennow K, et al. . Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer's disease. Alzheimers Dement. 2018;14:1505-1521.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10013957</ArticleId><ArticleId IdType="pubmed">30316776</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaplow J, Vandijck M, Gray J, et al. . Concordance of Lumipulse cerebrospinal fluid t-tau/Abeta42 ratio with amyloid PET status. Alzheimers Dement. 2020;16:144-152.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7061432</ArticleId><ArticleId IdType="pubmed">31914216</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson O, Seibyl J, Stomrud E, et al. . CSF biomarkers of Alzheimer's disease concord with amyloid-beta PET and predict clinical progression: a study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimers Dement. 2018;14:1470-1481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6119541</ArticleId><ArticleId IdType="pubmed">29499171</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindler SE, Gray JD, Gordon BA, et al. . Cerebrospinal fluid biomarkers measured by Elecsys assays compared with amyloid imaging. Alzheimers Dement. 2018;14:1460-1469.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6119652</ArticleId><ArticleId IdType="pubmed">29501462</ArticleId></ArticleIdList></Reference><Reference><Citation>Howell JC, Watts KD, Parker MW, et al. . Race modifies the relationship between cognition and Alzheimer's disease cerebrospinal fluid biomarkers. Alzheimers Res Ther. 2017;9(1):88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5668981</ArticleId><ArticleId IdType="pubmed">29096697</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Schindler SE, McCue LM, et al. . Assessment of racial disparities in biomarkers for Alzheimer disease. JAMA Neurol. 2019;76(3):264-273.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6439726</ArticleId><ArticleId IdType="pubmed">30615028</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindler SE, Cruchaga C, Joseph A, et al. . African Americans have differences in CSF soluble TREM2 and associated genetic variants. Neurol Genet. 2021;7(2):e571.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8054965</ArticleId><ArticleId IdType="pubmed">33884297</ArticleId></ArticleIdList></Reference><Reference><Citation>Garrett SL, McDaniel D, Obideen M, et al. . Racial disparity in cerebrospinal fluid amyloid and tau biomarkers and associated cutoffs for mild cognitive impairment. JAMA Netw Open. 2019;2(12):e1917363.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6991300</ArticleId><ArticleId IdType="pubmed">31834392</ArticleId></ArticleIdList></Reference><Reference><Citation>Babulal GM, Quiroz YT, Albensi BC, et al. . Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: update and areas of immediate need. Alzheimers Dement. 2019;15:292-312.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6368893</ArticleId><ArticleId IdType="pubmed">30555031</ArticleId></ArticleIdList></Reference><Reference><Citation>Meeker KL, Wisch JK, Hudson D, et al. . Socioeconomic status mediates racial differences seen using the AT(N) framework. Ann Neurol. 2021;89(2):254-265.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7903892</ArticleId><ArticleId IdType="pubmed">33111990</ArticleId></ArticleIdList></Reference><Reference><Citation>Deters KD, Napolioni V, Sperling RA, et al. . Amyloid PET imaging in self-identified non-Hispanic black participants of the Anti-Amyloid in Asymptomatic Alzheimer's Disease (A4) study. Neurology. 2021;96(11):e1491-e1500.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8032379</ArticleId><ArticleId IdType="pubmed">33568538</ArticleId></ArticleIdList></Reference><Reference><Citation>Powe NR. Black kidney function matters: use or misuse of race? JAMA. 2020;324:737-738.</Citation><ArticleIdList><ArticleId IdType="pubmed">32761164</ArticleId></ArticleIdList></Reference><Reference><Citation>Vyas DA, Eisenstein LG, Jones DS. Hidden in plain sight: reconsidering the use of race correction in clinical algorithms. N Engl J Med. 2020;383(9):874-882.</Citation><ArticleIdList><ArticleId IdType="pubmed">32853499</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashton NJ, Leuzy A, Karikari TK, et al. . The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers. Eur J Nucl Med Mol Imaging. 2021;48(7):2140-2156.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8175325</ArticleId><ArticleId IdType="pubmed">33677733</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirmess KM, Meyer MR, Holubasch MS, et al. . The PrecivityAD&#x2122; test: accurate and reliable LC-MS/MS assays for quantifying plasma amyloid beta 40 and 42 and apolipoprotein E proteotype for the assessment of brain amyloidosis. Clin Chim Acta. 2021;519:267-275.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10292789</ArticleId><ArticleId IdType="pubmed">34015303</ArticleId></ArticleIdList></Reference><Reference><Citation>West T, Kirmess KM, Meyer MR, et al. . A blood-based diagnostic test incorporating plasma Abeta42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis. Mol Neurodegener. 2021;16:30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8088704</ArticleId><ArticleId IdType="pubmed">33933117</ArticleId></ArticleIdList></Reference><Reference><Citation>Moscoso A, Grothe MJ, Ashton NJ, et al. . Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum. Brain. 2021;144(1):325-339.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7880671</ArticleId><ArticleId IdType="pubmed">33257949</ArticleId></ArticleIdList></Reference><Reference><Citation>Karikari TK, Pascoal TA, Ashton NJ, et al. . Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 2020;19:422-433.</Citation><ArticleIdList><ArticleId IdType="pubmed">32333900</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S, Janelidze S, Quiroz YT, et al. . Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA. 2020;324(8):772-781.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7388060</ArticleId><ArticleId IdType="pubmed">32722745</ArticleId></ArticleIdList></Reference><Reference><Citation>Barth&#xe9;lemy NR, Horie K, Sato C, Bateman RJ. Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer's disease. J Exp Med. 2020;217(11):217.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7596823</ArticleId><ArticleId IdType="pubmed">32725127</ArticleId></ArticleIdList></Reference><Reference><Citation>Thijssen EH, La Joie R, Strom A, et al. . Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. Lancet Neurol. 2021;20(9):739-752.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8711249</ArticleId><ArticleId IdType="pubmed">34418401</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashton NJ, Pascoal TA, Karikari TK, et al. . Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology. Acta Neuropathol. 2021;141(5):709-724.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8043944</ArticleId><ArticleId IdType="pubmed">33585983</ArticleId></ArticleIdList></Reference><Reference><Citation>Preische O, Schultz S, Apel A, et al. . Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease. Nat Med. 2019;25:277-283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6367005</ArticleId><ArticleId IdType="pubmed">30664784</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Weintraub S, Chui HC, et al. . The Uniform data Set (UDS): clinical and cognitive variables and descriptive data from alzheimer disease centers. Alzheimer Dis Assoc Disord. 2006;20:210-216.</Citation><ArticleIdList><ArticleId IdType="pubmed">17132964</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412-2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollingshead Two Factor Index of Social Position, 5th ed. Sage Publications; 1991.</Citation></Reference><Reference><Citation>Cruchaga C, Kauwe JS, Mayo K, et al. . SNPs associated with cerebrospinal fluid phospho-tau levels influence rate of decline in Alzheimer's disease. PLoS Genet. 2010;6(9):e1001101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2940763</ArticleId><ArticleId IdType="pubmed">20862329</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindler SE, Bollinger JG, Ovod V, et al. . High-precision plasma beta-amyloid 42/40 predicts current and future brain amyloidosis. Neurology. 2019;93:e1647-e1659.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6946467</ArticleId><ArticleId IdType="pubmed">31371569</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, Blazey TM, Snyder AZ, et al. . Partial volume correction in quantitative amyloid imaging. NeuroImage. 2015;107:55-64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4300252</ArticleId><ArticleId IdType="pubmed">25485714</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, Flores S, Wang G, et al. . Comparison of Pittsburgh compound B and florbetapir in cross-sectional and longitudinal studies. Alzheimers Dement. 2019;11:180-190.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6389727</ArticleId><ArticleId IdType="pubmed">30847382</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, Flores S, Hornbeck RC, et al. . Utilizing the Centiloid scale in cross-sectional and longitudinal PiB PET studies. Neuroimage Clin. 2018;19:406-416.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6051499</ArticleId><ArticleId IdType="pubmed">30035025</ArticleId></ArticleIdList></Reference><Reference><Citation>Volluz KE, Schindler SE, Henson RL, et al. . Correspondence of CSF Biomarkers Measured by Lumipulse Assays with Amyloid PET. 2021 Alzheimer's Association International Conference; 2021.</Citation></Reference><Reference><Citation>Vlassenko AG, McCue L, Jasielec MS, et al. . Imaging and cerebrospinal fluid biomarkers in early preclinical Alzheimer disease. Ann Neurol. 2016;80(3):379-387.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5016232</ArticleId><ArticleId IdType="pubmed">27398953</ArticleId></ArticleIdList></Reference><Reference><Citation>DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44(3):837-845.</Citation><ArticleIdList><ArticleId IdType="pubmed">3203132</ArticleId></ArticleIdList></Reference><Reference><Citation>Brickman AM, Manly JJ, Honig LS, et al. . Plasma p-tau181, p-tau217, and other blood-based Alzheimer's disease biomarkers in a multi-ethnic, community study. Alzheimers Dement. 2021;17:1353-1364.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8451860</ArticleId><ArticleId IdType="pubmed">33580742</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong JR, Ashton NJ, Karikari TK, et al. . Plasma P-tau181 to Abeta42 ratio is associated with brain amyloid burden and hippocampal atrophy in an Asian cohort of Alzheimer's disease patients with concomitant cerebrovascular disease. Alzheimers Dement. 2021;17(10):1649-1662.</Citation><ArticleIdList><ArticleId IdType="pubmed">33792168</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Bryant S, Petersen M, Hall J, et al. . Characterizing plasma NfL in a community-dwelling multi-ethnic cohort: results from the HABLE study. Alzheimers Dement. 2022;18(2):240-250.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9228481</ArticleId><ArticleId IdType="pubmed">34310015</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottesman RF, Schneider AL, Zhou Y, et al. . The ARIC-PET amyloid imaging study: brain amyloid differences by age, race, sex, and APOE. Neurology. 2016;87(5):473-480.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4970663</ArticleId><ArticleId IdType="pubmed">27371485</ArticleId></ArticleIdList></Reference><Reference><Citation>Raman R, Quiroz YT, Langford O, et al. . Disparities by race and ethnicity among adults recruited for a preclinical alzheimer disease trial. JAMA Netw Open. 2021;4(7):e2114364.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8261604</ArticleId><ArticleId IdType="pubmed">34228129</ArticleId></ArticleIdList></Reference><Reference><Citation>Gleason CE, Norton D, Zuelsdorff M, et al. . Association between enrollment factors and incident cognitive impairment in Blacks and Whites: data from the Alzheimer's Disease Center. Alzheimers Dement. 2019;15:1533-1545.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6925619</ArticleId><ArticleId IdType="pubmed">31601516</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze S, Teunissen CE, Zetterberg H, et al. . Head-to-head comparison of 8 plasma amyloid-beta 42/40 assays in Alzheimer disease. JAMA Neurol. 2021;78(11):1375-1382.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8453354</ArticleId><ArticleId IdType="pubmed">34542571</ArticleId></ArticleIdList></Reference><Reference><Citation>Mielke MM, Frank RD, Dage JL, et al. . Comparison of plasma phosphorylated tau species with amyloid and tau positron emission tomography, neurodegeneration, vascular pathology, and cognitive outcomes. JAMA Neurol. 2021;78(9):1108-1117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8314178</ArticleId><ArticleId IdType="pubmed">34309632</ArticleId></ArticleIdList></Reference><Reference><Citation>Keshavan A, Pannee J, Karikari TK, et al. . Population-based blood screening for preclinical Alzheimer's disease in a British birth cohort at age 70. Brain. 2021;144(2):434-449.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7940173</ArticleId><ArticleId IdType="pubmed">33479777</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottesman RF, Hamilton R. Recruiting diverse populations in clinical trials: how do we overcome selection bias? Neurology. 2021;96:509-510.</Citation><ArticleIdList><ArticleId IdType="pubmed">33568536</ArticleId></ArticleIdList></Reference><Reference><Citation>Syrjanen JA, Campbell MR, Algeciras-Schimnich A, et al. . Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities. Alzheimers Dement. Epub 2021 Sep 27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8957642</ArticleId><ArticleId IdType="pubmed">34569696</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkins CH, Schindler SE, Morris JC. Addressing health disparities among minority populations: why clinical trial recruitment is not enough. JAMA Neurol. 2020;77(9):1063-1064.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7983552</ArticleId><ArticleId IdType="pubmed">32539100</ArticleId></ArticleIdList></Reference><Reference><Citation>Howell JC, Parker MW, Watts KD, Kollhoff A, Tsvetkova DZ, Hu WT. Research lumbar punctures among African Americans and Caucasians: perception predicts experience. Front Aging Neurosci. 2016;8:296.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5133251</ArticleId><ArticleId IdType="pubmed">27994549</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes LL. Alzheimer disease in African American individuals: increased incidence or not enough data? Nat Rev Neurol. 2022;18:56-62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8647782</ArticleId><ArticleId IdType="pubmed">34873310</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35476634</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>24</Day></DateCompleted><DateRevised><Year>2022</Year><Month>06</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1533-4406</ISSN><JournalIssue CitedMedium="Internet"><Volume>386</Volume><Issue>25</Issue><PubDate><Year>2022</Year><Month>Jun</Month><Day>23</Day></PubDate></JournalIssue><Title>The New England journal of medicine</Title><ISOAbbreviation>N Engl J Med</ISOAbbreviation></Journal><ArticleTitle>A Data Infrastructure for Clinical Trial Diversity.</ArticleTitle><Pagination><StartPage>2355</StartPage><EndPage>2356</EndPage><MedlinePgn>2355-2356</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1056/NEJMp2201433</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Blumenthal</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>From the Commonwealth Fund, New York (D.B.); and Grantmakers in Health, Washington, DC (C.V.J.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>James</LastName><ForeName>Cara V</ForeName><Initials>CV</Initials><AffiliationInfo><Affiliation>From the Commonwealth Fund, New York (D.B.); and Grantmakers in Health, Washington, DC (C.V.J.).</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>04</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>N Engl J Med</MedlineTA><NlmUniqueID>0255562</NlmUniqueID><ISSNLinking>0028-4793</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>28</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>27</Day><Hour>17</Hour><Minute>9</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35476634</ArticleId><ArticleId IdType="doi">10.1056/NEJMp2201433</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35486730</PMID><DateRevised><Year>2022</Year><Month>09</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2375-2548</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>17</Issue><PubDate><Year>2022</Year><Month>Apr</Month><Day>29</Day></PubDate></JournalIssue><Title>Science advances</Title><ISOAbbreviation>Sci Adv</ISOAbbreviation></Journal><ArticleTitle>Axonal transport of late endosomes and amphisomes is selectively modulated by local Ca<sup>2+</sup> efflux and disrupted by PSEN1 loss of function.</ArticleTitle><Pagination><StartPage>eabj5716</StartPage><MedlinePgn>eabj5716</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">eabj5716</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1126/sciadv.abj5716</ELocationID><Abstract><AbstractText>Dysfunction and mistrafficking of organelles in autophagy- and endosomal-lysosomal pathways are implicated in neurodegenerative diseases. Here, we reveal selective vulnerability of maturing degradative organelles (late endosomes/amphisomes) to disease-relevant local calcium dysregulation. These organelles undergo exclusive retrograde transport in axons, with occasional pauses triggered by regulated calcium efflux from agonist-evoked transient receptor potential cation channel mucolipin subfamily member 1 (TRPML1) channels-an effect greatly exaggerated by exogenous agonist mucolipin synthetic agonist 1 (ML-SA1). Deacidification of degradative organelles, as seen after Presenilin 1 (PSEN1) loss of function, induced pathological constitutive "inside-out" TRPML1 hyperactivation, slowing their transport comparably to ML-SA1 and causing accumulation in dystrophic axons. The mechanism involved calcium-mediated c-Jun N-terminal kinase (JNK) activation, which hyperphosphorylated dynein intermediate chain (DIC), reducing dynein activity. Blocking TRPML1 activation, JNK activity, or DIC1B serine-80 phosphorylation reversed transport deficits in <i>PSEN1</i> knockout neurons. Our results, including features demonstrated in Alzheimer-mutant <i>PSEN1</i> knockin mice, define a mechanism linking dysfunction and mistrafficking in lysosomal pathways to neuritic dystrophy under neurodegenerative conditions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lie</LastName><ForeName>Pearl P Y</ForeName><Initials>PPY</Initials><Identifier Source="ORCID">0000-0001-5838-958X</Identifier><AffiliationInfo><Affiliation>Center for Dementia Research, Nathan S. Kline Institute, Orangeburg, NY 10962, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, New York University Langone Medical Center, New York, NY 10016, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoo</LastName><ForeName>Lang</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-3623-0425</Identifier><AffiliationInfo><Affiliation>Center for Dementia Research, Nathan S. Kline Institute, Orangeburg, NY 10962, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, New York University Langone Medical Center, New York, NY 10016, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goulbourne</LastName><ForeName>Chris N</ForeName><Initials>CN</Initials><Identifier Source="ORCID">0000-0003-1185-2682</Identifier><AffiliationInfo><Affiliation>Center for Dementia Research, Nathan S. Kline Institute, Orangeburg, NY 10962, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berg</LastName><ForeName>Martin J</ForeName><Initials>MJ</Initials><Identifier Source="ORCID">0000-0002-7353-8851</Identifier><AffiliationInfo><Affiliation>Center for Dementia Research, Nathan S. Kline Institute, Orangeburg, NY 10962, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stavrides</LastName><ForeName>Philip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Center for Dementia Research, Nathan S. Kline Institute, Orangeburg, NY 10962, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huo</LastName><ForeName>Chunfeng</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Center for Dementia Research, Nathan S. Kline Institute, Orangeburg, NY 10962, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Ju-Hyun</ForeName><Initials>JH</Initials><Identifier Source="ORCID">0000-0002-0280-8375</Identifier><AffiliationInfo><Affiliation>Center for Dementia Research, Nathan S. Kline Institute, Orangeburg, NY 10962, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, New York University Langone Medical Center, New York, NY 10016, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nixon</LastName><ForeName>Ralph A</ForeName><Initials>RA</Initials><Identifier Source="ORCID">0000-0003-2352-4715</Identifier><AffiliationInfo><Affiliation>Center for Dementia Research, Nathan S. Kline Institute, Orangeburg, NY 10962, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, New York University Langone Medical Center, New York, NY 10016, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cell Biology, New York University Langone Medical Center, New York, NY 10016, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NYU Neuroscience Institute, New York University Langone Medical Center, New York, NY 10016, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG062376</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>04</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Adv</MedlineTA><NlmUniqueID>101653440</NlmUniqueID><ISSNLinking>2375-2548</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>29</Day><Hour>14</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>30</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>4</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35486730</ArticleId><ArticleId IdType="pmc">PMC9054012</ArticleId><ArticleId IdType="doi">10.1126/sciadv.abj5716</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Encalada S. E., Goldstein L. S., Biophysical challenges to axonal transport: Motor-cargo deficiencies and neurodegeneration. Annu. Rev. Biophys. 43, 141&#x2013;169 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24702007</ArticleId></ArticleIdList></Reference><Reference><Citation>Maday S., Twelvetrees A. E., Moughamian A. J., Holzbaur E. L., Axonal transport: Cargo-specific mechanisms of motility and regulation. Neuron 84, 292&#x2013;309 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4269290</ArticleId><ArticleId IdType="pubmed">25374356</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravikumar B., Acevedo-Arozena A., Imarisio S., Berger Z., Vacher C., O&#x2019;Kane C. J., Brown S. D., Rubinsztein D. C., Dynein mutations impair autophagic clearance of aggregate-prone proteins. Nat. Genet. 37, 771&#x2013;776 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15980862</ArticleId></ArticleIdList></Reference><Reference><Citation>R. A. Nixon, in Lysosomes: Biology, Diseases, and Therapeutics, F. R. Maxfield, J. M. Willard, S. Lu, Eds. (John Wiley &amp; Sons Inc., 2016), chap. 9.</Citation></Reference><Reference><Citation>Lie P. P. Y., Nixon R. A., Lysosome trafficking and signaling in health and neurodegenerative diseases. Neurobiol. Dis. 122, 94&#x2013;105 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6381838</ArticleId><ArticleId IdType="pubmed">29859318</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng X. T., Zhou B., Lin M. Y., Cai Q., Sheng Z. H., Axonal autophagosomes use the ride-on service for retrograde transport toward the soma. Autophagy 11, 1434&#x2013;1436 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4590659</ArticleId><ArticleId IdType="pubmed">26102591</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S., Sato Y., Nixon R. A., Lysosomal proteolysis inhibition selectively disrupts axonal transport of degradative organelles and causes an Alzheimer&#x2019;s-like axonal dystrophy. J. Neurosci. 31, 7817&#x2013;7830 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3351137</ArticleId><ArticleId IdType="pubmed">21613495</ArticleId></ArticleIdList></Reference><Reference><Citation>Maday S., Wallace K. E., Holzbaur E. L., Autophagosomes initiate distally and mature during transport toward the cell soma in primary neurons. J. Cell Biol. 196, 407&#x2013;417 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3283992</ArticleId><ArticleId IdType="pubmed">22331844</ArticleId></ArticleIdList></Reference><Reference><Citation>Lie P. P. Y., Yang D. S., Stavrides P., Goulbourne C. N., Zheng P., Mohan P. S., Cataldo A. M., Nixon R. A., Post-Golgi carriers, not lysosomes, confer lysosomal properties to pre-degradative organelles in normal and dystrophic axons. Cell Rep. 35, 109034 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8135226</ArticleId><ArticleId IdType="pubmed">33910020</ArticleId></ArticleIdList></Reference><Reference><Citation>McKenney R. J., Huynh W., Tanenbaum M. E., Bhabha G., Vale R. D., Activation of cytoplasmic dynein motility by dynactin-cargo adapter complexes. Science 345, 337&#x2013;341 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4224444</ArticleId><ArticleId IdType="pubmed">25035494</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao F. J., Hebbar S., Gao X. A., Alexander M., Pandey J. P., Walla M. D., Cotham W. E., King S. J., Smith D. S., GSK-3&#x3b2; phosphorylation of cytoplasmic dynein reduces Ndel1 binding to intermediate chains and alters dynein motility. Traffic 16, 941&#x2013;961 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4543430</ArticleId><ArticleId IdType="pubmed">26010407</ArticleId></ArticleIdList></Reference><Reference><Citation>Whyte J., Bader J. R., Tauhata S. B., Raycroft M., Hornick J., Pfister K. K., Lane W. S., Chan G. K., Hinchcliffe E. H., Vaughan P. S., Vaughan K. T., Phosphorylation regulates targeting of cytoplasmic dynein to kinetochores during mitosis. J. Cell Biol. 183, 819&#x2013;834 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2592828</ArticleId><ArticleId IdType="pubmed">19029334</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell D. J., Blasier K. R., Jeffery E. D., Ross M. W., Pullikuth A. K., Suo D., Park J., Smiley W. R., Lo K. W., Shabanowitz J., Deppmann C. D., Trinidad J. C., Hunt D. F., Catling A. D., Pfister K. K., Trk activation of the ERK1/2 kinase pathway stimulates intermediate chain phosphorylation and recruits cytoplasmic dynein to signaling endosomes for retrograde axonal transport. J. Neurosci. 32, 15495&#x2013;15510 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3500848</ArticleId><ArticleId IdType="pubmed">23115187</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherer J., Yi J., Vallee R. B., PKA-dependent dynein switching from lysosomes to adenovirus: A novel form of host-virus competition. J. Cell Biol. 205, 163&#x2013;177 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4003248</ArticleId><ArticleId IdType="pubmed">24778311</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J. H., Yu W. H., Kumar A., Lee S., Mohan P. S., Peterhoff C. M., Wolfe D. M., Martinez-Vicente M., Massey A. C., Sovak G., Uchiyama Y., Westaway D., Cuervo A. M., Nixon R. A., Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer-related PS1 mutations. Cell 141, 1146&#x2013;1158 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3647462</ArticleId><ArticleId IdType="pubmed">20541250</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J. H., McBrayer M. K., Wolfe D. M., Haslett L. J., Kumar A., Sato Y., Lie P. P., Mohan P., Coffey E. E., Kompella U., Mitchell C. H., Lloyd-Evans E., Nixon R. A., Presenilin 1 maintains lysosomal Ca(2+) homeostasis via TRPML1 by regulating vATPase-mediated lysosome acidification. Cell Rep. 12, 1430&#x2013;1444 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4558203</ArticleId><ArticleId IdType="pubmed">26299959</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun L., Zhou R., Yang G., Shi Y., Analysis of 138 pathogenic mutations in presenilin-1 on the in vitro production of A&#x3b2;42 and A&#x3b2;40 peptides by &#x3b3;-secretase. Proc. Natl. Acad. Sci. U.S.A. 114, E476&#x2013;E485 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5278480</ArticleId><ArticleId IdType="pubmed">27930341</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B., Loss-of-function presenilin mutations in Alzheimer disease. Talking point on the role of presenilin mutations in Alzheimer disease. EMBO Rep. 8, 141&#x2013;146 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1796779</ArticleId><ArticleId IdType="pubmed">17268505</ArticleId></ArticleIdList></Reference><Reference><Citation>Coen K., Flannagan R. S., Baron S., Carraro-Lacroix L. R., Wang D., Vermeire W., Michiels C., Munck S., Baert V., Sugita S., Wuytack F., Hiesinger P. R., Grinstein S., Annaert W., Lysosomal calcium homeostasis defects, not proton pump defects, cause endo-lysosomal dysfunction in PSEN-deficient cells. J. Cell Biol. 198, 23&#x2013;35 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3392942</ArticleId><ArticleId IdType="pubmed">22753898</ArticleId></ArticleIdList></Reference><Reference><Citation>Tu H., Nelson O., Bezprozvanny A., Wang Z., Lee S. F., Hao Y. H., Serneels L., De Strooper B., Yu G., Bezprozvanny I., Presenilins form ER Ca2+ leak channels, a function disrupted by familial Alzheimer&#x2019;s disease-linked mutations. Cell 126, 981&#x2013;993 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3241869</ArticleId><ArticleId IdType="pubmed">16959576</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H., Sun S., Herreman A., De Strooper B., Bezprozvanny I., Role of presenilins in neuronal calcium homeostasis. J. Neurosci. 30, 8566&#x2013;8580 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2906098</ArticleId><ArticleId IdType="pubmed">20573903</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B., Annaert W., Novel research horizons for presenilins and &#x3b3;-secretases in cell biology and disease. Annu. Rev. Cell Dev. Biol. 26, 235&#x2013;260 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20604710</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel S., Cai X., Evolution of acidic Ca2+ stores and their resident Ca2+&#x2212;permeable channels. Cell Calcium 57, 222&#x2013;230 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25591931</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu H., Martinoia E., Szabo I., Organellar channels and transporters. Cell Calcium 58, 1&#x2013;10 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4458415</ArticleId><ArticleId IdType="pubmed">25795199</ArticleId></ArticleIdList></Reference><Reference><Citation>Avrahami L., Farfara D., Shaham-Kol M., Vassar R., Frenkel D., Eldar-Finkelman H., Inhibition of glycogen synthase kinase-3 ameliorates &#x3b2;-amyloid pathology and restores lysosomal acidification and mammalian target of rapamycin activity in the Alzheimer disease mouse model. J. Biol. Chem. 288, 1295&#x2013;1306 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3543013</ArticleId><ArticleId IdType="pubmed">23155049</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobrowolski R., Vick P., Ploper D., Gumper I., Snitkin H., Sabatini D. D., De Robertis E. M., Presenilin deficiency or lysosomal inhibition enhances Wnt signaling through relocalization of GSK3 to the late-endosomal compartment. Cell Rep. 2, 1316&#x2013;1328 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3538832</ArticleId><ArticleId IdType="pubmed">23122960</ArticleId></ArticleIdList></Reference><Reference><Citation>Torres M., Jimenez S., Sanchez-Varo R., Navarro V., Trujillo-Estrada L., Sanchez-Mejias E., Carmona I., Davila J. C., Vizuete M., Gutierrez A., Vitorica J., Defective lysosomal proteolysis and axonal transport are early pathogenic events that worsen with age leading to increased APP metabolism and synaptic Abeta in transgenic APP/PS1 hippocampus. Mol. Neurodegener. 7, 59 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3575255</ArticleId><ArticleId IdType="pubmed">23173743</ArticleId></ArticleIdList></Reference><Reference><Citation>Coffey E. E., Beckel J. M., Laties A. M., Mitchell C. H., Lysosomal alkalization and dysfunction in human fibroblasts with the Alzheimer&#x2019;s disease-linked presenilin 1 A246E mutation can be reversed with cAMP. Neuroscience 263, 111&#x2013;124 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4028113</ArticleId><ArticleId IdType="pubmed">24418614</ArticleId></ArticleIdList></Reference><Reference><Citation>R. A. Nixon, J. H. Lee, D. Wolfe, Methods for screening to identify therapeutic agents for Alzheimer&#x2019;s disease and use thereof. U.S. Patent US 15/046,291 (2016).</Citation></Reference><Reference><Citation>Raychowdhury M. K., Gonzalez-Perrett S., Montalbetti N., Timpanaro G. A., Chasan B., Goldmann W. H., Stahl S., Cooney A., Goldin E., Cantiello H. F., Molecular pathophysiology of mucolipidosis type IV: pH dysregulation of the mucolipin-1 cation channel. Hum. Mol. Genet. 13, 617&#x2013;627 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">14749347</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z., Yan Y., Wang B., &#x3b3;-Secretase genetics of hidradenitis suppurativa: A systematic literature review. Dermatology 237, 698&#x2013;704 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8491499</ArticleId><ArticleId IdType="pubmed">33333507</ArticleId></ArticleIdList></Reference><Reference><Citation>Nilius B., Flockerzi V., Mammalian transient receptor potential (TRP) cation channels. Preface. Handb. Exp. Pharmacol. 223, v&#x2013;vi (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25296415</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C. C., Keller M., Hess M., Schiffmann R., Urban N., Wolfgardt A., Schaefer M., Bracher F., Biel M., Wahl-Schott C., Grimm C., A small molecule restores function to TRPML1 mutant isoforms responsible for mucolipidosis type IV. Nat. Commun. 5, 4681 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25119295</ArticleId></ArticleIdList></Reference><Reference><Citation>Hui L., Soliman M. L., Geiger N. H., Miller N. M., Afghah Z., Lakpa K. L., Chen X., Geiger J. D., Acidifying endolysosomes prevented low-density lipoprotein-induced amyloidogenesis. J. Alzheimers Dis. 67, 393&#x2013;410 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6425476</ArticleId><ArticleId IdType="pubmed">30594929</ArticleId></ArticleIdList></Reference><Reference><Citation>Tedeschi V., Petrozziello T., Sisalli M. J., Boscia F., Canzoniero L. M. T., Secondo A., The activation of Mucolipin TRP channel 1 (TRPML1) protects motor neurons from L-BMAA neurotoxicity by promoting autophagic clearance. Sci. Rep. 9, 10743 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6656764</ArticleId><ArticleId IdType="pubmed">31341250</ArticleId></ArticleIdList></Reference><Reference><Citation>Bae M., Patel N., Xu H., Lee M., Tominaga-Yamanaka K., Nath A., Geiger J., Gorospe M., Mattson M. P., Haughey N. J., Activation of TRPML1 clears intraneuronal A&#x3b2; in preclinical models of HIV infection. J. Neurosci. 34, 11485&#x2013;11503 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4138351</ArticleId><ArticleId IdType="pubmed">25143627</ArticleId></ArticleIdList></Reference><Reference><Citation>McBrayer M., Nixon R. A., Lysosome and calcium dysregulation in Alzheimer&#x2019;s disease: Partners in crime. Biochem. Soc. Trans. 41, 1495&#x2013;1502 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3960943</ArticleId><ArticleId IdType="pubmed">24256243</ArticleId></ArticleIdList></Reference><Reference><Citation>Burke J. E., Structural basis for regulation of phosphoinositide kinases and their involvement in human disease. Mol. Cell 71, 653&#x2013;673 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30193094</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin N., Lang M. J., Weisman L. S., Phosphatidylinositol 3,5-bisphosphate: Regulation of cellular events in space and time. Biochem. Soc. Trans. 44, 177&#x2013;184 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4836390</ArticleId><ArticleId IdType="pubmed">26862203</ArticleId></ArticleIdList></Reference><Reference><Citation>Samie M. A., Xu H., Lysosomal exocytosis and lipid storage disorders. J. Lipid Res. 55, 995&#x2013;1009 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4031951</ArticleId><ArticleId IdType="pubmed">24668941</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson D. E., Ostrowski P., Jaumouille V., Grinstein S., The position of lysosomes within the cell determines their luminal pH. J. Cell Biol. 212, 677&#x2013;692 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4792074</ArticleId><ArticleId IdType="pubmed">26975849</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin X., Zhang Y., Alharbi A., Hanbashi A., Alhoshani A., Parrington J., Targeting two-pore channels: Current progress and future challenges. Trends Pharmacol. Sci. 41, 582&#x2013;594 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7365084</ArticleId><ArticleId IdType="pubmed">32679067</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmitt J. M., Wayman G. A., Nozaki N., Soderling T. R., Calcium activation of ERK mediated by calmodulin kinase I. J. Biol. Chem. 279, 24064&#x2013;24072 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15150258</ArticleId></ArticleIdList></Reference><Reference><Citation>Veeranna T., Kaji B., Boland T., Odrljin P., Mohan B., Basavarajappa S., Peterhoff C., Cataldo A., Rudnicki A., Amin N., Li B. S., Pant H. C., Hungund B. L., Arancio O., Nixon R. A., Calpain mediates calcium-induced activation of the erk1,2 MAPK pathway and cytoskeletal phosphorylation in neurons: Relevance to Alzheimer&#x2019;s disease. Am. J. Pathol. 165, 795&#x2013;805 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1618589</ArticleId><ArticleId IdType="pubmed">15331404</ArticleId></ArticleIdList></Reference><Reference><Citation>Xue Y., Ren J., Gao X., Jin C., Wen L., Yao X., GPS 2.0, a tool to predict kinase-specific phosphorylation sites in hierarchy. Mol. Cell. Proteomics 7, 1598&#x2013;1608 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2528073</ArticleId><ArticleId IdType="pubmed">18463090</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonny C., Oberson A., Negri S., Sauser C., Schorderet D. F., Cell-permeable peptide inhibitors of JNK: Novel blockers of beta-cell death. Diabetes 50, 77&#x2013;82 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11147798</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J. H., Rao M. V., Yang D. S., Stavrides P., Im E., Pensalfini A., Huo C., Sarkar P., Yoshimori T., Nixon R. A., Transgenic expression of a ratiometric autophagy probe specifically in neurons enables the interrogation of brain autophagy in vivo. Autophagy 15, 543&#x2013;557 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6351128</ArticleId><ArticleId IdType="pubmed">30269645</ArticleId></ArticleIdList></Reference><Reference><Citation>Millecamps S., Julien J. P., Axonal transport deficits and neurodegenerative diseases. Nat. Rev. Neurosci. 14, 161&#x2013;176 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23361386</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon R. A., Yang D. S., Lee J. H., Neurodegenerative lysosomal disorders: A continuum from development to late age. Autophagy 4, 590&#x2013;599 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18497567</ArticleId></ArticleIdList></Reference><Reference><Citation>Maday S., Holzbaur E. L., Compartment-specific regulation of autophagy in primary neurons. J. Neurosci. 36, 5933&#x2013;5945 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4887563</ArticleId><ArticleId IdType="pubmed">27251616</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong X. P., Shen D., Wang X., Dawson T., Li X., Zhang Q., Cheng X., Zhang Y., Weisman L. S., Delling M., Xu H., PI(3,5)P2 controls membrane trafficking by direct activation of mucolipin Ca2+ release channels in the endolysosome. Nat. Commun. 1, 38 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2928581</ArticleId><ArticleId IdType="pubmed">20802798</ArticleId></ArticleIdList></Reference><Reference><Citation>Waller-Evans H., Lloyd-Evans E., Regulation of TRPML1 function. Biochem. Soc. Trans. 43, 442&#x2013;446 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26009188</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon R. A., Wegiel J., Kumar A., Yu W. H., Peterhoff C., Cataldo A., Cuervo A. M., Extensive involvement of autophagy in Alzheimer disease: An immuno-electron microscopy study. J. Neuropathol. Exp. Neurol. 64, 113&#x2013;122 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15751225</ArticleId></ArticleIdList></Reference><Reference><Citation>Colacurcio D. J., Nixon R. A., Disorders of lysosomal acidification&#x2014;The emerging role of v-ATPase in aging and neurodegenerative disease. Ageing Res. Rev. 32, 75&#x2013;88 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5112157</ArticleId><ArticleId IdType="pubmed">27197071</ArticleId></ArticleIdList></Reference><Reference><Citation>Miao Y., Li G., Zhang X., Xu H., Abraham S. N., A TRP channel senses lysosome neutralization by pathogens to trigger their expulsion. Cell 161, 1306&#x2013;1319 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4458218</ArticleId><ArticleId IdType="pubmed">26027738</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X., Rydzewski N., Hider A., Zhang X., Yang J., Wang W., Gao Q., Cheng X., Xu H., A molecular mechanism to regulate lysosome motility for lysosome positioning and tubulation. Nat. Cell Biol. 18, 404&#x2013;417 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4871318</ArticleId><ArticleId IdType="pubmed">26950892</ArticleId></ArticleIdList></Reference><Reference><Citation>McKenney R. J., Vershinin M., Kunwar A., Vallee R. B., Gross S. P., LIS1 and NudE induce a persistent dynein force-producing state. Cell 141, 304&#x2013;314 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2881166</ArticleId><ArticleId IdType="pubmed">20403325</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaughan P. S., Leszyk J. D., Vaughan K. T., Cytoplasmic dynein intermediate chain phosphorylation regulates binding to dynactin. J. Biol. Chem. 276, 26171&#x2013;26179 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11340075</ArticleId></ArticleIdList></Reference><Reference><Citation>Jie J., Lohr F., Barbar E., Dynein binding of competitive regulators dynactin and NudE involves novel interplay between phosphorylation site and disordered spliced linkers. Structure 25, 421&#x2013;433 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28162951</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J. W., Chang T. S., Lee J. E., Huh S. H., Yeon S. W., Yang W. S., Joe C. O., Mook-Jung I., Tanzi R. E., Kim T. W., Choi E. J., Negative regulation of the SAPK/JNK signaling pathway by presenilin 1. J. Cell Biol. 153, 457&#x2013;464 (2001).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2190568</ArticleId><ArticleId IdType="pubmed">11331298</ArticleId></ArticleIdList></Reference><Reference><Citation>Coffey E. T., Nuclear and cytosolic JNK signalling in neurons. Nat. Rev. Neurosci. 15, 285&#x2013;299 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24739785</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitmarsh A. J., The JIP family of MAPK scaffold proteins. Biochem. Soc. Trans. 34, 828&#x2013;832 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17052208</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu M. M., Nirschl J. J., Holzbaur E. L., LC3 binding to the scaffolding protein JIP1 regulates processive dynein-driven transport of autophagosomes. Dev. Cell 29, 577&#x2013;590 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4109720</ArticleId><ArticleId IdType="pubmed">24914561</ArticleId></ArticleIdList></Reference><Reference><Citation>Drerup C. M., Nechiporuk A. V., JNK-interacting protein 3 mediates the retrograde transport of activated c-Jun N-terminal kinase and lysosomes. PLOS Genet. 9, e1003303 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3585007</ArticleId><ArticleId IdType="pubmed">23468645</ArticleId></ArticleIdList></Reference><Reference><Citation>Gowrishankar S., Wu Y., Ferguson S. M., Impaired JIP3-dependent axonal lysosome transport promotes amyloid plaque pathology. J. Cell Biol. 216, 3291&#x2013;3305 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5626538</ArticleId><ArticleId IdType="pubmed">28784610</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon S. Y., Choi J. E., Choi J. M., Kim D. H., Dynein cleavage and microtubule accumulation in okadaic acid-treated neurons. Neurosci. Lett. 437, 111&#x2013;115 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18448253</ArticleId></ArticleIdList></Reference><Reference><Citation>Weible M. W. II, Ozsarac N., Grimes M. L., Hendry I. A., Comparison of nerve terminal events in vivo effecting retrograde transport of vesicles containing neurotrophins or synaptic vesicle components. J. Neurosci. Res. 75, 771&#x2013;781 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">14994338</ArticleId></ArticleIdList></Reference><Reference><Citation>Neisch A. L., Neufeld T. P., Hays T. S., A STRIPAK complex mediates axonal transport of autophagosomes and dense core vesicles through PP2A regulation. J. Cell Biol. 216, 441&#x2013;461 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5294782</ArticleId><ArticleId IdType="pubmed">28100687</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon S. Y., Choi J. E., Yoon J. H., Huh J. W., Kim D. H., BACE inhibitor reduces APP-beta-C-terminal fragment accumulation in axonal swellings of okadaic acid-induced neurodegeneration. Neurobiol. Dis. 22, 435&#x2013;444 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16480887</ArticleId></ArticleIdList></Reference><Reference><Citation>Vergarajauregui S., Martina J. A., Puertollano R., Identification of the penta-EF-hand protein ALG-2 as a Ca2+&#x2212;dependent interactor of mucolipin-1. J. Biol. Chem. 284, 36357&#x2013;36366 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2794751</ArticleId><ArticleId IdType="pubmed">19864416</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuda M., Seong K. H., Aigaki T., POSH, a scaffold protein for JNK signaling, binds to ALG-2 and ALIX in Drosophila. FEBS Lett. 580, 3296&#x2013;3300 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16698022</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura S., Noda T., Yoshimori T., Dissection of the autophagosome maturation process by a novel reporter protein, tandem fluorescent-tagged LC3. Autophagy 3, 452&#x2013;460 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17534139</ArticleId></ArticleIdList></Reference><Reference><Citation>Choudhury A., Dominguez M., Puri V., Sharma D. K., Narita K., Wheatley C. L., Marks D. L., Pagano R. E., Rab proteins mediate Golgi transport of caveola-internalized glycosphingolipids and correct lipid trafficking in Niemann-Pick C cells. J. Clin. Invest. 109, 1541&#x2013;1550 (2002).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC151017</ArticleId><ArticleId IdType="pubmed">12070301</ArticleId></ArticleIdList></Reference><Reference><Citation>Ambrosio A. L., Boyle J. A., Di Pietro S. M., TPC2 mediates new mechanisms of platelet dense granule membrane dynamics through regulation of Ca2+ release. Mol. Biol. Cell 26, 3263&#x2013;3274 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4569316</ArticleId><ArticleId IdType="pubmed">26202466</ArticleId></ArticleIdList></Reference><Reference><Citation>Boland B., Kumar A., Lee S., Platt F. M., Wegiel J., Yu W. H., Nixon R. A., Autophagy induction and autophagosome clearance in neurons: Relationship to autophagic pathology in Alzheimer&#x2019;s disease. J. Neurosci. 28, 6926&#x2013;6937 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2676733</ArticleId><ArticleId IdType="pubmed">18596167</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson C. A., Murphy D. D., Giasson B. I., Zhang B., Trojanowski J. Q., Lee V. M., Degradative organelles containing mislocalized alpha-and beta-synuclein proliferate in presenilin-1 null neurons. J. Cell Biol. 165, 335&#x2013;346 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2172178</ArticleId><ArticleId IdType="pubmed">15123735</ArticleId></ArticleIdList></Reference><Reference><Citation>Millet L. J., Stewart M. E., Sweedler J. V., Nuzzo R. G., Gillette M. U., Microfluidic devices for culturing primary mammalian neurons at low densities. Lab Chip 7, 987&#x2013;994 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17653340</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe D. M., Lee J. H., Kumar A., Lee S., Orenstein S. J., Nixon R. A., Autophagy failure in Alzheimer&#x2019;s disease and the role of defective lysosomal acidification. Eur. J. Neurosci. 37, 1949&#x2013;1961 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3694736</ArticleId><ArticleId IdType="pubmed">23773064</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker M. W., Lloyd-Evans E., A rapid method for the preparation of ultrapure, functional lysosomes using functionalized superparamagnetic iron oxide nanoparticles. Methods Cell Biol. 126, 21&#x2013;43 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25665439</ArticleId></ArticleIdList></Reference><Reference><Citation>Derivery E., Sousa C., Gautier J. J., Lombard B., Loew D., Gautreau A., The Arp2/3 activator WASH controls the fission of endosomes through a large multiprotein complex. Dev. Cell 17, 712&#x2013;723 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19922875</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37118445</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>01</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2662-8465</ISSN><JournalIssue CitedMedium="Internet"><Volume>2</Volume><Issue>6</Issue><PubDate><Year>2022</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Nature aging</Title><ISOAbbreviation>Nat Aging</ISOAbbreviation></Journal><ArticleTitle>Biomarker modeling of Alzheimer's disease using PET-based Braak staging.</ArticleTitle><Pagination><StartPage>526</StartPage><EndPage>535</EndPage><MedlinePgn>526-535</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s43587-022-00204-0</ELocationID><Abstract><AbstractText>Gold-standard diagnosis of Alzheimer's disease (AD) relies on histopathological staging systems. Using the topographical information from [<sup>18</sup>F]MK6240 tau positron-emission tomography (PET), we applied the Braak tau staging system to 324 living individuals. We used PET-based Braak stage to model the trajectories of amyloid-&#x3b2;, phosphorylated tau (pTau) in cerebrospinal fluid (pTau<sub>181</sub>, pTau<sub>217</sub>, pTau<sub>231</sub> and pTau<sub>235</sub>) and plasma (pTau<sub>181</sub> and pTau<sub>231</sub>), neurodegeneration and cognitive symptoms. We identified nonlinear AD biomarker trajectories corresponding to the spatial extent of tau-PET, with modest biomarker changes detectable by Braak stage II and significant changes occurring at stages III-IV, followed by plateaus. Early Braak stages were associated with isolated memory impairment, whereas Braak stages V-VI were incompatible with normal cognition. In 159 individuals with follow-up tau-PET, progression beyond stage III took place uniquely in the presence of amyloid-&#x3b2; positivity. Our findings support PET-based Braak staging as a framework to model the natural history of AD and monitor AD severity in living humans.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Therriault</LastName><ForeName>Joseph</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-7826-4781</Identifier><AffiliationInfo><Affiliation>Translational Neuroimaging Laboratory, McGill Research Centre for Studies in Aging, Douglas Mental Health Institute, Le Centre int&#xe9;gr&#xe9; universitaire de sant&#xe9; et de services sociaux (CIUSSS) de l'Ouest de l'&#xce;le de Montr&#xe9;al, Montreal, Quebec, Canada. joseph.therriault@mail.mcgill.ca.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology and Neurosurgery, Faculty of Medicine, McGill University, Montreal, Quebec, Canada. joseph.therriault@mail.mcgill.ca.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pascoal</LastName><ForeName>Tharick A</ForeName><Initials>TA</Initials><Identifier Source="ORCID">0000-0001-9057-8014</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lussier</LastName><ForeName>Firoza Z</ForeName><Initials>FZ</Initials><Identifier Source="ORCID">0000-0002-6877-4825</Identifier><AffiliationInfo><Affiliation>Translational Neuroimaging Laboratory, McGill Research Centre for Studies in Aging, Douglas Mental Health Institute, Le Centre int&#xe9;gr&#xe9; universitaire de sant&#xe9; et de services sociaux (CIUSSS) de l'Ouest de l'&#xce;le de Montr&#xe9;al, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology and Neurosurgery, Faculty of Medicine, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tissot</LastName><ForeName>C&#xe9;cile</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-2711-3833</Identifier><AffiliationInfo><Affiliation>Translational Neuroimaging Laboratory, McGill Research Centre for Studies in Aging, Douglas Mental Health Institute, Le Centre int&#xe9;gr&#xe9; universitaire de sant&#xe9; et de services sociaux (CIUSSS) de l'Ouest de l'&#xce;le de Montr&#xe9;al, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology and Neurosurgery, Faculty of Medicine, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chamoun</LastName><ForeName>Mira</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Translational Neuroimaging Laboratory, McGill Research Centre for Studies in Aging, Douglas Mental Health Institute, Le Centre int&#xe9;gr&#xe9; universitaire de sant&#xe9; et de services sociaux (CIUSSS) de l'Ouest de l'&#xce;le de Montr&#xe9;al, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology and Neurosurgery, Faculty of Medicine, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bezgin</LastName><ForeName>Gleb</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Translational Neuroimaging Laboratory, McGill Research Centre for Studies in Aging, Douglas Mental Health Institute, Le Centre int&#xe9;gr&#xe9; universitaire de sant&#xe9; et de services sociaux (CIUSSS) de l'Ouest de l'&#xce;le de Montr&#xe9;al, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology and Neurosurgery, Faculty of Medicine, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Servaes</LastName><ForeName>Stijn</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Translational Neuroimaging Laboratory, McGill Research Centre for Studies in Aging, Douglas Mental Health Institute, Le Centre int&#xe9;gr&#xe9; universitaire de sant&#xe9; et de services sociaux (CIUSSS) de l'Ouest de l'&#xce;le de Montr&#xe9;al, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology and Neurosurgery, Faculty of Medicine, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benedet</LastName><ForeName>Andrea L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Translational Neuroimaging Laboratory, McGill Research Centre for Studies in Aging, Douglas Mental Health Institute, Le Centre int&#xe9;gr&#xe9; universitaire de sant&#xe9; et de services sociaux (CIUSSS) de l'Ouest de l'&#xce;le de Montr&#xe9;al, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ashton</LastName><ForeName>Nicholas J</ForeName><Initials>NJ</Initials><Identifier Source="ORCID">0000-0002-3579-8804</Identifier><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>King's College London, Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Institute Clinical Neuroscience Institute, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Research Unit for Dementia at South London, NIHR Biomedical Research Centre for Mental Health and Maudsley NHS Foundation, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karikari</LastName><ForeName>Thomas K</ForeName><Initials>TK</Initials><Identifier Source="ORCID">0000-0003-1422-4358</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lantero-Rodriguez</LastName><ForeName>Juan</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-7426-678X</Identifier><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kunach</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Translational Neuroimaging Laboratory, McGill Research Centre for Studies in Aging, Douglas Mental Health Institute, Le Centre int&#xe9;gr&#xe9; universitaire de sant&#xe9; et de services sociaux (CIUSSS) de l'Ouest de l'&#xce;le de Montr&#xe9;al, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology and Neurosurgery, Faculty of Medicine, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yi-Ting</ForeName><Initials>YT</Initials><AffiliationInfo><Affiliation>Translational Neuroimaging Laboratory, McGill Research Centre for Studies in Aging, Douglas Mental Health Institute, Le Centre int&#xe9;gr&#xe9; universitaire de sant&#xe9; et de services sociaux (CIUSSS) de l'Ouest de l'&#xce;le de Montr&#xe9;al, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology and Neurosurgery, Faculty of Medicine, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fernandez-Arias</LastName><ForeName>Jaime</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Translational Neuroimaging Laboratory, McGill Research Centre for Studies in Aging, Douglas Mental Health Institute, Le Centre int&#xe9;gr&#xe9; universitaire de sant&#xe9; et de services sociaux (CIUSSS) de l'Ouest de l'&#xce;le de Montr&#xe9;al, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology and Neurosurgery, Faculty of Medicine, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Massarweh</LastName><ForeName>Gassan</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurosurgery, Faculty of Medicine, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vitali</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurosurgery, Faculty of Medicine, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soucy</LastName><ForeName>Jean-Paul</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurosurgery, Faculty of Medicine, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saha-Chaudhuri</LastName><ForeName>Paramita</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-1987-320X</Identifier><AffiliationInfo><Affiliation>Department of Math &amp; Statistics, University of Vermont, Burlington, VT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-1890-4193</Identifier><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-3930-4354</Identifier><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute at UCL, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gauthier</LastName><ForeName>Serge</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Translational Neuroimaging Laboratory, McGill Research Centre for Studies in Aging, Douglas Mental Health Institute, Le Centre int&#xe9;gr&#xe9; universitaire de sant&#xe9; et de services sociaux (CIUSSS) de l'Ouest de l'&#xce;le de Montr&#xe9;al, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology and Neurosurgery, Faculty of Medicine, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosa-Neto</LastName><ForeName>Pedro</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-9116-1376</Identifier><AffiliationInfo><Affiliation>Translational Neuroimaging Laboratory, McGill Research Centre for Studies in Aging, Douglas Mental Health Institute, Le Centre int&#xe9;gr&#xe9; universitaire de sant&#xe9; et de services sociaux (CIUSSS) de l'Ouest de l'&#xce;le de Montr&#xe9;al, Montreal, Quebec, Canada. pedro.rosa@mcgill.ca.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology and Neurosurgery, Faculty of Medicine, McGill University, Montreal, Quebec, Canada. pedro.rosa@mcgill.ca.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG068398</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>#170846</GrantID><Agency>Gouvernement du Canada | Canadian Institutes of Health Research (Instituts de Recherche en Sant&#xe9; du Canada)</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>04</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Aging</MedlineTA><NlmUniqueID>101773306</NlmUniqueID><ISSNLinking>2662-8465</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Aging. 2022 Jun;2(6):465-467. doi: 10.1038/s43587-022-00236-6.</RefSource><PMID Version="1">37118453</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>9</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>1</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>29</Day><Hour>6</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>28</Day><Hour>23</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>4</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37118445</ArticleId><ArticleId IdType="pmc">PMC10154209</ArticleId><ArticleId IdType="doi">10.1038/s43587-022-00204-0</ArticleId><ArticleId IdType="pii">10.1038/s43587-022-00204-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gonnella JS, Hornbrook MC, Louis DZ. Staging of disease: a case-mix measurement. JAMA. 1984;251:637&#x2013;644. doi: 10.1001/jama.1984.03340290051021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.1984.03340290051021</ArticleId><ArticleId IdType="pubmed">6418903</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, et al. Tracking pathophysiological processes in Alzheimer&#x2019;s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12:207&#x2013;216. doi: 10.1016/S1474-4422(12)70291-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(12)70291-0</ArticleId><ArticleId IdType="pmc">PMC3622225</ArticleId><ArticleId IdType="pubmed">23332364</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, et al. Clinical and biomarker changes in dominantly inherited Alzheimer&#x2019;s disease. N. Engl. J. Med. 2012;367:795&#x2013;804. doi: 10.1056/NEJMoa1202753.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1202753</ArticleId><ArticleId IdType="pmc">PMC3474597</ArticleId><ArticleId IdType="pubmed">22784036</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, et al. Amyloid-&#x3b2; deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer&#x2019;s disease: a prospective cohort study. Lancet Neurol. 2013;12:357&#x2013;367. doi: 10.1016/S1474-4422(13)70044-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(13)70044-9</ArticleId><ArticleId IdType="pubmed">23477989</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, et al. NIA-AA research framework: toward a biological definition of Alzheimer&#x2019;s disease. Alzheimers Dement. 2018;14:535&#x2013;562. doi: 10.1016/j.jalz.2018.02.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.02.018</ArticleId><ArticleId IdType="pmc">PMC5958625</ArticleId><ArticleId IdType="pubmed">29653606</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT, et al. National Institute on Aging-Alzheimer&#x2019;s Association guidelines for the neuropathologic assessment of Alzheimer&#x2019;s disease. Alzheimers Dement. 2012;8:1&#x2013;13. doi: 10.1016/j.jalz.2011.10.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2011.10.007</ArticleId><ArticleId IdType="pmc">PMC3266529</ArticleId><ArticleId IdType="pubmed">22265587</ArticleId></ArticleIdList></Reference><Reference><Citation>Montine TJ, et al. National Institute on Aging-Alzheimer&#x2019;s Association guidelines for the neuropathologic assessment of Alzheimer&#x2019;s disease: a practical approach. Acta Neuropathol. 2012;123:1&#x2013;11. doi: 10.1007/s00401-011-0910-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-011-0910-3</ArticleId><ArticleId IdType="pmc">PMC3268003</ArticleId><ArticleId IdType="pubmed">22101365</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239&#x2013;259. doi: 10.1007/BF00308809.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00308809</ArticleId><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 2006;112:389&#x2013;404. doi: 10.1007/s00401-006-0127-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-006-0127-z</ArticleId><ArticleId IdType="pmc">PMC3906709</ArticleId><ArticleId IdType="pubmed">16906426</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Staging of alzheimer&#x2019;s disease-related neurofibrillary changes. Neurobiol. Aging. 1995;16:271&#x2013;278. doi: 10.1016/0197-4580(95)00021-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0197-4580(95)00021-6</ArticleId><ArticleId IdType="pubmed">7566337</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Tredici K, Braak H. To stage, or not to stage. Curr. Opin. Neurobiol. 2020;61:10&#x2013;22. doi: 10.1016/j.conb.2019.11.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.conb.2019.11.008</ArticleId><ArticleId IdType="pubmed">31862625</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampel H, et al. Developing the ATX(N) classification for use across the Alzheimer disease continuum. Nat. Rev. Neurol. 2021;17:580&#x2013;589. doi: 10.1038/s41582-021-00520-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-021-00520-w</ArticleId><ArticleId IdType="pubmed">34239130</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman DS, et al. Alzheimer disease. Nat. Rev. Dis. Prim. 2021;7:33. doi: 10.1038/s41572-021-00269-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41572-021-00269-y</ArticleId><ArticleId IdType="pmc">PMC8574196</ArticleId><ArticleId IdType="pubmed">33986301</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheltens P, et al. Alzheimer&#x2019;s disease. Lancet. 2021;397:1577&#x2013;1590. doi: 10.1016/S0140-6736(20)32205-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32205-4</ArticleId><ArticleId IdType="pmc">PMC8354300</ArticleId><ArticleId IdType="pubmed">33667416</ArticleId></ArticleIdList></Reference><Reference><Citation>Su&#xe1;rez&#x2010;Calvet M, et al. Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer&#x2019;s continuum when only subtle changes in A&#x3b2; pathology are detected. EMBO Mol. Med. 2020;12:e12921. doi: 10.15252/emmm.202012921.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.202012921</ArticleId><ArticleId IdType="pmc">PMC7721364</ArticleId><ArticleId IdType="pubmed">33169916</ArticleId></ArticleIdList></Reference><Reference><Citation>Barth&#xe9;lemy NR, et al. A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer&#x2019;s disease. Nat. Med. 2020;26:398&#x2013;407. doi: 10.1038/s41591-020-0781-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0781-z</ArticleId><ArticleId IdType="pmc">PMC7309367</ArticleId><ArticleId IdType="pubmed">32161412</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson O. Biomarkers for neurodegenerative diseases. Nat. Med. 2021;27:954&#x2013;963. doi: 10.1038/s41591-021-01382-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01382-x</ArticleId><ArticleId IdType="pubmed">34083813</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagust W. Imaging the evolution and pathophysiology of Alzheimer disease. Nat. Rev. Neurosci. 2018;19:687&#x2013;700. doi: 10.1038/s41583-018-0067-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41583-018-0067-3</ArticleId><ArticleId IdType="pmc">PMC7032048</ArticleId><ArticleId IdType="pubmed">30266970</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC. Mild cognitive impairment as a diagnostic entity. J. Intern. Med. 2004;256:183&#x2013;194. doi: 10.1111/j.1365-2796.2004.01388.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2796.2004.01388.x</ArticleId><ArticleId IdType="pubmed">15324362</ArticleId></ArticleIdList></Reference><Reference><Citation>Fortea J, et al. Clinical and biomarker changes of Alzheimer&#x2019;s disease in adults with Down syndrome: a cross-sectional study. Lancet. 2020;395:1988&#x2013;1997. doi: 10.1016/S0140-6736(20)30689-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30689-9</ArticleId><ArticleId IdType="pmc">PMC7322523</ArticleId><ArticleId IdType="pubmed">32593336</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe D, Hardy J. The amyloid hypothesis of Alzheimer&#x2019;s disease at 25 years. EMBO Mol. Med. 2016;8:595&#x2013;608. doi: 10.15252/emmm.201606210.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201606210</ArticleId><ArticleId IdType="pmc">PMC4888851</ArticleId><ArticleId IdType="pubmed">27025652</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xf6;ll M, et al. PET Imaging of Tau deposition in the aging human brain. Neuron. 2016;89:971&#x2013;982. doi: 10.1016/j.neuron.2016.01.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.01.028</ArticleId><ArticleId IdType="pmc">PMC4779187</ArticleId><ArticleId IdType="pubmed">26938442</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowe, V. J. et al. Widespread brain tau and its association with ageing, Braak stage and Alzheimer&#x2019;s dementia. Brain141, 271&#x2013;287, 10.1093/brain/awx320 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5837250</ArticleId><ArticleId IdType="pubmed">29228201</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson KA, et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann. Neurol. 2016;79:110&#x2013;119. doi: 10.1002/ana.24546.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24546</ArticleId><ArticleId IdType="pmc">PMC4738026</ArticleId><ArticleId IdType="pubmed">26505746</ArticleId></ArticleIdList></Reference><Reference><Citation>Pascoal TA, et al. 18F-MK-6240 PET for early and late detection of neurofibrillary tangles. Brain. 2020;143:2818&#x2013;2830. doi: 10.1093/brain/awaa180.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa180</ArticleId><ArticleId IdType="pubmed">32671408</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R, et al. Assessment of demographic, genetic, and imaging variables associated with brain resilience and cognitive resilience to pathological tau in patients with Alzheimer disease. JAMA Neurol. 2020;77:632&#x2013;642. doi: 10.1001/jamaneurol.2019.5154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2019.5154</ArticleId><ArticleId IdType="pmc">PMC7042808</ArticleId><ArticleId IdType="pubmed">32091549</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology. 2007;69:2197&#x2013;2204. doi: 10.1212/01.wnl.0000271090.28148.24.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000271090.28148.24</ArticleId><ArticleId IdType="pubmed">17568013</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R, et al. Discriminative accuracy of [18F]flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders. JAMA. 2018;320:1151&#x2013;1162. doi: 10.1001/jama.2018.12917.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2018.12917</ArticleId><ArticleId IdType="pmc">PMC6233630</ArticleId><ArticleId IdType="pubmed">30326496</ArticleId></ArticleIdList></Reference><Reference><Citation>Tapper EB, Lok AS-F. Use of liver imaging and biopsy in clinical practice. N. Engl. J. Med. 2017;377:756&#x2013;768. doi: 10.1056/NEJMra1610570.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1610570</ArticleId><ArticleId IdType="pubmed">28834467</ArticleId></ArticleIdList></Reference><Reference><Citation>Therriault J, et al. Frequency of biologically defined Alzheimer disease in relation to age, sex, APOE&#x3b5;4, and cognitive impairment. Neurology. 2021;96:e975&#x2013;e985.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8055338</ArticleId><ArticleId IdType="pubmed">33443136</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabinovici GD, et al. Association of amyloid positron emission tomography with subsequent change in clinical management among medicare beneficiaries with mild cognitive impairment or dementia. JAMA. 2019;321:1286&#x2013;1294. doi: 10.1001/jama.2019.2000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2019.2000</ArticleId><ArticleId IdType="pmc">PMC6450276</ArticleId><ArticleId IdType="pubmed">30938796</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, et al. Prevalence of biologically vs clinically defined Alzheimer spectrum entities using the national institute on aging-Alzheimer&#x2019;s association research framework. JAMA Neurol. 2019;76:1174&#x2013;1183. doi: 10.1001/jamaneurol.2019.1971.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2019.1971</ArticleId><ArticleId IdType="pmc">PMC6632154</ArticleId><ArticleId IdType="pubmed">31305929</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, et al. Associations of amyloid, tau, and neurodegeneration biomarker profiles with rates of memory decline among individuals without dementia. JAMA. 2019;321:2316&#x2013;2325. doi: 10.1001/jama.2019.7437.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2019.7437</ArticleId><ArticleId IdType="pmc">PMC6582267</ArticleId><ArticleId IdType="pubmed">31211344</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogel JW, et al. Four distinct trajectories of tau deposition identified in Alzheimer&#x2019;s disease. Nat. Med. 2021;27:871&#x2013;881. doi: 10.1038/s41591-021-01309-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01309-6</ArticleId><ArticleId IdType="pmc">PMC8686688</ArticleId><ArticleId IdType="pubmed">33927414</ArticleId></ArticleIdList></Reference><Reference><Citation>Franzmeier N, et al. Patient-centered connectivity-based prediction of tau pathology spread in Alzheimer&#x2019;s disease. Sci. Adv. 2020;6:eabd1327. doi: 10.1126/sciadv.abd1327.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.abd1327</ArticleId><ArticleId IdType="pmc">PMC7695466</ArticleId><ArticleId IdType="pubmed">33246962</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez JS, et al. The cortical origin and initial spread of medial temporal tauopathy in Alzheimer&#x2019;s disease assessed with positron emission tomography. Sci. Transl. Med. 2021;13:eabc0655. doi: 10.1126/scitranslmed.abc0655.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abc0655</ArticleId><ArticleId IdType="pmc">PMC7978042</ArticleId><ArticleId IdType="pubmed">33472953</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Del Tredici K. Spreading of tau pathology in sporadic Alzheimer&#x2019;s disease along cortico-cortical top-down connections. Cereb. Cortex. 2018;28:3372&#x2013;3384. doi: 10.1093/cercor/bhy152.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cercor/bhy152</ArticleId><ArticleId IdType="pmc">PMC6095209</ArticleId><ArticleId IdType="pubmed">29982389</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen C, et al. Alzheimer&#x2019;s disease clinical variants show distinct regional patterns of neurofibrillary tangle accumulation. Acta Neuropathol. 2019;138:597&#x2013;612. doi: 10.1007/s00401-019-02036-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-019-02036-6</ArticleId><ArticleId IdType="pmc">PMC7012374</ArticleId><ArticleId IdType="pubmed">31250152</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesulam M, et al. Alzheimer and frontotemporal pathology in subsets of primary progressive aphasia. Ann. Neurol. 2008;63:709&#x2013;719. doi: 10.1002/ana.21388.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21388</ArticleId><ArticleId IdType="pmc">PMC2858311</ArticleId><ArticleId IdType="pubmed">18412267</ArticleId></ArticleIdList></Reference><Reference><Citation>Pascoal TA, et al. Longitudinal 18F-MK-6240 tau tangles accumulation follows Braak stages. Brain. 2021;144:3517&#x2013;3528. doi: 10.1093/brain/awab248.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awab248</ArticleId><ArticleId IdType="pmc">PMC8677534</ArticleId><ArticleId IdType="pubmed">34515754</ArticleId></ArticleIdList></Reference><Reference><Citation>Soleimani-Meigooni DN, et al. 18F-flortaucipir PET to autopsy comparisons in Alzheimer&#x2019;s disease and other neurodegenerative diseases. Brain. 2020;143:3477&#x2013;3494. doi: 10.1093/brain/awaa276.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa276</ArticleId><ArticleId IdType="pmc">PMC7719031</ArticleId><ArticleId IdType="pubmed">33141172</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleisher AS, et al. Positron emission tomography imaging with [18F]flortaucipir and postmortem assessment of Alzheimer disease neuropathologic changes. JAMA Neurol. 2020;77:829&#x2013;839. doi: 10.1001/jamaneurol.2020.0528.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2020.0528</ArticleId><ArticleId IdType="pmc">PMC7186920</ArticleId><ArticleId IdType="pubmed">32338734</ArticleId></ArticleIdList></Reference><Reference><Citation>Hostetler ED, et al. Preclinical characterization of 18F-MK-6240, a promising PET tracer for in vivo quantification of human neurofibrillary tangles. J. Nucl. Med. 2016;57:1599&#x2013;1606. doi: 10.2967/jnumed.115.171678.</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.115.171678</ArticleId><ArticleId IdType="pubmed">27230925</ArticleId></ArticleIdList></Reference><Reference><Citation>Wesseling H, et al. Tau PTM profiles identify patient heterogeneity and stages of Alzheimer&#x2019;s disease. Cell. 2020;183:1699&#x2013;1713.e13. doi: 10.1016/j.cell.2020.10.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.10.029</ArticleId><ArticleId IdType="pmc">PMC8168922</ArticleId><ArticleId IdType="pubmed">33188775</ArticleId></ArticleIdList></Reference><Reference><Citation>Mintun MA, et al. Donanemab in early Alzheimer&#x2019;s disease. N. Engl. J. Med. 2021;384:1691&#x2013;1704. doi: 10.1056/NEJMoa2100708.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2100708</ArticleId><ArticleId IdType="pubmed">33720637</ArticleId></ArticleIdList></Reference><Reference><Citation>Levey AI. Progress with treatments for Alzheimer&#x2019;s disease. N. Engl. J. Med. 2021;384:1762&#x2013;1763. doi: 10.1056/NEJMe2103722.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMe2103722</ArticleId><ArticleId IdType="pubmed">33951366</ArticleId></ArticleIdList></Reference><Reference><Citation>Therriault J, et al. Association of apolipoprotein e &#x3f5;4 with medial temporal tau independent of amyloid-&#x3b2;. JAMA Neurol. 2020;77:470&#x2013;479. doi: 10.1001/jamaneurol.2019.4421.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2019.4421</ArticleId><ArticleId IdType="pmc">PMC6990684</ArticleId><ArticleId IdType="pubmed">31860000</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, et al. Clinical diagnosis of Alzheimer&#x2019;s disease: report of the NINCDS-ADRDA Work Group* under the auspices of department of health and human services task force on Alzheimer&#x2019;s disease. Neurology. 1984;34:939&#x2013;939. doi: 10.1212/WNL.34.7.939.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.34.7.939</ArticleId><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorno-Tempini ML, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76:1006&#x2013;1014. doi: 10.1212/WNL.0b013e31821103e6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e31821103e6</ArticleId><ArticleId IdType="pmc">PMC3059138</ArticleId><ArticleId IdType="pubmed">21325651</ArticleId></ArticleIdList></Reference><Reference><Citation>Crutch SJ, et al. Consensus classification of posterior cortical atrophy. Alzheimer&#x2019;s Dement. 2017;13:870&#x2013;884. doi: 10.1016/j.jalz.2017.01.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2017.01.014</ArticleId><ArticleId IdType="pmc">PMC5788455</ArticleId><ArticleId IdType="pubmed">28259709</ArticleId></ArticleIdList></Reference><Reference><Citation>Therriault J, et al. Topographical distribution of amyloid-&#x3b2;, tau and atrophy in behavioral/dysexecutive AD patients. Neurology. 2020;96:e81&#x2013;e92. doi: 10.1212/WNL.0000000000011081.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000011081</ArticleId><ArticleId IdType="pmc">PMC7884976</ArticleId><ArticleId IdType="pubmed">33093220</ArticleId></ArticleIdList></Reference><Reference><Citation>Pascoal TA, et al. In vivo quantification of neurofibrillary tangles with [18F]MK-6240. Alzheimers Res. Ther. 2018;10:1&#x2013;14. doi: 10.1186/s13195-018-0402-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-018-0402-y</ArticleId><ArticleId IdType="pmc">PMC6069775</ArticleId><ArticleId IdType="pubmed">30064520</ArticleId></ArticleIdList></Reference><Reference><Citation>Therriault J, et al. Determining amyloid-B positivity using 18F-AZD4694 PET imaging. J. Nucl. Med. 2021;62:247&#x2013;252. doi: 10.2967/jnumed.120.245209.</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.120.245209</ArticleId><ArticleId IdType="pubmed">32737243</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, et al. Longitudinal tau PET in ageing and Alzheimer&#x2019;s disease. Brain. 2018;141:1517&#x2013;1528. doi: 10.1093/brain/awy059.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awy059</ArticleId><ArticleId IdType="pmc">PMC5917767</ArticleId><ArticleId IdType="pubmed">29538647</ArticleId></ArticleIdList></Reference><Reference><Citation>Diedrichsen J, et al. A probabilistic MR atlas of the human cerebellum. Neuroimage. 2009;46:39&#x2013;46. doi: 10.1016/j.neuroimage.2009.01.045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2009.01.045</ArticleId><ArticleId IdType="pubmed">19457380</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, et al. Defining imaging biomarker cut points for brain aging and Alzheimer&#x2019;s disease. Alzheimers Dement. 2017;13:205&#x2013;216. doi: 10.1016/j.jalz.2016.08.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2016.08.005</ArticleId><ArticleId IdType="pmc">PMC5344738</ArticleId><ArticleId IdType="pubmed">27697430</ArticleId></ArticleIdList></Reference><Reference><Citation>Tward DJ. Entorhinal and transentorhinal atrophy in mild cognitive impairment using longitudinal diffeomorphometry. Alzheimers Dement. 2017;9:41&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5608074</ArticleId><ArticleId IdType="pubmed">28971142</ArticleId></ArticleIdList></Reference><Reference><Citation>Insausti R, et al. MR volumetric analysis of the human entorhinal, perirhinal, and temporopolar cortices. Am. J. Neuroradiol. 1998;19:659&#x2013;671.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8337393</ArticleId><ArticleId IdType="pubmed">9576651</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor KI, Probst A. Anatomic localization of the transentorhinal region of the perirhinal cortex. Neurobiol. Aging. 2008;29:1591&#x2013;1596. doi: 10.1016/j.neurobiolaging.2007.03.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2007.03.024</ArticleId><ArticleId IdType="pubmed">17478012</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. On areas of transition between entorhinal allocortex and temporal isocortex in the human brain. Normal morphology and lamina-specific pathology in Alzheimer&#x2019;s disease. Acta Neuropathol. 1985;68:325&#x2013;332. doi: 10.1007/BF00690836.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00690836</ArticleId><ArticleId IdType="pubmed">4090943</ArticleId></ArticleIdList></Reference><Reference><Citation>Pascoal TA, et al. Microglial activation and tau propagate jointly across Braak stages. Nat. Med. 2021;27:1592&#x2013;1599. doi: 10.1038/s41591-021-01456-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01456-w</ArticleId><ArticleId IdType="pubmed">34446931</ArticleId></ArticleIdList></Reference><Reference><Citation>Desikan RS, et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage. 2006;31:968&#x2013;980. doi: 10.1016/j.neuroimage.2006.01.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2006.01.021</ArticleId><ArticleId IdType="pubmed">16530430</ArticleId></ArticleIdList></Reference><Reference><Citation>Lantero&#x2010;Rodriguez J. P&#x2010;tau235: a novel biomarker for staging preclinical Alzheimer&#x2019;s disease. EMBO Mol. Med. 2021;13:e15098. doi: 10.15252/emmm.202115098.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.202115098</ArticleId><ArticleId IdType="pmc">PMC8649868</ArticleId><ArticleId IdType="pubmed">34725927</ArticleId></ArticleIdList></Reference><Reference><Citation>Leit&#xe3;o MJ, et al. Clinical validation of the Lumipulse G cerebrospinal fluid assays for routine diagnosis of Alzheimer&#x2019;s disease. Alzheimer&#x2019;s Res. Ther. 2019;11:1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6875031</ArticleId><ArticleId IdType="pubmed">31759396</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson O, Lehmann S, Otto M, Zetterberg H, Lewczuk P. Advantages and disadvantages of the use of the CSF amyloid &#x3b2; (A&#x3b2;) 42/40 ratio in the diagnosis of Alzheimer&#x2019;s Disease. Alzheimer&#x2019;s Res. Ther. 2019;11:1&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6477717</ArticleId><ArticleId IdType="pubmed">31010420</ArticleId></ArticleIdList></Reference><Reference><Citation>Karikari TK, et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer&#x2019;s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 2020;19:422&#x2013;433. doi: 10.1016/S1474-4422(20)30071-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(20)30071-5</ArticleId><ArticleId IdType="pubmed">32333900</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashton NJ, et al. Plasma p-tau231: a new biomarker for incipient Alzheimer&#x2019;s disease pathology. Acta Neuropathol. 2021;141:709&#x2013;724. doi: 10.1007/s00401-021-02275-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-021-02275-6</ArticleId><ArticleId IdType="pmc">PMC8043944</ArticleId><ArticleId IdType="pubmed">33585983</ArticleId></ArticleIdList></Reference><Reference><Citation>Benedet AL, et al. Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer&#x2019;s disease. Brain. 2020;143:3793&#x2013;3804. doi: 10.1093/brain/awaa342.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa342</ArticleId><ArticleId IdType="pmc">PMC7805809</ArticleId><ArticleId IdType="pubmed">33210117</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunnett CW. A multiple comparison procedure for comparing several treatments with a control. J. Am. Stat. Assoc. 1955;272:1096&#x2013;1121. doi: 10.1080/01621459.1955.10501294.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/01621459.1955.10501294</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35508140</PMID><DateCompleted><Year>2022</Year><Month>05</Month><Day>06</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2211-1247</ISSN><JournalIssue CitedMedium="Internet"><Volume>39</Volume><Issue>5</Issue><PubDate><Year>2022</Year><Month>May</Month><Day>03</Day></PubDate></JournalIssue><Title>Cell reports</Title><ISOAbbreviation>Cell Rep</ISOAbbreviation></Journal><ArticleTitle>Cholesterol determines the cytosolic entry and seeded aggregation of tau.</ArticleTitle><Pagination><StartPage>110776</StartPage><MedlinePgn>110776</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">110776</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.celrep.2022.110776</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2211-1247(22)00540-X</ELocationID><Abstract><AbstractText>Assemblies of tau can transit between neurons, seeding aggregation in a prion-like manner. To accomplish this, tau must cross cell-limiting membranes, a process that is poorly understood. Here, we establish assays for the study of tau entry into the cytosol as a phenomenon distinct from uptake, in real time, and at physiological concentrations. The entry pathway of tau is cell type specific and, in neurons, highly sensitive to cholesterol. Depletion of the cholesterol transporter Niemann-Pick type C1 or extraction of membrane cholesterol renders neurons highly permissive to tau entry and potentiates seeding even at low levels of exogenous tau assemblies. Conversely, cholesterol supplementation reduces entry and almost completely blocks seeded aggregation. Our findings establish entry as a rate-limiting step to seeded aggregation and demonstrate that dysregulated cholesterol, a feature of several neurodegenerative diseases, potentiates tau aggregation by promoting entry of tau assemblies into the cell interior.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tuck</LastName><ForeName>Benjamin J</ForeName><Initials>BJ</Initials><AffiliationInfo><Affiliation>UK Dementia Research Institute at the University of Cambridge, Department of Clinical Neurosciences, Hills Road, Cambridge, CB2 0AH, UK. Electronic address: bjt44@cam.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Lauren V C</ForeName><Initials>LVC</Initials><AffiliationInfo><Affiliation>UK Dementia Research Institute at the University of Cambridge, Department of Clinical Neurosciences, Hills Road, Cambridge, CB2 0AH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katsinelos</LastName><ForeName>Taxiarchis</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>UK Dementia Research Institute at the University of Cambridge, Department of Clinical Neurosciences, Hills Road, Cambridge, CB2 0AH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Annabel E</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>UK Dementia Research Institute at the University of Cambridge, Department of Clinical Neurosciences, Hills Road, Cambridge, CB2 0AH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilson</LastName><ForeName>Emma L</ForeName><Initials>EL</Initials><AffiliationInfo><Affiliation>UK Dementia Research Institute at the University of Cambridge, Department of Clinical Neurosciences, Hills Road, Cambridge, CB2 0AH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keeling</LastName><ForeName>Sophie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>UK Dementia Research Institute at the University of Cambridge, Department of Clinical Neurosciences, Hills Road, Cambridge, CB2 0AH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Shi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>UK Dementia Research Institute at the University of Cambridge, Department of Clinical Neurosciences, Hills Road, Cambridge, CB2 0AH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vaysburd</LastName><ForeName>Marina J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>MRC Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge, CB2 0QH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knox</LastName><ForeName>Claire</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>MRC Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge, CB2 0QH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tredgett</LastName><ForeName>Lucy</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>MRC Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge, CB2 0QH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Metzakopian</LastName><ForeName>Emmanouil</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>UK Dementia Research Institute at the University of Cambridge, Department of Clinical Neurosciences, Hills Road, Cambridge, CB2 0AH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>James</LastName><ForeName>Leo C</ForeName><Initials>LC</Initials><AffiliationInfo><Affiliation>MRC Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge, CB2 0QH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McEwan</LastName><ForeName>William A</ForeName><Initials>WA</Initials><AffiliationInfo><Affiliation>UK Dementia Research Institute at the University of Cambridge, Department of Clinical Neurosciences, Hills Road, Cambridge, CB2 0AH, UK. Electronic address: wm305@cam.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_U105181010</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_U105184326</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>206248/Z/17/Z</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Rep</MedlineTA><NlmUniqueID>101573691</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011328">Prions</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>97C5T2UQ7J</RegistryNumber><NameOfSubstance UI="D002784">Cholesterol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2022 Jul;18(7):381. doi: 10.1038/s41582-022-00685-y.</RefSource><PMID Version="1">35676369</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002784" MajorTopicYN="N">Cholesterol</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003600" MajorTopicYN="N">Cytosol</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011328" MajorTopicYN="Y">Prions</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">CP: Metabolism</Keyword><Keyword MajorTopicYN="N">CP: Neuroscience</Keyword><Keyword MajorTopicYN="N">Niemann-Pick disease</Keyword><Keyword MajorTopicYN="N">cholesterol</Keyword><Keyword MajorTopicYN="N">endocytosis</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">seeded aggregation</Keyword><Keyword MajorTopicYN="N">tau</Keyword></KeywordList><CoiStatement>Declaration of interests The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>9</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>3</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>4</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>4</Day><Hour>18</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>5</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35508140</ArticleId><ArticleId IdType="pmc">PMC9108550</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2022.110776</ArticleId><ArticleId IdType="pii">S2211-1247(22)00540-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ait-Bouziad N., Lv G., Mahul-Mellier A.-L., Xiao S., Zorludemir G., Eliezer D., Walz T., Lashuel H.A. Discovery and characterization of stable and toxic Tau/phospholipid oligomeric complexes. Nat. Commun. 2017;8:1678. doi: 10.1038/s41467-017-01575-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-01575-4</ArticleId><ArticleId IdType="pmc">PMC5698329</ArticleId><ArticleId IdType="pubmed">29162800</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen B., Ingram E., Takao M., Smith M.J., Jakes R., Virdee K., Yoshida H., Holzer M., Craxton M., Emson P.C., et al. Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J.&#xa0;Neurosci. 2002;22:9340&#x2013;9351. doi: 10.1523/jneurosci.22-21-09340.2002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/jneurosci.22-21-09340.2002</ArticleId><ArticleId IdType="pmc">PMC6758022</ArticleId><ArticleId IdType="pubmed">12417659</ArticleId></ArticleIdList></Reference><Reference><Citation>Arenas F., Garcia-Ruiz C., Fernandez-Checa J.C. Intracellular cholesterol trafficking and impact in neurodegeneration. Front. Mol. Neurosci. 2017;10 doi: 10.3389/fnmol.2017.00382.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2017.00382</ArticleId><ArticleId IdType="pmc">PMC5698305</ArticleId><ArticleId IdType="pubmed">29204109</ArticleId></ArticleIdList></Reference><Reference><Citation>Beaudoin G.M.J., Lee S.H., Singh D., Yuan Y., Ng Y.G., Reichardt L.F., Arikkath J. Culturing pyramidal neurons from the early postnatal mouse hippocampus and cortex. Nat. Protoc. 2012;7:1741&#x2013;1754. doi: 10.1038/nprot.2012.099.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2012.099</ArticleId><ArticleId IdType="pubmed">22936216</ArticleId></ArticleIdList></Reference><Reference><Citation>Biswas A., Kashyap P., Datta S., Sengupta T., Sinha B. Cholesterol depletion by M&#x3b2;CD enhances cell membrane tension and its variations-reducing integrity. Biophys. J. 2019;116:1456&#x2013;1468. doi: 10.1016/j.bpj.2019.03.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bpj.2019.03.016</ArticleId><ArticleId IdType="pmc">PMC6486507</ArticleId><ArticleId IdType="pubmed">30979551</ArticleId></ArticleIdList></Reference><Reference><Citation>Bj&#xf6;rkhem I., Patra K., Boxer A.L., Svenningsson P. 24S-Hydroxycholesterol correlates with tau and is increased in cerebrospinal fluid in Parkinson&#x2019;s disease and corticobasal syndrome. Front. Neurol. 2018;9:756. doi: 10.3389/fneur.2018.00756.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2018.00756</ArticleId><ArticleId IdType="pmc">PMC6137204</ArticleId><ArticleId IdType="pubmed">30245667</ArticleId></ArticleIdList></Reference><Reference><Citation>Calafate S., Buist A., Miskiewicz K., Vijayan V., Daneels G., de Strooper B., de Wit J., Verstreken P., Moechars D. Synaptic contacts enhance cell-to-cell tau pathology propagation. Cell Rep. 2015;11:1176&#x2013;1183. doi: 10.1016/j.celrep.2015.04.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2015.04.043</ArticleId><ArticleId IdType="pubmed">25981034</ArticleId></ArticleIdList></Reference><Reference><Citation>Calafate S., Flavin W., Verstreken P., Moechars D. Loss of Bin1 promotes the propagation of tau pathology. Cell Rep. 2016;17:931&#x2013;940. doi: 10.1016/J.CELREP.2016.09.063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.CELREP.2016.09.063</ArticleId><ArticleId IdType="pubmed">27760323</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J.J., Nathaniel D.L., Raghavan P., Nelson M., Tian R., Tse E., Hong J.Y., See S.K., Mok S.-A., Hein M.Y., et al. Compromised function of the ESCRT pathway promotes endolysosomal escape of tau seeds and propagation of tau aggregation. J.&#xa0;Biol. Chem. 2019;294:18952&#x2013;18966. doi: 10.1074/jbc.RA119.009432.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.RA119.009432</ArticleId><ArticleId IdType="pmc">PMC6916486</ArticleId><ArticleId IdType="pubmed">31578281</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng S., Tereshchenko J., Zimmer V., Vachey G., Pythoud C., Rey M., Liefhebber J., Raina A., Streit F., Mazur A., et al. Therapeutic efficacy of regulable GDNF expression for Huntington&#x2019;s and Parkinson&#x2019;s disease by a high-induction, background-free &#x201c;GeneSwitch&#x201d; vector. Exp. Neurol. 2018;309:79&#x2013;90. doi: 10.1016/j.expneurol.2018.07.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2018.07.017</ArticleId><ArticleId IdType="pubmed">30076831</ArticleId></ArticleIdList></Reference><Reference><Citation>Clavaguera F., Bolmont T., Crowther R.A., Abramowski D., Frank S., Probst A., Fraser G., Stalder A.K., Beibel M., Staufenbiel M., et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat. Cell Biol. 2009;11:909&#x2013;913. doi: 10.1038/ncb1901.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncb1901</ArticleId><ArticleId IdType="pmc">PMC2726961</ArticleId><ArticleId IdType="pubmed">19503072</ArticleId></ArticleIdList></Reference><Reference><Citation>Clavaguera F., Akatsu H., Fraser G., Crowther R.A., Frank S., Hench J., Probst A., Winkler D.T., Reichwald J., Staufenbiel M., et al. Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Proc. Natl. Acad. Sci. U&#xa0;S&#xa0;A. 2013;110:9535&#x2013;9540. doi: 10.1073/pnas.1301175110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1301175110</ArticleId><ArticleId IdType="pmc">PMC3677441</ArticleId><ArticleId IdType="pubmed">23690619</ArticleId></ArticleIdList></Reference><Reference><Citation>Clift D., McEwan W.A., Labzin L.I., Konieczny V., Mogessie B., James L.C., Schuh M. A method for the acute and rapid degradation of endogenous proteins. Cell. 2017;171:1692&#x2013;1706.e18. doi: 10.1016/j.cell.2017.10.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.10.033</ArticleId><ArticleId IdType="pmc">PMC5733393</ArticleId><ArticleId IdType="pubmed">29153837</ArticleId></ArticleIdList></Reference><Reference><Citation>Croft C.L., Futch H.S., Moore B.D., Golde T.E. Organotypic brain slice cultures to model neurodegenerative proteinopathies. Mol. Neurodegener. 2019;14:45. doi: 10.1186/s13024-019-0346-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-019-0346-0</ArticleId><ArticleId IdType="pmc">PMC6889333</ArticleId><ArticleId IdType="pubmed">31791377</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai L., Zou L., Meng L., Qiang G., Yan M., Zhang Z. Cholesterol metabolism in neurodegenerative diseases: molecular mechanisms and therapeutic targets. Mol. Neurobiol. 2021;58:2183&#x2013;2201. doi: 10.1007/s12035-020-02232-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-020-02232-6</ArticleId><ArticleId IdType="pubmed">33411241</ArticleId></ArticleIdList></Reference><Reference><Citation>De La-Rocque S., Moretto E., Butnaru I., Schiavo G. Knockin&#x2019; on heaven&#x2019;s door: molecular mechanisms of neuronal tau uptake. J.&#xa0;Neurochem. 2021;156:563&#x2013;588. doi: 10.1111/jnc.15144.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.15144</ArticleId><ArticleId IdType="pmc">PMC8432157</ArticleId><ArticleId IdType="pubmed">32770783</ArticleId></ArticleIdList></Reference><Reference><Citation>Dixon A.S., Schwinn M.K., Hall M.P., Zimmerman K., Otto P., Lubben T.H., Butler B.L., Binkowski B.F., MacHleidt T., Kirkland T.A., et al. NanoLuc complementation reporter optimized for accurate measurement of protein interactions in cells. ACS Chem. Biol. 2016;11:400&#x2013;408. doi: 10.1021/acschembio.5b00753.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschembio.5b00753</ArticleId><ArticleId IdType="pubmed">26569370</ArticleId></ArticleIdList></Reference><Reference><Citation>Dopico A.M., Tigyi G.J. A glance at the structural and functional diversity of membrane lipids. Methods Mol. Biol. 2007;400:1&#x2013;14. doi: 10.1007/978-1-59745-519-0_1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-59745-519-0_1</ArticleId><ArticleId IdType="pubmed">17951723</ArticleId></ArticleIdList></Reference><Reference><Citation>Egawa J., Pearn M.L., Lemkuil B.P., Patel P.M., Head B.P. Membrane lipid rafts and neurobiology: age-related changes in membrane lipids and loss of neuronal function. J.&#xa0;Physiol. 2016;594:4565&#x2013;4579. doi: 10.1113/JP270590.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/JP270590</ArticleId><ArticleId IdType="pmc">PMC4983616</ArticleId><ArticleId IdType="pubmed">26332795</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans L.D., Wassmer T., Fraser G., Smith J., Perkinton M., Billinton A., Livesey F.J. Extracellular monomeric and aggregated tau efficiently enter human neurons through overlapping but distinct pathways. Cell Rep. 2018;22:3612&#x2013;3624. doi: 10.1016/j.celrep.2018.03.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2018.03.021</ArticleId><ArticleId IdType="pmc">PMC5896171</ArticleId><ArticleId IdType="pubmed">29590627</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans L.D., Strano A., Campbell A., Karakoc E., Iorio F., Bassett A.R., Livesey F.J. Whole genome CRISPR screens identify LRRK2-regulated endocytosis as a major mechanism for extracellular tau uptake by human neurons. bioRxiv. 2020 doi: 10.1101/2020.08.11.246363. Preprint at. 2020.08.11.246363.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.08.11.246363</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcon B., Cavallini A., Angers R., Glover S., Murray T.K., Barnham L., Jackson S., O M.J., Isaacs A.M., Hutton M.L., et al. Conformation determines the seeding potencies of native and recombinant Tau aggregates. 2014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M114.589309</ArticleId><ArticleId IdType="pmc">PMC4294473</ArticleId><ArticleId IdType="pubmed">25406315</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcon B., Noad J., McMahon H., Randow F., Goedert M. Galectin-8-mediated selective autophagy protects against seeded tau aggregation. J.&#xa0;Biol. Chem. 2018;293:2438&#x2013;2451. doi: 10.1074/jbc.M117.809293.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M117.809293</ArticleId><ArticleId IdType="pmc">PMC5818177</ArticleId><ArticleId IdType="pubmed">29282296</ArticleId></ArticleIdList></Reference><Reference><Citation>Flavin W.P., Bousset L., Green Z.C., Chu Y., Skarpathiotis S., Chaney M.J., Kordower J.H., Melki R., Campbell E.M. Endocytic vesicle rupture is a conserved mechanism of cellular invasion by amyloid proteins. Acta Neuropathol. 2017;134:629&#x2013;653. doi: 10.1007/s00401-017-1722-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-017-1722-x</ArticleId><ArticleId IdType="pubmed">28527044</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost B., Jacks R.L., Diamond M.I. Propagation of tau misfolding from the outside to the inside of a cell. J.&#xa0;Biol. Chem. 2009;284:12845&#x2013;12852. doi: 10.1074/jbc.M808759200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M808759200</ArticleId><ArticleId IdType="pmc">PMC2676015</ArticleId><ArticleId IdType="pubmed">19282288</ArticleId></ArticleIdList></Reference><Reference><Citation>Garver W.S., Krishnan K., Gallagos J.R., Michikawa M., Francis G.A., Heidenreich R.A. Niemann-Pick C1 protein regulates cholesterol transport to the trans-Golgi network and plasma membrane caveolae. J.&#xa0;Lipid Res. 2002;43:579&#x2013;589. doi: 10.1016/s0022-2275(20)31487-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0022-2275(20)31487-5</ArticleId><ArticleId IdType="pubmed">11907140</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M., Spillantini M.G., Cairns N.J., Crowther R.A. Tau proteins of Alzheimer paired helical filaments: abnormal phosphorylation of all six brain isoforms. Neuron. 1992;8:159&#x2013;168. doi: 10.1016/0896-6273(92)90117-V.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0896-6273(92)90117-V</ArticleId><ArticleId IdType="pubmed">1530909</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M., Eisenberg D.S., Crowther R.A. Propagation of tau aggregates and neurodegeneration. Annu. Rev. Neurosci. 2017;40:189&#x2013;210. doi: 10.1146/annurev-neuro-072116-031153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-neuro-072116-031153</ArticleId><ArticleId IdType="pubmed">28772101</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M. Tau filaments in neurodegenerative diseases. FEBS Lett. 2018;592:2383&#x2013;2391. doi: 10.1002/1873-3468.13108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1873-3468.13108</ArticleId><ArticleId IdType="pubmed">29790176</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomes B., Gon&#xe7;alves S., Disalvo A., Hollmann A., Santos N.C. Effect of 25-hydroxycholesterol in viral membrane fusion: insights on HIV inhibition. Biochim. Biophys. Acta Biomembr. 2018;1860:1171&#x2013;1178. doi: 10.1016/j.bbamem.2018.02.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbamem.2018.02.001</ArticleId><ArticleId IdType="pubmed">29408450</ArticleId></ArticleIdList></Reference><Reference><Citation>Grabrucker A., Vaida B., Bockmann J., Boeckers T.M. Synaptogenesis of hippocampal neurons in primary cell culture. Cell Tissue Res. 2009;338:333&#x2013;341. doi: 10.1007/s00441-009-0881-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00441-009-0881-z</ArticleId><ArticleId IdType="pubmed">19885679</ArticleId></ArticleIdList></Reference><Reference><Citation>Grinstein S., Rotin D., Mason M.J. Na+/H+ exchange and growth factor-induced cytosolic pH changes. Role in cellular proliferation. Biochim. Biophys. Acta. 1989;988:73&#x2013;97. doi: 10.1016/0304-4157(89)90004-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0304-4157(89)90004-x</ArticleId><ArticleId IdType="pubmed">2535787</ArticleId></ArticleIdList></Reference><Reference><Citation>Guill&#xe9;n-Samander A., Leonzino M., Hanna M.G., IV. Tang N., Shen H., De Camilli P. VPS13D bridges the ER to mitochondria and peroxisomes via Miro. J.&#xa0;Cell Biol. 2021;220:e202010004. doi: 10.1083/jcb.202010004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.202010004</ArticleId><ArticleId IdType="pmc">PMC8077184</ArticleId><ArticleId IdType="pubmed">33891013</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo J.L., Narasimhan S., Changolkar L., He Z., Stieber A., Zhang B., Gathagan R.J., Iba M., McBride J.D., Trojanowski J.Q., Lee V.M. Unique pathological tau conformers from Alzheimer&#x2019;s brains transmit tau pathology in nontransgenic mice. J.&#xa0;Exp. Med. 2016;213:2635&#x2013;2654. doi: 10.1084/jem.20160833.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20160833</ArticleId><ArticleId IdType="pmc">PMC5110027</ArticleId><ArticleId IdType="pubmed">27810929</ArticleId></ArticleIdList></Reference><Reference><Citation>Harold D., Abraham R., Hollingworth P., Sims R., Gerrish A., Hamshere M.L., Pahwa J.S., Moskvina V., Dowzell K., Williams A., et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer&#x2019;s disease. Nat. Genet. 2009;41:1088&#x2013;1093. doi: 10.1038/ng.440.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.440</ArticleId><ArticleId IdType="pmc">PMC2845877</ArticleId><ArticleId IdType="pubmed">19734902</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes B.B., DeVos S.L., Kfoury N., Li M., Jacks R., Yanamandra K., Ouidja M.O., Brodsky F.M., Marasa J., Bagchi D.P., et al. Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds. Proc. Natl. Acad. Sci. U&#xa0;S&#xa0;A. 2013;110:E3138&#x2013;E3147. doi: 10.1073/pnas.1301440110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1301440110</ArticleId><ArticleId IdType="pmc">PMC3746848</ArticleId><ArticleId IdType="pubmed">23898162</ArticleId></ArticleIdList></Reference><Reference><Citation>Iba M., Guo J.L., McBride J.D., Zhang B., Trojanowski J.Q., Lee V.M.-Y. Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer&#x2019;s-like tauopathy. J.&#xa0;Neurosci. 2013;33:1024&#x2013;1037. doi: 10.1523/JNEUROSCI.2642-12.2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2642-12.2013</ArticleId><ArticleId IdType="pmc">PMC3575082</ArticleId><ArticleId IdType="pubmed">23325240</ArticleId></ArticleIdList></Reference><Reference><Citation>Ilangumaran S., Hoessli D.C. Effects of cholesterol depletion by cyclodextrin on the sphingolipid microdomains of the plasma membrane. Biochem. J. 1998;335:433&#x2013;440. doi: 10.1042/bj3350433.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/bj3350433</ArticleId><ArticleId IdType="pmc">PMC1219799</ArticleId><ArticleId IdType="pubmed">9761744</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsinelos T., Zeitler M., Dimou E., Ruiz De Almodovar C., Nickel W., Correspondence T.R.J., Karakatsani A., M&#xfc;ller H.-M., Nachman E., Steringer J.P., et al. Unconventional secretion mediates the trans-cellular spreading of tau. Cell Rep. 2018;23:2039&#x2013;2055. doi: 10.1016/j.celrep.2018.04.056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2018.04.056</ArticleId><ArticleId IdType="pubmed">29768203</ArticleId></ArticleIdList></Reference><Reference><Citation>Kfoury N., Holmes B.B., Jiang H., Holtzman D.M., Diamond M.I. Trans-cellular propagation of Tau aggregation by fibrillar species. J.&#xa0;Biol. Chem. 2012;287:19440&#x2013;19451. doi: 10.1074/jbc.M112.346072.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.346072</ArticleId><ArticleId IdType="pmc">PMC3365982</ArticleId><ArticleId IdType="pubmed">22461630</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolay S., Vega A.R., Dodd D.A., Perez V.A., Kashmer O.M., White C.L., Diamond M.I. Dual fates of exogenous tau seeds: lysosomal clearance vs. cytoplasmic amplification. bioRxiv. 2022 doi: 10.1101/2022.01.03.474802. Preprint at. 01.03.474802.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.01.03.474802</ArticleId><ArticleId IdType="pmc">PMC9163595</ArticleId><ArticleId IdType="pubmed">35525272</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert J.-C., Heath S., Even G., Campion D., Sleegers K., Hiltunen M., Combarros O., Zelenika D., Bullido M.J., Tavernier B., et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer&#x2019;s disease. Nat. Genet. 2009;41:1094&#x2013;1099. doi: 10.1038/ng.439.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.439</ArticleId><ArticleId IdType="pubmed">19734903</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L., Drouet V., Wu J.W., Witter M.P., Small S.A., Clelland C., Duff K. Trans-synaptic spread of tau pathology in&#xa0;vivo. PLoS One. 2012;7:e31302. doi: 10.1371/journal.pone.0031302.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0031302</ArticleId><ArticleId IdType="pmc">PMC3270029</ArticleId><ArticleId IdType="pubmed">22312444</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C.-C., Kanekiyo T., Xu H., Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms, and therapy. Nat. Rev. Neurol. 2013;9:106&#x2013;118. doi: 10.1038/nrneurol.2012.263.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2012.263</ArticleId><ArticleId IdType="pmc">PMC3726719</ArticleId><ArticleId IdType="pubmed">23296339</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y., Wei Z., Ma X., Yang X., Chen Y., Sun L., Ma C., Miao Q.R., Hajjar D.P., Han J., Duan Y. 25-Hydroxycholesterol activates the expression of cholesterol 25-hydroxylase in an LXR-dependent mechanism. J.&#xa0;Lipid Res. 2018;59:439&#x2013;451. doi: 10.1194/jlr.M080440.</Citation><ArticleIdList><ArticleId IdType="doi">10.1194/jlr.M080440</ArticleId><ArticleId IdType="pmc">PMC5832929</ArticleId><ArticleId IdType="pubmed">29298812</ArticleId></ArticleIdList></Reference><Reference><Citation>Love S., Bridges L.R., Case C.P. Neurofibrillary tangles in Niemann-Pick disease type C. Brain. 1995;118:119&#x2013;129. doi: 10.1093/brain/118.1.119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/118.1.119</ArticleId><ArticleId IdType="pubmed">7894998</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;n-Segura A., Ahmed T., Casadom&#xe9;-Perales &#xc1;., Palomares-Perez I., Palomer E., Kerstens A., Munck S., Balschun D., Dotti C.G. Age-associated cholesterol reduction triggers brain insulin resistance by facilitating ligand-independent receptor activation and pathway desensitization. Aging Cell. 2019;18:e12932. doi: 10.1111/acel.12932.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/acel.12932</ArticleId><ArticleId IdType="pmc">PMC6516156</ArticleId><ArticleId IdType="pubmed">30884121</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayor S., Parton R.G., Donaldson J.G. Clathrin-independent pathways of endocytosis. Cold Spring Harb. Perspect. Biol. 2014;6:a016758. doi: 10.1101/cshperspect.a016758.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a016758</ArticleId><ArticleId IdType="pmc">PMC4031960</ArticleId><ArticleId IdType="pubmed">24890511</ArticleId></ArticleIdList></Reference><Reference><Citation>McEwan W.A., Falcon B., Vaysburd M., Clift D., Oblak A.L., Ghetti B., Goedert M., James L.C. Cytosolic Fc receptor TRIM21 inhibits seeded tau aggregation. Proc. Natl. Acad. Sci. U&#xa0;S&#xa0;A. 2017;114:574&#x2013;579. doi: 10.1073/PNAS.1607215114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/PNAS.1607215114</ArticleId><ArticleId IdType="pmc">PMC5255578</ArticleId><ArticleId IdType="pubmed">28049840</ArticleId></ArticleIdList></Reference><Reference><Citation>Millard E.E., Srivastava K., Traub L.M., Schaffer J.E., Ory D.S. Niemann-pick type C1 (NPC1) overexpression alters cellular cholesterol homeostasis. J.&#xa0;Biol. Chem. 2000;275:38445&#x2013;38451. doi: 10.1074/jbc.M003180200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M003180200</ArticleId><ArticleId IdType="pubmed">10964915</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller L.V.C., Mukadam A.S., Durrant C.S., Vaysburd M.J., Katsinelos T., Tuck B.J., Sanford S., Sheppard O., Knox C., Cheng S., et al. Tau assemblies do not behave like independently acting prion-like particles in mouse neural tissue. Acta Neuropathol. Commun. 2021;9:41. doi: 10.1186/s40478-021-01141-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-021-01141-6</ArticleId><ArticleId IdType="pmc">PMC7953780</ArticleId><ArticleId IdType="pubmed">33712082</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirbaha H., Holmes B.B., Sanders D.W., Bieschke J., Diamond M.I. Tau trimers are the minimal propagation unit spontaneously internalized to seed intracellular aggregation. J.&#xa0;Biol. Chem. 2015;290:14893&#x2013;14903. doi: 10.1074/jbc.M115.652693.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M115.652693</ArticleId><ArticleId IdType="pmc">PMC4463437</ArticleId><ArticleId IdType="pubmed">25887395</ArticleId></ArticleIdList></Reference><Reference><Citation>Mudher A., Colin M., Dujardin S., Medina M., Dewachter I., Alavi Naini S.M., Mandelkow E.-M., Mandelkow E., Bu&#xe9;e L., Goedert M., Brion J.P. What is the evidence that tau pathology spreads through prion-like propagation? Acta Neuropathol. Commun. 2017;5:99. doi: 10.1186/s40478-017-0488-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-017-0488-7</ArticleId><ArticleId IdType="pmc">PMC5735872</ArticleId><ArticleId IdType="pubmed">29258615</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon R.A. Amyloid precursor protein and endosomal-lysosomal dysfunction in Alzheimer&#x2019;s disease: inseparable partners in a multifactorial disease. FASEB J. 2017;31:2729&#x2013;2743. doi: 10.1096/fj.201700359.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.201700359</ArticleId><ArticleId IdType="pmc">PMC6137496</ArticleId><ArticleId IdType="pubmed">28663518</ArticleId></ArticleIdList></Reference><Reference><Citation>Notkola I.L., Sulkava R., Pekkanen J., Erkinjuntti T., Ehnholm C., Kivinen P., Tuomilehto J., Nissinen A. Serum Total Cholesterol, Apolipoprotein E {FC12}e4 Allele, and Alzheimer&#x2019;s Disease. Neuroepidemiology. 1998;17:14&#x2013;20. doi: 10.1159/000026149.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000026149</ArticleId><ArticleId IdType="pubmed">9549720</ArticleId></ArticleIdList></Reference><Reference><Citation>Palomer E., Mart&#xed;n-Segura A., Baliyan S., Ahmed T., Balschun D., Venero C., Martin M.G., Dotti C.G. Aging triggers a repressive chromatin state at bdnf promoters in hippocampal neurons. Cell Rep. 2016;16:2889&#x2013;2900. doi: 10.1016/j.celrep.2016.08.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2016.08.028</ArticleId><ArticleId IdType="pubmed">27626660</ArticleId></ArticleIdList></Reference><Reference><Citation>Papassotiropoulos A., L&#xfc;tjohann D., Bagli M., Locatelli S., Jessen F., Buschfort R., Ptok U., Bj&#xf6;rkhem I., von Bergmann K., Heun R. 24S-hydroxycholesterol in cerebrospinal fluid is elevated in early stages of dementia. J.&#xa0;Psychiatr. Res. 2002;36:27&#x2013;32. doi: 10.1016/s0022-3956(01)00050-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0022-3956(01)00050-4</ArticleId><ArticleId IdType="pubmed">11755458</ArticleId></ArticleIdList></Reference><Reference><Citation>Park W.D., O&#x2019;Brien J.F., Lundquist P.A., Kraft D.L., Vockley C.W., Karnes P.S., Patterson M.C., Snow K. Identification of 58 novel mutations in Niemann-Pick disease type C: correlation with biochemical phenotype and importance of PTC1-like domains in NPC1. Hum. Mutat. 2003;22:313&#x2013;325. doi: 10.1002/humu.10255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.10255</ArticleId><ArticleId IdType="pubmed">12955717</ArticleId></ArticleIdList></Reference><Reference><Citation>Pawlowski M., Ortmann D., Bertero A., Tavares J.M., Pedersen R.A., Vallier L., Kotter M.R.N. Inducible and deterministic forward programming of human pluripotent stem cells into neurons, skeletal myocytes, and oligodendrocytes. Stem Cell Rep. 2017;8:803&#x2013;812. doi: 10.1016/j.stemcr.2017.02.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2017.02.016</ArticleId><ArticleId IdType="pmc">PMC5390118</ArticleId><ArticleId IdType="pubmed">28344001</ArticleId></ArticleIdList></Reference><Reference><Citation>Polanco J.C., G&#xf6;tz J. Exosomal and vesicle-free tau seeds - propagation and convergence in endolysosomal permeabilization. FEBS J. 2021 doi: 10.1111/febs.16055. Published online June 6, 2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/febs.16055</ArticleId><ArticleId IdType="pubmed">34092031</ArticleId></ArticleIdList></Reference><Reference><Citation>Rauch J.N., Chen J.J., Sorum A.W., Miller G.M., Sharf T., See S.K., Hsieh-Wilson L.C., Kampmann M., Kosik K.S. Tau internalization is regulated by 6-O sulfation on heparan sulfate proteoglycans&#xa0;(HSPGs) Sci. Rep. 2018;8:6382. doi: 10.1038/s41598-018-24904-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-24904-z</ArticleId><ArticleId IdType="pmc">PMC5913225</ArticleId><ArticleId IdType="pubmed">29686391</ArticleId></ArticleIdList></Reference><Reference><Citation>Rauch J.N., Luna G., Guzman E., Audouard M., Challis C., Sibih Y.E., Leshuk C., Hernandez I., Wegmann S., Hyman B.T., et al. LRP1 is a master regulator of tau uptake and spread. Nature. 2020;580:381&#x2013;385. doi: 10.1038/s41586-020-2156-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2156-5</ArticleId><ArticleId IdType="pmc">PMC7687380</ArticleId><ArticleId IdType="pubmed">32296178</ArticleId></ArticleIdList></Reference><Reference><Citation>William Rebeck G., Reiter J.S., Strickland D.K., Hyman B.T. Apolipoprotein E in sporadic Alzheimer&#x2019;s disease: allelic variation and receptor interactions. Neuron. 1993;11:575&#x2013;580. doi: 10.1016/0896-6273(93)90070-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0896-6273(93)90070-8</ArticleId><ArticleId IdType="pubmed">8398148</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders D.W., Kaufman S.K., DeVos S.L., Sharma A.M., Mirbaha H., Li A., Barker S.J., Foley A.C., Thorpe J.R., Serpell L.C., et al. Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron. 2014;82:1271&#x2013;1288. doi: 10.1016/j.neuron.2014.04.047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.04.047</ArticleId><ArticleId IdType="pmc">PMC4171396</ArticleId><ArticleId IdType="pubmed">24857020</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindelin J., Arganda-Carreras I., Frise E., Kaynig V., Longair M., Pietzsch T., Preibisch S., Rueden C., Saalfeld S., Schmid B., et al. Fiji: an open-source platform for biological-image analysis. Nat. Methods. 2012;9:676&#x2013;682. doi: 10.1038/nmeth.2019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.2019</ArticleId><ArticleId IdType="pmc">PMC3855844</ArticleId><ArticleId IdType="pubmed">22743772</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y., Yamada K., Liddelow S.A., Smith S.T., Zhao L., Luo W., Tsai R.M., Spina S., Grinberg L.T., Rojas J.C., et al. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature. 2017;549:523&#x2013;527. doi: 10.1038/nature24016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature24016</ArticleId><ArticleId IdType="pmc">PMC5641217</ArticleId><ArticleId IdType="pubmed">28959956</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y., Manis M., Long J., Wang K., Sullivan P.M., Remolina Serrano J., Hoyle R., Holtzman D.M. Microglia drive APOE-dependent neurodegeneration in a tauopathy mouse model. J.&#xa0;Exp. Med. 2019;216:2546&#x2013;2561. doi: 10.1084/jem.20190980.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20190980</ArticleId><ArticleId IdType="pmc">PMC6829593</ArticleId><ArticleId IdType="pubmed">31601677</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrivastava A.N., Redeker V., Pieri L., Bousset L., Renner M., Madiona K., Mailhes-Hamon C., Coens A., Bu&#xe9;e L., Hantraye P., et al. Clustering of Tau fibrils impairs the synaptic composition of &#x3b1;3-Na+/K+-ATPase and AMPA receptors. EMBO J. 2019;38:e99871. doi: 10.15252/embj.201899871.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.201899871</ArticleId><ArticleId IdType="pmc">PMC6356061</ArticleId><ArticleId IdType="pubmed">30630857</ArticleId></ArticleIdList></Reference><Reference><Citation>Soares A.C., Ferreira A., Mari&#xeb;n J., Delay C., Lee E., Trojanowski J.Q., Moechars D., Annaert W., De Muynck L. PIKfyve activity is required for lysosomal trafficking of tau aggregates and tau seeding. J.&#xa0;Biol. Chem. 2021;296:100636. doi: 10.1016/j.jbc.2021.100636.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbc.2021.100636</ArticleId><ArticleId IdType="pmc">PMC8134070</ArticleId><ArticleId IdType="pubmed">33831417</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki K., Bose P., Leong-Quong R.Y., Fujita D.J., Riabowol K. REAP: a two minute cell fractionation method. BMC Res. Notes. 2010;3:294. doi: 10.1186/1756-0500-3-294.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1756-0500-3-294</ArticleId><ArticleId IdType="pmc">PMC2993727</ArticleId><ArticleId IdType="pubmed">21067583</ArticleId></ArticleIdList></Reference><Reference><Citation>Therriault J., Benedet A.L., Pascoal T.A., Mathotaarachchi S., Chamoun M., Savard M., Thomas E., Kang M.S., Lussier F., Tissot C., et al. Association of apolipoprotein E &#x3b5;4 with medial temporal tau independent of amyloid-&#x3b2;. JAMA Neurol. 2020;77:470&#x2013;479. doi: 10.1001/jamaneurol.2019.4421.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2019.4421</ArticleId><ArticleId IdType="pmc">PMC6990684</ArticleId><ArticleId IdType="pubmed">31860000</ArticleId></ArticleIdList></Reference><Reference><Citation>Vagnozzi A.N., Li J.-G., Chiu J., Razmpour R., Warfield R., Ramirez S.H., Pratic&#xf2; D. VPS35 regulates tau phosphorylation and neuropathology in tauopathy. Mol. Psychiatry. 2019;26:6992&#x2013;7005. doi: 10.1038/s41380-019-0453-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-019-0453-x</ArticleId><ArticleId IdType="pmc">PMC6949432</ArticleId><ArticleId IdType="pubmed">31289348</ArticleId></ArticleIdList></Reference><Reference><Citation>Valenza M., Cattaneo E. Cholesterol dysfunction in neurodegenerative diseases: is Huntington&#x2019;s disease in the list? Prog. Neurobiol. 2006;80:165&#x2013;176. doi: 10.1016/j.pneurobio.2006.09.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pneurobio.2006.09.005</ArticleId><ArticleId IdType="pubmed">17067733</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Kant R., Langness V.F., Herrera C.M., Williams D.A., Fong L.K., Leestemaker Y., Steenvoorden E., Rynearson K.D., Brouwers J.F., Helms J.B., et al. Cholesterol metabolism is a druggable axis that independently regulates tau and amyloid-&#x3b2; in iPSC-derived Alzheimer&#x2019;s disease neurons. Cell Stem Cell. 2019;24:363&#x2013;375.e9. doi: 10.1016/j.stem.2018.12.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2018.12.013</ArticleId><ArticleId IdType="pmc">PMC6414424</ArticleId><ArticleId IdType="pubmed">30686764</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Kant R., Goldstein L.S.B., Ossenkoppele R. Amyloid-&#x3b2;-independent regulators of tau pathology in Alzheimer disease. Nat. Rev. Neurosci. 2020;21:21&#x2013;35. doi: 10.1038/s41583-019-0240-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41583-019-0240-3</ArticleId><ArticleId IdType="pubmed">31780819</ArticleId></ArticleIdList></Reference><Reference><Citation>Vance J.E. Dysregulation of cholesterol balance in the brain: contribution to neurodegenerative diseases. Dis. Model Mech. 2012;5:746&#x2013;755. doi: 10.1242/dmm.010124.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dmm.010124</ArticleId><ArticleId IdType="pmc">PMC3484857</ArticleId><ArticleId IdType="pubmed">23065638</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanier M.T., Duthel S., Rodriguez-Lafrasse C., Pentchev P., Carstea E.D. Genetic heterogeneity in Niemann-Pick C disease: a study using somatic cell hybridization and linkage analysis. Am. J. Hum. Genet. 1996;58:118&#x2013;125.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1914948</ArticleId><ArticleId IdType="pubmed">8554047</ArticleId></ArticleIdList></Reference><Reference><Citation>Verstraelen P., Van Dyck M., Verschuuren M., Kashikar N.D., Nuydens R., Timmermans J.-P., De Vos W.H. Image-based profiling of synaptic connectivity in primary neuronal cell culture. Front. Neurosci. 2018;12 doi: 10.3389/fnins.2018.00389.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2018.00389</ArticleId><ArticleId IdType="pmc">PMC6028601</ArticleId><ArticleId IdType="pubmed">29997468</ArticleId></ArticleIdList></Reference><Reference><Citation>Vilari&#xf1;o-G&#xfc;ell C., Wider C., Ross O.A., Dachsel J.C., Kachergus J.M., Lincoln S.J., Soto-Ortolaza A.I., Cobb S.A., Wilhoite G.J., Bacon J.A., et al. VPS35 mutations in Parkinson disease. Am. J. Hum. Genet. 2011;89:162&#x2013;167. doi: 10.1016/j.ajhg.2011.06.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2011.06.001</ArticleId><ArticleId IdType="pmc">PMC3135796</ArticleId><ArticleId IdType="pubmed">21763482</ArticleId></ArticleIdList></Reference><Reference><Citation>von Delwig A., Hilkens C.M., Altmann D.M., Holmdahl R., Isaacs J.D., Harding C.V., Robertson H., McKie N., Robinson J.H. Inhibition of macropinocytosis blocks antigen presentation of type II collagen in&#xa0;vitro and in&#xa0;vivo in HLA-DR1 transgenic mice. Arthritis Res. Ther. 2006;8:R93. doi: 10.1186/ar1964.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar1964</ArticleId><ArticleId IdType="pmc">PMC1779380</ArticleId><ArticleId IdType="pubmed">16704744</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J., Fang N., Xiong J., Du Y., Cao Y., Ji W.-K. An ESCRT-dependent step in fatty acid transfer from lipid droplets to mitochondria through VPS13D-TSG101 interactions. Nat. Commun. 2021;12:1252. doi: 10.1038/s41467-021-21525-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-21525-5</ArticleId><ArticleId IdType="pmc">PMC7902631</ArticleId><ArticleId IdType="pubmed">33623047</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegmann S., Nicholls S., Takeda S., Fan Z., Hyman B.T. Formation, release, and internalization of stable tau oligomers in cells. J.&#xa0;Neurochem. 2016;139:1163&#x2013;1174. doi: 10.1111/jnc.13866.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.13866</ArticleId><ArticleId IdType="pmc">PMC5283951</ArticleId><ArticleId IdType="pubmed">27731899</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen L., Tang F.-L., Hong Y., Luo S.-W., Wang C.-L., He W., Shen C., Jung J.-U., Xiong F., Lee D.-h., et al. VPS35 haploinsufficiency increases Alzheimer&#x2019;s disease neuropathology. J.&#xa0;Cell Biol. 2011;195:765&#x2013;779. doi: 10.1083/jcb.201105109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.201105109</ArticleId><ArticleId IdType="pmc">PMC3257571</ArticleId><ArticleId IdType="pubmed">22105352</ArticleId></ArticleIdList></Reference><Reference><Citation>Woerman A.L., Aoyagi A., Patel S., Kazmi S.A., Lobach I., Grinberg L.T., McKee A.C., Seeley W.W., Olson S.H., Prusiner S.B. Tau prions from Alzheimer&#x2019;s disease and chronic traumatic encephalopathy patients propagate in cultured cells. Proc. Natl. Acad. Sci. U&#xa0;S&#xa0;A. 2016;113:E8187&#x2013;E8196. doi: 10.1073/pnas.1616344113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1616344113</ArticleId><ArticleId IdType="pmc">PMC5167200</ArticleId><ArticleId IdType="pubmed">27911827</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J.W., Herman M., Liu L., Simoes S., Acker C.M., Figueroa H., Steinberg J.I., Margittai M., Kayed R., Zurzolo C., et al. Small misfolded Tau species are internalized via bulk endocytosis and anterogradely and retrogradely transported in neurons&#x2217;. 2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.394528</ArticleId><ArticleId IdType="pmc">PMC3548495</ArticleId><ArticleId IdType="pubmed">23188818</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J.W., Herman M., Liu L., Simoes S., Acker C.M., Figueroa H., Steinberg J.I., Margittai M., Kayed R., Zurzolo C., et al. Small misfolded Tau species are internalized via bulk endocytosis and anterogradely and retrogradely transported in neurons. J.&#xa0;Biol. Chem. 2013;288:1856&#x2013;1870. doi: 10.1074/jbc.M112.394528.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.394528</ArticleId><ArticleId IdType="pmc">PMC3548495</ArticleId><ArticleId IdType="pubmed">23188818</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J.W., Hussaini S.A., Bastille I.M., Rodriguez G.A., Mrejeru A., Rilett K., Sanders D.W., Cook C., Fu H., Boonen R.A.C.M., et al. Neuronal activity enhances tau propagation and tau pathology in&#xa0;vivo. Nat. Neurosci. 2016;19:1085&#x2013;1092. doi: 10.1038/nn.4328.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4328</ArticleId><ArticleId IdType="pmc">PMC4961585</ArticleId><ArticleId IdType="pubmed">27322420</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshimori T., Yamamoto A., Moriyama Y., Futai M., Tashiro Y. Bafilomycin A1, a specific inhibitor of vacuolar-type H(+)-ATPase, inhibits acidification and protein degradation in lysosomes of cultured cells. J.&#xa0;Biol. Chem. 1991;266:17707&#x2013;17712. doi: 10.1016/S0021-9258(19)47429-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0021-9258(19)47429-2</ArticleId><ArticleId IdType="pubmed">1832676</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu W., Ko M., Yanagisawa K., Michikawa M. Neurodegeneration in heterozygous niemann-pick type C1 (NPC1) mouse. J.&#xa0;Biol. Chem. 2005;280:27296&#x2013;27302. doi: 10.1074/jbc.M503922200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M503922200</ArticleId><ArticleId IdType="pubmed">15919659</ArticleId></ArticleIdList></Reference><Reference><Citation>Zang R., Case J.B., Yutuc E., Ma X., Shen S., Gomez Castro M.F., Liu Z., Zeng Q., Zhao H., Son J., et al. Cholesterol 25-hydroxylase suppresses SARS-CoV-2 replication by blocking membrane fusion. Proc. Natl. Acad. Sci. U&#xa0;S&#xa0;A. 2020;117:32105&#x2013;32113. doi: 10.1073/pnas.2012197117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2012197117</ArticleId><ArticleId IdType="pmc">PMC7749331</ArticleId><ArticleId IdType="pubmed">33239446</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W., Falcon B., Murzin A.G., Fan J., Crowther R.A., Goedert M., Scheres S.H. Heparin-induced tau filaments are polymorphic and differ from those in Alzheimer&#x2019;s and Pick&#x2019;s diseases. eLife. 2019;8:e43584. doi: 10.7554/eLife.43584.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.43584</ArticleId><ArticleId IdType="pmc">PMC6375701</ArticleId><ArticleId IdType="pubmed">30720432</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao N., Liu C.-C., Van Ingelgom A.J., Linares C., Kurti A., Knight J.A., Heckman M.G., Diehl N.N., Shinohara M., Martens Y.A., et al. APOE &#x3b5;2 is associated with increased tau pathology in primary tauopathy. Nat. Commun. 2018;9:4388. doi: 10.1038/s41467-018-06783-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-06783-0</ArticleId><ArticleId IdType="pmc">PMC6197187</ArticleId><ArticleId IdType="pubmed">30348994</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35516801</PMID><DateRevised><Year>2022</Year><Month>05</Month><Day>07</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1662-4548</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Frontiers in neuroscience</Title><ISOAbbreviation>Front Neurosci</ISOAbbreviation></Journal><ArticleTitle>High-Resolution Digital Panorama of Multiple Structures in Whole Brain of Alzheimer's Disease Mice.</ArticleTitle><Pagination><StartPage>870520</StartPage><MedlinePgn>870520</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">870520</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fnins.2022.870520</ELocationID><Abstract><AbstractText>Simultaneously visualizing Amyloid-&#x3b2; (A&#x3b2;) plaque with its surrounding brain structures at the subcellular level in the intact brain is essential for understanding the complex pathology of Alzheimer's disease, but is still rarely achieved due to the technical limitations. Combining the micro-optical sectioning tomography (MOST) system, whole-brain Nissl staining, and customized image processing workflow, we generated a whole-brain panorama of Alzheimer's disease mice without specific labeling. The workflow employed the steps that include virtual channel splitting, feature enhancement, iso-surface rendering, direct volume rendering, and feature fusion to extract and reconstruct the different signals with distinct gray values and morphologies. Taking advantage of this workflow, we found that the denser-distribution areas of A&#x3b2; plaques appeared with relatively more somata and smaller vessels, but show a dissimilar distributing pattern with nerve tracts. In addition, the entorhinal cortex and adjacent subiculum regions present the highest density and biggest diameter of plaques. The neuronal processes in the vicinity of these A&#x3b2; plaques showed significant structural alternation such as bending or abrupt branch ending. The capillaries inside or adjacent to the plaques were observed with abundant distorted micro-vessels and abrupt ending. Depicting A&#x3b2; plaques, somata, nerve processes and tracts, and blood vessels simultaneously, this panorama enables us for the first time, to analyze how the A&#x3b2; plaques interact with capillaries, somata, and processes at a submicron resolution of 3D whole-brain scale, which reveals potential pathological effects of A&#x3b2; plaques from a new cross-scale view. Our approach opens a door to routine systematic studies of complex interactions among brain components in mouse models of Alzheimer's disease.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Yin, Zhang, Zhang, Yang, Sun, Zhang, Gao and Jiang.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yin</LastName><ForeName>Xianzhen</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Center for MOST and Image Fusion Analysis, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Lingang Laboratory, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xiaochuan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Center for MOST and Image Fusion Analysis, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jingjing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Weicheng</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Xian</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Center for MOST and Image Fusion Analysis, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Haiyan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Zhaobing</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhongshan Institute of Drug Discovery, Institution for Drug Discovery Innovation, Chinese Academy of Science, Zhongshan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Hualiang</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Lingang Laboratory, Shanghai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Life Science and Technology, Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>04</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Neurosci</MedlineTA><NlmUniqueID>101478481</NlmUniqueID><ISSNLinking>1662-453X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">cross-scale</Keyword><Keyword MajorTopicYN="N">micro-optical sectioning tomography</Keyword><Keyword MajorTopicYN="N">multiple structures</Keyword><Keyword MajorTopicYN="N">simultaneous visualization</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>2</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>6</Day><Hour>5</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>7</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35516801</ArticleId><ArticleId IdType="pmc">PMC9067162</ArticleId><ArticleId IdType="doi">10.3389/fnins.2022.870520</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Adalbert R., Nogradi A., Babetto E., Janeckova L., Walker S. A., Kerschensteiner M., et al. . (2009). Severely dystrophic axons at amyloid plaques remain continuous and connected to viable cell bodies. Brain 132 (Pt 2), 402&#x2013;416. 10.1093/brain/awn312</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awn312</ArticleId><ArticleId IdType="pubmed">19059977</ArticleId></ArticleIdList></Reference><Reference><Citation>Apostolova L. G., Green A. E., Babakchanian S., Hwang K. S., Chou Y. Y., Toga A. W., et al. . (2012). Hippocampal atrophy and ventricular enlargement in normal aging, mild cognitive impairment (MCI), Alzheimer Disease. Alzheimer Dis. Assoc. Disord. 26, 17&#x2013;27. 10.1097/WAD.0b013e3182163b62</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WAD.0b013e3182163b62</ArticleId><ArticleId IdType="pmc">PMC3286134</ArticleId><ArticleId IdType="pubmed">22343374</ArticleId></ArticleIdList></Reference><Reference><Citation>Appaix F., Girod S., Boisseau S., Romer J., Vial J. C., Albrieux M., et al. . (2012). Specific in vivo staining of astrocytes in the whole brain after intravenous injection of sulforhodamine dyes. PLoS ONE 7, e35169. 10.1371/journal.pone.0035169</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0035169</ArticleId><ArticleId IdType="pmc">PMC3324425</ArticleId><ArticleId IdType="pubmed">22509398</ArticleId></ArticleIdList></Reference><Reference><Citation>Bacskai B. J., Hickey G. A., Skoch J., Kajdasz S. T., Wang Y., Huang G. F., et al. . (2003). Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-beta ligand in transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 100, 12462&#x2013;12467. 10.1073/pnas.2034101100</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2034101100</ArticleId><ArticleId IdType="pmc">PMC218780</ArticleId><ArticleId IdType="pubmed">14517353</ArticleId></ArticleIdList></Reference><Reference><Citation>Bittner T., Burgold S., Dorostkar M. M., Fuhrmann M., Wegenast-Braun B. M., Schmidt B., et al. . (2012). Amyloid plaque formation precedes dendritic spine loss. Acta Neuropathol. 124, 797&#x2013;807. 10.1007/s00401-012-1047-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-012-1047-8</ArticleId><ArticleId IdType="pmc">PMC3508278</ArticleId><ArticleId IdType="pubmed">22993126</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolmont T., Bouwens A., Pache C., Dimitrov M., Berclaz C., Villiger M., et al. . (2012). Label-free imaging of cerebral beta-amyloidosis with extended-focus optical coherence microscopy. J. Neurosci. 32, 14548&#x2013;14556. 10.1523/JNEUROSCI.0925-12.2012</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0925-12.2012</ArticleId><ArticleId IdType="pmc">PMC6621450</ArticleId><ArticleId IdType="pubmed">23077040</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosma M., Jaap S., Steven J. (1998). &#x201c;Storage lobregt retrieval for image, video databases,&#x201d; in Iso-Surface Volume Rendering (San Diego, CA: ).</Citation></Reference><Reference><Citation>Bozzali M., Falini A., Franceschi M., Cercignani M., Zuffi M., Scotti G., et al. . (2002). White matter damage in Alzheimer's disease assessed in vivo using diffusion tensor magnetic resonance imaging. J. Neurol Neurosurg. Psychiatry 72, 742&#x2013;746. 10.1136/jnnp.72.6.742</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.72.6.742</ArticleId><ArticleId IdType="pmc">PMC1737921</ArticleId><ArticleId IdType="pubmed">12023417</ArticleId></ArticleIdList></Reference><Reference><Citation>Buggenthin F., Carsten M., Michael S., Philipp Hoppe S., Oliver H., Timm S., et al. . (2013). An automatic method for robust and fast cell detection in bright field images from high-throughput microscopy. BMC Bioinformatics 14, 297. 10.1186/1471-2105-14-297</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2105-14-297</ArticleId><ArticleId IdType="pmc">PMC3850979</ArticleId><ArticleId IdType="pubmed">24090363</ArticleId></ArticleIdList></Reference><Reference><Citation>Daigle T. L., Madisen L., Hage T. A., Valley M. T., Knoblich U., Larsen R. S., et al. . (2018). A suite of transgenic driver and reporter mouse lines with enhanced brain-cell-type targeting and functionality. Cell 174, 465.e22&#x2013;480.e22. 10.1016/j.cell.2018.06.035</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2018.06.035</ArticleId><ArticleId IdType="pmc">PMC6086366</ArticleId><ArticleId IdType="pubmed">30007418</ArticleId></ArticleIdList></Reference><Reference><Citation>Delafontaine-Martel P., Lefebvre J., Tardif P. L., Levy B. I., Pouliot P., Lesage F. (2018). Whole brain vascular imaging in a mouse model of Alzheimer's disease with two-photon microscopy. J. Biomed. Opt. 23, 1&#x2013;10. 10.1117/1.JBO.23.7.076501</Citation><ArticleIdList><ArticleId IdType="doi">10.1117/1.JBO.23.7.076501</ArticleId><ArticleId IdType="pubmed">29998647</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson T. C., Vickers J. C. (2001). The morphological phenotype of beta-amyloid plaques and associated neuritic changes in Alzheimer's disease. Neuroscience 105, 99&#x2013;107. 10.1016/S0306-4522(01)00169-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0306-4522(01)00169-5</ArticleId><ArticleId IdType="pubmed">11483304</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding W., Wu L. i., A Yang J., Meng Z., Wang Y., et al. . (2013). Automatic macroscopic density artefact removal in a Nissl-stained microscopic atlas of whole mouse brain. J. Microsc. 251, 168&#x2013;177. 10.1111/jmi.12058</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jmi.12058</ArticleId><ArticleId IdType="pubmed">23781931</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodt H. U., Leischner U., Schierloh A., Jahrling N., Mauch C. P., Deininger K., et al. . (2007). Ultramicroscopy: three-dimensional visualization of neuronal networks in the whole mouse brain. Nat. Methods 4, 331&#x2013;336. 10.1038/nmeth1036</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth1036</ArticleId><ArticleId IdType="pubmed">17384643</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorr A., Sled J. G., Kabani N. (2007). Three-dimensional cerebral vasculature of the CBA mouse brain: a magnetic resonance imaging and micro computed tomography study. Neuroimage 35, 1409&#x2013;1423. 10.1016/j.neuroimage.2006.12.040</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2006.12.040</ArticleId><ArticleId IdType="pubmed">17369055</ArticleId></ArticleIdList></Reference><Reference><Citation>Enzlein T., Cordes J., Munteanu B., Michno W., Serneels L., Strooper D. C., et al. . (2020). Computational analysis of alzheimer amyloid plaque composition in 2D-and elastically reconstructed 3D-MALDI MS images. Anal. Chem. 92, 14484&#x2013;14493. 10.1021/acs.analchem.0c02585</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.analchem.0c02585</ArticleId><ArticleId IdType="pubmed">33138378</ArticleId></ArticleIdList></Reference><Reference><Citation>Fakhoury M. (2018). Microglia and astrocytes in Alzheimer's disease: implications for therapy. Curr. Neuropharmacol. 16, 508&#x2013;518. 10.2174/1570159X15666170720095240</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1570159X15666170720095240</ArticleId><ArticleId IdType="pmc">PMC5997862</ArticleId><ArticleId IdType="pubmed">28730967</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu H., Tu P., Zhao L., Liu D. A. I. J., Cui B. M. (2016). Amyloid-beta deposits target efficient near-infrared fluorescent probes: synthesis, in vitro evaluation, and in vivo imaging. Anal. Chem. 88, 1944&#x2013;1950. 10.1021/acs.analchem.5b04441</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.analchem.5b04441</ArticleId><ArticleId IdType="pubmed">26717442</ArticleId></ArticleIdList></Reference><Reference><Citation>Gang Y., Liu X., Wang X., Zhang Q., Zhou H., Chen R., et al. . (2017). Plastic embedding immunolabeled large-volume samples for three-dimensional high-resolution imaging. Biomed. Opt. Express 8, 3583&#x2013;3596. 10.1364/BOE.8.003583</Citation><ArticleIdList><ArticleId IdType="doi">10.1364/BOE.8.003583</ArticleId><ArticleId IdType="pmc">PMC5560827</ArticleId><ArticleId IdType="pubmed">28856037</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao R., Asano S. M., Upadhyayula S., Pisarev I., Milkie D. E., Liu T. L., et al. . (2019). Cortical column and whole-brain imaging with molecular contrast and nanoscale resolution. Science 363, 6424. 10.1126/science.aau8302</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aau8302</ArticleId><ArticleId IdType="pmc">PMC6481610</ArticleId><ArticleId IdType="pubmed">30655415</ArticleId></ArticleIdList></Reference><Reference><Citation>Giovanna D. I., Tibo A. P., Silvestri A., Mullenbroich L., Costantini M. C., Allegra Mascaro I., et al. . (2018). Whole-brain vasculature reconstruction at the single capillary level. Sci. Rep. 8, 12573. 10.1038/s41598-018-30533-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-30533-3</ArticleId><ArticleId IdType="pmc">PMC6105658</ArticleId><ArticleId IdType="pubmed">30135559</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong H., Xu D., Yuan J., Li X., Guo C., Peng J., et al. . (2016). High-throughput dual-colour precision imaging for brain-wide connectome with cytoarchitectonic landmarks at the cellular level. Nat. Commun. 7, 12142. 10.1038/ncomms12142</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms12142</ArticleId><ArticleId IdType="pmc">PMC4932192</ArticleId><ArticleId IdType="pubmed">27374071</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenberg S. M., Bacskai B. J., Hernandez-Guillamon M., Pruzin J., Sperling R., van Veluw J. S. (2020). Cerebral amyloid angiopathy and Alzheimer disease - one peptide, two pathways. Nat. Rev. Neurol. 16, 30&#x2013;42. 10.1038/s41582-019-0281-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-019-0281-2</ArticleId><ArticleId IdType="pmc">PMC7268202</ArticleId><ArticleId IdType="pubmed">31827267</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurol M. E., Becker J. A., Fotiadis P., Riley G., Schwab K., Johnson K. A., et al. . (2016). Florbetapir-PET to diagnose cerebral amyloid angiopathy: a prospective study. Neurology 87, 2043&#x2013;2049. 10.1212/WNL.0000000000003197</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000003197</ArticleId><ArticleId IdType="pmc">PMC5109947</ArticleId><ArticleId IdType="pubmed">27605173</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji M., Arbel L., Zhang M., Freudiger L., Hou C. W., Lin S. S., et al. . (2018). Label-free imaging of amyloid plaques in Alzheimer's disease with stimulated Raman scattering microscopy. Sci. Adv. 4, eaat7715. 10.1126/sciadv.aat7715</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.aat7715</ArticleId><ArticleId IdType="pmc">PMC6239428</ArticleId><ArticleId IdType="pubmed">30456301</ArticleId></ArticleIdList></Reference><Reference><Citation>Jing D., Zhang S., Luo W., Gao X., Men Y., Ma C., et al. . (2018). Tissue clearing of both hard and soft tissue organs with the PEGASOS method. Cell Res. 28, 803&#x2013;818. 10.1038/s41422-018-0049-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41422-018-0049-z</ArticleId><ArticleId IdType="pmc">PMC6082844</ArticleId><ArticleId IdType="pubmed">29844583</ArticleId></ArticleIdList></Reference><Reference><Citation>Johansson P. K., Koelsch P. (2017). Label-free imaging of amyloids using their intrinsic linear and nonlinear optical properties. Biomed. Opt. Express 8, 743&#x2013;756. 10.1364/BOE.8.000743</Citation><ArticleIdList><ArticleId IdType="doi">10.1364/BOE.8.000743</ArticleId><ArticleId IdType="pmc">PMC5330564</ArticleId><ArticleId IdType="pubmed">28270981</ArticleId></ArticleIdList></Reference><Reference><Citation>Kadowaki H., Nishitoh H., Urano F., Sadamitsu C., Matsuzawa A., Takeda K., et al. . (2005). Amyloid beta induces neuronal cell death through ROS-mediated ASK1 activation. Cell Death Differ. 12, 19&#x2013;24. 10.1038/sj.cdd.4401528</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.cdd.4401528</ArticleId><ArticleId IdType="pubmed">15592360</ArticleId></ArticleIdList></Reference><Reference><Citation>Khouri K., Xie D. F., Crouzet C., Bahani A. W., Cribbs D. H., Fisher M. J., et al. . (2021). Simple methodology to visualize whole-brain microvasculature in three dimensions. Neurophotonics 8, 025004. 10.1117/1.NPh.8.2.025004</Citation><ArticleIdList><ArticleId IdType="doi">10.1117/1.NPh.8.2.025004</ArticleId><ArticleId IdType="pmc">PMC8056070</ArticleId><ArticleId IdType="pubmed">33884280</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimbrough I. F., Robel S., Roberson E. D., Sontheimer H. (2015). Vascular amyloidosis impairs the gliovascular unit in a mouse model of Alzheimer's disease. Brain 138 (Pt 12), 3716&#x2013;3733. 10.1093/brain/awv327</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awv327</ArticleId><ArticleId IdType="pmc">PMC5006220</ArticleId><ArticleId IdType="pubmed">26598495</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirst C., Skriabine S., Vieites-Prado A., Topilko T., Bertin P., Gerschenfeld G., et al. . (2020). Mapping the fine-scale organization and plasticity of the brain vasculature. Cell 180, 780&#x2013;795. e25. 10.1016/j.cell.2020.01.028</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.01.028</ArticleId><ArticleId IdType="pubmed">32059781</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk W. E., Bacskai B. J., Mathis C. A., Kajdasz S. T., McLellan M. E., Frosch M. P., et al. . (2002). Imaging Abeta plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative. J. Neuropathol. Exp. Neurol. 61, 797&#x2013;805. 10.1093/jnen/61.9.797</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnen/61.9.797</ArticleId><ArticleId IdType="pubmed">12230326</ArticleId></ArticleIdList></Reference><Reference><Citation>Konno A., Matsumoto N., Tomono Y., Okazaki S. (2020). Pathological application of carbocyanine dye-based multicolour imaging of vasculature and associated structures. Sci. Rep. 10, 12613. 10.1038/s41598-020-69394-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-69394-0</ArticleId><ArticleId IdType="pmc">PMC7387484</ArticleId><ArticleId IdType="pubmed">32724051</ArticleId></ArticleIdList></Reference><Reference><Citation>Leiva-Salinas C., Jiang B., Wintermark M. (2018). Computed tomography, computed tomography angiography, and perfusion computed tomography evaluation of acute ischemic stroke. Neuroimaging Clin. N. Am. 28, 565&#x2013;572. 10.1016/j.nic.2018.06.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nic.2018.06.002</ArticleId><ArticleId IdType="pubmed">30322593</ArticleId></ArticleIdList></Reference><Reference><Citation>Li A., Gong H., Zhang H., Wang B., Yan Q., Wu C., et al. . (2010). Micro-optical sectioning tomography to obtain a high-resolution atlas of the mouse brain. Science 330, 1404&#x2013;1408. 10.1126/science.1191776</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1191776</ArticleId><ArticleId IdType="pubmed">21051596</ArticleId></ArticleIdList></Reference><Reference><Citation>Liebmann T., Renier N., Bettayeb K., Greengard P., Tessier-Lavigne M., Flajolet M. (2016). Three-dimensional study of Alzheimer's disease hallmarks using the iDISCO clearing method. Cell Rep. 16, 1138&#x2013;1152. 10.1016/j.celrep.2016.06.060</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2016.06.060</ArticleId><ArticleId IdType="pmc">PMC5040352</ArticleId><ArticleId IdType="pubmed">27425620</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z., Condello C., Schain A., Harb R., Grutzendler J. (2010), CX3CR.1 in microglia regulates brain amyloid deposition through selective protofibrillar amyloid-beta phagocytosis. J. Neurosci. 30, 17091&#x2013;17101. 10.1523/JNEUROSCI.4403-10.2010</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4403-10.2010</ArticleId><ArticleId IdType="pmc">PMC3077120</ArticleId><ArticleId IdType="pubmed">21159979</ArticleId></ArticleIdList></Reference><Reference><Citation>Long B., Xiangning L., Jianping Z., Siqi C., Wenwei L., Qiuyuan Z., et al. . (2019). Three-dimensional quantitative analysis of amyloid plaques in the whole brain with high voxel resolution. Scientia Sinica Vitae 49, 140&#x2013;150. 10.1360/N052019-00001</Citation><ArticleIdList><ArticleId IdType="doi">10.1360/N052019-00001</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo Y., Wang A., Liu M., Lei T., Zhang X., Gao Z., et al. . (2017). Label-free brainwide visualization of senile plaque using cryo-micro-optical sectioning tomography. Opt. Lett. 42, 4247&#x2013;4250. 10.1364/OL.42.004247</Citation><ArticleIdList><ArticleId IdType="doi">10.1364/OL.42.004247</ArticleId><ArticleId IdType="pubmed">29088144</ArticleId></ArticleIdList></Reference><Reference><Citation>Mano T., Albanese A., Dodt H. U., Erturk A., Gradinaru V., Treweek J. B., et al. . (2018). Whole-brain analysis of cells and circuits by tissue clearing and light-sheet microscopy. J. Neurosci. 38, 9330&#x2013;9337. 10.1523/JNEUROSCI.1677-18.2018</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1677-18.2018</ArticleId><ArticleId IdType="pmc">PMC6706004</ArticleId><ArticleId IdType="pubmed">30381424</ArticleId></ArticleIdList></Reference><Reference><Citation>Marin M. A., Ziburkus J., Jankowsky J., Rasband M. N. (2016). Amyloid-beta plaques disrupt axon initial segments. Exp. Neurol. 281, 93&#x2013;98. 10.1016/j.expneurol.2016.04.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2016.04.018</ArticleId><ArticleId IdType="pmc">PMC4877279</ArticleId><ArticleId IdType="pubmed">27109181</ArticleId></ArticleIdList></Reference><Reference><Citation>McRae T. D., Oleksyn D., Miller J., Gao Y. R. (2019). Robust blind spectral unmixing for fluorescence microscopy using unsupervised learning. PLoS ONE 14, e0225410. 10.1371/journal.pone.0225410</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0225410</ArticleId><ArticleId IdType="pmc">PMC6886781</ArticleId><ArticleId IdType="pubmed">31790435</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer E. P., Ulmann-Schuler A., Staufenbiel M., Krucker T. (2008). Altered morphology and 3D architecture of brain vasculature in a mouse model for Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 105, 3587&#x2013;3592. 10.1073/pnas.0709788105</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0709788105</ArticleId><ArticleId IdType="pmc">PMC2265182</ArticleId><ArticleId IdType="pubmed">18305170</ArticleId></ArticleIdList></Reference><Reference><Citation>Miners J. S., Schulz I., Love S. (2018). Differing associations between Abeta accumulation, hypoperfusion, blood-brain barrier dysfunction and loss of PDGFRB pericyte marker in the precuneus and parietal white matter in Alzheimer's disease. J. Cereb. Blood Flow Metab. 38, 103&#x2013;115. 10.1177/0271678X17690761</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0271678X17690761</ArticleId><ArticleId IdType="pmc">PMC5757436</ArticleId><ArticleId IdType="pubmed">28151041</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyawaki T., Morikawa S., Susaki E. A., Nakashima A., Takeuchi H., Yamaguchi S., et al. . (2020). Visualization and molecular characterization of whole-brain vascular networks with capillary resolution. Nat. Commun. 11, 1104. 10.1038/s41467-020-14786-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-14786-z</ArticleId><ArticleId IdType="pmc">PMC7046771</ArticleId><ArticleId IdType="pubmed">32107377</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy M. P., LeVine H., III. (2010). Alzheimer's disease and the amyloid-beta peptide. J. Alzheimers Dis. 19, 311&#x2013;323. 10.3233/JAD-2010-1221</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2010-1221</ArticleId><ArticleId IdType="pmc">PMC2813509</ArticleId><ArticleId IdType="pubmed">20061647</ArticleId></ArticleIdList></Reference><Reference><Citation>Nobakht M., Hoseini S. M., Mortazavi P., Sohrabi I., Esmailzade B., Rahbar Rooshandel N., et al. . (2011). Neuropathological changes in brain cortex and hippocampus in a rat model of Alzheimer's disease. Iran. Biomed. J. 15, 51&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3639737</ArticleId><ArticleId IdType="pubmed">21725500</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakley H., Cole S. L., Logan S., Maus E., Shao P., Craft J., et al. . (2006). Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J. Neurosci. 26, 10129&#x2013;10140. 10.1523/JNEUROSCI.1202-06.2006</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1202-06.2006</ArticleId><ArticleId IdType="pmc">PMC6674618</ArticleId><ArticleId IdType="pubmed">17021169</ArticleId></ArticleIdList></Reference><Reference><Citation>Pini L., Pievani M., Bocchetta M., Altomare D., Bosco P., Cavedo E., et al. . (2016). Brain atrophy in Alzheimer's disease and aging. Ageing Res. Rev. 30, 25&#x2013;48. 10.1016/j.arr.2016.01.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arr.2016.01.002</ArticleId><ArticleId IdType="pubmed">26827786</ArticleId></ArticleIdList></Reference><Reference><Citation>Ragan T., Kadiri L. R., Venkataraju K. U., Bahlmann K., Sutin J., Taranda J., et al. . (2012). Serial two-photon tomography for automated ex vivo mouse brain imaging. Nat. Methods 9, 255&#x2013;258. 10.1038/nmeth.1854</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.1854</ArticleId><ArticleId IdType="pmc">PMC3297424</ArticleId><ArticleId IdType="pubmed">22245809</ArticleId></ArticleIdList></Reference><Reference><Citation>Robertson R. T., Levine S. T., Haynes S. M., Gutierrez P., Baratta J. L., Tan Z., et al. . (2015). Use of labeled tomato lectin for imaging vasculature structures. Histochem. Cell Biol. 143, 225&#x2013;234. 10.1007/s00418-014-1301-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00418-014-1301-3</ArticleId><ArticleId IdType="pubmed">25534591</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrano-Pozo A., Frosch M. P., Masliah E., Hyman B. T. (2011). Neuropathological alterations in Alzheimer disease. Cold Spring Harb. Perspect. Med. 1, a006189. 10.1101/cshperspect.a006189</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a006189</ArticleId><ArticleId IdType="pmc">PMC3234452</ArticleId><ArticleId IdType="pubmed">22229116</ArticleId></ArticleIdList></Reference><Reference><Citation>Valm A. M., Oldenbourg R., Borisy G. G. (2016). Multiplexed spectral imaging of 120 different fluorescent labels. PLoS ONE 11, e0158495. 10.1371/journal.pone.0158495</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0158495</ArticleId><ArticleId IdType="pmc">PMC4938436</ArticleId><ArticleId IdType="pubmed">27391327</ArticleId></ArticleIdList></Reference><Reference><Citation>Wessels J. T., Hoffman R. M., Wouters F. S. (2008). The use of transgenic fluorescent mouse strains, fluorescent protein coding vectors, and innovative imaging techniques in the life sciences. Cytometry A 73, 490&#x2013;491. 10.1002/cyto.a.20548</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cyto.a.20548</ArticleId><ArticleId IdType="pubmed">18307256</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitesell J. D., Buckley A. R., Knox J. E., Kuan L., Graddis N., Pelos A., et al. . (2019). Whole brain imaging reveals distinct spatial patterns of amyloid beta deposition in three mouse models of Alzheimer's disease. J. Comp. Neurol. 527, 2122&#x2013;2145. 10.1002/cne.24555</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cne.24555</ArticleId><ArticleId IdType="pmc">PMC8026112</ArticleId><ArticleId IdType="pubmed">30311654</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J., He Y., Yang Z., Guo C., Luo Q., Zhou W., et al. . (2014). 3D BrainCV: simultaneous visualization and analysis of cells and capillaries in a whole mouse brain with one-micron voxel resolution. Neuroimage 87, 199&#x2013;208. 10.1016/j.neuroimage.2013.10.036</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2013.10.036</ArticleId><ArticleId IdType="pubmed">24185025</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong B., Li A., Lou Y., Chen S., Long B., Peng J., et al. . (2017). Precise cerebral vascular atlas in stereotaxic coordinates of whole mouse brain. Front. Neuroanat. 11, 128. 10.3389/fnana.2017.00128</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnana.2017.00128</ArticleId><ArticleId IdType="pmc">PMC5742197</ArticleId><ArticleId IdType="pubmed">29311856</ArticleId></ArticleIdList></Reference><Reference><Citation>Youmans K. L., Tai L. M., Kanekiyo T., Stine W. B., Jr., Michon S. C., et al. . (2012). Intraneuronal A&#x3b2; detection in 5xFAD mice by a new A&#x3b2;-specific antibody. Mol. Neurodegener. 7, 8. 10.1186/1750-1326-7-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-7-8</ArticleId><ArticleId IdType="pmc">PMC3355009</ArticleId><ArticleId IdType="pubmed">22423893</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan J., Gong H., Li A., Li X., Chen S., Zeng S., et al. . (2015). Visible rodent brain-wide networks at single-neuron resolution. Front. Neuroanat. 9, 70. 10.3389/fnana.2015.00070</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnana.2015.00070</ArticleId><ArticleId IdType="pmc">PMC4446545</ArticleId><ArticleId IdType="pubmed">26074784</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan P., Condello C., Keene C. D., Wang Y., Bird T. D., Paul S. M., et al. . (2016). TREM2 haplodeficiency in mice and humans impairs the microglia barrier function leading to decreased amyloid compaction and severe axonal dystrophy. Neuron 90, 724&#x2013;739. 10.1016/j.neuron.2016.05.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.05.003</ArticleId><ArticleId IdType="pmc">PMC4898967</ArticleId><ArticleId IdType="pubmed">27196974</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J., Long B., Li A., Sun J., Tian J., Luo T., et al. . (2020). Whole-brain three-dimensional profiling reveals brain region specific axon vulnerability in 5xFAD mouse model. Front. Neuroanat. 14, 608177. 10.3389/fnana.2020.608177</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnana.2020.608177</ArticleId><ArticleId IdType="pmc">PMC7726261</ArticleId><ArticleId IdType="pubmed">33324177</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X., Xianzhen Y., Jingjing Z., Anan L., Hui G., Qingming L., et al. . (2019). High-resolution mapping of brain vasculature and its impairment in the hippocampus of Alzheimer's disease mice. National Science Review 6, 1223&#x2013;1238. 10.1093/nsr/nwz124</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nsr/nwz124</ArticleId><ArticleId IdType="pmc">PMC8291402</ArticleId><ArticleId IdType="pubmed">34692000</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong W., Gao X., Wang S., Han K., Ema M., Adams S., et al. . (2017). Prox1-GFP/Flt1-DsRed transgenic mice: an animal model for simultaneous live imaging of angiogenesis and lymphangiogenesis. Angiogenesis 20, 581&#x2013;598. 10.1007/s10456-017-9572-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10456-017-9572-7</ArticleId><ArticleId IdType="pmc">PMC5782821</ArticleId><ArticleId IdType="pubmed">28795242</ArticleId></ArticleIdList></Reference><Reference><Citation>Zingg B., Chou X. L., Zhang Z. G., Mesik L., Liang F., Tao H. W., et al. . (2017). AAV-Mediated anterograde transsynaptic tagging: mapping corticocollicular input-defined neural pathways for defense behaviors. Neuron 93, 33&#x2013;47. 10.1016/j.neuron.2016.11.045</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.11.045</ArticleId><ArticleId IdType="pmc">PMC5538794</ArticleId><ArticleId IdType="pubmed">27989459</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">35513515</PMID><DateCompleted><Year>2022</Year><Month>05</Month><Day>10</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>5</Issue><PubDate><Year>2022</Year><Month>May</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Single-cell genomic profiling of human dopamine neurons identifies a population that selectively degenerates in Parkinson's disease.</ArticleTitle><Pagination><StartPage>588</StartPage><EndPage>595</EndPage><MedlinePgn>588-595</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41593-022-01061-1</ELocationID><Abstract><AbstractText>The loss of dopamine (DA) neurons within the substantia nigra pars compacta (SNpc) is a defining pathological hallmark of Parkinson's disease (PD). Nevertheless, the molecular features associated with DA neuron vulnerability have not yet been fully identified. Here, we developed a protocol to enrich and transcriptionally profile DA neurons from patients with PD and matched controls, sampling a total of 387,483&#x2009;nuclei, including 22,048&#x2009;DA neuron profiles. We identified ten populations and spatially localized each within the SNpc using Slide-seq. A single subtype, marked by the expression of the gene AGTR1 and spatially confined to the ventral tier of SNpc, was highly susceptible to loss in PD and showed the strongest upregulation of targets of TP53 and NR2F2, nominating molecular processes associated with degeneration. This same vulnerable population was specifically enriched for the heritable risk associated with PD, highlighting the importance of cell-intrinsic processes in determining the differential vulnerability of DA neurons to PD-associated degeneration.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Kamath</LastName><ForeName>Tushar</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Broad Institute of Harvard and MIT, Stanley Center for Psychiatric Research, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Graduate Program in Biophysics, Harvard University, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Abdulraouf</LastName><ForeName>Abdulraouf</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Broad Institute of Harvard and MIT, Stanley Center for Psychiatric Research, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burris</LastName><ForeName>S J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Broad Institute of Harvard and MIT, Stanley Center for Psychiatric Research, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Langlieb</LastName><ForeName>Jonah</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-9949-1123</Identifier><AffiliationInfo><Affiliation>Broad Institute of Harvard and MIT, Stanley Center for Psychiatric Research, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gazestani</LastName><ForeName>Vahid</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Broad Institute of Harvard and MIT, Stanley Center for Psychiatric Research, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nadaf</LastName><ForeName>Naeem M</ForeName><Initials>NM</Initials><Identifier Source="ORCID">0000-0002-7805-8523</Identifier><AffiliationInfo><Affiliation>Broad Institute of Harvard and MIT, Stanley Center for Psychiatric Research, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Balderrama</LastName><ForeName>Karol</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-8458-1364</Identifier><AffiliationInfo><Affiliation>Broad Institute of Harvard and MIT, Stanley Center for Psychiatric Research, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vanderburg</LastName><ForeName>Charles</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-8979-5054</Identifier><AffiliationInfo><Affiliation>Broad Institute of Harvard and MIT, Stanley Center for Psychiatric Research, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Macosko</LastName><ForeName>Evan Z</ForeName><Initials>EZ</Initials><Identifier Source="ORCID">0000-0002-2794-5165</Identifier><AffiliationInfo><Affiliation>Broad Institute of Harvard and MIT, Stanley Center for Psychiatric Research, Cambridge, MA, USA. emacosko@broadinstitute.org.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Massachusetts General Hospital, Department of Psychiatry, Boston, MA, USA. emacosko@broadinstitute.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>F30 AG069446</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM007753</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DP2 AG058488</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 MH124602</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM008313</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>05</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Neurosci. 2022 May;25(5):536-538. doi: 10.1038/s41593-022-01069-7.</RefSource><PMID Version="1">35513514</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2022 Jul;18(7):381. doi: 10.1038/s41582-022-00682-1.</RefSource><PMID Version="1">35676370</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Mov Disord. 2022 Aug;37(8):1610-1611. doi: 10.1002/mds.29137.</RefSource><PMID Version="1">35766438</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D059290" MajorTopicYN="Y">Dopaminergic Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D023281" MajorTopicYN="N">Genomics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="Y">Parkinson Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013378" MajorTopicYN="N">Substantia Nigra</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>E.Z.M. is a consultant for Atlas Bio, Inc. The remaining authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>11</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>5</Day><Hour>23</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>5</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35513515</ArticleId><ArticleId IdType="pmc">PMC9076534</ArticleId><ArticleId IdType="doi">10.1038/s41593-022-01061-1</ArticleId><ArticleId IdType="pii">10.1038/s41593-022-01061-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bloem, B. R., Okun, M. S. &amp; Klein, C. Parkinson&#x2019;s disease. Lancet397, P2284&#x2013;P2303 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33848468</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada T, McGeer PL, Baimbridge KG, McGeer EG. Relative sparing in Parkinson&#x2019;s disease of substantia nigra dopamine neurons containing calbindin-D28K. Brain Res. 1990;526:303&#x2013;307. doi: 10.1016/0006-8993(90)91236-A.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0006-8993(90)91236-A</ArticleId><ArticleId IdType="pubmed">2257487</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider JS, Yuwiler A, Markham CH. Selective loss of subpopulations of ventral mesencephalic dopaminergic neurons in the monkey following exposure to MPTP. Brain Res. 1987;411:144&#x2013;150. doi: 10.1016/0006-8993(87)90691-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0006-8993(87)90691-3</ArticleId><ArticleId IdType="pubmed">2886180</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu L, et al. Regional vulnerability of mesencephalic dopaminergic neurons prone to degenerate in Parkinson&#x2019;s disease: a post-mortem study in human control subjects. Neurobiol. Dis. 2006;23:409&#x2013;421. doi: 10.1016/j.nbd.2006.04.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2006.04.002</ArticleId><ArticleId IdType="pubmed">16753304</ArticleId></ArticleIdList></Reference><Reference><Citation>Varastet M, Riche D, Maziere M, Hantraye P. Chronic MPTP treatment reproduces in baboons the differential vulnerability of mesencephalic dopaminergic neurons observed in Parkinson&#x2019;s disease. Neuroscience. 1994;63:47&#x2013;56. doi: 10.1016/0306-4522(94)90006-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0306-4522(94)90006-X</ArticleId><ArticleId IdType="pubmed">7898660</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibb WR, Lees AJ. Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson&#x2019;s disease. J. Neurol. Neurosurg. Psychiatry. 1991;54:388&#x2013;396. doi: 10.1136/jnnp.54.5.388.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.54.5.388</ArticleId><ArticleId IdType="pmc">PMC488535</ArticleId><ArticleId IdType="pubmed">1865199</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung CY, Koprich JB, Hallett PJ, Isacson O. Functional enhancement and protection of dopaminergic terminals by RAB3B overexpression. Proc. Natl Acad. Sci. USA. 2009;106:22474&#x2013;22479. doi: 10.1073/pnas.0912193106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0912193106</ArticleId><ArticleId IdType="pmc">PMC2791667</ArticleId><ArticleId IdType="pubmed">20007772</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu H, Hardy J, Duff KE. Selective vulnerability in neurodegenerative diseases. Nat. Neurosci. 2018;21:1350&#x2013;1358. doi: 10.1038/s41593-018-0221-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0221-2</ArticleId><ArticleId IdType="pmc">PMC6360529</ArticleId><ArticleId IdType="pubmed">30250262</ArticleId></ArticleIdList></Reference><Reference><Citation>Macosko EZ, et al. Highly parallel genome-wide expression profiling of individual cells using nanoliter droplets. Cell. 2015;161:1202&#x2013;1214. doi: 10.1016/j.cell.2015.05.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2015.05.002</ArticleId><ArticleId IdType="pmc">PMC4481139</ArticleId><ArticleId IdType="pubmed">26000488</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein AM, et al. Droplet barcoding for single-cell transcriptomics applied to embryonic stem cells. Cell. 2015;161:1187&#x2013;1201. doi: 10.1016/j.cell.2015.04.044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2015.04.044</ArticleId><ArticleId IdType="pmc">PMC4441768</ArticleId><ArticleId IdType="pubmed">26000487</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng GXY, et al. Massively parallel digital transcriptional profiling of single cells. Nat. Commun. 2017;8:14049. doi: 10.1038/ncomms14049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms14049</ArticleId><ArticleId IdType="pmc">PMC5241818</ArticleId><ArticleId IdType="pubmed">28091601</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathys H, et al. Single-cell transcriptomic analysis of Alzheimer&#x2019;s disease. Nature. 2019;570:332&#x2013;337. doi: 10.1038/s41586-019-1195-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-1195-2</ArticleId><ArticleId IdType="pmc">PMC6865822</ArticleId><ArticleId IdType="pubmed">31042697</ArticleId></ArticleIdList></Reference><Reference><Citation>Leng K, et al. Molecular characterization of selectively vulnerable neurons in Alzheimer&#x2019;s disease. Nat. Neurosci. 2021;24:276&#x2013;287. doi: 10.1038/s41593-020-00764-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-020-00764-7</ArticleId><ArticleId IdType="pmc">PMC7854528</ArticleId><ArticleId IdType="pubmed">33432193</ArticleId></ArticleIdList></Reference><Reference><Citation>Velmeshev D, et al. Single-cell genomics identifies cell type&#x2013;specific molecular changes in autism. Science. 2019;364:685&#x2013;689. doi: 10.1126/science.aav8130.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aav8130</ArticleId><ArticleId IdType="pmc">PMC7678724</ArticleId><ArticleId IdType="pubmed">31097668</ArticleId></ArticleIdList></Reference><Reference><Citation>Schirmer L, et al. Neuronal vulnerability and multilineage diversity in multiple sclerosis. Nature. 2019;573:75&#x2013;82. doi: 10.1038/s41586-019-1404-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-1404-z</ArticleId><ArticleId IdType="pmc">PMC6731122</ArticleId><ArticleId IdType="pubmed">31316211</ArticleId></ArticleIdList></Reference><Reference><Citation>J&#xe4;kel S, et al. Altered human oligodendrocyte heterogeneity in multiple sclerosis. Nature. 2019;566:543&#x2013;547. doi: 10.1038/s41586-019-0903-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-0903-2</ArticleId><ArticleId IdType="pmc">PMC6544546</ArticleId><ArticleId IdType="pubmed">30747918</ArticleId></ArticleIdList></Reference><Reference><Citation>Welch JD, et al. Single-cell multi-omic integration compares and contrasts features of brain cell identity. Cell. 2019;177:1873&#x2013;1887. doi: 10.1016/j.cell.2019.05.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2019.05.006</ArticleId><ArticleId IdType="pmc">PMC6716797</ArticleId><ArticleId IdType="pubmed">31178122</ArticleId></ArticleIdList></Reference><Reference><Citation>Smajic, S., Prada-Medina, C. A. &amp; Landoulsi, Z. Single-cell sequencing of the human midbrain reveals glial activation and a neuronal state specific to Parkinson&#x2019;s disease. BrainDec 17, awab446 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9050543</ArticleId><ArticleId IdType="pubmed">34919646</ArticleId></ArticleIdList></Reference><Reference><Citation>Agarwal D, et al. A single-cell atlas of the human substantia nigra reveals cell-specific pathways associated with neurological disorders. Nat. Commun. 2020;11:4183. doi: 10.1038/s41467-020-17876-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-17876-0</ArticleId><ArticleId IdType="pmc">PMC7442652</ArticleId><ArticleId IdType="pubmed">32826893</ArticleId></ArticleIdList></Reference><Reference><Citation>La Manno G, et al. Molecular diversity of midbrain development in mouse, human, and stem cells. Cell. 2016;167:566&#x2013;580. doi: 10.1016/j.cell.2016.09.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2016.09.027</ArticleId><ArticleId IdType="pmc">PMC5055122</ArticleId><ArticleId IdType="pubmed">27716510</ArticleId></ArticleIdList></Reference><Reference><Citation>Damier P, Hirsch EC, Agid Y, Graybiel AM. The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry. Brain. 1999;122:1421&#x2013;1436. doi: 10.1093/brain/122.8.1421.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/122.8.1421</ArticleId><ArticleId IdType="pubmed">10430829</ArticleId></ArticleIdList></Reference><Reference><Citation>Saunders A, et al. Molecular diversity and specializations among the cells of the adult mouse brain. Cell. 2018;174:1015&#x2013;1030. doi: 10.1016/j.cell.2018.07.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2018.07.028</ArticleId><ArticleId IdType="pmc">PMC6447408</ArticleId><ArticleId IdType="pubmed">30096299</ArticleId></ArticleIdList></Reference><Reference><Citation>Poulin J-F, Gaertner Z, Moreno-Ramos OA, Awatramani R. Classification of midbrain dopamine neurons using single-cell gene expression profiling approaches. Trends Neurosci. 2020;43:155&#x2013;169. doi: 10.1016/j.tins.2020.01.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2020.01.004</ArticleId><ArticleId IdType="pmc">PMC7285906</ArticleId><ArticleId IdType="pubmed">32101709</ArticleId></ArticleIdList></Reference><Reference><Citation>Panman L, et al. Sox6 and Otx2 control the specification of substantia nigra and ventral tegmental area dopamine neurons. Cell Rep. 2014;8:1018&#x2013;1025. doi: 10.1016/j.celrep.2014.07.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2014.07.016</ArticleId><ArticleId IdType="pubmed">25127144</ArticleId></ArticleIdList></Reference><Reference><Citation>Krienen FM, et al. Innovations present in the primate interneuron repertoire. Nature. 2020;586:262&#x2013;269. doi: 10.1038/s41586-020-2781-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2781-z</ArticleId><ArticleId IdType="pmc">PMC7957574</ArticleId><ArticleId IdType="pubmed">32999462</ArticleId></ArticleIdList></Reference><Reference><Citation>Hodge RD, et al. Conserved cell types with divergent features in human versus mouse cortex. Nature. 2019;573:61&#x2013;68. doi: 10.1038/s41586-019-1506-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-1506-7</ArticleId><ArticleId IdType="pmc">PMC6919571</ArticleId><ArticleId IdType="pubmed">31435019</ArticleId></ArticleIdList></Reference><Reference><Citation>Villaescusa JC, et al. A PBX1 transcriptional network controls dopaminergic neuron development and is impaired in Parkinson&#x2019;s disease. EMBO J. 2016;35:1963&#x2013;1978. doi: 10.15252/embj.201593725.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.201593725</ArticleId><ArticleId IdType="pmc">PMC5282836</ArticleId><ArticleId IdType="pubmed">27354364</ArticleId></ArticleIdList></Reference><Reference><Citation>Fearnley JM, Lees AJ. Ageing and Parkinson&#x2019;s disease: substantia nigra regional selectivity. Brain. 1991;114:2283&#x2013;2301. doi: 10.1093/brain/114.5.2283.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/114.5.2283</ArticleId><ArticleId IdType="pubmed">1933245</ArticleId></ArticleIdList></Reference><Reference><Citation>Brichta L, Greengard P. Molecular determinants of selective dopaminergic vulnerability in Parkinson&#x2019;s disease: an update. Front. Neuroanat. 2014;8:152. doi: 10.3389/fnana.2014.00152.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnana.2014.00152</ArticleId><ArticleId IdType="pmc">PMC4266033</ArticleId><ArticleId IdType="pubmed">25565977</ArticleId></ArticleIdList></Reference><Reference><Citation>Damier P, Hirsch EC, Agid Y, Graybiel AM. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson&#x2019;s disease. Brain. 1999;122:1437&#x2013;1448. doi: 10.1093/brain/122.8.1437.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/122.8.1437</ArticleId><ArticleId IdType="pubmed">10430830</ArticleId></ArticleIdList></Reference><Reference><Citation>Stickels RR, et al. Highly sensitive spatial transcriptomics at near-cellular resolution with Slide-seqV2. Nat. Biotechnol. 2021;39:313&#x2013;319. doi: 10.1038/s41587-020-0739-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41587-020-0739-1</ArticleId><ArticleId IdType="pmc">PMC8606189</ArticleId><ArticleId IdType="pubmed">33288904</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriques, S. G., Stickels, R. R., Goeva, A. &amp; Martin, C. A. Slide-seq: a scalable technology for measuring genome-wide expression at high spatial resolution. Science363, 1463&#x2013;1467 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6927209</ArticleId><ArticleId IdType="pubmed">30923225</ArticleId></ArticleIdList></Reference><Reference><Citation>Cable, D. M. et al. Robust decomposition of cell type mixtures in spatial transcriptomics. Nat. Biotechnol.10.1038/s41587-021-00830-w (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8606190</ArticleId><ArticleId IdType="pubmed">33603203</ArticleId></ArticleIdList></Reference><Reference><Citation>Monz&#xf3;n-Sandoval J, et al. Human-specific transcriptome of ventral and dorsal midbrain dopamine neurons. Ann. Neurol. 2020;87:853&#x2013;868. doi: 10.1002/ana.25719.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25719</ArticleId><ArticleId IdType="pmc">PMC8651008</ArticleId><ArticleId IdType="pubmed">32167609</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H, et al. A unique microglia type associated with restricting development of Alzheimer&#x2019;s disease. Cell. 2017;169:1276&#x2013;1290. doi: 10.1016/j.cell.2017.05.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.05.018</ArticleId><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerrits E, et al. Distinct amyloid-&#x3b2; and tau-associated microglia profiles in Alzheimer&#x2019;s disease. Acta Neuropathol. 2021;141:681&#x2013;696. doi: 10.1007/s00401-021-02263-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-021-02263-w</ArticleId><ArticleId IdType="pmc">PMC8043951</ArticleId><ArticleId IdType="pubmed">33609158</ArticleId></ArticleIdList></Reference><Reference><Citation>Decressac M, Volakakis N, Bj&#xf6;rklund A, Perlmann T. NURR1 in Parkinson disease&#x2014;from pathogenesis to therapeutic potential. Nat. Rev. Neurol. 2013;9:629&#x2013;636. doi: 10.1038/nrneurol.2013.209.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2013.209</ArticleId><ArticleId IdType="pubmed">24126627</ArticleId></ArticleIdList></Reference><Reference><Citation>Bustos, B. I., Krainc, D., Lubbe, S. J. &amp; for The International Parkinson&#x2019;s Disease Genomics Consortium (IPDGC). Whole-exome analysis in Parkinson&#x2019;s disease reveals a high burden of ultra rare variants in early onset cases. Preprint at https://www.biorxiv.org/content/10.1101/2020.06.06.137299v1 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.06.06.137299v1</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalls MA, et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson&#x2019;s disease: a meta-analysis of genome-wide association studies. Lancet Neurol. 2019;18:1091&#x2013;1102. doi: 10.1016/S1474-4422(19)30320-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(19)30320-5</ArticleId><ArticleId IdType="pmc">PMC8422160</ArticleId><ArticleId IdType="pubmed">31701892</ArticleId></ArticleIdList></Reference><Reference><Citation>de Leeuw CA, Mooij JM, Heskes T, Posthuma D. MAGMA: generalized gene-set analysis of GWAS data. PLoS Comput. Biol. 2015;11:e1004219. doi: 10.1371/journal.pcbi.1004219.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pcbi.1004219</ArticleId><ArticleId IdType="pmc">PMC4401657</ArticleId><ArticleId IdType="pubmed">25885710</ArticleId></ArticleIdList></Reference><Reference><Citation>Bryois J, et al. Genetic identification of cell types underlying brain complex traits yields insights into the etiology of Parkinson&#x2019;s disease. Nat. Genet. 2020;52:482&#x2013;493. doi: 10.1038/s41588-020-0610-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-020-0610-9</ArticleId><ArticleId IdType="pmc">PMC7930801</ArticleId><ArticleId IdType="pubmed">32341526</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartzentruber J, et al. Genome-wide meta-analysis, fine-mapping and integrative prioritization implicate new Alzheimer&#x2019;s disease risk genes. Nat. Genet. 2021;53:392&#x2013;402. doi: 10.1038/s41588-020-00776-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-020-00776-w</ArticleId><ArticleId IdType="pmc">PMC7610386</ArticleId><ArticleId IdType="pubmed">33589840</ArticleId></ArticleIdList></Reference><Reference><Citation>Finucane HK, et al. Heritability enrichment of specifically expressed genes identifies disease-relevant tissues and cell types. Nat. Genet. 2018;50:621&#x2013;629. doi: 10.1038/s41588-018-0081-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-018-0081-4</ArticleId><ArticleId IdType="pmc">PMC5896795</ArticleId><ArticleId IdType="pubmed">29632380</ArticleId></ArticleIdList></Reference><Reference><Citation>Berwick DC, et al. Pathogenic LRRK2 variants are gain-of-function mutations that enhance LRRK2-mediated repression of &#x3b2;-catenin signaling. Mol. Neurodegener. 2017;12:9. doi: 10.1186/s13024-017-0153-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-017-0153-4</ArticleId><ArticleId IdType="pmc">PMC5248453</ArticleId><ArticleId IdType="pubmed">28103901</ArticleId></ArticleIdList></Reference><Reference><Citation>Arenas E. Wnt signaling in midbrain dopaminergic neuron development and regenerative medicine for Parkinson&#x2019;s disease. J. Mol. Cell. Biol. 2014;6:42&#x2013;53. doi: 10.1093/jmcb/mju001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jmcb/mju001</ArticleId><ArticleId IdType="pubmed">24431302</ArticleId></ArticleIdList></Reference><Reference><Citation>Korotkevich, G. et al. Fast gene set enrichment analysis. Preprint at https://www.biorxiv.org/content/10.1101/060012v3 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/060012v3</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA. 2005;102:15545&#x2013;15550. doi: 10.1073/pnas.0506580102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0506580102</ArticleId><ArticleId IdType="pmc">PMC1239896</ArticleId><ArticleId IdType="pubmed">16199517</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie, Z. et al. Gene set knowledge discovery with Enrichr. Curr. Protoc. 1, e90 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8152575</ArticleId><ArticleId IdType="pubmed">33780170</ArticleId></ArticleIdList></Reference><Reference><Citation>Arenas, E., Denham, M. &amp; Villaescusa, J. C. How to make a midbrain dopaminergic neuron. Development142, 1918&#x2013;1936 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26015536</ArticleId></ArticleIdList></Reference><Reference><Citation>Costa CAda, et al. Transcriptional repression of p53 by parkin and impairment by mutations associated with autosomal recessive juvenile Parkinson&#x2019;s disease. Nat. Cell Biol. 2009;11:1370&#x2013;1375. doi: 10.1038/ncb1981.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncb1981</ArticleId><ArticleId IdType="pmc">PMC2952934</ArticleId><ArticleId IdType="pubmed">19801972</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi X, et al. Dopaminergic neuron-specific deletion of p53 gene is neuroprotective in an experimental Parkinson&#x2019;s disease model. J. Neurochem. 2016;138:746&#x2013;757. doi: 10.1111/jnc.13706.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.13706</ArticleId><ArticleId IdType="pmc">PMC5155515</ArticleId><ArticleId IdType="pubmed">27317935</ArticleId></ArticleIdList></Reference><Reference><Citation>Kao C-Y, et al. Elevated COUP-TFII expression in dopaminergic neurons accelerates the progression of Parkinson&#x2019;s disease through mitochondrial dysfunction. PLoS Genet. 2020;16:e1008868. doi: 10.1371/journal.pgen.1008868.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1008868</ArticleId><ArticleId IdType="pmc">PMC7340320</ArticleId><ArticleId IdType="pubmed">32579581</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell, J. M., Nemesh, J., Ghosh, S. &amp; Handsaker, R. E. Mapping genetic effects on cellular phenotypes with "cell villages". Preprint at https://www.biorxiv.org/content/10.1101/2020.06.29.174383v1 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.06.29.174383v1</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguet F, et al. The GTEx Consortium atlas of genetic regulatory effects across human tissues. Science. 2020;369:1318&#x2013;1330. doi: 10.1126/science.aaz1776.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaz1776</ArticleId><ArticleId IdType="pmc">PMC7737656</ArticleId><ArticleId IdType="pubmed">32913098</ArticleId></ArticleIdList></Reference><Reference><Citation>Skene NG, et al. Genetic identification of brain cell types underlying schizophrenia. Nat. Genet. 2018;50:825&#x2013;833. doi: 10.1038/s41588-018-0129-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-018-0129-5</ArticleId><ArticleId IdType="pmc">PMC6477180</ArticleId><ArticleId IdType="pubmed">29785013</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, et al. Staging of brain pathology related to sporadic Parkinson&#x2019;s disease. Neurobiol. Aging. 2003;24:197&#x2013;211. doi: 10.1016/S0197-4580(02)00065-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0197-4580(02)00065-9</ArticleId><ArticleId IdType="pubmed">12498954</ArticleId></ArticleIdList></Reference><Reference><Citation>Seidel K, et al. The brainstem pathologies of Parkinson&#x2019;s disease and dementia with Lewy bodies. Brain Pathol. 2015;25:121&#x2013;135. doi: 10.1111/bpa.12168.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bpa.12168</ArticleId><ArticleId IdType="pmc">PMC4397912</ArticleId><ArticleId IdType="pubmed">24995389</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu S-P, et al. Increased COUP-TFII expression in adult hearts induces mitochondrial dysfunction resulting in heart failure. Nat. Commun. 2015;6:8245. doi: 10.1038/ncomms9245.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms9245</ArticleId><ArticleId IdType="pmc">PMC4568566</ArticleId><ArticleId IdType="pubmed">26356605</ArticleId></ArticleIdList></Reference><Reference><Citation>Maor-Nof M, et al. p53 is a central regulator driving neurodegeneration caused by C9orf72 poly(PR) Cell. 2021;184:689&#x2013;708. doi: 10.1016/j.cell.2020.12.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.12.025</ArticleId><ArticleId IdType="pmc">PMC7886018</ArticleId><ArticleId IdType="pubmed">33482083</ArticleId></ArticleIdList></Reference><Reference><Citation>de la Monte SM, Sohn YK, Wands JR. Correlates of p53- and Fas (CD95)-mediated apoptosis in Alzheimer&#x2019;s disease. J. Neurol. Sci. 1997;152:73&#x2013;83. doi: 10.1016/S0022-510X(97)00131-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(97)00131-7</ArticleId><ArticleId IdType="pubmed">9395128</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitamura Y, et al. Changes of p53 in the brains of patients with Alzheimer&#x2019;s disease. Biochem. Biophys. Res. Commun. 1997;232:418&#x2013;421. doi: 10.1006/bbrc.1997.6301.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/bbrc.1997.6301</ArticleId><ArticleId IdType="pubmed">9125193</ArticleId></ArticleIdList></Reference><Reference><Citation>Bae B-I, et al. p53 mediates cellular dysfunction and behavioral abnormalities in Huntington&#x2019;s disease. Neuron. 2005;47:29&#x2013;41. doi: 10.1016/j.neuron.2005.06.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2005.06.005</ArticleId><ArticleId IdType="pubmed">15996546</ArticleId></ArticleIdList></Reference><Reference><Citation>Kozareva, V. et al. A transcriptomic atlas of mouse cerebellar cortex comprehensively defines cell types. Nature598, 214&#x2013;219 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8494635</ArticleId><ArticleId IdType="pubmed">34616064</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler A, Hoffman P, Smibert P, Papalexi E, Satija R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. 2018;36:411&#x2013;420. doi: 10.1038/nbt.4096.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.4096</ArticleId><ArticleId IdType="pmc">PMC6700744</ArticleId><ArticleId IdType="pubmed">29608179</ArticleId></ArticleIdList></Reference><Reference><Citation>Osorio D, Cai JJ. Systematic determination of the mitochondrial proportion in human and mice tissues for single-cell RNA-sequencing data quality control. Bioinformatics. 2021;37:963&#x2013;967. doi: 10.1093/bioinformatics/btaa751.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btaa751</ArticleId><ArticleId IdType="pmc">PMC8599307</ArticleId><ArticleId IdType="pubmed">32840568</ArticleId></ArticleIdList></Reference><Reference><Citation>Korsunsky I, et al. Fast, sensitive and accurate integration of single-cell data with Harmony. Nat. Methods. 2019;16:1289&#x2013;1296. doi: 10.1038/s41592-019-0619-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41592-019-0619-0</ArticleId><ArticleId IdType="pmc">PMC6884693</ArticleId><ArticleId IdType="pubmed">31740819</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakken TE, et al. Single-nucleus and single-cell transcriptomes compared in matched cortical cell types. PLoS ONE. 2018;13:e0209648. doi: 10.1371/journal.pone.0209648.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0209648</ArticleId><ArticleId IdType="pmc">PMC6306246</ArticleId><ArticleId IdType="pubmed">30586455</ArticleId></ArticleIdList></Reference><Reference><Citation>Odh G, Hindemith A, Rosengren AM, Rosengren E, Rorsman H. Isolation of a new tautomerase monitored by the conversion of D-dopachrome to 5,6-dihydroxyindole. Biochem. Biophys. Res. Commun. 1993;197:619&#x2013;624. doi: 10.1006/bbrc.1993.2524.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/bbrc.1993.2524</ArticleId><ArticleId IdType="pubmed">8267597</ArticleId></ArticleIdList></Reference><Reference><Citation>Fonseka CY, et al. Mixed-effects association of single cells identifies an expanded effector CD4+T cell subset in rheumatoid arthritis. Sci. Transl. Med. 2018;10:eaaq0305. doi: 10.1126/scitranslmed.aaq0305.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aaq0305</ArticleId><ArticleId IdType="pmc">PMC6448773</ArticleId><ArticleId IdType="pubmed">30333237</ArticleId></ArticleIdList></Reference><Reference><Citation>Finak G, et al. MAST: a flexible statistical framework for assessing transcriptional changes and characterizing heterogeneity in single-cell RNA sequencing data. Genome Biol. 2015;16:278. doi: 10.1186/s13059-015-0844-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-015-0844-5</ArticleId><ArticleId IdType="pmc">PMC4676162</ArticleId><ArticleId IdType="pubmed">26653891</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35513514</PMID><DateCompleted><Year>2022</Year><Month>05</Month><Day>10</Day></DateCompleted><DateRevised><Year>2022</Year><Month>08</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>5</Issue><PubDate><Year>2022</Year><Month>May</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Parkinson's disease in the single-cell era.</ArticleTitle><Pagination><StartPage>536</StartPage><EndPage>538</EndPage><MedlinePgn>536-538</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41593-022-01069-7</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Arenas</LastName><ForeName>Ernest</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-0197-6577</Identifier><AffiliationInfo><Affiliation>Karolinska Institutet, MBB, Molecular Neurobiology, Stockholm, Sweden. ernest.arenas@ki.se.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Nat Neurosci. 2022 May;25(5):588-595. doi: 10.1038/s41593-022-01061-1.</RefSource><PMID Version="1">35513515</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="Y">Parkinson Disease</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>5</Day><Hour>23</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35513514</ArticleId><ArticleId IdType="doi">10.1038/s41593-022-01069-7</ArticleId><ArticleId IdType="pii">10.1038/s41593-022-01069-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Dahlstrom, A. &amp; Fuxe, K. Acta Physiol. Scand. Suppl. 232, 231&#x2013;255 (1964).</Citation></Reference><Reference><Citation>Anden, N. E. et al. Life Sci. 3, 523&#x2013;530 (1964).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0024-3205(64)90161-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Poulin, J. F. et al. Cell Rep. 9, 930&#x2013;943 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2014.10.008</ArticleId></ArticleIdList></Reference><Reference><Citation>Poulin, J. F., Gaertner, Z., Moreno-Ramos, O. A. &amp; Awatramani, R. Trends Neurosci. 43, 155&#x2013;169 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2020.01.004</ArticleId></ArticleIdList></Reference><Reference><Citation>La Manno, G. et al. Cell 167, 566&#x2013;580.e19 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2016.09.027</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamath, T. et al. Nat. Neurosci. https://doi.org/10.1038/s41593-022-01061-1 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-022-01061-1</ArticleId><ArticleId IdType="pubmed">35260865</ArticleId></ArticleIdList></Reference><Reference><Citation>Oosterveen, T. et al. Stem Cell Reports 16, 2718&#x2013;2735 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2021.09.014</ArticleId></ArticleIdList></Reference><Reference><Citation>Panman, L. et al. Cell Rep. 8, 1018&#x2013;1025 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2014.07.016</ArticleId></ArticleIdList></Reference><Reference><Citation>Inestrosa, N. C. &amp; Arenas, E. Nat. Rev. Neurosci. 11, 77&#x2013;86 (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn2755</ArticleId></ArticleIdList></Reference><Reference><Citation>Pereira Luppi, M. et al. Cell Rep. 37, 109975 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.109975</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito, S. et al. J. Hum. Genet. 48, 461&#x2013;468 (2003).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10038-003-0062-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Reardon, K. A., Mendelsohn, F. A., Chai, S. Y. &amp; Horne, M. K. Aust. N. Z. J. Med. 30, 48&#x2013;53 (2000).</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1445-5994.2000.tb01054.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Labandeira-Garc&#xed;a, J. L. et al. Front. Neuroanat. 8, 67 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25071471</ArticleId><ArticleId IdType="pmc">4086395</ArticleId></ArticleIdList></Reference><Reference><Citation>Bryois, J. et al. Nat. Genet. 52, 482&#x2013;493 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-020-0610-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Surmeier, D. J., Obeso, J. A. &amp; Halliday, G. M. Nat. Rev. Neurosci. 18, 101&#x2013;113 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn.2016.178</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">35535997</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>22</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2050-084X</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><PubDate><Year>2022</Year><Month>May</Month><Day>10</Day></PubDate></JournalIssue><Title>eLife</Title><ISOAbbreviation>Elife</ISOAbbreviation></Journal><ArticleTitle>Repressing PTBP1 fails to convert reactive astrocytes to dopaminergic neurons in a 6-hydroxydopamine mouse model of Parkinson's disease.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e75636</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.7554/eLife.75636</ELocationID><Abstract><AbstractText>Lineage reprogramming of resident glial cells to dopaminergic neurons (DAns) is an attractive prospect of the cell-replacement therapy for Parkinson's disease (PD). However, it is unclear whether repressing polypyrimidine tract binding protein 1 (PTBP1) could efficiently convert astrocyte to DAns in the substantia nigra and striatum. Although reporter-positive DAns were observed in both groups after delivering the adeno-associated virus (AAV) expressing a reporter with shRNA or CRISPR-CasRx to repress astroglial PTBP1, the possibility of AAV leaking into endogenous DAns could not be excluded without using a reliable lineage-tracing method. By adopting stringent lineage-tracing strategy, two other studies show that either knockdown or genetic deletion of quiescent astroglial PTBP1 fails to obtain induced DAns under physiological condition. However, the role of reactive astrocytes might be underestimated because upon brain injury, reactive astrocyte can acquire certain stem cell hallmarks that may facilitate the lineage conversion process. Therefore, whether reactive astrocytes could be genuinely converted to DAns after PTBP1 repression in a PD model needs further validation. In this study, we used <i>Aldh1l1-CreERT2</i>-mediated specific astrocyte-lineage-tracing method to investigate whether reactive astrocytes could be converted to DAns in a 6-hydroxydopamine (6-OHDA) mouse model of PD. However, we found that no astrocyte-originated DAn was generated after effective and persistent knockdown of astroglial PTBP1 either in the substantia nigra or in striatum, while AAV 'leakage' to nearby neurons was easily observed. Our results confirm that repressing PTBP1 does not convert astrocytes to DAns, regardless of physiological or PD-related pathological conditions.</AbstractText><CopyrightInformation>&#xa9; 2022, Chen et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Chen</LastName><ForeName>Weizhao</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0002-6753-4854</Identifier><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Brain Function and Disease, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Zheng</LastName><ForeName>Qiongping</ForeName><Initials>Q</Initials><Identifier Source="ORCID">0000-0002-1989-9234</Identifier><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Brain Function and Disease, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Qiaoying</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Brain Function and Disease, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Shanshan</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-3004-9468</Identifier><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Brain Function and Disease, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Mingtao</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-5714-9322</Identifier><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Brain Function and Disease, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>05</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Elife</MedlineTA><NlmUniqueID>101579614</NlmUniqueID><ISSNLinking>2050-084X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034441">Heterogeneous-Nuclear Ribonucleoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C573992">Ptbp1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>139076-35-0</RegistryNumber><NameOfSubstance UI="D038941">Polypyrimidine Tract-Binding Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>8HW4YBZ748</RegistryNumber><NameOfSubstance UI="D016627">Oxidopamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>doi: 10.7554/eLife.80232</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000229" MajorTopicYN="N">Dependovirus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059290" MajorTopicYN="Y">Dopaminergic Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D034441" MajorTopicYN="N">Heterogeneous-Nuclear Ribonucleoproteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016627" MajorTopicYN="N">Oxidopamine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="Y">Parkinson Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D038941" MajorTopicYN="N">Polypyrimidine Tract-Binding Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013378" MajorTopicYN="N">Substantia Nigra</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">6-OHDA model</Keyword><Keyword MajorTopicYN="N">PTBP1</Keyword><Keyword MajorTopicYN="N">Parkinson's disease</Keyword><Keyword MajorTopicYN="N">astrocyte</Keyword><Keyword MajorTopicYN="N">astrocyte-to-neuron conversion</Keyword><Keyword MajorTopicYN="N">lineage reprogramming</Keyword><Keyword MajorTopicYN="N">mouse</Keyword><Keyword MajorTopicYN="N">neuroscience</Keyword><Keyword MajorTopicYN="N">regenerative medicine</Keyword><Keyword MajorTopicYN="N">stem cells</Keyword></KeywordList><CoiStatement>WC, QZ, QH, SM, ML No competing interests declared</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>11</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>5</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>10</Day><Hour>8</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>5</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35535997</ArticleId><ArticleId IdType="pmc">PMC9208759</ArticleId><ArticleId IdType="doi">10.7554/eLife.75636</ArticleId><ArticleId IdType="pii">75636</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arenas E. Method to combat Parkinson&#x2019;s disease by astrocyte-to-neuron conversion. Nature. 2020;582:489&#x2013;490. doi: 10.1038/d41586-020-01817-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-020-01817-4</ArticleId><ArticleId IdType="pubmed">32581373</ArticleId></ArticleIdList></Reference><Reference><Citation>Belenguer G, Duart-Abadia P, Jord&#xe1;n-Pla A, Domingo-Muelas A, Blasco-Chamarro L, Ferr&#xf3;n SR, Morante-Redolat JM, Fari&#xf1;as I. Adult Neural Stem Cells Are Alerted by Systemic Inflammation through TNF-&#x3b1; Receptor Signaling. Cell Stem Cell. 2021;28:285&#x2013;299. doi: 10.1016/j.stem.2020.10.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2020.10.016</ArticleId><ArticleId IdType="pubmed">33207218</ArticleId></ArticleIdList></Reference><Reference><Citation>Blackshaw S, Hoang T, Kim DW, Appel H, Pannullo N, Ozawa M, Zheng S, Yu M, Peachey N, Kim J. Ptbp1 Deletion Does Not Induce Glia-to-Neuron Conversion in Adult Mouse Retina and Brain. bioRxiv. 2021 doi: 10.1101/2021.10.04.462784.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.10.04.462784</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Brulet R, Matsuda T, Zhang L, Miranda C, Giacca M, Kaspar BK, Nakashima K, Hsieh J. NEUROD1 Instructs Neuronal Conversion in Non-Reactive Astrocytes. Stem Cell Reports. 2017;8:1506&#x2013;1515. doi: 10.1016/j.stemcr.2017.04.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2017.04.013</ArticleId><ArticleId IdType="pmc">PMC5470076</ArticleId><ArticleId IdType="pubmed">28506534</ArticleId></ArticleIdList></Reference><Reference><Citation>Buffo A, Vosko MR, Ert&#xfc;rk D, Hamann GF, Jucker M, Rowitch D, G&#xf6;tz M. Expression pattern of the transcription factor Olig2 in response to brain injuries: implications for neuronal repair. PNAS. 2005;102:18183&#x2013;18188. doi: 10.1073/pnas.0506535102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0506535102</ArticleId><ArticleId IdType="pmc">PMC1312388</ArticleId><ArticleId IdType="pubmed">16330768</ArticleId></ArticleIdList></Reference><Reference><Citation>Buffo A, Rite I, Tripathi P, Lepier A, Colak D, Horn AP, Mori T, G&#xf6;tz M. Origin and progeny of reactive gliosis: A source of multipotent cells in the injured brain. PNAS. 2008;105:3581&#x2013;3586. doi: 10.1073/pnas.0709002105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0709002105</ArticleId><ArticleId IdType="pmc">PMC2265175</ArticleId><ArticleId IdType="pubmed">18299565</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen YC, Ma NX, Pei ZF, Wu Z, Do-Monte FH, Keefe S, Yellin E, Chen MS, Yin JC, Lee G, Minier-Toribio A, Hu Y, Bai YT, Lee K, Quirk GJ, Chen G. A NeuroD1 AAV-Based Gene Therapy for Functional Brain Repair after Ischemic Injury through In Vivo Astrocyte-to-Neuron Conversion. Molecular Therapy. 2020;28:217&#x2013;234. doi: 10.1016/j.ymthe.2019.09.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2019.09.003</ArticleId><ArticleId IdType="pmc">PMC6952185</ArticleId><ArticleId IdType="pubmed">31551137</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarke LE, Liddelow SA, Chakraborty C, M&#xfc;nch AE, Heiman M, Barres BA. Normal aging induces A1-like astrocyte reactivity. PNAS. 2018;115:E1896&#x2013;E1905. doi: 10.1073/pnas.1800165115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1800165115</ArticleId><ArticleId IdType="pmc">PMC5828643</ArticleId><ArticleId IdType="pubmed">29437957</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasc&#xf3;n S, Murenu E, Masserdotti G, Ortega F, Russo GL, Petrik D, Deshpande A, Heinrich C, Karow M, Robertson SP, Schroeder T, Beckers J, Irmler M, Berndt C, Angeli JPF, Conrad M, Berninger B, G&#xf6;tz M. Identification and Successful Negotiation of a Metabolic Checkpoint in Direct Neuronal Reprogramming. Cell Stem Cell. 2016;18:396&#x2013;409. doi: 10.1016/j.stem.2015.12.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2015.12.003</ArticleId><ArticleId IdType="pubmed">26748418</ArticleId></ArticleIdList></Reference><Reference><Citation>Grande A, Sumiyoshi K, L&#xf3;pez-Ju&#xe1;rez A, Howard J, Sakthivel B, Aronow B, Campbell K, Nakafuku M. Environmental impact on direct neuronal reprogramming in vivo in the adult brain. Nature Communications. 2013;4:2373. doi: 10.1038/ncomms3373.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms3373</ArticleId><ArticleId IdType="pmc">PMC3786770</ArticleId><ArticleId IdType="pubmed">23974433</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Z, Zhang L, Wu Z, Chen Y, Wang F, Chen G. In vivo direct reprogramming of reactive glial cells into functional neurons after brain injury and in an Alzheimer&#x2019;s disease model. Cell Stem Cell. 2014;14:188&#x2013;202. doi: 10.1016/j.stem.2013.12.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2013.12.001</ArticleId><ArticleId IdType="pmc">PMC3967760</ArticleId><ArticleId IdType="pubmed">24360883</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinrich C, Bergami M, Gasc&#xf3;n S, Lepier A, Vigan&#xf2; F, Dimou L, Sutor B, Berninger B, G&#xf6;tz M. Sox2-mediated conversion of NG2 glia into induced neurons in the injured adult cerebral cortex. Stem Cell Reports. 2014;3:1000&#x2013;1014. doi: 10.1016/j.stemcr.2014.10.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2014.10.007</ArticleId><ArticleId IdType="pmc">PMC4264057</ArticleId><ArticleId IdType="pubmed">25458895</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu K, Huang Q, Liu C, Li Y, Liu Y, Wang H, Li M, Ma S. c-Jun/Bim Upregulation in Dopaminergic Neurons Promotes Neurodegeneration in the MPTP Mouse Model of Parkinson&#x2019;s Disease. Neuroscience. 2019;399:117&#x2013;124. doi: 10.1016/j.neuroscience.2018.12.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2018.12.026</ArticleId><ArticleId IdType="pubmed">30590105</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Y, Wang Y, Huang Z. Targeting PTB as a One-Step Procedure for In Situ Astrocyte-to-Dopamine Neuron Reprogramming in Parkinson&#x2019;s Disease. Neuroscience Bulletin. 2021;37:430&#x2013;432. doi: 10.1007/s12264-021-00630-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12264-021-00630-x</ArticleId><ArticleId IdType="pmc">PMC7954921</ArticleId><ArticleId IdType="pubmed">33439451</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnston S, Parylak SL, Kim S, Mac N, Lim C, Gallina I, Bloyd C, Newberry A, Saavedra CD, Novak O, Gon&#xe7;alves JT, Gage FH, Shtrahman M. AAV ablates neurogenesis in the adult murine hippocampus. eLife. 2021;10:e59291. doi: 10.7554/eLife.59291.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.59291</ArticleId><ArticleId IdType="pmc">PMC8331179</ArticleId><ArticleId IdType="pubmed">34259630</ArticleId></ArticleIdList></Reference><Reference><Citation>Karimi-Abdolrezaee S, Billakanti R. Reactive astrogliosis after spinal cord injury-beneficial and detrimental effects. Molecular Neurobiology. 2012;46:251&#x2013;264. doi: 10.1007/s12035-012-8287-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-012-8287-4</ArticleId><ArticleId IdType="pubmed">22684804</ArticleId></ArticleIdList></Reference><Reference><Citation>Kretzschmar K, Watt FM. Lineage tracing. Cell. 2012;148:33&#x2013;45. doi: 10.1016/j.cell.2012.01.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2012.01.002</ArticleId><ArticleId IdType="pubmed">22265400</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai M, Pan M, Ge L, Liu J, Deng J, Wang X, Li L, Wen J, Tan D, Zhang H, Hu X, Fu L, Xu Y, Li Z, Qiu X, Chen G, Guo J. NeuroD1 overexpression in spinal neurons accelerates axonal regeneration after sciatic nerve injury. Experimental Neurology. 2020;327:113215. doi: 10.1016/j.expneurol.2020.113215.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2020.113215</ArticleId><ArticleId IdType="pubmed">31991126</ArticleId></ArticleIdList></Reference><Reference><Citation>Leib D, Chen YH, Monteys AM, Davidson BL. Limited astrocyte-to-neuron conversion in the mouse brain using NeuroD1 overexpression. Molecular Therapy. 2022;30:982&#x2013;986. doi: 10.1016/j.ymthe.2022.01.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2022.01.028</ArticleId><ArticleId IdType="pmc">PMC8899704</ArticleId><ArticleId IdType="pubmed">35123657</ArticleId></ArticleIdList></Reference><Reference><Citation>Lentini C, d&#x2019;Orange M, Marichal N, Trottmann M-M, Vignoles R, Foucault L, Verrier C, Massera C, Raineteau O, Conzelmann K-K, Rival-Gervier S, Depaulis A, Berninger B, Heinrich C. Reprogramming reactive glia into interneurons reduces chronic seizure activity in a mouse model of mesial temporal lobe epilepsy. Cell Stem Cell. 2021;28:2104&#x2013;2121. doi: 10.1016/j.stem.2021.09.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2021.09.002</ArticleId><ArticleId IdType="pmc">PMC8657801</ArticleId><ArticleId IdType="pubmed">34592167</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Miao Q, Yuan J, Han S, Zhang P, Li S, Rao Z, Zhao W, Ye Q, Geng J, Zhang X, Cheng L. Ascl1 Converts Dorsal Midbrain Astrocytes into Functional Neurons In Vivo. The Journal of Neuroscience. 2015;35:9336&#x2013;9355. doi: 10.1523/JNEUROSCI.3975-14.2015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3975-14.2015</ArticleId><ArticleId IdType="pmc">PMC6605193</ArticleId><ArticleId IdType="pubmed">26109658</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu MH, Li W, Zheng JJ, Xu YG, He Q, Chen G. Differential neuronal reprogramming induced by NeuroD1 from astrocytes in grey matter versus white matter. Neural Regeneration Research. 2020;15:342&#x2013;351. doi: 10.4103/1673-5374.265185.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1673-5374.265185</ArticleId><ArticleId IdType="pmc">PMC6905344</ArticleId><ArticleId IdType="pubmed">31552908</ArticleId></ArticleIdList></Reference><Reference><Citation>Magnusson JP, G&#xf6;ritz C, Tatarishvili J, Dias DO, Smith EMK, Lindvall O, Kokaia Z, Fris&#xe9;n J. A latent neurogenic program in astrocytes regulated by Notch signaling in the mouse. Science (New York, N.Y.) 2014;346:237&#x2013;241. doi: 10.1126/science.346.6206.237.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.346.6206.237</ArticleId><ArticleId IdType="pubmed">25301628</ArticleId></ArticleIdList></Reference><Reference><Citation>Maimon R, Chillon-Marinas C, Snethlage CE, Singhal SM, McAlonis-Downes M, Ling K, Rigo F, Bennett CF, Da Cruz S, Hnasko TS, Muotri AR, Cleveland DW. Therapeutically viable generation of neurons with antisense oligonucleotide suppression of PTB. Nature Neuroscience. 2021;24:1089&#x2013;1099. doi: 10.1038/s41593-021-00864-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-021-00864-y</ArticleId><ArticleId IdType="pmc">PMC8338913</ArticleId><ArticleId IdType="pubmed">34083786</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattugini N, Bocchi R, Scheuss V, Russo GL, Torper O, Lao CL, G&#xf6;tz M. Inducing Different Neuronal Subtypes from Astrocytes in the Injured Mouse Cerebral Cortex. Neuron. 2019;103:1086&#x2013;1095. doi: 10.1016/j.neuron.2019.08.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2019.08.009</ArticleId><ArticleId IdType="pmc">PMC6859713</ArticleId><ArticleId IdType="pubmed">31488328</ArticleId></ArticleIdList></Reference><Reference><Citation>Niu W, Zang T, Zou Y, Fang S, Smith DK, Bachoo R, Zhang CL. In vivo reprogramming of astrocytes to neuroblasts in the adult brain. Nature Cell Biology. 2013;15:1164&#x2013;1175. doi: 10.1038/ncb2843.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncb2843</ArticleId><ArticleId IdType="pmc">PMC3867822</ArticleId><ArticleId IdType="pubmed">24056302</ArticleId></ArticleIdList></Reference><Reference><Citation>Niu W, Zang T, Smith DK, Vue TY, Zou Y, Bachoo R, Johnson JE, Zhang CL. SOX2 reprograms resident astrocytes into neural progenitors in the adult brain. Stem Cell Reports. 2015;4:780&#x2013;794. doi: 10.1016/j.stemcr.2015.03.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2015.03.006</ArticleId><ArticleId IdType="pmc">PMC4437485</ArticleId><ArticleId IdType="pubmed">25921813</ArticleId></ArticleIdList></Reference><Reference><Citation>Park KM, Bowers WJ. Tumor necrosis factor-alpha mediated signaling in neuronal homeostasis and dysfunction. Cellular Signalling. 2010;22:977&#x2013;983. doi: 10.1016/j.cellsig.2010.01.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cellsig.2010.01.010</ArticleId><ArticleId IdType="pmc">PMC2860549</ArticleId><ArticleId IdType="pubmed">20096353</ArticleId></ArticleIdList></Reference><Reference><Citation>Pereira M, Birtele M, Shrigley S, Benitez JA, Hedlund E, Parmar M, Ottosson DR. Direct Reprogramming of Resident NG2 Glia into Neurons with Properties of Fast-Spiking Parvalbumin-Containing Interneurons. Stem Cell Reports. 2017;9:742&#x2013;751. doi: 10.1016/j.stemcr.2017.07.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2017.07.023</ArticleId><ArticleId IdType="pmc">PMC5599255</ArticleId><ArticleId IdType="pubmed">28844658</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian H, Kang X, Hu J, Zhang D, Liang Z, Meng F, Zhang X, Xue Y, Maimon R, Dowdy SF, Devaraj NK, Zhou Z, Mobley WC, Cleveland DW, Fu XD. Reversing a model of Parkinson&#x2019;s disease with in situ converted nigral neurons. Nature. 2020;582:550&#x2013;556. doi: 10.1038/s41586-020-2388-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2388-4</ArticleId><ArticleId IdType="pmc">PMC7521455</ArticleId><ArticleId IdType="pubmed">32581380</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian C, Dong B, Wang XY, Zhou FQ. In vivo glial trans-differentiation for neuronal replacement and functional recovery in central nervous system. The FEBS Journal. 2021;288:4773&#x2013;4785. doi: 10.1111/febs.15681.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/febs.15681</ArticleId><ArticleId IdType="pmc">PMC8217397</ArticleId><ArticleId IdType="pubmed">33351267</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivetti di Val Cervo P, Romanov RA, Spigolon G, Masini D, Mart&#xed;n-Monta&#xf1;ez E, Toledo EM, La Manno G, Feyder M, Pifl C, Ng YH, S&#xe1;nchez SP, Linnarsson S, Wernig M, Harkany T, Fisone G, Arenas E. Induction of functional dopamine neurons from human astrocytes in vitro and mouse astrocytes in a Parkinson&#x2019;s disease model. Nature Biotechnology. 2017;35:444&#x2013;452. doi: 10.1038/nbt.3835.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.3835</ArticleId><ArticleId IdType="pubmed">28398344</ArticleId></ArticleIdList></Reference><Reference><Citation>Robel S, Berninger B, G&#xf6;tz M. The stem cell potential of glia: lessons from reactive gliosis. Nature Reviews. Neuroscience. 2011;12:88&#x2013;104. doi: 10.1038/nrn2978.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn2978</ArticleId><ArticleId IdType="pubmed">21248788</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryu YK, Go J, Park HY, Choi YK, Seo YJ, Choi JH, Rhee M, Lee TG, Lee CH, Kim KS. Metformin regulates astrocyte reactivity in Parkinson&#x2019;s disease and normal aging. Neuropharmacology. 2020;175:108173. doi: 10.1016/j.neuropharm.2020.108173.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2020.108173</ArticleId><ArticleId IdType="pubmed">32497590</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanz E, Yang L, Su T, Morris DR, McKnight GS, Amieux PS. Cell-type-specific isolation of ribosome-associated mRNA from complex tissues. PNAS. 2009;106:13939&#x2013;13944. doi: 10.1073/pnas.0907143106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0907143106</ArticleId><ArticleId IdType="pmc">PMC2728999</ArticleId><ArticleId IdType="pubmed">19666516</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimada IS, LeComte MD, Granger JC, Quinlan NJ, Spees JL. Self-renewal and differentiation of reactive astrocyte-derived neural stem/progenitor cells isolated from the cortical peri-infarct area after stroke. The Journal of Neuroscience. 2012;32:7926&#x2013;7940. doi: 10.1523/JNEUROSCI.4303-11.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4303-11.2012</ArticleId><ArticleId IdType="pmc">PMC3398807</ArticleId><ArticleId IdType="pubmed">22674268</ArticleId></ArticleIdList></Reference><Reference><Citation>Sirko S, Behrendt G, Johansson PA, Tripathi P, Costa M, Bek S, Heinrich C, Tiedt S, Colak D, Dichgans M, Fischer IR, Plesnila N, Staufenbiel M, Haass C, Snapyan M, Saghatelyan A, Tsai LH, Fischer A, Grobe K, Dimou L, G&#xf6;tz M. Reactive glia in the injured brain acquire stem cell properties in response to sonic hedgehog. Cell Stem Cell. 2013;12:426&#x2013;439. doi: 10.1016/j.stem.2013.01.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2013.01.019</ArticleId><ArticleId IdType="pubmed">23561443</ArticleId></ArticleIdList></Reference><Reference><Citation>Srinivasan R, Lu TY, Chai H, Xu J, Huang BS, Golshani P, Coppola G, Khakh BS. New Transgenic Mouse Lines for Selectively Targeting Astrocytes and Studying Calcium Signals in Astrocyte Processes In Situ and In Vivo. Neuron. 2016;92:1181&#x2013;1195. doi: 10.1016/j.neuron.2016.11.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.11.030</ArticleId><ArticleId IdType="pmc">PMC5403514</ArticleId><ArticleId IdType="pubmed">27939582</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Z, Niu W, Liu ML, Zou Y, Zhang CL. In vivo conversion of astrocytes to neurons in the injured adult spinal cord. Nature Communications. 2014;5:3338. doi: 10.1038/ncomms4338.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms4338</ArticleId><ArticleId IdType="pmc">PMC3966078</ArticleId><ArticleId IdType="pubmed">24569435</ArticleId></ArticleIdList></Reference><Reference><Citation>Torper O, Pfisterer U, Wolf DA, Pereira M, Lau S, Jakobsson J, Bj&#xf6;rklund A, Grealish S, Parmar M. Generation of induced neurons via direct conversion in vivo. PNAS. 2013;110:7038&#x2013;7043. doi: 10.1073/pnas.1303829110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1303829110</ArticleId><ArticleId IdType="pmc">PMC3637783</ArticleId><ArticleId IdType="pubmed">23530235</ArticleId></ArticleIdList></Reference><Reference><Citation>Torper O, Ottosson DR, Pereira M, Lau S, Cardoso T, Grealish S, Parmar M. In Vivo Reprogramming of Striatal NG2 Glia into Functional Neurons that Integrate into Local Host Circuitry. Cell Reports. 2015;12:474&#x2013;481. doi: 10.1016/j.celrep.2015.06.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2015.06.040</ArticleId><ArticleId IdType="pmc">PMC4521079</ArticleId><ArticleId IdType="pubmed">26166567</ArticleId></ArticleIdList></Reference><Reference><Citation>Torper O, G&#xf6;tz M. Brain repair from intrinsic cell sources: Turning reactive glia into neurons. Progress in Brain Research. 2017;230:69&#x2013;97. doi: 10.1016/bs.pbr.2016.12.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/bs.pbr.2016.12.010</ArticleId><ArticleId IdType="pubmed">28552236</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan J, Zhao XF, Vojtek A, Goldman D. Retinal injury, growth factors, and cytokines converge on &#x3b2;-catenin and pStat3 signaling to stimulate retina regeneration. Cell Reports. 2014;9:285&#x2013;297. doi: 10.1016/j.celrep.2014.08.048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2014.08.048</ArticleId><ArticleId IdType="pmc">PMC4194164</ArticleId><ArticleId IdType="pubmed">25263555</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang LL, Su Z, Tai W, Zou Y, Xu XM, Zhang CL. The p53 Pathway Controls SOX2-Mediated Reprogramming in the Adult Mouse Spinal Cord. Cell Reports. 2016;17:891&#x2013;903. doi: 10.1016/j.celrep.2016.09.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2016.09.038</ArticleId><ArticleId IdType="pmc">PMC5094368</ArticleId><ArticleId IdType="pubmed">27732862</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang LL, Serrano C, Zhong X, Ma S, Zou Y, Zhang CL. Revisiting astrocyte to neuron conversion with lineage tracing in vivo. Cell. 2021;184:5465&#x2013;5481. doi: 10.1016/j.cell.2021.09.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.09.005</ArticleId><ArticleId IdType="pmc">PMC8526404</ArticleId><ArticleId IdType="pubmed">34582787</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinberg MS, Criswell HE, Powell SK, Bhatt AP, McCown TJ. Viral Vector Reprogramming of Adult Resident Striatal Oligodendrocytes into Functional Neurons. Molecular Therapy. 2017;25:928&#x2013;934. doi: 10.1016/j.ymthe.2017.01.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2017.01.016</ArticleId><ArticleId IdType="pmc">PMC5383550</ArticleId><ArticleId IdType="pubmed">28202388</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Z, Parry M, Hou XY, Liu MH, Wang H, Cain R, Pei ZF, Chen YC, Guo ZY, Abhijeet S, Chen G. Gene therapy conversion of striatal astrocytes into GABAergic neurons in mouse models of Huntington&#x2019;s disease. Nature Communications. 2020;11:1105. doi: 10.1038/s41467-020-14855-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-14855-3</ArticleId><ArticleId IdType="pmc">PMC7046613</ArticleId><ArticleId IdType="pubmed">32107381</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang Z, Xu L, Liu M, Wang Q, Li W, Lei W, Chen G. Lineage tracing of direct astrocyte-to-neuron conversion in the mouse cortex. Neural Regeneration Research. 2021;16:750&#x2013;756. doi: 10.4103/1673-5374.295925.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1673-5374.295925</ArticleId><ArticleId IdType="pmc">PMC8067918</ArticleId><ArticleId IdType="pubmed">33063738</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Q, Huang Q, Du X, Xu S, Li M, Ma S. Early activation of Egr-1 promotes neuroinflammation and dopaminergic neurodegeneration in an experimental model of Parkinson&#x2019;s disease. Experimental Neurology. 2018;302:145&#x2013;154. doi: 10.1016/j.expneurol.2018.01.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2018.01.009</ArticleId><ArticleId IdType="pubmed">29337144</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Li B, Cananzi S, Han C, Wang LL, Zou Y, Fu YX, Hon GC, Zhang CL. A single factor elicits multilineage reprogramming of astrocytes in the adult mouse striatum. PNAS. 2022;119:e2107339119. doi: 10.1073/pnas.2107339119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2107339119</ArticleId><ArticleId IdType="pmc">PMC8931246</ArticleId><ArticleId IdType="pubmed">35254903</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng J, Li T, Qi S, Qin B, Yu J, Chen G. Neuroregenerative gene therapy to treat temporal lobe epilepsy in a rat model. Progress in Neurobiology. 2022;208:102198. doi: 10.1016/j.pneurobio.2021.102198.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pneurobio.2021.102198</ArticleId><ArticleId IdType="pubmed">34852273</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou H, Su J, Hu X, Zhou C, Li H, Chen Z, Xiao Q, Wang B, Wu W, Sun Y, Zhou Y, Tang C, Liu F, Wang L, Feng C, Liu M, Li S, Zhang Y, Xu H, Yao H, Shi L, Yang H. Glia-to-Neuron Conversion by CRISPR-CasRx Alleviates Symptoms of Neurological Disease in Mice. Cell. 2020;181:590&#x2013;603. doi: 10.1016/j.cell.2020.03.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.03.024</ArticleId><ArticleId IdType="pubmed">32272060</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">35544272</PMID><DateCompleted><Year>2022</Year><Month>07</Month><Day>08</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6238</ISSN><JournalIssue CitedMedium="Internet"><Volume>79</Volume><Issue>7</Issue><PubDate><Year>2022</Year><Month>Jul</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA psychiatry</Title><ISOAbbreviation>JAMA Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Neuropsychiatric Ramifications of Severe COVID-19 and Other Severe Acute Respiratory Infections.</ArticleTitle><Pagination><StartPage>690</StartPage><EndPage>698</EndPage><MedlinePgn>690-698</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamapsychiatry.2022.1067</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Individuals surviving severe COVID-19 may be at increased risk of neuropsychiatric sequelae. Robust assessment of these risks may help improve clinical understanding of the post-COVID syndrome, aid clinical care during the ongoing pandemic, and inform postpandemic planning.</AbstractText><AbstractText Label="OBJECTIVE">To quantify the risks of new-onset neuropsychiatric conditions and new neuropsychiatric medication prescriptions after discharge from a COVID-19-related hospitalization, and to compare these with risks after discharge from hospitalization for other severe acute respiratory infections (SARI) during the COVID-19 pandemic.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">In this cohort study, adults (&#x2265;18 years of age) were identified from QResearch primary care and linked electronic health record databases, including national SARS-CoV-2 testing, hospital episode statistics, intensive care admissions data, and mortality registers in England, from January 24, 2020, to July 7, 2021.</AbstractText><AbstractText Label="EXPOSURES">COVID-19-related or SARI-related hospital admission (including intensive care admission).</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">New-onset diagnoses of neuropsychiatric conditions (anxiety, dementia, psychosis, depression, bipolar disorder) or first prescription for relevant medications (antidepressants, hypnotics/anxiolytics, antipsychotics) during 12 months of follow-up from hospital discharge. Maximally adjusted hazard ratios (HR) with 95% CIs were estimated using flexible parametric survival models.</AbstractText><AbstractText Label="RESULTS">In this cohort study of data from 8.38 million adults (4.18 million women, 4.20 million men; mean [SD] age 49.18 [18.45] years); 16&#x202f;679 (0.02%) survived a hospital admission for SARI, and 32&#x202f;525 (0.03%) survived a hospital admission for COVID-19. Compared with the remaining population, survivors of SARI and COVID-19 hospitalization had higher risks of subsequent neuropsychiatric diagnoses. For example, the HR for anxiety in survivors of SARI was 1.86 (95% CI, 1.56-2.21) and for survivors of COVID-19 infection was 2.36 (95% CI, 2.03-2.74); the HR for dementia for survivors of SARI was 2.55 (95% CI, 2.17-3.00) and for survivors of COVID-19 infection was 2.63 (95% CI, 2.21-3.14). Similar findings were observed for all medications analyzed; for example, the HR for first prescriptions of antidepressants in survivors of SARI was 2.55 (95% CI, 2.24-2.90) and for survivors of COVID-19 infection was 3.24 (95% CI, 2.91-3.61). There were no significant differences observed when directly comparing the COVID-19 group with the SARI group apart from a lower risk of antipsychotic prescriptions in the former (HR, 0.80; 95% CI, 0.69-0.92).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">In this cohort study, the neuropsychiatric sequelae of severe COVID-19 infection were found to be similar to those for other SARI. This finding may inform postdischarge support for people surviving SARI.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Clift</LastName><ForeName>Ashley Kieran</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cancer Research UK Oxford Centre, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ranger</LastName><ForeName>Tom Alan</ForeName><Initials>TA</Initials><AffiliationInfo><Affiliation>Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patone</LastName><ForeName>Martina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coupland</LastName><ForeName>Carol A C</ForeName><Initials>CAC</Initials><AffiliationInfo><Affiliation>Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Primary Care, School of Medicine, University of Nottingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hatch</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thomas</LastName><ForeName>Karen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Intensive Care National Audit and Research Centre, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hippisley-Cox</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watkinson</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Oxford Biomedical Research Centre, Oxford University Hospitals NHS Trust, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>221514/Z/20/Z</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>C5255/A18085</GrantID><Acronym>CRUK_</Acronym><Agency>Cancer Research UK</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>C2195/A31310</GrantID><Acronym>CRUK_</Acronym><Agency>Cancer Research UK</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>204826/Z/16/Z</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Psychiatry</MedlineTA><NlmUniqueID>101589550</NlmUniqueID><ISSNLinking>2168-622X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000359" MajorTopicYN="N">Aftercare</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086742" MajorTopicYN="N">COVID-19 Testing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="Y">Dementia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010351" MajorTopicYN="N">Patient Discharge</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Clift reported receiving grants from Cancer Research UK during the conduct of the study. Dr Coupland reported receiving grants from Wellcome Trust during the conduct of the study; grants from HDR UK Grants for other research studies, grants from the National Institutes for Health Research (NIHR) Grants for other research studies, and grants from MRC Grants for other research studies outside the submitted work. Dr Hatch reported receiving grants from NIHR Doctoral Research Fellowship during the conduct of the study. Ms Thomas reported receiving grants from Wellcome Trust during the conduct of the study. Dr Hippisley-Cox reported receiving grants from Wellcome Trust and grants from Oxford NIHR Biomedical Research Centre during the conduct of the study; being an unpaid director of QResearch (a not-for-profit organization that is a partnership between the University of Oxford and EMIS Health, which supply the QResearch database); and being a member of Scientific Advisory Group for Emergencies on COVID-19 and chair of the NERVTAG risk stratification subgroup. Dr Watkinson reported receiving grants from Wellcome during the conduct of the study; grants from the National Institute for Health Research and grants from Sensyne Health outside the submitted work; and being Chief Medical Officer for Sensyne Health prior to this work and holding shares in the company. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>11</Day><Hour>11</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>5</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35544272</ArticleId><ArticleId IdType="pmc">PMC9096686</ArticleId><ArticleId IdType="doi">10.1001/jamapsychiatry.2022.1067</ArticleId><ArticleId IdType="pii">2792404</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Johns Hopkins Coronavirus Resource Center . COVID-19 map. Accessed March 1, 2022. https://coronavirus.jhu.edu/map.html.</Citation></Reference><Reference><Citation>Crook H, Raza S, Nowell J, Young M, Edison P. Long covid-mechanisms, risk factors, and management. BMJ. 2021;374(1648):n1648. doi:10.1136/bmj.n1648</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1648</ArticleId><ArticleId IdType="pubmed">34312178</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, et al. . Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601-615. doi:10.1038/s41591-021-01283-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatch R, Young D, Barber VS, Griffiths J, Harrison DA, Watkinson PJ. Anxiety, depression and post-traumatic stress disorder management after critical illness: a UK multi-centre prospective cohort study. Crit Care. 2020;24(1):633. doi:10.1186/s13054-020-03354-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-020-03354-y</ArticleId><ArticleId IdType="pmc">PMC7607621</ArticleId><ArticleId IdType="pubmed">33138832</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandharipande PP, Girard TD, Ely EW. Long-term cognitive impairment after critical illness. N Engl J Med. 2014;370(2):185-186.</Citation><ArticleIdList><ArticleId IdType="pubmed">24401069</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers JP, Chesney E, Oliver D, et al. . Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry. 2020;7(7):611-627. doi:10.1016/S2215-0366(20)30203-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2215-0366(20)30203-0</ArticleId><ArticleId IdType="pmc">PMC7234781</ArticleId><ArticleId IdType="pubmed">32437679</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M, Luciano S, Geddes JR, Harrison PJ. Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62354 COVID-19 cases in the USA. Lancet Psychiatry. 2021;8(2):130-140. doi:10.1016/S2215-0366(20)30462-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2215-0366(20)30462-4</ArticleId><ArticleId IdType="pmc">PMC7820108</ArticleId><ArticleId IdType="pubmed">33181098</ArticleId></ArticleIdList></Reference><Reference><Citation>Cowling BJ, Ali ST, Ng TWY, et al. . Impact assessment of non-pharmaceutical interventions against coronavirus disease 2019 and influenza in Hong Kong: an observational study. Lancet Public Health. 2020;5(5):e279-e288. doi:10.1016/S2468-2667(20)30090-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-2667(20)30090-6</ArticleId><ArticleId IdType="pmc">PMC7164922</ArticleId><ArticleId IdType="pubmed">32311320</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans RA, McAuley H, Harrison EM, et al. ; PHOSP-COVID Collaborative Group . Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study. Lancet Respir Med. 2021;9(11):1275-1287. doi:10.1016/S2213-2600(21)00383-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00383-0</ArticleId><ArticleId IdType="pmc">PMC8497028</ArticleId><ArticleId IdType="pubmed">34627560</ArticleId></ArticleIdList></Reference><Reference><Citation>QResearch-ICNARC Collaboration . Investigating neuropsychological disease and treatments before and after severe COVID-19 disease. Published July 2021. Accessed April 6, 2022. https://www.qresearch.org/media/1338/ox79-qresearch-icnarc-covid-19-psychological-outcomes.pdf</Citation></Reference><Reference><Citation>QResearch . QCode Group Library. Accessed April 6, 2022. https://www.qresearch.org/qcode-group-library/</Citation></Reference><Reference><Citation>GOV.UK . Ethnicity facts and figures: list of ethnic groups. Accessed April 15, 2022. https://www.ethnicity-facts-figures.service.gov.uk/style-guide/ethnic-groups</Citation></Reference><Reference><Citation>Sterne JA, White IR, Carlin JB, et al. . Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ. 2009;338:b2393. doi:10.1136/bmj.b2393</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.b2393</ArticleId><ArticleId IdType="pmc">PMC2714692</ArticleId><ArticleId IdType="pubmed">19564179</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubin D. Multiple Imputation for Nonresponse in Surveys. Wiley; 1987. doi:10.1002/9780470316696</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/9780470316696</ArticleId></ArticleIdList></Reference><Reference><Citation>Rousseau AF, Prescott HC, Brett SJ, et al. . Long-term outcomes after critical illness: recent insights. Crit Care. 2021;25(1):108. doi:10.1186/s13054-021-03535-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-021-03535-3</ArticleId><ArticleId IdType="pmc">PMC7968190</ArticleId><ArticleId IdType="pubmed">33731201</ArticleId></ArticleIdList></Reference><Reference><Citation>Krumholz HM. Post-hospital syndrome&#x2013;an acquired, transient condition of generalized risk. N Engl J Med. 2013;368(2):100-102. doi:10.1056/NEJMp1212324</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMp1212324</ArticleId><ArticleId IdType="pmc">PMC3688067</ArticleId><ArticleId IdType="pubmed">23301730</ArticleId></ArticleIdList></Reference><Reference><Citation>Rousseau AF, Minguet P, Colson C, et al. . Post-intensive care syndrome after a critical COVID-19: cohort study from a Belgian follow-up clinic. Ann Intensive Care. 2021;11(1):118. doi:10.1186/s13613-021-00910-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13613-021-00910-9</ArticleId><ArticleId IdType="pmc">PMC8319705</ArticleId><ArticleId IdType="pubmed">34324073</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickie I, Davenport T, Wakefield D, et al. ; Dubbo Infection Outcomes Study Group . Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort study. BMJ. 2006;333(7568):575. doi:10.1136/bmj.38933.585764.AE</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.38933.585764.AE</ArticleId><ArticleId IdType="pmc">PMC1569956</ArticleId><ArticleId IdType="pubmed">16950834</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenhalgh T, Knight M, A&#x2019;Court C, Buxton M, Husain L. Management of post-acute covid-19 in primary care. BMJ. 2020;370:m3026. doi:10.1136/bmj.m3026</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m3026</ArticleId><ArticleId IdType="pubmed">32784198</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-month neurological and psychiatric outcomes in 236&#x2009;379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry. 2021;8(5):416-427. doi:10.1016/S2215-0366(21)00084-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2215-0366(21)00084-5</ArticleId><ArticleId IdType="pmc">PMC8023694</ArticleId><ArticleId IdType="pubmed">33836148</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers JP, David AS. A longer look at COVID-19 and neuropsychiatric outcomes. Lancet Psychiatry. 2021;8(5):351-352. doi:10.1016/S2215-0366(21)00120-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2215-0366(21)00120-6</ArticleId><ArticleId IdType="pmc">PMC8023693</ArticleId><ArticleId IdType="pubmed">33836149</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35545674</PMID><DateCompleted><Year>2022</Year><Month>05</Month><Day>20</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>605</Volume><Issue>7910</Issue><PubDate><Year>2022</Year><Month>May</Month></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Young CSF restores oligodendrogenesis and memory in aged mice via Fgf17.</ArticleTitle><Pagination><StartPage>509</StartPage><EndPage>515</EndPage><MedlinePgn>509-515</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41586-022-04722-0</ELocationID><Abstract><AbstractText>Recent understanding of how the systemic environment shapes the brain throughout life has led to numerous intervention strategies to slow brain ageing<sup>1-3</sup>. Cerebrospinal fluid (CSF) makes up the immediate environment of brain cells, providing them with nourishing compounds<sup>4,5</sup>. We discovered that infusing young CSF directly into aged brains improves memory function. Unbiased transcriptome analysis of the hippocampus identified oligodendrocytes to be most responsive to this rejuvenated CSF environment. We further showed that young CSF boosts oligodendrocyte progenitor cell (OPC) proliferation and differentiation in the aged hippocampus and in primary OPC cultures. Using SLAMseq to metabolically label nascent mRNA, we identified serum response factor (SRF), a transcription factor that drives actin cytoskeleton rearrangement, as a mediator of OPC proliferation following exposure to young CSF. With age, SRF expression decreases in hippocampal OPCs, and the pathway is induced by acute injection with young CSF. We screened for potential SRF activators in CSF and found that fibroblast growth factor 17 (Fgf17) infusion is sufficient to induce OPC proliferation and long-term memory consolidation in aged mice while Fgf17 blockade impairs cognition in young mice. These findings demonstrate the rejuvenating power of young CSF and identify Fgf17 as a key target to restore oligodendrocyte function in the ageing brain.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s), under exclusive licence to Springer Nature Limited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Iram</LastName><ForeName>Tal</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA. tal.iram@stanford.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wu Tsai Neurosciences Institute, Stanford University School of Medicine, Stanford, CA, USA. tal.iram@stanford.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kern</LastName><ForeName>Fabian</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-8223-3750</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Bioinformatics, Saarland University, Saarbr&#xfc;cken, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Bioinformatics, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS)-Helmholtz Centre for Infection Research (HZI), Saarland University Campus, Saarbr&#xfc;cken, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaur</LastName><ForeName>Achint</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wu Tsai Neurosciences Institute, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Myneni</LastName><ForeName>Saket</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-9484-2617</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wu Tsai Neurosciences Institute, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morningstar</LastName><ForeName>Allison R</ForeName><Initials>AR</Initials><Identifier Source="ORCID">0000-0002-3857-0450</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wu Tsai Neurosciences Institute, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shin</LastName><ForeName>Heather</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wu Tsai Neurosciences Institute, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garcia</LastName><ForeName>Miguel A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Stanford University School of Medicine, Palo Alto, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yerra</LastName><ForeName>Lakshmi</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Palo Alto Veterans Institute for Research, Palo Alto, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palovics</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wu Tsai Neurosciences Institute, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Andrew C</ForeName><Initials>AC</Initials><Identifier Source="ORCID">0000-0002-6756-4746</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wu Tsai Neurosciences Institute, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hahn</LastName><ForeName>Oliver</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wu Tsai Neurosciences Institute, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Nannan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wu Tsai Neurosciences Institute, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shuken</LastName><ForeName>Steven R</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wu Tsai Neurosciences Institute, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Chemistry, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haney</LastName><ForeName>Michael S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wu Tsai Neurosciences Institute, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lehallier</LastName><ForeName>Benoit</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wu Tsai Neurosciences Institute, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iyer</LastName><ForeName>Manasi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Stanford University School of Medicine, Palo Alto, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Jian</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-2064-8467</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Palo Alto Veterans Institute for Research, Palo Alto, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-3930-4354</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute at UCL, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keller</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Bioinformatics, Saarland University, Saarbr&#xfc;cken, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Bioinformatics, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS)-Helmholtz Centre for Infection Research (HZI), Saarland University Campus, Saarbr&#xfc;cken, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Bioinformatics, Saarland Informatics Campus, Saarbr&#xfc;cken, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zuchero</LastName><ForeName>J Bradley</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Stanford University School of Medicine, Palo Alto, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wyss-Coray</LastName><ForeName>Tony</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-5893-0831</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA. twc@stanford.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wu Tsai Neurosciences Institute, Stanford University School of Medicine, Stanford, CA, USA. twc@stanford.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Paul F. Glenn Center for the Biology of Aging, Stanford University School of Medicine, Stanford, CA, USA. twc@stanford.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Acronym>ERC_</Acronym><Agency>European Research Council</Agency><Country>International</Country></Grant><Grant><GrantID>T32 AG000266</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG064897</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS119823</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS123533</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>05</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C484726">Fgf17 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>62031-54-3</RegistryNumber><NameOfSubstance UI="D005346">Fibroblast Growth Factors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2022 Jun;18(6):319-320. doi: 10.1038/s41582-022-00650-9.</RefSource><PMID Version="1">35322261</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2022 May;605(7910):428-429. doi: 10.1038/d41586-022-00860-7.</RefSource><PMID Version="1">35546616</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurosci. 2022 Jul;23(7):393. doi: 10.1038/s41583-022-00610-8.</RefSource><PMID Version="1">35668296</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Signal Transduct Target Ther. 2022 Jul 16;7(1):237. doi: 10.1038/s41392-022-01092-x.</RefSource><PMID Version="1">35842438</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Neurol. 2022 Sep;21(9):765-767. doi: 10.1016/S1474-4422(22)00296-4.</RefSource><PMID Version="1">35963250</PMID></CommentsCorrections><CommentsCorrections RefType="ErratumIn"><RefSource>Nature. 2023 Jan;613(7942):E1. doi: 10.1038/s41586-022-05630-z.</RefSource><PMID Version="1">36513761</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="Y">Aging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="Y">Brain</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002555" MajorTopicYN="Y">Cerebrospinal Fluid</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005346" MajorTopicYN="N">Fibroblast Growth Factors</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073637" MajorTopicYN="Y">Oligodendrocyte Precursor Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009836" MajorTopicYN="Y">Oligodendroglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing interests:</b> T.W.-C. and T.I. are co-inventors on a patent application related to the work published in this paper (STDU2-39617.101, S21-153 - METHODS AND COMPOSITIONS FOR IMPROVED MEMORY IN THE AGING). HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Alector, Annexon, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Pinteon Therapeutics, Red Abbey Labs, Passage Bio, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>5</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>4</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>11</Day><Hour>23</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>11</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35545674</ArticleId><ArticleId IdType="mid">NIHMS1823962</ArticleId><ArticleId IdType="pmc">PMC9377328</ArticleId><ArticleId IdType="doi">10.1038/s41586-022-04722-0</ArticleId><ArticleId IdType="pii">10.1038/s41586-022-04722-0</ArticleId></ArticleIdList><ReferenceList><Title>Main text references</Title><Reference><Citation>Pluvinage JV &amp; Wyss-Coray T. Systemic factors as mediators of brain homeostasis, ageing and neurodegeneration. Nat Rev Neurosci 21, 93&#x2013;102, doi:10.1038/s41583-019-0255-9 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41583-019-0255-9</ArticleId><ArticleId IdType="pubmed">31913356</ArticleId></ArticleIdList></Reference><Reference><Citation>Castellano JM et al. Human umbilical cord plasma proteins revitalize hippocampal function in aged mice. Nature 544, 488&#x2013;492, doi:10.1038/nature22067 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature22067</ArticleId><ArticleId IdType="pmc">PMC5586222</ArticleId><ArticleId IdType="pubmed">28424512</ArticleId></ArticleIdList></Reference><Reference><Citation>Villeda SA et al. Young blood reverses age-related impairments in cognitive function and synaptic plasticity in mice. Nat Med 20, 659&#x2013;663, doi:10.1038/nm.3569 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.3569</ArticleId><ArticleId IdType="pmc">PMC4224436</ArticleId><ArticleId IdType="pubmed">24793238</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehtinen MK et al. The cerebrospinal fluid provides a proliferative niche for neural progenitor cells. Neuron 69, 893&#x2013;905, doi:10.1016/j.neuron.2011.01.023 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.01.023</ArticleId><ArticleId IdType="pmc">PMC3085909</ArticleId><ArticleId IdType="pubmed">21382550</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva-Vargas V, Maldonado-Soto AR, Mizrak D, Codega P. &amp; Doetsch F. Age-Dependent Niche Signals from the Choroid Plexus Regulate Adult Neural Stem Cells. Cell Stem Cell 19, 643&#x2013;652, doi:10.1016/j.stem.2016.06.013 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2016.06.013</ArticleId><ArticleId IdType="pubmed">27452173</ArticleId></ArticleIdList></Reference><Reference><Citation>Fame RM &amp; Lehtinen MK Emergence and Developmental Roles of the Cerebrospinal Fluid System. Dev Cell 52, 261&#x2013;275, doi:10.1016/j.devcel.2020.01.027 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.devcel.2020.01.027</ArticleId><ArticleId IdType="pubmed">32049038</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen CP, Chen RL &amp; Preston JE The influence of ageing in the cerebrospinal fluid concentrations of proteins that are derived from the choroid plexus, brain, and plasma. Exp Gerontol 47, 323&#x2013;328, doi:10.1016/j.exger.2012.01.008 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.exger.2012.01.008</ArticleId><ArticleId IdType="pubmed">22532968</ArticleId></ArticleIdList></Reference><Reference><Citation>Baird GS et al. Age-dependent changes in the cerebrospinal fluid proteome by slow off-rate modified aptamer array. Am J Pathol 180, 446&#x2013;456, doi:10.1016/j.ajpath.2011.10.024 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajpath.2011.10.024</ArticleId><ArticleId IdType="pmc">PMC3349859</ArticleId><ArticleId IdType="pubmed">22122984</ArticleId></ArticleIdList></Reference><Reference><Citation>Li G. et al. Cerebrospinal fluid concentration of brain-derived neurotrophic factor and cognitive function in non-demented subjects. PLoS One 4, e5424, doi:10.1371/journal.pone.0005424 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0005424</ArticleId><ArticleId IdType="pmc">PMC2671606</ArticleId><ArticleId IdType="pubmed">19412541</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan S, Mayoral SR, Choi HS, Chan JR &amp; Kheirbek MA Preservation of a remote fear memory requires new myelin formation. Nat Neurosci 23, 487&#x2013;499, doi:10.1038/s41593-019-0582-1 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-019-0582-1</ArticleId><ArticleId IdType="pmc">PMC7213814</ArticleId><ArticleId IdType="pubmed">32042175</ArticleId></ArticleIdList></Reference><Reference><Citation>Vetere G. et al. Chemogenetic Interrogation of a Brain-wide Fear Memory Network in Mice. Neuron 94, 363&#x2013;374 e364, doi:10.1016/j.neuron.2017.03.037 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2017.03.037</ArticleId><ArticleId IdType="pubmed">28426969</ArticleId></ArticleIdList></Reference><Reference><Citation>Fogel SM et al. fMRI and sleep correlates of the age-related impairment in motor memory consolidation. Hum Brain Mapp 35, 3625&#x2013;3645, doi:10.1002/hbm.22426 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hbm.22426</ArticleId><ArticleId IdType="pmc">PMC6869653</ArticleId><ArticleId IdType="pubmed">24302373</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson EM et al. Neuronal activity promotes oligodendrogenesis and adaptive myelination in the mammalian brain. Science 344, 1252304, doi:10.1126/science.1252304 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1252304</ArticleId><ArticleId IdType="pmc">PMC4096908</ArticleId><ArticleId IdType="pubmed">24727982</ArticleId></ArticleIdList></Reference><Reference><Citation>Dugas JC &amp; Emery B. Purification of oligodendrocyte precursor cells from rat cortices by immunopanning. Cold Spring Harb Protoc 2013, 745&#x2013;758, doi:10.1101/pdb.prot070862 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/pdb.prot070862</ArticleId><ArticleId IdType="pubmed">23906908</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun LO et al. Spatiotemporal Control of CNS Myelination by Oligodendrocyte Programmed Cell Death through the TFEB-PUMA Axis. Cell 175, 1811&#x2013;1826 e1821, doi:10.1016/j.cell.2018.10.044 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2018.10.044</ArticleId><ArticleId IdType="pmc">PMC6295215</ArticleId><ArticleId IdType="pubmed">30503207</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuchero JB et al. CNS myelin wrapping is driven by actin disassembly. Dev Cell 34, 152&#x2013;167, doi:10.1016/j.devcel.2015.06.011 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.devcel.2015.06.011</ArticleId><ArticleId IdType="pmc">PMC4519368</ArticleId><ArticleId IdType="pubmed">26166300</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarz N. et al. Human Cerebrospinal fluid promotes long-term neuronal viability and network function in human neocortical organotypic brain slice cultures. Sci Rep 7, 12249, doi:10.1038/s41598-017-12527-9 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-12527-9</ArticleId><ArticleId IdType="pmc">PMC5613008</ArticleId><ArticleId IdType="pubmed">28947761</ArticleId></ArticleIdList></Reference><Reference><Citation>Wentling M. et al. A metabolic perspective on CSF-mediated neurodegeneration in multiple sclerosis. Brain 142, 2756&#x2013;2774, doi:10.1093/brain/awz201 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz201</ArticleId><ArticleId IdType="pubmed">31305892</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathur D. et al. Bioenergetic Failure in Rat Oligodendrocyte Progenitor Cells Treated with Cerebrospinal Fluid Derived from Multiple Sclerosis Patients. Front Cell Neurosci 11, 209, doi:10.3389/fncel.2017.00209 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2017.00209</ArticleId><ArticleId IdType="pmc">PMC5517784</ArticleId><ArticleId IdType="pubmed">28775680</ArticleId></ArticleIdList></Reference><Reference><Citation>Braun T. &amp; Gautel M. Transcriptional mechanisms regulating skeletal muscle differentiation, growth and homeostasis. Nat Rev Mol Cell Biol 12, 349&#x2013;361, doi:10.1038/nrm3118 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm3118</ArticleId><ArticleId IdType="pubmed">21602905</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Y. et al. Hierarchical and stage-specific regulation of murine cardiomyocyte maturation by serum response factor. Nat Commun 9, 3837, doi:10.1038/s41467-018-06347-2 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-06347-2</ArticleId><ArticleId IdType="pmc">PMC6155060</ArticleId><ArticleId IdType="pubmed">30242271</ArticleId></ArticleIdList></Reference><Reference><Citation>Knoll B. &amp; Nordheim A. Functional versatility of transcription factors in the nervous system: the SRF paradigm. Trends Neurosci 32, 432&#x2013;442, doi:10.1016/j.tins.2009.05.004 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2009.05.004</ArticleId><ArticleId IdType="pubmed">19643506</ArticleId></ArticleIdList></Reference><Reference><Citation>Miralles F, Posern G, Zaromytidou AI &amp; Treisman R. Actin dynamics control SRF activity by regulation of its coactivator MAL. Cell 113, 329&#x2013;342, doi:10.1016/s0092-8674(03)00278-2 (2003).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0092-8674(03)00278-2</ArticleId><ArticleId IdType="pubmed">12732141</ArticleId></ArticleIdList></Reference><Reference><Citation>Knoll B. et al. Serum response factor controls neuronal circuit assembly in the hippocampus. Nat Neurosci 9, 195&#x2013;204, doi:10.1038/nn1627 (2006).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn1627</ArticleId><ArticleId IdType="pubmed">16415869</ArticleId></ArticleIdList></Reference><Reference><Citation>Lahoute C. et al. Premature aging in skeletal muscle lacking serum response factor. PLoS One 3, e3910, doi:10.1371/journal.pone.0003910 (2008).</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0003910</ArticleId><ArticleId IdType="pmc">PMC2593784</ArticleId><ArticleId IdType="pubmed">19079548</ArticleId></ArticleIdList></Reference><Reference><Citation>Mergoud Dit Lamarche A. et al. UNC-120/SRF independently controls muscle aging and lifespan in Caenorhabditis elegans. Aging Cell 17, doi:10.1111/acel.12713 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/acel.12713</ArticleId><ArticleId IdType="pmc">PMC5847867</ArticleId><ArticleId IdType="pubmed">29314608</ArticleId></ArticleIdList></Reference><Reference><Citation>Ximerakis M. et al. Single-cell transcriptomic profiling of the aging mouse brain. Nat Neurosci 22, 1696&#x2013;1708, doi:10.1038/s41593-019-0491-3 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-019-0491-3</ArticleId><ArticleId IdType="pubmed">31551601</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcao AM et al. Disease-specific oligodendrocyte lineage cells arise in multiple sclerosis. Nat Med 24, 1837&#x2013;1844, doi:10.1038/s41591-018-0236-y (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-018-0236-y</ArticleId><ArticleId IdType="pmc">PMC6544508</ArticleId><ArticleId IdType="pubmed">30420755</ArticleId></ArticleIdList></Reference><Reference><Citation>Iacono G, Altafini C. &amp; Torre V. Early phase of plasticity-related gene regulation and SRF dependent transcription in the hippocampus. PLoS One 8, e68078, doi:10.1371/journal.pone.0068078 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0068078</ArticleId><ArticleId IdType="pmc">PMC3720722</ArticleId><ArticleId IdType="pubmed">23935853</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuzniewska B. et al. Brain-derived neurotrophic factor induces matrix metalloproteinase 9 expression in neurons via the serum response factor/c-Fos pathway. Mol Cell Biol 33, 2149&#x2013;2162, doi:10.1128/MCB.00008-13 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.00008-13</ArticleId><ArticleId IdType="pmc">PMC3648073</ArticleId><ArticleId IdType="pubmed">23508111</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasayama D. et al. Genome-wide quantitative trait loci mapping of the human cerebrospinal fluid proteome. Hum Mol Genet 26, 44&#x2013;51, doi:10.1093/hmg/ddw366 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddw366</ArticleId><ArticleId IdType="pubmed">28031287</ArticleId></ArticleIdList></Reference><Reference><Citation>Sathyan S. et al. Plasma proteomic profile of age, health span, and all-cause mortality in older adults. Aging Cell 19, e13250, doi:10.1111/acel.13250 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/acel.13250</ArticleId><ArticleId IdType="pmc">PMC7681045</ArticleId><ArticleId IdType="pubmed">33089916</ArticleId></ArticleIdList></Reference><Reference><Citation>Esnault C. et al. Rho-actin signaling to the MRTF coactivators dominates the immediate transcriptional response to serum in fibroblasts. Genes Dev 28, 943&#x2013;958, doi:10.1101/gad.239327.114 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gad.239327.114</ArticleId><ArticleId IdType="pmc">PMC4018493</ArticleId><ArticleId IdType="pubmed">24732378</ArticleId></ArticleIdList></Reference><Reference><Citation>Fortin D, Rom E, Sun H, Yayon A. &amp; Bansal R. Distinct fibroblast growth factor (FGF)/FGF receptor signaling pairs initiate diverse cellular responses in the oligodendrocyte lineage. J Neurosci 25, 7470&#x2013;7479, doi:10.1523/JNEUROSCI.2120-05.2005 (2005).</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2120-05.2005</ArticleId><ArticleId IdType="pmc">PMC6725305</ArticleId><ArticleId IdType="pubmed">16093398</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramanan N. et al. SRF mediates activity-induced gene expression and synaptic plasticity but not neuronal viability. Nat Neurosci 8, 759&#x2013;767, doi:10.1038/nn1462 (2005).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn1462</ArticleId><ArticleId IdType="pubmed">15880109</ArticleId></ArticleIdList></Reference><Reference><Citation>Etkin A. et al. A role in learning for SRF: deletion in the adult forebrain disrupts LTD and the formation of an immediate memory of a novel context. Neuron 50, 127&#x2013;143, doi:10.1016/j.neuron.2006.03.013 (2006).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2006.03.013</ArticleId><ArticleId IdType="pubmed">16600861</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan S, Mayoral SR, Choi HS, Chan JR &amp; Kheirbek MA Preservation of a remote fear memory requires new myelin formation. Nat Neurosci, doi:10.1038/s41593-019-0582-1 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-019-0582-1</ArticleId><ArticleId IdType="pmc">PMC7213814</ArticleId><ArticleId IdType="pubmed">32042175</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao L. et al. Rapid production of new oligodendrocytes is required in the earliest stages of motor-skill learning. Nat Neurosci 19, 1210&#x2013;1217, doi:10.1038/nn.4351 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4351</ArticleId><ArticleId IdType="pmc">PMC5008443</ArticleId><ArticleId IdType="pubmed">27455109</ArticleId></ArticleIdList></Reference><Reference><Citation>Steadman PE et al. Disruption of Oligodendrogenesis Impairs Memory Consolidation in Adult Mice. Neuron 105, 150&#x2013;164 e156, doi:10.1016/j.neuron.2019.10.013 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2019.10.013</ArticleId><ArticleId IdType="pmc">PMC7579726</ArticleId><ArticleId IdType="pubmed">31753579</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang F. et al. Myelin degeneration and diminished myelin renewal contribute to age-related deficits in memory. Nat Neurosci, doi:10.1038/s41593-020-0588-8 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-020-0588-8</ArticleId><ArticleId IdType="pmc">PMC7306053</ArticleId><ArticleId IdType="pubmed">32042174</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen JF et al. Enhancing myelin renewal reverses cognitive dysfunction in a murine model of Alzheimer&#x2019;s disease. Neuron 109, 2292&#x2013;2307 e2295, doi:10.1016/j.neuron.2021.05.012 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2021.05.012</ArticleId><ArticleId IdType="pmc">PMC8298291</ArticleId><ArticleId IdType="pubmed">34102111</ArticleId></ArticleIdList></Reference><Reference><Citation>Segel M. et al. Niche stiffness underlies the ageing of central nervous system progenitor cells. Nature 573, 130&#x2013;134, doi:10.1038/s41586-019-1484-9 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-1484-9</ArticleId><ArticleId IdType="pmc">PMC7025879</ArticleId><ArticleId IdType="pubmed">31413369</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann B. et al. Metformin Restores CNS Remyelination Capacity by Rejuvenating Aged Stem Cells. Cell Stem Cell 25, 473&#x2013;485 e478, doi:10.1016/j.stem.2019.08.015 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2019.08.015</ArticleId><ArticleId IdType="pmc">PMC6863391</ArticleId><ArticleId IdType="pubmed">31585093</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonetto G, Belin D. &amp; Karadottir RT Myelin: A gatekeeper of activity-dependent circuit plasticity? Science 374, eaba6905, doi:10.1126/science.aba6905 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aba6905</ArticleId><ArticleId IdType="pubmed">34618550</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J, Liu Z. &amp; Ornitz DM Temporal and spatial gradients of Fgf8 and Fgf17 regulate proliferation and differentiation of midline cerebellar structures. Development 127, 1833&#x2013;1843 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10751172</ArticleId></ArticleIdList></Reference><Reference><Citation>Furusho M, Ishii A, Hebert JM &amp; Bansal R. Developmental stage-specific role of Frs adapters as mediators of FGF receptor signaling in the oligodendrocyte lineage cells. Glia 68, 617&#x2013;630, doi:10.1002/glia.23743 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.23743</ArticleId><ArticleId IdType="pmc">PMC8353651</ArticleId><ArticleId IdType="pubmed">31670856</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh LY et al. Fibroblast growth factor receptor 3 signaling regulates the onset of oligodendrocyte terminal differentiation. J Neurosci 23, 883&#x2013;894 (2003).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6741926</ArticleId><ArticleId IdType="pubmed">12574417</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang W, Nguyen KCQ &amp; Hebert JM Transient Redirection of SVZ Stem Cells to Oligodendrogenesis by FGFR3 Activation Promotes Remyelination. Stem Cell Reports 12, 1223&#x2013;1231, doi:10.1016/j.stemcr.2019.05.006 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2019.05.006</ArticleId><ArticleId IdType="pmc">PMC6565886</ArticleId><ArticleId IdType="pubmed">31189094</ArticleId></ArticleIdList></Reference><Reference><Citation>Jen YH, Musacchio M. &amp; Lander AD Glypican-1 controls brain size through regulation of fibroblast growth factor signaling in early neurogenesis. Neural Dev 4, 33, doi:10.1186/1749-8104-4-33 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1749-8104-4-33</ArticleId><ArticleId IdType="pmc">PMC2746204</ArticleId><ArticleId IdType="pubmed">19732411</ArticleId></ArticleIdList></Reference><Reference><Citation>Scearce-Levie K. et al. Abnormal social behaviors in mice lacking Fgf17. Genes Brain Behav 7, 344&#x2013;354, doi:10.1111/j.1601-183X.2007.00357.x (2008).</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1601-183X.2007.00357.x</ArticleId><ArticleId IdType="pubmed">17908176</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Methods references</Title><Reference><Citation>De Miguel Z. et al. Exercise plasma boosts memory and dampens brain inflammation via clusterin. Nature 600, 494&#x2013;499, doi:10.1038/s41586-021-04183-x (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04183-x</ArticleId><ArticleId IdType="pmc">PMC9721468</ArticleId><ArticleId IdType="pubmed">34880498</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L. &amp; Duff K. A technique for serial collection of cerebrospinal fluid from the cisterna magna in mouse. J Vis Exp, doi:10.3791/960 (2008).</Citation><ArticleIdList><ArticleId IdType="doi">10.3791/960</ArticleId><ArticleId IdType="pmc">PMC2762909</ArticleId><ArticleId IdType="pubmed">19066529</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith A, Wu AH, Lynch KL, Ko N. &amp; Grenache DG Multi-wavelength spectrophotometric analysis for detection of xanthochromia in cerebrospinal fluid and accuracy for the diagnosis of subarachnoid hemorrhage. Clin Chim Acta 424, 231&#x2013;236, doi:10.1016/j.cca.2013.06.017 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cca.2013.06.017</ArticleId><ArticleId IdType="pubmed">23800427</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsson M, Arlig J, Hedner J, Blennow K. &amp; Zetterberg H. Sleep deprivation and cerebrospinal fluid biomarkers for Alzheimer&#x2019;s disease. Sleep 41, doi:10.1093/sleep/zsy025 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/sleep/zsy025</ArticleId><ArticleId IdType="pubmed">29425372</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsson M, Arlig J, Hedner J, Blennow K. &amp; Zetterberg H. Sleep deprivation and plasma biomarkers for Alzheimer&#x2019;s disease. Sleep Med 57, 92&#x2013;93, doi:10.1016/j.sleep.2018.12.029 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sleep.2018.12.029</ArticleId><ArticleId IdType="pubmed">30953929</ArticleId></ArticleIdList></Reference><Reference><Citation>Lynch HJ, Rivest RW &amp; Wurtman RJ Artificial induction of melatonin rhythms by programmed microinfusion. Neuroendocrinology 31, 106&#x2013;111, doi:10.1159/000123059 (1980).</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000123059</ArticleId><ArticleId IdType="pubmed">7393407</ArticleId></ArticleIdList></Reference><Reference><Citation>Pluvinage JV et al. CD22 blockade restores homeostatic microglial phagocytosis in ageing brains. Nature 568, 187&#x2013;192, doi:10.1038/s41586-019-1088-4 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-1088-4</ArticleId><ArticleId IdType="pmc">PMC6574119</ArticleId><ArticleId IdType="pubmed">30944478</ArticleId></ArticleIdList></Reference><Reference><Citation>Lukinavicius G. et al. Fluorogenic probes for live-cell imaging of the cytoskeleton. Nat Methods 11, 731&#x2013;733, doi:10.1038/nmeth.2972 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.2972</ArticleId><ArticleId IdType="pubmed">24859753</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman PL &amp; Ellisman MH Enhanced visualization of peripheral nerve and sensory receptors in the scanning electron microscope using cryofracture and osmium-thiocarbohydrazide-osmium impregnation. J Neurocytol 10, 111&#x2013;131, doi:10.1007/BF01181748 (1981).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF01181748</ArticleId><ArticleId IdType="pubmed">7310442</ArticleId></ArticleIdList></Reference><Reference><Citation>Willingham MC &amp; Rutherford AV The use of osmium-thiocarbohydrazide-osmium (OTO) and ferrocyanide-reduced osmium methods to enhance membrane contrast and preservation in cultured cells. J Histochem Cytochem 32, 455&#x2013;460, doi:10.1177/32.4.6323574 (1984).</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/32.4.6323574</ArticleId><ArticleId IdType="pubmed">6323574</ArticleId></ArticleIdList></Reference><Reference><Citation>Ewald AJ et al. Mammary collective cell migration involves transient loss of epithelial features and individual cell migration within the epithelium. J Cell Sci 125, 2638&#x2013;2654, doi:10.1242/jcs.096875 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.096875</ArticleId><ArticleId IdType="pmc">PMC3403234</ArticleId><ArticleId IdType="pubmed">22344263</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonald KL &amp; Webb RI Freeze substitution in 3 hours or less. J Microsc 243, 227&#x2013;233, doi:10.1111/j.1365-2818.2011.03526.x (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2818.2011.03526.x</ArticleId><ArticleId IdType="pubmed">21827481</ArticleId></ArticleIdList></Reference><Reference><Citation>Emery B. &amp; Dugas JC Purification of oligodendrocyte lineage cells from mouse cortices by immunopanning. Cold Spring Harb Protoc 2013, 854&#x2013;868, doi:10.1101/pdb.prot073973 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/pdb.prot073973</ArticleId><ArticleId IdType="pubmed">24003195</ArticleId></ArticleIdList></Reference><Reference><Citation>Muhar M. et al. SLAM-seq defines direct gene-regulatory functions of the BRD4-MYC axis. Science 360, 800&#x2013;805, doi:10.1126/science.aao2793 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aao2793</ArticleId><ArticleId IdType="pmc">PMC6409205</ArticleId><ArticleId IdType="pubmed">29622725</ArticleId></ArticleIdList></Reference><Reference><Citation>Stockel D. et al. Multi-omics enrichment analysis using the GeneTrail2 web service. Bioinformatics 32, 1502&#x2013;1508, doi:10.1093/bioinformatics/btv770 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btv770</ArticleId><ArticleId IdType="pubmed">26787660</ArticleId></ArticleIdList></Reference><Reference><Citation>Hahn O. et al. CoolMPS for robust sequencing of single-nuclear RNAs captured by droplet-based method. Nucleic Acids Res 49, e11, doi:10.1093/nar/gkaa1127 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkaa1127</ArticleId><ArticleId IdType="pmc">PMC7826285</ArticleId><ArticleId IdType="pubmed">33264392</ArticleId></ArticleIdList></Reference><Reference><Citation>Newman AM et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat Biotechnol 37, 773&#x2013;782, doi:10.1038/s41587-019-0114-2 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41587-019-0114-2</ArticleId><ArticleId IdType="pmc">PMC6610714</ArticleId><ArticleId IdType="pubmed">31061481</ArticleId></ArticleIdList></Reference><Reference><Citation>Steen CB, Liu CL, Alizadeh AA &amp; Newman AM Profiling Cell Type Abundance and Expression in Bulk Tissues with CIBERSORTx. Methods Mol Biol 2117, 135&#x2013;157, doi:10.1007/978-1-0716-0301-7_7 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-0716-0301-7_7</ArticleId><ArticleId IdType="pmc">PMC7695353</ArticleId><ArticleId IdType="pubmed">31960376</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf FA, Angerer P. &amp; Theis FJ SCANPY: large-scale single-cell gene expression data analysis. Genome Biol 19, 15, doi:10.1186/s13059-017-1382-0 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-017-1382-0</ArticleId><ArticleId IdType="pmc">PMC5802054</ArticleId><ArticleId IdType="pubmed">29409532</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaum N. et al. Ageing hallmarks exhibit organ-specific temporal signatures. Nature 583, 596&#x2013;602, doi:10.1038/s41586-020-2499-y (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2499-y</ArticleId><ArticleId IdType="pmc">PMC7757734</ArticleId><ArticleId IdType="pubmed">32669715</ArticleId></ArticleIdList></Reference><Reference><Citation>Spitzer SO et al. Oligodendrocyte Progenitor Cells Become Regionally Diverse and Heterogeneous with Age. Neuron 101, 459&#x2013;471 e455, doi:10.1016/j.neuron.2018.12.020 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2018.12.020</ArticleId><ArticleId IdType="pmc">PMC6372724</ArticleId><ArticleId IdType="pubmed">30654924</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathys H. et al. Single-cell transcriptomic analysis of Alzheimer&#x2019;s disease. Nature 570, 332&#x2013;337, doi:10.1038/s41586-019-1195-2 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-1195-2</ArticleId><ArticleId IdType="pmc">PMC6865822</ArticleId><ArticleId IdType="pubmed">31042697</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y. et al. Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer&#x2019;s disease. Nat Med 26, 131&#x2013;142, doi:10.1038/s41591-019-0695-9 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-019-0695-9</ArticleId><ArticleId IdType="pmc">PMC6980793</ArticleId><ArticleId IdType="pubmed">31932797</ArticleId></ArticleIdList></Reference><Reference><Citation>Matys V. et al. TRANSFAC and its module TRANSCompel: transcriptional gene regulation in eukaryotes. Nucleic Acids Res 34, D108&#x2013;110, doi:10.1093/nar/gkj143 (2006).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkj143</ArticleId><ArticleId IdType="pmc">PMC1347505</ArticleId><ArticleId IdType="pubmed">16381825</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerstner N. et al. GeneTrail 3: advanced high-throughput enrichment analysis. Nucleic Acids Res, doi:10.1093/nar/gkaa306 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkaa306</ArticleId><ArticleId IdType="pmc">PMC7319559</ArticleId><ArticleId IdType="pubmed">32379325</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35584626</PMID><DateCompleted><Year>2022</Year><Month>05</Month><Day>20</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2666-3791</ISSN><JournalIssue CitedMedium="Internet"><Volume>3</Volume><Issue>5</Issue><PubDate><Year>2022</Year><Month>May</Month><Day>17</Day></PubDate></JournalIssue><Title>Cell reports. Medicine</Title><ISOAbbreviation>Cell Rep Med</ISOAbbreviation></Journal><ArticleTitle>A&#x3b2; oligomer concentration in mouse and human brain and its drug-induced reduction ex&#xa0;vivo.</ArticleTitle><Pagination><StartPage>100630</StartPage><MedlinePgn>100630</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">100630</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.xcrm.2022.100630</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2666-3791(22)00155-0</ELocationID><Abstract><AbstractText>The elimination of amyloid beta (A&#x3b2;) oligomers is a promising strategy for therapeutic drug development of Alzheimer's disease (AD). AD mouse models that develop A&#x3b2; pathology have been used to demonstrate in&#xa0;vivo efficacy of compounds that later failed in clinical development. Here, we analyze the concentration and size distribution of A&#x3b2; oligomers in different transgenic mouse models of AD and in human brain samples by surface-based fluorescence intensity distribution analysis (sFIDA), a highly sensitive method for detecting and quantitating protein aggregates. We demonstrate dose- and time-dependent oligomer elimination by the compound RD2 in mouse and human AD brain homogenates as sources of native A&#x3b2; oligomers. Such ex&#xa0;vivo target engagement analyses with mouse- and human-brain-derived oligomers have the potential to enhance the translational value from pre-clinical proof-of-concept studies to clinical trials.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 The Author(s). Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kass</LastName><ForeName>Bettina</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Institute of Biological Information Processing, Structural Biochemistry (IBI-7), Forschungszentrum J&#xfc;lich, J&#xfc;lich 52428, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schemmert</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Biological Information Processing, Structural Biochemistry (IBI-7), Forschungszentrum J&#xfc;lich, J&#xfc;lich 52428, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zafiu</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute of Biological Information Processing, Structural Biochemistry (IBI-7), Forschungszentrum J&#xfc;lich, J&#xfc;lich 52428, Germany; attyloid GmbH, D&#xfc;sseldorf, 40225, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pils</LastName><ForeName>Marlene</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Biological Information Processing, Structural Biochemistry (IBI-7), Forschungszentrum J&#xfc;lich, J&#xfc;lich 52428, Germany; Institut f&#xfc;r Physikalische Biologie, Heinrich-Heine-Universit&#xe4;t D&#xfc;sseldorf, D&#xfc;sseldorf 40225, Germany; attyloid GmbH, D&#xfc;sseldorf, 40225, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bannach</LastName><ForeName>Oliver</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Institute of Biological Information Processing, Structural Biochemistry (IBI-7), Forschungszentrum J&#xfc;lich, J&#xfc;lich 52428, Germany; Institut f&#xfc;r Physikalische Biologie, Heinrich-Heine-Universit&#xe4;t D&#xfc;sseldorf, D&#xfc;sseldorf 40225, Germany; attyloid GmbH, D&#xfc;sseldorf, 40225, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kutzsche</LastName><ForeName>Janine</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Biological Information Processing, Structural Biochemistry (IBI-7), Forschungszentrum J&#xfc;lich, J&#xfc;lich 52428, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bujnicki</LastName><ForeName>Tuyen</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Institute of Biological Information Processing, Structural Biochemistry (IBI-7), Forschungszentrum J&#xfc;lich, J&#xfc;lich 52428, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Willbold</LastName><ForeName>Dieter</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Institute of Biological Information Processing, Structural Biochemistry (IBI-7), Forschungszentrum J&#xfc;lich, J&#xfc;lich 52428, Germany; Institut f&#xfc;r Physikalische Biologie, Heinrich-Heine-Universit&#xe4;t D&#xfc;sseldorf, D&#xfc;sseldorf 40225, Germany; attyloid GmbH, D&#xfc;sseldorf, 40225, Germany; Priavoid GmbH, D&#xfc;sseldorf, 40225, Germany. Electronic address: d.willbold@fz-juelich.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Rep Med</MedlineTA><NlmUniqueID>101766894</NlmUniqueID><ISSNLinking>2666-3791</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="Y">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyloid beta oligomer quantitation</Keyword><Keyword MajorTopicYN="N">brain homogenates</Keyword><Keyword MajorTopicYN="N">d-enantiomeric peptides</Keyword><Keyword MajorTopicYN="N">ex&#xa0;vivo target engagement</Keyword><Keyword MajorTopicYN="N">sFIDA</Keyword></KeywordList><CoiStatement>Declaration of interests D.W. is a founder and shareholder of the company Priavoid and member of its supervisory board. D.W. is co-inventor of patents related to the compound RD2. C.Z., D.W., and B.K. are inventors of patent WO2019101250A1 (method for quantifying protein aggregates of a protein misfolding disease in a sample). D.W., O.B., and C.Z. are founders and shareholders of attyloid. D.W. is member of attyloid&#x2019;s supervisory board. These had no influence on the interpretation of the data. All other authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>12</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>2</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>4</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>18</Day><Hour>18</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>5</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35584626</ArticleId><ArticleId IdType="pmc">PMC9133466</ArticleId><ArticleId IdType="doi">10.1016/j.xcrm.2022.100630</ArticleId><ArticleId IdType="pii">S2666-3791(22)00155-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Prince M.J., Wimo A., Guerchet M., Ali G.-C., Wu Y.-T., Prina M., et al. Alzheimer's Disease International; 2015. World Alzheimer Report 2015: The Global Impact of Dementia: an Analysis of Prevalence, Incidence, Cost and Trends.</Citation></Reference><Reference><Citation>2020 Alzheimer's disease facts and figures. Alzheimer's Dementia. 2020;16:391&#x2013;460.</Citation><ArticleIdList><ArticleId IdType="pubmed">32157811</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling R.A., Aisen P.S., Beckett L.A., Bennett D.A., Craft S., Fagan A.M., Iwatsubo T., Jack C.R., Jr., Kaye J., Montine T.J., et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer&#x2019;s Dementia. 2011;7:280&#x2013;292. doi: 10.1016/j.jalz.2011.03.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2011.03.003</ArticleId><ArticleId IdType="pmc">PMC3220946</ArticleId><ArticleId IdType="pubmed">21514248</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadjichrysanthou C., Evans S., Bajaj S., Siakallis L.C., McRae-McKee K., de Wolf F., Anderson R.M., The Alzheimer&#x2019;s Disease Neuroimaging I The dynamics of biomarkers across the clinical spectrum of Alzheimer&#x2019;s disease. Alzheimer's Res. Ther. 2020;12:74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7293779</ArticleId><ArticleId IdType="pubmed">32534594</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., Rowan M.J., Selkoe D.J. Naturally secreted oligomers of amyloid &#x3b2; protein potently inhibit hippocampal long-term potentiation in&#xa0;vivo. Nature. 2002;416:535&#x2013;539. doi: 10.1038/416535a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/416535a</ArticleId><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Benilova I., Karran E., De Strooper B. The toxic A&#x3b2; oligomer and Alzheimer's disease: an emperor in need of clothes. Nat. Neurosci. 2012;15:349&#x2013;357. doi: 10.1038/nn.3028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3028</ArticleId><ArticleId IdType="pubmed">22286176</ArticleId></ArticleIdList></Reference><Reference><Citation>Elfgen A., Hupert M., Bochinsky K., Tusche M., Gonzalez de San Roman Martin E., Gering I., Sacchi S., Pollegioni L., Huesgen P.F., Hartmann R., et al. Metabolic resistance of the D-peptide RD2 developed for direct elimination of amyloid-&#x3b2; oligomers. Sci. Rep. 2019;9:5715. doi: 10.1038/s41598-019-41993-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-41993-6</ArticleId><ArticleId IdType="pmc">PMC6450887</ArticleId><ArticleId IdType="pubmed">30952881</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiesehan K., Willbold D. Mirror-image phage display: aiming at the mirror. Chembiochem. 2003;4:811&#x2013;815. doi: 10.1002/cbic.200300570.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cbic.200300570</ArticleId><ArticleId IdType="pubmed">12964153</ArticleId></ArticleIdList></Reference><Reference><Citation>Funke S.A., Willbold D. Mirror image phage display - a method to generate D-peptide ligands for use in diagnostic or therapeutical applications. Mol. Biosyst. 2009;5:783&#x2013;786. doi: 10.1039/b904138a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/b904138a</ArticleId><ArticleId IdType="pubmed">19603110</ArticleId></ArticleIdList></Reference><Reference><Citation>van Groen T., Wiesehan K., Funke S.A., Kadish I., Nagel-Steger L., Willbold D. Reduction of Alzheimer&#x2019;s disease amyloid plaque load in transgenic mice by D3, a D-enantiomeric peptide identified by mirror image phage display. ChemMedChem. 2008;3:1848&#x2013;1852. doi: 10.1002/cmdc.200800273.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cmdc.200800273</ArticleId><ArticleId IdType="pubmed">19016284</ArticleId></ArticleIdList></Reference><Reference><Citation>van Groen T., Kadish I., Funke S.A., Bartnik D., Willbold D. Treatment with D3 removes amyloid deposits, reduces inflammation, and improves cognition in aged A&#x3b2;PP/PS1 double transgenic mice. J.&#xa0;Alzheimer's Dis. 2013;34:609&#x2013;620. doi: 10.3233/jad-121792.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/jad-121792</ArticleId><ArticleId IdType="pmc">PMC5558238</ArticleId><ArticleId IdType="pubmed">23271316</ArticleId></ArticleIdList></Reference><Reference><Citation>Funke S.A., van Groen T., Kadish I., Bartnik D., Nagel-Steger L., Brener O., Sehl T., Batra-Safferling R., Moriscot C., Schoehn G., et al. Oral treatment with the &lt;scp&gt;d&lt;/scp&gt;-Enantiomeric peptide D3 improves the pathology and behavior of Alzheimer&#x2019;s disease transgenic mice. ACS Chem. Neurosci. 2010;1:639&#x2013;648. doi: 10.1021/cn100057j.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/cn100057j</ArticleId><ArticleId IdType="pmc">PMC3368690</ArticleId><ArticleId IdType="pubmed">22778851</ArticleId></ArticleIdList></Reference><Reference><Citation>Leithold L.H.E., Jiang N., Post J., Niemietz N., Schartmann E., Ziehm T., Kutzsche J., Shah N.J., Breitkreutz J., Langen K.-J., et al. Pharmacokinetic properties of tandem d-peptides designed for treatment of Alzheimer's disease. Eur. J. Pharm. Sci. 2016;89:31&#x2013;38. doi: 10.1016/j.ejps.2016.04.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejps.2016.04.016</ArticleId><ArticleId IdType="pubmed">27086111</ArticleId></ArticleIdList></Reference><Reference><Citation>Schartmann E., Schemmert S., Ziehm T., Leithold L.H.E., Jiang N., Tusche M., Joni Shah N., Langen K.J., Kutzsche J., Willbold D., Willuweit A. Comparison of blood-brain barrier penetration efficiencies between linear and cyclic all-d-enantiomeric peptides developed for the treatment of Alzheimer's disease. Eur. J. Pharm. Sci. 2018;114:93&#x2013;102. doi: 10.1016/j.ejps.2017.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejps.2017.12.005</ArticleId><ArticleId IdType="pubmed">29225107</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziehm T., Buell A.K., Willbold D. Role of hydrophobicity and charge of amyloid-beta oligomer eliminating &lt;scp&gt;d&lt;/scp&gt;-Peptides in the interaction with amyloid-beta monomers. ACS Chem. Neurosci. 2018;9:2679&#x2013;2688. doi: 10.1021/acschemneuro.8b00132.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschemneuro.8b00132</ArticleId><ArticleId IdType="pubmed">29893543</ArticleId></ArticleIdList></Reference><Reference><Citation>Olubiyi O.O., Frenzel D., Bartnik D., Gl&#xfc;ck J.M., Brener O., Nagel-Steger L., Funke S.A., Willbold D., Strodel B. Amyloid aggregation inhibitory mechanism of arginine-rich D-peptides. Curr. Med. Chem. 2014;21:1448&#x2013;1457. doi: 10.2174/0929867321666131129122247.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/0929867321666131129122247</ArticleId><ArticleId IdType="pubmed">24304283</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang T., Gering I., Kutzsche J., Nagel-Steger L., Willbold D. Toward the mode of action of the clinical stage all-&lt;scp&gt;d&lt;/scp&gt;-enantiomeric peptide RD2 on A&#x3b2;42 aggregation. ACS Chem. Neurosci. 2019;10:4800&#x2013;4809. doi: 10.1021/acschemneuro.9b00458.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschemneuro.9b00458</ArticleId><ArticleId IdType="pubmed">31710458</ArticleId></ArticleIdList></Reference><Reference><Citation>van Groen T., Schemmert S., Brener O., Gremer L., Ziehm T., Tusche M., Nagel-Steger L., Kadish I., Schartmann E., Elfgen A., et al. The A&#x3b2; oligomer eliminating D-enantiomeric peptide RD2 improves cognition without changing plaque pathology. Sci. Rep. 2017;7:16275. doi: 10.1038/s41598-017-16565-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-16565-1</ArticleId><ArticleId IdType="pmc">PMC5701182</ArticleId><ArticleId IdType="pubmed">29176708</ArticleId></ArticleIdList></Reference><Reference><Citation>Leithold L.H.E., Jiang N., Post J., Ziehm T., Schartmann E., Kutzsche J., Shah N.J., Breitkreutz J., Langen K.-J., Willuweit A., Willbold D. Pharmacokinetic properties of a novel d-peptide developed to be therapeutically active against toxic &#x3b2;-amyloid oligomers. Pharm. Res. 2016;33:328&#x2013;336. doi: 10.1007/s11095-015-1791-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11095-015-1791-2</ArticleId><ArticleId IdType="pubmed">26381279</ArticleId></ArticleIdList></Reference><Reference><Citation>Kutzsche J., Schemmert S., Tusche M., Neddens J., Rabl R., Jurgens D., Brener O., Willuweit A., Hutter-Paier B., Willbold D. Large-scale oral treatment study with the four most promising D3-derivatives for the treatment of Alzheimer's disease. Molecules. 2017;22:1693. doi: 10.3390/molecules22101693.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules22101693</ArticleId><ArticleId IdType="pmc">PMC6151452</ArticleId><ArticleId IdType="pubmed">28994710</ArticleId></ArticleIdList></Reference><Reference><Citation>Schemmert S., Schartmann E., Zafiu C., Kass B., Hartwig S., Lehr S., Bannach O., Langen K.J., Shah N.J., Kutzsche J., et al. A&#x3b2; oligomer elimination restores cognition in transgenic Alzheimer's mice with full-blown pathology. Mol. Neurobiol. 2019;56:2211&#x2013;2223. doi: 10.1007/s12035-018-1209-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-018-1209-3</ArticleId><ArticleId IdType="pmc">PMC6394605</ArticleId><ArticleId IdType="pubmed">30003517</ArticleId></ArticleIdList></Reference><Reference><Citation>Birkmann E., Henke F., Weinmann N., Dumpitak C., Groschup M., Funke A., Willbold D., Riesner D. Counting of single prion particles bound to a capture-antibody surface (surface-FIDA) Vet. Microbiol. 2007;123:294&#x2013;304. doi: 10.1016/j.vetmic.2007.04.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vetmic.2007.04.001</ArticleId><ArticleId IdType="pubmed">17499942</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang-Dietrich L., Funke S.A., Kuhbach K., Wang K., Besmehn A., Willbold S., Cinar Y., Bannach O., Birkmann E., Willbold D. The amyloid-&#x3b2; oligomer count in cerebrospinal fluid is a biomarker for Alzheimer's disease. J.&#xa0;Alzheimers Dis. 2013;34:985&#x2013;994. doi: 10.3233/jad-122047.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/jad-122047</ArticleId><ArticleId IdType="pubmed">23313925</ArticleId></ArticleIdList></Reference><Reference><Citation>Kravchenko K., Kulawik A., Hulsemann M., Kuhbach K., Zafiu C., Herrmann Y., Linnartz C., Peters L., Bujnicki T., Willbold J., et al. Analysis of anticoagulants for blood-based quantitation of amyloid &#x3b2; oligomers in the sFIDA assay. Biol. Chem. 2017;398:465&#x2013;475. doi: 10.1515/hsz-2016-0153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/hsz-2016-0153</ArticleId><ArticleId IdType="pubmed">27811340</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulawik A., Heise H., Zafiu C., Willbold D., Bannach O. Advancements of the sFIDA method for oligomer-based diagnostics of neurodegenerative diseases. FEBS Lett. 2018;592:516&#x2013;534. doi: 10.1002/1873-3468.12983.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1873-3468.12983</ArticleId><ArticleId IdType="pubmed">29360176</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xfc;lsemann M., Zafiu C., Kuhbach K., Luhmann N., Herrmann Y., Peters L., Linnartz C., Willbold J., Kravchenko K., Kulawik A., et al. Biofunctionalized silica nanoparticles: standards in amyloid-&#x3b2; oligomer-based diagnosis of Alzheimer's disease. J.&#xa0;Alzheimers Dis. 2016;54:79&#x2013;88. doi: 10.3233/jad-160253.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/jad-160253</ArticleId><ArticleId IdType="pubmed">27472876</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrmann Y., Bujnicki T., Zafiu C., Kulawik A., Kuhbach K., Peters L., Fabig J., Willbold J., Bannach O., Willbold D. Nanoparticle standards for immuno-based quantitation of &#x3b1;-synuclein oligomers in diagnostics of Parkinson's disease and other synucleinopathies. Clin. Chim. Acta. 2017;466:152&#x2013;159. doi: 10.1016/j.cca.2017.01.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cca.2017.01.010</ArticleId><ArticleId IdType="pubmed">28088342</ArticleId></ArticleIdList></Reference><Reference><Citation>Brener O., Dunkelmann T., Gremer L., van Groen T., Mirecka E.A., Kadish I., Willuweit A., Kutzsche J., Jurgens D., Rudolph S., et al. QIAD assay for quantitating a compound's efficacy in elimination of toxic A&#x3b2; oligomers. Sci. Rep. 2015;5:13222. doi: 10.1038/srep13222.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep13222</ArticleId><ArticleId IdType="pmc">PMC4585794</ArticleId><ArticleId IdType="pubmed">26394756</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiesehan K., Buder K., Linke R.P., Patt S., Stoldt M., Unger E., Schmitt B., Bucci E., Willbold D. Selection of &#x1d05;-amino-acid peptides that bind to Alzheimer's disease amyloid peptide A&#x3b2;1-42 by mirror image phage display. Chembiochem. 2003;4:748&#x2013;753. doi: 10.1002/cbic.200300631.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cbic.200300631</ArticleId><ArticleId IdType="pubmed">12898626</ArticleId></ArticleIdList></Reference><Reference><Citation>Funke S.A., Bartnik D., Gluck J.M., Piorkowska K., Wiesehan K., Weber U., Gulyas B., Halldin C., Pfeifer A., Spenger C., et al. Development of a small D-enantiomeric Alzheimer's amyloid-&#x3b2; binding peptide ligand for future in&#xa0;vivo imaging applications. PLoS One. 2012;7:e41457. doi: 10.1371/journal.pone.0041457.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0041457</ArticleId><ArticleId IdType="pmc">PMC3404088</ArticleId><ArticleId IdType="pubmed">22848501</ArticleId></ArticleIdList></Reference><Reference><Citation>Guly&#xe1;s B., Spenger C., Beliczai Z., Gulya K., K&#xe1;sa P., Jahan M., Jia Z., Weber U., Pfeifer A., Muhs A., et al. Distribution and binding of 18F-labeled and 125I-labeled analogues of ACI-80, a prospective molecular imaging biomarker of disease: a whole hemisphere post mortem autoradiography study in human brains obtained from Alzheimer's disease patients. Neurochem. Int. 2012;60:153&#x2013;162. doi: 10.1016/j.neuint.2011.10.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuint.2011.10.010</ArticleId><ArticleId IdType="pubmed">22100791</ArticleId></ArticleIdList></Reference><Reference><Citation>Jahan M., Nag S., Krasikova R., Weber U., Muhs A., Pfeifer A., Spenger C., Willbold D., Guly&#xe1;s B., Halldin C. Fluorine-18 labeling of three novel D-peptides by conjugation with N-succinimidyl-4-[18F]fluorobenzoate and preliminary examination by postmortem whole-hemisphere human brain autoradiography. Nucl. Med. Biol. 2012;39:315&#x2013;323. doi: 10.1016/j.nucmedbio.2011.09.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nucmedbio.2011.09.008</ArticleId><ArticleId IdType="pubmed">22136889</ArticleId></ArticleIdList></Reference><Reference><Citation>Sehlin D., Englund H., Simu B., Karlsson M., Ingelsson M., Nikolajeff F., Lannfelt L., Pettersson F.E. Large aggregates are the major soluble A&#x3b2; species in AD brain fractionated with density gradient ultracentrifugation. PLoS One. 2012;7:e32014. doi: 10.1371/journal.pone.0032014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0032014</ArticleId><ArticleId IdType="pmc">PMC3280222</ArticleId><ArticleId IdType="pubmed">22355408</ArticleId></ArticleIdList></Reference><Reference><Citation>Mc Donald J.M., O'Malley T.T., Liu W., Mably A.J., Brinkmalm G., Portelius E., Wittbold W.M., 3rd, Frosch M.P., Walsh D.M. The aqueous phase of Alzheimer's disease brain contains assemblies built from &#x223c;4 and &#x223c;7&#xa0;kDa A&#x3b2; species. Alzheimers Dementia. 2015;11:1286&#x2013;1305. doi: 10.1016/j.jalz.2015.01.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2015.01.005</ArticleId><ArticleId IdType="pmc">PMC4592782</ArticleId><ArticleId IdType="pubmed">25846299</ArticleId></ArticleIdList></Reference><Reference><Citation>Upadhaya A.R., Lungrin I., Yamaguchi H., Fandrich M., Thal D.R. High-molecular weight A&#x3b2; oligomers and protofibrils are the predominant A&#x3b2; species in the native soluble protein fraction of the AD brain. J.&#xa0;Cell Mol. Med. 2012;16:287&#x2013;295. doi: 10.1111/j.1582-4934.2011.01306.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1582-4934.2011.01306.x</ArticleId><ArticleId IdType="pmc">PMC3823292</ArticleId><ArticleId IdType="pubmed">21418518</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang T., Li S., Xu H., Walsh D.M., Selkoe D.J. Large soluble oligomers of amyloid &#x3b2;-protein from Alzheimer brain are far less neuroactive than the smaller oligomers to which they dissociate. J.&#xa0;Neurosci. 2017;37:152&#x2013;163. doi: 10.1523/jneurosci.1698-16.2016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/jneurosci.1698-16.2016</ArticleId><ArticleId IdType="pmc">PMC5214627</ArticleId><ArticleId IdType="pubmed">28053038</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong W., Wang Z., Liu W., O'Malley T.T., Jin M., Willem M., Haass C., Frosch M.P., Walsh D.M. Diffusible, highly bioactive oligomers represent a critical minority of soluble A&#x3b2; in Alzheimer's disease brain. Acta Neuropathol. 2018;136:19&#x2013;40. doi: 10.1007/s00401-018-1846-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-1846-7</ArticleId><ArticleId IdType="pmc">PMC6647843</ArticleId><ArticleId IdType="pubmed">29687257</ArticleId></ArticleIdList></Reference><Reference><Citation>Lana E., Gellerbring A., Jung S., Nordberg A., Unger Lithner C., Darreh-Shori T. Homomeric and heteromeric A&#x3b2; species exist in human brain and CSF regardless of Alzheimer's disease status and risk genotype. Front. Mol. Neurosci. 2019;12:176. doi: 10.3389/fnmol.2019.00176.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2019.00176</ArticleId><ArticleId IdType="pmc">PMC6684963</ArticleId><ArticleId IdType="pubmed">31417354</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal D.R., Walter J., Saido T.C., F&#xe4;ndrich M. Neuropathology and biochemistry of A&#x3b2; and its aggregates in Alzheimer&#x2019;s disease. Acta Neuropathol. 2015;129:167&#x2013;182. doi: 10.1007/s00401-014-1375-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-014-1375-y</ArticleId><ArticleId IdType="pubmed">25534025</ArticleId></ArticleIdList></Reference><Reference><Citation>Meloni B.P., Mastaglia F.L., Knuckey N.W. Cationic arginine-rich peptides (CARPs): a novel class of neuroprotective agents with a multimodal mechanism of action. Front. Neurol. 2020;11:108. doi: 10.3389/fneur.2020.00108.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2020.00108</ArticleId><ArticleId IdType="pmc">PMC7052017</ArticleId><ArticleId IdType="pubmed">32158425</ArticleId></ArticleIdList></Reference><Reference><Citation>Borgia A., Borgia M.B., Bugge K., Kissling V.M., Heidarsson P.O., Fernandes C.B., Sottini A., Soranno A., Buholzer K.J., Nettels D., et al. Extreme disorder in an ultrahigh-affinity protein complex. Nature. 2018;555:61&#x2013;66. doi: 10.1038/nature25762.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature25762</ArticleId><ArticleId IdType="pmc">PMC6264893</ArticleId><ArticleId IdType="pubmed">29466338</ArticleId></ArticleIdList></Reference><Reference><Citation>Arosio P., Michaels T.C.T., Linse S., M&#xe5;nsson C., Emanuelsson C., Presto J., Johansson J., Vendruscolo M., Dobson C.M., Knowles T.P.J. Kinetic analysis reveals the diversity of microscopic mechanisms through which molecular chaperones suppress amyloid formation. Nat. Commun. 2016;7:10948. doi: 10.1038/ncomms10948.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms10948</ArticleId><ArticleId IdType="pmc">PMC4820785</ArticleId><ArticleId IdType="pubmed">27009901</ArticleId></ArticleIdList></Reference><Reference><Citation>Kutzsche J., Jurgens D., Willuweit A., Adermann K., Fuchs C., Simons S., Windisch M., Humpel M., Rossberg W., Wolzt M., Willbold D. Safety and pharmacokinetics of the orally available antiprionic compound PRI-002: a single and multiple ascending dose phase I study. Alzheimers Dement (N Y) 2020;6:e12001. doi: 10.1002/trc2.12001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/trc2.12001</ArticleId><ArticleId IdType="pmc">PMC7087413</ArticleId><ArticleId IdType="pubmed">32211506</ArticleId></ArticleIdList></Reference><Reference><Citation>Jager S., Leuchtenberger S., Martin A., Czirr E., Wesselowski J., Dieckmann M., Waldron E., Korth C., Koo E.H., Heneka M., et al. &#xce;&#xb1;-secretase mediated conversion of the amyloid precursor protein derived membrane stub C99 to C83 limits A&#xce;&#xb2; generation. J.&#xa0;Neurochem. 2009;111:1369&#x2013;1382. doi: 10.1111/j.1471-4159.2009.06420.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2009.06420.x</ArticleId><ArticleId IdType="pubmed">19804379</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky J.L., Slunt H.H., Ratovitski T., Jenkins N.A., Copeland N.G., Borchelt D.R. Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol. Eng. 2001;17:157&#x2013;165. doi: 10.1016/s1389-0344(01)00067-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1389-0344(01)00067-3</ArticleId><ArticleId IdType="pubmed">11337275</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky J.L., Fadale D.J., Anderson J., Xu G.M., Gonzales V., Jenkins N.A., Copeland N.G., Lee M.K., Younkin L.H., Wagner S.L., et al. Mutant presenilins specifically elevate the levels of the 42 residue &#x3b2;-amyloid peptide in&#xa0;vivo: evidence for augmentation of a 42-specific &#x3b3; secretase. Hum. Mol. Genet. 2004;13:159&#x2013;170. doi: 10.1093/hmg/ddh019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddh019</ArticleId><ArticleId IdType="pubmed">14645205</ArticleId></ArticleIdList></Reference><Reference><Citation>Borchelt D.R., Davis J., Fischer M., Lee M.K., Slunt H.H., Ratovitsky T., Regard J., Copeland N.G., Jenkins N.A., Sisodia S.S., Price D.L. A vector for expressing foreign genes in the brains and hearts of transgenic mice. Genet. Anal. Biomol. Eng. 1996;13:159&#x2013;163. doi: 10.1016/s1050-3862(96)00167-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1050-3862(96)00167-2</ArticleId><ArticleId IdType="pubmed">9117892</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee M.K., Borchelt D.R., Kim G., Thinakaran G., Slunt H.H., Ratovitski T., Martin L.J., Kittur A., Gandy S., Levey A.I., et al. Hyperaccumulation of FAD-linked presenilin 1 variants in&#xa0;vivo. Nat. Med. 1997;3:756&#x2013;760. doi: 10.1038/nm0797-756.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm0797-756</ArticleId><ArticleId IdType="pubmed">9212102</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Alloza M., Robbins E.M., Zhang-Nunes S.X., Purcell S.M., Betensky R.A., Raju S., Prada C., Greenberg S.M., Bacskai B.J., Frosch M.P. Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. Neurobiol. Dis. 2006;24:516&#x2013;524. doi: 10.1016/j.nbd.2006.08.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2006.08.017</ArticleId><ArticleId IdType="pubmed">17029828</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong S., Beja-Glasser V.F., Nfonoyim B.M., Frouin A., Li S., Ramakrishnan S., Merry K.M., Shi Q., Rosenthal A., Barres B.A., et al. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science. 2016;352:712&#x2013;716. doi: 10.1126/science.aad8373.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aad8373</ArticleId><ArticleId IdType="pmc">PMC5094372</ArticleId><ArticleId IdType="pubmed">27033548</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamphuis W., Mamber C., Moeton M., Kooijman L., Sluijs J.A., Jansen A.H.P., Verveer M., de Groot L.R., Smith V.D., Rangarajan S., et al. GFAP isoforms in adult mouse brain with a focus on neurogenic astrocytes and reactive astrogliosis in mouse models of Alzheimer disease. PLoS One. 2012;7:e42823. doi: 10.1371/journal.pone.0042823.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0042823</ArticleId><ArticleId IdType="pmc">PMC3418292</ArticleId><ArticleId IdType="pubmed">22912745</ArticleId></ArticleIdList></Reference><Reference><Citation>Kilgore M., Miller C.A., Fass D.M., Hennig K.M., Haggarty S.J., Sweatt J.D., Rumbaugh G. Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer's disease. Neuropsychopharmacology. 2010;35:870&#x2013;880. doi: 10.1038/npp.2009.197.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/npp.2009.197</ArticleId><ArticleId IdType="pmc">PMC3055373</ArticleId><ArticleId IdType="pubmed">20010553</ArticleId></ArticleIdList></Reference><Reference><Citation>Lalonde R., Kim H.D., Maxwell J.A., Fukuchi K. Exploratory activity and spatial learning in 12-month-old APP695SWE/co+PS1/&#x394;E9 mice with amyloid plaques. Neurosci. Lett. 2005;390:87&#x2013;92. doi: 10.1016/j.neulet.2005.08.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2005.08.028</ArticleId><ArticleId IdType="pubmed">16169151</ArticleId></ArticleIdList></Reference><Reference><Citation>Rupp N.J., Wegenast-Braun B.M., Radde R., Calhoun M.E., Jucker M. Early onset amyloid lesions lead to severe neuritic abnormalities and local, but not global neuron loss in APPPS1 transgenic mice. Neurobiol. Aging. 2011;32:2324.e1. doi: 10.1016/j.neurobiolaging.2010.08.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2010.08.014</ArticleId><ArticleId IdType="pubmed">20970889</ArticleId></ArticleIdList></Reference><Reference><Citation>Minkeviciene R., Ihalainen J., Malm T., Matilainen O., Keksa-Goldsteine V., Goldsteins G., Iivonen H., Leguit N., Glennon J., Koistinaho J., et al. Age-related decrease in stimulated glutamate release and vesicular glutamate transporters in APP/PS1 transgenic and wild-type mice. J.&#xa0;Neurochem. 2008;105:584&#x2013;594. doi: 10.1111/j.1471-4159.2007.05147.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2007.05147.x</ArticleId><ArticleId IdType="pubmed">18042177</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis J., Xu F., Deane R., Romanov G., Previti M.L., Zeigler K., Zlokovic B.V., Van Nostrand W.E. Early-onset and robust cerebral microvascular accumulation of amyloid &#x3b2;-protein in transgenic mice expressing low levels of a vasculotropic Dutch/Iowa mutant form of amyloid &#x3b2;-protein precursor. J.&#xa0;Biol. Chem. 2004;279:20296&#x2013;20306. doi: 10.1074/jbc.m312946200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.m312946200</ArticleId><ArticleId IdType="pubmed">14985348</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy E., Carman M.D., Fernandez-Madrid I.J., Power M.D., Lieberburg I., van Duinen S.G., Bots G.T.A.M., Luyendijk W., Frangione B. Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. Science. 1990;248:1124&#x2013;1126. doi: 10.1126/science.2111584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.2111584</ArticleId><ArticleId IdType="pubmed">2111584</ArticleId></ArticleIdList></Reference><Reference><Citation>Grabowski T.J., Cho H.S., Vonsattel J.P.G., Rebeck G.W., Greenberg S.M. Novel amyloid precursor protein mutation in an Iowa family with dementia and severe cerebral amyloid angiopathy. Ann. Neurol. 2001;49:697&#x2013;705. doi: 10.1002/ana.1009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.1009</ArticleId><ArticleId IdType="pubmed">11409420</ArticleId></ArticleIdList></Reference><Reference><Citation>Miao J., Xu F., Davis J., Otte-H&#xf6;ller I., Verbeek M.M., Van Nostrand W.E. Cerebral microvascular amyloid &#x3b2; protein deposition induces vascular degeneration and neuroinflammation in transgenic mice expressing human vasculotropic mutant amyloid &#x3b2; precursor protein. Am. J. Pathol. 2005;167:505&#x2013;515. doi: 10.1016/s0002-9440(10)62993-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0002-9440(10)62993-8</ArticleId><ArticleId IdType="pmc">PMC1603574</ArticleId><ArticleId IdType="pubmed">16049335</ArticleId></ArticleIdList></Reference><Reference><Citation>Moechars D., Dewachter I., Lorent K., Revers&#xe9; D., Baekelandt V., Naidu A., Tesseur I., Spittaels K., Haute C.V.D., Checler F., et al. Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J.&#xa0;Biol. Chem. 1999;274:6483&#x2013;6492. doi: 10.1074/jbc.274.10.6483.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.274.10.6483</ArticleId><ArticleId IdType="pubmed">10037741</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Dorpe J., Smeijers L., Dewachter I., Nuyens D., Spittaels K., Van Den Haute C., Mercken M., Moechars D., Laenen I., Kuiperi C., et al. Prominent cerebral amyloid angiopathy in transgenic mice overexpressing the london mutant of human APP in neurons. Am. J. Pathol. 2000;157:1283&#x2013;1298. doi: 10.1016/s0002-9440(10)64644-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0002-9440(10)64644-5</ArticleId><ArticleId IdType="pmc">PMC1850171</ArticleId><ArticleId IdType="pubmed">11021833</ArticleId></ArticleIdList></Reference><Reference><Citation>Dominguez-del-Toro E., Rodriguez-Moreno A., Porras-Garcia E., Sanchez-Campusano R., Blanchard V., Laville M., Bohme G.A., Benavides J., Delgado-Garcia J.M. An in&#xa0;vitro and in&#xa0;vivo study of early deficits in associative learning in transgenic mice that over-express a mutant form of human APP associated with Alzheimer's disease. Eur. J. Neurosci. 2004;20:1945&#x2013;1952. doi: 10.1111/j.1460-9568.2004.03643.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1460-9568.2004.03643.x</ArticleId><ArticleId IdType="pubmed">15380017</ArticleId></ArticleIdList></Reference><Reference><Citation>Rzepecki P., Nagel-Steger L., Feuerstein S., Linne U., Molt O., Zadmard R., Aschermann K., Wehner M., Schrader T., Riesner D. Prevention of Alzheimer's disease-associated A&#x3b2; aggregation by rationally designed nonpeptidic &#x3b2;-sheet ligands. J.&#xa0;Biol. Chem. 2004;279:47497&#x2013;47505. doi: 10.1074/jbc.m405914200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.m405914200</ArticleId><ArticleId IdType="pubmed">15322133</ArticleId></ArticleIdList></Reference><Reference><Citation>Schemmert S., Schartmann E., Honold D., Zafiu C., Ziehm T., Langen K.J., Shah N.J., Kutzsche J., Willuweit A., Willbold D. Deceleration of the neurodegenerative phenotype in pyroglutamate-A&#x3b2; accumulating transgenic mice by oral treatment with the A&#x3b2; oligomer eliminating compound RD2. Neurobiol. Dis. 2019;124:36&#x2013;45. doi: 10.1016/j.nbd.2018.10.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2018.10.021</ArticleId><ArticleId IdType="pubmed">30391539</ArticleId></ArticleIdList></Reference><Reference><Citation>van Groen T., Kadish I., Wiesehan K., Funke S.A., Willbold D. In&#xa0;vitro and in vivo staining characteristics of small, fluorescent, A&#x3b2;42-binding D-enantiomeric peptides in transgenic AD mouse models. ChemMedChem. 2009;4:276&#x2013;282. doi: 10.1002/cmdc.200800289.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cmdc.200800289</ArticleId><ArticleId IdType="pubmed">19072935</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35594347</PMID><DateCompleted><Year>2022</Year><Month>05</Month><Day>24</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2375-2548</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>20</Issue><PubDate><Year>2022</Year><Month>May</Month><Day>20</Day></PubDate></JournalIssue><Title>Science advances</Title><ISOAbbreviation>Sci Adv</ISOAbbreviation></Journal><ArticleTitle>Protein lifetimes in aged brains reveal a proteostatic adaptation linking physiological aging to neurodegeneration.</ArticleTitle><Pagination><StartPage>eabn4437</StartPage><MedlinePgn>eabn4437</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">eabn4437</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1126/sciadv.abn4437</ELocationID><Abstract><AbstractText>Aging is a prominent risk factor for neurodegenerative disorders (NDDs); however, the molecular mechanisms rendering the aged brain particularly susceptible to neurodegeneration remain unclear. Here, we aim to determine the link between physiological aging and NDDs by exploring protein turnover using metabolic labeling and quantitative pulse-SILAC proteomics. By comparing protein lifetimes between physiologically aged and young adult mice, we found that in aged brains protein lifetimes are increased by ~20% and that aging affects distinct pathways linked to NDDs. Specifically, a set of neuroprotective proteins are longer-lived in aged brains, while some mitochondrial proteins linked to neurodegeneration are shorter-lived. Strikingly, we observed a previously unknown alteration in proteostasis that correlates to parsimonious turnover of proteins with high biosynthetic costs, revealing an overall metabolic adaptation that preludes neurodegeneration. Our findings suggest that future therapeutic paradigms, aimed at addressing these metabolic adaptations, might be able to delay NDD onset.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kluever</LastName><ForeName>Verena</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-0505-8231</Identifier><AffiliationInfo><Affiliation>Department of Neuro- and Sensory Physiology, University Medical Center G&#xf6;ttingen, 37073 G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Russo</LastName><ForeName>Belisa</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0003-4389-4414</Identifier><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases, DZNE Bonn, Venusberg Campus 1, 53127 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mandad</LastName><ForeName>Sunit</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-2327-3602</Identifier><AffiliationInfo><Affiliation>Department of Neuro- and Sensory Physiology, University Medical Center G&#xf6;ttingen, 37073 G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Chemistry, University Medical Center G&#xf6;ttingen, 37077 G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Bioanalytical Mass Spectrometry Group, Max Planck Institute for Multidisciplinary Sciences, 37077 G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Nisha Hemandhar</ForeName><Initials>NH</Initials><Identifier Source="ORCID">0000-0001-5397-3242</Identifier><AffiliationInfo><Affiliation>Department of Neuro- and Sensory Physiology, University Medical Center G&#xf6;ttingen, 37073 G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alevra</LastName><ForeName>Mihai</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-1384-0071</Identifier><AffiliationInfo><Affiliation>Department of Neuro- and Sensory Physiology, University Medical Center G&#xf6;ttingen, 37073 G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ori</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-3046-0871</Identifier><AffiliationInfo><Affiliation>Leibniz Institute on Aging-Fritz Lipmann Institute (FLI), 07745 Jena, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rizzoli</LastName><ForeName>Silvio O</ForeName><Initials>SO</Initials><Identifier Source="ORCID">0000-0002-1667-7839</Identifier><AffiliationInfo><Affiliation>Department of Neuro- and Sensory Physiology, University Medical Center G&#xf6;ttingen, 37073 G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Urlaub</LastName><ForeName>Henning</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-1837-5233</Identifier><AffiliationInfo><Affiliation>Department of Clinical Chemistry, University Medical Center G&#xf6;ttingen, 37077 G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Bioanalytical Mass Spectrometry Group, Max Planck Institute for Multidisciplinary Sciences, 37077 G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Anja</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-9540-8700</Identifier><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases, DZNE Bonn, Venusberg Campus 1, 53127 Bonn, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital Bonn, 53127 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fornasiero</LastName><ForeName>Eugenio F</ForeName><Initials>EF</Initials><Identifier Source="ORCID">0000-0001-7643-4962</Identifier><AffiliationInfo><Affiliation>Department of Neuro- and Sensory Physiology, University Medical Center G&#xf6;ttingen, 37073 G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>05</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Adv</MedlineTA><NlmUniqueID>101653440</NlmUniqueID><ISSNLinking>2375-2548</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="Y">Aging</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059748" MajorTopicYN="N">Proteolysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D040901" MajorTopicYN="N">Proteomics</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>20</Day><Hour>14</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>5</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35594347</ArticleId><ArticleId IdType="pmc">PMC9122331</ArticleId><ArticleId IdType="doi">10.1126/sciadv.abn4437</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hou Y., Dan X., Babbar M., Wei Y., Hasselbalch S. G., Croteau D. L., Bohr V. A., Ageing as a risk factor for neurodegenerative disease. Nat. Rev. Neurol. 15, 565&#x2013;581 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31501588</ArticleId></ArticleIdList></Reference><Reference><Citation>Walther D. M., Mann M., Accurate quantification of more than 4000 mouse tissue proteins reveals minimal proteome changes during aging. Mol. Cell. Proteomics 10, (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3033683</ArticleId><ArticleId IdType="pubmed">21048193</ArticleId></ArticleIdList></Reference><Reference><Citation>Ori A., Toyama B. H., Harris M. S., Bock T., Iskar M., Bork P., Ingolia N. T., Hetzer M. W., Beck M., Integrated transcriptome and proteome analyses reveal organ-specific proteome deterioration in old rats. Cell Syst. 1, 224&#x2013;237 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4802414</ArticleId><ArticleId IdType="pubmed">27135913</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelmer Sacramento E., Kirkpatrick J. M., Mazzetto M., Baumgart M., Bartolome A., Di Sanzo S., Caterino C., Sanguanini M., Papaevgeniou N., Lefaki M., Childs D., Bagnoli S., Terzibasi Tozzini E., Di Fraia D., Romanov N., Sudmant P. H., Huber W., Chondrogianni N., Vendruscolo M., Cellerino A., Ori A., Reduced proteasome activity in the aging brain results in ribosome stoichiometry loss and aggregation. Mol. Syst. Biol. 16, e9596 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7301280</ArticleId><ArticleId IdType="pubmed">32558274</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward W. F., The relentless effects of the aging process on protein turnover. Biogerontology 1, 195&#x2013;199 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">11707896</ArticleId></ArticleIdList></Reference><Reference><Citation>Karunadharma P. P., Basisty N., Chiao Y. A., Dai D. F., Drake R., Levy N., Koh W. J., Emond M. J., Kruse S., Marcinek D., Maccoss M. J., Rabinovitch P. S., Respiratory chain protein turnover rates in mice are highly heterogeneous but strikingly conserved across tissues, ages, and treatments. FASEB J. 29, 3582&#x2013;3592 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4511201</ArticleId><ArticleId IdType="pubmed">25977255</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourdenx M., Mart&#xed;n-Segura A., Scrivo A., Rodriguez-Navarro J. A., Kaushik S., Tasset I., Diaz A., Storm N. J., Xin Q., Juste Y. R., Stevenson E., Luengo E., Clement C. C., Choi S. J., Krogan N. J., Mosharov E. V., Santambrogio L., Grueninger F., Collin L., Swaney D. L., Sulzer D., Gavathiotis E., Cuervo A. M., Chaperone-mediated autophagy prevents collapse of the neuronal metastable proteome. Cell 184, 2696&#x2013;2714.e25 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8152331</ArticleId><ArticleId IdType="pubmed">33891876</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf3;pez-Ot&#xed;n C., Blasco M. A., Partridge L., Serrano M., Kroemer G., The hallmarks of aging. Cell 153, 1194&#x2013;1217 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3836174</ArticleId><ArticleId IdType="pubmed">23746838</ArticleId></ArticleIdList></Reference><Reference><Citation>Hetz C., Adapting the proteostasis capacity to sustain brain healthspan. Cell 184, 1545&#x2013;1560 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33691137</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai D.-F., Karunadharma P. P., Chiao Y. A., Basisty N., Crispin D., Hsieh E. J., Chen T., Gu H., Djukovic D., Raftery D., Beyer R. P., MacCoss M. J., Rabinovitch P. S., Altered proteome turnover and remodeling by short-term caloric restriction or rapamycin rejuvenate the aging heart. Aging Cell 13, 529&#x2013;539 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4040127</ArticleId><ArticleId IdType="pubmed">24612461</ArticleId></ArticleIdList></Reference><Reference><Citation>Kruse S. E., Karunadharma P. P., Basisty N., Johnson R., Beyer R. P., MacCoss M. J., Rabinovitch P. S., Marcinek D. J., Age modifies respiratory complex I and protein homeostasis in a muscle type-specific manner. Aging Cell 15, 89&#x2013;99 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4717270</ArticleId><ArticleId IdType="pubmed">26498839</ArticleId></ArticleIdList></Reference><Reference><Citation>Karunadharma P. P., Basisty N., Dai D.-F., Chiao Y. A., Quarles E. K., Hsieh E. J., Crispin D., Bielas J. H., Ericson N. G., Beyer R. P., MacKay V. L., MacCoss M. J., Rabinovitch P. S., Subacute calorie restriction and rapamycin discordantly alter mouse liver proteome homeostasis and reverse aging effects. Aging Cell 14, 547&#x2013;557 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4531069</ArticleId><ArticleId IdType="pubmed">25807975</ArticleId></ArticleIdList></Reference><Reference><Citation>Basisty N., Meyer J. G., Schilling B., Protein turnover in aging and longevity. Proteomics 18, e1700108 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6022828</ArticleId><ArticleId IdType="pubmed">29453826</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincow E. S., Thomas R. E., Merrihew G. E., MacCoss M. J., Pallanck L. J., Slowed protein turnover in aging Drosophila reflects a shift in cellular priorities. J. Gerontol. A Biol. Sci. Med. Sci. 76, 1734&#x2013;1739 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8436993</ArticleId><ArticleId IdType="pubmed">33453098</ArticleId></ArticleIdList></Reference><Reference><Citation>Visscher M., De Henau S., Wildschut M. H. E., van Es R. M., Dhondt I., Michels H., Kemmeren P., Nollen E. A., Braeckman B. P., Burgering B. M. T., Vos H. R., Dansen T. B., Proteome-wide changes in protein turnover rates in C. elegans models of longevity and age-related disease. Cell Rep. 16, 3041&#x2013;3051 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27626671</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L., Davis S. S., Borch Jensen M., Rodriguez-Fernandez I. A., Apaydin C., Juhasz G., Gibson B. W., Schilling B., Ramanathan A., Ghaemmaghami S., Jasper H., JNK modifies neuronal metabolism to promote proteostasis and longevity. Aging Cell 18, e12849 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6516429</ArticleId><ArticleId IdType="pubmed">30810280</ArticleId></ArticleIdList></Reference><Reference><Citation>Basisty N., Holtz A., Schilling B., Accumulation of &#x201c;Old Proteins&#x201d; and the critical need for MS-based protein turnover measurements in aging and longevity. Proteomics 20, e1800403 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7015777</ArticleId><ArticleId IdType="pubmed">31408259</ArticleId></ArticleIdList></Reference><Reference><Citation>Alevra M., Mandad S., Ischebeck T., Urlaub H., Rizzoli S. O., Fornasiero E. F., A mass spectrometry workflow for measuring protein turnover rates in vivo. Nat. Protoc. 14, 3333&#x2013;3365 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31685960</ArticleId></ArticleIdList></Reference><Reference><Citation>Fornasiero E. F., Mandad S., Wildhagen H., Alevra M., Rammner B., Keihani S., Opazo F., Urban I., Ischebeck T., Sakib M. S., Fard M. K., Kirli K., Centeno T. P., Vidal R. O., Rahman R.-U., Benito E., Fischer A., Dennerlein S., Rehling P., Feussner I., Bonn S., Simons M., Urlaub H., Rizzoli S. O., Precisely measured protein lifetimes in the mouse brain reveal differences across tissues and subcellular fractions. Nat. Commun. 9, 4230 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6185916</ArticleId><ArticleId IdType="pubmed">30315172</ArticleId></ArticleIdList></Reference><Reference><Citation>Price J. C., Guan S., Burlingame A., Prusiner S. B., Ghaemmaghami S., Analysis of proteome dynamics in the mouse brain. Proc. Natl. Acad. Sci. U.S.A. 107, 14508&#x2013;14513 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2922600</ArticleId><ArticleId IdType="pubmed">20699386</ArticleId></ArticleIdList></Reference><Reference><Citation>Kr&#xfc;ger M., Moser M., Ussar S., Thievessen I., Luber C. A., Forner F., Schmidt S., Zanivan S., F&#xe4;ssler R., Mann M., SILAC mouse for quantitative proteomics uncovers kindlin-3 as an essential factor for red blood cell function. Cell 134, 353&#x2013;364 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18662549</ArticleId></ArticleIdList></Reference><Reference><Citation>Klann K., Tascher G., M&#xfc;nch C., Functional translatome proteomics reveal converging and dose-dependent regulation by mTORC1 and eIF2&#x3b1;. Mol. Cell 77, 913&#x2013;925.e4 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7033560</ArticleId><ArticleId IdType="pubmed">31812349</ArticleId></ArticleIdList></Reference><Reference><Citation>Heo S., Diering G. H., Na C. H., Nirujogi R. S., Bachman J. L., Pandey A., Huganir R. L., Identification of long-lived synaptic proteins by proteomic analysis of synaptosome protein turnover. Proc. Natl. Acad. Sci. U.S.A. , 201720956 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5910858</ArticleId><ArticleId IdType="pubmed">29610302</ArticleId></ArticleIdList></Reference><Reference><Citation>Koopmans F., van Nierop P., Andres-Alonso M., Byrnes A., Cijsouw T., Coba M. P., Cornelisse L. N., Farrell R. J., Goldschmidt H. L., Howrigan D. P., Hussain N. K., Imig C., de Jong A. P. H., Jung H., Kohansalnodehi M., Kramarz B., Lipstein N., Lovering R. C., MacGillavry H., Mariano V., Mi H., Ninov M., Osumi-Sutherland D., Pielot R., Smalla K. H., Tang H., Tashman K., Toonen R. F. G., Verpelli C., Reig-Viader R., Watanabe K., van Weering J., Achsel T., Ashrafi G., Asi N., Brown T. C., De Camilli P., Feuermann M., Foulger R. E., Gaudet P., Joglekar A., Kanellopoulos A., Malenka R., Nicoll R. A., Pulido C., de Juan-Sanz J., Sheng M., S&#xfc;dhof T. C., Tilgner H. U., Bagni C., Bay&#xe9;s &#xc0;., Biederer T., Brose N., Chua J. J. E., Dieterich D. C., Gundelfinger E. D., Hoogenraad C., Huganir R. L., Jahn R., Kaeser P. S., Kim E., Kreutz M. R., McPherson P. S., Neale B. M., O&#x2019;Connor V., Posthuma D., Ryan T. A., Sala C., Feng G., Hyman S. E., Thomas P. D., Smit A. B., Verhage M., SynGO: An evidence-based, expert-curated knowledge base for the synapse. Neuron 103, 217&#x2013;234.e4 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6764089</ArticleId><ArticleId IdType="pubmed">31171447</ArticleId></ArticleIdList></Reference><Reference><Citation>Toyama B. H., Savas J. N., Park S. K., Harris M. S., Ingolia N. T., Yates J. R., Hetzer M. W., Identification of long-lived proteins reveals exceptional stability of essential cellular structures. Cell 154, 971&#x2013;982 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3788602</ArticleId><ArticleId IdType="pubmed">23993091</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau E., Cao Q., Ng D. C. M., Bleakley B. J., Dincer T. U., Bot B. M., Wang D., Liem D. A., Lam M. P. Y., Ge J., Ping P., A large dataset of protein dynamics in the mammalian heart proteome. Sci. Data 3, 160015 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4792174</ArticleId><ArticleId IdType="pubmed">26977904</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacey L. F., Keene O. N., Pritchard J. F., Bye A., Common noncompartmental pharmacokinetic variables: Are they normally or log-normally distributed? J. Biopharm. Stat. 7, 171&#x2013;178 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9056596</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato C., Barth&#xe9;lemy N. R., Mawuenyega K. G., Patterson B. W., Gordon B. A., Jockel-Balsarotti J., Sullivan M., Crisp M. J., Kasten T., Kirmess K. M., Kanaan N. M., Yarasheski K. E., Baker-Nigh A., Benzinger T. L. S., Miller T. M., Karch C. M., Bateman R. J., Tau kinetics in neurons and the human central nervous system. Neuron 97, 1284&#x2013;1298.e7 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6137722</ArticleId><ArticleId IdType="pubmed">29566794</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen M., Carrasquillo M. M., Funk C., Heavner B. D., Zou F., Younkin C. S., Burgess J. D., Chai H.-S., Crook J., Eddy J. A., Li H., Logsdon B., Peters M. A., Dang K. K., Wang X., Serie D., Wang C., Nguyen T., Lincoln S., Malphrus K., Bisceglio G., Li M., Golde T. E., Mangravite L. M., Asmann Y., Price N. D., Petersen R. C., Graff-Radford N. R., Dickson D. W., Younkin S. G., Ertekin-Taner N., Human whole genome genotype and transcriptome data for Alzheimer&#x2019;s and other neurodegenerative diseases. Sci. Data 3, 160089 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5058336</ArticleId><ArticleId IdType="pubmed">27727239</ArticleId></ArticleIdList></Reference><Reference><Citation>Li K. W., Ganz A. B., Smit A. B., Proteomics of neurodegenerative diseases: Analysis of human post-mortem brain. J. Neurochem. 151, 435&#x2013;445 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6899881</ArticleId><ArticleId IdType="pubmed">30289976</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho D.-H., Nakamura T., Lipton S. A., Mitochondrial dynamics in cell death and neurodegeneration. Cell. Mol. Life Sci. 67, 3435&#x2013;3447 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11115814</ArticleId><ArticleId IdType="pubmed">20577776</ArticleId></ArticleIdList></Reference><Reference><Citation>Lane D. J. R., Ayton S., Bush A. I., Iron and Alzheimer&#x2019;s disease: An update on emerging mechanisms. J. Alzheimers Dis. 64, S379&#x2013;S395 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29865061</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiland A., Wang Y., Wu W., Lan X., Han X., Li Q., Wang J., Ferroptosis and its role in diverse brain diseases. Mol. Neurobiol. 56, 4880&#x2013;4893 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6506411</ArticleId><ArticleId IdType="pubmed">30406908</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaushik S., Cuervo A. M., Proteostasis and aging. Nat. Med. 21, 1406&#x2013;1415 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26646497</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollard A. K., Craig E. L., Chakrabarti L., Mitochondrial complex 1 activity measured by spectrophotometry is reduced across all brain regions in ageing and more specifically in neurodegeneration. PLOS ONE 11, e0157405 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4917223</ArticleId><ArticleId IdType="pubmed">27333203</ArticleId></ArticleIdList></Reference><Reference><Citation>Stauch K. L., Purnell P. R., Villeneuve L. M., Fox H. S., Proteomic analysis and functional characterization of mouse brain mitochondria during aging reveal alterations in energy metabolism. Proteomics 15, 1574&#x2013;1586 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4465935</ArticleId><ArticleId IdType="pubmed">25546256</ArticleId></ArticleIdList></Reference><Reference><Citation>Almanzar N., Antony J., Baghel A. S., Bakerman I., Bansal I., Barres B. A., Beachy P. A., Berdnik D., Bilen B., Brownfield D., Cain C., Chan C. K. F., Chen M. B., Clarke M. F., Conley S. D., Darmanis S., Demers A., Demir K., de Morree A., Divita T., du Bois H., Ebadi H., Espinoza F. H., Fish M., Gan Q., George B. M., Gillich A., G&#xf2;mez-Sj&#xf6;berg R., Green F., Genetiano G., Gu X., Gulati G. S., Hahn O., Haney M. S., Hang Y., Harris L., He M., Hosseinzadeh S., Huang A., Huang K. C., Iram T., Isobe T., Ives F., Jones R. C., Kao K. S., Karkanias J., Karnam G., Keller A., Kershner A. M., Khoury N., Kim S. K., Kiss B. M., Kong W., Krasnow M. A., Kumar M. E., Kuo C. S., Lam J., Lee D. P., Lee S. E., Lehallier B., Leventhal O., Li G., Li Q., Liu L., Lo A., Lu W.-J., Lugo-Fagundo M. F., Manjunath A., May A. P., Maynard A., McGeever A., McKay M., McNerney M. W., Merrill B., Metzger R. J., Mignardi M., Min D., Nabhan A. N., Neff N. F., Ng K. M., Nguyen P. K., Noh J., Nusse R., P&#xe1;lovics R., Patkar R., Peng W. C., Penland L., Pisco A. O., Pollard K., Puccinelli R., Qi Z., Quake S. R., Rando T. A., Rulifson E. J., Schaum N., Segal J. M., Sikandar S. S., Sinha R., Sit R. V., Sonnenburg J., Staehli D., Szade K., Tan M., Tan W., Tato C., Tellez K., Dulgeroff L. B. T., Travaglini K. J., Tropini C., Tsui M., Waldburger L., Wang B. M., van Weele L. J., Weinberg K., Weissman I. L., Wosczyna M. N., Wu S. M., Wyss-Coray T., Xiang J., Xue S., Yamauchi K. A., Yang A. C., Yerra L. P., Youngyunpipatkul J., Yu B., Zanini F., Zardeneta M. E., Zee A., Zhao C., Zhang F., Zhang H., Zhang M. J., Zhou L., Zou J.; Tabula Muris Consortium , A single-cell transcriptomic atlas characterizes ageing tissues in the mouse. Nature 583, 590&#x2013;595 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8240505</ArticleId><ArticleId IdType="pubmed">32669714</ArticleId></ArticleIdList></Reference><Reference><Citation>Kluever V., Fornasiero E. F., Principles of brain aging: Status and challenges of modeling human molecular changes in mice. Ageing Res. Rev. 72, 101465 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34555542</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma K., Schmitt S., Bergner C. G., Tyanova S., Kannaiyan N., Manrique-Hoyos N., Kongi K., Cantuti L., Hanisch U.-K., Philips M.-A., Rossner M. J., Mann M., Simons M., Cell type&#x2013; and brain region&#x2013;resolved mouse brain proteome. Nat. Neurosci. 18, 1819&#x2013;1831 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7116867</ArticleId><ArticleId IdType="pubmed">26523646</ArticleId></ArticleIdList></Reference><Reference><Citation>Boisvert M. M., Erikson G. A., Shokhirev M. N., Allen N. J., The aging astrocyte transcriptome from multiple regions of the mouse brain. Cell Rep. 22, 269&#x2013;285 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5783200</ArticleId><ArticleId IdType="pubmed">29298427</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang K. J., Carlson E. S., Resistance, vulnerability and resilience: A review of the cognitive cerebellum in aging and neurodegenerative diseases. Neurobiol. Learn. Mem. 170, 106981 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6612482</ArticleId><ArticleId IdType="pubmed">30630042</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurotani A., Tokmakov A. A., Sato K.-I., Stefanov V. E., Yamada Y., Sakurai T., Localization-specific distributions of protein pI in human proteome are governed by local pH and membrane charge. BMC Mol. Cell Biol. 20, 36 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6701068</ArticleId><ArticleId IdType="pubmed">31429701</ArticleId></ArticleIdList></Reference><Reference><Citation>Dice J. F., Goldberg A. L., Relationship between in vivo degradative rates and isoelectric points of proteins. Proc. Natl. Acad. Sci. U.S.A. 72, 3893&#x2013;3897 (1975).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC433102</ArticleId><ArticleId IdType="pubmed">1060070</ArticleId></ArticleIdList></Reference><Reference><Citation>Kri&#x161;ti&#x107; J., Vu&#x10d;kovi&#x107; F., Menni C., Klari&#x107; L., Keser T., Beceheli I., Pu&#x10d;i&#x107;-Bakovi&#x107; M., Novokmet M., Mangino M., Thaqi K., Rudan P., Novokmet N., Sarac J., Missoni S., Kol&#x10d;i&#x107; I., Pola&#x161;ek O., Rudan I., Campbell H., Hayward C., Aulchenko Y., Valdes A., Wilson J. F., Gornik O., Primorac D., Zoldo&#x161; V., Spector T., Lauc G., Glycans are a novel biomarker of chronological and biological ages. J. Gerontol. A Biol. Sci. Med. Sci. 69, 779&#x2013;789 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4049143</ArticleId><ArticleId IdType="pubmed">24325898</ArticleId></ArticleIdList></Reference><Reference><Citation>Frenkel-Pinter M., Stempler S., Tal-Mazaki S., Losev Y., Singh-Anand A., Escobar-&#xc1;lvarez D., Lezmy J., Gazit E., Ruppin E., Segal D., Altered protein glycosylation predicts Alzheimer&#x2019;s disease and modulates its pathology in disease model Drosophila. Neurobiol. Aging 56, 159&#x2013;171 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28552182</ArticleId></ArticleIdList></Reference><Reference><Citation>Raghunathan R., Polinski N. K., Klein J. A., Hogan J. D., Shao C., Khatri K., Leon D., McComb M. E., Manfredsson F. P., Sortwell C. E., Zaia J., Glycomic and proteomic changes in aging brain nigrostriatal pathway. Mol. Cell. Proteomics 17, 1778&#x2013;1787 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6126385</ArticleId><ArticleId IdType="pubmed">29915149</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J., Ha S., Kim M., Kim S.-W., Yun J., Ozcan S., Hwang H., Ji I. J., Yin D., Webster M. J., Shannon Weickert C., Kim J.-H., Yoo J. S., Grimm R., Bahn S., Shin H.-S., An H. J., Spatial and temporal diversity of glycome expression in mammalian brain. Proc. Natl. Acad. Sci. U.S.A. 117, 28743&#x2013;28753 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7682437</ArticleId><ArticleId IdType="pubmed">33139572</ArticleId></ArticleIdList></Reference><Reference><Citation>Ivanisevic J., Stauch K. L., Petrascheck M., Benton H. P., Epstein A. A., Fang M., Gorantla S., Tran M., Hoang L., Kurczy M. E., Boska M. D., Gendelman H. E., Fox H. S., Siuzdak G., Metabolic drift in the aging brain. Aging 8, 1000&#x2013;1020 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4931850</ArticleId><ArticleId IdType="pubmed">27182841</ArticleId></ArticleIdList></Reference><Reference><Citation>Kepp K. P., A quantitative model of human neurodegenerative diseases involving protein aggregation. Neurobiol. Aging 80, 46&#x2013;55 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31102901</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H., Wang Y., Li J., Chen H., He X., Zhang H., Liang H., Lu J., Biosynthetic energy cost for amino acids decreases in cancer evolution. Nat. Commun. 9, 4124 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6175916</ArticleId><ArticleId IdType="pubmed">30297703</ArticleId></ArticleIdList></Reference><Reference><Citation>Agozzino L., Dill K. A., Protein evolution speed depends on its stability and abundance and on chaperone concentrations. Proc. Natl. Acad. Sci. U.S.A. 115, 9092&#x2013;9097 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6140491</ArticleId><ArticleId IdType="pubmed">30150386</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts J. H., Liu F., Karnuta J. M., Fitzgerald M. C., Discovery of age-related protein folding stability differences in the mouse brain proteome. J. Proteome Res. 15, 4731&#x2013;4741 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5296835</ArticleId><ArticleId IdType="pubmed">27806573</ArticleId></ArticleIdList></Reference><Reference><Citation>Basisty N. B., Liu Y., Reynolds J., Karunadharma P. P., Dai D. F., Fredrickson J., Beyer R. P., Maccoss M. J., Rabinovitch P. S., Stable isotope labeling reveals novel insights into ubiquitin-mediated protein aggregation with age, calorie restriction, and rapamycin treatment. J. Gerontol. Ser. A Biol. Sci. Med. Sci. 73, 561&#x2013;570 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6380815</ArticleId><ArticleId IdType="pubmed">28958078</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Q., Xiao H., Jedrychowski M. P., Schweppe D. K., Navarrete-Perea J., Knott J., Rogers J., Chouchani E. T., Gygi S. P., Sample multiplexing for targeted pathway proteomics in aging mice. Proc. Natl. Acad. Sci. U.S.A. 117, 9723&#x2013;9732 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7211924</ArticleId><ArticleId IdType="pubmed">32332170</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson M. P., Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives. Physiol. Rev. 77, 1081&#x2013;1132 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9354812</ArticleId></ArticleIdList></Reference><Reference><Citation>Knupp A., Mishra S., Martinez R., Small S. A., Jayadev S., Correspondence J. E. Y., Depletion of the AD risk gene SORL1 selectively impairs neuronal endosomal traffic independent of amyloidogenic APP processing. Cell Rep. 31, 107719 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7409533</ArticleId><ArticleId IdType="pubmed">32492427</ArticleId></ArticleIdList></Reference><Reference><Citation>Grear K. E., Ling I. F., Simpson J. F., Furman J. L., Simmons C. R., Peterson S. L., Schmitt F. A., Markesbery W. R., Liu Q., Crook J. E., Younkin S. G., Bu G., Estus S., Expression of SORL1 and a novel SORL1 splice variant in normal and Alzheimers disease brain. Mol. Neurodegener. 4, 46 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2776013</ArticleId><ArticleId IdType="pubmed">19889229</ArticleId></ArticleIdList></Reference><Reference><Citation>Steuble M., Diep T. M., Sch&#xe4;tzle P., Ludwig A., Tagaya M., Kunz B., Sonderegger P., Calsyntenin-1 shelters APP from proteolytic processing during anterograde axonal transport. Biol. Open 1, 761&#x2013;774 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3507217</ArticleId><ArticleId IdType="pubmed">23213470</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurochkin I. V., Insulin-degrading enzyme: Embarking on amyloid destruction. Trends Biochem. Sci. 26, 421&#x2013;425 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11440853</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoka V., Turk V., Turk B., Lysosomal cathepsins and their regulation in aging and neurodegeneration. Ageing Res. Rev. 32, 22&#x2013;37 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27125852</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian R., Abarientos A., Hong J., Hashemi S. H., Yan R., Dr&#xe4;ger N., Leng K., Nalls M. A., Singleton A. B., Xu K., Faghri F., Kampmann M., Genome-wide CRISPRi/a screens in human neurons link lysosomal failure to ferroptosis. Nat. Neurosci. 24, 1020&#x2013;1034 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8254803</ArticleId><ArticleId IdType="pubmed">34031600</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukherjee C., Kling T., Russo B., Miebach K., Kess E., Schifferer M., Pedro L. D., Weikert U., Fard M. K., Kannaiyan N., Rossner M., Aicher M.-L., Goebbels S., Nave K.-A., Kr&#xe4;mer-Albers E.-M., Schneider A., Simons M., Oligodendrocytes provide antioxidant defense function for neurons by secreting ferritin heavy chain. Cell Metab. 32, 259&#x2013;272.e10 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7116799</ArticleId><ArticleId IdType="pubmed">32531201</ArticleId></ArticleIdList></Reference><Reference><Citation>Koster K. P., Yoshii A., Depalmitoylation by palmitoyl-protein thioesterase 1 in neuronal health and degeneration. Front. Synaptic Neurosci. 11, 25 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6727029</ArticleId><ArticleId IdType="pubmed">31555119</ArticleId></ArticleIdList></Reference><Reference><Citation>Bomba-Warczak E., Edassery S. L., Hark T. J., Savas J. N., Long-lived mitochondrial cristae proteins in mouse heart and brain. J. Cell Biol. 220, e202005193 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8282663</ArticleId><ArticleId IdType="pubmed">34259807</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonz&#xe1;lez-Rodr&#xed;guez P., Zampese E., Stout K. A., Guzman J. N., Ilijic E., Yang B., Tkatch T., Stavarache M. A., Wokosin D. L., Gao L., Kaplitt M. G., L&#xf3;pez-Barneo J., Schumacker P. T., Surmeier D. J., Disruption of mitochondrial complex I induces progressive parkinsonism. Nature 599, 650&#x2013;656 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9189968</ArticleId><ArticleId IdType="pubmed">34732887</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H., Dey K. K., Chen P. C., Li Y., Niu M., Cho J. H., Wang X., Bai B., Jiao Y., Chepyala S. R., Haroutunian V., Zhang B., Beach T. G., Peng J., Integrated analysis of ultra-deep proteomes in cortex, cerebrospinal fluid and serum reveals a mitochondrial signature in Alzheimer&#x2019;s disease. Mol. Neurodegener. 15, 1&#x2013;20 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7382148</ArticleId><ArticleId IdType="pubmed">32711556</ArticleId></ArticleIdList></Reference><Reference><Citation>Yousefi R., Jevdokimenko K., Kluever V., Pacheu-Grau D., Fornasiero E. F., Influence of subcellular localization and functional state on protein turnover. Cell 10, 1747 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8306977</ArticleId><ArticleId IdType="pubmed">34359917</ArticleId></ArticleIdList></Reference><Reference><Citation>Schanzenb&#xe4;cher C. T., Sambandan S., Langer J. D., Schuman E. M., Nascent proteome remodeling following homeostatic scaling at hippocampal synapses. Neuron 92, 358&#x2013;371 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5078608</ArticleId><ArticleId IdType="pubmed">27764671</ArticleId></ArticleIdList></Reference><Reference><Citation>Glock C., Biever A., Tushev G., Nassim-Assir B., Kao A., Bartnik I., Tom Dieck S., Schuman E. M., The translatome of neuronal cell bodies, dendrites, and axons. Proc. Natl. Acad. Sci. U.S.A. 118, e2113929118 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8639352</ArticleId><ArticleId IdType="pubmed">34670838</ArticleId></ArticleIdList></Reference><Reference><Citation>Hark T. J., Rao N. R., Castillon C., Basta T., Smukowski S., Bao H., Upadhyay A., Bomba-Warczak E., Nomura T., O&#x2019;Toole E. T., Morgan G. P., Ali L., Saito T., Guillermier C., Saido T. C., Steinhauser M. L., Stowell M. H. B., Chapman E. R., Contractor A., Savas J. N., Pulse-chase proteomics of the app knockin mouse models of Alzheimer&#x2019;s disease reveals that synaptic dysfunction originates in presynaptic terminals. Cell Syst. 12, 141&#x2013;158.e9 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7897324</ArticleId><ArticleId IdType="pubmed">33326751</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu H., Sadygov R. G., Yates J. R., A model for random sampling and estimation of relative protein abundance in shotgun proteomics. Anal. Chem. 76, 4193&#x2013;4201 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15253663</ArticleId></ArticleIdList></Reference><Reference><Citation>Breschi A., Gingeras T. R., Guig&#xf3; R., Comparative transcriptomics in human and mouse. Nat. Rev. Genet. 18, 425&#x2013;440 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6413734</ArticleId><ArticleId IdType="pubmed">28479595</ArticleId></ArticleIdList></Reference><Reference><Citation>Bay&#xe9;s &#xc0;., Collins M. O., Croning M. D. R., van de Lagemaat L. N., Choudhary J. S., Grant S. G. N., Comparative study of human and mouse postsynaptic proteomes finds high compositional conservation and abundance differences for key synaptic proteins. PLOS ONE 7, e46683 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3465276</ArticleId><ArticleId IdType="pubmed">23071613</ArticleId></ArticleIdList></Reference><Reference><Citation>Swovick K., Welle K. A., Hryhorenko J. R., Seluanov A., Gorbunova V., Ghaemmaghami S., Cross-species comparison of proteome turnover kinetics. Mol. Cell. Proteomics 17, 580&#x2013;591 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5880112</ArticleId><ArticleId IdType="pubmed">29321186</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh E. J., Shulman N. J., Dai D.-F., Vincow E. S., Karunadharma P. P., Pallanck L., Rabinovitch P. S., MacCoss M. J., Topograph, a software platform for precursor enrichment corrected global protein turnover measurements. Mol. Cell. Proteomics 11, 1468&#x2013;1474 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3494182</ArticleId><ArticleId IdType="pubmed">22865922</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman A., Martin M.-J., Orchard S., Magrane M., Agivetova R., Ahmad S., Alpi E., Bowler-Barnett E. H., Britto R., Bursteinas B., Bye-A-Jee H., Coetzee R., Cukura A., Da Silva A., Denny P., Dogan T., Ebenezer T., Fan J., Castro L. G., Garmiri P., Georghiou G., Gonzales L., Hatton-Ellis E., Hussein A., Ignatchenko A., Insana G., Ishtiaq R., Jokinen P., Joshi V., Jyothi D., Lock A., Lopez R., Luciani A., Luo J., Lussi Y., MacDougall A., Madeira F., Mahmoudy M., Menchi M., Mishra A., Moulang K., Nightingale A., Oliveira C. S., Pundir S., Qi G., Raj S., Rice D., Lopez M. R., Saidi R., Sampson J., Sawford T., Speretta E., Turner E., Tyagi N., Vasudev P., Volynkin V., Warner K., Watkins X., Zaru R., Zellner H., Bridge A., Poux S., Redaschi N., Aimo L., Argoud-Puy G., Auchincloss A., Axelsen K., Bansal P., Baratin D., Blatter M.-C., Bolleman J., Boutet E., Breuza L., Casals-Casas C., de Castro E., Echioukh K. C., Coudert E., Cuche B., Doche M., Dornevil D., Estreicher A., Famiglietti M. L., Feuermann M., Gasteiger E., Gehant S., Gerritsen V., Gos A., Gruaz-Gumowski N., Hinz U., Hulo C., Hyka-Nouspikel N., Jungo F., Keller G., Kerhornou A., Lara V., Le Mercier P., Lieberherr D., Lombardot T., Martin X., Masson P., Morgat A., Neto T. B., Paesano S., Pedruzzi I., Pilbout S., Pourcel L., Pozzato M., Pruess M., Rivoire C., Sigrist C., Sonesson K., Stutz A., Sundaram S., Tognolli M., Verbregue L., Wu C. H., Arighi C. N., Arminski L., Chen C., Chen Y., Garavelli J. S., Huang H., Laiho K., McGarvey P., Natale D. A., Ross K., Vinayaka C. R., Wang Q., Wang Y., Yeh L.-S., Zhang J., Ruch P., Teodoro D., UniProt: The universal protein knowledgebase in 2021. Nucleic Acids Res. 49, D480&#x2013;D489 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7778908</ArticleId><ArticleId IdType="pubmed">33237286</ArticleId></ArticleIdList></Reference><Reference><Citation>Szklarczyk D., Gable A. L., Lyon D., Junge A., Wyder S., Huerta-Cepas J., Simonovic M., Doncheva N. T., Morris J. H., Bork P., Jensen L. J., von Mering C., STRING v11: Protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 47, D607&#x2013;D613 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6323986</ArticleId><ArticleId IdType="pubmed">30476243</ArticleId></ArticleIdList></Reference><Reference><Citation>Doszt&#xe1;nyi Z., Csizmok V., Tompa P., Simon I., IUPred: Web server for the prediction of intrinsically unstructured regions of proteins based on estimated energy content. Bioinformatics 21, 3433&#x2013;3434 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15955779</ArticleId></ArticleIdList></Reference><Reference><Citation>Piovesan D., Necci M., Escobedo N., Monzon A. M., Hatos A., Mi&#x10d;eti&#x107; I., Quaglia F., Paladin L., Ramasamy P., Doszt&#xe1;nyi Z., Vranken W. F., Davey N. E., Parisi G., Fuxreiter M., Tosatto S. C. E., MobiDB: Intrinsically disordered proteins in 2021. Nucleic Acids Res. 49, D361&#x2013;D367 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7779018</ArticleId><ArticleId IdType="pubmed">33237329</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao Y., Wang J., Jaehnig E. J., Shi Z., Zhang B., WebGestalt 2019: Gene set analysis toolkit with revamped UIs and APIs. Nucleic Acids Res. 47, W199&#x2013;W205 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6602449</ArticleId><ArticleId IdType="pubmed">31114916</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen L. L. D., Zuchman R., Sorokina O., M&#xfc;ller A., Dieterich D. C., Armstrong J. D., Ziv T., Ziv N. E., Metabolic turnover of synaptic proteins: Kinetics, interdependencies and implications for synaptic maintenance. PLOS ONE 8, e63191 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3642143</ArticleId><ArticleId IdType="pubmed">23658807</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#xf6;rrbaum A. R., Kochen L., Langer J. D., Schuman E. M., Local and global influences on protein turnover in neurons and glia. eLife 7, 1&#x2013;24 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6008053</ArticleId><ArticleId IdType="pubmed">29914620</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathieson T., Franken H., Kosinski J., Kurzawa N., Zinn N., Sweetman G., Poeckel D., Ratnu V. S., Schramm M., Becher I., Steidel M., Noh K. M., Bergamini G., Beck M., Bantscheff M., Savitski M. M., Systematic analysis of protein turnover in primary cells. Nat. Commun. 9, 1&#x2013;10 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5814408</ArticleId><ArticleId IdType="pubmed">29449567</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabb D. L., Vega-Montoto L., Rudnick P. A., Variyath A. M., Ham A.-J. L., Bunk D. M., Kilpatrick L. E., Billheimer D. D., Blackman R. K., Cardasis H. L., Carr S. A., Clauser K. R., Jaffe J. D., Kowalski K. A., Neubert T. A., Regnier F. E., Schilling B., Tegeler T. J., Wang M., Wang P., Whiteaker J. R., Zimmerman L. J., Fisher S. J., Gibson B. W., Kinsinger C. R., Mesri M., Rodriguez H., Stein S. E., Tempst P., Paulovich A. G., Liebler D. C., Spiegelman C., Repeatability and reproducibility in proteomic identifications by liquid chromatography-tandem mass spectrometry. J. Proteome Res. 9, 761&#x2013;776 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2818771</ArticleId><ArticleId IdType="pubmed">19921851</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross A. B., Langer J. D., Jovanovic M., Proteome turnover in the spotlight: Approaches, applications, and perspectives. Mol. Cell. Proteomics 20, 100016 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7950106</ArticleId><ArticleId IdType="pubmed">33556866</ArticleId></ArticleIdList></Reference><Reference><Citation>Popa-Wagner A., Sandu R. E., Cristin C., Uzoni A., Welle K. A., Hryhorenko J. R., Ghaemmaghami S., Increased degradation rates in the components of the mitochondrial oxidative phosphorylation chain in the cerebellum of old mice. Front. Aging Neurosci. 10, 1&#x2013;10 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5820363</ArticleId><ArticleId IdType="pubmed">29503614</ArticleId></ArticleIdList></Reference><Reference><Citation>Attia H., Taha M., Abdellatif A., Effects of aging on the myelination of the optic nerve in rats. Int. J. Neurosci. 129, 320&#x2013;324 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30260726</ArticleId></ArticleIdList></Reference><Reference><Citation>Cellerino A., Ori A., What have we learned on aging from omics studies? Semin. Cell Dev. Biol. 70, 177&#x2013;189 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28630026</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirchner P., Bourdenx M., Madrigal-Matute J., Tiano S., Diaz A., Bartholdy B. A., Will B., Cuervo A. M., Proteome-wide analysis of chaperone-mediated autophagy targeting motifs. PLOS Biol. 17, e3000301 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6561683</ArticleId><ArticleId IdType="pubmed">31150375</ArticleId></ArticleIdList></Reference><Reference><Citation>Truckenbrodt S., Viplav A., J&#xe4;hne S., Vogts A., Denker A., Wildhagen H., Fornasiero E. F., Rizzoli S. O., Newly produced synaptic vesicle proteins are preferentially used in synaptic transmission. EMBO J. 37, 1&#x2013;24 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6068464</ArticleId><ArticleId IdType="pubmed">29950309</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersson A., Remnest&#xe5;l J., Nellg&#xe5;rd B., Vunk H., Kotol D., Edfors F., Uhl&#xe9;n M., Schwenk J. M., Ilag L. L., Zetterberg H., Blennow K., M&#xe5;nberg A., Nilsson P., Fredolini C., Development of parallel reaction monitoring assays for cerebrospinal fluid proteins associated with Alzheimer&#x2019;s disease. Clin. Chim. Acta 494, 79&#x2013;93 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30858094</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendsaikhan A., Tooyama I., Bellier J. P., Serrano G. E., Sue L. I., Lue L. F., Beach T. G., Walker D. G., Characterization of lysosomal proteins progranulin and prosaposin and their interactions in Alzheimer&#x2019;s disease and aged brains: Increased levels correlate with neuropathology. Acta Neuropathol. Commun. 7, 215 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6925443</ArticleId><ArticleId IdType="pubmed">31864418</ArticleId></ArticleIdList></Reference><Reference><Citation>Vesa J., Hellsten E., Verkruyse L. A., Camp L. A., Rapola J., Santavuori P., Hofmann S. L., Peltonen L., Mutations in the palmitoyl protein thioesterase gene causing infantile neuronal ceroid lipofuscinosis. Nature 376, 584&#x2013;587 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">7637805</ArticleId></ArticleIdList></Reference><Reference><Citation>Kon T., Tanji K., Mori F., Kimura A., Kakita A., Wakabayashi K., Immunoreactivity of myelin-associated oligodendrocytic basic protein in Lewy bodies. Neuropathology 39, 279&#x2013;285 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31183926</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xf6;glinger G. U., Melhem N. M., Dickson D. W., Sleiman P. M. A., Wang L. S., Klei L., Rademakers R., De Silva R., Litvan I., Riley D. E., Van Swieten J. C., Heutink P., Wszolek Z. K., Uitti R. J., Vandrovcova J., Hurtig H. I., Gross R. G., Maetzler W., Goldwurm S., Tolosa E., Borroni B., Pastor P.; PSP Genetics Study Group, Cantwell L. B., Han M. R., Dillman A., Van Der Brug M. P., Gibbs J. R., Cookson M. R., Hernandez D. G., Singleton A. B., Farrer M. J., Yu C. E., Golbe L. I., Revesz T., Hardy J., Lees A. J., Devlin B., Hakonarson H., M&#xfc;ller U., Schellenberg G. D., Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat. Genet. 43, 699&#x2013;705 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3125476</ArticleId><ArticleId IdType="pubmed">21685912</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Brien R. J., Wong P. C., Amyloid precursor protein processing and Alzheimer&#x2019;s disease. Annu. Rev. Neurosci. 34, 185&#x2013;204 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3174086</ArticleId><ArticleId IdType="pubmed">21456963</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng Y., Cawley N. X., Yanik T., Murthy S. R. K., Liu C., Kasikci F., Abebe D., Loh Y. P., A human carboxypeptidase E/NF-&#x3b1;1 gene mutation in an Alzheimer&#x2019;s disease patient leads to dementia and depression in mice. Transl. Psychiatry 6, e973 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5315563</ArticleId><ArticleId IdType="pubmed">27922637</ArticleId></ArticleIdList></Reference><Reference><Citation>Pl&#xe1; V., Paco S., Ghezali G., Ciria V., Pozas E., Ferrer I., Aguado F., Secretory sorting receptors carboxypeptidase E and secretogranin III in amyloid &#x3b2;-associated neural degeneration in Alzheimer&#x2019;s disease. Brain Pathol. 23, 274&#x2013;284 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8028878</ArticleId><ArticleId IdType="pubmed">22998035</ArticleId></ArticleIdList></Reference><Reference><Citation>Begcevic I., Tsolaki M., Brinc D., Brown M., Martinez-Morillo E., Lazarou I., Kozori M., Tagaraki F., Nenopoulou S., Gkioka M., Lazarou E., Lim B., Batruch I., Diamandis E. P., Neuronal pentraxin receptor-1 is a new cerebrospinal fluid biomarker of Alzheimer&#x2019;s disease progression. F1000Res. 7, 1012 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6081984</ArticleId><ArticleId IdType="pubmed">30191060</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao M. F., Xu D., Craig M. T., Pelkey K. A., Chien C. C., Shi Y., Zhang J., Resnick S., Pletnikova O., Salmon D., Brewer J., Edland S., Wegiel J., Tycko B., Savonenko A., Reeves R. H., Troncoso J. C., McBain C. J., Galasko D., Wegiel P. F., NPTX2 and cognitive dysfunction in Alzheimer&#x2019;s disease. eLife 6, 1&#x2013;27 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5404919</ArticleId><ArticleId IdType="pubmed">28440221</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakaya T., Maragkakis M., Amyotrophic lateral sclerosis associated FUS mutation shortens mitochondria and induces neurotoxicity. Sci. Rep. 8, 1&#x2013;15 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6197261</ArticleId><ArticleId IdType="pubmed">30349096</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravanidis S., Doxakis E., RNA-binding proteins implicated in mitochondrial damage and mitophagy. Front. Cell Dev. Biol. 8, 372 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7287033</ArticleId><ArticleId IdType="pubmed">32582692</ArticleId></ArticleIdList></Reference><Reference><Citation>Vagnoni A., Perkinton M. S., Gray E. H., Francis P. T., Noble W., Miller C. C. J., Calsyntenin-1 mediates axonal transport of the amyloid precursor protein and regulates a&#x3b2; production. Hum. Mol. Genet. 21, 2845&#x2013;2854 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3373235</ArticleId><ArticleId IdType="pubmed">22434822</ArticleId></ArticleIdList></Reference><Reference><Citation>Hallock P., Thomas M. A., Integrating the Alzheimer&#x2019;s disease proteome and transcriptome: A comprehensive network model of a complex disease. OMICS 16, 37&#x2013;49 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3275800</ArticleId><ArticleId IdType="pubmed">22321014</ArticleId></ArticleIdList></Reference><Reference><Citation>Gabrych D. R., Lau V. Z., Niwa S., Silverman M. A., Going too far is the same as falling short&#x2020;: Kinesin-3 family members in hereditary spastic paraplegia. Front. Cell. Neurosci. 13, 419 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6775250</ArticleId><ArticleId IdType="pubmed">31616253</ArticleId></ArticleIdList></Reference><Reference><Citation>Vidoni C., Follo C., Savino M., Melone M. A. B., Isidoro C., The role of cathepsin D in the pathogenesis of human neurodegenerative disorders. Med. Res. Rev. 36, 845&#x2013;870 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27114232</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J., Cao F., Yin H.-l., Huang Z.-j., Lin Z.-t., Mao N., Sun B., Wang G., Ferroptosis: Past, present and future. Cell Death Dis. 11, 88 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6997353</ArticleId><ArticleId IdType="pubmed">32015325</ArticleId></ArticleIdList></Reference><Reference><Citation>Vacher M., Porter T., Villemagne V. L., Milicic L., Peretti M., Fowler C., Martins R., Rainey-Smith S., Ames D., Masters C. L., Rowe C. C., Doecke J. D., Laws S. M., Validation of a priori candidate Alzheimer&#x2019;s disease SNPs with brain amyloid-beta deposition. Sci. Rep. 9, 1&#x2013;8 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6863876</ArticleId><ArticleId IdType="pubmed">31745181</ArticleId></ArticleIdList></Reference><Reference><Citation>Peterson D., Munger C., Crowley J., Corcoran C., Cruchaga C., Goate A. M., Norton M. C., Green R. C., Munger R. G., Breitner J. C. S., Welsh-Bohmer K. A., Lyketsos C., Tschanz J., Kauwe J. S. K., Variants in PPP3R1 and MAPT are associated with more rapid functional decline in Alzheimer&#x2019;s disease: The Cache County Dementia Progression Study. Alzheimers Dement. 10, 366&#x2013;371 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3809344</ArticleId><ArticleId IdType="pubmed">23727081</ArticleId></ArticleIdList></Reference><Reference><Citation>Perkovic M. N., Strac D. S., Tudor L., Konjevod M., Erjavec G. N., Pivac N., Catechol-O-methyltransferase, cognition and Alzheimer&#x2019;s disease. Curr. Alzheimer Res. 15, 408&#x2013;419 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29231139</ArticleId></ArticleIdList></Reference><Reference><Citation>Finberg J. P. M., Inhibitors of MAO-B and COMT: Their effects on brain dopamine levels and uses in Parkinson&#x2019;s disease. J. Neural Transm. 126, 433&#x2013;448 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30386930</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng H. X., Chen W., Hong S. T., Boycott K. M., Gorrie G. H., Siddique N., Yang Y., Fecto F., Shi Y., Zhai H., Jiang H., Hirano M., Rampersaud E., Jansen G. H., Donkervoort S., Bigio E. H., Brooks B. R., Ajroud K., Sufit R. L., Haines J. L., Mugnaini E., Pericak-Vance M. A., Siddique T., Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature 477, 211&#x2013;215 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3169705</ArticleId><ArticleId IdType="pubmed">21857683</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerson J. E., Linton H., Xing J., Sutter A. B., Kakos F. S., Ryou J., Liggans N., Sharkey L. M., Safren N., Paulson H. L., Ivanova M. I., Shared and divergent phase separation and aggregation properties of brain-expressed ubiquilins. Sci. Rep. 11, 287 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7801659</ArticleId><ArticleId IdType="pubmed">33431932</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H.-J., Mitchell J. C., Novoselov S., Miller J., Nishimura A. L., Scotter E. L., Vance C. A., Cheetham M. E., Shaw C. E., The heat shock response plays an important role in TDP-43 clearance: Evidence for dysfunction in amyotrophic lateral sclerosis. Brain 139, 1417&#x2013;1432 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4845254</ArticleId><ArticleId IdType="pubmed">26936937</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitbread A. K., Masoumi A., Tetlow N., Schmuck E., Coggan M., Board P. G., Characterization of the omega class of glutathione transferases. Methods Enzymol. 401, 78&#x2013;99 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16399380</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y. J., Oliveira S. A., Xu P., Martin E. R., Stenger J. E., Scherzer C. R., Hauser M. A., Scott W. K., Small G. W., Nance M. A., Watts R. L., Hubble J. P., Koller W. C., Pahwa R., Stern M. B., Hiner B. C., Jankovic J., Goetz C. G., Mastaglia F., Middleton L. T., Roses A. D., Saunders A. M., Schmechel D. E., Gullans S. R., Haines J. L., Gilbert J. R., Vance J. M., Pericak-Vance M. A., Glutathione S-transferase omega-1 modifies age-at-onset of Alzheimer disease and Parkinson disease. Hum. Mol. Genet. 12, 3259&#x2013;3267 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">14570706</ArticleId></ArticleIdList></Reference><Reference><Citation>Kay L., Pienaar I. S., Cooray R., Black G., Soundararajan M., Understanding miro GTPases: Implications in the treatment of neurodegenerative disorders. Mol. Neurobiol. 55, 7352&#x2013;7365 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6096957</ArticleId><ArticleId IdType="pubmed">29411264</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang F., Wang W., Siedlak S. L., Liu Y., Liu J., Jiang K., Perry G., Zhu X., Wang X., Miro1 deficiency in amyotrophic lateral sclerosis. Front. Aging Neurosci. 7, 100 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4443026</ArticleId><ArticleId IdType="pubmed">26074815</ArticleId></ArticleIdList></Reference><Reference><Citation>Grossmann D., Berenguer-Escuder C., Chemla A., Arena G., Kr&#xfc;ger R., The emerging role of RHOT1/Miro1 in the pathogenesis of Parkinson&#x2019;s disease. Front. Neurol. 11, 587 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7523470</ArticleId><ArticleId IdType="pubmed">33041957</ArticleId></ArticleIdList></Reference><Reference><Citation>S. Quintremil, F. Medina Ferrer, J. Puente, M. Elsa Pando, M. Antonieta Valenzuela, in Neurons&#x2014;Dendrites and Axons (IntechOpen, 2019).</Citation></Reference><Reference><Citation>Cant&#xf3; E., Tintor&#xe9; M., Villar L. M., Borr&#xe1;s E., &#xc1;lvarez-Cerme&#xf1;o J. C., Chiva C., Sabid&#xf3; E., Rovira A., Montalban X., Comabella M., Validation of semaphorin 7A and ala-&#x3b2;-hisdipeptidase as biomarkers associated with the conversion from clinically isolated syndrome to multiple sclerosis. J. Neuroinflammation 11, 181 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4236472</ArticleId><ArticleId IdType="pubmed">25406498</ArticleId></ArticleIdList></Reference><Reference><Citation>Mueller-Steiner S., Zhou Y., Arai H., Roberson E. D., Sun B., Chen J., Wang X., Yu G., Esposito L., Mucke L., Gan L., Antiamyloidogenic and neuroprotective functions of cathepsin B: Implications for Alzheimer&#x2019;s disease. Neuron 51, 703&#x2013;714 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16982417</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">35604654</PMID><DateCompleted><Year>2022</Year><Month>07</Month><Day>13</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>79</Volume><Issue>7</Issue><PubDate><Year>2022</Year><Month>Jul</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>TDP-43 Accumulation Within Intramuscular Nerve Bundles of Patients With Amyotrophic Lateral Sclerosis.</ArticleTitle><Pagination><StartPage>693</StartPage><EndPage>701</EndPage><MedlinePgn>693-701</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e221113</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2022.1113</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Degeneration of neuromuscular junctions and axons is considered an important aspect of the pathomechanism of amyotrophic lateral sclerosis (ALS). However, a mechanism including the role of transactive response DNA-binding protein 43 (TDP-43) in axons has not been pathologically clarified.</AbstractText><AbstractText Label="OBJECTIVE">To identify and characterize the histopathology of peripheral axons in the skeletal muscle of patients with ALS.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">This study comprised 2 parts: a postmortem case-control study and a retrospective population-based cohort study with a minimum of 1 year of follow-up. Patients in the cohort study were enrolled from January 1, 2004, to September 30, 2019. The postmortem study included patients with sporadic ALS (SALS) with TDP-43 pathology and control patients with non-ALS disease. The cohort study enrolled patients without a family history of ALS or other neuromuscular disease and those not diagnosed with a muscle disease at biopsy. Patients were excluded if their clinical records were not screened after biopsy, if they were diagnosed with a muscular disease, and if they were harboring known causative genes of ALS. Data were collected between September 2019 and June 2021 and analyzed in June 2021.</AbstractText><AbstractText Label="EXPOSURES">Muscle biopsy or postmortem muscle tissue examination.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Clinical information and muscle pathological characteristics.</AbstractText><AbstractText Label="RESULTS">A total of 10 patients with autopsy-confirmed SALS (mean [SD] age at death, 76.1 [8.5] years; 8 men [80%]) exhibited axonal phosphorylated TDP-43 (pTDP-43)-positive accumulations in intramuscular nerve bundles; the 12 control patients without ALS did not. Among the 114 patients in the cohort study (mean [SD] age, 62.3 [16.1] years; 76 men [67%]), 71 patients (62.3%) exhibited intramuscular nerve bundles; 43 (37.7%) did not. Among those who exhibited pTDP-43-positive intramuscular nerve bundles, 33 patients (22 men [66.7%]; mean [SD] age, 65.2 [15.6] years) were later diagnosed with ALS. The other 38 patients (26 men [68.4%]; mean [SD] age, 59.3 [18.0] years) showed no pTDP-43-positive bundles and did not develop ALS. Among those without evident nerve bundles (28 men [65.1%]; mean [SD] age, 61.3 [15.3] years), 3 were later diagnosed with ALS. Among patients with ALS in the biopsy cohort, 9 with pTDP-43-positive bundles showed only lower motor neuron symptoms at biopsy.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">Results of this dual case-control and retrospective cohort study suggest that axonal pTDP-43 accumulations may be characteristic for patients with ALS. As such findings precede clinical fulfillment of the Gold Coast criteria, TDP-43 in nerve bundles may be a novel diagnostic biomarker for ALS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kurashige</LastName><ForeName>Takashi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Kure, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Neuroscience and Therapeutics, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morino</LastName><ForeName>Hiroyuki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Clinical Neuroscience and Therapeutics, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murao</LastName><ForeName>Tomomi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Kure, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Izumi</LastName><ForeName>Yuishin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Clinical Neuroscience, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sugiura</LastName><ForeName>Tomohito</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Kure, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuraoka</LastName><ForeName>Kazuya</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Diagnostic Pathology, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Kure, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kawakami</LastName><ForeName>Hideshi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torii</LastName><ForeName>Tsuyoshi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Kure, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maruyama</LastName><ForeName>Hirofumi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Clinical Neuroscience and Therapeutics, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>JAMA Neurol. 2022 Jul 1;79(7):727. doi: 10.1001/jamaneurol.2022.1883.</RefSource><PMID Version="1">35816181</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Kurashige reported receiving grants from the Taiju Life Social Welfare Foundation, Takeda Science Foundation, and the Tsuchiya Memorial Medical Foundation during the conduct of the study. Dr Izumi reported receiving grants from the Japan Agency for Medical Research and Development, the Ministry of Health, Labor and Welfare, Takeda Pharmaceutical Company Limited, and Sumitomo Dainippon Pharma Company Limited outside the submitted work. Dr Maruyama reported receiving grants from Grants-in-Aid for Scientific Research, Eisai, Takeda Pharmaceutical, Otsuka Pharmaceutical, Nihon Pharmaceutical, Shionogi, Teijin Pharma, Fuji Film, Sumitomo Dainippon Pharma, Nihon Medi-Physics, Daiichi Sankyo, Kyowa Kirin, Sanofi, Novartis, Tsumura, Japan Blood Products Organization, Pfizer, Astellas Pharma, and grants from Mitsubishi Tanabe Pharma outside the submitted work; and speaker fees from Eisai, Pfizer, Takeda Pharmaceutical, Otsuka Pharmaceutical, Nihon Pharmaceutical, Teijin Pharma, Sumitomo Dainippon Pharma, Daiichi Sankyo, Kyowa Kirin, Novartis, Mitsubishi Tanabe Pharma, Ono Pharmaceutical, Biogen, Bristol Myers Squibb, AbbVie GK, Chugai Pharmaceutical, CSL Behring, UCB Japan, Alexion Pharma, Amgen, Boehringer Ingelheim, Bayer, MSD, Astellas Pharma, and Japan Blood Products Organization. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>23</Day><Hour>11</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>5</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35604654</ArticleId><ArticleId IdType="pmc">PMC9127711</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2022.1113</ArticleId><ArticleId IdType="pii">2792745</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ince PG, Highley JR, Wharton SB. Motor neuron disorders. In: Love S, Perry A, Ironside J, Budka H, eds. Greenfield&#x2019;s Neuropathology. 9th ed. CRC Press, 2015.</Citation></Reference><Reference><Citation>Kiernan MC, Vucic S, Cheah BC, et al. . Amyotrophic lateral sclerosis. Lancet. 2011;377(9769):942-955. doi:10.1016/S0140-6736(10)61156-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(10)61156-7</ArticleId><ArticleId IdType="pubmed">21296405</ArticleId></ArticleIdList></Reference><Reference><Citation>Gubbay SS, Kahana E, Zilber N, Cooper G, Pintov S, Leibowitz Y. Amyotrophic lateral sclerosis: a study of its presentation and prognosis. J Neurol. 1985;232(5):295-300. doi:10.1007/BF00313868</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00313868</ArticleId><ArticleId IdType="pubmed">4056836</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, et al. . Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314(5796):130-133. doi:10.1126/science.1134108</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1134108</ArticleId><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Mackenzie IRA. Review: neuropathology of nontau frontotemporal lobar degeneration. Neuropathol Appl Neurobiol. 2019;45(1):19-40. doi:10.1111/nan.12526</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nan.12526</ArticleId><ArticleId IdType="pubmed">30357887</ArticleId></ArticleIdList></Reference><Reference><Citation>Onozato T, Nakahara A, Suzuki-Kouyama E, et al. . Axonal TDP-43 aggregates in sporadic amyotrophic lateral sclerosis. Neuropathol Appl Neurobiol. 2016;42(6):561-572. doi:10.1111/nan.12310</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nan.12310</ArticleId><ArticleId IdType="pubmed">26819002</ArticleId></ArticleIdList></Reference><Reference><Citation>England JD, Asbury AK. Peripheral neuropathy. Lancet. 2004;363(9427):2151-2161. doi:10.1016/S0140-6736(04)16508-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(04)16508-2</ArticleId><ArticleId IdType="pubmed">15220040</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer LR, Culver DG, Tennant P, et al. . Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. Exp Neurol. 2004;185(2):232-240. doi:10.1016/j.expneurol.2003.10.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2003.10.004</ArticleId><ArticleId IdType="pubmed">14736504</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer LR, Glass JD. Axonal degeneration in motor neuron disease. Neurodegener Dis. 2007;4(6):431-442. doi:10.1159/000107704</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000107704</ArticleId><ArticleId IdType="pubmed">17934327</ArticleId></ArticleIdList></Reference><Reference><Citation>Iguchi Y, Katsuno M, Niwa J, et al. . Loss of TDP-43 causes age-dependent progressive motor neuron degeneration. Brain. 2013;136(Pt 5):1371-1382. doi:10.1093/brain/awt029</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awt029</ArticleId><ArticleId IdType="pubmed">23449777</ArticleId></ArticleIdList></Reference><Reference><Citation>Isak B, Pugdahl K, Karlsson P, et al. . Quantitative sensory testing and structural assessment of sensory nerve fibres in amyotrophic lateral sclerosis. J Neurol Sci. 2017;373:329-334. doi:10.1016/j.jns.2017.01.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2017.01.005</ArticleId><ArticleId IdType="pubmed">28131214</ArticleId></ArticleIdList></Reference><Reference><Citation>Alami NH, Smith RB, Carrasco MA, et al. . Axonal transport of TDP-43 mRNA granules is impaired by ALS-causing mutations. Neuron. 2014;81(3):536-543. doi:10.1016/j.neuron.2013.12.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.12.018</ArticleId><ArticleId IdType="pmc">PMC3939050</ArticleId><ArticleId IdType="pubmed">24507191</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagano S, Jinno J, Abdelhamid RF, et al. . TDP-43 transports ribosomal protein mRNA to regulate axonal local translation in neuronal axons. Acta Neuropathol. 2020;140(5):695-713. doi:10.1007/s00401-020-02205-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-020-02205-y</ArticleId><ArticleId IdType="pubmed">32803350</ArticleId></ArticleIdList></Reference><Reference><Citation>Rotem N, Magen I, Ionescu A, et al. . ALS along the axons&#x2014;expression of coding and noncoding RNA differs in axons of ALS models. Sci Rep. 2017;7:44500. doi:10.1038/srep44500</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep44500</ArticleId><ArticleId IdType="pmc">PMC5353576</ArticleId><ArticleId IdType="pubmed">28300211</ArticleId></ArticleIdList></Reference><Reference><Citation>Altman T, Ionescu A, Ibraheem A, et al. . Axonal TDP-43 condensates drive neuromuscular junction disruption through inhibition of local synthesis of nuclear encoded mitochondrial proteins. Nat Commun. 2021;12(1):6914. doi:10.1038/s41467-021-27221-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-27221-8</ArticleId><ArticleId IdType="pmc">PMC8617040</ArticleId><ArticleId IdType="pubmed">34824257</ArticleId></ArticleIdList></Reference><Reference><Citation>Shefner JM, Al-Chalabi A, Baker MR, et al. . A proposal for new diagnostic criteria for ALS. Clin Neurophysiol. 2020;131(8):1975-1978. doi:10.1016/j.clinph.2020.04.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2020.04.005</ArticleId><ArticleId IdType="pubmed">32387049</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwong LK, Neumann M, Sampathu DM, Lee VM, Trojanowski JQ. TDP-43 proteinopathy: the neuropathology underlying major forms of sporadic and familial frontotemporal lobar degeneration and motor neuron disease. Acta Neuropathol. 2007;114(1):63-70. doi:10.1007/s00401-007-0226-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-007-0226-5</ArticleId><ArticleId IdType="pubmed">17492294</ArticleId></ArticleIdList></Reference><Reference><Citation>Cykowski MD, Powell SZ, Appel JW, Arumanayagam AS, Rivera AL, Appel SH. Phosphorylated TDP-43 (pTDP-43) aggregates in the axial skeletal muscle of patients with sporadic and familial amyotrophic lateral sclerosis. Acta Neuropathol Commun. 2018;6(1):28. doi:10.1186/s40478-018-0528-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-018-0528-y</ArticleId><ArticleId IdType="pmc">PMC5899326</ArticleId><ArticleId IdType="pubmed">29653597</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori F, Tada M, Kon T, et al. . Phosphorylated TDP-43 aggregates in skeletal and cardiac muscle are a marker of myogenic degeneration in amyotrophic lateral sclerosis and various conditions. Acta Neuropathol Commun. 2019;7(1):165. doi:10.1186/s40478-019-0824-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-019-0824-1</ArticleId><ArticleId IdType="pmc">PMC6816170</ArticleId><ArticleId IdType="pubmed">31661037</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35613261</PMID><DateRevised><Year>2022</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2375-2548</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>21</Issue><PubDate><Year>2022</Year><Month>May</Month><Day>27</Day></PubDate></JournalIssue><Title>Science advances</Title><ISOAbbreviation>Sci Adv</ISOAbbreviation></Journal><ArticleTitle>Actin-binding protein filamin-A drives tau aggregation and contributes to progressive supranuclear palsy pathology.</ArticleTitle><Pagination><StartPage>eabm5029</StartPage><MedlinePgn>eabm5029</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">eabm5029</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1126/sciadv.abm5029</ELocationID><Abstract><AbstractText>While amyloid-&#x3b2; lies upstream of tau pathology in Alzheimer's disease, key drivers for other tauopathies, including progressive supranuclear palsy (PSP), are largely unknown. Various tau mutations are known to facilitate tau aggregation, but how the nonmutated tau, which most cases with PSP share, increases its propensity to aggregate in neurons and glial cells has remained elusive. Here, we identified genetic variations and protein abundance of filamin-A in the PSP brains without tau mutations. We provided in vivo biochemical evidence that increased filamin-A levels enhance the phosphorylation and insolubility of tau through interacting actin filaments. In addition, reduction of filamin-A corrected aberrant tau levels in the culture cells from PSP cases. Moreover, transgenic mice carrying human filamin-A recapitulated tau pathology in the neurons. Our data highlight that filamin-A promotes tau aggregation, providing a potential mechanism by which filamin-A contributes to PSP pathology.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tsujikawa</LastName><ForeName>Koyo</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-9316-2476</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology , National Hospital Organization Suzuka National Hospital, Suzuka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamanaka</LastName><ForeName>Kohei</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Human Genetics, Yokohama City University Graduate School of Medicine, Yokohama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Riku</LastName><ForeName>Yuichi</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-6493-8976</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuropathology, Institute for Medical Science of Aging, Aichi Medical University, Nagakute, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hattori</LastName><ForeName>Yuki</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0001-6576-0121</Identifier><AffiliationInfo><Affiliation>Department of Anatomy and Cell Biology, Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hara</LastName><ForeName>Norikazu</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-8525-3469</Identifier><AffiliationInfo><Affiliation>Department of Molecular Genetics, Brain Research Institute, Niigata University, Niigata, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iguchi</LastName><ForeName>Yohei</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ishigaki</LastName><ForeName>Shinsuke</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-9555-0659</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Division of Dementia and Neurodegenerative Disease, Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hashizume</LastName><ForeName>Atsushi</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-3098-7390</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Research Education, Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miyatake</LastName><ForeName>Satoko</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-7587-5168</Identifier><AffiliationInfo><Affiliation>Department of Human Genetics, Yokohama City University Graduate School of Medicine, Yokohama, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Genetics Department, Yokohama City University Hospital, Yokohama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mitsuhashi</LastName><ForeName>Satomi</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-4769-5922</Identifier><AffiliationInfo><Affiliation>Department of Human Genetics, Yokohama City University Graduate School of Medicine, Yokohama, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genomic Function and Diversity, Medical Research Institute Tokyo Medical and Dental University, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miyazaki</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kataoka</LastName><ForeName>Mayumi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiayi</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yasui</LastName><ForeName>Keizo</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuru</LastName><ForeName>Satoshi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology , National Hospital Organization Suzuka National Hospital, Suzuka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koike</LastName><ForeName>Haruki</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-4612-3183</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kobayashi</LastName><ForeName>Kenta</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-7389-3693</Identifier><AffiliationInfo><Affiliation>Section of Viral Vector Development, National Institute for Physiological Sciences, Okazaki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sahara</LastName><ForeName>Naruhiko</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Functional Brain Imaging, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ozaki</LastName><ForeName>Norio</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoshida</LastName><ForeName>Mari</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neuropathology, Institute for Medical Science of Aging, Aichi Medical University, Nagakute, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kakita</LastName><ForeName>Akiyoshi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pathology, Brain Research Institute, Niigata University, Niigata, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saito</LastName><ForeName>Yuko</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neuropathology (The Brain Bank for Aging Research), Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iwasaki</LastName><ForeName>Yasushi</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-0059-3104</Identifier><AffiliationInfo><Affiliation>Department of Neuropathology, Institute for Medical Science of Aging, Aichi Medical University, Nagakute, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miyashita</LastName><ForeName>Akinori</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Molecular Genetics, Brain Research Institute, Niigata University, Niigata, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iwatsubo</LastName><ForeName>Takeshi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neuropathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Japanese Alzheimer&#x2019;s Disease Neuroimaging Initiative (J-ADNI)</CollectiveName></Author><Author ValidYN="Y"><LastName>Ikeuchi</LastName><ForeName>Takeshi</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-8828-8085</Identifier><AffiliationInfo><Affiliation>Department of Molecular Genetics, Brain Research Institute, Niigata University, Niigata, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Japanese Longitudinal Biomarker Study in PSP and CBD (JALPAC) Consortium</CollectiveName></Author><Author ValidYN="Y"><LastName>Miyata</LastName><ForeName>Takaki</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-5952-0241</Identifier><AffiliationInfo><Affiliation>Department of Anatomy and Cell Biology, Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sobue</LastName><ForeName>Gen</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Research Division of Dementia and Neurodegenerative Disease, Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matsumoto</LastName><ForeName>Naomichi</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-9846-6500</Identifier><AffiliationInfo><Affiliation>Department of Human Genetics, Yokohama City University Graduate School of Medicine, Yokohama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sahashi</LastName><ForeName>Kentaro</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0003-3256-9659</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katsuno</LastName><ForeName>Masahisa</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-9453-9311</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Research Education, Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>05</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Adv</MedlineTA><NlmUniqueID>101653440</NlmUniqueID><ISSNLinking>2375-2548</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>25</Day><Hour>14</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>26</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>5</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35613261</ArticleId><ArticleId IdType="pmc">PMC9132466</ArticleId><ArticleId IdType="doi">10.1126/sciadv.abm5029</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Boxer A. L., Yu J. T., Golbe L. I., Litvan I., Lang A. E., H&#xf6;glinger G. U., Advances in progressive supranuclear palsy: New diagnostic criteria, biomarkers, and therapeutic approaches. Lancet Neurol. 16, 552&#x2013;563 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5802400</ArticleId><ArticleId IdType="pubmed">28653647</ArticleId></ArticleIdList></Reference><Reference><Citation>Uttl B., Santacruz P., Litvan I., Grafman J., Caregiving in progressive supranuclear palsy. Neurology 51, 1303&#x2013;1309 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9818850</ArticleId></ArticleIdList></Reference><Reference><Citation>Glasmacher S. A., Leigh P. N., Saha R. A., Predictors of survival in progressive supranuclear palsy and multiple system atrophy: A systematic review and meta-analysis. J. Neurol. Neurosurg. Psychiatry 88, 402&#x2013;411 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28250027</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida M., Astrocytic inclusions in progressive supranuclear palsy and corticobasal degeneration. Neuropathology 34, 555&#x2013;570 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25124031</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishigaki S., Fujioka Y., Okada Y., Riku Y., Udagawa T., Honda D., Yokoi S., Endo K., Ikenaka K., Takagi S., Iguchi Y., Sahara N., Takashima A., Okano H., Yoshida M., Warita H., Aoki M., Watanabe H., Okado H., Katsuno M., Sobue G., Altered tau isoform ratio caused by loss of FUS and SFPQ function leads to FTLD-like phenotypes. Cell Rep. 18, 1118&#x2013;1131 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28147269</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishigaki S., Riku Y., Fujioka Y., Endo K., Iwade N., Kawai K., Ishibashi M., Yokoi S., Katsuno M., Watanabe H., Mori K., Akagi A., Yokota O., Terada S., Kawakami I., Suzuki N., Warita H., Aoki M., Yoshida M., Sobue G., Aberrant interaction between FUS and SFPQ in neurons in a wide range of FTLD spectrum diseases. Brain 143, 2398&#x2013;2405 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32770214</ArticleId></ArticleIdList></Reference><Reference><Citation>Delisle M. B., Murrell J. R., Richardson R., Trofatter J. A., Rascol O., Soulages X., Mohr M., Calvas P., Ghetti B., A mutation at codon 279 (N279K) in exon 10 of the tau gene causes a tauopathy with dementia and supranuclear palsy. Acta Neuropathol. 98, 62&#x2013;77 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10412802</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu F., Gong C. X., Tau exon 10 alternative splicing and tauopathies. Mol. Neurodegen. 3, 8 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2483273</ArticleId><ArticleId IdType="pubmed">18616804</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandewalle J., van Esch H., Govaerts K., Verbeeck J., Zweier C., Madrigal I., Mila M., Pijkels E., Fernandez I., Kohlhase J., Spaich C., Rauch A., Fryns J. P., Marynen P., Froyen G., Dosage-dependent severity of the phenotype in patients with mental retardation due to a recurrent copy-number gain at Xq28 mediated by an unusual recombination. Am. J. Hum. Genet. 85, 809&#x2013;822 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2790561</ArticleId><ArticleId IdType="pubmed">20004760</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabrales Fontela Y., Kadavath H., Biernat J., Riedel D., Mandelkow E., Zweckstetter M., Multivalent cross-linking of actin filaments and microtubules through the microtubule-associated protein tau. Nat. Commun. 8, 1981 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5719408</ArticleId><ArticleId IdType="pubmed">29215007</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura F., Osborn T. M., Hartemink C. A., Hartwig J. H., Stossel T. P., Structural basis of filamin A functions. J. Cell Biol. 179, 1011&#x2013;1025 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2099194</ArticleId><ArticleId IdType="pubmed">18056414</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwamoto D. V., Huehn A., Simon B., Huet-Calderwood C., Baldassarre M., Sindelar C. V., Calderwood D. A., Structural basis of the filamin A actin-binding domain interaction with F-actin. Nat. Struct. Mol. Biol. 25, 918&#x2013;927 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6173970</ArticleId><ArticleId IdType="pubmed">30224736</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohta Y., Hartwigm J. H., Actin filament cross-linking by chicken gizzard filamin is regulated by phosphorylation in vitro. Biochemistry 34, 6745&#x2013;6754 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">7756305</ArticleId></ArticleIdList></Reference><Reference><Citation>Borbiev T., Verin A. D., Shi S., Liu F., Garcia J. G. N., Regulation of endothelial cell barrier function by calcium/calmodulin-dependent protein kinase II. Am. J. Physiol. Lung Cell. Mol. Physiol. 280, 983&#x2013;990 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11290523</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham V., Khudyakov J., Ellis P., Pevny L., SOX2 functions to maintain neural progenitor identity. Neuron 39, 749&#x2013;765 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12948443</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcamo E. A., Chirivella L., Dautzenberg M., Dobreva G., Fari&#xf1;as I., Grosschedl R., McConnell S. K., Satb2 regulates callosal projection neuron identity in the developing cerebral cortex. Neuron 57, 364&#x2013;377 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18255030</ArticleId></ArticleIdList></Reference><Reference><Citation>McMillan P., Korvatska E., Poorkaj P., Evstafjeva Z., Robinson L., Greenup L., Leverenz J., Schellenberg G. D., D&#x2019;Souza I., Tau isoform regulation is region- and cell-specific in mouse brain. J. Comp. Neurol. 511, 788&#x2013;803 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2845852</ArticleId><ArticleId IdType="pubmed">18925637</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W., Han S. W., Mckeel D. W., Goate A., Wu J. Y., Interaction of presenilins with the filamin family of actin-binding proteins. J. Neurosci. 18, 914&#x2013;922 (1998).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2042137</ArticleId><ArticleId IdType="pubmed">9437013</ArticleId></ArticleIdList></Reference><Reference><Citation>Feuillette S., Deramecourt V., Laquerriere A., Duyckaerts C., Delisle M. B., Maurage C. A., Blum D., Bu&#xe9;e L., Fr&#xe9;bourg T., Campion D., Lecourtois M., Filamin-A and myosin VI colocalize with fibrillary Tau protein in Alzheimer&#x2019;s disease and FTDP-17 brains. Brain Res. 1345, 182&#x2013;189 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20460118</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S., Caccamo A., Shepherd J. D., Murphy M. P., Golde T. E., Kayed R., Metherate R., Mattson M. P., Akbari Y., Laferla F. M., Triple-transgenic model of Alzheimer&#x2019;s disease with plaques and tangles: Intracellular A and synaptic dysfunction. Neuron 39, 409&#x2013;421 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12895417</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballatore C., Lee V. M. Y., Trojanowski J. Q., Tau-mediated neurodegeneration in Alzheimer&#x2019;s disease and related disorders. Nat. Rev. Neurosci. 8, 663&#x2013;672 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17684513</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou A. X., Hartwig J. H., Aky&#xfc;rek L. M., Filamins in cell signaling, transcription and organ development. Trends Cell Biol. 20, 113&#x2013;123 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20061151</ArticleId></ArticleIdList></Reference><Reference><Citation>Savoy R. M., Ghosh P. M., The dual role of filamin A in cancer: Can&#x2019;t live with (too much of) it, can&#x2019;t live without it. Endocr. Relat. Cancer 20, R341&#x2013;R356 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4376317</ArticleId><ArticleId IdType="pubmed">24108109</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox J. W., Lamperti E. D., Ek&#x15f;io&#x11f;lu Y. Z., Hong S. E., Feng Y., Graham D. A., Scheffer I. E., Dobyns W. B., Hirsch B. A., Radtke R. A., Berkovic S. F., Huttenlocher P. R., Walsh C. A., Mutations in filamin 1 prevent migration of cerebral cortical neurons in human periventricular heterotopia. Neuron 21, 1315&#x2013;1325 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9883725</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L., Bartley C. M., Gong X., Hsieh L. S., Lin T. V., Feliciano D. M., Bordey A., MEK-ERK1/2-dependent FLNA overexpression promotes abnormal dendritic patterning in tuberous sclerosis independent of mTOR. Neuron 84, 78&#x2013;91 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4185153</ArticleId><ArticleId IdType="pubmed">25277454</ArticleId></ArticleIdList></Reference><Reference><Citation>Fulga T. A., Elson-Schwab I., Khurana V., Steinhilb M. L., Spires T. L., Hyman B. T., Feany M. B., Abnormal bundling and accumulation of F-actin mediates tau-induced neuronal degeneration in vivo. Nat. Cell Biol. 9, 139&#x2013;148 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17187063</ArticleId></ArticleIdList></Reference><Reference><Citation>Bardai F. H., Wang L., Mutreja Y., Yenjerla M., Gamblin T. C., Feany M. B., A conserved cytoskeletal signaling cascade mediates neurotoxicity of FTDP-17 tau mutations in vivo. J. Neurosci. 38, 108&#x2013;119 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5761430</ArticleId><ArticleId IdType="pubmed">29138281</ArticleId></ArticleIdList></Reference><Reference><Citation>Spanaki C., Latsoudis H., Plaitakis A., LRRK2 mutations on Crete: R1441H associated with PD evolving to PSP. Neurology 67, 1518&#x2013;1519 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17060595</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez-Contreras M., Heckman M. G., Tacik P., Diehl N., Brown P. H., Soto-Ortolaza A. I., Christopher E. A., Walton R. L., Ross O. A., Golbe L. I., Graff-Radford N., Wszolek Z. K., Dickson D. W., Rademakers R., Study of LRRK2 variation in tauopathy: Progressive supranuclear palsy and corticobasal degeneration. Mov. Disord. 32, 115&#x2013;123 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5269612</ArticleId><ArticleId IdType="pubmed">27709685</ArticleId></ArticleIdList></Reference><Reference><Citation>Blauwendraat C., Pletnikva O., Geiger J. T., Murphy N. A., Abramzon Y., Rudow G., Mamais A., Sabir M. S., Crain C. B., Ahmed S., Rosenthal L. S., Bakker C. C., Faghri F., Chia R., Ding J., Dawson T. M., Pantelyat A., Albert M. S., Nalls M. A., Resnick S. M., Ferrucci L., Cookson M. R., Hillis A. E., Troncoso J. C., Scholz S. W., Genetic analysis of neurodegenerative diseases in a pathology cohort. Neurobiol. Aging 76, 214.e1&#x2013;214.e9 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6391207</ArticleId><ArticleId IdType="pubmed">30528841</ArticleId></ArticleIdList></Reference><Reference><Citation>Bardai F. H., Ordonez D. G., Bailey R. M., Hamm M., Lewis J., Feany M. B., Lrrk promotes tau neurotoxicity through dysregulation of actin and mitochondrial dynamics. PLOS Biol. 16, e2006265 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6319772</ArticleId><ArticleId IdType="pubmed">30571694</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuboi Y., Slowinski J., Josephs K. A., Honer W. G., Wszolek Z. K., Dickson D. W., Atrophy of superior cerebellar peduncle in progressive supranuclear palsy. Neurology 60, 1766&#x2013;1769 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12796528</ArticleId></ArticleIdList></Reference><Reference><Citation>Verny M., Duyckaerts C., Agid Y., Hauw J. J., The significance of cortical pathology in progressive supranuclear palsy clinico-pathological data in 10 cases. Brain 119, 1123&#x2013;1136 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8813277</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrer I., Blanco R., Carmona M., Puig B., Phosphorylated mitogen-activated protein kinase (MAPK/ERK-P), protein kinase of 38kDa (p38-P), stress-activated protein kinase (SAPK/JNK-P), and calcium/calmodulin-dependent kinase II (CaM kinase II) are differentially expressed in tau deposits in neurons and glial cells in tauopathies. J. Neural Transm. (Vienna) 108, 1397&#x2013;1415 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11810404</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrer I., Blanco R., Carmona M., Ribera R., Goutan E., Puig B., Rey M. J., Cardozo A., Vi&#xf1;als F., Ribalta T., Phosphorylated map kinase (ERK1, ERK2) expression is associated with early tau deposition in neurones and glial cells, but not with increased nuclear DNA vulnerability and cell death, in Alzheimer disease, Pick&#x2019;s disease, progressive supranuclear palsy and corticobasal degeneration. Brain Pathol. 11, 144&#x2013;158 (2001).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8098611</ArticleId><ArticleId IdType="pubmed">11303790</ArticleId></ArticleIdList></Reference><Reference><Citation>van Vliet A. R., Giordano F., Gerlo S., Segura I., van Eygen S., Molenberghs G., Rocha S., Houcine A., Derua R., Verfaillie T., Vangindertael J., de Keersmaecker H., Waelkens E., Tavernier J., Hofkens J., Annaert W., Carmeliet P., Samali A., Mizuno H., Agostinis P., The ER stress sensor PERK coordinates ER-Plasma membrane contact site formation through interaction with filamin-A and F-actin REMODELING. Mol. Cell 65, 885&#x2013;899.e6 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28238652</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xf6;glinger G. U., Melhem N. M., Dickson D. W., Sleiman P. M. A., Wang L.-S., Klei L., Rademakers R., de Silva R., Litvan I., Riley D. E., van Swieten J. C., Heutink P., Wszolek Z. K., Uitti R. J., Vandrovcova J., Hurtig H. I., Gross R. G., Maetzler W., Goldwurm S., Tolosa E., Borroni B., Pastor P.; PSP Genetics Study Group, Cantwell L. B., Han M. R., Dillman A., van der Brug M. P., Gibbs J. R., Cookson M. R., Hernandez D. G., Singleton A. B., Farrer M. J., Yu C.-E., Golbe L. I., Revesz T., Hardy J., Lees A. J., Devlin B., Hakonarson H., M&#xfc;ller U., Schellenberg G. D., Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat. Genet. 43, 699&#x2013;705 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3125476</ArticleId><ArticleId IdType="pubmed">21685912</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrari R., Ryten M., Simone R., Trabzuni D., Nicolaou N., Hondhamuni G., Ramasamy A., Vandrovcova J., Weale M. E., Lees A. J., Momeni P., Hardy J., de Silva R., Assessment of common variability and expression quantitative trait loci for genome-wide associations for progressive supranuclear palsy. Neurobiol. Aging 35, 1514.e1&#x2013;1514.e12 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4104112</ArticleId><ArticleId IdType="pubmed">24503276</ArticleId></ArticleIdList></Reference><Reference><Citation>Nijholt D. A. T., van Haastert E. S., Rozemuller A. J. M., Scheper W., Hoozemans J. J. M., The unfolded protein response is associated with early tau pathology in the hippocampus of tauopathies. J. Pathol. 226, 693&#x2013;702 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22102449</ArticleId></ArticleIdList></Reference><Reference><Citation>Stutzbach L. D., Xie S. X., Naj A. C., Albin R., Gilman S., Lee V. M. Y., Trojanowski J. Q., Devlin B., Schellenberg G. D., The unfolded protein response is activated in disease-affected brain regions in progressive supranuclear palsy and Alzheimer&#x2019;s disease. Acta Neuropathol. Commun. 1, 31 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3893579</ArticleId><ArticleId IdType="pubmed">24252572</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns L. H., Wang H.-Y., Altered filamin A enables amyloid beta-induced tau hyperphosphorylation and neuroinflammation in Alzheimer&#x2019;s disease. Neuroimmunol. Neuroinflam. 4, 263&#x2013;271 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8294116</ArticleId><ArticleId IdType="pubmed">34295950</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H. Y., Bakshi K., Frankfurt M., Stucky A., Goberdhan M., Shah S. M., Burns L. H., Reducing amyloid-related Alzheimer&#x2019;s disease pathogenesis by a small molecule targeting filamin A. J. Neurosci. 32, 9773&#x2013;9784 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6621293</ArticleId><ArticleId IdType="pubmed">22815492</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X., Wang L., Xiao W., Su Z., Zheng C., Zhang Z., Wang Y., Xu B., Yang X., Hoi M. P. M., Memantine improves cognitive function and alters hippocampal and cortical proteome in triple transgenic mouse model of Alzheimer&#x2019;s disease. Exp. Neurobiol. 28, 390&#x2013;403 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6614075</ArticleId><ArticleId IdType="pubmed">31308798</ArticleId></ArticleIdList></Reference><Reference><Citation>Litvan I., Hauw J. J., Bartko J. J., Lantos P. L., Daniel S. E., Horoupian D. S., McKee A., Dickson D., Bancher C., Tabaton M., Jellinger K., Anderson D. W., Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders. J. Neuropathol. Exp. Neurol. 55, 97&#x2013;105 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8558176</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson D. W., Bergeron C., Chin S. S., Horoupian D., Ikeda K., Jellinger K., Lantos P. L., Lippa C. F., Mirra S. S., Tabaton M., Vonsattel J. P., Wakabayashi K., Litvan I., Office of rare diseases neuropathologic criteria for corticobasal degeneration. J. Neuropathol. Exp. Neurol. 61, 935&#x2013;946 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12430710</ArticleId></ArticleIdList></Reference><Reference><Citation>Montine T. J., Phelps C. H., Beach T. G., Bigio E. H., Cairns N. J., Dickson D. W., Duyckaerts C., Frosch M. P., Masliah E., Mirra S. S., Nelson P. T., Schneider J. A., Thal D. R., Trojanowski J. Q., van Vinters H., Hyman B. T., National institute on aging-Alzheimer&#x2019;s association guidelines for the neuropathologic assessment of Alzheimer&#x2019;s disease: A practical approach. Acta Neuropathol. 123, 1&#x2013;11 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3268003</ArticleId><ArticleId IdType="pubmed">22101365</ArticleId></ArticleIdList></Reference><Reference><Citation>Gelb D. J., Oliver E., Gilman S., Diagnostic criteria for Parkinson disease. Arch. Neurol. 56, 33&#x2013;39 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">9923759</ArticleId></ArticleIdList></Reference><Reference><Citation>Mckeith I. G., Dickson D., Lowe J., Emre M., O&#x2019;brien J., Feldman H., Cummings J., Duda J., Lippa C., Perry E., Aarsland D., Arai H., Ballard C., Boeve B., Burn D., Costa D., del Ser T., Dubois B., Galasko D., Gauthier S., Goetz C., Gomez-Tortosa E., Halliday G., Hansen L., Hardy J., Iwatsubo T., Kalaria R., Kaufer D., Kenny R., Korczyn A., Kosaka K., Lee M.-Y., Lees A., Litvan I., Londos E., Lopez O., Minoshima S., Mizuno Y., Molina J. A., Mukaetova-Ladinska E., Pasquier F., Perry R. H., Schulz J. B., Trojanowski J., Yamada M., Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium. Neurology 65, 1863&#x2013;1872 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16237129</ArticleId></ArticleIdList></Reference><Reference><Citation>Neary D., Snowden J. S., Gustafson L., Passant U., Stuss D., Black S., Freedman M., Kertesz A., Robert P. H., Albert M., Boone K., Miller B. L., Cummings J., Benson D. F., Frontotemporal lobar degeneration A consensus on clinical diagnostic criteria. Neurology 51, 1546&#x2013;1554 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9855500</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H., Braak E., Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82, 239&#x2013;259 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H., Alafuzoff I., Arzberger T., Kretzschmar H., Tredici K., Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 112, 389&#x2013;404 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3906709</ArticleId><ArticleId IdType="pubmed">16906426</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito Y., Ruberu N. N., Sawabe M., Arai T., Tanaka N., Kakuta Y., Yamanouchi H., Murayama S., Staging of Argyrophilic Grains: An age-associated tauopathy. J. Neuropathol. Exp. Neurol. 63, 911&#x2013;918 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15453090</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirra S., Heyman A., McKeel D., Sumi S., Crain B., Brownlee L., Vogel F., Hughes J., van Belle G., Berg L., The Consortium to Establish a Registry for Alzheimer&#x2019;s Disease (CERAD). Part 11. Standardization of the neuropathologic assessment of Alzheimer&#x2019;s disease. Neurology 41, 479&#x2013;486 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">2011243</ArticleId></ArticleIdList></Reference><Reference><Citation>Okamoto M., Namba T., Shinoda T., Kondo T., Watanabe T., Inoue Y., Takeuchi K., Enomoto Y., Ota K., Oda K., Wada Y., Sagou K., Saito K., Sakakibara A., Kawaguchi A., Nakajima K., Adachi T., Fujimori T., Ueda M., Hayashi S., Kaibuchi K., Miyata T., TAG-1-assisted progenitor elongation streamlines nuclear migration to optimize subapical crowding. Nat. Neurosci. 16, 1556&#x2013;1566 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">24056697</ArticleId></ArticleIdList></Reference><Reference><Citation>Hattori Y., Miyata T., Embryonic neocortical microglia express toll-like receptor 9 and respond to plasmid DNA injected into the ventricle: Technical considerations regarding microglial distribution in electroporated brain walls. eNeuro. 5, ENEURO.0312-18 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6325556</ArticleId><ArticleId IdType="pubmed">30627652</ArticleId></ArticleIdList></Reference><Reference><Citation>Hattori Y., Naito Y., Tsugawa Y., Nonaka S., Wake H., Nagasawa T., Kawaguchi A., Miyata T., Transient microglial absence assists postmigratory cortical neurons in proper differentiation. Nat. Commun. 11, 1631 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7118101</ArticleId><ArticleId IdType="pubmed">32242005</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Balasubramaniyan V., Peng J., Hurlock E. C., Tallquist M., Li J., Lu Q. R., Isolation and culture of rat and mouse oligodendrocyte precursor cells. Nat. Protoc. 2, 1044&#x2013;1051 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17546009</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahara N., de Ture M., Ren Y., Ebrahim A. S., Kang D., Knight J., Volbracht C., Pedersen J. T., Dickson D. W., Yen S. H., Lewis J., Characteristics of TBS-extractable hyperphosphorylated tau species: Aggregation intermediates in rTg4510 mouse brain. J. Alzheimers Dis. 33, 249&#x2013;263 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3514650</ArticleId><ArticleId IdType="pubmed">22941973</ArticleId></ArticleIdList></Reference><Reference><Citation>Fromer M., Moran J. L., Chambert K., Banks E., Bergen S. E., Ruderfer D. M., Handsaker R. E., McCarroll S. A., O&#x2019;Donovan M. C., Owen M. J., Kirov G., Sullivan P. F., Hultman C. M., Sklar P., Purcell S. M., Discovery and statistical genotyping of copy-number variation from whole-exome sequencing depth. Am. J. Hum. Genet. 91, 597&#x2013;607 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3484655</ArticleId><ArticleId IdType="pubmed">23040492</ArticleId></ArticleIdList></Reference><Reference><Citation>Fromer M., Purcell S. M., Using XHMM software to detect copy number variation in whole-exome sequencing data. Curr. Protoc. Hum. Genet. 81, 7.23.1&#x2013;7.23.21 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4065038</ArticleId><ArticleId IdType="pubmed">24763994</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings B. B., Karczewski K. J., Kosmicki J. A., Seaby E. G., Watts N. A., Singer-Berk M., Mudge J. M., Karjalainen J., Satterstrom F. K., O&#x2019;Donnell-Luria A. H., Poterba T., Seed C., Solomonson M., Alf&#xf6;ldi J., Alf&#xf6;ldi J., Armean I. M., Banks E., Bergelson L., Cibulskis K., Collins R. L., Connolly K. M., Covarrubias M., Cummings B. B., Daly M. J., Donnelly S., Farjoun Y., Ferriera S., Francioli L., Gabriel S., Gauthier L. D., Gentry J., Gupta N., Jeandet T., Kaplan D., Karczewski K. J., Laricchia K. M., Llanwarne C., van Minikel E., Munshi R., Neale B. M., Novod S., O&#x2019;Donnell-Luria A. H., Petrillo N., Poterba T., Roazen D., Ruano-Rubio V., Saltzman A., Samocha K. E., Schleicher M., Seed C., Solomonson M., Soto J., Tiao G., Tibbetts K., Tolonen C., Vittal C., Wade G., Wang A., Wang Q., Ware J. S., Watts N. A., Weisburd B., Whiffin N., Salinas C. A. A., Ahmad T., Albert C. M., Ardissino D., Atzmon G., Barnard J., Beaugerie L., Benjamin E. J., Boehnke M., Bonnycastle L. L., Bottinger E. P., Bowden D. W., Bown M. J., Chambers J. C., Chan J. C., Chasman D., Cho J., Chung M. K., Cohen B., Correa A., Dabelea D., Daly M. J., Darbar D., Duggirala R., Dupuis J., Ellinor P. T., Elosua R., Erdmann J., Esko T., F&#xe4;rkkil&#xe4; M., Florez J., Franke A., Getz G., Glaser B., Glatt S. J., Goldstein D., Gonzalez C., Groop L., Haiman C., Hanis C., Harms M., Hiltunen M., Holi M. M., Hultman C. M., Kallela M., Kaprio J., Kathiresan S., Kim B. J., Kim Y. J., Kirov G., Kooner J., Koskinen S., Krumholz H. M., Kugathasan S., Kwak S. H., Laakso M., Lehtim&#xe4;ki T., Loos R. J. F., Lubitz S. A., Ma R. C. W., MacArthur D. G., Marrugat J., Mattila K. M., McCarroll S., McCarthy M. I., McGovern D., McPherson R., Meigs J. B., Melander O., Metspalu A., Neale B. M., Nilsson P. M., O&#x2019;Donovan M. C., Ongur D., Orozco L., Owen M. J., Palmer C. N. A., Palotie A., Park K. S., Pato C., Pulver A. E., Rahman N., Remes A. M., Rioux J. D., Ripatti S., Roden D. M., Saleheen D., Salomaa V., Samani N. J., Scharf J., Schunkert H., Shoemaker M. B., Sklar P., Soininen H., Sokol H., Spector T., Sullivan P. F., Suvisaari J., Tai E. S., Teo Y. Y., Tiinamaija T., Tsuang M., Turner D., Tusie-Luna T., Vartiainen E., Ware J. S., Watkins H., Weersma R. K., Wessman M., Wilson J. G., Xavier R. J., Daly M. J., MacArthur D. G., Transcript expression-aware annotation improves rare variant interpretation. Nature 581, 452&#x2013;458 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7334198</ArticleId><ArticleId IdType="pubmed">32461655</ArticleId></ArticleIdList></Reference><Reference><Citation>Saitsu H., Nishimura T., Muramatsu K., Kodera H., Kumada S., Sugai K., Kasai-Yoshida E., Sawaura N., Nishida H., Hoshino A., Ryujin F., Yoshioka S., Nishiyama K., Kondo Y., Tsurusaki Y., Nakashima M., Miyake N., Arakawa H., Kato M., Mizushima N., Matsumoto N., De novo mutations in the autophagy gene WDR45 cause static encephalopathy of childhood with neurodegeneration in adulthood. Nat. Genet. 45, 445&#x2013;449 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23435086</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim J., Balastik M., Lee T. H., Nakamura K., Liou Y. C., Sun A., Finn G., Pastorino L., Lee V. M. Y., Lu K. P., Pin1 has opposite effects on wild-type and P301L tau stability and tauopathy. J. Clin. Investig. 118, 1877&#x2013;1889 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2323189</ArticleId><ArticleId IdType="pubmed">18431510</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi K., Sano H., Kato S., Kuroda K., Nakamuta S., Isa T., Nambu A., Kaibuchi K., Kobayashi K., Survival of corticostriatal neurons by rho/rho-kinase signaling pathway. Neurosci. Lett. 630, 45&#x2013;52 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27424794</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsujikawa K., Hara K., Muro Y., Nakanishi H., Niwa Y., Koike M., Noda S., Riku Y., Sahashi K., Atsuta N., Ito M., Shimoyama Y., Akiyama M., Katsuno M., HMGCR antibody-associated myopathy as a paraneoplastic manifestation of esophageal carcinoma. Neurology 87, 841&#x2013;843 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4999323</ArticleId><ArticleId IdType="pubmed">27449065</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">35654956</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>09</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>6</Issue><PubDate><Year>2022</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Faulty autolysosome acidification in Alzheimer's disease mouse models induces autophagic build-up of A&#x3b2; in neurons, yielding senile plaques.</ArticleTitle><Pagination><StartPage>688</StartPage><EndPage>701</EndPage><MedlinePgn>688-701</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41593-022-01084-8</ELocationID><Abstract><AbstractText>Autophagy is markedly impaired in Alzheimer's disease (AD). Here we reveal unique autophagy dysregulation within neurons in five AD mouse models in vivo and identify its basis using a neuron-specific transgenic mRFP-eGFP-LC3 probe of autophagy and pH, multiplex confocal imaging and correlative light electron microscopy. Autolysosome acidification declines in neurons well before extracellular amyloid deposition, associated with markedly lowered vATPase activity and build-up of A&#x3b2;/APP-&#x3b2;CTF selectively within enlarged de-acidified autolysosomes. In more compromised yet still intact neurons, profuse A&#x3b2;-positive autophagic vacuoles (AVs) pack into large membrane blebs forming flower-like perikaryal rosettes. This unique pattern, termed PANTHOS (poisonous anthos (flower)), is also present in AD brains. Additional AVs coalesce into peri-nuclear networks of membrane tubules where fibrillar &#x3b2;-amyloid accumulates intraluminally. Lysosomal membrane permeabilization, cathepsin release and lysosomal cell death ensue, accompanied by microglial invasion. Quantitative analyses confirm that individual neurons exhibiting PANTHOS are the principal source of senile plaques in amyloid precursor protein AD models.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Ju-Hyun</ForeName><Initials>JH</Initials><Identifier Source="ORCID">0000-0002-0280-8375</Identifier><AffiliationInfo><Affiliation>Center for Dementia Research, Nathan S. Kline Institute, Orangeburg, NY, USA. Ju-hyun.Lee@NKI.RFMH.ORG.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, New York University Langone Health, New York, NY, USA. Ju-hyun.Lee@NKI.RFMH.ORG.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Dun-Sheng</ForeName><Initials>DS</Initials><Identifier Source="ORCID">0000-0001-9259-3015</Identifier><AffiliationInfo><Affiliation>Center for Dementia Research, Nathan S. Kline Institute, Orangeburg, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, New York University Langone Health, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goulbourne</LastName><ForeName>Chris N</ForeName><Initials>CN</Initials><AffiliationInfo><Affiliation>Center for Dementia Research, Nathan S. Kline Institute, Orangeburg, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Im</LastName><ForeName>Eunju</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-7839-8878</Identifier><AffiliationInfo><Affiliation>Center for Dementia Research, Nathan S. Kline Institute, Orangeburg, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, New York University Langone Health, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stavrides</LastName><ForeName>Philip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Center for Dementia Research, Nathan S. Kline Institute, Orangeburg, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pensalfini</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Center for Dementia Research, Nathan S. Kline Institute, Orangeburg, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Han</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Thermo Fisher Scientific, Hillsboro, OR, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bouchet-Marquis</LastName><ForeName>Cedric</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Thermo Fisher Scientific, Hillsboro, OR, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bleiwas</LastName><ForeName>Cynthia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Center for Dementia Research, Nathan S. Kline Institute, Orangeburg, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berg</LastName><ForeName>Martin J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Center for Dementia Research, Nathan S. Kline Institute, Orangeburg, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huo</LastName><ForeName>Chunfeng</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Center for Dementia Research, Nathan S. Kline Institute, Orangeburg, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peddy</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Center for Dementia Research, Nathan S. Kline Institute, Orangeburg, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pawlik</LastName><ForeName>Monika</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-0138-7529</Identifier><AffiliationInfo><Affiliation>Center for Dementia Research, Nathan S. Kline Institute, Orangeburg, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levy</LastName><ForeName>Efrat</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-6890-6763</Identifier><AffiliationInfo><Affiliation>Center for Dementia Research, Nathan S. Kline Institute, Orangeburg, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, New York University Langone Health, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departments of Biochemistry &amp; Molecular Pharmacology, New York University Langone Health, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NYU Neuroscience Institute, New York University Langone Health, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rao</LastName><ForeName>Mala</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center for Dementia Research, Nathan S. Kline Institute, Orangeburg, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, New York University Langone Health, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Staufenbiel</LastName><ForeName>Mathias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nixon</LastName><ForeName>Ralph A</ForeName><Initials>RA</Initials><Identifier Source="ORCID">0000-0001-5124-1021</Identifier><AffiliationInfo><Affiliation>Center for Dementia Research, Nathan S. Kline Institute, Orangeburg, NY, USA. Ralph.Nixon@NKI.RFMH.ORG.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, New York University Langone Health, New York, NY, USA. Ralph.Nixon@NKI.RFMH.ORG.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NYU Neuroscience Institute, New York University Langone Health, New York, NY, USA. Ralph.Nixon@NKI.RFMH.ORG.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cell Biology, New York University Langone Health, New York, NY, USA. Ralph.Nixon@NKI.RFMH.ORG.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG017617</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG025688</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG062376</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Signal Transduct Target Ther. 2022 Oct 2;7(1):344. doi: 10.1038/s41392-022-01204-7.</RefSource><PMID Version="1">36184585</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006863" MajorTopicYN="N">Hydrogen-Ion Concentration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008247" MajorTopicYN="N">Lysosomes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>All authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>8</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>4</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>2</Day><Hour>23</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>6</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35654956</ArticleId><ArticleId IdType="pmc">PMC9174056</ArticleId><ArticleId IdType="doi">10.1038/s41593-022-01084-8</ArticleId><ArticleId IdType="pii">10.1038/s41593-022-01084-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Menzies FM, et al. Autophagy and neurodegeneration: pathogenic mechanisms and therapeutic opportunities. Neuron. 2017;93:1015&#x2013;1034. doi: 10.1016/j.neuron.2017.01.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2017.01.022</ArticleId><ArticleId IdType="pubmed">28279350</ArticleId></ArticleIdList></Reference><Reference><Citation>Boland B, et al. Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing. Nat. Rev. Drug Discov. 2018;17:660&#x2013;688. doi: 10.1038/nrd.2018.109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd.2018.109</ArticleId><ArticleId IdType="pmc">PMC6456907</ArticleId><ArticleId IdType="pubmed">30116051</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf3;pez-Ot&#xed;n C, Kroemer G. Hallmarks of health. Cell. 2021;184:33&#x2013;63. doi: 10.1016/j.cell.2020.11.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.11.034</ArticleId><ArticleId IdType="pubmed">33340459</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizushima N, Levine B, Cuervo AM, Klionsky DJ. Autophagy fights disease through cellular self-digestion. Nature. 2008;451:1069&#x2013;1075. doi: 10.1038/nature06639.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature06639</ArticleId><ArticleId IdType="pmc">PMC2670399</ArticleId><ArticleId IdType="pubmed">18305538</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreira PI, et al. Autophagy in Alzheimer&#x2019;s disease. Expert Rev. Neurother. 2010;10:1209&#x2013;1218. doi: 10.1586/ern.10.84.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/ern.10.84</ArticleId><ArticleId IdType="pubmed">20586699</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon RA. The role of autophagy in neurodegenerative disease. Nat. Med. 2013;19:983&#x2013;997. doi: 10.1038/nm.3232.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.3232</ArticleId><ArticleId IdType="pubmed">23921753</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon RA. Autophagy, amyloidogenesis and Alzheimer disease. J. Cell Sci. 2007;120:4081&#x2013;4091. doi: 10.1242/jcs.019265.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.019265</ArticleId><ArticleId IdType="pubmed">18032783</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman DS, et al. Alzheimer disease. Nat. Rev. Dis. Prim. 2021;7:33. doi: 10.1038/s41572-021-00269-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41572-021-00269-y</ArticleId><ArticleId IdType="pmc">PMC8574196</ArticleId><ArticleId IdType="pubmed">33986301</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harb. Perspect. Med. 2011;1:a006189. doi: 10.1101/cshperspect.a006189.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a006189</ArticleId><ArticleId IdType="pmc">PMC3234452</ArticleId><ArticleId IdType="pubmed">22229116</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauritzen I, et al. Intraneuronal aggregation of the &#x3b2;-CTF fragment of APP (C99) induces A&#x3b2;-independent lysosomal&#x2013;autophagic pathology. Acta Neuropathol. 2016;132:257&#x2013;276. doi: 10.1007/s00401-016-1577-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-016-1577-6</ArticleId><ArticleId IdType="pmc">PMC4947121</ArticleId><ArticleId IdType="pubmed">27138984</ArticleId></ArticleIdList></Reference><Reference><Citation>LaFerla FM, Green KN, Oddo S. Intracellular amyloid-&#x3b2; in Alzheimer&#x2019;s disease. Nat. Rev. Neurosci. 2007;8:499&#x2013;509. doi: 10.1038/nrn2168.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn2168</ArticleId><ArticleId IdType="pubmed">17551515</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu WH, et al. Macroautophagy&#x2014;a novel &#x3b2;-amyloid peptide-generating pathway activated in Alzheimer&#x2019;s disease. J. Cell Biol. 2005;171:87&#x2013;98. doi: 10.1083/jcb.200505082.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.200505082</ArticleId><ArticleId IdType="pmc">PMC2171227</ArticleId><ArticleId IdType="pubmed">16203860</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J-H, et al. Transgenic expression of a ratiometric autophagy probe specifically in neurons enables the interrogation of brain autophagy in vivo. Autophagy. 2019;15:543&#x2013;557. doi: 10.1080/15548627.2018.1528812.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15548627.2018.1528812</ArticleId><ArticleId IdType="pmc">PMC6351128</ArticleId><ArticleId IdType="pubmed">30269645</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura S, Noda T, Yoshimori T. Dissection of the autophagosome maturation process by a novel reporter protein, tandem fluorescent-tagged LC3. Autophagy. 2007;3:452&#x2013;460. doi: 10.4161/auto.4451.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/auto.4451</ArticleId><ArticleId IdType="pubmed">17534139</ArticleId></ArticleIdList></Reference><Reference><Citation>Shinoda H, Shannon M, Nagai T. Fluorescent proteins for investigating biological events in acidic environments. Int. J. Mol. Sci. 2018;19:1548. doi: 10.3390/ijms19061548.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms19061548</ArticleId><ArticleId IdType="pmc">PMC6032295</ArticleId><ArticleId IdType="pubmed">29789517</ArticleId></ArticleIdList></Reference><Reference><Citation>Lie PPY, et al. Post-Golgi carriers, not lysosomes, confer lysosomal properties to pre-degradative organelles in normal and dystrophic axons. Cell Rep. 2021;35:109034. doi: 10.1016/j.celrep.2021.109034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.109034</ArticleId><ArticleId IdType="pmc">PMC8135226</ArticleId><ArticleId IdType="pubmed">33910020</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawarabayashi T, et al. Age-dependent changes in brain, CSF, and plasma amyloid &#x3b2; protein in the Tg2576 transgenic mouse model of Alzheimer&#x2019;s disease. J. Neurosci. 2001;21:372&#x2013;381. doi: 10.1523/JNEUROSCI.21-02-00372.2001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.21-02-00372.2001</ArticleId><ArticleId IdType="pmc">PMC6763819</ArticleId><ArticleId IdType="pubmed">11160418</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JH, et al. Presenilin 1 maintains lysosomal Ca2+ homeostasis via TRPML1 by regulating vATPase-mediated lysosome acidification. Cell Rep. 2015;12:1430&#x2013;1444. doi: 10.1016/j.celrep.2015.07.050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2015.07.050</ArticleId><ArticleId IdType="pmc">PMC4558203</ArticleId><ArticleId IdType="pubmed">26299959</ArticleId></ArticleIdList></Reference><Reference><Citation>Cataldo AM, et al. A&#x3b2; localization in abnormal endosomes: association with earliest A&#x3b2; elevations in AD and Down syndrome. Neurobiol. Aging. 2004;25:1263&#x2013;1272. doi: 10.1016/j.neurobiolaging.2004.02.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2004.02.027</ArticleId><ArticleId IdType="pubmed">15465622</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Y, et al. Lysosomal dysfunction in Down syndrome is APP-dependent and mediated by APP-&#x3b2;CTF (C99) J. Neurosci. 2019;39:5255&#x2013;5268. doi: 10.1523/JNEUROSCI.0578-19.2019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0578-19.2019</ArticleId><ArticleId IdType="pmc">PMC6607756</ArticleId><ArticleId IdType="pubmed">31043483</ArticleId></ArticleIdList></Reference><Reference><Citation>Wirths O, et al. Intraneuronal A&#x3b2; accumulation precedes plaque formation in &#x3b2;-amyloid precursor protein and presenilin-1 double-transgenic mice. Neurosci. Lett. 2001;306:116&#x2013;120. doi: 10.1016/S0304-3940(01)01876-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0304-3940(01)01876-6</ArticleId><ArticleId IdType="pubmed">11403971</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathews PM, et al. Calpain activity regulates the cell surface distribution of amyloid precursor protein. Inhibition of calpains enhances endosomal generation of &#x3b2;-cleaved C-terminal APP fragments. J. Biol. Chem. 2002;277:36415&#x2013;36424. doi: 10.1074/jbc.M205208200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M205208200</ArticleId><ArticleId IdType="pubmed">12087104</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodendorf U, et al. Expression of human &#x3b2;-secretase in the mouse brain increases the steady-state level of &#x3b2;-amyloid. J. Neurochem. 2002;80:799&#x2013;806. doi: 10.1046/j.0022-3042.2002.00770.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.0022-3042.2002.00770.x</ArticleId><ArticleId IdType="pubmed">11948243</ArticleId></ArticleIdList></Reference><Reference><Citation>Avrahami L, et al. Inhibition of GSK-3 ameliorates &#x3b2;-amyloid pathology and restores lysosomal acidification and mTOR activity in the Alzheimer&#x2019;s disease mouse model. J. Biol. Chem. 2013;288:1295&#x2013;1306. doi: 10.1074/jbc.M112.409250.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.409250</ArticleId><ArticleId IdType="pmc">PMC3543013</ArticleId><ArticleId IdType="pubmed">23155049</ArticleId></ArticleIdList></Reference><Reference><Citation>Eimer WA, Vassar R. Neuron loss in the 5XFAD mouse model of Alzheimer&#x2019;s disease correlates with intraneuronal A&#x3b2;42 accumulation and caspase-3 activation. Mol. Neurodegener. 2013;8:2. doi: 10.1186/1750-1326-8-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-8-2</ArticleId><ArticleId IdType="pmc">PMC3552866</ArticleId><ArticleId IdType="pubmed">23316765</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura R, Ohno M. Impairments in remote memory stabilization precede hippocampal synaptic and cognitive failures in 5XFAD Alzheimer mouse model. Neurobiol. Dis. 2009;33:229&#x2013;235. doi: 10.1016/j.nbd.2008.10.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2008.10.006</ArticleId><ArticleId IdType="pmc">PMC2741400</ArticleId><ArticleId IdType="pubmed">19026746</ArticleId></ArticleIdList></Reference><Reference><Citation>Fricker M, Tolkovsky AM, Borutaite V, Coleman M, Brown GC. Neuronal cell death. Physiol. Rev. 2018;98:813&#x2013;880. doi: 10.1152/physrev.00011.2017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physrev.00011.2017</ArticleId><ArticleId IdType="pmc">PMC5966715</ArticleId><ArticleId IdType="pubmed">29488822</ArticleId></ArticleIdList></Reference><Reference><Citation>Han S, et al. Amyloid plaque structure and cell surface interactions of &#x3b2;-amyloid fibrils revealed by electron tomography. Sci. Rep. 2017;7:43577. doi: 10.1038/srep43577.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep43577</ArticleId><ArticleId IdType="pmc">PMC5327471</ArticleId><ArticleId IdType="pubmed">28240273</ArticleId></ArticleIdList></Reference><Reference><Citation>Bordi M, et al. Autophagy flux in CA1 neurons of Alzheimer hippocampus: increased induction overburdens failing lysosomes to propel neuritic dystrophy. Autophagy. 2016;12:2467&#x2013;2483. doi: 10.1080/15548627.2016.1239003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15548627.2016.1239003</ArticleId><ArticleId IdType="pmc">PMC5173282</ArticleId><ArticleId IdType="pubmed">27813694</ArticleId></ArticleIdList></Reference><Reference><Citation>Boya P, Kroemer G. Lysosomal membrane permeabilization in cell death. Oncogene. 2008;27:6434&#x2013;6451. doi: 10.1038/onc.2008.310.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/onc.2008.310</ArticleId><ArticleId IdType="pubmed">18955971</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian Y, Bustos V, Flajolet M, Greengard P. A small-molecule enhancer of autophagy decreases levels of A&#x3b2; and APP-CTF via Atg5-dependent autophagy pathway. FASEB J. 2011;25:1934&#x2013;1942. doi: 10.1096/fj.10-175158.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.10-175158</ArticleId><ArticleId IdType="pmc">PMC3101026</ArticleId><ArticleId IdType="pubmed">21368103</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonz&#xe1;lez, A. E. et al. Autophagosomes cooperate in the degradation of intracellular C-terminal fragments of the amyloid precursor protein via the MVB/lysosomal pathway. FASEB J.31, 2446&#x2013;2459 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28254759</ArticleId></ArticleIdList></Reference><Reference><Citation>Park JS, Kim DH, Yoon SY. Regulation of amyloid precursor protein processing by its KFERQ motif. BMB Rep. 2016;49:337&#x2013;342. doi: 10.5483/BMBRep.2016.49.6.212.</Citation><ArticleIdList><ArticleId IdType="doi">10.5483/BMBRep.2016.49.6.212</ArticleId><ArticleId IdType="pmc">PMC5070722</ArticleId><ArticleId IdType="pubmed">26779997</ArticleId></ArticleIdList></Reference><Reference><Citation>Wheeler S, et al. Cytosolic glucosylceramide regulates endolysosomal function in Niemann&#x2013;Pick type C disease. Neurobiol. Dis. 2019;127:242&#x2013;252. doi: 10.1016/j.nbd.2019.03.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2019.03.005</ArticleId><ArticleId IdType="pubmed">30872158</ArticleId></ArticleIdList></Reference><Reference><Citation>Bach G, Chen C-S, Pagano RE. Elevated lysosomal pH in mucolipidosis type IV cells. Clin. Chim. Acta. 1999;280:173&#x2013;179. doi: 10.1016/S0009-8981(98)00183-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0009-8981(98)00183-1</ArticleId><ArticleId IdType="pubmed">10090534</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon RA. Niemann&#x2013;Pick type C disease and Alzheimer&#x2019;s disease: the APP-endosome connection fattens up. Am. J. Pathol. 2004;164:757&#x2013;761. doi: 10.1016/S0002-9440(10)63163-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9440(10)63163-X</ArticleId><ArticleId IdType="pmc">PMC1613265</ArticleId><ArticleId IdType="pubmed">14982829</ArticleId></ArticleIdList></Reference><Reference><Citation>Esposito M, et al. In vivo evidence of cortical amyloid deposition in the adult form of Niemann Pick type C. Heliyon. 2019;5:e02776. doi: 10.1016/j.heliyon.2019.e02776.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.heliyon.2019.e02776</ArticleId><ArticleId IdType="pmc">PMC6895717</ArticleId><ArticleId IdType="pubmed">31844711</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabeza C, et al. Cholinergic abnormalities, endosomal alterations and up-regulation of nerve growth factor signaling in Niemann&#x2013;Pick type C disease. Mol. Neurodegener. 2012;7:11. doi: 10.1186/1750-1326-7-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-7-11</ArticleId><ArticleId IdType="pmc">PMC3395862</ArticleId><ArticleId IdType="pubmed">22458984</ArticleId></ArticleIdList></Reference><Reference><Citation>Heon-Roberts, R., Nguyen, A. L. A. &amp; Pshezhetsky, A. V. Molecular bases of neurodegeneration and cognitive decline, the major burden of Sanfilippo disease. J. Clin. Med.9, 344 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7074161</ArticleId><ArticleId IdType="pubmed">32012694</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon RA, Yang DS. Autophagy failure in Alzheimer&#x2019;s disease&#x2014;locating the primary defect. Neurobiol. Dis. 2011;43:38&#x2013;45. doi: 10.1016/j.nbd.2011.01.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2011.01.021</ArticleId><ArticleId IdType="pmc">PMC3096679</ArticleId><ArticleId IdType="pubmed">21296668</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipinski MM, et al. Genome-wide analysis reveals mechanisms modulating autophagy in normal brain aging and in Alzheimer&#x2019;s disease. Proc. Natl Acad. Sci. USA. 2010;107:14164&#x2013;14169. doi: 10.1073/pnas.1009485107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1009485107</ArticleId><ArticleId IdType="pmc">PMC2922576</ArticleId><ArticleId IdType="pubmed">20660724</ArticleId></ArticleIdList></Reference><Reference><Citation>Raiders S, et al. Engulfed by glia: glial pruning in development, function, and injury across species. J. Neurosci. 2021;41:823&#x2013;833. doi: 10.1523/JNEUROSCI.1660-20.2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1660-20.2020</ArticleId><ArticleId IdType="pmc">PMC7880271</ArticleId><ArticleId IdType="pubmed">33468571</ArticleId></ArticleIdList></Reference><Reference><Citation>McLaughlin CN, Perry-Richardson JJ, Coutinho-Budd JC, Broihier HT. Dying neurons utilize innate immune signaling to prime glia for phagocytosis during development. Dev. Cell. 2019;48:506&#x2013;522. doi: 10.1016/j.devcel.2018.12.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.devcel.2018.12.019</ArticleId><ArticleId IdType="pmc">PMC6394877</ArticleId><ArticleId IdType="pubmed">30745142</ArticleId></ArticleIdList></Reference><Reference><Citation>Gouras GK, Willen K, Faideau M. The inside-out amyloid hypothesis and synapse pathology in Alzheimer&#x2019;s disease. Neurodegener. Dis. 2014;13:142&#x2013;146. doi: 10.1159/000354776.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000354776</ArticleId><ArticleId IdType="pubmed">24080821</ArticleId></ArticleIdList></Reference><Reference><Citation>Cataldo AM, Hamilton DJ, Nixon RA. Lysosomal abnormalities in degenerating neurons link neuronal compromise to senile plaque development in Alzheimer disease. Brain Res. 1994;640:68&#x2013;80. doi: 10.1016/0006-8993(94)91858-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0006-8993(94)91858-9</ArticleId><ArticleId IdType="pubmed">8004466</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, et al. Comparison of neurodegenerative pathology in transgenic mice overexpressing V717F &#x3b2;-amyloid precursor protein and Alzheimer&#x2019;s disease. J. Neurosci. 1996;16:5795&#x2013;5811. doi: 10.1523/JNEUROSCI.16-18-05795.1996.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.16-18-05795.1996</ArticleId><ArticleId IdType="pmc">PMC6578961</ArticleId><ArticleId IdType="pubmed">8795633</ArticleId></ArticleIdList></Reference><Reference><Citation>Pensalfini A, et al. Intracellular amyloid and the neuronal origin of Alzheimer neuritic plaques. Neurobiol. Dis. 2014;71:53&#x2013;61. doi: 10.1016/j.nbd.2014.07.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2014.07.011</ArticleId><ArticleId IdType="pmc">PMC4179983</ArticleId><ArticleId IdType="pubmed">25092575</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Andrea MR, Nagele RG, Wang HY, Peterson PA, Lee DH. Evidence that neurones accumulating amyloid can undergo lysis to form amyloid plaques in Alzheimer&#x2019;s disease. Histopathology. 2001;38:120&#x2013;134. doi: 10.1046/j.1365-2559.2001.01082.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2559.2001.01082.x</ArticleId><ArticleId IdType="pubmed">11207825</ArticleId></ArticleIdList></Reference><Reference><Citation>Cataldo AM, Paskevich PA, Kominami E, Nixon RA. Lysosomal hydrolases of different classes are abnormally distributed in brains of patients with Alzheimer disease. Proc. Natl Acad. Sci. USA. 1991;88:10998&#x2013;11002. doi: 10.1073/pnas.88.24.10998.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.88.24.10998</ArticleId><ArticleId IdType="pmc">PMC53060</ArticleId><ArticleId IdType="pubmed">1837142</ArticleId></ArticleIdList></Reference><Reference><Citation>Colacurcio DJ, Nixon RA. Disorders of lysosomal acidification&#x2014;the emerging role of v-ATPase in aging and neurodegenerative disease. Ageing Res. Rev. 2016;32:75&#x2013;88. doi: 10.1016/j.arr.2016.05.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arr.2016.05.004</ArticleId><ArticleId IdType="pmc">PMC5112157</ArticleId><ArticleId IdType="pubmed">27197071</ArticleId></ArticleIdList></Reference><Reference><Citation>Thinakaran G, Teplow DB, Siman R, Greenberg B, Sisodia SS. Metabolism of the &#x2018;Swedish&#x2019; amyloid precursor protein variant in neuro2a (N2a) cells. J. Biol. Chem. 1996;271:9390&#x2013;9397. doi: 10.1074/jbc.271.16.9390.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.271.16.9390</ArticleId><ArticleId IdType="pubmed">8621605</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao K, et al. Correlative memory deficits, A&#x3b2; elevation, and amyloid plaques in transgenic mice. Science. 1996;274:99&#x2013;102. doi: 10.1126/science.274.5284.99.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.274.5284.99</ArticleId><ArticleId IdType="pubmed">8810256</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakley H, et al. Intraneuronal &#x3b2;-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial alzheimer&#x2019;s disease mutations: potential factors in amyloid plaque formation. J. Neurosci. 2006;26:10129&#x2013;10140. doi: 10.1523/JNEUROSCI.1202-06.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1202-06.2006</ArticleId><ArticleId IdType="pmc">PMC6674618</ArticleId><ArticleId IdType="pubmed">17021169</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang DS, et al. Reversal of autophagy dysfunction in the TgCRND8 mouse model of Alzheimer&#x2019;s disease ameliorates amyloid pathologies and memory deficits. Brain. 2011;134:258&#x2013;277. doi: 10.1093/brain/awq341.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awq341</ArticleId><ArticleId IdType="pmc">PMC3009842</ArticleId><ArticleId IdType="pubmed">21186265</ArticleId></ArticleIdList></Reference><Reference><Citation>Cataldo AM, et al. Presenilin mutations in familial Alzheimer disease and transgenic mouse models accelerate neuronal lysosomal pathology. J. Neuropathol. Exp. Neurol. 2004;63:821&#x2013;830. doi: 10.1093/jnen/63.8.821.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnen/63.8.821</ArticleId><ArticleId IdType="pubmed">15330337</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. Office of Science and Technology Policy. Laboratory animal welfare; U.S. government principles for the utilization and care of vertebrate animals used in testing, research and training; notice. Fed. Regist. 50, 20864&#x2013;20865 (1985).</Citation><ArticleIdList><ArticleId IdType="pubmed">11655791</ArticleId></ArticleIdList></Reference><Reference><Citation>Janus C, et al. A&#x3b2; peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer&#x2019;s disease. Nature. 2000;408:979&#x2013;982. doi: 10.1038/35050110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35050110</ArticleId><ArticleId IdType="pubmed">11140685</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J-H, et al. Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer-related PS1 mutations. Cell. 2010;141:1146&#x2013;1158. doi: 10.1016/j.cell.2010.05.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2010.05.008</ArticleId><ArticleId IdType="pmc">PMC3647462</ArticleId><ArticleId IdType="pubmed">20541250</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomes I, Sierra S, Devi LA. Detection of receptor heteromerization using in situ proximity ligation assay. Curr. Protoc. Pharmacol. 2016;75:2.16.1&#x2013;2.16.31. doi: 10.1002/cpph.15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpph.15</ArticleId><ArticleId IdType="pmc">PMC5758307</ArticleId><ArticleId IdType="pubmed">27960030</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Luehmann M, et al. Rapid appearance and local toxicity of amyloid-&#x3b2; plaques in a mouse model of Alzheimer&#x2019;s disease. Nature. 2008;451:720&#x2013;724. doi: 10.1038/nature06616.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature06616</ArticleId><ArticleId IdType="pmc">PMC3264491</ArticleId><ArticleId IdType="pubmed">18256671</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">35639372</PMID><DateCompleted><Year>2022</Year><Month>07</Month><Day>13</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>79</Volume><Issue>7</Issue><PubDate><Year>2022</Year><Month>Jul</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Association of Rare APOE Missense Variants V236E and R251G With Risk of Alzheimer Disease.</ArticleTitle><Pagination><StartPage>652</StartPage><EndPage>663</EndPage><MedlinePgn>652-663</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2022.1166</ELocationID><Abstract><AbstractText Label="IMPORTANCE">The APOE &#x3b5;2 and APOE &#x3b5;4 alleles are the strongest protective and risk-increasing, respectively, genetic variants for late-onset Alzheimer disease (AD). However, the mechanisms linking APOE to AD-particularly the apoE protein's role in AD pathogenesis and how this is affected by APOE variants-remain poorly understood. Identifying missense variants in addition to APOE &#x3b5;2 and APOE &#x3b5;4 could provide critical new insights, but given the low frequency of additional missense variants, AD genetic cohorts have previously been too small to interrogate this question robustly.</AbstractText><AbstractText Label="OBJECTIVE">To determine whether rare missense variants on APOE are associated with AD risk.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">Association with case-control status was tested in a sequenced discovery sample (stage 1) and followed up in several microarray imputed cohorts as well as the UK Biobank whole-exome sequencing resource using a proxy-AD phenotype (stages 2 and 3). This study combined case-control, family-based, population-based, and longitudinal AD-related cohorts that recruited referred and volunteer participants. Stage 1 included 37&#x202f;409 nonunique participants of European or admixed European ancestry, with 11&#x202f;868 individuals with AD and 11&#x202f;934 controls passing analysis inclusion criteria. In stages 2 and 3, 475&#x202f;473 participants were considered across 8 cohorts, of which 84&#x202f;513 individuals with AD and proxy-AD and 328&#x202f;372 controls passed inclusion criteria. Selection criteria were cohort specific, and this study was performed a posteriori on individuals who were genotyped. Among the available genotypes, 76&#x202f;195 were excluded. All data were retrieved between September 2015 and November 2021 and analyzed between April and November 2021.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">In primary analyses, the AD risk associated with each missense variant was estimated, as appropriate, with either linear mixed-model regression or logistic regression. In secondary analyses, associations were estimated with age at onset using linear mixed-model regression and risk of conversion to AD using competing-risk regression.</AbstractText><AbstractText Label="RESULTS">A total of 544&#x202f;384 participants were analyzed in the primary case-control analysis; 312&#x202f;476 (57.4%) were female, and the mean (SD; range) age was 64.9 (15.2; 40-110) years. Two missense variants were associated with a 2-fold to 3-fold decreased AD risk: APOE &#x3b5;4 (R251G) (odds ratio, 0.44; 95% CI, 0.33-0.59; P&#x2009;=&#x2009;4.7&#x2009;&#xd7;&#x2009;10-8) and APOE &#x3b5;3 (V236E) (odds ratio, 0.37; 95% CI, 0.25-0.56; P&#x2009;=&#x2009;1.9&#x2009;&#xd7;&#x2009;10-6). Additionally, the cumulative incidence of AD in carriers of these variants was found to grow more slowly with age compared with noncarriers.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">In this genetic association study, a novel variant associated with AD was identified: R251G always coinherited with &#x3b5;4 on the APOE gene, which mitigates the &#x3b5;4-associated AD risk. The protective effect of the V236E variant, which is always coinherited with &#x3b5;3 on the APOE gene, was also confirmed. The location of these variants confirms that the carboxyl-terminal portion of apoE plays an important role in AD pathogenesis. The large risk reductions reported here suggest that protein chemistry and functional assays of these variants should be pursued, as they have the potential to guide drug development targeting APOE.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Le Guen</LastName><ForeName>Yann</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University, Palo Alto, California.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institut du Cerveau, Paris Brain Institute, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Belloy</LastName><ForeName>Michael E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University, Palo Alto, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grenier-Boley</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>University of Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1167-RID-AGE Facteurs de risque et d&#xe9;terminants mol&#xe9;culaires des maladies li&#xe9;es au vieillissement, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Rojas</LastName><ForeName>Itziar</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Research Center and Memory Clinic Fundaci&#xf3; ACE, Institut Catal&#xe0; de Neuroci&#xe8;ncies Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castillo-Morales</LastName><ForeName>Atahualpa</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>UKDRI@Cardiff, School of Medicine, Cardiff University, Cardiff, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jansen</LastName><ForeName>Iris</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Complex Trait Genetics, Center for Neurogenomics and Cognitive Research, Amsterdam Neuroscience, Vrije University, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nicolas</LastName><ForeName>Aude</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>University of Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1167-RID-AGE Facteurs de risque et d&#xe9;terminants mol&#xe9;culaires des maladies li&#xe9;es au vieillissement, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bellenguez</LastName><ForeName>C&#xe9;line</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>University of Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1167-RID-AGE Facteurs de risque et d&#xe9;terminants mol&#xe9;culaires des maladies li&#xe9;es au vieillissement, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dalmasso</LastName><ForeName>Carolina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Estudios en Neurociencias y Sistemas Complejos (ENyS) CONICET-HEC-UNAJ, Universidad Nacional Arturo Jauretche, Florencio Varela, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>K&#xfc;&#xe7;&#xfc;kali</LastName><ForeName>Fahri</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Complex Genetics of Alzheimer's Disease Group, VIB Center for Molecular Neurology, VIB, Antwerp, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Neurogenetics, Born-Bunge Institute, Antwerp, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eger</LastName><ForeName>Sarah J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University, Palo Alto, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rasmussen</LastName><ForeName>Katrine Laura</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>Department of Clinical Biochemistry, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thomassen</LastName><ForeName>Jesper Qvist</ForeName><Initials>JQ</Initials><AffiliationInfo><Affiliation>Department of Clinical Biochemistry, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deleuze</LastName><ForeName>Jean-Fran&#xe7;ois</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Universit&#xe9; Paris-Saclay, CEA, Centre National de Recherche en G&#xe9;nomique Humaine, Evry, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Zihuai</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University, Palo Alto, California.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Quantitative Sciences Unit, Department of Medicine, Stanford University, Palo Alto, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Napolioni</LastName><ForeName>Valerio</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>School of Biosciences and Veterinary Medicine, University of Camerino, Camerino, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amouyel</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>University of Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1167-RID-AGE Facteurs de risque et d&#xe9;terminants mol&#xe9;culaires des maladies li&#xe9;es au vieillissement, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jessen</LastName><ForeName>Frank</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cluster of Excellence Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kehoe</LastName><ForeName>Patrick G</ForeName><Initials>PG</Initials><AffiliationInfo><Affiliation>Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Duijn</LastName><ForeName>Cornelia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, ErasmusMC, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Nuffield Department of Population Health Oxford University, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsolaki</LastName><ForeName>Magda</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>1st Department of Neurology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S&#xe1;nchez-Juan</LastName><ForeName>Pascual</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Alzheimer's Centre Reina Sofia-CIEN Foundation, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sleegers</LastName><ForeName>Kristel</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Complex Genetics of Alzheimer's Disease Group, VIB Center for Molecular Neurology, VIB, Antwerp, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Neurogenetics, Born-Bunge Institute, Antwerp, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ingelsson</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Public Health and Caring Sciences / Geriatrics, Uppsala University, Uppsala, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Krembil Brain Institute, University Health Network, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine and Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rossi</LastName><ForeName>Giacomina</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hiltunen</LastName><ForeName>Mikko</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Biomedicine, University of Eastern Finland, Joensuu, Kuopio, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sims</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of Psychological Medicine and Clinical Neuroscience, School of Medicine, Cardiff University, Cardiff, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Flier</LastName><ForeName>Wiesje M</ForeName><Initials>WM</Initials><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramirez</LastName><ForeName>Alfredo</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cluster of Excellence Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital Bonn, Bonn, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, UT Health San Antonio, The University of Texas Health Science Center at San Antonio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andreassen</LastName><ForeName>Ole A</ForeName><Initials>OA</Initials><AffiliationInfo><Affiliation>NORMENT Centre, Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frikke-Schmidt</LastName><ForeName>Ruth</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Clinical Biochemistry, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Julie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>UKDRI@Cardiff, School of Medicine, Cardiff University, Cardiff, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Psychological Medicine and Clinical Neuroscience, School of Medicine, Cardiff University, Cardiff, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruiz</LastName><ForeName>Agust&#xed;n</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Research Center and Memory Clinic Fundaci&#xf3; ACE, Institut Catal&#xe0; de Neuroci&#xe8;ncies Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lambert</LastName><ForeName>Jean-Charles</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>University of Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1167-RID-AGE Facteurs de risque et d&#xe9;terminants mol&#xe9;culaires des maladies li&#xe9;es au vieillissement, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greicius</LastName><ForeName>Michael D</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University, Palo Alto, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Members of the EADB, GR@ACE, DEGESCO, DemGene, GERAD, and EADI Groups</CollectiveName></Author><Author ValidYN="Y"><LastName>Arosio</LastName><ForeName>Beatrice</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benussi</LastName><ForeName>Luisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Molecular Markers Laboratory, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boland</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Universit&#xe9; Paris-Saclay, CEA, Centre National de Recherche en G&#xe9;nomique Humaine, Evry, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borroni</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Centre for Neurodegenerative Disorders, Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caffarra</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Unit of Neurology, University of Parma, Parma, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daian</LastName><ForeName>Delphine</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Universit&#xe9; Paris-Saclay, CEA, Centre National de Recherche en G&#xe9;nomique Humaine, Evry, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daniele</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Universit&#xe0; Cattolica del Sacro Cuore, Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology Unit, IRCCS Fondazione Policlinico Universitario A. Gemelli, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Debette</LastName><ForeName>St&#xe9;phanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>University Bordeaux, Inserm, Bordeaux Population Health Research Center, Bordeaux, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Bordeaux University Hospital, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dufouil</LastName><ForeName>Carole</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Inserm, Bordeaux Population Health Research Center, UMR 1219, University of Bordeaux, ISPED, CIC 1401-EC, Universit&#xe9; de Bordeaux, Bordeaux, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CHU de Bordeaux, Pole sant&#xe9; publique, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D&#xfc;zel</LastName><ForeName>Emrah</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Cognitive Neurology and Dementia Research (IKND), Otto-von-Guericke University, Magdeburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galimberti</LastName><ForeName>Daniela</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Neurodegenerative Diseases Unit, Fondazione IRCCS Ca' Granda, Ospedale Policlinico, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giedraitis</LastName><ForeName>Vilmantas</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Public Health and Caring Sciences / Geriatrics, Uppsala University, Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grimmer</LastName><ForeName>Timo</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Technical University of Munich, School of Medicine, Klinikum rechts der Isar, Department of Psychiatry and Psychotherapy, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graff</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Unit for Hereditary Dementias, Theme Aging, Karolinska University Hospital-Solna, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gr&#xfc;nblatt</LastName><ForeName>Edna</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Child and Adolescent Psychiatry and Psychotherapy, Psychiatric University Hospital Zurich, University of Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Center Zurich, University of Zurich and ETH Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zurich Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hanon</LastName><ForeName>Olivier</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Universit&#xe9; de Paris, EA 4468, APHP, H&#xf4;pital Broca, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hausner</LastName><ForeName>Lucrezia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Geriatric Psychiatry, Central Institute of Mental Health Mannheim, Faculty Mannheim, University of Heidelberg, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heilmann-Heimbach</LastName><ForeName>Stefanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Human Genetics, University of Bonn, School of Medicine, University Hospital Bonn, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holstege</LastName><ForeName>Henne</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Genetics, VU University Medical Centre, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hort</LastName><ForeName>Jakub</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Memory Clinic, Department of Neurology, Charles University, 2nd Faculty of Medicine and Motol University Hospital, Prague, Czech Republic.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>International Clinical Research Center, St Anne's University Hospital Brno, Brno, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>J&#xfc;rgen</LastName><ForeName>Deckert</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Psychosomatics and Psychotherapy, Center of Mental Health, University Hospital of W&#xfc;rzburg, W&#xfc;rzburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuulasmaa</LastName><ForeName>Teemu</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Institute of Biomedicine, University of Eastern Finland, Joensuu, Kuopio, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Lugt</LastName><ForeName>Aad</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Radiology and Nuclear Medicine, ErasmusMC, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masullo</LastName><ForeName>Carlo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute of Neurology, Catholic University of the Sacred Heart, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mecocci</LastName><ForeName>Patrizia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institute of Gerontology and Geriatrics, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mehrabian</LastName><ForeName>Shima</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Clinic of Neurology, UH Alexandrovska, Medical University Sofia, Sofia, Bulgaria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Mendon&#xe7;a</LastName><ForeName>Alexandre</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Lisbon, Lisbon, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moebus</LastName><ForeName>Susanne</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute for Urban Public Health, University Hospital of University Duisburg-Essen, Essen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nacmias</LastName><ForeName>Benedetta</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nicolas</LastName><ForeName>Gael</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Normandie Universit&#xe9;, UNIROUEN, Inserm U1245 and CHU Rouen, Department of Genetics and CNR-MAJ, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olaso</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Universit&#xe9; Paris-Saclay, CEA, Centre National de Recherche en G&#xe9;nomique Humaine, Evry, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Papenberg</LastName><ForeName>Goran</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm University, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parnetti</LastName><ForeName>Lucilla</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Centre for Memory Disturbances, Lab of Clinical Neurochemistry, Section of Neurology, University of Perugia, Perugia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pasquier</LastName><ForeName>Florence</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Universit&#xe9; de Lille, Inserm 1172, CHU Clinical and Research Memory Research Centre (CMRR) of Distalz, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peters</LastName><ForeName>Oliver</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Freie Universit&#xe4;t Berlin, Humboldt-Universit&#xe4;t zu Berlin, and Berlin Institute of Health, Institute of Psychiatry and Psychotherapy, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pijnenburg</LastName><ForeName>Yolande A L</ForeName><Initials>YAL</Initials><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Popp</LastName><ForeName>Julius</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Old Age Psychiatry, Department of Psychiatry, Lausanne University Hospital, Lausanne, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Geriatric Psychiatry, University Hospital of Psychiatry Z&#xfc;rich, Zurich, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Regenerative Medicine, University of Z&#xfc;rich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rainero</LastName><ForeName>Innocenzo</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Neuroscience "Rita Levi Montalcini," University of Torino, Torino, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramakers</LastName><ForeName>Inez</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Maastricht University, Department of Psychiatry and Neuropsychologie, Alzheimer Center Limburg, Maastricht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Riedel-Heller</LastName><ForeName>Steffi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Social Medicine, Occupational Health and Public Health, University of Leipzig, Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scarmeas</LastName><ForeName>Nikolaos</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>1st Department of Neurology, Aiginition Hospital, National and Kapodistrian University of Athens, Medical School, Athens, Greece.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Taub Institute for Research in Alzheimer's Disease and the Aging Brain, The Gertrude H. Sergievsky Center, Department of Neurology, Columbia University, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scheltens</LastName><ForeName>Philip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scherbaum</LastName><ForeName>Norbert</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>LVR-Hospital Essen, Department of Psychiatry and Psychotherapy, Medical Faculty, University of Duisburg-Essen, Essen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Anja</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital Bonn, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seripa</LastName><ForeName>Davide</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Laboratory for Advanced Hematological Diagnostics, Department of Hematology and Stem Cell Transplant, "Vito Fazzi" Hospital, Lecce, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soininen</LastName><ForeName>Hilkka</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Institute of Clinical Medicine - Neurology, University of Eastern Finland, Kuopio, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Solfrizzi</LastName><ForeName>Vincenzo</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Interdisciplinary Department of Medicine, Geriatric Medicine and Memory Unit, University of Bari Aldo Moro, Bari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spalletta</LastName><ForeName>Gianfranco</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Laboratory of Neuropsychiatry, IRCCS Santa Lucia Foundation, Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, Texas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Squassina</LastName><ForeName>Alessio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, University of Cagliari, Cagliari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Swieten</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, ErasmusMC, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tegos</LastName><ForeName>Thomas J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>1st Department of Neurology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tremolizzo</LastName><ForeName>Lucio</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Neurology, "San Gerardo" Hospital, Monza and University of Milano-Bicocca, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verhey</LastName><ForeName>Frans</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Maastricht University, Department of Psychiatry and Neuropsychologie, Alzheimer Center Limburg, Maastricht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vyhnalek</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Memory Clinic, Department of Neurology, Charles University, 2nd Faculty of Medicine and Motol University Hospital, Prague, Czech Republic.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>International Clinical Research Center, St Anne's University Hospital Brno, Brno, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wiltfang</LastName><ForeName>Jens</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, University Medical Center Goettingen, Goettingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Goettingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurosciences and Signaling Group, Institute of Biomedicine (iBiMED), Department of Medical Sciences, University of Aveiro, Aveiro, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boada</LastName><ForeName>Merc&#xe8;</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Research Center and Memory Clinic Fundaci&#xf3; ACE, Institut Catal&#xe0; de Neuroci&#xe8;ncies Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xed;a-Gonz&#xe1;lez</LastName><ForeName>Pablo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Research Center and Memory Clinic Fundaci&#xf3; ACE, Institut Catal&#xe0; de Neuroci&#xe8;ncies Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Puerta</LastName><ForeName>Raquel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Research Center and Memory Clinic Fundaci&#xf3; ACE, Institut Catal&#xe0; de Neuroci&#xe8;ncies Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Real</LastName><ForeName>Luis M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Unidad Cl&#xed;nica de Enfermedades Infecciosas y Microbiolog&#xed;a, Hospital Universitario de Valme, Sevilla, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Depatamento de Especialidades Quir&#xfa;rgicas, Bioqu&#xed;mica e Inmunolog&#xed;a, Facultad de Medicina, Universidad de M&#xe1;laga, M&#xe1;laga, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>&#xc1;lvarez</LastName><ForeName>Victoria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Laboratorio de Gen&#xe9;tica, Hospital Universitario Central de Asturias, Oviedo, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto de Investigaci&#xf3;n Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bullido</LastName><ForeName>Mar&#xed;a J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Biolog&#xed;a Molecular Severo Ochoa (UAM-CSIC), Universidad Aut&#xf3;noma de Madrid, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto de Investigacion Sanitaria 'Hospital la Paz' (IdIPaz), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clarimon</LastName><ForeName>Jordi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, II B Sant Pau, Hospital de la Santa Creu i Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xed;a-Alberca</LastName><ForeName>Jos&#xe9; Mar&#xed;a</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Alzheimer Research Center &amp; Memory Clinic, Andalusian Institute for Neuroscience, M&#xe1;laga, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mir</LastName><ForeName>Pablo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unidad de Trastornos del Movimiento, Servicio de Neurolog&#xed;a y Neurofisiolog&#xed;a, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Roc&#xed;o/CSIC/Universidad de Sevilla, Seville, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moreno</LastName><ForeName>Fermin</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Hospital Universitario Donostia, San Sebastian, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurosciences Area, Instituto Biodonostia, San Sebastian, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pastor</LastName><ForeName>Pau</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3; Doc&#xe8;ncia i Recerca M&#xfa;tuaTerrassa, Terrassa, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory Disorders Unit, Department of Neurology, Hospital Universitari Mutua de Terrassa, Terrassa, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pi&#xf1;ol-Ripoll</LastName><ForeName>Gerard</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Unitat Trastorns Cognitius, Hospital Universitari Santa Maria de Lleida, Lleida, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institut de Recerca Biomedica de Lleida (IRBLLeida), Lleida, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Molina-Porcel</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Neurological Tissue Bank (Biobanc), Hospital Clinic IDIBAPS, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Department, Hospital Clinic, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>P&#xe9;rez-Tur</LastName><ForeName>Jordi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unitat de Gen&#xe8;tica Molecular, Institut de Biomedicina de Val&#xe8;ncia-CSIC, Valencia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unidad Mixta de Neurologia Gen&#xe8;tica, Instituto de Investigaci&#xf3;n Sanitaria La Fe, Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodr&#xed;guez-Rodr&#xed;guez</LastName><ForeName>Eloy</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology Service, Marqu&#xe9;s de Valdecilla University Hospital (University of Cantabria and IDIVAL), Santander, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Royo</LastName><ForeName>Jose Lu&#xed;s</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Depatamento de Especialidades Quir&#xfa;rgicas, Bioqu&#xed;mica e Inmunolog&#xed;a, Facultad de Medicina, Universidad de M&#xe1;laga, M&#xe1;laga, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S&#xe1;nchez-Valle</LastName><ForeName>Raquel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease and Other Cognitive Disorders Unit, Service of Neurology, Hospital Cl&#xed;nic of Barcelona, Institut d'Investigacions Biom&#xe8;diques August Pi i Sunyer, University of Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dichgans</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Stroke and Dementia Research (ISD), University Hospital, Ludwig Maximilian University of Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rujescu</LastName><ForeName>Dan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Medical University of Vienna, Department of Psychiatry and Psychotherapy, Vienna, Austria.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MC_PC_17228</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_QA137853</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/L010305/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053329">Apolipoprotein E2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>doi: 10.1001/jamaneurol.2022.0854</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053329" MajorTopicYN="N">Apolipoprotein E2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Belloy reported grants from Alzheimer&#x2019;s Association during the conduct of the study. Dr K&#xfc;&#xe7;&#xfc;kali reported grants from the Research Foundation Flanders and grants from The University of Antwerp Research Fund during the conduct of the study. Dr Borroni reported personal fees from Alector, Wave Life Sciences, and Denali outside the submitted work. Dr Debette reported grants from Leducq Foundation, European Research Council Starting Grant, French National Research Agency, Horizon 2020, and EU Joint Programme&#x2014;Neurodegenerative Disease Research during the conduct of the study. Dr Dufouil reported grants from Fondation Plan Alzheimer, French Ministry of Research, GE Healthcare, and Avid Radiopharmaceuticals/Lilly during the conduct of the study. Dr D&#xfc;zel reported grants from German Research Foundation, German Federal Ministry of Education and Research, and Human Brain Project as well as personal fees from Roche, Biogen, and neotiv GmbH outside the submitted work. Dr Grimmer reported personal fees from AbbVie, Alector, Anavex, Biogen, Eli Lilly, Functional Neuromodulation, Grifols, Iqvia, Life Molecular Imaging, Novo Nordisk, Noselab, NuiCare, Roche Diagnostics, Roche Pharma, Schwabe, Toyama, UCB, and Vivoryon outside the submitted work. Dr Graff reported grants from Swedish Medical Research Council, ALF Medicine Region Stockholm, Swedish Demensfonden, Alzheimer Foundation, Karolinska Institutet StratNeuro, and Swedish Brain Foundation during the conduct of the study. Dr Hanon reported personal fees from Bayer, Servier, Pfizer, AstraZeneca, Bristol Myers Squibb, and Boehringer outside the submitted work. Dr Heilmann-Heimbach reported personal fees from Life &amp; Brain GmbH during the conduct of the study. Dr Hort reported stock options from Alzheon outside the submitted work. Dr J&#xfc;rgen reported grants from Vogel Foundation during the conduct of the study; grants from German Research Foundation, German Federal Ministry of Education and Research, Bavarian Secretary of Commerce, and European Union outside the submitted work. Dr Boada reported personal fees from Grifols, Araclon Biotech, Roche, Biogen, Lilly, Merck, Zambon, Novo Nordisk, Bioiberica, Eisai, Servier, and Schwabe as well as grants from Grifols, La Caixa, Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red Enfermedades Neurodegenerativas, and European Federation of Pharmaceutical Industries and Associations outside the submitted work. Dr Moreno reported grants from Instituto de Salud Carlos III and Tau Consortium outside the submitted work. Dr Peters reported grants from Roche, Biogen, Eisai, and Vivoryon as well as personal fees from Roche, Biogen, Eisai, and Griffols outside the submitted work. Dr Popp reported grants from Swiss National Research Foundation during the conduct of the study. Dr Molina-Porcel reported institutional research fees from Biogen outside the submitted work. Dr Ramakers reported grants from Janssen Pharmaceuticals outside the submitted work. Dr Scarmeas reported grants from Alzheimer&#x2019;s Association, European Social Fund, European Strategic Partnership Agreement Program and Ministry for Health Greece during the conduct of the study. Dr Scheltens reported part-time employment from Lump Sum; grants from Alzheimer&#x2019;s Drug Discovery Foundation and Cure Alzheimer; is a principal investigator for UCB, Toyama, and Alzheon; and serves on the steering committee of Vivoryon and NOVO outside the submitted work. Dr Schneider reported grants from Cure Alzheimer Foundation, Verum Foundation, and MjFF Foundation outside the submitted work. Dr Spalletta reported grants from Italian Ministry of Health during the conduct of the study. Dr S&#xe1;nchez-Valle reported personal fees from Wave Pharmaceuticals and Ionis-Biogen as well as grants from Biogen and Sage Pharmaceuticals outside the submitted work. Dr Wiltfang reported personal fees from Abbott, Biogen, Boehringer-Ingelheim, Immungenetics, Janssen, Lilly, Merck Sharp &amp; Dohme, Pfizer, Roche Pharma, Actelion, Amgen, Beejing Yibai Science and Technology, and Roboscreen outside the submitted work; and had a patent for PCT/EP 2011 001724 issued and a patent for PCT/EP 2015 052945 issued. Dr Amouyel reported personal fees from Fondation Alzheimer and Genoscreen Biotech outside the submitted work. Dr Jessen reported grants from German Center for Neurodegenerative Diseases (DZNE) during the conduct of the study. Dr Sleegers reported grants from Alzheimer Research Foundation Belgium, Research Foundation Flanders, and University of Antwerp Research Fund during the conduct of the study. Dr Ingelsson reported personal fees from BioArctic AB. Dr van der Flier reported grants from Netherlands Organisation for Health Research and Development (ZonMW) European Alzheimer&#x2019;s Disease DNA Biobank during the conduct of the study; grants from Alzheimer Nederland, Hersenstichting, CardioVascular Onderzoek Nederland, Health~Holland, Topsector Life Sciences &amp; Health, Alzheimer &amp; Neuropsychiatrie Foundation, Philips, Biogen MA, Novartis-NL, Life-MI, Avid Radiopharmaceuticals, Roche BV, Fujifilm, Combinostics, Gieskes-Strijbis, Dioraphte, Edwin Bouw, Equilibrio, and Pasman outside the submitted work; has performed contract research for Biogen MA and Boehringer Ingelheim; has been an invited speaker at Boehringer Ingelheim, Biogen MA, Danone, Eisai, WebMD Neurology (Medscape), and Springer Healthcare; is consultant to Oxford Health Policy Forum CIC, Roche, and Biogen MA; participated in advisory boards of Biogen MA and Roche; was associate editor of Alzheimer, Research and Therapy in 2020/2021; and is associate editor at Brain. Dr Ramirez reported grants from Bundesministerium f&#xfc;r Bildung und Forschung and German Research Foundation (Deutsche Forschungsgemeinschaft) during the conduct of the study. Dr Andreassen reported grants from KG Jebsen Stiftelsen, South East Norway Health Authority, Research Council of Norway, and European Union Horizon 2020 during the conduct of the study as well as personal fees from HealthLytix, Lundbeck, and Sunovion outside the submitted work. Dr Ruiz reported grants from Grifols, Fundaci&#xf3;n Bancaria La Caixa, Instituto de Salud Carlos III, Joint Programming for Neurological Disease&#x2014;Precision Medicine Program, European Union Innovative Medicine Initiative, and EuroNanoMed, personal fees from Landsteiner Genmed; nonfinancial support from Araclon Biotech and Prevail Therapeutics; and has contracts with Roche, Cortexyme, Janssen outside the submitted work. Dr Greicius reported grants from the National Institutes of Health during the conduct of the study. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>31</Day><Hour>15</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>5</Month><Day>31</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35639372</ArticleId><ArticleId IdType="pmc">PMC9157381</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2022.1166</ArticleId><ArticleId IdType="pii">2793004</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bellenguez C, K&#xfc;&#xe7;&#xfc;kali F, Jansen I, et al. . New insights on the genetic etiology of Alzheimer&#x2019;s and related dementia. medRxiv. Preprint posted online December 14, 2020. doi:10.1101/2020.10.01.20200659</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.10.01.20200659</ArticleId></ArticleIdList></Reference><Reference><Citation>de Rojas I, Moreno-Grau S, Tesi N, et al. ; EADB contributors; GR@ACE study group; DEGESCO consortium; IGAP (ADGC, CHARGE, EADI, GERAD); PGC-ALZ consortia . Common variants in Alzheimer&#x2019;s disease and risk stratification by polygenic risk scores. Nat Commun. 2021;12(1):3417. doi:10.1038/s41467-021-22491-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-22491-8</ArticleId><ArticleId IdType="pmc">PMC8184987</ArticleId><ArticleId IdType="pubmed">34099642</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Risch NJ, et al. . Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet. 1994;7(2):180-184. doi:10.1038/ng0694-180</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng0694-180</ArticleId><ArticleId IdType="pubmed">7920638</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Strittmatter WJ, et al. . Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer&#x2019;s disease in late onset families. Science. 1993;261(5123):921-923. doi:10.1126/science.8346443</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.8346443</ArticleId><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Ridge PG, Hoyt KB, Boehme K, et al. ; Alzheimer&#x2019;s Disease Genetics Consortium (ADGC) . Assessment of the genetic variance of late-onset Alzheimer&#x2019;s disease. Neurobiol Aging. 2016;41:200.e13-200.e20. doi:10.1016/j.neurobiolaging.2016.02.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2016.02.024</ArticleId><ArticleId IdType="pmc">PMC4948179</ArticleId><ArticleId IdType="pubmed">27036079</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Roe CM, Xiong C, et al. . APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol. 2010;67(1):122-131. doi:10.1002/ana.21843</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21843</ArticleId><ArticleId IdType="pmc">PMC2830375</ArticleId><ArticleId IdType="pubmed">20186853</ArticleId></ArticleIdList></Reference><Reference><Citation>Castellano JM, Kim J, Stewart FR, et al. . Human apoE isoforms differentially regulate brain amyloid-&#x3b2; peptide clearance. Sci Transl Med. 2011;3(89):89ra57. doi:10.1126/scitranslmed.3002156</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3002156</ArticleId><ArticleId IdType="pmc">PMC3192364</ArticleId><ArticleId IdType="pubmed">21715678</ArticleId></ArticleIdList></Reference><Reference><Citation>Belloy ME, Napolioni V, Greicius MD. A quarter century of APOE and Alzheimer&#x2019;s disease: progress to date and the path forward. Neuron. 2019;101(5):820-838. doi:10.1016/j.neuron.2019.01.056</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2019.01.056</ArticleId><ArticleId IdType="pmc">PMC6407643</ArticleId><ArticleId IdType="pubmed">30844401</ArticleId></ArticleIdList></Reference><Reference><Citation>Mak ACY, Pullinger CR, Tang LF, et al. . Effects of the absence of apolipoprotein e on lipoproteins, neurocognitive function, and retinal function. JAMA Neurol. 2014;71(10):1228-1236. doi:10.1001/jamaneurol.2014.2011</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.2011</ArticleId><ArticleId IdType="pmc">PMC4714860</ArticleId><ArticleId IdType="pubmed">25111166</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Guen Y, Belloy ME, Eger SJ, et al. . APOE missense variant R145C is associated with increased Alzheimer&#x2019;s disease risk in African ancestry individuals with the APOE E3/E4 genotype. medRxiv. Preprint posted online October 26, 2021. doi:10.1101/2021.10.20.21265141</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.10.20.21265141</ArticleId></ArticleIdList></Reference><Reference><Citation>Arboleda-Velasquez JF, Lopera F, O&#x2019;Hare M, et al. . Resistance to autosomal dominant Alzheimer&#x2019;s disease in an APOE3 Christchurch homozygote: a case report. Nat Med. 2019;25(11):1680-1683. doi:10.1038/s41591-019-0611-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-019-0611-3</ArticleId><ArticleId IdType="pmc">PMC6898984</ArticleId><ArticleId IdType="pubmed">31686034</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Murray ME, Li X, et al. . APOE3-Jacksonville (V236E) variant reduces self-aggregation and risk of dementia. Sci Transl Med. 2021;13(613):eabc9375. doi:10.1126/scitranslmed.abc9375</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abc9375</ArticleId><ArticleId IdType="pmc">PMC8824726</ArticleId><ArticleId IdType="pubmed">34586832</ArticleId></ArticleIdList></Reference><Reference><Citation>Medway CW, Abdul-Hay S, Mims T, et al. . ApoE variant p.V236E is associated with markedly reduced risk of Alzheimer&#x2019;s disease. Mol Neurodegener. 2014;9(1):11. doi:10.1186/1750-1326-9-11</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-9-11</ArticleId><ArticleId IdType="pmc">PMC3995879</ArticleId><ArticleId IdType="pubmed">24607147</ArticleId></ArticleIdList></Reference><Reference><Citation>Taliun D, Harris DN, Kessler MD, et al. ; NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium . Sequencing of 53,831 diverse genomes from the NHLBI TOPMed program. Nature. 2021;590(7845):290-299. doi:10.1038/s41586-021-03205-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03205-y</ArticleId><ArticleId IdType="pmc">PMC7875770</ArticleId><ArticleId IdType="pubmed">33568819</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasmussen KL, Tybjaerg-Hansen A, Nordestgaard BG, Frikke-Schmidt R. APOE and dementia&#x2014;resequencing and genotyping in 105,597 individuals. Alzheimers Dement. 2020;16(12):1624-1637. doi:10.1002/alz.12165</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.12165</ArticleId><ArticleId IdType="pmc">PMC7984319</ArticleId><ArticleId IdType="pubmed">32808727</ArticleId></ArticleIdList></Reference><Reference><Citation>Beecham GW, Bis JC, Martin ER, et al. . The Alzheimer&#x2019;s Disease Sequencing Project: study design and sample selection. Neurol Genet. 2017;3(5):e194. doi:10.1212/NXG.0000000000000194</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXG.0000000000000194</ArticleId><ArticleId IdType="pmc">PMC5646177</ArticleId><ArticleId IdType="pubmed">29184913</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiner MW, Aisen PS, Jack CR Jr, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . The Alzheimer&#x2019;s Disease Neuroimaging Initiative: progress report and future plans. Alzheimers Dement. 2010;6(3):202-11.e7. doi:10.1016/j.jalz.2010.03.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2010.03.007</ArticleId><ArticleId IdType="pmc">PMC2927112</ArticleId><ArticleId IdType="pubmed">20451868</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Buchman AS, Barnes LL, Boyle PA, Wilson RS. Overview and findings from the Rush Memory and Aging Project. Curr Alzheimer Res. 2012;9(6):646-663. doi:10.2174/156720512801322663</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156720512801322663</ArticleId><ArticleId IdType="pmc">PMC3439198</ArticleId><ArticleId IdType="pubmed">22471867</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunkle BW, Grenier-Boley B, Sims R, et al. ; Alzheimer Disease Genetics Consortium (ADGC); European Alzheimer&#x2019;s Disease Initiative (EADI); Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium (CHARGE); Genetic and Environmental Risk in AD/Defining Genetic, Polygenic and Environmental Risk for Alzheimer&#x2019;s Disease Consortium (GERAD/PERADES) . Genetic meta-analysis of diagnosed Alzheimer&#x2019;s disease identifies new risk loci and implicates A&#x3b2;, tau, immunity and lipid processing. Nat Genet. 2019;51(3):414-430. doi:10.1038/s41588-019-0358-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-019-0358-2</ArticleId><ArticleId IdType="pmc">PMC6463297</ArticleId><ArticleId IdType="pubmed">30820047</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunkle BW, Schmidt M, Klein HU, et al. ; Writing Group for the Alzheimer&#x2019;s Disease Genetics Consortium (ADGC) . Novel Alzheimer disease risk loci and pathways in African American individuals using the African Genome Resources Panel: a meta-analysis. JAMA Neurol. 2021;78(1):102-113. doi:10.1001/jamaneurol.2020.3536</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2020.3536</ArticleId><ArticleId IdType="pmc">PMC7573798</ArticleId><ArticleId IdType="pubmed">33074286</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK: rising to the challenge of larger and richer datasets. Gigascience. 2015;4(1):7. doi:10.1186/s13742-015-0047-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13742-015-0047-8</ArticleId><ArticleId IdType="pmc">PMC4342193</ArticleId><ArticleId IdType="pubmed">25722852</ArticleId></ArticleIdList></Reference><Reference><Citation>Karczewski KJ, Francioli LC, Tiao G, et al. ; Genome Aggregation Database Consortium . The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2020;581(7809):434-443. doi:10.1038/s41586-020-2308-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2308-7</ArticleId><ArticleId IdType="pmc">PMC7334197</ArticleId><ArticleId IdType="pubmed">32461654</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Guen Y, Belloy ME, Napolioni V, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . A novel age-informed approach for genetic association analysis in Alzheimer&#x2019;s disease. Alzheimers Res Ther. 2021;13(1):72. doi:10.1186/s13195-021-00808-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-021-00808-5</ArticleId><ArticleId IdType="pmc">PMC8017764</ArticleId><ArticleId IdType="pubmed">33794991</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Guen Y, Napolioni V, Belloy ME, et al. . Common X-chromosome variants are associated with Parkinson disease risk. Ann Neurol. 2021;90(1):22-34. doi:10.1002/ana.26051</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.26051</ArticleId><ArticleId IdType="pmc">PMC8601399</ArticleId><ArticleId IdType="pubmed">33583074</ArticleId></ArticleIdList></Reference><Reference><Citation>Manichaikul A, Mychaleckyj JC, Rich SS, Daly K, Sale M, Chen WM. Robust relationship inference in genome-wide association studies. Bioinformatics. 2010;26(22):2867-2873. doi:10.1093/bioinformatics/btq559</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btq559</ArticleId><ArticleId IdType="pmc">PMC3025716</ArticleId><ArticleId IdType="pubmed">20926424</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen CY, Pollack S, Hunter DJ, Hirschhorn JN, Kraft P, Price AL. Improved ancestry inference using weights from external reference panels. Bioinformatics. 2013;29(11):1399-1406. doi:10.1093/bioinformatics/btt144</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btt144</ArticleId><ArticleId IdType="pmc">PMC3661048</ArticleId><ArticleId IdType="pubmed">23539302</ArticleId></ArticleIdList></Reference><Reference><Citation>Auton A, Brooks LD, Durbin RM, et al. ; 1000 Genomes Project Consortium . A global reference for human genetic variation. Nature. 2015;526(7571):68-74. doi:10.1038/nature15393</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature15393</ArticleId><ArticleId IdType="pmc">PMC4750478</ArticleId><ArticleId IdType="pubmed">26432245</ArticleId></ArticleIdList></Reference><Reference><Citation>Bis JC, Jian X, Kunkle BW, et al. ; Alzheimer&#x2019;s Disease Sequencing Project . Whole exome sequencing study identifies novel rare and common Alzheimer&#x2019;s-associated variants involved in immune response and transcriptional regulation. Mol Psychiatry. 2020;25(8):1859-1875. doi:10.1038/s41380-018-0112-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-018-0112-7</ArticleId><ArticleId IdType="pmc">PMC6375806</ArticleId><ArticleId IdType="pubmed">30108311</ArticleId></ArticleIdList></Reference><Reference><Citation>Gogarten SM, Sofer T, Chen H, et al. . Genetic association testing using the GENESIS R/Bioconductor package. Bioinformatics. 2019;35(24):5346-5348. doi:10.1093/bioinformatics/btz567</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btz567</ArticleId><ArticleId IdType="pmc">PMC7904076</ArticleId><ArticleId IdType="pubmed">31329242</ArticleId></ArticleIdList></Reference><Reference><Citation>Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496-509. doi:10.1080/01621459.1999.10474144</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/01621459.1999.10474144</ArticleId></ArticleIdList></Reference><Reference><Citation>Conomos MP, Miller MB, Thornton TA. Robust inference of population structure for ancestry prediction and correction of stratification in the presence of relatedness. Genet Epidemiol. 2015;39(4):276-293. doi:10.1002/gepi.21896</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/gepi.21896</ArticleId><ArticleId IdType="pmc">PMC4836868</ArticleId><ArticleId IdType="pubmed">25810074</ArticleId></ArticleIdList></Reference><Reference><Citation>Conomos MP, Laurie CA, Stilp AM, et al. . Genetic diversity and association studies in US Hispanic/Latino populations: applications in the Hispanic Community Health Study/Study of Latinos. Am J Hum Genet. 2016;98(1):165-184. doi:10.1016/j.ajhg.2015.12.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2015.12.001</ArticleId><ArticleId IdType="pmc">PMC4716704</ArticleId><ArticleId IdType="pubmed">26748518</ArticleId></ArticleIdList></Reference><Reference><Citation>Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Softw. 2010;36(3):1-48. doi:10.18637/jss.v036.i03</Citation><ArticleIdList><ArticleId IdType="doi">10.18637/jss.v036.i03</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y, Weisgraber KH, Mucke L, Mahley RW. Apolipoprotein E: diversity of cellular origins, structural and biophysical properties, and effects in Alzheimer&#x2019;s disease. J Mol Neurosci. 2004;23(3):189-204. doi:10.1385/JMN:23:3:189</Citation><ArticleIdList><ArticleId IdType="doi">10.1385/JMN:23:3:189</ArticleId><ArticleId IdType="pubmed">15181247</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y, Mahley RW. Apolipoprotein E: structure and function in lipid metabolism, neurobiology, and Alzheimer&#x2019;s diseases. Neurobiol Dis. 2014;72(pt A):3-12. doi:10.1016/j.nbd.2014.08.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2014.08.025</ArticleId><ArticleId IdType="pmc">PMC4253862</ArticleId><ArticleId IdType="pubmed">25173806</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris FM, Brecht WJ, Xu Q, et al. . Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer&#x2019;s disease-like neurodegeneration and behavioral deficits in transgenic mice. Proc Natl Acad Sci U S A. 2003;100(19):10966-10971. doi:10.1073/pnas.1434398100</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1434398100</ArticleId><ArticleId IdType="pmc">PMC196910</ArticleId><ArticleId IdType="pubmed">12939405</ArticleId></ArticleIdList></Reference><Reference><Citation>Bien-Ly N, Andrews-Zwilling Y, Xu Q, Bernardo A, Wang C, Huang Y. C-terminal-truncated apolipoprotein (apo) E4 inefficiently clears amyloid-&#x3b2; (Abeta) and acts in concert with Abeta to elicit neuronal and behavioral deficits in mice. Proc Natl Acad Sci U S A. 2011;108(10):4236-4241. doi:10.1073/pnas.1018381108</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1018381108</ArticleId><ArticleId IdType="pmc">PMC3053957</ArticleId><ArticleId IdType="pubmed">21368138</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang YA, Zhou B, Wernig M, S&#xfc;dhof TC. ApoE2, ApoE3, and ApoE4 differentially stimulate APP transcription and A&#x3b2; secretion. Cell. 2017;168(3):427-441.e21. doi:10.1016/j.cell.2016.12.044</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2016.12.044</ArticleId><ArticleId IdType="pmc">PMC5310835</ArticleId><ArticleId IdType="pubmed">28111074</ArticleId></ArticleIdList></Reference><Reference><Citation>Choy N, Raussens V, Narayanaswami V. Inter-molecular coiled-coil formation in human apolipoprotein E C-terminal domain. J Mol Biol. 2003;334(3):527-539. doi:10.1016/j.jmb.2003.09.059</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2003.09.059</ArticleId><ArticleId IdType="pubmed">14623192</ArticleId></ArticleIdList></Reference><Reference><Citation>Westerlund JA, Weisgraber KH. Discrete carboxyl-terminal segments of apolipoprotein E mediate lipoprotein association and protein oligomerization. J Biol Chem. 1993;268(21):15745-15750. doi:10.1016/S0021-9258(18)82318-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0021-9258(18)82318-3</ArticleId><ArticleId IdType="pubmed">8340399</ArticleId></ArticleIdList></Reference><Reference><Citation>Flowers SA, Rebeck GW. APOE in the normal brain. Neurobiol Dis. 2020;136:104724. doi:10.1016/j.nbd.2019.104724</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2019.104724</ArticleId><ArticleId IdType="pmc">PMC7002287</ArticleId><ArticleId IdType="pubmed">31911114</ArticleId></ArticleIdList></Reference><Reference><Citation>Dyer CA, Cistola DP, Parry GC, Curtiss LK. Structural features of synthetic peptides of apolipoprotein E that bind the LDL receptor. J Lipid Res. 1995;36(1):80-88. doi:10.1016/S0022-2275(20)39756-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-2275(20)39756-X</ArticleId><ArticleId IdType="pubmed">7706950</ArticleId></ArticleIdList></Reference><Reference><Citation>Weisgraber KH, Shinto LH. Identification of the disulfide-linked homodimer of apolipoprotein E3 in plasma. impact on receptor binding activity. J Biol Chem. 1991;266(18):12029-12034. doi:10.1016/S0021-9258(18)99060-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0021-9258(18)99060-5</ArticleId><ArticleId IdType="pubmed">2050696</ArticleId></ArticleIdList></Reference><Reference><Citation>Minami SS, Cordova A, Cirrito JR, et al. . ApoE mimetic peptide decreases Abeta production in vitro and in vivo. Mol Neurodegener. 2010;5:16. doi:10.1186/1750-1326-5-16</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-5-16</ArticleId><ArticleId IdType="pmc">PMC2890633</ArticleId><ArticleId IdType="pubmed">20406479</ArticleId></ArticleIdList></Reference><Reference><Citation>Minagawa H, Gong JS, Jung CG, et al. . Mechanism underlying apolipoprotein E (ApoE) isoform-dependent lipid efflux from neural cells in culture. J Neurosci Res. 2009;87(11):2498-2508. doi:10.1002/jnr.22073</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.22073</ArticleId><ArticleId IdType="pmc">PMC3065888</ArticleId><ArticleId IdType="pubmed">19326444</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao N, Liu CC, Qiao W, Bu G. Apolipoprotein E, receptors, and modulation of Alzheimer&#x2019;s disease. Biol Psychiatry. 2018;83(4):347-357. doi:10.1016/j.biopsych.2017.03.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopsych.2017.03.003</ArticleId><ArticleId IdType="pmc">PMC5599322</ArticleId><ArticleId IdType="pubmed">28434655</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams T, Borchelt DR, Chakrabarty P. Therapeutic approaches targeting apolipoprotein E function in Alzheimer&#x2019;s disease. Mol Neurodegener. 2020;15(1):8. doi:10.1186/s13024-020-0358-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-020-0358-9</ArticleId><ArticleId IdType="pmc">PMC6995170</ArticleId><ArticleId IdType="pubmed">32005122</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35639398</PMID><DateCompleted><Year>2022</Year><Month>07</Month><Day>13</Day></DateCompleted><DateRevised><Year>2025</Year><Month>01</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>79</Volume><Issue>7</Issue><PubDate><Year>2022</Year><Month>Jul</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Rare APOE Missense Variants-Can We Overcome APOE &#x3b5;4 and Alzheimer Disease Risk?</ArticleTitle><Pagination><StartPage>649</StartPage><EndPage>651</EndPage><MedlinePgn>649-651</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2022.0854</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rabinovici</LastName><ForeName>Gil D</ForeName><Initials>GD</Initials><AffiliationInfo><Affiliation>Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory and Aging Center, University of California, San Francisco, San Francisco.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Associate Editor, JAMA Neurology.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dubal</LastName><ForeName>Dena B</ForeName><Initials>DB</Initials><AffiliationInfo><Affiliation>Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Associate Editor, JAMA Neurology.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS092918</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="Y">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>31</Day><Hour>15</Hour><Minute>54</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35639398</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2022.0854</ArticleId><ArticleId IdType="pii">2793005</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35648810</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>03</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>647</Issue><PubDate><Year>2022</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>Reversal of synapse loss in Alzheimer mouse models by targeting mGluR5 to prevent synaptic tagging by C1Q.</ArticleTitle><Pagination><StartPage>eabi8593</StartPage><MedlinePgn>eabi8593</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.abi8593</ELocationID><Abstract><AbstractText>Microglia-mediated synaptic loss contributes to the development of cognitive impairments in Alzheimer's disease (AD). However, the basis for this immune-mediated attack on synapses remains to be elucidated. Treatment with the metabotropic glutamate receptor 5 (mGluR5) silent allosteric modulator (SAM), BMS-984923, prevents &#x3b2;-amyloid oligomer-induced aberrant synaptic signaling while preserving physiological glutamate response. Here, we show that oral BMS-984923 effectively occupies brain mGluR5 sites visualized by [<sup>18</sup>F]FPEB positron emission tomography (PET) at doses shown to be safe in rodents and nonhuman primates. In aged mouse models of AD (<i>APPswe/PS1</i>&#x394;<i>E9</i> overexpressing transgenic and <i>App<sup>NL-G-F</sup></i>/<i>hMapt</i> double knock-in), SAM treatment fully restored synaptic density as measured by [<sup>18</sup>F]SynVesT-1 PET for SV2A and by histology, and the therapeutic benefit persisted after drug washout. Phospho-TAU accumulation in double knock-in mice was also reduced by SAM treatment. Single-nuclei transcriptomics demonstrated that SAM treatment in both models normalized expression patterns to a far greater extent in neurons than glia. Last, treatment prevented synaptic localization of the complement component C1Q and synaptic engulfment in AD mice. Thus, selective modulation of mGluR5 reversed neuronal gene expression changes to protect synapses from damage by microglial mediators in rodents.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Spurrier</LastName><ForeName>Joshua</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-6267-7231</Identifier><AffiliationInfo><Affiliation>Cellular Neuroscience, Neurodegeneration and Repair Program, Departments of Neurology and Neuroscience, Yale University School of Medicine, New Haven, CT 06510, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nicholson</LastName><ForeName>LaShae</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-5171-181X</Identifier><AffiliationInfo><Affiliation>Cellular Neuroscience, Neurodegeneration and Repair Program, Departments of Neurology and Neuroscience, Yale University School of Medicine, New Haven, CT 06510, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fang</LastName><ForeName>Xiaotian T</ForeName><Initials>XT</Initials><Identifier Source="ORCID">0000-0001-9706-1122</Identifier><AffiliationInfo><Affiliation>Yale PET Center, Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT 06510, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stoner</LastName><ForeName>Austin J</ForeName><Initials>AJ</Initials><Identifier Source="ORCID">0000-0002-3788-9347</Identifier><AffiliationInfo><Affiliation>Cellular Neuroscience, Neurodegeneration and Repair Program, Departments of Neurology and Neuroscience, Yale University School of Medicine, New Haven, CT 06510, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toyonaga</LastName><ForeName>Takuya</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-0369-8294</Identifier><AffiliationInfo><Affiliation>Yale PET Center, Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT 06510, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holden</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Yale PET Center, Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT 06510, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siegert</LastName><ForeName>Timothy R</ForeName><Initials>TR</Initials><Identifier Source="ORCID">0000-0002-3055-443X</Identifier><AffiliationInfo><Affiliation>Allyx Therapeutics Inc., New Haven, CT 06513, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laird</LastName><ForeName>William</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Cellular Neuroscience, Neurodegeneration and Repair Program, Departments of Neurology and Neuroscience, Yale University School of Medicine, New Haven, CT 06510, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Allnutt</LastName><ForeName>Mary Alice</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Cellular Neuroscience, Neurodegeneration and Repair Program, Departments of Neurology and Neuroscience, Yale University School of Medicine, New Haven, CT 06510, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiasseu</LastName><ForeName>Marius</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Cellular Neuroscience, Neurodegeneration and Repair Program, Departments of Neurology and Neuroscience, Yale University School of Medicine, New Haven, CT 06510, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brody</LastName><ForeName>A Harrison</ForeName><Initials>AH</Initials><Identifier Source="ORCID">0000-0001-9655-6713</Identifier><AffiliationInfo><Affiliation>Cellular Neuroscience, Neurodegeneration and Repair Program, Departments of Neurology and Neuroscience, Yale University School of Medicine, New Haven, CT 06510, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takahashi</LastName><ForeName>Hideyuki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Cellular Neuroscience, Neurodegeneration and Repair Program, Departments of Neurology and Neuroscience, Yale University School of Medicine, New Haven, CT 06510, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nies</LastName><ForeName>Sarah Helena</ForeName><Initials>SH</Initials><Identifier Source="ORCID">0000-0002-5619-1454</Identifier><AffiliationInfo><Affiliation>Cellular Neuroscience, Neurodegeneration and Repair Program, Departments of Neurology and Neuroscience, Yale University School of Medicine, New Haven, CT 06510, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate School of Cellular and Molecular Neuroscience, University of T&#xfc;bingen, T&#xfc;bingen 72074, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>P&#xe9;rez-Ca&#xf1;am&#xe1;s</LastName><ForeName>Azucena</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-3635-6298</Identifier><AffiliationInfo><Affiliation>Cellular Neuroscience, Neurodegeneration and Repair Program, Departments of Neurology and Neuroscience, Yale University School of Medicine, New Haven, CT 06510, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sadasivam</LastName><ForeName>Pragalath</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Yale PET Center, Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT 06510, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Supum</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-5017-9032</Identifier><AffiliationInfo><Affiliation>Yale PET Center, Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT 06510, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Songye</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-6096-8756</Identifier><AffiliationInfo><Affiliation>Yale PET Center, Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT 06510, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Le</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-4860-831X</Identifier><AffiliationInfo><Affiliation>Cellular Neuroscience, Neurodegeneration and Repair Program, Departments of Neurology and Neuroscience, Yale University School of Medicine, New Haven, CT 06510, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Yiyun H</ForeName><Initials>YH</Initials><AffiliationInfo><Affiliation>Yale PET Center, Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT 06510, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carson</LastName><ForeName>Richard E</ForeName><Initials>RE</Initials><Identifier Source="ORCID">0000-0002-9338-7966</Identifier><AffiliationInfo><Affiliation>Yale PET Center, Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT 06510, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cai</LastName><ForeName>Zhengxin</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0002-2005-6760</Identifier><AffiliationInfo><Affiliation>Yale PET Center, Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT 06510, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strittmatter</LastName><ForeName>Stephen M</ForeName><Initials>SM</Initials><Identifier Source="ORCID">0000-0001-8188-3092</Identifier><AffiliationInfo><Affiliation>Cellular Neuroscience, Neurodegeneration and Repair Program, Departments of Neurology and Neuroscience, Yale University School of Medicine, New Haven, CT 06510, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>F31 AG066483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG066165</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001863</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 NS041228</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066508</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG058608</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG034924</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG070926</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 AG074015</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG069921</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 NS007224</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064529">Receptor, Metabotropic Glutamate 5</NameOfSubstance></Chemical><Chemical><RegistryNumber>80295-33-6</RegistryNumber><NameOfSubstance UI="D015922">Complement C1q</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2022 Aug;18(8):453. doi: 10.1038/s41582-022-00691-0.</RefSource><PMID Version="1">35725818</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015922" MajorTopicYN="N">Complement C1q</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064529" MajorTopicYN="Y">Receptor, Metabotropic Glutamate 5</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>1</Day><Hour>14</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>6</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35648810</ArticleId><ArticleId IdType="mid">NIHMS1839242</ArticleId><ArticleId IdType="pmc">PMC9554345</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.abi8593</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jack CR Jr., Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, Holtzman DM, Jagust W, Jessen F, Karlawish J, Liu E, Molinuevo JL, Montine T, Phelps C, Rankin KP, Rowe CC, Scheltens P, Siemers E, Snyder HM, Sperling R, NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 14, 535&#x2013;562 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5958625</ArticleId><ArticleId IdType="pubmed">29653606</ArticleId></ArticleIdList></Reference><Reference><Citation>Long JM, Holtzman DM, Alzheimer disease: An update on pathobiology and treatment strategies. Cell 179, 312&#x2013;339 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6778042</ArticleId><ArticleId IdType="pubmed">31564456</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B, Karran E, The cellular phase of Alzheimer's disease. Cell 164, 603&#x2013;615 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26871627</ArticleId></ArticleIdList></Reference><Reference><Citation>Pimenova AA, Raj T, Goate AM, Untangling genetic risk for Alzheimer's disease. Biol. Psychiatry 83, 300&#x2013;310 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5699970</ArticleId><ArticleId IdType="pubmed">28666525</ArticleId></ArticleIdList></Reference><Reference><Citation>McDade E, Wang G, Gordon BA, Hassenstab J, Benzinger TLS, Buckles V, Fagan AM, Holtzman DM, Cairns NJ, Goate AM, Marcus DS, Morris JC, Paumier K, Xiong C, Allegri R, Berman SB, Klunk W, Noble J, Ringman J, Ghetti B, Farlow M, Sperling RA, Chhatwal J, Salloway S, Graff-Radford NR, Schofield PR, Masters C, Rossor MN, Fox NC, Levin J, Jucker M, Bateman RJ; Dominantly Inherited Alzheimer Network, Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease. Neurology 91, e1295&#x2013;e1306 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6177272</ArticleId><ArticleId IdType="pubmed">30217935</ArticleId></ArticleIdList></Reference><Reference><Citation>Deczkowska A, Weiner A, Amit I, The physiology, pathology, and potential therapeutic applications of the TREM2 signaling pathway. Cell 181, 1207&#x2013;1217 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32531244</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong S, Beja-Glasser VF, Nfonoyim BM, Frouin A, Li S, Ramakrishnan S, Merry KM, Shi Q, Rosenthal A, Barres BA, Lemere CA, Selkoe DJ, Stevens B, Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science 352, 712&#x2013;716 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5094372</ArticleId><ArticleId IdType="pubmed">27033548</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheff SW, DeKosky ST, Price DA, Quantitative assessment of cortical synaptic density in Alzheimer's disease. Neurobiol. Aging 11, 29&#x2013;37 (1990).</Citation><ArticleIdList><ArticleId IdType="pubmed">2325814</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheff SW, Price DA, Schmitt FA, Mufson EJ, Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment. Neurobiol. Aging 27, 1372&#x2013;1384 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16289476</ArticleId></ArticleIdList></Reference><Reference><Citation>Mecca AP, Chen MK, O'Dell RS, Naganawa M, Toyonaga T, Godek TA, Harris JE, Bartlett HH, Zhao W, Nabulsi NB, Wyk BCV, Varma P, Arnsten AFT, Huang Y, Carson RE, van Dyck CH, In vivo measurement of widespread synaptic loss in Alzheimer's disease with SV2A PET. Alzheimers Dement. 16, 974&#x2013;982 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7383876</ArticleId><ArticleId IdType="pubmed">32400950</ArticleId></ArticleIdList></Reference><Reference><Citation>Colom-Cadena M, Spires-Jones T, Zetterberg H, Blennow K, Caggiano A, DeKosky ST, Fillit H, Harrison JE, Schneider LS, Scheltens P, de Haan W, Grundman M, van Dyck CH, Izzo NJ, Catalano SM; Synaptic Health Endpoints Working Group, The clinical promise of biomarkers of synapse damage or loss in Alzheimer&#x2019;s disease. Alzheimers Res. Ther 12, 21 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7053087</ArticleId><ArticleId IdType="pubmed">32122400</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen MK, Mecca AP, Naganawa M, Finnema SJ, Toyonaga T, Lin SF, Najafzadeh S, Ropchan J, Lu Y, McDonald JW, Michalak HR, Nabulsi NB, Arnsten AFT, Huang Y, Carson RE, van Dyck CH, Assessing synaptic density in Alzheimer disease with synaptic vesicle glycoprotein 2A positron emission tomographic imaging. JAMA Neurol. 75, 1215&#x2013;1224 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6233853</ArticleId><ArticleId IdType="pubmed">30014145</ArticleId></ArticleIdList></Reference><Reference><Citation>Nabulsi NB, Mercier J, Holden D, Carre S, Najafzadeh S, Vandergeten MC, Lin SF, Deo A, Price N, Wood M, Lara-Jaime T, Montel F, Laruelle M, Carson RE, Hannestad J, Huang Y, Synthesis and preclinical evaluation of 11C-UCB-J as a PET tracer for imaging the synaptic vesicle glycoprotein 2A in the brain. J. Nucl. Med 57, 777&#x2013;784 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26848175</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA, Copeland NG, Lee MK, Younkin LH, Wagner SL, Younkin SG, Borchelt DR, Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: Evidence for augmentation of a 42-specific gamma secretase. Hum.Mol. Genet 13, 159&#x2013;170 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">14645205</ArticleId></ArticleIdList></Reference><Reference><Citation>Toyonaga T, Smith LM, Finnema SJ, Gallezot JD, Naganawa M, Bini J, Mulnix T, Cai Z, Ropchan J, Huang Y, Strittmatter SM, Carson RE, In vivo synaptic density imaging with 11C-UCB-J detects treatment effects of saracatinib in a mouse model of Alzheimer disease. J. Nucl. Med 60, 1780&#x2013;1786 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6894376</ArticleId><ArticleId IdType="pubmed">31101744</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadasivam P, Fang XT, Toyonaga T, Lee S, Xu Y, Zheng MQ, Spurrier J, Huang Y, Strittmatter SM, Carson RE, Cai Z, Quantification of SV2A binding in rodent brain using [18F]SynVesT-1 and PET imaging. Mol. Imaging Biol 23, 372&#x2013;381 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8105262</ArticleId><ArticleId IdType="pubmed">33258040</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauren J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM, Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 457, 1128&#x2013;1132 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2748841</ArticleId><ArticleId IdType="pubmed">19242475</ArticleId></ArticleIdList></Reference><Reference><Citation>Kostylev MA, Kaufman AC, Nygaard HB, Patel P, Haas LT, Gunther EC, Vortmeyer A, Strittmatter SM, Prion-protein-interacting Amyloid-&#x3b2; oligomers of high molecular weight are tightly correlated with memory impairment in multiple Alzheimer mouse models. J. Biol. Chem 290, 17415&#x2013;17438 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4498078</ArticleId><ArticleId IdType="pubmed">26018073</ArticleId></ArticleIdList></Reference><Reference><Citation>Um JW, Nygaard HB, Heiss JK, Kostylev MA, Stagi M, Vortmeyer A, Wisniewski T, Gunther EC, Strittmatter SM, Alzheimer amyloid-&#x3b2; oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. Nat. Neurosci 15, 1227&#x2013;1235 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3431439</ArticleId><ArticleId IdType="pubmed">22820466</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith LM, Strittmatter SM, Binding sites for amyloid-&#x3b2; oligomers and synaptic toxicity. Cold Spring Harb. Perspect. Med 7, a024075 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5411685</ArticleId><ArticleId IdType="pubmed">27940601</ArticleId></ArticleIdList></Reference><Reference><Citation>Kostylev MA, Tuttle MD, Lee S, Klein LE, Takahashi H, Cox TO, Gunther EC, Zilm KW, Strittmatter SM, Liquid and hydrogel phases of PrPC linked to conformation shifts and triggered by Alzheimer's Amyloid-&#x3b2; oligomers. Mol. Cell 72, 426&#x2013;443.e12 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6226277</ArticleId><ArticleId IdType="pubmed">30401430</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S, Yadav SP, Surewicz WK, Interaction between human prion protein and amyloid-beta (Abeta) oligomers: Role of N-terminal residues. J. Biol. Chem 285, 26377&#x2013;26383 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2924066</ArticleId><ArticleId IdType="pubmed">20576610</ArticleId></ArticleIdList></Reference><Reference><Citation>Haas LT, Kostylev MA, Strittmatter SM, Therapeutic molecules and endogenous ligands regulate the interaction between brain cellular prion protein (PrPC) and metabotropic glutamate receptor 5 (mGluR5). J. Biol. Chem 289, 28460&#x2013;28477 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4192497</ArticleId><ArticleId IdType="pubmed">25148681</ArticleId></ArticleIdList></Reference><Reference><Citation>Fluharty BR, Biasini E, Stravalaci M, Sclip A, Diomede L, Balducci C, La Vitola P, Messa M, Colombo L, Forloni G, Borsello T, Gobbi M, Harris DA, An N-terminal fragment of the prion protein binds to Amyloid-&#x3b2; oligomers and inhibits their neurotoxicity in vivo. J. Biol. Chem 288, 7857&#x2013;7866 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3597823</ArticleId><ArticleId IdType="pubmed">23362282</ArticleId></ArticleIdList></Reference><Reference><Citation>Haas LT, Salazar SV, Kostylev MA, Um JW, Kaufman AC, Strittmatter SM, Metabotropic glutamate receptor 5 couples cellular prion protein to intracellular signalling in Alzheimer's disease. Brain 139, 526&#x2013;546 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4840505</ArticleId><ArticleId IdType="pubmed">26667279</ArticleId></ArticleIdList></Reference><Reference><Citation>Salazar SV, Gallardo C, Kaufman AC, Herber CS, Haas LT, Robinson S, Manson JC, Lee MK, Strittmatter SM, Conditional deletion of Prnp rescues behavioral and synaptic deficits after disease onset in transgenic Alzheimer's disease. J. Neurosci 37, 9207&#x2013;9221 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5607466</ArticleId><ArticleId IdType="pubmed">28842420</ArticleId></ArticleIdList></Reference><Reference><Citation>Gimbel DA, Nygaard HB, Coffey EE, Gunther EC, Lauren J, Gimbel ZA, Strittmatter SM, Memory impairment in transgenic Alzheimer mice requires cellular prion protein. J. Neurosci 30, 6367&#x2013;6374 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3323924</ArticleId><ArticleId IdType="pubmed">20445063</ArticleId></ArticleIdList></Reference><Reference><Citation>Corbett GT, Wang Z, Hong W, Colom-Cadena M, Rose J, Liao M, Asfaw A, Hall TC, Ding L, DeSousa A, Frosch MP, Collinge J, Harris DA, Perkinton MS, Spires-Jones TL, Young-Pearse TL, Billinton A, Walsh DM, PrP is a central player in toxicity mediated by soluble aggregates of neurodegeneration-causing proteins. Acta Neuropathol. 139, 503&#x2013;526 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7035229</ArticleId><ArticleId IdType="pubmed">31853635</ArticleId></ArticleIdList></Reference><Reference><Citation>Purro SA, Nicoll AJ, Collinge J, Prion protein as a toxic acceptor of Amyloid-&#x3b2; oligomers. Biol. Psychiatry 83, 358&#x2013;368 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29331212</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee G, Newman ST, Gard DL, Band H, Panchamoorthy G, Tau interacts with src-family non-receptor tyrosine kinases. J. Cell Sci 111(Pt. 21), 3167&#x2013;3177 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9763511</ArticleId></ArticleIdList></Reference><Reference><Citation>Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, Wolfing H, Chieng BC, Christie MJ, Napier IA, Eckert A, Staufenbiel M, Hardeman E, Gotz J, Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell 142, 387&#x2013;397 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20655099</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberson ED, Halabisky B, Yoo JW, Yao J, Chin J, Yan F, Wu T, Hamto P, Devidze N, Yu GQ, Palop JJ, Noebels JL, Mucke L, Amyloid-&#x3b2;/Fyn-Induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease. J. Neurosci 31, 700&#x2013;711 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3325794</ArticleId><ArticleId IdType="pubmed">21228179</ArticleId></ArticleIdList></Reference><Reference><Citation>Larson M, Sherman MA, Amar F, Nuvolone M, Schneider JA, Bennett DA, Aguzzi A, Lesne SE, The complex PrPc-Fyn couples human oligomeric A&#x3b2; with pathological tau changes in Alzheimer's disease. J. Neurosci 32, 16857&#x2013;16871 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3568961</ArticleId><ArticleId IdType="pubmed">23175838</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufman AC, Salazar SV, Haas LT, Yang J, Kostylev MA, Jeng AT, Robinson SA, Gunther EC, van Dyck CH, Nygaard HB, Strittmatter SM, Fyn inhibition rescues established memory and synapse loss in Alzheimer mice. Ann. Neurol 77, 953&#x2013;971 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4447598</ArticleId><ArticleId IdType="pubmed">25707991</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, DeStafano AL, Bis JC, Beecham GW, Grenier-Boley B, Russo G, Thorton-Wells TA, Jones N, Smith AV, Chouraki V, Thomas C, Ikram MA, Zelenika D, Vardarajan BN, Kamatani Y, Lin CF, Gerrish A, Schmidt H, Kunkle B, Dunstan ML, Ruiz A, Bihoreau MT, Choi SH, Reitz C, Pasquier F, Cruchaga C, Craig D, Amin N, Berr C, Lopez OL, De Jager PL, Deramecourt V, Johnston JA, Evans D, Lovestone S, Letenneur L, Moron FJ, Rubinsztein DC, Eiriksdottir G, Sleegers K, Goate AM, Fievet N, Huentelman MW, Gill M, Brown K, Kamboh MI, Keller L, Barberger-Gateau P, McGuiness B, Larson EB, Green R, Myers AJ, Dufouil C, Todd S, Wallon D, Love S, Rogaeva E, Gallacher J, George-Hyslop PS, Clarimon J, Lleo A, Bayer A, Tsuang DW, Yu L, Tsolaki M, Bossu P, Spalletta G, Proitsi P, Collinge J, Sorbi S, Sanchez-Garcia F, Fox NC, Hardy J, Naranjo MCD, Bosco P, Clarke R, Brayne C, Galimberti D, Mancuso M, Matthews F; European Alzheimer's Disease Initiative (EADI); Genetic and Environmental Risk in Alzheimer's Disease; Alzheimer's Disease Genetic Consortium; Cohorts for Heart and Aging Research in Genomic Epidemiology, Moebus S, Mecocci P, Del Zompo M, Maier W, Hampel H, Pilotto A, Bullido M, Panza F, Caffarra P, Nacmias B, Gilbert JR, Mayhaus M, Lannefelt L, Hakonarson H, Pichler S, Carrasquillo MM, Ingelsson M, Beekly D, Alvarez V, Zou F, Valladares O, Younkin SG, Coto E, Hamilton-Nelson KL, Gu W, Razquin C, Pastor P, Mateo I, Owen MJ, Faber KM, Jonsson PV, Combarros O, O'Donovan MC, Cantwell LB, Soininen H, Blacker D, Mead S, Mosley TH Jr., Bennett DA, Harris TB, Fratiglioni L, Holmes C, de Bruijn RF, Passmore P, Montine TJ, Bettens K, Rotter JI, Brice A, Morgan K, Foroud TM, Kukull WA, Hannequin D, Powell JF, Nalls MA, Ritchie K, Lunetta KL, Kauwe JS, Boerwinkle E, Riemenschneider M, Boada M, Hiltuenen M, Martin ER, Schmidt R, Rujescu D, Wang LS, Dartigues JF, Mayeux R, Tzourio C, Hofman A, Nothen MM, Graff C, Psaty BM, Jones L, Haines JL, Holmans PA, Lathrop M, Pericak-Vance MA, Launer LJ, Farrer LA, van Duijn CM, Van Broeckhoven C, Moskvina V, Seshadri S, Williams J, Schellenberg GD, Amouyel P, Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat. Genet 45, 1452&#x2013;1458 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3896259</ArticleId><ArticleId IdType="pubmed">24162737</ArticleId></ArticleIdList></Reference><Reference><Citation>Um JW, Kaufman AC, Kostylev M, Heiss JK, Stagi M, Takahashi H, Kerrisk ME, Vortmeyer A, Wisniewski T, Koleske AJ, Gunther EC, Nygaard HB, Strittmatter SM, Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer A&#x3b2; oligomer bound to cellular prion protein. Neuron 79, 887&#x2013;902 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3768018</ArticleId><ArticleId IdType="pubmed">24012003</ArticleId></ArticleIdList></Reference><Reference><Citation>Beraldo FH, Ostapchenko VG, Caetano FA, Guimaraes AL, Ferretti GD, Daude N, Bertram L, Nogueira KO, Silva JL, Westaway D, Cashman NR, Martins VR, Prado VF, Prado MA, Regulation of amyloid &#x3b2; oligomer binding to neurons and neurotoxicity by the prion protein-mGluR5 complex. J. Biol. Chem 291, 21945&#x2013;21955 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5063978</ArticleId><ArticleId IdType="pubmed">27563063</ArticleId></ArticleIdList></Reference><Reference><Citation>Haas LT, Strittmatter SM, Oligomers of amyloid &#x3b2; prevent physiological activation of the cellular prion protein-metabotropic glutamate receptor 5 complex by glutamate in Alzheimer disease. J. Biol. Chem 291, 17112&#x2013;17121 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5016115</ArticleId><ArticleId IdType="pubmed">27325698</ArticleId></ArticleIdList></Reference><Reference><Citation>Haas LT, Salazar SV, Smith LM, Zhao HR, Cox TO, Herber CS, Degnan AP, Balakrishnan A, Macor JE, Albright CF, Strittmatter SM, Silent allosteric modulation of mGluR5 maintains glutamate signaling while rescuing Alzheimer's mouse phenotypes. Cell Rep. 20, 76&#x2013;88 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5547898</ArticleId><ArticleId IdType="pubmed">28683325</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamilton A, Vasefi M, Vander Tuin C, McQuaid RJ, Anisman H, Ferguson SS, Chronic pharmacological mGluR5 inhibition prevents cognitive impairment and reduces pathogenesis in an Alzheimer disease mouse model. Cell Rep. 15, 1859&#x2013;1865 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27210751</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamilton A, Esseltine JL, DeVries RA, Cregan SP, Ferguson SS, Metabotropic glutamate receptor 5 knockout reduces cognitive impairment and pathogenesis in a mouse model of Alzheimer's disease. Mol. Brain 7, 40 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4050478</ArticleId><ArticleId IdType="pubmed">24886239</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu N-W, Nicoll AJ, Zhang D, Mably AJ, O'Malley T, Purro SA, Terry C, Collinge J, Walsh DM, Rowan MJ, mGlu5 receptors and cellular prion protein mediate amyloid-&#x3b2;-facilitated synaptic long-term depression in vivo. Nat. Commun 5, 3374 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4354159</ArticleId><ArticleId IdType="pubmed">24594908</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang D, Qi Y, Klyubin I, Ondrejcak T, Sarell CJ, Cuello AC, Collinge J, Rowan MJ, Targeting glutamatergic and cellular prion protein mechanisms of amyloid &#x3b2;-mediated persistent synaptic plasticity disruption: Longitudinal studies. Neuropharmacology 121, 231&#x2013;246 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28390893</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S, Salazar SV, Cox TO, Strittmatter SM, Pyk2 signaling through Graf1 and RhoA GTPase is required for amyloid-&#x3b2; oligomer-triggered synapse loss. J. Neurosci 39, 1910&#x2013;1929 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6407289</ArticleId><ArticleId IdType="pubmed">30626696</ArticleId></ArticleIdList></Reference><Reference><Citation>Salazar SV, Cox TO, Lee S, Brody AH, Chyung AS, Haas LT, Strittmatter SM, Alzheimer's disease risk factor Pyk2 mediates amyloid-&#x3b2;-induced synaptic dysfunction and loss. J. Neurosci 39, 758&#x2013;772 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6343652</ArticleId><ArticleId IdType="pubmed">30518596</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Walsh DM, Rowan MJ, Selkoe DJ, Anwyl R, Block of long-term potentiation by naturally secreted and synthetic amyloid beta-peptide in hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclin-dependent kinase 5, and p38 mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5. J. Neurosci 24, 3370&#x2013;3378 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6730034</ArticleId><ArticleId IdType="pubmed">15056716</ArticleId></ArticleIdList></Reference><Reference><Citation>Renner M, Lacor PN, Velasco PT, Xu J, Contractor A, Klein WL, Triller A, Deleterious effects of amyloid beta oligomers acting as an extracellular scaffold for mGluR5. Neuron 66, 739&#x2013;754 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3111138</ArticleId><ArticleId IdType="pubmed">20547131</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Wu L, Pchitskaya E, Zakharova O, Saito T, Saido T, Bezprozvanny I, Neuronal store-operated calcium entry and mushroom spine loss in amyloid precursor protein knock-in mouse model of Alzheimer's disease. J. Neurosci 35, 13275&#x2013;13286 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4588605</ArticleId><ArticleId IdType="pubmed">26424877</ArticleId></ArticleIdList></Reference><Reference><Citation>Raka F, Di Sebastiano AR, Kulhawy SC, Ribeiro FM, Godin CM, Caetano FA, Angers S, Ferguson SS, Ca2+/Calmodulin-dependent protein kinase II interacts with group I metabotropic glutamate and facilitates receptor endocytosis and ERK1/2 signaling: Role of &#x3b2;-amyloid. Mol. Brain 8, 21 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4378271</ArticleId><ArticleId IdType="pubmed">25885040</ArticleId></ArticleIdList></Reference><Reference><Citation>Overk CR, Cartier A, Shaked G, Rockenstein E, Ubhi K, Spencer B, Price DL, Patrick C, Desplats P, Masliah E, Hippocampal neuronal cells that accumulate &#x3b1;-synuclein fragments are more vulnerable to A&#x3b2; oligomer toxicity via mGluR5&#x2013;implications for dementia with Lewy bodies. Mol. Neurodegener 9, 18 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4041038</ArticleId><ArticleId IdType="pubmed">24885390</ArticleId></ArticleIdList></Reference><Reference><Citation>He Y, Wei M, Wu Y, Qin H, Li W, Ma X, Cheng J, Ren J, Shen Y, Chen Z, Sun B, Huang ED, Shen Y, Zhou YD, Amyloid &#x3b2; oligomers suppress excitatory transmitter release via presynaptic depletion of phosphatidylinositol-4,5-bisphosphate. Nat. Commun 10, 1193 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6416269</ArticleId><ArticleId IdType="pubmed">30867420</ArticleId></ArticleIdList></Reference><Reference><Citation>Abd-Elrahman KS, Hamilton A, Albaker A, Ferguson SSG, mGluR5 contribution to neuropathology in Alzheimer mice is disease stage-dependent. ACS Pharmacol. Transl. Sci 3, 334&#x2013;344 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7155195</ArticleId><ArticleId IdType="pubmed">32296772</ArticleId></ArticleIdList></Reference><Reference><Citation>Kazim SF, Chuang SC, Zhao W, Wong RK, Bianchi R, Iqbal K, Early-onset network hyperexcitability in presymptomatic Alzheimer's disease transgenic mice is suppressed by passive immunization with anti-human APP/A&#x3b2; antibody and by mGluR5 blockade. Front. Aging Neurosci 9, 71 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5364175</ArticleId><ArticleId IdType="pubmed">28392767</ArticleId></ArticleIdList></Reference><Reference><Citation>Abd-Elrahman KS, Albaker A, de Souza JM, Ribeiro FM, Schlossmacher MG, Tiberi M, Hamilton A, Ferguson SSG, A&#x3b2; oligomers induce pathophysiological mGluR5 signaling in Alzheimer's disease model mice in a sex-selective manner. Sci. Signal 13, eabd2494 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33323410</ArticleId></ArticleIdList></Reference><Reference><Citation>Porter RH, Jaeschke G, Spooren W, Ballard TM, Buttelmann B, Kolczewski S, Peters JU, Prinssen E, Wichmann J, Vieira E, Muhlemann A, Gatti S, Mutel V, Malherbe P, Fenobam: A clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity. J. Pharmacol. Exp. Ther 315, 711&#x2013;721 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16040814</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez AL, Grier MD, Jones CK, Herman EJ, Kane AS, Smith RL, Williams R, Zhou Y, Marlo JE, Days EL, Blatt TN, Jadhav S, Menon UN, Vinson PN, Rook JM, Stauffer SR, Niswender CM, Lindsley CW, Weaver CD, Conn PJ, Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity and in vivo activity in rat behavioral models of anxiolytic and antipsychotic activity. Mol. Pharmacol 78, 1105&#x2013;1123 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2993468</ArticleId><ArticleId IdType="pubmed">20923853</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell UC, Lalwani K, Hernandez L, Kinney GG, Conn PJ, Bristow LJ, The mGluR5 antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) potentiates PCP-induced cognitive deficits in rats. Psychopharmacology 175, 310&#x2013;318 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15024550</ArticleId></ArticleIdList></Reference><Reference><Citation>Abou Farha K, Bruggeman R, Balje-Volkers C, Metabotropic glutamate receptor 5 negative modulation in phase I clinical trial: Potential impact of circadian rhythm on the neuropsychiatric adverse reactions-do hallucinations matter? ISRN Psychiatry 2014, 652750 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3960763</ArticleId><ArticleId IdType="pubmed">24729909</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu YM, Jia Z, Janus C, Henderson JT, Gerlai R, Wojtowicz JM, Roder JC, Mice lacking metabotropic glutamate receptor 5 show impaired learning and reduced CA1 long-term potentiation (LTP) but normal CA3 LTP. J. Neurosci 17, 5196&#x2013;5205 (1997).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573299</ArticleId><ArticleId IdType="pubmed">9185557</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J, Zhu Y, Contractor A, Heinemann SF, mGluR5 has a critical role in inhibitory learning. J. Neurosci 29, 3676&#x2013;3684 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2746052</ArticleId><ArticleId IdType="pubmed">19321764</ArticleId></ArticleIdList></Reference><Reference><Citation>Gregory KJ, Dong EN, Meiler J, Conn PJ, Allosteric modulation of metabotropic glutamate receptors: Structural insights and therapeutic potential. Neuropharmacology 60, 66&#x2013;81 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2981682</ArticleId><ArticleId IdType="pubmed">20637216</ArticleId></ArticleIdList></Reference><Reference><Citation>Gregory KJ, Malosh C, Turlington M, Morrison R, Vinson P, Daniels JS, Jones C, Niswender CM, Conn PJ, Lindsley CW, Stauffer SR, in Probe Reports from the NIH Molecular Libraries Program (National Center for Biotechnology Information, 2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">21433368</ArticleId></ArticleIdList></Reference><Reference><Citation>Gregory KJ, Noetzel MJ, Rook JM, Vinson PN, Stauffer SR, Rodriguez AL, Emmitte KA, Zhou Y, Chun AC, Felts AS, Chauder BA, Lindsley CW, Niswender CM, Conn PJ, Investigating metabotropic glutamate receptor 5 allosteric modulator cooperativity, affinity, and agonism: Enriching structure-function studies and structure-activity relationships. Mol. Pharmacol 82, 860&#x2013;875 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3477233</ArticleId><ArticleId IdType="pubmed">22863693</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito T, Matsuba Y, Mihira N, Takano J, Nilsson P, Itohara S, Iwata N, Saido TC, Single App knock-in mouse models of Alzheimer's disease. Nat. Neurosci 17, 661&#x2013;663 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24728269</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito T, Mihira N, Matsuba Y, Sasaguri H, Hashimoto S, Narasimhan S, Zhang B, Murayama S, Higuchi M, Lee VMY, Trojanowski JQ, Saido TC, Humanization of the entire murine Mapt gene provides a murine model of pathological human tau propagation. J. Biol. Chem 294, 12754&#x2013;12765 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6709628</ArticleId><ArticleId IdType="pubmed">31273083</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens B, Allen NJ, Vazquez LE, Howell GR, Christopherson KS, Nouri N, Micheva KD, Mehalow AK, Huberman AD, Stafford B, Sher A, Litke AM, Lambris JD, Smith SJ, John SW, Barres BA, The classical complement cascade mediates CNS synapse elimination. Cell 131, 1164&#x2013;1178 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">18083105</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang F, Snyder LB, Balakrishnan A, Brown JM, Sivarao DV, Easton A, Fernandes A, Gulianello M, Hanumegowda UM, Huang H, Huang Y, Jones KM, Li YW, Matchett M, Mattson G, Miller R, Santone KS, Senapati A, Shields EE, Simutis FJ, Westphal R, Whiterock VJ, Bronson JJ, Macor JE, Degnan AP, Discovery and preclinical evaluation of BMS-955829, a potent positive allosteric modulator of mGluR5. ACS Med. Chem. Lett 7, 289&#x2013;293 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4789665</ArticleId><ArticleId IdType="pubmed">26985317</ArticleId></ArticleIdList></Reference><Reference><Citation>Sauerbeck AD, Gangolli M, Reitz SJ, Salyards MH, Kim SH, Hemingway C, Gratuze M, Makkapati T, Kerschensteiner M, Holtzman DM, Brody DL, Kummer TT, SEQUIN multiscale imaging of mammalian central synapses reveals loss of synaptic connectivity resulting from diffuse traumatic brain injury. Neuron 107, 257&#x2013;273.e5 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7381374</ArticleId><ArticleId IdType="pubmed">32392471</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L, Selkoe DJ, Neurotoxicity of amyloid &#x3b2;-protein: Synaptic and network dysfunction. Cold Spring Harb. Perspect. Med 2, a006338 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3385944</ArticleId><ArticleId IdType="pubmed">22762015</ArticleId></ArticleIdList></Reference><Reference><Citation>Tu S, Okamoto S, Lipton SA, Xu H, Oligomeric A&#x3b2;-induced synaptic dysfunction in Alzheimer's disease. Mol. Neurodegener 9, 48 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4237769</ArticleId><ArticleId IdType="pubmed">25394486</ArticleId></ArticleIdList></Reference><Reference><Citation>Busche MA, Hyman BT, Synergy between amyloid-&#x3b2; and tau in Alzheimer's disease. Nat. Neurosci 23, 1183&#x2013;1193 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11831977</ArticleId><ArticleId IdType="pubmed">32778792</ArticleId></ArticleIdList></Reference><Reference><Citation>Mondragon-Rodriguez S, Perry G, Luna-Munoz J, Acevedo-Aquino MC, Williams S, Phosphorylation of tau protein at sites Ser(396-404) is one of the earliest events in Alzheimer's disease and Down syndrome. Neuropathol. Appl. Neurobiol 40, 121&#x2013;135 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24033439</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S, Janelidze S, Quiroz YT, Zetterberg H, Lopera F, Stomrud E, Su Y, Chen Y, Serrano GE, Leuzy A, Mattsson-Carlgren N, Strandberg O, Smith R, Villegas A, Sepulveda-Falla D, Chai X, Proctor NK, Beach TG, Blennow K, Dage JL, Reiman EM, Hansson O, Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA 324, 772&#x2013;781 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7388060</ArticleId><ArticleId IdType="pubmed">32722745</ArticleId></ArticleIdList></Reference><Reference><Citation>Bindea G, Mlecnik B, Hackl H, Charoentong P, Tosolini M, Kirilovsky A, Fridman WH, Pages F, Trajanoski Z, Galon J, ClueGO: A Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics 25, 1091&#x2013;1093 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2666812</ArticleId><ArticleId IdType="pubmed">19237447</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H, Spinrad A, Weiner A, Matcovitch-Natan O, Dvir-Szternfeld R, Ulland TK, David E, Baruch K, Lara-Astaiso D, Toth B, Itzkovitz S, Colonna M, Schwartz M, Amit I, A unique microglia type associated with restricting development of Alzheimer's disease. Cell 169, 1276&#x2013;1290.e17 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Habib N, McCabe C, Medina S, Varshavsky M, Kitsberg D, Dvir-Szternfeld R, Green G, Dionne D, Nguyen L, Marshall JL, Chen F, Zhang F, Kaplan T, Regev A, Schwartz M, Disease-associated astrocytes in Alzheimer's disease and aging. Nat. Neurosci 23, 701&#x2013;706 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9262034</ArticleId><ArticleId IdType="pubmed">32341542</ArticleId></ArticleIdList></Reference><Reference><Citation>Iram T, Ramirez-Ortiz Z, Byrne MH, Coleman UA, Kingery ND, Means TK, Frenkel D, El Khoury J, Megf10 is a receptor for C1Q that mediates clearance of apoptotic cells by astrocytes. J. Neurosci 36, 5185&#x2013;5192 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4863057</ArticleId><ArticleId IdType="pubmed">27170117</ArticleId></ArticleIdList></Reference><Reference><Citation>Henstridge CM, Tzioras M, Paolicelli RC, Glial contribution to excitatory and inhibitory synapse loss in neurodegeneration. Front. Cell. Neurosci 13, 63 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6399113</ArticleId><ArticleId IdType="pubmed">30863284</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox TO, Gunther EC, Brody AH, Chiasseu MT, Stoner A, Smith LM, Haas LT, Hammersley J, Rees G, Dosanjh B, Groves M, Gardener M, Dobson C, Vaughan T, Chessell I, Billinton A, Strittmatter SM, Anti-PrPC antibody rescues cognition and synapses in transgenic alzheimer mice. Ann. Clin. Transl. Neurol 6, 554&#x2013;574 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6414488</ArticleId><ArticleId IdType="pubmed">30911579</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunther EC, Smith LM, Kostylev MA, Cox TO, Kaufman AC, Lee S, Folta-Stogniew E, Maynard GD, Um JW, Stagi M, Heiss JK, Stoner A, Noble GP, Takahashi H, Haas LT, Schneekloth JS, Merkel J, Teran C, Naderi ZK, Supattapone S, Strittmatter SM, Rescue of transgenic Alzheimer's pathophysiology by polymeric cellular prion protein antagonists. Cell Rep. 26, 145&#x2013;158.e8 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6358723</ArticleId><ArticleId IdType="pubmed">30605671</ArticleId></ArticleIdList></Reference><Reference><Citation>Lui H, Zhang J, Makinson SR, Cahill MK, Kelley KW, Huang HY, Shang Y, Oldham MC, Martens LH, Gao F, Coppola G, Sloan SA, Hsieh CL, Kim CC, Bigio EH, Weintraub S, Mesulam MM, Rademakers R, Mackenzie IR, Seeley WW, Karydas A, Miller BL, Borroni B, Ghidoni R, Farese RV Jr., Paz JT, Barres BA, Huang EJ, Progranulin deficiency promotes circuit-specific synaptic pruning by microglia via complement activation. Cell 165, 921&#x2013;935 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4860138</ArticleId><ArticleId IdType="pubmed">27114033</ArticleId></ArticleIdList></Reference><Reference><Citation>Dejanovic B, Huntley MA, De Maziere A, Meilandt WJ, Wu T, Srinivasan K, Jiang Z, Gandham V, Friedman BA, Ngu H, Foreman O, Carano RAD, Chih B, Klumperman J, Bakalarski C, Hanson JE, Sheng M, Changes in the synaptic proteome in tauopathy and rescue of Tau-induced synapse loss by C1q antibodies. Neuron 100, 1322&#x2013;1336.e7 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30392797</ArticleId></ArticleIdList></Reference><Reference><Citation>Damisah EC, Hill RA, Rai A, Chen F, Rothlin CV, Ghosh S, Grutzendler J, Astrocytes and microglia play orchestrated roles and respect phagocytic territories during neuronal corpse removal in vivo. Sci. Adv 6, eaba3239 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7319765</ArticleId><ArticleId IdType="pubmed">32637606</ArticleId></ArticleIdList></Reference><Reference><Citation>Naganawa M, Li S, Nabulsi N, Henry S, Zheng MQ, Pracitto R, Cai Z, Gao H, Kapinos M, Labaree D, Matuskey D, Huang Y, Carson RE, First-in-human evaluation of 18F-SynVesT-1, a radioligand for PET imaging of synaptic vesicle glycoprotein 2A. J. Nucl. Med 62, 561&#x2013;567 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8049363</ArticleId><ArticleId IdType="pubmed">32859701</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S, Cai Z, Wu X, Holden D, Pracitto R, Kapinos M, Gao H, Labaree D, Nabulsi N, Carson RE, Huang Y, Synthesis and in vivo evaluation of a novel PET radiotracer for imaging of synaptic vesicle glycoprotein 2A (SV2A) in nonhuman primates. ACS Chem. Nerosci 10, 1544&#x2013;1554 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6810685</ArticleId><ArticleId IdType="pubmed">30396272</ArticleId></ArticleIdList></Reference><Reference><Citation>Mostany R, Anstey JE, Crump KL, Maco B, Knott G, Portera-Cailliau C, Altered synaptic dynamics during normal brain aging. J. Neurosci 33, 4094&#x2013;4104 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6619332</ArticleId><ArticleId IdType="pubmed">23447617</ArticleId></ArticleIdList></Reference><Reference><Citation>Heiss JK, Barrett J, Yu Z, Haas LT, Kostylev MA, Strittmatter SM, Early activation of experience-independent dendritic spine turnover in a mouse model of Alzheimer's disease. Cereb. Cortex 27, 3660&#x2013;3674 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6059166</ArticleId><ArticleId IdType="pubmed">27365298</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM, Triple-transgenic model of Alzheimer's disease with plaques and Tangles. Neuron 39, 409&#x2013;421 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12895417</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C, Gotz J, Pyk2 is a novel Tau tyrosine kinase that is regulated by the tyrosine kinase Fyn. J. Alzheimers Dis 64, 205&#x2013;221 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6004899</ArticleId><ArticleId IdType="pubmed">29782321</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathys H, Davila-Velderrain J, Peng Z, Gao F, Mohammadi S, Young JZ, Menon M, He L, Abdurrob F, Jiang X, Martorell AJ, Ransohoff RM, Hafler BP, Bennett DA, Kellis M, Tsai LH, Single-cell transcriptomic analysis of Alzheimer's disease. Nature 570, 332&#x2013;337 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6865822</ArticleId><ArticleId IdType="pubmed">31042697</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks WM, Lynch PJ, Ingle CC, Hatton A, Emson PC, Faull RL, Starkey MP, Gene expression profiles of metabolic enzyme transcripts in Alzheimer's disease. Brain Res. 1127, 127&#x2013;135 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17109828</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou M, Haque RU, Dammer EB, Duong DM, Ping L, Johnson ECB, Lah JJ, Levey AI, Seyfried NT, Targeted mass spectrometry to quantify brain-derived cerebrospinal fluid biomarkers in Alzheimer's disease. Clin. Proteomics 17, 19 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7257173</ArticleId><ArticleId IdType="pubmed">32514259</ArticleId></ArticleIdList></Reference><Reference><Citation>Cong W, Meng X, Li J, Zhang Q, Chen F, Liu W, Wang Y, Cheng S, Yao X, Yan J, Kim S, Saykin AJ, Liang H, Shen L; Alzheimer&#x2019;s Disease Neuroimaging Initiative, Genome-wide network-based pathway analysis of CSF t-tau/A&#x3b2;1-42 ratio in the ADNI cohort. BMC Genomics 18, 421 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5450240</ArticleId><ArticleId IdType="pubmed">28558704</ArticleId></ArticleIdList></Reference><Reference><Citation>Sundelof J, Sundstrom J, Hansson O, Eriksdotter-Jonhagen M, Giedraitis V, Larsson A, Degerman-Gunnarsson M, Ingelsson M, Minthon L, Blennow K, Kilander L, Basun H, Lannfelt L, Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls. J. Alzheimers Dis 21, 471&#x2013;478 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20555147</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson SF, Andreasson U, Wall M, Skoog I, Andreasen N, Wallin A, Zetterberg H, Blennow K, Reduced levels of amyloid-beta-binding proteins in cerebrospinal fluid from Alzheimer's disease patients. J. Alzheimers Dis 16, 389&#x2013;397 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19221428</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q, Ma C, Gearing M, Wang PG, Chin LS, Li L, Integrated proteomics and network analysis identifies protein hubs and network alterations in Alzheimer's disease. Acta Neuropathol. Commun 6, 19 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5831854</ArticleId><ArticleId IdType="pubmed">29490708</ArticleId></ArticleIdList></Reference><Reference><Citation>Higginbotham L, Ping L, Dammer EB, Duong DM, Zhou M, Gearing M, Hurst C, Glass JD, Factor SA, Johnson ECB, Hajjar I, Lah JJ, Levey AI, Seyfried NT, Integrated proteomics reveals brain-based cerebrospinal fluid biomarkers in asymptomatic and symptomatic Alzheimer's disease. Sci. Adv 6, (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7577712</ArticleId><ArticleId IdType="pubmed">33087358</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahajan UV, Varma VR, Griswold ME, Blackshear CT, An Y, Oommen AM, Varma S, Troncoso JC, Pletnikova O, O'Brien R, Hohman TJ, Legido-Quigley C, Thambisetty M, Dysregulation of multiple metabolic networks related to brain transmethylation and polyamine pathways in Alzheimer disease: A targeted metabolomic and transcriptomic study. PLOS Med. 17, e1003012 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6980402</ArticleId><ArticleId IdType="pubmed">31978055</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao W, Yin T, Tambini MD, D'Adamio L, The familial dementia gene ITM2b/BRI2 facilitates glutamate transmission via both presynaptic and postsynaptic mechanisms. Sci. Rep 9, 4862 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6425013</ArticleId><ArticleId IdType="pubmed">30890756</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Campo M, Teunissen CE, Role of BRI2 in dementia. J. Alzheimers Dis 40, 481&#x2013;494 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24473189</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Campo M, Hoozemans JJ, Dekkers LL, Rozemuller AJ, Korth C, Muller-Schiffmann A, Scheltens P, Blankenstein MA, Jimenez CR, Veerhuis R, Teunissen CE, BRI2-BRICHOS is increased in human amyloid plaques in early stages of Alzheimer's disease. Neurobiol. Aging 35, 1596&#x2013;1604 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24524963</ArticleId></ArticleIdList></Reference><Reference><Citation>Reese LC, Laezza F, Woltjer R, Taglialatela G, Dysregulated phosphorylation of Ca2+/calmodulin-dependent protein kinase II-&#x3b1; in the hippocampus of subjects with mild cognitive impairment and Alzheimer's disease. J. Neurochem 119, 791&#x2013;804 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4021864</ArticleId><ArticleId IdType="pubmed">21883216</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss-Coray T, Rogers J, Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. Cold Spring Harb. Perspect. Med 2, a006346 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3253025</ArticleId><ArticleId IdType="pubmed">22315714</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu T, Dejanovic B, Gandham VD, Gogineni A, Edmonds R, Schauer S, Srinivasan K, Huntley MA, Wang Y, Wang TM, Hedehus M, Barck KH, Stark M, Ngu H, Foreman O, Meilandt WJ, Elstrott J, Chang MC, Hansen DV, Carano RAD, Sheng M, Hanson JE, Complement C3 is activated in human AD brain and is required for neurodegeneration in mouse models of amyloidosis and tauopathy. Cell Rep. 28, 2111&#x2013;2123.e6 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31433986</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung WS, Clarke LE, Wang GX, Stafford BK, Sher A, Chakraborty C, Joung J, Foo LC, Thompson A, Chen C, Smith SJ, Barres BA, Astrocytes mediate synapse elimination through MEGF10 and MERTK pathways. Nature 504, 394&#x2013;400 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3969024</ArticleId><ArticleId IdType="pubmed">24270812</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehrman EK, Wilton DK, Litvina EY, Welsh CA, Chang ST, Frouin A, Walker AJ, Heller MD, Umemori H, Chen C, Stevens B, CD47 protects synapses from excess microglia-mediated pruning during development. Neuron 100, 120&#x2013;134.e6 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6314207</ArticleId><ArticleId IdType="pubmed">30308165</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler A, Hoffman P, Smibert P, Papalexi E, Satija R, Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol 36, 411&#x2013;420 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6700744</ArticleId><ArticleId IdType="pubmed">29608179</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang H, Degnan AP, Balakrishnan A, Easton A, Gulianello M, Huang Y, Matchett M, Mattson G, Miller R, Santone KS, Senapati A, Shields EE, Sivarao DV, Snyder LB, Westphal R, Whiterock VJ, Yang F, Bronson JJ, Macor JE, Oxazolidinone-based allosteric modulators of mGluR5: Defining molecular switches to create a pharmacological tool box. Bioorg. Med. Chem. Lett 26, 4165&#x2013;4169 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27496211</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheldrick GM, A short history of SHELX. Acta Crystallogr. A 64, 112&#x2013;122 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18156677</ArticleId></ArticleIdList></Reference><Reference><Citation>Bachmanov AA, Reed DR, Beauchamp GK, Tordoff MG, Food intake, water intake, and drinking spout side preference of 28 mouse strains. Behav. Genet 32, 435&#x2013;443 (2002).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1397713</ArticleId><ArticleId IdType="pubmed">12467341</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim K, Labaree D, Li S, Huang Y, Preparation of the metabotropic glutamate receptor 5 (mGluR5) PET tracer [(18)F]FPEB for human use: An automated radiosynthesis and a novel one-pot synthesis of its radiolabeling precursor. Appl. Radiat. Isot 94, 349&#x2013;354 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4253068</ArticleId><ArticleId IdType="pubmed">25305528</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandiego CM, Nabulsi N, Lin SF, Labaree D, Najafzadeh S, Huang Y, Cosgrove K, Carson RE, Studies of the metabotropic glutamate receptor 5 radioligand [11C]ABP688 with N-acetylcysteine challenge in rhesus monkeys. Synapse 67, 489&#x2013;501 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3710146</ArticleId><ArticleId IdType="pubmed">23424090</ArticleId></ArticleIdList></Reference><Reference><Citation>Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, Holden J, Houle S, Huang SC, Ichise M, Iida H, Ito H, Kimura Y, Koeppe RA, Knudsen GM, Knuuti J, Lammertsma AA, Laruelle M, Logan J, Maguire RP, Mintun MA, Morris ED, Parsey R, Price JC, Slifstein M, Sossi V, Suhara T, Votaw JR, Wong DF, Carson RE, Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J. Cereb. Blood Flow Metab 27, 1533&#x2013;1539 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17519979</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunningham VJ, Rabiner EA, Slifstein M, Laruelle M, Gunn RN, Measuring drug occupancy in the absence of a reference region: The Lassen plot re-visited. J. Cereb. Blood Flow Metab 30, 46&#x2013;50 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2949110</ArticleId><ArticleId IdType="pubmed">19738632</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma Y, Smith D, Hof PR, Foerster B, Hamilton S, Blackband SJ, Yu M, Benveniste H, In vivo 3D digital atlas database of the adult C57BL/6J mouse brain by magnetic resonance microscopy. Front. Neuroanat 2, 1 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2525925</ArticleId><ArticleId IdType="pubmed">18958199</ArticleId></ArticleIdList></Reference><Reference><Citation>Verhaeghe J, Bertoglio D, Kosten L, Thomae D, Verhoye M, Van Der Linden A, Wyffels L, Stroobants S, Wityak J, Dominguez C, Mrzljak L, Staelens S, Noninvasive relative quantification of [11C]ABP688 PET imaging in mice versus an input function measured over an arteriovenous shunt. Front. Neurol 9, 516 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6036254</ArticleId><ArticleId IdType="pubmed">30013509</ArticleId></ArticleIdList></Reference><Reference><Citation>Racine RJ, Modification of seizure activity by electrical stimulation: II. Motor seizure. Electroencephalogr. Clin. Neurophysiol 32, 281&#x2013;294 (1972).</Citation><ArticleIdList><ArticleId IdType="pubmed">4110397</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolte S, Cordelieres FP, A guided tour into subcellular colocalization analysis in light microscopy. J. Microsc 224, 213&#x2013;232 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17210054</ArticleId></ArticleIdList></Reference><Reference><Citation>McGinnis CS, Murrow LM, Gartner ZJ, DoubletFinder: Doublet detection in single-cell RNA sequencing data using artificial nearest neighbors. Cell Syst. 8, 329&#x2013;337.e4 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6853612</ArticleId><ArticleId IdType="pubmed">30954475</ArticleId></ArticleIdList></Reference><Reference><Citation>Wickham H, in Use R! (Springer International Publishing, 2016).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35675433</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>10</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>648</Issue><PubDate><Year>2022</Year><Month>Jun</Month><Day>08</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson's disease.</ArticleTitle><Pagination><StartPage>eabj2658</StartPage><MedlinePgn>eabj2658</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.abj2658</ELocationID><Abstract><AbstractText>Mutations in leucine-rich repeat kinase 2 (<i>LRRK2</i>) are the most common genetic risk factors for Parkinson's disease (PD). Increased LRRK2 kinase activity is thought to impair lysosomal function and may contribute to the pathogenesis of PD. Thus, inhibition of LRRK2 is a potential disease-modifying therapeutic strategy for PD. DNL201 is an investigational, first-in-class, CNS-penetrant, selective, ATP-competitive, small-molecule LRRK2 kinase inhibitor. In preclinical models, DNL201 inhibited LRRK2 kinase activity as evidenced by reduced phosphorylation of both LRRK2 at serine-935 (pS935) and Rab10 at threonine-73 (pT73), a direct substrate of LRRK2. Inhibition of LRRK2 by DNL201 demonstrated improved lysosomal function in cellular models of disease, including primary mouse astrocytes and fibroblasts from patients with Gaucher disease. Chronic administration of DNL201 to cynomolgus macaques at pharmacologically relevant doses was not associated with adverse findings. In phase 1 and phase 1b clinical trials in 122 healthy volunteers and in 28 patients with PD, respectively, DNL201 at single and multiple doses inhibited LRRK2 and was well tolerated at doses demonstrating LRRK2 pathway engagement and alteration of downstream lysosomal biomarkers. Robust cerebrospinal fluid penetration of DNL201 was observed in both healthy volunteers and patients with PD. These data support the hypothesis that LRRK2 inhibition has the potential to correct lysosomal dysfunction in patients with PD at doses that are generally safe and well tolerated, warranting further clinical development of LRRK2 inhibitors as a therapeutic modality for PD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jennings</LastName><ForeName>Danna</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-0753-6281</Identifier><AffiliationInfo><Affiliation>Denali Therapeutics Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huntwork-Rodriguez</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-1583-5038</Identifier><AffiliationInfo><Affiliation>Denali Therapeutics Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henry</LastName><ForeName>Anastasia G</ForeName><Initials>AG</Initials><Identifier Source="ORCID">0000-0002-8124-5477</Identifier><AffiliationInfo><Affiliation>Denali Therapeutics Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sasaki</LastName><ForeName>Jennifer C</ForeName><Initials>JC</Initials><Identifier Source="ORCID">0000-0002-5050-7200</Identifier><AffiliationInfo><Affiliation>Denali Therapeutics Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meisner</LastName><ForeName>Ren&#xe9;</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-3246-9140</Identifier><AffiliationInfo><Affiliation>Denali Therapeutics Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diaz</LastName><ForeName>Dolores</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-2821-2614</Identifier><AffiliationInfo><Affiliation>Denali Therapeutics Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Solanoy</LastName><ForeName>Hilda</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-3188-9928</Identifier><AffiliationInfo><Affiliation>Denali Therapeutics Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xiang</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0001-5134-1292</Identifier><AffiliationInfo><Affiliation>Denali Therapeutics Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Negrou</LastName><ForeName>Elvira</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-2475-7409</Identifier><AffiliationInfo><Affiliation>Denali Therapeutics Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bondar</LastName><ForeName>Vitaliy V</ForeName><Initials>VV</Initials><AffiliationInfo><Affiliation>REGENXBIO, Rockville, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghosh</LastName><ForeName>Rajarshi</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-5780-8241</Identifier><AffiliationInfo><Affiliation>Denali Therapeutics Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maloney</LastName><ForeName>Michael T</ForeName><Initials>MT</Initials><Identifier Source="ORCID">0000-0002-1805-1477</Identifier><AffiliationInfo><Affiliation>Denali Therapeutics Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Propson</LastName><ForeName>Nicholas E</ForeName><Initials>NE</Initials><AffiliationInfo><Affiliation>Denali Therapeutics Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Yuda</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-3119-1378</Identifier><AffiliationInfo><Affiliation>Denali Therapeutics Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maciuca</LastName><ForeName>Romeo D</ForeName><Initials>RD</Initials><Identifier Source="ORCID">0000-0002-5960-3901</Identifier><AffiliationInfo><Affiliation>Denali Therapeutics Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harris</LastName><ForeName>Laura</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-5895-9404</Identifier><AffiliationInfo><Affiliation>Denali Therapeutics Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kay</LastName><ForeName>Angela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Denali Therapeutics Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>LeWitt</LastName><ForeName>Peter</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-4976-4445</Identifier><AffiliationInfo><Affiliation>Henry Ford Health System, Detroit, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>King</LastName><ForeName>T Alex</ForeName><Initials>TA</Initials><Identifier Source="ORCID">0000-0003-0525-5726</Identifier><AffiliationInfo><Affiliation>Covance, Dallas, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kern</LastName><ForeName>Drew</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>University of Colorado, School of Medicine, Aurora, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ellenbogen</LastName><ForeName>Aaron</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-4086-8336</Identifier><AffiliationInfo><Affiliation>Michigan Institute for Neurological Disorders, Farmington Hills, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goodman</LastName><ForeName>Ira</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-7942-5508</Identifier><AffiliationInfo><Affiliation>Bioclinica Research, Orlando, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siderowf</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>University of Pennsylvania, Penn Neurology Pennsylvania Hospital, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aldred</LastName><ForeName>Jason</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-7441-0967</Identifier><AffiliationInfo><Affiliation>Inland Northwest Research, Spokane, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Omidvar</LastName><ForeName>Omid</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0003-0011-836X</Identifier><AffiliationInfo><Affiliation>Collaborative Neuroscience Research, Long Beach, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masoud</LastName><ForeName>Shababa T</ForeName><Initials>ST</Initials><Identifier Source="ORCID">0000-0001-6695-1667</Identifier><AffiliationInfo><Affiliation>Denali Therapeutics Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>Sonnet S</ForeName><Initials>SS</Initials><Identifier Source="ORCID">0000-0001-7189-1427</Identifier><AffiliationInfo><Affiliation>Denali Therapeutics Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arguello</LastName><ForeName>Annie</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-0313-0041</Identifier><AffiliationInfo><Affiliation>Denali Therapeutics Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Estrada</LastName><ForeName>Anthony A</ForeName><Initials>AA</Initials><Identifier Source="ORCID">0000-0001-7615-5912</Identifier><AffiliationInfo><Affiliation>Denali Therapeutics Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Vicente</LastName><ForeName>Javier</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-2498-0843</Identifier><AffiliationInfo><Affiliation>Denali Therapeutics Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sweeney</LastName><ForeName>Zachary K</ForeName><Initials>ZK</Initials><Identifier Source="ORCID">0000-0002-9852-1802</Identifier><AffiliationInfo><Affiliation>Interline Therapeutics, South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Astarita</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-6700-301X</Identifier><AffiliationInfo><Affiliation>Denali Therapeutics Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Henry Ford Health System, Detroit, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borin</LastName><ForeName>Marie T</ForeName><Initials>MT</Initials><Identifier Source="ORCID">0000-0002-4948-7943</Identifier><AffiliationInfo><Affiliation>Denali Therapeutics Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Bradley K</ForeName><Initials>BK</Initials><Identifier Source="ORCID">0000-0002-5901-5501</Identifier><AffiliationInfo><Affiliation>Denali Therapeutics Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Harvey</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-1550-5071</Identifier><AffiliationInfo><Affiliation>University of British Columbia, Vancouver, BC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Hoang</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-6608-7581</Identifier><AffiliationInfo><Affiliation>Denali Therapeutics Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scearce-Levie</LastName><ForeName>Kimberly</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0003-0568-802X</Identifier><AffiliationInfo><Affiliation>Denali Therapeutics Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ho</LastName><ForeName>Carole</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Denali Therapeutics Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Troyer</LastName><ForeName>Matthew D</ForeName><Initials>MD</Initials><Identifier Source="ORCID">0000-0002-0821-7509</Identifier><AffiliationInfo><Affiliation>Denali Therapeutics Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="C495280">LRRK2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D000071158">Leucine-Rich Repeat Serine-Threonine Protein Kinase-2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Sci Transl Med. 2022 Jun 8;14(648):eabq7374. doi: 10.1126/scitranslmed.abq7374.</RefSource><PMID Version="1">35675432</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Drug Discov. 2022 Aug;21(8):558. doi: 10.1038/d41573-022-00121-2.</RefSource><PMID Version="1">35804045</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Cell Rep Med. 2022 Oct 18;3(10):100778. doi: 10.1016/j.xcrm.2022.100778.</RefSource><PMID Version="1">36260987</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071158" MajorTopicYN="Y">Leucine-Rich Repeat Serine-Threonine Protein Kinase-2</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008247" MajorTopicYN="N">Lysosomes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="Y">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>8</Day><Hour>14</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35675433</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.abj2658</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35675432</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>10</Day></DateCompleted><DateRevised><Year>2025</Year><Month>03</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>648</Issue><PubDate><Year>2022</Year><Month>Jun</Month><Day>08</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>A step forward for LRRK2 inhibitors in Parkinson's disease.</ArticleTitle><Pagination><StartPage>eabq7374</StartPage><MedlinePgn>eabq7374</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.abq7374</ELocationID><Abstract><AbstractText>A phase 1 clinical trial for kinase inhibitors targeting LRRK2 provides the foundation for testing the efficacy of LRRK2 kinase inhibitors in Parkinson's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lewis</LastName><ForeName>Patrick A</ForeName><Initials>PA</Initials><Identifier Source="ORCID">0000-0003-4537-0489</Identifier><AffiliationInfo><Affiliation>Royal Veterinary College, London NW1 0TU, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UCL Queen Square Institute of Neurology, London WC1N 3BG, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Aligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD 20815, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="C495280">LRRK2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D000071158">Leucine-Rich Repeat Serine-Threonine Protein Kinase-2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Sci Transl Med. 2022 Jun 8;14(648):eabj2658. doi: 10.1126/scitranslmed.abj2658.</RefSource><PMID Version="1">35675433</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071158" MajorTopicYN="N">Leucine-Rich Repeat Serine-Threonine Protein Kinase-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="Y">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>8</Day><Hour>14</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35675432</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.abq7374</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35688132</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>14</Day></DateCompleted><DateRevised><Year>2022</Year><Month>08</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4172</ISSN><JournalIssue CitedMedium="Internet"><Volume>185</Volume><Issue>12</Issue><PubDate><Year>2022</Year><Month>Jun</Month><Day>09</Day></PubDate></JournalIssue><Title>Cell</Title><ISOAbbreviation>Cell</ISOAbbreviation></Journal><ArticleTitle>The Parkinson's disease protein alpha-synuclein is a modulator of processing bodies and mRNA stability.</ArticleTitle><Pagination><StartPage>2035</StartPage><EndPage>2056.e33</EndPage><MedlinePgn>2035-2056.e33</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cell.2022.05.008</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0092-8674(22)00592-X</ELocationID><Abstract><AbstractText>Alpha-synuclein (&#x3b1;S) is a conformationally plastic protein that reversibly binds to cellular membranes. It aggregates and is genetically linked to Parkinson's disease (PD). Here, we show that &#x3b1;S directly modulates processing bodies (P-bodies), membraneless organelles that function in mRNA turnover and storage. The N terminus of &#x3b1;S, but not other synucleins, dictates mutually exclusive binding either to cellular membranes or to P-bodies in the cytosol. &#x3b1;S associates with multiple decapping proteins in close proximity on the Edc4 scaffold. As &#x3b1;S pathologically accumulates, aberrant interaction with Edc4 occurs at the expense of physiologic decapping-module interactions. mRNA decay kinetics within PD-relevant pathways are correspondingly disrupted in PD patient neurons and brain. Genetic modulation of P-body components alters &#x3b1;S toxicity, and human genetic analysis lends support to the disease-relevance of these interactions. Beyond revealing an unexpected aspect of &#x3b1;S function and pathology, our data highlight the versatility of conformationally plastic proteins with high intrinsic disorder.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hallacli</LastName><ForeName>Erinc</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA; Division of Movement Disorders, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA; Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kayatekin</LastName><ForeName>Can</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nazeen</LastName><ForeName>Sumaiya</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA; Division of Movement Disorders, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA; Department of Biomedical Informatics, Harvard Medical School, Boston, MA 02115, USA; Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xiou H</ForeName><Initials>XH</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA; Division of Movement Disorders, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sheinkopf</LastName><ForeName>Zoe</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA; Division of Movement Disorders, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sathyakumar</LastName><ForeName>Shubhangi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA; Division of Movement Disorders, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sarkar</LastName><ForeName>Souvarish</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Xin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Yumanity Therapeutics, Boston, MA 02135, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dong</LastName><ForeName>Xianjun</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA; Genomics and Bioinformatics Hub, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA; Aligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD 20815, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Maio</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Pittsburgh Institute for Neurodegenerative Diseases and Department of Neurology, Pittsburgh, PA 15213, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Wen</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Computer Science and Engineering, University of Minnesota, Minneapolis, MN 55455, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keeney</LastName><ForeName>Matthew T</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Pittsburgh Institute for Neurodegenerative Diseases and Department of Neurology, Pittsburgh, PA 15213, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Felsky</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Krembil Centre for Neuroinformatics and Department of Psychiatry, University of Toronto, Toronto, ON M5T 1R8, Canada; Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto, 1 King's College Circle, Toronto, ON M5S 1A8, Canada; Division of Biostatistics, Dalla Lana School of Public Health, University of Toronto, 155 College Street, Toronto, ON M5T 3M7, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sandoe</LastName><ForeName>Jackson</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vahdatshoar</LastName><ForeName>Aazam</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA; Division of Movement Disorders, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Udeshi</LastName><ForeName>Namrata D</ForeName><Initials>ND</Initials><AffiliationInfo><Affiliation>Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mani</LastName><ForeName>D R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carr</LastName><ForeName>Steven A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lindquist</LastName><ForeName>Susan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA; Howard Hughes Medical Institute, Cambridge, MA 02142, USA; Department of Biology, MIT, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Jager</LastName><ForeName>Philip L</ForeName><Initials>PL</Initials><AffiliationInfo><Affiliation>Center for Translational &amp; Computational Neuroimmunology, Department of Neurology, Columbia University Irving Medical Center, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bartel</LastName><ForeName>David P</ForeName><Initials>DP</Initials><AffiliationInfo><Affiliation>Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA; Howard Hughes Medical Institute, Cambridge, MA 02142, USA; Department of Biology, MIT, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Myers</LastName><ForeName>Chad L</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>Department of Computer Science and Engineering, University of Minnesota, Minneapolis, MN 55455, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greenamyre</LastName><ForeName>J Timothy</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>Pittsburgh Institute for Neurodegenerative Diseases and Department of Neurology, Pittsburgh, PA 15213, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feany</LastName><ForeName>Mel B</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sunyaev</LastName><ForeName>Shamil R</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Harvard Medical School, Boston, MA 02115, USA; Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Chee Yeun</ForeName><Initials>CY</Initials><AffiliationInfo><Affiliation>Yumanity Therapeutics, Boston, MA 02135, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khurana</LastName><ForeName>Vikram</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA; Division of Movement Disorders, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA; Aligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD 20815, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Harvard Stem Cell Institute, Cambridge, MA 02138, USA. Electronic address: vkhurana@bwh.harvard.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS109209</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS112858</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH101244</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R35 GM127131</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell</MedlineTA><NlmUniqueID>0413066</NlmUniqueID><ISSNLinking>0092-8674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C507914">EDC4 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurosci. 2022 Aug;23(8):456-457. doi: 10.1038/s41583-022-00618-0.</RefSource><PMID Version="1">35789327</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="Y">Parkinson Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000088142" MajorTopicYN="N">Processing Bodies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020871" MajorTopicYN="N">RNA Stability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="Y">alpha-Synuclein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Lewy body disease</Keyword><Keyword MajorTopicYN="N">Parkinson's disease</Keyword><Keyword MajorTopicYN="N">Processing bodies</Keyword><Keyword MajorTopicYN="N">RNA-binding proteins</Keyword><Keyword MajorTopicYN="N">alpha-synuclein</Keyword><Keyword MajorTopicYN="N">iPSC</Keyword><Keyword MajorTopicYN="N">mRNA degradation</Keyword><Keyword MajorTopicYN="N">mRNA stability</Keyword><Keyword MajorTopicYN="N">rare variant</Keyword><Keyword MajorTopicYN="N">synucleinopathy</Keyword></KeywordList><CoiStatement>Declaration of interests V.K. is a co-founder of and senior advisor to DaCapo Brainscience and Yumanity Therapeutics, companies focused on CNS diseases. C.Y.C. and X.J. contributed to this work as employees of Yumanity Therapeutics.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>8</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>4</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>5</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>10</Day><Hour>18</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>8</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35688132</ArticleId><ArticleId IdType="mid">NIHMS1815371</ArticleId><ArticleId IdType="pmc">PMC9394447</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2022.05.008</ArticleId><ArticleId IdType="pii">S0092-8674(22)00592-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Andrews S (2010). FastQC: A Quality Control Tool for High Throughput Sequence Data; Available online at: http://www.bioinformatics.babraham.ac.uk/projects/fastqc/</Citation></Reference><Reference><Citation>Carlson M (2019). GO.db: A set of annotation maps describing the entire Gene Ontology. R package version 3.8.2.</Citation></Reference><Reference><Citation>J.W., and Domaszewska T (2016). tmod: an R package for general and multivariate enrichment analysis. Peerj Prepr 4, e2420v1. 10.7287/peerj.preprints.2420v1.</Citation><ArticleIdList><ArticleId IdType="doi">10.7287/peerj.preprints.2420v1</ArticleId></ArticleIdList></Reference><Reference><Citation>Adiconis X, Borges-Rivera D, Satija R, DeLuca DS, Busby MA, Berlin AM, Sivachenko A, Thompson DA, Wysoker A, Fennell T, et al. (2013). Comparative analysis of RNA sequencing methods for degraded or low-input samples. Nature Methods 10, 623&#x2013;629. 10.1038/nmeth.2483.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.2483</ArticleId><ArticleId IdType="pmc">PMC3821180</ArticleId><ArticleId IdType="pubmed">23685885</ArticleId></ArticleIdList></Reference><Reference><Citation>Anders S, Pyl PT, and Huber W (2015). HTSeq&#x2014;a Python framework to work with high-throughput sequencing data. Bioinformatics 31, 166&#x2013;169. 10.1093/bioinformatics/btu638.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btu638</ArticleId><ArticleId IdType="pmc">PMC4287950</ArticleId><ArticleId IdType="pubmed">25260700</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, et al. (2000). Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nature Publishing Group; 25, 25&#x2013;29. 10.1038/75556.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/75556</ArticleId><ArticleId IdType="pmc">PMC3037419</ArticleId><ArticleId IdType="pubmed">10802651</ArticleId></ArticleIdList></Reference><Reference><Citation>Auer PL, Johnsen JM, Johnson AD, Logsdon BA, Lange LA, Nalls MA, Zhang G, Franceschini N, Fox K, Lange EM, et al. (2012). Imputation of Exome Sequence Variants into Population- Based Samples and Blood-Cell-Trait-Associated Loci in African Americans: NHLBI GO Exome Sequencing Project. Am J Hum Genetics 91, 794&#x2013;808. 10.1016/j.ajhg.2012.08.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2012.08.031</ArticleId><ArticleId IdType="pmc">PMC3487117</ArticleId><ArticleId IdType="pubmed">23103231</ArticleId></ArticleIdList></Reference><Reference><Citation>Auluck PK, Caraveo G, and Lindquist S (2010). &#x3b1;-Synuclein: membrane interactions and toxicity in Parkinson&#x2019;s disease. Annu Rev Cell Dev Bi 26, 211&#x2013;233. 10.1146/annurev.cellbio.042308.113313.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.cellbio.042308.113313</ArticleId><ArticleId IdType="pubmed">20500090</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandres-Ciga S, Saez-Atienzar S, Kim JJ, Makarious MB, Faghri F, Diez-Fairen M, Iwaki H, Leonard H, Botia J, Ryten M, et al. (2020). Large-scale pathway specific polygenic risk and transcriptomic community network analysis identifies novel functional pathways in Parkinson disease. Acta Neuropathol 140, 341&#x2013;358. 10.1007/s00401-020-02181-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-020-02181-3</ArticleId><ArticleId IdType="pmc">PMC8096770</ArticleId><ArticleId IdType="pubmed">32601912</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbour R, Kling K, Anderson JP, Banducci K, Cole T, Diep L, Fox M, Goldstein JM, Soriano F, Seubert P, et al. (2008). Red Blood Cells Are the Major Source of Alpha-Synuclein in Blood. Neurodegener Dis 5, 55&#x2013;59. 10.1159/000112832.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000112832</ArticleId><ArticleId IdType="pubmed">18182779</ArticleId></ArticleIdList></Reference><Reference><Citation>Beatman EL, Massey A, Shives KD, Burrack KS, Chamanian M, Morrison TE, and Beckham JD (2016). Alpha-Synuclein Expression Restricts RNA Viral Infections in the Brain. J Virol 90, 2767&#x2013;2782. 10.1128/jvi.02949-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.02949-15</ArticleId><ArticleId IdType="pmc">PMC4810656</ArticleId><ArticleId IdType="pubmed">26719256</ArticleId></ArticleIdList></Reference><Reference><Citation>Beckham CJ, and Parker R (2008). P Bodies, Stress Granules, and Viral Life Cycles. Cell Host Microbe 3, 206&#x2013;212. 10.1016/j.chom.2008.03.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2008.03.004</ArticleId><ArticleId IdType="pmc">PMC2396818</ArticleId><ArticleId IdType="pubmed">18407064</ArticleId></ArticleIdList></Reference><Reference><Citation>Beecham GW, Dickson DW, Scott WK, Martin ER, Schellenberg G, Nuytemans K, Larson EB, Buxbaum JD, Trojanowski JQ, Deerlin VMV, et al. (2015). PARK10 is a major locus for sporadic neuropathologically confirmed Parkinson disease. Neurology 84, 972&#x2013;980. 10.1212/wnl.0000000000001332.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.0000000000001332</ArticleId><ArticleId IdType="pmc">PMC4352096</ArticleId><ArticleId IdType="pubmed">25663231</ArticleId></ArticleIdList></Reference><Reference><Citation>Bendapudi PK, Nazeen S, Ryu J, S&#xf6;ylemez O, Rouaisnel B, Colling M, Pasko B, Robbins A, Bouzinier M, Tomczak L, et al. (2022). Pathway-based Rare Variant Burden Analysis Identifies a Role for the Complement System in an Extreme Phenotype of Sepsis with Coagulopathy. Medrxiv 2022.02.24.22271459. 10.1101/2022.02.24.22271459.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.02.24.22271459</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Arvanitakis Z, Kelly JF, Aggarwal NT, Shah RC, and Wilson RS (2006). Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology 66, 1837&#x2013;1844. 10.1212/01.wnl.0000219668.47116.e6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000219668.47116.e6</ArticleId><ArticleId IdType="pubmed">16801647</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Arvanitakis Z, and Wilson RS (2012a). Overview and findings from the religious orders study. Current Alzheimer Research 9, 628&#x2013;645. 10.2174/156720512801322573.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156720512801322573</ArticleId><ArticleId IdType="pmc">PMC3409291</ArticleId><ArticleId IdType="pubmed">22471860</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Buchman AS, Barnes LL, Boyle PA, and Wilson RS (2012b). Overview and findings from the rush Memory and Aging Project. Current Alzheimer Research 9, 646&#x2013;663. 10.2174/156720512801322663.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156720512801322663</ArticleId><ArticleId IdType="pmc">PMC3439198</ArticleId><ArticleId IdType="pubmed">22471867</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Buchman AS, Boyle PA, Barnes LL, Wilson RS, and Schneider JA (2018). Religious Orders Study and Rush Memory and Aging Project. Journal of Alzheimer&#x2019;s Disease 64, S161&#x2013;S189. 10.3233/jad-179939.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/jad-179939</ArticleId><ArticleId IdType="pmc">PMC6380522</ArticleId><ArticleId IdType="pubmed">29865057</ArticleId></ArticleIdList></Reference><Reference><Citation>Bozic M, Caus M, Rodrigues-Diez RR, Pedraza N, Ruiz-Ortega M, Gar&#xed; E, Gallel P, Panad&#xe9;s MJ, Martinez A, Fern&#xe1;ndez E, et al. (2020). Protective role of renal proximal tubular alpha- synuclein in the pathogenesis of kidney fibrosis. Nature Communications 11, 1&#x2013;16. 10.1038/s41467-020-15732-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-15732-9</ArticleId><ArticleId IdType="pmc">PMC7181766</ArticleId><ArticleId IdType="pubmed">32327648</ArticleId></ArticleIdList></Reference><Reference><Citation>Br&#xfc;ck D, Wenning GK, Stefanova N, and Fellner L (2016). Glia and alpha-synuclein in neurodegeneration: A complex interaction. Neurobiol Dis 85, 262&#x2013;274. 10.1016/j.nbd.2015.03.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2015.03.003</ArticleId><ArticleId IdType="pmc">PMC4730552</ArticleId><ArticleId IdType="pubmed">25766679</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchman AS, Shulman JM, Nag S, Leurgans SE, Arnold SE, Morris MC, Schneider JA, and Bennett DA (2012). Nigral pathology and parkinsonian signs in elders without Parkinson disease. Annals of Neurology 71, 258&#x2013;266. 10.1002/ana.22588.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.22588</ArticleId><ArticleId IdType="pmc">PMC3367476</ArticleId><ArticleId IdType="pubmed">22367997</ArticleId></ArticleIdList></Reference><Reference><Citation>Burr&#xe9; J, Sharma M, and S&#xfc;dhof TC (2015). Definition of a molecular pathway mediating &#x3b1;-synuclein neurotoxicity. The Journal of Neuroscience : The Official Journal of the Society for Neuroscience 35, 5221&#x2013;5232. 10.1523/jneurosci.4650-14.2015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/jneurosci.4650-14.2015</ArticleId><ArticleId IdType="pmc">PMC4380997</ArticleId><ArticleId IdType="pubmed">25834048</ArticleId></ArticleIdList></Reference><Reference><Citation>Burr&#xe9; J, Sharma M, and S&#xfc;dhof TC (2018). Cell Biology and Pathophysiology of &#x3b1;-Synuclein. Csh Perspect Med 8, a024091&#x2013;29. 10.1101/cshperspect.a024091.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a024091</ArticleId><ArticleId IdType="pmc">PMC5519445</ArticleId><ArticleId IdType="pubmed">28108534</ArticleId></ArticleIdList></Reference><Reference><Citation>Byers B, Cord B, Nguyen HN, Sch&#xfc;le B, Fenno L, Lee PC, Deisseroth K, Langston JW, Pera RR, and Palmer TD (2011). SNCA Triplication Parkinson&#x2019;s Patient&#x2019;s iPSC-derived DA Neurons Accumulate &#x3b1;-Synuclein and Are Susceptible to Oxidative Stress. PLoS ONE 6, e26159&#x2013;13. 10.1371/journal.pone.0026159.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0026159</ArticleId><ArticleId IdType="pmc">PMC3217921</ArticleId><ArticleId IdType="pubmed">22110584</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabin DE, Shimazu K, Murphy D, Cole NB, Gottschalk W, McIlwain KL, Orrison B, Chen A, Ellis CE, Paylor R, et al. (2002). Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. 22, 8797&#x2013;8807. 10.1523/jneurosci.22-20-08797.2002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/jneurosci.22-20-08797.2002</ArticleId><ArticleId IdType="pmc">PMC6757677</ArticleId><ArticleId IdType="pubmed">12388586</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang C-T, Bercovich N, Loh B, Jonas S, and Izaurralde E (2014). The activation of the decapping enzyme DCP2 by DCP1 occurs on the EDC4 scaffold and involves a conserved loop in DCP1. Nucleic Acids Res 42, 5217&#x2013;5233. 10.1093/nar/gku129.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gku129</ArticleId><ArticleId IdType="pmc">PMC4005699</ArticleId><ArticleId IdType="pubmed">24510189</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang D, Nalls MA, Hallgr&#xed;msd&#xf3;ttir IB, Hunkapiller J, Brug M. van der, Cai F, Kerchner GA, Ayalon G, Bingol B, Sheng M, et al. (2017). A meta-analysis of genome-wide association studies identifies 17 new Parkinson&#x2019;s disease risk loci. Nat Genet 7, 1&#x2013;10. 10.1038/ng.3955.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3955</ArticleId><ArticleId IdType="pmc">PMC5812477</ArticleId><ArticleId IdType="pubmed">28892059</ArticleId></ArticleIdList></Reference><Reference><Citation>Chartier-Harlin M-C, Dachsel JC, Vilari&#xf1;o-G&#xfc;ell C, Lincoln SJ, Lepr&#xea;tre F, Hulihan MM, Kachergus J, Milnerwood AJ, Tapia L, Song M-S, et al. (2011). Translation initiator EIF4G1 mutations in familial Parkinson disease. Am J Hum Genetics 89, 398&#x2013;406. 10.1016/j.ajhg.2011.08.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2011.08.009</ArticleId><ArticleId IdType="pmc">PMC3169825</ArticleId><ArticleId IdType="pubmed">21907011</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Schymick JC, Restagno G, Scholz SW, Lombardo F, Lai S-L, Mora G, Fung H-C, Britton A, Arepalli S, et al. (2009). A two-stage genome-wide association study of sporadic amyotrophic lateral sclerosis. Human Molecular Genetics 18, 1524&#x2013;1532. 10.1093/hmg/ddp059.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddp059</ArticleId><ArticleId IdType="pmc">PMC2664150</ArticleId><ArticleId IdType="pubmed">19193627</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung CY, Khurana V, Auluck PK, Tardiff DF, Mazzulli JR, Soldner F, Baru V, Lou Y, Freyzon Y, Cho S, et al. (2013). Identification and rescue of &#x3b1;-synuclein toxicity in Parkinson patient-derived neurons. Science 342, 983&#x2013;987. 10.1126/science.1245296.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1245296</ArticleId><ArticleId IdType="pmc">PMC4022187</ArticleId><ArticleId IdType="pubmed">24158904</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung CY, Khurana V, Yi S, Sahni N, Loh KH, Auluck PK, Baru V, Udeshi ND, Freyzon Y, Carr SA, et al. (2017). In Situ Peroxidase Labeling and Mass-Spectrometry Connects Alpha-Synuclein Directly to Endocytic Trafficking and mRNA Metabolism in Neurons. Cell Syst 4, 242&#x2013;250.e4. 10.1016/j.cels.2017.01.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cels.2017.01.002</ArticleId><ArticleId IdType="pmc">PMC5578869</ArticleId><ArticleId IdType="pubmed">28131823</ArticleId></ArticleIdList></Reference><Reference><Citation>Corbet GA, and Parker R (2020). RNP Granule Formation: Lessons from P-Bodies and Stress Granules. Cold Spring Harb Sym 84, 040329. 10.1101/sqb.2019.84.040329.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/sqb.2019.84.040329</ArticleId><ArticleId IdType="pubmed">32482896</ArticleId></ArticleIdList></Reference><Reference><Citation>Cronin S, Berger S, Ding J, Schymick JC, Washecka N, Hernandez DG, Greenway MJ, Bradley DG, Traynor BJ, and Hardiman O (2008). A genome-wide association study of sporadic ALS in a homogenous Irish population. Hum Mol Genet 17, 768&#x2013;774. 10.1093/hmg/ddm361.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddm361</ArticleId><ArticleId IdType="pubmed">18057069</ArticleId></ArticleIdList></Reference><Reference><Citation>Das T, and Eliezer D (2019). Membrane interactions of intrinsically disordered proteins_ The example of alpha-synuclein. BBA - Proteins and Proteomics 1867, 879&#x2013;889. 10.1016/j.bbapap.2019.05.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbapap.2019.05.001</ArticleId><ArticleId IdType="pmc">PMC6661188</ArticleId><ArticleId IdType="pubmed">31096049</ArticleId></ArticleIdList></Reference><Reference><Citation>Decker CJ, and Parker R (2012). P-Bodies and Stress Granules: Possible Roles in the Control of Translation and mRNA Degradation. Csh Perspect Biol 4, a012286&#x2013;a012286. 10.1101/cshperspect.a012286.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a012286</ArticleId><ArticleId IdType="pmc">PMC3428773</ArticleId><ArticleId IdType="pubmed">22763747</ArticleId></ArticleIdList></Reference><Reference><Citation>Dettmer U (2018). Rationally Designed Variants of &#x3b1;-Synuclein Illuminate Its in vivo Structural Properties in Health and Disease. Frontiers in Neuroscience 12, 239&#x2013;14. 10.3389/fnins.2018.00623.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2018.00623</ArticleId><ArticleId IdType="pmc">PMC6167557</ArticleId><ArticleId IdType="pubmed">30319334</ArticleId></ArticleIdList></Reference><Reference><Citation>Dettmer U, Selkoe D, and Bartels T (2016). New insights into cellular &#x3b1;-synuclein homeostasis in health and disease. Curr Opin Neurobiol 36, 15&#x2013;22. 10.1016/j.conb.2015.07.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.conb.2015.07.007</ArticleId><ArticleId IdType="pubmed">26282834</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhungel N, Eleuteri S, Li L, Kramer NJ, Chartron JW, Spencer B, Kosberg K, Fields JA, Stafa K, Adame A, et al. (2015). Parkinson&#x2019;s disease genes VPS35 and EIF4G1 interact genetically and converge on &#x3b1;-synuclein. Neuron 85, 76&#x2013;87. 10.1016/j.neuron.2014.11.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.11.027</ArticleId><ArticleId IdType="pmc">PMC4289081</ArticleId><ArticleId IdType="pubmed">25533483</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobin A, and Gingeras TR (2015). Mapping RNA-seq Reads with STAR. Curr Protoc Bioinform 51, 11.14.1&#x2013;11.14.19. 10.1002/0471250953.bi1114s51.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/0471250953.bi1114s51</ArticleId><ArticleId IdType="pmc">PMC4631051</ArticleId><ArticleId IdType="pubmed">26334920</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, and Gingeras TR (2013). STAR: ultrafast universal RNA-seq aligner. Bioinformatics (Oxford, England) 29, 15&#x2013;21. 10.1093/bioinformatics/bts635.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/bts635</ArticleId><ArticleId IdType="pmc">PMC3530905</ArticleId><ArticleId IdType="pubmed">23104886</ArticleId></ArticleIdList></Reference><Reference><Citation>Eulalio A, Behm-Ansmant I, Schweizer D, and Izaurralde E (2007). P-body formation is a consequence, not the cause, of RNA-mediated gene silencing. Mol Cell Biol 27, 3970&#x2013;3981. 10.1128/mcb.00128-07.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mcb.00128-07</ArticleId><ArticleId IdType="pmc">PMC1900022</ArticleId><ArticleId IdType="pubmed">17403906</ArticleId></ArticleIdList></Reference><Reference><Citation>Ewels P, Magnusson M, Lundin S, and K&#xe4;ller M (2016). MultiQC: summarize analysis results for multiple tools and samples in a single report. Bioinformatics 32, 3047&#x2013;3048. 10.1093/bioinformatics/btw354.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btw354</ArticleId><ArticleId IdType="pmc">PMC5039924</ArticleId><ArticleId IdType="pubmed">27312411</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang G, Wang W, Paunic V, Heydari H, Costanzo M, Liu X, Liu X, VanderSluis B, Oately B, Steinbach M, et al. (2019). Discovering genetic interactions bridging pathways in genome-wide association studies. Nature Communications 10, 1&#x2013;18. 10.1038/s41467-019-12131-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-12131-7</ArticleId><ArticleId IdType="pmc">PMC6753138</ArticleId><ArticleId IdType="pubmed">31537791</ArticleId></ArticleIdList></Reference><Reference><Citation>Feany MB, and Bender WW (2000). A Drosophila model of Parkinson&#x2019;s disease. Nature 404, 394&#x2013;398. 10.1038/35006074.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35006074</ArticleId><ArticleId IdType="pubmed">10746727</ArticleId></ArticleIdList></Reference><Reference><Citation>Felsky D, Sariya S, Santa-Maria I, French L, Schneider JA, Bennett DA, Mayeux R, Jager PLD, and Tosto G (2020). The Caribbean-Hispanic Alzheimer&#x2019;s Brain Transcriptome Reveals Ancestry-Specific Disease Mechanisms. Biorxiv 2020.05.28.122234. 10.1101/2020.05.28.122234.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.05.28.122234</ArticleId></ArticleIdList></Reference><Reference><Citation>Foffani G, and Obeso JA (2018). A Cortical Pathogenic Theory of Parkinson&#x2019;s Disease. Neuron 99, 1116&#x2013;1128. 10.1016/j.neuron.2018.07.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2018.07.028</ArticleId><ArticleId IdType="pubmed">30236282</ArticleId></ArticleIdList></Reference><Reference><Citation>Fromm SA, Truffault V, Kamenz J, Braun JE, Hoffmann NA, Izaurralde E, and Sprangers R (2011). The structural basis of Edc3- and Scd6-mediated activation of the Dcp1:Dcp2 mRNA decapping complex. The EMBO Journal 31, 279&#x2013;290. 10.1038/emboj.2011.408.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emboj.2011.408</ArticleId><ArticleId IdType="pmc">PMC3261563</ArticleId><ArticleId IdType="pubmed">22085934</ArticleId></ArticleIdList></Reference><Reference><Citation>Fung H-C, Scholz S, Matarin M, Sim&#xf3;n-S&#xe1;nchez J, Hernandez D, Britton A, Gibbs JR, Langefeld C, Stiegert ML, Schymick J, et al. (2006). Genome-wide genotyping in Parkinson&#x2019;s disease and neurologically normal controls: first stage analysis and public release of data. The Lancet Neurology 5, 911&#x2013;916. 10.1016/s1474-4422(06)70578-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1474-4422(06)70578-6</ArticleId><ArticleId IdType="pubmed">17052657</ArticleId></ArticleIdList></Reference><Reference><Citation>Fusco G, Gopinath T, Vostrikov V, Vendruscolo M, Simone AD, Dobson CM, and Veglia G (2014). Direct observation of the three regions in &amp;alpha;-synuclein that determine its membrane-bound behaviour. Nature Communications 5, 1&#x2013;8. 10.1038/ncomms4827.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms4827</ArticleId><ArticleId IdType="pmc">PMC4046108</ArticleId><ArticleId IdType="pubmed">24871041</ArticleId></ArticleIdList></Reference><Reference><Citation>Fusco G, Sanz-Hernandez M, and Simone AD (2018). Order and disorder in the physiological membrane binding of &#x3b1;-synuclein. Curr Opin Struc Biol 48, 49&#x2013;57. 10.1016/j.sbi.2017.09.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sbi.2017.09.004</ArticleId><ArticleId IdType="pubmed">29100107</ArticleId></ArticleIdList></Reference><Reference><Citation>Fushimi K, Long C, Jayaram N, Chen X, Li L, and Wu JY (2011). Expression of human FUS/TLS in yeast leads to protein aggregation and cytotoxicity, recapitulating key features of FUS proteinopathy. Protein Cell 2, 141&#x2013;149. 10.1007/s13238-011-1014-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13238-011-1014-5</ArticleId><ArticleId IdType="pmc">PMC3093303</ArticleId><ArticleId IdType="pubmed">21327870</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaete-Argel A, M&#xe1;rquez CL, Barriga GP, Soto-Rifo R, and Valiente-Echeverr&#xed;a F (2019). Strategies for Success. Viral Infections and Membraneless Organelles. Frontiers in Cellular and Infection Microbiology 9, 369&#x2013;28. 10.3389/fcimb.2019.00336.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2019.00336</ArticleId><ArticleId IdType="pmc">PMC6797609</ArticleId><ArticleId IdType="pubmed">31681621</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Spillantini M-G, Tredici KD, and Braak H (2012). 100 years of Lewy pathology. Nat Rev Neurol 9, 1&#x2013;12. 10.1038/nrneurol.2012.242.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2012.242</ArticleId><ArticleId IdType="pubmed">23183883</ArticleId></ArticleIdList></Reference><Reference><Citation>Greten-Harrison B, Polydoro M, Morimoto-Tomita M, Diao L, Williams AM, Nie EH, Makani S, Tian N, Castillo PE, Buchman VL, et al. (2010). &#x3b1;&#x3b2;&#x3b3;-Synuclein triple knockout mice reveal age-dependent neuronal dysfunction. Proc National Acad Sci 107, 19573&#x2013;19578. 10.1073/pnas.1005005107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1005005107</ArticleId><ArticleId IdType="pmc">PMC2984188</ArticleId><ArticleId IdType="pubmed">20974939</ArticleId></ArticleIdList></Reference><Reference><Citation>Gudkova D, Panasyuk G, Nemazanyy I, Zhyvoloup A, Monteil P, Filonenko V, and Gout I (2012). EDC4 interacts with and regulates the dephospho-CoA kinase activity of CoA synthase. FEBS Letters 586, 3590&#x2013;3595. 10.1016/j.febslet.2012.08.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.febslet.2012.08.033</ArticleId><ArticleId IdType="pubmed">22982864</ArticleId></ArticleIdList></Reference><Reference><Citation>Halliday GM, and Stevens CH (2011). Glia: Initiators and progressors of pathology in Parkinson&#x2019;s disease. Movement Disord 26, 6&#x2013;17. 10.1002/mds.23455.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.23455</ArticleId><ArticleId IdType="pubmed">21322014</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamza TH, Zabetian CP, Tenesa A, Laederach A, Montimurro J, Yearout D, Kay DM, Doheny KF, Paschall J, Pugh E, et al. (2010). Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson&#x2019;s disease. Nature Genetics 42, 781&#x2013;785. 10.1038/ng.642.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.642</ArticleId><ArticleId IdType="pmc">PMC2930111</ArticleId><ArticleId IdType="pubmed">20711177</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayden E, Chen S, Chumley A, Xia C, Zhong Q, and Ju S (2020). A Genetic Screen for Human Genes Suppressing FUS Induced Toxicity in Yeast. G3 Genes Genomes Genetics 10, g3.401164.2020. 10.1534/g3.120.401164</Citation><ArticleIdList><ArticleId IdType="doi">10.1534/g3.120.401164</ArticleId><ArticleId IdType="pmc">PMC7263679</ArticleId><ArticleId IdType="pubmed">32276960</ArticleId></ArticleIdList></Reference><Reference><Citation>Hein MY, Hubner NC, Poser I, Cox J, Nagaraj N, Toyoda Y, Gak IA, Weisswange I, Mansfeld J, Buchholz F, et al. (2015). A Human Interactome in Three Quantitative Dimensions Organized by Stoichiometries and Abundances. Cell 163, 712&#x2013;723. 10.1016/j.cell.2015.09.053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2015.09.053</ArticleId><ArticleId IdType="pubmed">26496610</ArticleId></ArticleIdList></Reference><Reference><Citation>Hern&#xe1;ndez G, Ram&#xed;rez MJ, Minguill&#xf3;n J, Quiles P, Garibay G.R. de, Aza-Carmona M, Bogliolo M, Pujol R, Prados-Carvajal R, Fern&#xe1;ndez J, et al. (2018). Decapping protein EDC4 regulates DNA repair and phenocopies BRCA1. Nature Communications 9, 967&#x2013;11. 10.1038/s41467-018-03433-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-03433-3</ArticleId><ArticleId IdType="pmc">PMC5840268</ArticleId><ArticleId IdType="pubmed">29511213</ArticleId></ArticleIdList></Reference><Reference><Citation>Hontz RD, Niederer RO, Johnson JM, and Smith JS (2009). Genetic identification of factors that modulate ribosomal DNA transcription in Saccharomyces cerevisiae. Genetics 182, 105&#x2013;119. 10.1534/genetics.108.100313.</Citation><ArticleIdList><ArticleId IdType="doi">10.1534/genetics.108.100313</ArticleId><ArticleId IdType="pmc">PMC2674809</ArticleId><ArticleId IdType="pubmed">19270272</ArticleId></ArticleIdList></Reference><Reference><Citation>Horvathova I, Voigt F, Kotrys AV, Zhan Y, Artus-Revel CG, Eglinger J, Stadler MB, Giorgetti L, and Chao JA (2017). The Dynamics of mRNA Turnover Revealed by Single-Molecule Imaging in Single Cells. Mol Cell 68, 615&#x2013;624.e10. 10.1016/j.molcel.2017.09.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2017.09.030</ArticleId><ArticleId IdType="pubmed">29056324</ArticleId></ArticleIdList></Reference><Reference><Citation>Hubstenberger A, Courel M, B&#xe9;nard M, Souquere S, Ernoult-Lange M, Chouaib R, Yi Z, Morlot J-B, Munier A, Fradet M, et al. (2017). P-Body Purification Reveals the Condensation of Repressed mRNA Regulons. Mol Cell 68, 1&#x2013;30. 10.1016/j.molcel.2017.09.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2017.09.003</ArticleId><ArticleId IdType="pubmed">28965817</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung V, Udeshi ND, Lam SS, Loh KH, Cox KJ, Pedram K, Carr SA, and Ting AY (2016). Spatially resolved proteomic mapping in living cells with the engineered peroxidase APEX2. Nature Protocols 11, 456&#x2013;475. 10.1038/nprot.2016.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2016.018</ArticleId><ArticleId IdType="pmc">PMC4863649</ArticleId><ArticleId IdType="pubmed">26866790</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunn BHM, Cragg SJ, Bolam JP, Spillantini M-G, and Wade-Martins R (2016). Impaired intracellular trafficking defines early Parkinson&#x2019;s disease. Trends Neurosci 38, 1&#x2013;11. 10.1016/j.tins.2014.12.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2014.12.009</ArticleId><ArticleId IdType="pmc">PMC4740565</ArticleId><ArticleId IdType="pubmed">25639775</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurtig HI, Trojanowski JQ, Galvin J, Ewbank D, Schmidt ML, Lee VM-Y, Clark CM, Glosser G, Stern MB, Gollomp SM, et al. (2000). Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson&#x2019;s disease. Neurology 54, 1916&#x2013;1921. 10.1212/wnl.54.10.1916.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.54.10.1916</ArticleId><ArticleId IdType="pubmed">10822429</ArticleId></ArticleIdList></Reference><Reference><Citation>(IPDGC), I.P.D.G.C., and (WTCCC2), W.T.C.C.C. 2 (2011). A Two-Stage Meta-Analysis Identifies Several New Loci for Parkinson&#x2019;s Disease. Plos Genet 7, e1002142. 10.1371/journal.pgen.1002142.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1002142</ArticleId><ArticleId IdType="pmc">PMC3128098</ArticleId><ArticleId IdType="pubmed">21738488</ArticleId></ArticleIdList></Reference><Reference><Citation>Ivanov P, and Anderson P (2013). Post-transcriptional regulatory networks in immunity. Immunological Reviews 253, 253&#x2013;272. 10.1111/imr.12051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imr.12051</ArticleId><ArticleId IdType="pmc">PMC6989036</ArticleId><ArticleId IdType="pubmed">23550651</ArticleId></ArticleIdList></Reference><Reference><Citation>Jager PLD, Yang H-S, and Bennett DA (2018). Deconstructing and targeting the genomic architecture of human neurodegeneration. Nat Neurosci 21, 1&#x2013;8. 10.1038/s41593-018-0240-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0240-z</ArticleId><ArticleId IdType="pubmed">30258235</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarosz DF, and Khurana V (2017). Specification of Physiologic and Disease States by Distinct Proteins and Protein Conformations. Cell 171, 1001&#x2013;1014. 10.1016/j.cell.2017.10.047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.10.047</ArticleId><ArticleId IdType="pubmed">29149602</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonas S, and Izaurralde E (2013). The role of disordered protein regions in the assembly of decapping complexes and RNP granules. Gene Dev 27, 2628&#x2013;2641. 10.1101/gad.227843.113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gad.227843.113</ArticleId><ArticleId IdType="pmc">PMC3877753</ArticleId><ArticleId IdType="pubmed">24352420</ArticleId></ArticleIdList></Reference><Reference><Citation>Ju S, Tardiff DF, Han H, Divya K, Zhong Q, Maquat LE, Bosco DA, Hayward LJ, Brown RH, Lindquist S, et al. (2011). A Yeast Model of FUS/TLS-Dependent Cytotoxicity. Plos Biol 9, e1001052. 10.1371/journal.pbio.1001052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.1001052</ArticleId><ArticleId IdType="pmc">PMC3082520</ArticleId><ArticleId IdType="pubmed">21541368</ArticleId></ArticleIdList></Reference><Reference><Citation>Kedersha N, and Anderson P (2007). Mammalian Stress Granules and Processing Bodies. Methods Enzymol 431, 61&#x2013;81. 10.1016/s0076-6879(07)31005-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0076-6879(07)31005-7</ArticleId><ArticleId IdType="pubmed">17923231</ArticleId></ArticleIdList></Reference><Reference><Citation>Keeney M, Hoffman E, Greenamyre J, and Maio RD (2021). Measurement of LRRK2 Kinase Activity by Proximity Ligation Assay. Bio-Protocol 11, e4140. 10.21769/bioprotoc.4140.</Citation><ArticleIdList><ArticleId IdType="doi">10.21769/bioprotoc.4140</ArticleId><ArticleId IdType="pmc">PMC8443460</ArticleId><ArticleId IdType="pubmed">34604446</ArticleId></ArticleIdList></Reference><Reference><Citation>Keller MF, Saad M, Br&#xe1;s J, Bettella F, Nicolaou N, Sim&#xf3;n-S&#xe1;nchez J, Mittag F, B&#xfc;chel F, Sharma M, Gibbs JR, et al. (2012). Using genome-wide complex trait analysis to quantify &#x201c;missing heritability&#x201d; in Parkinson&#x2019;s disease. Hum Mol Genet 21, 4996&#x2013;5009. 10.1093/hmg/dds335.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/dds335</ArticleId><ArticleId IdType="pmc">PMC3576713</ArticleId><ArticleId IdType="pubmed">22892372</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy SA, Jarboui M-A, Srihari S, Raso C, Bryan K, Dernayka L, Charitou T, Bernal-Llinares M, Herrera-Montavez C, Krstic A, et al. (2020). Extensive rewiring of the EGFR network in colorectal cancer cells expressing transforming levels of KRASG13D. Nat Commun 11, 499. 10.1038/s41467-019-14224-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-14224-9</ArticleId><ArticleId IdType="pmc">PMC6981206</ArticleId><ArticleId IdType="pubmed">31980649</ArticleId></ArticleIdList></Reference><Reference><Citation>Keryer-Bibens C, Barreau C, and Osborne HB (2008). Tethering of proteins to RNAs by bacteriophage proteins. Biol Cell 100, 125&#x2013;138. 10.1042/bc20070067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/bc20070067</ArticleId><ArticleId IdType="pubmed">18199049</ArticleId></ArticleIdList></Reference><Reference><Citation>Khurana V, Peng J, Chung CY, Auluck PK, Fanning S, Tardiff DF, Bartels T, Koeva M, Eichhorn SW, Benyamini H, et al. (2017). Genome-Scale Networks Link Neurodegenerative Disease Genes to &#x3b1;-Synuclein through Specific Molecular Pathways. Cell Syst 4, 157&#x2013;170.e14. 10.1016/j.cels.2016.12.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cels.2016.12.011</ArticleId><ArticleId IdType="pmc">PMC5388136</ArticleId><ArticleId IdType="pubmed">28131822</ArticleId></ArticleIdList></Reference><Reference><Citation>Kontopoulos E, Parvin JD, and Feany MB (2006). &#x3b1;-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. Human Molecular Genetics 15, 3012&#x2013;3023. 10.1093/hmg/ddl243.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddl243</ArticleId><ArticleId IdType="pubmed">16959795</ArticleId></ArticleIdList></Reference><Reference><Citation>Laaksovirta H, Peuralinna T, Schymick JC, Scholz SW, Lai S-L, Myllykangas L, Sulkava R, Jansson L, Hernandez DG, Gibbs JR, et al. (2010). Chromosome 9p21 in amyotrophic lateral sclerosis in Finland: a genome-wide association study. Lancet Neurology 9, 978&#x2013;985. 10.1016/s1474-4422(10)70184-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1474-4422(10)70184-8</ArticleId><ArticleId IdType="pmc">PMC2965392</ArticleId><ArticleId IdType="pubmed">20801718</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam I, Hallacli E, and Khurana V (2020). Proteome-Scale Mapping of Perturbed Proteostasis in Living Cells. Cold Spring Harbor Perspectives in Biology 12, a034124&#x2013;26. 10.1101/cshperspect.a034124.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a034124</ArticleId><ArticleId IdType="pmc">PMC6996455</ArticleId><ArticleId IdType="pubmed">30910772</ArticleId></ArticleIdList></Reference><Reference><Citation>Law CW, Chen Y, Shi W, and Smyth GK (2014). voom: Precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biology 15, R29&#x2013;17. 10.1186/gb-2014-15-2-r29.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/gb-2014-15-2-r29</ArticleId><ArticleId IdType="pmc">PMC4053721</ArticleId><ArticleId IdType="pubmed">24485249</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee BR, and Kamitani T (2011). Improved Immunodetection of Endogenous &#x3b1;-Synuclein. Plos One 6, e23939&#x2013;8. 10.1371/journal.pone.0023939.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0023939</ArticleId><ArticleId IdType="pmc">PMC3158774</ArticleId><ArticleId IdType="pubmed">21886844</ArticleId></ArticleIdList></Reference><Reference><Citation>Levin JZ, Yassour M, Adiconis X, Nusbaum C, Thompson DA, Friedman N, Gnirke A, and Regev A (2010). Comprehensive comparative analysis of strand-specific RNA sequencing methods. Nature Methods 7, 709&#x2013;715. 10.1038/nmeth.1491.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.1491</ArticleId><ArticleId IdType="pmc">PMC3005310</ArticleId><ArticleId IdType="pubmed">20711195</ArticleId></ArticleIdList></Reference><Reference><Citation>Li B, and Dewey CN (2011). RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics 12, 323&#x2013;16. 10.1186/1471-2105-12-323.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2105-12-323</ArticleId><ArticleId IdType="pmc">PMC3163565</ArticleId><ArticleId IdType="pubmed">21816040</ArticleId></ArticleIdList></Reference><Reference><Citation>Locascio JJ, Eberly S, Liao Z, Liu G, Hoesing AN, Duong K, Trisini-Lipsanopoulos A, Dhima K, Hung AY, Flaherty AW, et al. (2015). Association between &#x3b1;-synuclein blood transcripts and early, neuroimaging-supported Parkinson&#x2019;s disease. Brain 138, 2659&#x2013;2671. 10.1093/brain/awv202.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awv202</ArticleId><ArticleId IdType="pmc">PMC4643625</ArticleId><ArticleId IdType="pubmed">26220939</ArticleId></ArticleIdList></Reference><Reference><Citation>Love MI, Huber W, and Anders S (2014). Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15, 550. 10.1186/s13059-014-0550-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-014-0550-8</ArticleId><ArticleId IdType="pmc">PMC4302049</ArticleId><ArticleId IdType="pubmed">25516281</ArticleId></ArticleIdList></Reference><Reference><Citation>Maio RD, Barrett PJ, Hoffman EK, Barrett CW, Zharikov A, Borah A, Hu X, McCoy J, Chu CT, Burton EA, et al. (2016). &#x3b1;-Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson&#x2019;s disease. Science Translational Medicine 8, 342ra78&#x2013;342ra78. 10.1126/scitranslmed.aaf3634.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aaf3634</ArticleId><ArticleId IdType="pmc">PMC5016095</ArticleId><ArticleId IdType="pubmed">27280685</ArticleId></ArticleIdList></Reference><Reference><Citation>Maraganore DM, Andrade M. de, Lesnick TG, Strain KJ, Farrer MJ, Rocca WA, Pant PVK, Frazer KA, Cox DR, and Ballinger DG (2005). High-Resolution Whole-Genome Association Study of Parkinson Disease. Am J Hum Genetics 77, 685&#x2013;693. 10.1086/496902.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/496902</ArticleId><ArticleId IdType="pmc">PMC1271381</ArticleId><ArticleId IdType="pubmed">16252231</ArticleId></ArticleIdList></Reference><Reference><Citation>Marras C, Beck JC, Bower JH, Roberts E, Ritz B, Ross GW, Abbott RD, Savica R, Eeden SKVD, Willis AW, et al. (2018). Prevalence of Parkinson&#x2019;s disease across North America. Npj Parkinson&#x2019;s Disease 4, 1&#x2013;7. 10.1038/s41531-018-0058-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41531-018-0058-0</ArticleId><ArticleId IdType="pmc">PMC6039505</ArticleId><ArticleId IdType="pubmed">30003140</ArticleId></ArticleIdList></Reference><Reference><Citation>Massey AR, and Beckham JD (2016). Alpha-Synuclein, a Novel Viral Restriction Factor Hiding in Plain Sight. DNA and Cell Biology 35, 643&#x2013;645. 10.1089/dna.2016.3488.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/dna.2016.3488</ArticleId><ArticleId IdType="pubmed">27631132</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzulli JR, Zunke F, Isacson O, Studer L, and Krainc D (2016). &#x3b1;-Synuclein-induced lysosomal dysfunction occurs through disruptions in protein trafficking in human midbrain synucleinopathy models. Proceedings of the National Academy of Sciences of the United States of America 113, 1931&#x2013;1936. 10.1073/pnas.1520335113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1520335113</ArticleId><ArticleId IdType="pmc">PMC4763774</ArticleId><ArticleId IdType="pubmed">26839413</ArticleId></ArticleIdList></Reference><Reference><Citation>McFarland MA, Ellis CE, Markey SP, and Nussbaum RL (2008). Proteomics Analysis Identifies Phosphorylation-dependent &#x3b1;-Synuclein Protein Interactions. Mol Cell Proteomics 7, 2123&#x2013;2137. 10.1074/mcp.m800116-mcp200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/mcp.m800116-mcp200</ArticleId><ArticleId IdType="pmc">PMC2577212</ArticleId><ArticleId IdType="pubmed">18614564</ArticleId></ArticleIdList></Reference><Reference><Citation>McKeith IG (2006). Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop, pp. 417&#x2013;423.</Citation><ArticleIdList><ArticleId IdType="pubmed">16914880</ArticleId></ArticleIdList></Reference><Reference><Citation>Mostafavi S, Gaiteri C, Sullivan SE, White CC, Tasaki S, Xu J, Taga M, Klein H-U, Patrick E, Komashko V, et al. (2018). A molecular network of the aging human brain provides insights into the pathology and cognitive decline of Alzheimer&#x2019;s disease. Nat Neurosci 21, 811&#x2013;819. 10.1038/s41593-018-0154-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0154-9</ArticleId><ArticleId IdType="pmc">PMC6599633</ArticleId><ArticleId IdType="pubmed">29802388</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalls MA, Pankratz N, Lill CM, Do CB, Hernandez DG, Saad M, DeStefano AL, Kara E, Br&#xe1;s J, Sharma M, et al. (2014). Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson&#x2019;s disease. Nat Genet 46, 989&#x2013;993. 10.1038/ng.3043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3043</ArticleId><ArticleId IdType="pmc">PMC4146673</ArticleId><ArticleId IdType="pubmed">25064009</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalls MA, Bras J, Hernandez DG, Keller MF, Majounie E, Renton AE, Saad M, Jansen I, Guerreiro R, Lubbe S, et al. (2015). NeuroX, a fast and efficient genotyping platform for investigation of neurodegenerative diseases. Neurobiol Aging 36, 1605.e7&#x2013;1605.e12. 10.1016/j.neurobiolaging.2014.07.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2014.07.028</ArticleId><ArticleId IdType="pmc">PMC4317375</ArticleId><ArticleId IdType="pubmed">25444595</ArticleId></ArticleIdList></Reference><Reference><Citation>Newby GA, Kiriakov S, Hallacli E, Kayatekin C, Tsvetkov P, Mancuso CP, Bonner JM, Hesse WR, Chakrabortee S, Manogaran AL, et al. (2017). A Genetic Tool to Track Protein Aggregates and Control Prion Inheritance. Cell 171, 966&#x2013;968.e18. 10.1016/j.cell.2017.09.041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.09.041</ArticleId><ArticleId IdType="pmc">PMC5675731</ArticleId><ArticleId IdType="pubmed">29056345</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen M, Wong YC, Ysselstein D, Severino A, and Krainc D (2019). Synaptic, Mitochondrial, and Lysosomal Dysfunction in Parkinson&#x2019;s Disease. Trends in Neurosciences 42, 140&#x2013;149. 10.1016/j.tins.2018.11.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2018.11.001</ArticleId><ArticleId IdType="pmc">PMC6452863</ArticleId><ArticleId IdType="pubmed">30509690</ArticleId></ArticleIdList></Reference><Reference><Citation>Nichols WC, Pankratz N, Hernandez D, Pais&#xe1;n-Ru&#xed;z C, Jain S, Halter CA, Michaels VE, Reed T, Rudolph A, Shults CW, et al. (2005). Genetic screening for a single common LRRK2 mutation in familial Parkinson&#x2019;s disease. Lancet 365, 410&#x2013;412. 10.1016/s0140-6736(05)17828-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(05)17828-3</ArticleId><ArticleId IdType="pubmed">15680455</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsen AL, and Feany MB (2019). Glial &#x3b1;-synuclein promotes neurodegeneration characterized by a distinct transcriptional program in vivo. Glia 67, 1933&#x2013;1957. 10.1002/glia.23671.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.23671</ArticleId><ArticleId IdType="pmc">PMC7212549</ArticleId><ArticleId IdType="pubmed">31267577</ArticleId></ArticleIdList></Reference><Reference><Citation>Paillusson S, Gomez-Suaga P, Stoica R, Little D, Gissen P, Devine MJ, Noble W, Hanger DP, and Miller CCJ (2017). &#x3b1;-Synuclein binds to the ER&#x2013;mitochondria tethering protein VAPB to disrupt Ca2+ homeostasis and mitochondrial ATP production. Acta Neuropathol 134, 129&#x2013;149. 10.1007/s00401-017-1704-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-017-1704-z</ArticleId><ArticleId IdType="pmc">PMC5486644</ArticleId><ArticleId IdType="pubmed">28337542</ArticleId></ArticleIdList></Reference><Reference><Citation>Paull D, Sevilla A, Zhou H, Hahn AK, Kim H, Napolitano C, Tsankov A, Shang L, Krumholz K, Jagadeesan P, et al. (2015). Automated, high-throughput derivation, characterization and differentiation of induced pluripotent stem cells. Nat Methods 12, 885&#x2013;892. 10.1038/nmeth.3507.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.3507</ArticleId><ArticleId IdType="pubmed">26237226</ArticleId></ArticleIdList></Reference><Reference><Citation>Pei Y, and Maitta RW (2019). Alpha synuclein in hematopoiesis and immunity. Heliyon 5, e02590. 10.1016/j.heliyon.2019.e02590.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.heliyon.2019.e02590</ArticleId><ArticleId IdType="pmc">PMC6806402</ArticleId><ArticleId IdType="pubmed">31692680</ArticleId></ArticleIdList></Reference><Reference><Citation>Perrin RJ, Woods WS, Clayton DF, and George JM (2000). Interaction of human alpha-Synuclein and Parkinson&#x2019;s disease variants with phospholipids. Structural analysis using site-directed mutagenesis. The Journal of Biological Chemistry 275, 34393&#x2013;34398. 10.1074/jbc.m004851200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.m004851200</ArticleId><ArticleId IdType="pubmed">10952980</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, et al. (1997). Mutation in the alpha-synuclein gene identified in families with Parkinson&#x2019;s disease. Science 276, 2045&#x2013;2047. 10.1126/science.276.5321.2045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.276.5321.2045</ArticleId><ArticleId IdType="pubmed">9197268</ArticleId></ArticleIdList></Reference><Reference><Citation>Price AL, Kryukov GV, Bakker P.I.W. de, Purcell SM, Staples J, Wei L-J, and Sunyaev SR (2010). Pooled Association Tests for Rare Variants in Exon-Resequencing Studies. Am J Hum Genetics 86, 832&#x2013;838. 10.1016/j.ajhg.2010.04.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2010.04.005</ArticleId><ArticleId IdType="pmc">PMC3032073</ArticleId><ArticleId IdType="pubmed">20471002</ArticleId></ArticleIdList></Reference><Reference><Citation>Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, and Zhang F (2013). Genome engineering using the CRISPR-Cas9 system. Nat Protoc 8, 2281&#x2013;2308. 10.1038/nprot.2013.143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2013.143</ArticleId><ArticleId IdType="pmc">PMC3969860</ArticleId><ArticleId IdType="pubmed">24157548</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, and Smyth GK (2015). limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Research 43, e47&#x2013;e47. 10.1093/nar/gkv007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkv007</ArticleId><ArticleId IdType="pmc">PMC4402510</ArticleId><ArticleId IdType="pubmed">25605792</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan SD, Dolatabadi N, Chan SF, Zhang X, Akhtar MW, Parker J, Soldner F, Sunico CR, Nagar S, Talantova M, et al. (2013). Isogenic Human iPSC Parkinson&#x2019;s Model Shows Nitrosative Stress-Induced Dysfunction in MEF2-PGC1&amp;alpha; Transcription. Cell 155, 1351&#x2013;1364. 10.1016/j.cell.2013.11.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2013.11.009</ArticleId><ArticleId IdType="pmc">PMC4028128</ArticleId><ArticleId IdType="pubmed">24290359</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarkar S, Rokad D, Malovic E, Luo J, Harischandra DS, Jin H, Anantharam V, Huang X, Lewis M, Kanthasamy A, et al. (2019). Manganese activates NLRP3 inflammasome signaling and propagates exosomal release of ASC in microglial cells. Science Signaling 12, eaat9900. 10.1126/scisignal.aat9900.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scisignal.aat9900</ArticleId><ArticleId IdType="pmc">PMC6420319</ArticleId><ArticleId IdType="pubmed">30622196</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaser AJ, Osterberg VR, Dent SE, Stackhouse TL, Wakeham CM, Boutros SW, Weston LJ, Owen N, Weissman TA, Luna E, et al. (2019). Alpha-synuclein is a DNA binding protein that modulates DNA repair with implications for Lewy body disorders. Scientific Reports 9, 1&#x2013;19. 10.1038/s41598-019-47227-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-47227-z</ArticleId><ArticleId IdType="pmc">PMC6662836</ArticleId><ArticleId IdType="pubmed">31358782</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheiblich H, Dansokho C, Mercan D, Schmidt SV, Bousset L, Wischhof L, Eikens F, Odainic A, Spitzer J, Griep A, et al. (2021). Microglia jointly degrade fibrillar alpha-synuclein cargo by distribution through tunneling nanotubes. Cell 10.1016/j.cell.2021.09.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.09.007</ArticleId><ArticleId IdType="pmc">PMC8527836</ArticleId><ArticleId IdType="pubmed">34555357</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider JA, Arvanitakis Z, Yu L, Boyle PA, Leurgans SE, and Bennett DA (2012). Cognitive impairment, decline and fluctuations in older community-dwelling subjects with Lewy bodies. Brain 135, 3005&#x2013;3014. 10.1093/brain/aws234.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aws234</ArticleId><ArticleId IdType="pmc">PMC3470712</ArticleId><ArticleId IdType="pubmed">23065790</ArticleId></ArticleIdList></Reference><Reference><Citation>She M, Decker CJ, Svergun DI, Round A, Chen N, Muhlrad D, Parker R, and Song H (2008). Structural Basis of Dcp2 Recognition and Activation by Dcp1. Molecular Cell 29, 337&#x2013;349. 10.1016/j.molcel.2008.01.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2008.01.002</ArticleId><ArticleId IdType="pmc">PMC2323275</ArticleId><ArticleId IdType="pubmed">18280239</ArticleId></ArticleIdList></Reference><Reference><Citation>Shulman JM, Jager PLD, and Feany MB (2011). Parkinson&#x2019;s disease: genetics and pathogenesis. Pathology Mech Dis 6, 193&#x2013;222. 10.1146/annurev-pathol-011110-130242.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-pathol-011110-130242</ArticleId><ArticleId IdType="pubmed">21034221</ArticleId></ArticleIdList></Reference><Reference><Citation>Siitonen A, Nalls MA, Hern&#xe1;ndez D, Gibbs JR, Ding J, Ylikotila P, Edsall C, Singleton A, and Majamaa K (2017). Genetics of early-onset Parkinson&#x2019;s disease in Finland: exome sequencing and genome-wide association study. Neurobiol Aging 53, 195.e7&#x2013;195.e10. 10.1016/j.neurobiolaging.2017.01.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2017.01.019</ArticleId><ArticleId IdType="pmc">PMC5385296</ArticleId><ArticleId IdType="pubmed">28256260</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon-Sanchez J, Scholz S, Fung H-C, Matarin M, Hernandez D, Gibbs JR, Britton A, Vrieze F.W. de, Peckham E, Gwinn-Hardy K, et al. (2007). Genome-wide SNP assay reveals structural genomic variation, extended homozygosity and cell-line induced alterations in normal individuals. Hum Mol Genet 16, 1&#x2013;14. 10.1093/hmg/ddl436.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddl436</ArticleId><ArticleId IdType="pubmed">17116639</ArticleId></ArticleIdList></Reference><Reference><Citation>Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, et al. (2003). alpha-Synuclein locus triplication causes Parkinson&#x2019;s disease. Science 302, 841. 10.1126/science.1090278.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1090278</ArticleId><ArticleId IdType="pubmed">14593171</ArticleId></ArticleIdList></Reference><Reference><Citation>Snead D, and Eliezer D (2019). Intrinsically disordered proteins in synaptic vesicle trafficking and release. The Journal of Biological Chemistry 294, 3325&#x2013;3342. 10.1074/jbc.rev118.006493.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.rev118.006493</ArticleId><ArticleId IdType="pmc">PMC6416451</ArticleId><ArticleId IdType="pubmed">30700558</ArticleId></ArticleIdList></Reference><Reference><Citation>Soldner F, Stelzer Y, Shivalila CS, Abraham BJ, Latourelle JC, Barrasa MI, Goldmann J, Myers RH, Young RA, and Jaenisch R (2016). Parkinson-associated risk variant in distal enhancer of &#x3b1;-synuclein modulates target gene expression. Nature 533, 95&#x2013;99. 10.1038/nature17939.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature17939</ArticleId><ArticleId IdType="pmc">PMC5042324</ArticleId><ArticleId IdType="pubmed">27096366</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, and Goedert M (1997). Alpha-synuclein in Lewy bodies. Nature 388, 839&#x2013;840. 10.1038/42166.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/42166</ArticleId><ArticleId IdType="pubmed">9278044</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefano BD, Luo E-C, Haggerty C, Aigner S, Charlton J, Brumbaugh J, Ji F, Jim&#xe9;nez IR, Clowers KJ, Huebner AJ, et al. (2019). The RNA Helicase DDX6 Controls Cellular Plasticity by Modulating P-Body Homeostasis. 1&#x2013;31. 10.1016/j.stem.2019.08.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2019.08.018</ArticleId><ArticleId IdType="pmc">PMC7247364</ArticleId><ArticleId IdType="pubmed">31588046</ArticleId></ArticleIdList></Reference><Reference><Citation>Supek F, Bo&#x161;njak M, &#x160;kunca N, and &#x160;muc T (2011). REVIGO summarizes and visualizes long lists of gene ontology terms. PLoS ONE 6, e21800. 10.1371/journal.pone.0021800.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0021800</ArticleId><ArticleId IdType="pmc">PMC3138752</ArticleId><ArticleId IdType="pubmed">21789182</ArticleId></ArticleIdList></Reference><Reference><Citation>Trapnell C, Roberts A, Goff L, Pertea G, Kim D, Kelley DR, Pimentel H, Salzberg SL, Rinn JL, and Pachter L (2012). Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat Protoc 7, 562&#x2013;578. 10.1038/nprot.2012.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2012.016</ArticleId><ArticleId IdType="pmc">PMC3334321</ArticleId><ArticleId IdType="pubmed">22383036</ArticleId></ArticleIdList></Reference><Reference><Citation>Uhlen M, Fagerberg L, Hallstrom BM, Lindskog C, Oksvold P, Mardinoglu A, Sivertsson A, Kampf C, Sjostedt E, Asplund A, et al. (2015). Tissue-based map of the human proteome. Science (New York, NY) 347, 1260419&#x2013;1260419. 10.1126/science.1260419.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1260419</ArticleId><ArticleId IdType="pubmed">25613900</ArticleId></ArticleIdList></Reference><Reference><Citation>Volpicelli-Daley LA, Luk KC, and Lee VM-Y (2014). Addition of exogenous &#x3b1;-synuclein preformed fibrils to primary neuronal cultures to seed recruitment of endogenous &#x3b1;-synuclein to Lewy body and Lewy neurite&#x2013;like aggregates. Nat Protoc 9, 2135&#x2013;2146. 10.1038/nprot.2014.143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2014.143</ArticleId><ArticleId IdType="pmc">PMC4372899</ArticleId><ArticleId IdType="pubmed">25122523</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W, Xu ZZ, Costanzo M, Boone C, Lange CA, and Myers CL (2017). Pathway-based discovery of genetic interactions in breast cancer. PLoS Genetics 13, e1006973&#x2013;29. 10.1371/journal.pgen.1006973.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1006973</ArticleId><ArticleId IdType="pmc">PMC5619706</ArticleId><ArticleId IdType="pubmed">28957314</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilhelm BG, Mandad S, Truckenbrodt S, Kr&#xf6;hnert K, Sch&#xe4;fer C, Rammner B, Koo SJ, Cla&#xdf;en GA, Krauss M, Haucke V, et al. (2014). Composition of isolated synaptic boutons reveals the amounts of vesicle trafficking proteins. Science 344, 1023&#x2013;1028. 10.1126/science.1252884.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1252884</ArticleId><ArticleId IdType="pubmed">24876496</ArticleId></ArticleIdList></Reference><Reference><Citation>Winstall E, Sadowski M, K&#xfc;hn U, Wahle E, and Sachs AB (2000). The Saccharomyces cerevisiaeRNA-binding Protein Rbp29 Functions in Cytoplasmic mRNA Metabolism. The Journal of Biological Chemistry 275, 21817&#x2013;21826. 10.1074/jbc.m002412200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.m002412200</ArticleId><ArticleId IdType="pubmed">10764794</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Pak C, Han Y, Ahlenius H, Zhang Z, Chanda S, Marro S, Patzke C, Acuna C, Covy J, et al. (2013). Rapid single-step induction of functional neurons from human pluripotent stem cells. Neuron 78, 785&#x2013;798. 10.1016/j.neuron.2013.05.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.05.029</ArticleId><ArticleId IdType="pmc">PMC3751803</ArticleId><ArticleId IdType="pubmed">23764284</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35690868</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>14</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>18</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1750-1326</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Jun</Month><Day>11</Day></PubDate></JournalIssue><Title>Molecular neurodegeneration</Title><ISOAbbreviation>Mol Neurodegener</ISOAbbreviation></Journal><ArticleTitle>Novel App knock-in mouse model shows key features of amyloid pathology and reveals profound metabolic dysregulation of microglia.</ArticleTitle><Pagination><StartPage>41</StartPage><MedlinePgn>41</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">41</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13024-022-00547-7</ELocationID><Abstract><AbstractText Label="BACKGROUND">Genetic mutations underlying familial Alzheimer's disease (AD) were identified decades ago, but the field is still in search of transformative therapies for patients. While mouse models based on overexpression of mutated transgenes have yielded key insights in mechanisms of disease, those models are subject to artifacts, including random genetic integration of the transgene, ectopic expression and non-physiological protein levels. The genetic engineering of novel mouse models using knock-in approaches addresses some of those limitations. With mounting evidence of the role played by microglia in AD, high-dimensional approaches to phenotype microglia in those models are critical to refine our understanding of the immune response in the brain.</AbstractText><AbstractText Label="METHODS">We engineered a novel App knock-in mouse model (App<sup>SAA</sup>) using homologous recombination to introduce three disease-causing coding mutations (Swedish, Arctic and Austrian) to the mouse App gene. Amyloid-&#x3b2; pathology, neurodegeneration, glial responses, brain metabolism and behavioral phenotypes were characterized in heterozygous and homozygous App<sup>SAA</sup> mice at different ages in brain and/ or biofluids. Wild type littermate mice were used as experimental controls. We used in situ imaging technologies to define the whole-brain distribution of amyloid plaques and compare it to other AD mouse models and human brain pathology. To further explore the microglial response to AD relevant pathology, we isolated microglia with fibrillar A&#x3b2; content from the brain and performed transcriptomics and metabolomics analyses and in vivo brain imaging to measure energy metabolism and microglial response. Finally, we also characterized the mice in various behavioral assays.</AbstractText><AbstractText Label="RESULTS">Leveraging multi-omics approaches, we discovered profound alteration of diverse lipids and metabolites as well as an exacerbated disease-associated transcriptomic response in microglia with high intracellular A&#x3b2; content. The App<sup>SAA</sup> knock-in mouse model recapitulates key pathological features of AD such as a progressive accumulation of parenchymal amyloid plaques and vascular amyloid deposits, altered astroglial and microglial responses and elevation of CSF markers of neurodegeneration. Those observations were associated with increased TSPO and FDG-PET brain signals and a hyperactivity phenotype as the animals aged.</AbstractText><AbstractText Label="DISCUSSION">Our findings demonstrate that fibrillar A&#x3b2; in microglia is associated with lipid dyshomeostasis consistent with lysosomal dysfunction and foam cell phenotypes as well as profound immuno-metabolic perturbations, opening new avenues to further investigate metabolic pathways at play in microglia responding to AD-relevant pathogenesis. The in-depth characterization of pathological hallmarks of AD in this novel and open-access mouse model should serve as a resource for the scientific community to investigate disease-relevant biology.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Xia</LastName><ForeName>Dan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Denali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Lianoglou</LastName><ForeName>Steve</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Denali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sandmann</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Denali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calvert</LastName><ForeName>Meredith</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Denali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suh</LastName><ForeName>Jung H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Denali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thomsen</LastName><ForeName>Elliot</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Denali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dugas</LastName><ForeName>Jason</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Denali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pizzo</LastName><ForeName>Michelle E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Denali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeVos</LastName><ForeName>Sarah L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Denali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Earr</LastName><ForeName>Timothy K</ForeName><Initials>TK</Initials><AffiliationInfo><Affiliation>Denali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Chia-Ching</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Denali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>Sonnet</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Denali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ha</LastName><ForeName>Connie</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Denali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leung</LastName><ForeName>Amy Wing-Sze</ForeName><Initials>AW</Initials><AffiliationInfo><Affiliation>Denali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Hoang</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Denali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chau</LastName><ForeName>Roni</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Denali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yulyaningsih</LastName><ForeName>Ernie</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Denali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lopez</LastName><ForeName>Isabel</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Denali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Solanoy</LastName><ForeName>Hilda</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Denali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masoud</LastName><ForeName>Shababa T</ForeName><Initials>ST</Initials><AffiliationInfo><Affiliation>Denali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Chun-Chi</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Denali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Karin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Denali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Astarita</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Denali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khoury</LastName><ForeName>Nathalie</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Denali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zuchero</LastName><ForeName>Joy Yu</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Denali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thorne</LastName><ForeName>Robert G</ForeName><Initials>RG</Initials><AffiliationInfo><Affiliation>Denali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmaceutics, University of Minnesota, 9-177 Weaver-Densford Hall, 308 Harvard St. SE, Minneapolis, MN, 55455, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA, 94158, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco, CA, 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA, 94158, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco, CA, 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palop</LastName><ForeName>Jorge J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA, 94158, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco, CA, 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garceau</LastName><ForeName>Dylan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>The Jackson Lab, Bar Harbor, Maine, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sasner</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>The Jackson Lab, Bar Harbor, Maine, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Whitesell</LastName><ForeName>Jennifer D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Allen Institute for Brain Science, Seattle, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harris</LastName><ForeName>Julie A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Allen Institute for Brain Science, Seattle, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hummel</LastName><ForeName>Selina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, 81377, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gn&#xf6;rich</LastName><ForeName>Johannes</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, 81377, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wind</LastName><ForeName>Karin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, 81377, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kunze</LastName><ForeName>Lea</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, 81377, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zatcepin</LastName><ForeName>Artem</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, 81377, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brendel</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, 81377, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Willem</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haass</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, 81377, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Metabolic Biochemistry, Biomedical Center (BMC), Faculty of Medicine, Ludwig- Maximilians-Universit&#xe4;t, M&#xfc;nchen, 81377, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), 81377, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barnett</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Appel Alzheimer's Disease Research Institute, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Graduate Program, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zimmer</LastName><ForeName>Till S</ForeName><Initials>TS</Initials><AffiliationInfo><Affiliation>Appel Alzheimer's Disease Research Institute, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Orr</LastName><ForeName>Anna G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>Appel Alzheimer's Disease Research Institute, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Graduate Program, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scearce-Levie</LastName><ForeName>Kimberly</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Denali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lewcock</LastName><ForeName>Joseph W</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Denali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Paolo</LastName><ForeName>Gilbert</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Denali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanchez</LastName><ForeName>Pascal E</ForeName><Initials>PE</Initials><Identifier Source="ORCID">0000-0002-2620-5165</Identifier><AffiliationInfo><Affiliation>Denali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA. sanchez@dnli.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG047589</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG062629</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 NS118569</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG062234</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG073082</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG068091</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Neurodegener</MedlineTA><NlmUniqueID>101266600</NlmUniqueID><ISSNLinking>1750-1326</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018079">Receptors, GABA</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C499229">TSPO protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="Y">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000686" MajorTopicYN="N">Amyloidosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018079" MajorTopicYN="N">Receptors, GABA</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Astrogliosis</Keyword><Keyword MajorTopicYN="N">Lipid dyshomeostasis</Keyword><Keyword MajorTopicYN="N">Neuritic plaques</Keyword><Keyword MajorTopicYN="N">Neurodegeneration</Keyword><Keyword MajorTopicYN="N">Phagocytic microglia</Keyword><Keyword MajorTopicYN="N">Vascular amyloid</Keyword></KeywordList><CoiStatement>D.X., S.L., T.S., M.C., J.S., E.T., J.D., M.P., N.E.K, J.Y.Z., S.L.D., T.K.E., C.C.L., S.D., C.H., H.H., R.C., E.Y., H.S., S.T.M., R.L., K.L., R.G.T., K.S.L., J.W.L., G.D.P. and P.E.S are paid employees and shareholders of Denali Therapeutic Inc. J.D.W. and J.A.H are currently employed by Cajal Neuroscience.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>12</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>5</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>11</Day><Hour>23</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>6</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35690868</ArticleId><ArticleId IdType="pmc">PMC9188195</ArticleId><ArticleId IdType="doi">10.1186/s13024-022-00547-7</ArticleId><ArticleId IdType="pii">10.1186/s13024-022-00547-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Scearce-Levie K, Sanchez PE, Lewcock JW. Leveraging preclinical models for the development of Alzheimer disease therapeutics. Nat Rev Drug Discov. 2020;19(7):447&#x2013;462.</Citation><ArticleIdList><ArticleId IdType="pubmed">32612262</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL, Zheng H. Practical considerations for choosing a mouse model of Alzheimer's disease. Mol Neurodegener. 2017;12(1):89.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5741956</ArticleId><ArticleId IdType="pubmed">29273078</ArticleId></ArticleIdList></Reference><Reference><Citation>Gotz J, Bodea LG, Goedert M. Rodent models for Alzheimer disease. Nat Rev Neurosci. 2018;19(10):583&#x2013;598.</Citation><ArticleIdList><ArticleId IdType="pubmed">30194347</ArticleId></ArticleIdList></Reference><Reference><Citation>Myers A, McGonigle P. Overview of Transgenic Mouse Models for Alzheimer's Disease. Curr Protoc Neurosci. 2019;89(1):e81.</Citation><ArticleIdList><ArticleId IdType="pubmed">31532917</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaguri H, Nilsson P, Hashimoto S, Nagata K, Saito T, De Strooper B, Hardy J, Vassar R, Winblad B, Saido TC. APP mouse models for Alzheimer's disease preclinical studies. EMBO J. 2017;36(17):2473&#x2013;2487.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5579350</ArticleId><ArticleId IdType="pubmed">28768718</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakakibara Y, Sekiya M, Saito T, Saido TC, Iijima KM. Amyloid-beta plaque formation and reactive gliosis are required for induction of cognitive deficits in App knock-in mouse models of Alzheimer's disease. BMC Neurosci. 2019;20(1):13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6425634</ArticleId><ArticleId IdType="pubmed">30894120</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito T, Matsuba Y, Mihira N, Takano J, Nilsson P, Itohara S, Iwata N, Saido TC. Single App knock-in mouse models of Alzheimer's disease. Nat Neurosci. 2014;17(5):661&#x2013;663.</Citation><ArticleIdList><ArticleId IdType="pubmed">24728269</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen WT, Lu A, Craessaerts K, Pavie B, Sala Frigerio C, Corthout N, Qian X, Lalakova J, Kuhnemund M, Voytyuk I, et al. Spatial Transcriptomics and In Situ Sequencing to Study Alzheimer's Disease. Cell. 2020;182(4):976&#x2013;991 e919.</Citation><ArticleIdList><ArticleId IdType="pubmed">32702314</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen DV, Hanson JE, Sheng M. Microglia in Alzheimer's disease. J Cell Biol. 2018;217(2):459&#x2013;472.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5800817</ArticleId><ArticleId IdType="pubmed">29196460</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewcock JW, Schlepckow K, Di Paolo G, Tahirovic S, Monroe KM, Haass C. Emerging Microglia Biology Defines Novel Therapeutic Approaches for Alzheimer's Disease. Neuron. 2020.</Citation><ArticleIdList><ArticleId IdType="pubmed">33096024</ArticleId></ArticleIdList></Reference><Reference><Citation>Song WM, Colonna M. The identity and function of microglia in neurodegeneration. Nat Immunol. 2018;19(10):1048&#x2013;1058.</Citation><ArticleIdList><ArticleId IdType="pubmed">30250185</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman BA, Srinivasan K, Ayalon G, Meilandt WJ, Lin H, Huntley MA, Cao Y, Lee SH, Haddick PCG, Ngu H, et al. Diverse Brain Myeloid Expression Profiles Reveal Distinct Microglial Activation States and Aspects of Alzheimer's Disease Not Evident in Mouse Models. Cell Rep. 2018;22(3):832&#x2013;847.</Citation><ArticleIdList><ArticleId IdType="pubmed">29346778</ArticleId></ArticleIdList></Reference><Reference><Citation>Grubman A, Choo XY, Chew G, Ouyang JF, Sun G, Croft NP, Rossello FJ, Simmons R, Buckberry S, Landin DV, et al. Transcriptional signature in microglia associated with Abeta plaque phagocytosis. Nat Commun. 2021;12(1):3015.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8140091</ArticleId><ArticleId IdType="pubmed">34021136</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H, Spinrad A, Weiner A, Matcovitch-Natan O, Dvir-Szternfeld R, Ulland TK, David E, Baruch K, Lara-Astaiso D, Toth B, et al. A Unique Microglia Type Associated with Restricting Development of Alzheimer's Disease. Cell. 2017;169(7):1276&#x2013;1290 e1217.</Citation><ArticleIdList><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Krasemann S, Madore C, Cialic R, Baufeld C, Calcagno N, El Fatimy R, Beckers L, O'Loughlin E, Xu Y, Fanek Z, et al. The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases. Immunity. 2017;47(3):566&#x2013;581 e569.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5719893</ArticleId><ArticleId IdType="pubmed">28930663</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathys H, Adaikkan C, Gao F, Young JZ, Manet E, Hemberg M, De Jager PL, Ransohoff RM, Regev A, Tsai LH. Temporal Tracking of Microglia Activation in Neurodegeneration at Single-Cell Resolution. Cell Rep. 2017;21(2):366&#x2013;380.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5642107</ArticleId><ArticleId IdType="pubmed">29020624</ArticleId></ArticleIdList></Reference><Reference><Citation>Sala Frigerio C, Wolfs L, Fattorelli N, Thrupp N, Voytyuk I, Schmidt I, Mancuso R, Chen WT, Woodbury ME, Srivastava G, et al. The Major Risk Factors for Alzheimer's Disease: Age, Sex, and Genes Modulate the Microglia Response to Abeta Plaques. Cell Rep. 2019;27(4):1293&#x2013;1306 e1296.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7340153</ArticleId><ArticleId IdType="pubmed">31018141</ArticleId></ArticleIdList></Reference><Reference><Citation>Srinivasan K, Friedman BA, Etxeberria A, Huntley MA, van der Brug MP, Foreman O, Paw JS, Modrusan Z, Beach TG, Serrano GE, et al. Alzheimer's Patient Microglia Exhibit Enhanced Aging and Unique Transcriptional Activation. Cell Rep. 2020;31(13):107843.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7422733</ArticleId><ArticleId IdType="pubmed">32610143</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathys H, Davila-Velderrain J, Peng Z, Gao F, Mohammadi S, Young JZ, Menon M, He L, Abdurrob F, Jiang X, et al. Single-cell transcriptomic analysis of Alzheimer's disease. Nature. 2019;570(7761):332&#x2013;337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6865822</ArticleId><ArticleId IdType="pubmed">31042697</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang X, Wind K, Wiedemann T, Blume T, Shi Y, Briel N, Beyer L, Biechele G, Eckenweber F, Zatcepin A, et al. Microglial activation states drive glucose uptake and FDG-PET alterations in neurodegenerative diseases. Sci Transl Med. 2021;13(615):eabe5640.</Citation><ArticleIdList><ArticleId IdType="pubmed">34644146</ArticleId></ArticleIdList></Reference><Reference><Citation>Cantuti-Castelvetri L, Fitzner D, Bosch-Queralt M, Weil MT, Su M, Sen P, Ruhwedel T, Mitkovski M, Trendelenburg G, Lutjohann D, et al. Defective cholesterol clearance limits remyelination in the aged central nervous system. Science. 2018;359(6376):684&#x2013;688.</Citation><ArticleIdList><ArticleId IdType="pubmed">29301957</ArticleId></ArticleIdList></Reference><Reference><Citation>Nugent AA, Lin K, van Lengerich B, Lianoglou S, Przybyla L, Davis SS, Llapashtica C, Wang J, Kim DJ, Xia D, et al. TREM2 Regulates Microglial Cholesterol Metabolism upon Chronic Phagocytic Challenge. Neuron. 2020;105(5):837&#x2013;854 e839.</Citation><ArticleIdList><ArticleId IdType="pubmed">31902528</ArticleId></ArticleIdList></Reference><Reference><Citation>Poliani PL, Wang Y, Fontana E, Robinette ML, Yamanishi Y, Gilfillan S, Colonna M. TREM2 sustains microglial expansion during aging and response to demyelination. J Clin Invest. 2015;125(5):2161&#x2013;2170.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4463196</ArticleId><ArticleId IdType="pubmed">25893602</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuner SM, Tcw J, Goate AM. Genetic architecture of Alzheimer's disease. Neurobiol Dis. 2020;143:104976.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7409822</ArticleId><ArticleId IdType="pubmed">32565066</ArticleId></ArticleIdList></Reference><Reference><Citation>Koentgen F, Lin J, Katidou M, Chang I, Khan M, Watts J, Mombaerts P. Exclusive transmission of the embryonic stem cell-derived genome through the mouse germline. Genesis. 2016;54(6):326&#x2013;333.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5084746</ArticleId><ArticleId IdType="pubmed">27012318</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, Guillozet-Bongaarts A, Ohno M, Disterhoft J, Van Eldik L, et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J Neurosci. 2006;26(40):10129&#x2013;10140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674618</ArticleId><ArticleId IdType="pubmed">17021169</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL, Slunt HH, Ratovitski T, Jenkins NA, Copeland NG, Borchelt DR. Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol Eng. 2001;17(6):157&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pubmed">11337275</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 1996;274(5284):99&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">8810256</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitehead JC, Hildebrand BA, Sun M, Rockwood MR, Rose RA, Rockwood K, Howlett SE. A clinical frailty index in aging mice: comparisons with frailty index data in humans. J Gerontol A Biol Sci Med Sci. 2014;69(6):621&#x2013;632.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4022099</ArticleId><ArticleId IdType="pubmed">24051346</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlepckow K, Monroe KM, Kleinberger G, Cantuti-Castelvetri L, Parhizkar S, Xia D, Willem M, Werner G, Pettkus N, Brunner B, et al. Enhancing protective microglial activities with a dual function TREM2 antibody to the stalk region. EMBO Mol Med. 2020;12(4):e11227.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7136959</ArticleId><ArticleId IdType="pubmed">32154671</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitesell JD, Buckley AR, Knox JE, Kuan L, Graddis N, Pelos A, Mukora A, Wakeman W, Bohn P, Ho A, et al. Whole brain imaging reveals distinct spatial patterns of amyloid beta deposition in three mouse models of Alzheimer's disease. J Comp Neurol. 2019;527(13):2122&#x2013;2145.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8026112</ArticleId><ArticleId IdType="pubmed">30311654</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Ding SL, Li Y, Royall J, Feng D, Lesnar P, Graddis N, Naeemi M, Facer B, Ho A, et al. The Allen Mouse Brain Common Coordinate Framework: A 3D Reference Atlas. Cell. 2020;181(4):936&#x2013;953 e920.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8152789</ArticleId><ArticleId IdType="pubmed">32386544</ArticleId></ArticleIdList></Reference><Reference><Citation>Grady L. Random walks for image segmentation. IEEE Trans Pattern Anal Mach Intell. 2006;28(11):1768&#x2013;1783.</Citation><ArticleIdList><ArticleId IdType="pubmed">17063682</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Walt S, Schonberger JL, Nunez-Iglesias J, Boulogne F, Warner JD, Yager N, Gouillart E, Yu T. scikit-image c: scikit-image: image processing in Python. PeerJ. 2014;2:e453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4081273</ArticleId><ArticleId IdType="pubmed">25024921</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012;9(7):676&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3855844</ArticleId><ArticleId IdType="pubmed">22743772</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang H, Lei R, Ding SW, Zhu S. Skewer: a fast and accurate adapter trimmer for next-generation sequencing paired-end reads. BMC Bioinformatics. 2014;15:182.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4074385</ArticleId><ArticleId IdType="pubmed">24925680</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, Gingeras TR. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29(1):15&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3530905</ArticleId><ArticleId IdType="pubmed">23104886</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2014;30(7):923&#x2013;930.</Citation><ArticleIdList><ArticleId IdType="pubmed">24227677</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu R, Holik AZ, Su S, Jansz N, Chen K, Leong HS, Blewitt ME, Asselin-Labat ML, Smyth GK, Ritchie ME. Why weight? Modelling sample and observational level variability improves power in RNA-seq analyses. Nucleic Acids Res. 2015;43(15):e97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4551905</ArticleId><ArticleId IdType="pubmed">25925576</ArticleId></ArticleIdList></Reference><Reference><Citation>Law CW, Chen Y, Shi W, Smyth GK. voom: Precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biol. 2014;15(2):R29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4053721</ArticleId><ArticleId IdType="pubmed">24485249</ArticleId></ArticleIdList></Reference><Reference><Citation>Smyth GKMJ, Scott HS. Use of within-array replicate spots for assessing differential expression in microarray experiments. Bioinformatics. 2005;21(9):2067&#x2013;2075.</Citation><ArticleIdList><ArticleId IdType="pubmed">15657102</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarthy DJ, Smyth GK. Testing significance relative to a fold-change threshold is a TREAT. Bioinformatics. 2009;25(6):765&#x2013;771.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2654802</ArticleId><ArticleId IdType="pubmed">19176553</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulland TK, Song WM, Huang SC, Ulrich JD, Sergushichev A, Beatty WL, Loboda AA, Zhou Y, Cairns NJ, Kambal A, et al. TREM2 Maintains Microglial Metabolic Fitness in Alzheimer's Disease. Cell. 2017;170(4):649&#x2013;663 e613.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5573224</ArticleId><ArticleId IdType="pubmed">28802038</ArticleId></ArticleIdList></Reference><Reference><Citation>Young MD, Wakefield MJ, Smyth GK, Oshlack A. Gene ontology analysis for RNA-seq: accounting for selection bias. Genome Biol. 2010;11(2):R14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2872874</ArticleId><ArticleId IdType="pubmed">20132535</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 2000;25(1):25&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3037419</ArticleId><ArticleId IdType="pubmed">10802651</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28(1):27&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC102409</ArticleId><ArticleId IdType="pubmed">10592173</ArticleId></ArticleIdList></Reference><Reference><Citation>The Gene Ontology C The Gene Ontology Resource: 20 years and still GOing strong. Nucleic Acids Res. 2019;47(D1):D330&#x2013;D338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6323945</ArticleId><ArticleId IdType="pubmed">30395331</ArticleId></ArticleIdList></Reference><Reference><Citation>Huber W, Carey VJ, Gentleman R, Anders S, Carlson M, Carvalho BS, Bravo HC, Davis S, Gatto L, Girke T, et al. Orchestrating high-throughput genomic analysis with Bioconductor. Nat Methods. 2015;12(2):115&#x2013;121.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4509590</ArticleId><ArticleId IdType="pubmed">25633503</ArticleId></ArticleIdList></Reference><Reference><Citation>Overhoff F, Brendel M, Jaworska A, Korzhova V, Delker A, Probst F, Focke C, Gildehaus FJ, Carlsen J, Baumann K, et al. Automated Spatial Brain Normalization and Hindbrain White Matter Reference Tissue Give Improved [(18)F]-Florbetaben PET Quantitation in Alzheimer's Model Mice. Front Neurosci. 2016;10:45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4770021</ArticleId><ArticleId IdType="pubmed">26973442</ArticleId></ArticleIdList></Reference><Reference><Citation>Deussing M, Blume T, Vomacka L, Mahler C, Focke C, Todica A, Unterrainer M, Albert NL, Lindner S, von Ungern-Sternberg B, et al. Coupling between physiological TSPO expression in brain and myocardium allows stabilization of late-phase cerebral [(18)F]GE180 PET quantification. Neuroimage. 2018;165:83&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">28988133</ArticleId></ArticleIdList></Reference><Reference><Citation>Rominger A, Brendel M, Burgold S, Keppler K, Baumann K, Xiong G, Mille E, Gildehaus FJ, Carlsen J, Schlichtiger J, et al. Longitudinal assessment of cerebral beta-amyloid deposition in mice overexpressing Swedish mutant beta-amyloid precursor protein using 18F-florbetaben PET. J Nucl Med. 2013;54(7):1127&#x2013;1134.</Citation><ArticleIdList><ArticleId IdType="pubmed">23729696</ArticleId></ArticleIdList></Reference><Reference><Citation>Leek JT, Johnson WE, Parker HS, Jaffe AE, Storey JD. The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics. 2012;28(6):882&#x2013;883.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3307112</ArticleId><ArticleId IdType="pubmed">22257669</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4402510</ArticleId><ArticleId IdType="pubmed">25605792</ArticleId></ArticleIdList></Reference><Reference><Citation>Mullan M, Crawford F, Axelman K, Houlden H, Lilius L, Winblad B, Lannfelt L. A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid. Nat Genet. 1992;1(5):345&#x2013;347.</Citation><ArticleIdList><ArticleId IdType="pubmed">1302033</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamino K, Orr HT, Payami H, Wijsman EM, Alonso ME, Pulst SM, Anderson L, O'Dahl S, Nemens E, White JA, et al. Linkage and mutational analysis of familial Alzheimer disease kindreds for the APP gene region. Am J Hum Genet. 1992;51(5):998&#x2013;1014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1682859</ArticleId><ArticleId IdType="pubmed">1415269</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar-Singh S, De Jonghe C, Cruts M, Kleinert R, Wang R, Mercken M, De Strooper B, Vanderstichele H, Lofgren A, Vanderhoeven I, et al. Nonfibrillar diffuse amyloid deposition due to a gamma(42)-secretase site mutation points to an essential role for N-truncated A beta(42) in Alzheimer's disease. Hum Mol Genet. 2000;9(18):2589&#x2013;2598.</Citation><ArticleIdList><ArticleId IdType="pubmed">11063718</ArticleId></ArticleIdList></Reference><Reference><Citation>Citron M, Haass C, Selkoe DJ. Production of amyloid-beta-peptide by cultured cells: no evidence for internal initiation of translation at Met596. Neurobiol Aging. 1993;14(6):571&#x2013;573.</Citation><ArticleIdList><ArticleId IdType="pubmed">8295660</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Lemere CA, Capell A, Citron M, Seubert P, Schenk D, Lannfelt L, Selkoe DJ. The Swedish mutation causes early-onset Alzheimer's disease by beta-secretase cleavage within the secretory pathway. Nat Med. 1995;1(12):1291&#x2013;1296.</Citation><ArticleIdList><ArticleId IdType="pubmed">7489411</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgold S, Bittner T, Dorostkar MM, Kieser D, Fuhrmann M, Mitteregger G, Kretzschmar H, Schmidt B, Herms J. In vivo multiphoton imaging reveals gradual growth of newborn amyloid plaques over weeks. Acta Neuropathol. 2011;121(3):327&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3038220</ArticleId><ArticleId IdType="pubmed">21136067</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Bacskai BJ, Mathis CA, Kajdasz ST, McLellan ME, Frosch MP, Debnath ML, Holt DP, Wang Y, Hyman BT. Imaging Abeta plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative. J Neuropathol Exp Neurol. 2002;61(9):797&#x2013;805.</Citation><ArticleIdList><ArticleId IdType="pubmed">12230326</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR, Rub U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58(12):1791&#x2013;1800.</Citation><ArticleIdList><ArticleId IdType="pubmed">12084879</ArticleId></ArticleIdList></Reference><Reference><Citation>Adalbert R, Nogradi A, Babetto E, Janeckova L, Walker SA, Kerschensteiner M, Misgeld T, Coleman MP. Severely dystrophic axons at amyloid plaques remain continuous and connected to viable cell bodies. Brain. 2009;132(Pt 2):402&#x2013;416.</Citation><ArticleIdList><ArticleId IdType="pubmed">19059977</ArticleId></ArticleIdList></Reference><Reference><Citation>Escartin C, Galea E, Lakatos A, O'Callaghan JP, Petzold GC, Serrano-Pozo A, Steinhauser C, Volterra A, Carmignoto G, Agarwal A, et al. Reactive astrocyte nomenclature, definitions, and future directions. Nat Neurosci. 2021;24(3):312&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8007081</ArticleId><ArticleId IdType="pubmed">33589835</ArticleId></ArticleIdList></Reference><Reference><Citation>Tzingounis AV, Wadiche JI. Glutamate transporters: confining runaway excitation by shaping synaptic transmission. Nat Rev Neurosci. 2007;8(12):935&#x2013;947.</Citation><ArticleIdList><ArticleId IdType="pubmed">17987031</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy-Royal C, Dupuis J, Groc L, Oliet SHR. Astroglial glutamate transporters in the brain: Regulating neurotransmitter homeostasis and synaptic transmission. J Neurosci Res. 2017;95(11):2140&#x2013;2151.</Citation><ArticleIdList><ArticleId IdType="pubmed">28150867</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacob CP, Koutsilieri E, Bartl J, Neuen-Jacob E, Arzberger T, Zander N, Ravid R, Roggendorf W, Riederer P, Grunblatt E. Alterations in expression of glutamatergic transporters and receptors in sporadic Alzheimer's disease. J Alzheimers Dis. 2007;11(1):97&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pubmed">17361039</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, Alford M, DeTeresa R, Mallory M, Hansen L. Deficient glutamate transport is associated with neurodegeneration in Alzheimer's disease. Ann Neurol. 1996;40(5):759&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pubmed">8957017</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott HA, Gebhardt FM, Mitrovic AD, Vandenberg RJ, Dodd PR. Glutamate transporter variants reduce glutamate uptake in Alzheimer's disease. Neurobiol Aging. 2011:32(3):553 e551-511.</Citation><ArticleIdList><ArticleId IdType="pubmed">20416976</ArticleId></ArticleIdList></Reference><Reference><Citation>Liddelow SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L, Bennett ML, Munch AE, Chung WS, Peterson TC, et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017;541(7638):481&#x2013;487.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5404890</ArticleId><ArticleId IdType="pubmed">28099414</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu T, Dejanovic B, Gandham VD, Gogineni A, Edmonds R, Schauer S, Srinivasan K, Huntley MA, Wang Y, Wang TM, et al. Complement C3 Is Activated in Human AD Brain and Is Required for Neurodegeneration in Mouse Models of Amyloidosis and Tauopathy. Cell Rep. 2019;28(8):2111&#x2013;2123 e2116.</Citation><ArticleIdList><ArticleId IdType="pubmed">31433986</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Chen K, Sloan SA, Bennett ML, Scholze AR, O'Keeffe S, Phatnani HP, Guarnieri P, Caneda C, Ruderisch N, et al. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J Neurosci. 2014;34(36):11929&#x2013;11947.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4152602</ArticleId><ArticleId IdType="pubmed">25186741</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan RB, Oliveira TG, Cortes EP, Honig LS, Duff KE, Small SA, Wenk MR, Shui G, Di Paolo G. Comparative lipidomic analysis of mouse and human brain with Alzheimer disease. J Biol Chem. 2012;287(4):2678&#x2013;2688.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3268426</ArticleId><ArticleId IdType="pubmed">22134919</ArticleId></ArticleIdList></Reference><Reference><Citation>Claes C, Danhash EP, Hasselmann J, Chadarevian JP, Shabestari SK, England WE, Lim TE, Hidalgo JLS, Spitale RC, Davtyan H, et al. Plaque-associated human microglia accumulate lipid droplets in a chimeric model of Alzheimer's disease. Mol Neurodegener. 2021;16(1):50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8305935</ArticleId><ArticleId IdType="pubmed">34301296</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamilton LK, Dufresne M, Joppe SE, Petryszyn S, Aumont A, Calon F, Barnabe-Heider F, Furtos A, Parent M, Chaurand P, et al. Aberrant Lipid Metabolism in the Forebrain Niche Suppresses Adult Neural Stem Cell Proliferation in an Animal Model of Alzheimer's Disease. Cell Stem Cell. 2015;17(4):397&#x2013;411.</Citation><ArticleIdList><ArticleId IdType="pubmed">26321199</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Ulland TK, Ulrich JD, Song W, Tzaferis JA, Hole JT, Yuan P, Mahan TE, Shi Y, Gilfillan S, et al. TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques. J Exp Med. 2016;213(5):667&#x2013;675.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4854736</ArticleId><ArticleId IdType="pubmed">27091843</ArticleId></ArticleIdList></Reference><Reference><Citation>Karlstetter M, Nothdurfter C, Aslanidis A, Moeller K, Horn F, Scholz R, Neumann H, Weber BH, Rupprecht R, Langmann T. Translocator protein (18 kDa) (TSPO) is expressed in reactive retinal microglia and modulates microglial inflammation and phagocytosis. J Neuroinflammation. 2014;11:3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3895821</ArticleId><ArticleId IdType="pubmed">24397957</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandiego CM, Gallezot JD, Pittman B, Nabulsi N, Lim K, Lin SF, Matuskey D, Lee JY, O'Connor KC, Huang Y, et al. Imaging robust microglial activation after lipopolysaccharide administration in humans with PET. Proc Natl Acad Sci U S A. 2015;112(40):12468&#x2013;12473.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4603509</ArticleId><ArticleId IdType="pubmed">26385967</ArticleId></ArticleIdList></Reference><Reference><Citation>Kreisl WC, Lyoo CH, Liow JS, Wei M, Snow J, Page E, Jenko KJ, Morse CL, Zoghbi SS, Pike VW, et al. (11)C-PBR28 binding to translocator protein increases with progression of Alzheimer's disease. Neurobiol Aging. 2016;44:53&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4939713</ArticleId><ArticleId IdType="pubmed">27318133</ArticleId></ArticleIdList></Reference><Reference><Citation>Pascoal TA, Benedet AL, Ashton NJ, Kang MS, Therriault J, Chamoun M, Savard M, Lussier FZ, Tissot C, Karikari TK, et al. Microglial activation and tau propagate jointly across Braak stages. Nat Med. 2021;27(9):1592&#x2013;1599.</Citation><ArticleIdList><ArticleId IdType="pubmed">34446931</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosel F, Pelley JMS, Franklin TB. Behavioural and psychological symptoms of dementia in mouse models of Alzheimer's disease-related pathology. Neurosci Biobehav Rev. 2020;112:634&#x2013;647.</Citation><ArticleIdList><ArticleId IdType="pubmed">32070692</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster SJ, Bachstetter AD, Nelson PT, Schmitt FA, Van Eldik LJ. Using mice to model Alzheimer's dementia: an overview of the clinical disease and the preclinical behavioral changes in 10 mouse models. Front Genet. 2014;5:88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4005958</ArticleId><ArticleId IdType="pubmed">24795750</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson ECB, Ho K, Yu GQ, Das M, Sanchez PE, Djukic B, Lopez I, Yu X, Gill M, Zhang W, et al. Behavioral and neural network abnormalities in human APP transgenic mice resemble those of App knock-in mice and are modulated by familial Alzheimer's disease mutations but not by inhibition of BACE1. Mol Neurodegener. 2020;15(1):53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7489007</ArticleId><ArticleId IdType="pubmed">32921309</ArticleId></ArticleIdList></Reference><Reference><Citation>Masuda A, Kobayashi Y, Kogo N, Saito T, Saido TC, Itohara S. Cognitive deficits in single App knock-in mouse models. Neurobiol Learn Mem. 2016;135:73&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">27377630</ArticleId></ArticleIdList></Reference><Reference><Citation>Verret L, Mann EO, Hang GB, Barth AM, Cobos I, Ho K, Devidze N, Masliah E, Kreitzer AC, Mody I, et al. Inhibitory interneuron deficit links altered network activity and cognitive dysfunction in Alzheimer model. Cell. 2012;149:708&#x2013;721.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3375906</ArticleId><ArticleId IdType="pubmed">22541439</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalimo H, Lalowski M, Bogdanovic N, Philipson O, Bird TD, Nochlin D, Schellenberg GD, Brundin R, Olofsson T, Soliymani R, et al. The Arctic AbetaPP mutation leads to Alzheimer's disease pathology with highly variable topographic deposition of differentially truncated Abeta. Acta Neuropathol Commun. 2013;1:60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4226306</ArticleId><ArticleId IdType="pubmed">24252272</ArticleId></ArticleIdList></Reference><Reference><Citation>Gowrishankar S, Yuan P, Wu Y, Schrag M, Paradise S, Grutzendler J, De Camilli P, Ferguson SM. Massive accumulation of luminal protease-deficient axonal lysosomes at Alzheimer's disease amyloid plaques. Proc Natl Acad Sci U S A. 2015;112(28):E3699&#x2013;E3708.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4507205</ArticleId><ArticleId IdType="pubmed">26124111</ArticleId></ArticleIdList></Reference><Reference><Citation>Leyns CEG, Gratuze M, Narasimhan S, Jain N, Koscal LJ, Jiang H, Manis M, Colonna M, Lee VMY, Ulrich JD, et al. TREM2 function impedes tau seeding in neuritic plaques. Nat Neurosci. 2019;22(8):1217&#x2013;1222.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6660358</ArticleId><ArticleId IdType="pubmed">31235932</ArticleId></ArticleIdList></Reference><Reference><Citation>Logan T, Simon MJ, Rana A, Cherf GM, Srivastava A, Davis SS, Low RLY, Chiu CL, Fang M, Huang F, et al. Rescue of a lysosomal storage disorder caused by Grn loss of function with a brain penetrant progranulin biologic. Cell. 2021;184(18):4651&#x2013;4668 e4625.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8489356</ArticleId><ArticleId IdType="pubmed">34450028</ArticleId></ArticleIdList></Reference><Reference><Citation>Ullman JC, Arguello A, Getz JA, Bhalla A, Mahon CS, Wang J, et al. Brain delivery and activity of a lysosomal enzyme using a blood-brain barrier transport vehicle in mice. Sci Transl Med. 2020;12(545).</Citation><ArticleIdList><ArticleId IdType="pubmed">32461331</ArticleId></ArticleIdList></Reference><Reference><Citation>Marschallinger J, Iram T, Zardeneta M, Lee SE, Lehallier B, Haney MS, Pluvinage JV, Mathur V, Hahn O, Morgens DW, et al. Lipid-droplet-accumulating microglia represent a dysfunctional and proinflammatory state in the aging brain. Nat Neurosci. 2020;23(2):194&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7595134</ArticleId><ArticleId IdType="pubmed">31959936</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreone BJ, Przybyla L, Llapashtica C, Rana A, Davis SS, van Lengerich B, Lin K, Shi J, Mei Y, Astarita G, et al. Alzheimer's-associated PLCgamma2 is a signaling node required for both TREM2 function and the inflammatory response in human microglia. Nat Neurosci. 2020;23(8):927&#x2013;938.</Citation><ArticleIdList><ArticleId IdType="pubmed">32514138</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer A, Stelzmann RA, Schnitzlein HN, Murtagh FR. An English translation of Alzheimer's 1907 paper, "Uber eine eigenartige Erkankung der Hirnrinde". Clin Anat. 1995;8(6):429&#x2013;431.</Citation><ArticleIdList><ArticleId IdType="pubmed">8713166</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C, Brazill JM, Liu S, Bello C, Zhu Y, Morimoto M, Cascio L, Pauly R, Diaz-Perez Z, Malicdan MCV, et al. Spermine synthase deficiency causes lysosomal dysfunction and oxidative stress in models of Snyder-Robinson syndrome. Nat Commun. 2017;8(1):1257.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5668419</ArticleId><ArticleId IdType="pubmed">29097652</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo J, Mohammed I, Warmlander SK, Hiruma Y, Graslund A, Abrahams JP. Endogenous polyamines reduce the toxicity of soluble abeta peptide aggregates associated with Alzheimer's disease. Biomacromolecules. 2014;15(6):1985&#x2013;1991.</Citation><ArticleIdList><ArticleId IdType="pubmed">24750033</ArticleId></ArticleIdList></Reference><Reference><Citation>Vemula PK, Jing Y, Cicolini J, Zhang H, Mockett BG, Abraham WC, Liu P. Altered brain arginine metabolism with age in the APPswe/PSEN1dE9 mouse model of Alzheimer's disease. Neurochem Int. 2020;140:104798.</Citation><ArticleIdList><ArticleId IdType="pubmed">32711019</ArticleId></ArticleIdList></Reference><Reference><Citation>van Veen S, Martin S, Van den Haute C, Benoy V, Lyons J, Vanhoutte R, Kahler JP, Decuypere JP, Gelders G, Lambie E, et al. ATP13A2 deficiency disrupts lysosomal polyamine export. Nature. 2020;578(7795):419&#x2013;424.</Citation><ArticleIdList><ArticleId IdType="pubmed">31996848</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Colonna M. Microglia in Alzheimer's disease at single-cell level. Are there common patterns in humans and mice? J Exp Med. 2021;218(9).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8302448</ArticleId><ArticleId IdType="pubmed">34292312</ArticleId></ArticleIdList></Reference><Reference><Citation>Gafson AR, Barthelemy NR, Bomont P, Carare RO, Durham HD, Julien JP, Kuhle J, Leppert D, Nixon RA, Weller RO, et al. Neurofilaments: neurobiological foundations for biomarker applications. Brain. 2020;143(7):1975&#x2013;1998.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7363489</ArticleId><ArticleId IdType="pubmed">32408345</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Andreasson U, Zetterberg H, Blennow K. Alzheimer's Disease Neuroimaging I: Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease. JAMA Neurol. 2017;74(5):557&#x2013;566.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5822204</ArticleId><ArticleId IdType="pubmed">28346578</ArticleId></ArticleIdList></Reference><Reference><Citation>Zetterberg H, Skillback T, Mattsson N, Trojanowski JQ, Portelius E, Shaw LM, Weiner MW, Blennow K. Alzheimer's Disease Neuroimaging I: Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression. JAMA Neurol. 2016;73(1):60&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5624219</ArticleId><ArticleId IdType="pubmed">26524180</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersson E, Janelidze S, Lampinen B, Nilsson M, Leuzy A, Stomrud E, Blennow K, Zetterberg H, Hansson O. Blood and cerebrospinal fluid neurofilament light differentially detect neurodegeneration in early Alzheimer's disease. Neurobiol Aging. 2020;95:143&#x2013;153.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7649343</ArticleId><ArticleId IdType="pubmed">32810755</ArticleId></ArticleIdList></Reference><Reference><Citation>Bacioglu M, Maia LF, Preische O, Schelle J, Apel A, Kaeser SA, Schweighauser M, Eninger T, Lambert M, Pilotto A, et al. Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases. Neuron. 2016;91(1):56&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">27292537</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsson B, Lautner R, Andreasson U, Ohrfelt A, Portelius E, Bjerke M, Holtta M, Rosen C, Olsson C, Strobel G, et al. CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Lancet Neurol. 2016;15(7):673&#x2013;684.</Citation><ArticleIdList><ArticleId IdType="pubmed">27068280</ArticleId></ArticleIdList></Reference><Reference><Citation>Benedet AL, Ashton NJ, Pascoal TA, Leuzy A, Mathotaarachchi S, Kang MS, Therriault J, Savard M, Chamoun M, Scholl M, et al. Plasma neurofilament light associates with Alzheimer's disease metabolic decline in amyloid-positive individuals. Alzheimers Dement (Amst) 2019;11:679&#x2013;689.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6816316</ArticleId><ArticleId IdType="pubmed">31673598</ArticleId></ArticleIdList></Reference><Reference><Citation>Arbizu J, Festari C, Altomare D, Walker Z, Bouwman F, Rivolta J, Orini S, Barthel H, Agosta F, Drzezga A, et al. Clinical utility of FDG-PET for the clinical diagnosis in MCI. Eur J Nucl Med Mol Imaging. 2018;45(9):1497&#x2013;1508.</Citation><ArticleIdList><ArticleId IdType="pubmed">29704037</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato T, Inui Y, Nakamura A, Ito K. Brain fluorodeoxyglucose (FDG) PET in dementia. Ageing Res Rev. 2016;30:73&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">26876244</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosconi L, Brys M, Glodzik-Sobanska L, De Santi S, Rusinek H, de Leon MJ. Early detection of Alzheimer's disease using neuroimaging. Exp Gerontol. 2007;42(1-2):129&#x2013;138.</Citation><ArticleIdList><ArticleId IdType="pubmed">16839732</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosconi L, Tsui WH, Herholz K, Pupi A, Drzezga A, Lucignani G, Reiman EM, Holthoff V, Kalbe E, Sorbi S, et al. Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias. J Nucl Med. 2008;49(3):390&#x2013;398.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3703818</ArticleId><ArticleId IdType="pubmed">18287270</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasrallah IM, Wolk DA. Multimodality imaging of Alzheimer disease and other neurodegenerative dementias. J Nucl Med. 2014;55(12):2003&#x2013;2011.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4702268</ArticleId><ArticleId IdType="pubmed">25413136</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmer ER, Parent MJ, Souza DG, Leuzy A, Lecrux C, Kim HI, Gauthier S, Pellerin L, Hamel E, Rosa-Neto P. [(18)F]FDG PET signal is driven by astroglial glutamate transport. Nat Neurosci. 2017;20(3):393&#x2013;395.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5378483</ArticleId><ArticleId IdType="pubmed">28135241</ArticleId></ArticleIdList></Reference><Reference><Citation>Born HA, Kim JY, Savjani RR, Das P, Dabaghian YA, Guo Q, Yoo JW, Schuler DR, Cirrito JR, Zheng H, et al. Genetic suppression of transgenic APP rescues Hypersynchronous network activity in a mouse model of Alzeimer's disease. J Neurosci. 2014;34(11):3826&#x2013;3840.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3951689</ArticleId><ArticleId IdType="pubmed">24623762</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez-Losa M, Tracy TE, Ma K, Verret L, Clemente-Perez A, Khan AS, Cobos I, Ho K, Gan L, Mucke L et al: Nav1.1-overexpressing interneuron transplants restore brain rhythms and cognition in a mouse model of Alzheimer&#x2019;s disease. Neuron 2018, 98(1):75&#x2013;89 E75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5886814</ArticleId><ArticleId IdType="pubmed">29551491</ArticleId></ArticleIdList></Reference><Reference><Citation>Baglietto-Vargas D, Forner S, Cai L, Martini AC, Trujillo-Estrada L, Swarup V, Nguyen MMT, Do Huynh K, Javonillo DI, Tran KM, et al. Generation of a humanized Abeta expressing mouse demonstrating aspects of Alzheimer's disease-like pathology. Nat Commun. 2021;12(1):2421.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8065162</ArticleId><ArticleId IdType="pubmed">33893290</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">35696185</PMID><DateCompleted><Year>2022</Year><Month>08</Month><Day>10</Day></DateCompleted><DateRevised><Year>2024</Year><Month>01</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>79</Volume><Issue>8</Issue><PubDate><Year>2022</Year><Month>Aug</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease: A Randomized Clinical Trial.</ArticleTitle><Pagination><StartPage>758</StartPage><EndPage>767</EndPage><MedlinePgn>758-767</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2022.1375</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Neurofibrillary tangles composed of aggregated tau protein are one of the neuropathological hallmarks of Alzheimer disease (AD) and correlate with clinical disease severity. Monoclonal antibodies targeting tau may have the potential to ameliorate AD progression by slowing or stopping the spread and/or accumulation of pathological tau.</AbstractText><AbstractText Label="OBJECTIVE">To evaluate the safety and efficacy of the monoclonal anti-tau antibody semorinemab in prodromal to mild AD.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">This phase 2 randomized, double-blind, placebo-controlled, parallel-group clinical trial was conducted between October 18, 2017, and July 16, 2020, at 97 sites in North America, Europe, and Australia. Individuals aged 50 to 80 years (inclusive) with prodromal to mild AD, Mini-Mental State Examination scores between 20 and 30 (inclusive), and confirmed &#x3b2;-amyloid pathology (by positron emission tomography or cerebrospinal fluid) were included.</AbstractText><AbstractText Label="INTERVENTIONS">During the 73-week blinded study period, participants received intravenous infusions of placebo or semorinemab (1500 mg, 4500 mg, or 8100 mg) every 2 weeks for the first 3 infusions and every 4 weeks thereafter.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">The primary outcomes were change from baseline on the Clinical Dementia Rating-Sum of Boxes score from baseline to week 73 and assessments of the safety and tolerability for semorinemab compared with placebo.</AbstractText><AbstractText Label="RESULTS">In the modified intent-to-treat cohort (n&#x2009;=&#x2009;422; mean [SD] age, 69.6 [7.0] years; 235 women [55.7%]), similar increases were seen on the Clinical Dementia Rating-Sum of Boxes score in the placebo (n&#x2009;=&#x2009;126; &#x394;&#x2009;=&#x2009;2.19 [95% CI, 1.74-2.63]) and semorinemab (1500 mg: n&#x2009;=&#x2009;86; &#x394;&#x2009;=&#x2009;2.36 [95% CI, 1.83-2.89]; 4500 mg: n&#x2009;=&#x2009;126; &#x394;&#x2009;=&#x2009;2.36 [95% CI, 1.92-2.79]; 8100 mg: n&#x2009;=&#x2009;84; &#x394;&#x2009;=&#x2009;2.41 [95% CI, 1.88-2.94]) arms. In the safety-evaluable cohort (n&#x2009;=&#x2009;441), similar proportions of participants experienced adverse events in the placebo (130 [93.1%]) and semorinemab (1500 mg: 89 [88.8%]; 4500 mg: 132 [94.7%]; 8100 mg: 90 [92.2%]) arms.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">In participants with prodromal to mild AD in this randomized clinical trial, semorinemab did not slow clinical AD progression compared with placebo throughout the 73-week study period but did demonstrate an acceptable and well-tolerated safety profile. Additional studies of anti-tau antibodies may be needed to determine the clinical utility of this therapeutic approach.</AbstractText><AbstractText Label="TRIAL REGISTRATION">ClinicalTrials.gov Identifier: NCT03289143.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Teng</LastName><ForeName>Edmond</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Early Clinical Development, Genentech Inc, South San Francisco, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manser</LastName><ForeName>Paul T</ForeName><Initials>PT</Initials><AffiliationInfo><Affiliation>Biostatistics, Genentech Inc, South San Francisco, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pickthorn</LastName><ForeName>Karen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Early Clinical Development, Genentech Inc, South San Francisco, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brunstein</LastName><ForeName>Flavia</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Product Development Safety, Genentech Inc, South San Francisco, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blendstrup</LastName><ForeName>Mira</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Clinical Operations, Genentech Inc, South San Francisco, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanabria Bohorquez</LastName><ForeName>Sandra</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Clinical Imaging Group, Genentech Inc, South San Francisco, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wildsmith</LastName><ForeName>Kristin R</ForeName><Initials>KR</Initials><AffiliationInfo><Affiliation>Biomarker Development, Genentech Inc, South San Francisco, California.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Now with Eisai Inc, Woodcliff Lake, New Jersey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toth</LastName><ForeName>Bali</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Biostatistics, Genentech Inc, South San Francisco, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dolton</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Roche Products Pty Limited, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramakrishnan</LastName><ForeName>Vidya</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Clinical Pharmacology, Genentech Inc, South San Francisco, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bobbala</LastName><ForeName>Ashwini</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Product Development Safety, Genentech Inc, South San Francisco, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sikkes</LastName><ForeName>Sietske A M</ForeName><Initials>SAM</Initials><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Amsterdam Neuroscience, Amsterdam University Medical Center, VU University Amsterdam, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical, Neuro- and Developmental Psychology, VU University, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ward</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Early Clinical Development, Genentech Inc, South San Francisco, California.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Now with Alector Inc, South San Francisco, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fuji</LastName><ForeName>Reina N</ForeName><Initials>RN</Initials><AffiliationInfo><Affiliation>Safety Assessment, Genentech Inc, South San Francisco, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kerchner</LastName><ForeName>Geoffrey A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>F. Hoffmann-La Roche AG, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Tauriel Investigators</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT03289143</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG066462</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Teng reported a patent for semorinemab pending (no royalties received) and is a shareholder of F. Hoffmann La Roche Ltd as a full-time employee of Genentech Inc. Dr Manser reported personal fees from Genentech Inc during the conduct of the study and is a shareholder of F. Hoffmann La Roche Ltd. Dr Blendstrup is a shareholder of F. Hoffmann La Roche Ltd as an employee of Genentech Inc. Dr Sanabria Bohorquez reported personal fees from Genentech during the conduct of the study and outside the submitted work. Dr Wildsmith reported personal fees from Genentech Inc outside the submitted work and is a shareholder of F. Hoffmann La Roche Ltd as a previous employee of Genentech Inc. Dr Dolton is a shareholder of F. Hoffmann La Roche Ltd as an employee of Genentech Inc. Dr Ramakrishnan is a shareholder of F. Hoffmann La Roche Ltd as an employee of Genentech Inc. Dr Sikkes is the developer of the Amsterdam Instrumental Activities of Daily Living Questionnaire (A-IADL-Q) and reported license fees for this during the conduct of the study; grants from Health~Holland and Topsector Life Sciences &amp; Health outside the submitted work; consultancy fees from Toyama, Boehringer, Biogen, and Lundbeck outside the submitted work; and a patent for A-IADL-Q licensed to Genentech, Roche, Vivoryon, Alzheon, VtV Therapeutics, Green Valley; all consultancy and license fees, and grants are paid to the organization. Dr Ward reported a patent for semorinemab pending (no royalties received). Dr Kerchner is a shareholder of F. Hoffmann La Roche Ltd as an employee of Genentech Inc and has a patent for semorinemab pending (no royalties received). No other disclosures were reported.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Farnbach</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kyndt</LastName><ForeName>Chris</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>O'Brien</LastName><ForeName>Terence</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yassi</LastName><ForeName>Nawaf</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schwartz</LastName><ForeName>Raymond</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lieten</LastName><ForeName>Siddhartha</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vandenberghe</LastName><ForeName>Rik</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vanhee</LastName><ForeName>Frederik</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bergeron</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Black</LastName><ForeName>Sandra</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cohen</LastName><ForeName>Sharon</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frank</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nisker</LastName><ForeName>William</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tartaglia</LastName><ForeName>Maria Carmela</ForeName><Initials>MC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Justesen</LastName><ForeName>Annette</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alexandersen</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nielsen</LastName><ForeName>Soren</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Areovimata</LastName><ForeName>Anna</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anthony</LastName><ForeName>Pierre</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Belliard</LastName><ForeName>Serge</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blanc</LastName><ForeName>Fr&#xe9;d&#xe9;ric</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ceccaldi</LastName><ForeName>Mathieu</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dubois</LastName><ForeName>Bruno</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Krolak-Salmon</LastName><ForeName>Pierre</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mollion</LastName><ForeName>H&#xe9;l&#xe8;ne</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pasquier</LastName><ForeName>Florence</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grimmer</LastName><ForeName>Timo</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kottke-Arbeiter</LastName><ForeName>Monika Elisabeth</ForeName><Initials>ME</Initials></Investigator><Investigator ValidYN="Y"><LastName>Laske</LastName><ForeName>Christoph</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Peters</LastName><ForeName>Oliver</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Polivka</LastName><ForeName>D&#xf6;rte</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>von Arnim</LastName><ForeName>Christine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bruno</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>De Lena</LastName><ForeName>Carlo</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cassetta</LastName><ForeName>Emanuele</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Centonze</LastName><ForeName>Diego</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Logroscino</LastName><ForeName>Giancarlo</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dautzenberg</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rutgers</LastName><ForeName>Sterre</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Prins</LastName><ForeName>Niels</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Czarnecki</LastName><ForeName>Maciej</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dobryniewski</LastName><ForeName>Jacek</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ilkowski</LastName><ForeName>Jan</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Klodowska</LastName><ForeName>Gabriela</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Krygowska-Wajs</LastName><ForeName>Anna</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kucharski</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mickielewicz</LastName><ForeName>Anatol</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ratajczak</LastName><ForeName>Marcin</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zboch</LastName><ForeName>Marzena</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zielinski</LastName><ForeName>Tomasz</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Abizanda Soler</LastName><ForeName>Pedro</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ag&#xfc;era Morales</LastName><ForeName>Eduardo</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Baquero Toledo</LastName><ForeName>Miquel</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blesa Gonz&#xe1;lez</LastName><ForeName>Rafael</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boada Rovira</LastName><ForeName>Merc&#xe8;</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Del Olmo Rodriguez</LastName><ForeName>Antonio</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Krupinski</LastName><ForeName>Jerzy</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Linazasoro Cristobal</LastName><ForeName>Gurutz</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>L&#xf3;pez Arrieta</LastName><ForeName>Jes&#xfa;s</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Riverol Fernandez</LastName><ForeName>Mario</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sanchez Del Valle Diaz</LastName><ForeName>Raquel</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vi&#xf1;uela Fernandez</LastName><ForeName>F&#xe9;lix</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jonsson</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>&#xd6;stlund</LastName><ForeName>Henrik</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>MacSweeney</LastName><ForeName>Josephine Emer</ForeName><Initials>JE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mummery</LastName><ForeName>Catherine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Agronin</LastName><ForeName>Marc</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ala</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bond</LastName><ForeName>Wendy</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schaerf</LastName><ForeName>Frederick</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brody</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Edwards</LastName><ForeName>Keith</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Forchetti</LastName><ForeName>Concetta</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sood</LastName><ForeName>Ajay</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Geldmacher</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goldstein</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goodman</LastName><ForeName>Ira</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hart</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Honig</LastName><ForeName>Lawrence</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Justiz</LastName><ForeName>William</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Levey</LastName><ForeName>Allan</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Losk</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marshall</LastName><ForeName>Gad</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martinez</LastName><ForeName>Walter</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>McAllister</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>McElveen</LastName><ForeName>William Alvin</ForeName><Initials>WA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maldonado-Robles</LastName><ForeName>Orlando</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Murphy</LastName><ForeName>Cynthia</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nair</LastName><ForeName>Malini</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nair</LastName><ForeName>Anil</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Omidvar</LastName><ForeName>Omid</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oskooilar</LastName><ForeName>Nader</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Porsteinsson</LastName><ForeName>Anton</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosenbloom</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Russell</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sajjadi</LastName><ForeName>Seyed Ahmad</ForeName><Initials>SA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pierce</LastName><ForeName>Aimee</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Salloway</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sha</LastName><ForeName>Sharon</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shah</LastName><ForeName>Raj</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sharma</LastName><ForeName>Sanjiv</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>William</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stein</LastName><ForeName>Lee</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stoukides</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thein</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Turner</LastName><ForeName>Raymond</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Watson</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weisman</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>13</Day><Hour>11</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>6</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35696185</ArticleId><ArticleId IdType="pmc">PMC9194753</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2022.1375</ArticleId><ArticleId IdType="pii">2793069</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Spillantini MG, Goedert M. Tau pathology and neurodegeneration. Lancet Neurol. 2013;12(6):609-622. doi:10.1016/S1474-4422(13)70090-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(13)70090-5</ArticleId><ArticleId IdType="pubmed">23684085</ArticleId></ArticleIdList></Reference><Reference><Citation>Long JM, Holtzman DM. Alzheimer disease: an update on pathobiology and treatment strategies. Cell. 2019;179(2):312-339. doi:10.1016/j.cell.2019.09.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2019.09.001</ArticleId><ArticleId IdType="pmc">PMC6778042</ArticleId><ArticleId IdType="pubmed">31564456</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Staging of Alzheimer&#x2019;s disease-related neurofibrillary changes. Neurobiol Aging. 1995;16(3):271-278. doi:10.1016/0197-4580(95)00021-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0197-4580(95)00021-6</ArticleId><ArticleId IdType="pubmed">7566337</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Alafuzoff I, Bigio EH, et al. . Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol. 2012;71(5):362-381. doi:10.1097/NEN.0b013e31825018f7</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e31825018f7</ArticleId><ArticleId IdType="pmc">PMC3560290</ArticleId><ArticleId IdType="pubmed">22487856</ArticleId></ArticleIdList></Reference><Reference><Citation>Pontecorvo MJ, Devous MD Sr, Navitsky M, et al. ; 18F-AV-1451-A05 investigators . Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition. Brain. 2017;140(3):748-763. doi:10.1093/brain/aww334</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aww334</ArticleId><ArticleId IdType="pmc">PMC5382945</ArticleId><ArticleId IdType="pubmed">28077397</ArticleId></ArticleIdList></Reference><Reference><Citation>Teng E, Ward M, Manser PT, et al. . Cross-sectional associations between [18F]GTP1 tau PET and cognition in Alzheimer&#x2019;s disease. Neurobiol Aging. 2019;81:138-145. doi:10.1016/j.neurobiolaging.2019.05.026</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2019.05.026</ArticleId><ArticleId IdType="pubmed">31280117</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibbons GS, Lee VMY, Trojanowski JQ. Mechanisms of cell-to-cell transmission of pathological tau: a review. JAMA Neurol. 2019;76(1):101-108. doi:10.1001/jamaneurol.2018.2505</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2018.2505</ArticleId><ArticleId IdType="pmc">PMC6382549</ArticleId><ArticleId IdType="pubmed">30193298</ArticleId></ArticleIdList></Reference><Reference><Citation>Colin M, Dujardin S, Schraen-Maschke S, et al. . From the prion-like propagation hypothesis to therapeutic strategies of anti-tau immunotherapy. Acta Neuropathol. 2020;139(1):3-25. doi:10.1007/s00401-019-02087-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-019-02087-9</ArticleId><ArticleId IdType="pmc">PMC6942016</ArticleId><ArticleId IdType="pubmed">31686182</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayalon G, Lee SH, Adolfsson O, et al. . Antibody semorinemab reduces tau pathology in a transgenic mouse model and engages tau in patients with Alzheimer&#x2019;s disease. Sci Transl Med. 2021;13(593):eabb2639. doi:10.1126/scitranslmed.abb2639</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abb2639</ArticleId><ArticleId IdType="pubmed">33980574</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulz KF, Altman DG, Moher D; CONSORT Group . CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med. 2010;152(11):726-732. doi:10.7326/0003-4819-152-11-201006010-00232</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-152-11-201006010-00232</ArticleId><ArticleId IdType="pubmed">20335313</ArticleId></ArticleIdList></Reference><Reference><Citation>World Medical Association . World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191-2194. doi:10.1001/jama.2013.281053</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2013.281053</ArticleId><ArticleId IdType="pubmed">24141714</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert MS, DeKosky ST, Dickson D, et al. . The diagnosis of mild cognitive impairment due to Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7(3):270-279. doi:10.1016/j.jalz.2011.03.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2011.03.008</ArticleId><ArticleId IdType="pmc">PMC3312027</ArticleId><ArticleId IdType="pubmed">21514249</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann GM, Knopman DS, Chertkow H, et al. . The diagnosis of dementia due to Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7(3):263-269. doi:10.1016/j.jalz.2011.03.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2011.03.005</ArticleId><ArticleId IdType="pmc">PMC3312024</ArticleId><ArticleId IdType="pubmed">21514250</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-mental state&#x201d;: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-198. doi:10.1016/0022-3956(75)90026-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-3956(75)90026-6</ArticleId><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412-2414. doi:10.1212/WNL.43.11.2412-a</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.43.11.2412-a</ArticleId><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Randolph C, Tierney MC, Mohr E, Chase TN. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol. 1998;20(3):310-319. doi:10.1076/jcen.20.3.310.823</Citation><ArticleIdList><ArticleId IdType="doi">10.1076/jcen.20.3.310.823</ArticleId><ArticleId IdType="pubmed">9845158</ArticleId></ArticleIdList></Reference><Reference><Citation>Piramal Imaging . Neuraceq (florbetaben F 18 injection) [package insert]. Updated March 2014. Accessed December 28, 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204677s000lbl.pdf</Citation></Reference><Reference><Citation>Eli Lilly and Co . Amyvid (florbetapir F 18 injection) [package insert]. Updated April 2012. Accessed December 29, 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202008s000lbl.pdf</Citation></Reference><Reference><Citation>Healthcare GE. Vizamyl (flutemetamol F 18 injection) [package insert]. Updated April 2016. Accessed December 28, 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/203137s005lbl.pdf</Citation></Reference><Reference><Citation>Ng KP, Pascoal TA, Mathotaarachchi S, et al. . Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain. Alzheimers Res Ther. 2017;9(1):25. doi:10.1186/s13195-017-0253-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-017-0253-y</ArticleId><ArticleId IdType="pmc">PMC5374697</ArticleId><ArticleId IdType="pubmed">28359327</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg L, Miller JP, Storandt M, et al. . Mild senile dementia of the Alzheimer type: 2: longitudinal assessment. Ann Neurol. 1988;23(5):477-484. doi:10.1002/ana.410230509</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410230509</ArticleId><ArticleId IdType="pubmed">3389756</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohs RC, Knopman D, Petersen RC, et al. . Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer&#x2019;s Disease Assessment Scale that broaden its scope: the Alzheimer&#x2019;s Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11(suppl 2):S13-S21. doi:10.1097/00002093-199700112-00003</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00002093-199700112-00003</ArticleId><ArticleId IdType="pubmed">9236948</ArticleId></ArticleIdList></Reference><Reference><Citation>Galasko D, Bennett D, Sano M, et al. . An inventory to assess activities of daily living for clinical trials in Alzheimer&#x2019;s disease: the Alzheimer&#x2019;s Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11(suppl 2):S33-S39. doi:10.1097/00002093-199700112-00005</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00002093-199700112-00005</ArticleId><ArticleId IdType="pubmed">9236950</ArticleId></ArticleIdList></Reference><Reference><Citation>Sikkes SA, de Lange-de Klerk ES, Pijnenburg YA, et al. . A new informant-based questionnaire for instrumental activities of daily living in dementia. Alzheimers Dement. 2012;8(6):536-543. doi:10.1016/j.jalz.2011.08.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2011.08.006</ArticleId><ArticleId IdType="pubmed">23102123</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanabria Boh&#xf3;rquez S, Marik J, Ogasawara A, et al. . [18F]GTP1 (Genentech Tau Probe 1), a radioligand for detecting neurofibrillary tangle tau pathology in Alzheimer&#x2019;s disease. Eur J Nucl Med Mol Imaging. 2019;46(10):2077-2089. doi:10.1007/s00259-019-04399-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-019-04399-0</ArticleId><ArticleId IdType="pubmed">31254035</ArticleId></ArticleIdList></Reference><Reference><Citation>Yanamandra K, Patel TK, Jiang H, et al. . Anti-tau antibody administration increases plasma tau in transgenic mice and patients with tauopathy. Sci Transl Med. 2017;9(386):eaal2029. doi:10.1126/scitranslmed.aal2029</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aal2029</ArticleId><ArticleId IdType="pmc">PMC5727571</ArticleId><ArticleId IdType="pubmed">28424326</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xf6;ll M, Lockhart SN, Schonhaut DR, et al. . PET imaging of tau deposition in the aging human brain. Neuron. 2016;89(5):971-982. doi:10.1016/j.neuron.2016.01.028</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.01.028</ArticleId><ArticleId IdType="pmc">PMC4779187</ArticleId><ArticleId IdType="pubmed">26938442</ArticleId></ArticleIdList></Reference><Reference><Citation>Goos JD, Henneman WJ, Sluimer JD, et al. . Incidence of cerebral microbleeds: a longitudinal study in a memory clinic population. Neurology. 2010;74(24):1954-1960. doi:10.1212/WNL.0b013e3181e396ea</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181e396ea</ArticleId><ArticleId IdType="pubmed">20548041</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostrowitzki S, Lasser RA, Dorflinger E, et al. ; SCarlet RoAD Investigators . A phase III randomized trial of gantenerumab in prodromal Alzheimer&#x2019;s disease. Alzheimers Res Ther. 2017;9(1):95. doi:10.1186/s13195-017-0318-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-017-0318-y</ArticleId><ArticleId IdType="pmc">PMC5723032</ArticleId><ArticleId IdType="pubmed">29221491</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlson C, Siemers E, Hake A, et al. . Amyloid-related imaging abnormalities from trials of solanezumab for Alzheimer&#x2019;s disease. Alzheimers Dement (Amst). 2016;2:75-85. doi:10.1016/j.dadm.2016.02.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dadm.2016.02.004</ArticleId><ArticleId IdType="pmc">PMC4879647</ArticleId><ArticleId IdType="pubmed">27239538</ArticleId></ArticleIdList></Reference><Reference><Citation>Ketter N, Brashear HR, Bogert J, et al. . Central review of amyloid-related imaging abnormalities in two phase III clinical trials of bapineuzumab in mild-to-moderate Alzheimer&#x2019;s disease patients. J Alzheimers Dis. 2017;57(2):557-573. doi:10.3233/JAD-160216</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-160216</ArticleId><ArticleId IdType="pubmed">28269765</ArticleId></ArticleIdList></Reference><Reference><Citation>Teng E, Manser P, Hu N, et al. . Comparison of the FCSRT and RBANS in screening for early AD clinical trials: Enrichment for disease progression. J Prev Alzheimers Dis. 2021;8(4):S27-S28.</Citation></Reference><Reference><Citation>Jack CR Jr, Wiste HJ, Schwarz CG, et al. . Longitudinal tau PET in ageing and Alzheimer&#x2019;s disease. Brain. 2018;141(5):1517-1528. doi:10.1093/brain/awy059</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awy059</ArticleId><ArticleId IdType="pmc">PMC5917767</ArticleId><ArticleId IdType="pubmed">29538647</ArticleId></ArticleIdList></Reference><Reference><Citation>Pontecorvo MJ, Devous MD, Kennedy I, et al. . A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer&#x2019;s disease dementia. Brain. 2019;142(6):1723-1735. doi:10.1093/brain/awz090</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz090</ArticleId><ArticleId IdType="pmc">PMC6536847</ArticleId><ArticleId IdType="pubmed">31009046</ArticleId></ArticleIdList></Reference><Reference><Citation>Logovinsky V, Satlin A, Lai R, et al. . Safety and tolerability of BAN2401: a clinical study in Alzheimer&#x2019;s disease with a protofibril selective A&#x3b2; antibody. Alzheimers Res Ther. 2016;8(1):14. doi:10.1186/s13195-016-0181-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-016-0181-2</ArticleId><ArticleId IdType="pmc">PMC4822297</ArticleId><ArticleId IdType="pubmed">27048170</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida K, Moein A, Bittner T, et al. . Pharmacokinetics and pharmacodynamic effect of crenezumab on plasma and cerebrospinal fluid beta-amyloid in patients with mild-to-moderate Alzheimer&#x2019;s disease. Alzheimers Res Ther. 2020;12(1):16. doi:10.1186/s13195-020-0580-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-020-0580-2</ArticleId><ArticleId IdType="pmc">PMC6977279</ArticleId><ArticleId IdType="pubmed">31969177</ArticleId></ArticleIdList></Reference><Reference><Citation>West T, Hu Y, Verghese PB, et al. . Preclinical and clinical development of ABBV-8E12, a humanized anti-tau antibody, for treatment of Alzheimer&#x2019;s disease and other tauopathies. J Prev Alzheimers Dis. 2017;4(4):236-241. doi:10.14283/jpad.2017.36</Citation><ArticleIdList><ArticleId IdType="doi">10.14283/jpad.2017.36</ArticleId><ArticleId IdType="pubmed">29181488</ArticleId></ArticleIdList></Reference><Reference><Citation>Boxer AL, Qureshi I, Ahlijanian M, et al. . Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial. Lancet Neurol. 2019;18(6):549-558. doi:10.1016/S1474-4422(19)30139-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(19)30139-5</ArticleId><ArticleId IdType="pubmed">31122495</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandermeeren M, Borgers M, Van Kolen K, et al. . Anti-tau monoclonal antibodies derived from soluble and filamentous tau show diverse functional properties in vitro and in vivo. J Alzheimers Dis. 2018;65(1):265-281. doi:10.3233/JAD-180404</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-180404</ArticleId><ArticleId IdType="pubmed">30040731</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert M, Mairet-Coello G, Danis C, et al. . Prevention of tau seeding and propagation by immunotherapy with a central tau epitope antibody. Brain. 2019;142(6):1736-1750. doi:10.1093/brain/awz100</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz100</ArticleId><ArticleId IdType="pmc">PMC6536853</ArticleId><ArticleId IdType="pubmed">31038156</ArticleId></ArticleIdList></Reference><Reference><Citation>Courade JP, Angers R, Mairet-Coello G, et al. . Epitope determines efficacy of therapeutic anti-tau antibodies in a functional assay with human Alzheimer tau. Acta Neuropathol. 2018;136(5):729-745. doi:10.1007/s00401-018-1911-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-1911-2</ArticleId><ArticleId IdType="pmc">PMC6208734</ArticleId><ArticleId IdType="pubmed">30238240</ArticleId></ArticleIdList></Reference><Reference><Citation>Dujardin S, Commins C, Lathuiliere A, et al. . Tau molecular diversity contributes to clinical heterogeneity in Alzheimer&#x2019;s disease. Nat Med. 2020;26(8):1256-1263. doi:10.1038/s41591-020-0938-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0938-9</ArticleId><ArticleId IdType="pmc">PMC7603860</ArticleId><ArticleId IdType="pubmed">32572268</ArticleId></ArticleIdList></Reference><Reference><Citation>Wesseling H, Mair W, Kumar M, et al. . Tau PTM profiles identify patient heterogeneity and stages of Alzheimer&#x2019;s disease. Cell. 2020;183(6):1699-1713.e13. doi:10.1016/j.cell.2020.10.029</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.10.029</ArticleId><ArticleId IdType="pmc">PMC8168922</ArticleId><ArticleId IdType="pubmed">33188775</ArticleId></ArticleIdList></Reference><Reference><Citation>Moloney CM, Lowe VJ, Murray ME. Visualization of neurofibrillary tangle maturity in Alzheimer&#x2019;s disease: a clinicopathologic perspective for biomarker research. Alzheimers Dement. 2021;17(9):1554-1574. doi:10.1002/alz.12321</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.12321</ArticleId><ArticleId IdType="pmc">PMC8478697</ArticleId><ArticleId IdType="pubmed">33797838</ArticleId></ArticleIdList></Reference><Reference><Citation>Dujardin S, B&#xe9;gard S, Caillierez R, et al. . Ectosomes: a new mechanism for non-exosomal secretion of tau protein. PLoS One. 2014;9(6):e100760. doi:10.1371/journal.pone.0100760</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0100760</ArticleId><ArticleId IdType="pmc">PMC4074092</ArticleId><ArticleId IdType="pubmed">24971751</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang CW, Shao E, Mucke L. Tau: Enabler of diverse brain disorders and target of rapidly evolving therapeutic strategies. Science. 2021;371(6532):eabb8255. doi:10.1126/science.abb8255</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abb8255</ArticleId><ArticleId IdType="pmc">PMC8118650</ArticleId><ArticleId IdType="pubmed">33632820</ArticleId></ArticleIdList></Reference><Reference><Citation>Shulman M, Rajagovindan R, Kong J, et al. . Top-line results from TANGO, a Phase 2 study of gosuranemab in participants with mild cognitive impairment due to Alzheimer&#x2019;s disease and mild Alzheimer&#x2019;s disease. J Prev Alzheimers Dis. 2021;8(4):S65-S66.</Citation></Reference><Reference><Citation>Florian H, Wang D, Guo Q, Jin Z, Fisseha N, Rendenbach-Mueller B. Phase 2 study of tilavonemab, an anti-tau antibody, in early Alzheimer&#x2019;s disease. J Prev Alzheimers Dis. 2021;8(4):S50-S51.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">35697880</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>24</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-0533</ISSN><JournalIssue CitedMedium="Internet"><Volume>144</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Acta neuropathologica</Title><ISOAbbreviation>Acta Neuropathol</ISOAbbreviation></Journal><ArticleTitle>Frequency of LATE neuropathologic change across the spectrum of Alzheimer's disease neuropathology: combined data from 13 community-based or population-based autopsy cohorts.</ArticleTitle><Pagination><StartPage>27</StartPage><EndPage>44</EndPage><MedlinePgn>27-44</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00401-022-02444-1</ELocationID><Abstract><AbstractText>Limbic-predominant age-related TDP-43 encephalopathy neuropathologic change (LATE-NC) and Alzheimer's disease neuropathologic change (ADNC) are each associated with substantial cognitive impairment in aging populations. However, the prevalence of LATE-NC across the full range of ADNC remains uncertain. To address this knowledge gap, neuropathologic, genetic, and clinical data were compiled from 13 high-quality community- and population-based longitudinal studies. Participants were recruited from United States (8 cohorts, including one focusing on Japanese-American men), United Kingdom (2 cohorts), Brazil, Austria, and Finland. The total number of participants included was 6196, and the average age of death was 88.1&#xa0;years. Not all data were available on each individual and there were differences between the cohorts in study designs and the amount of missing data. Among those with known cognitive status before death (n&#x2009;=&#x2009;5665), 43.0% were cognitively normal, 14.9% had MCI, and 42.4% had dementia-broadly consistent with epidemiologic data in this age group. Approximately 99% of participants (n&#x2009;=&#x2009;6125) had available CERAD neuritic amyloid plaque score data. In this subsample, 39.4% had autopsy-confirmed LATE-NC of any stage. Among brains with "frequent" neuritic amyloid plaques, 54.9% had comorbid LATE-NC, whereas in brains with no detected neuritic amyloid plaques, 27.0% had LATE-NC. Data on LATE-NC stages were available for 3803 participants, of which 25% had LATE-NC stage&#x2009;&gt;&#x2009;1 (associated with cognitive impairment). In the subset of individuals with Thal A&#x3b2; phase&#x2009;=&#x2009;0 (lacking detectable A&#x3b2; plaques), the brains with LATE-NC had relatively more severe primary age-related tauopathy (PART). A total of 3267 participants had available clinical data relevant to frontotemporal dementia (FTD), and none were given the clinical diagnosis of definite FTD nor the pathological diagnosis of frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP). In the 10 cohorts with detailed neurocognitive assessments proximal to death, cognition tended to be worse with LATE-NC across the full spectrum of ADNC severity. This study provided a credible estimate of the current prevalence of LATE-NC in advanced age. LATE-NC was seen in almost 40% of participants and often, but not always, coexisted with Alzheimer's disease neuropathology.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nelson</LastName><ForeName>Peter T</ForeName><Initials>PT</Initials><AffiliationInfo><Affiliation>University of Kentucky, Rm 311 Sanders-Brown Center on Aging, Lexington, KY, USA. pnels2@email.uky.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brayne</LastName><ForeName>Carol</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flanagan</LastName><ForeName>Margaret E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Northwestern University Medical Center, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abner</LastName><ForeName>Erin L</ForeName><Initials>EL</Initials><AffiliationInfo><Affiliation>University of Kentucky, Rm 311 Sanders-Brown Center on Aging, Lexington, KY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agrawal</LastName><ForeName>Sonal</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Rush University Medical Center, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Attems</LastName><ForeName>Johannes</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Newcastle University, Newcastle upon Tyne, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castellani</LastName><ForeName>Rudolph J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Northwestern University Medical Center, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corrada</LastName><ForeName>Maria M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>University of California, Irvine, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cykowski</LastName><ForeName>Matthew D</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Houston Methodist Hospital, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>University of Kentucky, Rm 311 Sanders-Brown Center on Aging, Lexington, KY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dickson</LastName><ForeName>Dennis W</ForeName><Initials>DW</Initials><AffiliationInfo><Affiliation>Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dugger</LastName><ForeName>Brittany N</ForeName><Initials>BN</Initials><AffiliationInfo><Affiliation>University of California, Davis, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ervin</LastName><ForeName>John F</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Duke University, Durham, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fleming</LastName><ForeName>Jane</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graff-Radford</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grinberg</LastName><ForeName>Lea T</ForeName><Initials>LT</Initials><AffiliationInfo><Affiliation>University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Sao Paulo Medical School, Sao Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hokkanen</LastName><ForeName>Suvi R K</ForeName><Initials>SRK</Initials><AffiliationInfo><Affiliation>University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hunter</LastName><ForeName>Sally</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kapasi</LastName><ForeName>Alifiya</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Rush University Medical Center, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kawas</LastName><ForeName>Claudia H</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>University of California, Irvine, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keage</LastName><ForeName>Hannah A D</ForeName><Initials>HAD</Initials><AffiliationInfo><Affiliation>University of South Australia, Adelaide, SA, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keene</LastName><ForeName>C Dirk</ForeName><Initials>CD</Initials><AffiliationInfo><Affiliation>University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kero</LastName><ForeName>Mia</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>University of Helsinki and Helsinki University Hospital, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knopman</LastName><ForeName>David S</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kouri</LastName><ForeName>Naomi</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kovacs</LastName><ForeName>Gabor G</ForeName><Initials>GG</Initials><AffiliationInfo><Affiliation>Tanz Centre for Research in Neurodegenerative Disease, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory Medicine Program, University Health Network, Toronto, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Neurology, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Labuzan</LastName><ForeName>Sydney A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Larson</LastName><ForeName>Eric B</ForeName><Initials>EB</Initials><AffiliationInfo><Affiliation>Kaiser Permanente Washington Health Research Institute, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Latimer</LastName><ForeName>Caitlin S</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leite</LastName><ForeName>Renata E P</ForeName><Initials>REP</Initials><AffiliationInfo><Affiliation>University of Sao Paulo Medical School, Sao Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matchett</LastName><ForeName>Billie J</ForeName><Initials>BJ</Initials><AffiliationInfo><Affiliation>Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matthews</LastName><ForeName>Fiona E</ForeName><Initials>FE</Initials><AffiliationInfo><Affiliation>Newcastle University, Newcastle upon Tyne, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Merrick</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montine</LastName><ForeName>Thomas J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murray</LastName><ForeName>Melissa E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Myllykangas</LastName><ForeName>Liisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>University of Helsinki and Helsinki University Hospital, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nag</LastName><ForeName>Sukriti</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Rush University Medical Center, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nelson</LastName><ForeName>Ruth S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Emory University, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neltner</LastName><ForeName>Janna H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>University of Kentucky, Rm 311 Sanders-Brown Center on Aging, Lexington, KY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Aivi T</ForeName><Initials>AT</Initials><AffiliationInfo><Affiliation>Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Polvikoski</LastName><ForeName>Tuomo</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Newcastle University, Newcastle upon Tyne, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reichard</LastName><ForeName>R Ross</ForeName><Initials>RR</Initials><AffiliationInfo><Affiliation>Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodriguez</LastName><ForeName>Roberta D</ForeName><Initials>RD</Initials><AffiliationInfo><Affiliation>University of Sao Paulo Medical School, Sao Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suemoto</LastName><ForeName>Claudia K</ForeName><Initials>CK</Initials><AffiliationInfo><Affiliation>University of Sao Paulo Medical School, Sao Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Shih-Hsiu J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Duke University, Durham, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wharton</LastName><ForeName>Stephen B</ForeName><Initials>SB</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>White</LastName><ForeName>Lon</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Pacific Health Research and Education Institute, Honolulu, HI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Julie A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Rush University Medical Center, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K08 AG065463</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG061111</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG054449</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 NS118584</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U.1052.00.0013</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 AG062517</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066519</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UF1 NS125417</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G0601022</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P30 AG010161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG038651</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG064233</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066509</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MRC/G0900582</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 AG022018</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG006786</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG057187</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG072975</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G0900582</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>RF1 AG069052</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG072946</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG021055</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG034676</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG021886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG067482</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG072080</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 AG053435</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R33 AG058738</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UF1 AG057707</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG072977</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 AG065426</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062677</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG069701</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG072958</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MRC/G9901400</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P30 AG072972</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G9901400</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>U19 AG066567</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Acta Neuropathol</MedlineTA><NlmUniqueID>0412041</NlmUniqueID><ISSNLinking>0001-6322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001344" MajorTopicYN="N">Autopsy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009422" MajorTopicYN="Y">Nervous System Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ACT</Keyword><Keyword MajorTopicYN="N">ADRD</Keyword><Keyword MajorTopicYN="N">APOE</Keyword><Keyword MajorTopicYN="N">Biobank for aging studies</Keyword><Keyword MajorTopicYN="N">CC75C</Keyword><Keyword MajorTopicYN="N">CFAS</Keyword><Keyword MajorTopicYN="N">Epidemiology</Keyword><Keyword MajorTopicYN="N">HAAS</Keyword><Keyword MajorTopicYN="N">Mayo clinic study of aging</Keyword><Keyword MajorTopicYN="N">NFT</Keyword><Keyword MajorTopicYN="N">Nondemented</Keyword><Keyword MajorTopicYN="N">Nun study</Keyword><Keyword MajorTopicYN="N">Oldest-old</Keyword><Keyword MajorTopicYN="N">ROS-MAP</Keyword><Keyword MajorTopicYN="N">Tau</Keyword><Keyword MajorTopicYN="N">The 90&#x2009;+&#x2009;study</Keyword><Keyword MajorTopicYN="N">VITA</Keyword><Keyword MajorTopicYN="N">Vantaa 85&#x2009;+&#x2009;</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>1</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>5</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>5</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>13</Day><Hour>23</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>10</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35697880</ArticleId><ArticleId IdType="mid">NIHMS1838461</ArticleId><ArticleId IdType="pmc">PMC9552938</ArticleId><ArticleId IdType="doi">10.1007/s00401-022-02444-1</ArticleId><ArticleId IdType="pii">10.1007/s00401-022-02444-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>(2017) https://www.ssa.gov/oact/STATS/table4c6.html. Accessed 14 Dec 2021</Citation></Reference><Reference><Citation>(2021) Provisional life expectancy estimates for January through June, 2020. 
https://www.cdc.gov/nchs/data/vsrr/VSRR10-508.pdf. Accessed 14 Dec 2021</Citation></Reference><Reference><Citation>Agrawal S, Yu L, Kapasi A, James BD, Arfanakis K, Barnes LL et al. (2021) Limbic-predominant age-related TDP-43 encephalopathy neuropathologic change and microvascular pathologies in community-dwelling older persons. Brain Pathol. 10.1111/bpa.12939</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bpa.12939</ArticleId><ArticleId IdType="pmc">PMC8363209</ArticleId><ArticleId IdType="pubmed">33624322</ArticleId></ArticleIdList></Reference><Reference><Citation>Alafuzoff I, Arzberger T, Al-Sarraj S, Bodi I, Bogdanovic N, Braak H et al. (2008) Staging of neurofibrillary pathology in Alzheimer&#x2019;s disease: a study of the BRAINNEt Europe consortium. Brain Pathol 18:484&#x2013;496. 10.1111/j.1750-3639.2008.00147.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1750-3639.2008.00147.x</ArticleId><ArticleId IdType="pmc">PMC2659377</ArticleId><ArticleId IdType="pubmed">18371174</ArticleId></ArticleIdList></Reference><Reference><Citation>Alafuzoff I, Pikkarainen M, Arzberger T, Thal DR, Al-Sarraj S, Bell J et al. (2008) Inter-laboratory comparison of neuropathological assessments of beta-amyloid protein: a study of the brainnet Europe consortium. Acta Neuropathol 115:533&#x2013;546. 10.1007/s00401-008-0358-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-008-0358-2</ArticleId><ArticleId IdType="pubmed">18343933</ArticleId></ArticleIdList></Reference><Reference><Citation>Alafuzoff I, Thal DR, Arzberger T, Bogdanovic N, Al-Sarraj S, Bodi I et al. (2009) Assessment of beta-amyloid deposits in human brain: a study of the brainnet Europe consortium. Acta Neuropathol 117:309&#x2013;320. 10.1007/s00401-009-0485-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-009-0485-4</ArticleId><ArticleId IdType="pmc">PMC2910889</ArticleId><ArticleId IdType="pubmed">19184666</ArticleId></ArticleIdList></Reference><Reference><Citation>Altamura C, Scrascia F, Quattrocchi CC, Errante Y, Gangemi E, Curcio G et al. (2016) Regional MRI diffusion, white-matter hyperintensities, and cognitive function in Alzheimer&#x2019;s disease and vascular dementia. J Clin Neurol 12:201&#x2013;208. 10.3988/jcn.2016.12.2.201</Citation><ArticleIdList><ArticleId IdType="doi">10.3988/jcn.2016.12.2.201</ArticleId><ArticleId IdType="pmc">PMC4828567</ArticleId><ArticleId IdType="pubmed">27074295</ArticleId></ArticleIdList></Reference><Reference><Citation>Bachstetter AD, Garrett FG, Jicha GA, Nelson PT (2021) Space-occupying brain lesions, trauma-related tau astrogliopathy, and ARTAG: a report of two cases and a literature review. Acta Neuropathol Commun 9:49. 10.1186/s40478-021-01152-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-021-01152-3</ArticleId><ArticleId IdType="pmc">PMC7986305</ArticleId><ArticleId IdType="pubmed">33757579</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellenguez C, Kucukali F, Jansen IE, Kleineidam L, Moreno-Grau S, Amin N et al. (2022) New insights into the genetic etiology of Alzheimer&#x2019;s disease and related dementias. Nat Genet 54:412&#x2013;436. 10.1038/s41588-022-01024-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-022-01024-z</ArticleId><ArticleId IdType="pmc">PMC9005347</ArticleId><ArticleId IdType="pubmed">35379992</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Arvanitakis Z, Wilson RS (2012) Overview and findings from the religious orders study. Curr Alzheimer Res 9:628&#x2013;645. 10.2174/156720512801322573</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156720512801322573</ArticleId><ArticleId IdType="pmc">PMC3409291</ArticleId><ArticleId IdType="pubmed">22471860</ArticleId></ArticleIdList></Reference><Reference><Citation>Blevins BL, Vinters HV, Love S, Wilcock DM, Grinberg LT, Schneider JA et al. (2020) Brain arteriolosclerosis. Acta Neuropathol. 10.1007/s00401-020-02235-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-020-02235-6</ArticleId><ArticleId IdType="pmc">PMC8503820</ArticleId><ArticleId IdType="pubmed">33098484</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyle PA, Yu L, Leurgans SE, Wilson RS, Brookmeyer R, Schneider JA et al. (2019) Attributable risk of Alzheimer&#x2019;s dementia attributed to age-related neuropathologies. Ann Neurol 85:114&#x2013;124. 10.1002/ana.25380</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25380</ArticleId><ArticleId IdType="pmc">PMC10128614</ArticleId><ArticleId IdType="pubmed">30421454</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E (1997) Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 18:351&#x2013;357</Citation><ArticleIdList><ArticleId IdType="pubmed">9330961</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82:239&#x2013;259</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Thal DR, Ghebremedhin E, Del Tredici K (2011) Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol 70:960&#x2013;969. 10.1097/NEN.0b013e318232a379</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e318232a379</ArticleId><ArticleId IdType="pubmed">22002422</ArticleId></ArticleIdList></Reference><Reference><Citation>Brayne C, Richardson K, Matthews FE, Fleming J, Hunter S, Xuereb JH et al. (2009) Neuropathological correlates of dementia in over-80-year-old brain donors from the population-based Cambridge city over-75s cohort (CC75C) study. J Alzheimers Dis 18:645&#x2013;658. 10.3233/JAD-2009-1182</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2009-1182</ArticleId><ArticleId IdType="pubmed">19661624</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenowitz WD, Nelson PT, Besser LM, Heller KB, Kukull WA (2015) Cerebral amyloid angiopathy and its co-occurrence with Alzheimer&#x2019;s disease and other cerebrovascular neuropathologic changes. Neurobiol Aging. 10.1016/j.neurobiolaging.2015.06.028</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2015.06.028</ArticleId><ArticleId IdType="pmc">PMC4562901</ArticleId><ArticleId IdType="pubmed">26239176</ArticleId></ArticleIdList></Reference><Reference><Citation>Buciuc M, Tosakulwong N, Machulda MM, Whitwell JL, Weigand SD, Murray ME et al. (2021) TAR DNA-binding protein 43 is associated with rate of memory, functional and global cognitive decline in the decade prior to death. J Alzheimers Dis 80:683&#x2013;693. 10.3233/JAD-201166</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-201166</ArticleId><ArticleId IdType="pmc">PMC8020877</ArticleId><ArticleId IdType="pubmed">33579840</ArticleId></ArticleIdList></Reference><Reference><Citation>Chornenkyy Y, Fardo DW, Nelson PT (2019) Tau and TDP-43 proteinopathies: kindred pathologic cascades and genetic pleiotropy. Lab Invest 99:993&#x2013;1007. 10.1038/s41374-019-0196-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41374-019-0196-y</ArticleId><ArticleId IdType="pmc">PMC6609463</ArticleId><ArticleId IdType="pubmed">30742063</ArticleId></ArticleIdList></Reference><Reference><Citation>Corbo RM, Scacchi R (1999) Apolipoprotein E (APOE) allele distribution in the world. Is APOE*4 a &#x201c;thrifty&#x201d; allele? Ann Hum Genet 63:301&#x2013;310. 10.1046/j.1469-1809.1999.6340301.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1469-1809.1999.6340301.x</ArticleId><ArticleId IdType="pubmed">10738542</ArticleId></ArticleIdList></Reference><Reference><Citation>Coyle-Gilchrist IT, Dick KM, Patterson K, Vazquez Rodriquez P, Wehmann E, Wilcox A et al. (2016) Prevalence, characteristics, and survival of frontotemporal lobar degeneration syndromes. Neurology 86:1736&#x2013;1743. 10.1212/WNL.0000000000002638</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000002638</ArticleId><ArticleId IdType="pmc">PMC4854589</ArticleId><ArticleId IdType="pubmed">27037234</ArticleId></ArticleIdList></Reference><Reference><Citation>Crary JF, Trojanowski JQ, Schneider JA, Abisambra JF, Abner EL, Alafuzoff I et al. (2014) Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol 128:755&#x2013;766. 10.1007/s00401-014-1349-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-014-1349-0</ArticleId><ArticleId IdType="pmc">PMC4257842</ArticleId><ArticleId IdType="pubmed">25348064</ArticleId></ArticleIdList></Reference><Reference><Citation>Crean S, Ward A, Mercaldi CJ, Collins JM, Cook MN, Baker NL et al. (2011) Apolipoprotein E epsilon4 prevalence in Alzheimer&#x2019;s disease patients varies across global populations: a systematic literature review and meta-analysis. Dement Geriatr Cogn Disord 31:20&#x2013;30. 10.1159/000321984</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000321984</ArticleId><ArticleId IdType="pubmed">21124030</ArticleId></ArticleIdList></Reference><Reference><Citation>Cykowski MD, Arumanayagam AS, Powell SZ, Rivera AL, Abner EL, Roman GC et al. (2022) Patterns of amygdala region pathology in LATE-NC: subtypes that differ with regard to TDP-43 histopathology, genetic risk factors, and comorbid pathologies. Acta Neuropathol. 10.1007/s00401-022-02416-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-022-02416-5</ArticleId><ArticleId IdType="pmc">PMC9038848</ArticleId><ArticleId IdType="pubmed">35366087</ArticleId></ArticleIdList></Reference><Reference><Citation>Debatin L, Streffer J, Geissen M, Matschke J, Aguzzi A, Glatzel M (2008) Association between deposition of beta-amyloid and pathological prion protein in sporadic Creutzfeldt-Jakob disease. Neurodegener Dis 5:347&#x2013;354. 10.1159/000121389</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000121389</ArticleId><ArticleId IdType="pubmed">18349519</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson DW, Rademakers R, Nicholson AM, Schneider JA, Yu L, Bennett DA (2015) The TMEM106B locus and TDP-43 pathology in older persons without FTLD. Neurology 85:1354&#x2013;1355. 10.1212/01.wnl.0000472918.79256.a9</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000472918.79256.a9</ArticleId><ArticleId IdType="pmc">PMC5990310</ArticleId><ArticleId IdType="pubmed">26459943</ArticleId></ArticleIdList></Reference><Reference><Citation>Dooneief G, Marder K, Tang MX, Stern Y (1996) The clinical dementia rating scale: community-based validation of &#x201c;profound&#x201d; and &#x201c;terminal&#x201d; stages. Neurology 46:1746&#x2013;1749. 10.1212/wnl.46.6.1746</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.46.6.1746</ArticleId><ArticleId IdType="pubmed">8649584</ArticleId></ArticleIdList></Reference><Reference><Citation>Dugan AJ, Nelson PT, Katsumata Y, Shade LMP, Boehme KL, Teylan MA et al. (2021) Analysis of genes (TMEM106B, GRN, ABCC9, KCNMB2, and APOE) implicated in risk for LATE-NC and hippocampal sclerosis provides pathogenetic insights: a retrospective genetic association study. Acta Neuropathol Commun 9:152. 10.1186/s40478-021-01250-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-021-01250-2</ArticleId><ArticleId IdType="pmc">PMC8442328</ArticleId><ArticleId IdType="pubmed">34526147</ArticleId></ArticleIdList></Reference><Reference><Citation>Duyckaerts C, Braak H, Brion JP, Buee L, Del Tredici K, Goedert M et al. (2015) PART is part of Alzheimer disease. Acta Neuropathol 129:749&#x2013;756. 10.1007/s00401-015-1390-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-015-1390-7</ArticleId><ArticleId IdType="pmc">PMC4405349</ArticleId><ArticleId IdType="pubmed">25628035</ArticleId></ArticleIdList></Reference><Reference><Citation>Ewbank DC (2004) The APOE gene and differences in life expectancy in Europe. J Gerontol A Biol Sci Med Sci 59:16&#x2013;20. 10.1093/gerona/59.1.b16</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/gerona/59.1.b16</ArticleId><ArticleId IdType="pubmed">14718482</ArticleId></ArticleIdList></Reference><Reference><Citation>Filshtein TJ, Dugger BN, Jin LW, Olichney JM, Farias ST, Carvajal-Carmona L et al. (2019) Neuropathological diagnoses of demented hispanic, black, and non-hispanic white decedents seen at an Alzheimer&#x2019;s disease center. J Alzheimers Dis 68:145&#x2013;158. 10.3233/JAD-180992</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-180992</ArticleId><ArticleId IdType="pmc">PMC7286069</ArticleId><ArticleId IdType="pubmed">30775996</ArticleId></ArticleIdList></Reference><Reference><Citation>Flanagan ME, Cholerton B, Latimer CS, Hemmy LS, Edland SD, Montine KS et al. (2018) TDP-43 neuropathologic associations in the nun study and the honolulu-asia aging study. J Alzheimers Dis 66:1549&#x2013;1558. 10.3233/JAD-180162</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-180162</ArticleId><ArticleId IdType="pmc">PMC6382067</ArticleId><ArticleId IdType="pubmed">30452409</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR (1975) &#x201c;Mini-mental state&#x201d; a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189&#x2013;198</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenberg SG, Davies P, Schein JD, Binder LI (1992) Hydrofluoric acid-treated tau PHF proteins display the same biochemical properties as normal tau. J Biol Chem 267:564&#x2013;569</Citation><ArticleIdList><ArticleId IdType="pubmed">1370450</ArticleId></ArticleIdList></Reference><Reference><Citation>Halliday GM, Del Tredici K, Braak H (2006) Critical appraisal of brain pathology staging related to presymptomatic and symptomatic cases of sporadic Parkinson&#x2019;s disease. J Neural Transm Suppl. 10.1007/978-3-211-45295-0_16</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-211-45295-0_16</ArticleId><ArticleId IdType="pubmed">17017515</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison WT, Lusk JB, Liu B, Ervin JF, Johnson KG, Green CL et al. (2021) Limbic-predominant age-related TDP-43 encephalopathy neuropathological change (LATE-NC) is independently associated with dementia and strongly associated with arteriolosclerosis in the oldest-old. Acta Neuropathol. 10.1007/s00401-021-02360-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-021-02360-w</ArticleId><ArticleId IdType="pmc">PMC8816525</ArticleId><ArticleId IdType="pubmed">34415381</ArticleId></ArticleIdList></Reference><Reference><Citation>Hokkanen SRK, Hunter S, Polvikoski TM, Keage HAD, Minett T, Matthews FE et al. (2018) Hippocampal sclerosis, hippocampal neuron loss patterns and TDP-43 in the aged population. Brain Pathol 28:548&#x2013;559. 10.1111/bpa.12556</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bpa.12556</ArticleId><ArticleId IdType="pmc">PMC6099461</ArticleId><ArticleId IdType="pubmed">28833898</ArticleId></ArticleIdList></Reference><Reference><Citation>Hokkanen SRK, Kero M, Kaivola K, Hunter S, Keage HAD, Kiviharju A et al. (2020) Putative risk alleles for LATE-NC with hippocampal sclerosis in population-representative autopsy cohorts. Brain Pathol 30:364&#x2013;372. 10.1111/bpa.12773</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bpa.12773</ArticleId><ArticleId IdType="pmc">PMC7065086</ArticleId><ArticleId IdType="pubmed">31376286</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunter S, Hokkanen SRK, Keage HAD, Fleming J, Minett T, Polvikoski T et al. (2020) TDP-43 related neuropathologies and phosphorylation state: associations with age and clinical dementia in the Cambridge city over-75s cohort. J Alzheimers Dis: 10.3233/JAD-191093</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-191093</ArticleId><ArticleId IdType="pubmed">32280087</ArticleId></ArticleIdList></Reference><Reference><Citation>James BD, Wilson RS, Boyle PA, Trojanowski JQ, Bennett DA, Schneider JA (2016) TDP-43 stage, mixed pathologies, and clinical Alzheimer&#x2019;s-type dementia. Brain 139:2983&#x2013;2993. 10.1093/brain/aww224</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aww224</ArticleId><ArticleId IdType="pmc">PMC5091047</ArticleId><ArticleId IdType="pubmed">27694152</ArticleId></ArticleIdList></Reference><Reference><Citation>Jellinger KA (2022) Recent update on the heterogeneity of the Alzheimer&#x2019;s disease spectrum. J Neural Transm (Vienna) 129:1&#x2013;24. 10.1007/s00702-021-02449-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00702-021-02449-2</ArticleId><ArticleId IdType="pubmed">34919190</ArticleId></ArticleIdList></Reference><Reference><Citation>Jicha GA, Abner EL, Schmitt FA, Kryscio RJ, Riley KP, Cooper GE et al. (2012) Preclinical AD workgroup staging: pathological correlates and potential challenges. Neurobiol Aging 33(622):e621&#x2013;622. 10.1016/j.neurobiolaging.2011.02.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2011.02.018</ArticleId><ArticleId IdType="pmc">PMC3245887</ArticleId><ArticleId IdType="pubmed">21507528</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Mackenzie I, Frosch MP, Bigio EH, Neumann M, Arai T et al. (2019) LATE to the PART-y. Brain 142:e47. 10.1093/brain/awz224</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz224</ArticleId><ArticleId IdType="pmc">PMC6736234</ArticleId><ArticleId IdType="pubmed">31359030</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Murray ME, Tosakulwong N, Weigand SD, Serie AM, Perkerson RB et al. (2019) Pathological, imaging and genetic characteristics support the existence of distinct TDP-43 types in non-FTLD brains. Acta Neuropathol 137:227&#x2013;238. 10.1007/s00401-018-1951-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-1951-7</ArticleId><ArticleId IdType="pmc">PMC6358471</ArticleId><ArticleId IdType="pubmed">30604226</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Murray ME, Whitwell JL, Tosakulwong N, Weigand SD, Petrucelli L (2016) Updated TDP-43 in Alzheimer,s disease staging scheme. Acta Neuropathol 131:571&#x2013;585. 10.1007/s00401-016-1537-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-016-1537-1</ArticleId><ArticleId IdType="pmc">PMC5946692</ArticleId><ArticleId IdType="pubmed">26810071</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Whitwell JL, Knopman DS, Hu WT, Stroh DA, Baker M et al. (2008) Abnormal TDP-43 immunoreactivity in AD modifies clinicopathologic and radiologic phenotype. Neurology 70:1850&#x2013;1857</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2779031</ArticleId><ArticleId IdType="pubmed">18401022</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Whitwell JL, Weigand SD, Murray ME, Tosakulwong N, Liesinger AM et al. (2014) TDP-43 is a key player in the clinical features associated with Alzheimer&#x2019;s disease. Acta Neuropathol 127:811&#x2013;824. 10.1007/s00401-014-1269-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-014-1269-z</ArticleId><ArticleId IdType="pmc">PMC4172544</ArticleId><ArticleId IdType="pubmed">24659241</ArticleId></ArticleIdList></Reference><Reference><Citation>Karanth S, Nelson PT, Katsumata Y, Kryscio RJ, Schmitt FA, Fardo DW et al. (2020) Prevalence and clinical phenotype of quadruple misfolded proteins in older adults. JAMA Neurol 77:1299&#x2013;1307. 10.1001/jamaneurol.2020.1741</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2020.1741</ArticleId><ArticleId IdType="pmc">PMC7309572</ArticleId><ArticleId IdType="pubmed">32568358</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsumata Y, Abner EL, Karanth S, Teylan MA, Mock CN, Cykowski MD et al. (2020) Distinct clinicopathologic clusters of persons with TDP-43 proteinopathy. Acta Neuropathol 140:659&#x2013;674. 10.1007/s00401-020-02211-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-020-02211-0</ArticleId><ArticleId IdType="pmc">PMC7572241</ArticleId><ArticleId IdType="pubmed">32797255</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawas CH, Kim RC, Sonnen JA, Bullain SS, Trieu T, Corrada MM (2015) Multiple pathologies are common and related to dementia in the oldest-old: the 90+ study. Neurology 85:535&#x2013;542. 10.1212/WNL.0000000000001831</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000001831</ArticleId><ArticleId IdType="pmc">PMC4540246</ArticleId><ArticleId IdType="pubmed">26180144</ArticleId></ArticleIdList></Reference><Reference><Citation>Keage HA, Hunter S, Matthews FE, Ince PG, Hodges J, Hokkanen SR (2014) TDP-43 pathology in the population: prevalence and associations with dementia and age. J Alzheimers Dis 42:641&#x2013;650. 10.3233/JAD-132351</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-132351</ArticleId><ArticleId IdType="pubmed">25170584</ArticleId></ArticleIdList></Reference><Reference><Citation>Kero M, Raunio A, Polvikoski T, Tienari PJ, Paetau A, Myllykangas L (2018) Hippocampal sclerosis in the oldest old: a finnish population-based study. J Alzheimers Dis 63:263&#x2013;272. 10.3233/JAD-171068</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-171068</ArticleId><ArticleId IdType="pmc">PMC5900558</ArticleId><ArticleId IdType="pubmed">29614661</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman DS, Roberts RO (2011) Estimating the number of persons with frontotemporal lobar degeneration in the US population. J Mol Neurosci 45:330&#x2013;335. 10.1007/s12031-011-9538-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-011-9538-y</ArticleId><ArticleId IdType="pmc">PMC3208074</ArticleId><ArticleId IdType="pubmed">21584654</ArticleId></ArticleIdList></Reference><Reference><Citation>Kon T, Tomiyama M, Wakabayashi K (2020) Neuropathology of lewy body disease: clinicopathological crosstalk between typical and atypical cases. Neuropathology 40:30&#x2013;39. 10.1111/neup.12597</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/neup.12597</ArticleId><ArticleId IdType="pubmed">31498507</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs GG, Milenkovic I, Wohrer A, Hoftberger R, Gelpi E, Haberler C et al. (2013) Non-alzheimer neurodegenerative pathologies and their combinations are more frequent than commonly believed in the elderly brain: a community-based autopsy series. Acta Neuropathol 126:365&#x2013;384. 10.1007/s00401-013-1157-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1157-y</ArticleId><ArticleId IdType="pubmed">23900711</ArticleId></ArticleIdList></Reference><Reference><Citation>Latimer CS, Burke BT, Liachko NF, Currey HN, Kilgore MD, Gibbons LE et al. (2019) Resistance and resilience to Alzheimer&#x2019;s disease pathology are associated with reduced cortical pTau and absence of limbic-predominant age-related TDP-43 encephalopathy in a community-based cohort. Acta Neuropathol Commun 7:91. 10.1186/s40478-019-0743-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-019-0743-1</ArticleId><ArticleId IdType="pmc">PMC6556006</ArticleId><ArticleId IdType="pubmed">31174609</ArticleId></ArticleIdList></Reference><Reference><Citation>Latimer CS, Keene CD, Flanagan ME, Hemmy LS, Lim KO, White LR et al. (2017) Resistance to Alzheimer disease neuropathologic changes and apparent cognitive resilience in the nun and honolulu-asia aging studies. J Neuropathol Exp Neurol 76:458&#x2013;466. 10.1093/jnen/nlx030</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnen/nlx030</ArticleId><ArticleId IdType="pmc">PMC6334750</ArticleId><ArticleId IdType="pubmed">28499012</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee CS, Latimer CS, Henriksen JC, Blazes M, Larson EB, Crane PK et al. (2021) Application of deep learning to understand resilience to Alzheimer&#x2019;s disease pathology. Brain Pathol 31:e12974. 10.1111/bpa.12974</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bpa.12974</ArticleId><ArticleId IdType="pmc">PMC8549025</ArticleId><ArticleId IdType="pubmed">34009663</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez OL, Kofler J, Chang Y, Berman SB, Becker JT, Sweet RA et al. (2020) Hippocampal sclerosis, TDP-43, and the duration of the symptoms of dementia of AD patients. Ann Clin Transl Neurol 7:1546&#x2013;1556. 10.1002/acn3.51135</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51135</ArticleId><ArticleId IdType="pmc">PMC7480925</ArticleId><ArticleId IdType="pubmed">32735084</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthews FE, Arthur A, Barnes LE, Bond J, Jagger C, Robinson L et al. (2013) A two-decade comparison of prevalence of dementia in individuals aged 65 years and older from three geographical areas of England: results of the cognitive function and ageing study I and II. Lancet 382:1405&#x2013;1412. 10.1016/S0140-6736(13)61570-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(13)61570-6</ArticleId><ArticleId IdType="pmc">PMC3906607</ArticleId><ArticleId IdType="pubmed">23871492</ArticleId></ArticleIdList></Reference><Reference><Citation>McAleese KE, Walker L, Erskine D, Thomas AJ, McKeith IG, Attems J (2017) TDP-43 pathology in Alzheimer&#x2019;s disease, dementia with lewy bodies and ageing. Brain Pathol 27:472&#x2013;479. 10.1111/bpa.12424</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bpa.12424</ArticleId><ArticleId IdType="pmc">PMC8029292</ArticleId><ArticleId IdType="pubmed">27495267</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta RI, Schneider JA (2021) What is Alzheimer&#x2019;s disease? The neuropathological heterogeneity of clinically defined Alzheimer&#x2019;s dementia. Curr Opin Neurol 34:237&#x2013;245. 10.1097/WCO.0000000000000912</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000912</ArticleId><ArticleId IdType="pubmed">33591030</ArticleId></ArticleIdList></Reference><Reference><Citation>Meneses A, Koga S, O&#x2019;Leary J, Dickson DW, Bu G, Zhao N (2021) TDP-43 pathology in Alzheimer&#x2019;s disease. Mol Neurodegener 16:84. 10.1186/s13024-021-00503-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-021-00503-x</ArticleId><ArticleId IdType="pmc">PMC8691026</ArticleId><ArticleId IdType="pubmed">34930382</ArticleId></ArticleIdList></Reference><Reference><Citation>Miklossy J, Steele JC, Yu S, McCall S, Sandberg G, McGeer EG et al. (2008) Enduring involvement of tau, beta-amyloid, alpha-synuclein, ubiquitin and TDP-43 pathology in the amyotrophic lateral sclerosis/parkinsonism-dementia complex of guam (ALS/PDC). Acta Neuropathol 116:625&#x2013;637. 10.1007/s00401-008-0439-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-008-0439-2</ArticleId><ArticleId IdType="pubmed">18843496</ArticleId></ArticleIdList></Reference><Reference><Citation>Mimuro M, Yoshida M (2020) Chameleons and mimics: Progressive supranuclear palsy and corticobasal degeneration. Neuropathology 40:57&#x2013;67. 10.1111/neup.12590</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/neup.12590</ArticleId><ArticleId IdType="pubmed">31515852</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM et al. (1991) The consortium to establish a registry for Alzheimer&#x2019;s Disease (CERAD) part II standardization of the neuropathologic assessment of Alzheimer&#x2019;s disease. Neurology 41:479&#x2013;486</Citation><ArticleIdList><ArticleId IdType="pubmed">2011243</ArticleId></ArticleIdList></Reference><Reference><Citation>Mock C, Teylan M, Beecham G, Besser L, Cairns NJ, Crary JF et al. (2020) The utility of the national Alzheimer&#x2019;s coordinating Center&#x2019;s database for the rapid assessment of evolving neuropathologic conditions. Alzheimer Dis Assoc Disord 34:105&#x2013;111. 10.1097/WAD.0000000000000380</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WAD.0000000000000380</ArticleId><ArticleId IdType="pmc">PMC7242145</ArticleId><ArticleId IdType="pubmed">32304374</ArticleId></ArticleIdList></Reference><Reference><Citation>Montine TJ, Monsell SE, Beach TG, Bigio EH, Bu Y, Cairns NJ et al. (2016) Multisite assessment of NIA-AA guidelines for the neuropathologic evaluation of Alzheimer&#x2019;s disease. Alzheimers Dement 12:164&#x2013;169. 10.1016/j.jalz.2015.07.492</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2015.07.492</ArticleId><ArticleId IdType="pmc">PMC4562409</ArticleId><ArticleId IdType="pubmed">26327235</ArticleId></ArticleIdList></Reference><Reference><Citation>Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW et al. (2012) National institute on aging-Alzheimer&#x2019;s association guidelines for the neuropathologic assessment of Alzheimer&#x2019;s disease: a practical approach. Acta Neuropathol 123:1&#x2013;11. 10.1007/s00401-011-0910-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-011-0910-3</ArticleId><ArticleId IdType="pmc">PMC3268003</ArticleId><ArticleId IdType="pubmed">22101365</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray ME, Cannon A, Graff-Radford NR, Liesinger AM, Rutherford NJ, Ross OA et al. (2014) Differential clinicopathologic and genetic features of late-onset amnestic dementias. Acta Neuropathol 128:411&#x2013;421. 10.1007/s00401-014-1302-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-014-1302-2</ArticleId><ArticleId IdType="pmc">PMC4412022</ArticleId><ArticleId IdType="pubmed">24899141</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray ME, Graff-Radford NR, Ross OA, Petersen RC, Duara R, Dickson DW (2011) Neuropathologically defined subtypes of Alzheimer&#x2019;s disease with distinct clinical characteristics: a retrospective study. Lancet Neurol 10:785&#x2013;796</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3175379</ArticleId><ArticleId IdType="pubmed">21802369</ArticleId></ArticleIdList></Reference><Reference><Citation>Nag S, Barnes LL, Yu L, Wilson RS, Bennett DA, Schneider JA (2020) Limbic-predominant age-related TDP-43 encephalopathy in black and white decedents. Neurology 95:e2056&#x2013;e2064. 10.1212/WNL.0000000000010602</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000010602</ArticleId><ArticleId IdType="pmc">PMC7713750</ArticleId><ArticleId IdType="pubmed">32759188</ArticleId></ArticleIdList></Reference><Reference><Citation>Nag S, Yu L, Boyle PA, Leurgans SE, Bennett DA, Schneider JA (2018) TDP-43 pathology in anterior temporal pole cortex in aging and Alzheimer&#x2019;s disease. Acta Neuropathol Commun 6:33. 10.1186/s40478-018-0531-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-018-0531-3</ArticleId><ArticleId IdType="pmc">PMC5928580</ArticleId><ArticleId IdType="pubmed">29716643</ArticleId></ArticleIdList></Reference><Reference><Citation>Nag S, Yu L, Capuano AW, Wilson RS, Leurgans SE, Bennett DA et al. (2015) Hippocampal sclerosis and TDP-43 pathology in aging and Alzheimer disease. Ann Neurol 77:942&#x2013;952. 10.1002/ana.24388</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24388</ArticleId><ArticleId IdType="pmc">PMC4447563</ArticleId><ArticleId IdType="pubmed">25707479</ArticleId></ArticleIdList></Reference><Reference><Citation>Nag S, Yu L, Wilson RS, Chen EY, Bennett DA, Schneider JA (2017) TDP-43 pathology and memory impairment in elders without pathologic diagnoses of AD or FTLD. Neurology 88:653&#x2013;660. 10.1212/WNL.0000000000003610</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000003610</ArticleId><ArticleId IdType="pmc">PMC5317379</ArticleId><ArticleId IdType="pubmed">28087828</ArticleId></ArticleIdList></Reference><Reference><Citation>Nascimento C, Di Lorenzo Alho AT, Bazan Conceicao Amaral C, Leite REP, Nitrini R, Jacob-Filho W et al. (2018) Prevalence of transactive response DNA-binding protein 43 (TDP-43) proteinopathy in cognitively normal older adults: systematic review and meta-analysis. Neuropathol Appl Neurobiol 44:286&#x2013;297. 10.1111/nan.12430</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nan.12430</ArticleId><ArticleId IdType="pmc">PMC5902737</ArticleId><ArticleId IdType="pubmed">28793370</ArticleId></ArticleIdList></Reference><Reference><Citation>Nascimento C, Suemoto CK, Rodriguez RD, Alho AT, Leite RP, Farfel JM (2016) Higher prevalence of TDP-43 proteinopathy in cognitively normal asians: a clinicopathological study on a multiethnic sample. Brain Pathol 26:177&#x2013;185. 10.1111/bpa.12296</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bpa.12296</ArticleId><ArticleId IdType="pmc">PMC4751066</ArticleId><ArticleId IdType="pubmed">26260327</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT (2021) LATE neuropathologic changes with little or no Alzheimer disease is common and is associated with cognitive impairment but not frontotemporal dementia. J Neuropathol Exp Neurol. 10.1093/jnen/nlab050</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnen/nlab050</ArticleId><ArticleId IdType="pmc">PMC8357339</ArticleId><ArticleId IdType="pubmed">34270750</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Abner EL, Schmitt FA, Kryscio RJ, Jicha GA, Smith CD et al. (2010) Modeling the association between 43 different clinical and pathological variables and the severity of cognitive impairment in a large autopsy cohort of elderly persons. Brain Pathol 20:66&#x2013;79. 10.1111/j.1750-3639.2008.00244.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1750-3639.2008.00244.x</ArticleId><ArticleId IdType="pmc">PMC2864342</ArticleId><ArticleId IdType="pubmed">19021630</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ et al. (2012) Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol 71:362&#x2013;381. 10.1097/NEN.0b013e31825018f7</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e31825018f7</ArticleId><ArticleId IdType="pmc">PMC3560290</ArticleId><ArticleId IdType="pubmed">22487856</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Dickson DW, Trojanowski JQ, Jack CR, Boyle PA, Arfanakis K et al. (2019) Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain. 10.1093/brain/awz099</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz099</ArticleId><ArticleId IdType="pmc">PMC6536849</ArticleId><ArticleId IdType="pubmed">31039256</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Dickson DW, Trojanowski JQ, Jack CR, Boyle PA, Arfanakis K et al. (2019) Reply: LATE to the PART-y. Brain 142:e48. 10.1093/brain/awz226</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz226</ArticleId><ArticleId IdType="pmc">PMC6931389</ArticleId><ArticleId IdType="pubmed">31359039</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Gal Z, Wang WX, Niedowicz DM, Artiushin SC, Wycoff S et al. (2019) TDP-43 proteinopathy in aging: associations with risk-associated gene variants and with brain parenchymal thyroid hormone levels. Neurobiol Dis 125:67&#x2013;76. 10.1016/j.nbd.2019.01.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2019.01.013</ArticleId><ArticleId IdType="pmc">PMC6696921</ArticleId><ArticleId IdType="pubmed">30682540</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT et al. (2006) Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314:130&#x2013;133</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen ML, Huie EZ, Whitmer RA, George KM, Dugger BN (2022) Neuropathology studies of dementia in US persons other than non-hispanic whites. Free Neuropathol. 10.17879/freeneuropathology-2022-3795</Citation><ArticleIdList><ArticleId IdType="doi">10.17879/freeneuropathology-2022-3795</ArticleId><ArticleId IdType="pmc">PMC9007571</ArticleId><ArticleId IdType="pubmed">35425946</ArticleId></ArticleIdList></Reference><Reference><Citation>Plassman BL, Langa KM, Fisher GG, Heeringa SG, Weir DR, Ofstedal MB et al. (2007) Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology 29:125&#x2013;132. 10.1159/000109998</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000109998</ArticleId><ArticleId IdType="pmc">PMC2705925</ArticleId><ArticleId IdType="pubmed">17975326</ArticleId></ArticleIdList></Reference><Reference><Citation>Rademakers R, Eriksen JL, Baker M, Robinson T, Ahmed Z, Lincoln SJ et al. (2008) Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementia. Hum Mol Genet 17:3631&#x2013;3642. 10.1093/hmg/ddn257</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddn257</ArticleId><ArticleId IdType="pmc">PMC2581433</ArticleId><ArticleId IdType="pubmed">18723524</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahimi J, Kovacs GG (2014) Prevalence of mixed pathologies in the aging brain. Alzheimers Res Ther 6:82. 10.1186/s13195-014-0082-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-014-0082-1</ArticleId><ArticleId IdType="pmc">PMC4239398</ArticleId><ArticleId IdType="pubmed">25419243</ArticleId></ArticleIdList></Reference><Reference><Citation>Rascovsky K, Hodges JR, Kipps CM, Johnson JK, Seeley WW, Mendez MF et al. (2007) Diagnostic criteria for the behavioral variant of frontotemporal dementia (bvFTD): current limitations and future directions. Alzheimer Dis Assoc Disord 21:S14&#x2013;18. 10.1097/WAD.0b013e31815c3445</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WAD.0b013e31815c3445</ArticleId><ArticleId IdType="pubmed">18090417</ArticleId></ArticleIdList></Reference><Reference><Citation>Ribeiro FS, de Oliveira Duarte YA, Santos JLF, Leist AK (2021) Changes in prevalence of cognitive impairment and associated risk factors 2000&#x2013;2015 in Sao Paulo. Brazil BMC Geriatr 21:609. 10.1186/s12877-021-02542-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12877-021-02542-x</ArticleId><ArticleId IdType="pmc">PMC8554830</ArticleId><ArticleId IdType="pubmed">34706666</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts RO, Geda YE, Knopman DS, Cha RH, Pankratz VS, Boeve BF et al. (2008) The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology 30:58&#x2013;69. 10.1159/000115751</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000115751</ArticleId><ArticleId IdType="pmc">PMC2821441</ArticleId><ArticleId IdType="pubmed">18259084</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson JL, Corrada MM, Kovacs GG, Dominique M, Caswell C, Xie SX et al. (2018) Non-Alzheimer&#x2019;s contributions to dementia and cognitive resilience in the 90+ Study. Acta Neuropathol. 10.1007/s00401-018-1872-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-1872-5</ArticleId><ArticleId IdType="pmc">PMC6534149</ArticleId><ArticleId IdType="pubmed">29916037</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson JL, Lee EB, Xie SX, Rennert L, Suh E, Bredenberg C et al. (2018) Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated. Brain 141:2181&#x2013;2193. 10.1093/brain/awy146</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awy146</ArticleId><ArticleId IdType="pmc">PMC6022546</ArticleId><ArticleId IdType="pubmed">29878075</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson JL, Porta S, Garrett FG, Zhang P, Xie SX, Suh E et al. (2020) Limbic-predominant age-related TDP-43 encephalopathy differs from frontotemporal lobar degeneration. Brain 143:2844&#x2013;2857. 10.1093/brain/awaa219</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa219</ArticleId><ArticleId IdType="pmc">PMC7526723</ArticleId><ArticleId IdType="pubmed">32830216</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson JL, Richardson H, Xie SX, Suh E, Van Deerlin VM, Alfaro B et al. (2021) The development and convergence of co-pathologies in Alzheimer&#x2019;s disease. Brain 144:953&#x2013;962. 10.1093/brain/awaa438</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa438</ArticleId><ArticleId IdType="pmc">PMC8041349</ArticleId><ArticleId IdType="pubmed">33449993</ArticleId></ArticleIdList></Reference><Reference><Citation>Rutherford NJ, Carrasquillo MM, Li M, Bisceglio G, Menke J, Josephs KA et al. (2012) TMEM106B risk variant is implicated in the pathologic presentation of Alzheimer disease. Neurology 79:717&#x2013;718. 10.1212/WNL.0b013e318264e3ac</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e318264e3ac</ArticleId><ArticleId IdType="pmc">PMC3467659</ArticleId><ArticleId IdType="pubmed">22855871</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabbagh MN, Sandhu SS, Farlow MR, Vedders L, Shill HA, Caviness JN et al. (2009) Correlation of clinical features with argyrophilic grains at autopsy. Alzheimer Dis Assoc Disord 23:229&#x2013;233</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2760041</ArticleId><ArticleId IdType="pubmed">19812464</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmitt FA, Nelson PT, Abner E, Scheff S, Jicha GA, Smith C et al. (2012) University of kentucky sanders-brown healthy brain aging volunteers: donor characteristics, procedures, and neuropathology. Curr Alzheimer Res 9:724&#x2013;733</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3409295</ArticleId><ArticleId IdType="pubmed">22471862</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider JA, Aggarwal NT, Barnes L, Boyle P, Bennett DA (2009) The Neuropathology of older persons with and without dementia from community versus clinic cohorts. J Alzheimers Dis. 10.3233/JAD-2009-1227</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2009-1227</ArticleId><ArticleId IdType="pmc">PMC2853869</ArticleId><ArticleId IdType="pubmed">19749406</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider JA, Watts RL, Gearing M, Brewer RP, Mirra SS (1997) Corticobasal degeneration: neuropathologic and clinical heterogeneity. Neurology 48:959&#x2013;969. 10.1212/wnl.48.4.959</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.48.4.959</ArticleId><ArticleId IdType="pubmed">9109885</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh PP, Singh M, Mastana SS (2006) APOE distribution in world populations with new data from India and the UK. Ann Hum Biol 33:279&#x2013;308. 10.1080/03014460600594513</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/03014460600594513</ArticleId><ArticleId IdType="pubmed">17092867</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith CD, Johnson ES, Van Eldik LJ, Jicha GA, Schmitt FA, Nelson PT et al. (2016) Peripheral (deep) but not periventricular MRI white matter hyperintensities are increased in clinical vascular dementia compared to Alzheimer&#x2019;s disease. Brain Behav. 10.1002/brb3.438</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/brb3.438</ArticleId><ArticleId IdType="pmc">PMC4754499</ArticleId><ArticleId IdType="pubmed">26925303</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith VD, Bachstetter AD, Ighodaro E, Roberts K, Abner EL, Fardo DW et al. (2017) Overlapping but distinct TDP-43 and tau pathologic patterns in aged hippocampi. Brain Pathol 28:264&#x2013;273. 10.1111/bpa.12505</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bpa.12505</ArticleId><ArticleId IdType="pmc">PMC5591757</ArticleId><ArticleId IdType="pubmed">28281308</ArticleId></ArticleIdList></Reference><Reference><Citation>Strong MJ, Abrahams S, Goldstein LH, Woolley S, McLaughlin P, Snowden J et al. (2017) Amyotrophic lateral sclerosis&#x2014;frontotemporal spectrum disorder (ALS-FTSD): revised diagnostic criteria. Amyotroph Lateral Scler Frontotemporal Degener 18:153&#x2013;174. 10.1080/21678421.2016.1267768</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2016.1267768</ArticleId><ArticleId IdType="pmc">PMC7409990</ArticleId><ArticleId IdType="pubmed">28054827</ArticleId></ArticleIdList></Reference><Reference><Citation>Suemoto CK, Ferretti-Rebustini RE, Rodriguez RD, Leite RE, Soterio L, Brucki SM et al. (2017) Neuropathological diagnoses and clinical correlates in older adults in Brazil: a cross-sectional study. PLoS Med 14:e1002267. 10.1371/journal.pmed.1002267</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1002267</ArticleId><ArticleId IdType="pmc">PMC5369698</ArticleId><ArticleId IdType="pubmed">28350821</ArticleId></ArticleIdList></Reference><Reference><Citation>Suemoto CK, Leite REP, Ferretti-Rebustini REL, Rodriguez RD, Nitrini R, Pasqualucci CA et al. (2019) Neuropathological lesions in the very old: results from a large Brazilian autopsy study. Brain Pathol 29:771&#x2013;781. 10.1111/bpa.12719</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bpa.12719</ArticleId><ArticleId IdType="pmc">PMC6742578</ArticleId><ArticleId IdType="pubmed">30861605</ArticleId></ArticleIdList></Reference><Reference><Citation>Teng EL, Hasegawa K, Homma A, Imai Y, Larson E, Graves A et al. (1994) The cognitive abilities screening instrument (CASI): a practical test for cross-cultural epidemiological studies of dementia. Int Psychogeriatr 6:45&#x2013;58. 10.1017/s1041610294001602 (Discussion 62)</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/s1041610294001602</ArticleId><ArticleId IdType="pubmed">8054493</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR, Capetillo-Zarate E, Del Tredici K, Braak H (2006) The development of amyloid beta protein deposits in the aged brain. Sci Aging Knowl Environ. 10.1126/sageke.2006.6.re1</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sageke.2006.6.re1</ArticleId><ArticleId IdType="pubmed">16525193</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR, Griffin WS, Braak H (2008) Parenchymal and vascular abeta-deposition and its effects on the degeneration of neurons and cognition in Alzheimer&#x2019;s disease. J Cell Mol Med 12:1848&#x2013;1862. 10.1111/j.1582-4934.2008.00411.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1582-4934.2008.00411.x</ArticleId><ArticleId IdType="pmc">PMC4506155</ArticleId><ArticleId IdType="pubmed">18624777</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas DX, Bajaj S, McRae-McKee K, Hadjichrysanthou C, Anderson RM, Collinge J (2020) Association of TDP-43 proteinopathy, cerebral amyloid angiopathy, and lewy bodies with cognitive impairment in individuals with or without Alzheimer&#x2019;s disease neuropathology. Sci Rep 10:14579. 10.1038/s41598-020-71305-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-71305-2</ArticleId><ArticleId IdType="pmc">PMC7471113</ArticleId><ArticleId IdType="pubmed">32883971</ArticleId></ArticleIdList></Reference><Reference><Citation>Tome SO, Vandenberghe R, Ospitalieri S, Van Schoor E, Tousseyn T, Otto M et al. (2020) Distinct molecular patterns of TDP-43 pathology in Alzheimer&#x2019;s disease: relationship with clinical phenotypes. Acta Neuropathol Commun 8:61. 10.1186/s40478-020-00934-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-020-00934-5</ArticleId><ArticleId IdType="pmc">PMC7189555</ArticleId><ArticleId IdType="pubmed">32349792</ArticleId></ArticleIdList></Reference><Reference><Citation>Tyas SL, Salazar JC, Snowdon DA, Desrosiers MF, Riley KP, Mendiondo MS et al. (2007) Transitions to mild cognitive impairments, dementia, and death: findings from the nun study. Am J Epidemiol 165:1231&#x2013;1238. 10.1093/aje/kwm085</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwm085</ArticleId><ArticleId IdType="pmc">PMC2516202</ArticleId><ArticleId IdType="pubmed">17431012</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegiel J, Flory M, Kuchna I, Nowicki K, Wegiel J, Ma SY et al. (2022) Developmental deficits and staging of dynamics of age associated Alzheimer&#x2019;s disease neurodegeneration and neuronal loss in subjects with down syndrome. Acta Neuropathol Commun 10:2. 10.1186/s40478-021-01300-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-021-01300-9</ArticleId><ArticleId IdType="pmc">PMC8728914</ArticleId><ArticleId IdType="pubmed">34983655</ArticleId></ArticleIdList></Reference><Reference><Citation>Wennberg AM, Tosakulwong N, Lesnick TG, Murray ME, Whitwell JL, Liesinger AM et al. (2018) Association of apolipoprotein e epsilon4 with transactive response DNA-binding protein 43. JAMA Neurol 75:1347&#x2013;1354. 10.1001/jamaneurol.2018.3139</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2018.3139</ArticleId><ArticleId IdType="pmc">PMC6248121</ArticleId><ArticleId IdType="pubmed">30422173</ArticleId></ArticleIdList></Reference><Reference><Citation>Wharton SB, Brayne C, Savva GM, Matthews FE, Forster G, Simpson J et al. (2011) Epidemiological neuropathology: the MRC cognitive function and aging study experience. J Alzheimers Dis 25:359&#x2013;372. 10.3233/JAD-2011-091402</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2011-091402</ArticleId><ArticleId IdType="pubmed">21422529</ArticleId></ArticleIdList></Reference><Reference><Citation>White L, Small BJ, Petrovitch H, Ross GW, Masaki K, Abbott RD et al. (2005) Recent clinical-pathologic research on the causes of dementia in late life: update from the honolulu-asia aging study. J Geriatr Psychiatry Neurol 18:224&#x2013;227. 10.1177/0891988705281872</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0891988705281872</ArticleId><ArticleId IdType="pubmed">16306244</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson AC, Dugger BN, Dickson DW, Wang DS (2011) TDP-43 in aging and Alzheimer&#x2019;s disease&#x2014;a review. Int J Clin Exp Pathol 4:147&#x2013;155</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3037200</ArticleId><ArticleId IdType="pubmed">21326809</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang HS, Yu L, White CC, Chibnik LB, Chhatwal JP, Sperling RA et al. (2018) Evaluation of TDP-43 proteinopathy and hippocampal sclerosis in relation to APOE epsilon4 haplotype status: a community-based cohort study. Lancet Neurol. 10.1016/S1474-4422(18)30251-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30251-5</ArticleId><ArticleId IdType="pmc">PMC6154505</ArticleId><ArticleId IdType="pubmed">30093249</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu L, Schneider JA, Kapasi A, Bennett DA, Boyle PA (2020) Limbic-predominant age-related TDP-43 encephalopathy and distinct longitudinal profiles of domain-specific literacy. Alzheimer Dis Assoc Disord 34:299&#x2013;305. 10.1097/WAD.0000000000000389</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WAD.0000000000000389</ArticleId><ArticleId IdType="pmc">PMC7679283</ArticleId><ArticleId IdType="pubmed">32452861</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">35705056</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>17</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2211-1247</ISSN><JournalIssue CitedMedium="Internet"><Volume>39</Volume><Issue>11</Issue><PubDate><Year>2022</Year><Month>Jun</Month><Day>14</Day></PubDate></JournalIssue><Title>Cell reports</Title><ISOAbbreviation>Cell Rep</ISOAbbreviation></Journal><ArticleTitle>Absence of microglia promotes diverse pathologies and early lethality in Alzheimer's disease mice.</ArticleTitle><Pagination><StartPage>110961</StartPage><MedlinePgn>110961</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.celrep.2022.110961</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2211-1247(22)00743-4</ELocationID><Abstract><AbstractText>Microglia are strongly implicated in the development and progression of Alzheimer's disease (AD), yet their impact on pathology and lifespan remains unclear. Here we utilize a CSF1R hypomorphic mouse to generate a model of AD that genetically lacks microglia. The resulting microglial-deficient mice exhibit a profound shift from parenchymal amyloid plaques to cerebral amyloid angiopathy (CAA), which is accompanied by numerous transcriptional changes, greatly increased brain calcification and hemorrhages, and premature lethality. Remarkably, a single injection of wild-type microglia into adult mice repopulates the microglial niche and prevents each of these pathological changes. Taken together, these results indicate the protective functions of microglia in reducing CAA, blood-brain barrier dysfunction, and brain calcification. To further understand the clinical implications of these findings, human AD tissue and iPSC-microglia were examined, providing evidence that microglia phagocytose calcium crystals, and this process is impaired by loss of the AD risk gene, TREM2.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kiani Shabestari</LastName><ForeName>Sepideh</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurobiology &amp; Behavior, UC Irvine, Irvine, CA 92697, USA; Sue and Bill Gross Stem Cell Research Center, UC Irvine, Irvine, CA 92697, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morabito</LastName><ForeName>Samuel</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Mathematical, Computational and System Biology (MCSB) Program, UC Irvine, Irvine, CA 92697, USA; Institute for Memory Impairments and Neurological Disorders, UC Irvine, Irvine, CA 92697, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Danhash</LastName><ForeName>Emma Pascal</ForeName><Initials>EP</Initials><AffiliationInfo><Affiliation>Sue and Bill Gross Stem Cell Research Center, UC Irvine, Irvine, CA 92697, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McQuade</LastName><ForeName>Amanda</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurobiology &amp; Behavior, UC Irvine, Irvine, CA 92697, USA; Sue and Bill Gross Stem Cell Research Center, UC Irvine, Irvine, CA 92697, USA; Institute for Memory Impairments and Neurological Disorders, UC Irvine, Irvine, CA 92697, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanchez</LastName><ForeName>Jessica Ramirez</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Department of Neurobiology &amp; Behavior, UC Irvine, Irvine, CA 92697, USA; Sue and Bill Gross Stem Cell Research Center, UC Irvine, Irvine, CA 92697, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miyoshi</LastName><ForeName>Emily</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurobiology &amp; Behavior, UC Irvine, Irvine, CA 92697, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chadarevian</LastName><ForeName>Jean Paul</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Department of Neurobiology &amp; Behavior, UC Irvine, Irvine, CA 92697, USA; Sue and Bill Gross Stem Cell Research Center, UC Irvine, Irvine, CA 92697, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Claes</LastName><ForeName>Christel</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Sue and Bill Gross Stem Cell Research Center, UC Irvine, Irvine, CA 92697, USA; Institute for Memory Impairments and Neurological Disorders, UC Irvine, Irvine, CA 92697, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coburn</LastName><ForeName>Morgan Alexandra</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Neurobiology &amp; Behavior, UC Irvine, Irvine, CA 92697, USA; Sue and Bill Gross Stem Cell Research Center, UC Irvine, Irvine, CA 92697, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hasselmann</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurobiology &amp; Behavior, UC Irvine, Irvine, CA 92697, USA; Sue and Bill Gross Stem Cell Research Center, UC Irvine, Irvine, CA 92697, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hidalgo</LastName><ForeName>Jorge</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Sue and Bill Gross Stem Cell Research Center, UC Irvine, Irvine, CA 92697, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tran</LastName><ForeName>Kayla Nhi</ForeName><Initials>KN</Initials><AffiliationInfo><Affiliation>Sue and Bill Gross Stem Cell Research Center, UC Irvine, Irvine, CA 92697, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martini</LastName><ForeName>Alessandra C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Institute for Memory Impairments and Neurological Disorders, UC Irvine, Irvine, CA 92697, USA; Department of Pathology &amp; Laboratory Medicine, UC Irvine, Irvine, CA 92697, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang Rothermich</LastName><ForeName>Winston</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Sue and Bill Gross Stem Cell Research Center, UC Irvine, Irvine, CA 92697, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pascual</LastName><ForeName>Jesse</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute for Memory Impairments and Neurological Disorders, UC Irvine, Irvine, CA 92697, USA; Department of Pathology &amp; Laboratory Medicine, UC Irvine, Irvine, CA 92697, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Head</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Institute for Memory Impairments and Neurological Disorders, UC Irvine, Irvine, CA 92697, USA; Department of Pathology &amp; Laboratory Medicine, UC Irvine, Irvine, CA 92697, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hume</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Mater Research Institute-University of Queensland, Brisbane, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pridans</LastName><ForeName>Clare</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>University of Edinburgh Centre for Inflammation Research, Edinburgh, UK; Simons Initiative for the Developing Brain Centre, University of Edinburgh, Edinburgh, UK; The Muir Maxwell Epilepsy Centre, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davtyan</LastName><ForeName>Hayk</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Sue and Bill Gross Stem Cell Research Center, UC Irvine, Irvine, CA 92697, USA; Institute for Memory Impairments and Neurological Disorders, UC Irvine, Irvine, CA 92697, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swarup</LastName><ForeName>Vivek</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Neurobiology &amp; Behavior, UC Irvine, Irvine, CA 92697, USA; Institute for Memory Impairments and Neurological Disorders, UC Irvine, Irvine, CA 92697, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blurton-Jones</LastName><ForeName>Mathew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurobiology &amp; Behavior, UC Irvine, Irvine, CA 92697, USA; Sue and Bill Gross Stem Cell Research Center, UC Irvine, Irvine, CA 92697, USA; Institute for Memory Impairments and Neurological Disorders, UC Irvine, Irvine, CA 92697, USA. Electronic address: mblurton@uci.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG066519</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG073088</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/M019969/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>T32 AG000096</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG061895</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG055524</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 DA048813</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 NS082174</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R61 HL154307</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG056303</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Rep</MedlineTA><NlmUniqueID>101573691</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498716">Trem2 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016657" MajorTopicYN="Y">Cerebral Amyloid Angiopathy</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057026" MajorTopicYN="N">Induced Pluripotent Stem Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="Y">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease co-pathologies</Keyword><Keyword MajorTopicYN="N">CP: Neuroscience</Keyword><Keyword MajorTopicYN="N">TREM2</Keyword><Keyword MajorTopicYN="N">brain calcification</Keyword><Keyword MajorTopicYN="N">cerebral amyloid angiopathy</Keyword><Keyword MajorTopicYN="N">hemorrhage</Keyword><Keyword MajorTopicYN="N">iPSC-microglia</Keyword><Keyword MajorTopicYN="N">microglia</Keyword><Keyword MajorTopicYN="N">mortality</Keyword><Keyword MajorTopicYN="N">neurovascular</Keyword></KeywordList><CoiStatement>Declaration of interests M.B.-J. is a co-inventor of patent application WO/2018/160496, related to the differentiation of pluripotent stem cells into microglia, and co-founder of NovoGlia. All other authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>11</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>4</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>5</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>15</Day><Hour>18</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>7</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35705056</ArticleId><ArticleId IdType="mid">NIHMS1816595</ArticleId><ArticleId IdType="pmc">PMC9285116</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2022.110961</ArticleId><ArticleId IdType="pii">S2211-1247(22)00743-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arnold TD, Niaudet C, Pang M-F, Siegenthaler J, Gaengel K, Jung B, Ferrero GM, Mukouyama Y.s., Fuxe J, Akhurst R, et al. (2014). Excessive vascular sprouting underlies cerebral hemorrhage in mice lacking &#x3b1;V&#x3b2;8-TGF&#x3b2; signaling in the brain. Dev. Camb. Engl 141, 4489&#x2013;4499. 10.1242/dev.107193.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dev.107193</ArticleId><ArticleId IdType="pmc">PMC4302931</ArticleId><ArticleId IdType="pubmed">25406396</ArticleId></ArticleIdList></Reference><Reference><Citation>Arvanitakis Z, Leurgans SE, Wang Z, Wilson RS, Bennett DA, and Schneider JA (2011). Cerebral amyloid angiopathy pathology and cognitive domains in older persons. Ann. Neurol 69, 320&#x2013;327. 10.1002/ana.22112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.22112</ArticleId><ArticleId IdType="pmc">PMC3228518</ArticleId><ArticleId IdType="pubmed">21387377</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayrignac X, Nicolas G, Carra-Dalli&#xe8;re C, Hannequin D, and Labauge P (2017). Brain calcifications in adult-onset genetic leukoencephalopathies: a review. JAMA Neurol 74, 1000. 10.1001/jamaneurol.2017.1062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2017.1062</ArticleId><ArticleId IdType="pubmed">28628708</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell RD, and Zlokovic BV (2009). Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer&#x2019;s disease. Acta Neuropathol. 118, 103&#x2013;113. 10.1007/s00401-009-0522-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-009-0522-3</ArticleId><ArticleId IdType="pmc">PMC2853006</ArticleId><ArticleId IdType="pubmed">19319544</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett RE, Bryant A, Hu M, Robbins AB, Hopp SC, and Hyman BT (2018). Partial reduction of microglia does not affect tau pathology in aged mice. J. Neuroinflammation 15, 311. 10.1186/s12974-018-1348-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-018-1348-5</ArticleId><ArticleId IdType="pmc">PMC6230271</ArticleId><ArticleId IdType="pubmed">30413160</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruttger J, Karram K, W&#xf6;rtge S, Regen T, Marini F, Hoppmann N, Klein M, Blank T, Yona S, Wolf Y, et al. (2015). Genetic cell ablation reveals clusters of local self-renewing microglia in the mammalian central nervous system. Immunity 43, 92&#x2013;106. 10.1016/j.immuni.2015.06.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2015.06.012</ArticleId><ArticleId IdType="pubmed">26163371</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckwalter M, Pepper J-P, Gaertner RF, Euw DV, Lacombe P, and Wyss-Coraya T (2002). Molecular and functional dissection of TGF-&#x3b2;1-induced cerebrovascular abnormalities in transgenic mice. Ann. N. Y. Acad. Sci 977, 87&#x2013;95. 10.1111/j.1749-6632.2002.tb04801.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1749-6632.2002.tb04801.x</ArticleId><ArticleId IdType="pubmed">12480736</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler A, Hoffman P, Smibert P, Papalexi E, and Satija R (2018). Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol 36, 411&#x2013;420. 10.1038/nbt.4096.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.4096</ArticleId><ArticleId IdType="pmc">PMC6700744</ArticleId><ArticleId IdType="pubmed">29608179</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen EY, Tan CM, Kou Y, Duan Q, Wang Z, Meirelles GV, Clark NR, and Ma&#x2019;ayan A (2013). Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinf 14, 128. 10.1186/1471-2105-14-128.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2105-14-128</ArticleId><ArticleId IdType="pmc">PMC3637064</ArticleId><ArticleId IdType="pubmed">23586463</ArticleId></ArticleIdList></Reference><Reference><Citation>Chitu V, and Stanley ER (2017). Regulation of embryonic and postnatal development by the CSF-1 receptor. Curr. Top. Dev. Biol 123, 229&#x2013;275. 10.1016/bs.ctdb.2016.10.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/bs.ctdb.2016.10.004</ArticleId><ArticleId IdType="pmc">PMC5479137</ArticleId><ArticleId IdType="pubmed">28236968</ArticleId></ArticleIdList></Reference><Reference><Citation>Da Mesquita S, Herz J, Wall M, Dykstra T, de Lima KA, Norris GT, Dabhi N, Kennedy T, Baker W, and Kipnis J (2021). Aging-associated deficit in CCR7 is linked to worsened glymphatic function, cognition, neuroinflammation, and &#x3b2;-amyloid pathology. Sci. Adv 7, eabe4601. 10.1126/sciadv.abe4601.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.abe4601</ArticleId><ArticleId IdType="pmc">PMC8139596</ArticleId><ArticleId IdType="pubmed">34020948</ArticleId></ArticleIdList></Reference><Reference><Citation>Dagher NN, Najafi AR, Kayala KMN, Elmore MRP, White TE, Medeiros R, West BL, and Green KN (2015). Colony-stimulating factor 1 receptor inhibition prevents microglial plaque association and improves cognition in 3xTg-AD mice. J. Neuroinflammation 12, 139. 10.1186/s12974-015-0366-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-015-0366-9</ArticleId><ArticleId IdType="pmc">PMC4522109</ArticleId><ArticleId IdType="pubmed">26232154</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai X-M, Ryan GR, Hapel AJ, Dominguez MG, Russell RG, Kapp S, Sylvestre V, and Stanley ER (2002). Targeted disruption of the mouse colony-stimulating factor 1 receptor gene results in osteopetrosis, mononuclear phagocyte deficiency, increased primitive progenitor cell frequencies, and reproductive defects. Blood 99, 111&#x2013;120. 10.1182/blood.v99.1.111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.v99.1.111</ArticleId><ArticleId IdType="pubmed">11756160</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Andrea MR, Cole GM, and Ard MD (2004). The microglial phagocytic role with specific plaque types in the Alzheimer disease brain. Neurobiol. Aging 25, 675&#x2013;683. 10.1016/j.neurobiolaging.2003.12.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2003.12.026</ArticleId><ArticleId IdType="pubmed">15172747</ArticleId></ArticleIdList></Reference><Reference><Citation>DeTure MA, and Dickson DW (2019). The neuropathological diagnosis of Alzheimer&#x2019;s disease. Mol. Neurodegener 14, 32. 10.1186/s13024-019-0333-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-019-0333-5</ArticleId><ArticleId IdType="pmc">PMC6679484</ArticleId><ArticleId IdType="pubmed">31375134</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, and Gingeras TR (2013). STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15&#x2013;21. 10.1093/bioinformatics/bts635.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/bts635</ArticleId><ArticleId IdType="pmc">PMC3530905</ArticleId><ArticleId IdType="pubmed">23104886</ArticleId></ArticleIdList></Reference><Reference><Citation>Efthymiou AG, and Goate AM (2017). Late onset Alzheimer&#x2019;s disease genetics implicates microglial pathways in disease risk. Mol. Neurodegener 12, 43. 10.1186/s13024-017-0184-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-017-0184-x</ArticleId><ArticleId IdType="pmc">PMC5446752</ArticleId><ArticleId IdType="pubmed">28549481</ArticleId></ArticleIdList></Reference><Reference><Citation>Elmore MRP, Najafi AR, Koike MA, Dagher NN, Spangenberg EE, Rice RA, Kitazawa M, Matusow B, Nguyen H, West BL, and Green K (2014). Colony-stimulating factor 1 receptor signaling is necessary for microglia viability, unmasking a microglia progenitor cell in the adult brain. Neuron 82, 380&#x2013;397. 10.1016/j.neuron.2014.02.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.02.040</ArticleId><ArticleId IdType="pmc">PMC4161285</ArticleId><ArticleId IdType="pubmed">24742461</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujita D, Terada S, Ishizu H, Yokota O, Nakashima H, Ishihara T, and Kuroda S (2003). Immunohistochemical examination on intracranial calcification in neurodegenerative diseases. Acta Neuropathol 105, 259&#x2013;264. 10.1007/s00401-002-0640-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-002-0640-7</ArticleId><ArticleId IdType="pubmed">12557013</ArticleId></ArticleIdList></Reference><Reference><Citation>Grabert K, Sehgal A, Irvine KM, Wollscheid-Lengeling E, Ozdemir DD, Stables J, Luke GA, Ryan MD, Adamson A, Humphreys NE, Sandrock CJ, et al. (2020). A transgenic line that reports CSF1R protein expression provides a definitive marker for the mouse mononuclear phagocyte system. J. Immunol 205, 3154&#x2013;3166. 10.4049/jimmunol.2000835.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.2000835</ArticleId><ArticleId IdType="pubmed">33139489</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu Z, Eils R, and Schlesner M (2016). Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics 32, 2847&#x2013;2849. 10.1093/bioinformatics/btw313.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btw313</ArticleId><ArticleId IdType="pubmed">27207943</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo L, Bertola DR, Takanohashi A, Saito A, Segawa Y, Yokota T, Ishibashi S, Nishida Y, Yamamoto GL, Franco JFd.S., et al. (2019). Bi-allelic CSF1R mutations cause skeletal dysplasia of dysosteosclerosis-pyle disease spectrum and degenerative encephalopathy with brain malformation. Am. J. Hum. Genet 104, 925&#x2013;935. 10.1016/j.ajh0067.2019.03.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajh0067.2019.03.004</ArticleId><ArticleId IdType="pmc">PMC6507048</ArticleId><ArticleId IdType="pubmed">30982609</ArticleId></ArticleIdList></Reference><Reference><Citation>Han J, Fan Y, Zhou K, Zhu K, Blomgren K, Lund H, Zhang X-M, and Harris RA (2020). Underestimated peripheral effects following pharmacological and conditional genetic microglial depletion. Int. J. Mol. Sci 21, E8603. 10.3390/ijms21228603.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21228603</ArticleId><ArticleId IdType="pmc">PMC7696443</ArticleId><ArticleId IdType="pubmed">33203068</ArticleId></ArticleIdList></Reference><Reference><Citation>Hohsfield LA, Najafi AR, Ghorbanian Y, Soni N, Crapser J, Figueroa Velez DX, Jiang S, Royer SE, Kim SJ, Henningfield CM, et al. (2021). Subventricular zone/white matter microglia reconstitute the empty adult microglial niche in a dynamic wave. Elife 10, e66738. 10.7554/eLife.66738.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.66738</ArticleId><ArticleId IdType="pmc">PMC8425950</ArticleId><ArticleId IdType="pubmed">34423781</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y, Happonen KE, Burrola PG, O&#x2019;Connor C, Hah N, Huang L, Nimmerjahn A, and Lemke G (2021). Microglia use TAM receptors to detect and engulf amyloid &#x3b2; plaques. Nat. Immunol 22, 586&#x2013;594. 10.1038/s41590-021-00913-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-00913-5</ArticleId><ArticleId IdType="pmc">PMC8102389</ArticleId><ArticleId IdType="pubmed">33859405</ArticleId></ArticleIdList></Reference><Reference><Citation>Hume DA, Caruso M, Ferrari-Cestari M, Summers KM, Pridans C, and Irvine KM (2020). Phenotypic impacts of CSF1R deficiencies in humans and model organisms. J. Leukoc. Biol 107, 205&#x2013;219. 10.1002/JLB.MR0519-143R.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/JLB.MR0519-143R</ArticleId><ArticleId IdType="pubmed">31330095</ArticleId></ArticleIdList></Reference><Reference><Citation>J&#xe4;kel L, Van Nostrand WE, Nicoll JAR, Werring DJ, and Verbeek MM (2017). Animal models of cerebral amyloid angiopathy. Clin. Sci. Lond. Engl 131, 2469&#x2013;2488. 10.1042/CS20170033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/CS20170033</ArticleId><ArticleId IdType="pubmed">28963121</ArticleId></ArticleIdList></Reference><Reference><Citation>J&#xe4;kel L, De Kort AM, Klijn CJM, Schreuder FHBM, and Verbeek MM (2021). Prevalence of cerebral amyloid angiopathy: a systematic review and meta-analysis. Alzheimers Dement 18, 10&#x2013;28. 10.1002/alz.12366.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.12366</ArticleId><ArticleId IdType="pmc">PMC9290643</ArticleId><ArticleId IdType="pubmed">34057813</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen IE, Savage JE, Watanabe K, Bryois J, Williams DM, Steinberg S, Sealock J, Karlsson IK, H&#xe4;gg S, Athanasiu L, et al. (2019). Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer&#x2019;s disease risk. Nat. Genet 51, 404&#x2013;413. 10.1038/s41588-018-0311-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-018-0311-9</ArticleId><ArticleId IdType="pmc">PMC6836675</ArticleId><ArticleId IdType="pubmed">30617256</ArticleId></ArticleIdList></Reference><Reference><Citation>Jay TR, Hirsch AM, Broihier ML, Miller CM, Neilson LE, Ransohoff RM, Lamb BT, and Landreth GE (2017). Disease progression-dependent effects of TREM2 deficiency in a mouse model of Alzheimer&#x2019;s disease. J. Neurosci 37, 637&#x2013;647. 10.1523/JNEUROSCI.2110-16.2016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2110-16.2016</ArticleId><ArticleId IdType="pmc">PMC5242410</ArticleId><ArticleId IdType="pubmed">28100745</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin S, Guerrero-Juarez CF, Zhang L, Chang I, Myung P, Plikus MV, and Nie Q (2020). Inference and analysis of cell-cell communication using CellChat. Preprint at bioRxiv 10.1101/2020.07.21.214387.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.07.21.214387</ArticleId><ArticleId IdType="pmc">PMC7889871</ArticleId><ArticleId IdType="pubmed">33597522</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin S, Guerrero-Juarez CF, Zhang L, Chang I, Ramos R, Kuan C-H, Myung P, Plikus MV, and Nie Q (2021). Inference and analysis of cell-cell communication using CellChat. Nat. Commun 12, 1088. 10.1038/s41467-021-21246-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-21246-9</ArticleId><ArticleId IdType="pmc">PMC7889871</ArticleId><ArticleId IdType="pubmed">33597522</ArticleId></ArticleIdList></Reference><Reference><Citation>Kandasamy M, Anusuyadevi M, Aigner KM, Unger MS, Kniewallner KM, Sousa D.M. B.d., Altendorfer B, Mrowetz H, Bogdahn U, and Aigner L (2020). TGF-&#x3b2; signaling: a therapeutic target to reinstate regenerative plasticity in vascular dementia? Aging Dis 11, 828. 10.14336/AD.2020.0222.</Citation><ArticleIdList><ArticleId IdType="doi">10.14336/AD.2020.0222</ArticleId><ArticleId IdType="pmc">PMC7390515</ArticleId><ArticleId IdType="pubmed">32765949</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H, Spinrad A, Weiner A, Matcovitch-Natan O, Dvir-Szternfeld R, Ulland TK, David E, Baruch K, Lara-Astaiso D, Toth B, et al. (2017). A unique microglia type Associated with restricting development of Alzheimer&#x2019;s disease. Cell 169, 1276&#x2013;1290.e17. 10.1016/j.cell.2017.05.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.05.018</ArticleId><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Korsunsky I, Millard N, Fan J, Slowikowski K, Zhang F, Wei K, Baglaenko Y, Brenner M, Loh P ru, and Raychaudhuri, S. (2019). Fast, sensitive and accurate integration of single-cell data with Harmony. Nat. Methods 16, 1289&#x2013;1296. 10.1038/s41592-019-0619-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41592-019-0619-0</ArticleId><ArticleId IdType="pmc">PMC6884693</ArticleId><ArticleId IdType="pubmed">31740819</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuleshov MV, Jones MR, Rouillard AD, Fernandez NF, Duan Q, Wang Z, Koplev S, Jenkins SL, Jagodnik KM, Lachmann A, et al. (2016). Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res 44, W90&#x2013;W97. 10.1093/nar/gkw377.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkw377</ArticleId><ArticleId IdType="pmc">PMC4987924</ArticleId><ArticleId IdType="pubmed">27141961</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunkle BW, Grenier-Boley B, Sims R, Bis JC, Damotte V, Naj AC, Boland A, Vronskaya M, van der Lee SJ, Amlie-Wolf A, et al. (2019). Genetic meta-analysis of diagnosed Alzheimer&#x2019;s disease identifies new risk loci and implicates A&#x3b2;, tau, immunity and lipid processing. Nat. Genet 51, 414&#x2013;430. 10.1038/s41588-019-0358-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-019-0358-2</ArticleId><ArticleId IdType="pmc">PMC6463297</ArticleId><ArticleId IdType="pubmed">30820047</ArticleId></ArticleIdList></Reference><Reference><Citation>Langfelder P, and Horvath S (2008). WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics 29, 559. 10.1186/1471-2105-9-559.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2105-9-559</ArticleId><ArticleId IdType="pmc">PMC2631488</ArticleId><ArticleId IdType="pubmed">19114008</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S-H, Meilandt WJ, Xie L, Gandham VD, Ngu H, Barck KH, Rezzonico MG, Imperio J, Lalehzadeh G, Huntley MA, et al. (2021). Trem2 restrains the enhancement of tau accumulation and neurodegeneration by &#x3b2;-amyloid pathology. Neuron 109, 1283&#x2013;1301.e6. 10.1016/j.neuron.2021.02.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2021.02.010</ArticleId><ArticleId IdType="pubmed">33675684</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei F, Cui N, Zhou C, Chodosh J, Vavvas DG, and Paschalis EI (2020). CSF1R inhibition by a small-molecule inhibitor is not microglia specific; affecting hematopoiesis and the function of macrophages. Proc. Natl. Acad. Sci. U S A 117, 23336&#x2013;23338. 10.1073/pnas.1922788117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1922788117</ArticleId><ArticleId IdType="pmc">PMC7519218</ArticleId><ArticleId IdType="pubmed">32900927</ArticleId></ArticleIdList></Reference><Reference><Citation>Leyns CEG, Ulrich JD, Finn MB, Stewart FR, Koscal LJ, Remolina Serrano J, Robinson GO, Anderson E, Colonna M, and Holtzman DM (2017). TREM2 deficiency attenuates neuroinflammation and protects against neurodegeneration in a mouse model of tauopathy. Proc. Natl. Acad. Sci. U S A 114, 11524&#x2013;11529. 10.1073/pnas.1710311114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1710311114</ArticleId><ArticleId IdType="pmc">PMC5663386</ArticleId><ArticleId IdType="pubmed">29073081</ArticleId></ArticleIdList></Reference><Reference><Citation>Liddelow SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L, Bennett ML, M&#xfc;nch AE, Chung W-S, Peterson TC, et al. (2017). Neurotoxic reactive astrocytes are induced by activated microglia. Nature 541, 481&#x2013;487. 10.1038/nature21029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature21029</ArticleId><ArticleId IdType="pmc">PMC5404890</ArticleId><ArticleId IdType="pubmed">28099414</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindahl P, Johansson BR, Lev&#xe9;en P, and Betsholtz C (1997). Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 277, 242&#x2013;245. 10.1126/science.277.5323.242.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.277.5323.242</ArticleId><ArticleId IdType="pubmed">9211853</ArticleId></ArticleIdList></Reference><Reference><Citation>Lund H, Pieber M, Parsa R, Han J, Grommisch D, Ewing E, Kular L, Needhamsen M, Espinosa A, Nilsson E, et al. (2018). Competitive repopulation of an empty microglial niche yields functionally distinct subsets of microglia-like cells. Nat. Commun 9, 4845. 10.1038/s41467-018-07295-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-07295-7</ArticleId><ArticleId IdType="pmc">PMC6242869</ArticleId><ArticleId IdType="pubmed">30451869</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo J, Elwood F, Britschgi M, Villeda S, Zhang H, Ding Z, Zhu L, Alabsi H, Getachew R, Narasimhan R, et al. (2013). Colony-stimulating factor 1 receptor (CSF1R) signaling in injured neurons facilitates protection and survival. J. Exp. Med 210, 157&#x2013;172. 10.1084/jem.20120412.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20120412</ArticleId><ArticleId IdType="pmc">PMC3549715</ArticleId><ArticleId IdType="pubmed">23296467</ArticleId></ArticleIdList></Reference><Reference><Citation>Marino Lee S, Hudobenko J, McCullough LD, and Chauhan A (2021). Microglia depletion increase brain injury after acute ischemic stroke in aged mice. Exp. Neurol 336, 113530. 10.1016/j.expneurol.2020.113530.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2020.113530</ArticleId><ArticleId IdType="pmc">PMC7856174</ArticleId><ArticleId IdType="pubmed">33221396</ArticleId></ArticleIdList></Reference><Reference><Citation>Marsh SE, Abud EM, Lakatos A, Karimzadeh A, Yeung ST, Davtyan H, Fote GM, Lau L, Weinger JG, Lane TE, et al. (2016). The adaptive immune system restrains Alzheimer&#x2019;s disease pathogenesis by modulating microglial function. Proc. Natl. Acad. Sci. U S A 113, E1316&#x2013;E1325. 10.1073/pnas.1525466113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1525466113</ArticleId><ArticleId IdType="pmc">PMC4780638</ArticleId><ArticleId IdType="pubmed">26884167</ArticleId></ArticleIdList></Reference><Reference><Citation>McGinnis CS, Murrow LM, and Gartner ZJ (2019). DoubletFinder: doublet detection in single-cell RNA sequencing data using artificial nearest neighbors. Cell Syst 8, 329&#x2013;337.e4. 10.1016/j.cels.2019.03.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cels.2019.03.003</ArticleId><ArticleId IdType="pmc">PMC6853612</ArticleId><ArticleId IdType="pubmed">30954475</ArticleId></ArticleIdList></Reference><Reference><Citation>McInnes L, Healy J, Saul N, and Gro&#xdf;berger L (2018). UMAP: Uniform Manifold approximation and projection. J. Open Source Softw 3, 861. 10.21105/joss.00861.</Citation><ArticleIdList><ArticleId IdType="doi">10.21105/joss.00861</ArticleId></ArticleIdList></Reference><Reference><Citation>McQuade A, and Blurton-Jones M (2019). Microglia in Alzheimer&#x2019;s disease: exploring how genetics and phenotype influence risk. J. Mol. Biol 431, 1805&#x2013;1817. 10.1016/j.jmb.2019.01.045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2019.01.045</ArticleId><ArticleId IdType="pmc">PMC6475606</ArticleId><ArticleId IdType="pubmed">30738892</ArticleId></ArticleIdList></Reference><Reference><Citation>McQuade A, Coburn M, Tu CH, Hasselmann J, Davtyan H, and Blurton-Jones M (2018). Development and validation of a simplified method to generate human microglia from pluripotent stem cells. Mol. Neurodegener 13, 67. 10.1186/s13024-018-0297-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-018-0297-x</ArticleId><ArticleId IdType="pmc">PMC6303871</ArticleId><ArticleId IdType="pubmed">30577865</ArticleId></ArticleIdList></Reference><Reference><Citation>McQuade A, Kang YJ, Hasselmann J, Jairaman A, Sotelo A, Coburn M, Shabestari SK, Chadarevian JP, Fote G, Tu CH, et al. (2020). Gene expression and functional deficits underlie TREM2-knockout microglia responses in human models of Alzheimer&#x2019;s disease. Nat. Commun 11, 5370. 10.1038/s41467-020-19227-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-19227-5</ArticleId><ArticleId IdType="pmc">PMC7584603</ArticleId><ArticleId IdType="pubmed">33097708</ArticleId></ArticleIdList></Reference><Reference><Citation>Miron VE (2017). Microglia-driven regulation of oligodendrocyte lineage cells, myelination, and remyelination. J. Leukoc. Biol 101, 1103&#x2013;1108. 10.1189/jlb.3RI1116-494R.</Citation><ArticleIdList><ArticleId IdType="doi">10.1189/jlb.3RI1116-494R</ArticleId><ArticleId IdType="pubmed">28250011</ArticleId></ArticleIdList></Reference><Reference><Citation>Morabito S, Miyoshi E, Michael N, and Swarup V (2020). Integrative genomics approach identifies conserved transcriptomic networks in Alzheimer&#x2019;s disease. Hum. Mol. Genet 29, 2899&#x2013;2919. 10.1093/hmg/ddaa182.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddaa182</ArticleId><ArticleId IdType="pmc">PMC7566321</ArticleId><ArticleId IdType="pubmed">32803238</ArticleId></ArticleIdList></Reference><Reference><Citation>Morabito S, Miyoshi E, Michael N, Shahin S, Martini AC, Head E, Silva J, Leavy K, Perez-Rosendahl M, and Swarup V (2021). Single-nucleus chromatin accessibility and transcriptomic characterization of Alzheimer&#x2019;s disease. Nat. Genet 53, 1143&#x2013;1155. 10.1038/s41588-021-00894-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-021-00894-z</ArticleId><ArticleId IdType="pmc">PMC8766217</ArticleId><ArticleId IdType="pubmed">34239132</ArticleId></ArticleIdList></Reference><Reference><Citation>Munro DAD, Bradford BM, Mariani SA, Hampton DW, Vink CS, Chandran S, Hume DA, Pridans C, and Priller J (2020). CNS macrophages differentially rely on an intronic Csf1r enhancer for their development. Dev. Camb. Engl 147, dev194449. 10.1242/dev.194449.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dev.194449</ArticleId><ArticleId IdType="pmc">PMC7758622</ArticleId><ArticleId IdType="pubmed">33323375</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, Guillozet-Bongaarts A, Ohno M, Disterhoft J, Van Eldik L, et al. (2006). Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer&#x2019;s disease mutations: potential factors in amyloid plaque formation. J. Neurosci 26, 10129&#x2013;10140. 10.1523/JNEUROSCI.1202-06.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1202-06.2006</ArticleId><ArticleId IdType="pmc">PMC6674618</ArticleId><ArticleId IdType="pubmed">17021169</ArticleId></ArticleIdList></Reference><Reference><Citation>Olmos-Alonso A, Schetters STT, Sri S, Askew K, Mancuso R, Vargas-Caballero M, Holscher C, Perry VH, and Gomez-Nicola D (2016). Pharmacological targeting of CSF1R inhibits microglial proliferation and prevents the progression of Alzheimer&#x2019;s-like pathology. Brain J. Neurol 139, 891&#x2013;907. 10.1093/brain/awv379.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awv379</ArticleId><ArticleId IdType="pmc">PMC4766375</ArticleId><ArticleId IdType="pubmed">26747862</ArticleId></ArticleIdList></Reference><Reference><Citation>Parhizkar S, Arzberger T, Brendel M, Kleinberger G, Deussing M, Focke C, Nuscher B, Xiong M, Ghasemigharagoz A, Katzmarski N, et al. (2019). Loss of TREM2 function increases amyloid seeding but reduces plaque-associated ApoE. Nat. Neurosci 22, 191&#x2013;204. 10.1038/s41593-018-0296-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0296-9</ArticleId><ArticleId IdType="pmc">PMC6417433</ArticleId><ArticleId IdType="pubmed">30617257</ArticleId></ArticleIdList></Reference><Reference><Citation>Patkar OL, Caruso M, Teakle N, Keshvari S, Bush SJ, Pridans C, Belmer A, Summers KM, Irvine KM, and Hume DA (2021). Analysis of homozygous and heterozygous Csf1r knockout in the rat as a model for understanding microglial function in brain development and the impacts of human CSF1R mutations. Neurobiol. Dis 151, 105268. 10.1016/j.nbd.2021.105268.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2021.105268</ArticleId><ArticleId IdType="pmc">PMC7941205</ArticleId><ArticleId IdType="pubmed">33450391</ArticleId></ArticleIdList></Reference><Reference><Citation>Pons V, Laflamme N, Pr&#xe9;fontaine P, and Rivest S (2020). Role of macrophage colony-stimulating factor receptor on the proliferation and survival of microglia following systemic nerve and cuprizone-induced injuries. Front. Immunol 11, 47. 10.3389/fimmu.2020.00047.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.00047</ArticleId><ArticleId IdType="pmc">PMC7001158</ArticleId><ArticleId IdType="pubmed">32082318</ArticleId></ArticleIdList></Reference><Reference><Citation>Pons V, L&#xe9;vesque P, Plante M-M, and Rivest S (2021). Conditional genetic deletion of CSF1 receptor in microglia ameliorates the physiopathology of Alzheimer&#x2019;s disease. Alzheimer&#x2019;s Res. Ther 13, 8. 10.1186/s13195-020-00747-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-020-00747-7</ArticleId><ArticleId IdType="pmc">PMC7783991</ArticleId><ArticleId IdType="pubmed">33402196</ArticleId></ArticleIdList></Reference><Reference><Citation>Pridans C, Raper A, Davis GM, Alves J, Sauter KA, Lefevre L, Regan T, Meek S, Sutherland L, Thomson AJ, et al. (2018). Pleiotropic impacts of macrophage and microglial deficiency on development in rats with targeted mutation of the Csf1r locus. J. Immunol 201, 2683&#x2013;2699. 10.4049/jimmunol.1701783.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1701783</ArticleId><ArticleId IdType="pmc">PMC6196293</ArticleId><ArticleId IdType="pubmed">30249809</ArticleId></ArticleIdList></Reference><Reference><Citation>Roelofs AJ, Coxon FP, Ebetino FH, Lundy MW, Henneman ZJ, Nan-collas GH, Sun S, Blazewska KM, Bala JLF, Kashemirov BA, et al. (2010). Fluorescent risedronate analogues reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in vivo. J. Bone Miner. Res 25, 606&#x2013;616. 10.1359/jbmr.091009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1359/jbmr.091009</ArticleId><ArticleId IdType="pmc">PMC3153397</ArticleId><ArticleId IdType="pubmed">20422624</ArticleId></ArticleIdList></Reference><Reference><Citation>Rojo R, Raper A, Ozdemir DD, Lefevre L, Grabert K, Wollscheid-Lengeling E, Bradford B, Caruso M, Gazova I, S&#xe1;nchez A, et al. (2019). Deletion of a Csf1r enhancer selectively impacts CSF1R expression and development of tissue macrophage populations. Nat. Commun 10, 3215. 10.1038/s41467-019-11053-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-11053-8</ArticleId><ArticleId IdType="pmc">PMC6642117</ArticleId><ArticleId IdType="pubmed">31324781</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenberg AB, Roco CM, Muscat RA, Kuchina A, Sample P, Yao Z, Graybuck LT, Peeler DJ, Mukherjee S, Chen W, et al. (2018). Single-cell profiling of the developing mouse brain and spinal cord with split-pool barcoding. Science 360, 176&#x2013;182. 10.1126/science.aam8999.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aam8999</ArticleId><ArticleId IdType="pmc">PMC7643870</ArticleId><ArticleId IdType="pubmed">29545511</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadick JS, O&#x2019;Dea MR, Hasel P, Dykstra T, Faustin A, and Liddelow SA (2022). Astrocytes and oligodendrocytes undergo subtype-specific transcriptional changes in Alzheimer&#x2019;s disease. Neuron. 10.1016/j.neuron.2022.03.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2022.03.008</ArticleId><ArticleId IdType="pmc">PMC9167747</ArticleId><ArticleId IdType="pubmed">35381189</ArticleId></ArticleIdList></Reference><Reference><Citation>Sagare AP, Bell RD, Zhao Z, Ma Q, Winkler EA, Ramanathan A, and Zlokovic BV (2013). Pericyte loss influences Alzheimer-like neurodegeneration in mice. Nat. Commun 4, 2932. 10.1038/ncomms3932.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms3932</ArticleId><ArticleId IdType="pmc">PMC3945879</ArticleId><ArticleId IdType="pubmed">24336108</ArticleId></ArticleIdList></Reference><Reference><Citation>Schafer DP, Lehrman EK, Kautzman AG, Koyama R, Mardinly AR, Yamasaki R, Ransohoff RM, Greenberg ME, Barres BA, and Stevens B (2012). Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. Neuron 74, 691&#x2013;705. 10.1016/j.neuron.2012.03.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2012.03.026</ArticleId><ArticleId IdType="pmc">PMC3528177</ArticleId><ArticleId IdType="pubmed">22632727</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartzentruber J, Cooper S, Liu JZ, Barrio-Hernandez I, Bello E, Kumasaka N, Young AMH, Franklin RJM, Johnson T, Estrada K, et al. (2021). Genome-wide meta-analysis, fine-mapping and integrative prioritization implicate new Alzheimer&#x2019;s disease risk genes. Nat. Genet 53, 392&#x2013;402. 10.1038/s41588-020-00776-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-020-00776-w</ArticleId><ArticleId IdType="pmc">PMC7610386</ArticleId><ArticleId IdType="pubmed">33589840</ArticleId></ArticleIdList></Reference><Reference><Citation>Sellal F, Wallon D, Martinez-Almoyna L, Marelli C, Dhar A, Oesterl&#xe9; H, Rovelet-Lecrux A, Rousseau S, Kourkoulis CE, Rosand J, et al. (2017). APP mutations in cerebral amyloid angiopathy with or without cortical calcifications: report of three Families and a literature review. J. Alzheimers Dis 56, 37&#x2013;46. 10.3233/JAD-160709.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-160709</ArticleId><ArticleId IdType="pubmed">27858710</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, Manis M, Long J, Wang K, Sullivan PM, Remolina Serrano J, Hoyle R, and Holtzman DM (2019). Microglia drive APOE-dependent neurodegeneration in a tauopathy mouse model. J. Exp. Med 216, 2546&#x2013;2561. 10.1084/jem.20190980.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20190980</ArticleId><ArticleId IdType="pmc">PMC6829593</ArticleId><ArticleId IdType="pubmed">31601677</ArticleId></ArticleIdList></Reference><Reference><Citation>Sosna J, Philipp S, Albay R, Reyes-Ruiz JM, Baglietto-Vargas D, La-Ferla FM, and Glabe CG (2018). Early long-term administration of the CSF1R inhibitor PLX3397 ablates microglia and reduces accumulation of intraneuronal amyloid, neuritic plaque deposition and pre-fibrillar oligomers in 5XFAD mouse model of Alzheimer&#x2019;s disease. Mol. Neurodegener 13, 11. 10.1186/s13024-018-0244-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-018-0244-x</ArticleId><ArticleId IdType="pmc">PMC5831225</ArticleId><ArticleId IdType="pubmed">29490706</ArticleId></ArticleIdList></Reference><Reference><Citation>Spangenberg E, Severson PL, Hohsfield LA, Crapser J, Zhang J, Burton EA, Zhang Y, Spevak W, Lin J, Phan NY, et al. (2019). Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer&#x2019;s disease model. Nat. Commun 10, 3758. 10.1038/s41467-019-11674-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-11674-z</ArticleId><ArticleId IdType="pmc">PMC6704256</ArticleId><ArticleId IdType="pubmed">31434879</ArticleId></ArticleIdList></Reference><Reference><Citation>Spangenberg EE, Lee RJ, Najafi AR, Rice RA, Elmore MRP, Blurton-Jones M, West BL, and Green KN (2016). Eliminating microglia in Alzheimer&#x2019;s mice prevents neuronal loss without modulating amyloid-&#x3b2; pathology. Brain J. Neurol 139, 1265&#x2013;1281. 10.1093/brain/aww016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aww016</ArticleId><ArticleId IdType="pmc">PMC5006229</ArticleId><ArticleId IdType="pubmed">26921617</ArticleId></ArticleIdList></Reference><Reference><Citation>Stuart T, Butler A, Hoffman P, Hafemeister C, Papalexi E, Mauck WM, Hao Y, Stoeckius M, Smibert P, and Satija R (2019). Comprehensive integration of single-cell data. Cell 177, 1888&#x2013;1902.e21. 10.1016/j.cell.2019.05.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2019.05.031</ArticleId><ArticleId IdType="pmc">PMC6687398</ArticleId><ArticleId IdType="pubmed">31178118</ArticleId></ArticleIdList></Reference><Reference><Citation>Tadic V, Westenberger A, Domingo A, Alvarez-Fischer D, Klein C, and Kasten M (2015). Primary familial brain calcification with known gene mutations: a systematic review and challenges of phenotypic characterization. JAMA Neurol 72, 460. 10.1001/jamaneurol.2014.3889.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.3889</ArticleId><ArticleId IdType="pubmed">25686319</ArticleId></ArticleIdList></Reference><Reference><Citation>Tai LM, Thomas R, Marottoli FM, Koster KP, Kanekiyo T, Morris AWJ, and Bu G (2016). The role of APOE in cerebrovascular dysfunction. Acta Neuropathol 131, 709&#x2013;723. 10.1007/s00401-016-1547-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-016-1547-z</ArticleId><ArticleId IdType="pmc">PMC4837016</ArticleId><ArticleId IdType="pubmed">26884068</ArticleId></ArticleIdList></Reference><Reference><Citation>Thrupp N, Sala Frigerio C, Wolfs L, Skene NG, Fattorelli N, Poovathingal S, Fourne Y, Matthews PM, Theys T, Mancuso R, et al. (2020). Single-nucleus RNA-seq is not suitable for detection of microglial activation genes in humans. Cell Rep 32, 108189. 10.1016/j.celrep.2020.108189.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2020.108189</ArticleId><ArticleId IdType="pmc">PMC7527779</ArticleId><ArticleId IdType="pubmed">32997994</ArticleId></ArticleIdList></Reference><Reference><Citation>Traag VA, Waltman L, and van Eck NJ (2019). From Louvain to Leiden: guaranteeing well-connected communities. Sci. Rep 9, 5233. 10.1038/s41598-019-41695-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-41695-z</ArticleId><ArticleId IdType="pmc">PMC6435756</ArticleId><ArticleId IdType="pubmed">30914743</ArticleId></ArticleIdList></Reference><Reference><Citation>Unger MS, Schernthaner P, Marschallinger J, Mrowetz H, and Aigner L (2018). Microglia prevent peripheral immune cell invasion and promote an anti-inflammatory environment in the brain of APP-PS1 transgenic mice. J. Neuroinflammation 15, 274. 10.1186/s12974-018-1304-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-018-1304-4</ArticleId><ArticleId IdType="pmc">PMC6151006</ArticleId><ArticleId IdType="pubmed">30241479</ArticleId></ArticleIdList></Reference><Reference><Citation>Vidoni ED, Yeh H-W, Morris JK, Newell KL, Alqahtani A, Burns NC, Burns JM, and Billinger SA (2016). Cerebral &#x3b2;-amyloid angiopathy is associated with earlier dementia onset in Alzheimer&#x2019;s disease. Neurodegener. Dis 16, 218&#x2013;224. 10.1159/000441919.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000441919</ArticleId><ArticleId IdType="pmc">PMC4915344</ArticleId><ArticleId IdType="pubmed">26756746</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf FA, Angerer P, and Theis FJ (2018). SCANPY: large-scale single-cell gene expression data analysis. Genome Biol 19, 15. 10.1186/s13059-017-1382-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-017-1382-0</ArticleId><ArticleId IdType="pmc">PMC5802054</ArticleId><ArticleId IdType="pubmed">29409532</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf FA, Hamey FK, Plass M, Solana J, Dahlin JS, G&#xf6;ttgens B, Rajewsky N, Simon L, and Theis FJ (2019). PAGA: graph abstraction reconciles clustering with trajectory inference through a topology preserving map of single cells. Genome Biol 20, 59. 10.1186/s13059-019-1663-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-019-1663-x</ArticleId><ArticleId IdType="pmc">PMC6425583</ArticleId><ArticleId IdType="pubmed">30890159</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan P, Condello C, Keene CD, Wang Y, Bird TD, Paul SM, Luo W, Colonna M, Baddeley D, and Grutzendler J (2016). TREM2 haplodeficiency in mice and humans impairs the microglia barrier function leading to decreased amyloid compaction and severe axonal dystrophy. Neuron 90, 724&#x2013;739. 10.1016/j.neuron.2016.05.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.05.003</ArticleId><ArticleId IdType="pmc">PMC4898967</ArticleId><ArticleId IdType="pubmed">27196974</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarb Y, Sridhar S, Nassiri S, Utz SG, Schaffenrath J, Maheshwari U, Rushing EJ, Nilsson KPR, Delorenzi M, Colonna M, et al. (2021). Microglia control small vessel calcification via TREM2. Sci. Adv 7, eabc4898. 10.1126/sciadv.abc4898.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.abc4898</ArticleId><ArticleId IdType="pmc">PMC7909879</ArticleId><ArticleId IdType="pubmed">33637522</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Chen K, Sloan SA, Bennett ML, Scholze AR, O&#x2019;Keeffe S, Phatnani HP, Guarnieri P, Caneda C, Ruderisch N, et al. (2014). An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J. Neurosci 34, 11929&#x2013;11947. 10.1523/JNEUROSCI.1860-14.2014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1860-14.2014</ArticleId><ArticleId IdType="pmc">PMC4152602</ArticleId><ArticleId IdType="pubmed">25186741</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Sloan SA, Clarke LE, Caneda C, Plaza CA, Blumenthal PD, Vogel H, Steinberg GK, Edwards MSB, Li G, et al. (2016). Purification and characterization of progenitor and mature human astrocytes reveals transcriptional and functional differences with mouse. Neuron 89, 37&#x2013;53. 10.1016/j.neuron.2015.11.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2015.11.013</ArticleId><ArticleId IdType="pmc">PMC4707064</ArticleId><ArticleId IdType="pubmed">26687838</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang-Nunes SX, Maat-Schieman MLC, van Duinen SG, Roos RAC, Frosch MP, and Greenberg SM (2006). The cerebral beta-amyloid angiopathies: hereditary and sporadic. Brain Pathol 16, 30&#x2013;39. 10.1111/j.1750-3639.2006.tb00559.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1750-3639.2006.tb00559.x</ArticleId><ArticleId IdType="pmc">PMC8095991</ArticleId><ArticleId IdType="pubmed">16612980</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">35705053</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>17</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2211-1247</ISSN><JournalIssue CitedMedium="Internet"><Volume>39</Volume><Issue>11</Issue><PubDate><Year>2022</Year><Month>Jun</Month><Day>14</Day></PubDate></JournalIssue><Title>Cell reports</Title><ISOAbbreviation>Cell Rep</ISOAbbreviation></Journal><ArticleTitle>Genetic loss of function of Ptbp1 does not induce glia-to-neuron conversion in retina.</ArticleTitle><Pagination><StartPage>110849</StartPage><MedlinePgn>110849</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.celrep.2022.110849</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2211-1247(22)00622-2</ELocationID><Abstract><AbstractText>Direct reprogramming of glia into neurons is a potentially promising approach for the replacement of neurons lost to injury or neurodegenerative disorders. Knockdown of the polypyrimidine tract-binding protein Ptbp1 has been recently reported to induce efficient conversion of retinal M&#x3cb;ller glia into functional neurons. Here, we use a combination of genetic lineage tracing, single-cell RNA sequencing (scRNA-seq), and electroretinogram analysis to show that selective induction of either heterozygous or homozygous loss-of-function mutants of Ptbp1 in adult retinal M&#x3cb;ller glia does not lead to any detectable level of neuronal conversion. Only a few changes in gene expression are observed in M&#x3cb;ller glia following Ptbp1 deletion, and glial identity is maintained. These findings highlight the importance of using genetic manipulation and lineage-tracing methods in studying cell-type conversion.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 The Author(s). Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hoang</LastName><ForeName>Thanh</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: vhoang3@jhmi.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Dong Won</ForeName><Initials>DW</Initials><AffiliationInfo><Affiliation>Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: dkim195@jhmi.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Appel</LastName><ForeName>Haley</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pannullo</LastName><ForeName>Nicole A</ForeName><Initials>NA</Initials><AffiliationInfo><Affiliation>Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leavey</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ozawa</LastName><ForeName>Manabu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center for Experimental Medicine and Systems Biology, University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Sika</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Biomedical Sciences, University of California, Riverside, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Minzhong</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Ophthalmic Research, Cole Eye Institute, Cleveland, OH, USA; Department of Ophthalmology, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peachey</LastName><ForeName>Neal S</ForeName><Initials>NS</Initials><AffiliationInfo><Affiliation>Department of Ophthalmic Research, Cole Eye Institute, Cleveland, OH, USA; Department of Ophthalmology, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blackshaw</LastName><ForeName>Seth</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Kavli Neuroscience Discovery Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: sblack@jhmi.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 EY020560</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH116220</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 EY027267</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 EY025585</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS125276</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 EY031685</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R24 EY027283</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS104041</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Rep</MedlineTA><NlmUniqueID>101573691</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034441">Heterogeneous-Nuclear Ribonucleoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>139076-35-0</RegistryNumber><NameOfSubstance UI="D038941">Polypyrimidine Tract-Binding Protein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D034441" MajorTopicYN="Y">Heterogeneous-Nuclear Ribonucleoproteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009457" MajorTopicYN="N">Neuroglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D038941" MajorTopicYN="Y">Polypyrimidine Tract-Binding Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012160" MajorTopicYN="N">Retina</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CP: Cell biology</Keyword><Keyword MajorTopicYN="N">M&#x3cb;ller glia</Keyword><Keyword MajorTopicYN="N">PTBP1</Keyword><Keyword MajorTopicYN="N">Ptbp1</Keyword><Keyword MajorTopicYN="N">RNA splicing</Keyword><Keyword MajorTopicYN="N">cell reprogramming</Keyword><Keyword MajorTopicYN="N">glia-to-neuron conversion</Keyword><Keyword MajorTopicYN="N">regeneration</Keyword><Keyword MajorTopicYN="N">retina</Keyword><Keyword MajorTopicYN="N">retinal ganglion cell</Keyword><Keyword MajorTopicYN="N">transdifferentiation</Keyword></KeywordList><CoiStatement>Declaration of interests S.B. is a co-founder of, and shareholder in, CDI Labs, LLC, and receives financial support from Genentech.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>11</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>1</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>4</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>15</Day><Hour>18</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>10</Month><Day>31</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35705053</ArticleId><ArticleId IdType="mid">NIHMS1832300</ArticleId><ArticleId IdType="pmc">PMC9619396</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2022.110849</ArticleId><ArticleId IdType="pii">S2211-1247(22)00622-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Berninger B, Costa MR, Koch U, Schroeder T, Sutor B, Grothe B, and G&#xf6;tz M (2007). Functional properties of neurons derived from in vitro reprogrammed postnatal astroglia. J. Neurosci 27, 8654&#x2013;8664. 10.1523/jneurosci.1615-07.2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/jneurosci.1615-07.2007</ArticleId><ArticleId IdType="pmc">PMC6672931</ArticleId><ArticleId IdType="pubmed">17687043</ArticleId></ArticleIdList></Reference><Reference><Citation>Blackshaw S, and Sanes JR (2021). Turning lead into gold: reprogramming retinal cells to cure blindness. J. Clin. Invest 131, e146134. 10.1172/jci146134.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci146134</ArticleId><ArticleId IdType="pmc">PMC7843217</ArticleId><ArticleId IdType="pubmed">33529169</ArticleId></ArticleIdList></Reference><Reference><Citation>Boutz PL, Stoilov P, Li Q, Lin C-H, Chawla G, Ostrow K, Shiue L, Ares M Jr., and Black DL (2007). A post-transcriptional regulatory switch in polypyrimidine tract-binding proteins reprograms alternative splicing in developing neurons. Genes Dev. 21, 1636&#x2013;1652. 10.1101/gad.1558107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gad.1558107</ArticleId><ArticleId IdType="pmc">PMC1899473</ArticleId><ArticleId IdType="pubmed">17606642</ArticleId></ArticleIdList></Reference><Reference><Citation>Caiazzo M, Dell&#x2019;Anno MT, Dvoretskova E, Lazarevic D,Taverna S, Leo D, Sotnikova TD, Menegon A, Roncaglia P, Colciago G, et al. (2011). Direct generation of functional dopaminergic neurons from mouse and human fibroblasts. Nature 476, 224&#x2013;227. 10.1038/nature10284.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature10284</ArticleId><ArticleId IdType="pubmed">21725324</ArticleId></ArticleIdList></Reference><Reference><Citation>Cervo PR, di V, di Val Cervo PR, Romanov RA, Spigolon G, Masini D, Mart&#xed;n-Monta&#xf1;ez E, Toledo EM, La Manno G, Ng YH, et al. (2017). Induction of functional dopamine neurons from human astrocytes in vitro and mouse astrocytes in a Parkinson&#x2019;s disease model. Nat. Biotechnol 35, 444&#x2013;452. 10.1038/nbt.3835.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.3835</ArticleId><ArticleId IdType="pubmed">28398344</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen W, Zheng Q, Huang Q, Ma S, and Li M Repressing PTBP1 is incapable to convert reactive astrocytes to dopaminergic neurons in a mouse model of Parkinson&#x2019;s disease. Preprint at bioRxiv.10.1101/2021.11.12.468309</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.11.12.468309</ArticleId><ArticleId IdType="pmc">PMC9208759</ArticleId><ArticleId IdType="pubmed">35535997</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu X, Zhu J, Duan Y, Li G, Cai H, Zheng L, Qian H, Zhang C, Jin Z, Fu X-D, et al. (2020). Visual function restoration in genetically blind mice via endogenous cellular reprogramming. Preprint at bioRxiv. 10.1101/2020.04.08.030981.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.04.08.030981</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujita T, Chen MJ, Li B, Smith NA, Peng W, Sun W, Toner MJ, Kress BT, Wang L, Benraiss A, et al. (2014). Neuronal transgene expression in dominant-negative SNARE mice. J. Neurosci 34, 16594&#x2013;16604. 10.1523/jneurosci.2585-14.2014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/jneurosci.2585-14.2014</ArticleId><ArticleId IdType="pmc">PMC4261088</ArticleId><ArticleId IdType="pubmed">25505312</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoang T, Wang J, Boyd P, Wang F, Santiago C, Jiang L, Yoo S, Lahne M, Todd LJ, Jia M, et al. (2020). Gene regulatory networks controlling vertebrate retinal regeneration. Science 370, eabb8598. 10.1126/science.abb8598.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abb8598</ArticleId><ArticleId IdType="pmc">PMC7899183</ArticleId><ArticleId IdType="pubmed">33004674</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorstad NL, Wilken MS, Grimes WN, Wohl SG, VandenBosch LS, Yoshimatsu T, Wong RO, Rieke F, and Reh TA (2017). Stimulation of functional neuronal regeneration from M&#xfc;ller glia in adult mice. Nature 548, 103&#x2013;107. 10.1038/nature23283.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature23283</ArticleId><ArticleId IdType="pmc">PMC5991837</ArticleId><ArticleId IdType="pubmed">28746305</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinoshita J, and Peachey NS (2018). Noninvasive electroretinographic procedures for the study of the mouse retina. Curr. Protoc. Mouse Biol 8, 1&#x2013;16. 10.1002/cpmo.39.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpmo.39</ArticleId><ArticleId IdType="pmc">PMC6060644</ArticleId><ArticleId IdType="pubmed">30040236</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin L, Zhang M, Stoilov P, Chen L, and Zheng S (2020). Developmental attenuation of neuronal apoptosis by neural-specific splicing of Bak1 microexon. Neuron 107, 1180&#x2013;1196.e8. 10.1016/j.neuron.2020.06.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2020.06.036</ArticleId><ArticleId IdType="pmc">PMC7529960</ArticleId><ArticleId IdType="pubmed">32710818</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling JP, Chhabra R, Merran JD, Schaughency PM, Wheelan SJ, Corden JL, and Wong PC (2016). PTBP1 and PTBP2 repress nonconserved cryptic exons. Cell Rep. 17, 104&#x2013;113. 10.1016/j.celrep.2016.08.071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2016.08.071</ArticleId><ArticleId IdType="pmc">PMC5082185</ArticleId><ArticleId IdType="pubmed">27681424</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Miao Q, Yuan J, Han S&#x2019;E, Zhang P, Li S, Rao Z, Zhao W, Ye Q, Geng J, et al. (2015). Ascl1 converts dorsal midbrain astrocytes into functional neurons in vivo. J. Neurosci 35, 9336&#x2013;9355. 10.1523/jneurosci.3975-14.2015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/jneurosci.3975-14.2015</ArticleId><ArticleId IdType="pmc">PMC6605193</ArticleId><ArticleId IdType="pubmed">26109658</ArticleId></ArticleIdList></Reference><Reference><Citation>Maimon R, Chillon-Marinas C, Snethlage CE, Singhal SM, McAlonis-Downes M, Ling K, Rigo F, Bennett CF, Da Cruz S, Hnasko TS, et al. (2021). Therapeutically viable generation of neurons with antisense oligonucleotide suppression of PTB. Nat. Neurosci 24,1089&#x2013;1099. 10.1038/s41593-021-00864-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-021-00864-y</ArticleId><ArticleId IdType="pmc">PMC8338913</ArticleId><ArticleId IdType="pubmed">34083786</ArticleId></ArticleIdList></Reference><Reference><Citation>Makeyev EV, Zhang J, Carrasco MA, and Maniatis T (2007). The MicroRNA miR-124 promotes neuronal differentiation by triggering brain-specific alternative pre-mRNA splicing. Mol. Cell 27, 435&#x2013;448. 10.1016/j.molcel.2007.07.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2007.07.015</ArticleId><ArticleId IdType="pmc">PMC3139456</ArticleId><ArticleId IdType="pubmed">17679093</ArticleId></ArticleIdList></Reference><Reference><Citation>de Melo J, Miki K, Rattner A, Smallwood P, Zibetti C, Hirokawa K, Monuki ES, Campochiaro PA, and Blackshaw S (2012). Injury-independent induction of reactive gliosis in retina by loss of function of the LIM homeodomain transcription factor Lhx2. Proc. Natl. Acad. Sci. U S A 109, 4657&#x2013;4662. 10.1073/pnas.1107488109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1107488109</ArticleId><ArticleId IdType="pmc">PMC3311371</ArticleId><ArticleId IdType="pubmed">22393024</ArticleId></ArticleIdList></Reference><Reference><Citation>Mo A, Mukamel EA, Davis FP, Luo C, Henry GL, Picard S, Urich MA, Nery JR, Sejnowski TJ, Lister R, et al. (2015). Epigenomic signatures of neuronal diversity in the mammalian brain. Neuron 86, 1369&#x2013;1384. 10.1016/j.neuron.2015.05.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2015.05.018</ArticleId><ArticleId IdType="pmc">PMC4499463</ArticleId><ArticleId IdType="pubmed">26087164</ArticleId></ArticleIdList></Reference><Reference><Citation>Niu W, Zang T, Zou Y, Fang S, Smith DK, Bachoo R, and Zhang C-L (2013). In vivo reprogramming of astrocytes to neuroblasts in the adult brain. Nat. Cell Biol 15, 1164&#x2013;1175. 10.1038/ncb2843.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncb2843</ArticleId><ArticleId IdType="pmc">PMC3867822</ArticleId><ArticleId IdType="pubmed">24056302</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian C, Dong B, Wang X-Y, and Zhou F-Q (2021). In vivo glial trans-differentiation for neuronal replacement and functional recovery in central nervous system. FEBS J. 288, 4773&#x2013;4785. 10.1111/febs.15681.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/febs.15681</ArticleId><ArticleId IdType="pmc">PMC8217397</ArticleId><ArticleId IdType="pubmed">33351267</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian H, Kang X, Hu J, Zhang D, Liang Z, Meng F, Zhang X, Xue Y, Maimon R, Dowdy SF, et al. (2020). Reversing a model of Parkinson&#x2019;s disease with in situ converted nigral neurons. Nature 582, 550&#x2013;556. 10.1038/s41586-020-2388-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2388-4</ArticleId><ArticleId IdType="pmc">PMC7521455</ArticleId><ArticleId IdType="pubmed">32581380</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibasaki T, Tokunaga A, Sakamoto R, Sagara H, Noguchi S, Sasaoka T, and Yoshida N (2013). PTB deficiency causes the loss of adherens junctions in the dorsal telencephalon and leads to lethal hydrocephalus. Cereb. Cortex 23, 1824&#x2013;1835. 10.1093/cercor/bhs161.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cercor/bhs161</ArticleId><ArticleId IdType="pubmed">22705452</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibayama M, Ohno S, Osaka T, Sakamoto R, Tokunaga A, Nakatake Y, Sato M, and Yoshida N (2009). Polypyrimidine tract-binding protein is essential for early mouse development and embryonic stem cell proliferation. FEBS J. 276, 6658&#x2013;6668. 10.1111/j.1742-4658.2009.07380.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1742-4658.2009.07380.x</ArticleId><ArticleId IdType="pubmed">19843185</ArticleId></ArticleIdList></Reference><Reference><Citation>Stuart T, Butler A, Hoffman P, Hafemeister C, Papalexi E, Mauck WM, Hao Y, Stoeckius M, Smibert P, and Satija R (2019). Comprehensive integration of single-cell data. Cell 177, 1888&#x2013;1902.e21. 10.1016/j.cell.2019.05.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2019.05.031</ArticleId><ArticleId IdType="pmc">PMC6687398</ArticleId><ArticleId IdType="pubmed">31178118</ArticleId></ArticleIdList></Reference><Reference><Citation>Su M, Hu H, Lee Y, d&#x2019;Azzo A, Messing A, and Brenner M (2004). Expression specificity of GFAP transgenes. Neurochem. Res 29, 2075&#x2013;2093. 10.1007/s11064-004-6881-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11064-004-6881-1</ArticleId><ArticleId IdType="pubmed">15662842</ArticleId></ArticleIdList></Reference><Reference><Citation>Vignoles R, Lentini C, d&#x2019;Orange M, and Heinrich C (2019). Direct lineage reprogramming for brain repair: breakthroughs and challenges. Trends Mol. Med 25, 897&#x2013;914. 10.1016/j.molmed.2019.06.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2019.06.006</ArticleId><ArticleId IdType="pubmed">31371156</ArticleId></ArticleIdList></Reference><Reference><Citation>Vuong JK, Lin C-H, Zhang M, Chen L, Black DL, and Zheng S (2016). PTBP1 and PTBP2 serve both specific and redundant functions in neuronal pre-mRNA splicing. Cell Rep. 17, 2766&#x2013;2775. 10.1016/j.cel-rep.2016.11.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cel-rep.2016.11.034</ArticleId><ArticleId IdType="pmc">PMC5179036</ArticleId><ArticleId IdType="pubmed">27926877</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L-L, Serrano C, Zhong X, Ma S, Zuo Y, and Zhang C-L (2021). Revisiting astrocyte to neuron conversion with lineage tracing in vivo. Cell 184, 5465&#x2013;5481.e16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8526404</ArticleId><ArticleId IdType="pubmed">34582787</ArticleId></ArticleIdList></Reference><Reference><Citation>Xue Y, Ouyang K, Huang J, Zhou Y, Ouyang H, Li H, Wang G, Wu Q, Wei C, Bi Y, et al. (2013). Direct conversion of fibroblasts to neurons by reprogramming PTB-regulated microRNA circuits. Cell 152, 82&#x2013;96. 10.1016/j.cell.2012.11.045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2012.11.045</ArticleId><ArticleId IdType="pmc">PMC3552026</ArticleId><ArticleId IdType="pubmed">23313552</ArticleId></ArticleIdList></Reference><Reference><Citation>Zamboni M, Llorens-Bobadilla E, Magnusson JP, and Fris&#xe9;n J (2020). A widespread neurogenic potential of neocortical astrocytes is induced by injury. Cell Stem Cell 27, 605&#x2013;617.e5. 10.1016/j.stem.2020.07.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2020.07.006</ArticleId><ArticleId IdType="pmc">PMC7534841</ArticleId><ArticleId IdType="pubmed">32758425</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Yin J-C, Yeh H, Ma N-X, Lee G, Chen XA, Wang Y, Lin L, Chen L, Jin P, and Wu GY (2015). Small molecules efficiently reprogram human astroglial cells into functional neurons. Cell Stem Cell 17, 735&#x2013;747. 10.1016/j.stem.2015.09.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2015.09.012</ArticleId><ArticleId IdType="pmc">PMC4675726</ArticleId><ArticleId IdType="pubmed">26481520</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou H, Su J, Hu X, Zhou C, Li H, Chen Z, Xiao Q, Wang B, Wu W, Sun Y, et al. (2020). Glia-to-Neuron conversion by CRISPR-CasRx alleviates symptoms of neurological disease in mice. Cell 181, 590&#x2013;603. 10.1016/j.cell.2020.03.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.03.024</ArticleId><ArticleId IdType="pubmed">32272060</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35706029</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>17</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1742-2094</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Jun</Month><Day>15</Day></PubDate></JournalIssue><Title>Journal of neuroinflammation</Title><ISOAbbreviation>J Neuroinflammation</ISOAbbreviation></Journal><ArticleTitle>Microglial amyloid beta clearance is driven by PIEZO1 channels.</ArticleTitle><Pagination><StartPage>147</StartPage><MedlinePgn>147</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">147</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12974-022-02486-y</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Microglia are the endogenous immune cells of the brain and act as sensors of pathology to maintain brain homeostasis and eliminate potential threats. In Alzheimer's disease (AD), toxic amyloid beta (A&#x3b2;) accumulates in the brain and forms stiff plaques. In late-onset AD accounting for 95% of all cases, this is thought to be due to reduced clearance of A&#x3b2;. Human genome-wide association studies and animal models suggest that reduced clearance results from aberrant function of microglia. While the impact of neurochemical pathways on microglia had been broadly studied, mechanical receptors regulating microglial functions remain largely unexplored.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Here we showed that a mechanotransduction ion channel, PIEZO1, is expressed and functional in human and mouse microglia. We used a small molecule agonist, Yoda1, to study how activation of PIEZO1 affects AD-related functions in human induced pluripotent stem cell (iPSC)-derived microglia-like cells (iMGL) under controlled laboratory experiments. Cell survival, metabolism, phagocytosis and lysosomal activity were assessed using real-time functional assays. To evaluate the effect of activation of PIEZO1 in vivo, 5-month-old 5xFAD male mice were infused daily with Yoda1 for two weeks through intracranial cannulas. Microglial Iba1 expression and A&#x3b2; pathology were quantified with immunohistochemistry and confocal microscopy. Published human and mouse AD datasets were used for in-depth analysis of PIEZO1 gene expression and related pathways in microglial subpopulations.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We show that PIEZO1 orchestrates A&#x3b2; clearance by enhancing microglial survival, phagocytosis, and lysosomal activity. A&#x3b2; inhibited PIEZO1-mediated calcium transients, whereas activation of PIEZO1 with a selective agonist, Yoda1, improved microglial phagocytosis resulting in A&#x3b2; clearance both in human and mouse models of AD. Moreover, PIEZO1 expression was associated with a unique microglial transcriptional phenotype in AD as indicated by assessment of cellular metabolism, and human and mouse single-cell datasets.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These results indicate that the compromised function of microglia in AD could be improved by controlled activation of PIEZO1 channels resulting in alleviated A&#x3b2; burden. Pharmacological regulation of these mechanoreceptors in microglia could represent a novel therapeutic paradigm for AD.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>J&#xe4;ntti</LastName><ForeName>Henna</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, 70211, Kuopio, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Sitnikova</LastName><ForeName>Valeriia</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, 70211, Kuopio, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Ishchenko</LastName><ForeName>Yevheniia</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, 70211, Kuopio, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departments of Molecular Biophysics and Biochemistry and Neuroscience, Yale School of Medicine, Yale University, New Haven, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shakirzyanova</LastName><ForeName>Anastasia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, 70211, Kuopio, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giudice</LastName><ForeName>Luca</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, 70211, Kuopio, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Computer Science, University of Verona, 37134, Verona, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ugidos</LastName><ForeName>Irene F</ForeName><Initials>IF</Initials><AffiliationInfo><Affiliation>A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, 70211, Kuopio, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xf3;mez-Budia</LastName><ForeName>Mireia</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, 70211, Kuopio, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Korvenlaita</LastName><ForeName>Nea</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, 70211, Kuopio, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ohtonen</LastName><ForeName>Sohvi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, 70211, Kuopio, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Belaya</LastName><ForeName>Irina</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, 70211, Kuopio, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fazaludeen</LastName><ForeName>Feroze</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, 70211, Kuopio, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mikhailov</LastName><ForeName>Nikita</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, 70211, Kuopio, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gotkiewicz</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, 70211, Kuopio, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ketola</LastName><ForeName>Kirsi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Institute of Biomedicine, University of Eastern Finland, 70210, Kuopio, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lehtonen</LastName><ForeName>&#x160;&#xe1;rka</ForeName><Initials>&#x160;</Initials><AffiliationInfo><Affiliation>A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, 70211, Kuopio, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Center, University of Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koistinaho</LastName><ForeName>Jari</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, 70211, Kuopio, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Center, University of Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kanninen</LastName><ForeName>Katja M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, 70211, Kuopio, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hern&#xe1;ndez</LastName><ForeName>Damian</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Anatomy and Physiology, The University of Melbourne, Parkville, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>P&#xe9;bay</LastName><ForeName>Alice</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Anatomy and Physiology, The University of Melbourne, Parkville, VIC, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery, Royal Melbourne Hospital, The University of Melbourne, Parkville, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giugno</LastName><ForeName>Rosalba</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Computer Science, University of Verona, 37134, Verona, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Korhonen</LastName><ForeName>Paula</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, 70211, Kuopio, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giniatullin</LastName><ForeName>Rashid</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, 70211, Kuopio, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malm</LastName><ForeName>Tarja</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, 70211, Kuopio, Finland. tarja.malm@uef.fi.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>325392</GrantID><Agency>Academy of Finland</Agency><Country/></Grant><Grant><GrantID>325392</GrantID><Agency>Academy of Finland</Agency><Country/></Grant><Grant><GrantID>328287</GrantID><Agency>Academy of Finland</Agency><Country/></Grant><Grant><GrantID>6478/31/2019</GrantID><Agency>Business Finland</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Neuroinflammation</MedlineTA><NlmUniqueID>101222974</NlmUniqueID><ISSNLinking>1742-2094</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007473">Ion Channels</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C515204">PIEZO1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C552920">Piezo1 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="Y">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057026" MajorTopicYN="Y">Induced Pluripotent Stem Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007473" MajorTopicYN="N">Ion Channels</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D040542" MajorTopicYN="N">Mechanotransduction, Cellular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">Amyloid</Keyword><Keyword MajorTopicYN="N">Mechanoreceptor</Keyword><Keyword MajorTopicYN="N">Microglia</Keyword><Keyword MajorTopicYN="N">Piezo1</Keyword><Keyword MajorTopicYN="N">iMGL</Keyword><Keyword MajorTopicYN="N">iPSC-derived microglia</Keyword></KeywordList><CoiStatement>Malm and Giniatullin are inventors of PCT patent application related to this topic.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>1</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>5</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>15</Day><Hour>23</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>6</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35706029</ArticleId><ArticleId IdType="pmc">PMC9199162</ArticleId><ArticleId IdType="doi">10.1186/s12974-022-02486-y</ArticleId><ArticleId IdType="pii">10.1186/s12974-022-02486-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hammond TR, Robinton D, Stevens B. Microglia and the brain: complementary partners in development and disease. Annu Rev Cell Dev Biol. 2018;34:523&#x2013;544. doi: 10.1146/annurev-cellbio-100616-060509.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-cellbio-100616-060509</ArticleId><ArticleId IdType="pubmed">30089221</ArticleId></ArticleIdList></Reference><Reference><Citation>Malm TM, Jay TR, Landreth GE. The evolving biology of microglia in Alzheimer&#x2019;s disease. Neurotherapeutics. 2015;12:81&#x2013;93. doi: 10.1007/s13311-014-0316-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-014-0316-8</ArticleId><ArticleId IdType="pmc">PMC4322081</ArticleId><ArticleId IdType="pubmed">25404051</ArticleId></ArticleIdList></Reference><Reference><Citation>Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, et al. Decreased clearance of CNS &#x3b2;-amyloid in Alzheimer&#x2019;s disease. Science. 2010;330:1774. doi: 10.1126/science.1197623.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1197623</ArticleId><ArticleId IdType="pmc">PMC3073454</ArticleId><ArticleId IdType="pubmed">21148344</ArticleId></ArticleIdList></Reference><Reference><Citation>Wildsmith KR, Holley M, Savage JC, Skerrett R, Landreth GE. Evidence for impaired amyloid &#x3b2; clearance in Alzheimer&#x2019;s disease. Alzheimer&#x2019;s Res Therapy. 2013;5:33. doi: 10.1186/alzrt187.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/alzrt187</ArticleId><ArticleId IdType="pmc">PMC3978761</ArticleId><ArticleId IdType="pubmed">23849219</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickman SE, Allison EK, El Khoury J. Microglial dysfunction and defective &#x3b2;-amyloid clearance pathways in aging Alzheimer&#x2019;s disease mice. J Neurosci. 2008;28:8354&#x2013;8360. doi: 10.1523/JNEUROSCI.0616-08.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0616-08.2008</ArticleId><ArticleId IdType="pmc">PMC2597474</ArticleId><ArticleId IdType="pubmed">18701698</ArticleId></ArticleIdList></Reference><Reference><Citation>Beutner C, Lepperhof V, Dann A, Linnartz-Gerlach B, Litwak S, Napoli I, Prinz M et al. Stem cell-derived microglia as therapeutic vehicle for experimental autoimmune encephalomyelitis. Gene Therapy. 2013;20:797&#x2013;806.</Citation><ArticleIdList><ArticleId IdType="pubmed">23324824</ArticleId></ArticleIdList></Reference><Reference><Citation>Moeendarbary E, Weber IP, Sheridan GK, Koser DE, Soleman S, Haenzi B, et al. The soft mechanical signature of glial scars in the central nervous system. Nat Commun. 2017;20:8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5364386</ArticleId><ArticleId IdType="pubmed">28317912</ArticleId></ArticleIdList></Reference><Reference><Citation>ElSheikh M, Arani A, Perry A, Boeve BF, Meyer FB, Savica R, et al. MR elastography demonstrates unique regional brain stiffness patterns in dementias. Am J Roentgenol. 2017;209:403&#x2013;408. doi: 10.2214/AJR.16.17455.</Citation><ArticleIdList><ArticleId IdType="doi">10.2214/AJR.16.17455</ArticleId><ArticleId IdType="pmc">PMC5597304</ArticleId><ArticleId IdType="pubmed">28570101</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy MC, Jones DT, Jack CR, Glaser KJ, Senjem ML, Manduca A, et al. Regional brain stiffness changes across the Alzheimer&#x2019;s disease spectrum. NeuroImage Clin. 2016;10:283&#x2013;290. doi: 10.1016/j.nicl.2015.12.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nicl.2015.12.007</ArticleId><ArticleId IdType="pmc">PMC4724025</ArticleId><ArticleId IdType="pubmed">26900568</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith JF, Knowles TPJ, Dobson CM, Macphee CE, Welland ME. Characterization of the nanoscale properties of individual amyloid fibrils. Proc Natl Acad Sci USA. 2006;103:15806&#x2013;15811. doi: 10.1073/pnas.0604035103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0604035103</ArticleId><ArticleId IdType="pmc">PMC1635084</ArticleId><ArticleId IdType="pubmed">17038504</ArticleId></ArticleIdList></Reference><Reference><Citation>Bollmann L, Koser DE, Shahapure R, Gautier HOB, Holzapfel GA, Scarcelli G, et al. Microglia mechanics: immune activation alters traction forces and durotaxis. Front Cell Neurosci. 2015;9:363. doi: 10.3389/fncel.2015.00363.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2015.00363</ArticleId><ArticleId IdType="pmc">PMC4585148</ArticleId><ArticleId IdType="pubmed">26441534</ArticleId></ArticleIdList></Reference><Reference><Citation>Moshayedi P, Ng G, Kwok JCF, Yeo GSH, Bryant CE, Fawcett JW, et al. The relationship between glial cell mechanosensitivity and foreign body reactions in the central nervous system. Biomaterials. 2014;35:3919&#x2013;3925. doi: 10.1016/j.biomaterials.2014.01.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biomaterials.2014.01.038</ArticleId><ArticleId IdType="pubmed">24529901</ArticleId></ArticleIdList></Reference><Reference><Citation>Condello C, Yuan P, Schain A, Grutzendler J. Microglia constitute a barrier that prevents neurotoxic protofibrillar A&#x3b2;42 hotspots around plaques. Nat Commun. 2015;6:6176. doi: 10.1038/ncomms7176.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms7176</ArticleId><ArticleId IdType="pmc">PMC4311408</ArticleId><ArticleId IdType="pubmed">25630253</ArticleId></ArticleIdList></Reference><Reference><Citation>Coste B, Xiao B, Santos JS, Syeda R, Grandl J, Spencer KS, et al. Piezo proteins are pore-forming subunits of mechanically activated channels. Nature. 2012;483:176&#x2013;181. doi: 10.1038/nature10812.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature10812</ArticleId><ArticleId IdType="pmc">PMC3297710</ArticleId><ArticleId IdType="pubmed">22343900</ArticleId></ArticleIdList></Reference><Reference><Citation>Coste B, Mathur J, Schmidt M, Earley TJ, Ranade S, Petrus MJ, et al. Piezo1 and Piezo2 are essential components of distinct mechanically activated cation channels. Science. 2010;330:55&#x2013;60. doi: 10.1126/science.1193270.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1193270</ArticleId><ArticleId IdType="pmc">PMC3062430</ArticleId><ArticleId IdType="pubmed">20813920</ArticleId></ArticleIdList></Reference><Reference><Citation>Bron R, Wood RJ, Brock JA, Ivanusic JJ. Piezo2 expression in corneal afferent neurons. J Comp Neurol. 2014;522:2967&#x2013;2979. doi: 10.1002/cne.23560.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cne.23560</ArticleId><ArticleId IdType="pubmed">24549492</ArticleId></ArticleIdList></Reference><Reference><Citation>Eijkelkamp N, Linley JE, Torres JM, Bee L, Dickenson AH, Gringhuis M, et al. A role for Piezo2 in EPAC1-dependent mechanical allodynia. Nat Commun. 2013;4:1682.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3644070</ArticleId><ArticleId IdType="pubmed">23575686</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SE, Coste B, Chadha A, Cook B, Patapoutian A. The role of Drosophila Piezo in mechanical nociception. 2012;483:209&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3297676</ArticleId><ArticleId IdType="pubmed">22343891</ArticleId></ArticleIdList></Reference><Reference><Citation>Velasco-Estevez M, Mampay M, Boutin H, Chaney A, Warn P, Sharp A, et al. Infection augments expression of mechanosensing piezo1 channels in amyloid plaque-reactive astrocytes. Front Aging Neurosci. 2018;10:332. doi: 10.3389/fnagi.2018.00332.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2018.00332</ArticleId><ArticleId IdType="pmc">PMC6204357</ArticleId><ArticleId IdType="pubmed">30405400</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J, Lewis AH, Grandl J. Touch, tension, and transduction&#x2014;the function and regulation of piezo ion channels. Trends Biochem Sci. 2017;42:57&#x2013;71. doi: 10.1016/j.tibs.2016.09.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tibs.2016.09.004</ArticleId><ArticleId IdType="pmc">PMC5407468</ArticleId><ArticleId IdType="pubmed">27743844</ArticleId></ArticleIdList></Reference><Reference><Citation>Maneshi MM, Ziegler L, Sachs F, Hua SZ, Gottlieb PA. Enantiomeric A&#x3b2; peptides inhibit the fluid shear stress response of PIEZO1. Sci Rep. 2018;8:14267. doi: 10.1038/s41598-018-32572-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-32572-2</ArticleId><ArticleId IdType="pmc">PMC6155315</ArticleId><ArticleId IdType="pubmed">30250223</ArticleId></ArticleIdList></Reference><Reference><Citation>Chow S, Shao J, Wang H. Sample size calculations in clinical research. 2nd ed. Chapman &amp; Hall/CRC Biostatistics Series; 2008.</Citation></Reference><Reference><Citation>Oksanen M, Petersen AJ, Naumenko N, Puttonen K, Lehtonen &#x160;, GubertOliv&#xe9; M, et al. PSEN1 mutant iPSC-derived model reveals severe astrocyte pathology in Alzheimer&#x2019;s disease. Stem Cell Rep. 2017;9:1885&#x2013;1897. doi: 10.1016/j.stemcr.2017.10.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2017.10.016</ArticleId><ArticleId IdType="pmc">PMC5785689</ArticleId><ArticleId IdType="pubmed">29153989</ArticleId></ArticleIdList></Reference><Reference><Citation>Mu&#xf1;oz SS, Engel M, Balez R, Do-Ha D, Cabral-da-Silva MC, Hern&#xe1;ndez D, et al. A simple differentiation protocol for generation of induced pluripotent stem cell-derived basal forebrain-like cholinergic neurons for Alzheimer&#x2019;s disease and frontotemporal dementia disease modeling. Cells. 2020;9:2018. doi: 10.3390/cells9092018.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9092018</ArticleId><ArticleId IdType="pmc">PMC7564334</ArticleId><ArticleId IdType="pubmed">32887382</ArticleId></ArticleIdList></Reference><Reference><Citation>Guneykaya D, Ivanov A, Hernandez DP, Haage V, Wojtas B, Meyer N, et al. Transcriptional and translational differences of microglia from male and female brains. Cell Rep. 2018;24:2773&#x2013;2783.e6. doi: 10.1016/j.celrep.2018.08.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2018.08.001</ArticleId><ArticleId IdType="pubmed">30184509</ArticleId></ArticleIdList></Reference><Reference><Citation>Konttinen H, Cabral-da-Silva MeC, Ohtonen S, Wojciechowski S, Shakirzyanova A, Caligola S, et al. PSEN1&#x394;E9, APPswe, and APOE4 confer disparate phenotypes in human iPSC-derived microglia. Stem Cell Reports. 2019;13:669&#x2013;683. doi: 10.1016/j.stemcr.2019.08.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2019.08.004</ArticleId><ArticleId IdType="pmc">PMC6829767</ArticleId><ArticleId IdType="pubmed">31522977</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagerlund I, Dougalis A, Shakirzyanova A, G&#xf3;mez-Budia M, Pelkonen A, Konttinen H, et al. Microglia-like cells promote neuronal functions in cerebral organoids. Cells. 2021;11:124. doi: 10.3390/cells11010124.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells11010124</ArticleId><ArticleId IdType="pmc">PMC8750120</ArticleId><ArticleId IdType="pubmed">35011686</ArticleId></ArticleIdList></Reference><Reference><Citation>Crook R, Verkkoniemi A, Perez-Tur J, Mehta N, Baker M, Houlden H, et al. A variant of Alzheimer&#x2019;s disease with spastic paraparesis and unusual plaques due to deletion of exon 9 of presenilin 1. Nat Med. 1998;4:452&#x2013;455. doi: 10.1038/nm0498-452.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm0498-452</ArticleId><ArticleId IdType="pubmed">9546792</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasmussen MA, Holst B, T&#xfc;mer Z, Johnsen MG, Zhou S, Stummann TC, et al. Transient p53 suppression increases reprogramming of human fibroblasts without affecting apoptosis and DNA damage. Stem Cell Rep. 2014;3:404&#x2013;413. doi: 10.1016/j.stemcr.2014.07.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2014.07.006</ArticleId><ArticleId IdType="pmc">PMC4266010</ArticleId><ArticleId IdType="pubmed">25241739</ArticleId></ArticleIdList></Reference><Reference><Citation>Janabi N, Peudenier S, H&#xe9;ron B, Ng KH, Tardieu M. Establishment of human microglial cell lines after transfection of primary cultures of embryonic microglial cells with the SV40 large T antigen. Neurosci Lett. 1995;195:105&#x2013;108. doi: 10.1016/0304-3940(94)11792-H.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0304-3940(94)11792-H</ArticleId><ArticleId IdType="pubmed">7478261</ArticleId></ArticleIdList></Reference><Reference><Citation>Malm T, Mariani M, Donovan LJ, Neilson L, Landreth GE. Activation of the nuclear receptor PPAR&#x3b4; is neuroprotective in a transgenic mouse model of Alzheimer&#x2019;s disease through inhibition of inflammation. J Neuroinflamm. 2015;12:7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4310027</ArticleId><ArticleId IdType="pubmed">25592770</ArticleId></ArticleIdList></Reference><Reference><Citation>Yegutkin GG, Guerrero-Toro C, Kilinc E, Koroleva K, Ishchenko Y, Abushik P, et al. Nucleotide homeostasis and purinergic nociceptive signaling in rat meninges in migraine-like conditions. Purinergic Signal. 2016;12:561&#x2013;574. doi: 10.1007/s11302-016-9521-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11302-016-9521-8</ArticleId><ArticleId IdType="pmc">PMC5023636</ArticleId><ArticleId IdType="pubmed">27369815</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceruti S, Fumagalli M, Villa G, Verderio C, Abbracchio MP. Purinoceptor-mediated calcium signaling in primary neuron-glia trigeminal cultures. Cell Calcium. 2008;43:576&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">18031810</ArticleId></ArticleIdList></Reference><Reference><Citation>Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162:156&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">2440339</ArticleId></ArticleIdList></Reference><Reference><Citation>DeVos SL, Miller TM. Direct intraventricular delivery of drugs to the rodent central nervous system. J Vis Exp. 2013;75:50326.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3679837</ArticleId><ArticleId IdType="pubmed">23712122</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolmont T, Haiss F, Eicke D, Radde R, Mathis CA, Klunk WE, et al. Dynamics of the microglial/amyloid interaction indicate a role in plaque maintenance. J Neurosci. 2008;28:4283&#x2013;4292. doi: 10.1523/JNEUROSCI.4814-07.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4814-07.2008</ArticleId><ArticleId IdType="pmc">PMC3844768</ArticleId><ArticleId IdType="pubmed">18417708</ArticleId></ArticleIdList></Reference><Reference><Citation>Abud EM, Ramirez RN, Martinez ES, Healy LM, Nguyen CHH, Newman SA, et al. iPSC-derived human microglia-like cells to study neurological diseases. Neuron. 2017;94:278&#x2013;293.e9. doi: 10.1016/j.neuron.2017.03.042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2017.03.042</ArticleId><ArticleId IdType="pmc">PMC5482419</ArticleId><ArticleId IdType="pubmed">28426964</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolstad BM, Irizarry RA, &#xc5;strand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics. 2003;19:185&#x2013;193. doi: 10.1093/bioinformatics/19.2.185.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/19.2.185</ArticleId><ArticleId IdType="pubmed">12538238</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler A, Hoffman P, Smibert P, Papalexi E, Satija R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat Biotechnol. 2018;36:411&#x2013;420. doi: 10.1038/nbt.4096.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.4096</ArticleId><ArticleId IdType="pmc">PMC6700744</ArticleId><ArticleId IdType="pubmed">29608179</ArticleId></ArticleIdList></Reference><Reference><Citation>Grubman A, Chew G, Ouyang JF, Sun G, Choo XY, McLean C, et al. A single-cell atlas of entorhinal cortex from individuals with Alzheimer&#x2019;s disease reveals cell-type-specific gene expression regulation. Nat Neurosci. 2019;22:2087&#x2013;2097. doi: 10.1038/s41593-019-0539-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-019-0539-4</ArticleId><ArticleId IdType="pubmed">31768052</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H, Spinrad A, Weiner A, Matcovitch-Natan O, Dvir-Szternfeld R, Ulland TK, et al. A unique microglia type associated with restricting development of Alzheimer&#x2019;s disease. Cell. 2017;169:1276&#x2013;1290.e17. doi: 10.1016/j.cell.2017.05.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.05.018</ArticleId><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Song WM, Andhey PS, Swain A, Levy T, Miller KR, et al. Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer&#x2019;s disease. Nat Med. 2020;26:131&#x2013;142. doi: 10.1038/s41591-019-0695-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-019-0695-9</ArticleId><ArticleId IdType="pmc">PMC6980793</ArticleId><ArticleId IdType="pubmed">31932797</ArticleId></ArticleIdList></Reference><Reference><Citation>Bais AS, Kostka D. Scds: Computational annotation of doublets in single-cell RNA sequencing data. Bioinformatics. 2020;36:1150&#x2013;1158. doi: 10.1093/bioinformatics/btz698.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btz698</ArticleId><ArticleId IdType="pmc">PMC7703774</ArticleId><ArticleId IdType="pubmed">31501871</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y, Zhang K. Tools for the analysis of high-dimensional single-cell RNA sequencing data. Nat Rev Nephrol. 2020;16:408&#x2013;421. doi: 10.1038/s41581-020-0262-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41581-020-0262-0</ArticleId><ArticleId IdType="pubmed">32221477</ArticleId></ArticleIdList></Reference><Reference><Citation>Potter SS. Single-cell RNA sequencing for the study of development, physiology and disease. Nat Rev Nephrol. 2018;14:479&#x2013;492. doi: 10.1038/s41581-018-0021-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41581-018-0021-7</ArticleId><ArticleId IdType="pmc">PMC6070143</ArticleId><ArticleId IdType="pubmed">29789704</ArticleId></ArticleIdList></Reference><Reference><Citation>Vallejos CA, Risso D, Scialdone A, Dudoit S, Marioni JC. Normalizing single-cell RNA sequencing data: challenges and opportunities. Nat Methods. 2017;14:565&#x2013;571. doi: 10.1038/nmeth.4292.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.4292</ArticleId><ArticleId IdType="pmc">PMC5549838</ArticleId><ArticleId IdType="pubmed">28504683</ArticleId></ArticleIdList></Reference><Reference><Citation>Shao X, Liao J, Lu X, Xue R, Ai N, Fan X. scCATCH: automatic annotation on cell types of clusters from single-cell RNA sequencing data. iScience. 2020;23:100882.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7031312</ArticleId><ArticleId IdType="pubmed">32062421</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xe4;nzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-Seq data. BMC Bioinform. 2013.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3618321</ArticleId><ArticleId IdType="pubmed">23323831</ArticleId></ArticleIdList></Reference><Reference><Citation>Diaz-Mejia JJ, Meng EC, Pico AR, MacParland SA, Ketela T, Pugh TJ, et al. Evaluation of methods to assign cell type labels to cell clusters from single-cell RNA-sequencing data. F1000Research. 2019;8:296. doi: 10.12688/f1000research.18490.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/f1000research.18490.1</ArticleId><ArticleId IdType="pmc">PMC6720041</ArticleId><ArticleId IdType="pubmed">31508207</ArticleId></ArticleIdList></Reference><Reference><Citation>Mikhailov N, Leskinen J, Fagerlund I, Poguzhelskaya E, Giniatullina R, Gafurov O, et al. Mechanosensitive meningeal nociception via Piezo channels: implications for pulsatile pain in migraine? Neuropharmacology. 2019;1:113&#x2013;123. doi: 10.1016/j.neuropharm.2019.02.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2019.02.015</ArticleId><ArticleId IdType="pubmed">30768945</ArticleId></ArticleIdList></Reference><Reference><Citation>Velasco-Estevez M, Gadalla KKE, Li&#xf1;an-Barba N, Cobb S, Dev KK, Sheridan GK. Inhibition of Piezo1 attenuates demyelination in the central nervous system. Glia. 2020;68:356&#x2013;375. doi: 10.1002/glia.23722.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.23722</ArticleId><ArticleId IdType="pubmed">31596529</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Sloan SA, Clarke LE, Caneda C, Plaza CA, Blumenthal PD, et al. Purification and characterization of progenitor and mature human astrocytes reveals transcriptional and functional differences with mouse. Neuron. 2016;89:37&#x2013;53. doi: 10.1016/j.neuron.2015.11.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2015.11.013</ArticleId><ArticleId IdType="pmc">PMC4707064</ArticleId><ArticleId IdType="pubmed">26687838</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Chen K, Sloan SA, Bennett ML, Scholze AR, O&#x2019;Keeffe S, et al. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J Neurosci. 2014;34:11929&#x2013;11947. doi: 10.1523/JNEUROSCI.1860-14.2014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1860-14.2014</ArticleId><ArticleId IdType="pmc">PMC4152602</ArticleId><ArticleId IdType="pubmed">25186741</ArticleId></ArticleIdList></Reference><Reference><Citation>Gosselin D, Skola D, Coufal NG, Holtman IR, Schlachetzki JCM, Sajti E, et al. An environment-dependent transcriptional network specifies human microglia identity. Science. 2017;356:1248&#x2013;1259. doi: 10.1126/science.aal3222.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aal3222</ArticleId><ArticleId IdType="pmc">PMC5858585</ArticleId><ArticleId IdType="pubmed">28546318</ArticleId></ArticleIdList></Reference><Reference><Citation>Srinivasan K, Friedman BA, Etxeberria A, Huntley MA, van der Brug MP, Foreman O, et al. Alzheimer&#x2019;s patient microglia exhibit enhanced aging and unique transcriptional activation. Cell Rep. 2020;31:107843. doi: 10.1016/j.celrep.2020.107843.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2020.107843</ArticleId><ArticleId IdType="pmc">PMC7422733</ArticleId><ArticleId IdType="pubmed">32610143</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathys H, Davila-Velderrain J, Peng Z, Gao F, Mohammadi S, Young JZ, et al. Single-cell transcriptomic analysis of Alzheimer&#x2019;s disease. Nature. 2019;570:332&#x2013;337. doi: 10.1038/s41586-019-1195-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-1195-2</ArticleId><ArticleId IdType="pmc">PMC6865822</ArticleId><ArticleId IdType="pubmed">31042697</ArticleId></ArticleIdList></Reference><Reference><Citation>Galatro TF, Holtman IR, Lerario AM, Vainchtein ID, Brouwer N, Sola PR, et al. Transcriptomic analysis of purified human cortical microglia reveals age-associated changes. Nat Neurosci. 2017;20:1162&#x2013;1171. doi: 10.1038/nn.4597.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4597</ArticleId><ArticleId IdType="pubmed">28671693</ArticleId></ArticleIdList></Reference><Reference><Citation>Syeda R, Xu J, Dubin AE, Coste B, Mathur J, Huynh T, et al. Chemical activation of the mechanotransduction channel Piezo1. Elife. 2015;4:e07369. doi: 10.7554/eLife.07369.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.07369</ArticleId><ArticleId IdType="pmc">PMC4456433</ArticleId><ArticleId IdType="pubmed">26001275</ArticleId></ArticleIdList></Reference><Reference><Citation>Bae C, Sachs F, Gottlieb PA. The mechanosensitive ion channel Piezo1 is inhibited by the peptide GsMTx4. Biochemistry. 2011;50:6295&#x2013;6300. doi: 10.1021/bi200770q.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi200770q</ArticleId><ArticleId IdType="pmc">PMC3169095</ArticleId><ArticleId IdType="pubmed">21696149</ArticleId></ArticleIdList></Reference><Reference><Citation>Montilla A, Zabala A, Matute C, Domercq M. Functional and metabolic characterization of microglia culture in a defined medium. Front Cell Neurosci. 2020;14:22. doi: 10.3389/fncel.2020.00022.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2020.00022</ArticleId><ArticleId IdType="pmc">PMC7025516</ArticleId><ArticleId IdType="pubmed">32116565</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayata P, Schaefer A. Innate sensing of mechanical properties of brain tissue by microglia. Curr Opin Immunol. 2020;62:123&#x2013;130. doi: 10.1016/j.coi.2020.01.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coi.2020.01.003</ArticleId><ArticleId IdType="pmc">PMC7067639</ArticleId><ArticleId IdType="pubmed">32058296</ArticleId></ArticleIdList></Reference><Reference><Citation>Nunes P, Demaurex N. The role of calcium signaling in phagocytosis. J Leukoc Biol. 2010;88:57&#x2013;68. doi: 10.1189/jlb.0110028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1189/jlb.0110028</ArticleId><ArticleId IdType="pubmed">20400677</ArticleId></ArticleIdList></Reference><Reference><Citation>Podle&#x15b;ny-Drabiniok A, Marcora E, Goate AM. Microglial phagocytosis: a disease-associated process emerging from Alzheimer&#x2019;s disease genetics. Trends Neurosci. 2020;43:965&#x2013;979. doi: 10.1016/j.tins.2020.10.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2020.10.002</ArticleId><ArticleId IdType="pmc">PMC9080913</ArticleId><ArticleId IdType="pubmed">33127097</ArticleId></ArticleIdList></Reference><Reference><Citation>Novikova G, Kapoor M, Julia TCW, Abud EM, Efthymiou AG, Chen SX, et al. Integration of Alzheimer&#x2019;s disease genetics and myeloid genomics identifies disease risk regulatory elements and genes. Nat Commun. 2021;12(1):1&#x2013;14. doi: 10.1038/s41467-021-21823-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-21823-y</ArticleId><ArticleId IdType="pmc">PMC7955030</ArticleId><ArticleId IdType="pubmed">33712570</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng J, Su L, Xu Z, Chen G. Progranulin polymorphism rs5848 is associated with increased risk of Alzheimer&#x2019;s disease. Gene. 2014;542:141&#x2013;145. doi: 10.1016/j.gene.2014.03.041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gene.2014.03.041</ArticleId><ArticleId IdType="pubmed">24680777</ArticleId></ArticleIdList></Reference><Reference><Citation>Brawek B, Schwendele B, Riester K, Kohsaka S, Lerdkrai C, Liang Y, et al. Impairment of in vivo calcium signaling in amyloid plaque-associated microglia. Acta Neuropathol. 2014;127:495&#x2013;505. doi: 10.1007/s00401-013-1242-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1242-2</ArticleId><ArticleId IdType="pubmed">24407428</ArticleId></ArticleIdList></Reference><Reference><Citation>Savchenko E, Malm T, Konttinen H, H&#xe4;m&#xe4;l&#xe4;inen RH, Guerrero-Toro C, Wojciechowski S, et al. A&#x3b2; and inflammatory stimulus activate diverse signaling pathways in monocytic cells: implications in retaining phagocytosis in A&#x3b2;-laden environment. Front Cell Neurosci. 2016;10:279. doi: 10.3389/fncel.2016.00279.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2016.00279</ArticleId><ArticleId IdType="pmc">PMC5136556</ArticleId><ArticleId IdType="pubmed">27994540</ArticleId></ArticleIdList></Reference><Reference><Citation>McLarnon JG, Choi HB, Lue LF, Walker DG, Kim SU. Perturbations in calcium-mediated signal transduction in microglia from Alzheimer&#x2019;s disease patients. J Neurosci Res. 2005;81:426&#x2013;435. doi: 10.1002/jnr.20487.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.20487</ArticleId><ArticleId IdType="pubmed">15948178</ArticleId></ArticleIdList></Reference><Reference><Citation>Esparza TJ, Wildburger NC, Jiang H, Gangolli M, Cairns NJ, Bateman RJ, et al. Soluble amyloid-beta aggregates from human Alzheimer&#x2019;s disease brains. Sci Rep. 2016;6:38187. doi: 10.1038/srep38187.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep38187</ArticleId><ArticleId IdType="pmc">PMC5137165</ArticleId><ArticleId IdType="pubmed">27917876</ArticleId></ArticleIdList></Reference><Reference><Citation>Malmberg M, Malm T, Gustafsson O, Sturchio A, Graff C, Espay AJ, et al. Disentangling the amyloid pathways: a mechanistic approach to etiology. Front Neurosci. 2020;14:256. doi: 10.3389/fnins.2020.00256.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2020.00256</ArticleId><ArticleId IdType="pmc">PMC7186396</ArticleId><ArticleId IdType="pubmed">32372895</ArticleId></ArticleIdList></Reference><Reference><Citation>Malm T, Ort M, T&#xe4;htivaara L, Jukarainen N, Goldsteins G, Puoliv&#xe4;li J, et al. &#x3b2;-amyloid infusion results in delayed and age-dependent learning deficits without role of inflammation or &#x3b2;-amyloid deposits. Proc Natl Acad Sci U S A. 2006;103:8852&#x2013;8857. doi: 10.1073/pnas.0602896103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0602896103</ArticleId><ArticleId IdType="pmc">PMC1482667</ArticleId><ArticleId IdType="pubmed">16723396</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen GF, Xu TH, Yan Y, Zhou YR, Jiang Y, Melcher K, et al. Amyloid beta: structure, biology and structure-based therapeutic development. Acta Pharmacol Sin. 2017;38:1205&#x2013;1235. doi: 10.1038/aps.2017.28.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/aps.2017.28</ArticleId><ArticleId IdType="pmc">PMC5589967</ArticleId><ArticleId IdType="pubmed">28713158</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabaton M, Piccini A. Role of water-soluble amyloid-b in the pathogenesis of Alzheimer&#x2019;s disease. Int J Exp Pathol. 2005;86:139-45</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2517412</ArticleId><ArticleId IdType="pubmed">15910548</ArticleId></ArticleIdList></Reference><Reference><Citation>Richard BC, Kurdakova A, Baches S, Bayer TA, Weggen S, Wirths O. Gene dosage dependent aggravation of the neurological phenotype in the 5XFAD mouse model of Alzheimer&#x2019;s disease. J Alzheimer&#x2019;s Dis. 2015;45:1223&#x2013;1236. doi: 10.3233/JAD-143120.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-143120</ArticleId><ArticleId IdType="pubmed">25697701</ArticleId></ArticleIdList></Reference><Reference><Citation>Jawhar S, Trawicka A, Jenneckens C, Bayer TA, Wirths O. Motor deficits, neuron loss, and reduced anxiety coinciding with axonal degeneration and intraneuronal A&#x3b2; aggregation in the 5XFAD mouse model of Alzheimer&#x2019;s disease. Neurobiol Aging. 2012;33:196.e29&#x2013;196.e40. doi: 10.1016/j.neurobiolaging.2010.05.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2010.05.027</ArticleId><ArticleId IdType="pubmed">20619937</ArticleId></ArticleIdList></Reference><Reference><Citation>Unger MS, Schernthaner P, Marschallinger J, Mrowetz H, Aigner L. Microglia prevent peripheral immune cell invasion and promote an anti-inflammatory environment in the brain of APP-PS1 transgenic mice. J Neuroinflamm. 2018;15:274. doi: 10.1186/s12974-018-1304-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-018-1304-4</ArticleId><ArticleId IdType="pmc">PMC6151006</ArticleId><ArticleId IdType="pubmed">30241479</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka MT, Carson MJ, El KJ, Landreth GE, Brosseron F, Feinstein DL, et al. Neuroinflammation in Alzheimer&#x2019;s disease. Lancet Neurol. 2015;14:388&#x2013;405. doi: 10.1016/S1474-4422(15)70016-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(15)70016-5</ArticleId><ArticleId IdType="pmc">PMC5909703</ArticleId><ArticleId IdType="pubmed">25792098</ArticleId></ArticleIdList></Reference><Reference><Citation>Krabbe G, Halle A, Matyash V, Rinnenthal JL, Eom GD, Bernhardt U, et al. Functional impairment of microglia coincides with beta-amyloid deposition in mice with Alzheimer-like pathology. PLoS ONE. 2013;8:60921. doi: 10.1371/journal.pone.0060921.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0060921</ArticleId><ArticleId IdType="pmc">PMC3620049</ArticleId><ArticleId IdType="pubmed">23577177</ArticleId></ArticleIdList></Reference><Reference><Citation>Perlmutter L, Scott S, Barron E, Chui H. MHC Class II-positive microglia in human brain: association with Alzheimer lesions. J Neurosci Res. 1992;33:549-58.</Citation><ArticleIdList><ArticleId IdType="pubmed">1484388</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanninen K, Malm TM, Jyrkk&#xe4;nen HK, Goldsteins G, Keksa-Goldsteine V, Tanila H, et al. Nuclear factor erythroid 2-related factor 2 protects against beta amyloid. Mol Cell Neurosci. 2008;39:302&#x2013;313. doi: 10.1016/j.mcn.2008.07.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2008.07.010</ArticleId><ArticleId IdType="pubmed">18706502</ArticleId></ArticleIdList></Reference><Reference><Citation>Galloway DA, Phillips AEM, Owen DRJ, Moore CS. Phagocytosis in the brain: homeostasis and disease. Front Immunol. 2019;10:790. doi: 10.3389/fimmu.2019.00790.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.00790</ArticleId><ArticleId IdType="pmc">PMC6477030</ArticleId><ArticleId IdType="pubmed">31040847</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu Z, Guo J, Kala S, Zhu J, Xian Q, Qiu W, et al. The mechanosensitive ion channel piezo1 significantly mediates in vitro ultrasonic stimulation of neurons. iScience. 2019;21:448&#x2013;457. doi: 10.1016/j.isci.2019.10.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2019.10.037</ArticleId><ArticleId IdType="pmc">PMC6849147</ArticleId><ArticleId IdType="pubmed">31707258</ArticleId></ArticleIdList></Reference><Reference><Citation>Bobola MS, Chen L, Ezeokeke CK, Olmstead TA, Nguyen C, Sahota A, et al. Transcranial focused ultrasound, pulsed at 40 Hz, activates microglia acutely and reduces A&#x3b2; load chronically, as demonstrated in vivo. Brain Stimul. 2020;13:1014&#x2013;1023. doi: 10.1016/j.brs.2020.03.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brs.2020.03.016</ArticleId><ArticleId IdType="pmc">PMC7308193</ArticleId><ArticleId IdType="pubmed">32388044</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottlieb PA, Sachs F. Piezo1: Properties of a cation selective mechanical channel. Channels. 2012;6:214. doi: 10.4161/chan.21050.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/chan.21050</ArticleId><ArticleId IdType="pmc">PMC3508900</ArticleId><ArticleId IdType="pubmed">22790400</ArticleId></ArticleIdList></Reference><Reference><Citation>Bae C, Gottlieb PA, Sachs F. Human PIEZO1: removing inactivation. Biophys J. 2013;105:880&#x2013;886. doi: 10.1016/j.bpj.2013.07.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bpj.2013.07.019</ArticleId><ArticleId IdType="pmc">PMC3752115</ArticleId><ArticleId IdType="pubmed">23972840</ArticleId></ArticleIdList></Reference><Reference><Citation>Maroto R, Kurosky A, Hamill OP. Mechanosensitive Ca2+ permeant cation channels in human prostate tumor cells. Channels. 2012;6:290&#x2013;307. doi: 10.4161/chan.21063.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/chan.21063</ArticleId><ArticleId IdType="pmc">PMC3508908</ArticleId><ArticleId IdType="pubmed">22874798</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamill OP, Mcbride DW. Mechanogated channels in Xenopus oocytes: different gating modes enable a channel to switch from a phasic to a tonic mechanotransducer. Biol Bull. 1997;192:121&#x2013;124. doi: 10.2307/1542583.</Citation><ArticleIdList><ArticleId IdType="doi">10.2307/1542583</ArticleId><ArticleId IdType="pubmed">9057280</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuchiya M, Hara Y, Okuda M, Itoh K, Nishioka R, Shiomi A, et al. Cell surface flip-flop of phosphatidylserine is critical for PIEZO1-mediated myotube formation. Nat Commun. 2018;9:1&#x2013;15. doi: 10.1038/s41467-017-02088-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-02088-w</ArticleId><ArticleId IdType="pmc">PMC5967302</ArticleId><ArticleId IdType="pubmed">29799007</ArticleId></ArticleIdList></Reference><Reference><Citation>Bohlen CJ, Bennett FC, Tucker AF, Collins HY, Mulinyawe SB, Barres BA. Diverse requirements for microglial survival, specification, and function revealed by defined-medium cultures. Neuron. 2017;94:759&#x2013;773.e8. doi: 10.1016/j.neuron.2017.04.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2017.04.043</ArticleId><ArticleId IdType="pmc">PMC5523817</ArticleId><ArticleId IdType="pubmed">28521131</ArticleId></ArticleIdList></Reference><Reference><Citation>Ridone P, Pandzic E, Vassalli M, Cox CD, Macmillan A, Gottlieb PA, et al. Disruption of membrane cholesterol organization impairs the activity of PIEZO1 channel clusters. J Gen Physiol. 2020;152:e201912515. doi: 10.1085/jgp.201912515.</Citation><ArticleIdList><ArticleId IdType="doi">10.1085/jgp.201912515</ArticleId><ArticleId IdType="pmc">PMC7398139</ArticleId><ArticleId IdType="pubmed">32582958</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y, Zhang J, Li L, Ye Z, Zhang Y, Gao X, et al. Complex regulation of capsaicin on intracellular second messengers by calcium dependent and independent mechanisms in primary sensory neurons. Neurosci Lett. 2012;517:30&#x2013;35. doi: 10.1016/j.neulet.2012.04.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2012.04.011</ArticleId><ArticleId IdType="pubmed">22516465</ArticleId></ArticleIdList></Reference><Reference><Citation>Poole K, Herget R, Lapatsina L, Ngo HD, Lewin GR. Tuning Piezo ion channels to detect molecular-scale movements relevant for fine touch. Nat Commun. 2014;5:3520. doi: 10.1038/ncomms4520.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms4520</ArticleId><ArticleId IdType="pmc">PMC3973071</ArticleId><ArticleId IdType="pubmed">24662763</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi Y, Andolfi L, Frattini F, Mayer F, Lazzarino M, Hu J. Membrane stiffening by STOML3 facilitates mechanosensation in sensory neurons. Nat Commun. 2015;6:8512. doi: 10.1038/ncomms9512.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms9512</ArticleId><ArticleId IdType="pmc">PMC4633829</ArticleId><ArticleId IdType="pubmed">26443885</ArticleId></ArticleIdList></Reference><Reference><Citation>TCW Julia, Liang S, Qian L, Pipalia N, Chao M, Shi Y, et al. Cholesterol and matrisome pathways dysregulated in human APOE &#x220a;4 Glia. SSRN Electron J. 2019 doi: 10.2139/ssrn.3435267.</Citation><ArticleIdList><ArticleId IdType="doi">10.2139/ssrn.3435267</ArticleId></ArticleIdList></Reference><Reference><Citation>Lukacs V, Mathur J, Mao R, Bayrak-Toydemir P, Procter M, Cahalan SM, et al. Impaired PIEZO1 function in patients with a novel autosomal recessive congenital lymphatic dysplasia. Nat Commun. 2015;6:8329. doi: 10.1038/ncomms9329.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms9329</ArticleId><ArticleId IdType="pmc">PMC4578306</ArticleId><ArticleId IdType="pubmed">26387913</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma S, Cahalan S, LaMonte G, Grubaugh ND, Zeng W, Murthy SE, et al. Common PIEZO1 Allele in African populations causes RBC dehydration and attenuates plasmodium infection. Cell. 2018;173:443&#x2013;455.e12. doi: 10.1016/j.cell.2018.02.047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2018.02.047</ArticleId><ArticleId IdType="pmc">PMC5889333</ArticleId><ArticleId IdType="pubmed">29576450</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguetse CN, Purington N, Ebel ER, Shakya B, Tetard M, Kremsner PG, et al. A common polymorphism in the mechanosensitive ion channel PIEZO1 is associated with protection from severe malaria in humans. Proc Natl Acad Sci U S A. 2020;117:9074&#x2013;9081. doi: 10.1073/pnas.1919843117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1919843117</ArticleId><ArticleId IdType="pmc">PMC7183233</ArticleId><ArticleId IdType="pubmed">32265284</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma S, Dubin AE, Zhang Y, Mousavi SAR, Wang Y, Coombs AM, et al. A role of PIEZO1 in iron metabolism in mice and humans. Cell. 2021;184:969&#x2013;982.e13. doi: 10.1016/j.cell.2021.01.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.01.024</ArticleId><ArticleId IdType="pmc">PMC7927959</ArticleId><ArticleId IdType="pubmed">33571427</ArticleId></ArticleIdList></Reference><Reference><Citation>Pathak MM, Nourse JL, Tran T, Hwe J, Arulmoli J, Le DTT, et al. Stretch-activated ion channel Piezo1 directs lineage choice in human neural stem cells. Proc Natl Acad Sci U S A. 2014;111:16148&#x2013;16153. doi: 10.1073/pnas.1409802111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1409802111</ArticleId><ArticleId IdType="pmc">PMC4234578</ArticleId><ArticleId IdType="pubmed">25349416</ArticleId></ArticleIdList></Reference><Reference><Citation>Blumenthal NR, Hermanson O, Heimrich B, Shastri VP. Stochastic nanoroughness modulates neuron-astrocyte interactions and function via mechanosensing cation channels. Proc Natl Acad Sci U S A. 2014;111:16124&#x2013;16129. doi: 10.1073/pnas.1412740111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1412740111</ArticleId><ArticleId IdType="pmc">PMC4234571</ArticleId><ArticleId IdType="pubmed">25349433</ArticleId></ArticleIdList></Reference><Reference><Citation>Satoh K, Hata M, Takahara S, Tsuzaki H, Yokota H, Akatsu H, et al. A novel membrane protein, encoded by the gene covering KIAA0233, is transcriptionally induced in senile plaque-associated astrocytes. Brain Res. 2006;1108:19&#x2013;27. doi: 10.1016/j.brainres.2006.06.050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2006.06.050</ArticleId><ArticleId IdType="pubmed">16854388</ArticleId></ArticleIdList></Reference><Reference><Citation>Liddelow SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L, et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017;541:481&#x2013;487. doi: 10.1038/nature21029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature21029</ArticleId><ArticleId IdType="pmc">PMC5404890</ArticleId><ArticleId IdType="pubmed">28099414</ArticleId></ArticleIdList></Reference><Reference><Citation>McCaughey T, Sanfilippo PG, Gooden GEC, Budden DM, Fan L, Fenwick E, et al. A global social media survey of attitudes to human genome editing. Cell Stem Cell. 2016;18:569&#x2013;572. doi: 10.1016/j.stem.2016.04.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2016.04.011</ArticleId><ArticleId IdType="pubmed">27152441</ArticleId></ArticleIdList></Reference><Reference><Citation>Brand A, Allen L, Altman M, Hlava M, Scott J. Beyond authorship: attribution, contribution, collaboration, and credit. Learn Publ. 2015;28:151&#x2013;155. doi: 10.1087/20150211.</Citation><ArticleIdList><ArticleId IdType="doi">10.1087/20150211</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmqvist S, Lehtonen S, Chumarina M, Puttonen KA, Azevedo C, Lebedeva O, et al. Creation of a library of induced pluripotent stem cells from Parkinsonian patients. NPJ Parkinson's Dis. 2016;2:16009.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5516589</ArticleId><ArticleId IdType="pubmed">28725696</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35714196</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2375-2548</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>24</Issue><PubDate><Year>2022</Year><Month>Jun</Month><Day>17</Day></PubDate></JournalIssue><Title>Science advances</Title><ISOAbbreviation>Sci Adv</ISOAbbreviation></Journal><ArticleTitle>BACE-1 inhibition facilitates the transition from homeostatic microglia to DAM-1.</ArticleTitle><Pagination><StartPage>eabo1286</StartPage><MedlinePgn>eabo1286</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">eabo1286</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1126/sciadv.abo1286</ELocationID><Abstract><AbstractText>BACE-1 is required for generating &#x3b2;-amyloid (A&#x3b2;) peptides in Alzheimer's disease (AD). Here, we report that microglial BACE-1 regulates the transition of homeostatic to stage 1 disease-associated microglia (DAM-1) signature. BACE-1 deficiency elevated levels of transcription factors including <i>Jun</i>, <i>Jund</i>, <i>Btg2</i>, <i>Erg1</i>, <i>Junb</i>, <i>Fos</i>, and <i>Fosb</i> in the transition signature, which transition from more homeostatic to highly phagocytic DAM-1. Consistently, similar transition-state microglia in human AD brains correlated with lowered levels of BACE-1 expression. Targeted deletion of <i>Bace-1</i> in adult 5xFAD mice microglia elevated these phagocytic microglia, correlated with significant reduction in amyloid plaques without synaptic toxicity. Silencing or pharmacologically inhibiting BACE-1 in cultured microglia-derived cells shows higher phagocytic function in microglia. Mechanistic exploration suggests that abolished cleavage of IL-1R2 and Toll-like receptors via BACE-1 inhibition contributes to the enhanced signaling via the PI3K and p38 MAPK kinase pathway. Together, targeted inhibition of BACE-1 in microglia may offer AD treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Neeraj</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-2044-0375</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, UConn Health, Farmington, CT 06030-3401, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benoit</LastName><ForeName>Marc R</ForeName><Initials>MR</Initials><Identifier Source="ORCID">0000-0001-6777-8472</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, UConn Health, Farmington, CT 06030-3401, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, UConn Health, Farmington, CT 06030-3401, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Das</LastName><ForeName>Brati</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-5800-3912</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, UConn Health, Farmington, CT 06030-3401, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davila-Velderrain</LastName><ForeName>Jose</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-0271-6267</Identifier><AffiliationInfo><Affiliation>Human Technopole, Viale Rita Levi-Montalcini 1, 20157, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Computer Science and Artificial Intelligence Lab, Massachusetts Institute of Technology, Cambridge, MA 02138, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02138, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kellis</LastName><ForeName>Manolis</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-7113-9630</Identifier><AffiliationInfo><Affiliation>Computer Science and Artificial Intelligence Lab, Massachusetts Institute of Technology, Cambridge, MA 02138, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02138, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Broad Institute of MIT and Harvard, Cambridge, MA 02138, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>Li-Huei</ForeName><Initials>LH</Initials><Identifier Source="ORCID">0000-0003-1262-0592</Identifier><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02138, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Broad Institute of MIT and Harvard, Cambridge, MA 02138, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Xiangyou</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, UConn Health, Farmington, CT 06030-3401, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Riqiang</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-7195-7617</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, UConn Health, Farmington, CT 06030-3401, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG025493</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 NS074256</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG058261</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS074256</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG046929</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG025493</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG046929</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Adv</MedlineTA><NlmUniqueID>101653440</NlmUniqueID><ISSNLinking>2375-2548</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>17</Day><Hour>14</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>18</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>6</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35714196</ArticleId><ArticleId IdType="pmc">PMC9205595</ArticleId><ArticleId IdType="doi">10.1126/sciadv.abo1286</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Corriveau R. A., Koroshetz W. J., Gladman J. T., Jeon S., Babcock D., Bennett D. A., Carmichael S. T., Dickinson S. L., Dickson D. W., Emr M., Fillit H., Greenberg S. M., Hutton M. L., Knopman D. S., Manly J. J., Marder K. S., Moy C. S., Phelps C. H., Scott P. A., Seeley W. W., Sieber B. A., Silverberg N. B., Sutherland M. L., Taylor A., Torborg C. L., Waddy S. P., Gubitz A. K., Holtzman D. M., Alzheimer&#x2019;s disease&#x2013;related dementias summit 2016: National research priorities. Neurology 89, 2381&#x2013;2391 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5719928</ArticleId><ArticleId IdType="pubmed">29117955</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai H., Wang Y., McCarthy D., Wen H., Borchelt D. R., Price D. L., Wong P. C., BACE1 is the major &#x3b2;-secretase for generation of A&#x3b2; peptides by neurons. Nat. Neurosci. 4, 233&#x2013;234 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11224536</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo Y., Bolon B., Kahn S., Bennett B. D., Babu-Khan S., Denis P., Fan W., Kha H., Zhang J., Gong Y., Martin L., Louis J. C., Yan Q., Richards W. G., Citron M., Vassar R., Mice deficient in BACE1, the Alzheimer&#x2019;s beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nat. Neurosci. 4, 231&#x2013;232 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11224535</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberds S. L., Anderson J., Basi G., Bienkowski M. J., Branstetter D. G., Chen K. S., Freedman S. B., Frigon N. L., Games D., Hu K., Johnson-Wood K., Kappenman K. E., Kawabe T. T., Kola I., Kuehn R., Lee M., Liu W., Motter R., Nichols N. F., Power M., Robertson D. W., Schenk D., Schoor M., Shopp G. M., Shuck M. E., Sinha S., Svensson K. A., Tatsuno G., Tintrup H., Wijsman J., Wright S., McConlogue L., BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: Implications for Alzheimer&#x2019;s disease therapeutics. Hum. Mol. Genet. 10, 1317&#x2013;1324 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11406613</ArticleId></ArticleIdList></Reference><Reference><Citation>Egan M. F., Kost J., Voss T., Mukai Y., Aisen P. S., Cummings J. L., Tariot P. N., Vellas B., van Dyck C. H., Boada M., Zhang Y., Li W., Furtek C., Mahoney E., Harper Mozley L., Mo Y., Sur C., Michelson D., Randomized trial of verubecestat for prodromal alzheimer&#x2019;s disease. N. Engl. J. Med. 380, 1408&#x2013;1420 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6776078</ArticleId><ArticleId IdType="pubmed">30970186</ArticleId></ArticleIdList></Reference><Reference><Citation>Wessels A. M., Tariot P. N., Zimmer J. A., Selzler K. J., Bragg S. M., Andersen S. W., Landry J., Krull J. H., Downing A. M., Willis B. A., Shcherbinin S., Mullen J., Barker P., Schumi J., Shering C., Matthews B. R., Stern R. A., Vellas B., Cohen S., MacSweeney E., Boada M., Sims J. R., Efficacy and safety of lanabecestat for treatment of early and mild alzheimer disease: The AMARANTH and DAYBREAK-ALZ randomized clinical trials. JAMA Neurol. 77, 199&#x2013;209 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6902191</ArticleId><ArticleId IdType="pubmed">31764959</ArticleId></ArticleIdList></Reference><Reference><Citation>Imbimbo B. P., Watling M., Investigational BACE inhibitors for the treatment of Alzheimer&#x2019;s disease. Expert Opin. Investig. Drugs 28, 967&#x2013;975 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31661331</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu X., Das B., Hou H., He W., Yan R., BACE1 deletion in the adult mouse reverses preformed amyloid deposition and improves cognitive functions. J. Exp. Med. 215, 927&#x2013;940 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5839766</ArticleId><ArticleId IdType="pubmed">29444819</ArticleId></ArticleIdList></Reference><Reference><Citation>Tansey K. E., Cameron D., Hill M. J., Genetic risk for Alzheimer&#x2019;s disease is concentrated in specific macrophage and microglial transcriptional networks. Genome Med. 10, 14 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5828245</ArticleId><ArticleId IdType="pubmed">29482603</ArticleId></ArticleIdList></Reference><Reference><Citation>Nott A., Holtman I. R., Coufal N. G., Schlachetzki J. C. M., Yu M., Hu R., Han C. Z., Pena M., Xiao J., Wu Y., Keulen Z., Pasillas M. P., O&#x2019;Connor C., Nickl C. K., Schafer S. T., Shen Z., Rissman R. A., Brewer J. B., Gosselin D., Gonda D. D., Levy M. L., Rosenfeld M. G., McVicker G., Gage F. H., Ren B., Glass C. K., Brain cell type-specific enhancer-promoter interactome maps and disease-risk association. Science 366, 1134&#x2013;1139 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7028213</ArticleId><ArticleId IdType="pubmed">31727856</ArticleId></ArticleIdList></Reference><Reference><Citation>Deczkowska A., Keren-Shaul H., Weiner A., Colonna M., Schwartz M., Amit I., Disease-associated microglia: A universal immune sensor of neurodegeneration. Cell 173, 1073&#x2013;1081 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29775591</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y., Song W. M., Andhey P. S., Swain A., Levy T., Miller K. R., Poliani P. L., Cominelli M., Grover S., Gilfillan S., Cella M., Ulland T. K., Zaitsev K., Miyashita A., Ikeuchi T., Sainouchi M., Kakita A., Bennett D. A., Schneider J. A., Nichols M. R., Beausoleil S. A., Ulrich J. D., Holtzman D. M., Artyomov M. N., Colonna M., Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer&#x2019;s disease. Nat. Med. 26, 131&#x2013;142 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6980793</ArticleId><ArticleId IdType="pubmed">31932797</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y., Happonen K. E., Burrola P. G., O&#x2019;Connor C., Hah N., Huang L., Nimmerjahn A., Lemke G., Microglia use TAM receptors to detect and engulf amyloid &#x3b2; plaques. Nat. Immunol. 22, 586&#x2013;594 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8102389</ArticleId><ArticleId IdType="pubmed">33859405</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakley H., Cole S. L., Logan S., Maus E., Shao P., Craft J., Guillozet-Bongaarts A., Ohno M., Disterhoft J., Van E. L., Berry R., Vassar R., Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer&#x2019;s disease mutations: Potential factors in amyloid plaque formation. J. Neurosci. 26, 10129&#x2013;10140 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674618</ArticleId><ArticleId IdType="pubmed">17021169</ArticleId></ArticleIdList></Reference><Reference><Citation>Grubman A., Chew G., Ouyang J. F., Sun G., Choo X. Y., McLean C., Simmons R. K., Buckberry S., Vargas-Landin D. B., Poppe D., Pflueger J., Lister R., Rackham O. J. L., Petretto E., Polo J. M., A single-cell atlas of entorhinal cortex from individuals with Alzheimer&#x2019;s disease reveals cell-type-specific gene expression regulation. Nat. Neurosci. 22, 2087&#x2013;2097 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31768052</ArticleId></ArticleIdList></Reference><Reference><Citation>Eketjall S., Janson J., Kaspersson K., Bogstedt A., Jeppsson F., Falting J., Haeberlein S. B., Kugler A. R., Alexander R. C., Cebers G., AZD3293: A novel, orally active BACE1 inhibitor with high potency and permeability and markedly slow off-rate kinetics. J. Alzheimers Dis. 50, 1109&#x2013;1123 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4927864</ArticleId><ArticleId IdType="pubmed">26890753</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy M. E., Stamford A. W., Chen X., Cox K., Cumming J. N., Dockendorf M. F., Egan M., Ereshefsky L., Hodgson R. A., Hyde L. A., Jhee S., Kleijn H. J., Kuvelkar R., Li W., Mattson B. A., Mei H., Palcza J., Scott J. D., Tanen M., Troyer M. D., Tseng J. L., Stone J. A., Parker E. M., Forman M. S., The BACE1 inhibitor verubecestat (MK-8931) reduces CNS &#x3b2;-amyloid in animal models and in Alzheimer&#x2019;s disease patients. Sci. Transl. Med. 8, 363ra150 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27807285</ArticleId></ArticleIdList></Reference><Reference><Citation>Groves E., Dart A. E., Covarelli V., Caron E., Molecular mechanisms of phagocytic uptake in mammalian cells. Cell. Mol. Life Sci. 65, 1957&#x2013;1976 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11131742</ArticleId><ArticleId IdType="pubmed">18322649</ArticleId></ArticleIdList></Reference><Reference><Citation>Massol P., Montcourrier P., Guillemot J. C., Chavrier P., Fc receptor-mediated phagocytosis requires CDC42 and Rac1. EMBO J. 17, 6219&#x2013;6229 (1998).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1170948</ArticleId><ArticleId IdType="pubmed">9799231</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkinson B., Koenigsknecht-Talboo J., Grommes C., Lee C. Y., Landreth G., Fibrillar beta-amyloid-stimulated intracellular signaling cascades require Vav for induction of respiratory burst and phagocytosis in monocytes and microglia. J. Biol. Chem. 281, 20842&#x2013;20850 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16728400</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan J., Kao Y. L., Joshi S., Jeetendran S., Dipette D., Singh U. S., Activation of Rac1 by phosphatidylinositol 3-kinase in vivo: Role in activation of mitogen-activated protein kinase (MAPK) pathways and retinoic acid-induced neuronal differentiation of SH-SY5Y cells. J. Neurochem. 93, 571&#x2013;583 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15836616</ArticleId></ArticleIdList></Reference><Reference><Citation>Koyasu S., The role of PI3K in immune cells. Nat. Immunol. 4, 313&#x2013;319 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12660731</ArticleId></ArticleIdList></Reference><Reference><Citation>Dislich B., Wohlrab F., Bachhuber T., Mueller S., Kuhn P. H., Hogl S., Meyer-Luehmann M., Lichtenthaler S. F., Label-free quantitative proteomics of mouse cerebrospinal fluid detects &#x3b2;-site APP cleaving enzyme (BACE1) protease substrates in vivo. Mol. Cell. Proteomics 14, 2550&#x2013;2563 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4597136</ArticleId><ArticleId IdType="pubmed">26139848</ArticleId></ArticleIdList></Reference><Reference><Citation>Boraschi D., Italiani P., Weil S., Martin M. U., The family of the interleukin-1 receptors. Immunol. Rev. 281, 197&#x2013;232 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29248002</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhn P. H., Marjaux E., Imhof A., De Strooper B., Haass C., Lichtenthaler S. F., Regulated intramembrane proteolysis of the interleukin-1 receptor II by alpha-, beta-, and gamma-secretase. J. Biol. Chem. 282, 11982&#x2013;11995 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17307738</ArticleId></ArticleIdList></Reference><Reference><Citation>Sizemore N., Leung S., Stark G. R., Activation of phosphatidylinositol 3-kinase in response to interleukin-1 leads to phosphorylation and activation of the NF-kappaB p65/RelA subunit. Mol. Cell. Biol. 19, 4798&#x2013;4805 (1999).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC84278</ArticleId><ArticleId IdType="pubmed">10373529</ArticleId></ArticleIdList></Reference><Reference><Citation>Doan H. Q., Bowen K. A., Jackson L. A., Evers B. M., Toll-like receptor 4 activation increases Akt phosphorylation in colon cancer cells. Anticancer Res 29, 2473&#x2013;2478 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2901163</ArticleId><ArticleId IdType="pubmed">19596916</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H., Spinrad A., Weiner A., Matcovitch-Natan O., Dvir-Szternfeld R., Ulland T. K., David E., Baruch K., Lara-Astaiso D., Toth B., Itzkovitz S., Colonna M., Schwartz M., Amit I., A unique microglia type associated with restricting development of alzheimer&#x2019;s disease. Cell 169, 1276&#x2013;1290.e17 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathys H., Adaikkan C., Gao F., Young J. Z., Manet E., Hemberg M., De Jager P. L., Ransohoff R. M., Regev A., Tsai L. H., Temporal tracking of microglia activation in neurodegeneration at single-cell resolution. Cell Rep. 21, 366&#x2013;380 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5642107</ArticleId><ArticleId IdType="pubmed">29020624</ArticleId></ArticleIdList></Reference><Reference><Citation>Mrdjen D., Pavlovic A., Hartmann F. J., Schreiner B., Utz S. G., Leung B. P., Lelios I., Heppner F. L., Kipnis J., Merkler D., Greter M., Becher B., High-dimensional single-cell mapping of central nervous system immune cells reveals distinct myeloid subsets in health, aging, and disease. Immunity 48, 599 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29562204</ArticleId></ArticleIdList></Reference><Reference><Citation>Song W. M., Colonna M., The identity and function of microglia in neurodegeneration. Nat. Immunol. 19, 1048&#x2013;1058 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30250185</ArticleId></ArticleIdList></Reference><Reference><Citation>Krasemann S., Madore C., Cialic R., Baufeld C., Calcagno N., El Fatimy R., Beckers L., O&#x2019;Loughlin E., Xu Y., Fanek Z., Greco D. J., Smith S. T., Tweet G., Humulock Z., Zrzavy T., Conde-Sanroman P., Gacias M., Weng Z., Chen H., Tjon E., Mazaheri F., Hartmann K., Madi A., Ulrich J. D., Glatzel M., Worthmann A., Heeren J., Budnik B., Lemere C., Ikezu T., Heppner F. L., Litvak V., Holtzman D. M., Lassmann H., Weiner H. L., Ochando J., Haass C., Butovsky O., The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. Immunity 47, 566&#x2013;581.e9 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5719893</ArticleId><ArticleId IdType="pubmed">28930663</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee C. Y., Tse W., Smith J. D., Landreth G. E., Apolipoprotein E promotes &#x3b2;-amyloid trafficking and degradation by modulating microglial cholesterol levels. J. Biol. Chem. 287, 2032&#x2013;2044 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3265883</ArticleId><ArticleId IdType="pubmed">22130662</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y. T., Seo J., Gao F., Feldman H. M., Wen H. L., Penney J., Cam H. P., Gjoneska E., Raja W. K., Cheng J., Rueda R., Kritskiy O., Abdurrob F., Peng Z., Milo B., Yu C. J., Elmsaouri S., Dey D., Ko T., Yankner B. A., Tsai L. H., APOE4 causes widespread molecular and cellular alterations associated with alzheimer&#x2019;s disease phenotypes in human iPSC-derived brain cell types. Neuron 98, 1141&#x2013;1154.e7 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6023751</ArticleId><ArticleId IdType="pubmed">29861287</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson J. L., Chambers E., Jayasundera K., Application of a bioinformatics-based approach to identify novel putative in vivo BACE1 substrates. Biomed. Eng. Comput. Biol. 5, 1&#x2013;15 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4147752</ArticleId><ArticleId IdType="pubmed">25288897</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampel H., Lista S., Vanmechelen E., Zetterberg H., Giorgi F. S., Galgani A., Blennow K., Caraci F., Das B., Yan R., Vergallo A., &#x3b2;-Secretase1 biological markers for Alzheimer&#x2019;s disease: State-of-art of validation and qualification. Alzheimers Res. Ther. 12, 130 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7566058</ArticleId><ArticleId IdType="pubmed">33066807</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajendran L., Paolicelli R. C., Microglia-mediated synapse loss in Alzheimer&#x2019;s disease. J. Neurosci. 38, 2911&#x2013;2919 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6596066</ArticleId><ArticleId IdType="pubmed">29563239</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X., Stoeck A., Lee S. J., Shih I., Wang M. M., Wang T. L., Jagged1 expression regulated by Notch3 and Wnt/&#x3b2;-catenin signaling pathways in ovarian cancer. Oncotarget 1, 210&#x2013;218 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2953807</ArticleId><ArticleId IdType="pubmed">20953350</ArticleId></ArticleIdList></Reference><Reference><Citation>Cory A. H., Owen T. C., Barltrop J. A., Cory J. G., Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. Cancer Commun. 3, 207&#x2013;212 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">1867954</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobin A., Davis C. A., Schlesinger F., Drenkow J., Zaleski C., Jha S., Batut P., Chaisson M., Gingeras T. R., STAR: Ultrafast universal RNA-seq aligner. Bioinformatics 29, 15&#x2013;21 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3530905</ArticleId><ArticleId IdType="pubmed">23104886</ArticleId></ArticleIdList></Reference><Reference><Citation>Satija R., Farrell J. A., Gennert D., Schier A. F., Regev A., Spatial reconstruction of single-cell gene expression data. Nat. Biotechnol. 33, 495&#x2013;502 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4430369</ArticleId><ArticleId IdType="pubmed">25867923</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng G. X., Terry J. M., Belgrader P., Ryvkin P., Bent Z. W., Wilson R., Ziraldo S. B., Wheeler T. D., McDermott G. P., Zhu J., Gregory M. T., Shuga J., Montesclaros L., Underwood J. G., Masquelier D. A., Nishimura S. Y., Schnall-Levin M., Wyatt P. W., Hindson C. M., Bharadwaj R., Wong A., Ness K. D., Beppu L. W., Deeg H. J., McFarland C., Loeb K. R., Valente W. J., Ericson N. G., Stevens E. A., Radich J. P., Mikkelsen T. S., Hindson B. J., Bielas J. H., Massively parallel digital transcriptional profiling of single cells. Nat. Commun. 8, 14049 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5241818</ArticleId><ArticleId IdType="pubmed">28091601</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M., Song W. M., Ming C., Wang Q., Zhou X., Xu P., Krek A., Yoon Y., Ho L., Orr M. E., Yuan G. C., Zhang B., Guidelines for bioinformatics of single-cell sequencing data analysis in Alzheimer&#x2019;s disease: Review, recommendation, implementation and application. Mol. Neurodegener. 17, 17 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8889402</ArticleId><ArticleId IdType="pubmed">35236372</ArticleId></ArticleIdList></Reference><Reference><Citation>Traag V. A., Waltman L., van Eck N. J., From Louvain to Leiden: Guaranteeing well-connected communities. Sci. Rep. 9, 5233 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6435756</ArticleId><ArticleId IdType="pubmed">30914743</ArticleId></ArticleIdList></Reference><Reference><Citation>Pola&#x144;ski K., Young M. D., Miao Z., Meyer K. B., Teichmann S. A., Park J. E., BBKNN: Fast batch alignment of single cell transcriptomes. Bioinformatics 36, 964&#x2013;965 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9883685</ArticleId><ArticleId IdType="pubmed">31400197</ArticleId></ArticleIdList></Reference><Reference><Citation>Hao Y., Hao S., Andersen-Nissen E., Mauck W. M. III, Zheng S., Butler A., Lee M. J., Wilk A. J., Darby C., Zager M., Hoffman P., Stoeckius M., Papalexi E., Mimitou E. P., Jain J., Srivastava A., Stuart T., Fleming L. M., Yeung B., Rogers A. J., McElrath J. M., Blish C. A., Gottardo R., Smibert P., Satija R., Integrated analysis of multimodal single-cell data. Cell 184, 3573&#x2013;3587.e29 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8238499</ArticleId><ArticleId IdType="pubmed">34062119</ArticleId></ArticleIdList></Reference><Reference><Citation>Shalem O., Sanjana N. E., Zhang F., High-throughput functional genomics using CRISPR-Cas9. Nat. Rev. Genet. 16, 299&#x2013;311 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4503232</ArticleId><ArticleId IdType="pubmed">25854182</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">35738259</PMID><DateCompleted><Year>2022</Year><Month>08</Month><Day>05</Day></DateCompleted><DateRevised><Year>2022</Year><Month>09</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1932-7420</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>8</Issue><PubDate><Year>2022</Year><Month>Aug</Month><Day>02</Day></PubDate></JournalIssue><Title>Cell metabolism</Title><ISOAbbreviation>Cell Metab</ISOAbbreviation></Journal><ArticleTitle>Astrocytic urea cycle detoxifies A&#x3b2;-derived ammonia while impairing memory in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>1104</StartPage><EndPage>1120.e8</EndPage><MedlinePgn>1104-1120.e8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cmet.2022.05.011</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1550-4131(22)00193-0</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) is one of the foremost neurodegenerative diseases, characterized by beta-amyloid (A&#x3b2;) plaques and significant progressive memory loss. In AD, astrocytes are proposed to take up and clear A&#x3b2; plaques. However, how A&#x3b2; induces pathogenesis and memory impairment in AD remains elusive. We report&#xa0;that normal astrocytes show non-cyclic urea metabolism, whereas A&#x3b2;-treated astrocytes show switched-on urea cycle with upregulated enzymes and accumulated entering-metabolite aspartate, starting-substrate ammonia, end-product urea, and side-product putrescine. Gene silencing of astrocytic ornithine decarboxylase-1 (ODC1), facilitating ornithine-to-putrescine conversion, boosts urea cycle and eliminates aberrant putrescine and its toxic byproducts ammonia and H<sub>2</sub>O<sub>2</sub> and its end product GABA to recover from reactive astrogliosis and memory impairment in AD. Our findings implicate that astrocytic urea cycle exerts opposing roles of beneficial A&#x3b2; detoxification and detrimental memory impairment in AD. We propose ODC1 inhibition as a promising therapeutic strategy for AD to facilitate removal of toxic molecules and prevent memory loss.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ju</LastName><ForeName>Yeon Ha</ForeName><Initials>YH</Initials><AffiliationInfo><Affiliation>Center for Cognition and Sociality, Institute for Basic Science (IBS), Daejeon, Republic of Korea; IBS School, University of Science and Technology (UST), Daejeon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhalla</LastName><ForeName>Mridula</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center for Cognition and Sociality, Institute for Basic Science (IBS), Daejeon, Republic of Korea; IBS School, University of Science and Technology (UST), Daejeon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hyeon</LastName><ForeName>Seung Jae</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Brain Science Institute (BSI), Korea Institute of Science and Technology (KIST), Seoul 02792, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oh</LastName><ForeName>Ju Eun</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Center for Advanced Biomolecular Recognition, Korea Institute of Science and Technology, Seoul 02792, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoo</LastName><ForeName>Seonguk</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center for Advanced Biomolecular Recognition, Korea Institute of Science and Technology, Seoul 02792, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chae</LastName><ForeName>Uikyu</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Brain Science Institute (BSI), Korea Institute of Science and Technology (KIST), Seoul 02792, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kwon</LastName><ForeName>Jea</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Center for Cognition and Sociality, Institute for Basic Science (IBS), Daejeon, Republic of Korea; Korea University-Korea Institute of Science and Technology, Graduate School of Convergence Technology, Korea University, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koh</LastName><ForeName>Wuhyun</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Center for Cognition and Sociality, Institute for Basic Science (IBS), Daejeon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Jiwoon</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Center for Cognition and Sociality, Institute for Basic Science (IBS), Daejeon, Republic of Korea; IBS School, University of Science and Technology (UST), Daejeon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Yongmin Mason</ForeName><Initials>YM</Initials><AffiliationInfo><Affiliation>Center for Cognition and Sociality, Institute for Basic Science (IBS), Daejeon, Republic of Korea; IBS School, University of Science and Technology (UST), Daejeon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Junghee</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Boston University Alzheimer's Disease Research Center and Department of Neurology, Boston University School of Medicine, Boston, MA 02138, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cho</LastName><ForeName>Il-Joo</ForeName><Initials>IJ</Initials><AffiliationInfo><Affiliation>Brain Science Institute (BSI), Korea Institute of Science and Technology (KIST), Seoul 02792, Republic of Korea; School of Electrical and Electronics Engineering, Yonsei University, Seoul, Republic of Korea; Yonsei-KIST Convergence Research Institute, Yonsei University, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Hyunbeom</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Center for Advanced Biomolecular Recognition, Korea Institute of Science and Technology, Seoul 02792, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryu</LastName><ForeName>Hoon</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Brain Science Institute (BSI), Korea Institute of Science and Technology (KIST), Seoul 02792, Republic of Korea. Electronic address: hoonryu@kist.re.kr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>C Justin</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Center for Cognition and Sociality, Institute for Basic Science (IBS), Daejeon, Republic of Korea; IBS School, University of Science and Technology (UST), Daejeon, Republic of Korea. Electronic address: cjl@ibs.re.kr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Metab</MedlineTA><NlmUniqueID>101233170</NlmUniqueID><ISSNLinking>1550-4131</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>7664-41-7</RegistryNumber><NameOfSubstance UI="D000641">Ammonia</NameOfSubstance></Chemical><Chemical><RegistryNumber>8W8T17847W</RegistryNumber><NameOfSubstance UI="D014508">Urea</NameOfSubstance></Chemical><Chemical><RegistryNumber>BBX060AN9V</RegistryNumber><NameOfSubstance UI="D006861">Hydrogen Peroxide</NameOfSubstance></Chemical><Chemical><RegistryNumber>V10TVZ52E4</RegistryNumber><NameOfSubstance UI="D011700">Putrescine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Cell Metab. 2022 Aug 2;34(8):1079-1081. doi: 10.1016/j.cmet.2022.07.001.</RefSource><PMID Version="1">35921813</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000641" MajorTopicYN="N">Ammonia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006861" MajorTopicYN="N">Hydrogen Peroxide</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011700" MajorTopicYN="N">Putrescine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014508" MajorTopicYN="N">Urea</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">A&#x3b2; detoxification</Keyword><Keyword MajorTopicYN="N">ODC1</Keyword><Keyword MajorTopicYN="N">ammonia detoxification</Keyword><Keyword MajorTopicYN="N">astrocytes</Keyword><Keyword MajorTopicYN="N">astrocytic GABA</Keyword><Keyword MajorTopicYN="N">beneficial</Keyword><Keyword MajorTopicYN="N">detrimental</Keyword><Keyword MajorTopicYN="N">reactive astrocytes</Keyword><Keyword MajorTopicYN="N">urea cycle</Keyword></KeywordList><CoiStatement>Declaration of interests The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>10</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>3</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>5</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>23</Day><Hour>18</Hour><Minute>52</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35738259</ArticleId><ArticleId IdType="doi">10.1016/j.cmet.2022.05.011</ArticleId><ArticleId IdType="pii">S1550-4131(22)00193-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35614216</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>17</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>606</Volume><Issue>7914</Issue><PubDate><Year>2022</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Divergent transcriptional regulation of astrocyte reactivity across disorders.</ArticleTitle><Pagination><StartPage>557</StartPage><EndPage>564</EndPage><MedlinePgn>557-564</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41586-022-04739-5</ELocationID><Abstract><AbstractText>Astrocytes respond to&#xa0;injury and disease in the central nervous system with reactive changes that influence the outcome of the disorder<sup>1-4</sup>. These changes include differentially expressed genes (DEGs) whose contextual diversity and regulation are poorly understood. Here we combined biological and informatic analyses, including RNA sequencing, protein detection, assay for transposase-accessible chromatin with high-throughput sequencing (ATAC-seq) and conditional gene deletion, to predict transcriptional regulators that differentially control more than 12,000 DEGs that are&#xa0;potentially&#xa0;associated with astrocyte reactivity across diverse central nervous system disorders in mice and humans. DEGs associated with astrocyte reactivity exhibited pronounced heterogeneity across disorders. Transcriptional regulators also exhibited disorder-specific differences, but a core group of 61 transcriptional regulators was identified as common across multiple disorders in both species. We show experimentally that DEG diversity is determined by combinatorial, context-specific interactions between transcriptional regulators. Notably, the same reactivity transcriptional regulators can regulate markedly different DEG cohorts in different disorders; changes in the access of transcriptional regulators to DNA-binding motifs differ markedly across disorders; and DEG changes can crucially require multiple reactivity transcriptional regulators. We show that, by modulating reactivity, transcriptional regulators can substantially alter disorder outcome, implicating them as therapeutic targets. We provide searchable resources of disorder-related reactive astrocyte DEGs and their predicted transcriptional regulators. Our findings show that transcriptional changes associated with astrocyte reactivity are highly heterogeneous and are customized from vast numbers of potential DEGs through context-specific combinatorial transcriptional-regulator interactions.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s), under exclusive licence to Springer Nature Limited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Burda</LastName><ForeName>Joshua E</ForeName><Initials>JE</Initials><Identifier Source="ORCID">0000-0001-5139-348X</Identifier><AffiliationInfo><Affiliation>Department of Neurobiology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA. Joshua.Burda@csmc.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA. Joshua.Burda@csmc.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Cedars-Sinai Medical Center, Los Angeles, CA, USA. Joshua.Burda@csmc.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Neural Science and Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA. Joshua.Burda@csmc.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA. Joshua.Burda@csmc.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>O'Shea</LastName><ForeName>Timothy M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ao</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suresh</LastName><ForeName>Keshav B</ForeName><Initials>KB</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Neural Science and Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Shinong</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bernstein</LastName><ForeName>Alexander M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chandra</LastName><ForeName>Ashu</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Computer Science, University of California Los Angeles, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deverasetty</LastName><ForeName>Sandeep</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of California Los Angeles, Los Angeles, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of California Los Angeles, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kawaguchi</LastName><ForeName>Riki</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of California Los Angeles, Los Angeles, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of California Los Angeles, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jae H</ForeName><Initials>JH</Initials><Identifier Source="ORCID">0000-0002-1027-8845</Identifier><AffiliationInfo><Affiliation>Department of Neurobiology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCallum</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-2156-3219</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Neural Science and Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rogers</LastName><ForeName>Alexandra</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-4675-6968</Identifier><AffiliationInfo><Affiliation>Department of Neurobiology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wahane</LastName><ForeName>Shalaka</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-3795-6407</Identifier><AffiliationInfo><Affiliation>Department of Neurobiology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sofroniew</LastName><ForeName>Michael V</ForeName><Initials>MV</Initials><Identifier Source="ORCID">0000-0001-6075-0178</Identifier><AffiliationInfo><Affiliation>Department of Neurobiology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA. sofroniew@mednet.ucla.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>F32 NS096858</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K99 NS105915</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R00 NS105915</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS084030</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>05</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002843">Chromatin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Nature. 2023 Apr;616(7956):E6. doi: 10.1038/s41586-023-05975-z.</RefSource><PMID Version="1">36977770</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="Y">Astrocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002493" MajorTopicYN="Y">Central Nervous System Diseases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002843" MajorTopicYN="N">Chromatin</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="Y">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059014" MajorTopicYN="N">High-Throughput Nucleotide Sequencing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017423" MajorTopicYN="N">Sequence Analysis, RNA</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014157" MajorTopicYN="Y">Transcription Factors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014158" MajorTopicYN="Y">Transcription, Genetic</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>3</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>4</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>25</Day><Hour>23</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>3</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35614216</ArticleId><ArticleId IdType="mid">NIHMS1874912</ArticleId><ArticleId IdType="pmc">PMC10027402</ArticleId><ArticleId IdType="doi">10.1038/s41586-022-04739-5</ArticleId><ArticleId IdType="pii">10.1038/s41586-022-04739-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sofroniew MV &amp; Vinters HV Astrocytes: biology and pathology. Acta Neuropathol 119, 7&#x2013;35, doi:10.1007/s00401-009-0619-8 (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-009-0619-8</ArticleId><ArticleId IdType="pmc">PMC2799634</ArticleId><ArticleId IdType="pubmed">20012068</ArticleId></ArticleIdList></Reference><Reference><Citation>Burda JE &amp; Sofroniew MV Reactive gliosis and the multicellular response to CNS damage and disease. Neuron 81, 229&#x2013;248, doi:10.1016/j.neuron.2013.12.034 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.12.034</ArticleId><ArticleId IdType="pmc">PMC3984950</ArticleId><ArticleId IdType="pubmed">24462092</ArticleId></ArticleIdList></Reference><Reference><Citation>Linnerbauer M, Wheeler MA &amp; Quintana FJ Astrocyte Crosstalk in CNS Inflammation. Neuron 108, 608&#x2013;622, doi:10.1016/j.neuron.2020.08.012 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2020.08.012</ArticleId><ArticleId IdType="pmc">PMC7704785</ArticleId><ArticleId IdType="pubmed">32898475</ArticleId></ArticleIdList></Reference><Reference><Citation>Escartin C et al. Reactive astrocyte nomenclature, definitions, and future directions. Nat Neurosci 24, 312&#x2013;325, doi:10.1038/s41593-020-00783-4 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-020-00783-4</ArticleId><ArticleId IdType="pmc">PMC8007081</ArticleId><ArticleId IdType="pubmed">33589835</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen NJ &amp; Eroglu C Cell Biology of Astrocyte-Synapse Interactions. Neuron 96, 697&#x2013;708, doi:10.1016/j.neuron.2017.09.056 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2017.09.056</ArticleId><ArticleId IdType="pmc">PMC5687890</ArticleId><ArticleId IdType="pubmed">29096081</ArticleId></ArticleIdList></Reference><Reference><Citation>Haim LB &amp; Rowitch DH Functional diversity of astrocytes in neural circuit regulation. Nat Rev Neurosci 18, 31&#x2013;41, doi:10.1038/nrn.2016.159 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn.2016.159</ArticleId><ArticleId IdType="pubmed">27904142</ArticleId></ArticleIdList></Reference><Reference><Citation>Khakh BS &amp; Deneen B The Emerging Nature of Astrocyte Diversity. Annu Rev Neurosci 42, 187&#x2013;207, doi:10.1146/annurev-neuro-070918-050443 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-neuro-070918-050443</ArticleId><ArticleId IdType="pubmed">31283899</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu TY et al. Axon degeneration induces glial responses through Draper-TRAF4-JNK signalling. Nature communications 8, doi:ARTN 14355 10.1038/ncomms14355 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms14355</ArticleId><ArticleId IdType="pmc">PMC5303877</ArticleId><ArticleId IdType="pubmed">28165006</ArticleId></ArticleIdList></Reference><Reference><Citation>Sofroniew MV Astrocyte barriers to neurotoxic inflammation. Nat Rev Neurosci 16, 249&#x2013;263, doi:10.1038/nrn3898 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn3898</ArticleId><ArticleId IdType="pmc">PMC5253239</ArticleId><ArticleId IdType="pubmed">25891508</ArticleId></ArticleIdList></Reference><Reference><Citation>Khakh BS &amp; Sofroniew MV Diversity of astrocyte functions and phenotypes in neural circuits. Nat Neurosci 18, 942&#x2013;952, doi:10.1038/nn.4043 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4043</ArticleId><ArticleId IdType="pmc">PMC5258184</ArticleId><ArticleId IdType="pubmed">26108722</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu X et al. Context-Specific Striatal Astrocyte Molecular Responses Are Phenotypically Exploitable. Neuron 108, 1146&#x2013;1162 e1110, doi:10.1016/j.neuron.2020.09.021 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2020.09.021</ArticleId><ArticleId IdType="pmc">PMC7813554</ArticleId><ArticleId IdType="pubmed">33086039</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson MA et al. Astrocyte scar formation aids central nervous system axon regeneration. Nature 532, 195&#x2013;200, doi:10.1038/nature17623 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature17623</ArticleId><ArticleId IdType="pmc">PMC5243141</ArticleId><ArticleId IdType="pubmed">27027288</ArticleId></ArticleIdList></Reference><Reference><Citation>Schreiner B et al. Astrocyte Depletion Impairs Redox Homeostasis and Triggers Neuronal Loss in the Adult CNS. Cell reports 12, 1377&#x2013;1384, doi:10.1016/j.celrep.2015.07.051 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2015.07.051</ArticleId><ArticleId IdType="pubmed">26299968</ArticleId></ArticleIdList></Reference><Reference><Citation>Wheeler MA et al. MAFG-driven astrocytes promote CNS inflammation. Nature 578, 593&#x2013;599, doi:10.1038/s41586-020-1999-0 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-1999-0</ArticleId><ArticleId IdType="pmc">PMC8049843</ArticleId><ArticleId IdType="pubmed">32051591</ArticleId></ArticleIdList></Reference><Reference><Citation>Buenrostro JD, Giresi PG, Zaba LC, Chang HY &amp; Greenleaf WJ Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position. Nature methods 10, 1213&#x2013;1218, doi:10.1038/nmeth.2688 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.2688</ArticleId><ArticleId IdType="pmc">PMC3959825</ArticleId><ArticleId IdType="pubmed">24097267</ArticleId></ArticleIdList></Reference><Reference><Citation>Wanner IB et al. Glial scar borders are formed by newly proliferated, elongated astrocytes that interact to corral inflammatory and fibrotic cells via STAT3-dependent mechanisms after spinal cord injury. J Neurosci 33, 12870&#x2013;12886, doi:10.1523/JNEUROSCI.2121-13.2013 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2121-13.2013</ArticleId><ArticleId IdType="pmc">PMC3728693</ArticleId><ArticleId IdType="pubmed">23904622</ArticleId></ArticleIdList></Reference><Reference><Citation>Diaz-Castro B, Bernstein AM, Coppola G, Sofroniew MV &amp; Khakh BS Molecular and functional properties of cortical astrocytes during peripherally induced neuroinflammation. Cell reports 36, 109508, doi:10.1016/j.celrep.2021.109508 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.109508</ArticleId><ArticleId IdType="pmc">PMC8418871</ArticleId><ArticleId IdType="pubmed">34380036</ArticleId></ArticleIdList></Reference><Reference><Citation>Inoue F, Kreimer A, Ashuach T, Ahituv N &amp; Yosef N Identification and Massively Parallel Characterization of Regulatory Elements Driving Neural Induction. Cell Stem Cell 25, 713&#x2013;727 e710, doi:10.1016/j.stem.2019.09.010 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2019.09.010</ArticleId><ArticleId IdType="pmc">PMC6850896</ArticleId><ArticleId IdType="pubmed">31631012</ArticleId></ArticleIdList></Reference><Reference><Citation>Lattke M et al. Extensive transcriptional and chromatin changes underlie astrocyte maturation in vivo and in culture. Nature communications 12, 4335, doi:10.1038/s41467-021-24624-5 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-24624-5</ArticleId><ArticleId IdType="pmc">PMC8282848</ArticleId><ArticleId IdType="pubmed">34267208</ArticleId></ArticleIdList></Reference><Reference><Citation>Granja JM et al. ArchR is a scalable software package for integrative single-cell chromatin accessibility analysis. Nat Genet 53, 403&#x2013;411, doi:10.1038/s41588-021-00790-6 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-021-00790-6</ArticleId><ArticleId IdType="pmc">PMC8012210</ArticleId><ArticleId IdType="pubmed">33633365</ArticleId></ArticleIdList></Reference><Reference><Citation>Schep AN, Wu B, Buenrostro JD &amp; Greenleaf WJ chromVAR: inferring transcription-factor-associated accessibility from single-cell epigenomic data. Nature methods 14, 975&#x2013;978, doi:10.1038/nmeth.4401 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.4401</ArticleId><ArticleId IdType="pmc">PMC5623146</ArticleId><ArticleId IdType="pubmed">28825706</ArticleId></ArticleIdList></Reference><Reference><Citation>Wingelhofer B et al. Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer. Leukemia 32, 1713&#x2013;1726, doi:10.1038/s41375-018-0117-x (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41375-018-0117-x</ArticleId><ArticleId IdType="pmc">PMC6087715</ArticleId><ArticleId IdType="pubmed">29728695</ArticleId></ArticleIdList></Reference><Reference><Citation>Henry CJ et al. Minocycline attenuates lipopolysaccharide (LPS)-induced neuroinflammation, sickness behavior, and anhedonia. J Neuroinflamm 5, 15, doi:10.1186/1742-2094-5-15 (2008).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-5-15</ArticleId><ArticleId IdType="pmc">PMC2412862</ArticleId><ArticleId IdType="pubmed">18477398</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrmann JE et al. STAT3 is a critical regulator of astrogliosis and scar formation after spinal cord injury. J. Neurosci 28, 7231&#x2013;7243, doi:28/28/7231 [pii] 10.1523/JNEUROSCI.1709-08.2008 (2008).</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1709-08.2008</ArticleId><ArticleId IdType="pmc">PMC2583788</ArticleId><ArticleId IdType="pubmed">18614693</ArticleId></ArticleIdList></Reference><Reference><Citation>Wohlfahrt T et al. PU.1 controls fibroblast polarization and tissue fibrosis. Nature 566, 344&#x2013;349, doi:10.1038/s41586-019-0896-x (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-0896-x</ArticleId><ArticleId IdType="pmc">PMC6526281</ArticleId><ArticleId IdType="pubmed">30700907</ArticleId></ArticleIdList></Reference><Reference><Citation>Sofroniew MV Astrocyte Reactivity: Subtypes, States, and Functions in CNS Innate Immunity. Trends Immunol 41, 758&#x2013;770, doi:10.1016/j.it.2020.07.004 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2020.07.004</ArticleId><ArticleId IdType="pmc">PMC7484257</ArticleId><ArticleId IdType="pubmed">32819810</ArticleId></ArticleIdList></Reference><Reference><Citation>Diaz-Castro B, Gangwani MR, Yu X, Coppola G &amp; Khakh BS Astrocyte molecular signatures in Huntington&#x2019;s disease. Sci Transl Med 11, doi:10.1126/scitranslmed.aaw8546 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aaw8546</ArticleId><ArticleId IdType="pubmed">31619545</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun SY et al. Translational profiling identifies a cascade of damage initiated in motor neurons and spreading to glia in mutant SOD1-mediated ALS. P Natl Acad Sci USA 112, E6993&#x2013;E7002, doi:10.1073/pnas.1520639112 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1520639112</ArticleId><ArticleId IdType="pmc">PMC4687558</ArticleId><ArticleId IdType="pubmed">26621731</ArticleId></ArticleIdList></Reference><Reference><Citation>Sekar S et al. Alzheimer&#x2019;s disease is associated with altered expression of genes involved in immune response and mitochondrial processes in astrocytes. Neurobiol Aging 36, 583&#x2013;591, doi:10.1016/j.neurobiolaging.2014.09.027 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2014.09.027</ArticleId><ArticleId IdType="pmc">PMC4315763</ArticleId><ArticleId IdType="pubmed">25448601</ArticleId></ArticleIdList></Reference><Reference><Citation>Habib N et al. Disease-associated astrocytes in Alzheimer&#x2019;s disease and aging. Nat Neurosci 23, 701&#x2013;706, doi:10.1038/s41593-020-0624-8 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-020-0624-8</ArticleId><ArticleId IdType="pmc">PMC9262034</ArticleId><ArticleId IdType="pubmed">32341542</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamphuis W et al. GFAP and vimentin deficiency alters gene expression in astrocytes and microglia in wild-type mice and changes the transcriptional response of reactive glia in mouse model for Alzheimer&#x2019;s disease. Glia 63, 1036&#x2013;1056, doi:10.1002/glia.22800 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.22800</ArticleId><ArticleId IdType="pubmed">25731615</ArticleId></ArticleIdList></Reference><Reference><Citation>Boisvert MM, Erikson GA, Shokhirev MN &amp; Allen NJ The Aging Astrocyte Transcriptome from Multiple Regions of the Mouse Brain. Cell reports 22, 269&#x2013;285, doi:10.1016/j.celrep.2017.12.039 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2017.12.039</ArticleId><ArticleId IdType="pmc">PMC5783200</ArticleId><ArticleId IdType="pubmed">29298427</ArticleId></ArticleIdList></Reference><Reference><Citation>Rojo AI et al. Deficiency in the transcription factor NRF2 worsens inflammatory parameters in a mouse model with combined tauopathy and amyloidopathy. Redox Biol 18, 173&#x2013;180, doi:10.1016/j.redox.2018.07.006 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.redox.2018.07.006</ArticleId><ArticleId IdType="pmc">PMC6052199</ArticleId><ArticleId IdType="pubmed">30029164</ArticleId></ArticleIdList></Reference><Reference><Citation>Oksanen M et al. NF-E2-related factor 2 activation boosts antioxidant defenses and ameliorates inflammatory and amyloid properties in human Presenilin-1 mutated Alzheimer&#x2019;s disease astrocytes. Glia 68, 589&#x2013;599, doi:10.1002/glia.23741 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.23741</ArticleId><ArticleId IdType="pmc">PMC7003860</ArticleId><ArticleId IdType="pubmed">31670864</ArticleId></ArticleIdList></Reference><Reference><Citation>Laug D et al. Nuclear factor I-A regulates diverse reactive astrocyte responses after CNS injury. J Clin Invest 129, 4408&#x2013;4418, doi:10.1172/JCI127492 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI127492</ArticleId><ArticleId IdType="pmc">PMC6763246</ArticleId><ArticleId IdType="pubmed">31498149</ArticleId></ArticleIdList></Reference><Reference><Citation>Venkatesh I et al. Co-occupancy identifies transcription factor co-operation for axon growth. Nature communications 12, 2555, doi:10.1038/s41467-021-22828-3 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-22828-3</ArticleId><ArticleId IdType="pmc">PMC8099911</ArticleId><ArticleId IdType="pubmed">33953205</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia ADR, Doan NB, Imura T, Bush TG &amp; Sofroniew MV GFAP-expressing progenitors are the principle source of constitutive neurogenesis in adult mouse forebrain. Nature Neurosci. 7, 1233&#x2013;1241 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15494728</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanz E et al. Cell-type-specific isolation of ribosome-associated mRNA from complex tissues. Proc Natl Acad Sci U S A 106, 13939&#x2013;13944, doi:10.1073/pnas.0907143106 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0907143106</ArticleId><ArticleId IdType="pmc">PMC2728999</ArticleId><ArticleId IdType="pubmed">19666516</ArticleId></ArticleIdList></Reference><Reference><Citation>Sumi-Ichinose C, Ichinose H, Metzger D &amp; Chambon P SNF2beta-BRG1 is essential for the viability of F9 murine embryonal carcinoma cells. Mol Cell Biol 17, 5976&#x2013;5986, doi:10.1128/mcb.17.10.5976 (1997).</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mcb.17.10.5976</ArticleId><ArticleId IdType="pmc">PMC232446</ArticleId><ArticleId IdType="pubmed">9315656</ArticleId></ArticleIdList></Reference><Reference><Citation>Metz GA &amp; Whishaw IQ The ladder rung walking task: a scoring system and its practical application. J Vis Exp, doi:10.3791/1204 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.3791/1204</ArticleId><ArticleId IdType="pmc">PMC2796662</ArticleId><ArticleId IdType="pubmed">19525918</ArticleId></ArticleIdList></Reference><Reference><Citation>Dantzer R, O&#x2019;Connor JC, Freund GG, Johnson RW &amp; Kelley KW From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 9, 46&#x2013;56, doi:10.1038/nrn2297 (2008).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn2297</ArticleId><ArticleId IdType="pmc">PMC2919277</ArticleId><ArticleId IdType="pubmed">18073775</ArticleId></ArticleIdList></Reference><Reference><Citation>Sukoff Rizzo SJ et al. Evidence for sustained elevation of IL-6 in the CNS as a key contributor of depressive-like phenotypes. Translational psychiatry 2, e199, doi:10.1038/tp.2012.120 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/tp.2012.120</ArticleId><ArticleId IdType="pmc">PMC3565187</ArticleId><ArticleId IdType="pubmed">23212583</ArticleId></ArticleIdList></Reference><Reference><Citation>Lachmann A et al. ChEA: transcription factor regulation inferred from integrating genome-wide ChIP-X experiments. Bioinformatics 26, 2438&#x2013;2444, doi:10.1093/bioinformatics/btq466 (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btq466</ArticleId><ArticleId IdType="pmc">PMC2944209</ArticleId><ArticleId IdType="pubmed">20709693</ArticleId></ArticleIdList></Reference><Reference><Citation>Fornes O et al. JASPAR 2020: update of the open-access database of transcription factor binding profiles. Nucleic Acids Res 48, D87&#x2013;D92, doi:10.1093/nar/gkz1001 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkz1001</ArticleId><ArticleId IdType="pmc">PMC7145627</ArticleId><ArticleId IdType="pubmed">31701148</ArticleId></ArticleIdList></Reference><Reference><Citation>Matys V et al. TRANSFAC: transcriptional regulation, from patterns to profiles. Nucleic Acids Res 31, 374&#x2013;378, doi:10.1093/nar/gkg108 (2003).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkg108</ArticleId><ArticleId IdType="pmc">PMC165555</ArticleId><ArticleId IdType="pubmed">12520026</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuleshov MV et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res 44, W90&#x2013;97, doi:10.1093/nar/gkw377 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkw377</ArticleId><ArticleId IdType="pmc">PMC4987924</ArticleId><ArticleId IdType="pubmed">27141961</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishnaswami SR et al. Using single nuclei for RNA-seq to capture the transcriptome of postmortem neurons. Nature protocols 11, 499&#x2013;524, doi:10.1038/nprot.2016.015 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2016.015</ArticleId><ArticleId IdType="pmc">PMC4941947</ArticleId><ArticleId IdType="pubmed">26890679</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhattacharyya S, Sathe AA, Bhakta M, Xing C &amp; Munshi NV PAN-INTACT enables direct isolation of lineage-specific nuclei from fibrous tissues. PLoS One 14, e0214677, doi:10.1371/journal.pone.0214677 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0214677</ArticleId><ArticleId IdType="pmc">PMC6445515</ArticleId><ArticleId IdType="pubmed">30939177</ArticleId></ArticleIdList></Reference><Reference><Citation>Batiuk MY et al. An immunoaffinity-based method for isolating ultrapure adult astrocytes based on ATP1B2 targeting by the ACSA-2 antibody. J Biol Chem 292, 8874&#x2013;8891, doi:10.1074/jbc.M116.765313 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M116.765313</ArticleId><ArticleId IdType="pmc">PMC5448122</ArticleId><ArticleId IdType="pubmed">28373281</ArticleId></ArticleIdList></Reference><Reference><Citation>Cusanovich DA et al. Multiplex single cell profiling of chromatin accessibility by combinatorial cellular indexing. Science 348, 910&#x2013;914, doi:10.1126/science.aab1601 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aab1601</ArticleId><ArticleId IdType="pmc">PMC4836442</ArticleId><ArticleId IdType="pubmed">25953818</ArticleId></ArticleIdList></Reference><Reference><Citation>Deschamps S et al. Chromatin loop anchors contain core structural components of the gene expression machinery in maize. BMC Genomics 22, 23, doi:10.1186/s12864-020-07324-0 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12864-020-07324-0</ArticleId><ArticleId IdType="pmc">PMC7789236</ArticleId><ArticleId IdType="pubmed">33407087</ArticleId></ArticleIdList></Reference><Reference><Citation>Weirauch MT et al. Determination and inference of eukaryotic transcription factor sequence specificity. Cell 158, 1431&#x2013;1443, doi:10.1016/j.cell.2014.08.009 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2014.08.009</ArticleId><ArticleId IdType="pmc">PMC4163041</ArticleId><ArticleId IdType="pubmed">25215497</ArticleId></ArticleIdList></Reference><Reference><Citation>Kheradpour P &amp; Kellis M Systematic discovery and characterization of regulatory motifs in ENCODE TF binding experiments. Nucleic Acids Res 42, 2976&#x2013;2987, doi:10.1093/nar/gkt1249 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkt1249</ArticleId><ArticleId IdType="pmc">PMC3950668</ArticleId><ArticleId IdType="pubmed">24335146</ArticleId></ArticleIdList></Reference><Reference><Citation>Courtine G et al. Transformation of nonfunctional spinal circuits into functional states after the loss of brain input. Nat. Neurosci 12, 1333&#x2013;1342, doi:nn.2401 [pii] 10.1038/nn.2401 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2401</ArticleId><ArticleId IdType="pmc">PMC2828944</ArticleId><ArticleId IdType="pubmed">19767747</ArticleId></ArticleIdList></Reference><Reference><Citation>Neve LD, Savage AA, Koke JR &amp; Garcia DM Activating transcription factor 3 and reactive astrocytes following optic nerve injury in zebrafish. Comp Biochem Physiol C Toxicol Pharmacol 155, 213&#x2013;218, doi:10.1016/j.cbpc.2011.08.006 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cbpc.2011.08.006</ArticleId><ArticleId IdType="pubmed">21889613</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim KH, Jeong JY, Surh YJ &amp; Kim KW Expression of stress-response ATF3 is mediated by Nrf2 in astrocytes. Nucleic Acids Res 38, 48&#x2013;59, doi:10.1093/nar/gkp865 (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkp865</ArticleId><ArticleId IdType="pmc">PMC2800224</ArticleId><ArticleId IdType="pubmed">19864258</ArticleId></ArticleIdList></Reference><Reference><Citation>Koyama Y et al. Endothelin-1 stimulates expression of cyclin D1 and S-phase kinase-associated protein 2 by activating the transcription factor STAT3 in cultured rat astrocytes. J Biol Chem 294, 3920&#x2013;3933, doi:10.1074/jbc.RA118.005614 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.RA118.005614</ArticleId><ArticleId IdType="pmc">PMC6422083</ArticleId><ArticleId IdType="pubmed">30670587</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardinaux JR, Allaman I &amp; Magistretti PJ Pro-inflammatory cytokines induce the transcription factors C/EBPbeta and C/EBPdelta in astrocytes. Glia 29, 91&#x2013;97 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10594926</ArticleId></ArticleIdList></Reference><Reference><Citation>Ko CY et al. Glycogen synthase kinase-3beta-mediated CCAAT/enhancer-binding protein delta phosphorylation in astrocytes promotes migration and activation of microglia/macrophages. Neurobiol Aging 35, 24&#x2013;34, doi:10.1016/j.neurobiolaging.2013.07.021 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2013.07.021</ArticleId><ArticleId IdType="pubmed">23993701</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardo L et al. Targeted activation of CREB in reactive astrocytes is neuroprotective in focal acute cortical injury. Glia 64, 853&#x2013;874, doi:10.1002/glia.22969 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.22969</ArticleId><ArticleId IdType="pubmed">26880229</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou F et al. Different functions of HIPK2 and CtBP2 in traumatic brain injury. J Mol Neurosci 49, 395&#x2013;408, doi:10.1007/s12031-012-9906-2 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-012-9906-2</ArticleId><ArticleId IdType="pubmed">23076816</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson KF, Narasipura SD, Wallace J, Ritz EM &amp; Al-Harthi L Negative regulation of IL-8 in human astrocytes depends on beta-catenin while positive regulation is mediated by TCFs/LEF/ATF2 interaction. Cytokine 136, doi:ARTN 155252 10.1016/j.cyto.2020.155252 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cyto.2020.155252</ArticleId><ArticleId IdType="pmc">PMC7554258</ArticleId><ArticleId IdType="pubmed">32818703</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang C et al. beta-Catenin signaling initiates the activation of astrocytes and its dysregulation contributes to the pathogenesis of astrocytomas. Proc Natl Acad Sci U S A 109, 6963&#x2013;6968, doi:10.1073/pnas.1118754109 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1118754109</ArticleId><ArticleId IdType="pmc">PMC3344971</ArticleId><ArticleId IdType="pubmed">22505738</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu JF et al. Ablation of the transcription factors E2F1&#x2013;2 limits neuroinflammation and associated neurological deficits after contusive spinal cord injury. Cell Cycle 14, 3698&#x2013;3712, doi:10.1080/15384101.2015.1104436 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15384101.2015.1104436</ArticleId><ArticleId IdType="pmc">PMC4825750</ArticleId><ArticleId IdType="pubmed">26505089</ArticleId></ArticleIdList></Reference><Reference><Citation>Beck H, Semisch M, Culmsee C, Plesnila N &amp; Hatzopoulos AK Egr-1 regulates expression of the glial scar component phosphacan in astrocytes after experimental stroke. American Journal of Pathology 173, 77&#x2013;92, doi:10.2353/ajpath.2008.070648 (2008).</Citation><ArticleIdList><ArticleId IdType="doi">10.2353/ajpath.2008.070648</ArticleId><ArticleId IdType="pmc">PMC2438287</ArticleId><ArticleId IdType="pubmed">18556777</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayer SI, Rossler OG, Endo T, Charnay P &amp; Thiel G Epidermal-growth-factor-induced proliferation of astrocytes requires Egr transcription factors. Journal of cell science 122, 3340&#x2013;3350, doi:10.1242/jcs.048272 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.048272</ArticleId><ArticleId IdType="pubmed">19706684</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang HH, Hsieh HL, Wu CY &amp; Yang CM Oxidized low-density lipoprotein-induced matrix metalloproteinase-9 expression via PKC-delta/p42/p44 MAPK/Elk-1 cascade in brain astrocytes. Neurotox Res 17, 50&#x2013;65, doi:10.1007/s12640-009-9077-2 (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12640-009-9077-2</ArticleId><ArticleId IdType="pubmed">19554388</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerhauser I, Alldinger S &amp; Baumgartner W Ets-1 represents a pivotal transcription factor for viral clearance, inflammation, and demyelination in a mouse model of multiple sclerosis. J Neuroimmunol 188, 86&#x2013;94, doi:10.1016/j.jneuroim.2007.05.019 (2007).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2007.05.019</ArticleId><ArticleId IdType="pubmed">17599467</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto K et al. Long-term activation of c-Fos and c-Jun in optic nerve head astrocytes in experimental ocular hypertension in monkeys and after exposure to elevated pressure in vitro. Brain Research 1054, 103&#x2013;115, doi:10.1016/j.brainres.2005.06.050 (2005).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2005.06.050</ArticleId><ArticleId IdType="pubmed">16081055</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang CC, Hsiao LD &amp; Yang CM Galangin Inhibits LPS-Induced MMP-9 Expression via Suppressing Protein Kinase-Dependent AP-1 and FoxO1 Activation in Rat Brain Astrocytes. J Inflamm Res 13, 945&#x2013;960, doi:10.2147/JIR.S276925 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/JIR.S276925</ArticleId><ArticleId IdType="pmc">PMC7685391</ArticleId><ArticleId IdType="pubmed">33244253</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui M, Huang Y, Tian C, Zhao Y &amp; Zheng J FOXO3a inhibits TNF-alpha- and IL-1beta-induced astrocyte proliferation:Implication for reactive astrogliosis. Glia 59, 641&#x2013;654, doi:10.1002/glia.21134 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.21134</ArticleId><ArticleId IdType="pmc">PMC3747776</ArticleId><ArticleId IdType="pubmed">21294163</ArticleId></ArticleIdList></Reference><Reference><Citation>Kizil C et al. Regenerative neurogenesis from neural progenitor cells requires injury-induced expression of Gata3. Developmental cell 23, 1230&#x2013;1237, doi:10.1016/j.devcel.2012.10.014 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.devcel.2012.10.014</ArticleId><ArticleId IdType="pubmed">23168169</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia AD, Petrova R, Eng L &amp; Joyner AL Sonic hedgehog regulates discrete populations of astrocytes in the adult mouse forebrain. J Neurosci 30, 13597&#x2013;13608, doi:30/41/13597 [pii] 10.1523/JNEUROSCI.0830-10.2010 (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0830-10.2010</ArticleId><ArticleId IdType="pmc">PMC2966838</ArticleId><ArticleId IdType="pubmed">20943901</ArticleId></ArticleIdList></Reference><Reference><Citation>Du F et al. Hyperthermic preconditioning protects astrocytes from ischemia/reperfusion injury by up-regulation of HIF-1 alpha expression and binding activity. Biochimica et biophysica acta 1802, 1048&#x2013;1053, doi:10.1016/j.bbadis.2010.06.013 (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2010.06.013</ArticleId><ArticleId IdType="pubmed">20599612</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi K, Ni L &amp; Jonakait GM Fas ligation and tumor necrosis factor alpha activation of murine astrocytes promote heat shock factor-1 activation and heat shock protein expression leading to chemokine induction and cell survival. J Neurochem 116, 438&#x2013;448, doi:10.1111/j.1471-4159.2010.07124.x (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2010.07124.x</ArticleId><ArticleId IdType="pubmed">21114495</ArticleId></ArticleIdList></Reference><Reference><Citation>Tzeng SF, Kahn M, Liva S &amp; De Vellis J Tumor necrosis factor-alpha regulation of the Id gene family in astrocytes and microglia during CNS inflammatory injury. Glia 26, 139&#x2013;152 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10384879</ArticleId></ArticleIdList></Reference><Reference><Citation>Aronica E et al. Expression of Id proteins increases in astrocytes in the hippocampus of epileptic rats. Neuroreport 12, 2461&#x2013;2465 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11496130</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarosinski KW &amp; Massa PT Interferon regulatory factor-1 is required for interferon-gamma-induced MHC class I genes in astrocytes. J Neuroimmunol 122, 74&#x2013;84, doi:10.1016/s0165-5728(01)00467-2 (2002).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0165-5728(01)00467-2</ArticleId><ArticleId IdType="pubmed">11777545</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarassishin L et al. Interferon regulatory factor 3 inhibits astrocyte inflammatory gene expression through suppression of the proinflammatory miR-155 and miR-155*. Glia 59, 1911&#x2013;1922, doi:10.1002/glia.21233 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.21233</ArticleId><ArticleId IdType="pmc">PMC3241213</ArticleId><ArticleId IdType="pubmed">22170100</ArticleId></ArticleIdList></Reference><Reference><Citation>Gadea A, Schinelli S &amp; Gallo V Endothelin-1 regulates astrocyte proliferation and reactive gliosis via a JNK/c-Jun signaling pathway. J. Neurosci 28, 2394&#x2013;2408, doi:28/10/2394 [pii]10.1523/JNEUROSCI.5652-07.2008 (2008).</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5652-07.2008</ArticleId><ArticleId IdType="pmc">PMC2695974</ArticleId><ArticleId IdType="pubmed">18322086</ArticleId></ArticleIdList></Reference><Reference><Citation>Park JH et al. Induction of Kruppel-like factor 4 expression in reactive astrocytes following ischemic injury in vitro and in vivo. Histochem Cell Biol 141, 33&#x2013;42, doi:10.1007/s00418-013-1134-5 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00418-013-1134-5</ArticleId><ArticleId IdType="pubmed">23934449</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeong KH, Lee KE, Kim SY &amp; Cho KO Upregulation of Kruppel-like factor 6 in the mouse hippocampus after pilocarpine-induced status epilepticus. Neuroscience 186, 170&#x2013;178, doi:10.1016/j.neuroscience.2011.02.046 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2011.02.046</ArticleId><ArticleId IdType="pubmed">21362463</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu F, Ni JJ, Huang JJ, Kou ZW &amp; Sun FY VEGF overexpression enhances the accumulation of phospho-S292 MeCP2 in reactive astrocytes in the adult rat striatum following cerebral ischemia. Brain Res 1599, 32&#x2013;43, doi:10.1016/j.brainres.2014.12.014 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2014.12.014</ArticleId><ArticleId IdType="pubmed">25511996</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang F et al. 2-Arachidonylglycerol Protects Primary Astrocytes Exposed to Oxygen-Glucose Deprivation Through a Blockade of NDRG2 Signaling and STAT3 Phosphorylation. Rejuvenation Res 19, 215&#x2013;222, doi:10.1089/rej.2015.1703 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/rej.2015.1703</ArticleId><ArticleId IdType="pubmed">26414218</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez-Ortiz JM et al. Mechanical lesion activates newly identified NFATc1 in primary astrocytes: implication of ATP and purinergic receptors. Eur J Neurosci 27, 2453&#x2013;2465, doi:10.1111/j.1460-9568.2008.06197.x (2008).</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1460-9568.2008.06197.x</ArticleId><ArticleId IdType="pubmed">18445232</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y et al. Hemoglobin pretreatment endows rat cortical astrocytes resistance to hemin-induced toxicity via Nrf2/HO-1 pathway. Experimental cell research 361, 217&#x2013;224, doi:10.1016/j.yexcr.2017.10.020 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yexcr.2017.10.020</ArticleId><ArticleId IdType="pubmed">29074371</ArticleId></ArticleIdList></Reference><Reference><Citation>Brambilla R et al. Inhibition of astroglial nuclear factor kappaB reduces inflammation and improves functional recovery after spinal cord injury. J. Exp. Med 202, 145&#x2013;156 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2212896</ArticleId><ArticleId IdType="pubmed">15998793</ArticleId></ArticleIdList></Reference><Reference><Citation>LeComte MD, Shimada IS, Sherwin C &amp; Spees JL Notch1-STAT3-ETBR signaling axis controls reactive astrocyte proliferation after brain injury. Proc Natl Acad Sci U S A 112, 8726&#x2013;8731, doi:10.1073/pnas.1501029112 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1501029112</ArticleId><ArticleId IdType="pmc">PMC4507218</ArticleId><ArticleId IdType="pubmed">26124113</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen XL et al. Effects of interleukin-6 and IL-6/AMPK signaling pathway on mitochondrial biogenesis and astrocytes viability under experimental septic condition. Int Immunopharmacol 59, 287&#x2013;294, doi:10.1016/j.intimp.2018.04.020 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2018.04.020</ArticleId><ArticleId IdType="pubmed">29674256</ArticleId></ArticleIdList></Reference><Reference><Citation>Gutbier S et al. Prevention of neuronal apoptosis by astrocytes through thiol-mediated stress response modulation and accelerated recovery from proteotoxic stress. Cell Death Differ 25, 2101&#x2013;2117, doi:10.1038/s41418-018-0229-x (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41418-018-0229-x</ArticleId><ArticleId IdType="pmc">PMC6261954</ArticleId><ArticleId IdType="pubmed">30390092</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y et al. The basic helix-loop-helix transcription factor olig2 is critical for reactive astrocyte proliferation after cortical injury. J. Neurosci 28, 10983&#x2013;10989, doi:28/43/10983 [pii]10.1523/JNEUROSCI.3545-08.2008 (2008).</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3545-08.2008</ArticleId><ArticleId IdType="pmc">PMC2631240</ArticleId><ArticleId IdType="pubmed">18945906</ArticleId></ArticleIdList></Reference><Reference><Citation>Koyama Y Signaling molecules regulating phenotypic conversions of astrocytes and glial scar formation in damaged nerve tissues. Neurochem Int 78, 35&#x2013;42, doi:10.1016/j.neuint.2014.08.005 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuint.2014.08.005</ArticleId><ArticleId IdType="pubmed">25180676</ArticleId></ArticleIdList></Reference><Reference><Citation>Steliga A et al. Transcription factor Pax6 is expressed by astroglia after transient brain ischemia in the rat model. Folia Neuropathol 51, 203&#x2013;213 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">24114637</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo X et al. The AMPK-PGC-1alpha signaling axis regulates the astrocyte glutathione system to protect against oxidative and metabolic injury. Neurobiol Dis 113, 59&#x2013;69, doi:10.1016/j.nbd.2018.02.004 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2018.02.004</ArticleId><ArticleId IdType="pubmed">29438738</ArticleId></ArticleIdList></Reference><Reference><Citation>Diehl JA, Tong W, Sun G &amp; Hannink M Tumor necrosis factor-alpha-dependent activation of a RelA homodimer in astrocytes. Increased phosphorylation of RelA and MAD-3 precede activation of RelA. J Biol Chem 270, 2703&#x2013;2707, doi:10.1074/jbc.270.6.2703 (1995).</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.270.6.2703</ArticleId><ArticleId IdType="pubmed">7852340</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoo KY et al. Time-course alterations of Toll-like receptor 4 and NF-kappaB p65, and their co-expression in the gerbil hippocampal CA1 region after transient cerebral ischemia. Neurochem Res 36, 2417&#x2013;2426, doi:10.1007/s11064-011-0569-0 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11064-011-0569-0</ArticleId><ArticleId IdType="pubmed">21842272</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta AS et al. RelB controls adaptive responses of astrocytes during sterile inflammation. Glia 67, 1449&#x2013;1461, doi:10.1002/glia.23619 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.23619</ArticleId><ArticleId IdType="pmc">PMC6557670</ArticleId><ArticleId IdType="pubmed">30957303</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H et al. The deficiency of NRSF/REST enhances the pro-inflammatory function of astrocytes in a model of Parkinson&#x2019;s disease. Biochim Biophys Acta Mol Basis Dis 1866, 165590, doi:10.1016/j.bbadis.2019.165590 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2019.165590</ArticleId><ArticleId IdType="pubmed">31706914</ArticleId></ArticleIdList></Reference><Reference><Citation>Marumo T et al. Notch signaling regulates nucleocytoplasmic Olig2 translocation in reactive astrocytes differentiation after ischemic stroke. Neuroscience research 75, 204&#x2013;209, doi:10.1016/j.neures.2013.01.006 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neures.2013.01.006</ArticleId><ArticleId IdType="pubmed">23396245</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanigaki K &amp; Honjo T Two opposing roles of RBP-J in Notch signaling. Curr Top Dev Biol 92, 231&#x2013;252, doi:10.1016/S0070-2153(10)92007-3 (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0070-2153(10)92007-3</ArticleId><ArticleId IdType="pubmed">20816397</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong JK et al. Attenuation of Cerebral Ischemic Injury in Smad1 Deficient Mice. PLoS One 10, e0136967, doi:10.1371/journal.pone.0136967 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0136967</ArticleId><ArticleId IdType="pmc">PMC4552810</ArticleId><ArticleId IdType="pubmed">26317208</ArticleId></ArticleIdList></Reference><Reference><Citation>Law AKT et al. TGF-beta 1 induction of the adenine nucleotide translocator 1 in astrocytes occurs through Smads and Sp1 transcription factors. BMC neuroscience 5, doi: 10.1186/1471-2202-5-1 (2004).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2202-5-1</ArticleId><ArticleId IdType="pmc">PMC324399</ArticleId><ArticleId IdType="pubmed">14720305</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C et al. Astrocyte-Specific Deletion of Sox2 Promotes Functional Recovery After Traumatic Brain Injury. Cereb Cortex 29, 54&#x2013;69, doi:10.1093/cercor/bhx303 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cercor/bhx303</ArticleId><ArticleId IdType="pmc">PMC6659023</ArticleId><ArticleId IdType="pubmed">29161339</ArticleId></ArticleIdList></Reference><Reference><Citation>Song W et al. Immunohistochemical staining of ERG and SOX9 as potential biomarkers of docetaxel response in patients with metastatic castration-resistant prostate cancer. Oncotarget 7, 83735&#x2013;83743, doi:10.18632/oncotarget.13407 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.13407</ArticleId><ArticleId IdType="pmc">PMC5347800</ArticleId><ArticleId IdType="pubmed">27863438</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao X, Moerman-Herzog AM, Wang W &amp; Barger SW Differential transcriptional control of the superoxide dismutase-2 kappaB element in neurons and astrocytes. J Biol Chem 281, 35863&#x2013;35872, doi:10.1074/jbc.M604166200 (2006).</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M604166200</ArticleId><ArticleId IdType="pmc">PMC2063448</ArticleId><ArticleId IdType="pubmed">17023425</ArticleId></ArticleIdList></Reference><Reference><Citation>Haroon F et al. Gp130-dependent astrocytic survival is critical for the control of autoimmune central nervous system inflammation. J Immunol 186, 6521&#x2013;6531, doi:jimmunol.1001135 [pii]10.4049/jimmunol.1001135 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1001135</ArticleId><ArticleId IdType="pubmed">21515788</ArticleId></ArticleIdList></Reference><Reference><Citation>Khorooshi R, Babcock AA &amp; Owens T NF-kappaB-driven STAT2 and CCL2 expression in astrocytes in response to brain injury. J Immunol 181, 7284&#x2013;7291 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18981150</ArticleId></ArticleIdList></Reference><Reference><Citation>Doherty J et al. PI3K signaling and Stat92E converge to modulate glial responsiveness to axonal injury. PLoS Biol 12, e1001985, doi:10.1371/journal.pbio.1001985 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.1001985</ArticleId><ArticleId IdType="pmc">PMC4219656</ArticleId><ArticleId IdType="pubmed">25369313</ArticleId></ArticleIdList></Reference><Reference><Citation>Park SJ et al. Astrocytes, but Not Microglia, Rapidly Sense H2O2 via STAT6 Phosphorylation, Resulting in Cyclooxygenase-2 Expression and Prostaglandin Release. Journal of Immunology 188, 5132&#x2013;5141, doi:10.4049/jimmunol.1101600 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1101600</ArticleId><ArticleId IdType="pubmed">22504638</ArticleId></ArticleIdList></Reference><Reference><Citation>Lurbke A et al. Limited TCF7L2 expression in MS lesions. PLoS One 8, e72822, doi:10.1371/journal.pone.0072822 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0072822</ArticleId><ArticleId IdType="pmc">PMC3748032</ArticleId><ArticleId IdType="pubmed">23977356</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung YH et al. Enhanced expression of p53 in reactive astrocytes following transient focal ischemia. Neurol Res 24, 324&#x2013;328, doi:10.1179/016164102101199828 (2002).</Citation><ArticleIdList><ArticleId IdType="doi">10.1179/016164102101199828</ArticleId><ArticleId IdType="pubmed">11958430</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang ZH et al. YAP Is a Critical Inducer of SOCS3, Preventing Reactive Astrogliosis. Cerebral Cortex 26, 2299&#x2013;2310, doi:10.1093/cercor/bhv292 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cercor/bhv292</ArticleId><ArticleId IdType="pmc">PMC4830299</ArticleId><ArticleId IdType="pubmed">26679195</ArticleId></ArticleIdList></Reference><Reference><Citation>Vivinetto AL et al. Zeb2 Is a Regulator of Astrogliosis and Functional Recovery after CNS Injury. Cell reports 31, 107834, doi:10.1016/j.celrep.2020.107834 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2020.107834</ArticleId><ArticleId IdType="pmc">PMC7416489</ArticleId><ArticleId IdType="pubmed">32610135</ArticleId></ArticleIdList></Reference><Reference><Citation>Itoh N et al. Cell-specific and region-specific transcriptomics in the multiple sclerosis model: Focus on astrocytes. Proc Natl Acad Sci U S A 115, E302&#x2013;E309, doi:10.1073/pnas.1716032115 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1716032115</ArticleId><ArticleId IdType="pmc">PMC5777065</ArticleId><ArticleId IdType="pubmed">29279367</ArticleId></ArticleIdList></Reference><Reference><Citation>Zamanian JL et al. Genomic analysis of reactive astrogliosis. J Neurosci 32, 6391&#x2013;6410, doi:10.1523/JNEUROSCI.6221-11.2012 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.6221-11.2012</ArticleId><ArticleId IdType="pmc">PMC3480225</ArticleId><ArticleId IdType="pubmed">22553043</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y et al. Purification and Characterization of Progenitor and Mature Human Astrocytes Reveals Transcriptional and Functional Differences with Mouse. Neuron 89, 37&#x2013;53, doi:10.1016/j.neuron.2015.11.013 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2015.11.013</ArticleId><ArticleId IdType="pmc">PMC4707064</ArticleId><ArticleId IdType="pubmed">26687838</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">35705044</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>17</Day></DateCompleted><DateRevised><Year>2022</Year><Month>09</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2211-1247</ISSN><JournalIssue CitedMedium="Internet"><Volume>39</Volume><Issue>11</Issue><PubDate><Year>2022</Year><Month>Jun</Month><Day>14</Day></PubDate></JournalIssue><Title>Cell reports</Title><ISOAbbreviation>Cell Rep</ISOAbbreviation></Journal><ArticleTitle>Critical examination of Ptbp1-mediated glia-to-neuron conversion in the mouse retina.</ArticleTitle><Pagination><StartPage>110960</StartPage><MedlinePgn>110960</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.celrep.2022.110960</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2211-1247(22)00742-2</ELocationID><Abstract><AbstractText>Reprogramming glial cells to convert them into neurons represents a potential therapeutic strategy that could repair damaged neural circuits and restore function. Recent studies show that downregulation of the RNA-binding protein PTBP1 leads to one-step conversion of M&#xfc;ller glia (MG) into retinal ganglion cells (RGCs) with a high efficiency. However, the original study did not perform fate-mapping experiments to confirm MG-to-RGC conversion after Ptbp1 downregulation. To address the fundamental question of whether Ptbp1 downregulation can convert MG into RGCs in the mouse retina, we perform fate-mapping experiments to lineage trace MG independent of the adeno-associated virus (AAV)-mediated labeling system. Here, we report that Ptbp1 downregulation by CRISPR-CasRx or small hairpin RNA is insufficient to convert MG to RGCs. The original conclusion of MG-to-RGC conversion is due to leaky labeling of endogenous RGCs. Our results emphasize the importance of using stringent fate mapping to determine glia-to-neuron conversion in cell reprogramming research.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 The Author(s). Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Ye</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Bo</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Cell, Developmental and Regenerative Biology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. Electronic address: bo.chen@mssm.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 EY024986</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 EY028921</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Rep</MedlineTA><NlmUniqueID>101573691</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034441">Heterogeneous-Nuclear Ribonucleoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C573992">Ptbp1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016601">RNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>139076-35-0</RegistryNumber><NameOfSubstance UI="D038941">Polypyrimidine Tract-Binding Protein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065150" MajorTopicYN="Y">Cellular Reprogramming</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000229" MajorTopicYN="N">Dependovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D034441" MajorTopicYN="Y">Heterogeneous-Nuclear Ribonucleoproteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009457" MajorTopicYN="Y">Neuroglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D038941" MajorTopicYN="Y">Polypyrimidine Tract-Binding Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016601" MajorTopicYN="N">RNA-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012160" MajorTopicYN="N">Retina</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012165" MajorTopicYN="Y">Retinal Ganglion Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CP: Neuroscience</Keyword><Keyword MajorTopicYN="N">CP: Stem cell research</Keyword><Keyword MajorTopicYN="N">M&#xfc;ller glia</Keyword><Keyword MajorTopicYN="N">fate mapping</Keyword><Keyword MajorTopicYN="N">glia-to-neuron conversion</Keyword><Keyword MajorTopicYN="N">lineage tracing</Keyword><Keyword MajorTopicYN="N">reprogramming</Keyword><Keyword MajorTopicYN="N">retinal ganglion cells</Keyword></KeywordList><CoiStatement>Declaration of interests The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>10</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>4</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>5</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>15</Day><Hour>18</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>8</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35705044</ArticleId><ArticleId IdType="mid">NIHMS1816593</ArticleId><ArticleId IdType="pmc">PMC9371382</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2022.110960</ArticleId><ArticleId IdType="pii">S2211-1247(22)00742-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Blackshaw S, and Sanes JR (2021). Turning lead into gold: reprogramming retinal cells to cure blindness. J. Clin. Invest. 131. 10.1172/jci146134.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci146134</ArticleId><ArticleId IdType="pmc">PMC7843217</ArticleId><ArticleId IdType="pubmed">33529169</ArticleId></ArticleIdList></Reference><Reference><Citation>Boudreau-Pinsonneault C, and Cayouette M (2018). Cell lineage tracing in the retina: could material transfer distort conclusions? Dev. Dynam. 247, 10&#x2013;17. 10.1002/dvdy.24535.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/dvdy.24535</ArticleId><ArticleId IdType="pubmed">28643368</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan KY, Jang MJ, Yoo BB, Greenbaum A, Ravi N, Wu WL, Sanchez-Guardado L, Lois C, Mazmanian SK, Deverman BE, and Gradinaru V (2017). Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems. Nat. Neurosci. 20, 1172&#x2013;1179. 10.1038/nn.4593.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4593</ArticleId><ArticleId IdType="pmc">PMC5529245</ArticleId><ArticleId IdType="pubmed">28671695</ArticleId></ArticleIdList></Reference><Reference><Citation>Elsaeidi F, Macpherson P, Mills EA, Jui J, Flannery JG, and Goldman D (2018). Notch suppression collaborates with Ascl1 and Lin28 to unleash a regenerative response in fish retina, but not in mice. J. Neurosci. 38, 2246&#x2013;2261. 10.1523/jneurosci.2126-17.2018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/jneurosci.2126-17.2018</ArticleId><ArticleId IdType="pmc">PMC5830513</ArticleId><ArticleId IdType="pubmed">29378863</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldman D (2014). Muller glial cell reprogramming and retina regeneration. Nat. Rev. Neurosci. 15, 431&#x2013;442. 10.1038/nrn3723.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn3723</ArticleId><ArticleId IdType="pmc">PMC4249724</ArticleId><ArticleId IdType="pubmed">24894585</ArticleId></ArticleIdList></Reference><Reference><Citation>Grieger JC, Choi VW, and Samulski RJ (2006). Production and characterization of adeno-associated viral vectors. Nat. Protoc. 1, 1412&#x2013;1428. 10.1038/nprot.2006.207.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2006.207</ArticleId><ArticleId IdType="pubmed">17406430</ArticleId></ArticleIdList></Reference><Reference><Citation>He Z, and Jin Y (2016). Intrinsic control of axon regeneration. Neuron 90, 437&#x2013;451. 10.1016/j.neuron.2016.04.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.04.022</ArticleId><ArticleId IdType="pubmed">27151637</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoang T, Wang J, Boyd P, Wang F, Santiago C, Jiang L, Yoo S, Lahne M, Todd LJ, Jia M, et al. (2020). Gene regulatory networks controlling vertebrate retinal regeneration. Science 370. 10.1126/science.abb8598.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abb8598</ArticleId><ArticleId IdType="pmc">PMC7899183</ArticleId><ArticleId IdType="pubmed">33004674</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorstad NL, Wilken MS, Grimes WN, Wohl SG, VandenBosch LS, Yoshimatsu T, Wong RO, Rieke F, and Reh TA (2017). Stimulation of functional neuronal regeneration from Muller glia in adult mice. Nature 548, 103&#x2013;107. 10.1038/nature23283.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature23283</ArticleId><ArticleId IdType="pmc">PMC5991837</ArticleId><ArticleId IdType="pubmed">28746305</ArticleId></ArticleIdList></Reference><Reference><Citation>Karl MO, and Reh TA (2010). Regenerative medicine for retinal diseases: activating endogenous repair mechanisms. Trends Mol. Med. 16, 193&#x2013;202. 10.1016/j.molmed.2010.02.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2010.02.003</ArticleId><ArticleId IdType="pmc">PMC2854262</ArticleId><ArticleId IdType="pubmed">20303826</ArticleId></ArticleIdList></Reference><Reference><Citation>Klimczak RR, Koerber JT, Dalkara D, Flannery JG, and Schaffer DV (2009). A novel adeno-associated viral variant for efficient and selective intravitreal transduction of rat Muller cells. PLoS One 4, e7467. 10.1371/journal.pone.0007467.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0007467</ArticleId><ArticleId IdType="pmc">PMC2758586</ArticleId><ArticleId IdType="pubmed">19826483</ArticleId></ArticleIdList></Reference><Reference><Citation>Levin LA, and Gordon LK (2002). Retinal ganglion cell disorders: types and treatments. Prog. Retin. Eye Res. 21, 465&#x2013;484. 10.1016/s1350-9462(02)00012-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1350-9462(02)00012-5</ArticleId><ArticleId IdType="pubmed">12207946</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin JF, and Poche RA (2019). Awakening the regenerative potential of the mammalian retina. Development 146. 10.1242/dev.182642.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dev.182642</ArticleId><ArticleId IdType="pmc">PMC6918753</ArticleId><ArticleId IdType="pubmed">31792065</ArticleId></ArticleIdList></Reference><Reference><Citation>Mo A, Mukamel EA, Davis FP, Luo C, Henry GL, Picard S, Urich MA, Nery JR, Sejnowski TJ, Lister R, et al. (2015). Epigenomic signatures of neuronal diversity in the mammalian brain. Neuron 86, 1369&#x2013;1384. 10.1016/j.neuron.2015.05.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2015.05.018</ArticleId><ArticleId IdType="pmc">PMC4499463</ArticleId><ArticleId IdType="pubmed">26087164</ArticleId></ArticleIdList></Reference><Reference><Citation>Niwa M, Aoki H, Hirata A, Tomita H, Green PG, and Hara A (2016). Retinal cell degeneration in animal models. Int. J. Mol. Sci. 17, 110. 10.3390/ijms17010110.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms17010110</ArticleId><ArticleId IdType="pmc">PMC4730351</ArticleId><ArticleId IdType="pubmed">26784179</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian H, Kang X, Hu J, Zhang D, Liang Z, Meng F, Zhang X, Xue Y, Maimon R, Dowdy SF, et al. (2020). Reversing a model of Parkinson&#x2019;s disease with in situ converted nigral neurons. Nature 582, 550&#x2013;556. 10.1038/s41586-020-2388-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2388-4</ArticleId><ArticleId IdType="pmc">PMC7521455</ArticleId><ArticleId IdType="pubmed">32581380</ArticleId></ArticleIdList></Reference><Reference><Citation>Rueda EM, Hall BM, Hill MC, Swinton PG, Tong X, Martin JF, and Poche RA (2019). The hippo pathway blocks mammalian retinal muller glial cell reprogramming. Cell Rep. 27, 1637&#x2013;1649.e6. 10.1016/j.celrep.2019.04.047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2019.04.047</ArticleId><ArticleId IdType="pmc">PMC6521882</ArticleId><ArticleId IdType="pubmed">31067451</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B, et al. (2012). Fiji: an open-source platform for biological-image analysis. Nat. Methods 9, 676&#x2013;682. 10.1038/nmeth.2019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.2019</ArticleId><ArticleId IdType="pmc">PMC3855844</ArticleId><ArticleId IdType="pubmed">22743772</ArticleId></ArticleIdList></Reference><Reference><Citation>Ueki Y, Wilken MS, Cox KE, Chipman L, Jorstad N, Sternhagen K, Simic M, Ullom K, Nakafuku M, and Reh TA (2015). Transgenic expression of the proneural transcription factor Ascl1 in Muller glia stimulates retinal regeneration in young mice. Proc. Natl. Acad. Sci. U. S. A. 112, 13717&#x2013;13722. 10.1073/pnas.1510595112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1510595112</ArticleId><ArticleId IdType="pmc">PMC4640735</ArticleId><ArticleId IdType="pubmed">26483457</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang LL, Serrano C, Zhong X, Ma S, Zou Y, and Zhang CL (2021). Revisiting astrocyte to neuron conversion with lineage tracing in vivo. Cell 184, 5465&#x2013;5481.e16. 10.1016/j.cell.2021.09.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.09.005</ArticleId><ArticleId IdType="pmc">PMC8526404</ArticleId><ArticleId IdType="pubmed">34582787</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Rattner A, Zhou Y, Williams J, Smallwood PM, and Nathans J (2012). Norrin/Frizzled4 signaling in retinal vascular development and blood brain barrier plasticity. Cell 151, 1332&#x2013;1344. 10.1016/j.cell.2012.10.042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2012.10.042</ArticleId><ArticleId IdType="pmc">PMC3535266</ArticleId><ArticleId IdType="pubmed">23217714</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, and Chen B (2022). Critical examination of muller glia-derived in vivo neurogenesis in the mouse retina. Front. Cell Dev. Biol. 10, 830382. 10.3389/fcell.2022.830382.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2022.830382</ArticleId><ArticleId IdType="pmc">PMC9008276</ArticleId><ArticleId IdType="pubmed">35433694</ArticleId></ArticleIdList></Reference><Reference><Citation>Xue Y, Ouyang K, Huang J, Zhou Y, Ouyang H, Li H, Wang G, Wu Q, Wei C, Bi Y, et al. (2013). Direct conversion of fibroblasts to neurons by reprogramming PTB-regulated microRNA circuits. Cell 152, 82&#x2013;96. 10.1016/j.cell.2012.11.045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2012.11.045</ArticleId><ArticleId IdType="pmc">PMC3552026</ArticleId><ArticleId IdType="pubmed">23313552</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao K, Qiu S, Tian L, Snider WD, Flannery JG, Schaffer DV, and Chen B (2016). Wnt regulates proliferation and neurogenic potential of muller glial cells via a lin28/let-7 miRNA-dependent pathway in adult mammalian retinas. Cell Rep. 17, 165&#x2013;178. 10.1016/j.celrep.2016.08.078.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2016.08.078</ArticleId><ArticleId IdType="pmc">PMC5076887</ArticleId><ArticleId IdType="pubmed">27681429</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao K, Qiu S, Wang YV, Park SJH, Mohns EJ, Mehta B, Liu X, Chang B, Zenisek D, Crair MC, et al. (2018). Restoration of vision after de novo genesis of rod photoreceptors in mammalian retinas. Nature 560, 484&#x2013;488. 10.1038/s41586-018-0425-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-018-0425-3</ArticleId><ArticleId IdType="pmc">PMC6107416</ArticleId><ArticleId IdType="pubmed">30111842</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou H, Su J, Hu X, Zhou C, Li H, Chen Z, Xiao Q, Wang B, Wu W, Sun Y, et al. (2020). Glia-to-Neuron conversion by CRISPR-CasRx alleviates symptoms of neurological disease in mice. Cell 181, 590&#x2013;603. 10.1016/j.cell.2020.03.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.03.024</ArticleId><ArticleId IdType="pubmed">32272060</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35771920</PMID><DateCompleted><Year>2022</Year><Month>07</Month><Day>04</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>377</Volume><Issue>6601</Issue><PubDate><Year>2022</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>Mutations linked to neurological disease enhance self-association of low-complexity protein sequences.</ArticleTitle><Pagination><StartPage>eabn5582</StartPage><MedlinePgn>eabn5582</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/science.abn5582</ELocationID><Abstract><AbstractText>Protein domains of low sequence complexity do not fold into stable, three-dimensional structures. Nevertheless, proteins with these sequences assist in many aspects of cell organization, including assembly of nuclear and cytoplasmic structures not surrounded by membranes. The dynamic nature of these cellular assemblies is caused by the ability of low-complexity domains (LCDs) to transiently self-associate through labile, cross-&#x3b2; structures. Mechanistic studies useful for the study of LCD self-association have evolved over the past decade in the form of simple assays of phase separation. Here, we have used such assays to demonstrate that the interactions responsible for LCD self-association can be dictated by labile protein structures poised close to equilibrium between the folded and unfolded states. Furthermore, missense mutations causing Charcot-Marie-Tooth disease, frontotemporal dementia, and Alzheimer's disease manifest their pathophysiology in vitro and in cultured cell systems by enhancing the stability of otherwise labile molecular structures formed upon LCD self-association.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Xiaoming</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0002-6840-973X</Identifier><AffiliationInfo><Affiliation>Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sumrow</LastName><ForeName>Lily</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-4285-6387</Identifier><AffiliationInfo><Affiliation>Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tashiro</LastName><ForeName>Kyuto</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-0174-1789</Identifier><AffiliationInfo><Affiliation>Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sutherland</LastName><ForeName>Lillian</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-3155-9646</Identifier><AffiliationInfo><Affiliation>Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Daifei</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-4500-4510</Identifier><AffiliationInfo><Affiliation>Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qin</LastName><ForeName>Tian</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-7225-3224</Identifier><AffiliationInfo><Affiliation>Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kato</LastName><ForeName>Masato</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-8437-6248</Identifier><AffiliationInfo><Affiliation>Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Quantum Life Science, National Institutes for Quantum and Radiological Science and Technology, Inage, Chiba, 263-8555, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liszczak</LastName><ForeName>Glen</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-8194-5281</Identifier><AffiliationInfo><Affiliation>Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McKnight</LastName><ForeName>Steven L</ForeName><Initials>SL</Initials><Identifier Source="ORCID">0000-0002-9014-9364</Identifier><AffiliationInfo><Affiliation>Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R35 GM130358</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 OD021684</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 CA231649</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598624">TARDBP protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Science. 2022 Jul;377(6601):31-32. doi: 10.1126/science.adc9969.</RefSource><PMID Version="1">35771902</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002607" MajorTopicYN="Y">Charcot-Marie-Tooth Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="Y">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020125" MajorTopicYN="N">Mutation, Missense</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072417" MajorTopicYN="N">Protein Domains</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017510" MajorTopicYN="N">Protein Folding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055550" MajorTopicYN="N">Protein Stability</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing interests:</b> Authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>30</Day><Hour>14</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35771920</ArticleId><ArticleId IdType="mid">NIHMS1838903</ArticleId><ArticleId IdType="pmc">PMC9610444</ArticleId><ArticleId IdType="doi">10.1126/science.abn5582</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Oates ME et al., D(2)P(2): database of disordered protein predictions. Nucleic Acids Res 41, D508&#x2013;516 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3531159</ArticleId><ArticleId IdType="pubmed">23203878</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma J, Ptashne M, Deletion analysis of GAL4 defines two transcriptional activating segments. Cell 48, 847&#x2013;853 (1987).</Citation><ArticleIdList><ArticleId IdType="pubmed">3028647</ArticleId></ArticleIdList></Reference><Reference><Citation>Triezenberg SJ, Kingsbury RC, McKnight SL, Functional dissection of VP16, the trans-activator of herpes simplex virus immediate early gene expression. Genes Dev 2, 718&#x2013;729 (1988).</Citation><ArticleIdList><ArticleId IdType="pubmed">2843425</ArticleId></ArticleIdList></Reference><Reference><Citation>Courey AJ, Holtzman DA, Jackson SP, Tjian R, Synergistic activation by the glutamine-rich domains of human transcription factor Sp1. Cell 59, 827&#x2013;836 (1989).</Citation><ArticleIdList><ArticleId IdType="pubmed">2512012</ArticleId></ArticleIdList></Reference><Reference><Citation>Pejaver V et al., The structural and functional signatures of proteins that undergo multiple events of post-translational modification. Protein Sci 23, 1077&#x2013;1093 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4116656</ArticleId><ArticleId IdType="pubmed">24888500</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodsmith J, Kamburov A, Stelzl U, Dual coordination of post translational modifications in human protein networks. PLoS Comput Biol 9, e1002933 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3591266</ArticleId><ArticleId IdType="pubmed">23505349</ArticleId></ArticleIdList></Reference><Reference><Citation>Frey S, Gorlich D, A saturated FG-repeat hydrogel can reproduce the permeability properties of nuclear pore complexes. Cell 130, 512&#x2013;523 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17693259</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato M et al., Cell-free formation of RNA granules: low complexity sequence domains form dynamic fibers within hydrogels. Cell 149, 753&#x2013;767 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6347373</ArticleId><ArticleId IdType="pubmed">22579281</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang S et al., The LC Domain of hnRNPA2 Adopts Similar Conformations in Hydrogel Polymers, Liquid-like Droplets, and Nuclei. Cell 163, 829&#x2013;839 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4879888</ArticleId><ArticleId IdType="pubmed">26544936</ArticleId></ArticleIdList></Reference><Reference><Citation>Molliex A et al., Phase separation by low complexity domains promotes stress granule assembly and drives pathological fibrillization. Cell 163, 123&#x2013;133 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5149108</ArticleId><ArticleId IdType="pubmed">26406374</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel A et al., A Liquid-to-Solid Phase Transition of the ALS Protein FUS Accelerated by Disease Mutation. Cell 162, 1066&#x2013;1077 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26317470</ArticleId></ArticleIdList></Reference><Reference><Citation>Das S, Vera M, Gandin V, Singer RH, Tutucci E, Intracellular mRNA transport and localized translation. Nat Rev Mol Cell Biol 22, 483&#x2013;504 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9346928</ArticleId><ArticleId IdType="pubmed">33837370</ArticleId></ArticleIdList></Reference><Reference><Citation>Alami NH et al., Axonal transport of TDP-43 mRNA granules is impaired by ALS-causing mutations. Neuron 81, 536&#x2013;543 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3939050</ArticleId><ArticleId IdType="pubmed">24507191</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu JF, Majumder P, Chatterjee B, Huang SL, Shen CJ, TDP-43 Regulates Coupled Dendritic mRNA Transport-Translation Processes in Co-operation with FMRP and Staufen1. Cell Rep 29, 3118&#x2013;3133 e3116 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31801077</ArticleId></ArticleIdList></Reference><Reference><Citation>Narayanan RK et al., Identification of RNA bound to the TDP-43 ribonucleoprotein complex in the adult mouse brain. Amyotroph Lateral Scler Frontotemporal Degener 14, 252&#x2013;260 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23134510</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T et al., TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun 351, 602&#x2013;611 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17084815</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M et al., Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314, 130&#x2013;133 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim L, Wei Y, Lu Y, Song J, ALS-Causing Mutations Significantly Perturb the Self-Assembly and Interaction with Nucleic Acid of the Intrinsically Disordered Prion-Like Domain of TDP-43. PLoS Biol 14, e1002338 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4703307</ArticleId><ArticleId IdType="pubmed">26735904</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y et al., Redox-mediated regulation of an evolutionarily conserved cross-beta structure formed by the TDP43 low complexity domain. Proc Natl Acad Sci U S A 117, 28727&#x2013;28734 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7682574</ArticleId><ArticleId IdType="pubmed">33144500</ArticleId></ArticleIdList></Reference><Reference><Citation>Portz B, Lee BL, Shorter J, FUS and TDP-43 Phases in Health and Disease. Trends Biochem Sci 46, 550&#x2013;563 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8195841</ArticleId><ArticleId IdType="pubmed">33446423</ArticleId></ArticleIdList></Reference><Reference><Citation>Murakami T et al., ALS/FTD Mutation-Induced Phase Transition of FUS Liquid Droplets and Reversible Hydrogels into Irreversible Hydrogels Impairs RNP Granule Function. Neuron 88, 678&#x2013;690 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4660210</ArticleId><ArticleId IdType="pubmed">26526393</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson BS et al., TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity. J Biol Chem 284, 20329&#x2013;20339 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2740458</ArticleId><ArticleId IdType="pubmed">19465477</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E, Functional Significance of TDP-43 Mutations in Disease. Adv Genet 91, 1&#x2013;53 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26410029</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt HB, Gorlich D, Nup98 FG domains from diverse species spontaneously phase-separate into particles with nuclear pore-like permselectivity. Elife 4, (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4283134</ArticleId><ArticleId IdType="pubmed">25562883</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y, Currie SL, Rosen MK, Intrinsically disordered sequences enable modulation of protein phase separation through distributed tyrosine motifs. J Biol Chem 292, 19110&#x2013;19120 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5704491</ArticleId><ArticleId IdType="pubmed">28924037</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin EW, Mittag T, Relationship of Sequence and Phase Separation in Protein Low-Complexity Regions. Biochemistry 57, 2478&#x2013;2487 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6476794</ArticleId><ArticleId IdType="pubmed">29517898</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Q, Boyer DR, Sawaya MR, Ge P, Eisenberg DS, Cryo-EM structures of four polymorphic TDP-43 amyloid cores. Nat Struct Mol Biol 26, 619&#x2013;627 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7047951</ArticleId><ArticleId IdType="pubmed">31235914</ArticleId></ArticleIdList></Reference><Reference><Citation>Guenther EL et al., Atomic structures of TDP-43 LCD segments and insights into reversible or pathogenic aggregation. Nat Struct Mol Biol 25, 463&#x2013;471 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5990464</ArticleId><ArticleId IdType="pubmed">29786080</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray DT et al., Structure of FUS Protein Fibrils and Its Relevance to Self-Assembly and Phase Separation of Low-Complexity Domains. Cell 171, 615&#x2013;627 e616 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5650524</ArticleId><ArticleId IdType="pubmed">28942918</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang LL et al., Structural transformation of the amyloidogenic core region of TDP-43 protein initiates its aggregation and cytoplasmic inclusion. J Biol Chem 288, 19614&#x2013;19624 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3707662</ArticleId><ArticleId IdType="pubmed">23689371</ArticleId></ArticleIdList></Reference><Reference><Citation>Conicella AE, Zerze GH, Mittal J, Fawzi NL, ALS Mutations Disrupt Phase Separation Mediated by alpha-Helical Structure in the TDP-43 Low-Complexity C-Terminal Domain. Structure 24, 1537&#x2013;1549 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5014597</ArticleId><ArticleId IdType="pubmed">27545621</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q, Babinchak WM, Surewicz WK, Cryo-EM structure of amyloid fibrils formed by the entire low complexity domain of TDP-43. Nat Commun 12, 1620 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7955110</ArticleId><ArticleId IdType="pubmed">33712624</ArticleId></ArticleIdList></Reference><Reference><Citation>Jordanova A et al., Mutations in the neurofilament light chain gene (NEFL) cause early onset severe Charcot-Marie-Tooth disease. Brain 126, 590&#x2013;597 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12566280</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin JS et al., NEFL Pro22Arg mutation in Charcot-Marie-Tooth disease type 1. J Hum Genet 53, 936&#x2013;940 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18758688</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez-Olle R, Jones ST, Liem RK, Phenotypic analysis of neurofilament light gene mutations linked to Charcot-Marie-Tooth disease in cell culture models. Hum Mol Genet 13, 2207&#x2013;2220 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15282209</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez-Olle R et al., Mutations in the neurofilament light gene linked to Charcot-Marie-Tooth disease cause defects in transport. J Neurochem 93, 861&#x2013;874 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15857389</ArticleId></ArticleIdList></Reference><Reference><Citation>Ching GY, Liem RK, Analysis of the roles of the head domains of type IV rat neuronal intermediate filament proteins in filament assembly using domain-swapped chimeric proteins. J Cell Sci 112 ( Pt 13), 2233&#x2013;2240 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10362553</ArticleId></ArticleIdList></Reference><Reference><Citation>Gill SR, Wong PC, Monteiro MJ, Cleveland DW, Assembly properties of dominant and recessive mutations in the small mouse neurofilament (NF-L) subunit. J Cell Biol 111, 2005&#x2013;2019 (1990).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2116331</ArticleId><ArticleId IdType="pubmed">2121744</ArticleId></ArticleIdList></Reference><Reference><Citation>Petzold A, Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss. J Neurol Sci 233, 183&#x2013;198 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15896809</ArticleId></ArticleIdList></Reference><Reference><Citation>Kornreich M, Avinery R, Malka-Gibor E, Laser-Azogui A, Beck R, Order and disorder in intermediate filament proteins. FEBS Lett 589, 2464&#x2013;2476 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26231765</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrmann H, Aebi U, Intermediate Filaments: Structure and Assembly. Cold Spring Harb Perspect Biol 8, (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5088526</ArticleId><ArticleId IdType="pubmed">27803112</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y et al., Toxic PR Poly-Dipeptides Encoded by the C9orf72 Repeat Expansion Target LC Domain Polymers. Cell 167, 789&#x2013;802 e712 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5076566</ArticleId><ArticleId IdType="pubmed">27768897</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X et al., Transiently structured head domains control intermediate filament assembly. Proc Natl Acad Sci U S A 118, (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7923618</ArticleId><ArticleId IdType="pubmed">33593918</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato M et al., Redox State Controls Phase Separation of the Yeast Ataxin-2 Protein via Reversible Oxidation of Its Methionine-Rich Low-Complexity Domain. Cell 177, 711&#x2013;721 e718 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6752730</ArticleId><ArticleId IdType="pubmed">30982603</ArticleId></ArticleIdList></Reference><Reference><Citation>An SSA et al., Retention of the Cis Proline Conformation in Tripeptide Fragments of Bovine Pancreatic Ribonuclease A Containing a Non-natural Proline Analogue, 5,5-Dimethylproline. Journal of the American Chemical Society 121, 11558&#x2013;11566 (1999).</Citation></Reference><Reference><Citation>Bugiani O et al., Frontotemporal dementia and corticobasal degeneration in a family with a P301S mutation in tau. J Neuropathol Exp Neurol 58, 667&#x2013;677 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10374757</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark LN et al., Pathogenic implications of mutations in the tau gene in pallido-ponto-nigral degeneration and related neurodegenerative disorders linked to chromosome 17. Proc Natl Acad Sci U S A 95, 13103&#x2013;13107 (1998).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC23724</ArticleId><ArticleId IdType="pubmed">9789048</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperfeld AD et al., FTDP-17: an early-onset phenotype with parkinsonism and epileptic seizures caused by a novel mutation. Ann Neurol 46, 708&#x2013;715 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10553987</ArticleId></ArticleIdList></Reference><Reference><Citation>Lossos A et al., Frontotemporal dementia and parkinsonism with the P301S tau gene mutation in a Jewish family. J Neurol 250, 733&#x2013;740 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12796837</ArticleId></ArticleIdList></Reference><Reference><Citation>Llado A et al., A novel MAPT mutation (P301T) associated with familial frontotemporal dementia. Eur J Neurol 14, e9&#x2013;10 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17662000</ArticleId></ArticleIdList></Reference><Reference><Citation>Strang KH et al., Distinct differences in prion-like seeding and aggregation between Tau protein variants provide mechanistic insights into tauopathies. J Biol Chem 293, 4579 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5868274</ArticleId><ArticleId IdType="pubmed">29572329</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen D et al., Tau local structure shields an amyloid-forming motif and controls aggregation propensity. Nat Commun 10, 2493 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6555816</ArticleId><ArticleId IdType="pubmed">31175300</ArticleId></ArticleIdList></Reference><Reference><Citation>Renner C et al., Fluoroprolines as Tools for Protein Design and Engineering. Angewandte Chemie International Edition 40, 923&#x2013;925 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">29712173</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes BB et al., Proteopathic tau seeding predicts tauopathy in vivo. Proc Natl Acad Sci U S A 111, E4376&#x2013;4385 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4205609</ArticleId><ArticleId IdType="pubmed">25261551</ArticleId></ArticleIdList></Reference><Reference><Citation>Seidler PM et al., Structure-based inhibitors halt prion-like seeding by Alzheimer&#x2019;s disease-and tauopathy-derived brain tissue samples. J Biol Chem 294, 16451&#x2013;16464 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6827308</ArticleId><ArticleId IdType="pubmed">31537646</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi X et al., Familial Early-Onset Paget&#x2019;s Disease of Bone Associated with a Novel hnRNPA2B1 Mutation. Calcif Tissue Int 101, 159&#x2013;169 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28389692</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray DT et al., Structural characterization of the D290V mutation site in hnRNPA2 low-complexity-domain polymers. Proc Natl Acad Sci U S A 115, E9782&#x2013;E9791 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6196502</ArticleId><ArticleId IdType="pubmed">30279180</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu J et al., CryoEM structure of the low-complexity domain of hnRNPA2 and its conversion to pathogenic amyloid. Nat Commun 11, 4090 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7427792</ArticleId><ArticleId IdType="pubmed">32796831</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan VH et al., Mechanistic View of hnRNPA2 Low-Complexity Domain Structure, Interactions, and Phase Separation Altered by Mutation and Arginine Methylation. Mol Cell 69, 465&#x2013;479 e467 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5801700</ArticleId><ArticleId IdType="pubmed">29358076</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang YS et al., Yeast Ataxin-2 Forms an Intracellular Condensate Required for the Inhibition of TORC1 Signaling during Respiratory Growth. Cell 177, 697&#x2013;710 e617 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6752053</ArticleId><ArticleId IdType="pubmed">30982600</ArticleId></ArticleIdList></Reference><Reference><Citation>Sysoev VO et al., Dynamic structural order of a low-complexity domain facilitates assembly of intermediate filaments. Proc Natl Acad Sci U S A 117, 23510&#x2013;23518 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7519307</ArticleId><ArticleId IdType="pubmed">32907935</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatterjee J, Rechenmacher F, Kessler H, N-methylation of peptides and proteins: an important element for modulating biological functions. Angew Chem Int Ed Engl 52, 254&#x2013;269 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23161799</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin EW et al., Valence and patterning of aromatic residues determine the phase behavior of prion-like domains. Science 367, 694&#x2013;699 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7297187</ArticleId><ArticleId IdType="pubmed">32029630</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes MP et al., Atomic structures of low-complexity protein segments reveal kinked beta sheets that assemble networks. Science 359, 698&#x2013;701 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6192703</ArticleId><ArticleId IdType="pubmed">29439243</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato M, McKnight SL, The low-complexity domain of the FUS RNA binding protein self-assembles via the mutually exclusive use of two distinct cross-beta cores. Proc Natl Acad Sci U S A 118, (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8545455</ArticleId><ArticleId IdType="pubmed">34654750</ArticleId></ArticleIdList></Reference><Reference><Citation>Gui X et al., Structural basis for reversible amyloids of hnRNPA1 elucidates their role in stress granule assembly. Nat Commun 10, 2006 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6494871</ArticleId><ArticleId IdType="pubmed">31043593</ArticleId></ArticleIdList></Reference><Reference><Citation>Ollivier N et al., Tidbits for the synthesis of bis(2-sulfanylethyl)amido (SEA) polystyrene resin, SEA peptides and peptide thioesters. J Pept Sci 20, 92&#x2013;97 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24254655</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Nuallain B et al., Kinetics and thermodynamics of amyloid assembly using a high-performance liquid chromatography-based sedimentation assay. Methods Enzymol 413, 34&#x2013;74 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17046390</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">35789365</PMID><DateCompleted><Year>2022</Year><Month>08</Month><Day>10</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>79</Volume><Issue>8</Issue><PubDate><Year>2022</Year><Month>Aug</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Detection of Brain Tau Pathology in Down Syndrome Using Plasma Biomarkers.</ArticleTitle><Pagination><StartPage>797</StartPage><EndPage>807</EndPage><MedlinePgn>797-807</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2022.1740</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Novel plasma biomarkers, especially phosphorylated tau (p-tau), can detect brain tau aggregates in Alzheimer disease.</AbstractText><AbstractText Label="OBJECTIVE">To determine which plasma biomarker combinations can accurately detect tau pathological brain changes in Down syndrome (DS).</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">The cross-sectional, multicenter Alzheimer's Biomarker Consortium-Down Syndrome study included adults with DS and a control group of siblings without DS. All participants with plasma, positron emission tomography (PET), and cognitive measures available by the time of data freeze 1.0 were included. Participants were enrolled between 2016 and 2019, and data were analyzed from August 2021 to April 2022.</AbstractText><AbstractText Label="EXPOSURES">Plasma p-tau217, glial fibrillary acidic protein (GFAP), amyloid &#x3b2;42/40 (A&#x3b2;42/A&#x3b2;40), neurofilament light (NfL), and total tau (t-tau); tau positron emission tomography (tau-PET) and A&#x3b2;-PET.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">The primary outcome was tau-PET status. Secondary outcomes included A&#x3b2;-PET status and cognitive performance.</AbstractText><AbstractText Label="RESULTS">Among 300 participants with DS and a control group of 37 non-DS siblings, mean (SD) age was 45.0 (10.1) years, and 167 (49.6%) were men. Among participants with DS who all underwent plasma p-tau217 and GFAP analyses, 258 had other plasma biomarker data available and 119, 213, and 288 participants had tau-PET, A&#x3b2;-PET, and cognitive assessments, respectively. Plasma p-tau217 and t-tau were significantly increased in A&#x3b2;-PET-positive tau-PET-positive (A+T+) DS and A+T- DS compared with A-T- DS while GFAP was only increased in A+T+ DS. Plasma p-tau217 levels were also significantly higher in A+T+ DS than A+T- DS. In participants with DS, plasma p-tau217 and GFAP (but not other plasma biomarkers) were consistently associated with abnormal tau-PET and A&#x3b2;-PET status in models covaried for age (odds ratio range, 1.59 [95% CI, 1.05-2.40] to 2.32 [95% CI, 1.36-3.96]; P&#x2009;&lt;&#x2009;.03). A combination of p-tau217 and age performed best when detecting tau-PET abnormality in temporal and neocortical regions (area under the curve [AUC] range, 0.96-0.99). The most parsimonious model for A&#x3b2;-PET status included p-tau217, t-tau, and age (AUC range, 0.93-0.95). In multivariable models, higher p-tau217 levels but not other biomarkers were associated with worse performance on DS Mental Status Examination (&#x3b2;, -0.24, 95% CI, -0.36 to -0.12; P&#x2009;&lt;&#x2009;.001) and Cued Recall Test (&#x3b2;, -0.40; 95% CI, -0.53 to -0.26; P&#x2009;&lt;&#x2009;.001).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">Plasma p-tau217 is a very accurate blood-based biomarker of both tau and A&#x3b2; pathological brain changes in DS that could help guide screening and enrichment strategies for inclusion of individuals with DS in future AD clinical trials, especially when it is combined with age as a covariate.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Janelidze</LastName><ForeName>Shorena</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences Malm&#xf6;, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Christian</LastName><ForeName>Bradley T</ForeName><Initials>BT</Initials><AffiliationInfo><Affiliation>Waisman Center, University of Wisconsin, Madison.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Price</LastName><ForeName>Julie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Harvard Medical School, Department of Radiology, Massachusetts General Hospital, Charlestown.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laymon</LastName><ForeName>Charles</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schupf</LastName><ForeName>Nicole</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klunk</LastName><ForeName>William E</ForeName><Initials>WE</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lott</LastName><ForeName>Ira</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>School of Medicine, Department of Pediatrics, University of California, Irvine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silverman</LastName><ForeName>Wayne</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>School of Medicine, Department of Pediatrics, University of California, Irvine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosas</LastName><ForeName>H Diana</ForeName><Initials>HD</Initials><AffiliationInfo><Affiliation>Harvard Medical School, Department of Radiology, Massachusetts General Hospital, Charlestown.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Department of Neurology, Massachusetts General Hospital, Charlestown.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zaman</LastName><ForeName>Shahid</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>School of Clinical Medicine, Department of Psychiatry, University of Cambridge, Cambridge, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mapstone</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California, Irvine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lai</LastName><ForeName>Florence</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Harvard Medical School, Department of Neurology, Massachusetts General Hospital, Charlestown.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ances</LastName><ForeName>Beau M</ForeName><Initials>BM</Initials><AffiliationInfo><Affiliation>Washington University School of Medicine in St Louis, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Handen</LastName><ForeName>Benjamin L</ForeName><Initials>BL</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hansson</LastName><ForeName>Oskar</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences Malm&#xf6;, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory Clinic, Sk&#xe5;ne University Hospital, Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG062715</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG051406</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG068054</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG021886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="Y">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004314" MajorTopicYN="Y">Down Syndrome</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Christian reported grants from the National Institutes of Health (NIH) and nonfinancial support from Avid Radiopharmaceuticals during the conduct of the study. Dr Price reported grants from Massachusetts General Hospital (U01 AG051412) during the conduct of the study. Dr Laymon reported grants from the NIH during the conduct of the study and grants from the NIH outside the submitted work. Dr Schupf reported grants from the NIH National Institute on Aging (NIA) during the conduct of the study. Dr Klunk reported a license from GE Healthcare for the University of Pittsburgh for Pittsburgh compound B (PiB) PET technology during the conduct of the study, grants from NIA outside the submitted work, and a patent for PiB PET technology licensed to GE Healthcare. Dr Silverman reported grants from the NIH during the conduct of the study and grants and other activities from the NIH outside the submitted work. Dr Mapstone reported grants from the NIH during the conduct of the study; personal fees from Brain Neurotherapy Bio, LLC, outside the submitted work; and a patent issued for biomarkers for dementia. Dr Handen reported grants from the NIA and Eunice Kennedy Shriver National Institute of Child Health and Human Development during the conduct of the study and grants from Autism Speaks and Roche Pharma outside the submitted work. Dr Hansson reported having acquired research support (for the institution) from ADx, Avid Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, Fujirebio, GE Healthcare, Pfizer, and Roche and having received consultancy, speaker, and other fees from Amylyx, Alzpath, BioArtic, Biogen, Cerveau, Fujirebio, Genentech, Lundbeck, Novartis, NovoNordisk, Roche, and Siemens outside the submitted work. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>5</Day><Hour>19</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>7</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35789365</ArticleId><ArticleId IdType="pmc">PMC9257682</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2022.1740</ArticleId><ArticleId IdType="pii">2793702</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Antonarakis SE, Skotko BG, Rafii MS, et al. . Down syndrome. Nat Rev Dis Primers. 2020;6(1):9. doi:10.1038/s41572-019-0143-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41572-019-0143-7</ArticleId><ArticleId IdType="pmc">PMC8428796</ArticleId><ArticleId IdType="pubmed">32029743</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiseman FK, Al-Janabi T, Hardy J, et al. . A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome. Nat Rev Neurosci. 2015;16(9):564-574. doi:10.1038/nrn3983</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn3983</ArticleId><ArticleId IdType="pmc">PMC4678594</ArticleId><ArticleId IdType="pubmed">26243569</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballard C, Mobley W, Hardy J, Williams G, Corbett A. Dementia in Down&#x2019;s syndrome. Lancet Neurol. 2016;15(6):622-636. doi:10.1016/S1474-4422(16)00063-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(16)00063-6</ArticleId><ArticleId IdType="pubmed">27302127</ArticleId></ArticleIdList></Reference><Reference><Citation>Neale N, Padilla C, Fonseca LM, Holland T, Zaman S. Neuroimaging and other modalities to assess Alzheimer&#x2019;s disease in Down syndrome. Neuroimage Clin. 2017;17:263-271. doi:10.1016/j.nicl.2017.10.022</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nicl.2017.10.022</ArticleId><ArticleId IdType="pmc">PMC5683343</ArticleId><ArticleId IdType="pubmed">29159043</ArticleId></ArticleIdList></Reference><Reference><Citation>Rafii MS, Lukic AS, Andrews RD, et al. ; Down Syndrome Biomarker Initiative and the Alzheimer&#x2019;s Disease Neuroimaging Initiative . PET imaging of tau pathology and relationship to amyloid, longitudinal MRI, and cognitive change in Down syndrome: results from the Down Syndrome Biomarker Initiative (DSBI). J Alzheimers Dis. 2017;60(2):439-450. doi:10.3233/JAD-170390</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-170390</ArticleId><ArticleId IdType="pubmed">28946567</ArticleId></ArticleIdList></Reference><Reference><Citation>Tudorascu DL, Laymon CM, Zammit M, et al. . Relationship of amyloid beta and neurofibrillary tau deposition in Neurodegeneration in Aging Down Syndrome (NiAD) study at baseline. Alzheimers Dement (N Y). 2020;6(1):e12096. doi:10.1002/trc2.12096</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/trc2.12096</ArticleId><ArticleId IdType="pmc">PMC7602678</ArticleId><ArticleId IdType="pubmed">33163613</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Henson RL, Li Y, et al. ; Alzheimer&#x2019;s Biomarker Consortium&#x2013;Down Syndrome; Dominantly Inherited Alzheimer Network . Comparison of CSF biomarkers in Down syndrome and autosomal dominant Alzheimer&#x2019;s disease: a cross-sectional study. Lancet Neurol. 2021;20(8):615-626. doi:10.1016/S1474-4422(21)00139-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(21)00139-3</ArticleId><ArticleId IdType="pmc">PMC8496347</ArticleId><ArticleId IdType="pubmed">34302786</ArticleId></ArticleIdList></Reference><Reference><Citation>Fortea J, Zaman SH, Hartley S, Rafii MS, Head E, Carmona-Iragui M. Alzheimer&#x2019;s disease associated with Down syndrome: a genetic form of dementia. Lancet Neurol. 2021;20(11):930-942. doi:10.1016/S1474-4422(21)00245-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(21)00245-3</ArticleId><ArticleId IdType="pmc">PMC9387748</ArticleId><ArticleId IdType="pubmed">34687637</ArticleId></ArticleIdList></Reference><Reference><Citation>Carmona-Iragui M, Alcolea D, Barroeta I, et al. . Diagnostic and prognostic performance and longitudinal changes in plasma neurofilament light chain concentrations in adults with Down syndrome: a cohort study. Lancet Neurol. 2021;20(8):605-614. doi:10.1016/S1474-4422(21)00129-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(21)00129-0</ArticleId><ArticleId IdType="pmc">PMC8852333</ArticleId><ArticleId IdType="pubmed">34302785</ArticleId></ArticleIdList></Reference><Reference><Citation>Fortea J, Carmona-Iragui M, Benejam B, et al. . Plasma and CSF biomarkers for the diagnosis of Alzheimer&#x2019;s disease in adults with Down syndrome: a cross-sectional study. Lancet Neurol. 2018;17(10):860-869. doi:10.1016/S1474-4422(18)30285-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30285-0</ArticleId><ArticleId IdType="pubmed">30172624</ArticleId></ArticleIdList></Reference><Reference><Citation>Lle&#xf3; A, Zetterberg H, Pegueroles J, et al. . Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer&#x2019;s disease in adults with Down syndrome. Nat Commun. 2021;12(1):4304. doi:10.1038/s41467-021-24319-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-24319-x</ArticleId><ArticleId IdType="pmc">PMC8280160</ArticleId><ArticleId IdType="pubmed">34262030</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen ME, Rafii MS, Zhang F, et al. ; Alzheimer&#x2019;s Biomarker Consortium&#x2013;Down Syndrome (ABC-DS) . Plasma total-tau and neurofilament light chain as diagnostic biomarkers of Alzheimer&#x2019;s disease dementia and mild cognitive impairment in adults with Down syndrome. J Alzheimers Dis. 2021;79(2):671-681. doi:10.3233/JAD-201167</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-201167</ArticleId><ArticleId IdType="pmc">PMC8273927</ArticleId><ArticleId IdType="pubmed">33337378</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson O. Biomarkers for neurodegenerative diseases. Nat Med. 2021;27(6):954-963. doi:10.1038/s41591-021-01382-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01382-x</ArticleId><ArticleId IdType="pubmed">34083813</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalil M, Teunissen CE, Otto M, et al. . Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol. 2018;14(10):577-589. doi:10.1038/s41582-018-0058-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-018-0058-z</ArticleId><ArticleId IdType="pubmed">30171200</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze S, Mattsson N, Palmqvist S, et al. . Plasma p-tau181 in Alzheimer&#x2019;s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer&#x2019;s dementia. Nat Med. 2020;26(3):379-386. doi:10.1038/s41591-020-0755-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0755-1</ArticleId><ArticleId IdType="pubmed">32123385</ArticleId></ArticleIdList></Reference><Reference><Citation>Karikari TK, Pascoal TA, Ashton NJ, et al. . Blood phosphorylated tau 181 as a biomarker for Alzheimer&#x2019;s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 2020;19(5):422-433. doi:10.1016/S1474-4422(20)30071-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(20)30071-5</ArticleId><ArticleId IdType="pubmed">32333900</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S, Janelidze S, Quiroz YT, et al. . Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA. 2020;324(8):772-781. doi:10.1001/jama.2020.12134</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12134</ArticleId><ArticleId IdType="pmc">PMC7388060</ArticleId><ArticleId IdType="pubmed">32722745</ArticleId></ArticleIdList></Reference><Reference><Citation>Mintun MA, Lo AC, Duggan Evans C, et al. . Donanemab in early Alzheimer&#x2019;s disease. N Engl J Med. 2021;384(18):1691-1704. doi:10.1056/NEJMoa2100708</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2100708</ArticleId><ArticleId IdType="pubmed">33720637</ArticleId></ArticleIdList></Reference><Reference><Citation>Barth&#xe9;lemy NR, Li Y, Joseph-Mathurin N, et al. ; Dominantly Inherited Alzheimer Network . A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer&#x2019;s disease. Nat Med. 2020;26(3):398-407. doi:10.1038/s41591-020-0781-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0781-z</ArticleId><ArticleId IdType="pmc">PMC7309367</ArticleId><ArticleId IdType="pubmed">32161412</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze S, Stomrud E, Smith R, et al. . Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer&#x2019;s disease. Nat Commun. 2020;11(1):1683. doi:10.1038/s41467-020-15436-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-15436-0</ArticleId><ArticleId IdType="pmc">PMC7125218</ArticleId><ArticleId IdType="pubmed">32246036</ArticleId></ArticleIdList></Reference><Reference><Citation>Thijssen EH, La Joie R, Strom A, et al. ; Advancing Research and Treatment for Frontotemporal Lobar Degeneration investigators . Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer&#x2019;s disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. Lancet Neurol. 2021;20(9):739-752. doi:10.1016/S1474-4422(21)00214-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(21)00214-3</ArticleId><ArticleId IdType="pmc">PMC8711249</ArticleId><ArticleId IdType="pubmed">34418401</ArticleId></ArticleIdList></Reference><Reference><Citation>Asken BM, Elahi FM, La Joie R, et al. . Plasma glial fibrillary acidic protein levels differ along the spectra of amyloid burden and clinical disease stage. J Alzheimers Dis. 2020;78(1):265-276. doi:10.3233/JAD-200755</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-200755</ArticleId><ArticleId IdType="pmc">PMC7727314</ArticleId><ArticleId IdType="pubmed">32986672</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatterjee P, Pedrini S, Stoops E, et al. . Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer&#x2019;s disease. Transl Psychiatry. 2021;11(1):27. doi:10.1038/s41398-020-01137-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41398-020-01137-1</ArticleId><ArticleId IdType="pmc">PMC7801513</ArticleId><ArticleId IdType="pubmed">33431793</ArticleId></ArticleIdList></Reference><Reference><Citation>Pereira JB, Janelidze S, Smith R, et al. . Plasma GFAP is an early marker of amyloid-&#x3b2; but not tau pathology in Alzheimer&#x2019;s disease. Brain. 2021;144(11):3505-3516. doi:10.1093/brain/awab223</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awab223</ArticleId><ArticleId IdType="pmc">PMC8677538</ArticleId><ArticleId IdType="pubmed">34259835</ArticleId></ArticleIdList></Reference><Reference><Citation>Lott IT, Head E. Dementia in Down syndrome: unique insights for Alzheimer disease research. Nat Rev Neurol. 2019;15(3):135-147. doi:10.1038/s41582-018-0132-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-018-0132-6</ArticleId><ArticleId IdType="pmc">PMC8061428</ArticleId><ArticleId IdType="pubmed">30733618</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institute on Aging . Alzheimer&#x2019;s Biomarker Consortium&#x2013;Down Syndrome study (ABC-DS). Accessed May 26, 2022. https://www.nia.nih.gov/research/abc-ds</Citation></Reference><Reference><Citation>Handen BL, Lott IT, Christian BT, et al. ; Alzheimer&#x2019;s Biomarker Consortium&#x2010;Down Syndrome (ABC&#x2010;DS) . The Alzheimer&#x2019;s Biomarker Consortium-Down Syndrome: rationale and methodology. Alzheimers Dement (Amst). 2020;12(1):e12065. doi:10.1002/dad2.12065</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/dad2.12065</ArticleId><ArticleId IdType="pmc">PMC7396809</ArticleId><ArticleId IdType="pubmed">32775597</ArticleId></ArticleIdList></Reference><Reference><Citation>Haxby JV. Neuropsychological evaluation of adults with Down&#x2019;s syndrome: patterns of selective impairment in non-demented old adults. J Ment Defic Res. 1989;33(pt 3):193-210. doi:10.1111/j.1365-2788.1989.tb01467.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2788.1989.tb01467.x</ArticleId><ArticleId IdType="pubmed">2526879</ArticleId></ArticleIdList></Reference><Reference><Citation>Devenny DA, Zimmerli EJ, Kittler P, Krinsky-McHale SJ. Cued recall in early-stage dementia in adults with Down&#x2019;s syndrome. J Intellect Disabil Res. 2002;46(pt 6):472-483. doi:10.1046/j.1365-2788.2002.00417.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2788.2002.00417.x</ArticleId><ArticleId IdType="pubmed">12354318</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze S, Palmqvist S, Leuzy A, et al. . Detecting amyloid positivity in early Alzheimer&#x2019;s disease using combinations of plasma A&#x3b2;42/A&#x3b2;40 and p-tau. Alzheimers Dement. 2022;18(2):283-293. doi:10.1002/alz.052117</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.052117</ArticleId><ArticleId IdType="pubmed">34151519</ArticleId></ArticleIdList></Reference><Reference><Citation>Zammit MD, Laymon CM, Betthauser TJ, et al. . Amyloid accumulation in Down syndrome measured with amyloid load. Alzheimers Dement (Amst). 2020;12(1):e12020. doi:10.1002/dad2.12020</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/dad2.12020</ArticleId><ArticleId IdType="pmc">PMC7233422</ArticleId><ArticleId IdType="pubmed">32435686</ArticleId></ArticleIdList></Reference><Reference><Citation>Zammit MD, Tudorascu DL, Laymon CM, et al. . Neurofibrillary tau depositions emerge with subthreshold cerebral beta-amyloidosis in Down syndrome. Neuroimage Clin. 2021;31:102740. doi:10.1016/j.nicl.2021.102740</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nicl.2021.102740</ArticleId><ArticleId IdType="pmc">PMC8252122</ArticleId><ArticleId IdType="pubmed">34182407</ArticleId></ArticleIdList></Reference><Reference><Citation>Zammit MD, Tudorascu DL, Laymon CM, et al. . PET measurement of longitudinal amyloid load identifies the earliest stages of amyloid-beta accumulation during Alzheimer&#x2019;s disease progression in Down syndrome. Neuroimage. 2021;228:117728. doi:10.1016/j.neuroimage.2021.117728</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2021.117728</ArticleId><ArticleId IdType="pmc">PMC7953340</ArticleId><ArticleId IdType="pubmed">33421595</ArticleId></ArticleIdList></Reference><Reference><Citation>R Foundation for Statistical Computing . R: a language and environment for statistical computing. Accessed May 26, 2022. http://www.R-project.org/</Citation></Reference><Reference><Citation>Dierssen M. Down syndrome: the brain in trisomic mode. Nat Rev Neurosci. 2012;13(12):844-858. doi:10.1038/nrn3314</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn3314</ArticleId><ArticleId IdType="pubmed">23165261</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin WS, Stanley LC, Ling C, et al. . Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci U S A. 1989;86(19):7611-7615. doi:10.1073/pnas.86.19.7611</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.86.19.7611</ArticleId><ArticleId IdType="pmc">PMC298116</ArticleId><ArticleId IdType="pubmed">2529544</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson-Carlgren N, Janelidze S, Palmqvist S, et al. . Longitudinal plasma p-tau217 is increased in early stages of Alzheimer&#x2019;s disease. Brain. 2020;143(11):3234-3241. doi:10.1093/brain/awaa286</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa286</ArticleId><ArticleId IdType="pmc">PMC7719022</ArticleId><ArticleId IdType="pubmed">33068398</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S, Tideman P, Cullen N, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Prediction of future Alzheimer&#x2019;s disease dementia using plasma phospho-tau combined with other accessible measures. Nat Med. 2021;27(6):1034-1042. doi:10.1038/s41591-021-01348-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01348-z</ArticleId><ArticleId IdType="pubmed">34031605</ArticleId></ArticleIdList></Reference><Reference><Citation>Cullen NC, Leuzy A, Palmqvist S, et al. . Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations. Nat Aging. 2021;1:114-123. doi:10.1038/s43587-020-00003-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s43587-020-00003-5</ArticleId><ArticleId IdType="pubmed">37117993</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze S, Teunissen CE, Zetterberg H, et al. . Head-to-head comparison of 8 plasma amyloid-&#x3b2; 42/40 assays in Alzheimer disease. JAMA Neurol. 2021;78(11):1375-1382. doi:10.1001/jamaneurol.2021.3180</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2021.3180</ArticleId><ArticleId IdType="pmc">PMC8453354</ArticleId><ArticleId IdType="pubmed">34542571</ArticleId></ArticleIdList></Reference><Reference><Citation>Strydom A, Coppus A, Blesa R, et al. . Alzheimer&#x2019;s disease in Down syndrome: an overlooked population for prevention trials. Alzheimers Dement (N Y). 2018;4:703-713. doi:10.1016/j.trci.2018.10.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trci.2018.10.006</ArticleId><ArticleId IdType="pmc">PMC6296162</ArticleId><ArticleId IdType="pubmed">30581976</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">35798951</PMID><DateCompleted><Year>2022</Year><Month>08</Month><Day>30</Day></DateCompleted><DateRevised><Year>2022</Year><Month>09</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1755-4349</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>9</Issue><PubDate><Year>2022</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Nature chemistry</Title><ISOAbbreviation>Nat Chem</ISOAbbreviation></Journal><ArticleTitle>Structure-specific amyloid precipitation in biofluids.</ArticleTitle><Pagination><StartPage>1045</StartPage><EndPage>1053</EndPage><MedlinePgn>1045-1053</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41557-022-00976-3</ELocationID><Abstract><AbstractText>The composition of soluble toxic protein aggregates formed in vivo is currently unknown in neurodegenerative diseases, due to their ultra-low concentration in human biofluids and their high degree of heterogeneity. Here we report a method to capture amyloid-containing aggregates in human biofluids in an unbiased way, a process we name amyloid precipitation. We use a structure-specific chemical dimer, a Y-shaped, bio-inspired small molecule with two capture groups, for amyloid precipitation to increase affinity. Our capture molecule for amyloid precipitation (CAP-1) consists of a derivative of Pittsburgh Compound B (dimer) to target the cross &#x3b2;-sheets of amyloids and a biotin moiety for surface immobilization. By coupling CAP-1 to magnetic beads, we demonstrate that we can target the amyloid structure of all protein aggregates present in human cerebrospinal fluid, isolate them for analysis and then characterize them using single-molecule fluorescence imaging and mass spectrometry. Amyloid precipitation enables unbiased determination of the molecular composition and structural features of the in vivo aggregates formed in neurodegenerative diseases.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s), under exclusive licence to Springer Nature Limited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rodrigues</LastName><ForeName>M</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-6364-7125</Identifier><AffiliationInfo><Affiliation>Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhattacharjee</LastName><ForeName>P</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-1116-5877</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brinkmalm</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Do</LastName><ForeName>D T</ForeName><Initials>DT</Initials><Identifier Source="ORCID">0000-0002-5717-4285</Identifier><AffiliationInfo><Affiliation>Department of Chemistry, Indiana University, Bloomington, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pearson</LastName><ForeName>C M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Chemistry, Indiana University, Bloomington, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De</LastName><ForeName>S</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-1675-0773</Identifier><AffiliationInfo><Affiliation>Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience, University of Sheffield, Western Bank, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ponjavic</LastName><ForeName>A</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-7561-1127</Identifier><AffiliationInfo><Affiliation>Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Physics and Astronomy, University of Leeds, Leeds, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Food Science and Nutrition, University of Leeds, Leeds, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Varela</LastName><ForeName>J A</ForeName><Initials>JA</Initials><Identifier Source="ORCID">0000-0003-1901-1378</Identifier><AffiliationInfo><Affiliation>Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Physics and Astronomy, University of St Andrews, St Andrews, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kulenkampff</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baudrexel</LastName><ForeName>I</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-3422-8340</Identifier><AffiliationInfo><Affiliation>Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Emin</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruggeri</LastName><ForeName>F S</ForeName><Initials>FS</Initials><Identifier Source="ORCID">0000-0002-1232-1907</Identifier><AffiliationInfo><Affiliation>Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Organic Chemistry, Wageningen University &amp; Research, Wageningen, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Physical Chemistry and Soft Matter, Wageningen University &amp; Research, Wageningen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>J E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Chemistry, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carr</LastName><ForeName>A R</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knowles</LastName><ForeName>T P J</ForeName><Initials>TPJ</Initials><Identifier Source="ORCID">0000-0002-7879-0140</Identifier><AffiliationInfo><Affiliation>Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>H</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute, UCL, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Snaddon</LastName><ForeName>T N</ForeName><Initials>TN</Initials><Identifier Source="ORCID">0000-0003-1119-0332</Identifier><AffiliationInfo><Affiliation>Department of Chemistry, Indiana University, Bloomington, IN, USA. tsnaddon@indiana.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gandhi</LastName><ForeName>S</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-4395-2661</Identifier><AffiliationInfo><Affiliation>Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK. sonia.gandhi@crick.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Francis Crick Institute, London, UK. sonia.gandhi@crick.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>S F</ForeName><Initials>SF</Initials><Identifier Source="ORCID">0000-0003-4492-5139</Identifier><AffiliationInfo><Affiliation>Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge, UK. sl591@cam.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klenerman</LastName><ForeName>D</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-7116-6954</Identifier><AffiliationInfo><Affiliation>Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge, UK. dk10012@cam.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute, University of Cambridge, Cambridge, UK. dk10012@cam.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Acronym>DH_</Acronym><Agency>Department of Health</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/T008199/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 GM121573</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Chem</MedlineTA><NlmUniqueID>101499734</NlmUniqueID><ISSNLinking>1755-4330</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D066329">Protein Aggregates</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="Y">Amyloid</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012634" MajorTopicYN="Y">Bodily Secretions</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066329" MajorTopicYN="Y">Protein Aggregates</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>9</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>5</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>7</Day><Hour>23</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35798951</ArticleId><ArticleId IdType="doi">10.1038/s41557-022-00976-3</ArticleId><ArticleId IdType="pii">10.1038/s41557-022-00976-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Knowles, T. P. J., Vendruscolo, M. &amp; Dobson, C. M. The amyloid state and its association with protein misfolding diseases. Nat. Rev. Mol. Cell Biol. 15, 384&#x2013;396 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24854788</ArticleId><ArticleId IdType="doi">10.1038/nrm3810</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak, H. et al. Pattern of brain destruction in Parkinson&#x2019;s and Alzheimer&#x2019;s diseases. J. Neural Transm. 103, 455&#x2013;490 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">9617789</ArticleId><ArticleId IdType="doi">10.1007/BF01276421</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert, M. Alzheimer&#x2019;s and Parkinson&#x2019;s diseases: the prion concept in relation to assembled A&#x3b2;, tau, and &#x3b1;-synuclein. Science 349, 61&#x2013;69 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1255555</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheltens, P. et al. Alzheimer&#x2019;s disease. Lancet 388, 505&#x2013;517 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26921134</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(15)01124-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisele, Y. S. et al. Peripherally applied A&#x3b2;-containing inoculates induce cerebral &#x3b2;-amyloidosis. Science 330, 980&#x2013;982 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20966215</ArticleId><ArticleId IdType="pmc">3233904</ArticleId><ArticleId IdType="doi">10.1126/science.1194516</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Luehmann, M. et al. Exogenous induction of cerebral &#x3b2;-amyloidogenesis is governed by agent and host. Science 313, 1781&#x2013;1784 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16990547</ArticleId><ArticleId IdType="doi">10.1126/science.1131864</ArticleId></ArticleIdList></Reference><Reference><Citation>Luk, K. C. et al. Intracerebral inoculation of pathological &#x3b1;-synuclein initiates a rapidly progressive neurodegenerative &#x3b1;-synucleinopathy in mice. J. Exp. Med. 209, 975&#x2013;988 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22508839</ArticleId><ArticleId IdType="pmc">3348112</ArticleId><ArticleId IdType="doi">10.1084/jem.20112457</ArticleId></ArticleIdList></Reference><Reference><Citation>Karampetsou, M. et al. Phosphorylated exogenous alpha-synuclein fibrils exacerbate pathology and induce neuronal dysfunction in mice. Sci Rep. 7, 16533 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29184069</ArticleId><ArticleId IdType="pmc">5705684</ArticleId><ArticleId IdType="doi">10.1038/s41598-017-15813-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Duran-Aniotz, C. et al. Aggregate-depleted brain fails to induce A&#x3b2; deposition in a mouse model of Alzheimer&#x2019;s disease. PLoS ONE 9, e89014 (2014).</Citation></Reference><Reference><Citation>Morales, R., Bravo-Alegria, J., Duran-Aniotz, C. &amp; Soto, C. Titration of biologically active amyloid&#x2013;&#x3b2; seeds in a transgenic mouse model of Alzheimer&#x2019;s disease. Sci Rep. 5, 9349 (2015).</Citation></Reference><Reference><Citation>Condello, C. et al. Structural heterogeneity and intersubject variability of A&#x3b2; in familial and sporadic Alzheimer&#x2019;s disease. Proc. Natl Acad. Sci. USA 115, E782&#x2013;E791 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29311311</ArticleId><ArticleId IdType="pmc">5789926</ArticleId><ArticleId IdType="doi">10.1073/pnas.1714966115</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xe1;zaro, D. F. et al. Systematic comparison of the effects of alpha-synuclein mutations on its oligomerization and aggregation. PLoS Genet. 10, e1004741 (2014).</Citation></Reference><Reference><Citation>Tosatto, L. et al. Single-molecule FRET studies on alpha-synuclein oligomerization of Parkinson&#x2019;s disease genetically related mutants. Sci Rep. 5, 16696 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26582456</ArticleId><ArticleId IdType="pmc">4652217</ArticleId><ArticleId IdType="doi">10.1038/srep16696</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyer, D. R. et al. The &#x3b1;-synuclein hereditary mutation E46K unlocks a more stable, pathogenic fibril structure. Proc. Natl Acad. Sci. USA 117, 3592&#x2013;3602 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32015135</ArticleId><ArticleId IdType="pmc">7035510</ArticleId><ArticleId IdType="doi">10.1073/pnas.1917914117</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee, J. E. et al. Mapping surface hydrophobicity of &#x3b1;-synuclein oligomers at the nanoscale. Nano Lett. 18, 7494&#x2013;7501 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30380895</ArticleId><ArticleId IdType="pmc">6295917</ArticleId><ArticleId IdType="doi">10.1021/acs.nanolett.8b02916</ArticleId></ArticleIdList></Reference><Reference><Citation>Cremades, N. et al. Direct observation of the interconversion of normal and toxic forms of &#x3b1;-synuclein. Cell 149, 1048&#x2013;1059 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22632969</ArticleId><ArticleId IdType="pmc">3383996</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2012.03.037</ArticleId></ArticleIdList></Reference><Reference><Citation>Iljina, M. et al. Kinetic model of the aggregation of alpha-synuclein provides insights into prion-like spreading. Proc. Natl Acad. Sci. USA 113, E1206&#x2013;E1215 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26884195</ArticleId><ArticleId IdType="pmc">4780632</ArticleId><ArticleId IdType="doi">10.1073/pnas.1524128113</ArticleId></ArticleIdList></Reference><Reference><Citation>Varela, J. A. et al. Optical structural analysis of individual &#x3b1;-synuclein oligomers. Angew. Chem. Int. Ed. 57, 4886&#x2013;4890 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/anie.201710779</ArticleId></ArticleIdList></Reference><Reference><Citation>Fusco, G. et al. Structural basis of membrane disruption and cellular toxicity by &#x3b1;-synuclein oligomers. Science 358, 1440&#x2013;1443 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29242346</ArticleId><ArticleId IdType="doi">10.1126/science.aan6160</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludtmann, M. H. R. et al. &#x3b1;-Synuclein oligomers interact with ATP synthase and open the permeability transition pore in Parkinson&#x2019;s disease. Nat. Commun. 9, 2293 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29895861</ArticleId><ArticleId IdType="pmc">5997668</ArticleId><ArticleId IdType="doi">10.1038/s41467-018-04422-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Outeiro, T. F. et al. Formation of toxic oligomeric &#x3b1;-synuclein species in living cells. PLoS ONE 3, e1867 (2008).</Citation></Reference><Reference><Citation>Flagmeier, P. et al. Ultrasensitive measurement of Ca<sup>2+</sup> influx into lipid vesicles induced by protein aggregates. Angew. Chem. Int. Ed. 56, 7750&#x2013;7754 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/anie.201700966</ArticleId></ArticleIdList></Reference><Reference><Citation>Whiten, D. R. et al. Single-molecule characterization of the interactions between extracellular chaperones and toxic &#x3b1;-synuclein oligomers. Cell Rep. 23, 3492&#x2013;3500 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29924993</ArticleId><ArticleId IdType="pmc">6024880</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2018.05.074</ArticleId></ArticleIdList></Reference><Reference><Citation>Mannini, B. et al. Stabilization and characterization of cytotoxic A&#x3b2;<sub>40</sub> oligomers isolated from an aggregation reaction in the presence of zinc ions. ACS Chem. Neurosci. 9, 2959&#x2013;2971 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29986583</ArticleId><ArticleId IdType="doi">10.1021/acschemneuro.8b00141</ArticleId></ArticleIdList></Reference><Reference><Citation>De, S. et al. Different soluble aggregates of A&#x3b2;42 can give rise to cellular toxicity through different mechanisms. Nat. Commun. 10, 1541 (2019).</Citation></Reference><Reference><Citation>Esteras, N. et al. Insoluble tau aggregates induce neuronal death through modification of membrane ion conductance, activation of voltage-gated calcium channels and NADPH oxidase. FEBS J. 288, 127&#x2013;141 (2020).</Citation></Reference><Reference><Citation>De, S. et al. Soluble aggregates present in cerebrospinal fluid change in size and mechanism of toxicity during Alzheimer&#x2019;s disease progression. Acta Neuropathol. Commun. 7, 113&#x2013;120 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-019-0777-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar, S. T., Donzelli, S., Chiki, A., Syed, M. M. K. &amp; Lashuel, H. A. A simple, versatile and robust centrifugation-based filtration protocol for the isolation and quantification of &#x3b1;-synuclein monomers, oligomers and fibrils: towards improving experimental reproducibility in &#x3b1;-synuclein research. J. Neurochem. 153, 103&#x2013;119 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31925956</ArticleId><ArticleId IdType="pmc">7155127</ArticleId><ArticleId IdType="doi">10.1111/jnc.14955</ArticleId></ArticleIdList></Reference><Reference><Citation>Iadanza, M. G., Jackson, M. P., Hewitt, E. W., Ranson, N. A. &amp; Radford, S. E. A new era for understanding amyloid structures and disease. Nat. Rev. Mol. Cell Biol. 19, 755&#x2013;773 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30237470</ArticleId><ArticleId IdType="doi">10.1038/s41580-018-0060-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Mollenhauer, B. et al. a-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol. 10, 230&#x2013;240 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21317042</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(11)70014-X</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaikath, N. N. et al. Antibodies against alpha-synuclein: tools and therapies. J. Neurochem. 150, 612&#x2013;625 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31055836</ArticleId><ArticleId IdType="doi">10.1111/jnc.14713</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitkevich, O. V. et al. DNA aptamers detecting generic amyloid epitopes. Prion 6, 400&#x2013;406 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22874671</ArticleId><ArticleId IdType="pmc">3609070</ArticleId><ArticleId IdType="doi">10.4161/pri.20678</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahimi, F. Aptamers selected for recognizing amyloid &#x3b2;-protein&#x2013;a case for cautious optimism. Int. J. Mol. Sci. 19, 668 (2018).</Citation></Reference><Reference><Citation>Bondarev, S. A., Antonets, K. S., Kajava, A. V., Nizhnikov, A. A. &amp; Zhouravleva, G. A. Protein co-aggregation related to amyloids: methods of investigation, diversity, and classification. Int. J. Mol. Sci. 19, 2292 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">6121665</ArticleId><ArticleId IdType="doi">10.3390/ijms19082292</ArticleId></ArticleIdList></Reference><Reference><Citation>Juhl, D. W. et al. Conservation of the amyloid interactome across diverse fibrillar structures. Sci. Rep. 9, 3863 (2019).</Citation></Reference><Reference><Citation>Voropai, E. S. et al. Spectral properties of thioflavin T and its complexes with amyloid fibrils. J. Appl. Spectrosc. 70, 868&#x2013;874 (2003).</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/B:JAPS.0000016303.37573.7e</ArticleId></ArticleIdList></Reference><Reference><Citation>Biancalana, M. &amp; Koide, S. Molecular mechanism of thioflavin-T binding to amyloid fibrils. Biochim. Biophys. Acta Proteins Proteom. 1804, 1405&#x2013;1412 (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbapap.2010.04.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk, W. E. et al. Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain. Life Sci. 69, 1471&#x2013;1484 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11554609</ArticleId><ArticleId IdType="doi">10.1016/S0024-3205(01)01232-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu, C., Bowers, M. T. &amp; Shea, J.-E. On the origin of the stronger binding of PIB over thioflavin T to protofibrils of the Alzheimer amyloid-&#x3b2; peptide: a molecular dynamics study. Biophys. J. 100, 1316&#x2013;1324 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21354405</ArticleId><ArticleId IdType="pmc">3043208</ArticleId><ArticleId IdType="doi">10.1016/j.bpj.2011.01.058</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho, H. J., Huynh, T. T., Rogers, B. E. &amp; Mirica, L. M. Design of a multivalent bifunctional chelator for diagnostic <sup>64</sup>Cu PET imaging in Alzheimer&#x2019;s disease. Proc. Natl Acad. Sci. USA 117, 30928&#x2013;30933 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33234563</ArticleId><ArticleId IdType="pmc">7733815</ArticleId><ArticleId IdType="doi">10.1073/pnas.2014058117</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin, L., Vastl, J. &amp; Gao, J. Highly sensitive amyloid detection enabled by thioflavin T dimers. Mol. Biosyst. 6, 1791&#x2013;1795 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20614050</ArticleId><ArticleId IdType="doi">10.1039/c005255h</ArticleId></ArticleIdList></Reference><Reference><Citation>Horrocks, M. H. et al. Single-molecule imaging of individual amyloid protein aggregates in human biofluids. ACS Chem. Neurosci. 7, 399&#x2013;406 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26800462</ArticleId><ArticleId IdType="doi">10.1021/acschemneuro.5b00324</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye, L. et al. In vitro high affinity &#x3b1;-synuclein binding sites for the amyloid imaging agent PIB are not matched by binding to Lewy bodies in postmortem human brain. J. Neurochem. 105, 1428&#x2013;1437 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18221373</ArticleId><ArticleId IdType="pmc">2408655</ArticleId><ArticleId IdType="doi">10.1111/j.1471-4159.2008.05245.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Sulatskaya, A. I. et al. Investigation of &#x3b1;-synuclein amyloid fibrils using the fluorescent probe thioflavin T. Int. J. Mol. Sci. 19, 2486 (2018).</Citation></Reference><Reference><Citation>Xiong, F., Ge, W. &amp; Ma, C. Quantitative proteomics reveals distinct composition of amyloid plaques in Alzheimer&#x2019;s disease. Alzheimers Dement. 15, 429&#x2013;440 (2018).</Citation></Reference><Reference><Citation>Heywood, W. E. et al. Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay. Mol. Neurodegener. 10, 64 (2015).</Citation></Reference><Reference><Citation>Guldbrandsen, A. et al. In-depth characterization of the cerebrospinal fluid (CSF) proteome displayed through the CSF proteome resource (CSF-PR). Mol. Cell. Proteomics 13, 3152&#x2013;3163 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25038066</ArticleId><ArticleId IdType="pmc">4223498</ArticleId><ArticleId IdType="doi">10.1074/mcp.M114.038554</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh, I., Seno, F., Tosatto, S. C. E. &amp; Trovato, A. PASTA 2.0: an improved server for protein aggregation prediction. Nucleic Acids Res. 42, 301&#x2013;307 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gku399</ArticleId></ArticleIdList></Reference><Reference><Citation>Niu, M., Li, Y., Wang, C. &amp; Han, K. RFAmyloid: a web server for predicting amyloid proteins. Int. J. Mol. Sci. 19, 2071 (2018).</Citation></Reference><Reference><Citation>Mair, A., Xu, S. L., Branon, T. C., Ting, A. Y. &amp; Bergmann, D. C. Proximity labeling of protein complexes and cell type-specific organellar proteomes in Arabidopsis enabled by TurboID. eLife 8, e47864 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31535972</ArticleId><ArticleId IdType="pmc">6791687</ArticleId><ArticleId IdType="doi">10.7554/eLife.47864</ArticleId></ArticleIdList></Reference><Reference><Citation>Sousa, M. M. L., Steen, K. W., Hagen, L. &amp; Slupphaug, G. Antibody cross-linking and target elution protocols used for immunoprecipitation significantly modulate signal-to noise ratio in downstream 2D-PAGE analysis. Proteome Sci. 9, 45 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21816076</ArticleId><ArticleId IdType="pmc">3162493</ArticleId><ArticleId IdType="doi">10.1186/1477-5956-9-45</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim, K., Lee, S., Ryu, S. &amp; Han, D. Efficient isolation and elution of cellular proteins using aptamer-mediated protein precipitation assay. Biochem. Biophys. Res. Commun. 448, 114&#x2013;119 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24768638</ArticleId><ArticleId IdType="doi">10.1016/j.bbrc.2014.04.086</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe, D. J. The molecular pathology of Alzheimer&#x2019;s disease. Neuron 6, 487&#x2013;498 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">1673054</ArticleId><ArticleId IdType="doi">10.1016/0896-6273(91)90052-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruggink, K. A., M&#xfc;ller, M., Kuiperij, H. B. &amp; Verbeek, M. M. Methods for analysis of amyloid-&#x3b2; aggregates. J. Alzheimers Dis. 28, 735&#x2013;758 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22156047</ArticleId><ArticleId IdType="doi">10.3233/JAD-2011-111421</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuster, J. &amp; Funke, S. A. Methods for the specific detection and quantitation of amyloid-&#x3b2; oligomers in cerebrospinal fluid. J. Alzheimers Dis. 53, 53&#x2013;67 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27163804</ArticleId><ArticleId IdType="doi">10.3233/JAD-151029</ArticleId></ArticleIdList></Reference><Reference><Citation>Soto, C. &amp; Pritzkow, S. Protein misfolding, aggregation, and conformational strains in neurodegenerative diseases. Nat. Neurosci. 21, 1332&#x2013;1340 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30250260</ArticleId><ArticleId IdType="pmc">6432913</ArticleId><ArticleId IdType="doi">10.1038/s41593-018-0235-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Str&#xf8;mland, &#xd8;., Kakubec, M. &amp; Halskau, &#xd8;. Detection of mis-folded protein aggregates from a clinical perspective. J. Clin. Transl. Res. 1, 11&#x2013;26 (2016).</Citation></Reference><Reference><Citation>Blennow, K. Cerebrospinal fluid protein biomarkers for Alzheimer&#x2019;s disease. NeuroRX 1, 213&#x2013;225 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15717022</ArticleId><ArticleId IdType="pmc">534929</ArticleId><ArticleId IdType="doi">10.1602/neurorx.1.2.213</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk, W. E. et al. Imaging brain amyloid in Alzheimer&#x2019;s disease with Pittsburgh Compound-B. Ann. Neurol. 55, 306&#x2013;319 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">14991808</ArticleId><ArticleId IdType="doi">10.1002/ana.20009</ArticleId></ArticleIdList></Reference><Reference><Citation>Mintun, M. A. et al. [<sup>11</sup>C]PIB in a nondemented population. Neurology 67, 446&#x2013;452 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16894106</ArticleId><ArticleId IdType="doi">10.1212/01.wnl.0000228230.26044.a4</ArticleId></ArticleIdList></Reference><Reference><Citation>Kramer, R. H. &amp; Karpen, J. W. Spanning binding sites on allosteric proteins with polymer-linked ligand dimers. Nature 395, 710&#x2013;713 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9790193</ArticleId><ArticleId IdType="doi">10.1038/27227</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang, J. et al. Dimerization of &#x3b1;-conotoxins as a strategy to enhance the inhibition of the human &#x3b1;7 and &#x3b1;9&#x3b1;10 nicotinic acetylcholine receptors. J. Med. Chem. 63, 2974&#x2013;2985 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32101438</ArticleId><ArticleId IdType="doi">10.1021/acs.jmedchem.9b01536</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xfc;hmer, A. F., Biringer, R. G., Amato, H., Fonteh, A. N. &amp; Harrington, M. G. Protein analysis in human cerebrospinal fluid: physiological aspects, current progress and future challenges. Dis. Markers 22, 3&#x2013;26 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16410649</ArticleId><ArticleId IdType="doi">10.1155/2006/158797</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu, X. et al. Molecular modeling and affinity determination of scFv antibody: proper linker peptide enhances its activity. Ann. Biomed. Eng. 38, 537&#x2013;549 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">19816775</ArticleId><ArticleId IdType="doi">10.1007/s10439-009-9810-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Silacci, M. et al. Linker length matters, Fynomer-Fc fusion with an optimized linker displaying picomolar IL-17A inhibition potency. J. Biol. Chem. 289, 14392&#x2013;14398 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24692552</ArticleId><ArticleId IdType="pmc">4022905</ArticleId><ArticleId IdType="doi">10.1074/jbc.M113.534578</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, W., Singh, S., Zeng, D. L., King, K. &amp; Nema, S. Antibody structure, instability, and formulation. J. Pharm. Sci. 96, 1&#x2013;26 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">16998873</ArticleId><ArticleId IdType="doi">10.1002/jps.20727</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng, S. et al. Investigating the degradation behaviors of a therapeutic monoclonal antibody associated with pH and buffer species. AAPS PharmSciTech 18, 42&#x2013;48 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">26340951</ArticleId><ArticleId IdType="doi">10.1208/s12249-015-0403-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Basle, Y., Chennell, P., Tokhadze, N., Astier, A. &amp; Sautou, V. Physicochemical stability of monoclonal antibodies: a review. J. Pharm. Sci. 109, 169&#x2013;190 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31465737</ArticleId><ArticleId IdType="doi">10.1016/j.xphs.2019.08.009</ArticleId></ArticleIdList></Reference><Reference><Citation>Savage, M. J. et al. A sensitive A&#x3b2; oligomer assay discriminates Alzheimer&#x2019;s and aged control cerebrospinal fluid. J. Neurosci. 34, 2884&#x2013;2897 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24553930</ArticleId><ArticleId IdType="pmc">6608513</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.1675-13.2014</ArticleId></ArticleIdList></Reference><Reference><Citation>Sengupta, U. et al. Tau oligomers in cerebrospinal fluid in Alzheimer&#x2019;s disease. Ann. Clin. Transl. Neurol. 4, 226&#x2013;235 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28382304</ArticleId><ArticleId IdType="pmc">5376754</ArticleId><ArticleId IdType="doi">10.1002/acn3.382</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolarova, M., Sengupta, U., Bartos, A., Ricny, J. &amp; Kayed, R. Tau oligomers in sera of patients with Alzheimer&#x2019;s disease and aged controls. J. Alzheimers Dis. 58, 471&#x2013;478 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28453485</ArticleId><ArticleId IdType="doi">10.3233/JAD-170048</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson, O. et al. Levels of cerebrospinal fluid &#x3b1;-synuclein oligomers are increased in Parkinson&#x2019;s disease with dementia and dementia with Lewy bodies compared to Alzheimer&#x2019;s disease. Alzheimers Res. Ther. 6, 25 (2014).</Citation></Reference><Reference><Citation>Hoyer, W. et al. Dependence of &#x3b1;-synuclein aggregate morphology on solution conditions. J. Mol. Biol. 322, 383&#x2013;393 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12217698</ArticleId><ArticleId IdType="doi">10.1016/S0022-2836(02)00775-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Arosio, P., Vendruscolo, M., Dobson, C. M. &amp; Knowles, T. P. J. Chemical kinetics for drug discovery to combat protein aggregation diseases. Trends Pharmacol. Sci. 35, 127&#x2013;135 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24560688</ArticleId><ArticleId IdType="doi">10.1016/j.tips.2013.12.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein, R. A., Wilkinson, J. C., Guyer, C. A. &amp; Staros, J. V. An analytical approach to the measurement of equilibrium binding constants: application to EGF binding to EGF receptors in intact cells measured by flow cytometry. Biochemistry 40, 6142&#x2013;6154 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11352752</ArticleId><ArticleId IdType="doi">10.1021/bi002817a</ArticleId></ArticleIdList></Reference><Reference><Citation>Breen, C. J., Raverdeau, M. &amp; Voorheis, H. P. Development of a quantitative fluorescence-based ligand-binding assay. Sci Rep. 6, 25769 (2016).</Citation></Reference><Reference><Citation>GraphPad. Fitting binding of fluorescent ligands. GraphPad Knowledge Base no. 1725 https://www.graphpad.com/support/faq/fitting-binding-of-fluorescent-ligands/ (2011).</Citation></Reference><Reference><Citation>Bhattacharjee, P. et al. Mass spectrometric analysis of Lewy body-enriched &#x3b1;-synuclein in Parkinson&#x2019;s disease. J. Proteome Res. 18, 2109&#x2013;2120 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30943367</ArticleId><ArticleId IdType="doi">10.1021/acs.jproteome.8b00982</ArticleId></ArticleIdList></Reference><Reference><Citation>Brinkmalm, A., &#xd6;hrfelt, A., Bhattacharjee, P. &amp; Zetterberg, H. in Alpha-Synuclein: Methods and Protocols (Springer, 2019).</Citation></Reference><Reference><Citation>Drews, A. et al. Inhibiting the Ca<sup>2+</sup> influx induced by human CSF. Cell Rep. 21, 3310&#x2013;3316 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29241555</ArticleId><ArticleId IdType="pmc">5745229</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2017.11.057</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35793088</PMID><DateCompleted><Year>2022</Year><Month>07</Month><Day>08</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>21</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2574-3805</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>7</Issue><PubDate><Year>2022</Year><Month>Jul</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA network open</Title><ISOAbbreviation>JAMA Netw Open</ISOAbbreviation></Journal><ArticleTitle>Variation in Population Attributable Fraction of Dementia Associated With Potentially Modifiable Risk Factors by Race and Ethnicity in the US.</ArticleTitle><Pagination><StartPage>e2219672</StartPage><MedlinePgn>e2219672</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e2219672</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamanetworkopen.2022.19672</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Identifying modifiable risk factors that are associated with dementia burden across racial and ethnic groups in the population can yield insights into the potential effectiveness of interventions in preventing dementia and reducing disparities.</AbstractText><AbstractText Label="OBJECTIVE">To calculate the population attributable fraction (PAF) of dementia associated with 12 established modifiable risk factors for all US adults, as well as separately by race and ethnicity.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">This cross-sectional study used survey data from nationally representative samples of US adults. PAFs were calculated using relative risks and prevalence estimates for 12 risk factors. Relative risks were taken from meta-analyses, as reported in a 2020 systematic review. Prevalence estimates for risk factors were derived from nationally representative cross-sectional survey data collected between 2011 and 2018. Combined PAFs were adjusted for risk factor communality using weights derived from the Atherosclerosis Risk in Communities (ARIC) study (1987-2018). Analyses were conducted May through October 2021.</AbstractText><AbstractText Label="EXPOSURES">Low education, hearing loss, traumatic brain injury, hypertension, excessive alcohol consumption, obesity, smoking, depression, social isolation, physical inactivity, diabetes, and air pollution.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">PAF for each dementia risk factor, a combined PAF, and the decrease in the number of prevalent dementia cases in 2020 that would be expected given a 15% proportional decrease in each exposure.</AbstractText><AbstractText Label="RESULTS">Among all US adults, an estimated 41.0% (95% CI, 22.7%-55.9%) of dementia cases were attributable to 12 risk factors. A 15% proportional decrease in each risk factor would reduce dementia prevalence in the population by an estimated 7.3% (95% CI, 3.7%-10.9%). The estimated PAF was greater for Black and Hispanic than it was for White and Asian individuals. The greatest attributable fraction of dementia cases was observed for hypertension (PAF, 20.2%; 95% CI, 6.3%-34.4%), obesity (PAF, 20.9%; 95% CI, 13.0%-28.8%), and physical inactivity (PAF, 20.1%; 95% CI, 9.1%-29.6%). These factors were also highest within each racial and ethnic group, although the proportions varied.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">A large fraction of dementia cases in the US were associated with potentially modifiable risk factors, especially for Black and Hispanic individuals. Targeting and reducing these risk factors may curb the projected rise in dementia cases over the next several decades.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Sociology, University of Minnesota, Minneapolis.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Minnesota Population Center, University of Minnesota, Minneapolis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Whitsel</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, School of Medicine, University of North Carolina at Chapel Hill.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Avery</LastName><ForeName>Christy</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hughes</LastName><ForeName>Timothy M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Alzheimer's Disease Research Center, Wake Forest School of Medicine, Winston-Salem, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Griswold</LastName><ForeName>Michael E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>School of Medicine, University of Mississippi Medical Center, Jackson.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sedaghat</LastName><ForeName>Sanaz</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Epidemiology and Community Health, University of Minnesota School of Public Health, Minneapolis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gottesman</LastName><ForeName>Rebecca F</ForeName><Initials>RF</Initials><AffiliationInfo><Affiliation>National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mosley</LastName><ForeName>Thomas H</ForeName><Initials>TH</Initials><AffiliationInfo><Affiliation>School of Medicine, University of Mississippi Medical Center, Jackson.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heiss</LastName><ForeName>Gerardo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lutsey</LastName><ForeName>Pamela L</ForeName><Initials>PL</Initials><AffiliationInfo><Affiliation>Division of Epidemiology and Community Health, University of Minnesota School of Public Health, Minneapolis.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P2C HD041023</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P2C HD050924</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG072947</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Netw Open</MedlineTA><NlmUniqueID>101729235</NlmUniqueID><ISSNLinking>2574-3805</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="Y">Dementia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005006" MajorTopicYN="N">Ethnicity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="Y">Hypertension</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009765" MajorTopicYN="N">Obesity</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Hughes reported receiving grants funding from the National Institutes of Health (NIH) during the conduct of the study. Dr Griswold reported receiving grants from the NIH during the conduct of the study. Dr Gottesman reported receiving research support from the National Institute of Neurological Disorders and Stroke Intramural Research Program; she reported previous service as an associate editor with the American Academy of Neurology and <i>Neurology</i> outside the submitted work. Dr Mosley reported receiving grants from NIH during the conduct of the study. Dr Lutsey reported grants from NIH during the conduct of the study and grants from NIH outside the submitted work. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>6</Day><Hour>11</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>7</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35793088</ArticleId><ArticleId IdType="pmc">PMC9260480</ArticleId><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.19672</ArticleId><ArticleId IdType="pii">2793916</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hebert LE, Weuve J, Scherr PA, Evans DA. Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. Neurology. 2013;80(19):1778-1783. doi:10.1212/WNL.0b013e31828726f5</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e31828726f5</ArticleId><ArticleId IdType="pmc">PMC3719424</ArticleId><ArticleId IdType="pubmed">23390181</ArticleId></ArticleIdList></Reference><Reference><Citation>US Department of Health and Human Services . National Plan to Address Alzheimer&#x2019;s Disease: 2019 Update. U.S. Department of Health and Human Services; 2019:117.</Citation></Reference><Reference><Citation>Livingston G, Huntley J, Sommerlad A, et al. . Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020;396(10248):413-446. doi:10.1016/S0140-6736(20)30367-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30367-6</ArticleId><ArticleId IdType="pmc">PMC7392084</ArticleId><ArticleId IdType="pubmed">32738937</ArticleId></ArticleIdList></Reference><Reference><Citation>Livingston G, Sommerlad A, Orgeta V, et al. . Dementia prevention, intervention, and care. Lancet. 2017;390(10113):2673-2734. doi:10.1016/S0140-6736(17)31363-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)31363-6</ArticleId><ArticleId IdType="pubmed">28735855</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer&#x2019;s disease prevalence. Lancet Neurol. 2011;10(9):819-828. doi:10.1016/S1474-4422(11)70072-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(11)70072-2</ArticleId><ArticleId IdType="pmc">PMC3647614</ArticleId><ArticleId IdType="pubmed">21775213</ArticleId></ArticleIdList></Reference><Reference><Citation>Norton S, Matthews FE, Barnes DE, Yaffe K, Brayne C. Potential for primary prevention of Alzheimer&#x2019;s disease: an analysis of population-based data. Lancet Neurol. 2014;13(8):788-794. doi:10.1016/S1474-4422(14)70136-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(14)70136-X</ArticleId><ArticleId IdType="pubmed">25030513</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukadam N, Sommerlad A, Huntley J, Livingston G. Population attributable fractions for risk factors for dementia in low-income and middle-income countries: an analysis using cross-sectional survey data. Lancet Glob Health. 2019;7(5):e596-e603. doi:10.1016/S2214-109X(19)30074-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2214-109X(19)30074-9</ArticleId><ArticleId IdType="pmc">PMC7617123</ArticleId><ArticleId IdType="pubmed">31000129</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinberger AH, Gbedemah M, Martinez AM, Nash D, Galea S, Goodwin RD. Trends in depression prevalence in the USA from 2005 to 2015: widening disparities in vulnerable groups. Psychol Med. 2018;48(8):1308-1315. doi:10.1017/S0033291717002781</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0033291717002781</ArticleId><ArticleId IdType="pubmed">29021005</ArticleId></ArticleIdList></Reference><Reference><Citation>Babb S, Malarcher A, Schauer G, Asman K, Jamal A. Quitting smoking among adults&#x2014;United States, 2000-2015. MMWR Morb Mortal Wkly Rep. 2017;65(52):1457-1464. doi:10.15585/mmwr.mm6552a1</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6552a1</ArticleId><ArticleId IdType="pubmed">28056007</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Li X, Wang Z, et al. . Trends in prevalence of diabetes and control of risk factors in diabetes among US adults, 1999-2018. JAMA. 2021;326(8):704-716. doi:10.1001/jama.2021.9883</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.9883</ArticleId><ArticleId IdType="pmc">PMC8233946</ArticleId><ArticleId IdType="pubmed">34170288</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogden CL, Fryar CD, Martin CB, et al. . Trends in obesity prevalence by race and Hispanic origin&#x2014;1999-2000 to 2017-2018. JAMA. 2020;324(12):1208-1210. doi:10.1001/jama.2020.14590</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.14590</ArticleId><ArticleId IdType="pmc">PMC7455882</ArticleId><ArticleId IdType="pubmed">32857101</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma&#x2019;u E, Cullum S, Cheung G, Livingston G, Mukadam N. Differences in the potential for dementia prevention between major ethnic groups within one country: a cross sectional analysis of population attributable fraction of potentially modifiable risk factors in New Zealand. Lancet Reg Health West Pac. 2021;13:100191. doi:10.1016/j.lanwpc.2021.100191</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanwpc.2021.100191</ArticleId><ArticleId IdType="pmc">PMC8358157</ArticleId><ArticleId IdType="pubmed">34527984</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayeda ER, Glymour MM, Quesenberry CP, Whitmer RA. Inequalities in dementia incidence between six racial and ethnic groups over 14 years. Alzheimers Dement. 2016;12(3):216-224. doi:10.1016/j.jalz.2015.12.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2015.12.007</ArticleId><ArticleId IdType="pmc">PMC4969071</ArticleId><ArticleId IdType="pubmed">26874595</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes LL, Bennett DA. Alzheimer&#x2019;s disease in African Americans: risk factors and challenges for the future. Health Aff (Millwood). 2014;33(4):580-586. doi:10.1377/hlthaff.2013.1353</Citation><ArticleIdList><ArticleId IdType="doi">10.1377/hlthaff.2013.1353</ArticleId><ArticleId IdType="pmc">PMC4084964</ArticleId><ArticleId IdType="pubmed">24711318</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer&#x2019;s Association . 2021 Alzheimer&#x2019;s disease facts and figures. Alzheimers Dement. 2021;17(3):327-406. doi:10.1002/alz.12328</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.12328</ArticleId><ArticleId IdType="pubmed">33756057</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H, Kwong JC, Copes R, et al. . Exposure to ambient air pollution and the incidence of dementia: a population-based cohort study. Environ Int. 2017;108:271-277. doi:10.1016/j.envint.2017.08.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.envint.2017.08.020</ArticleId><ArticleId IdType="pubmed">28917207</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruggles S, Flood S, Goeken R, Pacas J, Schouweiler M, Sobek M. IPUMS USA: Version 11.0 [data set]. Last updated May 25, 2022. Accessed February 23, 2022. 10.18128/D010.V11.0</Citation><ArticleIdList><ArticleId IdType="doi">10.18128/D010.V11.0</ArticleId></ArticleIdList></Reference><Reference><Citation>US Centers for Disease Control and Prevention, National Center for Health Statistics . National Health and Nutrition Examination Survey Data. US Department of Health and Human Services, Centers for Disease Control and Prevention; 2018.</Citation></Reference><Reference><Citation>Blewett LA, Rivera Drew JA, King ML, Williams KCW. IPUMS Health Surveys: National Health Interview Survey, Version 6.4 [data set]. Last updated May 10, 2022. Accessed February 23, 2022. 10.18128/D070.V6.4</Citation><ArticleIdList><ArticleId IdType="doi">10.18128/D070.V6.4</ArticleId></ArticleIdList></Reference><Reference><Citation>Waite LJ, Cagney K, Dale W, et al. . National Social Life, Health and Aging Project (NSHAP): Wave 3. Inter-University Consortium for Political and Social Research . Published October 25, 2017. Accessed February 23, 2022. 10.3886/ICPSR36873.v1</Citation><ArticleIdList><ArticleId IdType="doi">10.3886/ICPSR36873.v1</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SY, Bechle M, Hankey S, Sheppard L, Szpiro AA, Marshall JD. Concentrations of criteria pollutants in the contiguous US, 1979&#x2013;2015: role of prediction model parsimony in integrated empirical geographic regression. PLoS One. 2020;15(2):e0228535. doi:10.1371/journal.pone.0228535</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0228535</ArticleId><ArticleId IdType="pmc">PMC7028280</ArticleId><ArticleId IdType="pubmed">32069301</ArticleId></ArticleIdList></Reference><Reference><Citation>Manson S, Schroeder J, Van Riper D, Kugler T, Ruggles S. IPUMS National Historical Geographic Information System: Version 16.0 [data set]. Published 2021. Accessed February 23, 2022. 10.18128/D050.V16.0</Citation><ArticleIdList><ArticleId IdType="doi">10.18128/D050.V16.0</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett-Connor E, Edelstein SL, Corey-Bloom J, Wiederholt WC. Weight loss precedes dementia in community-dwelling older adults. J Am Geriatr Soc. 1996;44(10):1147-1152. doi:10.1111/j.1532-5415.1996.tb01362.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1532-5415.1996.tb01362.x</ArticleId><ArticleId IdType="pubmed">8855991</ArticleId></ArticleIdList></Reference><Reference><Citation>Levin ML. The occurrence of lung cancer in man. Acta Unio Int Contra Cancrum. 1953;9(3):531-541.</Citation><ArticleIdList><ArticleId IdType="pubmed">13124110</ArticleId></ArticleIdList></Reference><Reference><Citation>National Alzheimer&#x2019;s Project Act Advisory Council . Public Members of the Advisory Council on Alzheimer&#x2019;s Research, Care and Services: 2021 Recommendations. Published December 2021. Accessed May 5, 2022. https://aspe.hhs.gov/sites/default/files/documents/18454de4f0f9ef42dacef6ef167b1933/napa-2021-public-member-recommendations.pdf</Citation></Reference><Reference><Citation>Barendregt JJ, Veerman JL. Categorical versus continuous risk factors and the calculation of potential impact fractions. J Epidemiol Community Health. 2010;64(3):209-212. doi:10.1136/jech.2009.090274</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jech.2009.090274</ArticleId><ArticleId IdType="pubmed">19692711</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthews KA, Xu W, Gaglioti AH, et al. . Racial and ethnic estimates of Alzheimer&#x2019;s disease and related dementias in the United States (2015-2060) in adults aged &#x2265;65 years. Alzheimers Dement. 2019;15(1):17-24. doi:10.1016/j.jalz.2018.06.3063</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.06.3063</ArticleId><ArticleId IdType="pmc">PMC6333531</ArticleId><ArticleId IdType="pubmed">30243772</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenberg A, Ngandu T, Rusanen M, et al. . Multidomain lifestyle intervention benefits a large elderly population at risk for cognitive decline and dementia regardless of baseline characteristics: the FINGER trial. Alzheimers Dement. 2018;14(3):263-270. doi:10.1016/j.jalz.2017.09.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2017.09.006</ArticleId><ArticleId IdType="pubmed">29055814</ArticleId></ArticleIdList></Reference><Reference><Citation>Kivipelto M, Mangialasche F, Ngandu T. Lifestyle interventions to prevent cognitive impairment, dementia and Alzheimer disease. Nat Rev Neurol. 2018;14(11):653-666. doi:10.1038/s41582-018-0070-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-018-0070-3</ArticleId><ArticleId IdType="pubmed">30291317</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen TT, Tchetgen Tchetgen EJ, Kawachi I, et al. . Instrumental variable approaches to identifying the causal effect of educational attainment on dementia risk. Ann Epidemiol. 2016;26(1):71-76.e3. doi:10.1016/j.annepidem.2015.10.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.annepidem.2015.10.006</ArticleId><ArticleId IdType="pmc">PMC4688127</ArticleId><ArticleId IdType="pubmed">26633592</ArticleId></ArticleIdList></Reference><Reference><Citation>Benichou J. A review of adjusted estimators of attributable risk. Stat Methods Med Res. 2001;10(3):195-216. doi:10.1177/096228020101000303</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/096228020101000303</ArticleId><ArticleId IdType="pubmed">11446148</ArticleId></ArticleIdList></Reference><Reference><Citation>Darrow LA, Steenland NK. Confounding and bias in the attributable fraction. Epidemiology. 2011;22(1):53-58. doi:10.1097/EDE.0b013e3181fce49b</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/EDE.0b013e3181fce49b</ArticleId><ArticleId IdType="pubmed">20975564</ArticleId></ArticleIdList></Reference><Reference><Citation>R&#xfc;ckinger S, von Kries R, Toschke AM. An illustration of and programs estimating attributable fractions in large scale surveys considering multiple risk factors. BMC Med Res Methodol. 2009;9:7. doi:10.1186/1471-2288-9-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2288-9-7</ArticleId><ArticleId IdType="pmc">PMC2636839</ArticleId><ArticleId IdType="pubmed">19166593</ArticleId></ArticleIdList></Reference><Reference><Citation>Alonso A, Mosley TH Jr, Gottesman RF, Catellier D, Sharrett AR, Coresh J. Risk of dementia hospitalisation associated with cardiovascular risk factors in midlife and older age: the Atherosclerosis Risk in Communities (ARIC) study. J Neurol Neurosurg Psychiatry. 2009;80(11):1194-1201. doi:10.1136/jnnp.2009.176818</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2009.176818</ArticleId><ArticleId IdType="pmc">PMC2783764</ArticleId><ArticleId IdType="pubmed">19692426</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">35794106</PMID><DateCompleted><Year>2022</Year><Month>07</Month><Day>08</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>01</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Jul</Month><Day>06</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>Periarteriolar spaces modulate cerebrospinal fluid transport into brain and demonstrate altered morphology in aging and Alzheimer's disease.</ArticleTitle><Pagination><StartPage>3897</StartPage><MedlinePgn>3897</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">3897</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-022-31257-9</ELocationID><Abstract><AbstractText>Perivascular spaces (PVS) drain brain waste metabolites, but their specific flow paths are debated. Meningeal pia mater reportedly forms the outermost boundary that confines flow around blood vessels. Yet, we show that pia is perforated and permissive to PVS fluid flow. Furthermore, we demonstrate that pia is comprised of vascular and cerebral layers that coalesce in variable patterns along leptomeningeal arteries, often merging around penetrating arterioles. Heterogeneous pial architectures form variable sieve-like structures that differentially influence cerebrospinal fluid (CSF) transport along PVS. The degree of pial coverage correlates with macrophage density and phagocytosis of CSF tracer. In vivo imaging confirms transpial influx of CSF tracer, suggesting a role of pia in CSF filtration, but not flow restriction. Additionally, pial layers atrophy with age. Old mice also exhibit areas of pial denudation that are not observed in young animals, but pia is unexpectedly hypertrophied in a mouse model of Alzheimer's disease. Moreover, pial thickness correlates with improved CSF flow and reduced &#x3b2;-amyloid deposits in PVS of old mice. We show that PVS morphology in mice is variable and that the structure and function of pia suggests a previously unrecognized role in regulating CSF transport and amyloid clearance in aging and disease.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mestre</LastName><ForeName>Humberto</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-5876-5397</Identifier><AffiliationInfo><Affiliation>Center for Translational Neuromedicine, University of Rochester Medical Center, Rochester, NY, 14642, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, University of Rochester Medical Center, Rochester, NY, 14642, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of Pennsylvania, Philadelphia, PA, 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verma</LastName><ForeName>Natasha</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Center for Translational Neuromedicine, University of Rochester Medical Center, Rochester, NY, 14642, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greene</LastName><ForeName>Thom D</ForeName><Initials>TD</Initials><AffiliationInfo><Affiliation>Center for Translational Neuromedicine, University of Rochester Medical Center, Rochester, NY, 14642, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>LiJing A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Center for Translational Neuromedicine, University of Rochester Medical Center, Rochester, NY, 14642, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ladron-de-Guevara</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-1093-2509</Identifier><AffiliationInfo><Affiliation>Center for Translational Neuromedicine, University of Rochester Medical Center, Rochester, NY, 14642, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sweeney</LastName><ForeName>Amanda M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Center for Translational Neuromedicine, University of Rochester Medical Center, Rochester, NY, 14642, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Guojun</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Center for Translational Neuromedicine, University of Rochester Medical Center, Rochester, NY, 14642, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thomas</LastName><ForeName>V Kaye</ForeName><Initials>VK</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Physiology, University of Rochester Medical Center, Rochester, NY, 14642, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galloway</LastName><ForeName>Chad A</ForeName><Initials>CA</Initials><Identifier Source="ORCID">0000-0002-1978-7339</Identifier><AffiliationInfo><Affiliation>Department of Pathology, University of Rochester Medical Center, Rochester, NY, 14642, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Mesy Bentley</LastName><ForeName>Karen L</ForeName><Initials>KL</Initials><Identifier Source="ORCID">0000-0003-0176-1111</Identifier><AffiliationInfo><Affiliation>Department of Pathology, University of Rochester Medical Center, Rochester, NY, 14642, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nedergaard</LastName><ForeName>Maiken</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-6502-6031</Identifier><AffiliationInfo><Affiliation>Center for Translational Neuromedicine, University of Rochester Medical Center, Rochester, NY, 14642, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Translational Neuromedicine, Faculty of Health and Medical Sciences, University of Copenhagen, 2200, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mehta</LastName><ForeName>Rupal I</ForeName><Initials>RI</Initials><Identifier Source="ORCID">0000-0003-4917-6907</Identifier><AffiliationInfo><Affiliation>Center for Translational Neuromedicine, University of Rochester Medical Center, Rochester, NY, 14642, USA. rupal_mehta@rush.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, Rush University Medical Center, Chicago, IL, 60612, USA. rupal_mehta@rush.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, 60612, USA. rupal_mehta@rush.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>RF1 AG057575</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 OD023440</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS100366</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 NS110049</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 NS089830</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077502" MajorTopicYN="Y">Glymphatic System</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>7</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>6</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>6</Day><Hour>23</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>7</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35794106</ArticleId><ArticleId IdType="pmc">PMC9259669</ArticleId><ArticleId IdType="doi">10.1038/s41467-022-31257-9</ArticleId><ArticleId IdType="pii">10.1038/s41467-022-31257-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Fame RM, Lehtinen MK. Emergence and developmental roles of the cerebrospinal fluid system. Dev. Cell. 2020;52:261&#x2013;275. doi: 10.1016/j.devcel.2020.01.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.devcel.2020.01.027</ArticleId><ArticleId IdType="pubmed">32049038</ArticleId></ArticleIdList></Reference><Reference><Citation>Mestre H, et al. Cerebrospinal fluid influx drives acute ischemic tissue swelling. Science. 2020;367:eaax7171. doi: 10.1126/science.aax7171.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aax7171</ArticleId><ArticleId IdType="pmc">PMC7375109</ArticleId><ArticleId IdType="pubmed">32001524</ArticleId></ArticleIdList></Reference><Reference><Citation>Rennels ML, Gregory TF, Blaumanis OR, Fujimoto K, Grady PA. Evidence for a 'paravascular' fluid circulation in the mammalian central nervous system, provided by the rapid distribution of tracer protein throughout the brain from the subarachnoid space. Brain Res. 1985;326:47&#x2013;63. doi: 10.1016/0006-8993(85)91383-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0006-8993(85)91383-6</ArticleId><ArticleId IdType="pubmed">3971148</ArticleId></ArticleIdList></Reference><Reference><Citation>Mestre H, Kostrikov S, Mehta RI, Nedergaard M. Perivascular spaces, glymphatic dysfunction, and small vessel disease. Clin. Sci. 2017;131:2257&#x2013;2274. doi: 10.1042/CS20160381.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/CS20160381</ArticleId><ArticleId IdType="pmc">PMC5567781</ArticleId><ArticleId IdType="pubmed">28798076</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng W, et al. Suppression of glymphatic fluid transport in a mouse model of Alzheimer's disease. Neurobiol. Dis. 2016;93:215&#x2013;225. doi: 10.1016/j.nbd.2016.05.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2016.05.015</ArticleId><ArticleId IdType="pmc">PMC4980916</ArticleId><ArticleId IdType="pubmed">27234656</ArticleId></ArticleIdList></Reference><Reference><Citation>Woollam DH, Millen JW. The perivascular spaces of the mammalian central nervous system and their relation to the perineuronal and subarachnoid spaces. J. Anat. 1955;89:193&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1244781</ArticleId><ArticleId IdType="pubmed">14367214</ArticleId></ArticleIdList></Reference><Reference><Citation>Robin C. Recherches sur quelques particularites de lastructure des capillaires de l&#x2019;encephale. J. Physiol. Homme Animaux. 1859;2:537&#x2013;548.</Citation></Reference><Reference><Citation>Virchow R. Ueber die Erweiterung kleinerer Gefaesse. Arch. Pathol. Anat. Physiol. Klin. Med. 1851;3:427&#x2013;4622. doi: 10.1007/BF01960918.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF01960918</ArticleId></ArticleIdList></Reference><Reference><Citation>Adeeb N, et al. The pia mater: a comprehensive review of literature. Childs Nerv. Syst. 2013;29:1803&#x2013;1810. doi: 10.1007/s00381-013-2044-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00381-013-2044-5</ArticleId><ArticleId IdType="pubmed">23381008</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcolado R, Weller RO, Parrish EP, Garrod D. The cranial arachnoid and pia mater in man: anatomical and ultrastructural observations. Neuropathol. Appl. Neurobiol. 1988;14:1&#x2013;17. doi: 10.1111/j.1365-2990.1988.tb00862.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2990.1988.tb00862.x</ArticleId><ArticleId IdType="pubmed">3374751</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbott NJ, Pizzo ME, Preston JE, Janigro D, Thorne RG. The role of brain barriers in fluid movement in the CNS: is there a 'glymphatic' system? Acta Neuropathol. 2018;135:387&#x2013;407. doi: 10.1007/s00401-018-1812-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-1812-4</ArticleId><ArticleId IdType="pubmed">29428972</ArticleId></ArticleIdList></Reference><Reference><Citation>Pizzo ME, et al. Intrathecal antibody distribution in the rat brain: surface diffusion, perivascular transport and osmotic enhancement of delivery. J. Physiol. 2018;596:445&#x2013;475. doi: 10.1113/JP275105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/JP275105</ArticleId><ArticleId IdType="pmc">PMC5792566</ArticleId><ArticleId IdType="pubmed">29023798</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang ET, Inman CB, Weller RO. Interrelationships of the pia mater and the perivascular (Virchow&#x2013;Robin) spaces in the human cerebrum. J. Anat. 1990;170:111&#x2013;123.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1257067</ArticleId><ArticleId IdType="pubmed">2254158</ArticleId></ArticleIdList></Reference><Reference><Citation>Albargothy NJ, et al. Convective influx/glymphatic system: tracers injected into the CSF enter and leave the brain along separate periarterial basement membrane pathways. Acta Neuropathol. 2018;136:139&#x2013;152. doi: 10.1007/s00401-018-1862-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-1862-7</ArticleId><ArticleId IdType="pmc">PMC6015107</ArticleId><ArticleId IdType="pubmed">29754206</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris AW, et al. Vascular basement membranes as pathways for the passage of fluid into and out of the brain. Acta Neuropathol. 2016;131:725&#x2013;736. doi: 10.1007/s00401-016-1555-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-016-1555-z</ArticleId><ArticleId IdType="pmc">PMC4835509</ArticleId><ArticleId IdType="pubmed">26975356</ArticleId></ArticleIdList></Reference><Reference><Citation>Iliff JJ, et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid &#x3b2;. Sci. Transl. Med. 2012;4:147ra11. doi: 10.1126/scitranslmed.3003748.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3003748</ArticleId><ArticleId IdType="pmc">PMC3551275</ArticleId><ArticleId IdType="pubmed">22896675</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakker EN, et al. Lymphatic clearance of the brain: perivascular, paravascular and significance for neurodegenerative diseases. Cell. Mol. Neurobiol. 2016;36:181&#x2013;194. doi: 10.1007/s10571-015-0273-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10571-015-0273-8</ArticleId><ArticleId IdType="pmc">PMC4844641</ArticleId><ArticleId IdType="pubmed">26993512</ArticleId></ArticleIdList></Reference><Reference><Citation>Wardlaw JM, et al. Perivascular spaces in the brain: Anatomy, physiology and pathology. Nat. Rev. Neurol. 2020;16:137&#x2013;153. doi: 10.1038/s41582-020-0312-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-020-0312-z</ArticleId><ArticleId IdType="pubmed">32094487</ArticleId></ArticleIdList></Reference><Reference><Citation>Hannocks MJ, et al. Molecular characterization of perivascular drainage pathways in the murine brain. J. Cereb. Blood Flow. Metab. 2018;38:669&#x2013;686. doi: 10.1177/0271678X17749689.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0271678X17749689</ArticleId><ArticleId IdType="pmc">PMC5888861</ArticleId><ArticleId IdType="pubmed">29283289</ArticleId></ArticleIdList></Reference><Reference><Citation>Lie AA, et al. Plectin in the human central nervous system: predominant expression at pia/glia and endothelia/glia interfaces. Acta Neuropathol. 1998;96:215&#x2013;221. doi: 10.1007/s004010050885.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s004010050885</ArticleId><ArticleId IdType="pubmed">9754951</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaldjian EP, Gretz JE, Anderson AO, Shi Y, Shaw S. Spatial and molecular organization of lymph node T cell cortex: a labyrinthine cavity bounded by an epithelium-like monolayer of fibroblastic reticular cells anchored to basement membrane-like extracellular matrix. Int. Immunol. 2001;13:1243&#x2013;1253. doi: 10.1093/intimm/13.10.1243.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/intimm/13.10.1243</ArticleId><ArticleId IdType="pubmed">11581169</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollock H, Hutchings M, Weller RO, Zhang ET. Perivascular spaces in the basal ganglia of the human brain: their relationship to lacunes. J. Anat. 1997;191:337&#x2013;346. doi: 10.1046/j.1469-7580.1997.19130337.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1469-7580.1997.19130337.x</ArticleId><ArticleId IdType="pmc">PMC1467691</ArticleId><ArticleId IdType="pubmed">9418990</ArticleId></ArticleIdList></Reference><Reference><Citation>Mestre H, et al. Flow of cerebrospinal fluid is driven by arterial pulsations and is reduced in hypertension. Nat. Commun. 2018;9:4878. doi: 10.1038/s41467-018-07318-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-07318-3</ArticleId><ArticleId IdType="pmc">PMC6242982</ArticleId><ArticleId IdType="pubmed">30451853</ArticleId></ArticleIdList></Reference><Reference><Citation>Brinker T, Stopa E, Morrison J, Klinge P. A new look at cerebrospinal fluid circulation. Fluids Barriers CNS. 2014;11:10. doi: 10.1186/2045-8118-11-10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/2045-8118-11-10</ArticleId><ArticleId IdType="pmc">PMC4016637</ArticleId><ArticleId IdType="pubmed">24817998</ArticleId></ArticleIdList></Reference><Reference><Citation>Burrell BE, et al. Lymph node stromal fiber ER-TR7 modulates CD4+ T cell lymph node trafficking and transplant tolerance. Transplantation. 2015;99:1119&#x2013;1125. doi: 10.1097/TP.0000000000000664.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TP.0000000000000664</ArticleId><ArticleId IdType="pmc">PMC4452399</ArticleId><ArticleId IdType="pubmed">25769074</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta RI, Schneider JA. What is 'Alzheimer's disease'? The neuropathological heterogeneity of clinically defined Alzheimer's dementia. Curr. Opin. Neurol. 2021;34:237&#x2013;245. doi: 10.1097/WCO.0000000000000912.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000912</ArticleId><ArticleId IdType="pubmed">33591030</ArticleId></ArticleIdList></Reference><Reference><Citation>Prior R, Wihl G, Urmoneit B. Apolipoprotein E, smooth muscle cells and the pathogenesis of cerebral amyloid angiopathy: the potential role of impaired cerebrovascular A beta clearance. Ann. N. Y. Acad. Sci. 2000;903:180&#x2013;186. doi: 10.1111/j.1749-6632.2000.tb06367.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1749-6632.2000.tb06367.x</ArticleId><ArticleId IdType="pubmed">10818506</ArticleId></ArticleIdList></Reference><Reference><Citation>Masuda T, et al. Specification of CNS macrophage subsets occurs postnatally in defined niches. Nature. 2022;604:740&#x2013;748. doi: 10.1038/s41586-022-04596-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04596-2</ArticleId><ArticleId IdType="pubmed">35444273</ArticleId></ArticleIdList></Reference><Reference><Citation>Casley-Smith JR, F&#xf6;ldi-B&#xf6;rs&#xf6;k E, F&#xf6;ldi M. The prelymphatic pathways of the brain as revealed by cervical lymphatic obstruction and the passage of particles. Br. J. Exp. Pathol. 1976;57:179&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2041107</ArticleId><ArticleId IdType="pubmed">773400</ArticleId></ArticleIdList></Reference><Reference><Citation>Cserr HF, Knopf PM. Cervical lymphatics, the blood-brain barrier and the immunoreactivity of the brain: a new view. Immunol. Today. 1992;13:507&#x2013;512. doi: 10.1016/0167-5699(92)90027-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0167-5699(92)90027-5</ArticleId><ArticleId IdType="pubmed">1463583</ArticleId></ArticleIdList></Reference><Reference><Citation>F&#xf6;ldi M, Csillik B, Zolt&#xe1;n OT. Lymphatic drainage of the brain. Experientia. 1968;24:1283&#x2013;1287. doi: 10.1007/BF02146675.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF02146675</ArticleId><ArticleId IdType="pubmed">5703044</ArticleId></ArticleIdList></Reference><Reference><Citation>Hladky SB, Barrand MA. Elimination of substances from the brain parenchyma: efflux via perivascular pathways and via the blood-brain barrier. Fluids Barriers CNS. 2018;15:30. doi: 10.1186/s12987-018-0113-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12987-018-0113-6</ArticleId><ArticleId IdType="pmc">PMC6194691</ArticleId><ArticleId IdType="pubmed">30340614</ArticleId></ArticleIdList></Reference><Reference><Citation>Urmoneit B, et al. Cerebrovascular smooth muscle cells internalize Alzheimer amyloid beta protein via a lipoprotein pathway: Implications for cerebral amyloid angiopathy. Lab. Investig. 1997;77:157&#x2013;166.</Citation><ArticleIdList><ArticleId IdType="pubmed">9274858</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas JH. Fluid dynamics of cerebrospinal fluid flow in perivascular spaces. J. R. Soc. Interface. 2019;16:20190572. doi: 10.1098/rsif.2019.0572.</Citation><ArticleIdList><ArticleId IdType="doi">10.1098/rsif.2019.0572</ArticleId><ArticleId IdType="pmc">PMC6833335</ArticleId><ArticleId IdType="pubmed">31640500</ArticleId></ArticleIdList></Reference><Reference><Citation>Lilius TO, et al. Dexmedetomidine enhances glymphatic brain delivery of intrathecally administered drugs. J. Control Release. 2019;304:29&#x2013;38. doi: 10.1016/j.jconrel.2019.05.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2019.05.005</ArticleId><ArticleId IdType="pubmed">31067483</ArticleId></ArticleIdList></Reference><Reference><Citation>Vliet EV, Melis M, Foidart JM, Ewijk WF. Reticular fibroblasts in peripheral lymphoid organs identified by a monoclonal antibody. J. Histochem. Cytochem. 1986;34:883&#x2013;890. doi: 10.1177/34.7.3519751.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/34.7.3519751</ArticleId><ArticleId IdType="pubmed">3519751</ArticleId></ArticleIdList></Reference><Reference><Citation>Xavier ALR, Hauglund NL, von Holstein-Rathlou S, et al. Cannula implantation into the cisterna magna of rodents. J. Vis. Exp. 2018;135:57378.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6101354</ArticleId><ArticleId IdType="pubmed">29889209</ArticleId></ArticleIdList></Reference><Reference><Citation>Park YG, et al. Protection of tissue physicochemical properties using polyfunctional crosslinkers. Nat. Biotechnol. 2019;37:73. doi: 10.1038/nbt.4281.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.4281</ArticleId><ArticleId IdType="pmc">PMC6579717</ArticleId><ArticleId IdType="pubmed">30556815</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SY, et al. Stochastic electrotransport selectively enhances the transport of highly electromobile molecules. Proc. Natl Acad. Sci. USA. 2015;112:E6274&#x2013;E6283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4655572</ArticleId><ArticleId IdType="pubmed">26578787</ArticleId></ArticleIdList></Reference><Reference><Citation>Yun, D. H. et al. Ultrafast immunostaining of organ-scale tissues for scalable proteomic phenotyping. Preprint at bioRxiv10.1101/660373 (2019).</Citation></Reference><Reference><Citation>Murray E, et al. Simple, scalable proteomic imaging for high-dimensional profiling of intact systems. Cell. 2015;163:1500&#x2013;1514. doi: 10.1016/j.cell.2015.11.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2015.11.025</ArticleId><ArticleId IdType="pmc">PMC5275966</ArticleId><ArticleId IdType="pubmed">26638076</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">35857446</PMID><DateCompleted><Year>2022</Year><Month>07</Month><Day>22</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2375-2548</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>27</Issue><PubDate><Year>2022</Year><Month>Jul</Month><Day>08</Day></PubDate></JournalIssue><Title>Science advances</Title><ISOAbbreviation>Sci Adv</ISOAbbreviation></Journal><ArticleTitle>Alzheimer's disease: Ablating single master site abolishes tau hyperphosphorylation.</ArticleTitle><Pagination><StartPage>eabl8809</StartPage><MedlinePgn>eabl8809</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">eabl8809</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1126/sciadv.abl8809</ELocationID><Abstract><AbstractText>Hyperphosphorylation of the neuronal tau protein is a hallmark of neurodegenerative tauopathies such as Alzheimer's disease. A central unanswered question is why tau becomes progressively hyperphosphorylated. Here, we show that tau phosphorylation is governed by interdependence- a mechanistic link between initial site-specific and subsequent multi-site phosphorylation. Systematic assessment of site interdependence identified distinct residues (threonine-50, threonine-69, and threonine-181) as master sites that determine propagation of phosphorylation at multiple epitopes. CRISPR point mutation and expression of human tau in Alzheimer's mice showed that site interdependence governs physiologic and amyloid-associated multi-site phosphorylation and cognitive deficits, respectively. Combined targeting of master sites and p38&#x3b1;, the most central tau kinase linked to interdependence, synergistically ablated hyperphosphorylation. In summary, our work delineates how complex tau phosphorylation arises to inform therapeutic and biomarker design for tauopathies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Stefanoska</LastName><ForeName>Kristie</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-9322-9936</Identifier><AffiliationInfo><Affiliation>Flinders Health and Medical Research Institute, College of Medicine and Public Health, Flinders University, Adelaide, SA, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gajwani</LastName><ForeName>Mehul</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-7195-6822</Identifier><AffiliationInfo><Affiliation>Dementia Research Centre, Faculty of Health, Human and Medical Sciences, Macquarie University, Sydney, NSW, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Monash Biomedical Imaging, Monash University, Clayton,Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Amanda R P</ForeName><Initials>ARP</Initials><Identifier Source="ORCID">0000-0003-1654-5737</Identifier><AffiliationInfo><Affiliation>Flinders Health and Medical Research Institute, College of Medicine and Public Health, Flinders University, Adelaide, SA, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahel</LastName><ForeName>Holly I</ForeName><Initials>HI</Initials><Identifier Source="ORCID">0000-0001-7072-1231</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Faculty of Health, Human and Medical Sciences, Macquarie University, Sydney, NSW, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Life and Environmental Science, Faculty of Science, University of Sydney, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Asih</LastName><ForeName>Prita R</ForeName><Initials>PR</Initials><Identifier Source="ORCID">0000-0002-1973-9628</Identifier><AffiliationInfo><Affiliation>Flinders Health and Medical Research Institute, College of Medicine and Public Health, Flinders University, Adelaide, SA, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Volkerling</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Flinders Health and Medical Research Institute, College of Medicine and Public Health, Flinders University, Adelaide, SA, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poljak</LastName><ForeName>Anne</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-9953-1984</Identifier><AffiliationInfo><Affiliation>Bioanalytical Mass Spectrometry Facility, Mark Wainwright Analytical Centre, University of New South Wales, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ittner</LastName><ForeName>Arne</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-5244-6897</Identifier><AffiliationInfo><Affiliation>Flinders Health and Medical Research Institute, College of Medicine and Public Health, Flinders University, Adelaide, SA, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Adv</MedlineTA><NlmUniqueID>101653440</NlmUniqueID><ISSNLinking>2375-2548</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>2ZD004190S</RegistryNumber><NameOfSubstance UI="D013912">Threonine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="Y">Tauopathies</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013912" MajorTopicYN="N">Threonine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>20</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>7</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35857446</ArticleId><ArticleId IdType="pmc">PMC9258953</ArticleId><ArticleId IdType="doi">10.1126/sciadv.abl8809</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Scheltens P., Blennow K., Breteler M. M. B., de Strooper B., Frisoni G. B., Salloway S., van der Flier W. M., Alzheimer&#x2019;s disease. Lancet 388, 505&#x2013;517 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26921134</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe D. J., Hardy J., The amyloid hypothesis of Alzheimer&#x2019;s disease at 25 years. EMBO Mol. Med. 8, 595&#x2013;608 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4888851</ArticleId><ArticleId IdType="pubmed">27025652</ArticleId></ArticleIdList></Reference><Reference><Citation>Busche M. A., Hyman B. T., Synergy between amyloid-&#x3b2; and tau in Alzheimer&#x2019;s disease. Nat. Neurosci. 23, 1183&#x2013;1193 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11831977</ArticleId><ArticleId IdType="pubmed">32778792</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang C. W., Shao E., Mucke L., Tau: Enabler of diverse brain disorders and target of rapidly evolving therapeutic strategies. Science 371, (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8118650</ArticleId><ArticleId IdType="pubmed">33632820</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Mandelkow E., Tau in physiology and pathology. Nat. Rev. Neurosci. 17, 5&#x2013;21 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26631930</ArticleId></ArticleIdList></Reference><Reference><Citation>La Joie R., Visani A. V., Baker S. L., Brown J. A., Bourakova V., Cha J., Chaudhary K., Edwards L., Iaccarino L., Janabi M., Lesman-Segev O. H., Miller Z. A., Perry D. C., O&#x2019;Neil J. P., Pham J., Rojas J. C., Rosen H. J., Seeley W. W., Tsai R. M., Miller B. L., Jagust W. J., Rabinovici G. D., Prospective longitudinal atrophy in Alzheimer&#x2019;s disease correlates with the intensity and topography of baseline tau-PET. Sci. Transl. Med. 12, eaau5732 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7035952</ArticleId><ArticleId IdType="pubmed">31894103</ArticleId></ArticleIdList></Reference><Reference><Citation>Noble W., Hanger D. P., Miller C. C., Lovestone S., The importance of tau phosphorylation for neurodegenerative diseases. Front. Neurol. 4, 83 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3696910</ArticleId><ArticleId IdType="pubmed">23847585</ArticleId></ArticleIdList></Reference><Reference><Citation>Ittner A., Ittner L. M., Dendritic tau in Alzheimer&#x2019;s disease. Neuron 99, 13&#x2013;27 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30001506</ArticleId></ArticleIdList></Reference><Reference><Citation>Neddens J., Temmel M., Flunkert S., Kerschbaumer B., Hoeller C., Loeffler T., Niederkofler V., Daum G., Attems J., Hutter-Paier B., Phosphorylation of different tau sites during progression of Alzheimer&#x2019;s disease. Acta Neuropathol. Commun. 6, 52 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6027763</ArticleId><ArticleId IdType="pubmed">29958544</ArticleId></ArticleIdList></Reference><Reference><Citation>Flaherty D. B., Soria J. P., Tomasiewicz H. G., Wood J. G., Phosphorylation of human tau protein by microtubule-associated kinases: GSK3&#x3b2; and cdk5 are key participants. J. Neurosci. Res. 62, 463&#x2013;472 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">11054815</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi H., Prabakaran S., Cantrelle F. X., Chambraud B., Gunawardena J., Lippens G., Landrieu I., Characterization of neuronal tau protein as a target of extracellular signal-regulated kinase. J. Biol. Chem. 291, 7742&#x2013;7753 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4817198</ArticleId><ArticleId IdType="pubmed">26858248</ArticleId></ArticleIdList></Reference><Reference><Citation>Despres C., Byrne C., Qi H., Cantrelle F. X., Huvent I., Chambraud B., Baulieu E. E., Jacquot Y., Landrieu I., Lippens G., Smet-Nocca C., Identification of the Tau phosphorylation pattern that drives its aggregation. Proc. Natl. Acad. Sci. U.S.A. 114, 9080&#x2013;9085 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5576827</ArticleId><ArticleId IdType="pubmed">28784767</ArticleId></ArticleIdList></Reference><Reference><Citation>Ittner A., Asih P. R., Tan A. R. P., Prikas E., Bertz J., Stefanoska K., Lin Y., Volkerling A. M., Ke Y. D., Delerue F., Ittner L. M., Reduction of advanced tau-mediated memory deficits by the MAP kinase p38&#x3b3;. Acta Neuropathol. 140, 279&#x2013;294 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32725265</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., Liu Q., Li X. G., Zhou Q. Z., Wu D. Q., Li S. H., Liu Y. C., Wang J. Z., T217-phosphorylation exacerbates tau pathologies and tau-induced cognitive impairment. J. Alzheimers Dis. 81, 1403&#x2013;1418 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33935099</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris M., Knudsen G. M., Maeda S., Trinidad J. C., Ioanoviciu A., Burlingame A. L., Mucke L., Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice. Nat. Neurosci. 18, 1183&#x2013;1189 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8049446</ArticleId><ArticleId IdType="pubmed">26192747</ArticleId></ArticleIdList></Reference><Reference><Citation>Ittner A., Chua S. W., Bertz J., Volkerling A., van der Hoven J., Gladbach A., Przybyla M., Bi M., van Hummel A., Stevens C. H., Ippati S., Suh L. S., Macmillan A., Sutherland G., Kril J. J., Silva A. P. G., Mackay J. P., Poljak A., Delerue F., Ke Y. D., Ittner L. M., Site-specific phosphorylation of tau inhibits amyloid-&#x3b2; toxicity in Alzheimer&#x2019;s mice. Science 354, 904&#x2013;908 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27856911</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoover B. R., Reed M. N., Su J., Penrod R. D., Kotilinek L. A., Grant M. K., Pitstick R., Carlson G. A., Lanier L. M., Yuan L. L., Ashe K. H., Liao D., Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron 68, 1067&#x2013;1081 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3026458</ArticleId><ArticleId IdType="pubmed">21172610</ArticleId></ArticleIdList></Reference><Reference><Citation>Stepanov A., Karelina T., Markevich N., Demin O., Nicholas T., A mathematical model of multisite phosphorylation of tau protein. PLOS ONE 13, e0192519 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5800643</ArticleId><ArticleId IdType="pubmed">29408874</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomson M., Gunawardena J., Unlimited multistability in multisite phosphorylation systems. Nature 460, 274&#x2013;277 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2859978</ArticleId><ArticleId IdType="pubmed">19536158</ArticleId></ArticleIdList></Reference><Reference><Citation>Guillonneau M., Paris F., Dutoit S., Estephan H., B&#xe9;n&#xe9;teau E., Huot J., Corre I., Oxidative stress disassembles the p38/NPM/PP2A complex, which leads to modulation of nucleophosmin-mediated signaling to DNA damage response. FASEB J. 30, 2899&#x2013;2914 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27142525</ArticleId></ArticleIdList></Reference><Reference><Citation>Leslie S. N., Nairn A. C., cAMP regulation of protein phosphatases PP1 and PP2A in brain. Biochim. Biophys. Acta Mol. Cell Res. 1866, 64&#x2013;73 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6433392</ArticleId><ArticleId IdType="pubmed">30401536</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang D., Kanthasamy A., Yang Y., Anantharam V., Kanthasamy A., Protein kinase C&#x3b4; negatively regulates tyrosine hydroxylase activity and dopamine synthesis by enhancing protein phosphatase-2A activity in dopaminergic neurons. J. Neurosci. 27, 5349&#x2013;5362 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3407040</ArticleId><ArticleId IdType="pubmed">17507557</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K., Hampel H., Weiner M., Zetterberg H., Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat. Rev. Neurol. 6, 131&#x2013;144 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20157306</ArticleId></ArticleIdList></Reference><Reference><Citation>Barthelemy N. R., Li Y., Joseph-Mathurin N., Gordon B. A., Hassenstab J., Benzinger T. L. S., Buckles V., Fagan A. M., Perrin R. J., Goate A. M., Morris J. C., Karch C. M., Xiong C., Allegri R., Mendez P. C., Berman S. B., Ikeuchi T., Mori H., Shimada H., Shoji M., Suzuki K., Noble J., Farlow M., Chhatwal J., Graff-Radford N. R., Salloway S., Schofield P. R., Masters C. L., Martins R. N., O&#x2019;Connor A., Fox N. C., Levin J., Jucker M., Gabelle A., Lehmann S., Sato C., Bateman R. J., Dade E. M.; Dominantly Inherited Alzheimer Network , A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer&#x2019;s disease. Nat. Med. 26, 398&#x2013;407 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7309367</ArticleId><ArticleId IdType="pubmed">32161412</ArticleId></ArticleIdList></Reference><Reference><Citation>Grueninger F., Bohrmann B., Czech C., Ballard T. M., Frey J. R., Weidensteiner C., von Kienlin M., Ozmen L., Phosphorylation of Tau at S422 is enhanced by A&#x3b2; in TauPS2APP triple transgenic mice. Neurobiol. Dis. 37, 294&#x2013;306 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">19781645</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak E., Braak H., Mandelkow E. M., A sequence of cytoskeleton changes related to the formation of neurofibrillary tangles and neuropil threads. Acta Neuropathol. 87, 554&#x2013;567 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">7522386</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M., Jakes R., Vanmechelen E., Monoclonal antibody AT8 recognises tau protein phosphorylated at both serine 202 and threonine 205. Neurosci. Lett. 189, 167&#x2013;170 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">7624036</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinton L. K., Blurton-Jones M., Myczek K., Trojanowski J. Q., LaFerla F. M., Synergistic interactions between A&#x3b2;, tau, and &#x3b1;-synuclein: Acceleration of neuropathology and cognitive decline. J. Neurosci. 30, 7281&#x2013;7289 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3308018</ArticleId><ArticleId IdType="pubmed">20505094</ArticleId></ArticleIdList></Reference><Reference><Citation>Trushina N. I., Bakota L., Mulkidjanian A. Y., Brandt R., The evolution of tau phosphorylation and interactions. Front. Aging Neurosci. 11, 256 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6759874</ArticleId><ArticleId IdType="pubmed">31619983</ArticleId></ArticleIdList></Reference><Reference><Citation>Otth C., Concha I. I., Arendt T., Stieler J., Schliebs R., Gonz&#xe1;lez-Billault C., Maccioni R. B., A&#x3b2;PP induces cdk5-dependent tau hyperphosphorylation in transgenic mice Tg2576. J. Alzheimers Dis. 4, 417&#x2013;430 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12446973</ArticleId></ArticleIdList></Reference><Reference><Citation>Regan P., Piers T., Yi J. H., Kim D. H., Huh S., Park S. J., Ryu J. H., Whitcomb D. J., Cho K., Tau phosphorylation at serine 396 residue is required for hippocampal LTD. J. Neurosci. 35, 4804&#x2013;4812 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4389589</ArticleId><ArticleId IdType="pubmed">25810511</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefanoska K., Volkerling A., Bertz J., Poljak A., Ke Y. D., Ittner L. M., Ittner A., An N-terminal motif unique to primate tau enables differential protein-protein interactions. J. Biol. Chem. 293, 3710&#x2013;3719 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5846163</ArticleId><ArticleId IdType="pubmed">29382714</ArticleId></ArticleIdList></Reference><Reference><Citation>Ittner L. M., Ke Y. D., Delerue F., Bi M., Gladbach A., van Eersel J., W&#xf6;lfing H., Chieng B. C., Christie M. D. J., Napier I. A., Eckert A., Staufenbiel M., Hardeman E., G&#xf6;tz J., Dendritic function of tau mediates amyloid-q toxicity in Alzheimer&#x2019;s disease mouse models. Cell 142, 387&#x2013;397 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20655099</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberson E. D., Scearce-Levie K., Palop J. J., Yan F., Cheng I. H., Wu T., Gerstein H., Yu G. Q., Mucke L., Reducing endogenous tau ameliorates amyloid &#x3b2;-induced deficits in an Alzheimer&#x2019;s disease mouse model. Science 316, 750&#x2013;754 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17478722</ArticleId></ArticleIdList></Reference><Reference><Citation>Asih P. R., Prikas E., Stefanoska K., Tan A. R. P., Ahel H. I., Ittner A., Functions of p38 MAP kinases in the central nervous system. Front. Mol. Neurosci. 13, 570586 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7509416</ArticleId><ArticleId IdType="pubmed">33013322</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefanoska K., Bertz J., Volkerling A. M., van der Hoven J., Ittner L. M., Ittner A., Neuronal MAP kinase p38&#x3b1; inhibits c-Jun N-terminal kinase to modulate anxiety-related behaviour. Sci. Rep. 8, 14296 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6155170</ArticleId><ArticleId IdType="pubmed">30250211</ArticleId></ArticleIdList></Reference><Reference><Citation>Hooper C., Killick R., Lovestone S., The GSK3 hypothesis of Alzheimer&#x2019;s disease. J. Neurochem. 104, 1433&#x2013;1439 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3073119</ArticleId><ArticleId IdType="pubmed">18088381</ArticleId></ArticleIdList></Reference><Reference><Citation>Patrick G. N., Zukerberg L., Nikolic M., de la Monte S., Dikkes P., Tsai L. H., Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 402, 615&#x2013;622 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10604467</ArticleId></ArticleIdList></Reference><Reference><Citation>Seo J., Kritskiy O., Watson L. A., Barker S. J., Dey D., Raja W. K., Lin Y. T., Ko T., Cho S., Penney J., Silva M. C., Sheridan S. D., Lucente D., Gusella J. F., Dickerson B. C., Haggarty S. J., Tsai L. H., Inhibition of p25/Cdk5 attenuates tauopathy in mouse and iPSC models of frontotemporal dementia. J. Neurosci. 37, 9917&#x2013;9924 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5637118</ArticleId><ArticleId IdType="pubmed">28912154</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho J. H., Johnson G. V., Glycogen synthase kinase 3&#x3b2; phosphorylates tau at both primed and unprimed sites: Differential impact on microtubule binding. J. Biol. Chem. 278, 187&#x2013;193 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12409305</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee V. M., Brunden K. R., Hutton M., Trojanowski J. Q., Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targets. Cold Spring Harb. Perspect. Med. 1, a006437 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3234455</ArticleId><ArticleId IdType="pubmed">22229117</ArticleId></ArticleIdList></Reference><Reference><Citation>Domise M., Didier S., Marinangeli C., Zhao H., Chandakkar P., Bu&#xe9;e L., Viollet B., Davies P., Marambaud P., Vingtdeux V., AMP-activated protein kinase modulates tau phosphorylation and tau pathology in vivo. Sci. Rep. 6, 26758 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4882625</ArticleId><ArticleId IdType="pubmed">27230293</ArticleId></ArticleIdList></Reference><Reference><Citation>Hao B., Oehlmann S., Sowa M. E., Harper J. W., Pavletich N. P., Structure of a Fbw7-Skp1-cyclin E complex: Multisite-phosphorylated substrate recognition by SCF ubiquitin ligases. Mol. Cell 26, 131&#x2013;143 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17434132</ArticleId></ArticleIdList></Reference><Reference><Citation>Koivomagi M., Valk E., Venta R., Iofik A., Lepiku M., Balog E. R. M., Rubin S. M., Morgan D. O., Loog M., Cascades of multisite phosphorylation control Sic1 destruction at the onset of S phase. Nature 480, 128&#x2013;131 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3228899</ArticleId><ArticleId IdType="pubmed">21993622</ArticleId></ArticleIdList></Reference><Reference><Citation>Koivomagi M., &#xd6;rd M., Iofik A., Valk E., Venta R., Faustova I., Kivi R., Balog E. R. M., Rubin S. M., Loog M., Multisite phosphorylation networks as signal processors for Cdk1. Nat. Struct. Mol. Biol. 20, 1415&#x2013;1424 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3855452</ArticleId><ArticleId IdType="pubmed">24186061</ArticleId></ArticleIdList></Reference><Reference><Citation>Knight J. D., Tian R., Lee R. E. C., Wang F., Beauvais A., Zou H., Megeney L. A., Gingras A. C., Pawson T., Figeys D., Kothary R., A novel whole-cell lysate kinase assay identifies substrates of the p38 MAPK in differentiating myoblasts. Skelet. Muscle 2, 5 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3350448</ArticleId><ArticleId IdType="pubmed">22394512</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheridan D. L., Kong Y., Parker S. A., Dalby K. N., Turk B. E., Substrate discrimination among mitogen-activated protein kinases through distinct docking sequence motifs. J. Biol. Chem. 283, 19511&#x2013;19520 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2443660</ArticleId><ArticleId IdType="pubmed">18482985</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Y., Li Z., Schwarz E. M., Lin A., Guan K., Ulevitch R. J., Han J., Structure-function studies of p38 mitogen-activated protein kinase: Loop 12 influences substrate specificity and autophosphorylation, but not upstream kinase selection. J. Biol. Chem. 272, 11096&#x2013;11102 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9111004</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuenda A., Cohen P., Buee-Scherrer V., Goedert M., Activation of stress-activated protein kinase-3 (SAPK3) by cytokines and cellular stresses is mediated via SAPKK3 (MKK6); comparison of the specificities of SAPK3 and SAPK2 (RK/p38). EMBO J. 16, 295&#x2013;305 (1997).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1169636</ArticleId><ArticleId IdType="pubmed">9029150</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertrand J., Plouffe V., Senechal P., Leclerc N., The pattern of human tau phosphorylation is the result of priming and feedback events in primary hippocampal neurons. Neuroscience 168, 323&#x2013;334 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20394726</ArticleId></ArticleIdList></Reference><Reference><Citation>Ando K., Leroy K., H&#xe9;raud C., Yilmaz Z., Authelet M., Suain V., de Decker R., Brion J. P., Accelerated human mutant tau aggregation by knocking out murine tau in a transgenic mouse model. Am. J. Pathol. 178, 803&#x2013;816 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3069830</ArticleId><ArticleId IdType="pubmed">21281813</ArticleId></ArticleIdList></Reference><Reference><Citation>Irwin D. J., Lee V. M., Trojanowski J. Q., Parkinson&#x2019;s disease dementia: Convergence of &#x3b1;-synuclein, tau and amyloid-&#x3b2; pathologies. Nat. Rev. Neurosci. 14, 626&#x2013;636 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4017235</ArticleId><ArticleId IdType="pubmed">23900411</ArticleId></ArticleIdList></Reference><Reference><Citation>Ittner A., Block H., Reichel C. A., Varjosalo M., Gehart H., Sumara G., Gstaiger M., Krombach F., Zarbock A., Ricci R., Regulation of PTEN activity by p38&#x3b4;-PKD1 signaling in neutrophils confers inflammatory responses in the lung. J. Exp. Med. 209, 2229&#x2013;2246 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3501357</ArticleId><ArticleId IdType="pubmed">23129748</ArticleId></ArticleIdList></Reference><Reference><Citation>Avitzour M., Diskin R., Raboy B., Askari N., Engelberg D., Livnah O., Intrinsically active variants of all human p38 isoforms. FEBS J. 274, 963&#x2013;975 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17241234</ArticleId></ArticleIdList></Reference><Reference><Citation>Asih P. R., Stefanoska K., Prikas E., Ittner A., High level forebrain expression of active tau kinase p38&#x3b3; exacerbates cognitive dysfunction in aged APP-transgenic Alzheimer&#x2019;s mice. Neuroscience 484, 53&#x2013;65 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35031398</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan K. Y., Jang M. J., Yoo B. B., Greenbaum A., Ravi N., Wu W. L., S&#xe1;nchez-Guardado L., Lois C., Mazmanian S. K., Deverman B. E., Gradinaru V., Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems. Nat. Neurosci. 20, 1172&#x2013;1179 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5529245</ArticleId><ArticleId IdType="pubmed">28671695</ArticleId></ArticleIdList></Reference><Reference><Citation>Aurnhammer C., Haase M., Muether N., Hausl M., Rauschhuber C., Huber I., Nitschko H., Busch U., Sing A., Ehrhardt A., Baiker A., Universal real-time PCR for the detection and quantification of adeno-associated virus serotype 2-derived inverted terminal repeat sequences. Hum. Gene Ther. Methods 23, 18&#x2013;28 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22428977</ArticleId></ArticleIdList></Reference><Reference><Citation>Genovese C. R., Lazar N. A., Nichols T., Thresholding of statistical maps in functional neuroimaging using the false discovery rate. Neuroimage 15, 870&#x2013;878 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">11906227</ArticleId></ArticleIdList></Reference><Reference><Citation>Ignatiadis N., Klaus B., Zaugg J. B., Huber W., Data-driven hypothesis weighting increases detection power in genome-scale multiple testing. Nat. Methods 13, 577&#x2013;580 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4930141</ArticleId><ArticleId IdType="pubmed">27240256</ArticleId></ArticleIdList></Reference><Reference><Citation>Storey J., The positive false discovery rate: A Bayesian interpretation and the q-value. Ann. Stat. 31, 2013&#x2013;2035 (2003).</Citation></Reference><Reference><Citation>Watson J. B., Szijan I., Coulter P. M. II, Localization of RC3 (neurogranin) in rat brain subcellular fractions. Brain Res. Mol. Brain Res. 27, 323&#x2013;328 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">7898318</ArticleId></ArticleIdList></Reference><Reference><Citation>Lundgren D. H., Hwang S. I., Wu L., Han D. K., Role of spectral counting in quantitative proteomics. Expert Rev. Proteomics 7, 39&#x2013;53 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20121475</ArticleId></ArticleIdList></Reference><Reference><Citation>Sumara G., Formentini I., Collins S., Sumara I., Windak R., Bodenmiller B., Ramracheya R., Caille D., Jiang H., Platt K. A., Meda P., Aebersold R., Rorsman P., Ricci R., Regulation of PKD by the MAPK p38&#x3b4; in insulin secretion and glucose homeostasis. Cell 136, 235&#x2013;248 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2638021</ArticleId><ArticleId IdType="pubmed">19135240</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinrichsdorff J., Luedde T., Perdiguero E., Nebreda A. R., Pasparakis M., p38&#x3b1; MAPK inhibits JNK activation and collaborates with I&#x3ba;B kinase 2 to prevent endotoxin-induced liver failure. EMBO Rep. 9, 1048&#x2013;1054 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2572111</ArticleId><ArticleId IdType="pubmed">18704119</ArticleId></ArticleIdList></Reference><Reference><Citation>Ercan E., Eid S., Weber C., Kowalski A., Bichmann M., Behrendt A., Matthes F., Krauss S., Reinhardt P., Fulle S., Ehrnhoefer D. E., A validated antibody panel for the characterization of tau post-translational modifications. Mol. Neurodegener. 12, 87 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5697095</ArticleId><ArticleId IdType="pubmed">29157277</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao L., Liang Y., Liu Y., Xu Y., Wan W., Zhu C., Pseudo-phosphorylation at AT8 epitopes regulates the tau truncation at aspartate 421. Exp. Cell Res. 370, 103&#x2013;115 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29908160</ArticleId></ArticleIdList></Reference><Reference><Citation>Martorell A. J., Paulson A. L., Suk H.-J., Abdurrob F., Drummond G. T., Guan W., Young J. Z., Kim D. N.-W., Kritskiy O., Barker S. J., Mangena V., Prince S. M., Brown E. N., Chung K., Boyden E. S., Singer A. C., Tsai L.-H., Multi-sensory gamma stimulation ameliorates Alzheimer&#x2019;s-associated pathology and improves cognition. Cell 177, 256&#x2013;271.e22 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6774262</ArticleId><ArticleId IdType="pubmed">30879788</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi B., Yang Y., Cheng Y., Sun D., Wang X., Khanna R., Ju W., Nasal delivery of a CRMP2-derived CBD3 adenovirus improves cognitive function and pathology in APP/PS1 transgenic mice. Mol. Brain 13, 58 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7144060</ArticleId><ArticleId IdType="pubmed">32272942</ArticleId></ArticleIdList></Reference><Reference><Citation>Seo J. S., Lee S., Shin J. Y., Hwang Y. J., Cho H., Yoo S. K., Kim Y., Lim S., Kim Y. K., Hwang E. M., Kim S. H., Kim C. H., Hyeon S. J., Yun J. Y., Kim J., Kim Y., Alvarez V. E., Stein T. D., Lee J., Kim D. J., Kim J. I., Kowall N. W., Ryu H., McKee A. C., Transcriptome analyses of chronic traumatic encephalopathy show alterations in protein phosphatase expression associated with tauopathy. Exp. Mol. Med. 49, e333 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5454448</ArticleId><ArticleId IdType="pubmed">28524178</ArticleId></ArticleIdList></Reference><Reference><Citation>Foidl B. M., Humpel C., Differential hyperphosphorylation of Tau-S199, -T231 and -S396 in organotypic brain slices of Alzheimer mice. A model to study early tau hyperphosphorylation using okadaic acid. Front. Aging Neurosci. 10, 113 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5917035</ArticleId><ArticleId IdType="pubmed">29725295</ArticleId></ArticleIdList></Reference><Reference><Citation>Moosecker S., Gomes P., Dioli C., Yu S., Sotiropoulos I., Almeida O. F. X., Activated PPAR&#x3b3; abrogates misprocessing of amyloid precursor protein, tau missorting and synaptotoxicity. Front. Cell Neurosci. 13, 239 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6584807</ArticleId><ArticleId IdType="pubmed">31263400</ArticleId></ArticleIdList></Reference><Reference><Citation>Ittner A., Bertz J., Suh L. S., Stevens C. H., G&#xf6;tz J., Ittner L. M., Tau-targeting passive immunization modulates aspects of pathology in tau transgenic mice. J. Neurochem. 132, 135&#x2013;145 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25041093</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">35838824</PMID><DateCompleted><Year>2022</Year><Month>08</Month><Day>18</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-0533</ISSN><JournalIssue CitedMedium="Internet"><Volume>144</Volume><Issue>3</Issue><PubDate><Year>2022</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Acta neuropathologica</Title><ISOAbbreviation>Acta Neuropathol</ISOAbbreviation></Journal><ArticleTitle>Distinct tau neuropathology and cellular profiles of an APOE3 Christchurch homozygote protected against autosomal dominant Alzheimer's dementia.</ArticleTitle><Pagination><StartPage>589</StartPage><EndPage>601</EndPage><MedlinePgn>589-601</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00401-022-02467-8</ELocationID><Abstract><AbstractText>We describe in vivo follow-up PET imaging and postmortem findings from an autosomal dominant Alzheimer's disease (ADAD) PSEN1 E280A carrier who was also homozygous for the APOE3 Christchurch (APOE3ch) variant and was protected against Alzheimer's symptoms for almost three decades beyond the expected age of onset. We identified a distinct anatomical pattern of tau pathology with atypical accumulation in vivo and unusual postmortem regional distribution characterized by sparing in the frontal cortex and severe pathology in the occipital cortex. The frontal cortex and the hippocampus, less affected than the occipital cortex by tau pathology, contained Related Orphan Receptor B (RORB) positive neurons, homeostatic astrocytes and higher APOE expression. The occipital cortex, the only cortical region showing cerebral amyloid angiopathy (CAA), exhibited a distinctive chronic inflammatory microglial profile and lower APOE expression. Thus, the Christchurch variant may&#xa0;impact the distribution of tau pathology, modulate age at onset, severity, progression, and clinical presentation of ADAD, suggesting possible therapeutic strategies.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Sepulveda-Falla</LastName><ForeName>Diego</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-0176-2042</Identifier><AffiliationInfo><Affiliation>Molecular Neuropathology of Alzheimer's Disease, Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. dsepulve@uke.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Sanchez</LastName><ForeName>Justin S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Almeida</LastName><ForeName>Maria Camila</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Department of Molecular, Cellular and Developmental Biology, Neuroscience Research Institute, University of California, Santa Barbara, CA, 93106, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Natural and Human Sciences, Federal University of ABC, S&#xe3;o Bernardo do Campo, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boassa</LastName><ForeName>Daniela</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>National Center for Microscopy and Imaging Research (NCMIR), San Diego School of Medicine (UCSD), University of California, La Jolla, San Diego, CA, 92093, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosciences, San Diego School of Medicine (UCSD), University of California, La Jolla, San Diego, CA, 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Acosta-Uribe</LastName><ForeName>Juliana</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Molecular, Cellular and Developmental Biology, Neuroscience Research Institute, University of California, Santa Barbara, CA, 93106, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vila-Castelar</LastName><ForeName>Clara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramirez-Gomez</LastName><ForeName>Liliana</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baena</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Grupo de Neurociencias de Antioquia, Facultad de Medicina, Universidad de Antioquia, Medell&#xed;n, Antioquia, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aguillon</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Grupo de Neurociencias de Antioquia, Facultad de Medicina, Universidad de Antioquia, Medell&#xed;n, Antioquia, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Villalba-Moreno</LastName><ForeName>Nelson David</ForeName><Initials>ND</Initials><AffiliationInfo><Affiliation>Molecular Neuropathology of Alzheimer's Disease, Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Littau</LastName><ForeName>Jessica Lisa</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Molecular Neuropathology of Alzheimer's Disease, Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Villegas</LastName><ForeName>Andres</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Grupo de Neurociencias de Antioquia, Facultad de Medicina, Universidad de Antioquia, Medell&#xed;n, Antioquia, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beach</LastName><ForeName>Thomas G</ForeName><Initials>TG</Initials><AffiliationInfo><Affiliation>Department of Neuropathology, Banner Sun Health Research Institute, Sun City, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>White</LastName><ForeName>Charles L</ForeName><Initials>CL</Initials><Suffix>3rd</Suffix><AffiliationInfo><Affiliation>Department of Pathology, Neuropathology Laboratory, University of Texas Southwestern Medical Center, Dallas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ellisman</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>National Center for Microscopy and Imaging Research (NCMIR), San Diego School of Medicine (UCSD), University of California, La Jolla, San Diego, CA, 92093, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosciences, San Diego School of Medicine (UCSD), University of California, La Jolla, San Diego, CA, 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krasemann</LastName><ForeName>Susanne</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Experimental Pathology Core Facility, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Glatzel</LastName><ForeName>Markus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Keith A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reiman</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>The Banner Alzheimer's Institute, Phoenix, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arboleda-Velasquez</LastName><ForeName>Joseph F</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Schepens Eye Research Institute of Mass Eye and Ear and Department of Ophthalmology, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Kosik</LastName><ForeName>Kenneth S</ForeName><Initials>KS</Initials><AffiliationInfo><Affiliation>Department of Molecular, Cellular and Developmental Biology, Neuroscience Research Institute, University of California, Santa Barbara, CA, 93106, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Lopera</LastName><ForeName>Francisco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Grupo de Neurociencias de Antioquia, Facultad de Medicina, Universidad de Antioquia, Medell&#xed;n, Antioquia, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Quiroz</LastName><ForeName>Yakeel T</ForeName><Initials>YT</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. yquiroz@mgh.harvard.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. yquiroz@mgh.harvard.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Grupo de Neurociencias de Antioquia, Facultad de Medicina, Universidad de Antioquia, Medell&#xed;n, Antioquia, Colombia. yquiroz@mgh.harvard.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG062421</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG054671</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG065549</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UH3 NS100121</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 NS120055</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG019610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 NS110048</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG072980</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Acta Neuropathol</MedlineTA><NlmUniqueID>0412041</NlmUniqueID><ISSNLinking>0001-6322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053318">Apolipoprotein E3</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053318" MajorTopicYN="N">Apolipoprotein E3</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006720" MajorTopicYN="N">Homozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">APOE</Keyword><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">Dementia</Keyword><Keyword MajorTopicYN="N">PET</Keyword><Keyword MajorTopicYN="N">Tau</Keyword><Keyword MajorTopicYN="N">Transcriptomics</Keyword></KeywordList><CoiStatement>RAS has received personal compensation from AC Immune, Eisai, Roche, and Takeda, and research grant support from Eli Lilly and Janssen. YTQ, JFAV, EMR, FL are listed as co-inventors of a patent application for therapeutics modulating interactions between APOE and HSPG filed by MGB. All other authors have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>3</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>6</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>15</Day><Hour>11</Hour><Minute>57</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>7</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35838824</ArticleId><ArticleId IdType="pmc">PMC9381462</ArticleId><ArticleId IdType="doi">10.1007/s00401-022-02467-8</ArticleId><ArticleId IdType="pii">10.1007/s00401-022-02467-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arboleda-Velasquez JF, Lopera F, O&#x2019;Hare M, Delgado-Tirado S, Marino C, Chmielewska N, et al. Resistance to autosomal dominant Alzheimer&#x2019;s disease in an APOE3 Christchurch homozygote: a case report. Nat Med. 2019;25:1680&#x2013;1683. doi: 10.1038/s41591-019-0611-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-019-0611-3</ArticleId><ArticleId IdType="pmc">PMC6898984</ArticleId><ArticleId IdType="pubmed">31686034</ArticleId></ArticleIdList></Reference><Reference><Citation>Attems J, Jellinger KA, Lintner F. Alzheimer&#x2019;s disease pathology influences severity and topographical distribution of cerebral amyloid angiopathy. Acta Neuropathol. 2005;110:222&#x2013;231. doi: 10.1007/s00401-005-1064-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-005-1064-y</ArticleId><ArticleId IdType="pubmed">16133541</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahl E, Koomar T, Michaelson JJ. cerebroViz: an R package for anatomical visualization of spatiotemporal brain data. Bioinformatics. 2017;33:762&#x2013;763. doi: 10.1093/bioinformatics/btw726.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btw726</ArticleId><ArticleId IdType="pmc">PMC5870797</ArticleId><ArticleId IdType="pubmed">28011779</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239&#x2013;259. doi: 10.1007/bf00308809.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/bf00308809</ArticleId><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Crutch SJ, Schott JM, Rabinovici GD, Murray M, Snowden JS, van der Flier WM, et al. Consensus classification of posterior cortical atrophy. Alzheimers Dement. 2017;13:870&#x2013;884. doi: 10.1016/j.jalz.2017.01.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2017.01.014</ArticleId><ArticleId IdType="pmc">PMC5788455</ArticleId><ArticleId IdType="pubmed">28259709</ArticleId></ArticleIdList></Reference><Reference><Citation>Desikan RS, Cabral HJ, Hess CP, Dillon WP, Glastonbury CM, Weiner MW, et al. Automated MRI measures identify individuals with mild cognitive impairment and Alzheimer&#x2019;s disease. Brain. 2009;132:2048&#x2013;2057. doi: 10.1093/brain/awp123.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awp123</ArticleId><ArticleId IdType="pmc">PMC2714061</ArticleId><ArticleId IdType="pubmed">19460794</ArticleId></ArticleIdList></Reference><Reference><Citation>Dinkel F, Trujillo-Rodriguez D, Villegas A, Streffer J, Mercken M, Lopera F, et al. Decreased deposition of beta-amyloid 1&#x2013;38 and increased deposition of beta-amyloid 1&#x2013;42 in brain tissue of presenilin-1 E280A familial Alzheimer&#x2019;s disease patients. Front Aging Neurosci. 2020;12:220. doi: 10.3389/fnagi.2020.00220.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2020.00220</ArticleId><ArticleId IdType="pmc">PMC7399638</ArticleId><ArticleId IdType="pubmed">32848702</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischl B, Rajendran N, Busa E, Augustinack J, Hinds O, Yeo BTT, et al. Cortical folding patterns and predicting cytoarchitecture. Cereb Cortex. 2008;18:1973&#x2013;1980. doi: 10.1093/cercor/bhm225.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cercor/bhm225</ArticleId><ArticleId IdType="pmc">PMC2474454</ArticleId><ArticleId IdType="pubmed">18079129</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleisher AS, Chen K, Quiroz YT, Jakimovich LJ, Gomez MG, Langois CM, et al. Florbetapir PET analysis of amyloid-&#x3b2; deposition in the presenilin 1 E280A autosomal dominant Alzheimer&#x2019;s disease kindred: a cross-sectional study. Lancet Neurol. 2012;11:1057&#x2013;1065. doi: 10.1016/S1474-4422(12)70227-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(12)70227-2</ArticleId><ArticleId IdType="pmc">PMC3515078</ArticleId><ArticleId IdType="pubmed">23137949</ArticleId></ArticleIdList></Reference><Reference><Citation>Gal J, Katsumata Y, Zhu H, Srinivasan S, Chen J, Johnson LA, et al. Apolipoprotein E proteinopathy is a major dementia-associated pathologic biomarker in individuals with or without the APOE Epsilon 4 Allele. Am J Pathol. 2022;192:564&#x2013;578. doi: 10.1016/j.ajpath.2021.11.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajpath.2021.11.013</ArticleId><ArticleId IdType="pmc">PMC8895423</ArticleId><ArticleId IdType="pubmed">34954207</ArticleId></ArticleIdList></Reference><Reference><Citation>Greve DN, Svarer C, Fisher PM, Feng L, Hansen AE, Baare W, et al. Cortical surface-based analysis reduces bias and variance in kinetic modeling of brain PET data. Neuroimage. 2014;92:225&#x2013;236. doi: 10.1016/j.neuroimage.2013.12.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2013.12.021</ArticleId><ArticleId IdType="pmc">PMC4008670</ArticleId><ArticleId IdType="pubmed">24361666</ArticleId></ArticleIdList></Reference><Reference><Citation>Grubman A, Chew G, Ouyang JF, Sun G, Choo XY, McLean C, et al. A single-cell atlas of entorhinal cortex from individuals with Alzheimer&#x2019;s disease reveals cell-type-specific gene expression regulation. Nat Neurosci. 2019;22:2087&#x2013;2097. doi: 10.1038/s41593-019-0539-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-019-0539-4</ArticleId><ArticleId IdType="pubmed">31768052</ArticleId></ArticleIdList></Reference><Reference><Citation>Habib N, Avraham-Davidi I, Basu A, Burks T, Shekhar K, Hofree M, et al. Massively parallel single-nucleus RNA-seq with DroNc-seq. Nat Methods. 2017;14:955&#x2013;958. doi: 10.1038/nmeth.4407.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.4407</ArticleId><ArticleId IdType="pmc">PMC5623139</ArticleId><ArticleId IdType="pubmed">28846088</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanseeuw BJ, Betensky RA, Mormino EC, Schultz AP, Sepulcre J, Becker JA, et al. PET staging of amyloidosis using striatum. Alzheimers Dement. 2018;14:1281&#x2013;1292. doi: 10.1016/j.jalz.2018.04.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.04.011</ArticleId><ArticleId IdType="pmc">PMC6219621</ArticleId><ArticleId IdType="pubmed">29792874</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang M, Wang J, Torre E, Dueck H, Shaffer S, Bonasio R, et al. SAVER: gene expression recovery for single-cell RNA sequencing. Nat Methods. 2018;15:539&#x2013;542. doi: 10.1038/s41592-018-0033-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41592-018-0033-z</ArticleId><ArticleId IdType="pmc">PMC6030502</ArticleId><ArticleId IdType="pubmed">29941873</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, et al. National Institute on Aging-Alzheimer&#x2019;s Association guidelines for the neuropathologic assessment of Alzheimer&#x2019;s disease. Alzheimers Dement. 2012;8:1&#x2013;13. doi: 10.1016/j.jalz.2011.10.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2011.10.007</ArticleId><ArticleId IdType="pmc">PMC3266529</ArticleId><ArticleId IdType="pubmed">22265587</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson KA, Schultz A, Betensky RA, Becker JA, Sepulcre J, Rentz D, et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol. 2016;79:110&#x2013;119. doi: 10.1002/ana.24546.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24546</ArticleId><ArticleId IdType="pmc">PMC4738026</ArticleId><ArticleId IdType="pubmed">26505746</ArticleId></ArticleIdList></Reference><Reference><Citation>Krasemann S, Madore C, Cialic R, Baufeld C, Calcagno N, El Fatimy R, et al. The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. Immunity. 2017;47:566&#x2013;581.e9. doi: 10.1016/j.immuni.2017.08.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2017.08.008</ArticleId><ArticleId IdType="pmc">PMC5719893</ArticleId><ArticleId IdType="pubmed">28930663</ArticleId></ArticleIdList></Reference><Reference><Citation>Lake BB, Ai R, Kaeser GE, Salathia NS, Yung YC, Liu R, et al. Neuronal subtypes and diversity revealed by single-nucleus RNA sequencing of the human brain. Science. 2016;352:1586&#x2013;1590. doi: 10.1126/science.aaf1204.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaf1204</ArticleId><ArticleId IdType="pmc">PMC5038589</ArticleId><ArticleId IdType="pubmed">27339989</ArticleId></ArticleIdList></Reference><Reference><Citation>Lake BB, Chen S, Sos BC, Fan J, Kaeser GE, Yung YC, et al. Integrative single-cell analysis of transcriptional and epigenetic states in the human adult brain. Nat Biotechnol. 2018;36:70&#x2013;80. doi: 10.1038/nbt.4038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.4038</ArticleId><ArticleId IdType="pmc">PMC5951394</ArticleId><ArticleId IdType="pubmed">29227469</ArticleId></ArticleIdList></Reference><Reference><Citation>Leng K, Li E, Eser R, Piergies A, Sit R, Tan M, et al. Molecular characterization of selectively vulnerable neurons in Alzheimer&#x2019;s disease. Nat Neurosci. 2021;24:276&#x2013;287. doi: 10.1038/s41593-020-00764-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-020-00764-7</ArticleId><ArticleId IdType="pmc">PMC7854528</ArticleId><ArticleId IdType="pubmed">33432193</ArticleId></ArticleIdList></Reference><Reference><Citation>Littau JL, Velilla L, Hase Y, Villalba-Moreno ND, Hagel C, Drexler D, et al. Evidence of Amyloid &#x3b2; independent small vessel pathology in familial Alzheimer&#x2019;s disease. Brain Pathol. 2022 doi: 10.1111/bpa.13097.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bpa.13097</ArticleId><ArticleId IdType="pmc">PMC9616091</ArticleId><ArticleId IdType="pubmed">35695802</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathys H, Davila-Velderrain J, Peng Z, Gao F, Mohammadi S, Young JZ, et al. Single-cell transcriptomic analysis of Alzheimer&#x2019;s disease. Nature. 2019;570:332&#x2013;337. doi: 10.1038/s41586-019-1195-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-1195-2</ArticleId><ArticleId IdType="pmc">PMC6865822</ArticleId><ArticleId IdType="pubmed">31042697</ArticleId></ArticleIdList></Reference><Reference><Citation>McGinnis CS, Murrow LM, Gartner ZJ. DoubletFinder: doublet detection in single-cell RNA sequencing data using artificial nearest neighbors. Cell Syst. 2019;8:329&#x2013;337.e4. doi: 10.1016/j.cels.2019.03.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cels.2019.03.003</ArticleId><ArticleId IdType="pmc">PMC6853612</ArticleId><ArticleId IdType="pubmed">30954475</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno-Jim&#xe9;nez EP, Flor-Garc&#xed;a M, Terreros-Roncal J, R&#xe1;bano A, Cafini F, Pallas-Bazarra N, et al. Adult hippocampal neurogenesis is abundant in neurologically healthy subjects and drops sharply in patients with Alzheimer&#x2019;s disease. Nat Med. 2019;25:554&#x2013;560. doi: 10.1038/s41591-019-0375-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-019-0375-9</ArticleId><ArticleId IdType="pubmed">30911133</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormino EC, Betensky RA, Hedden T, Schultz AP, Amariglio RE, Rentz DM, et al. Synergistic effect of &#x3b2;-amyloid and neurodegeneration on cognitive decline in clinically normal individuals. JAMA Neurol. 2014;71:1379&#x2013;1385. doi: 10.1001/jamaneurol.2014.2031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.2031</ArticleId><ArticleId IdType="pmc">PMC4293023</ArticleId><ArticleId IdType="pubmed">25222039</ArticleId></ArticleIdList></Reference><Reference><Citation>Nichols JB, Malek-Ahmadi M, Tariot PN, Serrano GE, Sue LI, Beach TG. Vascular lesions, APOE &#x3b5;4, and tau pathology in Alzheimer disease. J Neuropathol Exp Neurol. 2021;80:240&#x2013;246. doi: 10.1093/jnen/nlaa160.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnen/nlaa160</ArticleId><ArticleId IdType="pmc">PMC7899190</ArticleId><ArticleId IdType="pubmed">33617650</ArticleId></ArticleIdList></Reference><Reference><Citation>Pikkarainen M, Kauppinen T, Alafuzoff I. Hyperphosphorylated tau in the occipital cortex in aged nondemented subjects. J Neuropathol Exp Neurol. 2009;68:653&#x2013;660. doi: 10.1097/NEN.0b013e3181a6ee45.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e3181a6ee45</ArticleId><ArticleId IdType="pubmed">19458543</ArticleId></ArticleIdList></Reference><Reference><Citation>Quiroz YT, Sperling RA, Norton DJ, Baena A, Arboleda-Velasquez JF, Cosio D, et al. Association between amyloid and tau accumulation in young adults with autosomal dominant Alzheimer disease. JAMA Neurol. 2018;75:548&#x2013;556. doi: 10.1001/jamaneurol.2017.4907.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2017.4907</ArticleId><ArticleId IdType="pmc">PMC5885174</ArticleId><ArticleId IdType="pubmed">29435558</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez JS, Becker JA, Jacobs HIL, Hanseeuw BJ, Jiang S, Schultz AP, et al. The cortical origin and initial spread of medial temporal tauopathy in Alzheimer&#x2019;s disease assessed with positron emission tomography. Sci Transl Med. 2021;13:eabc0655. doi: 10.1126/scitranslmed.abc0655.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abc0655</ArticleId><ArticleId IdType="pmc">PMC7978042</ArticleId><ArticleId IdType="pubmed">33472953</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez JS, Hanseeuw BJ, Lopera F, Sperling RA, Baena A, Bocanegra Y, et al. Longitudinal amyloid and tau accumulation in autosomal dominant Alzheimer&#x2019;s disease: findings from the Colombia-Boston (COLBOS) biomarker study. Alzheimers Res Ther. 2021;13:27. doi: 10.1186/s13195-020-00765-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-020-00765-5</ArticleId><ArticleId IdType="pmc">PMC7811244</ArticleId><ArticleId IdType="pubmed">33451357</ArticleId></ArticleIdList></Reference><Reference><Citation>Sepulveda-Falla D, Chavez-Gutierrez L, Portelius E, V&#xe9;lez JI, Dujardin S, Barrera-Ocampo A, et al. A multifactorial model of pathology for age of onset heterogeneity in familial Alzheimer&#x2019;s disease. Acta Neuropathol. 2021;141:217&#x2013;233. doi: 10.1007/s00401-020-02249-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-020-02249-0</ArticleId><ArticleId IdType="pmc">PMC7847436</ArticleId><ArticleId IdType="pubmed">33319314</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR, R&#xfc;b U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58:1791&#x2013;1800. doi: 10.1212/wnl.58.12.1791.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.58.12.1791</ArticleId><ArticleId IdType="pubmed">12084879</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulrich JD, Ulland TK, Mahan TE, Nystr&#xf6;m S, Nilsson KP, Song WM, et al. ApoE facilitates the microglial response to amyloid plaque pathology. J Exp Med. 2018;215:1047&#x2013;1058. doi: 10.1084/jem.20171265.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20171265</ArticleId><ArticleId IdType="pmc">PMC5881464</ArticleId><ArticleId IdType="pubmed">29483128</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C, Xiong M, Gratuze M, Bao X, Shi Y, Andhey PS, et al. Selective removal of astrocytic APOE4 strongly protects against tau-mediated neurodegeneration and decreases synaptic phagocytosis by microglia. Neuron. 2021;109:1657&#x2013;1674.e7. doi: 10.1016/j.neuron.2021.03.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2021.03.024</ArticleId><ArticleId IdType="pmc">PMC8141024</ArticleId><ArticleId IdType="pubmed">33831349</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams S, Chalmers K, Wilcock GK, Love S. Relationship of neurofibrillary pathology to cerebral amyloid angiopathy in Alzheimer&#x2019;s disease. Neuropathol Appl Neurobiol. 2005;31:414&#x2013;421. doi: 10.1111/j.1365-2990.2005.00663.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2990.2005.00663.x</ArticleId><ArticleId IdType="pubmed">16008825</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong M, Jiang H, Serrano JR, Gonzales ER, Wang C, Gratuze M, et al. APOE immunotherapy reduces cerebral amyloid angiopathy and amyloid plaques while improving cerebrovascular function. Sci Transl Med. 2021;13:eabd7522. doi: 10.1126/scitranslmed.abd7522.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abd7522</ArticleId><ArticleId IdType="pmc">PMC8128342</ArticleId><ArticleId IdType="pubmed">33597265</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu G, Wang L-G, Han Y, He Q-Y. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16:284&#x2013;287. doi: 10.1089/omi.2011.0118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/omi.2011.0118</ArticleId><ArticleId IdType="pmc">PMC3339379</ArticleId><ArticleId IdType="pubmed">22455463</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35835994</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>23</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2157-846X</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>9</Issue><PubDate><Year>2022</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Nature biomedical engineering</Title><ISOAbbreviation>Nat Biomed Eng</ISOAbbreviation></Journal><ArticleTitle>Multiscale optical and optoacoustic imaging of amyloid-&#x3b2; deposits in mice.</ArticleTitle><Pagination><StartPage>1031</StartPage><EndPage>1044</EndPage><MedlinePgn>1031-1044</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41551-022-00906-1</ELocationID><Abstract><AbstractText>Deposits of amyloid-&#x3b2; (A&#x3b2;) in the brains of rodents can be analysed by invasive intravital microscopy on a submillimetre scale, or via whole-brain images from modalities lacking the resolution or molecular specificity to accurately characterize A&#x3b2; pathologies. Here we show that large-field multifocal illumination fluorescence microscopy and panoramic volumetric multispectral optoacoustic tomography can be combined to longitudinally assess A&#x3b2; deposits in transgenic mouse models of Alzheimer's disease. We used fluorescent A&#x3b2;-targeted probes (the luminescent conjugated oligothiophene HS-169 and the oxazine-derivative AOI987) to transcranially detect A&#x3b2; deposits in the cortex of APP/PS1 and arcA&#x3b2; mice with single-plaque resolution (8&#x2009;&#x3bc;m) and across the whole brain (including the hippocampus and the thalamus, which are inaccessible by conventional intravital microscopy) at sub-150&#x2009;&#x3bc;m resolutions. Two-photon microscopy, light-sheet microscopy and immunohistochemistry of brain-tissue sections confirmed the specificity and regional distributions of the deposits. High-resolution multiscale optical and optoacoustic imaging of A&#x3b2; deposits across the entire brain in rodents thus facilitates the in vivo study of A&#x3b2; accumulation by brain region and by animal age and strain.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s), under exclusive licence to Springer Nature Limited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Ni</LastName><ForeName>Ruiqing</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-0793-2113</Identifier><AffiliationInfo><Affiliation>Institute for Biomedical Engineering, University of Zurich and ETH Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zurich Neuroscience Center (ZNZ), University of Zurich and ETH Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Regenerative Medicine, University of Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Chen</LastName><ForeName>Zhenyue</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Institute for Biomedical Engineering, University of Zurich and ETH Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>De&#xe1;n-Ben</LastName><ForeName>Xos&#xe9; Lu&#xed;s</ForeName><Initials>XL</Initials><Identifier Source="ORCID">0000-0002-8557-7778</Identifier><AffiliationInfo><Affiliation>Institute for Biomedical Engineering, University of Zurich and ETH Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Voigt</LastName><ForeName>Fabian F</ForeName><Initials>FF</Initials><AffiliationInfo><Affiliation>Zurich Neuroscience Center (ZNZ), University of Zurich and ETH Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Brain Research Institute, University of Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kirschenbaum</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Institute of Neuropathology, Universit&#xe4;tsspital Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Gloria</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Institute for Biomedical Engineering, University of Zurich and ETH Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Villois</LastName><ForeName>Alessia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Quanyu</ForeName><Initials>Q</Initials><Identifier Source="ORCID">0000-0001-7719-4649</Identifier><AffiliationInfo><Affiliation>Institute for Biomedical Engineering, University of Zurich and ETH Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crimi</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Neuropathology, Universit&#xe4;tsspital Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arosio</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nitsch</LastName><ForeName>Roger M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Zurich Neuroscience Center (ZNZ), University of Zurich and ETH Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Regenerative Medicine, University of Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nilsson</LastName><ForeName>K Peter R</ForeName><Initials>KPR</Initials><AffiliationInfo><Affiliation>Division of Chemistry, Department of Physics, Chemistry and Biology, Link&#xf6;ping University, Link&#xf6;ping, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aguzzi</LastName><ForeName>Adriano</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-0344-6708</Identifier><AffiliationInfo><Affiliation>Zurich Neuroscience Center (ZNZ), University of Zurich and ETH Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Neuropathology, Universit&#xe4;tsspital Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Helmchen</LastName><ForeName>Fritjof</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-8867-9569</Identifier><AffiliationInfo><Affiliation>Zurich Neuroscience Center (ZNZ), University of Zurich and ETH Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Brain Research Institute, University of Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klohs</LastName><ForeName>Jan</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-4065-2807</Identifier><AffiliationInfo><Affiliation>Institute for Biomedical Engineering, University of Zurich and ETH Zurich, Zurich, Switzerland. klohs@biomed.ee.ethz.ch.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zurich Neuroscience Center (ZNZ), University of Zurich and ETH Zurich, Zurich, Switzerland. klohs@biomed.ee.ethz.ch.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Razansky</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-8676-0964</Identifier><AffiliationInfo><Affiliation>Institute for Biomedical Engineering, University of Zurich and ETH Zurich, Zurich, Switzerland. daniel.razansky@uzh.ch.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zurich Neuroscience Center (ZNZ), University of Zurich and ETH Zurich, Zurich, Switzerland. daniel.razansky@uzh.ch.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland. daniel.razansky@uzh.ch.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>UF1 NS107680</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Biomed Eng</MedlineTA><NlmUniqueID>101696896</NlmUniqueID><ISSNLinking>2157-846X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010078">Oxazines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="Y">Amyloid beta-Peptides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010078" MajorTopicYN="N">Oxazines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="Y">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>3</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>5</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>14</Day><Hour>23</Hour><Minute>32</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35835994</ArticleId><ArticleId IdType="doi">10.1038/s41551-022-00906-1</ArticleId><ArticleId IdType="pii">10.1038/s41551-022-00906-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Selkoe, D. J. &amp; Hardy, J. The amyloid hypothesis of Alzheimer&#x2019;s disease at 25 years. EMBO Mol. Med. 8, 595&#x2013;608 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27025652</ArticleId><ArticleId IdType="pmc">4888851</ArticleId><ArticleId IdType="doi">10.15252/emmm.201606210</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark, C. M. et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA 305, 275&#x2013;283 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21245183</ArticleId><ArticleId IdType="pmc">7041965</ArticleId><ArticleId IdType="doi">10.1001/jama.2010.2008</ArticleId></ArticleIdList></Reference><Reference><Citation>Curtis, C. et al. Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density. JAMA Neurol. 72, 287&#x2013;294 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25622185</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2014.4144</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk, W. E. et al. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer&#x2019;s disease brain but not in transgenic mouse brain. J. Neurosci. 25, 10598&#x2013;10606 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16291932</ArticleId><ArticleId IdType="pmc">6725842</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.2990-05.2005</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabri, O. et al. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer&#x2019;s disease: phase 3 study. Alzheimers Dement. 11, 964&#x2013;974 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25824567</ArticleId><ArticleId IdType="doi">10.1016/j.jalz.2015.02.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack, C. R. Jr. et al. NIA-AA research framework: toward a biological definition of Alzheimer&#x2019;s disease. Alzheimers Dement. 14, 535&#x2013;562 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29653606</ArticleId><ArticleId IdType="pmc">5958625</ArticleId><ArticleId IdType="doi">10.1016/j.jalz.2018.02.018</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne, V. L., Dore, V., Burnham, S. C., Masters, C. L. &amp; Rowe, C. C. Imaging tau and amyloid-beta proteinopathies in Alzheimer disease and other conditions. Nat. Rev. Neurol. 14, 225&#x2013;236 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29449700</ArticleId><ArticleId IdType="doi">10.1038/nrneurol.2018.9</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack, C. R. Jr. et al. Hypothetical model of dynamic biomarkers of the Alzheimer&#x2019;s pathological cascade. Lancet Neurol. 9, 119&#x2013;128 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20083042</ArticleId><ArticleId IdType="pmc">2819840</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(09)70299-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhenain, M. et al. Characterization of in vivo MRI detectable thalamic amyloid plaques from APP/PS1 mice. Neurobiol. Aging 30, 41&#x2013;53 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">17588710</ArticleId><ArticleId IdType="doi">10.1016/j.neurobiolaging.2007.05.018</ArticleId></ArticleIdList></Reference><Reference><Citation>Higuchi, M. et al. 19F and 1H MRI detection of amyloid beta plaques in vivo. Nat. Neurosci. 8, 527&#x2013;533 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15768036</ArticleId><ArticleId IdType="doi">10.1038/nn1422</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack, C. R. Jr. et al. In vivo magnetic resonance microimaging of individual amyloid plaques in Alzheimer&#x2019;s transgenic mice. J. Neurosci. 25, 10041&#x2013;10048 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16251453</ArticleId><ArticleId IdType="pmc">2744887</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.2588-05.2005</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong, N.-J., Dibb, R., Bulk, M., van der Weerd, L. &amp; Liu, C. Imaging beta amyloid aggregation and iron accumulation in Alzheimer&#x2019;s disease using quantitative susceptibility mapping MRI. NeuroImage 191, 176&#x2013;185 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30739060</ArticleId><ArticleId IdType="doi">10.1016/j.neuroimage.2019.02.019</ArticleId></ArticleIdList></Reference><Reference><Citation>Dudeffant, C. et al. Contrast-enhanced MR microscopy of amyloid plaques in five mouse models of amyloidosis and in human Alzheimer&#x2019;s disease brains. Sci. Rep. 7, 4955 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28694463</ArticleId><ArticleId IdType="pmc">5504006</ArticleId><ArticleId IdType="doi">10.1038/s41598-017-05285-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Sehlin, D. et al. Antibody-based PET imaging of amyloid beta in mouse models of Alzheimer&#x2019;s disease. Nat. Commun. 7, 10759 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26892305</ArticleId><ArticleId IdType="pmc">4762893</ArticleId><ArticleId IdType="doi">10.1038/ncomms10759</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez-Vieitez, E. et al. Astrocytosis precedes amyloid plaque deposition in Alzheimer APPswe transgenic mouse brain: a correlative positron emission tomography and in vitro imaging study. Eur. J. Nucl. Med. Mol. Imaging 42, 1119&#x2013;1132 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25893384</ArticleId><ArticleId IdType="pmc">4424277</ArticleId><ArticleId IdType="doi">10.1007/s00259-015-3047-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacher, C. et al. Longitudinal PET monitoring of amyloidosis and microglial activation in a second-generation amyloid-&#x3b2; mouse model. J. Nucl. Med. 60, 1787&#x2013;1793 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31302633</ArticleId><ArticleId IdType="pmc">6894380</ArticleId><ArticleId IdType="doi">10.2967/jnumed.119.227322</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacher, C. et al. Asymmetry of fibrillar plaque burden in amyloid mouse models. J. Nucl. Med. 61, 1825&#x2013;1831 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32414948</ArticleId><ArticleId IdType="doi">10.2967/jnumed.120.242750</ArticleId></ArticleIdList></Reference><Reference><Citation>Snellman, A. et al. Applicability of [11C]PIB micro-PET imaging for in vivo follow-up of anti-amyloid treatment effects in APP23 mouse model. Neurobiol. Aging 57, 84&#x2013;94 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28605642</ArticleId><ArticleId IdType="doi">10.1016/j.neurobiolaging.2017.05.008</ArticleId></ArticleIdList></Reference><Reference><Citation>Mannheim, J. G. et al. PET/MRI hybrid systems. Semin. Nucl. Med. 48, 332&#x2013;347 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29852943</ArticleId><ArticleId IdType="doi">10.1053/j.semnuclmed.2018.02.011</ArticleId></ArticleIdList></Reference><Reference><Citation>Hintersteiner, M. et al. In vivo detection of amyloid-beta deposits by near-infrared imaging using an oxazine-derivative probe. Nat. Biotechnol. 23, 577&#x2013;583 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15834405</ArticleId><ArticleId IdType="doi">10.1038/nbt1085</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyde, D. et al. Hybrid FMT-CT imaging of amyloid-beta plaques in a murine Alzheimer&#x2019;s disease model. NeuroImage 44, 1304&#x2013;1311 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19041402</ArticleId><ArticleId IdType="doi">10.1016/j.neuroimage.2008.10.038</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, X. et al. Near-infrared fluorescence molecular imaging of amyloid beta species and monitoring therapy in animal models of Alzheimer&#x2019;s disease. Proc. Natl Acad. Sci. USA 112, 9734&#x2013;9739 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26199414</ArticleId><ArticleId IdType="pmc">4534214</ArticleId><ArticleId IdType="doi">10.1073/pnas.1505420112</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitesell, J. D. et al. Whole brain imaging reveals distinct spatial patterns of amyloid beta deposition in three mouse models of Alzheimer&#x2019;s disease. J. Comp. Neurol. 527, 2122&#x2013;2145 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30311654</ArticleId><ArticleId IdType="doi">10.1002/cne.24555</ArticleId></ArticleIdList></Reference><Reference><Citation>Bacskai, B. J. et al. Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-&#x3b2; ligand in transgenic mice. Proc. Natl Acad. Sci. USA 100, 12462&#x2013;12467 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">14517353</ArticleId><ArticleId IdType="pmc">218780</ArticleId><ArticleId IdType="doi">10.1073/pnas.2034101100</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Luehmann, M. et al. Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer&#x2019;s disease. Nature 451, 720&#x2013;724 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18256671</ArticleId><ArticleId IdType="pmc">3264491</ArticleId><ArticleId IdType="doi">10.1038/nature06616</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu, S., Yan, P., Maslov, K., Lee, J.-M. &amp; Wang, L. V. Optical-resolution photoacoustic microscopy of amyloid-beta deposits in vivo. Proc. SPIE 7564, 75643D (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.1117/12.843919</ArticleId></ArticleIdList></Reference><Reference><Citation>Calvo-Rodriguez, M. et al. In vivo detection of tau fibrils and amyloid beta aggregates with luminescent conjugated oligothiophenes and multiphoton microscopy. Acta Neuropathol. Commun. 7, 171 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31703739</ArticleId><ArticleId IdType="pmc">6839235</ArticleId><ArticleId IdType="doi">10.1186/s40478-019-0832-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Hefendehl, J. K. et al. Long-term in vivo imaging of beta-amyloid plaque appearance and growth in a mouse model of cerebral beta-amyloidosis. J. Neurosci. 31, 624&#x2013;629 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21228171</ArticleId><ArticleId IdType="pmc">6623424</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.5147-10.2011</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcock, D. M. et al. Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. J. Neurosci. 23, 3745&#x2013;3751 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12736345</ArticleId><ArticleId IdType="pmc">6742181</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.23-09-03745.2003</ArticleId></ArticleIdList></Reference><Reference><Citation>Sevigny, J. et al. The antibody aducanumab reduces A&#x3b2; plaques in Alzheimer&#x2019;s disease. Nature 537, 50&#x2013;56 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27582220</ArticleId><ArticleId IdType="doi">10.1038/nature19323</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, Z. et al. High-speed large-field multifocal illumination fluorescence microscopy. Laser Photon. Rev. 14, 1900070 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/lpor.201900070</ArticleId></ArticleIdList></Reference><Reference><Citation>Ni, R. et al. Detection of cerebral tauopathy in P301L mice using high-resolution large-field multifocal illumination fluorescence microscopy. Biomed. Opt. Express 11, 4989&#x2013;5002 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33014595</ArticleId><ArticleId IdType="pmc">7510859</ArticleId><ArticleId IdType="doi">10.1364/BOE.395803</ArticleId></ArticleIdList></Reference><Reference><Citation>Lassailly, F., Foster, K., Lopez-Onieva, L., Currie, E. &amp; Bonnet, D. Multimodal imaging reveals structural and functional heterogeneity in different bone marrow compartments: functional implications on hematopoietic stem cells. Blood 122, 1730&#x2013;1740 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23814020</ArticleId><ArticleId IdType="doi">10.1182/blood-2012-11-467498</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazo, I. B. et al. Hematopoietic progenitor cell rolling in bone marrow microvessels: parallel contributions by endothelial selectins and vascular cell adhesion molecule 1. J. Exp. Med. 188, 465&#x2013;474 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9687524</ArticleId><ArticleId IdType="pmc">2212463</ArticleId><ArticleId IdType="doi">10.1084/jem.188.3.465</ArticleId></ArticleIdList></Reference><Reference><Citation>De&#xe1;n-Ben, X. L. &amp; Razansky, D. Adding fifth dimension to optoacoustic imaging: volumetric time-resolved spectrally enriched tomography. Light Sci. Appl. 3, e137 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/lsa.2014.18</ArticleId></ArticleIdList></Reference><Reference><Citation>De&#xe1;n-Ben, X. L. et al. Functional optoacoustic neuro-tomography for scalable whole-brain monitoring of calcium indicators. Light Sci. Appl. 5, e16201 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">30167137</ArticleId><ArticleId IdType="pmc">6059886</ArticleId><ArticleId IdType="doi">10.1038/lsa.2016.201</ArticleId></ArticleIdList></Reference><Reference><Citation>Razansky, D. et al. Multispectral opto-acoustic tomography of deep-seated fluorescent proteins in vivo. Nat. Photonics 3, 412 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nphoton.2009.98</ArticleId></ArticleIdList></Reference><Reference><Citation>Omar, M., Aguirre, J. &amp; Ntziachristos, V. Optoacoustic mesoscopy for biomedicine. Nat. Biomed. Eng. 3, 354&#x2013;370 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30988470</ArticleId><ArticleId IdType="doi">10.1038/s41551-019-0377-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Razansky, D., Klohs, J. &amp; Ni, R. Multi-scale optoacoustic molecular imaging of brain diseases. Eur. J. Nucl. Med. Mol. Imaging 48, 4152&#x2013;4170 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33594473</ArticleId><ArticleId IdType="pmc">8566397</ArticleId><ArticleId IdType="doi">10.1007/s00259-021-05207-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Burmann, B. M. et al. Regulation of alpha-synuclein by chaperones in mammalian cells. Nature 577, 127&#x2013;132 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31802003</ArticleId><ArticleId IdType="doi">10.1038/s41586-019-1808-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, L. V. &amp; Hu, S. Photoacoustic tomography: in vivo imaging from organelles to organs. Science 335, 1458&#x2013;1462 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22442475</ArticleId><ArticleId IdType="pmc">3322413</ArticleId><ArticleId IdType="doi">10.1126/science.1216210</ArticleId></ArticleIdList></Reference><Reference><Citation>Taruttis, A. &amp; Ntziachristos, V. Advances in real-time multispectral optoacoustic imaging and its applications. Nat. Photonics 9, 219&#x2013;227 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nphoton.2015.29</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, Z., Dean-Ben, X. L., Gottschalk, S. &amp; Razansky, D. Hybrid system for in vivo epifluorescence and 4D optoacoustic imaging. Opt. Lett. 42, 4577&#x2013;4580 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29140316</ArticleId><ArticleId IdType="doi">10.1364/OL.42.004577</ArticleId></ArticleIdList></Reference><Reference><Citation>J&#xe4;hrling, N. et al. Cerebral &#x3b2;-amyloidosis in mice investigated by ultramicroscopy. PLoS ONE 10, e0125418 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26017149</ArticleId><ArticleId IdType="pmc">4446269</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0125418</ArticleId></ArticleIdList></Reference><Reference><Citation>Klohs, J. et al. Longitudinal assessment of amyloid pathology in transgenic ArcA&#x3b2; mice using multi-parametric magnetic resonance imaging. PLoS ONE 8, e66097 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23840405</ArticleId><ArticleId IdType="pmc">3686820</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0066097</ArticleId></ArticleIdList></Reference><Reference><Citation>Knobloch, M., Konietzko, U., Krebs, D. C. &amp; Nitsch, R. M. Intracellular Abeta and cognitive deficits precede beta-amyloid deposition in transgenic arcAbeta mice. Neurobiol. Aging 28, 1297&#x2013;1306 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">16876915</ArticleId><ArticleId IdType="doi">10.1016/j.neurobiolaging.2006.06.019</ArticleId></ArticleIdList></Reference><Reference><Citation>Merlini, M., Meyer, E. P., Ulmann-Schuler, A. &amp; Nitsch, R. M. Vascular beta-amyloid and early astrocyte alterations impair cerebrovascular function and cerebral metabolism in transgenic arcAbeta mice. Acta Neuropathol. 122, 293&#x2013;311 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21688176</ArticleId><ArticleId IdType="pmc">3168476</ArticleId><ArticleId IdType="doi">10.1007/s00401-011-0834-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Radde, R. et al. Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep. 7, 940&#x2013;946 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16906128</ArticleId><ArticleId IdType="pmc">1559665</ArticleId><ArticleId IdType="doi">10.1038/sj.embor.7400784</ArticleId></ArticleIdList></Reference><Reference><Citation>Voigt, F. F. et al. The mesoSPIM initiative: open-source light-sheet microscopes for imaging cleared tissue. Nat. Methods 16, 1105&#x2013;1108 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31527839</ArticleId><ArticleId IdType="pmc">6824906</ArticleId><ArticleId IdType="doi">10.1038/s41592-019-0554-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayed, R. et al. Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol. Neurodegener. 2, 18 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17897471</ArticleId><ArticleId IdType="pmc">2100048</ArticleId><ArticleId IdType="doi">10.1186/1750-1326-2-18</ArticleId></ArticleIdList></Reference><Reference><Citation>Shirani, H. et al. A palette of fluorescent thiophene-based ligands for the identification of protein aggregates. Chemistry 21, 15133&#x2013;15137 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26388448</ArticleId><ArticleId IdType="pmc">4641461</ArticleId><ArticleId IdType="doi">10.1002/chem.201502999</ArticleId></ArticleIdList></Reference><Reference><Citation>Tzoumas, S., Deliolanis, N., Morscher, S. &amp; Ntziachristos, V. Unmixing molecular agents from absorbing tissue in multispectral optoacoustic tomography. IEEE Trans. Med. Imaging 33, 48&#x2013;60 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24001986</ArticleId><ArticleId IdType="doi">10.1109/TMI.2013.2279994</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox, B., Laufer, J. G., Arridge, S. R. &amp; Beard, P. C. Quantitative spectroscopic photoacoustic imaging: a review. J. Biomed. Opt. 17, 061202 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22734732</ArticleId><ArticleId IdType="doi">10.1117/1.JBO.17.6.061202</ArticleId></ArticleIdList></Reference><Reference><Citation>Lord, A. et al. Observations in APP bitransgenic mice suggest that diffuse and compact plaques form via independent processes in Alzheimer&#x2019;s disease. Am. J. Pathol. 178, 2286&#x2013;2298 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21514441</ArticleId><ArticleId IdType="pmc">3081149</ArticleId><ArticleId IdType="doi">10.1016/j.ajpath.2011.01.052</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasmussen, J. et al. Amyloid polymorphisms constitute distinct clouds of conformational variants in different etiological subtypes of Alzheimer&#x2019;s disease. Proc. Natl Acad. Sci. USA 114, 13018&#x2013;13023 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29158413</ArticleId><ArticleId IdType="pmc">5724274</ArticleId><ArticleId IdType="doi">10.1073/pnas.1713215114</ArticleId></ArticleIdList></Reference><Reference><Citation>Ni, R. et al. Amyloid tracers binding sites in autosomal dominant and sporadic Alzheimer&#x2019;s disease. Alzheimers Dement. 13, 419&#x2013;430 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">27693181</ArticleId><ArticleId IdType="doi">10.1016/j.jalz.2016.08.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Ni, R., Gillberg, P. G., Bergfors, A., Marutle, A. &amp; Nordberg, A. Amyloid tracers detect multiple binding sites in Alzheimer&#x2019;s disease brain tissue. Brain 136, 2217&#x2013;2227 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23757761</ArticleId><ArticleId IdType="doi">10.1093/brain/awt142</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrmann, U. S. et al. Structure-based drug design identifies polythiophenes as antiprion compounds. Sci. Transl. Med. 7, 299ra123 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26246168</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.aab1923</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xfc;tz, A. K. et al. The amyloid-Congo red interface at atomic resolution. Angew. Chem. Int. Ed. Engl. 50, 5956&#x2013;5960 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21591034</ArticleId><ArticleId IdType="doi">10.1002/anie.201008276</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xfc;tz, A. K. et al. Binding of polythiophenes to amyloids: structural mapping of the pharmacophore. ACS Chem. Neurosci. 9, 475&#x2013;481 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29178774</ArticleId><ArticleId IdType="doi">10.1021/acschemneuro.7b00397</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xe4;ck, M., Appelqvist, H., LeVine, H. 3rd &amp; Nilsson, K. P. Anionic oligothiophenes compete for binding of X-34 but not PIB to recombinant A&#x3b2; amyloid fibrils and Alzheimer&#x2019;s disease brain-derived A&#x3b2;. Chemistry 22, 18335&#x2013;18338 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27767229</ArticleId><ArticleId IdType="pmc">5215536</ArticleId><ArticleId IdType="doi">10.1002/chem.201604583</ArticleId></ArticleIdList></Reference><Reference><Citation>Aslund, A. et al. Novel pentameric thiophene derivatives for in vitro and in vivo optical imaging of a plethora of protein aggregates in cerebral amyloidoses. ACS Chem. Biol. 4, 673&#x2013;684 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19624097</ArticleId><ArticleId IdType="pmc">2886514</ArticleId><ArticleId IdType="doi">10.1021/cb900112v</ArticleId></ArticleIdList></Reference><Reference><Citation>Nystr&#xf6;m, S. et al. Evidence for age-dependent in vivo conformational rearrangement within A&#x3b2; amyloid deposits. ACS Chem. Biol. 8, 1128&#x2013;1133 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23521783</ArticleId><ArticleId IdType="doi">10.1021/cb4000376</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulrich, J. D. et al. ApoE facilitates the microglial response to amyloid plaque pathology. J. Exp. Med. 215, 1047&#x2013;1058 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29483128</ArticleId><ArticleId IdType="pmc">5881464</ArticleId><ArticleId IdType="doi">10.1084/jem.20171265</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, Y. et al. Highly specific noninvasive photoacoustic and positron emission tomography of brain plaque with functionalized croconium dye labeled by a radiotracer. Chem. Sci. 8, 2710&#x2013;2716 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28451353</ArticleId><ArticleId IdType="pmc">5399633</ArticleId><ArticleId IdType="doi">10.1039/C6SC04798J</ArticleId></ArticleIdList></Reference><Reference><Citation>Miao, J. et al. Cerebral microvascular amyloid beta protein deposition induces vascular degeneration and neuroinflammation in transgenic mice expressing human vasculotropic mutant amyloid beta precursor protein. Am. J. Pathol. 167, 505&#x2013;515 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16049335</ArticleId><ArticleId IdType="pmc">1603574</ArticleId><ArticleId IdType="doi">10.1016/S0002-9440(10)62993-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer, V. W., Siddiqi, A. &amp; Yusufaly, Y. Altered angioarchitecture in selected areas of brains with Alzheimer&#x2019;s disease. Acta Neuropathol. 79, 672&#x2013;679 (1990).</Citation><ArticleIdList><ArticleId IdType="pubmed">2360411</ArticleId><ArticleId IdType="doi">10.1007/BF00294246</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulic, L. et al. Early accumulation of intracellular fibrillar oligomers and late congophilic amyloid angiopathy in mice expressing the Osaka intra-A&#x3b2; APP mutation. Transl. Psychiatry 2, e183 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">23149447</ArticleId><ArticleId IdType="pmc">3565767</ArticleId><ArticleId IdType="doi">10.1038/tp.2012.109</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim, H. Y. et al. EPPS rescues hippocampus-dependent cognitive deficits in APP/PS1 mice by disaggregation of amyloid-&#x3b2; oligomers and plaques. Nat. Commun. 6, 8997 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26646366</ArticleId><ArticleId IdType="doi">10.1038/ncomms9997</ArticleId></ArticleIdList></Reference><Reference><Citation>Ni, R. et al. In vitro characterization of the regional binding distribution of amyloid PET tracer florbetaben and the glia tracers Deprenyl and PK1195 in autopsy Alzheimer&#x2019;s brain tissue. J. Alzheimers Dis. 80, 1723&#x2013;1737 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33749648</ArticleId><ArticleId IdType="pmc">8150513</ArticleId><ArticleId IdType="doi">10.3233/JAD-201344</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim, H. M. &amp; Cho, B. R. Small-molecule two-photon probes for bioimaging applications. Chem. Rev. 115, 5014&#x2013;5055 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25938620</ArticleId><ArticleId IdType="doi">10.1021/cr5004425</ArticleId></ArticleIdList></Reference><Reference><Citation>Snellman, A. et al. Applicability of [(11)C]PIB micro-PET imaging for in vivo follow-up of anti-amyloid treatment effects in APP23 mouse model. Neurobiol. Aging 57, 84&#x2013;94 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28605642</ArticleId><ArticleId IdType="doi">10.1016/j.neurobiolaging.2017.05.008</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou, Q., Chen, Z., Robin, J., De&#xe1;n-Ben, X.-L. &amp; Razansky, D. Diffuse optical localization imaging for noninvasive deep brain microangiography in the NIR-II window. Optica 8, 796&#x2013;803 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1364/OPTICA.420378</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren, W. et al. Automated registration of magnetic resonance imaging and optoacoustic tomography data for experimental studies. Neurophotonics 6, 025001 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30989087</ArticleId><ArticleId IdType="pmc">6446211</ArticleId><ArticleId IdType="doi">10.1117/1.NPh.6.2.025001</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottschalk, S. et al. Rapid volumetric optoacoustic imaging of neural dynamics across the mouse brain. Nat. Biomed. Eng 3, 392&#x2013;401 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30992553</ArticleId><ArticleId IdType="pmc">6825512</ArticleId><ArticleId IdType="doi">10.1038/s41551-019-0372-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottschalk, S., Fehm, T. F., Dean-Ben, X. L., Tsytsarev, V. &amp; Razansky, D. Correlation between volumetric oxygenation responses and electrophysiology identifies deep thalamocortical activity during epileptic seizures. Neurophotonics 4, 011007 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">27725948</ArticleId><ArticleId IdType="doi">10.1117/1.NPh.4.1.011007</ArticleId></ArticleIdList></Reference><Reference><Citation>Dean-Ben, X. L. &amp; Razansky, D. On the link between the speckle free nature of optoacoustics and visibility of structures in limited-view tomography. Photoacoustics 4, 133&#x2013;140 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">28066714</ArticleId><ArticleId IdType="pmc">5200938</ArticleId><ArticleId IdType="doi">10.1016/j.pacs.2016.10.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Davoudi, N., De&#xe1;n-Ben, X. L. &amp; Razansky, D. Deep learning optoacoustic tomography with sparse data. Nat. Mach. Intell. 1, 453&#x2013;460 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42256-019-0095-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Blinder, P., Shih, A. Y., Rafie, C. &amp; Kleinfeld, D. Topological basis for the robust distribution of blood to rodent neocortex. Proc. Natl Acad. Sci. USA 107, 12670 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20616030</ArticleId><ArticleId IdType="pmc">2906564</ArticleId><ArticleId IdType="doi">10.1073/pnas.1007239107</ArticleId></ArticleIdList></Reference><Reference><Citation>Laufer, J., Zhang, E., Raivich, G. &amp; Beard, P. Three-dimensional noninvasive imaging of the vasculature in the mouse brain using a high resolution photoacoustic scanner. Appl. Opt. 48, D299&#x2013;D306 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19340121</ArticleId><ArticleId IdType="doi">10.1364/AO.48.00D299</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren, W. et al. Development of concurrent magnetic resonance imaging and volumetric optoacoustic tomography: a phantom feasibility study. J. Biophotonics 14, e202000293 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33169918</ArticleId><ArticleId IdType="doi">10.1002/jbio.202000293</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen, S. I. A. et al. A molecular chaperone breaks the catalytic cycle that generates toxic A&#x3b2; oligomers. Nat. Struct. Mol. Biol. 22, 207&#x2013;213 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25686087</ArticleId><ArticleId IdType="pmc">4595974</ArticleId><ArticleId IdType="doi">10.1038/nsmb.2971</ArticleId></ArticleIdList></Reference><Reference><Citation>Ni, R. et al. fMRI reveals mitigation of cerebrovascular dysfunction by bradykinin receptors 1 and 2 inhibitor noscapine in a mouse model of cerebral amyloidosis. Front. Aging Neurosci. 11, 27 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30890928</ArticleId><ArticleId IdType="pmc">6413713</ArticleId><ArticleId IdType="doi">10.3389/fnagi.2019.00027</ArticleId></ArticleIdList></Reference><Reference><Citation>Klohs, J. et al. Quantitative assessment of microvasculopathy in arcA&#x3b2; mice with USPIO-enhanced gradient echo MRI. J. Cereb. Blood Flow Metab. 36, 1614&#x2013;1624 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26661253</ArticleId><ArticleId IdType="doi">10.1177/0271678X15621500</ArticleId></ArticleIdList></Reference><Reference><Citation>Ni, R., Rudin, M. &amp; Klohs, J. Cortical hypoperfusion and reduced cerebral metabolic rate of oxygen in the arcAbeta mouse model of Alzheimer&#x2019;s disease. Photoacoustics 10, 38&#x2013;47 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29682448</ArticleId><ArticleId IdType="pmc">5909030</ArticleId><ArticleId IdType="doi">10.1016/j.pacs.2018.04.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, Z., Zhou, Q., Rebling, J. &amp; Razansky, D. Cortex-wide microcirculation mapping with ultrafast large-field multifocal illumination microscopy. J. Biophotonics 13, e202000198 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32761746</ArticleId></ArticleIdList></Reference><Reference><Citation>Gregor, I. &amp; Enderlein, J. Image scanning microscopy. Curr. Opin. Chem. Biol. 51, 74&#x2013;83 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31203139</ArticleId><ArticleId IdType="doi">10.1016/j.cbpa.2019.05.011</ArticleId></ArticleIdList></Reference><Reference><Citation>Dean-Ben, X. L., Robin, J., Ni, R. &amp; Razansky, D. Noninvasive three-dimensional optoacoustic localization microangiography of deep tissues. Preprint at https://arxiv.org/abs/2007.00372 (2020).</Citation></Reference><Reference><Citation>Ni, R. et al. In-vitro and in-vivo characterization of CRANAD-2 for multi-spectral optoacoustic tomography and fluorescence imaging of amyloid-beta deposits in Alzheimer mice. Photoacoustics 23, 100285 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34354924</ArticleId><ArticleId IdType="pmc">8321919</ArticleId><ArticleId IdType="doi">10.1016/j.pacs.2021.100285</ArticleId></ArticleIdList></Reference><Reference><Citation>American National Standard for the Safe Use of Lasers (American National Standards Institute, 1993).</Citation></Reference><Reference><Citation>Lein, E. S. et al. Genome-wide atlas of gene expression in the adult mouse brain. Nature 445, 168&#x2013;176 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17151600</ArticleId><ArticleId IdType="doi">10.1038/nature05453</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma, Y. et al. A three-dimensional digital atlas database of the adult C57BL/6J mouse brain by magnetic resonance microscopy. Neuroscience 135, 1203&#x2013;1215 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16165303</ArticleId><ArticleId IdType="doi">10.1016/j.neuroscience.2005.07.014</ArticleId></ArticleIdList></Reference><Reference><Citation>Vagenknecht, P. et al. Non-invasive imaging of tau-targeted probe uptake by whole brain multi-spectral optoacoustic tomography. Eur. J. Nucl. Med. Mol. Imaging 49, 2137&#x2013;2152 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35128565</ArticleId><ArticleId IdType="pmc">9165274</ArticleId><ArticleId IdType="doi">10.1007/s00259-022-05708-w</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung, K. et al. Structural and molecular interrogation of intact biological systems. Nature 497, 332&#x2013;337 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23575631</ArticleId><ArticleId IdType="pmc">4092167</ArticleId><ArticleId IdType="doi">10.1038/nature12107</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang, B. et al. Single-cell phenotyping within transparent intact tissue through whole-body clearing. Cell 158, 945&#x2013;958 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25088144</ArticleId><ArticleId IdType="pmc">4153367</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2014.07.017</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36108674</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>01</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>610</Volume><Issue>7933</Issue><PubDate><Year>2022</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Structures of &#x3b1;-synuclein filaments from human brains with Lewy pathology.</ArticleTitle><Pagination><StartPage>791</StartPage><EndPage>795</EndPage><MedlinePgn>791-795</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41586-022-05319-3</ELocationID><Abstract><AbstractText>Parkinson's disease (PD) is the most common movement disorder, with resting tremor, rigidity, bradykinesia and postural instability being major symptoms<sup>1</sup>. Neuropathologically, it is characterized by the presence of abundant filamentous inclusions of &#x3b1;-synuclein in the form of Lewy bodies and Lewy neurites in some brain cells, including dopaminergic nerve cells of the substantia nigra<sup>2</sup>. PD is increasingly recognised as a multisystem disorder, with cognitive decline being one of its most common non-motor symptoms. Many patients with PD develop dementia more than 10 years after diagnosis<sup>3</sup>. PD dementia (PDD) is clinically and neuropathologically similar to dementia with Lewy bodies (DLB), which is diagnosed when cognitive impairment precedes parkinsonian motor signs or begins within one year from their onset<sup>4</sup>. In PDD, cognitive impairment develops in the setting of well-established PD. Besides PD and DLB, multiple system atrophy (MSA) is the third major synucleinopathy<sup>5</sup>. It is characterized by the presence of abundant filamentous &#x3b1;-synuclein inclusions in brain cells, especially oligodendrocytes (Papp-Lantos bodies). We previously reported the electron cryo-microscopy structures of two types of &#x3b1;-synuclein filament extracted from the brains of individuals with MSA<sup>6</sup>. Each filament type is made of two different protofilaments. Here we report that the cryo-electron microscopy structures of &#x3b1;-synuclein filaments from the brains of individuals with PD, PDD and DLB are made of a single protofilament (Lewy fold) that is markedly different from the protofilaments of MSA. These findings establish the existence of distinct molecular conformers of assembled &#x3b1;-synuclein in neurodegenerative disease.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s), under exclusive licence to Springer Nature Limited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0003-2238-6437</Identifier><AffiliationInfo><Affiliation>Medical Research Council Laboratory of Molecular Biology, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0003-1579-7561</Identifier><AffiliationInfo><Affiliation>Medical Research Council Laboratory of Molecular Biology, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schweighauser</LastName><ForeName>Manuel</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-1848-1610</Identifier><AffiliationInfo><Affiliation>Medical Research Council Laboratory of Molecular Biology, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xianjun</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Thermo Fisher Scientific, Eindhoven, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kotecha</LastName><ForeName>Abhay</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-4480-5439</Identifier><AffiliationInfo><Affiliation>Thermo Fisher Scientific, Eindhoven, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murzin</LastName><ForeName>Alexey G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>Medical Research Council Laboratory of Molecular Biology, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garringer</LastName><ForeName>Holly J</ForeName><Initials>HJ</Initials><Identifier Source="ORCID">0000-0002-1899-7676</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cullinane</LastName><ForeName>Patrick W</ForeName><Initials>PW</Initials><AffiliationInfo><Affiliation>Department of Clinical and Movement Neurosciences, Queen Square Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Queen Square Brain Bank for Neurological Disorders, Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saito</LastName><ForeName>Yuko</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neuropathology, Metropolitan Institute of Gerontology, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Foroud</LastName><ForeName>Tatiana</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-5549-2212</Identifier><AffiliationInfo><Affiliation>Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Warner</LastName><ForeName>Thomas T</ForeName><Initials>TT</Initials><Identifier Source="ORCID">0000-0001-6195-6995</Identifier><AffiliationInfo><Affiliation>Department of Clinical and Movement Neurosciences, Queen Square Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Queen Square Brain Bank for Neurological Disorders, Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hasegawa</LastName><ForeName>Kazuko</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Neurology, Sagamihara National Hospital, Sagamihara, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vidal</LastName><ForeName>Ruben</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murayama</LastName><ForeName>Shigeo</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Molecular Research Centre for Children's Mental Development, United School of Child Development, University of Osaka, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Revesz</LastName><ForeName>Tamas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Queen Square Brain Bank for Neurological Disorders, Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, Queen Square Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghetti</LastName><ForeName>Bernardino</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-1842-8019</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hasegawa</LastName><ForeName>Masato</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-7415-8159</Identifier><AffiliationInfo><Affiliation>Department of Brain and Neurosciences, Metropolitan Institute of Medical Science, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lashley</LastName><ForeName>Tammaryn</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Queen Square Brain Bank for Neurological Disorders, Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, Queen Square Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scheres</LastName><ForeName>Sjors H W</ForeName><Initials>SHW</Initials><Identifier Source="ORCID">0000-0002-0462-6540</Identifier><AffiliationInfo><Affiliation>Medical Research Council Laboratory of Molecular Biology, Cambridge, UK. scheres@mrc-lmb.cam.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goedert</LastName><ForeName>Michel</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-5214-7886</Identifier><AffiliationInfo><Affiliation>Medical Research Council Laboratory of Molecular Biology, Cambridge, UK. mg@mrc-lmb.cam.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG010133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MC_U105184291</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>RF1 AG071177</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS037167</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P30 AG072976</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 NS110437</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MC_UP_A025_1013</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_EX_MR/N50192X/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Mov Disord. 2023 Jan;38(1):21-22. doi: 10.1002/mds.29272.</RefSource><PMID Version="1">36374937</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="Y">alpha-Synuclein</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="Y">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020285" MajorTopicYN="Y">Cryoelectron Microscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="Y">Lewy Body Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001923" MajorTopicYN="Y">Brain Chemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>
<b>Competing Interests</b>
. The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>9</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>15</Day><Hour>19</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>10</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36108674</ArticleId><ArticleId IdType="mid">EMS154603</ArticleId><ArticleId IdType="pmc">PMC7613749</ArticleId><ArticleId IdType="doi">10.1038/s41586-022-05319-3</ArticleId><ArticleId IdType="pii">10.1038/s41586-022-05319-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Berg D, et al. Time to redefine Parkinson&#x2019;s disease? Introductory statement of the MDS taskforce on the definition of Parkinson&#x2019;s disease. Mov Disord. 2014;29:454&#x2013;462.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4204150</ArticleId><ArticleId IdType="pubmed">24619848</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Spillantini MG, Del Tredici K, Braak H. 100 years of Lewy pathology. Nature Rev Neurol. 2013;9:13&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">23183883</ArticleId></ArticleIdList></Reference><Reference><Citation>Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-S&#xf8;rensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol. 2003;60:387&#x2013;392.</Citation><ArticleIdList><ArticleId IdType="pubmed">12633150</ArticleId></ArticleIdList></Reference><Reference><Citation>McKeith IG, et al. Diagnosis and management of dementia with Lewy bodies. Fourth consensus report of the DLB consortium. Neurology. 2017;879:88&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5496518</ArticleId><ArticleId IdType="pubmed">28592453</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanciulli A, Wenning GK. Multiple system atrophy. N Engl J Med. 2015;372:249&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pubmed">25587949</ArticleId></ArticleIdList></Reference><Reference><Citation>Schweighauser M, et al. Structures of &#x3b1;-synuclein filaments from multiple system atrophy. Nature. 2020;585:464&#x2013;469.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7116528</ArticleId><ArticleId IdType="pubmed">32461689</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymeropoulos MH, et al. Mutation in the &#x3b1;-synuclein gene identified in families with Parkinson&#x2019;s disease. Science. 1997;276:2045&#x2013;2047.</Citation><ArticleIdList><ArticleId IdType="pubmed">9197268</ArticleId></ArticleIdList></Reference><Reference><Citation>Singleton AB, et al. &#x3b1;-Synuclein locus triplication causes Parkinson&#x2019;s disease. Science. 2003;302:841.</Citation><ArticleIdList><ArticleId IdType="pubmed">14593171</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarranz JJ, et al. The new mutation, E46K, of alpha-synuclein causes Parkinson&#x2019;s disease and Lewy body dementia. Ann Neurol. 2004;55:164&#x2013;173.</Citation><ArticleIdList><ArticleId IdType="pubmed">14755719</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalls MA, et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson&#x2019;s disease. Nature Genet. 2014;46:989&#x2013;993.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4146673</ArticleId><ArticleId IdType="pubmed">25064009</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson WS, Jonas A, Clayton DF, George JM. Stabilization of &#x3b1;-synuclein secondary structure upon binding to synthetic membranes. J Biol Chem. 1998;273:9443&#x2013;9449.</Citation><ArticleIdList><ArticleId IdType="pubmed">9545270</ArticleId></ArticleIdList></Reference><Reference><Citation>Ueda K, et al. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc Natl Acad Sci USA. 1993;90:11282&#x2013;11286.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC47966</ArticleId><ArticleId IdType="pubmed">8248242</ArticleId></ArticleIdList></Reference><Reference><Citation>Li HT, Du HN, Tang L, Hu J, Hu HY. Structural transformation and aggregation of human &#x3b1;-synuclein in trifluoroethanol: non-amyloid component sequence is essential and &#x3b2;-sheet formation is prerequisite to aggregation. Biopolymers. 2002;64:221&#x2013;226.</Citation><ArticleIdList><ArticleId IdType="pubmed">12115139</ArticleId></ArticleIdList></Reference><Reference><Citation>Crowther RA, Jakes R, Spillantini MG, Goedert M. Synthetic filaments assembled from C-terminally truncated &#x3b1;-synuclein. FEBS Lett. 1998;436:309&#x2013;312.</Citation><ArticleIdList><ArticleId IdType="pubmed">9801138</ArticleId></ArticleIdList></Reference><Reference><Citation>Conway KA, Harper JD, Lansbury PT. Fibrils formed in vitro from &#x3b1;-synuclein and two mutant forms linked to Parkinson&#x2019;s disease are typical amyloid. Biochemistry. 2000;39:2525&#x2013;2563.</Citation><ArticleIdList><ArticleId IdType="pubmed">10704204</ArticleId></ArticleIdList></Reference><Reference><Citation>Serpell LC, Berriman J, Jakes R, Goedert M, Crowther RA. Fiber diffraction of synthetic &#x3b1;-synuclein filaments shows amyloid-like cross-&#xdf; conformation. Proc Natl Acad Sci USA. 2000;97:4897&#x2013;4902.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC18329</ArticleId><ArticleId IdType="pubmed">10781096</ArticleId></ArticleIdList></Reference><Reference><Citation>Miake H, Mizusawa H, Iwatsubo T, Hasegawa M. Biochemical characterization of the core structure of &#x3b1;-synuclein filaments. J Biol Chem. 2002;277:19213&#x2013;19219.</Citation><ArticleIdList><ArticleId IdType="pubmed">11893734</ArticleId></ArticleIdList></Reference><Reference><Citation>Mougenot AL, et al. Prion-like acceleration of a synucleinopathy in a transgenic mouse model. Neurobiol Aging. 2012;33:2225&#x2013;2228.</Citation><ArticleIdList><ArticleId IdType="pubmed">21813214</ArticleId></ArticleIdList></Reference><Reference><Citation>Luk KC, et al. Pathological &#x3b1;-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science. 2012;338:949&#x2013;953.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3552321</ArticleId><ArticleId IdType="pubmed">23161999</ArticleId></ArticleIdList></Reference><Reference><Citation>Masuda-Suzukake M, et al. Prion-like spreading of pathological &#x3b1;-synuclein in brain. Brain. 2013;136:1128&#x2013;1138.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3613715</ArticleId><ArticleId IdType="pubmed">23466394</ArticleId></ArticleIdList></Reference><Reference><Citation>Osterberg VR, et al. Progressive aggregation of &#x3b1;-synuclein and selective degeneration of Lewy inclusion-bearing neurons in a mouse model of parkinsonism. Cell Rep. 2015;10:1252&#x2013;1260.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4351119</ArticleId><ArticleId IdType="pubmed">25732816</ArticleId></ArticleIdList></Reference><Reference><Citation>Peelaerts W, et al. &#x3b1;-Synuclein strains cause distinct synucleinopathies after local and systemic administration. Nature. 2015;522:340&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pubmed">26061766</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng C, et al. Cellular milieu imparts pathological &#x3b1;-synuclein strains in &#x3b1;-synucleinopathies. Nature. 2018;557:558&#x2013;563.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5970994</ArticleId><ArticleId IdType="pubmed">29743672</ArticleId></ArticleIdList></Reference><Reference><Citation>Prusiner SB, et al. Evidence for &#x3b1;-synuclein prions causing multiple system atrophy in humans with parkinsonism. Proc Natl Acad Sci USA. 2015;112:E5308&#x2013;E5317.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4586853</ArticleId><ArticleId IdType="pubmed">26324905</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarutani A, Arai T, Murayama S, Hisanaga SI, Hasegawa M. Potent prion-like behaviors of pathogenic &#x3b1;-synuclein and evaluation of inactivation methods. Acta Neuropathol Commun. 2018;6:29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5907316</ArticleId><ArticleId IdType="pubmed">29669601</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamasaki TR, et al. Parkinson&#x2019;s disease and multiple system atrophy have distinct &#x3b1;-synuclein seed characteristics. J Biol Chem. 2019;294:1045&#x2013;1058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6341389</ArticleId><ArticleId IdType="pubmed">30478174</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavenir I, et al. Silver staining (Campbell-Switzer) of neuronal &#x3b1;-synuclein assemblies induced by multiple system atrophy and Parkinson&#x2019;s disease brain extracts in transgenic mice. Acta Neuropathol Commun. 2019;7:148.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6745790</ArticleId><ArticleId IdType="pubmed">31522685</ArticleId></ArticleIdList></Reference><Reference><Citation>Klingstedt T, et al. Luminescent conjugated oligothiophenes distinguish between &#x3b1;-synuclein assemblies of Parkinson&#x2019;s disease and multiple system atrophy. Acta Neuropathol Commun. 2019;7:193.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6892142</ArticleId><ArticleId IdType="pubmed">31796099</ArticleId></ArticleIdList></Reference><Reference><Citation>Stroh&#xe4;ker T, et al. Structural heterogeneity of &#x3b1;-synuclein fibrils amplified from patient brain extracts. Nature Commun. 2019;10:5535.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6893031</ArticleId><ArticleId IdType="pubmed">31797870</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau A, et al. &#x3b1;-Synuclein strains target distinct brain regions and cell types. Nature Neurosci. 2020;23:21&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6930851</ArticleId><ArticleId IdType="pubmed">31792467</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahnawaz M, et al. Discriminating &#x3b1;-synuclein strains in Parkinson&#x2019;s disease and multiple system atrophy. Nature. 2020;578:273&#x2013;277.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7066875</ArticleId><ArticleId IdType="pubmed">32025029</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayers JI, et al. Different &#x3b1;-synuclein prion strains cause dementia with Lewy bodies and multiple system atrophy. Proc Natl Acad Sci USA. 2022;119:e2113489119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8833220</ArticleId><ArticleId IdType="pubmed">35115402</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. &#x3b1;-Synuclein in filamentous inclusions of Lewy bodies from Parkinson&#x2019;s disease and dementia with Lewy bodies. Proc Natl Acad Sci USA. 1998;95:6469&#x2013;6473.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27806</ArticleId><ArticleId IdType="pubmed">9600990</ArticleId></ArticleIdList></Reference><Reference><Citation>Crowther RA, Daniel SE, Goedert M. Characterisation of isolated &#x3b1;-synuclein filaments from substantia nigra of Parkinson&#x2019;s disease brain. Neurosci Lett. 2000;292:128&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pubmed">10998565</ArticleId></ArticleIdList></Reference><Reference><Citation>Holec SAM, Liu SL, Woerman AL. Consequences of variability in &#x3b1;-synuclein fibril structure on strain biology. Acta Neuropathol. 2022;143:311&#x2013;330.</Citation><ArticleIdList><ArticleId IdType="pubmed">35122113</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao K, et al. Parkinson&#x2019;s disease-related phosphorylation at Tyr39 rearranges &#x3b1;-synuclein amyloid fibril structure revealed by cryo-EM. Proc Natl Acad Sci USA. 2020;117:20305&#x2013;20315.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7443891</ArticleId><ArticleId IdType="pubmed">32737160</ArticleId></ArticleIdList></Reference><Reference><Citation>McGlinchey RP, Ni X, Shadish JA, Jiang J, Lee JC. The N-terminus of &#x3b1;-synuclein dictates fibril formation. Proc Natl Acad Sci USA. 2021;118:e2023487118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8536336</ArticleId><ArticleId IdType="pubmed">34452994</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerrero-Ferreira R, et al. Two new polymorphic structures of human full-length alpha-synuclein fibrils solved by cryo-electron microscopy. eLife. 2019;8:e48907.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6957273</ArticleId><ArticleId IdType="pubmed">31815671</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, et al. Structure-based classification of tauopathies. Nature. 2021;598:359&#x2013;363.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7611841</ArticleId><ArticleId IdType="pubmed">34588692</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuboi Y, Dickson DW. Dementia with Lewy bodies and Parkinson&#x2019;s disease with dementia: Are they different? Parkinsonism Relat. Disord. 2005;11:S47&#x2013;S51.</Citation><ArticleIdList><ArticleId IdType="pubmed">15885629</ArticleId></ArticleIdList></Reference><Reference><Citation>Compta Y, et al. Lewy- and Alzheimer-type pathologies in Parkinson&#x2019;s disease dementia: which is more important? Brain. 2011;134:1493&#x2013;1505.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4194668</ArticleId><ArticleId IdType="pubmed">21596773</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Del Tredici K. Neuroanatomy and pathology of sporadic Parkinson&#x2019;s disease. Adv Anat Embryol Cell Biol. 2009;201:1&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pubmed">19230552</ArticleId></ArticleIdList></Reference><Reference><Citation>Poggiolini I, et al. Diagnostic value of cerebrospinal fluid alpha-synuclein seed quantification in synucleinopathies. Brain. 2022;145:584&#x2013;595.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9014737</ArticleId><ArticleId IdType="pubmed">34894214</ArticleId></ArticleIdList></Reference><Reference><Citation>Candelise N, et al. Seeding variability of different alpha-synuclein strains in synucleinopathies. Ann Neurol. 2019;85:691&#x2013;703.</Citation><ArticleIdList><ArticleId IdType="pubmed">30805957</ArticleId></ArticleIdList></Reference><Reference><Citation>Van der Perren A, et al. The structural differences between patient-derived &#x3b1;-synuclein strains dictate characteristics of Parkinson&#x2019;s disease, multiple system atrophy and dementia with Lewy bodies. Acta Neuropathol. 2020;139:977&#x2013;1000.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7244622</ArticleId><ArticleId IdType="pubmed">32356200</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf6;vestam S, et al. Seeded assembly in vitro does not replicate the structures of &#x3b1;-synuclein filaments from multiple system atrophy. FEBS Open Bio. 2021;11:999&#x2013;1013.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8016116</ArticleId><ArticleId IdType="pubmed">33548114</ArticleId></ArticleIdList></Reference><Reference><Citation>Burger D, Fenyi A, Bousset L, Stahlberg H, Melki R. Cryo-EM structure of alpha-synuclein fibrils amplified by PMCA from PD and MSA patient brains. BioRxiv</Citation></Reference><Reference><Citation>Frieg B, et al. &#x3b1;-Synuclein polymorphism determines oligodendroglial dysfunction. BioRxiv</Citation></Reference><Reference><Citation>Sokratian A, et al. Structural and functional landscape of &#x3b1;-synuclein fibril conformations amplified from cerebrospinal fluid. BioRxiv</Citation></Reference><Reference><Citation>Spillantini MG, Crowther RA, Jakes R, Cairns NJ, Lantos PL, Goedert M. Filamentous &#x3b1;-synuclein inclusions link multiple system atrophy with Parkinson&#x2019;s disease and dementia with Lewy bodies. Neurosci Lett. 1998;251:205&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pubmed">9726379</ArticleId></ArticleIdList></Reference><Reference><Citation>Woerman AL, et al. Familial Parkinson&#x2019;s point mutation abolishes multiple system atrophy prion replication. Proc Natl Acad Sci USA. 2018;115:409&#x2013;414.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5777081</ArticleId><ArticleId IdType="pubmed">29279394</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf6;vestam S, et al. Assembly of recombinant tau into filaments identical to those of Alzheimer&#x2019;s disease and chronic traumatic encephalopathy. eLife. 2022;11:e76494.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8983045</ArticleId><ArticleId IdType="pubmed">35244536</ArticleId></ArticleIdList></Reference><Reference><Citation>Schweighauser M, et al. Age-dependent formation of TMEM106B amyloid filaments in human brains. Nature. 2022;605:310&#x2013;314.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9095482</ArticleId><ArticleId IdType="pubmed">35344985</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Spillantini MG, Cairns NJ, Crowther RA. Tau proteins of Alzheimer paired helical filaments: abnormal phosphorylation of all six brain isoforms. Neuron. 1992;8:159&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pubmed">1530909</ArticleId></ArticleIdList></Reference><Reference><Citation>Giasson BI, et al. A panel of epitope-specific antibodies detects protein domains distributes throughout human &#x3b1;-synuclein in Lewy bodies of Parkinson&#x2019;s disease. J Neurosci Res. 2000;59:528&#x2013;533.</Citation><ArticleIdList><ArticleId IdType="pubmed">10679792</ArticleId></ArticleIdList></Reference><Reference><Citation>Perrin RJ, et al. Epitope mapping and specificity of the antialpha synuclein monoclonal antibody Syn-1 in mouse brain and cultured cell lines. Neurosci Lett. 2003;349:133&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pubmed">12946570</ArticleId></ArticleIdList></Reference><Reference><Citation>Spina S, et al. The tauopathy associated with mutation +3 in intron 10 of Tau: characterization of the MSTD family. Brain. 2008;131:72&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2702832</ArticleId><ArticleId IdType="pubmed">18065436</ArticleId></ArticleIdList></Reference><Reference><Citation>Zivanov J, Nakane T, Scheres SHW. A Bayesian approach to beam-induced motion correction in cryo-EM single particle analysis. IUCrJ. 2019;6:5&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6327179</ArticleId><ArticleId IdType="pubmed">30713699</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohou A, Grigorieff N. CTFFIND4: fast and accurate defocus estimation from electron micrographs. J Struct Biol. 2015;192:216&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6760662</ArticleId><ArticleId IdType="pubmed">26278980</ArticleId></ArticleIdList></Reference><Reference><Citation>He S, Scheres SHW. Helical reconstruction in RELION. J Struct Biol. 2017;198:163&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5479445</ArticleId><ArticleId IdType="pubmed">28193500</ArticleId></ArticleIdList></Reference><Reference><Citation>Zivanov J, et al. New tools for automated high-resolution cryo-EM structure determination in RELON-3. eLife. 2018;7:e42166.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6250425</ArticleId><ArticleId IdType="pubmed">30412051</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheres SHW. Amyloid structure determination in RELION-3.1. Acta Crystallogr D. 2020;76:94&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7008511</ArticleId><ArticleId IdType="pubmed">32038040</ArticleId></ArticleIdList></Reference><Reference><Citation>Zivanov J, Nakane T, Scheres SHW. Estimation of higher-order aberrations and anisotropic magnification from cryo-EM data sets in RELION-3.1. IUCrJ. 2020;7:253&#x2013;267.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7055373</ArticleId><ArticleId IdType="pubmed">32148853</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen VB, et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr D. 2010;66:12&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2803126</ArticleId><ArticleId IdType="pubmed">20057044</ArticleId></ArticleIdList></Reference><Reference><Citation>Casa&#xf1;al A, et al. Current developments in Coot for macromolecular model building of electron cryo-microscopy and crystallographic data. Protein Sci. 2020;29:1069&#x2013;1078.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7096722</ArticleId><ArticleId IdType="pubmed">31730249</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamashita K, Palmer CM, Burnley T, Murshudov GN. Cryo-EM single-particle structure refinement and map calculation using Servalcat . Acta Crystallogr D. 2021;77:1282&#x2013;1291.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8489229</ArticleId><ArticleId IdType="pubmed">34605431</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">35862524</PMID><DateCompleted><Year>2022</Year><Month>07</Month><Day>25</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>377</Volume><Issue>6604</Issue><PubDate><Year>2022</Year><Month>Jul</Month><Day>22</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>Blots on a field?</ArticleTitle><Pagination><StartPage>358</StartPage><EndPage>363</EndPage><MedlinePgn>358-363</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/science.add9993</ELocationID><Abstract><AbstractText>A neuroscience image sleuth finds signs of fabrication in scores of Alzheimer's articles, threatening a reigning theory of the disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Piller</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016433">News</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Science. 2022 Aug 26;377(6609):934-935. doi: 10.1126/science.ade1872.</RefSource><PMID Version="1">36007030</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Science. 2022 Aug 26;377(6609):935. doi: 10.1126/science.ade4073.</RefSource><PMID Version="1">36007039</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Br Dent J. 2023 May;234(9):635-636. doi: 10.1038/s41415-023-5879-5.</RefSource><PMID Version="1">37173467</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="Y">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="Y">Blotting, Western</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015871" MajorTopicYN="Y">Scientific Misconduct</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>21</Day><Hour>14</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35862524</ArticleId><ArticleId IdType="doi">10.1126/science.add9993</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">35857844</PMID><DateCompleted><Year>2022</Year><Month>07</Month><Day>22</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2375-2548</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>29</Issue><PubDate><Year>2022</Year><Month>Jul</Month><Day>22</Day></PubDate></JournalIssue><Title>Science advances</Title><ISOAbbreviation>Sci Adv</ISOAbbreviation></Journal><ArticleTitle>Targeted BACE-1 inhibition in microglia enhances amyloid clearance and improved cognitive performance.</ArticleTitle><Pagination><StartPage>eabo3610</StartPage><MedlinePgn>eabo3610</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">eabo3610</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1126/sciadv.abo3610</ELocationID><Abstract><AbstractText>Abnormal accumulation of &#x3b2;-amyloid (A&#x3b2;) peptides is a culprit in Alzheimer's disease (AD); blocking A&#x3b2; generation is therefore being explored as a logical approach for AD treatment. Here, we demonstrate that targeted inhibition of &#x3b2;-site amyloid precursor protein (APP) cleaving enzyme-1 (BACE-1) in microglia has unique advantages. When <i>Bace-1</i> was deleted in Alzheimer's 5xFAD microglia, fewer amyloid plaques developed, and this reduction was not due to changes in APP processing but rather to enhanced A&#x3b2; clearance, in line with the increase in a microglial gene signature favoring phagocytosis. Moreover, deletion of <i>Bace-1</i> in microglia enhances functions of autophagolysosomes and A&#x3b2;-induced metabolic reprogramming necessary for A&#x3b2; degradation by favoring phosphorylation of mammalian target of rapamycin complex (mTOR) at Ser<sup>2448</sup> and modulating the PI3K-mTOR-HIF-1&#x3b1; signaling pathways. Mice with deletion of <i>Bace-1</i> in microglia showed no reduction in long-term potentiation, unlike global deletion of <i>Bace-1</i>. Our results suggest that targeted inhibition of BACE-1 in microglia is a superior strategy for AD treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Neeraj</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-2044-0375</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, UConn Health, 263 Farmington Avenue, Farmington, CT 06030-3401, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Das</LastName><ForeName>Brati</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-5800-3912</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, UConn Health, 263 Farmington Avenue, Farmington, CT 06030-3401, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, UConn Health, 263 Farmington Avenue, Farmington, CT 06030-3401, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Xiangyou</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, UConn Health, 263 Farmington Avenue, Farmington, CT 06030-3401, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Riqiang</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-7195-7617</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, UConn Health, 263 Farmington Avenue, Farmington, CT 06030-3401, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG025493</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 NS074256</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG058261</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS074256</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG046929</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG025493</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG046929</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Adv</MedlineTA><NlmUniqueID>101653440</NlmUniqueID><ISSNLinking>2375-2548</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509282">Bace1 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008322" MajorTopicYN="N">Mammals</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="Y">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>20</Day><Hour>14</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>7</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35857844</ArticleId><ArticleId IdType="pmc">PMC9299535</ArticleId><ArticleId IdType="doi">10.1126/sciadv.abo3610</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jack C. R. Jr., Bennett D. A., Blennow K., Carrillo M. C., Dunn B., Haeberlein S. B., Holtzman D. M., Jagust W., Jessen F., Karlawish J., Liu E., Molinuevo J. L., Montine T., Phelps C., Rankin K. P., Rowe C. C., Scheltens P., Siemers E., Snyder H. M., Sperling R.; Contributors , NIA-AA Research Framework: Toward a biological definition of Alzheimer&#x2019;s disease. Alzheimers Dement. 14, 535&#x2013;562 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5958625</ArticleId><ArticleId IdType="pubmed">29653606</ArticleId></ArticleIdList></Reference><Reference><Citation>Egan M. F., Kost J., Voss T., Mukai Y., Aisen P. S., Cummings J. L., Tariot P. N., Vellas B., van Dyck C. H., Boada M., Zhang Y., Li W., Furtek C., Mahoney E., Harper Mozley L., Mo Y., Sur C., Michelson D., Randomized trial of verubecestat for prodromal Alzheimer&#x2019;s disease. N. Engl. J. Med. 380, 1408&#x2013;1420 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6776078</ArticleId><ArticleId IdType="pubmed">30970186</ArticleId></ArticleIdList></Reference><Reference><Citation>Wessels A. M., Tariot P. N., Zimmer J. A., Selzler K. J., Bragg S. M., Andersen S. W., Landry J., Krull J. H., Downing A. M., Willis B. A., Shcherbinin S., Mullen J., Barker P., Schumi J., Shering C., Matthews B. R., Stern R. A., Vellas B., Cohen S., MacSweeney E., Boada M., Sims J. R., Efficacy and safety of lanabecestat for treatment of early and mild Alzheimer disease: The AMARANTH and DAYBREAK-ALZ randomized clinical trials. JAMA Neurol. 77, 199&#x2013;209 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6902191</ArticleId><ArticleId IdType="pubmed">31764959</ArticleId></ArticleIdList></Reference><Reference><Citation>Das B., Yan R., A close look at BACE1 inhibitors for Alzheimer&#x2019;s disease treatment. CNS Drugs 33, 251&#x2013;263 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7330928</ArticleId><ArticleId IdType="pubmed">30830576</ArticleId></ArticleIdList></Reference><Reference><Citation>Imbimbo B. P., Watling M., Investigational BACE inhibitors for the treatment of Alzheimer&#x2019;s disease. Expert Opin. Investig. Drugs 28, 967&#x2013;975 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31661331</ArticleId></ArticleIdList></Reference><Reference><Citation>Sur C., Kost J., Scott D., Adamczuk K., Fox N. C., Cummings J. L., Tariot P. N., Aisen P. S., Vellas B., Voss T., Mahoney E., Mukai Y., Kennedy M. E., Lines C., Michelson D., Egan M. F., BACE inhibition causes rapid, regional, and non-progressive volume reduction in Alzheimer&#x2019;s disease brain. Brain 143, 3816&#x2013;3826 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8453290</ArticleId><ArticleId IdType="pubmed">33253354</ArticleId></ArticleIdList></Reference><Reference><Citation>Ou-Yang M. H., Kurz J. E., Nomura T., Popovic J., Rajapaksha T. W., Dong H., Contractor A., Chetkovich D. M., Tourtellotte W. G., Vassar R., Axonal organization defects in the hippocampus of adult conditional BACE1 knockout mice. Sci. Transl. Med. 10, eaao5620 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11017370</ArticleId><ArticleId IdType="pubmed">30232227</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu X., Das B., Hou H., He W., Yan R., BACE1 deletion in the adult mouse reverses preformed amyloid deposition and improves cognitive functions. J. Exp. Med. 215, 927&#x2013;940 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5839766</ArticleId><ArticleId IdType="pubmed">29444819</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H., Song L., Laird F., Wong P. C., Lee H. K., BACE1 knock-outs display deficits in activity-dependent potentiation of synaptic transmission at mossy fiber to CA3 synapses in the hippocampus. J. Neurosci. 28, 8677&#x2013;8681 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2728626</ArticleId><ArticleId IdType="pubmed">18753368</ArticleId></ArticleIdList></Reference><Reference><Citation>Lombardo S., Chiacchiaretta M., Tarr A., Kim W., Cao T., Sigal G., Rosahl T. W., Xia W., Haydon P. G., Kennedy M. E., Tesco G., BACE1 partial deletion induces synaptic plasticity deficit in adult mice. Sci. Rep. 9, 19877 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6934620</ArticleId><ArticleId IdType="pubmed">31882662</ArticleId></ArticleIdList></Reference><Reference><Citation>Vnencak M., Scholvinck M. L., Schwarzacher S. W., Deller T., Willem M., Jedlicka P., Lack of &#x3b2;-amyloid cleaving enzyme-1 (BACE1) impairs long-term synaptic plasticity but enhances granule cell excitability and oscillatory activity in the dentate gyrus in vivo. Brain Struct. Funct. 224, 1279&#x2013;1290 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30701309</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu K., Peters F., Filser S., Herms J., Consequences of pharmacological BACE inhibition on synaptic structure and function. Biol. Psychiatry 84, 478&#x2013;487 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29945719</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy M. E., Stamford A. W., Chen X., Cox K., Cumming J. N., Dockendorf M. F., Egan M., Ereshefsky L., Hodgson R. A., Hyde L. A., Jhee S., Kleijn H. J., Kuvelkar R., Li W., Mattson B. A., Mei H., Palcza J., Scott J. D., Tanen M., Troyer M. D., Tseng J. L., Stone J. A., Parker E. M., Forman M. S., The BACE1 inhibitor verubecestat (MK-8931) reduces CNS &#x3b2;-amyloid in animal models and in Alzheimer&#x2019;s disease patients. Sci. Transl. Med. 8, 363ra150 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27807285</ArticleId></ArticleIdList></Reference><Reference><Citation>Li R., Lindholm K., Yang L. B., Yue X., Citron M., Yan R., Beach T., Sue L., Sabbagh M., Cai H., Wong P., Price D., Shen Y., Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer&#x2019;s disease patients. Proc. Natl. Acad. Sci. U.S.A. 101, 3632&#x2013;3637 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC373514</ArticleId><ArticleId IdType="pubmed">14978286</ArticleId></ArticleIdList></Reference><Reference><Citation>Kandalepas P. C., Sadleir K. R., Eimer W. A., Zhao J., Nicholson D. A., Vassar R., The Alzheimer&#x2019;s &#x3b2;-secretase BACE1 localizes to normal presynaptic terminals and to dystrophic presynaptic terminals surrounding amyloid plaques. Acta Neuropathol. 126, 329&#x2013;352 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3753469</ArticleId><ArticleId IdType="pubmed">23820808</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh N., Benoit M. R., Zhou J., Das B., Davila-Velderrain J., Kellis M., Tsai L.-H., Hu X., Yan R., BACE-1 inhibition facilitates the transition from homeostatic microglia to DAM-1. Sci. Adv. 8, eabo1286 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9205595</ArticleId><ArticleId IdType="pubmed">35714196</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakley H., Cole S. L., Logan S., Maus E., Shao P., Craft J., Guillozet-Bongaarts A., Ohno M., Disterhoft J., Van E. L., Berry R., Vassar R., Intraneuronal &#x3b2;-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer&#x2019;s disease mutations: Potential factors in amyloid plaque formation. J. Neurosci. 26, 10129&#x2013;10140 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674618</ArticleId><ArticleId IdType="pubmed">17021169</ArticleId></ArticleIdList></Reference><Reference><Citation>Baik S. H., Kang S., Lee W., Choi H., Chung S., Kim J. I., Mook-Jung I., A breakdown in metabolic reprogramming causes microglia dysfunction in Alzheimer&#x2019;s disease. Cell Metab. 30, 493&#x2013;507.e6 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31257151</ArticleId></ArticleIdList></Reference><Reference><Citation>DeWaal D., Nogueira V., Terry A. R., Patra K. C., Jeon S. M., Guzman G., Au J., Long C. P., Antoniewicz M. R., Hay N., Hexokinase-2 depletion inhibits glycolysis and induces oxidative phosphorylation in hepatocellular carcinoma and sensitizes to metformin. Nat. Commun. 9, 446 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5792493</ArticleId><ArticleId IdType="pubmed">29386513</ArticleId></ArticleIdList></Reference><Reference><Citation>Latif-Hernandez A., Sabanov V., Ahmed T., Craessaerts K., Saito T., Saido T., Balschun D., The two faces of synaptic failure in AppNL-G-F knock-in mice. Alzheimers Res. Ther. 12, 100 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7445922</ArticleId><ArticleId IdType="pubmed">32838792</ArticleId></ArticleIdList></Reference><Reference><Citation>Long J. M., Holtzman D. M., Alzheimer disease: An update on pathobiology and treatment strategies. Cell 179, 312&#x2013;339 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6778042</ArticleId><ArticleId IdType="pubmed">31564456</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertram L., Tanzi R. E., Alzheimer disease risk genes: 29 and counting. Nat. Rev. Neurol. 15, 191&#x2013;192 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30833695</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh D. M., Selkoe D. J., Amyloid &#x3b2;-protein and beyond: The path forward in Alzheimer&#x2019;s disease. Curr. Opin. Neurobiol. 61, 116&#x2013;124 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32197217</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar R., Editorial: Implications for BACE1 inhibitor clinical trials: Adult conditional BACE1 knockout mice exhibit axonal organization defects in the hippocampus. J. Prev Alzheimers Dis. 6, 78&#x2013;84 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30756113</ArticleId></ArticleIdList></Reference><Reference><Citation>Villegas-Llerena C., Phillips A., Garcia-Reitboeck P., Hardy J., Pocock J. M., Microglial genes regulating neuroinflammation in the progression of Alzheimer&#x2019;s disease. Curr. Opin. Neurobiol. 36, 74&#x2013;81 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26517285</ArticleId></ArticleIdList></Reference><Reference><Citation>Sims R., van der Lee S. J., Naj A. C., Bellenguez C., Badarinarayan N., Jakobsdottir J., Kunkle B. W., Boland A., Raybould R., Bis J. C., Martin E. R., Grenier-Boley B., Heilmann-Heimbach S., Chouraki V., Kuzma A. B., Sleegers K., Vronskaya M., Ruiz A., Graham R. R., Olaso R., Hoffmann P., Grove M. L., Vardarajan B. N., Hiltunen M., Nothen M. M., White C. C., Hamilton-Nelson K. L., Epelbaum J., Maier W., Choi S. H., Beecham G. W., Dulary C., Herms S., Smith A. V., Funk C. C., Derbois C., Forstner A. J., Ahmad S., Li H., Bacq D., Harold D., Satizabal C. L., Valladares O., Squassina A., Thomas R., Brody J. A., Qu L., Sanchez-Juan P., Morgan T., Wolters F. J., Zhao Y., Garcia F. S., Denning N., Fornage M., Malamon J., Naranjo M. C. D., Majounie E., Mosley T. H., Dombroski B., Wallon D., Lupton M. K., Dupuis J., Whitehead P., Fratiglioni L., Medway C., Jian X., Mukherjee S., Keller L., Brown K., Lin H., Cantwell L. B., Panza F., McGuinness B., Moreno-Grau S., Burgess J. D., Solfrizzi V., Proitsi P., Adams H. H., Allen M., Seripa D., Pastor P., Cupples L. A., Price N. D., Hannequin D., Frank-Garcia A., Levy D., Chakrabarty P., Caffarra P., Giegling I., Beiser A. S., Giedraitis V., Hampel H., Garcia M. E., Wang X., Lannfelt L., Mecocci P., Eiriksdottir G., Crane P. K., Pasquier F., Boccardi V., Henandez I., Barber R. C., Scherer M., Tarraga L., Adams P. M., Leber M., Chen Y., Albert M. S., Riedel-Heller S., Emilsson V., Beekly D., Braae A., Schmidt R., Blacker D., Masullo C., Schmidt H., Doody R. S., Spalletta G., Longstreth W. T. Jr., Fairchild T. J., Bossu P., Lopez O. L., Frosch M. P., Sacchinelli E., Ghetti B., Yang Q., Huebinger R. M., Jessen F., Li S., Kamboh M. I., Morris J., Sotolongo-Grau O., Katz M. J., Corcoran C., Dunstan M., Braddel A., Thomas C., Meggy A., Marshall R., Gerrish A., Chapman J., Aguilar M., Taylor S., Hill M., Fairen M. D., Hodges A., Vellas B., Soininen H., Kloszewska I., Daniilidou M., Uphill J., Patel Y., Hughes J. T., Lord J., Turton J., Hartmann A. M., Cecchetti R., Fenoglio C., Serpente M., Arcaro M., Caltagirone C., Orfei M. D., Ciaramella A., Pichler S., Mayhaus M., Gu W., Lleo A., Fortea J., Blesa R., Barber I. S., Brookes K., Cupidi C., Maletta R. G., Carrell D., Sorbi S., Moebus S., Urbano M., Pilotto A., Kornhuber J., Bosco P., Todd S., Craig D., Johnston J., Gill M., Lawlor B., Lynch A., Fox N. C., Hardy J., Albin R. L., Apostolova L. G., Arnold S. E., Asthana S., Atwood C. S., Baldwin C. T., Barnes L. L., Barral S., Beach T. G., Becker J. T., Bigio E. H., Bird T. D., Boeve B. F., Bowen J. D., Boxer A., Burke J. R., Burns J. M., Buxbaum J. D., Cairns N. J., Cao C., Carlson C. S., Carlsson C. M., Carney R. M., Carrasquillo M. M., Carroll S. L., Diaz C. C., Chui H. C., Clark D. G., Cribbs D. H., Crocco E. A., DeCarli C., Dick M., Duara R., Evans D. A., Faber K. M., Fallon K. B., Fardo D. W., Farlow M. R., Ferris S., Foroud T. M., Galasko D. R., Gearing M., Geschwind D. H., Gilbert J. R., Graff-Radford N. R., Green R. C., Growdon J. H., Hamilton R. L., Harrell L. E., Honig L. S., Huentelman M. J., Hulette C. M., Hyman B. T., Jarvik G. P., Abner E., Jin L. W., Jun G., Karydas A., Kaye J. A., Kim R., Kowall N. W., Kramer J. H., LaFerla F. M., Lah J. J., Leverenz J. B., Levey A. I., Li G., Lieberman A. P., Lunetta K. L., Lyketsos C. G., Marson D. C., Martiniuk F., Mash D. C., Masliah E., McCormick W. C., McCurry S. M., McDavid A. N., McKee A. C., Mesulam M., Miller B. L., Miller C. A., Miller J. W., Morris J. C., Murrell J. R., Myers A. J., O&#x2019;Bryant S., Olichney J. M., Pankratz V. S., Parisi J. E., Paulson H. L., Perry W., Peskind E., Pierce A., Poon W. W., Potter H., Quinn J. F., Raj A., Raskind M., Reisberg B., Reitz C., Ringman J. M., Roberson E. D., Rogaeva E., Rosen H. J., Rosenberg R. N., Sager M. A., Saykin A. J., Schneider J. A., Schneider L. S., Seeley W. W., Smith A. G., Sonnen J. A., Spina S., Stern R. A., Swerdlow R. H., Tanzi R. E., Thornton-Wells T. A., Trojanowski J. Q., Troncoso J. C., Van Deerlin V. M., Van Eldik L. J., Vinters H. V., Vonsattel J. P., Weintraub S., Welsh-Bohmer K. A., Wilhelmsen K. C., Williamson J., Wingo T. S., Woltjer R. L., Wright C. B., Yu C. E., Yu L., Garzia F., Golamaully F., Septier G., Engelborghs S., Vandenberghe R., De Deyn P. P., Fernadez C. M., Benito Y. A., Thonberg H., Forsell C., Lilius L., Kinhult-Stahlbom A., Kilander L., Brundin R., Concari L., Helisalmi S., Koivisto A. M., Haapasalo A., Dermecourt V., Fievet N., Hanon O., Dufouil C., Brice A., Ritchie K., Dubois B., Himali J. J., Keene C. D., Tschanz J., Fitzpatrick A. L., Kukull W. A., Norton M., Aspelund T., Larson E. B., Munger R., Rotter J. I., Lipton R. B., Bullido M. J., Hofman A., Montine T. J., Coto E., Boerwinkle E., Petersen R. C., Alvarez V., Rivadeneira F., Reiman E. M., Gallo M., O&#x2019;Donnell C. J., Reisch J. S., Bruni A. C., Royall D. R., Dichgans M., Sano M., Galimberti D., George-Hyslop P. S., Scarpini E., Tsuang D. W., Mancuso M., Bonuccelli U., Winslow A. R., Daniele A., Wu C. K.; GERAD/PERADES, CHARGE, ADGC, EADI, Peters O., Nacmias B., Riemenschneider M., Heun R., Brayne C., Rubinsztein D. C., Bras J., Guerreiro R., Al-Chalabi A., Shaw C. E., Collinge J., Mann D., Tsolaki M., Clarimon J., Sussams R., Lovestone S., O&#x2019;Donovan M. C., Owen M. J., Behrens T. W., Mead S., Goate A. M., Uitterlinden A. G., Holmes C., Cruchaga C., Ingelsson M., Bennett D. A., Powell J., Golde T. E., Graff C., De Jager P. L., Morgan K., Ertekin-Taner N., Combarros O., Psaty B. M., Passmore P., Younkin S. G., Berr C., Gudnason V., Rujescu D., Dickson D. W., Dartigues J. F., DeStefano A. L., Ortega-Cubero S., Hakonarson H., Campion D., Boada M., Kauwe J. K., Farrer L. A., Van Broeckhoven C., Ikram M. A., Jones L., Haines J. L., Tzourio C., Launer L. J., Escott-Price V., Mayeux R., Deleuze J. F., Amin N., Holmans P. A., Pericak-Vance M. A., Amouyel P., van Duijn C. M., Ramirez A., Wang L. S., Lambert J. C., Seshadri S., Williams J., Schellenberg G. D., Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer&#x2019;s disease. Nat. Genet. 49, 1373&#x2013;1384 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5669039</ArticleId><ArticleId IdType="pubmed">28714976</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R., Wojtas A., Bras J., Carrasquillo M., Rogaeva E., Majounie E., Cruchaga C., Sassi C., Kauwe J. S., Younkin S., Hazrati L., Collinge J., Pocock J., Lashley T., Williams J., Lambert J. C., Amouyel P., Goate A., Rademakers R., Morgan K., Powell J., St George-Hyslop P., Singleton A., Hardy J.; Alzheimer Genetic Analysis Group , TREM2 Variants in Alzheimer&#x2019;s disease. N. Engl. J. Med. 368, 117&#x2013;127, (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3631573</ArticleId><ArticleId IdType="pubmed">23150934</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T., Stefansson H., Ph D. S., Jonsdottir I., Jonsson P. V., Snaedal J., Bjornsson S., Huttenlocher J., Levey A. I., Lah J. J., Rujescu D., Hampel H., Giegling I., Andreassen O. A., Engedal K., Ulstein I., Djurovic S., Ibrahim-Verbaas C., Hofman A., Ikram M. A., van Duijn C. M., Thorsteinsdottir U., Kong A., Stefansson K., Variant of TREM2 associated with the risk of Alzheimer&#x2019;s disease. N. Engl. J. Med. 368, 107&#x2013;116 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677583</ArticleId><ArticleId IdType="pubmed">23150908</ArticleId></ArticleIdList></Reference><Reference><Citation>Novak G., Streffer J. R., Timmers M., Henley D., Brashear H. R., Bogert J., Russu A., Janssens L., Tesseur I., Tritsmans L., Van Nueten L., Engelborghs S., Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer&#x2019;s disease spectrum patients: A randomized, double-blind, placebo-controlled study and a two-period extension study. Alzheimers Res. Ther. 12, 58 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7227237</ArticleId><ArticleId IdType="pubmed">32410694</ArticleId></ArticleIdList></Reference><Reference><Citation>Das B., Singh N., Yao A. Y., Zhou J., He W., Hu X., Yan R., BACE1 controls synaptic function through modulating release of synaptic vesicles. Mol. Psychiatry 26, 6394&#x2013;6410 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8760050</ArticleId><ArticleId IdType="pubmed">34158621</ArticleId></ArticleIdList></Reference><Reference><Citation>Dislich B., Wohlrab F., Bachhuber T., Mueller S., Kuhn P. H., Hogl S., Meyer-Luehmann M., Lichtenthaler S. F., Label-free quantitative proteomics of mouse cerebrospinal fluid detects &#x3b2;-site APP cleaving enzyme (BACE1) protease substrates in vivo. Mol. Cell. Proteomics 14, 2550&#x2013;2563 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4597136</ArticleId><ArticleId IdType="pubmed">26139848</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H., Spinrad A., Weiner A., Matcovitch-Natan O., Dvir-Szternfeld R., Ulland T. K., David E., Baruch K., Lara-Astaiso D., Toth B., Itzkovitz S., Colonna M., Schwartz M., Amit I., A unique microglia type associated with restricting development of Alzheimer&#x2019;s disease. Cell 169, 1276&#x2013;1290.e17 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathys H., Adaikkan C., Gao F., Young J. Z., Manet E., Hemberg M., De Jager P. L., Ransohoff R. M., Regev A., Tsai L. H., Temporal tracking of microglia activation in neurodegeneration at single-cell resolution. Cell Rep. 21, 366&#x2013;380 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5642107</ArticleId><ArticleId IdType="pubmed">29020624</ArticleId></ArticleIdList></Reference><Reference><Citation>Mrdjen D., Pavlovic A., Hartmann F. J., Schreiner B., Utz S. G., Leung B. P., Lelios I., Heppner F. L., Kipnis J., Merkler D., Greter M., Becher B., High-dimensional single-cell mapping of central nervous system immune cells reveals distinct myeloid subsets in health, aging, and disease. Immunity 48, 599 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29562204</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampel H., Lista S., Vanmechelen E., Zetterberg H., Giorgi F. S., Galgani A., Blennow K., Caraci F., Das B., Yan R., Vergallo A., &#x3b2;-Secretase1 biological markers for Alzheimer&#x2019;s disease: State-of-art of validation and qualification. Alzheimers Res. Ther. 12, 130 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7566058</ArticleId><ArticleId IdType="pubmed">33066807</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajendran L., Paolicelli R. C., Microglia-mediated synapse loss in Alzheimer&#x2019;s disease. J. Neurosci. 38, 2911&#x2013;2919 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6596066</ArticleId><ArticleId IdType="pubmed">29563239</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X., Stoeck A., Lee S. J., Shih I., Wang M. M., Wang T. L., Jagged1 expression regulated by Notch3 and Wnt/&#x3b2;-catenin signaling pathways in ovarian cancer. Oncotarget 1, 210&#x2013;218 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2953807</ArticleId><ArticleId IdType="pubmed">20953350</ArticleId></ArticleIdList></Reference><Reference><Citation>Shalem O., Sanjana N. E., Zhang F., High-throughput functional genomics using CRISPR-Cas9. Nat. Rev. Genet. 16, 299&#x2013;311 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4503232</ArticleId><ArticleId IdType="pubmed">25854182</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">35879464</PMID><DateCompleted><Year>2022</Year><Month>08</Month><Day>03</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>8</Issue><PubDate><Year>2022</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Neurovascular dysfunction in GRN-associated frontotemporal dementia identified by single-nucleus RNA sequencing of human cerebral cortex.</ArticleTitle><Pagination><StartPage>1034</StartPage><EndPage>1048</EndPage><MedlinePgn>1034-1048</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41593-022-01124-3</ELocationID><Abstract><AbstractText>Frontotemporal dementia (FTD) is the second most prevalent form of early-onset dementia, affecting predominantly frontal and temporal cerebral lobes. Heterozygous mutations in the progranulin gene (GRN) cause autosomal-dominant FTD (FTD-GRN), associated with TDP-43 inclusions, neuronal loss, axonal degeneration and gliosis, but FTD-GRN pathogenesis is largely unresolved. Here we report single-nucleus RNA sequencing of microglia, astrocytes and the neurovasculature from frontal, temporal and occipital cortical tissue from control and FTD-GRN brains. We show that fibroblast and mesenchymal cell numbers were enriched in FTD-GRN, and we identified disease-associated subtypes of astrocytes and endothelial cells. Expression of gene modules associated with blood-brain barrier (BBB) dysfunction was significantly enriched in FTD-GRN endothelial cells. The vasculature supportive function and capillary coverage by pericytes was reduced in FTD-GRN tissue, with increased and hypertrophic vascularization and an enrichment of perivascular T cells. Our results indicate a perturbed BBB and suggest that the neurovascular unit is severely affected in FTD-GRN.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s), under exclusive licence to Springer Nature America, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gerrits</LastName><ForeName>Emma</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-7248-8779</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Sciences of Cells &amp; Systems, Section of Molecular Neurobiology, University of Groningen and University Medical Center Groningen, Groningen, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giannini</LastName><ForeName>Lucia A A</ForeName><Initials>LAA</Initials><AffiliationInfo><Affiliation>Department of Neurology &amp; Alzheimer Center, Erasmus University Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brouwer</LastName><ForeName>Nieske</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences of Cells &amp; Systems, Section of Molecular Neurobiology, University of Groningen and University Medical Center Groningen, Groningen, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Melhem</LastName><ForeName>Shamiram</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology &amp; Alzheimer Center, Erasmus University Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seilhean</LastName><ForeName>Danielle</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neuropathology, Pitie Salpetriere Hospital, AP-HP Sorbonne Universit&#xe9;, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Paris Brain Institute - Institut du Cerveau (ICM), Sorbonne Universit&#xe9;, Inserm U1127, CNRS UMR 7225, AP-HP - H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Le Ber</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Paris Brain Institute - Institut du Cerveau (ICM), Sorbonne Universit&#xe9;, Inserm U1127, CNRS UMR 7225, AP-HP - H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Reference Center for Rare or Early Dementias, IM2A, D&#xe9;partement de Neurologie, AP-HP - H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Brainbank Neuro-CEB Neuropathology Network</CollectiveName></Author><Author ValidYN="Y"><LastName>Kamermans</LastName><ForeName>Alwin</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-3601-395X</Identifier><AffiliationInfo><Affiliation>MS Center Amsterdam, Department of Molecular Cell Biology and Immunology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kooij</LastName><ForeName>Gijs</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>MS Center Amsterdam, Department of Molecular Cell Biology and Immunology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Vries</LastName><ForeName>Helga E</ForeName><Initials>HE</Initials><AffiliationInfo><Affiliation>MS Center Amsterdam, Department of Molecular Cell Biology and Immunology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boddeke</LastName><ForeName>Erik W G M</ForeName><Initials>EWGM</Initials><Identifier Source="ORCID">0000-0002-5058-9648</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Sciences of Cells &amp; Systems, Section of Molecular Neurobiology, University of Groningen and University Medical Center Groningen, Groningen, Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Healthy Ageing, Department of Cellular and Molecular Medicine, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seelaar</LastName><ForeName>Harro</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-1989-7527</Identifier><AffiliationInfo><Affiliation>Department of Neurology &amp; Alzheimer Center, Erasmus University Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>van Swieten</LastName><ForeName>John C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Neurology &amp; Alzheimer Center, Erasmus University Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Eggen</LastName><ForeName>Bart J L</ForeName><Initials>BJL</Initials><Identifier Source="ORCID">0000-0001-8941-0353</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Sciences of Cells &amp; Systems, Section of Molecular Neurobiology, University of Groningen and University Medical Center Groningen, Groningen, Netherlands. b.j.l.eggen@umcg.nl.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C492314">GRN protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D036341">Intercellular Signaling Peptides and Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000077153">Progranulins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2022 Sep;18(9):509. doi: 10.1038/s41582-022-00705-x.</RefSource><PMID Version="1">35945458</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D001812" MajorTopicYN="N">Blood-Brain Barrier</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042783" MajorTopicYN="N">Endothelial Cells</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036341" MajorTopicYN="N">Intercellular Signaling Peptides and Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077153" MajorTopicYN="Y">Progranulins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017423" MajorTopicYN="N">Sequence Analysis, RNA</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013702" MajorTopicYN="N">Temporal Lobe</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>10</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>6</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>25</Day><Hour>23</Hour><Minute>28</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35879464</ArticleId><ArticleId IdType="doi">10.1038/s41593-022-01124-3</ArticleId><ArticleId IdType="pii">10.1038/s41593-022-01124-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Meeter, L. H., Kaat, L. D., Rohrer, J. D. &amp; van Swieten, J. C. Imaging and fluid biomarkers in frontotemporal dementia. Nat. Rev. Neurol. 13, 406&#x2013;419 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28621768</ArticleId><ArticleId IdType="doi">10.1038/nrneurol.2017.75</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie, I. R. A. &amp; Neumann, M. Molecular neuropathology of frontotemporal dementia: insights into disease mechanisms from postmortem studies. J. Neurochem. 138, 54&#x2013;70 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27306735</ArticleId><ArticleId IdType="doi">10.1111/jnc.13588</ArticleId></ArticleIdList></Reference><Reference><Citation>Woollacott, I. O. C. &amp; Rohrer, J. D. The clinical spectrum of sporadic and familial forms of frontotemporal dementia. J. Neurochem. 138, 6&#x2013;31 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27144467</ArticleId><ArticleId IdType="doi">10.1111/jnc.13654</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker, M. et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 442, 916&#x2013;919 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16862116</ArticleId><ArticleId IdType="doi">10.1038/nature05016</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruts, M. et al. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature 442, 920&#x2013;924 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16862115</ArticleId><ArticleId IdType="doi">10.1038/nature05017</ArticleId></ArticleIdList></Reference><Reference><Citation>Eguchi, R., Nakano, T. &amp; Wakabayashi, I. Progranulin and granulin-like protein as novel VEGF-independent angiogenic factors derived from human mesothelioma cells. Oncogene 36, 714&#x2013;722 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">27345409</ArticleId><ArticleId IdType="doi">10.1038/onc.2016.226</ArticleId></ArticleIdList></Reference><Reference><Citation>van Swieten, J. C. &amp; Heutink, P. Mutations in progranulin (GRN) within the spectrum of clinical and pathological phenotypes of frontotemporal dementia. Lancet Neurol. 7, 965&#x2013;974 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18771956</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(08)70194-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Kao, A. W., McKay, A., Singh, P. P., Brunet, A. &amp; Huang, E. J. Progranulin, lysosomal regulation and neurodegenerative disease. Nat. Rev. Neurosci. 18, 325&#x2013;333 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28435163</ArticleId><ArticleId IdType="pmc">6040832</ArticleId><ArticleId IdType="doi">10.1038/nrn.2017.36</ArticleId></ArticleIdList></Reference><Reference><Citation>Bright, F. et al. Neuroinflammation in frontotemporal dementia. Nat. Rev. Neurol. 15, 540&#x2013;555 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31324897</ArticleId><ArticleId IdType="doi">10.1038/s41582-019-0231-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Heller, C. et al. Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia. J. Neurol. Neurosurg. Psychiatry 91, 263&#x2013;270 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31937580</ArticleId><ArticleId IdType="doi">10.1136/jnnp-2019-321954</ArticleId></ArticleIdList></Reference><Reference><Citation>Boss&#xf9;, P. et al. Loss of function mutations in the progranulin gene are related to pro-inflammatory cytokine dysregulation in frontotemporal lobar degeneration patients. J. Neuroinflammation 8, 65 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21645364</ArticleId><ArticleId IdType="pmc">3141503</ArticleId><ArticleId IdType="doi">10.1186/1742-2094-8-65</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin, F. et al. Exaggerated inflammation, impaired host defense, and neuropathology in progranulin-deficient mice. J. Exp. Med. 207, 117&#x2013;128 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20026663</ArticleId><ArticleId IdType="pmc">2812536</ArticleId><ArticleId IdType="doi">10.1084/jem.20091568</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka, Y., Matsuwaki, T., Yamanouchi, K. &amp; Nishihara, M. Exacerbated inflammatory responses related to activated microglia after traumatic brain injury in progranulin-deficient mice. Neuroscience 231, 49&#x2013;60 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23201826</ArticleId><ArticleId IdType="doi">10.1016/j.neuroscience.2012.11.032</ArticleId></ArticleIdList></Reference><Reference><Citation>Lui, H. et al. Progranulin deficiency promotes circuit-specific synaptic pruning by microglia via complement activation. Cell 165, 921&#x2013;935 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27114033</ArticleId><ArticleId IdType="pmc">4860138</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2016.04.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith, K. R. et al. Strikingly different clinicopathological phenotypes determined by progranulin-mutation dosage. Am. J. Hum. Genet. 90, 1102&#x2013;1107 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22608501</ArticleId><ArticleId IdType="pmc">3370276</ArticleId><ArticleId IdType="doi">10.1016/j.ajhg.2012.04.021</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerrits, E. et al. Distinct amyloid-&#x3b2; and tau-associated microglia profiles in Alzheimer&#x2019;s disease. Acta Neuropathol. 141, 1&#x2013;16 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-021-02263-w</ArticleId></ArticleIdList></Reference><Reference><Citation>Benussi, L., Binetti, G. &amp; Ghidoni, R. Loss of neuroprotective factors in neurodegenerative dementias: the end or the starting point? Front. Neurosci. 11, 672 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29249935</ArticleId><ArticleId IdType="pmc">5717017</ArticleId><ArticleId IdType="doi">10.3389/fnins.2017.00672</ArticleId></ArticleIdList></Reference><Reference><Citation>Tann, J. Y., Wong, L., Sajikumar, S. &amp; Ib&#xe1;&#xf1;ez, C. F. Abnormal TDP-43 function impairs activity-dependent BDNF secretion, synaptic plasticity, and cognitive behavior through altered Sortilin splicing. EMBO J. 38, e100989 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30692134</ArticleId><ArticleId IdType="pmc">6396160</ArticleId><ArticleId IdType="doi">10.15252/embj.2018100989</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishii, Y. et al. Mouse brains deficient in neuronal PDGF receptor-&#x3b2; develop normally but are vulnerable to injury. J. Neurochem. 98, 588&#x2013;600 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16805849</ArticleId><ArticleId IdType="doi">10.1111/j.1471-4159.2006.03922.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, X. et al. Slit2 regulates the dispersal of oligodendrocyte precursor cells via Fyn/RhoA signaling. J. Biol. Chem. 287, 17503&#x2013;17516 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22433866</ArticleId><ArticleId IdType="pmc">3366791</ArticleId><ArticleId IdType="doi">10.1074/jbc.M111.317610</ArticleId></ArticleIdList></Reference><Reference><Citation>Habib, N. et al. Disease-associated astrocytes in Alzheimer&#x2019;s disease and aging. Nat. Neurosci. 23, 701&#x2013;706 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32341542</ArticleId><ArticleId IdType="pmc">9262034</ArticleId><ArticleId IdType="doi">10.1038/s41593-020-0624-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Jord&#xe3;o, M. J. C. et al. Single-cell profiling identifies myeloid cell subsets with distinct fates during neuroinflammation. Science 363, eaat7554 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30679343</ArticleId><ArticleId IdType="doi">10.1126/science.aat7554</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanlandewijck, M. et al. A molecular atlas of cell types and zonation in the brain vasculature. Nature 554, 475&#x2013;480 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29443965</ArticleId><ArticleId IdType="doi">10.1038/nature25739</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoffels, J. M. J. et al. Fibronectin aggregation in multiple sclerosis lesions impairs remyelination. Brain 136, 116&#x2013;131 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23365094</ArticleId><ArticleId IdType="doi">10.1093/brain/aws313</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamazaki, Y. et al. Selective loss of cortical endothelial tight junction proteins during Alzheimer&#x2019;s disease progression. Brain 142, 1077&#x2013;1092 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30770921</ArticleId><ArticleId IdType="pmc">6439325</ArticleId><ArticleId IdType="doi">10.1093/brain/awz011</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin, S. et al. Inference and analysis of cell-cell communication using CellChat. Nat. Commun. 12, 1088 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33597522</ArticleId><ArticleId IdType="pmc">7889871</ArticleId><ArticleId IdType="doi">10.1038/s41467-021-21246-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Haarmann, A. et al. Human brain endothelial CXCR2 is inflammation-inducible and mediates CXCL5- and CXCL8-triggered paraendothelial barrier breakdown. Int. J. Mol. Sci. 20, 602 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">6387364</ArticleId><ArticleId IdType="doi">10.3390/ijms20030602</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, K. K. Y. &amp; Dorovini-Zis, K. Regulation of CXCL12 and CXCR4 expression by human brain endothelial cells and their role in CD4<sup>+</sup> and CD8<sup>+</sup> T cell adhesion and transendothelial migration. J. Neuroimmunol. 215, 49&#x2013;64 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19765831</ArticleId><ArticleId IdType="doi">10.1016/j.jneuroim.2009.08.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Kniewallner, K. M., Grimm, N. &amp; Humpel, C. Platelet-derived nerve growth factor supports the survival of cholinergic neurons in organotypic rat brain slices. Neurosci. Lett. 574, 64&#x2013;69 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24861506</ArticleId><ArticleId IdType="pmc">4311057</ArticleId><ArticleId IdType="doi">10.1016/j.neulet.2014.05.033</ArticleId></ArticleIdList></Reference><Reference><Citation>Cantarella, G. et al. Nerve growth factor-endothelial cell interaction leads to angiogenesis in vitro and in vivo. FASEB J. 16, 1307&#x2013;1309 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12154004</ArticleId><ArticleId IdType="doi">10.1096/fj.01-1000fje</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-Klett, F. &amp; Priller, J. The fibrotic scar in neurological disorders. Brain Pathol. 24, 404&#x2013;413 (2014).</Citation></Reference><Reference><Citation>Zhang, J. et al. Neurotoxic microglia promote TDP-43 proteinopathy in progranulin deficiency. Nature 588, 459&#x2013;465 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32866962</ArticleId><ArticleId IdType="pmc">7746606</ArticleId><ArticleId IdType="doi">10.1038/s41586-020-2709-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Filiano, A. J. et al. Dissociation of frontotemporal dementia-related deficits and neuroinflammation in progranulin haploinsufficient mice. J. Neurosci. 33, 5352&#x2013;5361 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23516300</ArticleId><ArticleId IdType="pmc">3740510</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.6103-11.2013</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong, Y., Yan, W., Chen, S., Sun, C. &amp; Zhang, J. The role of Nrf2 signaling in the regulation of antioxidants and detoxifying enzymes after traumatic brain injury in rats and mice. Acta Pharmacol. Sin. 31, 1421&#x2013;1430 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20953205</ArticleId><ArticleId IdType="pmc">4003325</ArticleId><ArticleId IdType="doi">10.1038/aps.2010.101</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasel, P., Rose, I. V. L., Sadick, J. S., Kim, R. D. &amp; Liddelow, S. A. Neuroinflammatory astrocyte subtypes in the mouse brain. Nat. Neurosci. 24, 1475&#x2013;1487 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34413515</ArticleId><ArticleId IdType="doi">10.1038/s41593-021-00905-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Michael, B. D. et al. Astrocyte- and neuron-derived CXCL1 drives neutrophil transmigration and blood&#x2013;brain barrier permeability in viral encephalitis. Cell Rep. 32, 108150 (2020).</Citation></Reference><Reference><Citation>F&#xfc;chtbauer, L. et al. Angiotensin II type 1 receptor (AT1) signaling in astrocytes regulates synaptic degeneration-induced leukocyte entry to the central nervous system. Brain Behav. Immun. 25, 897&#x2013;904 (2010).</Citation></Reference><Reference><Citation>Hou, S. T. et al. Semaphorin3A elevates vascular permeability and contributes to cerebral ischemia-induced brain damage. Sci. Rep. 5, 7890 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25601765</ArticleId><ArticleId IdType="pmc">4298747</ArticleId><ArticleId IdType="doi">10.1038/srep07890</ArticleId></ArticleIdList></Reference><Reference><Citation>Jakovcevski, I., Miljkovic, D., Schachner, M. &amp; Andjus, P. R. Tenascins and inflammation in disorders of the nervous system. Amino Acids 44, 1115&#x2013;1127 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23269478</ArticleId><ArticleId IdType="doi">10.1007/s00726-012-1446-0</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xfc;dhof, T. C. Synaptic neurexin complexes: A molecular code for the logic of neural circuits. Cell 171, 745&#x2013;769 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29100073</ArticleId><ArticleId IdType="pmc">5694349</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2017.10.024</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardwick, S. A. et al. Single-nuclei isoform RNA sequencing unlocks barcoded exon connectivity in frozen brain tissue. Nat. Biotechnol. https://doi.org/10.1038/s41587-022-01231-3 (2022).</Citation></Reference><Reference><Citation>M&#xe4;e, M. A. et al. Single-cell analysis of blood&#x2013;brain barrier response to pericyte loss. Circ. Res. 128, e46&#x2013;e62 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33375813</ArticleId><ArticleId IdType="doi">10.1161/CIRCRESAHA.120.317473</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma, S.-C. et al. Claudin-5 regulates blood&#x2013;brain barrier permeability by modifying brain microvascular endothelial cell proliferation, migration, and adhesion to prevent lung cancer metastasis. CNS Neurosci. Ther. 23, 947&#x2013;960 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28961379</ArticleId><ArticleId IdType="pmc">6492739</ArticleId><ArticleId IdType="doi">10.1111/cns.12764</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar, P., Ning, Y., Polverini, P. J. &amp; Kumar, P. Endothelial cells expressing Bcl-2 promote tumor metastasis by enhancing tumor angiogenesis, blood vessel leakiness and tumor invasion. Lab. Invest. 88, 740&#x2013;749 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18490895</ArticleId><ArticleId IdType="doi">10.1038/labinvest.2008.46</ArticleId></ArticleIdList></Reference><Reference><Citation>Bussolati, B. et al. Neural-cell adhesion molecule (NCAM) expression by immature and tumor-derived endothelial cells favors cell organization into capillary-like structures. Exp. Cell. Res. 312, 913&#x2013;924 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16406048</ArticleId><ArticleId IdType="doi">10.1016/j.yexcr.2005.12.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Derada Troletti, C., de Goede, P., Kamermans, A. &amp; de Vries, H. E. Molecular alterations of the blood&#x2013;brain barrier under inflammatory conditions: the role of endothelial to mesenchymal transition. Biochim. Biophys. Acta 1862, 452&#x2013;460 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26493443</ArticleId><ArticleId IdType="doi">10.1016/j.bbadis.2015.10.010</ArticleId></ArticleIdList></Reference><Reference><Citation>Munji, R. N. et al. Profiling the mouse brain endothelial transcriptome in health and disease models reveals a core blood&#x2013;brain barrier dysfunction module. Nat. Neurosci. 22, 1892&#x2013;1902 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31611708</ArticleId><ArticleId IdType="pmc">6858546</ArticleId><ArticleId IdType="doi">10.1038/s41593-019-0497-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Daneman, R., Zhou, L., Kebede, A. A. &amp; Barres, B. A. Pericytes are required for blood&#x2013;brain barrier integrity during embryogenesis. Nature 468, 562&#x2013;566 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20944625</ArticleId><ArticleId IdType="pmc">3241506</ArticleId><ArticleId IdType="doi">10.1038/nature09513</ArticleId></ArticleIdList></Reference><Reference><Citation>Propson, N. E., Roy, E. R., Litvinchuk, A., K&#xf6;hl, J. &amp; Zheng, H. Endothelial C3a receptor mediates vascular inflammation and blood-brain barrier permeability during aging. J. Clin. Invest. 131, e140966 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">7773352</ArticleId><ArticleId IdType="doi">10.1172/JCI140966</ArticleId></ArticleIdList></Reference><Reference><Citation>Chappell, J. C., Mouillesseaux, K. P. &amp; Bautch, V. L. Flt-1 (vascular endothelial growth factor receptor-1) is essential for the vascular endothelial growth factor&#x2013;Notch feedback loop during angiogenesis. Arterioscler Thromb. Vasc. Biol. 33, 1952&#x2013;1959 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23744993</ArticleId><ArticleId IdType="pmc">4521230</ArticleId><ArticleId IdType="doi">10.1161/ATVBAHA.113.301805</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu, C.-H. et al. Increased expression of vascular endothelial growth factor in neo-vascularized canine brain tissue. Can. J. Vet. Res. 76, 62&#x2013;68 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22754097</ArticleId><ArticleId IdType="pmc">3244290</ArticleId></ArticleIdList></Reference><Reference><Citation>Ek Olofsson, H. &amp; Englund, E. A cortical microvascular structure in vascular dementia, Alzheimer&#x2019;s disease, frontotemporal lobar degeneration and nondemented controls: a sign of angiogenesis due to brain ischaemia? Neuropathol. Appl. Neurobiol. 45, 557&#x2013;569 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30957900</ArticleId><ArticleId IdType="pmc">6850314</ArticleId><ArticleId IdType="doi">10.1111/nan.12552</ArticleId></ArticleIdList></Reference><Reference><Citation>Lendahl, U., Nilsson, P. &amp; Betsholtz, C. Emerging links between cerebrovascular and neurodegenerative diseases&#x2014;a special role for pericytes. EMBO Rep. 20, e48070 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31617312</ArticleId><ArticleId IdType="pmc">6831996</ArticleId><ArticleId IdType="doi">10.15252/embr.201948070</ArticleId></ArticleIdList></Reference><Reference><Citation>Eilken, H. M. et al. Pericytes regulate VEGF-induced endothelial sprouting through VEGFR1. Nat. Commun. 8, 1574 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29146905</ArticleId><ArticleId IdType="pmc">5691060</ArticleId><ArticleId IdType="doi">10.1038/s41467-017-01738-3</ArticleId></ArticleIdList></Reference><Reference><Citation>T&#xf6;r&#xf6;k, O. et al. Pericytes regulate vascular immune homeostasis in the CNS. Proc. Natl Acad. Sci. USA 118, e2016587118 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33653955</ArticleId><ArticleId IdType="pmc">7958247</ArticleId><ArticleId IdType="doi">10.1073/pnas.2016587118</ArticleId></ArticleIdList></Reference><Reference><Citation>Menzel, L. et al. Progranulin protects against exaggerated axonal injury and astrogliosis following traumatic brain injury. Glia 65, 278&#x2013;292 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">27778404</ArticleId><ArticleId IdType="doi">10.1002/glia.23091</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward, M. E. et al. Individuals with progranulin haploinsufficiency exhibit features of neuronal ceroid lipofuscinosis. Sci. Transl. Med. 9, eaah5642 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28404863</ArticleId><ArticleId IdType="pmc">5526610</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.aah5642</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xe5;nberg, A. et al. Altered perivascular fibroblast activity precedes ALS disease onset. Nat. Med. 27, 640&#x2013;646 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33859435</ArticleId><ArticleId IdType="doi">10.1038/s41591-021-01295-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Abramzon, Y. A., Fratta, P., Traynor, B. J. &amp; Chia, R. The overlapping genetics of amyotrophic lateral sclerosis and frontotemporal dementia. Front. Neurosci. 14, 42 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32116499</ArticleId><ArticleId IdType="pmc">7012787</ArticleId><ArticleId IdType="doi">10.3389/fnins.2020.00042</ArticleId></ArticleIdList></Reference><Reference><Citation>Eriksen, J. L. &amp; Mackenzie, I. R. A. Progranulin: normal function and role in neurodegeneration. J. Neurochem. 104, 187&#x2013;197 (2008).</Citation></Reference><Reference><Citation>Zhou, M. et al. Progranulin protects against renal ischemia/reperfusion injury in mice. Kidney Int. 87, 918&#x2013;929 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25607110</ArticleId><ArticleId IdType="doi">10.1038/ki.2014.403</ArticleId></ArticleIdList></Reference><Reference><Citation>Piscopo, P. et al. Reduced miR-659-3p levels correlate with progranulin increase in hypoxic conditions: implications for frontotemporal dementia. Front. Mol. Neurosci. 9, 31 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27199656</ArticleId><ArticleId IdType="pmc">4853935</ArticleId><ArticleId IdType="doi">10.3389/fnmol.2016.00031</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanazawa, M. et al. Multiple therapeutic effects of progranulin on experimental acute ischaemic stroke. Brain 138, 1932&#x2013;1948 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25838514</ArticleId><ArticleId IdType="doi">10.1093/brain/awv079</ArticleId></ArticleIdList></Reference><Reference><Citation>Tangkeangsirisin, W. &amp; Serrero, G. PC cell-derived growth factor (PCDGF/GP88, progranulin) stimulates migration, invasiveness and VEGF expression in breast cancer cells. Carcinogenesis 25, 1587&#x2013;1592 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15117809</ArticleId><ArticleId IdType="doi">10.1093/carcin/bgh171</ArticleId></ArticleIdList></Reference><Reference><Citation>Gacche, R. N. Compensatory angiogenesis and tumor refractoriness. Oncogenesis 4, e153 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26029827</ArticleId><ArticleId IdType="pmc">4753522</ArticleId><ArticleId IdType="doi">10.1038/oncsis.2015.14</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez-Pinera, P., Chang, Y. &amp; Deuel, T. F. Pleiotrophin, a multifunctional tumor promoter through induction of tumor angiogenesis, remodeling of the tumor microenvironment, and activation of stromal fibroblasts. Cell Cycle 6, 2877&#x2013;2883 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">18156802</ArticleId><ArticleId IdType="doi">10.4161/cc.6.23.5090</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, L. &amp; Dimberg, A. Pleiotrophin is a driver of vascular abnormalization in glioblastoma. Mol. Cell. Oncol. 3, e1141087 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">28090572</ArticleId><ArticleId IdType="pmc">5160416</ArticleId><ArticleId IdType="doi">10.1080/23723556.2016.1141087</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorrier, C. E. et al. CNS fibroblasts form a fibrotic scar in response to immune cell infiltration. Nat. Neurosci. 24, 234&#x2013;244 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33526922</ArticleId><ArticleId IdType="pmc">7877789</ArticleId><ArticleId IdType="doi">10.1038/s41593-020-00770-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson, O. et al. CSF placental growth factor&#x2014;a novel candidate biomarker of frontotemporal dementia. Ann. Clin. Transl. Neurol. 6, 863&#x2013;872 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31139684</ArticleId><ArticleId IdType="pmc">6529985</ArticleId><ArticleId IdType="doi">10.1002/acn3.763</ArticleId></ArticleIdList></Reference><Reference><Citation>Eriksson, A. et al. Placenta growth factor-1 antagonizes VEGF-induced angiogenesis and tumor growth by the formation of functionally inactive PlGF-1/VEGF heterodimers. Cancer Cell 1, 99&#x2013;108 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12086892</ArticleId><ArticleId IdType="doi">10.1016/S1535-6108(02)00028-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellik, L., Vinci, M. C., Filippi, S., Ledda, F. &amp; Parenti, A. Intracellular pathways triggered by the selective FLT-1-agonist placental growth factor in vascular smooth muscle cells exposed to hypoxia. Br. J. Pharmacol. 146, 568&#x2013;75 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16086034</ArticleId><ArticleId IdType="pmc">1751184</ArticleId><ArticleId IdType="doi">10.1038/sj.bjp.0706347</ArticleId></ArticleIdList></Reference><Reference><Citation>De Falco, S. The discovery of placenta growth factor and its biological activity. Exp. Mol. Med. 44, 1&#x2013;9 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22228176</ArticleId><ArticleId IdType="pmc">3277892</ArticleId><ArticleId IdType="doi">10.3858/emm.2012.44.1.025</ArticleId></ArticleIdList></Reference><Reference><Citation>Maes, C. et al. Placental growth factor mediates mesenchymal cell development, cartilage turnover, and bone remodeling during fracture repair. J. Clin. Invest. 116, 1230&#x2013;1242 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16614757</ArticleId><ArticleId IdType="pmc">1435721</ArticleId><ArticleId IdType="doi">10.1172/JCI26772</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakraborty, A. et al. Angiopoietin like-4 as a novel vascular mediator in capillary cerebral amyloid angiopathy. Brain 141, 3377&#x2013;3388 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30462206</ArticleId><ArticleId IdType="doi">10.1093/brain/awy274</ArticleId></ArticleIdList></Reference><Reference><Citation>Riku, Y. et al. Increased prevalence of granulovacuolar degeneration in C9orf72 mutation. Acta Neuropathol. 138, 783&#x2013;793 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31144027</ArticleId><ArticleId IdType="doi">10.1007/s00401-019-02028-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Seilhean, D. et al. Fronto-temporal lobar degeneration: neuropathology in 60 cases. J. Neural Transm. 118, 753&#x2013;764 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21541771</ArticleId><ArticleId IdType="doi">10.1007/s00702-011-0649-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerrits, E., Heng, Y., Boddeke, E. W. G. M. &amp; Eggen, B. J. L. Transcriptional profiling of microglia; current state of the art and future perspectives. Glia 68, 740&#x2013;755 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31846124</ArticleId><ArticleId IdType="pmc">7064956</ArticleId><ArticleId IdType="doi">10.1002/glia.23767</ArticleId></ArticleIdList></Reference><Reference><Citation>Anders, S., Pyl, P. T. &amp; Huber, W. HTSeq&#x2014;a Python framework to work with high-throughput sequencing data. Bioinformatics 31, 166&#x2013;169 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25260700</ArticleId><ArticleId IdType="doi">10.1093/bioinformatics/btu638</ArticleId></ArticleIdList></Reference><Reference><Citation>Love, M. I., Huber, W. &amp; Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25516281</ArticleId><ArticleId IdType="pmc">4302049</ArticleId><ArticleId IdType="doi">10.1186/s13059-014-0550-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson, M. D., McCarthy, D. J. &amp; Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139&#x2013;140 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">19910308</ArticleId><ArticleId IdType="doi">10.1093/bioinformatics/btp616</ArticleId></ArticleIdList></Reference><Reference><Citation>Newman, A. M. et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat. Biotechnol. 37, 773&#x2013;782 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31061481</ArticleId><ArticleId IdType="pmc">6610714</ArticleId><ArticleId IdType="doi">10.1038/s41587-019-0114-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou, Y. et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat. Commun. 10, 1523 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30944313</ArticleId><ArticleId IdType="pmc">6447622</ArticleId><ArticleId IdType="doi">10.1038/s41467-019-09234-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, Y., Parmigiani, G. &amp; Johnson, W. E. ComBat-seq: batch effect adjustment for RNA-seq count data. NAR Genomics Bioinform. 2, lqaa078 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nargab/lqaa078</ArticleId></ArticleIdList></Reference><Reference><Citation>Xi, S. et al. ABACUS: a flexible UMI counter that leverages intronic reads for single-nucleus RNAseq analysis. Preprint at https://www.biorxiv.org/content/10.1101/2020.11.13.381624v1 (2020).</Citation></Reference><Reference><Citation>Wolock, S. L., Lopez, R. &amp; Klein, A. M. Scrublet: computational identification of cell doublets in single-cell transcriptomic data. Cell Syst. 8, 281&#x2013;291 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30954476</ArticleId><ArticleId IdType="pmc">6625319</ArticleId><ArticleId IdType="doi">10.1016/j.cels.2018.11.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Stuart, T. et al. Comprehensive integration of single-cell data. Cell 177, 1888&#x2013;1902 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31178118</ArticleId><ArticleId IdType="pmc">6687398</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2019.05.031</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu, X. et al. Reversed graph embedding resolves complex single-cell trajectories. Nat. Methods 14, 979&#x2013;982 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28825705</ArticleId><ArticleId IdType="pmc">5764547</ArticleId><ArticleId IdType="doi">10.1038/nmeth.4402</ArticleId></ArticleIdList></Reference><Reference><Citation>Irwin, D. J. et al. Semi-automated digital image analysis of Pick&#x2019;s disease and TDP-43 proteinopathy. J. Histochem. Cytochem. 64, 54&#x2013;66 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26538548</ArticleId><ArticleId IdType="doi">10.1369/0022155415614303</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannini, L. A. A. et al. Empiric methods to account for pre-analytical variability in digital histopathology in frontotemporal lobar degeneration. Front. Neurosci. 13, 682 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31333403</ArticleId><ArticleId IdType="pmc">6616086</ArticleId><ArticleId IdType="doi">10.3389/fnins.2019.00682</ArticleId></ArticleIdList></Reference><Reference><Citation>Bankhead, P. et al. QuPath: open source software for digital pathology image analysis. Sci. Rep. 7, 16878 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29203879</ArticleId><ArticleId IdType="pmc">5715110</ArticleId><ArticleId IdType="doi">10.1038/s41598-017-17204-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Irwin, D. J. et al. Asymmetry of post-mortem neuropathology in behavioural-variant frontotemporal dementia. Brain 141, 288&#x2013;301 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29228211</ArticleId><ArticleId IdType="doi">10.1093/brain/awx319</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannini, L. A. A. et al. Divergent patterns of TDP-43 and tau pathologies in primary progressive aphasia. Ann. Neurol. 85, 630&#x2013;643 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30851133</ArticleId><ArticleId IdType="pmc">6538935</ArticleId><ArticleId IdType="doi">10.1002/ana.25465</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">35895837</PMID><DateCompleted><Year>2022</Year><Month>07</Month><Day>29</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>655</Issue><PubDate><Year>2022</Year><Month>Jul</Month><Day>27</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>Network Tau spreading is vulnerable to the expression gradients of <i>APOE</i> and glutamatergic-related genes.</ArticleTitle><Pagination><StartPage>eabn7273</StartPage><MedlinePgn>eabn7273</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.abn7273</ELocationID><Abstract><AbstractText>A key hallmark of Alzheimer's disease (AD) pathology is the intracellular accumulation of tau protein in the form of neurofibrillary tangles across large-scale networks of the human brain cortex. Currently, it is still unclear how tau accumulates within specific cortical systems and whether in situ genetic traits play a role in this circuit-based propagation progression. In this study, using two independent cohorts of cognitively normal older participants, we reveal the brain network foundation of tau spreading and its association with using high-resolution transcriptomic genetic data. We observed that specific connectomic and genetic gradients exist along the tau spreading network. In particular, we identified 577 genes whose expression is associated with the spatial spreading of tau. Within this set of genes, <i>APOE</i> and glutamatergic synaptic genes, such as <i>SLC1A2</i>, play a central role. Thus, our study characterizes neurogenetic topological vulnerabilities in distinctive brain circuits of tau spreading and suggests that drug development strategies targeting the gradient expression of this set of genes should be explored to help reduce or prevent pathological tau accumulation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Montal</LastName><ForeName>Victor</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-5714-9282</Identifier><AffiliationInfo><Affiliation>Gordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autonoma de Barcelona, Barcelona 08041, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED), Madrid 28029, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diez</LastName><ForeName>Ibai</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0001-5769-0178</Identifier><AffiliationInfo><Affiliation>Gordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Chan-Mi</ForeName><Initials>CM</Initials><Identifier Source="ORCID">0000-0001-5686-1668</Identifier><AffiliationInfo><Affiliation>Gordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Orwig</LastName><ForeName>William</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Gordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bueichek&#xfa;</LastName><ForeName>Elisenda</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-3059-9806</Identifier><AffiliationInfo><Affiliation>Gordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guti&#xe9;rrez-Z&#xfa;&#xf1;iga</LastName><ForeName>Raquel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Gordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bejanin</LastName><ForeName>Alexandre</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-9958-0951</Identifier><AffiliationInfo><Affiliation>Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autonoma de Barcelona, Barcelona 08041, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED), Madrid 28029, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pegueroles</LastName><ForeName>Jordi</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-3554-2446</Identifier><AffiliationInfo><Affiliation>Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autonoma de Barcelona, Barcelona 08041, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED), Madrid 28029, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dols-Icardo</LastName><ForeName>Oriol</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0003-2656-8748</Identifier><AffiliationInfo><Affiliation>Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autonoma de Barcelona, Barcelona 08041, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED), Madrid 28029, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vannini</LastName><ForeName>Patrizia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>El-Fakhri</LastName><ForeName>Georges</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Gordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Keith A</ForeName><Initials>KA</Initials><Identifier Source="ORCID">0000-0002-5916-6043</Identifier><AffiliationInfo><Affiliation>Gordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa A</ForeName><Initials>RA</Initials><Identifier Source="ORCID">0000-0003-1535-6133</Identifier><AffiliationInfo><Affiliation>Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fortea</LastName><ForeName>Juan</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-1340-638X</Identifier><AffiliationInfo><Affiliation>Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autonoma de Barcelona, Barcelona 08041, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED), Madrid 28029, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sepulcre</LastName><ForeName>Jorge</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-4199-2304</Identifier><AffiliationInfo><Affiliation>Gordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P41 EB022544</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG061811</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG036694</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG061083</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027435</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG061445</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG046396</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="Y">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>27</Day><Hour>14</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>2</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35895837</ArticleId><ArticleId IdType="mid">NIHMS1865898</ArticleId><ArticleId IdType="pmc">PMC9942690</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.abn7273</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zang Z, Lin P, Levey A, Monetary Costs of Dementia in the United States To, N. Engl. J. Med 369, 487&#x2013;489 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23902509</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson KA, Schultz A, Betensky RA, Becker JA, Sepulcre J, Rentz D, Mormino E, Chhatwal J, Amariglio R, Papp K, Marshall G, Albers M, Mauro S, Pepin L, Alverio J, Judge K, Philiossaint M, Shoup T, Yokell D, Dickerson B, Gomez-Isla T, Hyman B, Vasdev N, Sperling R, Tau positron emission tomographic imaging in aging and early Alzheimer disease, Ann. Neurol 79, 110&#x2013;119 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4738026</ArticleId><ArticleId IdType="pubmed">26505746</ArticleId></ArticleIdList></Reference><Reference><Citation>Sepulcre J, Schultz A, Sabuncu M, Gomez-Isla T, Chhatwal J, Becker A, Sperling R, Johnson K, In vivo Tau, Amyloid and Grey Matter Profiles in the Aging Brain, J. Neurosci, 7364&#x2013;7374 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4945661</ArticleId><ArticleId IdType="pubmed">27413148</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xf6;ll M, Lockhart SN, Schonhaut DR, O&#x2019;Neil JP, Janabi M, Ossenkoppele R, Baker SL, Vogel JW, Faria J, Schwimmer HD, Rabinovici GD, Jagust WJ, PET Imaging of Tau Deposition in the Aging Human Brain, Neuron 89, 971&#x2013;982 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4779187</ArticleId><ArticleId IdType="pubmed">26938442</ArticleId></ArticleIdList></Reference><Reference><Citation>Marqui&#xe9; M, Siao Tick Chong M, Ant&#xf3;n-Fern&#xe1;ndez A, Verwer EE, S&#xe1;ez-Calveras N, Meltzer AC, Ramanan P, Amaral AC, Gonzalez J, Normandin MD, Frosch MP, G&#xf3;mez-Isla T, [F-18]-AV-1451 binding correlates with postmortem neurofibrillary tangle Braak staging, Acta Neuropathol. 134, 619&#x2013;628 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5772971</ArticleId><ArticleId IdType="pubmed">28612291</ArticleId></ArticleIdList></Reference><Reference><Citation>La Joie R, V Visani A, Baker SL, Brown JA, Bourakova V, Cha J, Chaudhary K, Edwards L, Iaccarino L, Janabi M, Lesman-Segev OH, Miller ZA, Perry DC, O&#x2019;Neil JP, Pham J, Rojas JC, Rosen HJ, Seeley WW, Tsai RM, Miller BL, Jagust WJ, Rabinovici GD, Prospective longitudinal atrophy in Alzheimer&#x2019;s disease correlates with the intensity and topography of baseline tau-PET., Sci. Transl. Med 12, 1&#x2013;13 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7035952</ArticleId><ArticleId IdType="pubmed">31894103</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Mormino EC, Schultz AP, Betensky RA, Papp KV, Amariglio RE, Hanseeuw BJ, Buckley R, Chhatwal J, Hedden T, Marshall GA, Quiroz YT, Donovan NJ, Jackson J, Gatchel JR, Rabin JS, Jacobs H, Yang HS, Properzi M, Kirn DR, Rentz DM, Johnson KA, The impact of amyloid-beta and tau on prospective cognitive decline in older individuals, Ann. Neurol 85, 181&#x2013;193 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6402593</ArticleId><ArticleId IdType="pubmed">30549303</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoenig MC, Bischof GN, Seemiller J, Hammes J, Kukolja J, Onur &#xd6;A, Jessen F, Fliessbach K, Neumaier B, Fink GR, Van Eimeren T, Drzezga A, Networks of tau distribution in Alzheimer&#x2019;s disease, Brain 141, 568&#x2013;581 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29315361</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R, Iaccarino L, Schonhaut DR, Brown JA, La Joie R, O&#x2019;Neil JP, Janabi M, Baker SL, Kramer JH, Gorno-Tempini ML, Miller BL, Rosen HJ, Seeley WW, Jagust WJ, Rabinovici GD, Tau covariance patterns in Alzheimer&#x2019;s disease patients match intrinsic connectivity networks in the healthy brain, NeuroImage Clin. 23, 101848 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6510968</ArticleId><ArticleId IdType="pubmed">31077982</ArticleId></ArticleIdList></Reference><Reference><Citation>Sepulcre J, Grothe MJ, Uquillas O, Ortiz-ter&#xe1;n L, Diez I, Yang H, Jacobs HIL, Hanseeuw BJ, Li Q, El-fakhri G, Sperling RA, Johnson KA, Neurogenetic contributions to amyloid beta and tau spreading in the human cortex, Nat. Med (2018), doi:10.1038/s41591-018-0206-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-018-0206-4</ArticleId><ArticleId IdType="pmc">PMC6518398</ArticleId><ArticleId IdType="pubmed">30374196</ArticleId></ArticleIdList></Reference><Reference><Citation>Mrdjen D, Fox EJ, Bukhari SA, Montine KS, Bendall SC, Montine TJ, The basis of cellular and regional vulnerability in Alzheimer&#x2019;s disease, Acta Neuropathol. 138, 729&#x2013;749 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6802290</ArticleId><ArticleId IdType="pubmed">31392412</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu H, Hardy J, Duff KE, Selective vulnerability in neurodegenerative diseases, Nat. Neurosci 21, 1350&#x2013;1358 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6360529</ArticleId><ArticleId IdType="pubmed">30250262</ArticleId></ArticleIdList></Reference><Reference><Citation>Leng K, Li E, Eser R, Piergies A, Sit R, Tan M, Neff N, Li SH, Rodriguez RD, Suemoto CK, Leite REP, Ehrenberg AJ, Pasqualucci CA, Seeley WW, Spina S, Heinsen H, Grinberg LT, Kampmann M, Molecular characterization of selectively vulnerable neurons in Alzheimer&#x2019;s disease, Nat. Neurosci 24, 276&#x2013;287 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7854528</ArticleId><ArticleId IdType="pubmed">33432193</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathys H, Davila-Velderrain J, Peng Z, Gao F, Mohammadi S, Young JZ, Menon M, He L, Abdurrob F, Jiang X, Martorell AJ, Ransohoff RM, Hafler BP, Bennett DA, Kellis M, Tsai L-H, Single-cell transcriptomic analysis of Alzheimer&#x2019;s disease, Nature 2 (2019), doi:10.1038/s41586-019-1195-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-1195-2</ArticleId><ArticleId IdType="pmc">PMC6865822</ArticleId><ArticleId IdType="pubmed">31042697</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen EH, Overly CC, Jones AR, The Allen Human Brain Atlas: comprehensive gene expression mapping of the human brain., Trends Neurosci. 35, 711&#x2013;714 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">23041053</ArticleId></ArticleIdList></Reference><Reference><Citation>Drummond E, Pires G, Macmurray C, Askenazi M, Nayak S, Bourdon M, Safar J, Ueberheide B, Wisniewski T, Phosphorylated tau interactome in the human Alzheimer&#x2019;s disease brain, Brain , 1&#x2013;15 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7526722</ArticleId><ArticleId IdType="pubmed">32812023</ArticleId></ArticleIdList></Reference><Reference><Citation>Acosta D, Powell F, Zhao Y, Raj A, Regional vulnerability in Alzheimer&#x2019;s: The role of cell-autonomous and transneuronal processes, Alzheimer&#x2019;s Dement. , 1&#x2013;13 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5994366</ArticleId><ArticleId IdType="pubmed">29306583</ArticleId></ArticleIdList></Reference><Reference><Citation>Seidlitz J, Nadig A, Liu S, Bethlehem RAI, V&#xe9;rtes PE, Morgan SE, V&#xe1;&#x161;a F, Romero-Garcia R, Lalonde FM, Clasen LS, Blumenthal JD, Paquola C, Bernhardt B, Wagstyl K, Polioudakis D, de la Torre-Ubieta L, Geschwind DH, Han JC, Lee NR, Murphy DG, Bullmore ET, Raznahan A, Transcriptomic and cellular decoding of regional brain vulnerability to neurogenetic disorders, Nat. Commun 11, 1&#x2013;14 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7335069</ArticleId><ArticleId IdType="pubmed">32620757</ArticleId></ArticleIdList></Reference><Reference><Citation>Diez I, Sepulcre J, Neurogenetic profiles delineate large-scale connectivity dynamics of the human brain, Nat. Commun 9, 3876 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6155203</ArticleId><ArticleId IdType="pubmed">30250030</ArticleId></ArticleIdList></Reference><Reference><Citation>Grothe MJ, Sepulcre J, Gonzalez-Escamilla G, Jelistratova I, Sch&#xf6; M, Hansson O, Teipel SJ, Molecular properties underlying regional vulnerability to Alzheimer&#x2019;s disease pathology8 for the Alzheimer&#x2019;s Disease Neuroimaging Initiative*, , 1&#x2013;17 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6113636</ArticleId><ArticleId IdType="pubmed">30016411</ArticleId></ArticleIdList></Reference><Reference><Citation>Raj A, Tora V, Gao X, Cho H, Choi JY, Ryu Y, Lyoo C, Franchi B, Combined Model of Aggregation And Network Diffusion Recapitulates Alzheimer&#x2019;s Regional Tau-PET, Brain Connect. , 1&#x2013;42 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8817716</ArticleId><ArticleId IdType="pubmed">33947253</ArticleId></ArticleIdList></Reference><Reference><Citation>Meisl G, Hidari E, Allinson K, Rittman T, DeVos SL, Sanchez JS, Xu CK, Duff KE, Johnson KA, Rowe JB, Hyman BT, Knowles TPJ, Klenerman D, In vivo rate-determining steps of tau seed accumulation in Alzheimer&#x2019;s disease, Sci. Adv 7 (2021), doi:10.1126/sciadv.abh1448.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.abh1448</ArticleId><ArticleId IdType="pmc">PMC8555892</ArticleId><ArticleId IdType="pubmed">34714685</ArticleId></ArticleIdList></Reference><Reference><Citation>Freer R, Sormanni P, Vecchi G, Ciryam P, Dobson CM, Vendruscolo M, A protein homeostasis signature in healthy brains recapitulates tissue vulnerability to Alzheimer&#x2019;s disease, Sci. Adv 2, 1&#x2013;8 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4980108</ArticleId><ArticleId IdType="pubmed">27532054</ArticleId></ArticleIdList></Reference><Reference><Citation>Cornblath EJ, Li HL, Changolkar L, Zhang B, Brown HJ, Gathagan RJ, Olufemi MF, Trojanowski JQ, Bassett DS, Lee VMY, Henderson MX, Computational modeling of tau pathology spread reveals patterns of regional vulnerability and the impact of a genetic risk factor, Sci. Adv , 1&#x2013;16 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8189700</ArticleId><ArticleId IdType="pubmed">34108219</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnsten AFT, Datta D, Del Tredici K, Braak H, Hypothesis : Tau pathology is an initiating factor in sporadic Alzheimer &#x2019; s disease, Alzheimers. Dement , 1&#x2013;10 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7983919</ArticleId><ArticleId IdType="pubmed">33075193</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma A, Kazim SF, Larson CS, Ramakrishnan A, Gray JD, McEwen BS, Rosenberg PA, Shen L, Pereira AC, Divergent roles of astrocytic versus neuronal EAAT2 deficiency on cognition and overlap with aging and Alzheimer&#x2019;s molecular signatures, Proc. Natl. Acad. Sci. U. S. A 116, 21800&#x2013;21811 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6815169</ArticleId><ArticleId IdType="pubmed">31591195</ArticleId></ArticleIdList></Reference><Reference><Citation>Foster JB, Lashley R, Zhao F, Wang X, Kung N, Askwith CC, Lin L, Shultis MW, Hodgetts KJ, Lin CLG, Enhancement of tripartite synapses as a potential therapeutic strategy for Alzheimer&#x2019;s disease: A preclinical study in rTg4510 mice, Alzheimer&#x2019;s Res. Ther 11, 1&#x2013;19 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6706914</ArticleId><ArticleId IdType="pubmed">31439023</ArticleId></ArticleIdList></Reference><Reference><Citation>Jablonski AM, Warren L, Usenovic M, Zhou H, Sugam J, Parmentier-Batteur S, Voleti B, Astrocytic expression of the Alzheimer&#x2019;s disease risk allele, ApoE&#x3b5;4, potentiates neuronal tau pathology in multiple preclinical models, Sci. Rep 11, 1&#x2013;18 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7873246</ArticleId><ArticleId IdType="pubmed">33564035</ArticleId></ArticleIdList></Reference><Reference><Citation>Litvinchuk A, Huynh TPV, Shi Y, Jackson RJ, Finn MB, Manis M, Francis CM, Tran AC, Sullivan PM, Ulrich JD, Hyman BT, Cole T, Holtzman DM, Apolipoprotein E4 Reduction with Antisense Oligonucleotides Decreases Neurodegeneration in a Tauopathy Model, Ann. Neurol (2021), doi:10.1002/ana.26043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.26043</ArticleId><ArticleId IdType="pmc">PMC8260038</ArticleId><ArticleId IdType="pubmed">33550655</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C, Xiong M, Gratuze M, Artyomov M, Ulrich JD, Holtzman DM, Wang C, Xiong M, Gratuze M, Bao X, Shi Y, Andhey PS, Manis M, Selective removal of astrocytic APOE4 strongly protects against tau-mediated neurodegeneration and decreases synaptic phagocytosis by microglia Article Selective removal of astrocytic APOE4 strongly protects against tau-mediated neurodegeneration, Neuron , 1&#x2013;18 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8141024</ArticleId><ArticleId IdType="pubmed">33831349</ArticleId></ArticleIdList></Reference><Reference><Citation>Zalocusky KA, Najm R, Taubes AL, Hao Y, Yoon SY, Koutsodendris N, Nelson MR, Rao A, Bennett DA, Bant J, Amornkul D. eun J., Xu Q, An A, Cisne-Thomson O, Huang Y, Neuronal ApoE upregulates MHC-I expression to drive selective neurodegeneration in Alzheimer&#x2019;s disease, Nat. Neurosci 24, 786&#x2013;798 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9145692</ArticleId><ArticleId IdType="pubmed">33958804</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Kanekiyo T, Xu H, Bu G, Apolipoprotein e and Alzheimer disease: Risk, mechanisms and therapy, Nat. Rev. Neurol 9, 106&#x2013;118 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3726719</ArticleId><ArticleId IdType="pubmed">23296339</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez S, Hug C, Todorov P, Moret N, Boswell SA, Evans K, Zhou G, Johnson NT, Hyman BT, Sorger PK, Albers MW, Sokolov A, Machine learning identifies candidates for drug repurposing in Alzheimer&#x2019;s disease, Nat. Commun 12 (2021), doi:10.1038/s41467-021-21330-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-21330-0</ArticleId><ArticleId IdType="pmc">PMC7884393</ArticleId><ArticleId IdType="pubmed">33589615</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez JS, Becker JA, Jacobs HIL, Hanseeuw BJ, Jiang S, Schultz AP, Properzi MJ, Katz SR, Beiser A, Satizabal CL, O&#x2019;Donnell A, DeCarli C, Killiany R, El Fakhri G, Normandin MD, G&#xf3;mez-Isla T, Quiroz YT, Rentz DM, Sperling RA, Seshadri S, Augustinack J, Price JC, Johnson KA, The cortical origin and initial spread of medial temporal tauopathy in Alzheimer&#x2019;s disease assessed with positron emission tomography, Sci. Transl. Med 13, eabc0655 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7978042</ArticleId><ArticleId IdType="pubmed">33472953</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogel JW, Iturria-Medina Y, Strandberg OT, Smith R, Levitis E, Evans AC, Hansson O, Spread of pathological tau proteins through communicating neurons in human Alzheimer&#x2019;s disease, Nat. Commun 11, 2612 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7251068</ArticleId><ArticleId IdType="pubmed">32457389</ArticleId></ArticleIdList></Reference><Reference><Citation>Franzmeier N, Dewenter A, Frontzkowski L, Dichgans M, Rubinski A, Neitzel J, Smith R, Strandberg O, Ossenkoppele R, Buerger K, Duering M, Hansson O, Ewers M, Patient-centered connectivity-based prediction of tau pathology spread in Alzheimer&#x2019;s disease., Sci. Adv 6 (2020), doi:10.1126/sciadv.abd1327.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.abd1327</ArticleId><ArticleId IdType="pmc">PMC7695466</ArticleId><ArticleId IdType="pubmed">33246962</ArticleId></ArticleIdList></Reference><Reference><Citation>Raj A, Graph Models of pathology spread in Alzheimer&#x2019;s Disease: An Alternative to Conventional Graph Theoretic Analysis, Brain Connect. , 1&#x2013;61 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8817711</ArticleId><ArticleId IdType="pubmed">33858198</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang F, Chowdhury SR, Jacobs HIL, Sepulcre J, Wedeen VJ, Johnson KA, Dutta J, Longitudinal predictive modeling of tau progression along the structural connectome, Neuroimage 237, 118126 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8260445</ArticleId><ArticleId IdType="pubmed">33957234</ArticleId></ArticleIdList></Reference><Reference><Citation>Anand C, Maia P, Torok J, Mezias C, Raj A, The Effects of Microglia on Tauopathy Progression Can Be Quanti ed Using Nexopathy in Silico ( Nexis ) Models The effects of microglia on tauopathy progression can be quantified using Nexopathy in silico ( Nex is ) models, (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9729195</ArticleId><ArticleId IdType="pubmed">36477076</ArticleId></ArticleIdList></Reference><Reference><Citation>Montal V, Vilaplana E, Pegueroles J, Bejanin A, Alcolea D, Carmona-Iragui M, Clarimon J, Levin J, Cruchaga C, Graf-Radford N, Noble JM, Lee J-H, Allegri R, Karch CM, Laske C, Schofield PR, Salloway S, Ances B, Benzinger T, McDade E, Bateman R, Blesa R, Sanchez-Valle R, Lleo A, Fortea J, Biphasic cortical macro and microstructural changes in autosomal dominant Alzheimer disease, Alzheimer&#x2019;s Dement. in press, 1&#x2013;11 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8043974</ArticleId><ArticleId IdType="pubmed">33196147</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormino EC, Betensky RA, Hedden T, Schultz AP, Ward A, Huijbers W, Rentz DM, Johnson KA, Sperling RA, Amyloid and APOE &#x3b5;4 interact to influence short-term decline in preclinical Alzheimer disease, Neurology 82, 1760&#x2013;1767 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4035706</ArticleId><ArticleId IdType="pubmed">24748674</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau SM, Breault C, Joshi AD, Pontecorvo M, a Mathis C, Jagust WJ, a Mintun M, Amyloid-&#x3b2; imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods., J. Nucl. Med 54, 70&#x2013;7 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3747730</ArticleId><ArticleId IdType="pubmed">23166389</ArticleId></ArticleIdList></Reference><Reference><Citation>Burt JB, Helmer M, Shinn M, Anticevic A, Murray JD, Generative modeling of brain maps with spatial autocorrelation, Neuroimage 220, 117038 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32585343</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander-Bloch A, Shou H, Liu S, Satterthwaite TD, Glahn DC, Shinohara RT, Vandekar SN, Raznahan A, On testing for spatial correspondence between maps of human brain structure and function, Neuroimage (2018), doi:10.1016/j.neuroimage.2018.05.070.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2018.05.070</ArticleId><ArticleId IdType="pmc">PMC6095687</ArticleId><ArticleId IdType="pubmed">29860082</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Wiste HJ, Weigand SD, Therneau TM, Lowe VJ, Knopman DS, Botha H, Graff-Radford J, Jones DT, Ferman TJ, Boeve BF, Kantarci K, Vemuri P, Mielke MM, Whitwell J, Josephs K, Schwarz CG, Senjem ML, Gunter JL, Petersen RC, Predicting future rates of tau accumulation on PET, Brain 143, 3136&#x2013;3150 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7586089</ArticleId><ArticleId IdType="pubmed">33094327</ArticleId></ArticleIdList></Reference><Reference><Citation>Diez I, Sepulcre J, Unveiling the neuroimaging-genetic intersections in the human brain., Curr. Opin. Neurol 34, 480&#x2013;487 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8265485</ArticleId><ArticleId IdType="pubmed">34227572</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnatkevic A, Fulcher BD, Fornito A, A practical guide to linking brain-wide gene expression and neuroimaging data, Neuroimage (2019), doi:10.1016/j.neuroimage.2019.01.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2019.01.011</ArticleId><ArticleId IdType="pubmed">30648605</ArticleId></ArticleIdList></Reference><Reference><Citation>Glasser MF, Coalson TS, Robinson EC, Hacker CD, Harwell J, Yacoub E, Ugurbil K, Andersson J, Beckmann CF, Jenkinson M, Smith SM, Van Essen DC, A multi-modal parcellation of human cerebral cortex, Nature 536, 171&#x2013;178 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4990127</ArticleId><ArticleId IdType="pubmed">27437579</ArticleId></ArticleIdList></Reference><Reference><Citation>De Jager PL, Ma Y, McCabe C, Xu J, Vardarajan BN, Felsky D, Klein HU, White CC, Peters MA, Lodgson B, Nejad P, Tang A, Mangravite LM, Yu L, Gaiteri C, Mostafavi S, Schneider JA, Bennett DA, Data descriptor: A multi-omic atlas of the human frontal cortex for aging and Alzheimer&#x2019;s disease research, Sci. Data 5, 1&#x2013;13 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6080491</ArticleId><ArticleId IdType="pubmed">30084846</ArticleId></ArticleIdList></Reference><Reference><Citation>Love MI, Huber W, Anders S, Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2, Genome Biol. 15, 1&#x2013;21 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4302049</ArticleId><ArticleId IdType="pubmed">25516281</ArticleId></ArticleIdList></Reference><Reference><Citation>Leek JT, Svaseq: Removing batch effects and other unwanted noise from sequencing data, Nucleic Acids Res. 42, e161 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4245966</ArticleId><ArticleId IdType="pubmed">25294822</ArticleId></ArticleIdList></Reference><Reference><Citation>Dols-Icardo O, Montal V, Sirisi S, L&#xf3;pez-Pernas G, Cervera-Carles L, Querol-Vilaseca M, Mu&#xf1;oz L, Belbin O, Alcolea D, Molina-Porcel L, Pegueroles J, Tur&#xf3;n-Sans J, Blesa R, Lle&#xf3; A, Fortea J, Rojas-Garc&#xed;a R, Clarim&#xf3;n J, Motor cortex transcriptome reveals microglial key events in amyotrophic lateral sclerosis, Neurol Neuroimmunol Neuroinflam 7, 1&#x2013;12 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7371375</ArticleId><ArticleId IdType="pubmed">32669313</ArticleId></ArticleIdList></Reference><Reference><Citation>Mi H, Muruganujan A, Thomas PD, PANTHER in 2013: Modeling the evolution of gene function, and other gene attributes, in the context of phylogenetic trees, Nucleic Acids Res. 41, 377&#x2013;386 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3531194</ArticleId><ArticleId IdType="pubmed">23193289</ArticleId></ArticleIdList></Reference><Reference><Citation>Mostafavi S, Ray D, Warde-Farley D, Grouios C, Morris Q, GeneMANIA: A real-time multiple association network integration algorithm for predicting gene function, Genome Biol. 9 (2008), doi:10.1186/gb-2008-9-s1-s4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/gb-2008-9-s1-s4</ArticleId><ArticleId IdType="pmc">PMC2447538</ArticleId><ArticleId IdType="pubmed">18613948</ArticleId></ArticleIdList></Reference><Reference><Citation>1 Shannon Paul, 1 Markiel Andrew, 2 Ozier Owen, 2 Baliga Nitin S., 1 Wang Jonathan T., 2 Ramage Daniel, 2 Amin Nada, 5 Schwikowski Benno, 1, 5 and Ideker Trey2, 3, 4, Cytoscape: A Software Environment for Integrated Models, Genome Res. 13, 426 (2003).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC403769</ArticleId><ArticleId IdType="pubmed">14597658</ArticleId></ArticleIdList></Reference><Reference><Citation>Krzywinski M, Schein J, Birol I, Connors J, Gascoyne R, Horsman D, Jones SJ, Marra MA, Circos: An information aesthetic for comparative genomics, Genome Res. 19, 1639&#x2013;1645 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2752132</ArticleId><ArticleId IdType="pubmed">19541911</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35908251</PMID><DateCompleted><Year>2023</Year><Month>01</Month><Day>02</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1552-5279</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>12</Issue><PubDate><Year>2022</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Alzheimer's &amp; dementia : the journal of the Alzheimer's Association</Title><ISOAbbreviation>Alzheimers Dement</ISOAbbreviation></Journal><ArticleTitle>The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>2669</StartPage><EndPage>2686</EndPage><MedlinePgn>2669-2686</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/alz.12756</ELocationID><Abstract><AbstractText>Blood-based markers (BBMs) have recently shown promise to revolutionize the diagnostic and prognostic work-up of Alzheimer's disease (AD), as well as to improve the design of interventional trials. Here we discuss in detail further research needed to be performed before widespread use of BBMs. We already now recommend use of BBMs as (pre-)screeners to identify individuals likely to have AD pathological changes for inclusion in trials evaluating disease-modifying therapies, provided the AD status is confirmed with positron emission tomography (PET) or cerebrospinal fluid (CSF) testing. We also encourage studying longitudinal BBM changes in ongoing as well as future interventional trials. However, BBMs should not yet be used as primary endpoints in pivotal trials. Further, we recommend to cautiously start using BBMs in specialized memory clinics as part of the diagnostic work-up of patients with cognitive symptoms and the results should be confirmed whenever possible with CSF or PET. Additional data are needed before use of BBMs as stand-alone diagnostic AD markers, or before considering use in primary care.</AbstractText><CopyrightInformation>&#xa9; 2022 The Authors. Alzheimer's &amp; Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hansson</LastName><ForeName>Oskar</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Clinical, Memory Research Unit, Department of Clinical Sciences Malm&#xf6;, Lund University, Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory Clinic, Sk&#xe5;ne University Hospital, Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Edelmayer</LastName><ForeName>Rebecca M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Alzheimer's Association, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boxer</LastName><ForeName>Adam L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California San Francisco, Memory and Aging Center, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carrillo</LastName><ForeName>Maria C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Alzheimer's Association, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mielke</LastName><ForeName>Michelle M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Prevention, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rabinovici</LastName><ForeName>Gil D</ForeName><Initials>GD</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California San Francisco, Memory and Aging Center, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salloway</LastName><ForeName>Stephen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Departments of Neurology and Psychiatry, Alpert Medical School of Brown University, Providence, Rhode Island, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Center, for Alzheimer Research and Treatment, Brigham and Women's Hospital, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute at UCL, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hong Kong Center for Neurodegenerative Diseases, Clear Water Bay, Hong Kong, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teunissen</LastName><ForeName>Charlotte E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Neurochemistry, Laboratory, Department of Clinical Chemistry, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam Neuroscience, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG054029</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG063911</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062422</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG019724</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R35 AG072362</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG053798</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG045390</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 NS092089</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG061848</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG063689</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 AG057195</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG057195</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG057437</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG036694</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG038791</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Alzheimers Dement</MedlineTA><NlmUniqueID>101231978</NlmUniqueID><ISSNLinking>1552-5260</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="Y">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">appropriate use recommendations</Keyword><Keyword MajorTopicYN="N">blood-based biomarkers</Keyword><Keyword MajorTopicYN="N">diagnosis</Keyword><Keyword MajorTopicYN="N">prognosis</Keyword></KeywordList><CoiStatement>
Author disclosures are available in the supporting information.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>6</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>5</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>7</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>31</Day><Hour>13</Hour><Minute>59</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>4</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35908251</ArticleId><ArticleId IdType="pmc">PMC10087669</ArticleId><ArticleId IdType="doi">10.1002/alz.12756</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Knopman DS, DeKosky ST, Cummings JL, et&#xa0;al. Practice parameter: diagnosis of dementia (an evidence&#x2010;based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56(9):1143&#x2010;1153. 10.1212/wnl.56.9.1143</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.56.9.1143</ArticleId><ArticleId IdType="pubmed">11342678</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizzo G, Arcuti S, Copetti M, et&#xa0;al. Accuracy of clinical diagnosis of dementia with Lewy bodies: a systematic review and meta&#x2010;analysis. J Neurol Neurosurg Psychiatry. 2018;89(4):358&#x2010;366. 10.1136/jnnp-2017-316844</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-316844</ArticleId><ArticleId IdType="pubmed">29030419</ArticleId></ArticleIdList></Reference><Reference><Citation>Beach TG, Monsell SE, Phillips LE, Kukull W. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005&#x2010;2010. J Neuropathol Exp Neurol. 2012;71(4):266&#x2010;273. 10.1097/NEN.0b013e31824b211b</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e31824b211b</ArticleId><ArticleId IdType="pmc">PMC3331862</ArticleId><ArticleId IdType="pubmed">22437338</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson O. Biomarkers for neurodegenerative diseases. Nat Med. 2021;27(6):954&#x2010;963. 10.1038/s41591-021-01382-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01382-x</ArticleId><ArticleId IdType="pubmed">34083813</ArticleId></ArticleIdList></Reference><Reference><Citation>Teunissen CE, Verberk IMW, Thijssen EH, et&#xa0;al. Blood&#x2010;based biomarkers for Alzheimer's disease: towards clinical implementation. Lancet Neurol. 2022;21(1):66&#x2010;77. 10.1016/S1474-4422(21)00361-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(21)00361-6</ArticleId><ArticleId IdType="pubmed">34838239</ArticleId></ArticleIdList></Reference><Reference><Citation>Karran E, Mercken M, De Strooper B. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov. 2011;10(9):698&#x2010;712. 10.1038/nrd3505</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd3505</ArticleId><ArticleId IdType="pubmed">21852788</ArticleId></ArticleIdList></Reference><Reference><Citation>Alves CRR, Petrillo M, Spellman R, et&#xa0;al. Implications of circulating neurofilamentsfor spinal muscular atrophytreatment early in life: a case series. Mol Ther Methods Clin Dev. 2021;23:524&#x2010;538. 10.1016/j.omtm.2021.10.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtm.2021.10.011</ArticleId><ArticleId IdType="pmc">PMC8605296</ArticleId><ArticleId IdType="pubmed">34853799</ArticleId></ArticleIdList></Reference><Reference><Citation>Disanto G, Barro C, Benkert P, et&#xa0;al. Serum Neurofilament light: a biomarker of neuronal damage in multiple sclerosis. Ann Neurol. 2017;81(6):857&#x2010;870. 10.1002/ana.24954</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24954</ArticleId><ArticleId IdType="pmc">PMC5519945</ArticleId><ArticleId IdType="pubmed">28512753</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson AM, Easley KA, Kasher N, et&#xa0;al. Neurofilament light chain in blood is negatively associated with neuropsychological performance in HIV&#x2010;infected adults and declines with initiation of antiretroviral therapy. J Neurovirol. 2018;24(6):695&#x2010;701. 10.1007/s13365-018-0664-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13365-018-0664-y</ArticleId><ArticleId IdType="pmc">PMC6279552</ArticleId><ArticleId IdType="pubmed">30105502</ArticleId></ArticleIdList></Reference><Reference><Citation>Zetterberg H, Blennow K. Moving fluid biomarkers for Alzheimer's disease from research tools to routine clinical diagnostics. Mol Neurodegener. 2021;16(1):10. 10.1186/s13024-021-00430-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-021-00430-x</ArticleId><ArticleId IdType="pmc">PMC7893769</ArticleId><ArticleId IdType="pubmed">33608044</ArticleId></ArticleIdList></Reference><Reference><Citation>Ovod V, Ramsey KN, Mawuenyega KG, et&#xa0;al. Amyloid beta concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimers Dement. 2017;13(8):841&#x2010;849. 10.1016/j.jalz.2017.06.2266</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2017.06.2266</ArticleId><ArticleId IdType="pmc">PMC5567785</ArticleId><ArticleId IdType="pubmed">28734653</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura A, Kaneko N, Villemagne VL, et&#xa0;al. High performance plasma amyloid&#x2010;beta biomarkers for Alzheimer's disease. Nature. 2018;554(7691):249&#x2010;254. 10.1038/nature25456</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature25456</ArticleId><ArticleId IdType="pubmed">29420472</ArticleId></ArticleIdList></Reference><Reference><Citation>Keshavan A, Pannee J, Karikari TK, et&#xa0;al. Population&#x2010;based blood screening for preclinical Alzheimer's disease in a British birth cohort at age 70. Brain. 2021;144(2):434&#x2010;449. 10.1093/brain/awaa403</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa403</ArticleId><ArticleId IdType="pmc">PMC7940173</ArticleId><ArticleId IdType="pubmed">33479777</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S, Janelidze S, Stomrud E, et&#xa0;al. Performance of fully automated plasma assays as screening tests for Alzheimer disease&#x2010;related beta&#x2010;amyloid status. JAMA Neurol. 2019;76(9):1060&#x2010;1069. 10.1001/jamaneurol.2019.1632</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2019.1632</ArticleId><ArticleId IdType="pmc">PMC6593637</ArticleId><ArticleId IdType="pubmed">31233127</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze S, Teunissen CE, Zetterberg H, et&#xa0;al. Head&#x2010;to&#x2010;head comparison of 8 plasma amyloid&#x2010;beta 42/40 assays in Alzheimer disease. JAMA Neurol. 2021;78(11):1375&#x2010;1382. 10.1001/jamaneurol.2021.3180</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2021.3180</ArticleId><ArticleId IdType="pmc">PMC8453354</ArticleId><ArticleId IdType="pubmed">34542571</ArticleId></ArticleIdList></Reference><Reference><Citation>Benedet AL, Brum WS, Hansson O, et&#xa0;al. The accuracy and robustness of plasma biomarker models for amyloid PET positivity. Alzheimers Res Ther. 2022;14(1):26. 10.1186/s13195-021-00942-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-021-00942-0</ArticleId><ArticleId IdType="pmc">PMC8819863</ArticleId><ArticleId IdType="pubmed">35130933</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Schindler SE, Bollinger JG, et&#xa0;al. Validation of Plasma amyloid&#x2010;beta 42/40 for detecting Alzheimer disease amyloid plaques. Neurology. 2022;98(7):e688&#x2010;e699. 10.1212/WNL.0000000000013211</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000013211</ArticleId><ArticleId IdType="pmc">PMC8865895</ArticleId><ArticleId IdType="pubmed">34906975</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato C, Barthelemy NR, Mawuenyega KG, et&#xa0;al. Tau kinetics in neurons and the human central nervous system. Neuron. 2018;98(4):861&#x2010;864. 10.1016/j.neuron.2018.04.035</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2018.04.035</ArticleId><ArticleId IdType="pmc">PMC6192252</ArticleId><ArticleId IdType="pubmed">29772204</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson&#x2010;Carlgren N, Janelidze S, Bateman RJ, et&#xa0;al. Soluble P&#x2010;tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau. EMBO Mol Med. 2021;13(6):e14022. 10.15252/emmm.202114022</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.202114022</ArticleId><ArticleId IdType="pmc">PMC8185545</ArticleId><ArticleId IdType="pubmed">33949133</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze S, Mattsson N, Palmqvist S, et&#xa0;al. Plasma P&#x2010;tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia. Nat Med. 2020;26(3):379&#x2010;386. 10.1038/s41591-020-0755-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0755-1</ArticleId><ArticleId IdType="pubmed">32123385</ArticleId></ArticleIdList></Reference><Reference><Citation>Lantero Rodriguez J, Karikari TK, Suarez&#x2010;Calvet M, et&#xa0;al. Plasma p&#x2010;tau181 accurately predicts Alzheimer's disease pathology at least 8 years prior to post&#x2010;mortem and improves the clinical characterisation of cognitive decline. Acta Neuropathol. 2020;140(3):267&#x2010;278. 10.1007/s00401-020-02195-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-020-02195-x</ArticleId><ArticleId IdType="pmc">PMC7423866</ArticleId><ArticleId IdType="pubmed">32720099</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S, Janelidze S, Quiroz YT, et&#xa0;al. Discriminative accuracy of plasma phospho&#x2010;tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA. 2020;324(8):772&#x2010;781. 10.1001/jama.2020.12134</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12134</ArticleId><ArticleId IdType="pmc">PMC7388060</ArticleId><ArticleId IdType="pubmed">32722745</ArticleId></ArticleIdList></Reference><Reference><Citation>Thijssen EH, La Joie R, Wolf A, et&#xa0;al. Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration. Nat Med. 2020;26(3):387&#x2010;397. 10.1038/s41591-020-0762-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0762-2</ArticleId><ArticleId IdType="pmc">PMC7101073</ArticleId><ArticleId IdType="pubmed">32123386</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashton NJ, Pascoal TA, Karikari TK, et&#xa0;al. Plasma p&#x2010;tau231: a new biomarker for incipient Alzheimer's disease pathology. Acta Neuropathol. 2021;141(5):709&#x2010;724. 10.1007/s00401-021-02275-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-021-02275-6</ArticleId><ArticleId IdType="pmc">PMC8043944</ArticleId><ArticleId IdType="pubmed">33585983</ArticleId></ArticleIdList></Reference><Reference><Citation>Mielke MM, Hagen CE, Xu J, et&#xa0;al. Plasma phospho&#x2010;tau181 increases with Alzheimer's disease clinical severity and is associated with tau&#x2010; and amyloid&#x2010;positron emission tomography. Alzheimers Dement. 2018;14(8):989&#x2010;997. 10.1016/j.jalz.2018.02.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.02.013</ArticleId><ArticleId IdType="pmc">PMC6097897</ArticleId><ArticleId IdType="pubmed">29626426</ArticleId></ArticleIdList></Reference><Reference><Citation>Wennstrom M, Janelidze S, Nilsson KPR, et&#xa0;al. Cellular localization of p&#x2010;tau217 in brain and its association with p&#x2010;tau217 plasma levels. Acta Neuropathol Commun. 2022;10(1):3. 10.1186/s40478-021-01307-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-021-01307-2</ArticleId><ArticleId IdType="pmc">PMC8734209</ArticleId><ArticleId IdType="pubmed">34991721</ArticleId></ArticleIdList></Reference><Reference><Citation>Karikari TK, Pascoal TA, Ashton NJ, et&#xa0;al. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 2020;19(5):422&#x2010;433. 10.1016/S1474-4422(20)30071-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(20)30071-5</ArticleId><ArticleId IdType="pubmed">32333900</ArticleId></ArticleIdList></Reference><Reference><Citation>Thijssen EH, La Joie R, Strom A, et&#xa0;al. Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. Lancet Neurol. 2021;20(9):739&#x2010;752. 10.1016/S1474-4422(21)00214-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(21)00214-3</ArticleId><ArticleId IdType="pmc">PMC8711249</ArticleId><ArticleId IdType="pubmed">34418401</ArticleId></ArticleIdList></Reference><Reference><Citation>Karikari TK, Benedet AL, Ashton NJ, et&#xa0;al. Diagnostic performance and prediction of clinical progression of plasma phospho&#x2010;tau181 in the Alzheimer's Disease Neuroimaging Initiative. Mol Psychiatry. 2021;26(2):429&#x2010;442. 10.1038/s41380-020-00923-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-020-00923-z</ArticleId><ArticleId IdType="pubmed">33106600</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S, Tideman P, Cullen N, et&#xa0;al. Prediction of future Alzheimer's disease dementia using plasma phospho&#x2010;tau combined with other accessible measures. Nat Med. 2021;27(6):1034&#x2010;1042. 10.1038/s41591-021-01348-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01348-z</ArticleId><ArticleId IdType="pubmed">34031605</ArticleId></ArticleIdList></Reference><Reference><Citation>Cullen N, Leuzy A, Palmqvist S, et&#xa0;al. Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations. Nature Aging. 2021;1(1): 114&#x2010;123. 10.1038/s43587-020-00003-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s43587-020-00003-5</ArticleId><ArticleId IdType="pubmed">37117993</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S, Insel PS, Stomrud E, et&#xa0;al. Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease. EMBO Mol Med. 2019;11(12):e11170. 10.15252/emmm.201911170</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201911170</ArticleId><ArticleId IdType="pmc">PMC6895602</ArticleId><ArticleId IdType="pubmed">31709776</ArticleId></ArticleIdList></Reference><Reference><Citation>Cullen NC, Leuzy A, Janelidze S, et&#xa0;al. Plasma biomarkers of Alzheimer's disease improve prediction of cognitive decline in cognitively unimpaired elderly populations. Nat Commun. 2021;12(1):3555. 10.1038/s41467-021-23746-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-23746-0</ArticleId><ArticleId IdType="pmc">PMC8196018</ArticleId><ArticleId IdType="pubmed">34117234</ArticleId></ArticleIdList></Reference><Reference><Citation>Leuzy A, Smith R, Cullen NC, et&#xa0;al. Biomarker&#x2010;Based prediction of longitudinal tau positron emission tomography in Alzheimer disease. JAMA Neurol. 2021. 10.1001/jamaneurol.2021.4654</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2021.4654</ArticleId><ArticleId IdType="pmc">PMC8689441</ArticleId><ArticleId IdType="pubmed">34928318</ArticleId></ArticleIdList></Reference><Reference><Citation>Pereira JB, Janelidze S, Stomrud E, et&#xa0;al. Plasma markers predict changes in amyloid, tau, atrophy and cognition in non&#x2010;demented subjects. Brain. 2021;144(9):2826&#x2010;2836. 10.1093/brain/awab163</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awab163</ArticleId><ArticleId IdType="pmc">PMC8557344</ArticleId><ArticleId IdType="pubmed">34077494</ArticleId></ArticleIdList></Reference><Reference><Citation>Bayoumy S, Verberk IMW, den Dulk B, et&#xa0;al. Clinical and analytical comparison of six Simoa assays for plasma P&#x2010;tau isoforms P&#x2010;tau181, P&#x2010;tau217, and P&#x2010;tau231. Alzheimers Res Ther. 2021;13(1):198. 10.1186/s13195-021-00939-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-021-00939-9</ArticleId><ArticleId IdType="pmc">PMC8645090</ArticleId><ArticleId IdType="pubmed">34863295</ArticleId></ArticleIdList></Reference><Reference><Citation>Mielke MM, Frank RD, Dage JL, et&#xa0;al. Comparison of plasma phosphorylated tau species with amyloid and tau positron emission tomography, neurodegeneration, vascular pathology, and cognitive outcomes. JAMA Neurol. 2021;78(9):1108&#x2010;1117. 10.1001/jamaneurol.2021.2293</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2021.2293</ArticleId><ArticleId IdType="pmc">PMC8314178</ArticleId><ArticleId IdType="pubmed">34309632</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson&#x2010;Carlgren N, Janelidze S, Palmqvist S, et&#xa0;al. Longitudinal plasma p&#x2010;tau217 is increased in early stages of Alzheimer's disease. Brain. 2020;143(11):3234&#x2010;3241. 10.1093/brain/awaa286</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa286</ArticleId><ArticleId IdType="pmc">PMC7719022</ArticleId><ArticleId IdType="pubmed">33068398</ArticleId></ArticleIdList></Reference><Reference><Citation>Budd Haeberlein S, Aisen PS, Barkhof F, et&#xa0;al. Two randomized phase 3 studies of aducanumab in early Alzheimer's disease. J Prev Alzheimers Dis. 2022;9(2):197&#x2010;210. 10.14283/jpad.2022.30</Citation><ArticleIdList><ArticleId IdType="doi">10.14283/jpad.2022.30</ArticleId><ArticleId IdType="pubmed">35542991</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashton NJ, Janelidze S, Al Khleifat A, et&#xa0;al. A multicentre validation study of the diagnostic value of plasma neurofilament light. Nat Commun. 2021;12(1):3400. 10.1038/s41467-021-23620-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-23620-z</ArticleId><ArticleId IdType="pmc">PMC8185001</ArticleId><ArticleId IdType="pubmed">34099648</ArticleId></ArticleIdList></Reference><Reference><Citation>Bridel C, van Wieringen WN, Zetterberg H, et&#xa0;al. Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta&#x2010;analysis. JAMA Neurol. 2019;76(9):1035&#x2010;1048. 10.1001/jamaneurol.2019.1534</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2019.1534</ArticleId><ArticleId IdType="pmc">PMC6580449</ArticleId><ArticleId IdType="pubmed">31206160</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaetani L, Blennow K, Calabresi P, Di Filippo M, Parnetti L, Zetterberg H. Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry. 2019;90(8):870&#x2010;881. 10.1136/jnnp-2018-320106</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-320106</ArticleId><ArticleId IdType="pubmed">30967444</ArticleId></ArticleIdList></Reference><Reference><Citation>Preische O, Schultz SA, Apel A, et&#xa0;al. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease. Nat Med. 2019;25(2):277&#x2010;283. 10.1038/s41591-018-0304-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-018-0304-3</ArticleId><ArticleId IdType="pmc">PMC6367005</ArticleId><ArticleId IdType="pubmed">30664784</ArticleId></ArticleIdList></Reference><Reference><Citation>Weston PSJ, Poole T, O'Connor A, et&#xa0;al. Longitudinal measurement of serum neurofilament light in presymptomatic familial Alzheimer's disease. Alzheimers Res Ther. 2019;11(1):19. 10.1186/s13195-019-0472-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-019-0472-5</ArticleId><ArticleId IdType="pmc">PMC6383280</ArticleId><ArticleId IdType="pubmed">30786919</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Andreasson U, Zetterberg H, Blennow K. Alzheimer's Disease Neuroimaging I. Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. JAMA Neurol. 2017;74(5):557&#x2010;566. 10.1001/jamaneurol.2016.6117</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2016.6117</ArticleId><ArticleId IdType="pmc">PMC5822204</ArticleId><ArticleId IdType="pubmed">28346578</ArticleId></ArticleIdList></Reference><Reference><Citation>Salloway S, Farlow M, McDade E, et&#xa0;al. A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. Nat Med. 2021;27(7):1187&#x2010;1196. 10.1038/s41591-021-01369-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01369-8</ArticleId><ArticleId IdType="pmc">PMC8988051</ArticleId><ArticleId IdType="pubmed">34155411</ArticleId></ArticleIdList></Reference><Reference><Citation>Swanson CJ, Zhang Y, Dhadda S, et&#xa0;al. A randomized, double&#x2010;blind, phase 2b proof&#x2010;of&#x2010;concept clinical trial in early Alzheimer's disease with lecanemab, an anti&#x2010;Abeta protofibril antibody. Alzheimers Res Ther. 2021;13(1):80. 10.1186/s13195-021-00813-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-021-00813-8</ArticleId><ArticleId IdType="pmc">PMC8053280</ArticleId><ArticleId IdType="pubmed">33865446</ArticleId></ArticleIdList></Reference><Reference><Citation>Verberk IMW, Misdorp EO, Koelewijn J, et&#xa0;al. Characterization of pre&#x2010;analytical sample handling effects on a panel of Alzheimer's disease&#x2010;related blood&#x2010;based biomarkers: results from the Standardization of Alzheimer's Blood Biomarkers (SABB) working group. Alzheimers Dement. 2022;18(8):1484&#x2010;1497. 10.1002/alz.12510</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.12510</ArticleId><ArticleId IdType="pmc">PMC9148379</ArticleId><ArticleId IdType="pubmed">34845818</ArticleId></ArticleIdList></Reference><Reference><Citation>Pereira JB, Janelidze S, Smith R, et&#xa0;al. Plasma GFAP is an early marker of amyloid&#x2010;beta but not tau pathology in Alzheimer's disease. Brain. 2021;144(11):3505&#x2010;3516. 10.1093/brain/awab223</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awab223</ArticleId><ArticleId IdType="pmc">PMC8677538</ArticleId><ArticleId IdType="pubmed">34259835</ArticleId></ArticleIdList></Reference><Reference><Citation>Benedet AL, Mila&#x2010;Aloma M, Vrillon A, et&#xa0;al. Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer disease continuum. JAMA Neurol. 2021;78(12):1471&#x2010;1483. 10.1001/jamaneurol.2021.3671</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2021.3671</ArticleId><ArticleId IdType="pmc">PMC8524356</ArticleId><ArticleId IdType="pubmed">34661615</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatterjee P, Pedrini S, Ashton NJ, et&#xa0;al. Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease. Alzheimers Dement. 2022;18(6):1141&#x2010;1154. 10.1002/alz.12447</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.12447</ArticleId><ArticleId IdType="pubmed">34494715</ArticleId></ArticleIdList></Reference><Reference><Citation>Cicognola C, Janelidze S, Hertze J, et&#xa0;al. Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment. Alzheimers Res Ther. 2021;13(1):68. 10.1186/s13195-021-00804-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-021-00804-9</ArticleId><ArticleId IdType="pmc">PMC8005231</ArticleId><ArticleId IdType="pubmed">33773595</ArticleId></ArticleIdList></Reference><Reference><Citation>Heller C, Foiani MS, Moore K, et&#xa0;al. Plasma glial fibrillary acidic protein is raised in progranulin&#x2010;associated frontotemporal dementia. J Neurol Neurosurg Psychiatry. 2020;91(3):263&#x2010;270. 10.1136/jnnp-2019-321954</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2019-321954</ArticleId><ArticleId IdType="pubmed">31937580</ArticleId></ArticleIdList></Reference><Reference><Citation>Shir D, Graff&#x2010;Radford J, Hofrenning EI, et&#xa0;al. Association of plasma glial fibrillary acidic protein (GFAP) with neuroimaging of Alzheimer's disease and vascular pathology. Alzheimers Dement (Amst). 2022;14(1):e12291. 10.1002/dad2.12291</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/dad2.12291</ArticleId><ArticleId IdType="pmc">PMC8883441</ArticleId><ArticleId IdType="pubmed">35252538</ArticleId></ArticleIdList></Reference><Reference><Citation>Verberk IMW, Thijssen E, Koelewijn J, et&#xa0;al. Combination of plasma amyloid beta(1&#x2010;42/1&#x2010;40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology. Alzheimers Res Ther. 2020;12(1):118. 10.1186/s13195-020-00682-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-020-00682-7</ArticleId><ArticleId IdType="pmc">PMC7523295</ArticleId><ArticleId IdType="pubmed">32988409</ArticleId></ArticleIdList></Reference><Reference><Citation>Verberk IMW, Laarhuis MB, van den Bosch KA, et&#xa0;al. Serum markers glial fibrillary acidic protein and neurofilament light for prognosis and monitoring in cognitively normal older people: a prospective memory clinic&#x2010;based cohort study. Lancet Healthy Longevity. 2021;2(2):E87&#x2010;E95. 10.1016/S2666-7568(20)30061-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-7568(20)30061-1</ArticleId><ArticleId IdType="pubmed">36098162</ArticleId></ArticleIdList></Reference><Reference><Citation>Laverse E, Guo T, Zimmerman K, et&#xa0;al. Plasma glial fibrillary acidic protein and neurofilament light chain, but not tau, are biomarkers of sports&#x2010;related mild traumatic brain injury. Brain Commun. 2020;2(2):fcaa137. 10.1093/braincomms/fcaa137</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcaa137</ArticleId><ArticleId IdType="pmc">PMC7846133</ArticleId><ArticleId IdType="pubmed">33543129</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattila OS, Ashton NJ, Blennow K, et&#xa0;al. Ultra&#x2010;early differential diagnosis of acute cerebral ischemia and hemorrhagic stroke by measuring the prehospital release rate of GFAP. Clin Chem. 2021;67(10):1361&#x2010;1372. 10.1093/clinchem/hvab128</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/clinchem/hvab128</ArticleId><ArticleId IdType="pubmed">34383905</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze S, Palmqvist S, Leuzy A, et&#xa0;al. Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Abeta42/Abeta40 and p&#x2010;tau. Alzheimers Dement. 2021;18(2):283&#x2010;293. 10.1002/alz.12395</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.12395</ArticleId><ArticleId IdType="pubmed">34151519</ArticleId></ArticleIdList></Reference><Reference><Citation>Lautner R, Palmqvist S, Hansson O. APOE genotype and the diagnostic accuracy of CSF biomarkers for Alzheimer disease. JAMA Psychiatry. 2014;71(10):1183&#x2010;1191. 10.1001/jamapsychiatry.2014.1060</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapsychiatry.2014.1060</ArticleId><ArticleId IdType="pubmed">25162367</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreasson U, Perret&#x2010;Liaudet A, van Waalwijk van Doorn LJ, et&#xa0;al. A practical guide to immunoassay method validation. Front Neurol. 2015;6:179. 10.3389/fneur.2015.00179</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2015.00179</ArticleId><ArticleId IdType="pmc">PMC4541289</ArticleId><ArticleId IdType="pubmed">26347708</ArticleId></ArticleIdList></Reference><Reference><Citation>Papp KV, Rentz DM, Orlovsky I, Sperling RA, Mormino EC. Optimizing the preclinical Alzheimer's cognitive composite with semantic processing: the PACC5. Alzheimers Dement (N Y). 2017;3(4):668&#x2010;677. 10.1016/j.trci.2017.10.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trci.2017.10.004</ArticleId><ArticleId IdType="pmc">PMC5726754</ArticleId><ArticleId IdType="pubmed">29264389</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson O, Mikulskis A, Fagan AM, et&#xa0;al. The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: a review. Alzheimers Dement. 2018;14(10):1313&#x2010;1333. 10.1016/j.jalz.2018.05.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.05.008</ArticleId><ArticleId IdType="pubmed">29940161</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson O, Batrla R, Brix B, et&#xa0;al. The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid beta and tau. Alzheimers Dement. 2021;17(9):1575&#x2010;1582. 10.1002/alz.12316</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.12316</ArticleId><ArticleId IdType="pubmed">33788410</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Andreasson U, Persson S, et&#xa0;al. CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimers Dement. 2013;9(3):251&#x2010;261. 10.1016/j.jalz.2013.01.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2013.01.010</ArticleId><ArticleId IdType="pmc">PMC3707386</ArticleId><ArticleId IdType="pubmed">23622690</ArticleId></ArticleIdList></Reference><Reference><Citation>Tijms BM, Willemse EAJ, Zwan MD, et&#xa0;al. Unbiased approach to counteract upward drift in cerebrospinal fluid amyloid&#x2010;beta 1&#x2010;42 analysis results. Clin Chem. 2018;64(3):576&#x2010;585. 10.1373/clinchem.2017.281055</Citation><ArticleIdList><ArticleId IdType="doi">10.1373/clinchem.2017.281055</ArticleId><ArticleId IdType="pubmed">29208658</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalil M, Teunissen CE, Otto M, et&#xa0;al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol. 2018;14(10):577&#x2010;589. 10.1038/s41582-018-0058-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-018-0058-z</ArticleId><ArticleId IdType="pubmed">30171200</ArticleId></ArticleIdList></Reference><Reference><Citation>Mielke MM, Syrjanen JA, Blennow K, et&#xa0;al. Comparison of variables associated with cerebrospinal fluid neurofilament, total&#x2010;tau, and neurogranin. Alzheimers Dement. 2019;15(11):1437&#x2010;1447. 10.1016/j.jalz.2019.07.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2019.07.009</ArticleId><ArticleId IdType="pmc">PMC6874755</ArticleId><ArticleId IdType="pubmed">31668594</ArticleId></ArticleIdList></Reference><Reference><Citation>Syrjanen JA, Campbell MR, Algeciras&#x2010;Schimnich A, et&#xa0;al. Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities. Alzheimers Dement. 2022;18(6):1128&#x2010;1140. 10.1002/alz.12466</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.12466</ArticleId><ArticleId IdType="pmc">PMC8957642</ArticleId><ArticleId IdType="pubmed">34569696</ArticleId></ArticleIdList></Reference><Reference><Citation>Ticau S, Sridharan GV, Tsour S, et&#xa0;al. Neurofilament light chain as a biomarker of hereditary transthyretin&#x2010;mediated amyloidosis. Neurology. 2021;96(3):e412&#x2010;e422. 10.1212/WNL.0000000000011090</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000011090</ArticleId><ArticleId IdType="pmc">PMC7884985</ArticleId><ArticleId IdType="pubmed">33087494</ArticleId></ArticleIdList></Reference><Reference><Citation>Ladang A, Kovacs S, Lengele L, et&#xa0;al. Neurofilament light chain concentration in an aging population. Aging Clin Exp Res. 2022;34(2):331&#x2010;339. 10.1007/s40520-021-02054-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40520-021-02054-z</ArticleId><ArticleId IdType="pmc">PMC8847291</ArticleId><ArticleId IdType="pubmed">35018623</ArticleId></ArticleIdList></Reference><Reference><Citation>Beydoun MA, Noren Hooten N, Maldonado AI, et&#xa0;al. Body mass index and allostatic load are directly associated with longitudinal increase in plasma neurofilament light among urban middle&#x2010;aged adults. J Nutr. 2022;152(2):535&#x2010;549. 10.1093/jn/nxab381</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jn/nxab381</ArticleId><ArticleId IdType="pmc">PMC8826916</ArticleId><ArticleId IdType="pubmed">34718678</ArticleId></ArticleIdList></Reference><Reference><Citation>Mielke MM, Dage JL, Frank RD, et&#xa0;al. Performance of plasma phosphorylated tau 181 and 217 in the community. Nat Med. 2022. 10.1038/s41591-022-01822-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01822-2</ArticleId><ArticleId IdType="pmc">PMC9329262</ArticleId><ArticleId IdType="pubmed">35618838</ArticleId></ArticleIdList></Reference><Reference><Citation>Binette AP, Janelidze S, Cullen N, et&#xa0;al. Confounding factors of Alzheimer's disease plasma biomarkers and their impact on clinical performance. medRxiv. 2022. 10.1101/2022.05.30.22275718</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.05.30.22275718</ArticleId><ArticleId IdType="pmc">PMC10499000</ArticleId><ArticleId IdType="pubmed">36152307</ArticleId></ArticleIdList></Reference><Reference><Citation>Brickman AM, Manly JJ, Honig LS, et&#xa0;al. Correlation of plasma and neuroimaging biomarkers in Alzheimer's disease. Ann Clin Transl Neurol. 2022;9(5):756&#x2010;761. 10.1002/acn3.51529</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51529</ArticleId><ArticleId IdType="pmc">PMC9082382</ArticleId><ArticleId IdType="pubmed">35306760</ArticleId></ArticleIdList></Reference><Reference><Citation>Windon C, Iaccarino L, Mundada N, et&#xa0;al. Comparison of plasma and CSF biomarkers across ethnoracial groups in the ADNI. Alzheimers Dement (Amst). 2022;14(1):e12315. 10.1002/dad2.12315</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/dad2.12315</ArticleId><ArticleId IdType="pmc">PMC9057320</ArticleId><ArticleId IdType="pubmed">35510092</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindler SE, Karikari TK, Ashton NJ, et&#xa0;al. Effect of race on prediction of brain amyloidosis by plasma abeta42/abeta40, phosphorylated tau, and neurofilament light. Neurology. 2022. 10.1212/WNL.0000000000200358</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000200358</ArticleId><ArticleId IdType="pmc">PMC9302933</ArticleId><ArticleId IdType="pubmed">35450967</ArticleId></ArticleIdList></Reference><Reference><Citation>Dybkaer R. Result, error and uncertainty. Scand J Clin Lab Invest. 1995;55(2):97&#x2010;118. 10.3109/00365519509089602</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/00365519509089602</ArticleId><ArticleId IdType="pubmed">7667613</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen WJ, Ossenkoppele R, Knol DL, et&#xa0;al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta&#x2010;analysis. JAMA. 2015;313(19):1924&#x2010;1938. 10.1001/jama.2015.4668</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2015.4668</ArticleId><ArticleId IdType="pmc">PMC4486209</ArticleId><ArticleId IdType="pubmed">25988462</ArticleId></ArticleIdList></Reference><Reference><Citation>Insel PS, Hansson O, Mattsson&#x2010;Carlgren N. Association Between apolipoprotein E epsilon2 vs epsilon4, age, and beta&#x2010;Amyloid in adults without cognitive impairment. JAMA Neurol. 2021;78(2):229&#x2010;235. 10.1001/jamaneurol.2020.3780</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2020.3780</ArticleId><ArticleId IdType="pmc">PMC7551211</ArticleId><ArticleId IdType="pubmed">33044487</ArticleId></ArticleIdList></Reference><Reference><Citation>Verberk IMW, Slot RE, Verfaillie SCJ, et&#xa0;al. Plasma amyloid as prescreener for the earliest Alzheimer pathological changes. Ann Neurol. 2018;84(5):648&#x2010;658. 10.1002/ana.25334</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25334</ArticleId><ArticleId IdType="pmc">PMC6282982</ArticleId><ArticleId IdType="pubmed">30196548</ArticleId></ArticleIdList></Reference><Reference><Citation>Grill JD, Raman R, Ernstrom K, et&#xa0;al. Short&#x2010;term psychological outcomes of disclosing amyloid imaging results to research participants who do not have cognitive impairment. JAMA Neurol. 2020;77(12):1504&#x2010;1513. 10.1001/jamaneurol.2020.2734</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2020.2734</ArticleId><ArticleId IdType="pmc">PMC7418046</ArticleId><ArticleId IdType="pubmed">32777010</ArticleId></ArticleIdList></Reference><Reference><Citation>Salloway S, Sperling R, Fox NC, et&#xa0;al. Two phase 3 trials of bapineuzumab in mild&#x2010;to&#x2010;moderate Alzheimer's disease. N Engl J Med. 2014;370(4):322&#x2010;333. 10.1056/NEJMoa1304839</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1304839</ArticleId><ArticleId IdType="pmc">PMC4159618</ArticleId><ArticleId IdType="pubmed">24450891</ArticleId></ArticleIdList></Reference><Reference><Citation>Sevigny J, Suhy J, Chiao P, et&#xa0;al. Amyloid PET screening for enrichment of early&#x2010;stage alzheimer disease clinical trials: experience in a phase 1b clinical trial. Alzheimer Dis Assoc Disord. 2016;30(1):1&#x2010;7. 10.1097/WAD.0000000000000144</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WAD.0000000000000144</ArticleId><ArticleId IdType="pubmed">26885819</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleming TR, Powers JH. Biomarkers and surrogate endpoints in clinical trials. Stat Med. 2012;31(25):2973&#x2010;2984. 10.1002/sim.5403</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.5403</ArticleId><ArticleId IdType="pmc">PMC3551627</ArticleId><ArticleId IdType="pubmed">22711298</ArticleId></ArticleIdList></Reference><Reference><Citation>Insel PS, Weiner M, Mackin RS, et&#xa0;al. Determining clinically meaningful decline in preclinical Alzheimer disease. Neurology. 2019;93(4):e322&#x2010;e333. 10.1212/WNL.0000000000007831</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000007831</ArticleId><ArticleId IdType="pmc">PMC6669933</ArticleId><ArticleId IdType="pubmed">31289148</ArticleId></ArticleIdList></Reference><Reference><Citation>
Administration USFaD
. https://wwwfdagov/drugs/development&#x2010;resources/surrogate&#x2010;endpoint&#x2010;resources&#x2010;drug&#x2010;and&#x2010;biologic&#x2010;development
</Citation></Reference><Reference><Citation>Benatar M, Zhang L, Wang L, et&#xa0;al. Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS. Neurology. 2020;95(1):e59&#x2010;e69. 10.1212/WNL.0000000000009559</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000009559</ArticleId><ArticleId IdType="pmc">PMC7371380</ArticleId><ArticleId IdType="pubmed">32385188</ArticleId></ArticleIdList></Reference><Reference><Citation>Delcoigne B, Manouchehrinia A, Barro C, et&#xa0;al. Blood neurofilament light levels segregate treatment effects in multiple sclerosis. Neurology. 2020;94(11):e1201&#x2010;e1212. 10.1212/WNL.0000000000009097</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000009097</ArticleId><ArticleId IdType="pmc">PMC7387108</ArticleId><ArticleId IdType="pubmed">32047070</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsson B, Alberg L, Cullen NC, et&#xa0;al. NFL is a marker of treatment response in children with SMA treated with nusinersen. J Neurol. 2019;266(9): 2129&#x2010;2136. 10.1007/s00415-019-09389-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-019-09389-8</ArticleId><ArticleId IdType="pmc">PMC6687695</ArticleId><ArticleId IdType="pubmed">31123861</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson KA, Minoshima S, Bohnen NI, et&#xa0;al. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. Alzheimers Dement. 2013;9(1):e1&#x2010;e16. 10.1016/j.jalz.2013.01.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2013.01.002</ArticleId><ArticleId IdType="pmc">PMC3733252</ArticleId><ArticleId IdType="pubmed">23360977</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw LM, Arias J, Blennow K, et&#xa0;al. Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer's disease. Alzheimers Dement. 2018;14(11):1505&#x2010;1521. 10.1016/j.jalz.2018.07.220</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.07.220</ArticleId><ArticleId IdType="pmc">PMC10013957</ArticleId><ArticleId IdType="pubmed">30316776</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois B, Villain N, Frisoni GB, et&#xa0;al. Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group. Lancet Neurol. 2021;20(6):484&#x2010;496. 10.1016/S1474-4422(21)00066-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(21)00066-1</ArticleId><ArticleId IdType="pmc">PMC8339877</ArticleId><ArticleId IdType="pubmed">33933186</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradford A, Kunik ME, Schulz P, Williams SP, Singh H. Missed and delayed diagnosis of dementia in primary care: prevalence and contributing factors. Alzheimer Dis Assoc Disord. 2009;23(4):306&#x2010;314. 10.1097/WAD.0b013e3181a6bebc</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WAD.0b013e3181a6bebc</ArticleId><ArticleId IdType="pmc">PMC2787842</ArticleId><ArticleId IdType="pubmed">19568149</ArticleId></ArticleIdList></Reference><Reference><Citation>
Wilson JMG JG
. Principles and practice of screening for disease. WHO
http://wwwwhoint/bulletin/volumes/86/4/07&#x2010;050112BPpdf
1968.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>